0001047469-18-001485.txt : 20180312 0001047469-18-001485.hdr.sgml : 20180312 20180312062534 ACCESSION NUMBER: 0001047469-18-001485 CONFORMED SUBMISSION TYPE: 20-F PUBLIC DOCUMENT COUNT: 156 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180312 DATE AS OF CHANGE: 20180312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hutchison China MediTech Ltd CENTRAL INDEX KEY: 0001648257 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-37710 FILM NUMBER: 18681927 BUSINESS ADDRESS: STREET 1: 22ND FLOOR HUTCHISON HOUSE STREET 2: 10 HARCOURT ROAD CITY: HONG KONG STATE: K3 ZIP: 00000 BUSINESS PHONE: 852-2121-3888 MAIL ADDRESS: STREET 1: 22ND FLOOR HUTCHISON HOUSE STREET 2: 10 HARCOURT ROAD CITY: HONG KONG STATE: K3 ZIP: 00000 20-F 1 a2234463z20-f.htm 20-F

Use these links to rapidly review the document
TABLE OF CONTENTS
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F


(Mark One)
o		REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
ý		ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017
OR
o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to
OR
o		SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report

Commission file number 001-37710

HUTCHISON CHINA MEDITECH LIMITED

(Exact name of Registrant as specified in its charter)

N/A

(Translation of Registrant's name into English)

Cayman Islands

(Jurisdiction of incorporation or organization)

22/F Hutchison House
10 Harcourt Road
Hong Kong
+852 2121 8200

(Address of principal executive offices)

Christian Hogg
Chief Executive Officer
Hutchison China MediTech Limited
Room 2108, 21/F, Hutchison House
10 Harcourt Road
Hong Kong
Telephone: +852 2121 8200
Facsimile: +852 2121 8281

(Name, telephone, email and/or facsimile number and address of Company contact person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class		Name of each exchange on which registered

American depositary shares, each representing one-half of one ordinary share, par value $1.00 per share		Nasdaq Global Select Market

Securities registered or to be registered pursuant to Section 12(g) of the Act:

None

(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

None

(Title of Class)

Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the Annual Report:

66,447,037 ordinary shares were issued and outstanding as of December 31, 2017.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

ý Yes o No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

o Yes ý No

Note—checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

ý Yes o No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

ý Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of "large accelerated filer,""accelerated filer," and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer ý		Accelerated filer o		Non-accelerated filer o		Emerging growth company o

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards^† provided pursuant to Section 13(a) of the Exchange Act. o

†The term "new or revised financial accounting standard" refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:


U.S. GAAP ý		International Financial Reporting Standards as issued by the International Accounting Standards Board o		Other o

If "Other" has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

o Item 17 o Item 18

If this is an Annual Report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o

o Yes ý No

Table of Contents

Hutchison China MediTech Limited
Table of Contents


Introduction		3
Forward-Looking Statements		4
PART I		7
Item 1.	Identity of Directors, Senior Management and Advisers	7
Item 2.	Offer Statistics and Expected Timetable	7
Item 3.	Key Information	7
Item 4.	Information on the Company	55
Item 4A.	Unresolved Staff Comments	164
Item 5.	Operating and Financial Review and Prospects	164
Item 6.	Directors, Senior Management and Employees	201
Item 7.	Major Shareholders and Related Party Transactions	217
Item 8.	Financial Information	222
Item 9.	The Offer and Listing	223
Item 10.	Additional Information	224
Item 11.	Quantitative and Qualitative Disclosures About Market Risk	236
Item 12.	Description of Securities Other Than Equity Securities	237
PART II		238
Item 13.	Defaults, Dividend Arrearages and Delinquencies	238
Item 14.	Material Modifications to the Rights of Security Holders and Use of Proceeds	238
Item 15.	Controls and Procedures	240
Item 16.	Reserved	241
Item 16A.	Audit Committee Financial Experts	241
Item 16B.	Code of Ethics	241
Item 16C.	Principal Accountant Fees and Services	241
Item 16D.	Exemptions From The Listing Standards For Audit Committees	242
Item 16E.	Purchases of Equity Securities by the Issuer and Affiliated Purchasers	242
Item 16F.	Change In Registrant's Certifying Accountant	242
Item 16G.	Corporate Governance	242
Item 16H.	Mine Safety Disclosure	242
PART III		243
Item 17.	Financial Statements	243
Item 18.	Financial Statements	243
Item 19.	Exhibits	244
SIGNATURES		247

Table of Contents

Introduction

This annual report on Form 20-F contains our audited consolidated statements of operations data for the years ended December 31, 2017, 2016 and 2015 and our audited consolidated balance sheet data as of December 31, 2017 and 2016. Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. Our historical consolidated financial statements which we made publicly available prior to our listing on the Nasdaq Global Select Market in connection with the listing of our ordinary shares on the AIM market were prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB.

This annual report also includes audited consolidated income statement data for the years ended December 31, 2017, 2016 and 2015 and the audited consolidated statements of financial position data as of December 31, 2017 and 2016 for each of our three non-consolidated joint ventures, Shanghai Hutchison Pharmaceuticals, Hutchison Baiyunshan and Nutrition Science Partners, which are accounted for using the equity accounting method. These consolidated financial statements have been prepared in accordance with IFRS as issued by the IASB.

Unless the context requires otherwise, references herein to the "company," "Chi-Med," "we," "us" and "our" refer to Hutchison China MediTech Limited and its consolidated subsidiaries and joint ventures.

Conventions Used in this Annual Report

Unless otherwise indicated, references in this annual report to:

•: "ADRs" are to the American depositary receipts, which evidence our ADSs;
•: "ADSs" are to our American depositary shares, each of which represents one-half of one ordinary share;
•: "China" or "PRC" are to the People's Republic of China, excluding, for the purposes of this annual report only, Taiwan and the special administrative regions of Hong Kong and Macau;
•: "CK Hutchison" are to CK Hutchison Holdings Limited, a company incorporated in the Cayman Islands and listed on The Stock Exchange of Hong Kong Limited, or the Hong Kong Stock Exchange, and the ultimate parent company of our majority shareholder, Hutchison Healthcare Holdings Limited;
•: "Guangzhou Baiyunshan" are to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, a leading China-based pharmaceutical company listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange;
•: "Hain Celestial" are to The Hain Celestial Group, Inc., a Nasdaq-listed, natural and organic food and personal care products company;
•: "HK$" or "HK dollar" are to the legal currency of the Hong Kong Special Administrative Region;
•: "Hutchison Baiyunshan" are to Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited, our non-consolidated joint venture with Guangzhou Baiyunshan in which we have a 50% interest through a holding company in which we have a 80% interest;
•: "Hutchison Consumer Products" are to Hutchison Consumer Products Limited, our wholly owned subsidiary;
•: "Hutchison Hain Organic" are to Hutchison Hain Organic Holdings Limited, our joint venture with Hain Celestial in which we have a 50% interest;
•: "Hutchison Healthcare" are to Hutchison Healthcare Limited, our wholly owned subsidiary;

Table of Contents

•: "Hutchison MediPharma" are to Hutchison MediPharma Limited, our subsidiary through which we operate our Innovation Platform in which we have a 99.8% interest;
•: "Hutchison MediPharma Holdings" are to Hutchison MediPharma Holdings Limited, our subsidiary in which we have a 99.8% interest and which is the indirect holding company of Hutchison MediPharma;
•: "Hutchison Sinopharm" are to Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited, our joint venture with Sinopharm in which we have a 51% interest;
•: "Nutrition Science Partners" are to Nutrition Science Partners Limited, our non-consolidated joint venture with Nestlé Health Science S.A. in which we have a 50% interest;
•: "ordinary shares" or "shares" are to our ordinary shares, par value $1.00 per share;
•: "RMB" or "renminbi" are to the legal currency of the PRC;
•: "Shanghai Hutchison Pharmaceuticals" are to Shanghai Hutchison Pharmaceuticals Limited, our non-consolidated joint venture with Shanghai Pharmaceuticals in which we have a 50% interest;
•: "Shanghai Pharmaceuticals" are to Shanghai Pharmaceuticals Holding Co., Ltd., a leading pharmaceutical company in China listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange;
•: "Sinopharm" are to Sinopharm Group Co. Ltd., a leading distributor of pharmaceutical and healthcare products and a leading supply chain service provider in China listed on the Hong Kong Stock Exchange;
•: "United States" or "U.S." are to the United States of America;
•: "$" or "U.S. dollars" are to the legal currency of the United States; and
•: "£" or "pound sterling" are to the legal currency of the United Kingdom.

Our reporting currency is the U.S. dollar. In addition, this annual report also contains translations of certain foreign currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise stated, all translations of pound sterling into U.S. dollar were made at £1.00 to $1.34 and all translations of HK dollars into U.S. dollars were made at HK$7.80 to $1.00, which are the exchange rates used in our audited consolidated financial statements as of and for the year ended December 31, 2017. We make no representation that the pound sterling, HK dollar or U.S. dollar amounts referred to in this annual report could have been or could be converted into U.S. dollars, pounds sterling or HK dollars, as the case may be, at any particular rate or at all.

Trademarks and Service Marks

We own or have been licensed rights to trademarks, service marks and trade names for use in connection with the operation of our business, including, but not limited to, our trademark Chi-Med. All other trademarks, service marks or trade names appearing in this annual report that are not identified as marks owned by us are the property of their respective owners.

Solely for convenience, the trademarks, service marks and trade names referred to in this annual report are listed without the ®, (TM) and (sm) symbols, but we will assert, to the fullest extent under applicable law, our applicable rights in these trademarks, service marks and trade names.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This annual report contains forward-looking statements made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to future events or to

Table of Contents

our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate," "expect," "goal," "intend," "may," "might," "objective," "plan," "potential," "predict," "project," "positioned," "seek," "should," "target," "will," "would," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management's beliefs and assumptions, are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors. These forward-looking statements include statements regarding:

•: the initiation, timing, progress and results of our or our collaboration partners' pre-clinical and clinical studies, and our research and development programs;
•: our or our collaboration partners' ability to advance our drug candidates into, and/or successfully complete, clinical studies;
•: the timing or regulatory filings and the likelihood of favorable regulatory outcomes and approvals;
•: regulatory developments in China, the United States and other countries;
•: the adaptation of our Commercial Platform to market and sell our drug candidates and the commercialization of our drug candidates, if approved;
•: the pricing and reimbursement of our and our joint ventures' products and our drug candidates, if approved;
•: our ability to contract on commercially reasonable terms with contract research organizations, or CROs, third-party suppliers and manufacturers;
•: the scope of protection we are able to establish and maintain for intellectual property rights covering our or our joint ventures' products and our drug candidates;
•: the ability of third parties with whom we contract to successfully conduct, supervise and monitor clinical studies for our drug candidates;
•: estimates of our expenses, future revenue, capital requirements and our needs for additional financing;
•: our ability to obtain additional funding for our operations;
•: the potential benefits of our collaborations and our ability to enter into future collaboration arrangements;
•: the ability and willingness of our collaborators to actively pursue development activities under our collaboration agreements;
•: our or our joint venture Nutrition Science Partners' receipt of milestone or royalty payments pursuant to our strategic alliances with AstraZeneca AB (publ), or AstraZeneca, Lilly (Shanghai) Management Company Limited (formerly known as Eli Lilly Trading (Shanghai) Company Limited), or Eli Lilly, and Nestlé Health Science S.A., or Nestlé Health Science, as applicable;
•: the rate and degree of market acceptance of our drug candidates;
•: our financial performance;
•: our ability to attract and retain key scientific and management personnel;

Table of Contents

•: our relationship with our joint venture and collaboration partners;
•: developments relating to our competitors and our industry, including competing drug products; and
•: changes in our tax status or the tax laws in the jurisdictions that we operate.

Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. As a result, any or all of our forward-looking statements in this annual report may turn out to be inaccurate. We have included important factors in the cautionary statements included in this annual report on Form 20-F, particularly in the section of this annual report on Form 20-F titled "Risk Factors," that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Moreover, we operate in a highly competitive and rapidly changing environment in which new risks often emerge. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

You should read this annual report and the documents that we reference herein and have filed as exhibits hereto completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained herein are made as of the date of this annual report, and we do not assume any obligation to update any forward-looking statements except as required by applicable law.

In addition, this annual report contains statistical data and estimates that we have obtained from industry publications and reports generated by third-party market research firms. Although we believe that the publications, reports and surveys are reliable, we have not independently verified the data and cannot guarantee the accuracy or completeness of such data. You are cautioned not to give undue weight to this data. Such data involves risks and uncertainties and are subject to change based on various factors, including those discussed above.

Table of Contents

PART I

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

Not applicable.

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE

Not applicable.

ITEM 3. KEY INFORMATION

A. Selected Financial Data.

Our Selected Financial Data

The following tables set forth our selected consolidated financial data. We have derived the selected consolidated statements of operations data for the years ended December 31, 2017, 2016 and 2015 and the selected consolidated balance sheet data as of December 31, 2017 and 2016 from our audited consolidated financial statements, which were prepared in accordance with U.S. GAAP and are included in this annual report. You should read this data together with such consolidated financial statements and the related notes and Item 5 "Operating and Financial Review and Prospects." Our historical results are not necessarily indicative of the results to be expected for any future periods. All of our operations are continuing operations and we have not proposed or paid dividends in any of the periods presented.

The following selected consolidated financial data for the years ended December 31, 2014 and 2013 and as of December 31, 2015 and 2014 have been derived from our audited consolidated financial statements for those years, which were prepared in accordance with U.S. GAAP and are not included in this annual report.

Table of Contents

	Year Ended December 31,

	2017			2016			2015			2014			2013
	(in thousands, except share and per share data)
Consolidated statements of operations data:
Revenues
Sales—third parties	$	196,720		$	171,058		$	118,113		$	59,162		$	8,667
Sales—related parties		8,486			9,794			8,074			7,823			7,803
Revenue from license and collaboration agreements—third parties		26,315			26,444			44,060			12,336			14,546
Revenue from research and development services—third parties		—			355			2,573			3,696			1,919
Revenue from research and development services—related parties		9,682			8,429			5,383			4,312			3,612

Total revenues		241,203			216,080			178,203			87,329			36,547

Operating expenses
Costs of sales—third parties		(169,764	)		(149,132	)		(104,859	)		(53,477	)		(5,380	)
Costs of sales—related parties		(6,056	)		(7,196	)		(5,918	)		(5,372	)		(5,814	)
Research and development expenses		(75,523	)		(66,871	)		(47,368	)		(29,914	)		(22,731	)
Selling expenses		(19,322	)		(17,998	)		(10,209	)		(4,112	)		(3,452	)
Administrative expenses		(23,955	)		(21,580	)		(19,620	)		(12,713	)		(12,366	)

Total operating expenses		(294,620	)		(262,777	)		(187,974	)		(105,588	)		(49,743	)

Loss from operations		(53,417	)		(46,697	)		(9,771	)		(18,259	)		(13,196	)
Other income/(expense)
Interest income		1,220			502			451			559			451
Gain on disposal of a business		—			—			—			—			30,000
Other income		808			609			386			20			1,221
Interest expense		(1,455	)		(1,631	)		(1,404	)		(1,516	)		(1,485	)
Other expense		(692	)		(139	)		(202	)		(761	)		(69	)

Total other income/(expense)		(119	)		(659	)		(769	)		(1,698	)		30,118
(Loss)/income before income taxes and equity in earnings of equity investees		(53,536	)		(47,356	)		(10,540	)		(19,957	)		16,922
Income tax expense		(3,080	)		(4,331	)		(1,605	)		(1,343	)		(1,050	)
Equity in earnings of equity investees, net of tax		33,653			66,244			22,572			15,180			11,031

Net (loss)/income from continuing operations		(22,963	)		14,557			10,427			(6,120	)		26,903
Income/(loss) from discontinued operations, net of tax		—			—			—			2,034			(1,978	)

Net (loss)/income		(22,963	)		14,557			10,427			(4,086	)		24,925
Less: Net income attributable to non-controlling interests		(3,774	)		(2,859	)		(2,434	)		(3,220	)		(983	)

Net (loss)/income attributable to the company		(26,737	)		11,698			7,993			(7,306	)		23,942

Accretion on redeemable non-controlling interests		—			—			(43,001	)		(25,510	)		—

Net (loss)/income attributable to ordinary shareholders of the company	$	(26,737	)	$	11,698		$	(35,008	)	$	(32,816	)	$	23,942

(Losses)/earnings per share attributable to ordinary shareholders of the company—basic ($ per share)
Continuing operations	$	(0.43	)	$	0.20		$	(0.64	)	$	(0.64	)	$	0.49
Discontinued operations	$	—		$	—		$	—		$	0.02		$	(0.03	)
(Losses)/earnings per share attributable to ordinary shareholders of the company—diluted ($ per share)
Continuing operations	$	(0.43	)	$	0.20		$	(0.64	)	$	(0.64	)	$	0.44
Discontinued operations	$	—		$	—		$	—		$	0.02		$	(0.03	)
Number of shares used in per share calculation—basic		61,717,171			59,715,173			54,659,315			52,563,387			52,050,988
Number of shares used in per share calculation—diluted		61,717,171			59,971,050			54,659,315			52,563,387			52,878,426
Net (loss)/income	$	(22,963	)	$	14,557		$	10,427		$	(4,086	)	$	24,925
Other comprehensive income/(loss):
Foreign currency translation gain/(loss)		10,964			(10,722	)		(5,557	)		(2,712	)		3,243

Total comprehensive (loss)/income		(11,999	)		3,835			4,870			(6,798	)		28,168
Less: Comprehensive income attributable to non-controlling interests		(5,033	)		(1,427	)		(1,732	)		(2,944	)		(1,296	)

Total comprehensive (loss)/income attributable to the company	$	(17,032	)	$	2,408		$	3,138		$	(9,742	)	$	26,872

Table of Contents

	As of December 31,

	2017		2016		2015		2014
	(in thousands)
Consolidated balance sheet data:
Cash and cash equivalents	$	85,265	$	79,431	$	31,941	$	38,946
Total assets	$	597,932	$	342,437	$	229,599	$	210,617
Total current liabilities	$	104,600	$	95,119	$	81,062	$	75,299
Total non-current liabilities	$	8,366	$	43,258	$	46,260	$	37,367
Total shareholders' equity	$	484,966	$	204,060	$	102,277	$	56,915

Selected Financial Data of Our Non-Consolidated Joint Ventures

We have three non-consolidated joint ventures—Shanghai Hutchison Pharmaceuticals, Hutchison Baiyunshan and Nutrition Science Partners. The following selected consolidated comprehensive income and cash flow data of each such joint venture for the years ended December 31, 2017, 2016 and 2015 and the following selected consolidated statements of financial position of each such joint venture as of December 31, 2017 and 2016 have been derived from their respective audited consolidated financial statements, which were prepared in accordance with IFRS as issued by the IASB and are included elsewhere in this annual report. You should read this data together with such consolidated financial statements of our non-consolidated joint ventures and the related notes and Item 5 "Operating and Financial Review and Prospects." The following selected consolidated financial data for the years ended December 31, 2014 and 2013 and as of December 31, 2015 and 2014 have been derived from their respective audited consolidated financial statements, which were prepared in accordance with IFRS as issued by the IASB and are not included in this annual report. The historical results of our joint ventures for any prior period are not necessarily indicative of results to be expected in any future periods.

Shanghai Hutchison Pharmaceuticals

	Year Ended December 31,

	2017			2016			2015			2014			2013
	(in thousands)
Income statement and cash flow data:
Revenue	$	244,557		$	222,368		$	181,140		$	154,703		$	138,160
Profit for the year	$	55,623		$	120,499		$	31,307		$	26,402		$	22,424
Dividends paid to shareholders	$	(81,299	)	$	(55,057	)	$	(6,410	)	$	(19,077	)	$	(17,162	)

Our equity in earnings of Shanghai Hutchison Pharmaceuticals reported under U.S. GAAP was $27.8 million, $60.3 million, $15.7 million, $13.2 million and $11.2 million for the years ended December 31, 2017, 2016, 2015, 2014 and 2013, respectively.

	As of December 31,

	2017		2016		2015		2014
	(in thousands)
Financial position data:
Cash and cash equivalents	$	43,527	$	20,292	$	43,141	$	16,575
Total assets	$	233,012	$	244,006	$	224,969	$	143,174
Total liabilities	$	100,281	$	93,872	$	131,706	$	71,268
Total shareholders' equity	$	132,731	$	150,134	$	93,263	$	71,906

Table of Contents

Hutchison Baiyunshan

	Year Ended December 31,

	2017			2016			2015			2014			2013
	(in thousands)
Income statement and cash flow data:
Revenue	$	227,422		$	224,131		$	211,603		$	243,746		$	247,626
Profit for the year	$	20,805		$	20,128		$	21,216		$	20,865		$	17,361
Profit for the year attributable to shareholders of Hutchison Baiyunshan	$	20,776		$	20,376		$	21,376		$	20,775		$	17,165
Dividends paid to shareholders	$	(29,872)	*	$	(6,000	)	$	(6,410	)	$	(12,820	)	$	(6,462	)

*: Dividends paid to shareholders exclude an additional $15.3 million of dividends declared but unpaid as of December 31, 2017.

Our equity in earnings of Hutchison Baiyunshan reported under U.S. GAAP was $10.4 million, $10.2 million, $10.7 million, $10.4 million and $8.6 million for the years ended December 31, 2017, 2016, 2015, 2014 and 2013, respectively.

	As of December 31,

	2017		2016		2015		2014
	(in thousands)
Financial position data:
Cash and cash equivalents	$	13,843	$	23,448	$	31,155	$	31,004
Total assets	$	208,796	$	221,735	$	202,646	$	217,171
Total liabilities	$	94,535	$	88,366	$	77,583	$	101,863
Total shareholders' equity	$	114,261	$	133,369	$	125,063	$	115,308

Nutrition Science Partners

	Year Ended December 31,

	2017			2016			2015			2014			2013
							(in thousands)
Income statement data:
Revenue	$	—		$	—		$	—		$	—		$	—
Loss for the year	$	(9,210	)	$	(8,482	)	$	(7,552	)	$	(16,812	)	$	(17,543	)

Our equity in loss of Nutrition Science Partners reported under U.S. GAAP was $4.6 million, $4.2 million, $3.8 million, $8.4 million and $8.8 million for the years ended December 31, 2017, 2016, 2015, 2014 and 2013, respectively.

	As of December 31,

	2017		2016		2015		2014
	(in thousands)
Financial position data:
Cash and cash equivalents	$	9,640	$	5,393	$	2,624	$	6,249
Total assets	$	39,640	$	35,393	$	33,034	$	38,548
Total liabilities	$	1,239	$	1,782	$	14,941	$	12,903
Total shareholders' equity	$	38,401	$	33,611	$	18,093	$	25,645

B. Capitalization and Indebtedness.

Not applicable.

C. Reasons for the Offer and Use of Proceeds.

Not applicable.

Table of Contents

D. Risk Factors.

Risks Related to Our Financial Position and Need for Capital

We may need substantial funding for our product development programs and commercialization efforts. If we are unable to raise capital on acceptable terms when needed, we could incur losses and be forced to delay, reduce or eliminate such efforts.

We expect our expenses to increase significantly in connection with our ongoing activities, particularly as we or our collaboration partners advance the clinical development of our eight clinical drug candidates which are currently in active or completed clinical studies in 36 target patient populations in various countries, including six Phase III studies on savolitinib, fruquintinib and sulfatinib, and continue research and development and initiate additional clinical trials of, and seek regulatory approval for, these and other future drug candidates. In addition, if we obtain regulatory approval for any of our drug candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. In particular, the costs that may be required for the manufacture of any drug candidate that receives regulatory approval may be substantial as we may have to modify or increase the production capacity at our current manufacturing facilities or contract with third-party manufacturers. We may also incur expenses as we create additional infrastructure to support our operations as a U.S. public company. Accordingly, we may need to obtain substantial funding in connection with our continuing operations through public or private equity offerings, debt financings, collaborations or licensing arrangements or other sources. If we are unable to raise capital when needed or on attractive terms, we could incur losses and be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.

We believe that our expected cashflow from operations (including from our Commercial Platform and milestone and other payments from our collaboration partners) and our cash and cash equivalents as of December 31, 2017, as well as (i) the HK$234.0 million ($30.0 million) revolving credit facility with The Hongkong and Shanghai Banking Corporation Limited, or HSBC, (ii) the aggregate HK$351.0 million ($45.0 million) in credit facilities entered into with Bank of America N.A., (iii) the aggregate HK$195.0 million ($25.0 million) in credit facilities entered into with Deutsche Bank AG, Hong Kong Branch and (iv) the HK$210.0 million ($26.9 million) three-year term loan and HK$190.0 million ($24.4 million) 18-month revolving loan facility from Scotiabank (Hong Kong) Limited, or Scotiabank, will enable us to fund our operating expenses, debt service and capital expenditure requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:

•: the number and development requirements of the drug candidates we pursue;
•: the scope, progress, timing, results and costs of researching and developing our drug candidates, and conducting pre-clinical and clinical trials;
•: the cost, timing and outcome of regulatory review of our drug candidates;
•: the cost and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our drug candidates for which we receive regulatory approval;
•: the amount and timing of any milestone payments from our collaboration partners, with whom we cooperate with respect to the development and potential commercialization of certain of our drug candidates;
•: the cash received, if any, received from commercial sales of any drug candidates for which we receive regulatory approval;

Table of Contents

•: our ability to establish and maintain strategic partnerships, collaboration, licensing or other arrangements and the financial terms of such agreements;
•: the cost, timing and outcome of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;
•: our headcount growth and associated costs; and
•: the costs of operating as a public company in the United States and on the AIM market.

Identifying potential drug candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive and uncertain process that may take years to complete, and our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available until we receive regulatory approval, if at all. We may never generate the necessary data or results required to obtain regulatory approval and achieve product sales, and even if one or more of our drug candidates is approved, they may not achieve commercial success. Accordingly, we will need to continue to rely on financing to achieve our business objectives. Adequate financing may not be available to us on acceptable terms, or at all.

If the CK Hutchison group ceases to own a majority stake in our company, we may incur significantly higher borrowing costs.

Hutchison Whampoa Limited, a wholly owned subsidiary of CK Hutchison, has historically guaranteed certain of our bank borrowings. The CK Hutchison group does not currently guarantee any of our loans and has no obligation to enter into new guarantees in the future. CK Hutchison has, however, issued letters of awareness to certain of our current lenders and committed not to reduce its shareholding to less than 40% of our issued share capital while such loans are outstanding. We may incur higher funding costs if we do not have the benefit of the CK Hutchison group guarantees or other similar arrangements by the CK Hutchison group.

Raising capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to technologies or drug candidates.

We expect to finance our cash needs in part through cash flow generated by our Commercial Platform, and we may also rely on raising capital through a combination of public or private equity offerings, debt financings and/or license and development agreements with collaboration partners. In addition, we may seek capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our existing shareholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. Additional debt financing would also result in increased fixed payment obligations.

In addition, if we raise funds through collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or grant licenses on terms that may not be favorable to us. We may also lose control of the development of drug candidates, such as the pace and scope of clinical trials, as a result of such third-party arrangements. If we are unable to raise funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves.

Table of Contents

Our existing and any future indebtedness could adversely affect our ability to operate our business.

Our outstanding indebtedness combined with current and future financial obligations and contractual commitments, including any additional indebtedness beyond our current facilities with HSBC, Scotiabank, Bank of America N.A. and Deutsche Bank AG could have significant adverse consequences, including:

•: requiring us to dedicate a portion of our cash resources to the payment of interest and principal, and prepayment and repayment fees and penalties, thereby reducing money available to fund working capital, capital expenditures, product development and other general corporate purposes;
•: increasing our vulnerability to adverse changes in general economic, industry and market conditions;
•: subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing;
•: limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and
•: placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.

We intend to satisfy our current and future debt service obligations with our existing cash and cash equivalents and short-term investments. Nevertheless, we may not have sufficient funds, and may be unable to arrange for financing, to pay the amounts due under our existing debt. Failure to make payments or comply with other covenants under our existing debt instruments could result in an event of default and acceleration of amounts due.

Risks Related to Our Innovation Platform

Historically, our in-house research and development division, known as our Innovation Platform, has not generated significant profits or has operated at a net loss.

We do not expect our Innovation Platform to be significantly profitable unless and until we obtain regulatory approval of, and begin to sell, one or more of our drug candidates. We expect to incur significant sales and marketing costs as we prepare to commercialize our drug candidates. Even if we initiate and successfully complete clinical trials of our drug candidates, and our drug candidates are approved for commercial sale, and despite expending these costs, our drug candidates may not be commercially successful. We may not achieve profitability soon after generating drug sales, if ever.

If we are unable to generate drug sales, we will not become profitable and may be unable to continue operations without continued funding.

All of our drug candidates are still in development. If we are unable to obtain regulatory approval and ultimately commercialize our drug candidates or experience significant delays in doing so, our business will be materially harmed.

All of our drug candidates are still in development including eight in clinical development. In June 2017, we completed our first new drug application, or NDA, submission in China, which was for fruquintinib in patients with third-line colorectal cancer. Although we and our joint venture Nutrition Science Partners receive certain payments from our collaboration partners, including upfront payments and payments for achieving certain development, regulatory or commercial milestones, for certain of our drug candidates, our ability to generate revenue from our drug candidates is dependent on their receipt of regulatory approval for and successfully commercializing such products, which may never occur. Each of our drug candidates will require additional pre-clinical and/or clinical development, regulatory approval in multiple jurisdictions, manufacturing supply, substantial investment and significant marketing efforts

Table of Contents

before we generate any revenue from product sales. The success of our drug candidates will depend on several factors, including the following:

•: successful completion of pre-clinical and/or clinical studies;
•: successful enrollment in, and completion of, clinical trials;
•: receipt of regulatory approvals from applicable regulatory authorities for planned clinical trials, future clinical trials or drug registrations;
•: successful completion of all safety studies required to obtain regulatory approval in the United States, China and other jurisdictions for our drug candidates;
•: adapting our commercial manufacturing capabilities to the specifications for our drug candidates for clinical supply and commercial manufacturing;
•: obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our drug candidates;
•: launching commercial sales of our drug candidates, if and when approved, whether alone or in collaboration with others;
•: acceptance of the drug candidates, if and when approved, by patients, the medical community and third-party payors;
•: effectively competing with other therapies;
•: obtaining and maintaining healthcare coverage and adequate reimbursement;
•: enforcing and defending intellectual property rights and claims; and
•: maintaining a continued acceptable safety profile of the drug candidates following approval.

If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our drug candidates, which would materially harm our business.

Our primary approach to the discovery and development of drug candidates focuses on the inhibition of kinases, some of which are unproven, and we do not know whether we will be able to develop any products of commercial value.

A primary focus of our research and development efforts is on identifying kinase targets for which drug compounds previously developed by others affecting those targets have been unsuccessful due to limited selectivity, off-target toxicity and other problems. We then work to engineer drug candidates which have the potential to have superior efficacy, safety and other features as compared to such prior drug compounds. We also focus on developing drug compounds with the potential to be global best-in-class/next-generation therapies for validated kinase targets.

Even if we are able to develop compounds that successfully target the relevant kinases in pre-clinical studies, we may not succeed in demonstrating safety and efficacy of the drug candidates in clinical trials. As a result, our efforts may not result in the discovery or development of drugs that are commercially viable or are superior to existing drugs or other therapies on the market. While the results of pre-clinical studies and early-stage clinical trials have suggested that certain of our drug candidates may successfully inhibit kinases and may have significant utility in several cancer indications, potentially in combination with other cancer drugs and with chemotherapy, we have not yet demonstrated efficacy and safety for most of our drug candidates in later stage clinical trials.

In addition, we have not yet had a drug candidate receive approval or clearance from the U.S. Food and Drug Administration, or FDA, the China Food and Drug Administration, or CFDA, or another

Table of Contents

regulatory authority. While the FDA and CFDA have approved kinases inhibitors before, the regulatory review process for our drug candidates is uncertain, and we may be required to conduct additional studies or trials beyond those we anticipate resulting in a longer regulatory approval pathway.

We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we must limit our research programs to specific drug candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. In addition, if we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements when it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate.

We have no history of commercializing our internally developed drugs, which may make it difficult to evaluate our future prospects.

The operations of our Innovation Platform have been limited to developing and securing our technology and undertaking pre-clinical studies and clinical trials of our drug candidates, either independently or with our collaboration partners. We have not yet demonstrated the ability to successfully complete development of any drug candidates, obtain marketing approvals, manufacture our internally developed drugs at a commercial scale, or conduct sales and regulatory activities necessary for successful product commercialization of our drug candidates. While we believe we will be able to successfully leverage our existing Commercial Platform to manufacture, sell and market our drug candidates in China once approved, any predictions about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing our internally developed pharmaceutical products.

The regulatory approval processes of the FDA, CFDA and comparable authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our ability to generate revenue will be materially impaired.

Our drug candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA, CFDA and other regulatory agencies in the United States and China and by comparable authorities in other countries. Securing regulatory approval requires the submission of extensive pre-clinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the drug candidate's safety and efficacy. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our drug candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use.

The process of obtaining regulatory approvals in the United States, China and other countries is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the drug candidates involved. Changes in regulatory approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each

Table of Contents

submitted NDA, pre-market approval or equivalent application types, may cause delays in the approval or rejection of an application. The FDA, CFDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional pre-clinical, clinical or other studies. Our drug candidates, including fruquintinib for which we submitted our first NDA in June 2017, could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following:

•: the FDA, CFDA or comparable regulatory authorities may disagree with the number, design, size, conduct or implementation of our clinical trials;
•: we may be unable to demonstrate to the satisfaction of the FDA, CFDA or comparable regulatory authorities that a drug candidate is safe and effective for its proposed indication;
•: the results of clinical trials may not meet the level of statistical significance required by the FDA, CFDA or comparable regulatory authorities for approval;
•: we may be unable to demonstrate that a drug candidate's clinical and other benefits outweigh its safety risks;
•: the FDA, CFDA or comparable regulatory authorities may disagree with our interpretation of data from pre-clinical studies or clinical trials;
•: the data collected from clinical trials of our drug candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere;
•: the FDA, CFDA or comparable regulatory authorities may fail to approve the manufacturing processes for our clinical and commercial supplies;
•: the approval policies or regulations of the FDA, CFDA or comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval;
•: the FDA, CFDA or comparable regulatory authorities may restrict the use of our products to a narrow population; and
•: our collaboration partners or CROs that are retained to conduct the clinical trials of our drug candidates may take actions that materially and adversely impact the clinical trials.

In addition, even if we were to obtain approval, regulatory authorities may approve any of our drug candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our drugs, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a drug candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that drug candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our drug candidates.

If the FDA, CFDA or another regulatory agency revokes its approval of, or if safety, efficacy, manufacturing or supply issues arise with, any therapeutic that we use in combination with our drug candidates, we may be unable to market such drug candidate or may experience significant regulatory delays or supply shortages, and our business could be materially harmed.

We are currently focusing on the clinical development of savolitinib as both a monotherapy and in combination with immunotherapy Imfinzi (durvalumab), targeted therapies (Tagrisso (osimertinib) and Iressa (gefitinib)) and chemotherapy (Taxotere (docetaxel)). We are also focusing on the clinical development of our drug candidate fruquintinib as both a monotherapy and in combination with chemotherapy (Taxol (paclitaxel)) and targeted therapies (Iressa (gefitinib)), and may focus on additional combinations in the future. However, we did not develop or obtain regulatory approval for, and we do not manufacture or sell, Tagrisso, Iressa, Taxotere, Taxol or Imfinzi or any other therapeutic we use in

Table of Contents

combination with our drug candidates. We may also seek to develop our drug candidates in combination with other therapeutics in the future.

If the FDA, CFDA or another regulatory agency revokes its approval of any of Tagrisso, Iressa, Taxotere, Taxol, Imfinzi or another therapeutic we use in combination with our drug candidates, we will not be able to market our drug candidates in combination with such revoked therapeutic. If safety or efficacy issues arise with these or other therapeutics that we seek to combine with our drug candidates in the future, we may experience significant regulatory delays, and we may be required to redesign or terminate the applicable clinical trials. In addition, if manufacturing or other issues result in a supply shortage of Tagrisso, Iressa, Taxotere, Taxol, Imfinzi or any other combination therapeutics, we may not be able to complete clinical development of savolitinib, fruquintinib and/or another of our drug candidates on our current timeline or at all.

Even if one or more of our drug candidates were to receive regulatory approval for use in combination with Tagrisso, Iressa, Taxotere, Taxol, Imfinzi or another therapeutic, we would continue to be subject to the risk that the FDA, CFDA or another regulatory agency could revoke its approval of the combination therapeutic, or that safety, efficacy, manufacturing or supply issues could arise with one of these combination therapeutics. This could result in savolitinib, fruquintinib or one of our other products being removed from the market or being less successful commercially.

We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do.

The development and commercialization of new drugs is highly competitive. We face competition with respect to our current drug candidates, and will face competition with respect to any drug candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market drugs or are pursuing the development of therapies in the field of kinase inhibition for cancer and other diseases. Some of these competitive drugs and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Specifically, there are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies.

Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any drugs that we or our collaborators may develop. Our competitors also may obtain FDA, CFDA or other regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all of

Table of Contents

our drug candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors.

Clinical development involves a lengthy and expensive process with an uncertain outcome.

There is a risk of failure for each of our drug candidates. It is difficult to predict when or if any of our drug candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining regulatory approval from regulatory authorities for the sale of any drug candidate, we or our collaboration partners must complete pre-clinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. Clinical testing is expensive, difficult to design and implement and can take many years to complete. The outcomes of pre-clinical development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their drug candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their drug candidates. Our current or future clinical trials may not be successful.

Commencing each of our clinical trials is subject to finalizing the trial design based on ongoing discussions with the FDA, CFDA or other regulatory authorities. The FDA, CFDA and other regulatory authorities could change their position on the acceptability of our trial designs or clinical endpoints, which could require us to complete additional clinical trials or impose approval conditions that we do not currently expect. Successful completion of our clinical trials is a prerequisite to submitting an NDA or analogous filing to the FDA, CFDA or other regulatory authorities for each drug candidate and, consequently, the ultimate approval and commercial marketing of our drug candidates. We do not know whether any of our clinical trials will begin or be completed on schedule, if at all.

We and our collaboration partners may incur additional costs or experience delays in completing our pre-clinical or clinical trials, or ultimately be unable to complete the development and commercialization of our drug candidates.

We and our collaboration partners, including AstraZeneca, Eli Lilly and Nestlé Health Science, may experience delays in completing our pre-clinical or clinical trials, and numerous unforeseen events could arise during, or as a result of, future clinical trials, which could delay or prevent us from receiving regulatory approval, including:

•: regulators or institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence or conduct a clinical trial at a prospective trial site;
•: we may experience delays in reaching, or we may fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, who conduct clinical trials on behalf of us and our collaboration partners, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
•: clinical trials may produce negative or inconclusive results, and we or our collaboration partners may decide, or regulators may require us or them, to conduct additional clinical trials or we may decide to abandon drug development programs;
•: the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;
•: third-party contractors used in our clinical trials may fail to comply with regulatory requirements or meet their contractual obligations in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we or our collaboration partners add new clinical trial sites or investigators;

Table of Contents

•: we or our collaboration partners may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research for various reasons, including non-compliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;
•: the cost of clinical trials of our drug candidates may be greater than we anticipate;
•: the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate; and
•: our drug candidates may have undesirable side effects or unexpected characteristics, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate the trials, or reports may arise from pre-clinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our drug candidates.

We could encounter regulatory delays if a clinical trial is suspended or terminated by us or our collaboration partners, by, as applicable, the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board, which is an independent group of experts that is formed to monitor clinical trials while ongoing, or by the FDA, CFDA or other regulatory authorities. Such authorities may impose a suspension or termination due to a number of factors, including: a failure to conduct the clinical trial in accordance with regulatory requirements or the applicable clinical protocols, inspection of the clinical trial operations or trial site by the FDA, CFDA or other regulatory authorities that results in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our drug candidates. Further, the FDA, CFDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials.

If we or our collaboration partners are required to conduct additional clinical trials or other testing of our drug candidates beyond those that are currently contemplated, if we or our collaboration partners are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:

•: be delayed in obtaining regulatory approval for our drug candidates;
•: not obtain regulatory approval at all;
•: obtain approval for indications or patient populations that are not as broad as intended or desired;
•: be subject to post-marketing testing requirements; or
•: have the drug removed from the market after obtaining regulatory approval.

Our drug development costs will also increase if we experience delays in testing or regulatory approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant pre-clinical study or clinical trial delays also could allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our drug candidates and may harm our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and prospects significantly.

Table of Contents

If we or our collaboration partners experience delays or difficulties in the enrollment of patients in clinical trials, the progress of such clinical trials and our receipt of necessary regulatory approvals could be delayed or prevented.

We or our collaboration partners may not be able to initiate or continue clinical trials for our drug candidates if we or our collaboration partners are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, CFDA or similar regulatory authorities. In particular, we and our collaboration partners have designed many of our clinical trials, and expect to design future trials, to include some patients with the applicable genomic alteration that causes the disease with a view to assessing possible early evidence of potential therapeutic effect. Genomically defined diseases, however, may have relatively low prevalence, and it may be difficult to identify patients with the applicable genomic alteration. In addition, for our fruquintinib trials, we focus on enrolling patients who have failed their first or second-line treatments, which limits the total size of the patient population available for such trials. The inability to enroll a sufficient number of patients with the applicable genomic alteration or that meet other applicable criteria for our clinical trials would result in significant delays and could require us or our collaboration partners to abandon one or more clinical trials altogether.

In addition, some of our competitors have ongoing clinical trials for drug candidates that treat the same indications as our drug candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors' drug candidates.

Patient enrollment may be affected by other factors including:

•: the severity of the disease under investigation;
•: the total size and nature of the relevant patient population;
•: the design and eligibility criteria for the clinical trial in question;
•: the availability of an appropriate genomic screening test;
•: the perceived risks and benefits of the drug candidate under study;
•: the efforts to facilitate timely enrollment in clinical trials;
•: the patient referral practices of physicians;
•: the availability of competing therapies which are undergoing clinical trials;
•: the ability to monitor patients adequately during and after treatment; and
•: the proximity and availability of clinical trial sites for prospective patients.

Enrollment delays in our clinical trials may result in increased development costs for our drug candidates, which could cause the value of our company to decline and limit our ability to obtain financing.

Our drug candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if any.

Undesirable side effects caused by our drug candidates could cause us or our collaboration partners to interrupt, delay or halt clinical trials or could cause regulatory authorities to interrupt, delay or halt our clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, CFDA or other regulatory authorities. In particular, as is the case with all oncology drugs, it is likely that there may be side effects, for example, hand-foot syndrome, associated with the use of certain of our drug candidates. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA, CFDA or comparable regulatory authorities could order us to cease further development of or deny approval of our

Table of Contents

drug candidates for some or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.

Further, our drug candidates could cause undesirable side effects related to off-target toxicity. Many of the currently approved tyrosine kinase inhibitors have been associated with off-target toxicities because they affect multiple kinases. While we believe that the kinase selectivity of our drug candidates has the potential to significantly improve the unfavorable adverse off-target toxicity issues, if patients were to experience off-target toxicity, we may not be able to achieve an effective dosage level, receive approval to market, or achieve the commercial success we anticipate with respect to any of our drug candidates, which could prevent us from ever generating revenue or achieving profitability. Many compounds that initially showed promise in early-stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound.

Clinical trials assess a sample of the potential patient population. With a limited number of patients and duration of exposure, rare and severe side effects of our drug candidates may only be uncovered with a significantly larger number of patients exposed to the drug candidate. If our drug candidates receive regulatory approval and we or others identify undesirable side effects caused by such drug candidates (or any other similar drugs) after such approval, a number of potentially significant negative consequences could result, including:

•: regulatory authorities may withdraw or limit their approval of such drug candidates;
•: regulatory authorities may require the addition of labeling statements, such as a "boxed" warning or a contra-indication;
•: we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;
•: we may be required to change the way such drug candidates are distributed or administered, conduct additional clinical trials or change the labeling of the drug candidates;
•: regulatory authorities may require a Risk Evaluation and Mitigation Strategy, or REMS, plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools;
•: we may be subject to regulatory investigations and government enforcement actions;
•: we may decide to remove such drug candidates from the marketplace;
•: we could be sued and held liable for injury caused to individuals exposed to or taking our drug candidates; and
•: our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of the affected drug candidates and could substantially increase the costs of commercializing our drug candidates, if approved, and significantly impact our ability to successfully commercialize our drug candidates and generate revenue.

Table of Contents

We and our collaboration partners have conducted and intend to conduct additional clinical trials for certain of our drug candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations or may require additional U.S.-based trials.

We and our collaboration partners have conducted, currently are conducting and intend in the future to conduct, clinical trials outside the United States, particularly in China where our Innovation Platform is headquartered as well as in Australia, Canada, Korea, U.K. and Spain.

Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted by qualified investigators in accordance with current good clinical practices, or GCPs, including review and approval by an independent ethics committee and receipt of informed consent from trial patients. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. Generally, the patient population for any clinical trial conducted outside of the United States must be representative of the population for which we intend to seek approval in the United States. In addition, while these clinical trials are subject to applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also comply with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from our clinical trials of fruquintinib, sulfatinib, epitinib or theliatinib in China, savolitinib in the U.K., Spain, South Korea, Canada and China, or HMPL-523, HMPL-689 and HMPL-453 in Australia and China, for example, or any other trial that we or our collaboration partners conduct outside the United States, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay or permanently halt our ability to develop and market these or other drug candidates in the United States.

In addition, there are risks inherent in conducting clinical trials in jurisdictions outside the United States including:

•: regulatory and administrative requirements of the jurisdiction where the trial is conducted that could burden or limit our ability to conduct our clinical trials;
•: foreign exchange fluctuations;
•: manufacturing, customs, shipment and storage requirements;
•: cultural differences in medical practice and clinical research; and
•: the risk that patient populations in such trials are not considered representative as compared to patient populations in the United States and other markets.

A Breakthrough Therapy designation by the FDA may not be granted to any of our drug candidates, and even if granted, may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our drug candidates will receive regulatory approval.

We intend to seek Breakthrough Therapy designation in the United States for some of our drug candidates, including savolitinib in patients with papillary renal cell carcinoma, non-small cell lung cancer and gastric cancer, sulfatinib in patients with neuroendocrine tumors and possibly epitinib in patients with non-small cell lung cancer with brain metastasis. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of

Table of Contents

patients placed in ineffective control regimens. Drugs designated as Breakthrough Therapies by the FDA are also eligible for accelerated approval.

Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our drug candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a drug candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our drug candidates qualify as Breakthrough Therapies, the FDA may later decide that the drugs no longer meet the conditions for qualification.

If we are unable to obtain and/or maintain CFDA approval for our drug candidates to be eligible for an expedited registration pathway, the time and cost we incur to obtain regulatory approvals may increase. Even if we receive such approvals, they may not lead to a faster development, review or approval process.

Under the Special Examination and Approval of the Registration of New Drugs provisions, the CFDA may grant "green-channel" approval to (i) active ingredients and their preparations extracted from plants, animals and minerals, and newly discovered medical materials and their preparations that have not been sold in the China market, (ii) chemical drugs and their preparations and biological products that have not been approved for sale at its origin country or abroad, (iii) new drugs with obvious clinical treatment advantages for diseases such as AIDS, therioma, and rare diseases, and (iv) new drugs for diseases that have not been treated effectively. We have achieved green-channel approval from the CFDA for savolitinib, fruquintinib, sulfatinib, epitinib and theliatinib. We anticipate that we may seek a green-channel development pathway for certain of our other drug candidates and indications. If granted, the green-channel will enable us to establish streamlined communication with the relevant review panel of the CFDA, thus improving the efficiency of new drug approval.

A failure to obtain and/or maintain green-channel approval or any other form of expedited development, review or approval for our drug candidates would result in a longer time period to commercialization of such drug candidate, could increase the cost of development of such drug candidate and could harm our competitive position in the marketplace. In addition, even if we obtain green-channel approval, there is no guarantee that we will experience a faster development process, review or approval compared to non-accelerated registration pathways or that a drug candidate will ultimately be approved for sale.

Even if we receive regulatory approval for any of our drug candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense.

If the FDA, CFDA or a comparable regulatory authority approves any of our drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the drug will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practices, or GMPs, and GCPs. Any regulatory approvals that we receive for our drug candidates may also be subject to limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the drug.

In addition, regulatory policies may change or additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able

Table of Contents

to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.

We may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any of our drugs that receive regulatory approval.

Once a drug is approved by the FDA, CFDA or a comparable regulatory authority for marketing, it is possible that there could be a subsequent discovery of previously unknown problems with the drug, including problems with third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements. If any of the foregoing occurs with respect to our drug products, it may result in, among other things:

•: restrictions on the marketing or manufacturing of the drug, withdrawal of the drug from the market, or drug recalls;
•: fines, warning letters or holds on clinical trials;
•: refusal by the FDA, CFDA or comparable regulatory authority to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of drug license approvals;
•: drug seizure or detention, or refusal to permit the import or export of drugs; and
•: injunctions or the imposition of civil or criminal penalties.

Any government investigation of alleged violations of law could require us to expend significant time and resources and could generate negative publicity. If we or our collaborators are not able to maintain regulatory compliance, regulatory approval that has been obtained may be lost and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.

The incidence and prevalence for target patient populations of our drug candidates are based on estimates and third-party sources. If the market opportunities for our drug candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially.

Periodically, we make estimates regarding the incidence and prevalence of target patient populations for particular diseases based on various third-party sources and internally generated analysis and use such estimates in making decisions regarding our drug development strategy, including determining indications on which to focus in pre-clinical or clinical trials.

These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity will depend on, among other things, their acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our drugs, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.

Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.

We are highly dependent on the expertise of the members of our research and development team, as well as the other principal members of our management, including Christian Hogg, our Chief Executive Officer and director, and Weiguo Su, Ph.D., our Chief Scientific Officer and director. Although we have entered into employment agreements with our executive officers, each of them may terminate their

Table of Contents

employment with us at any time with three months' prior written notice. We do not maintain "key person" insurance for any of our executives or other employees.

Recruiting and retaining qualified management, scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize drugs. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel.

Risks Related to Our Commercial Platform

As a significant portion of our Commercial Platform business, which consists of our Prescription Drugs and Consumer Health divisions, is conducted through joint ventures, we are largely dependent on the success of our joint ventures and our receipt of dividends or other payments from our joint ventures for cash to fund our operations.

We are party to joint venture agreements with Shanghai Pharmaceuticals and Guangzhou Baiyunshan, relating to our non-consolidated joint ventures, which together form part of our Commercial Platform business. Our equity in the earnings of these non-consolidated joint ventures was $26.3 million, $70.5 million and $38.2 million for the years ended December 31, 2015, 2016 and 2017, respectively, as recorded in our consolidated financial statements. Furthermore, we have consolidated joint ventures with each of Sinopharm and Hain Celestial which accounted for substantially all of our Commercial Platform's consolidated revenue for the years ended December 31, 2015, 2016 and 2017.

As a result, our ability to fund our operations and pay our expenses or to make future dividend payments, if any, is largely dependent on the earnings of our joint ventures and the payment of those earnings to us in the form of dividends. Payments to us by our joint ventures will be contingent upon our joint ventures' earnings and other business considerations and may be subject to statutory or contractual restrictions. Each joint venture's ability to distribute dividends to us is subject to approval by their respective boards of directors, which in the case of Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan are comprised of an equal number of representatives from each party.

Operationally, our joint venture partners have certain responsibilities and/or certain rights to exercise control or influence over operations and decision-making under the joint venture arrangements. Therefore, the success of our joint ventures depends on the efforts and abilities of our joint venture parties to varying degrees. For example, we share the ability to appoint the general manager of our joint venture with Guangzhou Baiyunshan, with each of us having a rotating four-year right, and therefore, our ability to manage the day-to-day operations of this joint venture is more limited. On the other hand, we appoint the general managers of Hutchison Sinopharm and Shanghai Hutchison Pharmaceuticals pursuant to the respective joint venture agreements governing these entities and therefore oversee the day-to-day management of these joint ventures. However, we still rely on our joint venture partners Sinopharm and Shanghai Pharmaceuticals to provide certain distribution and logistics services. See "—Risks Related to our Dependence on Third Parties—Joint ventures form an important part of our Commercial Platform business, and our ability to manage and develop the businesses conducted by these joint ventures depends in part on our relationship with our joint venture partners" for more information.

Table of Contents

We intend to use our Commercial Platform's Prescription Drugs business to commercialize our internally developed drug candidates, but we may not be successful in adapting this business to successfully manufacture, sell and market our drug candidates if and when they are approved, and we may not be able to generate any revenue from such products.

Our Prescription Drugs business is operated by our Shanghai Hutchison Pharmaceuticals and Hutchison Sinopharm joint ventures and currently has a manufacturing, sales and marketing infrastructure in China. If our drug candidates are approved, we intend to leverage our Prescription Drugs business to commercialize such drug candidates; however, to do so, we must adapt our Prescription Drugs business to cater to oncology and/or immunology drug sales to achieve commercial success for any approved drug candidate in these areas. In the future, we may need to expand the sales and marketing team of these joint ventures or refocus their activities to some of our drug candidates if and when they are approved.

There are risks involved with adapting our current Prescription Drugs business. For example, recruiting and/or training a sales force in new therapeutic areas is time consuming and could delay any drug launch. Factors that may inhibit our efforts to commercialize our drug candidates through our Prescription Drugs business include:

•: our joint ventures' inability to recruit and retain adequate numbers of effective sales and marketing personnel;
•: the inability of our joint ventures' sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs; and
•: the lack of complementary drugs to be offered by our joint ventures' sales personnel, which may put our joint ventures at a competitive disadvantage relative to companies with more extensive product lines.

In such case, our business, results of operations, financial condition and prospects will be materially and adversely affected.

Our Commercial Platform faces substantial competition.

Our Commercial Platform's Prescription Drugs business competes in the pharmaceutical industry in China, which is characterized by a number of established, large pharmaceutical companies, as well as some smaller emerging pharmaceutical companies. Our Prescription Drugs business competes with pharmaceutical companies engaged in the development, production, marketing or sales of prescription drugs, in particular cardiovascular drugs. The identities of the key competitors with respect to our Prescription Drugs business vary by product and, in certain cases, competitors have greater financial resources than us and may elect to focus these resources on developing, importing or in-licensing and marketing products in the PRC that are substitutes for our products and may have broader sales and marketing infrastructure with which to do so. Our Commercial Platform's Consumer Health business also competes in a highly fragmented market in Asia.

The products sold through our Commercial Platform, which may include our drug candidates if they receive regulatory approval, may compete against products that have lower prices, superior performance, greater ease of administration or other advantages compared to our products. In some circumstances, price competition may drive our competitors to conduct illegal manufacturing processes to lower their manufacturing costs. Increased competition may result in price reductions, reduced margins and loss of market share, whether achieved by either legal or illegal means, any of which could materially and adversely affect our profit margins. We and our joint ventures may not be able to compete effectively against current and future competitors.

Table of Contents

If we are not able to maintain and enhance brand recognition of the Commercial Platform's products to maintain its competitive advantage, our reputation, business and operating results may be harmed.

We believe that market awareness of the products sold through our Commercial Platform, which include our joint ventures' branded products, such as Baiyunshan and Shang Yao, and the brands of third-party products which are distributed through our joint ventures, such as AstraZeneca's Seroquel, has contributed significantly to the success of our Commercial Platform. We also believe that maintaining and enhancing such brands is critical to maintaining our competitive advantage. Although the sales and marketing staff of our Commercial Platform will continue to further promote such brands to remain competitive, they may not be successful. If our joint ventures are unable to further enhance brand recognition and increase awareness of their products, or if they are compelled to incur excessive marketing and promotion expenses in order to maintain brand awareness, our business and results of operations may be materially and adversely affected. Furthermore, our results of operations could be adversely affected if the Baiyunshan and Shang Yao brands, or the brands of any other products, or our reputation, are impaired by certain actions taken by our joint venture partners, distributors, competitors or relevant regulatory authorities.

Reimbursement may not be available for the products currently sold through our Commercial Platform or our drug candidates in China, the United States or other countries, which could diminish our sales or affect our profitability.

The regulations that govern pricing and reimbursement for pharmaceuticals vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after regulatory approval is granted. In some foreign markets, pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. Furthermore, once marketed and sold, government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Adverse pricing reimbursement levels may hinder market acceptance of products sold by our Commercial Platform or drug candidates.

In China, for example, the Ministry of Human Resources and Social Security of the PRC or provincial or local human resources and social security authorities, together with other government authorities, review the inclusion or removal of drugs from the PRC's National Medical Insurance Catalogue or provincial or local medical insurance catalogues for the National Medical Insurance Program every other year, and the tier under which a drug will be classified, both of which affect the amounts reimbursable to program participants for their purchases of those medicines. These determinations are made based on a number of factors, including price and efficacy. Depending on the tier under which a drug is classified in the provincial medicine catalogue, a National Medical Insurance Program participant residing in that province can be reimbursed for the full cost of Tier 1 medicine and for the majority of the cost of a Tier 2 medicine. In some instances, if the price range designated by the local or provincial government decreases, it may adversely affect our business and could reduce our total revenue, and if our revenue falls below production costs, we may stop manufacturing certain products. In addition, in order to access certain local or provincial-level markets, our joint ventures are periodically required to enter into competitive bidding processes for She Xiang Bao Xin pills (the best-selling product of our Shanghai Hutchison Pharmaceuticals joint venture), Fu Fang Dan Shen tablets (the best-selling product of our Hutchison Baiyunshan joint venture) and other products with a pre-defined price range. The competitive bidding in effect sets price ceilings for those products, thereby limiting our profitability.

In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs which may affect reimbursement rates of our drug candidates if approved. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the Affordable Care Act, was passed, which substantially changes the way health care is financed by both governmental and private insurers. The Affordable Care Act, among other things, subjects biologic products to potential competition by lower-cost biosimilars and establishes annual

Table of Contents

fees and taxes on manufacturers of certain branded prescription drugs. It also establishes a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer's outpatient drugs to be covered under Medicare Part D. In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted.

Modifications to or repeal of all or certain provisions of the Healthcare Reform Act are expected as a result of the outcome of the 2016 presidential election and Republicans maintaining control of Congress, consistent with statements made by President Donald Trump and members of Congress during the presidential campaign and following the election. We cannot predict the ultimate content, timing or effect of any changes to the Healthcare Reform Act or other federal and state reform efforts. There is no assurance that federal or state health care reform will not adversely affect our future business and financial results. We expect that additional U.S. state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our drug candidates or additional pricing pressures. We expect that the pharmaceutical industry will experience pricing pressures due to the increasing influence of managed care (and related implementation of managed care strategies to control utilization), additional federal and state legislative and regulatory proposals to regulate pricing of drugs, limit coverage of drugs or reduce reimbursement for drugs, public scrutiny and the Trump administration's agenda to control the price of pharmaceuticals through government negotiations of drug prices in Medicare Part D and importation of cheaper products from abroad.

Moreover, eligibility for reimbursement in the United States does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim U.S. reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by U.S. government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors in the United States often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition.

Sales of products sold by our Prescription Drugs business rely on the ability to win tender bids for the medicine purchases of hospitals in China.

Our Commercial Platform's Prescription Drugs business markets to hospitals in China who may make bulk purchases of a medicine only if that medicine is selected under a government-administered tender process. Periodically, a bidding process is organized on a provincial or municipal basis. Whether a drug manufacturer is invited to participate in the tender depends on the level of interest that hospitals have in purchasing this drug. The interest of a hospital in a medicine is evidenced by:

•: the inclusion of this medicine on the hospital's formulary, which establishes the scope of drug physicians at this hospital may prescribe to their patients, and
•: the willingness of physicians at this hospital to prescribe a particular drug to their patients.

We believe that effective marketing efforts are critical in making and keeping hospitals interested in purchasing the Prescription Drugs sold through our Commercial Platform so that we and our joint

Table of Contents

ventures are invited to submit the products to the tender. Even if we and our joint ventures are invited to do so, competitors may be able to substantially reduce the price of their products or services. If competitors are able to offer lower prices, our and our joint ventures' ability to win tender bids during the hospital tender process will be materially affected, and could reduce our total revenue or decrease our profit.

Counterfeit products in China could negatively impact our revenue, brand reputation, business and results of operations.

Our Commercial Platform's products are subject to competition from counterfeit products, especially counterfeit pharmaceuticals which are manufactured without proper licenses or approvals and are fraudulently mislabeled with respect to their content and/or manufacturer. Counterfeiters may illegally manufacture and market products under our or our joint venture's brand names, the brand names of the third-party products we or they sell, or those of our or their competitors. Counterfeit pharmaceuticals are generally sold at lower prices than the authentic products due to their low production costs, and in some cases are very similar in appearance to the authentic products. Counterfeit pharmaceuticals may or may not have the same chemical content as their authentic counterparts. If counterfeit pharmaceuticals illegally sold under our or our joint ventures' brand names or the brand names of third-party products we or they sell result in adverse side effects to consumers, we or our joint ventures may be associated with any negative publicity resulting from such incidents. In addition, consumers may buy counterfeit pharmaceuticals that are in direct competition with the products sold through our Commercial Platform, which could have an adverse impact on our revenue, business and results of operations. The proliferation of counterfeit pharmaceuticals in China and globally may grow in the future. Any such increase in the sales and production of counterfeit pharmaceuticals in China, or the technological capabilities of the counterfeiters, could negatively impact our revenue, brand reputation, business and results of operations.

Pharmaceutical companies in China are required to comply with extensive regulations and hold a number of permits and licenses to carry on their business. Our and our joint ventures' ability to obtain and maintain these regulatory approvals is uncertain, and future government regulation may place additional burdens on the Commercial Platform business.

The pharmaceutical industry in China is subject to extensive government regulation and supervision. The regulatory framework addresses all aspects of operating in the pharmaceutical industry, including approval, production, distribution, advertising, licensing and certification requirements and procedures, periodic renewal and reassessment processes, registration of new drugs and environmental protection. Violation of applicable laws and regulations may materially and adversely affect our business. In order to manufacture and distribute pharmaceutical products in China, we and our joint ventures are required to:

•: obtain a pharmaceutical manufacturing permit and GMP certificate for each production facility from the relevant food and drug administrative authority;
•: obtain a drug registration certificate, which includes a drug approval number, from the CFDA for each drug manufactured by us;
•: obtain a pharmaceutical distribution permit and good supply practice, or GSP, certificate from the CFDA; and
•: renew the pharmaceutical manufacturing permits, the pharmaceutical distribution permits, drug registration certificates, GMP certificates and GSP certificates, among other requirements.

If we or our joint ventures are unable to obtain or renew such permits or any other permits or licenses required for our or their operations, we will not be able to engage in the manufacture and distribution of our products and our business may be adversely affected.

Table of Contents

The regulatory framework regarding the pharmaceutical industry in China is subject to change and amendment from time to time. Any such change or amendment could materially and adversely impact our business, financial condition and results of operations. The PRC government has introduced various reforms to the Chinese healthcare system in recent years and may continue to do so, with an overall objective to expand basic medical insurance coverage and improve the quality and reliability of healthcare services. The specific regulatory changes under the reform still remain uncertain. The implementing measures to be issued may not be sufficiently effective to achieve the stated goals, and as a result, we may not be able to benefit from such reform to the level we expect, if at all. Moreover, the reform could give rise to regulatory developments, such as more burdensome administrative procedures, which may have an adverse effect on our business and prospects.

For further information regarding government regulation in China and other jurisdictions, see Item 4.B. "Business Overview—Regulation—Government Regulation of Pharmaceutical Product Development and Approval," "Business Overview—Regulation—Coverage and Reimbursement" and "Business Overview—Regulation—Other Healthcare Laws."

Rapid changes in the pharmaceutical industry may render our Commercial Platform's current products or our drug candidates obsolete.

Future technological improvements by our competitors and continual product developments in the pharmaceutical market may render our and our joint ventures' existing products, our or their third-party licensed products or our drug candidates obsolete or affect our Commercial Platform's viability and competitiveness. Therefore, our Commercial Platform's future success will largely depend on our and our joint ventures' ability to:

•: improve existing products;
•: develop innovative drug candidates;
•: diversify the product and drug candidate portfolio;
•: license diverse third-party products; and
•: develop new and competitively priced products which meet the requirements of the constantly changing market.

If we or our joint ventures fail to respond to this environment by improving our Commercial Platform's existing products, licensing new third-party products or developing new drug candidates in a timely fashion, or if such new or improved products do not achieve adequate market acceptance, our business and profitability may be materially and adversely affected.

Our Commercial Platform's principal products involve the cultivation or sourcing of key raw materials including botanical products, and any quality control or supply failure or price fluctuations could adversely affect our Commercial Platform's ability to manufacture our products and/or could materially and adversely affect our operating results.

The key raw materials used in the manufacturing process of certain of our Commercial Platform's principal products are medicinal herbs whose properties are related to the regions and climatic conditions in which they are grown. Access to quality raw materials and products necessary for the manufacture of our Commercial Platform products is not guaranteed. We rely on a combination of materials grown by our or our joint ventures' entities and materials sourced from third-party growers and suppliers. The availability, quality and prices of these raw materials are dependent on and closely affected by weather conditions and other seasonal factors which have an impact on the yields of the harvests each year. The quality, in some instances, also depends on the operations of third-party growers or suppliers. There is a risk that such growers or suppliers sell or attempt to sell us or our joint ventures raw materials which are not authentic. If

Table of Contents

there is any supply interruption for an indeterminate period of time, our joint ventures may not be able to identify and obtain alternative supplies that comply with our quality standards in a timely manner. Any supply disruption could adversely affect our ability to satisfy demand for our products, and materially and adversely affect our product sales and operating results. Moreover, any use by us or our joint ventures of unauthentic materials illegally sold to us by third-party growers or suppliers in our or our joint ventures' products may result in adverse side effects to the consumers, negative publicity, or product liability claims against us or our joint ventures, any of which may materially and adversely affect our operating results.

The prices of necessary raw materials and products may be subject to price fluctuations according to market conditions, and any sudden increases in demand in the case of a widespread illness such as SARS, MERS or avian flu may impact the costs of production. For example, the market price of Sanqi, one of the main natural raw materials in Hutchison Baiyunshan's Fu Fang Dan Shen tablets, fluctuated significantly between 2009 and 2017. Our Commercial Platform sources Sanqi and other necessary raw materials on a purchase order basis and does not have long-term supply contracts in place so that it can manage inventory levels to reduce its risk to price fluctuations; however, we cannot guarantee that we or our joint ventures will be successful. Raw material price fluctuations could increase the cost to manufacture our Commercial Platform's products and adversely affect our operating results.

Adverse publicity associated with our company, our joint ventures or our or their products or third-party licensed products or similar products manufactured by our competitors could have a material adverse effect on our results of operations.

Sales of the Commercial Platform's products are highly dependent upon market perceptions of the safety and quality of our and our joint ventures' products and the third-party products we and they distribute. Concerns over the safety of biopharmaceutical products manufactured in China could have an adverse effect on the reputation of our industry and the sale of such products, including products manufactured or distributed by us and our joint ventures.

We could be adversely affected if any of our or our joint ventures' products, third-party licensed products or any similar products manufactured by other companies prove to be, or are alleged to be, harmful to patients. Any negative publicity associated with severe adverse reactions or other adverse effects resulting from patients' use or misuse of our and our joint ventures' products or any similar products manufactured by other companies could also have a material adverse impact on our results of operations. We and our joint ventures have not, to date, experienced any significant quality control or safety problems. If in the future we or our joint ventures become involved in incidents of the type described above, such problems could severely and adversely impact our financial position and reputation.

We are dependent on our joint ventures' production facilities in Shanghai, Guangzhou and Bozhou, China for the manufacture of our principal Commercial Platform products.

The principal products sold by our Commercial Platform are mainly produced or expected to be produced at our joint ventures' manufacturing facilities in Shanghai, Guangzhou and Bozhou, China. A significant disruption at those facilities, even on a short-term basis, could impair our joint ventures' ability to timely produce and ship products, which could have a material adverse effect on our business, financial position and results of operations.

Our joint ventures' manufacturing operations are vulnerable to interruption and damage from natural and other types of disasters, including earthquake, fire, floods, environmental accidents, power loss, communications failures and similar events. If any disaster were to occur, our ability to operate our or our joint ventures' business at these facilities would be materially impaired. In addition, the nature of our production and research activities could cause significant delays in our programs and make it difficult for us to recover from a disaster. We and our joint ventures maintain insurance for business interruptions to

Table of Contents

cover some of our potential losses; however, such disasters could still disrupt our operations and thereby result in substantial costs and diversion of resources.

In addition, our and our joint ventures' production process requires a continuous supply of electricity. We and they have encountered power shortages historically due to restricted power supply to industrial users during summers when the usage of electricity is high and supply is limited or as a result of damage to the electricity supply network. Because the duration of those power shortages was brief, they had no material impact on our or their operations. Interruptions of electricity supply could result in lengthy production shutdowns, increased costs associated with restarting production and the loss of production in progress. Any major suspension or termination of electricity or other unexpected business interruptions could have a material adverse impact on our business, financial condition and results of operations.

Risks Related to our Dependence on Third Parties

Disagreements with our current or future collaboration partners, or the termination of any collaboration arrangement, could cause delays in our product development and materially and adversely affect our business.

Our collaborations with AstraZeneca, Eli Lilly and Nestlé Health Science and any future collaborations that we enter into may not be successful. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable drug candidate and, in some cases, termination of the collaboration arrangement. Because, among other things, we are much smaller than our collaboration partners and because they or their affiliates may sell competing products, our interests may not always be aligned. This may result in potential conflicts between our collaborators and us on matters that we may not be able to resolve on favorable terms or at all.

Collaborations with pharmaceutical or biotechnology companies and other third parties, including our existing agreements with AstraZeneca, Eli Lilly and Nestlé Health Science, are often terminable by the other party for any reason with certain advance notice. Any such termination or expiration would adversely affect us financially and could harm our business reputation. For instance, in the event one of the strategic alliances with a current collaborator is terminated, we may require significant time and resources to secure a new collaboration partner, if we are able to secure such an arrangement at all. As noted in the following risk factor, establishing new collaboration arrangements can be challenging and time-consuming. The loss of existing or future collaboration arrangements would not only delay or potentially terminate the possible development or commercialization of products we may derive from our technologies, but it may also delay or terminate our ability to test specific target candidates.

We rely on our collaborations with third parties for certain of our drug development activities, and, if we are unable to establish new collaborations when desired on commercially attractive terms or at all, we may have to alter our development and commercialization plans.

Certain of our drug development programs and the potential commercialization of certain drug candidates rely on collaborations with AstraZeneca, Eli Lilly and Nestlé Health Science. In the future, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of our other drug candidates.

We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for collaboration will depend, among other things, upon our assessment of the collaborator's resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator's evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, CFDA or similar regulatory authorities outside the United States and China, the potential market for the subject drug candidate, the costs and complexities of manufacturing and delivering such drug candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge

Table of Contents

to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative drug candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our drug candidate. The terms of any additional collaboration or other arrangements that we may establish may not be favorable to us.

We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.

We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the drug candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our drug candidates or bring them to market and generate drug revenue.

Further development and commercialization of our own drug candidates will depend, in part, on strategic alliances with our collaborators. If our collaborators do not diligently pursue product development efforts, impeding our ability to collect milestone and royalty payments, our progress may be delayed and our revenue may be deferred.

We rely and expect to continue to rely, to some extent, on our collaborators to provide funding in support of our own independent research and pre-clinical and clinical testing. We do not currently possess the financial resources necessary to fully develop and commercialize each of our drug candidates or the resources or capabilities to complete the lengthy regulatory approval processes that may be required for our drug candidates. Therefore, we rely and plan to continue to rely on strategic alliances to financially help us develop and commercialize certain of our drug candidates. As a result, our success depends, in part, on our ability to collect milestone and royalty payments from our existing collaborators, AstraZeneca, Eli Lilly, Nestlé Health Science and potential new collaborators. To the extent our collaborators do not aggressively pursue drug candidates for which we are entitled to such payments or pursue such drug candidates ineffectively, we will fail to realize these significant revenue streams, which could have an adverse effect on our business and future prospects.

If the alliances we currently have with AstraZeneca, Eli Lilly and Nestlé Health Science, or future collaborators with whom we may engage, are unable or unwilling to advance our programs, or if they do not diligently pursue product development and product approval, this may slow our progress and defer our revenue. Any such failure would have an adverse effect on our ability to collect key revenue streams and, for this reason, would adversely impact our business, financial position and prospects. Our collaborators may sub-license or abandon drug candidates or we may have disagreements with our collaborators, which would cause associated product development to slow or cease. There can be no assurance that our current strategic alliances will be successful, and we may require significant time to secure new strategic alliances because we need to effectively market the benefits of our technology to these future alliance partners, which may direct the attention and resources of our research and development personnel and management away from our primary business operations. Further, each strategic alliance arrangement will involve the negotiation of terms that may be unique to each collaborator. These business development efforts may not result in a strategic alliance or may result in unfavorable arrangements.

Table of Contents

Under typical collaboration agreements, we would expect to receive revenue for our selective kinase inhibitors based on achievement of specific development, sales or regulatory approval milestones, as well as royalties based on a percentage of sales of the commercialized products. Achieving these milestones will depend, in part, on the efforts of our partner as well as our own. If we, or any alliance partner, fail to meet specific milestones, then the strategic alliance may be terminated, which could reduce our revenue.

The third-party vendors upon whom we rely for the supply of the active pharmaceutical ingredient, drug product and drug substance used in our drug candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business.

The active pharmaceutical ingredients, or API, drug product and drug substance used in our drug candidates are supplied to us from third-party vendors. Our ability to successfully develop our drug candidates, and to ultimately supply our commercial drugs in quantities sufficient to meet the market demand, depends in part on our ability to obtain the API, drug product and drug substance for these drugs in accordance with regulatory requirements and in sufficient quantities for commercialization and clinical testing. While we do produce small amounts of API, we do not currently have arrangements in place for a redundant or second-source supply of any such API, drug product or drug substance in the event any of our current suppliers of such API, drug product and drug substance cease their operations for any reason, which may lead to an interruption in our production.

For all of our drug candidates, we intend to identify and qualify additional manufacturers to provide such API, drug product and drug substance prior to submission of an NDA to the FDA and/or CFDA. We are not certain, however, that our current suppliers will be able to meet our demand for their products, either because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those suppliers. It may be difficult for us to assess their ability to timely meet our demand in the future based on past performance. While our suppliers have generally met our demand for their products on a timely basis in the past, they may subordinate our needs in the future to their other customers.

Establishing additional or replacement suppliers for the API, drug product and drug substance used in our drug candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory approval, which could result in further delay. While we seek to maintain adequate inventory of the API, drug product and drug substance used in our drug candidates, any interruption or delay in the supply of components or materials, or our inability to obtain such API, drug product and drug substance from alternate sources at acceptable prices in a timely manner could impede, delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects.

We and our collaborators rely, and expect to continue to rely, on third parties to conduct certain of our clinical trials for our drug candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be harmed.

We do not have the ability to independently conduct large-scale clinical trials. We and our collaboration partners rely, and expect to continue to rely, on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct or otherwise support certain clinical trials for our drug candidates. Nevertheless, we and our collaboration partners (as applicable) will be responsible for ensuring that each clinical trial is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and reliance on CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of clinical trials for our drug candidates, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.

Table of Contents

Although we or our collaboration partners design the clinical trials for our drug candidates, CROs conduct most of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct clinical trials results in less control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:

•: have staffing difficulties;
•: fail to comply with contractual obligations;
•: experience regulatory compliance issues;
•: undergo changes in priorities or become financially distressed; or
•: form relationships with other entities, some of which may be our competitors.

These factors may materially and adversely affect the willingness or ability of third parties to conduct our and our collaboration partners' clinical trials and may subject us or them to unexpected cost increases that are beyond our or their control.

If any of our and our collaboration partners' relationships with these third-party CROs terminate, we or they may not be able to enter into arrangements with alternative CROs on reasonable terms or at all. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such CROs are associated with may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, we believe that our financial results and the commercial prospects for our drug candidates in the subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed.

We, our collaboration partners or our CROs may fail to comply with the regulatory requirements pertaining to clinical trials, which could result in fines, adverse publicity and civil or criminal sanctions.

We, our collaboration partners and our CROs are required to comply with regulations for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the CFDA and comparable foreign regulatory authorities for any drugs in clinical development. In the United States, the FDA regulates GCP through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we, our collaboration partners or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require additional clinical trials before approving the marketing applications for the relevant drug candidate. We cannot assure you that, upon inspection, the FDA or other applicable regulatory authority will determine that any of the future clinical trials for our drug candidates will comply with GCPs. In addition, clinical trials must be conducted with drug candidates produced under applicable GMP regulations. Our failure or the failure of our collaboration partners or CROs to comply with these regulations may require us or them to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action. We are also required to register applicable clinical trials and post certain results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil sanctions.

Table of Contents

Joint ventures form an important part of our Commercial Platform business, and our ability to manage and develop the businesses conducted by these joint ventures depends in part on our relationship with our joint venture partners.

We are party to joint venture agreements with each of Shanghai Pharmaceuticals, Guangzhou Baiyunshan, Sinopharm and Hain Celestial, which together form an important part of our Commercial Platform business. Under these arrangements, our joint venture partners have certain operational responsibilities and/or certain rights to exercise control or influence over operations and decision-making.

Our equity interests in these operating companies do not provide us with the ability to control actions which require shareholder approval. In addition, under the joint venture contracts for these entities, the consent of the directors nominated by our joint venture partners is required for the passing of resolutions in relation to certain matters concerning the operations of these companies. As a result, although we participate in the management, and in the case of Sinopharm and Shanghai Pharmaceuticals nominate the management and run the day-to-day operations, we may not be able to secure the consent of our joint venture partners to pursue activities or strategic objectives that are beneficial to or that facilitate our overall business strategies. With respect to Hutchison Baiyunshan, which is a jointly controlled and managed joint venture where we share the ability to appoint the general manager with our partner Guangzhou Baiyunshan, with each of us having a rotating four-year right, we rely on our relationship with our partner, and our ability to manage the day-to-day operations of this joint venture is more limited. To the extent Guangzhou Baiyunshan does not, for example, diligently perform its responsibilities with respect to any aspect of Hutchison Baiyunshan's operations, agree with or cooperate in the implementation of any plans we may have for Hutchison Baiyunshan's business in the future or take steps to ensure that Hutchison Baiyunshan is in compliance with applicable laws and regulations, our business and ability to comply with legal, regulatory and financial reporting requirements which will apply to us as a public company, as well as the results of this joint venture, could be materially and adversely affected. Furthermore, disagreements or disputes which arise between us and our joint venture partners may potentially require legal action to resolve and hinder the smooth operation of our Commercial Platform business or adversely affect our financial condition, results of operations and prospects.

We and our joint ventures rely on our distributors for logistics and distribution services for our Commercial Platform business.

We and our joint ventures rely on distributors to perform certain operational activities, including invoicing, logistics and delivery of the products we and they market to the end customers. Because we and our joint ventures rely on third-party distributors, we have less control than if we handled distribution logistics directly and can be adversely impacted by the actions of our distributors. Any disruption of our distribution network, including failure to renew existing distribution agreements with desired distributors, could negatively affect our ability to effectively sell our products and materially and adversely affect the business, financial condition and results of operations of us and our joint ventures.

There is no assurance that the benefits currently enjoyed by virtue of our association with CK Hutchison will continue to be available.

Historically, we have relied on the reputation and experience of, and support provided by, our founding shareholder, Hutchison Whampoa Limited (a wholly owned subsidiary of CK Hutchison), to advance our joint ventures and collaborations in China and elsewhere. CK Hutchison is a Hong Kong-based, multinational conglomerate with operations in over 50 countries. CK Hutchison is the ultimate parent company of Hutchison Healthcare Holdings Limited, which as of March 1, 2018, owns 60.4% of our total outstanding share capital. We believe that CK Hutchison group's reputation in China has given us an advantage in negotiating collaborations and obtaining opportunities.

We also benefit from sharing certain services with the CK Hutchison group including, among others, legal and regulatory services, company secretarial support services, tax and internal audit services, shared

Table of Contents

use of accounting software system and related services, participation in the CK Hutchison group's pension, medical and insurance plans, participation in the CK Hutchison group's procurement projects with third-party vendors/suppliers, other staff benefits and staff training services, company functions and activities and operation advisory and support services. We pay a management fee to an affiliate of CK Hutchison for the provision of such services. In the years ended December 31, 2015, 2016 and 2017, we paid a management fee of approximately $845,000, $874,000 and $897,000, respectively. In addition, we benefit from the fact that two retail chains affiliated with the CK Hutchison group, PARKnSHOP and Watsons, sell certain of our Commercial Platform products in their stores throughout Hong Kong and in other Asian countries. For the years ended December 31, 2015, 2016 and 2017, sales of our products to members of the CK Hutchison group amounted to $8.1 million, $9.8 million and $8.5 million, respectively.

Our business also depends on certain intellectual property rights licensed to us by the CK Hutchison group. See "—Risks Related to Intellectual Property—We and our joint ventures are dependent on trademark and other intellectual property rights licensed from others. If we lose our licenses for any of our products, we or our joint ventures may not be able to continue developing such products or may be required to change the way we market such products" for more information on risks associated with such intellectual property licensed to us.

There can be no assurance the CK Hutchison group will continue to provide the same benefits or support that they have provided to our business historically. Such benefit or support may no longer be available to us, in particular, if CK Hutchison's ownership interest in our company significantly decreases in the future.

Other Risks and Risks Related to Doing Business in China

We and our joint ventures may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act, or FCPA, the Bribery Act 2010 of the Parliament of the United Kingdom, or U.K. Bribery Act, and Chinese anti-corruption laws, and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.

In the day-to-day conduct of our business, we and our joint ventures are in frequent contact with persons who may be considered government officials under applicable anti-corruption, anti-bribery and anti-kickback laws, and therefore, we and our joint ventures are subject to risk of violations under the FCPA, the U.K. Bribery Act, and other laws in the countries where we do business. We and our joint ventures have operations, agreements with third parties and we and our joint ventures make most of our sales in China. The PRC also strictly prohibits bribery of government officials. Our and our joint ventures' activities in China create the risk of unauthorized payments or offers of payments by the directors, employees, representatives, distributors, consultants or agents of our company or our joint ventures, even though they may not always be subject to our control.

It is our policy to implement safeguards to discourage these practices by our and our joint ventures' employees. We have implemented and adopted policies designed by the R&D-based Pharmaceutical Association Committee, an industry association representing 40 global biopharmaceutical companies, to ensure compliance by us and our joint ventures and our and their directors, officers, employees, representatives, distributors, consultants and agents with the anti-corruption laws and regulations. We cannot assure you, however, that our existing safeguards are sufficient or that our or our joint ventures' directors, officers, employees, representatives, distributors, consultants and agents have not engaged and will not engage in conduct for which we may be held responsible, nor can we assure you that our business partners have not engaged and will not engage in conduct that could materially affect their ability to perform their contractual obligations to us or even result in our being held liable for such conduct. Violations of the FCPA, the U.K. Bribery Act or Chinese anti-corruption laws may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could have a material adverse effect on our business, reputation financial condition, cash flows and results of operations.

Table of Contents

Ensuring that our and our joint ventures' future business arrangements with third parties comply with applicable laws could also involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our or our joint ventures' operations were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment and exclusion from government funded healthcare programs, any of which could substantially disrupt our operations. If the physicians, hospitals or other providers or entities with whom we and our joint ventures do business are found not to be in compliance with applicable laws, they may also be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.

If we or our joint ventures fail to comply with environmental, health and safety laws and regulations, we or they could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We and our joint ventures are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemical materials. Our operations also produce hazardous waste products. We and our joint ventures are therefore subject to PRC laws and regulations concerning the discharge of waste water, gaseous waste and solid waste during our manufacturing processes. We and our joint ventures are required to establish and maintain facilities to dispose of waste and report the volume of waste to the relevant government authorities, which conduct scheduled or unscheduled inspections of our facilities and treatment of such discharge. We and our joint ventures may not at all times comply fully with environmental regulations. Any violation of these regulations may result in substantial fines, criminal sanctions, revocations of operating permits, shutdown of our facilities and obligation to take corrective measures. We and our joint ventures generally contract with third parties for the disposal of these materials and waste. We and our joint ventures cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from the use of hazardous materials, we and/or our joint ventures could be held liable for any resulting damages, and any liability could exceed our resources. We and/or our joint ventures also could incur significant costs associated with civil or criminal fines and penalties.

Although we and our joint ventures maintain workers' compensation insurance to cover costs and expenses incurred due to on-the-job injuries to our employees and third-party liability insurance for injuries caused by unexpected seepage, pollution or contamination, this insurance may not provide adequate coverage against potential liabilities. Furthermore, the PRC government may take steps towards the adoption of more stringent environmental regulations. Due to the possibility of unanticipated regulatory or other developments, the amount and timing of future environmental expenditures may vary substantially from those currently anticipated. If there is any unanticipated change in the environmental regulations, we and our joint ventures may need to incur substantial capital expenditures to install, replace, upgrade or supplement our equipment or make operational changes to limit any adverse impact or potential adverse impact on the environment in order to comply with new environmental protection laws and regulations. If such costs become prohibitively expensive, we may be forced to cease certain aspects of our or our joint ventures' business operations.

Product liability claims or lawsuits could cause us or our joint ventures to incur substantial liabilities.

We and our joint ventures face an inherent risk of product liability exposure related to the use of our drug candidates in clinical trials, sales of our or our joint ventures' products or the products we or they license from third parties through our Commercial Platform. If we and our joint ventures cannot

Table of Contents

successfully defend against claims that the use of such drug candidates in our clinical trials or any products sold through our Commercial Platform, including any of our drug candidates which receive regulatory approval, caused injuries, we and our joint ventures could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

•: decreased demand for any products sold through our Commercial Platform;
•: significant negative media attention and reputational damage;
•: withdrawal of clinical trial participants;
•: significant costs to defend the related litigation;
•: substantial monetary awards to trial participants or patients;
•: loss of revenue; and
•: the inability to commercialize any drug candidates that we may develop.

Existing PRC laws and regulations do not require us or our joint ventures to have, nor do we or they, maintain liability insurance to cover product liability claims. We and our joint ventures do not have business liability, or in particular, product liability for each of our drug candidates or certain of our or their products. Any litigation might result in substantial costs and diversion of resources. While we and our joint ventures maintain liability insurance for certain clinical trials, this insurance may not fully cover our potential liabilities. Inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or inhibit the commercialization of products that we or our collaborators develop.

We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.

We are heavily dependent on critical, complex and interdependent information technology systems, including internet-based systems, to support our business processes. Our information technology system security is continuously reviewed, maintained and upgraded in response to possible security breach incidents. Despite the implementation of these measures, our information technology systems and those of third parties with which we contract are vulnerable to damage from external or internal security incidents, breakdowns, malicious intrusions, cybercrimes, including State-sponsored cybercrimes, malware, misplaced or lost data, programming or human errors or other similar events. System failures, accidents or security breaches could cause interruptions in our operations and could result in inappropriately accessed, tampered with, modified or stolen scientific data or a material disruption of our clinical activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. Such event could significantly harm our Innovation Platform's operations, including resulting in the loss of clinical trial data which could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Such events could also lead to the loss of important information such as trade secrets or other intellectual property and could accelerate the development or manufacturing of competing products by third parties. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our research and development programs and the development of our drug candidates could be delayed.

The PRC's economic, political and social conditions, as well as governmental policies, could affect the business environment and financial markets in China, our ability to operate our business, our liquidity and our access to capital.

Substantially all of our and our joint ventures' business operations are conducted in China. Accordingly, our results of operations, financial condition and prospects are subject to a significant degree

Table of Contents

to economic, political and legal developments in China. China's economy differs from the economies of developed countries in many respects, including with respect to the amount of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. While the PRC economy has experienced significant growth in the past 30 years, growth has been uneven across different regions and among various economic sectors of China. The PRC government has implemented various measures to encourage economic development and guide the allocation of resources. Some of these measures benefit the overall PRC economy, but may have a negative effect on us or our joint ventures. For example, our financial condition and results of operations may be adversely affected by government control over capital investments or changes in tax regulations that are applicable to us or our joint ventures. More generally, if the business environment in China deteriorates from the perspective of domestic or international investors, our or our joint ventures' business in China may also be adversely affected.

Uncertainties with respect to the PRC legal system and changes in laws, regulations and policies in China could materially and adversely affect us.

We conduct our business primarily through our subsidiaries and joint ventures in China. PRC laws and regulations govern our and their operations in China. Our subsidiaries and joint ventures are generally subject to laws and regulations applicable to foreign investments in China, which may not sufficiently cover all of the aspects of our or their economic activities in China. In particular, some laws, particularly with respect to drug price reimbursement, are relatively new, and because of the limited volume of published judicial decisions and their non-binding nature, the interpretation and enforcement of these laws and regulations are uncertain. Furthermore, recent regulatory reform in the China pharmaceutical industry will limit the number of distributors allowed between a manufacturer and each hospital to one, which may limit the rate of sales growth of Hutchison Sinopharm in future periods. In addition, the implementation of laws and regulations may be in part based on government policies and internal rules that are subject to the interpretation and discretion of different government agencies (some of which are not published on a timely basis or at all) that may have a retroactive effect. As a result, we may not be aware of our, our collaboration partners' or our joint ventures' violation of these policies and rules until sometime after the violation. In addition, any litigation in China, regardless of outcome, may be protracted and result in substantial costs and diversion of resources and management attention.

For further information regarding government regulation in China and other jurisdictions, see Item 4.B. "Business Overview—Regulation—Government Regulation of Pharmaceutical Product Development and Approval—PRC Regulation of Pharmaceutical Product Development and Approval," "Business Overview—Regulation—Coverage and Reimbursement—PRC Coverage and Reimbursement" and "Business Overview—Regulation—Other Healthcare Laws—Other PRC Healthcare Laws."

Restrictions on currency exchange may limit our ability to receive and use our revenue effectively.

Substantially all of our revenue is denominated in renminbi, which currently is not a freely convertible currency. A portion of our revenue may be converted into other currencies to meet our foreign currency obligations, including, among others, payments of dividends declared, if any, in respect of our ordinary shares or ADSs. Under China's existing foreign exchange regulations, our subsidiaries and joint ventures are able to pay dividends in foreign currencies or convert renminbi into other currencies for use in operations without prior approval from the PRC State Administration of Foreign Exchange, or SAFE, by complying with certain procedural requirements. However, we cannot assure you that the PRC government will not take future measures to restrict access to foreign currencies for current account transactions.

Our PRC subsidiaries' and joint ventures' ability to obtain foreign exchange is subject to significant foreign exchange controls and, in the case of amounts under the capital account, requires the approval of and/or registration with PRC government authorities, including the SAFE. In particular, if we finance our PRC subsidiaries or joint ventures by means of foreign debt from us or other foreign lenders, the amount is

Table of Contents

not allowed to exceed either the cross-border financing risk weighted balance calculated based on a formula by the PBOC or the difference between the amount of total investment and the amount of the registered capital as acknowledged by the Ministry of Commerce, or MOFCOM, and the SAFE. Further, such loans must be filed with and registered with the SAFE or their local branches and the National Development and Reform Commission (if applicable). If we finance our PRC subsidiaries or joint ventures by means of additional capital contributions, the amount of these capital contributions must first be filed with the relevant government approval authority. These limitations could affect the ability of our PRC subsidiaries and joint ventures to obtain foreign exchange through debt or equity financing.

Our business benefits from certain PRC government tax incentives. The expiration of, changes to, or our PRC subsidiaries/joint ventures failing to continuously meet the criteria for these incentives could have a material adverse effect on our operating results by significantly increasing our tax expenses.

Certain of our PRC subsidiaries and joint ventures have been successful in their respective applications to renew the special High and New Technology Enterprise, or HNTE, status (since 2005, 2008 or 2014) and/or granted the Technological Advance Service Enterprise, or TASE, status (since 2010) by the relevant PRC authorities. Both of these statuses allow the relevant enterprise to enjoy a reduced Enterprise Income Tax, or EIT, rate at 15% on its taxable profits. The statuses are valid until the end of 2019 (for HNTE, renewal is done every three years) or 2018 (for TASE, renewal is done every three years in general) during which the relevant PRC enterprise must continue to meet the relevant criteria or else the 25% standard EIT rate will be applied from the beginning of the calendar year when the enterprise fails to meet the relevant criteria. In addition, it is unclear whether the HNTE/TASE status and tax incentives under the current policy will continue to be granted after their respective expiration dates. If the rules for such incentives are amended or the statutes are not renewed, higher EIT rates may apply resulting in increased tax burden which will impact our business, financial condition, results of operations and growth prospects.

We may be treated as a resident enterprise for PRC Tax purposes under the PRC EIT Law, and our global income may therefore be subject to PRC income tax.

China's EIT Law and the Regulation on the Implementation of the EIT Law, effective as of January 1, 2008, define the term "de facto management bodies" as "bodies that substantially carry out comprehensive management and control on the business operation, employees, accounts and assets of enterprises." Under the EIT Law, an enterprise incorporated outside of China whose "de facto management bodies" are located in China is considered a "resident enterprise" and will be subject to a uniform 25% EIT rate on its global income. On April 22, 2009, China's State Administration of Taxation, or the SAT, in the Notice Regarding the Determination of Chinese-Controlled Offshore-Incorporated Enterprises as PRC Tax Resident Enterprises on the Basis of De Facto Management Bodies, or Circular 82, further specified certain criteria for the determination of what constitutes "de facto management bodies." If all of these criteria are met, the relevant foreign enterprise may be regarded to have its "de facto management bodies" located in China and therefore be considered a resident enterprise in China. These criteria include: (i) the enterprise's day-to-day operational management is primarily exercised in China; (ii) decisions relating to the enterprise's financial and human resource matters are made or subject to approval by organizations or personnel in China; (iii) the enterprise's primary assets, accounting books and records, company seals, and board and shareholders' meeting minutes are located or maintained in China; and (iv) 50% or more of voting board members or senior executives of the enterprise habitually reside in China. Although Circular 82 only applies to foreign enterprises that are majority-owned and controlled by PRC enterprises, not those owned and controlled by foreign enterprises or individuals, the determining criteria set forth in Circular 82 may be adopted by the PRC tax authorities as the test for determining whether the enterprises are PRC tax residents, regardless of whether they are majority-owned and controlled by PRC enterprises.

Except for our PRC subsidiaries and joint ventures incorporated in China, we believe that none of our entities incorporated outside of China is a PRC resident enterprise for PRC tax purposes. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities, and uncertainties remain with respect to the interpretation of the term "de facto management body."

Table of Contents

If we are treated as a PRC tax resident, dividends distributed by us to our non-PRC shareholders and ADS holders or any gains realized by non-PRC shareholders and ADS holders from the transfer of our shares or ADSs may be subject to PRC tax.

Under the EIT Law, dividends payable by a PRC enterprise to its foreign investor who is a non-PRC resident enterprise, as well as gains on transfers of shares of a PRC enterprise by such a foreign investor will generally be subject to a 10% withholding tax, unless such non-PRC resident enterprise's jurisdiction of tax residency has an applicable tax treaty with the PRC that provides for a reduced rate of withholding tax.

If the PRC tax authorities determine that we should be considered a PRC resident enterprise for EIT purposes, any dividends payable by us to our non-PRC resident enterprise shareholders or ADS holders, as well as gains realized by such investors from the transfer of our shares or ADSs may be subject to a 10% withholding tax, unless a reduced rate is available under an applicable tax treaty. Furthermore, if we are considered a PRC resident enterprise for EIT purposes, it is unclear whether our non-PRC individual shareholders (including our ADS holders) would be subject to any PRC tax on dividends or gains obtained by such non-PRC individual shareholders. If any PRC tax were to apply to dividends or gains realized by non-PRC individuals, it would generally apply at a rate of up to 20% unless a reduced rate is available under an applicable tax treaty. If dividends payable to our non-PRC resident shareholders, or gains from the transfer of our shares or ADSs by such shareholders are subject to PRC tax, the value of your investment in our shares or ADSs may decline significantly.

There is uncertainty regarding the PRC withholding tax rate that will be applied to distributions from our PRC subsidiaries and joint ventures to their respective Hong Kong immediate holding companies, which could have a negative impact on our business.

The EIT Law provides that a withholding tax at the rate of 10% is applicable to dividends payable by a PRC resident enterprise to investors who are "non-resident enterprises" (i.e., that do not have an establishment or place of business in the PRC or that have such establishment or place of business but the relevant dividend is not effectively connected with the establishment or place of business). However, pursuant to the Arrangement between the Mainland of China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with respect to Taxes on Income, or the Arrangement, withholding tax at a reduced rate of 5% may be applicable to dividends payable by PRC resident enterprises to beneficial owners of the dividends that are Hong Kong tax residents if certain requirements are met.

There is uncertainty regarding whether the PRC tax authorities will consider us to be eligible to the reduced tax rate. If the Arrangement is deemed not to apply to dividends payable by our PRC subsidiaries and joint ventures to their respective Hong Kong immediate holding companies that are ultimately owned by us, the withholding tax rate applicable to us will be the statutory rate of 10% instead of 5% which may potentially impact our business, financial condition, results of operations and growth prospects.

We may be treated as a resident enterprise for U.K. corporate tax purposes, and our global income may therefore be subject to U.K. corporation tax.

U.K. resident companies are taxable in the United Kingdom on their worldwide profits. A company incorporated outside of the United Kingdom would be regarded as a resident if its central management and control resides in the United Kingdom. The place of central management and control generally means the place where the high-level strategic decisions of a company are made.

We are an investment holding company incorporated in the Cayman Islands that is listed on the AIM market of the London Stock Exchange. Our central management and control resides in Hong Kong, and therefore we believe that we are not a U.K. resident for corporate tax purposes. However, the tax resident status of a non-resident entity could be challenged by the U.K. tax authorities.

Table of Contents

If the U.K. tax authorities determine that we are a U.K. tax resident, our profits will be subject to U.K. Corporation Tax rate at 19.25%, subject to the potential availability of certain exemptions related to dividend income and capital gains. This may have a material adverse effect on our financial condition and results of operations.

Any failure to comply with PRC regulations regarding our employee equity incentive plans may subject the PRC plan participants or us to fines and other legal or administrative sanctions, which could adversely affect our business, financial condition and results of operations.

In February 2012, the SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies. Based on this regulation, PRC residents who are granted shares or share options by a company listed on an overseas stock market under its employee share option or share incentive plan are required to register with the SAFE or its local counterparts by following certain procedures. We and our employees who are PRC residents and individual beneficial owners who have been granted shares or share options have been subject to these rules due to our listing on the AIM market of the London Stock Exchange and the listing of our ADSs on the Nasdaq Global Select Market. We have registered the option schemes and the share incentive plan and will continue to assist our employees to register their share options or shares. However, any failure of our PRC individual beneficial owners and holders of share options or shares to comply with the SAFE registration requirements in the future may subject them to fines and legal sanctions and may, in rare instances, limit the ability of our PRC subsidiaries to distribute dividends to us.

In addition, the SAT has issued circulars concerning employee share options or restricted shares. Under these circulars, employees working in the PRC who exercise share options, or whose restricted shares vest, will be subject to PRC individual income tax, or IIT. The PRC subsidiaries of an overseas listed company have obligations to file documents related to employee share options or restricted shares with relevant tax authorities and to withhold IIT of those employees related to their share options or restricted shares. Although the PRC subsidiaries currently withhold IIT from the PRC employees in connection with their exercise of share options, if they fail to report and pay the tax withheld according to relevant laws, rules and regulations, the PRC subsidiaries may face sanctions imposed by the tax authorities or other PRC government authorities.

Risks Related to Intellectual Property

If we, our joint ventures or our collaboration partners are unable to protect our or their products and drug candidates through intellectual property rights, our competitors may compete directly against us or them.

Our success depends, in part, on our, our joint venture partners' and our collaboration partners' ability to protect our and our joint ventures' and our collaboration partners' products and drug candidates from competition by establishing, maintaining and enforcing our or their intellectual property rights. We, our joint ventures and our collaboration partners seek to protect the products and technology that we and they consider commercially important by filing PRC and international patent applications, relying on trade secrets or pharmaceutical regulatory protection or employing a combination of these methods. As of December 31, 2017, we had 151 issued patents, including 18 Chinese patents, 19 U.S. patents and eight European patents, 146 patent applications pending in the above major market jurisdictions, and two pending Patent Cooperation Treaty, or PCT, patent applications relating to the drug candidates of our Innovation Platform. Our collaboration partner AstraZeneca is responsible for maintaining and enforcing our intellectual property rights in relation to savolitinib. As of the same date, our joint venture Nutrition Science Partners had 24 issued patents and three pending patent applications relating to HMPL-004 and its reformulation HM004-6599. Additionally, our joint ventures collectively had 119 issued patents and 10 patent applications in China and other jurisdictions relating to our Commercial Platform's products as of December 31, 2017. For more details, see Item 4.B. "Business Overview—Patents and Other Intellectual Property." Patents may become invalid and patent applications may not be granted for a number of

Table of Contents

reasons, including known or unknown prior art, deficiencies in the patent application or the lack of originality of the technology. In addition, the PRC and the United States have adopted the "first-to-file" system under which whoever first files an invention patent application will be awarded the patent. Under the first-to-file system, third parties may be granted a patent relating to a technology which we invented. Furthermore, the terms of patents are finite. The patents we hold and patents to be issued from our currently pending patent applications generally have a twenty-year protection period starting from the date of application.

We, our joint ventures and/or our collaboration partners may become involved in patent litigation against third parties to enforce our or their patent rights, to invalidate patents held by such third parties, or to defend against such claims. A court may refuse to stop the other party from using the technology at issue on the grounds that our or our joint ventures' patents do not cover the third-party technology in question. Further, such third parties could counterclaim that we or our joint ventures infringe their intellectual property or that a patent we, our joint ventures or our collaboration partners have asserted against them is invalid or unenforceable. In patent litigation, defendant counterclaims challenging the validity, enforceability or scope of asserted patents are commonplace. In addition, third parties may initiate legal proceedings against us or our intellectual property to assert such challenges to our intellectual property rights.

The outcome of any such proceeding is generally unpredictable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Patents may be unenforceable if someone connected with prosecution of the patent withheld relevant information or made a misleading statement during prosecution. It is possible that prior art of which we, our joint ventures or our collaboration partners and the patent examiner were unaware during prosecution exists, which could render our or their patents invalid. Moreover, it is also possible that prior art may exist that we, our joint ventures or our collaboration partners are aware of but do not believe is relevant to our or their current or future patents, but that could nevertheless be determined to render our patents invalid. The cost to us or our joint ventures of any patent litigation or similar proceeding could be substantial, and it may consume significant management time. We and our joint ventures do not maintain insurance to cover intellectual property infringement.

An adverse result in any litigation proceeding could put one or more of our or our joint ventures' patents at risk of being invalidated or interpreted narrowly. If a defendant were to prevail on a legal assertion of invalidity or unenforceability of our patents covering one of our or our joint ventures' products or our drug candidates, we could lose at least part, and perhaps all, of the patent protection covering such product or drug candidate. Competing drugs may also be sold in other countries in which our or our joint ventures' patent coverage might not exist or be as strong. If we lose a foreign patent lawsuit, alleging our or our joint ventures' infringement of a competitor's patents, we could be prevented from marketing our drugs in one or more foreign countries. Any of these outcomes would have a materially adverse effect on our business.

Intellectual property and confidentiality legal regimes in China may not afford protection to the same extent as in the United States or other countries. Implementation and enforcement of PRC intellectual property laws may be deficient and ineffective. Policing unauthorized use of proprietary technology is difficult and expensive, and we or our joint ventures may need to resort to litigation to enforce or defend patents issued to us or them or to determine the enforceability, scope and validity of our proprietary rights or those of others. The experience and capabilities of PRC courts in handling intellectual property litigation varies, and outcomes are unpredictable. Further, such litigation may require a significant expenditure of cash and may divert management's attention from our or our joint ventures' operations, which could harm our business, financial condition and results of operations. An adverse determination in any such litigation could materially impair our or our joint ventures' intellectual property rights and may harm our business, prospects and reputation.

Table of Contents

Developments in patent law could have a negative impact on our business.

From time to time, authorities in the United States, China and other government authorities may change the standards of patentability, and any such changes could have a negative impact on our business.

For example, in the United States, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a "first-to-invent" system to a "first-to-file" system, changes to the way issued patents are challenged, and changes to the way patent applications are disputed during the examination process. As a result of these changes, patent law in the United States may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. The U.S. Patent and Trademark Office, or USPTO, has developed new and untested regulations and procedures to govern the full implementation of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions became effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any, impact the America Invents Act will have on the cost of prosecuting our or our joint ventures' patent applications and our or their ability to obtain patents based on our or our joint ventures' discoveries and to enforce or defend any patents that may issue from our or their patent applications, all of which could have a material adverse effect on our business.

If we are unable to maintain the confidentiality of our and our joint ventures' trade secrets, the business and competitive position of ourselves and our joint ventures may be harmed.

In addition to the protection afforded by patents and the PRC's State Secret certification, we and our joint ventures rely upon unpatented trade secret protection, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our and our joint ventures' proprietary technology and processes, in part, by entering into confidentiality agreements with our and their collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our and their consultants and employees. We and our joint ventures may not be able to prevent the unauthorized disclosure or use of our or their technical know-how or other trade secrets by the parties to these agreements, however, despite the existence generally of confidentiality agreements and other contractual restrictions. If any of the collaborators, scientific advisors, employees and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we and our joint ventures may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Enforcing a claim that a third-party illegally obtained and is using our or our joint ventures' trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts in China and other jurisdictions outside the United States are sometimes less prepared or willing to protect trade secrets.

Our and our joint ventures' trade secrets could otherwise become known or be independently discovered by our or their competitors. For example, competitors could purchase our drugs and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our or our joint ventures' trade secrets were to be lawfully obtained or independently developed by a competitor, we and our joint ventures would have no right to prevent them, or others to whom they communicate it, from using that technology or information to compete against us or our joint ventures. If our or our joint ventures' trade secrets are unable to adequately protect our business against competitors' drugs, our competitive position could be adversely affected, as could our business.

Table of Contents

We and our joint ventures are dependent on trademark and other intellectual property rights licensed from others. If we lose our licenses for any of our products, we or our joint ventures may not be able to continue developing such products or may be required to change the way we market such products.

We and our joint ventures are parties to licenses that give us or them rights to third-party intellectual property that are necessary or useful for our or our joint ventures' businesses. In particular, the "Hutchison," "Chi-Med" and "China-MediTech" brands, among others, have been licensed to us by Hutchison Whampoa Enterprises Limited, an affiliate of our majority shareholder, Hutchison Healthcare Holdings Limited. Hutchison Whampoa Enterprises Limited grants us a royalty-free, worldwide license to such brands. Hutchison Whampoa Enterprises Limited has the right to terminate the license during the 12-month period following each time the interest of Hutchison Whampoa Limited, an indirect shareholder of Hutchison Healthcare Holdings Limited, in us is reduced below 50%, 40%, 30% or 20%. Currently, Hutchison Whampoa Limited's interest in our company is less than 20%, but we do not anticipate that Hutchison Whampoa Enterprises Limited will terminate such license in the foreseeable future. In addition, the "Baiyunshan" brand, which is a key brand used by Hutchison Baiyunshan on its products, has been licensed to Hutchison Baiyunshan by our joint venture partner, Guangzhou Baiyunshan, for use during the 50-year joint venture period; however, Guangzhou Baiyunshan has the right to terminate the license if its interest in Hutchison Baiyunshan falls below 50%. If any such license is terminated, our or Hutchison Baiyunshan's business, and our or their positioning in the Chinese market and our financial condition, results of operations and prospects may be materially and adversely affected.

In some cases, our licensors have retained the right to prosecute and defend the intellectual property rights licensed to us or our joint ventures. We depend in part on the ability of our licensors to obtain, maintain and enforce intellectual property protection for such licensed intellectual property. Such licensors may not successfully maintain their intellectual property, may determine not to pursue litigation against other companies that are infringing on such intellectual property, or may pursue litigation less aggressively than we or our joint ventures would. Without protection for the intellectual property we or our joint ventures license, other companies might be able to offer substantially identical products or branding, which could adversely affect our competitive business position and harm our business prospects.

If our or our joint ventures' products or drug candidates infringe the intellectual property rights of third parties, we and they may incur substantial liabilities, and we and they may be unable to sell these products.

Our commercial success depends significantly on our and our joint ventures' ability to operate without infringing the patents and other proprietary rights of third parties. In the PRC, invention patent applications are generally maintained in confidence until their publication 18 months from the filing date. The publication of discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the underlying discoveries were made and invention patent applications are filed. Even after reasonable investigation, we may not know with certainty whether any third-party may have filed a patent application without our knowledge while we or our joint ventures are still developing or producing that product. While the success of pending patent applications and applicability of any of them to our or our joint ventures' programs are uncertain, if asserted against us or them, we could incur substantial costs and we or they may have to:

•: obtain licenses, which may not be available on commercially reasonable terms, if at all;
•: redesign products or processes to avoid infringement; and
•: stop producing products using the patents held by others, which could cause us or them to lose the use of one or more of our or their products.

Table of Contents

To date, we and our joint ventures have not received any material claims of infringement by any third parties. If a third-party claims that we or our joint ventures infringe its proprietary rights, any of the following may occur:

•: we or our joint ventures may have to defend litigation or administrative proceedings that may be costly whether we or they win or lose, and which could result in a substantial diversion of management resources;
•: we or our joint ventures may become liable for substantial damages for past infringement if a court decides that our technology infringes a third-party's intellectual property rights;
•: a court may prohibit us or our joint ventures from producing and selling our or their product(s) without a license from the holder of the intellectual property rights, which may not be available on commercially acceptable terms, if at all; and
•: we or our joint ventures may have to reformulate product(s) so that it does not infringe the intellectual property rights of others, which may not be possible or could be very expensive and time consuming.

Any costs incurred in connection with such events or the inability to sell our or our joint ventures' products may have a material adverse effect on our business and results of operations.

We, our joint ventures and our collaboration partners may not be able to effectively enforce our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on our or our joint venture's products or drug candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly in developing countries. Moreover, our, our joint ventures' or our collaboration partners' ability to protect and enforce our or their intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, the patent laws of some foreign countries do not afford intellectual property protection to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, may not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us or our joint ventures to stop the infringement of our or their patents or the misappropriation of our or their other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our or our joint ventures' inventions throughout the world. Competitors may use our or our joint ventures' technologies in jurisdictions where we or they have not obtained patent protection to develop their own drugs and, further, may export otherwise infringing drugs to territories where we or our joint ventures have patent protection, if our, our joint ventures' or our collaboration partners' ability to enforce our or their patents to stop infringing activities is inadequate. These drugs may compete with our drug candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Proceedings to enforce our or our joint ventures' patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our or their efforts and resources from other aspects of our and their businesses. While we intend to protect our intellectual property rights in the major markets for our drug candidates, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our drug candidates. Furthermore, as AstraZeneca is responsible for enforcing our intellectual property rights with respect to savolitinib on our behalf, we may be unable to ensure that such rights are enforced or maintained in all jurisdictions. Accordingly, our efforts to protect the intellectual property rights of our drug candidates in such countries may be inadequate.

Table of Contents

We and our joint ventures may be subject to damages resulting from claims that we or they, or our or their employees, have wrongfully used or disclosed alleged trade secrets of competitors or are in breach of non-competition or non-solicitation agreements with competitors.

We and our joint ventures could in the future be subject to claims that we or they, or our or their employees, have inadvertently or otherwise used or disclosed alleged trade secrets or other proprietary information of former employers or competitors. Although we try to ensure that our and our joint ventures' employees and consultants do not improperly use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us or our joint ventures, we or our joint ventures may in the future be subject to claims that we or they caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we, our joint ventures, or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. Litigation may be necessary to defend against these claims. Even if we and our joint ventures are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If our or our joint ventures' defenses to these claims fail, in addition to requiring us and them to pay monetary damages, a court could prohibit us or our joint ventures from using technologies or features that are essential to our or their products or our drug candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate such technologies or features would have a material adverse effect on our business, and may prevent us from successfully commercializing our drug candidates. In addition, we or our joint ventures may lose valuable intellectual property rights or personnel as a result of such claims. Moreover, any such litigation or the threat thereof may adversely affect our or our joint ventures' ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our drug candidates, which would have an adverse effect on our business, results of operations and financial condition.

Risks Related to Our ADSs

Certain shareholders own a significant percentage of our ordinary shares, which limits the ability of other shareholders to influence corporate matters.

As of March 1, 2018, Hutchison Healthcare Holdings Limited owns approximately 60.4% of our ordinary shares. Accordingly, Hutchison Healthcare Holdings Limited has a significant influence over the outcome of any corporate transaction or other matter submitted to shareholders for approval and the interests of Hutchison Healthcare Holdings Limited may differ from the interests of our other shareholders. Because we are incorporated in the Cayman Islands, certain matters, such as amendments to our memorandum and articles of association, require approval of at least two-thirds of our shareholders by law subject to higher thresholds which we may set in our memorandum and articles of association. Therefore, Hutchison Healthcare Holdings Limited's approval will be required to achieve any such threshold. In addition, Hutchison Healthcare Holdings Limited will have a significant influence over the management and the strategic direction of our company.

Substantial future sales or perceived potential sales of our ADSs, ordinary shares or other equity or equity-linked securities in the public market could cause the price of our ADSs to decline significantly.

Sales of our ADSs, ordinary shares or other equity or equity-linked securities in the public market, or the perception that these sales could occur, could cause the market price of our ADSs to decline significantly. All of our ordinary shares represented by ADSs are freely transferable by persons other than our affiliates without restriction or additional registration under the Securities Act of 1933, or the Securities Act. The ordinary shares held by our affiliates are also available for sale, subject to volume and other restrictions as applicable under Rules 144 and 701 under the Securities Act, under sales plans adopted pursuant to Rule 10b5-1 or otherwise.

Table of Contents

We have filed with the SEC a Registration Statement on Form F-3, commonly referred to as a "shelf registration," that permits us to sell any number of ADSs in a registered offering at our discretion. The shelf registration was automatically effective as of the filing date, April 3, 2017. On October 30, 2017, we completed a registered offering of 11,369,810 ADSs under the shelf registration statement, raising total gross proceeds of approximately $301.3 million. We may decide to conduct future offerings from time to time, and such sales could cause the price of our ADSs to decline significantly.

We may be at an increased risk of securities class action litigation.

Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant share price volatility in recent years. If we were to be sued, it could result in substantial costs and a diversion of management's attention and resources, which could harm our business.

If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our business, the price of our ADSs could decline.

The trading market for our ADSs will rely in part on the research and reports that industry or financial analysts publish about us or our business. We may never obtain research coverage by industry or financial analysts. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.

As a foreign private issuer, we are not subject to certain U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit the information publicly available to our shareholders.

As a foreign private issuer we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act and therefore there may be less publicly available information about us than if we were a U.S. domestic issuer. For example, we are not subject to the proxy rules in the United States and disclosure with respect to our annual general meetings will be governed by the AIM Rules for Companies, or the AIM Rules, and Cayman Islands requirements. In addition, our officers, directors and principal shareholders are exempt from the reporting and "short-swing" profit recovery provisions of Section 16 of the Exchange Act and the rules thereunder. Therefore, our shareholders may not know on a timely basis when our officers, directors and principal shareholders purchase or sell our ordinary shares or ADSs.

As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with corporate governance listing standards.

As a foreign private issuer, we are permitted to take advantage of certain provisions in the Nasdaq listing rules that allow us to follow Cayman Islands law for certain governance matters. Certain corporate governance practices in the Cayman Islands may differ significantly from corporate governance listing standards as, except for general fiduciary duties and duties of care, Cayman Islands law has no corporate governance regime which prescribes specific corporate governance standards. We intend to continue to follow Cayman Islands corporate governance practices in lieu of the corporate governance requirements of the Nasdaq Global Select Market in respect of the following: (i) the majority independent director requirement under Section 5605(b)(1) of the Nasdaq listing rules, (ii) the requirement under Section 5605(d) of the Nasdaq listing rules that a remuneration committee comprised solely of independent directors governed by a remuneration committee charter oversee executive compensation and (iii) the requirement under Section 5605(e) of the Nasdaq listing rules that director nominees be selected

Table of Contents

or recommended for selection by either a majority of the independent directors or a nominations committee comprised solely of independent directors. Cayman Islands law does not impose a requirement that our board of directors consist of a majority of independent directors. Nor does Cayman Islands law impose specific requirements on the establishment of a remuneration committee or nominating committee or nominating process. Therefore, our shareholders may be afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic issuers. We have voluntarily complied with, and plan to continue to comply with for the foreseeable future, the principles of the U.K. Corporate Governance Code published by the U.K. Financial Reporting Council which guides certain of our other corporate governance practices. See Item 6.C. "Board Practice—U.K. Corporate Governance Code" for more details.

We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses.

As discussed above, we are a foreign private issuer, and therefore, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act. The determination of foreign private issuer status is made annually on the last business day of an issuer's most recently completed second fiscal quarter, and, accordingly, the next determination will be made with respect to us on June 30, 2018. We would lose our foreign private issuer status if, for example, more than 50% of our ordinary shares are directly or indirectly held by residents of the United States on June 30, 2018 and we fail to meet additional requirements necessary to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms beginning on January 1, 2019, which are more detailed and extensive than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance requirements under the Nasdaq listing rules. As a U.S.-listed public company that is not a foreign private issuer, we will incur significant additional legal, accounting and other expenses that we will not incur as a foreign private issuer.

Certain audit reports included in this annual report were prepared by an auditor who is not inspected by the U.S. Public Company Accounting Oversight Board, or the PCAOB, and as such, you are deprived of the benefits of such inspection.

Auditors of companies that are registered with the SEC and traded publicly in the United States, including the independent registered public accounting firm of our company, must be registered with the PCAOB, and are required by the laws of the United States to undergo regular inspections by the PCAOB to assess their compliance with the laws of the United States and professional standards. Because we have substantial operations within the PRC, a jurisdiction where the PCAOB is currently unable to conduct inspections without the approval of the Chinese authorities, our auditor and the auditors of our joint ventures are not currently inspected by the PCAOB.

In May 2013, the PCAOB announced that it had entered into a Memorandum of Understanding on Enforcement Cooperation with the China Securities Regulatory Commission, or CSRC, and the Ministry of Finance, or MOF, which establishes a cooperative framework between the parties for the production and exchange of audit documents relevant to investigations undertaken by the PCAOB, the CSRC, or the MOF in the United States and the PRC, respectively. The PCAOB continues to be in discussions with the CSRC and the MOF to permit joint inspections in the PRC of audit firms that are registered with PCAOB and audit Chinese companies that trade on U.S. exchanges.

This lack of PCAOB inspections in China prevents the PCAOB from regularly evaluating audits and quality control procedures of any auditors operating in China, including our auditor and the auditors of

Table of Contents

our joint ventures. As a result, investors may be deprived of the benefits of PCAOB inspections. The inability of the PCAOB to conduct inspections of auditors in China makes it more difficult to evaluate the effectiveness of our auditor's audit procedures or quality control procedures as compared to auditors outside of China that are subject to PCAOB inspections. Investors may lose confidence in our reported financial information and procedures and the quality of our financial statements.

We do not currently intend to pay dividends on our securities, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of the ADSs.

We have never declared or paid any dividends on our ordinary shares. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your ADSs at least in the near term, and the success of an investment in ADSs will depend upon any future appreciation in its value. Consequently, investors may need to sell all or part of their holdings of ADSs after price appreciation, which may never occur, to realize any future gains on their investment. There is no guarantee that the ADSs will appreciate in value or even maintain the price at which our shareholders have purchased the ADSs.

The market price for our ADSs may be volatile which could result in substantial loss to you.

The market price of our ADSs has been volatile. From March 17, 2016 to March 1, 2018, the closing sale price of our ADSs ranged from a high of $41.14 to a low of $11.26 per ADS.

The market price for our ADSs is likely to be highly volatile and subject to wide fluctuations in response to factors, including the following:

•: announcements of competitive developments;
•: regulatory developments affecting us, our customers or our competitors;
•: announcements regarding litigation or administrative proceedings involving us;
•: actual or anticipated fluctuations in our period-to-period operating results;
•: changes in financial estimates by securities research analysts;
•: additions or departures of our executive officers;
•: release or expiry of lock-up or other transfer restrictions on our outstanding ordinary shares or ADSs; and
•: sales or perceived sales of additional ordinary shares or ADSs.

In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are not related to the operating performance of particular companies. For example, since August 2008, multiple exchanges in the United States and other countries and regions, including China, experienced sharp declines in response to the growing credit market crisis and the recession in the United States. As recently as July 2015, the exchanges in China experienced a sharp decline. Prolonged global capital markets volatility may affect overall investor sentiment towards our ADSs, which would also negatively affect the trading prices for our ADSs.

The dual listing of our ordinary shares and the ADSs may adversely affect the liquidity and value of the ADSs.

Our ordinary shares continue to be listed on the AIM market of the London Stock Exchange. The dual listing of our ordinary shares and the ADSs may dilute the liquidity of these securities in one or both markets and may adversely affect the development of an active trading market for the ADSs in the United States. The price of the ADSs could also be adversely affected by trading in our ordinary shares on the AIM market. Furthermore, our ordinary shares trade on the AIM market of the London Stock Exchange

Table of Contents

in the form of depository interests, each of which is an electronic book-entry interest representing one of our ordinary shares. However, the ADSs are backed by physical ordinary share certificates, and the depositary for our ADS program is unable to accept depository interests into its custody in order to issue ADSs. As a result, if an ADS holder wishes to cancel its ADSs and instead hold depository interests for trading on the AIM market or vice versa, the issuance and cancellation process may be longer than if the depositary could accept such depository interests.

Although our ordinary shares continue to be listed on the AIM market following our initial public offering in the United States completed in March 2016, we may decide at some point in the future to propose to our ordinary shareholders to delist our ordinary shares from the AIM market, and our ordinary shareholders may approve such delisting. We cannot predict the effect such delisting of our ordinary shares on the AIM market would have on the market price of the ADSs on the Nasdaq Global Select Market.

Fluctuations in the exchange rate between the U.S. dollar and the pound sterling may increase the risk of holding the ADSs.

Our share price is quoted on the AIM market of the London Stock Exchange in pence sterling, while the ADSs will trade on Nasdaq in U.S. dollars. Fluctuations in the exchange rate between the U.S. dollar and the pound sterling may result in temporary differences between the value of the ADSs and the value of our ordinary shares, which may result in heavy trading by investors seeking to exploit such differences. In addition, as a result of fluctuations in the exchange rate between the U.S. dollar and the pound sterling, the U.S. dollar equivalent of the proceeds that a holder of the ADSs would receive upon the sale in the United Kingdom of any shares withdrawn from the depositary and the U.S. dollar equivalent of any cash dividends paid in pound sterling on our shares represented by the ADSs could also decline.

Fluctuations in the value of the renminbi may have a material adverse effect on your investment.

The value of the renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions. On July 21, 2005, the PRC government changed its decade-old policy of pegging the value of the renminbi to the U.S. dollar, and the renminbi appreciated more than 20% against the U.S. dollar over the following three years. Between July 2008 and June 2010, this appreciation halted, and the exchange rate between the renminbi and U.S. dollar remained within a narrow band. In June 2010, China's People's Bank of China, or PBOC, announced that the PRC government would increase the flexibility of the exchange rate, and thereafter allowed the renminbi to appreciate slowly against the U.S. dollar within the narrow band fixed by the PBOC. However, more recently, on August 11, 12 and 13, 2015, the PBOC significantly devalued the renminbi by fixing its price against the U.S. dollar 1.9%, 1.6%, and 1.1% lower than the previous day's value, respectively. In 2016, the renminbi further depreciated against the U.S. dollar by approximately 6.7%, and from January 1, 2017 to December 31, 2017, the renminbi appreciated against the U.S. dollar by 6.0%.

Significant revaluation of the renminbi may have a material adverse effect on your investment. For example, to the extent that we need to convert U.S. dollars into renminbi for our operations, appreciation of the renminbi against the U.S. dollar would have an adverse effect on the renminbi amount we would receive from the conversion. Conversely, if we decide to convert our renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar against the renminbi would have a negative effect on the U.S. dollar amount available to us. In addition, appreciation or depreciation in the value of the renminbi relative to U.S. dollars would affect our financial results reported in U.S. dollar terms regardless of any underlying change in our business or results of operations.

Table of Contents

Very limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert renminbi into foreign currency.

Securities traded on the AIM market of the London Stock Exchange may carry a higher risk than shares traded on other exchanges and may impact the value of your investment.

Our ordinary shares are currently traded on the AIM market of the London Stock Exchange. Investment in equities traded on AIM is perceived by some to carry a higher risk than an investment in equities quoted on exchanges with more stringent listing requirements, such as the New York Stock Exchange or the Nasdaq. This is because the AIM market imposes less stringent ongoing reporting requirements than those other exchanges. You should be aware that the value of our ordinary shares may be influenced by many factors, some of which may be specific to us and some of which may affect AIM-listed companies generally, including the depth and liquidity of the market, our performance, a large or small volume of trading in our ordinary shares, legislative changes and general economic, political or regulatory conditions, and that the prices may be volatile and subject to extensive fluctuations. Therefore, the market price of our ordinary shares underlying the ADSs may not reflect the underlying value of our company.

The depositary for our ADSs gives us a discretionary proxy to vote our ordinary shares underlying your ADSs if you do not vote at shareholders' meetings, except in limited circumstances, which could adversely affect your interests.

Under the deposit agreement for the ADSs, the depositary gives us a discretionary proxy to vote our ordinary shares underlying your ADSs at shareholders' meetings if you do not vote, unless:

•: we do not wish a discretionary proxy to be given;
•: we are aware or should reasonably be aware that there is substantial opposition as to a matter to be voted on at the meeting; or
•: a matter to be voted on at the meeting would materially and adversely affect the rights of shareholders.

The effect of this discretionary proxy is that you cannot prevent our ordinary shares underlying your ADSs from being voted, absent the situations described above, and it may make it more difficult for shareholders to influence the management of our company. Holders of our ordinary shares are not subject to this discretionary proxy.

Holders of ADSs have fewer rights than shareholders and must act through the depositary to exercise their rights.

Holders of our ADSs do not have the same rights as our shareholders and may only exercise the voting rights with respect to the underlying ordinary shares in accordance with the provisions of the deposit agreement. Under our memorandum and articles of association, an annual general meeting and any extraordinary general meeting at which the passing of a special resolution is to be considered may be called with not less than 21 clear days' notice, and all other extraordinary general meetings may be called with not less than 14 clear days' notice. When a general meeting is convened, you may not receive sufficient notice of a shareholders' meeting to permit you to withdraw the ordinary shares underlying your ADSs to allow you to vote with respect to any specific matter. If we ask for your instructions, we will give the depositary notice of any such meeting and details concerning the matters to be voted upon at least 30 days in advance of the meeting date and the depositary will send a notice to you about the upcoming vote and will arrange to deliver our voting materials to you. The depositary and its agents, however, may not be able to send

Table of Contents

voting instructions to you or carry out your voting instructions in a timely manner. We will make all reasonable efforts to cause the depositary to extend voting rights to you in a timely manner, but we cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote the ordinary shares underlying your ADSs. Furthermore, the depositary will not be liable for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, you may not be able to exercise your right to vote and you may lack recourse if your ADSs are not voted as you request. In addition, in your capacity as an ADS holder, you will not be able to call a shareholders' meeting.

You may not receive distributions on our ADSs or any value for them if such distribution is illegal or if any required government approval cannot be obtained in order to make such distribution available to you.

Although we do not have any present plan to pay any dividends, the depositary of our ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities underlying our ADSs, after deducting its fees and expenses and any applicable taxes and governmental charges. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. However, the depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities whose offering would require registration under the Securities Act but is not so properly registered or distributed under an applicable exemption from registration. The depositary may also determine that it is not reasonably practicable to distribute certain property. In these cases, the depositary may determine not to distribute such property. We have no obligation to register under the U.S. securities laws any offering of ADSs, ordinary shares, rights or other securities received through such distributions. We also have no obligation to take any other action to permit the distribution of ADSs, ordinary shares, rights or anything else to holders of ADSs. This means that you may not receive distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline in the value of our ADSs.

Your right to participate in any future rights offerings may be limited, which may cause dilution to your holdings.

We may from time to time distribute rights to our shareholders, including rights to acquire our securities. However, we cannot make rights available to you in the United States unless we register the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. Also, under the deposit agreement, the depositary bank will not make rights available to you unless either both the rights and any related securities are registered under the Securities Act, or the distribution of them to ADS holders is exempted from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. If the depositary does not distribute the rights, it may, under the deposit agreement, either sell them, if possible, or allow them to lapse. Accordingly, you may be unable to participate in our rights offerings and may experience dilution in your holdings.

If we are classified as a passive foreign investment company, U.S. investors could be subject to adverse U.S. federal income tax consequences.

The rules governing passive foreign investment companies, or PFICs, can have adverse effects for U.S. investors for U.S. federal income tax purposes. The tests for determining PFIC status for a taxable year depend upon the relative values of certain categories of assets and the relative amounts of certain kinds of income. As discussed in "Taxation—Material U.S. Federal Income Tax Considerations," we do not believe that we are currently a PFIC. Notwithstanding the foregoing, the determination of whether we are a PFIC

Table of Contents

depends on particular facts and circumstances (such as the valuation of our assets, including goodwill and other intangible assets) and may also be affected by the application of the PFIC rules, which are subject to differing interpretations. The fair market value of our assets is expected to depend, in part, upon (1) the market price of our ordinary shares and ADSs and (2) the composition of our income and assets, which will be affected by how, and how quickly, we spend any cash that is raised in any financing transaction. In light of the foregoing, no assurance can be provided that we are not currently a PFIC or that we will not become a PFIC in any future taxable year. Furthermore, if we are treated as a PFIC, then one or more of our subsidiaries may also be treated as PFICs.

If we are or become a PFIC, and, if so, if one or more of our subsidiaries are treated as PFICs, U.S. holders of our ordinary shares and ADSs would be subject to adverse U.S. federal income tax consequences, such as ineligibility for any preferential tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements under U.S. federal income tax laws and regulations. Whether U.S. holders of our ordinary shares or ADSs make (or are eligible to make) a timely qualified electing fund, or QEF, election or a mark-to-market election may affect the U.S. federal income tax consequences to U.S. holders with respect to the acquisition, ownership and disposition of our ordinary shares and ADSs and any distributions such U.S. holders may receive. We do not, however, expect to provide the information regarding our income that would be necessary in order for a U.S. holder to make a QEF election if we are classified as a PFIC. Investors should consult their own tax advisors regarding all aspects of the application of the PFIC rules to our ordinary shares and ADSs.

You may have difficulty enforcing judgments obtained against us.

We are a company incorporated under the laws of the Cayman Islands, and substantially all of our assets are located outside the United States. Substantially all of our current operations are conducted in the PRC. In addition, most of our directors and officers are nationals and residents of countries other than the United States. A substantial portion of the assets of these persons are located outside the United States. As a result, it may be difficult for you to effect service of process within the United States upon these persons. It may also be difficult for you to enforce in U.S. courts judgments obtained in U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us and our officers and directors, all of whom are not residents in the United States and whose assets are located outside the United States. In addition, there is uncertainty as to whether the courts of the Cayman Islands or the PRC would recognize or enforce judgments of U.S. courts against us or such persons predicated upon the civil liability provisions of the securities laws of the United States or any state.

You may be subject to limitations on transfers of your ADSs.

Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason.

ITEM 4. INFORMATION ON THE COMPANY

A. History and Development of the Company.

Our company was founded in 2000 by Hutchison Whampoa Limited (which in 2015 became a wholly owned subsidiary of CK Hutchison), a Hong Kong based multinational conglomerate with operations in over 50 countries. CK Hutchison is the ultimate parent company of our majority shareholder Hutchison Healthcare Holdings Limited.

Table of Contents

We launched our Innovation Platform in 2002 with the establishment of our subsidiary Hutchison MediPharma. Our Innovation Platform is focused on the discovery and development of small-molecule compounds against novel but relatively well-characterized targets with global first-in-class potential against these targets, as well as compounds against validated targets to potentially be global best-in-class, next-generation therapies with a superior profile compared to existing approved drugs that act against these targets.

In the years since the launch of our Innovation Platform, we have assembled a leading drug research and development team in China to create a large scale and fully-integrated drug discovery and development operation covering chemistry, biology, pharmacology, toxicology, chemistry and manufacturing controls, clinical and regulatory and other functions, which work seamlessly together. Our approach has been to create a stable and supportive environment that allows our research and development team to innovate. We believe we have succeeded in this, and as of December 31, 2017, we and our collaboration partners discussed below have invested about $500 million in the discovery and development activities of our Innovation Platform. This has resulted in a significant clinical pipeline consisting of eight small molecule tyrosine kinase inhibitors, which are currently being investigated in clinical studies in 36 target patient populations around the world.

We have taken a multi-source approach to funding which has been key to our ability to continuously support our Innovation Platform. We completed our initial public offering and listing on the AIM market of the London Stock Exchange in 2006 raising gross proceeds of approximately £40 million (equivalent to approximately $75 million at the prevailing exchange rate at that time). We completed our initial public offering in the United States and listing on the Nasdaq Global Select Market in 2016, raising gross proceeds of approximately $110.2 million, and we completed another underwritten public offering of securities in 2017, raising gross proceeds of approximately $301.3 million. We have also utilized bank facilities in the aggregate principal amount of approximately $30.0 million as of December 31, 2017. In addition, we have received government grants totaling approximately $16.7 million and investments from other parties since our establishment, including investments by Mitsui & Co. Ltd., or Mitsui, one of our shareholders, totaling over $15 million in the aggregate since 2010.

Moreover, to further our research and development activities, we have entered into a number of collaboration agreements for the research, development and commercialization of certain of our drug candidates with leading global pharmaceutical and healthcare companies, including Janssen in 2008 (subsequently terminated in 2015), AstraZeneca in 2011 and Eli Lilly in 2013. In 2012, we also entered into a joint venture collaboration with Nestlé Health Science pursuant to which we share research and development expenses and receive payments for certain services. Under the terms of these collaborations, our partners have made certain upfront, milestone and service fee payments, clinical cost reimbursements and equity contributions, totaling approximately $260.0 million since 2008. In addition to financial support, we benefit from these arrangements by gaining access to our partners' scientific, development, regulatory and commercial capabilities.

Since 2001 to December 31, 2017, we have also developed a profitable Commercial Platform in China, which includes our non-consolidated joint ventures Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan, which have paid out dividends to our company and our partners totaling approximately $316.2 million. Our Commercial Platform encompasses two core areas: Prescription Drugs and Consumer Health products.

Our core Prescription Drugs business is conducted through the following two joint ventures for which we nominate the management and run the day-to-day operations:

•: Shanghai Hutchison Pharmaceuticals, which was formed in 2001 and primarily manufactures, markets and distributes approximately 74 prescription drug products, originally contributed by our joint venture partner, as well as third-party prescription drugs. As of December 31, 2017, it held 74 registered drug licenses in China. 50% of this joint venture is owned by us and 50% by Shanghai

Table of Contents

Pharmaceuticals, a leading pharmaceutical company in China listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange, and

•: Hutchison Sinopharm, which was formed in 2014 and focuses on providing logistics services to and distributing and marketing prescription drugs manufactured by pharmaceutical companies. 51% of this joint venture is owned by us and 49% is owned by Sinopharm, a leading distributor of pharmaceutical and healthcare products and a leading supply chain service provider in China listed on the Hong Kong Stock Exchange.

Through these joint ventures, we have steadily built up an extensive sales and distribution network across China, with approximately 2,300 medical sales representatives as of December 31, 2017. Net income attributable to our company from our Prescription Drugs business was $15.9 million, $61.1 million and $29.0 million for the years ended December 31, 2015, 2016 and 2017, respectively. Net income attributable to our company from our Prescription Drugs business included one-time gains of $40.4 million in 2016, primarily from land compensation received by Shanghai Hutchison Pharmaceuticals from the Shanghai government. In 2017, net income attributable to our company from our Prescription Drugs business included one-time gains of $2.5 million in government subsidies received by Shanghai Hutchison Pharmaceuticals from the Shanghai government.

Our Consumer Health business, which we do not consider to be core to our overall business and strategy, includes two joint ventures: Hutchison Baiyunshan, a joint venture which was formed in 2005 with Guangzhou Baiyunshan and focuses primarily on the manufacture, marketing and distribution of over-the-counter pharmaceutical products in China, and Hutchison Hain Organic, a joint venture which was established in 2009 and markets and distributes a broad range of natural and organic consumer products under brands owned by Hain Celestial in nine Asian territories. We also manufacture and distribute various infant nutrition products. Net income attributable to our company's shareholders from our Consumer Health business subsidiaries and joint ventures decreased marginally from $9.3 million in 2015 to $9.2 million in 2016 and increased by 19.7% to $11.0 million in 2017.

As of December 31, 2017, we were the second largest AIM-listed company in terms of market capitalization.

Table of Contents

Our Organizational Structure

The chart below shows our principal subsidiaries and joint ventures as of March 1, 2018.

Notes:

(1): Employees of Hutchison MediPharma Limited hold the remaining 0.2% shareholding.
(2): Nestlé Health Science S.A. is the other 50% joint venture partner.
(3): Shanghai Pharmaceuticals Holding Co., Ltd. is the other 50% joint venture partner.
(4): Sinopharm Group Co. Ltd. is the other 49% joint venture partner.
(5): Dian Son Development Limited holds the other 20% interest.
(6): Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is the other 50% joint venture partner.
(7): The Hain Celestial Group, Inc. is the other 50% joint venture partner.

Table of Contents

B. Business Overview.

Overview

We are an innovative biopharmaceutical company based in China aiming to become a global leader in the discovery, development and commercialization of targeted therapies for oncology and immunological diseases. Our approximately 360-person strong scientific team has created and developed a deep portfolio of eight drug candidates that are being investigated in active or completed clinical studies in 36 target patient populations around the world. These drug candidates are being developed to treat a wide spectrum of diseases, including solid tumors, hematological malignancies, and cover immunology applications which we believe address significant unmet medical needs and represent large commercial opportunities. Many of these drugs have the potential to be first-in-class or best-in-class. Our success in research and development has led to partnerships with leading global pharmaceutical companies, including AstraZeneca, Eli Lilly and Nestlé Health Science.

For seventeen years, we and our partners have invested about $500 million in building our Innovation Platform. Since inception to December 31, 2017, our Innovation Platform's drug pipeline has dosed over 3,500 patients/subjects in clinical trials of our drug candidates, with over 700 dosed in 2017, primarily driven by the enrollment of the six Phase III studies on savolitinib, fruquintinib, and sulfatinib.

Our core research and development strategy has been to take a highly rigorous and focused cross-disciplinary approach to design uniquely selective small molecule tyrosine kinase inhibitors deliberately engineered to improve drug efficacy and reduce known side effects. Accordingly, we believe our drug candidates such as savolitinib (targeting the mesenchymal epithelial transition factor, or c-Met), HMPL-523 (targeting the spleen tyrosine kinase, or Syk) and HMPL-453 (targeting fibroblast growth factor receptors, or FGFR1/2/3) have the potential to be global first-in-class therapies. In the cases of fruquintinib (targeting vascular endothelial growth factor receptor, or VEGFR 1/2/3), sulfatinib (targeting VEGFR/FGFR1/colony stimulating factor-1 receptor, or CSF-1R), epitinib (targeting epidermal growth factor receptor activating mutations, or EGFRm+, with brain metastasis), theliatinib (targeting EGFR wild-type) and HMPL-689 (targeting phosphoinositide 3-kinase d, or PI3Kd), we believe our drug candidates are sufficiently selective and/or differentiated to be potential global best-in-class, next-generation therapies. We also continue to focus on maximizing patient outcomes through clinical studies involving combinations or rotations of treatment of our drug candidates with other targeted therapies, immuno-oncology agents and chemotherapies.

In June 2017, we completed our first NDA submission, which was for fruquintinib in patients with third-line colorectal cancer in China. We also initiated our first global Phase III study in oncology, for savolitinib in patients with papillary renal cell carcinoma. Each triggered milestone payments from our partners Eli Lilly and AstraZeneca, respectively, and each represents a major achievement for Chi-Med and for the biotechnology industry in China.

In our view, the China oncology market represents a substantial and fast-growing market opportunity expected to be supported by China's increasing emphasis on innovation combined with its rapidly improving regulatory environment. We believe our well-established presence in China, combined with our ability to deliver global-quality innovation, positions us well to address the major unmet medical needs in the China oncology market as well as to identify opportunities for our differentiated assets in the global market.

In addition to our Innovation Platform, we have established a profitable Commercial Platform in China which manufactures, markets and distributes prescription drugs and consumer health products. This Commercial Platform has been built over the past 17 years and focuses on two business areas. The first is our core Prescription Drugs business operated by joint ventures, Shanghai Hutchison Pharmaceuticals and Hutchison Sinopharm, which operate a network of approximately 2,300 medical sales representatives covering about 22,500 hospitals in over 300 cities and towns in China as of December 31, 2017. The second

Table of Contents

is our Consumer Health business primarily operated by our joint venture, Hutchison Baiyunshan, which is a profitable and cash-generating business selling household-name, over-the-counter pharmaceutical products. Our Commercial Platform's total consolidated sales were $205.2 million in 2017, an increase of 13.5% compared to $180.9 million in 2016, mainly resulting from growth in Hutchison Sinopharm's Prescription Drug commercial services business. We and our joint ventures manufacture and sell about 4.6 billion doses of medicines a year, in the aggregate, through our well-established GMP-certified manufacturing bases. We intend to leverage this Commercial Platform to support the launch of products from our Innovation Platform if they are approved for use in China. Outside of China, we intend to commercialize our products, if approved, in the United States, Europe and other major markets on our own and/or through partnerships with leading biopharmaceutical companies.

Our Innovation Platform
Figure 1: Pipeline Chart

Notes: TPP = target patient population (TPP numbers are included for reference throughout the discussion below); Proof-of-concept = Phase Ib/II study (the dashed lines delineate the start and end of Phase Ib); combo = in combination with; brain mets = brain metastasis; VEGFR = vascular endothelial growth factor receptor; TKI = tyrosine kinase inhibitor; EGFR = epidermal growth factor receptor;

Table of Contents

NET = neuroendocrine tumors; ref = refractory, which means resistant to prior treatment; T790M= EGFR resistance mutation; EGFRm+ = EGFR activating mutations; EGFR+ = EGFR gene amplification; EGFR WT = EGFR wild-type; 5ASA = 5-aminosalicylic acids; chemo = chemotherapy; c-Met+ = c-Met gene amplification; c-Met O/E = c-Met over-expression; FGFR = fibroblast growth factor receptor; CSF-1R = colony stimulating factor-1 receptor; NCI = U.S. National Cancer Institute; CCTG = Canadian Cancer Trial Group; Aus = Australia; Can = Canada; SK = South Korea; PRC = People's Republic of China; Sp = Spain; UK = United Kingdom; US = United States; Global = >2 countries.

Overview of Our Clinical-stage Drug Candidates

Savolitinib (AZD6094/HMPL-504)

Savolitinib is a potential global first-in-class inhibitor of the mesenchymal epithelial transition factor, or c-Met, receptor tyrosine kinase, an enzyme which has been shown to function abnormally in many types of solid tumors. We designed savolitinib as a potent and highly selective oral inhibitor which through chemical structure modification addresses renal toxicity, the primary issue that halted development of several other selective c-Met inhibitors. In clinical studies to date, involving over 500 patients, savolitinib has shown promising signs of clinical efficacy and acceptable safety profile in patients with c-Met gene alterations in papillary renal cell carcinoma, non-small cell lung cancer, colorectal cancer, and gastric cancer.

We are currently testing savolitinib in partnership with AstraZeneca in multiple Phase Ib/II studies, both as a monotherapy and in combination with other targeted therapies. In June 2017, we initiated SAVOIR, a global pivotal Phase III, open-label, randomized multi-center registration study of savolitinib in c-Met driven metastatic papillary renal cell carcinoma. This is the first pivotal study ever conducted in c-Met driven papillary renal cell carcinoma and the first molecularly selected trial in renal cell carcinoma. We expect to complete enrollment in late 2019.

At the 2017 World Conference on Lung Cancer, we presented preliminary safety and clinical activity data of savolitinib when given in combination with either Tagrisso or Iressa in two Phase Ib/II proof-of-concept trials conducted in patients with EGFRm+ non-small cell lung cancer with Met-amplification who had progressed following first-line treatment with an EGFR inhibitor. In both trials, the addition of savolitinib (600 mg once daily) to Tagrisso (80 mg once daily) or Iressa (250 mg once daily) demonstrated preliminary anti-tumor activity. We and AstraZeneca have now agreed on the next stage of development in non-small cell lung cancer patients as discussed below.

Phase II gastric cancer studies are ongoing in China, and a multi-arm Phase II study, named the VIKTORY study, is being conducted at Samsung Medical Center in South Korea. Over 850 gastric cancer patients have been screened in these studies, and those patients with confirmed c-Met driven disease are being treated with either savolitinib monotherapy or savolitinib in combination with Taxotere. We presented preliminary data from these studies in 2017, and the China study concluded that savolitinib monotherapy demonstrated promising anti-tumor efficacy. We believe the potential benefit to the patients warrants further exploration with Phase II enrollment continuing in China. The VIKTORY Phase II study is ongoing, and we expect to present preliminary data at a major scientific conference in 2018.

The terms of our collaboration with AstraZeneca are governed by a December 2011 agreement under which we granted AstraZeneca co-exclusive, worldwide rights to develop, and exclusive worldwide rights to manufacture and commercialize savolitinib for all diagnostic, prophylactic and therapeutic uses. We refer to this agreement as the AstraZeneca Agreement. Under the original terms of the AstraZeneca Agreement, we and AstraZeneca agreed to share the development costs for savolitinib in China, with AstraZeneca being responsible for the development costs for savolitinib in the rest of the world. In August 2016, we and AstraZeneca agreed to amend the AstraZeneca Agreement, whereby we agreed to contribute up to $50 million, spread primarily over three years, to the joint development costs of the global

Table of Contents

pivotal Phase III study in patients with c-Met driven papillary renal cell carcinoma. Subject to approval in the papillary renal cell carcinoma indication, we will receive a five percentage point increase in the global tiered royalty rate payable on savolitinib sales across all indications in all regions excluding China. Taking into account such increase, AstraZeneca is obligated to pay us tiered royalties from 14.0% to 18.0% annually on all sales made of any product outside of China. After total aggregate sales of savolitinib have reached $5 billion outside of China, the royalty will step down over a two year period, to an ongoing royalty rate of 10.5% to 14.5%. See Item 4.B. "Business Overview—Overview of Our Collaborations—AstraZeneca" for more details.

Fruquintinib (HMPL-013)

Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor, or VEGFR, and consequently we believe that it has the potential to be a global best-in-class VEGFR inhibitor for many types of solid tumors. Based on pre-clinical and clinical data to date, fruquintinib's kinase selectivity has been shown to reduce off-target toxicity. This allows for drug exposure that is able to fully inhibit VEGFR, a receptor tyrosine kinase which contributes to angiogenesis, the buildup of new blood vessels around a tumor, thereby contributing to the growth of tumors, and use in potential combinations with other agents such as chemotherapies, targeted therapies and immunotherapies. We believe these are points of meaningful differentiation versus other small molecule VEGFR inhibitors that have already been approved, such as Sutent, Nexavar and Stivarga, and can potentially significantly expand the use and market potential of fruquintinib.

In partnership with Eli Lilly, we are currently studying fruquintinib in colorectal cancer, non-small cell lung cancer and gastric cancer in China.

In June 2017, the CFDA acknowledged acceptance of the NDA for fruquintinib for the treatment of patients with advanced colorectal cancer. Fruquintinib was subsequently awarded priority review status in view of its significant clinical value, according to a CFDA announcement in September 2017. The NDA is supported by data from the successful FRESCO study, a Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic colorectal cancer in China, which was highlighted in an oral presentation at the American Society of Clinical Oncology Annual Meeting in June 2017.

In February 2018, we completed patient enrollment of the FALUCA study, a Phase III pivotal trial of fruquintinib in 527 advanced, third-line, non-small cell lung cancer patients in China. Top-line data are expected to be reported in late 2018 when the overall survival data are mature, and subject to a positive outcome, would be followed by a second NDA submission thereafter. The FALUCA study was initiated following a similar Phase II clinical trial in 91 third-line non-small cell lung cancer patients that succeeded in meeting its primary efficacy endpoint of progression-free survival reporting only one treatment-related adverse event greater than or equal to grade 3, or grade ³3, based on the National Cancer Institute's Common Terminology Criteria for Adverse Event, or CTC, which is a set of criteria for the standardized classification of adverse effects of drugs used in cancer therapy (with 1 and 2 being relatively mild and higher numbers (up to 5) being more severe), which was hypertension (8.2%). Results were highlighted in an oral presentation at the World Conference on Lung Cancer in December 2016.

We believe the most significant global market opportunity for fruquintinib will come by combining it with other oncology therapies such as chemotherapy, immunotherapy and other tyrosine kinase inhibitors for use in earlier-line treatments. Along with the FALUCA study, fruquintinib is concurrently being studied in a Phase II study in combination with Iressa in a first-line setting for patients with advanced or metastatic non-small cell lung cancer. In October 2017, we reported preliminary clinical activity, safety and tolerability data of fruquintinib in combination with Iressa in patients with EGFRm+ non-small cell lung cancer. These data were from an ongoing Phase II proof-of-concept trial which was initiated in January 2017 and presented at the World Conference on Lung Cancer in October 2017.

Table of Contents

In October 2017, we initiated the FRUTIGA study, a pivotal Phase III clinical trial of fruquintinib in combination with Taxol in second-line gastric cancer. The FRUTIGA study was initiated following the results of an open-label, multi-center, Phase Ib dose finding/expansion study of fruquintinib in combination with Taxol in second-line gastric cancer, which established a well-tolerated combination dose with encouraging efficacy.

We have established a manufacturing (formulation) facility in Suzhou, China, which now produces Phase III clinical supplies and will be used to produce fruquintinib, as well as our other drugs, for commercial supply if approved.

In December 2017, we also initiated a multi-center, open-label, Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of fruquintinib in U.S. patients with advanced solid tumors.

Sulfatinib (HMPL-012)

Sulfatinib is an oral drug candidate with a unique angio-immuno kinase profile which provides both anti-angiogenesis effect and, we believe, activates and effectively enhances the body's immune system, specifically T-cells. Importantly, in 2016 we presented pre-clinical data that show sulfatinib, in addition to inhibiting VEGFR and FGFR1, is a potent inhibitor of CSF-1R, a signaling pathway involved in blocking the activation of tumor-associated macrophages, which cloak cancer cells from attack from T-cells.

We are currently conducting six clinical trials of sulfatinib and retain all rights to sulfatinib worldwide. In early 2017, we completed a Phase II study in neuroendocrine tumor patients in China and reported the results from this Phase II study in a total of 81 patients which indicated that sulfatinib was well tolerated with highly encouraging efficacy in patients with both pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors. Importantly, for purposes of our potential global development strategy, there were 14 patients who had progressed after treatment with systemic therapies (e.g., Sutent and Afinitor) and all benefited from sulfatinib treatment. Based on the promising Phase II efficacy data and tolerability in patients with advanced neuroendocrine tumors, we initiated two randomized Phase III trials in China along with development in the United States.

Sulfatinib is the first oncology candidate that we have taken through proof-of-concept in China and expanded to a U.S. clinical study ourselves. A Phase I study in cancer patients in the United States is now close to completion. Having established that the 300 mg once daily dose used in China is safe in U.S. patients, we are now also enrolling a final cohort to establish that a 400 mg dose is also safe in U.S. patients. We are currently in final planning stage for an expansion of sulfatinib development in the United States into a multi-arm proof-of-concept study to explore efficacy and safety in both Sutent and Afinitor refractory pancreatic neuroendocrine tumor patients as well as patients with biliary tract cancer (also known as cholangiocarcinoma).

We initiated a Phase II study in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer or medullary thyroid cancer in China in March 2016. We also initiated a further Phase II study in patients with biliary tract cancer in January 2017.

Epitinib (HMPL-813)

A significant portion of patients with non-small cell lung cancer go on to develop brain metastasis. Patients with brain metastasis suffer from poor prognosis. Epitinib is a potent and highly selective oral EGFR inhibitor which has demonstrated brain penetration and efficacy in pre-clinical and now clinical studies. EGFR inhibitors have revolutionized the treatment of non-small cell lung cancer with EGFR activating mutations. However, approved EGFR inhibitors such as Iressa and Tarceva cannot penetrate the blood-brain barrier effectively, leaving the majority of patients with brain metastasis without an effective targeted therapy. We currently retain all rights to epitinib worldwide.

Table of Contents

In December 2016, we presented positive results from our Phase Ib proof-of-concept study in non-small cell lung cancer patients with EGFR activating mutations and brain metastasis, in which epitinib demonstrated encouraging tumor response efficacy in both the lung and the brain. We expect to decide the Phase III dose in early 2018 and initiate Phase III shortly thereafter. If epitinib is able to provide clinical benefit to non-small cell lung cancer patients with brain metastasis in these studies, we believe that, subject to regulatory approval, we will be well-positioned to address a major global unmet medical need.

Additionally, in March 2018, we initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with EGFR gene amplification in China. Glioblastoma is a primary brain cancer that harbors high levels of EGFR gene amplification. This Phase Ib/II study will be a multi-center, single-arm, open-label study to evaluate the efficacy and safety of epitinib as a monotherapy in patients with EGFR gene amplified, histologically confirmed glioblastoma.

Theliatinib (HMPL-309)

Like epitinib, theliatinib is a novel molecule EGFR inhibitor under investigation for the treatment of solid tumors. Tumors with wild-type EGFR activation, for instance, through gene amplification or protein over-expression, are less sensitive to current EGFR tyrosine kinase inhibitors, Iressa and Tarceva, due to sub-optimal binding affinity. Theliatinib has been designed with strong affinity to the wild-type EGFR kinase and has been shown to be five to ten times more potent than Tarceva. Consequently, we believe that theliatinib could benefit patients with esophageal and head and neck cancer, tumor-types with a high incidence of wild-type EGFR activation. We currently retain all rights to theliatinib worldwide.

We are currently conducting a Phase I dose escalation study for theliatinib, with preliminary activity observed, and have initiated a Phase Ib study in patients with esophageal cancer with a high level of EGFR activation.

HMPL-523

We believe HMPL-523 is a potential global first/best-in-class oral inhibitor targeting spleen tyrosine kinase, or Syk, a key protein involved in B-cell signaling. Modulation of the B-cell signaling system has been proven to significantly advance the treatment of certain chronic immune diseases, such as rheumatoid arthritis as well as hematological cancers. To date, only monoclonal antibody immune modulators, which seek to use the patient's own immune system to treat the disease, have been approved. As an oral drug candidate, we believe HMPL-523 has important advantages over intravenous monoclonal antibody immune modulators in rheumatoid arthritis in that as small molecule compounds clear the system faster, thereby reducing the risk of infections from sustained suppression of the immune system.

Moreover, other drug development companies have tried to design small molecule Syk inhibitors for the treatment of chronic immune diseases, but designing an efficacious and safe Syk inhibitor has proven to be exceptionally difficult. No drug products targeting Syk have been approved to date due to severe off-target toxicity, such as hypertension, as a result of poor kinase selectivity. HMPL-523 is a potent and highly selective oral inhibitor specifically designed to overcome these off-target toxicity issues. We currently retain all rights to HMPL-523 worldwide.

With respect to the treatment of hematological cancers, Gilead Sciences Inc., or Gilead, and Takeda Pharmaceutical Company Ltd., or Takeda, both published in late 2015 encouraging proof-of-concept data showing strong signals of efficacy for their respective small molecule Syk inhibitors. The data are consistent with the major clinical successes and drug approvals in recent years of inhibitors targeting other kinases in the B-cell signaling pathway such as Bruton's tyrosine kinase, or BTK, and phosphoinositide 3-kinase d, or PI3Kd. While these BTK and PI3Kd inhibitors have been successful, resistance to these inhibitors can emerge over time, leading to loss in efficacy, and new targets in B-cell signaling such as Syk are potential solutions to this problem.

Table of Contents

Our Phase I clinical trial in healthy volunteers completed a single ascending dose segment in mid-2015, where a single dose is given and the volunteers are observed and tested to confirm safety, and the results were well above the expected efficacious dose. The multiple ascending dose segment of the trial, where multiple doses are given to learn how the drug candidate is processed within the body was successfully completed in October 2015. We have submitted our U.S. immunology Investigational New Drug, or IND, application and engaged with the FDA around our plan for development in rheumatoid arthritis. We are now preparing to submit additional data to the FDA after which we will consider our U.S. development strategy in immunology.

In addition, in early 2016 we initiated a Phase I trial in Australia in patients with relapsed and/or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia for whom there is no standard therapy. In mid-2016, we received clearance from the CFDA on our hematological cancer IND application and as a result, in January 2017, we started Phase I dose escalation in patients with B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia in China. We are now in the process of increasing the number of clinical sites in Australia and China to support Phase Ib/II expansion in a broad range of indolent non-Hodgkin's lymphoma sub-types. We target to present dose escalation and expansion results, including preliminary proof-of-concept data, at a major scientific conference later in 2018.

We believe the market potential for a successful Syk inhibitor is substantial. To our knowledge, we are the only company worldwide, other than Gilead, developing Syk inhibitors for chronic immune diseases as well as oncology.

HMPL-689

HMPL-689 is a novel, highly selective and potent small molecule inhibitor targeting the isoform PI3Kd, a key component in the B-cell receptor signaling pathway. We have designed HMPL-689 with superior PI3Kd isoform selectivity, in particular to not inhibit PI3Kg (gamma), to minimize the risk of serious infection caused by immune suppression. HMPL-689's strong potency, particularly at the whole blood level, also allows for reduced daily doses to minimize compound related toxicity, such as the high level of liver toxicity observed with the first-generation PI3Kd inhibitor Zydelig. HMPL-689's pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. We also expect HMPL-689 will have low risk of drug accumulation and drug-to-drug interaction. Given this, we believe that HMPL-689 has the potential to be a global best-in-class PI3Kd agent. We currently retain all rights to HMPL-689 worldwide.

In 2016, we completed a Phase I, first-in-human, dose escalation study in healthy adult volunteers in Australia to evaluate the pharmacokinetics and safety profile following single oral dosing HMPL-689. Results were as expected with linear pharmacokinetics properties and good safety profile.

We subsequently received IND clearance in China and then initiated a Phase I dose escalation and expansion study in patients with hematologic malignancies in August 2017.

HMPL-453

HMPL-453 is a novel, potentially first-in-class, highly selective and potent small molecule inhibitor that targets FGFR 1/2/3, a sub-family of receptor tyrosine kinases. Aberrant FGFR signaling has been found to be a driving force in tumor growth (through tissue growth and repair), promotion of angiogenesis and resistance to anti-tumor therapies. To date, there are no approved therapies specifically targeting the FGFR signaling pathway. In pre-clinical studies, HMPL-453 demonstrated superior kinase selectivity and safety profile as well as strong anti-tumor potency, as compared to drug candidates in the same class. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings. We currently retain all rights to HMPL-453 worldwide.

Table of Contents

In June 2017, we initiated a Phase I/II clinical trial in China to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-453 monotherapy in patients with solid tumors harboring FGFR genetic alterations. This study complements the first-in-human Phase I clinical trial in Australia that was initiated in February 2017.

For more detailed information on the pre-clinical and clinical studies of these and our other drug candidates, please see "—Our Clinical Pipeline."

Our Commercial Platform

Our Commercial Platform is principally operated through joint ventures with three of the largest China-based healthcare conglomerates, Shanghai Pharmaceuticals, Sinopharm and Guangzhou Baiyunshan. We are currently focusing primarily on the distribution and manufacture of cardiovascular and anti-viral products, as well as the distribution of third-party products such as Concor, a cardiovascular drug from Merck Serono Co., Ltd., or Merck Serono, and Seroquel, a drug for the treatment of various psychiatric disorders from AstraZeneca. Our Commercial Platform has generated substantial cashflow over the years and will serve to help bring products from our Innovation Platform to market quickly and efficiently in China upon regulatory approval. Net income attributable to our company from our Commercial Platform was $25.2 million $70.3 million and $40.0 million for the years ended December 31, 2015, 2016 and 2017, respectively. Net income attributable to our company from our Prescription Drugs business included one-time gains of $40.4 million and $2.5 million in the years ended December 31, 2016 and 2017, respectively, net of tax, from land compensation and other government subsidies paid to Shanghai Hutchison Pharmaceuticals by the Shanghai government.

Our Research and Development Approach

The strategy of our research and development program is to differentiate ourselves from companies developing and commercializing competing kinase inhibitors with a chemistry-focused approach. Our approach focuses on the development of kinases inhibitors with:

•: unique selectivity to limit target-based toxicity,
•: high potency to optimize the dose selection with the objective to lower the required dose and thereby limit compound-based toxicity,
•: chemical structures deliberately engineered to improve drug exposure in the targeted tissue, and
•: ability to be combined with other therapeutic agents.

Our approach consists of two main pillars, which we believe provides a balanced risk profile for our Innovation Platform: (i) developing synthetic compounds against novel targets with global first-in-class potential, which includes savolitinib (targeting c-Met), HMPL-523 (targeting Syk) and HMPL-453 (targeting FGFR1/2/3); and (ii) developing synthetic compounds against validated targets with clear differentiation to potentially be a global best-in-class/next-generation therapy in their respective categories, including fruquintinib (targeting VEGFR1/2/3), sulfatinib (targeting VEGFR/FGFR1/CSF-1R), epitinib (targeting EGFRm+ brain metastasis), theliatinib (targeting EGFR wild type) and HMPL-689 (targeting PI3Kd).

Our Clinical Pipeline

We are developing many of our drug candidates against multiple indications, which in some cases are common to one or more of our drug candidates.

Table of Contents

Savolitinib c-Met Inhibitor

We first became interested in studying c-Met over a decade ago as it became clear that c-Met functions abnormally in many types of solid tumors and as such increasingly represented an important possible target in the treatment of cancer. We designed savolitinib as a potent and highly selective oral inhibitor, which through chemical structure modification addressed renal toxicity, the primary issue that has prevented c-Met inhibitors developed by other biopharmaceutical companies from gaining regulatory approval.

Mechanism of Action

C-Met, which is also known as hepatocyte growth factor receptor, or HGFR, is a signaling pathway that has specific roles in normal mammalian growth and development. However, the HGFR pathway has also been shown to function abnormally in a range of different cancers, primarily through c-Met gene amplification, c-Met over-expression and gene mutations. The aberrant activation of c-Met has been demonstrated to be highly correlated in many cancer indications, including kidney, lung, gastric, colorectal, esophageal and brain cancer, and plays a major role in cancer pathogenesis (i.e., the development of the cancer), including tumor growth, survival, invasions, metastasis, the suppression of cell death as well as tumor angiogenesis. As a result, c-Met has become a widely investigated anti-cancer target in recent years with several c-Met inhibitors under development by different companies, although to date none have received regulatory approval.

C-Met also plays a role in drug resistance in many tumor types. For instance, c-Met gene amplification has been found in non-small cell lung cancer and colorectal cancer following anti-EGFR treatment, leading to drug resistance. Furthermore, c-Met over-expression has been found to emerge in renal cell carcinoma following anti-VEGFR treatment.

Savolitinib Research Background

Around the time of the 2008 American Association for Cancer Research meetings, selective c-Met compounds were unveiled by multinational pharmaceutical companies such as Pfizer Inc. (PF-04217903), Janssen (JNJ-38877605) as well as biotechnology companies including Incyte Corporation (INC280, which was later licensed to Novartis International AG, or Novartis) and SGX Pharmaceuticals (SGX-523, which was later licensed to Eli Lilly). These compounds all had positive pre-clinical data that supported their high c-Met selectivity and pharmacokinetic and toxicity profiles, and as a result they were all progressed into Phase I clinical studies in 2009. Unfortunately, this first wave of selective c-Met inhibitors did not progress very far in the clinic. The subsequent failure of many of this first wave of c-Met inhibitors was a major setback, and subsequently led to a decline in research interest in the c-Met target.

However, we took the decline in interest as an opportunity to increase our investment in our selective c-Met research program. We studied emerging hypotheses around the reason for the kidney toxicity issues in the above mentioned c-Met inhibitors. The issue appeared to be that certain metabolites of earlier compounds had dramatically reduced solubility and appeared to crystalize in the kidney, resulting in obstructive toxicity. These metabolites were not evident in the pre-clinical animal models and only became evident in human testing.

During 2010 and 2011, we designed and completed pre-clinical studies for our compound, savolitinib (also known as AZD6094 and HMPL-504, formerly known as volitinib). Despite replacing the quinoline region of the earlier c-Met compounds which was believed to help drive their selective properties, savolitinib remains a highly selective compound. It also has the important advantage that it has not shown any renal toxicity to date and does not appear to carry the same metabolites problems as the earlier selective c-Met compounds.

Table of Contents

Figure 2: Chemical structures of selective c-Met inhibitors versus
savolitinib chemical structure, showing replacement of the quinoline group

Sources:

1.: Zou H, et al, 99^th Annual Meeting for American Association for Cancer Research (AACR); 12 – 16 April 2008; San Diego, USA
2.: Perera T, et al, 99^th Annual Meeting for American Association for Cancer Research (AACR); 12 – 16 April 2008; San Diego, USA
3.: Bounaud et al, WO 2008/051808 A2
4.: Liu X, et al, 99^th Annual Meeting for American Association for Cancer Research (AACR); 12 – 16 April 2008; San Diego, USA
5.: Su W, et al, 105^th Annual Meeting of the American Association for Cancer Research (AACR); April 2014; San Diego, USA
6.: Diamond S, et. al, Species-specific metabolism of SGX523 by aldehyde oxidase, Drug Metabolism and Disposition, 2010, 38, 1277-85

Savolitinib Pre-clinical Evidence

In vitro biological profile

In pre-clinical studies, savolitinib demonstrated strong in vitro activity against c-Met, affecting its downstream signaling targets and thus blocking the related cellular functions effectively, including proliferation, migration, invasion, scattering and the secretion of vascular endothelial growth factor, or VEGF, that plays a pivotal role in tumor angiogenesis.

One of our key areas of focus in our pre-clinical studies was to achieve superior selectivity of savolitinib on a number of kinases. A commonly used quantitative measure of selectivity is IC₅₀, which represents the concentration of a drug that is required for 50% inhibition of the target kinase in vitro and the plasma concentration required for obtaining 50% of a maximum effect in vivo. High selectivity is achieved with a very low IC₅₀ for the target cells, and a very high IC₅₀ for the healthy cells (approximately 100 times higher than for the target cells). In the c-Met enzymatic assay, which is a method of measuring enzyme activity, savolitinib showed potent activity with IC₅₀ of 5 nM (nano-mole, a microscopic unit of measurement for the number of small molecules required to deliver the desired inhibitory effect). In a kinase selectivity screening with 274 kinases, savolitinib had potent activity against the c-Met Y1268T

Table of Contents

mutant (comparable to the wild-type), weaker activity against other c-Met mutants and almost no activity against all other kinases. Savolitinib was found to be approximately 1,000 times more potent to c-Met than the next non-c-Met kinase.

Figure 3: The high selectivity of savolitinib as shown on a panel of 274 different kinases

Source: W. Su, et al, 2014 American Association for Cancer Research

Note: The red dots shown in the graphic represent the five kinases, all c-Met wild-type or mutations, which are inhibited over 90% at 1,000 nM (1 m M) of savolitinib. The other 269 kinases are inhibited by less than 51%.

In cell-based assays measuring activity against c-Met phosphorylation, savolitinib demonstrated potent activity in both ligand-independent (gene amplified) and ligand-dependent (over-expression) cells with IC₅₀s at low nanomolar levels. Phosphorylation is the binding of a phosphate group to a protein or other organic molecule, which has the effect of activating the function of that protein.

In target related tumor cell function assays, including inhibition on HGF-dependent tumor cell proliferation, migration, and invasion, savolitinib showed high potency with IC₅₀ of less than 10 nM. In addition, savolitinib demonstrated potent in vitro anti-angiogenesis activity. Savolitinib inhibited VEGF secretion of lung cancer cell H441 in a dose-dependent manner with an IC₅₀ of 45 nM and inhibited HGF-dependent human umbilical vein endothelial cells tube formation with an IC₅₀ of 12 nM.

Furthermore, when we tested savolitinib in several different tumor cell lines, it demonstrated cytotoxicity only on tumor cells that were c-Met gene amplified or c-Met over-expressed. In other cells, inhibition measurements demonstrated that IC₅₀ amounts were over 30,000 nM, which is thousands of times higher than the IC₅₀ on c-Met tumor cells. For example, in testing savolitinib in NCI-H1993 non-small cell lung cancer cells, which have high c-Met gene amplification, IC₅₀ measurements were less than 10 nM. This suggests that it would require at least 3,000 times as much savolitinib to inhibit non-c-Met cells to the same degree as it inhibits a NCI-H1993 c-Met cell, thereby demonstrating savolitinib's high selectivity for c-Met. Similarly, in c-Met gene amplified gastric cancer cells such as SNU-5 and Hs746T, savolitinib demonstrated IC₅₀s of 3 nM and 5 nM, respectively.

Table of Contents

The data above suggest that (i) savolitinib has potent activity against tumor cell lines with c-Met gene amplification in the absence of HGF, indicating that there is HGF-independent c-Met activation in these cells; (ii) savolitinib has potent activity in tumor cell lines with c-Met over-expression, but only in the presence of HGF, indicating HGF-dependent c-Met activation; and (iii) savolitinib has no activity in tumor cell lines with low c-Met over-expression/gene amplification, suggesting that savolitinib has strong kinase selectivity.

In vivo efficacy

We tested the in vivo activity of savolitinib on different human tumor xenograft models (a common pre-clinical technique where human tumor cells are transplanted into various animal models). For example, in a gastric cancer Hs746T model with c-Met gene amplification, savolitinib was found to inhibit tumor growth potently with good dose response. At a 2.5 mg/kg (kg weight of the animal) once daily oral dose, savolitinib induced tumor shrinkage, suggesting potent anti-tumor activity. Moreover, the anti-tumor activity appeared to correlate well with the inhibition of c-Met phosphorylation and activation.

Similarly and as in the NCI-H1993 in vitro studies, in vivo studies on c-Met gene amplified NCI-H1993 xenografts also showed significant anti-tumor efficacy, with a median effective dose, or ED₅₀, of 4.7 mg/kg per day. The median effective dose is the dose that produces the desired effect in 50% of the population that takes it.

Savolitinib showed strong synergistic effects with other anti-cancer therapies in certain pre-clinical models. We developed the HCC827C4R model to test several savolitinib combinations, a model which has high c-Met gene amplification and is originally derived from a non-small cell cancer cell line that is highly sensitive to EGFR inhibitors. The combination of savolitinib with the EGFR inhibitor Iressa in the HCC827C4R xenograft model demonstrated strong synergistic effect, suggesting targeting multiple pathways simultaneously may provide a viable approach for the treatment of tumors with activation of multiple pathways. These data suggest that there is a strong rationale for patients whose disease progressed after EGFR tyrosine kinase inhibitor treatment with c-Met gene amplification to use a combination therapy including savolitinib.

Figure 4: Savolitinib in combination with Iressa in the HCC827C4R Met gene amplification
model to test several savolitinib (HMPL-504) combinations, showing a clear dose-dependent response

Source: Chi-Med pre-clinical data for savolitinib

Note: mpk = mg per kg of animal

Table of Contents

We also studied in several subcutaneous xenograft models the anti-tumor effect of savolitinib in combination with Taxotere, a commonly used chemotherapy in gastric cancer treatment. In our studies, the combination produced additive or synergistic anti-tumor effect, and no significant additive or synergistic toxicity between the two drugs was found.

Savolitinib Early and Completed Clinical Development

As discussed below, we have completed various clinical trials of savolitinib in Australia and China.

Savolitinib Phase I study in Australia

We conducted the first-in-human Phase I study of savolitinib in patients with advanced solid tumors starting in 2012 in Australia. The study was conducted to determine the maximum tolerated dose or recommended Phase II dose, dose-limiting toxicities, pharmacokinetics profile and preliminary anti-tumor activity of savolitinib. The first patient was enrolled in February 2012, and enrollment of a total of 47 patients was completed in June 2015.

The data of 35 patients in the dose escalation stage of this Phase I study were presented at the 2014 annual meeting of the American Society of Clinical Oncology. CTC grade ³3 adverse events with greater than 5% incidence associated with savolitinib treatment were fatigue (9.1%) and shortness of breath, or dyspnea (6.1%). Four patients reported five incidences of dose-limiting toxicities, including one CTC grade 3 incidence of elevated alanine transaminase (600 mg once daily), one incidence of CTC grade 3 fatigue (800 mg once daily), two incidences of CTC grade 3 fatigue and one incidence of CTC grade 3 headache (1,000 mg once daily). Notably, no obstructive kidney toxicity was seen in this study.

We identified 800 mg as the maximum tolerated dose of the once daily regimen. A pharmacokinetics analysis showed savolitinib was rapidly absorbed with a half-life of approximately five hours, and drug exposure increased in a dose-proportional manner and with no obvious accumulation. This study showed that savolitinib was well tolerated at doses of up to 800 mg once daily, proving that savolitinib is capable of providing complete target inhibition over 24 hours based on drug concentration required for complete c-Met phosphorylation inhibition derived in pre-clinical studies.

Savolitinib Phase I study in China

In June 2013, we initiated a Phase I dose escalation study of savolitinib in China. By June 2015, a total of 41 patients had been enrolled across the dose escalation and dose expansion stages of the study. We concluded that the data from this China Phase I study were consistent with the Australian Phase I study discussed above and that savolitinib was well tolerated at doses up to 800 mg once daily or 600 mg twice daily. The complete Phase I study results, combining data from Australia and China, were presented at the American Society of Clinical Oncology's annual meeting in 2015.

Kidney Cancer

Emerging Efficacy in Papillary Renal Cell Carcinoma

During the Australia Phase I study, our investigators began to notice positive outcomes among papillary renal cell carcinoma patients with a strong correlation to c-Met gene amplification status. As a result, we became interested in this area because there are no effective approved treatments to date for papillary renal cell carcinoma.

Out of a total of eight papillary renal cell carcinoma patients in our Australia Phase I study who have been treated with various doses of savolitinib, three have achieved confirmed partial response (tumor measurement reduction of greater than 30%). One of these patients has been on the drug for over 30 months and has had tumor measurement reduction of greater than 85%. A further three of these eight

Table of Contents

papillary renal cell carcinoma patients achieved stable disease, which means patients without partial response but with a tumor measurement increase of less than 20%.

The aggregate objective response rate (the percentage of patients in the study who show either partial response or complete response) of 38% is very encouraging for papillary renal cell carcinoma, which as stated above currently has no effective approved treatments on the global market. These responses were also durable as demonstrated by a patient who has been on the therapy for over 30 months. Prior to savolitinib, the highest objective response rate reported for a papillary renal cell carcinoma specific Phase II study (of 74 papillary renal cell carcinoma patients) was 13.5% by foretinib (a multi-kinase inhibitor of c-Met/VEGFR2, which was not submitted for regulatory approval) in 2012, as reported by the National Institutes of Health's National Center for Biotechnology Information.

Importantly, the level of tumor response among these papillary renal cell carcinoma patients correlated closely with the level of c-Met gene amplification. The patients with consistent c-Met gene amplification (across the whole tumor) respond most to savolitinib. Patients with c-Met gene amplification on parts of the tumor (focal Met) respond only if it is a large part of the tumor. Finally, patients with no c-Met gene amplification respond least. Importantly, the magnitude of c-Met gene amplification can vary widely between patients, with those patients with the highest level of c-Met gene amplification responding most to the treatment.

In addition, a colorectal cancer patient in the Phase I study with high levels of c-Met gene amplification in the 600 mg once daily cohort achieved 29% tumor reduction.

Phase II study of savolitinib monotherapy in papillary renal cell carcinoma in the United States, Canada and Europe

In early 2017, we presented the results of our 109-patient global Phase II study in papillary renal cell carcinoma at the American Society of Clinical Oncology Genitourinary Cancers Symposium as well as in the Journal of Clinical Oncology as a Rapid Communication Manuscript. This Phase II study was the largest and most comprehensive clinical study in papillary renal cell carcinoma ever conducted. Of 109 patients treated with savolitinib, papillary renal cell carcinoma was c-Met driven in 44 patients (40%), c-Met independent in 46 patients (42%) and Met status unknown in 19 patients (17%). c-Met driven papillary renal cell carcinoma was strongly associated with encouragingly durable response to savolitinib with an objective response rate in the c-Met driven group of 18.2% (8/44) as compared to 0% (0/46) in the c-Met independent group (p=0.002), based on confirmed partial responses. Median progression-free survival for patients with c-Met driven and c-Met independent papillary renal cell carcinoma patients was 6.2 months (95% confidence interval: 4.1-7.0) and 1.4 months (95% confidence interval: 1.4-2.7), respectively (hazard ratio=0.33; 95% confidence interval: 0.20-0.52; log-rank p<0.0001). Savolitinib was well tolerated, with no reported treatment related CTC grade ³3 adverse events with greater than 5% incidence. Total aggregate savolitinib treatment-related CTC grade ³3 adverse events occurred in just 19% of patients comparing very well to the 70-75% CTC grade ³3 adverse event level recorded in VEGFR inhibitors such as Sutent and Votrient (pazopanib) in multiple renal cell carcinoma studies (N Eng J Med 369;8, R J Motzer et al).

Table of Contents

Figure 5: Phase II study of savolitinib monotherapy in papillary renal cell carcinoma in the United States, Canada and Europe. This study clearly demonstrated c-Met driven patients had better progression-free survival compared to c-Met independent patients.

Non-Small Cell Lung Cancer

Phase I study of savolitinib in combination with Tagrisso T790M(+/–) non-small cell lung cancer (AstraZeneca TATTON (Part A) dose finding study)

In November 2015, AstraZeneca received FDA approval for Tagrisso, its drug candidate for the treatment of T790M+ EGFRm+, tyrosine kinase inhibitor-resistant non-small cell lung cancer. Tagrisso was granted Breakthrough Therapy designation and expedited approval by the FDA and was one of the fastest development programs ever recorded at just over two and a half years from the start of Phase I clinical trials to FDA approval. We understand that the speed of development and approval of Tagrisso was driven by the clearly defined molecular pathways (T790M), the existence of a major unmet medical need in the treatment of non-small cell lung cancer, and the high degree of efficacy demonstrated by Tagrisso. In this T790M+ patient population, Tagrisso recorded an objective response rate of 59% in two large-scale Phase II studies that formed the basis for FDA approval. Another portion of EGFRm+ tyrosine kinase inhibitor-resistant patients progresses because of c-Met gene amplification. The TATTON (Part A) Phase I study of Tagrisso plus savolitinib combination treatment was initiated in August 2014 to determine the safety and tolerability of the combination therapy and the recommended Phase II dose. Based on the positive safety and tolerability results and encouraging early clinical efficacy, a TATTON (Part B) Phase IIb proof-of-concept study was initiated to confirm safety and efficacy.

Table of Contents

The primary objective of the TATTON Phase I (Part A) study was to establish a safe and effective combination dose. All patients were screened for their T790M status (+/–) as well as some for their c-Met gene amplification status, if sufficient tissue samples were available, although patients of all tumor types were admitted to the trial regardless of status. A total of 12 patients were dosed with either 600 mg or 800 mg of savolitinib in combination with 80 mg of Tagrisso once daily. It was found that both 600 mg and 800 mg once daily could be combined with 80 mg of Tagrisso once daily with a safety profile consistent with single agent use. Furthermore, of the 11 evaluable patients in the study, six confirmed partial responses have been observed to date. This resulted in an objective response rate of 55% and contributed to a disease control rate of 100%.

Figure 6: Best percentage changes in tumor size versus baseline in patients
(with each column representing a single patient) treated with a combination of savolitinib and Tagrisso in the TATTON Phase I (Part A) study, by T790M status when available

Source: Oxnard et al, Preliminary results of TATTON (Part A), a multi-arm Phase I trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer, J Clin Oncol 33, 2015 (suppl; abstr 2509)

Note: 6 patients ongoing treatment at data cut-off

None of the adverse effects in the 600 mg dose were CTC grade ³3, and only two in the 800 mg dose were CTC grade ³3. These were nausea (8.3%) and decreased white blood cell count (8.3%).

This novel combination of two well-tolerated therapies, albeit on a low base size, has delivered significant objective response rate levels. As a result, we have expanded the TATTON Phase Ib study to demonstrate broader proof-of-concept, as discussed below in Target Patient Population 6 in the pipeline chart.

Savolitinib Current Clinical Development and Near-Term Plans

Table of Contents

first global Phase III registration study in papillary renal cell carcinoma. In late 2017, we presented positive Phase Ib/II data at the World Conference on Lung Cancer on savolitinib in combination with Tagrisso and Iressa, in both second- and third-line non-small cell lung cancer and are now working closely with AstraZeneca on next steps for development as discussed below.

Kidney Cancer

Phase III papillary renal cell carcinoma, savolitinib (600 mg once daily) monotherapy—Global (Target Patient Population 1 in pipeline chart; Status: enrolling; NCT03091192)

Papillary renal cell carcinoma is the most common of the non-clear cell renal cell carcinomas representing about 14% of kidney cancer. Approximately 366,000 new cases of kidney cancer were diagnosed globally in 2015, equating to about 50,000 cases of papillary renal cell carcinoma, with approximately half harboring c-Met driven disease. No targeted therapies have been approved specifically for papillary renal cell carcinoma, and to date only modest efficacy in non-clear cell renal cell carcinoma has been reported in sub-group analyses of broader renal cell carcinoma studies of VEGFR (e.g., Sutent) and mammalian target of rapamycin (e.g., Afinitor) tyrosine kinase inhibitors, with objective response rates of <10% and median progression-free survival in first-line setting of four to six months and second-line setting of only one to three months (ESPN study, Tannir N. M. et al.).

Based on the Phase II results we presented in early 2017, we initiated the SAVOIR study in June 2017. The SAVOIR study is a global Phase III, open-label, randomized, controlled trial evaluating the efficacy and safety of savolitinib, compared with sunitinib, in patients with c-Met driven, unresectable, locally advanced or metastatic papillary renal cell carcinoma. C-Met status is confirmed by the novel targeted next-generation sequencing assay developed for savolitinib. Patients will be randomized in a 1:1 ratio to receive either continuous treatment with savolitinib 600 mg (400 mg if <50 kg) orally, once daily, or intermittent treatment with sunitinib 50 mg orally once daily (four weeks on/two weeks off), on a six-week cycle. The primary endpoint for efficacy in the SAVOIR study is median progression-free survival, with secondary endpoints of overall survival, objective response rate, duration of response, best percentage change in tumor size, disease control rate, and safety and tolerability. We expect to complete enrollment in late 2019.

Furthermore, in order to fully understand the role of c-Met driven disease in papillary renal cell carcinoma, we are currently conducting a global molecular epidemiology study. The molecular epidemiology study is in the process of screening, using our companion diagnostic, archived tissue samples from over 300 papillary renal cell carcinoma patients to identify c-Met driven disease. Historical medical records from these patients will then be used to determine if c-Met driven disease is predictive of worse outcome, in terms of progression-free survival and overall survival, in papillary renal cell carcinoma patients. If this is proven to be the case, we will consider engaging in discussions regarding Breakthrough Therapy potential with the U.S. FDA.

Phase II study of multiple tyrosine kinase inhibitors in metastatic papillary renal cell carcinoma—United States (Target Patient Population 2 in pipeline chart; Status: enrolling; NCT02761057)

A Phase II study, sponsored by the U.S. National Cancer Institute, and named the PAPMET study, to assess the efficacy of multiple tyrosine kinase inhibitors in metastatic papillary renal cell carcinoma patients including Sutent, Cabometyx (cabozantinib), Xalkori (crizotinib) and savolitinib. PAPMET began enrolling patients in 2016. The PAPMET study is expected to enroll about 180 patients in over 70 locations in the United States with top-line data targeted for reporting in 2019.

Phase II study of savolitinib (600 mg once daily) monotherapy and in combination with Imfinzi (anti-programmed death-ligand 1) in both papillary renal cell carcinoma and clear cell renal cell carcinoma patients—U.K./Spain (Target Patient Populations 3, 4 and 5 in pipeline chart; Status: enrolling; NCT02819596)

Table of Contents

The CALYPSO study, a dose finding study to assess safety/tolerability of savolitinib and Imfinzi combination therapy as well as preliminary efficacy of savolitinib as a monotherapy or combination therapy in several c-Met driven kidney cancer patient populations, began at St. Bartholomew's Hospital in London in 2016. In 2016, the dose-finding phase of the CALYPSO study successfully established the combination dose of savolitinib and Imfinzi and the study moved on to the Phase II expansion stage in papillary renal cell carcinoma and clear cell renal cell carcinoma patients in the United Kingdom and Spain to further explore efficacy in 2017.

Non-small Cell Lung Cancer

Phase Ib/II expansion non-small cell lung cancer (second-line), EGFR tyrosine kinase inhibitor-refractory, savolitinib (600 mg once daily) in combination with Tagrisso—Global (Target Patient Population 6 in pipeline chart; Status: enrolling; NCT02143466)

In October 2016, at the European Society for Medical Oncology meeting, AstraZeneca presented preliminary proof-of-concept data from the TATTON study (Part A) on 17 evaluable first-generation EGFR tyrosine kinase inhibitor (Iressa/Tarceva) refractory second-line non-small cell lung cancer patients who had no prior exposure to third-generation EGFR tyrosine kinase inhibitors (Tagrisso/rocelitinib). Molecular analysis of both c-Met and T790M status was completed for patients with sufficient available tumor tissue. Of patients treated with the savolitinib and Tagrisso combination, confirmed partial responses were reported in 4/5 (80% objective response rate) c-Met positive/T790M negative patients and in 6/10 (60% objective response rate) c-Met positive patients regardless of T790M status.

In 2016, we initiated a global Phase Ib/II expansion study in second-line non-small cell lung cancer, called the TATTON study (Part B), aiming to recruit sufficient c-Met gene amplified patients who had progressed after prior treatment with a first-generation EGFR inhibitor (Iressa/Tarceva) to support a decision on global Phase II/III registration strategy. In this first-generation EGFR tyrosine kinase inhibitor refractory non-small cell lung cancer population, we estimate that c-Met gene amplification occurs in 15-20% of patients. Preliminary data from TATTON (Part B), in 34 evaluable patients, were presented at the 2017 World Conference on Lung Cancer and showed confirmed partial responses in 14/23 (61% objective response rate) of T790M mutation negative patients, as well as confirmed partial responses in 6/11 (55% objective response rate) of T790M mutation positive patients. AstraZeneca has recently decided to progress into the next stage of development in this indication, with plans outlined below.

Table of Contents

Figure 7: Preliminary data from TATTON study (Part B) were compelling and consistent with the TATTON study (Part A)

Note:: *Centrally confirmed MET-amplification (fluorescence in-situ hybridization, MET gene copy ³5 or MET/CEP7 ratio ³2)

Phase Ib/II non-small cell lung cancer (third-line), EGFR/T790M tyrosine kinase inhibitor-refractory, savolitinib (600 mg once daily) in combination with Tagrisso—Global (Target Patient Population 7 in pipeline chart; Status: enrolling; NCT02143466)

The TATTON study (Part B) also enrolled third-line non-small cell lung cancer patients that had progressed after treatment with Tagrisso as a result of c-Met gene amplification acquired resistance. Data presented in June 2017 at the American Society of Clinical Oncology, by Harvard Medical School and Massachusetts General Hospital Cancer Center showed that about 30% (7/23 patients) of Tagrisso-resistant third-line non-small cell lung cancer patients harbor c-Met gene amplification. This third-line patient population is generally heavily pre-treated and highly complex from a molecular analysis standpoint, with the study showing that more than half of the c-Met gene amplification patients also harbored additional genetic alterations, including but not limited to, EGFR gene amplification and K-Ras mutations.

The TATTON (Part B) study, presented at the 2017 World Conference on Lung Cancer, also included preliminary data in 30 evaluable patients previously treated with third-generation T790M-directed EGFR inhibitors, primarily Tagrisso. Confirmed partial responses were observed in 10/30 (33% objective response

Table of Contents

rate) of these patients, and while this is lower than the 55-61% objective response rate in Target Patient Population 6, it was as expected given the additional driver genes at work post-Tagrisso monotherapy failure. We believe that the savolitinib/Tagrisso combination is an important treatment option for these late-stage patients who have no remaining targeted treatment alternatives.

Tagrisso sales in 2017, only the second year since its launch, were $955 million. At current pricing, this would indicate that over 5,000 patients were treated with Tagrisso during 2017, thereby indicating that the market potential for savolitinib in third-line, Tagrisso resistant, non-small cell lung cancer could be material.

Figure 8: The savolitinib/Tagrisso combination could be an important treatment option for the third-line or above non-small cell lung cancer patients who have no remaining targeted treatment alternatives

Note:: *Centrally confirmed MET-amplification (fluorescence in-situ hybridization, MET gene copy ³5 or MET/CEP7 ratio ³2)

AstraZeneca decision on further development in Target Patient Populations 6 and 7

In December 2017, AstraZeneca's governance committee in oncology reviewed the TATTON (Part B) data that had been presented at the 2017 World Conference on Lung Cancer, to decide strategy for further development of the savolitinib and Tagrisso combination in first-generation (Iressa/Tarceva) and third-generation (Tagrisso) EGFR-tyrosine kinase inhibitor refractory non-small cell lung cancer.

At that time, while the above strong objective response rate data was available for the savolitinib (600 mg once daily) plus Tagrisso (80 mg once daily) combination dose regimen, neither median progression-free survival nor duration of response had been reached. Since then, both progression-free survival and duration of response have continued to mature. The safety profile of the combination is in line with previous reports for savolitinib (600 mg once daily) plus Tagrisso (80 mg once daily) and going forward, AstraZeneca has concluded that a weight-based dosing algorithm will be applied for the combination, similar to the dosing algorithm used in the SAVOIR Phase III study in papillary renal cell carcinoma.

Table of Contents

Encouraged by the TATTON (Part B) data, AstraZeneca has decided to proceed with development in second-line non-small cell lung cancer (Target Patient Population 6 in the pipeline chart). Planning is now underway to initiate a global randomized chemotherapy-doublet (platinum plus Alimta) controlled study of the savolitinib plus Tagrisso combination in first-generation (Iressa/Tarceva) EGFR-tyrosine kinase inhibitor refractory, c-Met driven and T790M negative non-small cell lung cancer patients. This second-line non-small cell lung cancer study, currently targeted to start in the second half of 2018, will start as a Phase II study until such time that regulatory discussions have taken place on dosing approach, and will be powered based on TATTON (Part B) for objective response rate and progression-free survival.

To further support dosing approach ahead of regulatory discussions, AstraZeneca has already initiated TATTON (Part D), exploring savolitinib (300 mg once daily) dose combined with Tagrisso (80 mg once daily), to explore the lower dose in the context of maximizing tolerability of the combination for patients who could be on the combination for long periods of time. A second supporting study, a Phase II, aiming at strengthening the dose justification in EGFR-tyrosine kinase inhibitor refractory, c-Met driven non-small cell lung cancer will also start in the second half of 2018, randomizing to either 300 mg savolitinib once daily plus Tagrisso (80 mg once daily) or 600 mg savolitinib (with weight-based dosing) once daily plus Tagrisso (80 mg once daily) with a primary endpoint of tolerability.

Late in 2018 or early in 2019, and subject to the outcome of the mature TATTON (Part B) data as well as preliminary TATTON (Part D) results, we expect AstraZeneca to engage in regulatory discussions regarding our dosing approach for the savolitinib and Tagrisso combination as well as potential Breakthrough Therapy. These regulatory discussions will also enable AstraZeneca to decide development strategy in third-line non-small cell lung cancer (Target Patient Population 7 in the pipeline chart), defined as third-generation (Tagrisso) EGFR-tyrosine kinase inhibitor refractory, c-Met gene amplified non-small cell lung cancer patients.

Phase II non-small cell lung cancer (second-line), EGFR tyrosine kinase inhibitor-refractory, savolitinib (600 mg once daily) in combination with Iressa—China (Target Patient Population 8 in pipeline chart; Status: completed; NCT02374645)

At the 2017 World Conference on Lung Cancer, we presented Phase II proof-of-concept data assessing savolitinib in combination with Iressa in patients in China with EGFRm+ advanced non-small cell lung cancer with centrally confirmed c-Met gene amplification who had progressed following first-generation EGFR inhibitor therapy. Preliminary results showed confirmed partial responses in 12/23 (52% objective response rate) of T790M mutation negative patients, as well as confirmed partial responses in 2/23 (9% objective response rate) of T790M mutation positive patients. The 52% objective response rate in T790M mutation negative patients was as expected and similar to that recorded in TATTON (Part B) for this target patient population, indicating that for these patients Iressa might be the most cost-efficient combination partner for savolitinib. The low 9% objective response rate in T790M mutation positive patients was also as expected, as Iressa does not effectively address T790M mutants. In terms of safety, the savolitinib plus Iressa combination dose was safe and well tolerated.

With the launch of multiple lower-priced and reimbursed generic first-generation EGFR tyrosine kinase inhibitors in China in 2017, combined with the approximately 50% proportion of non-small cell lung cancer patients who harbor the EGFRm+, we believe there may be a surge in c-Met gene amplified second-line non-small cell lung cancer patients in China over the coming years. We continue to discuss Phase III plans in this target patient population for the savolitinib/Iressa combination in China with AstraZeneca and expect to reach agreement in 2018.

Table of Contents

Figure 9: The savolitinib/Iressa combination has demonstrated strong and durable response in Met+ (T790M-) patients

Note:

1.: Cut-off as of August 21, 2017

Phase II c-Met driven non-small cell lung cancer, savolitinib (600 mg once daily) monotherapy—China (Target Patient Populations 9 and 10 in pipeline chart; Status: enrolling; NCT01935555/NCT02897479)

Phase II studies of savolitinib are also ongoing in non-small cell lung cancer and other lung cancer patient populations, focusing on those with c-Met driven disease.

Gastric Cancer

Phase II gastric cancer studies are ongoing in China as well as the Phase II VIKTORY study, being conducted at Samsung Medical Center in South Korea, in which savolitinib is represented in two out of the

Table of Contents

ten treatment arms. As of the latest report in 2017, a total of over 850 gastric cancer patients have been screened in these studies and those patients with confirmed c-Met driven disease are being treated with either savolitinib monotherapy or savolitinib in combination with Taxotere. Presentations of preliminary data from these studies were made in 2017 at the Chinese Society of Clinical Oncology (China Phase II) and the American Society of Clinical Oncology (VIKTORY Phase II).

In China as of June 2017, a total of 441 metastatic gastric cancer patients had been screened with 13.2% (58/441) determined to have aberrant c-Met, of which 5.3% (23/438) were c-Met gene amplified. A total of 31 patients in China have been enrolled to date in Target Patient Population 11 in the pipeline chart as discussed below. In South Korea as of January 2017, a total of 438 metastatic gastric cancer patients had been screened with 5.3% (23/438) being patients with c-Met driven (gene amplification or over-expression) disease. A total of 23 patients in South Korea have been enrolled to date in Target Patient Populations 11, 12 and 13 in the pipeline chart as discussed below.

Phase Ib gastric cancer, savolitinib monotherapy, patients with c-Met gene amplification—China and South Korea (Target Patient Population 11 in pipeline chart; Status: enrolling; NCT01985555/NCT02449551)

Preliminary results were presented at the 2017 Chinese Society of Clinical Oncology for the efficacy evaluable c-Met gene amplified patients in China. Based on confirmed and unconfirmed partial responses, the objective response rate was 42.9% (3/7) and disease control rate was 85.7% (6/7), with objective response rate of 13.6% (3/22) and disease control rate of 40.9% (9/22) among the overall efficacy evaluable aberrant c-Met set. As of data cut-off, the longest duration of treatment was in excess of two years. Savolitinib monotherapy was determined to be safe and well tolerated in patients with advanced gastric cancer. CTC grade ³3 treatment emergent adverse events with greater than 5% incidence included abnormal hepatic function in 12.9% (4/31), gastrointestinal bleeding or decreased appetite in 9.7% (3/31 each), and diarrhea or gastrointestinal perforation in 6.4% (2/31 each). This China study concluded that savolitinib monotherapy demonstrated promising anti-tumor efficacy in gastric cancer patients with c-Met gene amplification. We believe the potential benefit to these patients warrants further exploration, with Phase II enrollment continuing in China. The VIKTORY Phase II study is ongoing in c-Met gene amplified patients in South Korea, with preliminary data likely to be presented at a major scientific conference in 2018.

Phase II gastric cancer, savolitinib (600 mg once daily) in combination with Taxotere in c-Met over-expression or c-Met gene amplification—South Korea (Target Patient Populations 12 and 13 in pipeline chart; Status: enrolling; NCT02447380/NCT02447406)

Phase II studies are underway to assess safety/tolerability of savolitinib and Taxotere combination as well as preliminary efficacy of the combination therapy in both c-Met gene amplified patients and the approximately 40% of gastric cancer patients that harbor c-Met over-expression. The VIKTORY Phase II study is ongoing in South Korea in Target Patient Populations 12 and 13, with preliminary data likely to be presented at a major scientific conference in 2018.

Phase II metastatic castration-resistant prostate cancer, savolitinib monotherapy—Canada (Target Patient Populations 14 in pipeline chart; Status: enrolling; NCT03385655)

A Phase II study is sponsored by the Canadian Cancer Trials Group to determine the effect of savolitinib on prostate-specific antigen decline and time to prostate-specific antigen progression. The study will assess the objective response rate as determined by RECIST 1.1 criteria, evaluate the safety and toxicity profile of savolitinib in metastatic castration-resistant prostate cancer patients and identify potential predictive and prognostic factors. The umbrella study targets to enroll around 500 patients into six treatment arms based on molecular status, with patients with c-Met-driven disease receiving savolitinib. High levels of c-Met over expression can be prevalent in prostate cancer patients.

Table of Contents

Partnership with AstraZeneca

In December 2011, we entered into a global licensing, co-development, and commercialization agreement for savolitinib with AstraZeneca. Given the complexity of many of the signal transduction pathways and resistance mechanisms in oncology, the industry is increasingly studying combinations of targeted therapies (tyrosine kinase inhibitors, monoclonal antibodies and immunotherapies) and chemotherapy as potentially the best approach to treating this complex and constantly mutating disease. Based on savolitinib showing early clinical benefit as a highly selective c-Met inhibitor in a number of cancers, in August 2016 we and AstraZeneca amended our global licensing, co-development, and commercialization agreement for savolitinib. We believe that AstraZeneca's portfolio of proprietary targeted therapies is well suited to be used in combinations with savolitinib, and we are studying combinations with Iressa (EGFRm+), Tagrisso (T790M+) and anti-programmed death-ligand 1 antibody Imfinzi. These combinations of multiple global first-in-class compounds are difficult to replicate, and we believe represent a significant opportunity for us and AstraZeneca.

For more information regarding our partnership with AstraZeneca, see "—Overview of Our Collaborations."

Fruquintinib VEGFR 1, 2 and 3 Inhibitor

When we established our medicinal chemistry research platform in 2005, our first priority area of interest was to discover drug candidates to overcome the shortcomings of a few drugs or drug candidates that were in late-stage clinical development at the time, but had a well understood mechanism of action. As a result, we developed fruquintinib (also known as HMPL-013), a VEGFR inhibitor that we believe is highly differentiated due to its superior kinase selectivity compared to other small molecule VEGFR inhibitors, which can be prone to excessive off-target toxicities. Fruquintinib only inhibits VEGFR1, 2 and 3, resulting in fewer off-target toxicities, thereby allowing for better target coverage, as well as possible use in combination with other agents such as chemotherapies, targeted therapies and immunotherapies.

We believe these are meaningful points of differentiation compared to other approved small molecule VEGFR inhibitors such as Sutent, Nexavar and Stivarga, and can potentially significantly expand the use and market potential of fruquintinib. Consequently, we believe that fruquintinib has the potential to become the global best-in-class small molecule VEGFR inhibitor for many types of solid tumors.

Mechanism of Action

During the pathogenesis of cancer, tumors at an advanced stage can secrete large amounts of VEGF, a protein ligand, to stimulate formation of excessive vasculature (angiogenesis) around the tumor in order to provide greater blood flow, oxygen, and nutrients to fuel the rapid growth of the tumor. Since essentially all solid tumors require angiogenesis to progress beyond a few millimeters in diameter, anti-angiogenesis drugs have demonstrated benefits in a wide variety of tumor types. VEGF and other ligands can bind to three VEGF receptors, VEGFR1, 2 and 3, each of which has been shown to play a role in angiogenesis. Therefore, inhibition of the VEGF/VEGFR signaling pathway can act to stop the growth of the vasculature around the tumor and thereby starve the tumor of the nutrients and oxygen it needs to grow rapidly.

This therapeutic strategy has been well validated with several first-generation VEGF inhibitors having been approved globally since 2005 and 2006. These include both small molecule tyrosine kinase inhibitor drugs such as Nexavar and Sutent as well as monoclonal antibodies such as Avastin (bevacizumab). The success of these drugs validated VEGFR inhibition as a new class of therapy for the treatment of cancer.

Table of Contents

Fruquintinib Pre-clinical Evidence

Potency and Selectivity

Pre-clinical studies have demonstrated that fruquintinib is a highly selective VEGFR inhibitor with high potency and low cell toxicity at the enzymatic and cellular levels. Fruquintinib has been studied in nude mice models bearing various human tumors and has shown significant inhibition of tumor growth, with human gastric cancer showing the strongest sensitivity. A daily dose of 2 mg/kg was found to almost completely inhibit tumor growth in mice models.

As a result of off-target side effects, existing VEGFR inhibitors are often unable to be dosed high enough to completely inhibit VEGFR, the intended target. In addition, the complex off-target toxicities resulting from inhibition of multiple signaling pathways are often difficult to be managed in clinical practice. Combining such drugs with chemotherapy can lead to severe toxicities that can cause more harm than benefit to patients. To date, the first generation VEGFR tyrosine kinase inhibitors are rarely used in combination with other therapies, thereby limiting their potential. Because of the potency and selectivity of fruquintinib, we believe that it has the potential to be safely combined with other anti-cancer drugs, which could significantly expand its clinical potential.

The pharmacokinetic properties of fruquintinib in patients have also been found to have high drug exposures at the optimal 5 mg daily dose of approximately 6,000 h*ng/mL (i.e., hours multiplied by nanogram per milliliter, which is a measurement of drug exposure over time), well above the exposure of 898 h*ng/mL required to cover the VEGFR target to EC₅₀ levels in mouse models, suggesting potentially strong target coverage in humans at this dose. At this dose, we expect fruquintinib to fully inhibit VEGFR for an entire day through a single oral dose based on modeling using pre-clinical data. In contrast, Sutent achieved a drug exposure of only 592 h*ng/mL at the maximum tolerated dose of 50 mg per day, which is well below the drug exposures required for target inhibition determined in its pre-clinical models of 2,058 h*ng/mL, suggesting insufficient target coverage in humans.

Fruquintinib Early and Completed Clinical Development

As discussed below, we have completed various clinical trials of fruquintinib in China.

Phase I dose escalation study in patients with advanced solid tumors in China

This study was initiated in January 2011, and results were presented at the American Association for Cancer Research's meeting in 2013 and subsequently published in Cancer Chemotherapy and Pharmacology in August 2016. A total of 40 subjects with advanced solid tumors were enrolled in this clinical study. The primary endpoint was evaluation of safety during the first 28-day cycle of therapy following the initiation of multiple dosing of fruquintinib. The safety variables evaluated in this study were adverse events, physical examinations, vital signs (specifically including blood pressure), clinical laboratory evaluations including serum chemistry, hematology, urinalysis (with detailed sediment analysis, proteinuria, and 24-hour urine for collection of protein), and electrocardiograms.

Most adverse events were considered mild and graded as CTC grade 1 or 2. Adverse events CTC grade ³3 with greater than 5% incidence related to fruquintinib treatment were hypertension (17.5%), hand-foot syndrome (17.5%), thrombocytopenia (12.5%), diarrhea (7.5%), fatigue (7.5%) and proteinuria (5.0%).

Furthermore, the Phase I study validated in humans the pre-clinical pharmacokinetic animal model findings of fruquintinib's ability to provide strong target coverage. The chart below shows that fruquintinib fully inhibits VEGFR in humans for the entire day at the optimal 5 mg daily dose level.

Table of Contents

Figure 10: Fruquintinib plasma concentration in humans following once daily dosing in comparison to effective concentrations (EC) of fruquintinib required for VEGFR2 phosphorylation (activation) inhibition in mouse

Source: Chi-Med Phase I study data for fruquintinib

Note: EC₅₀ = concentration of a drug that gives 50% of maximal response; EC80 = concentration of a drug that gives 80% of maximal response

Tumor response and progression were evaluated using the Response Evaluation Criteria in Solid Tumors version 1.0. In terms of efficacy, in the entire intent-to-treat population of 40 subjects, 14 had confirmed partial response, 14 had stable disease, six had progressed disease, and six were not evaluable. The objective response rate was 41% in the 34 evaluable patients and 35% in the entire intent-to-treat population of 40 patients, and the disease control rate was 82% among evaluable patients and 70% in the intent-to-treat population. Out of the 34 evaluable patients, only six patients had tumor growth, with the rest experiencing substantial tumor shrinkage.

In this Phase I study, clear tumor response was observed in multiple tumor types, consistent with the fact that angiogenesis, driven by VEGFR activation, accelerates the growth of tumors in many settings. The highest objective response rate in this Phase I study was achieved in non-small cell lung cancer and gastric cancer patients with objective response rates of over 50%. However, we also observed objective response rates of approximately 30% in colorectal and breast cancer patients.

As a result of this study, we determined that either 4 mg once daily or 5 mg once daily on a 3-weeks-on/1-week-off basis was safe and tolerable. This study also found that doses above 4 mg once daily achieved drug exposures well above EC80 (the concentration that leads to an 80% maximal response) of the VEGFR phosphorylation inhibition over a 24-hour time period.

Table of Contents

Studies in Colorectal Cancer

Phase Ib and II studies in third-line or above metastatic colorectal cancer patients in China

In December 2012, we initiated a Phase Ib study in patients with advanced colorectal cancer to compare the safety and tolerability of a 5 mg once daily 3-weeks-on/1-week-off regimen versus a 4 mg continuous once daily regimen. The study was divided into a randomized comparison study with 20 patients taking each regimen. The primary endpoint was the incidence of adverse effects, including significant adverse events, CTC grades 3 or 4 adverse effects and adverse effects that lead to dose interruption or dose discontinuation. In this study, both dose regimens demonstrated similar clinical efficacy and safety profile with the 5 mg once daily 3-weeks-on/1-week-off regimen showing slightly more favorable results. An additional 22 patients were subsequently enrolled into the 5 mg once daily 3-weeks-on/1-week-off regimen to further confirm the safety and tolerability of this regimen. As a result of this study, we determined the recommended Phase II dose regimen to be 5 mg, once daily, on a 3-weeks-on/1-week-off basis. Full results of this study were presented at the American Society of Clinical Oncology's annual meeting in 2014.

In August 2014, we completed enrollment for a Phase II, double-blind, placebo-controlled, multi-center study in China in just over four months to test fruquintinib as a monotherapy among third-line metastatic colorectal cancer patients, using the 5 mg daily, 3-weeks-on/1-week-off dose regimen determined from our Phase I study discussed above. The goal of this study was to compare the efficacy, including progression-free survival, of fruquintinib versus placebo in metastatic colorectal cancer patients who failed at least two prior lines of treatment, including fluorouracil, oxaliplatin and irinotecan. A total of 71 patients were enrolled, with 47 in the fruquintinib arm and 24 in the placebo arm, respectively. Patient baseline characteristics were similar between the two treatment arms.

Fruquintinib demonstrated strong anti-tumor activity in this study. Median progression-free survival was 4.7 months in the fruquintinib arm compared to median progression-free survival of 1.0 month in the placebo arm (hazard ratio = 0.30 (p<0.001)). Hazard ratio is the probability of an event (such as disease progression or death) occurring in the treatment arm divided by the probability of the event occurring in the control arm of a study, with a ratio of less than one indicating a lower probability of an event occurring for patients in the treatment arm. P-value is a measure of the probability of obtaining the observed sample results, with a lower value indicating a higher degree of statistical confidence in these studies. The disease control rate in the fruquintinib arm was 68.1% compared with 20.8% in the placebo arm (p<0.001). The interim median overall survival rate was 7.6 months and 5.5 months in the fruquintinib arm and the placebo arm, respectively. In this study, fruquintinib has not shown any major unexpected safety issues and clearly met its primary endpoint of progression-free survival. The result of 4.7 months in median progression-free survival compares favorably with results recorded to date in third-line colorectal cancer in trials involving VEGFR tyrosine kinase inhibitors. The safety profile in this study was also consistent with our Phase Ib trial for fruquintinib in third-line metastatic colorectal cancer patients. The full results of this study were presented at the European Cancer Congress in September 2015.

Phase III study in colorectal cancer (third-line), fruquintinib monotherapy—China (Target Patient Population 15 in pipeline chart; Status: NDA submitted in June 2017; NCT02314819)

In December 2014, we initiated the FRESCO trial, which is a randomized, double-blind, placebo-controlled, multi-center, Phase III pivotal trial in patients with locally advanced or metastatic colorectal cancer who have failed at least two prior systemic antineoplastic therapies, including fluoropyrimidine, oxaliplatin and irinotecan. No drugs had been approved in third-line colorectal cancer in China with best supportive care being the general standard of care. Enrollment was completed in May 2016 and 519 patients were screened. The intent-to-treat population of 416 patients was randomized at a 2:1 ratio to receive either: 5 mg of fruquintinib orally once daily, on a three-weeks-on/one-week-off cycle, plus best supportive care (278 patients) or placebo plus best supportive care (138 patients). Randomization was stratified for prior anti-VEGF therapy and K-Ras gene status. The trial concluded in January 2017.

Table of Contents

In June 2017, we highlighted the results of the FRESCO study in an oral presentation during the American Society of Clinical Oncology Annual Meeting held in Chicago. Results showed that FRESCO met all primary and secondary endpoints including significant improvements in overall survival and progression-free survival with a manageable safety profile and lower off-target toxicities compared to other targeted therapies. The primary endpoint of median overall survival was 9.30 months (95% confidence interval: 8.18-10.45) in the fruquintinib group versus 6.57 months (95% confidence interval: 5.88-8.11) in the placebo group, with a hazard ratio of 0.65 (95% confidence interval: 0.51-0.83; two-sided p<0.001). The secondary endpoint of median progression-free survival was 3.71 months (95% confidence interval: 3.65-4.63) in the fruquintinib group versus 1.84 months (95% confidence interval: 1.81-1.84) in the placebo group, with a hazard ratio of 0.26 (95% confidence interval: 0.21-0.34; two-sided p<0.001). Significant benefits were also seen in other secondary endpoints. The disease control rate in the fruquintinib group was 62.2% versus 12.3% for placebo (p<0.001), while the objective response rate based on confirmed responses was 4.7% versus 0% for placebo (p=0.012).

Figure 11: Phase III study in China of fruquintinib monotherapy in third-line colorectal cancer.
FRESCO clearly succeeded in meeting the primary efficacy endpoint of OS.

In terms of safety, results showed that fruquintinib had a manageable safety profile with lower off-target toxicities compared to other VEGFR tyrosine kinase inhibitors. Of particular interest was that the CTC grade ³3 hepatotoxicity was similar for the fruquintinib group as compared to the placebo group, which is in contrast to Stivarga which was markedly worse and often difficult to manage in this patient population in the CONCUR study. The most frequently reported fruquintinib-related CTC grade ³3 adverse events included hypertension (21.2%), hand-foot skin reaction (10.8%), proteinuria (3.2%) and diarrhea (2.9%), all possibly associated with VEGFR inhibition. No other CTC grade ³3 adverse events exceeded 1.4% in the fruquintinib population, including hepatic function adverse events such as elevations in bilirubin (1.4%), alanine aminotransferase (0.7%) or aspartate aminotransferase (0.4%). In terms of tolerability, dose interruptions or reductions occurred in only 35.3% and 24.1% of patients in the fruquintinib arm, respectively, and only 15.1% of patients discontinued treatment of fruquintinib due to adverse events versus 5.8% for placebo.

Table of Contents

Studies in Non-small Cell Lung Cancer

Phase II fruquintinib monotherapy in non-small cell lung cancer in China

In June 2014, we initiated a Phase II randomized, double-blind, placebo-controlled, multi-center study of fruquintinib versus placebo among patients with advanced non-squamous non-small cell lung cancer who failed two lines of chemotherapy. By early March 2015, enrollment had been completed with a total of 91 patients randomized to 5 mg of fruquintinib orally once per day, on a 3-weeks-on/1-week-off regimen plus best supportive care, or placebo plus best supportive care at a 2:1 ratio.

In September 2015, we reported that fruquintinib had clearly met its primary endpoint of superior median progression-free survival versus placebo in this study, and in December 2016, we reported the full data from this study at the 2016 World Conference on Lung Cancer, which showed median progression-free survival of 3.8 months for the fruquintinib group compared with 1.1 months for the placebo group (hazard ratio=0.34; 95% confidence interval: 0.20-0.57; p<0.001), an objective response rate based on confirmed partial responses of 13.1% for the fruquintinib group compared with 0.0% for the placebo group (p=0.041), and a 47.5% increase in disease control rate for the fruquintinib group compared with the placebo group (p<0.001). All were assessed by blinded independent clinical review. Fruquintinib was well tolerated with treatment related CTC grade ³3 adverse events with greater than 5% incidence being hypertension (8.1%).

Figure 12: Phase II study in China of fruquintinib monotherapy in third-line non-small cell lung cancer. This study clearly met the median progression-free survival primary endpoint.

Source: Chi-Med

Studies in Gastric Cancer

Phase Ib/II study of fruquintinib combined with Taxol in second-line gastric cancer patients in China

In early 2017, we completed an open label, multi-center Phase Ib dose finding/expansion study of fruquintinib in combination with Taxol in second-line gastric cancer. As of September 10, 2016, a total of 32 patients were enrolled in the study and the recommended dose was determined to be 4 mg once daily on

Table of Contents

a 3-weeks-on/1-week-off schedule in combination with a weekly dose of 80 mg/m² of Taxol. A total of 28 out of the 32 patients were efficacy evaluable with an objective response rate of 36% (10/28, based on confirmed partial responses) and a disease control rate of 68% (19/28). At the recommended dose, progression-free survival of ³16 weeks was 50% of and overall survival of ³7 months was 50%. Tolerability of the recommended dose combination was as expected. In the drug expansion stage, CTC grade ³3 adverse events with greater than 5% incidence related to the treatment were neutropenia (57.9%), leukopenia (21.0%), hypertension (10.6%), decreased platelet count (5.3%), anemia (5.3%), hand-foot skin reaction (5.3%), mucositis oral (5.3%), hepatic disorder (5.3%), and upper gastrointestinal hemorrhage (5.3%), while neutropenia and leukopenia are common Taxol adverse events. The combination regime resulted in an approximately 30% increase in Taxol exposure in patients indicating the potential to decrease the required dose of Taxol in future development. In October 2017, based on the Phase Ib data, we initiated FRUTIGA, a pivotal Phase III clinical trial of fruquintinib in combination with Taxol in second-line gastric cancer. Updated results are expected to be published in an upcoming scientific journal.

Figure 13: Phase Ib/II study of fruquintinib combined with Taxol in gastric cancer. Phase III initiation made on the basis of these encouraging efficacy data.

Source: Chi-Med

Note: As of November 30, 2016

Fruquintinib Current Clinical Development and Near-Term Plans

As discussed below, we currently have various clinical trials of fruquintinib ongoing in China and the United States.

In partnership with Eli Lilly in China, we are conducting a Phase III study of fruquintinib in third-line non-small cell lung cancer patients, a Phase II study of fruquintinib in combination with Iressa in first-line non-small cell lung cancer patients, and a Phase III study of fruquintinib in combination with Taxol in second-line gastric cancer patients. In the United States, we have initiated Phase I study to evaluate the safety, tolerability and pharmacokinetics of fruquintinib in U.S. patients with advanced solid tumors.

Table of Contents

Studies in Colorectal Cancer

Since completing submission of the NDA to the CFDA in early June 2017, we have engaged with the Center for Drug Evaluation to conduct reviews in the areas of (i) pharmacology and toxicity, (ii) clinical data and statistical analysis, and (iii) chemistry, manufacturing and control of standards and process. We have also facilitated the conduct of clinical site visits including GCP and good laboratory practice inspections. We are currently entering in the pre-approval inspection process for our active pharmaceutical ingredient contract manufacturer as well as the pre-approval inspection and GMP-certification process for our Suzhou formulation facility.

Studies in Non-small Cell Lung Cancer

Phase III fruquintinib monotherapy in non-small cell lung cancer (third-line)—China (Target Patient Population 16 in pipeline chart; Status: enrollment complete; NCT02691299)

Following a positive Phase II study comparing fruquintinib with placebo in advanced non-squamous non-small cell lung cancer patients who have failed two prior systemic chemotherapies, or third-line non-small cell lung cancer, we initiated a Phase III registration study, the FALUCA study, in December 2015. In February 2018, we completed enrollment of the FALUCA study in China, in which a total of 527 patients were randomized at a 2:1 ratio to receive either 5 mg of fruquintinib orally once daily, on a 3-weeks-on/1-week-off cycle plus best supportive care, or placebo plus best supportive care. The primary endpoint for FALUCA is overall survival, with secondary endpoints including progression-free survival, objective response rate, disease control rate and duration of response. We expect to reach median overall survival endpoint maturity and report top-line results in late 2018.

Phase II study of fruquintinib in combination with Iressa in non-small cell lung cancer (first-line)—China (Target Patient Population 17 in pipeline chart; Status: enrolling; NCT02976116)

In early 2017, we initiated a multi-center, single-arm, open-label, dose-finding, Phase II study of fruquintinib in combination with Iressa in the first-line setting for patients with advanced or metastatic non-small cell lung cancer with EGFRm+. We have enrolled about 50 patients in this study with the objective to evaluate the safety and tolerability as well as efficacy of the combination therapy. Preliminary data were presented at the 2017 World Conference on Lung Cancer, with the 8 (31%) CTC grade ³3 treatment emergent adverse events being increased alanine aminotransferase (19%), increased aspartate aminotransferase (4%), proteinuria (4%) and hypertension (4%). There were no serious adverse events or those that lead to death. Preliminary results in 17 efficacy evaluable patients showed an objective response rate of 76% (13/17), including 9 confirmed and 4 unconfirmed partial responses at the time of data cut-off, as well as a disease control rate of 100% (17/17).

Fruquintinib's safety and tolerability profile, resulting from its high kinase selectivity, combined with flexibility to adjust dosage to manage treatment emergent toxicities due to its shorter half-life versus monoclonal antibody therapies, along with its potent anti-angiogenic effect, makes it a high potential combination partner for EGFR tyrosine kinase inhibitors. Subject to continued positive data in Target Patient Population 17, we will consider Phase III registration studies both inside and outside of China.

Table of Contents

Figure 14: Phase II study of fruquintinib combined with Iressa in non-small cell lung cancer. Preliminary data showed promising efficacy in the first-line setting.

Phase I fruquintinib monotherapy in advanced solid tumors—United States (Target Patient Population 18 in pipeline chart; Status: enrolling; NCT03251378)

In December 2017, we initiated a multi-center, open-label, Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of fruquintinib in U.S. patients with advanced solid tumors. Upon completion, likely late in 2018, our intention is to begin exploring multiple innovative combination studies of fruquintinib and other tyrosine kinase inhibitors, chemotherapy and immunotherapy agents in the United States.

Studies in Gastric Cancer

Phase III study of fruquintinib in combination with Taxol in gastric cancer (second-line)—China (Target Patient Population 19 in pipeline chart; Status: enrolling)

In October 2017, we initiated the FRUTIGA study, a pivotal Phase III clinical trial of fruquintinib in combination with Taxol for the treatment in advanced gastric or gastroesophageal junction adenocarcinoma patients in China. This randomized, double-blind, placebo-controlled, multi-center trial is being conducted in patients with advanced gastric cancer who have progressed after first-line standard chemotherapy. Over 500 patients will be enrolled in the FRUTIGA study to evaluate the efficacy and safety of fruquintinib combined with paclitaxel compared with paclitaxel monotherapy for second-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma. The trial will enroll patients with disease that has been confirmed through histology or cytology and who did not respond to first-line standard chemotherapy containing platinum and fluorouracil. All subjects will receive fruquintinib or placebo combined with paclitaxel. Patients will be randomized at a 1:1 ratio and stratified according to factors such as stomach versus gastroesophageal junction tumors and ECOG performance status, a scale established by the Eastern Cooperative Oncology Group which determines ability of patient to tolerate therapies in serious illness, specifically for chemotherapy. An independent data monitoring committee will be established to review safety and efficacy data.

The primary efficacy endpoint is overall survival. Secondary efficacy endpoints include progression-free survival, objective response rate, disease control rate, duration of response and quality-of-life score (EORTC QLQ-C30, version 3.0). Biomarkers related to the antitumor activity of fruquintinib will also be explored. We intend to conduct an interim analysis of the FRUTIGA study for futility some time during 2019.

Table of Contents

Advanced gastric cancer is a major medical need, particularly in Asian populations, with limited treatment options for patients who have failed first-line standard chemotherapy with 5-fluorouracil and platinum doublets. For gastric cancer, there are approximately 679,100 new cases and 498,000 deaths in China each year.

Partnership with Eli Lilly

In October 2013, we entered into a license agreement with Eli Lilly in order to accelerate and broaden our fruquintinib development program in China. As a result, we were able to quickly expand the clinical development of fruquintinib in three indications with major unmet medical needs in China: colorectal cancer, non-small cell lung cancer and gastric cancer, as discussed above.

Contingent upon strong proof-of-concept and Phase III results in our clinical trials in China, Eli Lilly and Company (Eli Lilly's parent company) may exercise the option to help us develop fruquintinib globally under an option agreement into which we entered in connection with the license agreement. Support from Eli Lilly has also helped us to establish our manufacturing (formulation) facility in Suzhou, China, which now produces Phase III clinical supplies and will be used to produce fruquintinib for commercial supply, if approved.

For more information regarding our partnership with Eli Lilly and Eli Lilly and Company, see "—Overview of Our Collaborations."

Sulfatinib VEGFR, FGFR1 and CSF-1R Inhibitor

As with fruquintinib, sulfatinib (also known as HMPL-012) was created as part of our initial research goals to develop better, more selective inhibitors than what was under late-stage development at the time, including inhibitors targeting VEGFR and FGFR, two tyrosine kinase receptors associated with angiogenesis and tumor growth. In early 2008, we declared our first small molecule oncology drug candidate, sulfatinib, and it was subsequently the first new compound IND application to be submitted, reviewed and approved by the CFDA under its "green channel" fast-track approval process.

Sulfatinib is an oral small molecule angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases that could simultaneously block tumor angiogenesis and immune evasion. Its unique angio-immuno kinase profile seems to support sulfatinib as an attractive candidate for exploration of possible combinations with checkpoint inhibitors against various cancers. Sulfatinib is currently in development as a single agent for neuroendocrine tumors, thyroid cancer and biliary tract cancer. It also has potential in other tumor types such as breast cancer with FGFR1 activation.

Our expanded Phase I data indicated that sulfatinib has the highest objective response rate reported to date in patients with neuroendocrine tumors. An objective response rate of 38.1% in the intent-to-treat population was observed for sulfatinib in this study, compared to less than 10.0% for Sutent and Afinitor, the two approved single agent therapies for neuroendocrine tumors.

Sulfatinib is the first oncology candidate that we have taken through proof-of-concept in China and expanded globally ourselves. We believe sulfatinib has the potential to receive Breakthrough Therapy designation for the treatment of neuroendocrine tumors if in the U.S. Phase II study we are able to achieve an objective response rate in line with that seen to date. A U.S. Phase I study is close to completion and we are planning a proof-of-concept study in neuroendocrine tumors in the United States.

Mechanism of Action

Both VEGFR and FGFR signaling pathways can mediate tumor angiogenesis. CSF-1R plays an important role on functions of macrophages. Recently, the roles in increasing tumor immune evasion of VEGFR, FGFR in regulation of T cells, tumor-associated macrophages and myeloid-derived suppressor cells have been demonstrated. Therefore, blockade of tumor angiogenesis and tumor immune evasion by

Table of Contents

simultaneously targeting VEGFR, FGFR and CSF-1R kinases may represent a promising approach for anti-cancer therapy.

For more information on the VEGF mechanism of action, see "—Our Clinical Pipeline—Fruquintinib VEGFR 1, 2 and 3 Inhibitor—Mechanism of Action."

Sulfatinib Pre-clinical Evidence

Sulfatinib inhibited VEGFR1, 2, and 3, FGFR1 and CSF-1R kinases with IC₅₀ in a range of 1 nM to 24 nM. It also strongly blocked VEGF-induced VEGFR2 phosphorylation in HEK293KDR cells and CSF-1R phosphorylation in RAW264.7 cells with an IC₅₀ of 2 nM and 79 nM, respectively. Sulfatinib also reduced VEGF- or FGF-stimulated human umbilical vein endothelial cell proliferation with an IC50 < 50 nM. In animal studies, a single oral dose of sulfatinib inhibited VEGF-stimulated VEGFR2 phosphorylation in lung tissues of nude mice in an exposure-dependent manner. Furthermore, elevation of FGF23 levels in plasma 24 hours post dosing suggested suppression of FGFR signaling.

Sulfatinib demonstrated potent tumor growth inhibition in multiple human xenograft models and decreased cluster of differentiation 31 expression remarkably, suggesting strong inhibition on angiogenesis through VEGFR and FGFR signaling. In a syngeneic murine colon cancer model, sulfatinib demonstrated moderate tumor growth inhibition after single-agent treatment. Flow cytometry and immunohistochemistry analysis revealed an increase of certain T cells and a significant reduction in certain tumor-associated macrophages, including CSF-1R mutation positive tumor-associated macrophages in tumor tissue, indicating sulfatinib has a strong effect on CSF-1R. Interestingly, a combination of sulfatinib with a programmed death-ligand 1 antibody resulted in enhanced anti-tumor effect. These results suggested that sulfatinib has a strong effect in modulating angiogenesis and cancer immunity.

Sulfatinib Early and Completed Clinical Development

As discussed below, we have completed two clinical trials of sulfatinib in China.

First-in-human Phase Ia trial

The multi-center, open-label, dose escalation, first-in-human Phase I study of sulfatinib was initiated in China in April 2010. Its primary objective was to study the safety and tolerability and determine the maximum tolerated dose or the recommended Phase II dose of sulfatinib in patients with advanced malignant solid tumors. Secondary endpoints included pharmacokinetic properties and clinical efficacy. The study consisted of a dose escalation period and dose expansion period. The initial sulfatinib dose was 50 mg, once daily. By April 2014, 12 dose groups of 50-350 mg sulfatinib per day had completed the dose escalation study. The maximum tolerated dose was not reached. However, the drug exposures appeared to stop increasing in proportion to dose from 300 mg to 350 mg. In addition, encouraging activity was seen both at 300 and 350 mg doses. A dose expansion study was conducted at the 300 mg and 350 mg dose levels to further investigate the safety, tolerability and pharmacokinetic profile, and preliminary efficacy of sulfatinib. Final results as of July 2015 were published in Oncotarget in February 2017.

A total of 77 patients were enrolled in the study. The first 43 patients were enrolled in sulfatinib, formulation 1, in 50 mg, 75 mg, 110 mg, 150 mg, 200 mg, 265 mg and 300 mg once daily, as well as 125 mg and 150 mg twice daily dose cohorts. As the study progressed, a new milled formulation, formulation 2, was developed with an improved pharmacokinetic profile to replace formulation 1 and was used in the remaining study. There was no subject treated with sulfatinib cross-over by formulations (i.e., no subject receiving formulation 1 had crossed over to formulation 2 during study treatment). A total of 34 patients were enrolled and treated with sulfatinib formulation 2. 23 of the patients were enrolled in the formulation 2 dose escalation study in dose cohorts of 200 mg, 300 mg and 350 mg once daily, and a further 11 were enrolled in an expansion study in dose cohorts of 300 mg and 350 mg once daily. All 34 patients on

Table of Contents

formulation 2 completed the safety and pharmacokinetic evaluation. The maximum tolerated dose was also not reached in this formulation.

CTC grade ³3 adverse events observed in formulation 2 patients with greater than 5% incidence include proteinuria (14.7%), hypertension (8.8%), increased aspartate aminotransferase (5.9%), diarrhea (5.9%), decreased hemoglobin (5.9%), decreased platelet count (5.9%) and hypophosphatemia (5.9%). No dose-limiting toxicity was observed, and maximum tolerated dose has not been determined. Overall, in this Phase I dose escalation study, sulfatinib showed a safety profile that is comparable to the other drugs in the same class and that, as a single agent, it was well tolerated in patients with advanced solid tumors.

Pharmacokinetic analyses showed that the inter- and intra-individual variability in drug concentration was optimized and the exposures in terms of Cmax, or the maximum concentration that a drug achieves in a specified test area of the body after the drug has been administrated and prior to the administration of a second dose, and AUC were increased compared with formulation 2, indicating optimized oral absorption. Phase Ia pharmacokinetic profile of sulfatinib in humans was consistent with pre-clinical findings in that sulfatinib at the 300 mg Phase II dose provides for consistent and sustained target inhibition over 24 hours through an oral dose.

In terms of Phase Ia efficacy, among 34 patients treated with formulation 2, 28 patients were evaluable by Response Evaluation Criteria in Solid Tumors Version 1.0 criteria, of which nine achieved confirmed partial response, including one patient with hepatocellular carcinoma receiving sulfatinib 200 mg once daily, and eight with neuroendocrine tumors receiving sulfatinib 300 or 350 mg once daily. There were 15 patients with stable disease (10 with neuroendocrine tumors, three with hepatocellular carcinoma, one with gastrointestinal stromal tumors, and one with an abdominal malignancy) and four patients with progressive disease. Based on confirmed responses, the objective response rate amongst all patients treated with sulfatinib formulation 2 was 26.5% (9/34) and the disease control rate was 70.6% (24/34), or an objective response rate of 32.1% (9/28) and a disease control rate was 85.7% (24/28) amongst efficacy evaluable formulation 2 patients. The recommended Phase II dose was determined to be 300 mg once daily based on overall safety, tolerability and early clinical efficacy results.

Favorable clinical efficacy has been seen with sulfatinib in patients with neuroendocrine tumors. The formulation 2 expansion study was conducted in neuroendocrine tumor patients who were given 300 mg or 350 mg once daily. Including dose escalation patients, a total of 21 neuroendocrine tumor patients were treated with formulation 2. There were eight confirmed partial response patients, 10 stable disease patients, and three patients were not evaluable for response. This yielded an objective response rate of 44.4% in the 18 evaluable neuroendocrine tumor patients and 38.1% in the entire intent-to-treat population of 21 neuroendocrine tumor formulation 2 patients (compared to an objective response rate of less than 10% for competing products, Sutent and Afinitor). The tumor origins of the eight neuroendocrine tumor patients with partial responses include pancreas (three patients), duodenum (one patient), rectum (one patient) and thymus (one patient), with the remaining two patients' tumors of unknown origin. Furthermore, neuroendocrine tumor responses to sulfatinib have been observed to improve gradually with time.

This early preliminary clinical efficacy of sulfatinib compares favorably to existing drugs approved for the treatment of neuroendocrine tumors. As shown below, however, approved therapies for neuroendocrine tumors are very limited with Afinitor and Sutent approved only for pancreatic neuroendocrine tumors (representing less than 10% of total neuroendocrine tumors) and showing an objective response rate of less than 10% compared to 38% for sulfatinib. The somatostatin analogues octreotide and lanreotide are also approved for narrow subsets of gastrointestinal neuroendocrine tumors, but their objective response rate is less than 5%. In January 2018, the FDA approved Lutathera (lutetium Lu 177 dotatate) injection, a radiolabeled somatostatin analog which, like octreotide and lanreotide, is indicated for the treatment of somatostatin receptor-positive neuroendocrine tumors (gastroenteropancreatic in the case of Lutathera), and has a half-life of less than seven days. Sulfatinib's

Table of Contents

superior objective response rate, and apparent efficacy across many different neuroendocrine tumor types, as compared to existing approved therapies, are the basis for our view that sulfatinib could potentially be eligible for Breakthrough Therapy designation.

Phase Ib/II study in neuroendocrine tumors (first-line), sulfatinib monotherapy (300 mg) in China

In early 2015, we began a 30-patient, 300 mg daily, Phase Ib study in China in broad spectrum neuroendocrine tumor patients (pancreatic, gastrointestinal, liver, lymph and lung, among others) which, due to the major unmet medical need and strong efficacy of sulfatinib, was expanded to over 65 patients and enrollment was completed in August 2015. We then amended the protocol from a Phase Ib study to a single arm Phase II study for which enrollment of 81 patients (41 with pancreatic neuroendocrine tumors and 40 with extra-pancreatic neuroendocrine tumors) was completed in December 2015.

The majority of the patients enrolled in this Phase II study had grade 2 diseases (79%) and had failed previous systemic treatments (65%). We reported the results of this Phase II study at the 2017 European Neuroendocrine Tumor Society conference. As of January 2017, 13 patients had confirmed partial response and 61 patients had stable disease corresponding to an overall objective response rate of 16.0%, with 17.1% in pancreatic neuroendocrine tumors and 15.0% in extra-pancreatic neuroendocrine tumors, and an overall disease control rate of 91.4%. Median overall progression-free survival has not been reached, but is estimated to be 16.6 months, with as-expected, longer median progression-free survival in pancreatic neuroendocrine tumors estimated to be 19.4 months and shorter median progression-free survival in extra-pancreatic neuroendocrine tumors estimated to be 13.4 months. Importantly, in the context of our potential global development strategy, there were 14 patients who had progressed after treatment with systemic therapies (Sutent and Afinitor) and all benefited from the sulfatinib treatment (four patients with partial response and 10 patients with stable disease). Sulfatinib was well tolerated with adverse events CTC grade ³3 with greater than 5% incidence being hypertension (30.9%), proteinuria (13.6%), hyperuricemia (9.9%), hypertriglyceridemia (8.6%), diarrhea (7.4%) and alanine aminotransferase increase (6.2%). Based on this promising efficacy data and tolerability in patients with advanced pancreatic neuroendocrine tumors, two randomized Phase III trials, SANET-p and SANET-ep, have been initiated, as discussed below.

Table of Contents

Figure 15: Phase II study in China of sulfatinib monotherapy in neuroendocrine tumors.
Interim data demonstrates promising efficacy.

Source: European Neuroendocrine Tumour Society Annual Conference 2017. Data cut-off as of January 20, 2017.

Sulfatinib Current Clinical Development and Near-Term Plans

We currently have various clinical trials of sulfatinib ongoing or expected to begin in the near term in China and the United States. Based on the data from our completed Phase Ib/II study in China in neuroendocrine tumors discussed above, we are progressing to two Phase III trials in China, one in pancreatic neuroendocrine tumor patients and one in advanced carcinoid (extra-pancreatic neuroendocrine) tumors, with the extra-pancreatic neuroendocrine tumor study having started enrollment in December 2015 and the pancreatic neuroendocrine tumor study having started enrollment in March 2016. A Phase I dose escalation study in Caucasian patients in the United States is close to completion. Additionally, two Phase II studies of sulfatinib as monotherapy are ongoing in China for recurrent/refractory thyroid cancer patients, with another Phase II study being conducted with Gemzar (gemcitabine) refractory biliary tract cancer patients.

Studies in Neuroendocrine Tumors

Phase III study in pancreatic neuroendocrine tumors, sulfatinib monotherapy—China (Target Patient Population 20 in pipeline chart; Status: enrolling; NCT02589821)

In March 2016, we initiated the SANET-p study, which is a Phase III study in patients with low- or intermediate-grade, advanced pancreatic neuroendocrine tumors. In this study, patients are randomized at a two-to-one ratio to receive either an oral dose of 300 mg of sulfatinib once daily or placebo on a 28-day treatment cycle. The primary endpoint is progression-free survival, with secondary endpoints an oral dose of including objective response rate, disease control rate, time to response, duration of response, overall survival, safety and tolerability. We expect to complete enrollment in 2019 and present top-line results thereafter. If the SANET-p Phase III data is consistent with the 17.1% objective response rate and

Table of Contents

estimated 19.4 month median progression-free survival reported in the above-mentioned Phase Ib/II study, we believe the benefits of sulfatinib as a monotherapy to the approximately 5,000 to 6,000 new patients with pancreatic neuroendocrine tumors in China will be significant as compared to the treatment alternatives currently available to them.

Phase III study in extra-pancreatic neuroendocrine tumors, sulfatinib monotherapy—China (Target Patient Population 21 in pipeline chart; Status: enrolling; NCT02588170)

In December 2015, we initiated the SANET-ep study, which is a Phase III study in patients with low- or intermediate-grade advanced extra-pancreatic neuroendocrine tumors. In this study, patients are randomized at a 2:1 ratio to receive either 300 mg of sulfatinib orally daily or placebo, on a 28-day treatment cycle. The primary endpoint is progression-free survival, with secondary endpoints including objective response rate, disease control rate, time to response, duration of response, overall survival, safety and tolerability. We expect to complete enrollment in 2019 and present top-line results thereafter. If the SANET-ep Phase III data is consistent with the 15.0% objective response rate and estimated 13.4 month median progression-free survival reported in the above-mentioned Phase II study, we believe the benefit of sulfatinib as a monotherapy to patients with extrapancreatic neuroendocrine tumors in China will be significant as compared to the minimal treatment alternatives currently available to them.

Phase I sulfatinib monotherapy in advanced solid tumors—United States (Target Patient Population 22 in pipeline chart; Status: enrolling; NCT02549937)

A Phase I study in cancer patients in the United States is now close to completion, having confirmed the Recommended Phase 2 dose.

We are currently in final planning for an expansion of sulfatinib development in the United States into a multi-arm Phase IIa study to explore efficacy and safety in both neuroendocrine tumor patients and solid tumor cancer patients.

Phase II sulfatinib monotherapy in recurrent/refractory thyroid cancer—China (Target Patient Populations 23 and 24 in pipeline chart; Status: enrollment complete; NCT02614495)

In March 2016, we initiated two Phase II studies in China to evaluate the safety, pharmacokinetics and efficacy of sulfatinib in patients with both medullary and differentiated thyroid cancer and are observing encouraging early efficacy in these open-label studies. We believe that sulfatinib's VEGFR/FGFR1/CSF-1R inhibition profile has strong potential in second-line thyroid cancer patients, particularly in China where there are few safe and effective treatment options for this patient population.

In June 2017, we presented preliminary results of the Phase II studies at the 2017 American Society of Clinical Oncology Annual Meeting and at the American Thyroid Association Annual Meetings. The preliminary data in 16 efficacy evaluable patients showed an objective response rate based on confirmed responses of 30% (3/10) in differentiated thyroid cancer and an objective response rate of 16.7% (1/6) in medullary thyroid cancer, with all other patients reporting stable disease.

Phase II sulfatinib monotherapy in chemotherapy refractory biliary tract cancer—China (Target Patient Population 25 in pipeline chart; Status: enrolling NCT02966821)

In January 2017, we began a Phase II study in patients with biliary tract cancer (also known as cholangiocarcinoma), a heterogeneous group of rare malignancies arising from the biliary tract epithelia. Gemzar is the currently approved first-line therapy for biliary tract cancer patients, with a total of approximately 18,000 new patients per year in the United States according to the National Cancer Institute, but median survival is less than 12 months for patients with unresectable or metastatic disease at diagnosis. As a result, we see a major unmet medical need for patients who have progressed on Gemzar, and sulfatinib may offer a new targeted treatment option in this tumor type.

Table of Contents

Epitinib EGFR Inhibitor

Epitinib (also known as HMPL-813) is a potent and highly selective oral EGFR inhibitor designed to optimize brain penetration. A significant portion of patients with non-small cell lung cancer go on to develop brain metastasis. Patients with brain metastasis suffer from poor prognosis and low quality of life with limited treatment options. Epitinib is a potent and highly selective oral EGFR inhibitor which has demonstrated brain penetration and efficacy in pre-clinical and now clinical studies. EGFR inhibitors have revolutionized the treatment of non-small cell lung cancer with EGFR activating mutations. However, approved EGFR inhibitors such as Iressa and Tarceva cannot penetrate the blood-brain barrier effectively, leaving the majority of patients with brain metastasis without an effective targeted therapy.

Our strategy has been to create targeted therapies in the EGFR area that would go beyond the already approved EGFRm+ non-small cell lung cancer patient population to address certain areas of unmet medical needs that represent significant market opportunities, including: (i) brain metastasis and/or primary brain tumors with EGFRm+, which we seek to address with epitinib; and (ii) tumors with EGFR gene amplification or EGFR over-expression, which we seek to address with theliatinib as discussed below.

Mechanism of Action

EGFR is a protein that is a cell-surface receptor tyrosine kinase for epidermal growth factor. Activation of EGFR can lead to a series of downstream signaling activities that activate tumor cell growth, survival, invasion, metastasis and inhibition of apoptosis. Tumor cell division can happen uncontrollably when the pathway is abnormally activated through EGFRm+, gene amplification of wild-type EGFR or over-expression of wild-type EGFR. Treatment strategies for certain cancers involve inhibiting EGFRs with small molecule tyrosine kinase inhibitors. Once the tyrosine kinase is disabled, it cannot activate the EGFR pathway and trigger downstream signaling activities, thereby suppressing cancer cell growth.

Outside of non-small cell lung cancer, EGFRm+ also occurs in glioblastoma, a common type of malignant primary brain tumor.

Epitinib Pre-clinical Evidence

Pre-clinical studies and orthotopic brain tumor models have shown that epitinib demonstrated brain penetration and efficacy superior to that of current globally marketed EGFRm+ inhibitors such as Iressa and Tarceva. In orthotopic brain tumor models, epitinib demonstrated good brain penetration, efficacy and pharmacokinetic properties as well as a favorable safety profile.

If the pre-clinical findings on drug exposure of epitinib in the brain are confirmed in humans in our clinical trials, we believe epitinib has the potential to qualify for U.S. Breakthrough Therapy designation for patients with EGFRm+ non-small cell lung cancer with tumors metastasized to the brain.

Epitinib Early Clinical Development

As discussed below, we have completed two clinical trials of epitinib in China.

Phase I epitinib monotherapy in non-small cell lung cancer—China

This first-in-human study was conducted to assess the maximum tolerated dose and dose-limiting toxicity, safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of epitinib. As of December 2014, 36 patients were enrolled in seven cohorts (20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 200 mg and 240 mg). This study found that the safety and tolerability of epitinib was acceptable. No dose-limiting toxicity was observed, and the maximum tolerated dose was not reached. The recommended dose from this study was 160 mg once daily based on pharmacokinetics data and safety data.

Table of Contents

Phase Ib epitinib monotherapy in non-small cell lung cancer (first-line), EGFRm+ with brain metastasis, (160 mg daily)—China

In this Phase Ib study, a total of 33 non-small cell lung cancer patients, of which 12 had previously received EGFR tyrosine kinase inhibitor treatment and 21 were EGFR tyrosine kinase inhibitor treatment naïve, were efficacy evaluable with an objective response rate of 39%, including 10 confirmed and three unconfirmed partial responses. All responses occurred in EGFR tyrosine kinase inhibitor treatment naïve patients resulting in an objective response rate of 62% and in the 11 EGFR tyrosine kinase inhibitor naïve patients who also had measurable brain metastasis (lesion diameter>10 mm per Response Evaluation Criteria In Solid Tumors 1.1) with a 64% objective response rate. Furthermore, when patients with c-Met gene amplification were excluded, epitinib's objective response rate increased to 68% in the EGFR tyrosine kinase inhibitor treatment naïve patients and 70% of those patients who also had measurable brain metastasis. Epitinib was well tolerated with treatment related adverse events in the dose expansion stage CTC grade ³3 with greater than 10% incidence were elevations in alanine transaminase (18.9%), elevations in gamma-glutamyltransferase (10.8%), and aspartate transaminase (10.8%).

Figure 16: Phase Ib study in China of epitinib monotherapy in EGFRm+ non-small lung cancer patients with brain metastasis. Phase III initiation made on the basis of this encouraging efficacy data

Dose expansion stage—data cut-off Sept 20, 2016; * Unconfirmed partial response, due to no further assessment at cut-off date; # Includes both confirmed and unconfirmed partial response; ^ c-MET amplification/high expression identified

Source: Chi-Med

Epitinib Current Clinical Development and Near-Term Plans

As discussed below, are currently planning to initiate two clinical studies of epitinib in China, including one Phase III trial.

Table of Contents

Phase Ib epitinib monotherapy in non-small cell lung cancer, EGFRm+ with brain metastasis—China (Target Patient Population 26 in pipeline chart; Status: continues to enroll; NCT02590952)

In December 2016 at the World Conference on Lung Cancer, we presented encouraging efficacy data for an open label, multi-center, Phase I dose expansion study. Patients treated with epitinib at a 160 mg once daily dose (detailed above). During 2017, we continued to enroll patients in this Phase Ib study exploring a lower 120 mg once daily dose in the context of further optimizing tolerability for long-term usage. We expect to decide the Phase III dose in early 2018 and initiate Phase III shortly thereafter.

Phase Ib/II epitinib monotherapy in glioblastoma—China (Target Patient Population 27 in pipeline chart; Status: enrolling; NCT03231501)

Glioblastoma is the most aggressive of the gliomas, which are tumors that arise from glial cells or their precursors within the central nervous system. Glioblastoma is classified as grade IV under the World Health Organization grading of central nervous system tumors, and is the most common brain and central nervous system malignancy, accounting for 46.6% of such tumors. In 2017, there were approximately 12,000 new glioblastoma cases in the United States, according to the Central Brain Tumor Registry of the United States. In 2015, there were approximately 101,600 new brain or central nervous system cancer cases in China. The standard of care for treatment is surgery, followed by radiotherapy and chemotherapy. Median survival is approximately 15 months, and the 5-year survival rate is 5.5%. There are limited treatment options for glioblastoma patients, particularly for patients with recurrent glioblastoma.

Epitinib is a highly differentiated EGFR inhibitor designed for optimal blood-brain barrier penetration. EGFR gene amplification has been identified in about half of glioblastoma patients, according to The Cancer Genome Atlas Research Network, and hence is a potential therapeutic target in glioblastoma.

In March 2018, we initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with EGFR gene amplification in China. This Phase Ib/II study will be a multi-center, single-arm, open-label study to evaluate the efficacy and safety of epitinib as a monotherapy in patients with EGFR gene amplified, histologically confirmed glioblastoma. The primary endpoint is objective response rate.

Theliatinib EGFR Inhibitor

Like epitinib, theliatinib (also known as HMPL-309) is a novel molecule EGFR inhibitor being investigated for the treatment of esophageal and other solid tumors. Tumors with wild-type EGFR activation, for instance, through gene amplification or protein over-expression, are less sensitive to EGFR tyrosine kinase inhibitors such as Iressa and Tarceva due to sub-optimal binding affinity. Theliatinib was designed with strong affinity to the wild-type EGFR kinase and has demonstrated five to ten times the potency than Tarceva in pre-clinical trials. This holds importance because tumors with wild-type EGFR activation have been found to be less sensitive to current EGFR inhibitors. This is notable in certain cancer types such as esophageal cancer, where 8-30% have EGFR gene amplification and 30-90% have EGFR over-expression. As a result, we believe that theliatinib could potentially be more effective than existing EGFR tyrosine kinase inhibitor products and benefit patients with esophageal and head and neck cancer, or other tumor types with a high incidence of wild-type EGFR activation. We currently retain all rights to theliatinib worldwide.

Mechanism of Action

Unlike c-Met, where targeted therapies have yet to be approved in the patient population with c-Met over-expression, there are successful examples of clinical efficacy among patients with EGFR over-expression in tumor types such as colorectal cancer and head and neck cancer. The most successful targeted therapy in the patient population with EGFR over-expression is the monoclonal antibody, Erbitux (cetuximab) (from Bristol Myers Squibb/Merck Serono), which is indicated for head and neck cancer and

Table of Contents

colorectal cancer. Importantly, there remain many tumor types with high levels of EGFR over-expression for which no targeted therapies have been approved. In addition, in patients with EGFR gene amplification, there are no approved targeted therapies despite high levels of EGFR gene amplification occurring in many of the above EGFR over-expressed tumor types.

Theliatinib Pre-clinical Evidence

EGFR is over-expressed in a significant proportion of epithelium-derived carcinomas, which are cancers that begin in a tissue that lines the inner or outer surfaces of the body. Theliatinib inhibits the epidermal growth factor-dependent proliferation of cells at nanomolar concentrations. Of most interest is the strong binding affinity to wild-type EGFR enzyme demonstrated by theliatinib. The data indicated that upon withdrawal of the drug, the EGFR phosphorylation rapidly returns to higher levels for Iressa and Tarceva, while EGFR phosphorylation remained low for theliatinib after drug withdrawal, suggesting theliatinib may demonstrate a sustained target occupancy or "slow-off" characteristic due to strong binding, as shown in Figure 17 below.

Figure 17: Comparison of binding affinity to wild-type EGFR enzyme

Source: Chi-Med

Note: When adenosine triphosphate (ATP) binds to an EGFR enzyme, the enzyme phosphorylates its peptide substrate to produce phosphorylated peptide, or phospho-peptide. Hence, low phospho-peptide levels are correlated with a high level of EGFR inhibition.

Theliatinib Current Clinical Development and Near-Term Plans

As discussed below, we currently have two clinical trials of theliatinib ongoing in China.

100

Table of Contents

Phase I study of theliatinib monotherapy in advanced solid tumors—China (Target Patient Population 28 in pipeline chart; Status: enrollment complete; NCT02601274)

In November 2012, we initiated the first-in-human Phase I, open-label, dose escalation study in China of theliatinib administered orally to patients with wild-type EGFR gene amplification or EGFR over-expression solid tumors who have failed standard therapy. The primary objectives of the study were to evaluate its safety and tolerability in patients with advanced solid tumors and to determine the maximum tolerated dose. The study also evaluated efficacy against non-small cell lung cancer, esophageal cancer and head and neck squamous cell lung cancer, determined the pharmacokinetics of theliatinib under single dose and repeat doses; and explored the relationship between the theliatinib's activity and certain biomarkers.

In September 2017, new clinical data were presented at the 20^th Annual Meeting of the Chinese Society of Clinical Oncology. Results showed that doses up to 500 mg once daily were determined to be safe and well-tolerated, with no dose-limiting toxicities and no clear maximum tolerated dose. Pharmacokinetic exposure increased with dose, with a 300 mg once daily or more considered to be sufficient to inhibit EGFR phosphorylation. Among the 21 patients that received 120 mg to 500 mg once daily, there were only four treatment-emergent adverse events of grade ³3: gastrointestinal bleeding, decreased white blood cell count, anemia or decreased platelet count (1/21 = 4.8% each). There were no incidences of grade ³3 rash or diarrhea. Among seven esophageal cancer patients, five had measurable lesions and could be evaluated for response. All five had stable disease. Of the efficacy evaluable patients in the 120 mg to 500 mg cohorts, 44.4% (8/18) had stable disease after 12 weeks. The study concluded that further study of theliatinib at 400 mg once daily among esophageal cancer patients with EGFR activation was warranted. This study is now in the process of expanding through the opening of further clinical sites in China.

Phase Ib expansion study of theliatinib monotherapy in esophageal cancer—China (Target Patient Population 29 in pipeline chart; Status: enrolling; NCT02601274)

In January 2017, we initiated a Phase Ib proof-of-concept expansion study at 300 mg of theliatinib once daily in esophageal cancer patients with EGFR protein overexpression or gene amplification.

HMPL-523 Syk Inhibitor

The result of our over six-year program of discovery and pre-clinical work against Syk is HMPL-523, a highly selective Syk inhibitor with a unique pharmacokinetic profile which provides for higher drug exposure in the tissue than on a whole blood level. We designed HMPL-523 intentionally to have high tissue distribution because it is in the tissue that the B-cell activation associated with rheumatoid arthritis and lupus occurs most often. Furthermore, and somewhat counter intuitively, in hematological cancer the vast majority of cancer cells nest in tissue, with a small proportion of cancer cells releasing and circulating in the blood where they cannot survive for long. In both rheumatoid arthritis and hematological cancer, we assessed that an effective small molecule Syk inhibitor would need to have superior tissue distribution.

However, many pharmaceutical and biotechnology companies had experienced difficulties in developing a safe and efficacious Syk-targeted drug. For example, the development of the Syk inhibitor fostamatinib for rheumatoid arthritis was one such failed program, although clear efficacy was observed in Phase II and Phase III trials. The main problem was off-target toxicities associated with poor kinase selectivity, such as hypertension and severe diarrhea. Therefore, we believe that kinase selectivity is critical to a successful Syk inhibitor. In addition, fostamatinib was designed as a prodrug in order to improve solubility and oral absorption. A prodrug is medication administered in a pharmacologically inactive form which is converted to an active form once absorbed into circulation. The rate of the metabolism required to release the active form can vary from patient to patient, resulting in large variation in active drug exposures that can impact efficacy. We believe HMPL-523 offers important advantages over intravenous

101

Table of Contents

monoclonal antibody immune modulators in rheumatoid arthritis in that small molecule compounds clear the system faster, thereby reducing the risk of infections from sustained suppression of the immune system.

Mechanism of Action

Targeting the B-cell signaling pathway is emerging as a potential means to treat both hematological cancer and immunology. Both PI3Kd and BTK (both kinases) along the B-cell signaling pathway have proven clinical efficacy in hematological cancers, and consequently the FDA has approved drugs targeting these kinases in the past few years. Syk is a key kinase upstream of the PI3Kd and BTK, and we believe should therefore be an important target for modulating B-cell signaling.

Figure 18: The B-cell signaling pathway and the approved drugs / drug candidates which target its component kinases

Source: Chi-Med

Note: This graphic is a highly simplified representation of the B-cell signaling pathways, which are each composed of a signaling cascade of the multiple kinases indicated in the graphic. Signaling from the B-cell receptor (BCR) through the cascade, in simple terms, triggers an immune response, including tumor cell activation, proliferation, survival and migration.

Syk, a target for autoimmune diseases

The central role of Syk in signaling processes is not only in cells of immune responses but also in cell types known to be involved in the expression of tissue pathology in autoimmune, inflammatory and allergic

102

Table of Contents

diseases. Therefore, interfering with Syk could represent a possible therapeutic approach for treating these disorders. Indeed, several studies have highlighted Syk as a key player in the pathogenesis of a multitude of diseases, including rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis.

Syk, a target for oncology

In hematological cancer, we believe Syk is a high potential target. In hematopoietic cells, Syk is recruited to the intracellular membrane by activated membrane receptors like B-cell receptors or another receptor called Fc and then binds to the intracellular domain of the receptors. Syk is activated after being phosphorylated by Src family kinases and then further induces downstream intracellular signals including B-cell linker, PI3Kd, BTK and Phospholipase Cg2 to regulate B-cell proliferation, growth, differentiation, homing, survival, maturation, and immune responses. Syk not only involves the regulation of lymphatic cells but also signal transduction of non-lymphatic cells such as mast cells, macrophages, and basophils, resulting in different immunological functions such as degranulation to release immune active substances, leading to immunological reaction and disease. Therefore, regulating B-cell signal pathways through Syk is expected to be effective for treating lymphoma.

The high efficacy and successful approvals of both Imbruvica (ibrutinib) (developed by AbbVie Inc.), a BTK inhibitor, and Zydelig (idelalisib) (developed by Gilead), a PI3Kd inhibitor, are evidence that modulation of the B-cell signaling pathway is critical for the effective treatment of B-cell malignancies. Syk is upstream of both BTK and PI3Kd, and we believe it could deliver the same outcome as Imbruvica and Zydelig, assuming no unintentional toxicities are derived from Syk inhibition. Entospletinib (GS-9973), a Syk inhibitor developed by Gilead, reported promising Phase II study results in late 2015 with a nodal response rate of 65% observed in chronic lymphocytic leukemia and small lymphocytic lymphoma. Nodal response is defined as a greater than 50% decrease from baseline in the sum of lymph node diameters. Gilead has also reported that entospletinib demonstrated a nodal response rate of 44.4% in an exploratory clinical study in chronic lymphocytic leukemia patients previously treated with Imbruvica and Zydelig, thereby indicating that Syk inhibition has the potential to overcome resistance to Imbruvica and Zydelig. Takeda reported similarly strong signs of efficacy for their TAK-659 Phase I dose escalation study in lymphoma, which was also published in late 2015.

HMPL-523 Research Background

The threshold of safety for a Syk inhibitor in chronic disease is extremely high, with no room for material toxicity. The failure of fostamatinib in a global Phase III registration study in rheumatoid arthritis provided important insights for us in the area of toxicity. While fostamatinib clearly showed patient benefit in rheumatoid arthritis, a critical proof-of-concept for Syk modulation, it also caused high levels of hypertension which is widely believed to be due to the high levels of off target KDR inhibition. In addition, fostamatinib has also been shown to strongly inhibit the Ret kinase, and in pre-clinical studies it was demonstrated that inhibition of the Ret kinase was associated with developmental and reproductive toxicities.

The requirement for Syk kinase activity in inflammatory responses was first evaluated with fostamatinib, which was co-developed by AstraZeneca/Rigel Pharmaceuticals, Inc. (also called R788, a prodrug of an active Syk inhibitor R406). In June 2013, AstraZeneca announced results from pivotal Phase III clinical trials that fostamatinib statistically significantly improved ACR20 (a 20% improvement from baseline based on the study criteria) response rates of patients inadequately responding to conventional disease-modifying anti-rheumatic drugs and a single anti-TNFa (a key pro-inflammatory cytokine involved in rheumatoid arthritis pathogenesis) antagonist at 24 weeks, but failed to demonstrate statistical significance in comparison to placebo at 24 weeks. As a result, AstraZeneca decided not to proceed.

103

Table of Contents

Fostamatinib was also in trials for B-cell lymphoma and T-cell lymphoma. It demonstrated some clinical efficacy in diffused large B-cell lymphoma patients with an objective response rate of 22%. Entospletinib, a Syk inhibitor developed by Gilead, has features of high potency and good selectivity toward kinases. However, while the Phase II study discussed above showed that it had significant efficacy in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, its poor solubility and permeability into intestinal epithelial cells resulted in unsatisfactory oral absorption and a great variation of individual drug exposure. In addition, entospletinib shows some inhibition of the CYP3A4, CYP2D6, and CYP1A2 enzymes involved in the metabolism of certain drugs, and therefore their inhibition could increase the risk of drug-to-drug interaction when used in combined therapy.

HMPL-523 Pre-clinical Evidence

The safety profile of HMPL-523 was evaluated in multiple in vitro and in vivo pre-clinical studies under GLP guidelines and found to be well tolerated following single dose oral administration. Toxic findings were seen in repeat dose animal safety evaluations in rats and dogs at higher doses and found to be reversible. These findings can be readily monitored in the clinical studies and fully recoverable upon drug withdrawal. The starting dose in humans was suggested to be 5 mg. This dose level is approximately 5% of the human equivalent dose extrapolated from the pre-clinical "no observed adverse event levels", which is below the 10% threshold recommended by FDA guidelines.

In vitro Pharmacology

HMPL-523 is a highly selective Syk inhibitor with an IC₅₀ of 24 ± 4 nM (n=7) in a Syk kinase enzymatic assay. HMPL-523 has been evaluated in a kinase selectivity panel of 287 kinases and a broad pharmacological panel of 79 targets. We believe, as shown in the chart below, HMPL-523's lack of KDR inhibition will mean a much lower risk of hypertension, which is a major off-target toxicity of R406 in clinical trials.

Figure 19: HMPL-523 kinase selectivity in comparison to R406 (the Syk inhibitor metabolite of fostamatinib). R406 is shown below to be as potent in inhibiting KDR as it is in inhibiting Syk, and significantly more potent in inhibiting FLT3 and Ret.

Sources: [a]: Chi-Med, Eun-ho Lee et al, 2011 American College of Rheumatology; [b]: S. P. McAdoo and F. W. Tam, Drugs Future, 2011, 36(4), PP273-283

104

Table of Contents

In vivo Pharmacology

HMPL-523 blocked B-cell activation in mouse whole blood and rat whole blood ex vivo challenge with an EC₅₀ of 1301 ng/mL (ED₅₀ of 2.9 mg/kg) and 332.8~471.7 ng/mL (ED₅₀ of 4.1~5.2 mg/kg) at 2 hours after dosing, respectively. The maximum inhibition was observed at 2 hours after oral dosing, while the significant inhibition was maintained for up to 4 hours.

HMPL-523 was further evaluated in collagen-induced rheumatoid arthritis in mice and rats. HMPL-523 treatment significantly reduced disease severity in a dose dependent manner with an estimated ED₅₀ of 4.0 - 6.8 mg/kg once daily in mouse collagen-induced arthritis, and suppressed paw swelling with an ED₅₀ of 1.4 - 2.0 mg/kg once daily in the rat collagen-induced arthritis model (AUC_0-24h was 1408 h*ng/mL) and with the minimum efficacious dose (ED_min) of 0.7 - 1.0 mg/kg once daily (AUC_0-24h was 413 h*ng/mL).

HMPL-523 not only halted disease progression, but also reversed aspects of the disease such as paw swelling and bone resorption to normal levels at higher doses in rat collagen-induced arthritis therapeutic models. Figure 20 below shows that HMPL-523 significantly reduced bone resorption at 3 mg/kg once daily dose. The 3 mg/kg once daily HMPL-523 dose delivered similar efficacy to both fostamatinib, at a significantly higher dosage of 10 mg/kg twice daily, and Enbrel (etanercept) (an approved monoclonal antibody from Amgen/Pfizer/Takeda), at the higher dosage of 10 mg/kg once every other day.

However, at the 10 mg/kg once daily dose, HMPL-523 reached maximum efficacy, which correlated with significant reduction of pro-inflammatory cytokines and chemokines in the joint lavage fluid of rats with collagen-induced arthritis, resulting in an almost total reversal of symptoms in the induced rheumatoid arthritis rat model.

In vivo efficacy of the orally active HMPL-523 was evaluated in lupus-prone (MRL/lpr) mice. HMPL-523, at 20 mg/kg, significantly blocked skin lesions, delayed the onset of proteinuria (the presence of abnormal quantities of proteins in urine which may indicate kidney damage) and reduced the immune organs to body weight ratios and suppressed production of anti-dsDNA antibodies (a group of anti-nuclear antibodies that act against certain DNA).

Anti-tumor activity and combination synergy with other therapies

In in vitro B-cell lymphoma cell lines with Syk/BCR dysregulation, HMPL-523 was found to block phosphorylation of B-cell linker protein as well as inhibit cell viability by inhibiting cell survival and increasing apoptotic rate. HMPL-523 also showed synergistic anti-tumor activity on human diffused large B-cell lymphoma cells, in combination with other drugs such as PI3Kd inhibitors, B-cell lymphoma 2 family inhibitors, or chemotherapies. Potent anti-tumor activity was also demonstrated in nude mice bearing B-cell lymphoma xenograft tumors with Syk/B-cell receptor dysregulation.

105

Table of Contents

Figure 20: HMPL-523 in hematological malignancies. Pre-clinical superiority versus both BTK/PI3Kd tyrosine kinase inhibitors as well as entospletinib (GS-9973)

A.: Syk inhibitors all showed a dose dependent increase in apoptotic rate (cell death) in REC-1 cells with HMPL-523 efficacy stand-out.
B.: HMPL-523 inhibited cells survival in panel of human lymphoma & leukemia cells—standout efficacy versus ibrutinib (BTK) & idelalisib (PI3Kd) inhibitors.
C.: Combination of HMPL-523 with other drugs (PI3Kd tyrosine kinase inhibitor; ABT-199; Lenalidomide) promote cell killing in DLBCL through inducing apoptosis.

HMPL-523 Current Clinical Development and Near-Term Plans

As discussed below, we currently have various clinical trials of HMPL-523 ongoing or expected to begin in the near term in Australia, the United States and China.

We have been in a Phase I clinical trial in Australia with HMPL-523 since mid-2014 and have completed 10 cohorts of a single ascending dose program in healthy volunteers. In mid-2015, we began a multiple ascending dose study in healthy volunteers, and we successfully completed the multiple dose section of this Phase I study in October 2015. In parallel with this study, we initiated a second Phase I clinical study in Australia in patients with hematological malignancies in January 2016.

106

Table of Contents

Phase I study of HMPL-523 in healthy volunteers in Australia and China (Target Patient Populations 30 and 31 in pipeline chart; Status: complete; NCT02105129)

In November 2016, we reported results of the Phase I dose-escalation study on HMPL-523 in healthy volunteers in Australia, in which a total of 118 adult male healthy subjects were enrolled at baseline and 114 (96.6%) subjects completed the study. The Phase I study showed HMPL-523 exhibited a tolerable safety profile. A total of 83 treatment emergent adverse events were reported, with 38.9% in the HMPL-523 groups and 32.1% in the placebo groups, respectively. Two serious adverse events were reported in the Phase I study and when HMPL-523 was discontinued in those subjects the serious adverse events were resolved. Off-target toxicities such as diarrhea and hypertension, seen with the first-generation Syk inhibitor fostamatinib, were not observed.

In an ex-vivo human whole blood pharmacodynamic assay, HMPL-523 inhibited anti-IgE-induced basophil activation (CD63+) in a concentration-dependent manner with an estimated half maximal effective concentration of 47.70mg/mL. Systemic exposure of HMPL-523 was increased up to 1.5 fold when administered in a fed condition compared to a fasted condition, indicating that food consumption increases the relative bioavailability of HMPL-523. Human pharmacokinetic exposures at 200 mg once daily and above can be expected to provide the target coverage required for clinical efficacy based on the pre-clinical human pharmacokinetic/pharmacodynamics analysis and as a result, a multiple-dose regimen of 300 mg or less of HMPL-523, administered once daily, is the recommended Phase II dose for clinical trials in autoimmune diseases. HMPL-523 demonstrated a dose dependent suppression of B-cell activation. The data were presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals in 2016. We have submitted IND applications for autoimmune diseases and expect, pending the imminent submission of additional data requested by the FDA, to progress into a Phase II proof-of-concept study in immunology in late 2018 or early 2019.

Phase I study of HMPL-523 in hematological cancer—Australia/China (Target Patient Populations 32 and 33 in pipeline chart; Status: enrolling; NCT02503033/NCT02857998)

In early 2016, we initiated a Phase I dose escalation study of HMPL-523 in Australia in hematological cancer patients and have completed seven dose cohorts. The Phase I study in China began in early 2017 and has now completed five dose cohorts. In both Australia and China, we have established both efficacious once daily and twice daily dose regimens. We are now in the process of increasing the number of clinical sites in Australia and China to support Phase Ib/II expansion in a broad range of indolent non-Hodgkin's lymphoma sub-types. We target to present dose escalation and expansion results, including preliminary proof-of-concept data, at a major scientific conference later in 2018.

HMPL-689 PI3Kd Inhibitor

HMPL-689 is a novel, highly selective and potent small molecule inhibitor targeting the isoform PI3Kd, a key component in the B-cell receptor signaling pathway. We have designed HMPL-689 with superior PI3Kd isoform selectivity, in particular to not inhibit PI3Kg (gamma), offering advantages over Zydelig to minimize the risk of serious infection caused by immune suppression. HMPL-689's strong potency, particularly at the whole blood level, also allows for reduced daily doses to minimize compound related toxicity, such as the high level of liver toxicity observed with the first-generation PI3Kd inhibitor Zydelig. HMPL-689's pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. We also expect that HMPL-689 will have low risk of drug accumulation and drug-to-drug interaction.

Given this, we believe that HMPL-689 has the potential to be a global best-in-class PI3Kd agent. We currently retain all rights to HMPL-689 worldwide.

107

Table of Contents

Mechanism of Action

Class I phosphatidylinositide-3-kinases, or PI3Ks, are lipid kinases that, through a series of intermediate processes, control the activation of several important signaling proteins including the serine/threonine kinase AKT. In most cells, AKT is a key PI3K effector that regulates cell proliferation, carbohydrate metabolism, cell motility and apoptosis, and other cellular processes. Please refer to Figure 18 ("The B-cell signaling pathway").

There are multiple sub-families of PI3K kinases, and PI3Kd plays important roles in B-cell activation, development, survival and migration. PI3Kd is mainly expressed in circulating leukocytes and lymphoid tissues and plays critical roles in B-cell activation and proliferation. PI3Kd is the central signaling enzyme that mediates the effects of multiple receptors on B-cells. Upon an antigen binding to B-cell receptors, PI3Kd can be activated through the Lyn and Syk signaling cascade.

Aberrant B-cell function has been observed in multiple autoimmune diseases and B-cell mediated malignancies. Therefore, PI3Kd is considered to be a promising target for drugs that aim to prevent or treat hematologic cancer, autoimmunity and transplant organ rejection and other related inflammation diseases.

HMPL-689 Pre-clinical Evidence

Compared to other PI3Kd inhibitors, HMPL-689 shows higher potency and selectivity.

Figure 21: Enzyme selectivity (IC₅₀, in nM) of HMPL-689 versus competing PI3Kd inhibitors; this shows HMPL-689 is approximately five-fold more potent than Zydelig (idelalisib) on whole blood level and, unlike duvelisib, does not inhibit PI3Kg.

Source: Chi-Med

HMPL-689 Clinical Development

Phase I dose escalation study of HMPL-689—Australia and China (Target Patient Populations 34 and 35 in pipeline chart; Status: enrolling; NCT02631642/NCT03128164)

We subsequently received IND clearance in China and then initiated a Phase I dose escalation and expansion study in patients with hematologic malignancies in August 2017.

108

Table of Contents

HMPL-453 FGFR Inhibitor

Mechanism of Action

Fibroblast growth factor receptors, or FGFRs, belong to a subfamily of receptor tyrosine kinases, or RTKs. Four different FGFRs (FGFR1-4) and at least 18 ligand FGFs constitute the FGF/FGFR signaling system. Activation of the FGFR pathway through the phosphorylation of various downstream molecules ultimately leads to increased cell proliferation, migration and survival. FGF/FGFR signaling regulates a wide range of basic biological processes, including tissue development, angiogenesis, and tissue regeneration. Given the inherent complexity and critical roles in physiological processes, dysfunction in the FGF/FGFR signaling leads to a number of developmental disorders and is consistently found to be a driving force in cancer. Deregulation of the FGFR can take many forms, including receptor amplification, activating mutations, gene fusions, and receptor isoform switching, and the molecular alterations are found at relatively low frequencies in most tumors. The incidence of FGFR aberrance in various cancer types is listed in Figure 22 below.

Figure 22: Common genetic alterations in FGFRs related to cancer

Source: M. Touat et al, "Targeting FGFR Signaling in Cancer," Clinical Cancer Research (2015); 21(12); 2684-94

HMPL-453 Research Background

We noted a growing body of evidence has demonstrated the oncogenic potential of FGFR aberrations in driving tumor growth, promoting angiogenesis, and conferring resistance mechanisms to anti-cancer therapies. Targeting the FGF/FGFR signaling pathway has therefore attracted a good deal of attention from biopharmaceutical companies and has become an important exploratory target for new anti-tumor target therapies.

109

Table of Contents

Currently, FGFR monoclonal antibodies, FGF ligand traps and small molecule FGFR tyrosine kinase inhibitors are being evaluated in early clinical studies. BGJ-398 (Novartis), AZD4547 (AstraZeneca) and JNJ-42756493 (Johnson & Johnson) are the leading FGFR selective tyrosine kinase inhibitors, and their early clinical trials provided substantial proof-of-concept with regard to anti-tumor efficacy and pharmacodynamic markers of effective FGFR pathway inhibition.

The main FGFR on-target toxicities observed to date in these compounds are all mild and manageable, including hyperphosphatemia, nail and mucosal disorder, and reversible retinal pigmented epithelial detachment. However, there are still many challenges in the development of FGFR-directed therapies. Uncertainties include the screening and stratifying of patients who are most likely to benefit from FGFR targeted therapy. Intra-tumor heterogeneity observed in FGFR amplified cancer may compromise the anti-tumor activity. In addition, the low frequency of specific FGFR molecular aberrance in each cancer type may hinder clinical trial enrollment. As a result, there have been no approved therapies specifically targeting the FGFR signaling pathway to date.

HMPL-453 Pre-clinical Evidence

HMPL-453 is a potential first-in-class novel, highly selective and potent, small molecule that targets FGFR 1/2/3 with an IC₅₀ in the low nanomolar range. Its good selectivity was revealed in the screening against 292 kinases. HMPL-453 exhibited strong anti-tumor activity that correlated with target inhibition in tumor models with abnormal FGFR activation.

HMPL-453 has good pharmacokinetic properties characterized by rapid absorption following oral dosing, good bioavailability, moderate tissue distribution and moderate clearance in all pre-clinical animal species. HMPL-453 was found to have little inhibitory effect on major cytochrome P450 enzymes, indicating low likelihood of drug-to-drug interaction issues.

HMPL-453 Clinical Development

Phase I dose escalation study of HMPL-453 in solid tumors—Australia and China (Target Patient Populations 36 and 37 in pipeline chart; Status: enrolling; NCT02966171/NCT03160833)

In June 2017, we initiated a Phase I/II clinical trial of HMPL-453 in China. This Phase I/II study is a multi-center, single-arm, open-label, two-stage study to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-453 monotherapy in patients with solid tumors harboring FGFR genetic alterations. The dose-escalation stage will enroll patients with locally advanced or metastatic solid tumors, for whom standard therapy either does not exist or has proven to be ineffective or intolerable, regardless genetic status, to determine the maximum tolerated dose and recommended Phase II dose. The dose-escalation will be followed by a dose-expansion stage, which will further evaluate safety, tolerability and pharmacokinetics as well as preliminary anti-tumor efficacy at the recommended Phase II dose. This stage will enroll primarily cancer patients harboring FGFR dysregulated tumors, including those with advanced bladder cancer, advanced cholangiocarcinoma and other solid tumors. For this second stage, the primary endpoint is objective response rate, with secondary endpoints including duration of response, disease control rate, progression-free survival, overall survival and safety.

This study complements the first-in-human Phase I clinical trial in Australia that was initiated in February 2017. The first-in-human dose-escalation trial aims to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of HMPL-453 in patients with advanced or metastatic solid malignancies, who have failed or are unable to tolerate standard therapies or for whom no standard therapies exist. This open-label study consists of two preliminary phases, a dose-escalation (stage 1) and a dose-expansion stage (stage 2).

110

Table of Contents

HMPL-004/HM004-6599 Botanical NF-kB Modulator

In November 2012, we established Nutrition Science Partners, a joint venture with Nestlé Health Science. The purpose of Nutrition Science Partners is to develop, manufacture and commercialize HMPL-004 for ulcerative colitis and Crohn's disease and to identify, develop, manufacture and commercialize products in gastrointestinal indications.

We have worked with Nestlé Health Science to prepare an IND application for HM004-6599, which was submitted in China in March 2017, and to prepare for a Phase I study of HM004-6599 in Australia in 2018. HM004-6599 is an enriched / purified re-formulation of HMPL-004, our drug candidate that reported positive Phase II results in ulcerative colitis in 2010 but then went on to prove futile in an interim analysis of the subsequent Phase III study in 2014. HM004-6599 has a higher level of biologically active components and improved manufacturing control, as compared to HMPL-004.

For more information regarding our partnership with Nestlé Health Science, see "—Overview of Our Collaborations."

HMPL-004/HM004-6599 Research Background

HMPL-004, and the newer, enriched version HM004-6599 discussed below, are proprietary botanical drugs for the treatment of inflammatory bowel diseases, namely ulcerative colitis and Crohn's disease.

The current standard of care for inflammatory bowel disease starts with 5-aminosalicylic acids, or 5-ASA, which can induce and maintain clinical response and remission in an average of approximately 50% of inflammatory bowel disease patients. For the 5-ASA non-responding patients with moderate-to-severe active diseases, various forms of corticosteroids and immunosuppressant drugs and anti-tumor necrosis factor agents such as biologics are prescribed. These agents, though effective, are associated with many side effects, sometimes serious, and are not often suitable for prolonged usage.

Accordingly, there remain clear unmet medical needs for new therapies which can induce and maintain remission among 5-ASA non-responding or intolerant patients, and the need for safer agents without the side effects of corticosteroids and immune suppressors.

HMPL-004 Pre-clinical Evidence

Extensive pre-clinical studies indicated that HMPL-004 exhibits its anti-inflammatory effects through the inhibition of multiple cytokines (proteins), such as NF-kB (a protein complex that controls transcription of DNA, cytokine production and cell survival), both systemically and locally, which are involved in causing digestive tract inflammation. HMPL-004's efficacy, when combined with 5-ASAs, in induction of clinical response, remission and healing of the mucosa (a mucous membrane lining the intestine), as well as a favorable safety profile has been established in multiple clinical trials, including a successful global Phase IIb study in mild-to-moderate ulcerative colitis patients.

HMPL-004 Early and Completed Clinical Development

As discussed below, we have completed various clinical trials of HMPL-004 in the United States, Canada, Europe and Ukraine.

Phase IIb ulcerative colitis trial

The Phase IIb ulcerative colitis trial was a multi-center, double-blind, randomized and placebo-controlled study conducted in 223 ulcerative colitis patients in the United States, Canada and Europe. Results were reported in November 2009. The three-arm clinical trial included eight week treatment with HMPL-004 at two dose levels, 1,200 mg per day or 1,800 mg per day, as compared to placebo. Completed data analysis demonstrated that all primary and key secondary endpoints were achieved. There were no

111

Table of Contents

treatment-related serious adverse events in either of the HMPL-004 arms reported by the investigators. Importantly, clinical efficacy, including response, remission, and mucosal healing, improved markedly as dose increased among the intent-to-treat patient population, with the higher 1,800 mg dose outperforming the 1,200 mg dose and placebo in all areas. The clinical response of the 1,800 mg arm was 71% (p = 0.0003) compared to 48% (p = 0.17) for the 1,200 mg arm and 35% for placebo. Remission of the 1,800 mg arm was 39% (p = 0.013) compared to 32% (p = 0.08) for the 1,200 mg arm and 17% for placebo. Mucosal healing of the 1,800 mg arm was 53% (p = 0.007) compared to 38% (p = 0.23) for the 1,200 mg arm and 27% for placebo. This trial was recognized as the Distinguished Abstract Plenary oral presentation at Digestive Disease Week in 2010, which is a distinguished honor in the global gastrointestinal disease field.

Phase II Crohn's disease trial

The Phase II Crohn's disease trial was a multi-center, double-blind, randomized, and placebo-controlled study conducted in 101 Crohn's disease patients in the United States and Ukraine. Results were reported in July 2009. The two-arm clinical trial demonstrated a clear trend of efficacy for HMPL-004 at the 1,200 mg per day dose level with no treatment-related serious adverse events. Clinical response of the 1,200 mg arm was 37% (p = 0.087) versus 22% for placebo. Remission of the 1,200 mg arm was 29% (p = 0.069) versus 14% for placebo.

NATRUL-3 global Phase III ulcerative colitis registration trial

In April 2013, Nestlé Health Science initiated the NATRUL-3 global Phase III registration trial in mild-to-moderate ulcerative colitis patients on HMPL-004, in combination treatment with 5-ASAs, and conducted an interim analysis in mid-August 2014. The interim analysis was intended to assess both futility, in terms of efficacy and safety on approximately one-third of the 420 planned patients in NATRUL-3. The result of the interim analysis was that HMPL-004 showed no overall material effect over the placebo-arm patients and consequently the NATRUL-3 study was terminated and the data un-blinded.

Subsequent post-hoc analysis of the un-blinded NATRUL-3 data indicates an efficacy signal among the 51% of NATRUL-3 patients who had been on 5-ASAs for more than one year prior to enrollment. These patients at the time of their enrollment in NATRUL-3 were in ulcerative colitis flare condition and as such could be considered as 5-ASA non-responders. The efficacy signal was further enhanced among these 5-ASA non-responders when patients with difficult-to-treat concurrent medical conditions, that could have affected ulcerative colitis response, were removed.

In summary, we believe the above clinical data demonstrates clinical efficacy for HMPL-004, with 5-ASA resistant/non-responding patients benefiting the most. Furthermore, HMPL-004's formulation contains almost 80% inactive substances, which leads to a heavy pill burden and patient compliance challenges. During 2015, we focused on optimizing the HMPL-004 formulation by adding several steps to the extraction process and thereby increasing the concentration of diterpenoids, the key bioactive ingredient of HMPL-004. The new enriched formulation of HMPL-004, which we have named HM004-6599, is now over 70% diterpinoids as compared to the original formulation which comprised approximately 15% diterpenoids. In extensive pre-clinical in-vitro models, HM004-6599 has demonstrated superior inhibition of NF-kB activation, pro-inflammatory cytokine IL-1ß (an important mediator in the regulation of immune and regulatory responses to infections) production and TNFa inhibitors dependent chemokine production including the CCL-20 cytokine. Given the enrichment, the predicted human dose of HM004-6599 could be as low as 400 mg to 800 mg daily versus the 2,400 mg daily usage of HMPL-004.

In the first half of 2017, we submitted our IND application for HM004-6599 in China and we now await clearance to proceed into Phase I clinical studies. We also target to initiate Phase I clinical studies in Australia in 2018.

Nutrition Science Partners has additional gastrointestinal drug candidates in research and pre-clinical development.

112

Table of Contents

Overview of Our Collaborations

Collaborations and joint ventures with corporate partners have provided us with significant funding and access to our partners' scientific, development, regulatory and commercial capabilities. Our current collaborations focus on savolitinib (collaboration with AstraZeneca), fruquintinib (collaboration with Eli Lilly) and HMPL-004/HM004-6599 (collaboration with our joint venture partner Nestlé Health Science). Our collaboration partners fund a significant portion of our research and development costs for drug candidates developed in collaboration with them. In addition, we receive upfront payments upon our entry into these collaboration arrangements and upon the achievement of certain development milestones for the relevant drug candidate. We and Nutrition Science Partners, in the aggregate, have received upfront payments, equity contributions and milestone payments totaling approximately $135.5 million mainly from our collaborations with AstraZeneca, Eli Lilly, Nestlé Health Science as of December 31, 2017. We and Nutrition Science Partners, in the aggregate, may potentially receive up to $340.0 million in future development and approval milestones, $145.0 million in option payments and $560.0 million in commercial milestones in the aggregate. In return, our collaboration partners are entitled to a significant proportion of any future revenue from our drug candidates developed in collaboration with them, as well as a degree of influence over the clinical development process for such drug candidates.

AstraZeneca

In December 2011, we entered into an agreement with AstraZeneca under which we granted to AstraZeneca co-exclusive, worldwide rights to develop, and exclusive worldwide rights to manufacture and commercialize savolitinib for all diagnostic, prophylactic and therapeutic uses. We refer to this agreement as the AstraZeneca Agreement. AstraZeneca paid $20.0 million upon execution of the AstraZeneca Agreement and agreed to pay royalties and additional amounts upon the achievement of development and sales milestones. Under the original terms of the AstraZeneca Agreement, we and AstraZeneca agreed to share the development costs for savolitinib in China, with AstraZeneca being responsible for the development costs for savolitinib in the rest of the world. Based on savolitinib showing early clinical benefit as a highly selective c-Met inhibitor in a number of cancers, in August 2016 we and AstraZeneca amended our global licensing, co-development, and commercialization agreement for savolitinib whereby we agreed to contribute up to $50 million, spread primarily over three years, to the joint development costs of the global pivotal Phase III study in patients with c-Met driven papillary renal cell carcinoma. As of December 31, 2017, we had received $24.9 million in milestone payments in addition to approximately $19.4 million in reimbursements for certain development costs. We may potentially receive future clinical development and first sales milestones payments of up to $95.0 million for clinical development and initial sales of savolitinib, plus significant further milestone payments based on sales. AstraZeneca also reimburses us for certain development costs. Subject to approval of savolitinib in papillary renal cell carcinoma, under the amended AstraZeneca Agreement, AstraZeneca is obligated to pay us increased tiered royalties from 14.0% to 18.0% annually on all sales made of any product outside of China, which represents a five percentage point increase over the original terms. After total aggregate sales of savolitinib have reached $5 billion, this royalty will step down over a two year period, to an ongoing royalty rate of 10.5% to 14.5%. AstraZeneca is also obligated to pay us a fixed royalty of 30.0% on all sales made of any product in China.

Development and collaboration under this agreement are overseen by a joint steering committee that is comprised of three of our senior representatives as well as three senior representatives from AstraZeneca. AstraZeneca is responsible for the development of savolitinib and all regulatory matters related to this agreement in all countries and territories other than China, and we are responsible for the development of savolitinib and all regulatory matters related to this agreement in China.

Subject to earlier termination, the AstraZeneca Agreement will continue in full force and effect on a country-by-country basis as long as any collaboration product is being developed or commercialized. The AstraZeneca Agreement is terminable by either party upon a breach that is uncured, upon the occurrence

113

Table of Contents

of bankruptcy or insolvency of either party, or by mutual agreement of the parties. The AstraZeneca Agreement may also be terminated by AstraZeneca for convenience with 180 days' prior written notice. Termination for cause by us or AstraZeneca or for convenience by AstraZeneca will have the effect of, among other things, terminating the applicable licenses granted by us. Termination for convenience by AstraZeneca will have the effect of obligating AstraZeneca to grant to us all of its rights to regulatory approvals and other rights necessary to commercialize savolitinib. Termination by AstraZeneca for convenience will not have the effect of terminating any license granted by AstraZeneca to us.

Eli Lilly

Eli Lilly Agreement

In October 2013, we entered into an agreement with Eli Lilly whereby we grant Eli Lilly an exclusive license to develop, manufacture and commercialize fruquintinib for all uses in China and Hong Kong. We refer to this agreement as the Eli Lilly Agreement. Eli Lilly paid a $6.5 million upfront fee following execution of the Eli Lilly Agreement, and agreed to pay royalties and additional amounts upon the achievement of development and regulatory approval milestones. As of December 31, 2017, Eli Lilly had paid us $23.7 million in milestone payments in addition to approximately $38.1 million in reimbursements for certain development costs. We may potentially receive future milestone payments of up to $55.0 million for the achievement of development and regulatory approval milestones in China and additional milestone payments of up to $300.0 million for the achievement of development, regulatory approval and commercial milestones in other jurisdictions if Eli Lilly exercises its option to develop fruquintinib in such other jurisdictions. See "—Eli Lilly Option Agreement" for further discussion of Eli Lilly's option to develop fruquintinib globally. Additionally, Eli Lilly is obligated to pay us tiered royalties from 15.0% to 20.0% annually on sales made of fruquintinib in China and Hong Kong, the rate to be determined based upon the dollar amount of sales made for all products in that year.

Development, collaboration and manufacture of products under this agreement are overseen by a joint steering committee comprised of equal numbers of representatives from each party. We are responsible for all development activities for fruquintinib.

We are responsible for all development costs in relation to fruquintinib in the following indications: third-line colorectal cancer, third-line non-small cell lung cancer and second-line advanced gastric cancer, until fruquintinib has achieved proof-of-concept. After achieving proof-of-concept for any such indication, Eli Lilly will be responsible for a majority of subsequent development costs.

Once development is complete, Eli Lilly is obligated to use commercially reasonable efforts to commercialize products and bears all the costs and expenses incurred in such commercialization efforts.

We are responsible in consultation with Eli Lilly for the supply of, and have the right to supply, all clinical and commercial supplies for fruquintinib pursuant to an agreed strategy for manufacturing. For the term of the Eli Lilly Agreement, such supplies will be provided by us at a transfer price that accounts for our cost of goods sold.

The Eli Lilly Agreement is terminable by either party for breach that is uncured. The Eli Lilly Agreement is also terminable by Eli Lilly for convenience with 120 days' prior written notice or if there is a major unexpected safety issue with respect to a product. Termination by either us or Eli Lilly for any reason will have the effect of, among other things, terminating the applicable licenses granted by us, and will obligate Eli Lilly to transfer to us all regulatory materials necessary for us to continue development efforts for fruquintinib.

Eli Lilly Option Agreement

In addition, we have entered into an option agreement with Eli Lilly and Company, under which Eli Lilly and Company can choose to include additional countries in the territory for development and

114

Table of Contents

commercialization of fruquintinib. The amount payable by Eli Lilly and Company to exercise the option is variable and depends upon the stage of development at which Eli Lilly and Company chooses to exercise its option. Additionally, we are eligible for milestone and royalty payments based on the territory where the option is exercised and the annual dollar amount of sales of a product.

Nestlé Health Science

Nutrition Science Partners Joint Venture Agreement

In November 2012, we entered into a joint venture agreement with Nestlé Health Science to form Nutrition Science Partners, a joint venture whose shares are owned in equal portions by us and Nestlé Health Science. The objective of Nutrition Science Partners is to develop, manufacture and commercialize HMPL-004/HM004-6599 for ulcerative colitis and Crohn's Disease and to identify, develop, manufacture and commercialize products in gastrointestinal indications. Upon execution of the joint venture agreement, Nestlé Health Science paid $30.0 million in exchange for its 50% of the equity in Nutrition Science Partners. We provided payment-in-kind by contributing global development and commercial rights to the HMPL-004/HM004-6599 compound and certain exclusive rights to our botanical library, among other things, to the joint venture for our 50% of the equity. Nutrition Science Partners may potentially receive future milestones payments of up to $150.0 million.

Neither we nor Nestlé Health Science was permitted to sell, transfer or otherwise dispose of our ownership in Nutrition Science Partners until November 27, 2016 without the other's prior written consent. After this lock-up period, if either we or Nestlé Health Science wish to sell, transfer or otherwise dispose of our or its shares, the other has a right of first refusal to purchase all, but not some, of the other's shares. Each of us is entitled to receive dividends from Nutrition Science Partners as approved by the board. To date, we have not received dividends from Nutrition Science Partners. We and Nestlé Health Science are responsible for providing additional funding required by Nutrition Science Partners in proportion to each of our ownership percentages. During 2016, we and Nestlé Health Science agreed to waive $7.0 million each in loans to Nutrition Science Partners, and each party capitalized the outstanding amount as share capital. Additionally, in 2016 we provided $5.0 million in share capital to Nutrition Science Partners, with Nestlé Health Science providing the same amount. In February 2017, we and Nestlé Health Science each contributed an additional $7.0 million share capital funding to Nutrition Science Partners.

The operations of Nutrition Science Partners are overseen by its shareholders and board of directors. The board of directors consists of eight directors, with four directors nominated by each of Nestlé Health Science and ourselves.

Nutrition Science Partners Services Agreement

In March 2013, we also entered into a services agreement with Nutrition Science Partners to provide research and development services to Nutrition Science Partners, including: (i) collection, monitoring, processing and distribution of adverse event reports and safety and medical information including side-effects; (ii) development of manufacturing and analytical technologies for HMPL-004 raw materials; (iii) quality control and assurance of product manufacturing management; and (iv) ongoing discovery research and non-clinical support for the development of HMPL-004/HM004-6599.

This services agreement is terminable by either party upon an uncured material breach or immediately upon the other party's bankruptcy and by Nutrition Science Partners for convenience with 90 days' prior written notice. If Nutrition Science Partners terminates for convenience, it will be required to pay all of our non-cancellable costs.

115

Table of Contents

Nutrition Science Partners Research and Collaboration Agreement

In March 2013, we also entered into a research and collaboration agreement with Nestlé Health Science and Nutrition Science Partners to develop new products with impact on gastrointestinal disorders and diseases of the gastrointestinal tract to the proof-of-concept stage. We are obligated, as is Nestlé Health Science, to use commercially reasonable efforts to conduct the activities designated to us and Nestlé Health Science respectively to achieve these research and development goals. We are entitled to compensation for performance under this agreement on the basis of the number of our full-time employees who perform research and development activities. For the years ended December 31, 2015, 2016 and 2017, we received approximately $5.1 million, $8.1 million and $8.9 million, respectively, for the provision of these research and development services to Nutrition Science Partners under this agreement and the services agreement discussed above.

Under this research and collaboration agreement, we have granted to Nutrition Science Partners an initial exclusivity period lasting until December 31, 2022. The exclusivity period will be automatically extended for further one-year periods provided Nutrition Science Partners meets certain budgetary and expenditure criteria. During the exclusivity period, we are obligated not to perform research for ourselves or third parties, or grant to any third parties the right to research or develop products from, or derived from, our botanical library that could be developed for treating gastrointestinal disorders and/or disease of the gastrointestinal tract. Research and collaboration under this agreement will be overseen by a research collaboration subcommittee of the board of directors of Nutrition Science Partners, comprised of equal numbers of representatives from us and Nestlé Health Science.

This research and collaboration agreement is terminable by any party for an uncured material breach of any other party or immediately upon any other party's bankruptcy. It is also terminable by Nutrition Science Partners for convenience with 90 days' prior written notice. If Nutrition Science Partners terminates for convenience, it will be required to pay all of our and Nestlé Health Science's non-cancellable costs.

Nutrition Science Partners Option Agreement

In March 2013, Nestec Ltd., which is an affiliate of Nestlé Health Science, and Nutrition Science Partners entered into an option agreement under which Nestec Ltd. is eligible to obtain exclusive licenses to commercialize HMPL-004/HM004-6599 products in certain territories. Nestec Ltd. could potentially pay Nutrition Science Partners up to $70 million in option exercise payments in the aggregate. The option exercise payments are made in one-time payments per territory and the individual amounts vary depending upon the territory for which the option is exercised. Each of these options is terminable by Nestec Ltd. at its convenience.

Our Commercial Platform

Since 2001, we have also developed a profitable Commercial Platform in China, which encompasses two businesses: our Prescription Drugs and Consumer Health businesses. The continuing operations of our Commercial Platform generated $40.0 million in net income attributable to our company in 2017, which has contributed to the funding of our Innovation Platform's drug development programs.

Our Commercial Platform has grown strongly since we began operations in 2001. In total, net income attributable to our company from the continuing operations of our Commercial Platform was $25.2 million, $70.3 million and $40.0 million for the years ended December 31, 2015, 2016 and 2017, respectively. Net income attributable to our company from our Commercial Platform included one-time gains of $40.4 million and $2.5 million in the years ended December 31, 2016 and 2017, respectively, net of tax, from land compensation and other government subsidies paid to Shanghai Hutchison Pharmaceuticals by the Shanghai government.

116

Table of Contents

The infrastructure of our Commercial Platform, particularly in commercial operations management, manufacturing and distribution, regulatory and reimbursement coverage, is well established in our therapeutic specialty areas such as cardiovascular and central nervous system health. In addition to this, in due course we intend to build a dedicated oncology and immunology sales and marketing organization to broaden our therapeutic focus and to prepare for commercialization of drug candidates from our Innovation Platform, if approved. Our Prescription Drugs business is now deploying its network of medical sales representatives to market and sell drugs in China in new therapeutic areas such as for Seroquel which is used to treat psychiatric disorders, which we believe demonstrates the adaptability of our Commercial Platform. As of December 31, 2017, Shanghai Hutchison Pharmaceuticals had a dedicated medical sales team of about 120 people in this new therapeutic area.

Prescription Drugs Business

Our Prescription Drugs division is conducted through the following two joint ventures in which we nominate management and run the day-to-day operations:

•: Shanghai Hutchison Pharmaceuticals, which primarily manufactures, markets and distributes prescription drug products originally contributed by our joint venture partner, as well as third-party prescription drugs. 50% of this joint venture is owned by us and 50% by Shanghai Pharmaceuticals, a leading pharmaceutical company in China listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange, and
•: Hutchison Sinopharm, which focuses on providing logistics services to, and distributing and marketing prescription drugs manufactured by, third-party pharmaceutical companies in China. 51% of this joint venture is owned by us and 49% is owned by Sinopharm, a leading distributor of pharmaceutical and healthcare products and a leading supply chain service provider in China listed on the Hong Kong Stock Exchange.

Our Prescription Drugs business employs a physician-targeted marketing model that is focused on promoting its products by providing physicians and hospitals with information on the benefits and differentiating clinical aspects of our products. In collaboration with our partners, we have built our joint ventures' extensive prescription drug sales and distribution network across China, with approximately 2,300 medical sales representatives as of December 31, 2017. These medical sales representatives covered about 22,500 hospitals and about 98,000 physicians in over 300 cities and towns in China as of December 31, 2017. Approximately 66% of these medical sales representatives cover eastern and central-southern China. Of the remaining medical sale representatives, approximately 24% cover northern China and approximately 10% cover western and south-western China.

Shanghai Hutchison Pharmaceuticals—manufacturing, marketing and distributing proprietary and licensed prescription drugs

Shanghai Hutchison Pharmaceuticals primarily engages in the manufacture and sale of prescription drug products originally contributed by our joint venture partner, as well as third-party prescription drugs with a focus on cardiovascular medicine. Shanghai Hutchison Pharmaceuticals' proprietary products are sold under the "Shang Yao" brand, literally meaning "Shanghai pharmaceuticals," a trademark that has been used for over 40 years in the pharmaceutical retail market, primarily in Eastern China. As of December 31, 2017, Shanghai Hutchison Pharmaceuticals held 74 registered drug licenses in China, of which 31 are included in the National Medicines Catalogue. In addition, 17 of Shanghai Hutchison Pharmaceuticals' products, of which three are in active production, are represented on China's National Essential Medicines List.

Its key product is She Xiang Bao Xin pills, a vasodilator for the long-term treatment of coronary artery and heart disease and for rapid control and prevention of acute angina pectoris, a form of chest pain, which is listed on China's low price drug list, or LPDL, and fully reimbursed in all provinces in China.

117

Table of Contents

She Xiang Bao Xin pills' sales represented 86% of all Shanghai Hutchison Pharmaceuticals sales in 2017. She Xiang Bao Xin pills accounted for 15.4% of China's rapidly growing botanical coronary artery disease prescription drug market, which is approximately $2.0 billion in 2017. During late 2016 and early 2017, we were able to effectively implement a pricing strategy that led to a 20.2% growth in second half 2017 sales of Shanghai Hutchison Pharmaceuticals (to $114.9 million) and materially improved margins. The average daily cost of She Xiang Bao Xin pills is RMB4.00, or approximately $0.60.

She Xiang Bao Xin pills were first approved in 1983 and subsequently enjoyed 23 proprietary commercial protections under the prevailing regulatory system in China. In 2005, Shanghai Hutchison Pharmaceuticals was able to attain "Confidential State Secret Technology" status protection, as certified by China's Ministry of Science and Technology and State Secrecy Bureau, which extended proprietary protection in China until late 2016, and it is in the process of renewing this protection. Shanghai Hutchison Pharmaceuticals holds an invention patent in China covering its formulation, which extends proprietary protection through 2029.

Prior to September 2016, Shanghai Hutchison Pharmaceuticals manufactured its products at its GMP-certified production facility in Shanghai, which had a site area of approximately 58,000 square meters. In December 2015, it entered into an agreement with the Shanghai government to surrender its land use rights of the property where this facility is located for cash compensation, which has been paid in full. In September 2016, Shanghai Hutchison Pharmaceuticals fully transitioned its 500-person production unit into and began production at its new facility located in Feng Pu district outside the center of Shanghai. The site area of the new facility is approximately 78,000 square meters with three times the production capacity as the old one. The new manufacturing facility cost approximately $102 million and was financed over the past three years mainly with operating cash flow and limited bank debts. After repayment of bank debts and taxes related to this new facility and the receipt of compensation for the land use rights where the old facility was located, Shanghai Hutchison Pharmaceuticals was able to distribute dividends of $81.3 million in 2017 equally to us and Shanghai Pharmaceuticals.

Shanghai Hutchison Pharmaceuticals, through its GSP-certified subsidiary, also markets and sells third-party prescription drugs in collaboration with Hutchison Sinopharm. As discussed below, in late 2014 and early 2015, Hutchison Sinopharm signed agreements with Merck Serono and AstraZeneca to provide marketing services for Merck Serono's Concor (a cardiovascular drug) and AstraZeneca's Seroquel (a drug for the treatment of various psychiatric disorders) to market and distribute such drugs in China. In connection with Hutchison Sinopharm's agreements with Merck Serono and AstraZeneca, Hutchison Sinopharm entered into agreements with Shanghai Hutchison Pharmaceuticals to provide certain promotion and marketing services within China for these drugs. Under these agreements, Shanghai Hutchison Pharmaceuticals manages marketing and is paid a fee for its services provided. Hutchison Sinopharm manages distribution and logistics for these products and is paid a fee for its services provided.

Shanghai Hutchison Pharmaceuticals, through its GSP-certified subsidiary, sells its products and its third-party licensed prescription drugs directly to distributors who on-sell such products to hospitals and clinics, pharmacies and other retail outlets in their respective areas, as well as to other local distributors. Its medical sales representatives promote its products to doctors and purchasing managers in hospitals, clinics and pharmacies as part of its marketing efforts. As of December 31, 2017, Shanghai Hutchison Pharmaceuticals had approximately 2,300 medical sales representatives and about 550 manufacturing employees across China.

Hutchison Sinopharm—providing logistics services and marketing and distribution primarily for prescription drugs manufactured by third parties

In April 2014, we commenced operating Hutchison Sinopharm, a consolidated joint venture in collaboration with Sinopharm. Based in Shanghai, Hutchison Sinopharm is a GSP-certified company focused on providing logistics services to, and distributing and marketing prescription drugs manufactured

118

Table of Contents

by, third-party pharmaceutical companies in China. Hutchison Sinopharm also distributes certain products from Hutchison Healthcare's Zhi Ling Tong infant nutrition brand. Hutchison Sinopharm also continues to operate its legacy business which was primarily focused on providing logistics and distribution services, primarily within Shanghai, to third-party pharmaceutical companies.

We intend to increasingly focus on expanding Hutchison Sinopharm to operate as a full-service, third-party prescription drug commercialization company in China. To this end, in 2015 Hutchison Sinopharm entered into agreements with multinational and Chinese pharmaceutical manufacturers seeking to market their products in China. Hutchison Sinopharm now has agreements to market and distribute two prescription products. The primary product is:

•: Seroquel—in the second quarter of 2015, we became the exclusive first-tier distributor to distribute and market AstraZeneca's quetiapine tablets, under the Seroquel trademark in China. Seroquel is a first-line antipsychotic medicine for the treatment of schizophrenia and bipolar disorder, which was launched in China in 2001. Seroquel holds a 5.6% market share in China's approximately $0.9 billion atypical anti-psychotic prescription drug market and 45% of China's generic quetiapine market, primarily as a result of being the first-mover and original patent holder on quetiapine. Seroquel is the only brand in China to have an extended release formulation, which in 2017 was included on China's National Drug reimbursement List, thereby providing us with major competitive advantage over quetiapine generics.

Hutchison Sinopharm is the exclusive marketing agent for Seroquel tablets in China. As of December 31, 2017, Shanghai Hutchison Pharmaceuticals had a dedicated medical sales team of about 120 people to support Hutchison Sinopharm's commercialization of Seroquel. The new China two-invoice system, explained in more detail below, came into effect in October 2017, at which point the Seroquel operating model began progressively switching to a fee-for-service model.

Subject to Hutchison Sinopharm's continued delivery of pre-specified annual sales targets, which would require approximately 22% sales growth in 2018 and 15% per year thereafter, we can continue to retain exclusive commercial rights to Seroquel in China until 2025.

In the first quarter of 2015, we began to exclusively co-promote Merck Serono's bisoprolol fumarate tablets, under the Concor trademark, in a few provinces in China. Concor is the number two beta-blocker in China with an approximately 18% national market share in China's beta-blocker drug market and 70% of China's generic bisoprolol market. Hutchison Sinopharm was the exclusive marketing agent in six provinces, markets that contain over 360 million people. Hutchison Sinopharm created synergy with Shanghai Hutchison Pharmaceuticals's existing cardiovascular medical sales team who now details Concor alongside its She Xiang Bao Xin pills on a fee-for-service basis.

China has begun implementing a new regulatory two-invoice system on a province-by-province basis. In principle, the purpose of the two-invoice system is to restrict the number of layers in the drug distribution system in China, in order to improve transparency, compliant business conduct and efficiency. The impact to us is that, starting in October 2017, the Seroquel sales model, in which our consolidated revenues historically reflected total gross sales of Seroquel, began to shift to a fee-for-service model similar to that used all along on Concor. This change will reduce the top-line revenues that Hutchison Sinopharm will in the future be able to record from sales of Seroquel as well as many of our other third-party customers. Importantly however, this drop in reported sales will have no material impact on profitability, the service fees paid to Hutchison Sinopharm, and will have limited impact to our commercial team operations and expansion plans.

119

Table of Contents

Consumer Health Business

Our Consumer Health business is a profitable business, focusing primarily on the manufacture, marketing and distribution of over-the-counter pharmaceutical products and other natural and organic consumer products in China. Our Consumer Health products business includes:

•: Hutchison Baiyunshan, a joint venture established in 2005 which focuses primarily on the manufacture, marketing and distribution of proprietary over-the-counter pharmaceutical products. 50% of this joint venture is owned by us and 50% by Guangzhou Baiyunshan, a leading China-based pharmaceutical company listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange,
•: Hutchison Hain Organic, a joint venture which was established in 2009 and has rights to market and distribute a broad range of natural and organic consumer products under brands owned by Hain Celestial in nine Asian territories,
•: Hutchison Healthcare, a wholly owned subsidiary which was established in 2001 and manufactures and sells health supplements and licenses its infant nutrition products to Hutchison Sinopharm for distribution, and
•: Hutchison Consumer Products, a wholly owned subsidiary which was established in 2007 that distributes and markets certain third-party health-related consumer products.

Hutchison Baiyunshan—manufacturing, marketing and distributing proprietary over-the-counter pharmaceutical products

Hutchison Baiyunshan primarily engages in the manufacture, marketing and distribution of proprietary over-the-counter pharmaceutical products. Its "Bai Yun Shan" brand is a market-leading household-name, established over 40 years ago and is known by the majority of Chinese consumers. As of December 31, 2017, Hutchison Baiyunshan held 189 registered drug licenses in China, of which 82 are included in the National Medicines Catalogue. In addition, 31 of Hutchison Baiyunshan's products, of which 12 are in active production, are represented on China's National Essential Medicines List. As of the end of 2017, substantially all pharmaceutical products manufactured and sold by Hutchison Baiyunshan in 2017 were capable of being reimbursed under the National Medicines Catalogue.

Hutchison Baiyunshan's key products are two generic over-the-counter therapies which are each listed on the LPDL:

•: Fu Fang Dan Shen tablets—generic over-the-counter drugs for the treatment of chest congestion and angina pectoris to promote blood circulation and relieve pain, which represented approximately 26% of the sales of Hutchison Baiyunshan in 2017; and
•: Banlangen granules—for the treatment of viral flu, fever, and respiratory tract infections which represented approximately 26% of the sales of Hutchison Baiyunshan in 2017.

Hutchison Baiyunshan's products are manufactured in-house at its GMP-certified facilities in Guangzhou, Guangdong province and Bozhou, Anhui province. A portion of Hutchison Baiyunshan's products had historically been manufactured by third-party contract manufacturers until its new higher capacity facility in Bozhou became operational in August 2017. Hutchison Baiyunshan is also in the process of negotiating the return of its land use rights for the approximately 30,000 square meter unused plot of land in Guangzhou, which has been listed for sale as part of the Guangzhou municipal government's urban redevelopment scheme plan since 2016.

Hutchison Baiyunshan also operates two Chinese good agriculture practice, or GAP, certified cultivation sites through its subsidiaries for growing the herbs used in its over-the-counter products in Heilongjiang and Henan provinces in China. In addition, Hutchison Baiyunshan generates revenue by

120

Table of Contents

supplying raw materials produced by its cultivation operations to its collaboration partner, Guangzhou Pharmaceuticals.

Hutchison Baiyunshan sells its products directly to regional distributors across China who on-sell to local distributors, hospitals and clinics, pharmacies and other retailers, and employs its own sales representatives at a local level to market its products and promote over-the-counter sales to retailers.

In September 2017, Hutchison Baiyunshan divested its 60% shareholding in Nanyang Baiyunshan Hutchison Whampoa Guanbao Pharmaceutical Company Limited, or Guanbao, for consideration approximately equal to its carrying value. Guanbao was a GSP distribution company which had been established via a joint venture in 2012. It was a low margin, primarily third-party over-the-counter logistics business, with operations limited mainly to Henan province, and had proven to be a business with no strategic value to our company.

As of December 31, 2017, Hutchison Baiyunshan had approximately 1,000 sales representatives and over 1,000 manufacturing employees across China.

Hutchison Hain Organic—marketing and distributing Hain Celestial-licensed natural and organic food and personal care products

Hutchison Hain Organic is a joint venture with Hain Celestial, a Nasdaq-listed, natural and organic food and personal care products company. Hutchison Hain Organic distributes a broad range of over 500 imported organic and natural products.

Pursuant to its joint venture agreement, Hutchison Hain Organic has rights to market and distribute Hain Celestial's products within nine Asian territories. We believe the key strategic product for Hutchison Hain Organic is Earth's Best organic infant formula, a leading brand in the United States, which Hutchison Hain Organic began to sell in China in mid-2015. Earth's Best organic infant formula is imported from U.S. manufacturer Perrigo Company and is sold in China through an online retailer and specialty retail outlets. Hutchison Hain Organic's other products are distributed to hypermarkets, specialty stores and other retail outlets in Hong Kong, China and across seven other territories in Asia mainly through third-party local distributors, including retail chains owned by affiliates of CK Hutchison.

Hutchison Healthcare—manufacturing, marketing and distributing health supplements

Hutchison Healthcare is our wholly owned subsidiary and is primarily engaged in the manufacture and sale of health supplements. Hutchison Healthcare's major product is Zhi Ling Tong DHA capsules, a health supplement, made from algae DHA oil, for the promotion of brain and retinal development in babies and young children, which is distributed by Hutchison Sinopharm.

The majority of Hutchison Healthcare's products are contract manufactured at a dedicated GMP-certified manufacturing facility operated by a third party and distributed to hospital pharmacies, specialty stores and drugstore chains.

Hutchison Consumer Products—distribution of consumer products

Hutchison Consumer Products is our wholly owned subsidiary that is primarily engaged in the distribution of third-party consumer products in Asia.

Competition

Innovation Platform Competition

The biotechnology and pharmaceutical industries are highly competitive. While we believe that our highly selective drug candidates, experienced development team and chemistry-focused scientific approach provide us with competitive advantages, we face potential competition from many different sources,

121

Table of Contents

including major pharmaceutical, specialty pharmaceutical and biotechnology companies. Any drug candidates that we successfully develop and commercialize will compete with existing drugs and/or new drugs that may become available in the future.

We compete in the segments of the pharmaceutical, biotechnology and other related markets that address inhibition of kinases in cancer and immunological diseases. There are other companies working to develop targeted therapies in the field of kinase inhibition for cancer and immunological diseases. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes. We also compete with pharmaceutical and biotechnology companies that develop and market monoclonal antibodies as targeted therapies for the treatment of cancer and immunological diseases.

Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of drug candidates, obtaining regulatory approvals of products and the commercialization of those products. Accordingly, our competitors may be more successful than we may be in obtaining approval for drugs and achieving widespread market acceptance. Our competitors' drugs may be more effective, or more effectively marketed and sold, than any drug we may commercialize and may render our drug candidates obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our drug candidates. We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available.

Below is a summary of existing therapies and therapies currently under development that may become available in the future which may compete with each of our eight clinical-stage drug candidates.

Savolitinib

While there are currently no approved selective c-Met inhibitors on the market, there are several c-Met inhibitors currently undergoing clinical trials for the treatment of renal cell carcinoma, non-small cell lung cancer and gastric cancer such as Cabometyx (cabozantinib) (VEGFR/c-Met/Ret inhibitor approved for renal cell carcinoma and in development for non-small cell lung cancer), tepotinib (c-Met inhibitor in development for non-small cell lung cancer), glesatinib (c-Met and Axl tyrosine kinase inhibitor in development for non-small cell lung cancer), emibetuzumab (MET inhibitor in development for non-small cell lung cancer) and AMG 337 (c-Met kinase inhibitor in development for stomach cancer). Xalkori (ALK, ROS1 and c-Met inhibitor marketed for non-small cell lung cancer) is a multi-kinase inhibitor that less selectively inhibits c-Met. Merestinib (MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2, MKNK1/2 and c-Met inhibitor in development for non-small cell lung cancer) is also a multi-kinase inhibitor.

Fruquintinib

Approved VEGF inhibitors on the market for the treatment of colorectal cancer include Avastin (anti-VEGF monoclonal antibody), Cyramza (anti-VEGFR2 monoclonal antibody), Stivarga (VEGFR/TIE2 inhibitor) and Zaltrap (ziv-aflibercept) (VEGF inhibitor). Cyramza is approved for the treatment of non-small cell lung cancer and gastric cancer, and Avastin is also approved for non-small cell lung cancer. In addition, Inlyta and Caprelsa (vandetanib) use a similar mechanism of action as the VEGF inhibitors on the market and are currently being studied for the treatment of colorectal cancer. Other VEGFR inhibitors being developed for the treatment of non-small cell lung cancer include anlotinib, apatinib, Cabometyx, Lenvima (lenvatinib), lucitanib and Caprelsa. VEGFR inhibitors being developed for the treatment of gastric cancer include dovitinib, telatinib and regorafenib. In China, apatinib has been approved for the treatment of third-line gastric cancer and anlotinib has an NDA under review for the treatment of third-line non-small cell lung cancer.

122

Table of Contents

Sulfatinib

Sutent (VEGFR inhibitor) and Afinitor (mTOR inhibitor) have been approved for the treatment of pancreatic neuroendocrine tumors. Somatuline Depot (Lanreotide) is a growth hormone release inhibitor that has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors. Sandostatin (octreotide) is a growth hormone and insulin-like growth factor-1 inhibitor that has also been approved for neuroendocrine tumors. Lutathera (Lu-dotatate), a somatostatin receptor targeting radiotherapy, recently received NDA approval from the FDA for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors. Furthermore, both small molecules and monoclonal antibodies are being developed for the treatment of neuroendocrine tumors. Compounds undergoing development for neuroendocrine tumors include Vargatef (nintedanib, a tyrosine kinase inhibitor), milciclib (tyrosine kinase inhibitor) and Zybrestat (fosbretabulin, a microtubule/tubulin inhibitor being studied for thyroid cancer). Cometriq (an additional brand name for cabozantinib) has been marketed for thyroid cancer and is being studied for neuroendocrine tumors. In addition, Avastin is an anti-VEGF monoclonal antibody being studied for neuroendocrine tumors.

Epitinib

Although no EGFR tyrosine kinase inhibitors have been specifically approved for non-small cell lung cancer with brain metastasis or primary brain tumor, many have been approved for the treatment of non-small cell lung cancer with EGFR activating mutations, including Gilotrif (EGFR/HER2 inhibitor), Iressa, Tarceva, Conmana and Tagrisso. Moreover, Tagrisso, tesevatinib (EGFR/HER2/VEGFR inhibitor) and AZD3759 (EGFR inhibitor) are in development for the treatment of non-small cell lung cancer with brain metastasis while Alecensa (alectinib, an ALK inhibitor) has already been approved.

Theliatinib

Approved EGFR inhibitors on the market include Iressa and Tarceva, although these drugs reach insufficient drug concentrations to suppress wild-type EGFR effectively. In addition, monoclonal antibodies, such as Erbitux, which are approved for the treatment of certain EGFR over-expression tumor types, are less effective for EGFR gene amplified patients. Other small molecule therapies currently being studied for the treatment of esophageal tumors include Gilotrif and Conmana.

HMPL-523

There has been extensive research on oral small-molecule Syk inhibitors due to the major unmet medical need in inflammation and oncology. No small molecule drug candidates targeting Syk specifically have been approved to date due to the severe off-target toxicity as a result of poor kinase selectivity and possibly poor pharmacokinetic properties. GS-9876 is a Syk inhibitor currently in clinical studies for rheumatoid arthritis. Syk inhibitors currently in clinical studies for hematological cancers include entospletinib, cerdulatinib and TAK-659. In addition, Janus tyrosine kinase, or JAK, inhibitors such as Xeljanz (tofacitinib JAK-3 inhibitor, marketed for rheumatoid arthritis and in development for ulcerative colitis, Crohn's disease and myelofibrosis), Jakafi (ruxolitinib, JAK-1/2 inhibitor, marketed for myelofibrosis and in development for acute myelogenous leukemia), baricitinib (JAK-1/2 inhibitor in development for rheumatoid arthritis), decernotinib (JAK-3 inhibitor in development for rheumatoid arthritis) and filgotinib (JAK-1 inhibitor in development for rheumatoid arthritis) and TNFa inhibitors marketed for rheumatoid arthritis, such as Enbrel, Remicade, Humira and Cimzia, are also expected to be potential competitors of HMPL-523 if it is approved.

However, most anti-TNFa monoclonal antibodies are applicable for severe disease only as these injectables significantly suppress the entire immune system for a substantial period of time.

123

Table of Contents

HMPL-689

Zydelig is a PI3Kd inhibitor that has been approved for the treatment of refractory/relapsed follicular lymphoma, small lymphocytic lymphoma as a monotherapy and chronic lymphatic leukemia in combination with Rituxan. In addition, several drug candidates that inhibit PI3Kd are in clinical development, including duvelisib, copanlisib, gedatolisib, INCB040093, GS-9901, umbralisib and AMG 319.

HMPL-453

To date, there are no approved therapies that specifically target the FGFR signaling pathway. Several small molecule FGFR tyrosine kinase inhibitors are in early clinical trials for solid tumors, including AZD4547, infigratinib, rogaratinib, BLU-554, erdafitinib, TAS-120, Debio 1347, INCB054828, and LY3076226. Similarly, FGFR specific monoclonal antibodies in development include MFGR1877S and B-701.

HM004-6599

The current standard of care for inflammatory bowel disease starts with mesalazine, while for the non-responding patients, various forms of corticosteroids and immunosuppressant drugs and anti-tumor necrosis factor agents are prescribed. Several anti-TNFa monoclonal antibody injectables, such as Cimzia, Humira, Remicade and Simponi (golimumab) (abandoned in Phase I for Crohn's disease), have been approved for the treatment of ulcerative colitis and Crohn's disease. However, most anti-TNFa monoclonal antibodies are applicable for severe disease only as these injectables significantly suppress the entire immune system for a substantial period of time.

Commercial Platform Competition

Our Commercial Platform's Prescription Drugs business competes in the pharmaceutical industry in China, which is highly competitive and is characterized by a number of established, large pharmaceutical companies, as well as some smaller emerging pharmaceutical companies. Our Prescription Drugs business faces competition from other pharmaceutical companies in China engaged in the development, production, marketing or sales of prescription drugs, in particular cardiovascular drugs. The barrier of entry for the PRC pharmaceutical industry primarily relates to regulatory requirements in connection with the production of pharmaceutical products and new product launches.

The identities of the key competitors with respect to our Prescription Drugs business vary by product, and, in certain cases, different competitors that have greater financial resources than us may elect to focus these resources on developing, importing or in-licensing and marketing products in the PRC that are substitutes for our products and may have broader sales and marketing infrastructure with which to do so.

We believe that we compete primarily on the basis of brand recognition, pricing, sales network, promotion activities, product efficacy, safety and reliability. We believe our continued success will depend on our Prescription Drugs business's capability to: maintain profitability of its core product, She Xiang Bao Xin pills, successfully market and distribute in-licensed products such as Seroquel and Concor, obtain and maintain regulatory approvals, develop drug candidates with market potential, maintain an efficient operational model, apply technologies to production lines, attract and retain talented personnel, maintain high quality standards, and effectively market and promote the products sold by our Prescription Drugs business. Key competitors for She Xiang Bao Xin pills include Tasly Holding (Compound Danshen Dropping Pill) and Shijiazhuang Yiling Pharmaceutical (Tong Xin Luo Capsule). In addition, Hunan Dongting Pharma and Suzhou First Pharma are key competitors to our Prescription Drugs business in licensed drug Seroquel.

124

Table of Contents

Our Commercial Platform's Consumer Health business competes in a highly fragmented market in Asia, particularly in our primary market in China. We believe that our Consumer Health business competes primarily on the basis of brand recognition, pricing, sales network, promotion activities, product safety and reliability. We believe our continued success will depend on our Consumer Health business's capability to: maintain profitability of its core products, Fu Fang Dan Shen tablets and Banlangen granules, differentiate its products vis-a-vis those of competitors, successfully market and distribute in-licensed products such as Earth's Best infant formula, maintain an efficient operational model, attract and retain talented personnel, maintain high quality standards, and effectively market and promote the products sold by our Consumer Health business. In China, Fu Fang Dan Shen tablets and Banlangen granules are generic over-the-counter drugs marketed by several manufacturers. Key competitors include Shanghai LeiYunShang Pharmaceutical, Yunnan Baiyao and Beijing Tongrentang in the Fu Fang Dan Shen market, and include Beijing Tongrentang and Guangzhou Xiangxue Pharmaceutical for the Banlangen market.

Patents and Other Intellectual Property

Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our Innovation Platform's drug candidates, our Commercial Platform's products and other know-how. Our policy is to seek to protect our proprietary and intellectual property position by, among other methods, filing patent applications in various jurisdictions related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.

Patents

We and our joint ventures file patent applications directed to our Innovation Platform's drug candidates and our Commercial Platform's products in an effort to establish intellectual property positions with regard to new small molecule compounds and/or extracts of natural herbs, their compositions as well as their medical uses in the treatment of diseases. In relation to our Innovation Platform, we also file patent applications directed to crystalline forms, formulations, processes, key intermediates, and secondary uses as clinical trials for our drug candidates evolve. We file such patent applications in major market jurisdictions, including the United States, Europe, Japan and China as well as Argentina, Australia, Brazil, Canada, Chile, Indonesia, Israel, India, South Korea, Mexico, Malaysia, New Zealand, Peru, Philippines, Singapore, Ukraine and South Africa. We do not currently in-license any patents except to the extent necessary to ensure our drug candidate fruquintinib has freedom to operate as discussed below.

Our Innovation Platform Patents

As of December 31, 2017, we had 151 issued patents, including 18 Chinese patents, 19 U.S. patents and eight European patents, 146 patent applications pending in the above major market jurisdictions, and two pending Patent Cooperation Treaty, or PCT, patent applications relating to the drug candidates of our Innovation Platform. As of the same date, our joint venture Nutrition Science Partners had 24 issued patents and three pending patent applications relating to HMPL-004 and its reformulation HM004-6599. The intellectual property portfolios for our most advanced drug candidates are summarized below. Some of these portfolios, such as HMPL-453 and HMPL-689, are in very early stages of development. With respect to most of the pending patent applications covering our drug candidates, prosecution has yet to commence. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the relevant patent office is often significantly narrowed by the time when they issue, if they issue at all. We expect this to be the case for our pending patent applications referred to below.

Savolitinib—The intellectual property portfolio for savolitinib contains issued patents and patent applications directed to novel small molecule compounds as well as methods of treating cancers with such compounds. As of December 31, 2017, we owned 20 patents in this family, including patents in the United

125

Table of Contents

States, Europe and Japan, and we had 30 patent applications pending in various other jurisdictions, including China. Our European patent is also registered in Hong Kong. Our issued patents will expire in 2030. Our collaboration partner AstraZeneca is responsible for maintaining and enforcing the intellectual property portfolio for savolitinib.

Fruquintinib—The intellectual property portfolio for fruquintinib contains three patent families.

The first patent family for fruquintinib is directed to novel small molecule compounds as well as methods of treating tumor angiogenesis-related disorders with such compounds. As of December 31, 2017, we owned three U.S. patents, one Chinese patent and one Taiwanese patent in this family, each of which will expire in 2028. We also owned patents in Europe and 13 other jurisdictions expiring in 2029 and had two patent applications pending in Japan.

The second patent family is directed to crystalline forms of fruquintinib as well as methods of treating tumor angiogenesis-related disorders with such forms. As of December 31, 2017, we had one patent application pending in China in this family, which, if issued, would have an expiration date in 2034. We have also filed PCT and Taiwanese patent applications for this family which, if issued, will each have expiration dates in 2035.

The third patent family is directed to the method of preparing one of the critical intermediates used in the manufacturing process of fruquintinib. With respect to this patent family, we have a patent application pending in China, which, if issued, will have an expiration date in 2034.

We also in-license certain freedom-to-operate rights from AstraZeneca, which grant us non-exclusive rights within China and Hong Kong to develop and commercialize pharmaceutical compounds used in fruquintinib which are covered by one of its patents.

Sulfatinib—The intellectual property portfolio for sulfatinib contains four patent families.

The first patent family for sulfatinib is directed to novel small molecule compounds as well as methods of treating tumor angiogenesis-related disorders with such compounds. As of December 31, 2017, in this patent family we owned one Chinese patent expiring in 2027 and 12 patents in various other jurisdictions, including the United States expiring in 2031, and Europe and Japan, each expiring in 2028. As of December 31, 2017, we also had one patent application pending in Brazil.

The second patent family is directed to the crystalline forms of sulfatinib as well as methods of treating tumor angiogenesis-related disorders with such forms. As of December 31, 2017, in this patent family we owned two patents in China expiring in 2029 and 2030, respectively, and we owned 14 patents in other countries, including the United States which will expire in 2031 and Europe which will expire in 2030. As of December 31, 2017, we also had two patent applications pending in other jurisdictions.

The third patent family is directed to the formulation of a micronized active pharmaceutical ingredient used in sulfatinib as well as methods of treating tumor angiogenesis-related disorders with such formulation. With respect to this patent family, we have 17 patent applications pending in various jurisdictions, including China, the U.S. and Europe.

The fourth patent family was filed in 2016 and is subject to confidential review by the patent authorities.

HMPL-523 Syk Inhibitor—The intellectual property portfolio for HMPL-523 contains two patent families.

The first patent family is directed to novel small molecule compounds as well as methods of treating cancers, inflammatory diseases, allergic diseases, cell-proliferative diseases, and autoimmune diseases with such compounds. As of December 31, 2017, we owned 16 patents in this family in various jurisdictions, including the United States, China and South Korea, each of which will expire in 2032. As of December 31,

126

Table of Contents

2017, we also had nine patent applications in this family pending in jurisdictions including the United States.

The second patent family was filed in 2017 and is subject to confidential review by the patent authorities.

Epitinib—The intellectual property portfolio for epitinib contains three patent families.

The first patent family is directed to novel small molecule compounds as well as methods of treating cancers with such compounds. As of December 31, 2017, we owned patents in China and Taiwan expiring in 2028, a patent in the United States expiring in 2031 and patents in 12 other jurisdictions, including Europe, each expiring in 2029. As of December 31, 2017, we also had two patent applications in this family pending in other jurisdictions.

The second and third patent families were filed in 2017 and are subject to confidential review by the patent authorities.

Theliatinib—The intellectual property portfolio for theliatinib contains two patent families.

The first patent family is directed to novel small molecule compounds as well as methods of treating cancers with such compounds. As of December 31, 2017, we owned 15 patents in this family in various jurisdictions, including China and Japan, each of which will expire in 2031. As of December 31, 2017, we also had four patent applications in this family pending in various jurisdictions. Our Chinese patent was also registered in Hong Kong and Macau.

The second patent family was filed in 2017 and is subject to confidential review by the patent authorities.

HMPL-689—The intellectual property portfolio for HMPL-689 contains patent applications directed to novel small molecule compounds as well as uses of such compounds. As of December 31, 2017, we had filed 24 patent applications pending in various jurisdictions, including Argentinean, Chinese, and Taiwanese and PCT applications, which, if issued, will each have expiration dates in 2035.

HMPL-004/HM004-6599—The intellectual property portfolio for HMPL-004/HM004-6599 is composed of four patent families.

The first patent family is directed to methods of treating inflammatory bowel disease with the compounds related to andrographolides, which are a type of organic plant extract used in drug formulation. As of December 31, 2017, we had one U.S. patent in this family with an expiration date in 2026.

The second patent family is directed to certain andrographolides as well as the method of treating inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, with such andrographolides. As of December 31, 2017, with respect to this family, we had one Chinese patent and 12 patents in various other jurisdictions, including the United States, Europe and Japan. Our Chinese patent expires in 2024, and each of our other issued patents expires in 2025.

The third patent family is directed to certain andrographolides, a solid dosage form comprising certain andrographolides, as well as the method of treating inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, with such andrographolides. As of December 31, 2017, we owned one Chinese patent expiring in 2027, two U.S. patents expiring in 2027 and 2029, respectively, and seven patents in various other jurisdictions, each expiring in 2028.

The fourth patent family was filed in 2016 and is subject to confidential review by the patent authorities.

127

Table of Contents

We had also taken steps to seek patent protection for a sustainable release formulation of andrographolides, but that was abandoned as of December 31, 2017.

HMPL-453—The intellectual property portfolio for HMPL-453 contains patent applications directed to novel small molecule compounds as well as methods of treating cancers with the compounds. As of December 31, 2017, we owned 6 patents in this family in various jurisdictions, including Japan and the United States, each of which will expire in 2034. As of December 31, 2017, we had 18 patent applications pending in various jurisdictions, including China.

Our Commercial Platform Patents

Prescription Drugs Patents

As of December 31, 2017, our Prescription Drugs joint venture Shanghai Hutchison Pharmaceuticals had 43 issued patents and ten pending patent applications in China, including patents for its key prescription products described below.

She Xiang Bao Xin Pills. As of December 31, 2017, Shanghai Hutchison Pharmaceuticals held an invention patent in China directed to the formulation of the She Xiang Bao Xin pill. Under PRC law, invention patents are granted for new technical innovations with respect to products or processes. Invention patents in China have a maximum term of 20 years. This patent will expire in 2029. The "Confidential State Secret Technology" status protection on the She Xiang Bao Xin pill technology held by Shanghai Hutchison Pharmaceuticals, as certified by China's Ministry of Science and Technology and State Secrecy Bureau, expired recently, and as of December 31, 2017, Shanghai Hutchison Pharmaceuticals was in the process of renewing such protection status.

Danning Tablets. As of December 31, 2017, Shanghai Hutchison Pharmaceuticals also held an invention patent in China directed to the formulation of the Danning tablet. This patent will expire in 2027.

Consumer Health Patents

Many of the products sold by our Consumer Health Products joint venture Hutchison Baiyunshan, including its Banlangen granules and Fu Fang Dan Shen tablets, are generic, over-the-counter products for which Hutchison Baiyunshan does not hold patents. As of December 31, 2017, Hutchison Baiyunshan had 74 issued patents in China and one in each of Australia and Singapore.

Patent Term

The term of a patent depends upon the laws of the country in which it is issued. In most jurisdictions, a patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent's term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug or biological product may also be eligible for patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. In the future, if and when our drug candidates receive approval by the FDA or other regulatory authorities, we expect to apply for patent term extensions on issued patents covering those drugs, depending upon the length of the clinical trials for each drug and other factors. There can be no assurance that any of our pending patent applications will be issued or that we will benefit from any patent term extension.

As with other pharmaceutical companies, our or our joint ventures' ability to maintain and solidify our proprietary and intellectual property position for our drug candidates or our or their Commercial Platform products and technologies will depend on our or our joint ventures' success in obtaining effective patent

128

Table of Contents

claims and enforcing those claims if granted. However, our or our joint ventures' pending patent applications and any patent applications that we or they may in the future file or license from third parties may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our or our joint ventures' patents. Any issued patents that we may receive in the future may be challenged, invalidated or circumvented. For example, we cannot be certain of the priority of filing covered by pending third-party patent applications. If third parties prepare and file patent applications in the United States, China or other markets that also claim technology or therapeutics to which we or our joint ventures have rights, we or our joint ventures may have to participate in interference proceedings, which could result in substantial costs to us, even if the eventual outcome is favorable to us, which is highly unpredictable. In addition, because of the extensive time required for clinical development and regulatory review of a drug candidate we may develop, it is possible that, before any of our drug candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting protection such patent would afford the respective product and any competitive advantage such patent may provide.

Trade Secrets

In addition to patents, we and our joint ventures rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our or their competitive position. We and our joint ventures seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors, and non-competition, non-solicitation, confidentiality, and invention assignment agreements with our employees and consultants. We and our joint ventures have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements we and our joint ventures enter into are designed to protect our or our joint ventures' proprietary information and the agreements or clauses requiring assignment of inventions to us or our joint ventures, as applicable, are designed to grant us or our joint ventures, as applicable, ownership of technologies that are developed through our or their relationship with the respective counterpart. We cannot guarantee, however, that these agreements will afford us or our joint ventures adequate protection of our or their intellectual property and proprietary information rights.

Trademarks and Domain Names

We conduct our business using trademarks with various forms of the "Hutchison," "Chi-Med" and "China-MediTech" brands, as well as domain names incorporating some or all of these trademarks. In April 2006, we entered into a brand license agreement with Hutchison Whampoa Enterprises Limited, an indirect wholly owned subsidiary of CK Hutchison, pursuant to which we have been granted a non-exclusive, non-transferrable, royalty-free right to use such trademarks, domain names and other intellectual property rights owned by the CK Hutchison group in connection with the operation of our business worldwide. See Item 7.B. "Related Party Transactions—Relationship with CK Hutchison—Intellectual property licensed by the CK Hutchison group" for more details.

In addition, our joint ventures seek trademark protection in China for their Commercial Platform products. As of December 31, 2017, our joint ventures Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan owned a total of 183 trademarks in the aggregate related to products sold by them. For example, the name "Shang Yao" is a registered trademark of Shanghai Hutchison Pharmaceuticals in China for certain uses including pharmaceutical preparations. In addition, our joint venture Hutchison Baiyunshan has been granted a royal-free license to use the registered trademark "Bai Yun Shan" for a term equal to its operational period of the joint venture by Guangzhou Baiyunshan.

129

Table of Contents

Raw Materials and Supplies

Raw materials and supplies are ordered based on our or our joint ventures' respective sales plans and reasonable order forecasts and are generally available from our or our joint ventures' own cultivation operations and various third-party suppliers in quantities adequate to meet our needs. While we do experience price fluctuations associated with our raw materials, we have not experienced any material disruptions in the supply of these raw materials in the past. See Item 3.D. "Risk Factors—Our Commercial Platform's principal products involve the cultivation or sourcing of key raw materials including botanical products, and any supply failure or price fluctuations could adversely affect our Commercial Platform's ability to manufacture our products."

If any one of these supply arrangements or agreements were to be terminated or the ability of any one of these suppliers to perform under the applicable agreements were to be materially and adversely affected, we believe that we will be able to locate, qualify and enter into an agreement with a new supplier on a timely basis. We expect that our and our joint ventures' existing manufacturing facilities, and outside sources will allow us to meet near-term manufacturing needs for our commercial products and other drug candidate products that are in clinical trials.

Quality Control and Assurance

We have our own independent quality control system and devote significant attention to quality control for the designing, manufacturing and testing of our products. We have established a strict quality control system in accordance with CFDA regulations. Our laboratories fully comply with the Chinese GMP guidelines and are staffed with highly educated and skilled technicians to ensure quality of all batches of product release. We monitor in real time our operations throughout the entire production process, from inspection of raw and auxiliary materials, manufacture, delivery of finished products, clinical testing at hospitals, to ethical sales tactics. Our quality assurance team is also responsible for ensuring that we are in compliance with all applicable regulations, standards and internal policies. Our senior management team is actively involved in setting quality policies and managing internal and external quality performance of our company and our joint ventures, Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan.

Certificates and Permits

Hutchison MediPharma (Suzhou) Limited holds a pharmaceutical manufacturing license issued by its local regulatory authority expiring on December 31, 2020.

Hutchison Sinopharm holds a GSP certificate issued by its local regulatory authority expiring on October 22, 2019. It also holds a pharmaceutical trading license issued by its local regulatory authority expiring on August 24, 2019.

Shanghai Hutchison Pharmaceuticals holds a pharmaceutical manufacturing license from its local regulatory authorities expiring on December 31, 2020. Shanghai Hutchison Pharmaceuticals also holds three GMP certificates issued by its local regulatory authority and the CFDA. The three GMP certificates will expire on November 16, 2021, August 14, 2021 and December 3, 2022, respectively.

Shanghai Shangyao Hutchison Whampoa GSP Company Limited, a subsidiary of Shanghai Hutchison Pharmaceuticals, holds a pharmaceutical trading license from its local regulatory authority expiring on December 29, 2019. It also holds a GSP certificate issued by its local regulatory authority expiring on April 21, 2020.

Hutchison Baiyunshan holds a pharmaceutical manufacturing license issued by its local regulatory authority expiring on December 31, 2020. Hutchison Baiyunshan holds three GMP certificates issued by its local regulatory authority expiring on December 10, 2018, December 21, 2020 and March 18, 2020, respectively.

130

Table of Contents

Hutchison Whampoa Guangzhou Baiyunshan Pharmaceuticals Limited, a subsidiary of Hutchison Baiyunshan, holds a GSP certificate issued by its local regulatory authority expiring on January 15, 2020. It also holds a pharmaceutical trading license issued by its local regulatory authority expiring on November 12, 2019.

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine (Bozhou) Company Limited, a subsidiary of Hutchison Baiyunshan, holds a GMP certificate issued by its local regulatory authority expiring January 18, 2022. It also holds a pharmaceutical manufacturing license issued by its local regulatory authority expiring on December 31, 2020.

Hutchison Whampoa Baiyunshan Lai Da Pharmaceutical (Shan Tou) Company Limited, a subsidiary of Hutchison Baiyunshan, holds a GMP certificate issued by its local regulatory authority expiring February 28, 2021. It also holds a pharmaceutical manufacturing license issued by its local regulatory authority expiring December 31, 2020.

Nanyang Baiyunshan Hutchison Whampoa Guanbao Pharmaceutical Company Limited, which was divested by Hutchison Baiyunshan in September 2017, held a pharmaceutical trading license and a GSP certificate from its local regulatory authority.

Regulation

This section sets forth a summary of the most significant rules and regulations affecting our business activities in China and the United States.

Government Regulation of Pharmaceutical Product Development and Approval

PRC Regulation of Pharmaceutical Product Development and Approval

Since China's entry to the World Trade Organization in 2001, the PRC government has made significant efforts to standardize regulations, develop its pharmaceutical regulatory system and strengthen intellectual property protection.

Regulatory Authorities

In the PRC, the CFDA is the authority that monitors and supervises the administration of pharmaceutical products and medical appliances and equipment as well as food, health food and cosmetics. The CFDA's predecessor, the State Food and Drug Administration, or the SFDA, was established on August 19, 1998 as an organization under the State Council to assume the responsibilities previously handled by the Ministry of Health of the PRC, or the MOH, the State Pharmaceutical Administration Bureau of the PRC and the State Administration of Traditional Chinese Medicine of the PRC. The CFDA was founded in March 2003 to replace the SFDA.

The primary responsibilities of the CFDA include:

•: monitoring and supervising the administration of pharmaceutical products, medical appliances and equipment as well as food, health food and cosmetics in the PRC;
•: formulating administrative rules and policies concerning the supervision and administration of food, health food, cosmetics and the pharmaceutical industry; evaluating, registering and approving of new drugs, generic drugs, imported drugs and traditional Chinese medicine;
•: approving and issuing permits for the manufacture and export/import of pharmaceutical products and medical appliances and equipment and approving the establishment of enterprises to be engaged in the manufacture and distribution of pharmaceutical products; and
•: examining and evaluating the safety of food, health food and cosmetics and handling significant accidents involving these products.

131

Table of Contents

The MOH is an authority at the ministerial level under the State Council and is primarily responsible for national public health. Following the establishment of the CFDA in 2003, the MOH was put in charge of the overall administration of the national health in the PRC excluding the pharmaceutical industry. In March 2008, the State Council placed the CFDA under the management and supervision of the MOH. The MOH performs a variety of tasks in relation to the health industry such as establishing social medical institutes and producing professional codes of ethics for public medical personnel. The MOH is also responsible for overseas affairs, such as dealings with overseas companies and governments. In 2013, the MOH and the National Population and Family Planning Commission were integrated into the National Health and Family Planning Commission of the PRC, or the NHFPC. The responsibilities of the NHFPC include organizing the formulation of national drug policies, the national essential medicine system and the National Essential Medicines List and drafting the administrative rules for the procurement, distribution and use of national essential medicines.

Healthcare System Reform

The PRC government recently promulgated several healthcare reform policies and regulations to reform the healthcare system. On March 17, 2009, the Central Committee of the PRC Communist Party and the State Council jointly issued the Guidelines on Strengthening the Reform of Healthcare System. On March 18, 2009, the State Council issued the Implementation Plan for the Recent Priorities of the Healthcare System Reform (2009-2011). On July 22, 2009, the General Office of the State Council issued the Five Main Tasks of Healthcare System Reform in 2009.

Highlights of these healthcare reform policies and regulations include the following:

•: The overall objective of the reform is to establish a basic healthcare system to cover both urban and rural residents and provide the Chinese people with safe, effective, convenient and affordable healthcare services. The PRC government aims to extend basic medical insurance coverage to at least 90% of the country's population by 2011 and increase the amount of subsidies on basic medical insurance for urban residents and rural cooperative medical insurance to RMB120 per person per year by 2010. By 2020, a basic healthcare system covering both urban and rural residents should be established.
•: The reforms aim to promote orderly market competition and improve the efficiency and quality of the healthcare system to meet the various medical needs of the Chinese population. From 2009, basic public healthcare services such as preventive healthcare, maternal and child healthcare and health education will be provided to urban and rural residents. In the meantime, the reforms also encourage innovations by pharmaceutical companies to eliminate low-quality and duplicative products.
•: The five key tasks of the reform from 2009 to 2011 are as follows: (1) to accelerate the formation of a basic medical insurance system, (2) to establish a national essential drug system, (3) to establish a basic healthcare service system, (4) to promote equal access to basic public healthcare services, and (5) to promote the reform of public hospitals.

Drug Administration Laws and Regulations

The PRC Drug Administration Law as promulgated by the Standing Committee of the National People's Congress in 1984 and the Implementing Measures of the PRC Drug Administration Law as promulgated by the MOH in 1989 have laid down the legal framework for the establishment of pharmaceutical manufacturing enterprises, pharmaceutical trading enterprises and for the administration of pharmaceutical products including the development and manufacturing of new drugs and medicinal preparations by medical institutions. The PRC Drug Administration Law also regulates the packaging, trademarks and the advertisements of pharmaceutical products in the PRC.

132

Table of Contents

Certain revisions to the PRC Drug Administration Law took effect on December 1, 2001. They were formulated to strengthen the supervision and administration of pharmaceutical products, and to ensure the quality of pharmaceutical products and the safety of pharmaceutical products for human use. The revised PRC Drug Administration Law applies to entities and individuals engaged in the development, production, trade, application, supervision and administration of pharmaceutical products. It regulates and prescribes a framework for the administration of pharmaceutical manufacturers, pharmaceutical trading companies, and medicinal preparations of medical institutions and the development, research, manufacturing, distribution, packaging, pricing and advertisements of pharmaceutical products.

The PRC Drug Administration Law was later amended on December 28, 2013 and April 24, 2015 by the Standing Committee of the National People's Congress. It provides the basic legal framework for the administration of the production and sale of pharmaceutical products in China and covers the manufacturing, distributing, packaging, pricing and advertising of pharmaceutical products.

According to the PRC Drug Administration Law, no pharmaceutical products may be produced without a pharmaceutical production license. A manufacturer of pharmaceutical products must obtain a pharmaceutical production license from one of CFDA's provincial level branches in order to commence production of pharmaceuticals. Prior to granting such license, the relevant government authority will inspect the manufacturer's production facilities, and decide whether the sanitary conditions, quality assurance system, management structure and equipment within the facilities have met the required standards.

The PRC Drug Administration Implementation Regulations promulgated by the State Council took effect on September 15, 2002 and were later amended on February 6, 2016 to provide detailed implementation regulations for the revised PRC Drug Administration Law.

Examination and Approval of New Medicines

On July 10, 2007, the CFDA promulgated the Administrative Measures on the Registration of Pharmaceutical Products, or the Registration Measures, which became effective on October 1, 2007. Under the Registration Measures, new medicines generally refer to those medicines that have not yet been marketed in the PRC. In addition, certain marketed medicines may also be treated as new medicines if the type or application method of such medicines has been changed or new therapeutic functions have been added to such medicines. According to the Registration Measures, the approval of new medicines requires the following steps:

•: upon completion of the pre-clinical research of the new medicine, application for registration of the new medicine will be submitted to the drug regulatory authorities at the provincial level for review in formalities. If all the formality requirements are met, the drug regulatory authorities at the provincial level will issue a notice of acceptance and conduct site inspections on the research and original data of the new medicine. The drug regulatory authorities at the provincial level will subsequently issue a preliminary opinion and notify a medical examination institute to conduct a sample examination on the new medicine (if the new medicine is a biological product);
•: the drug regulatory authorities at the provincial level will then submit their preliminary opinion, inspection report and application materials to the Drug Review Center of the CFDA and notify the applicant of the progress;
•: after receiving the application materials, the Drug Review Center of the CFDA will arrange for pharmaceutical, medical or other professionals to conduct a technical review on the application materials and request for supplemental materials and explanations, if necessary. After completion of the technical review, the Drug Review Center of the CFDA will issue an opinion and submit such opinion to the CFDA, along with the application materials;

133

Table of Contents

•

after receiving the technical opinion from the Drug Review Center, the CFDA will assess whether or not to grant the approval for conducting the clinical research on the new medicine;

•

after obtaining the CFDA's approval for conducting the clinical research, the applicant may proceed with the relevant clinical research (which is generally conducted in three phases for a new medicine under the Registration Measures) at institutions with appropriate qualification:

•: Phase I refers to the preliminary clinical trial for clinical pharmacology and body safety. It is conducted to observe the human body tolerance for new medicine and pharmacokinetics, so as to provide a basis for determining the prescription plan.
•: Phase II refers to the stage of preliminary evaluation of clinical effectiveness. The purpose is to preliminarily evaluate the clinical effectiveness and safety of the medicine used on patients with targeted indication, as well as to provide a basis for determining the Phase III clinical trial research plan and the volume under the prescription plan.
•: Phase III is a clinical trial stage to verify the clinical effectiveness. The purpose is to test and determine the clinical effectiveness and safety of the medicine used on patients with targeted indication, to evaluate the benefits and risks thereof and, eventually, to provide sufficient basis for review of the medicine registration application.
•: Phase IV refers the stage of surveillance and research after the new medicines is launched. The purpose is to observe the clinical effectiveness and adverse effects of the medicine over a much larger patient population and longer time period than in Phase I to III clinical trials, and evaluate the benefits and risks when it is administered to general or special patient population in larger prescription volume.

•

after completion of the relevant clinical research, the applicant shall submit its clinical research report together with the relevant supporting documents to the drug regulatory authorities at the provincial level and shall provide raw materials of the standard products and research result on relevant standard products to the PRC National Institute for the Control of Pharmaceutical and Biological Products;

•

the drug regulatory authorities at the provincial level will then review the relevant documents in formalities. If all the formality requirements are met, the drug regulatory authorities at the provincial level will issue a notice of acceptance and within five days of notice and start conducting site inspections. The drug regulatory authorities at the provincial level will issue a preliminary opinion and then collect three samples of the new medicine (if the new medicine is not a biological product) and notify the relevant medicine examination institute to review the medicine standards;

•

the drug regulatory authorities at the provincial level will then submit their preliminary opinion, inspection report and application materials to the Drug Review Center of the CFDA and notify the applicant of the progress;

•

the medical examination institute will review the medicine standards and report its opinion to the Drug Review Center of the CFDA and send a copy of the opinion to the drug regulatory authorities at the provincial level and the applicant;

•

after receiving the application materials, the Drug Review Center of the CFDA will arrange for pharmaceutical, medical or other professionals to conduct a technical review on the application materials and request for supplemental materials and explanations, if necessary. After completion of the technical review and if all the requirements are complied with, the Drug Review Center of the CFDA will report so to the Certification Center of the CFDA and notify the applicant that it may apply to the Certification Center of the CFDA for a site inspection;

•

the applicant will apply to the Certification Center of the CFDA for a site inspection within six months after receiving the notice from the Drug Review Center of the CFDA;

134

Table of Contents

•: the Certification Center of the CFDA will arrange a site inspection on the process of manufacturing samples within thirty days after the application from the applicant to ensure the feasibility of the manufacturing process. The Certification Center of the CFDA will collect a sample (three samples if the new medicine is a biological product) for the medicine examination institute to examine. The Certification Center of the CFDA will prepare an inspection report within 10 days after the site inspection and submit the report to the Drug Review Center of the CFDA;
•: the sample(s) shall be manufactured at a GMP-certified workshop. The medicine examination institute will examine the sample(s) under the reviewed medicine standards and prepare a report after completion the examination and submit the report to the Drug Review Center of the CFDA. A copy of the report will be available to the drug regulatory authorities at the provincial level and the applicant;
•: the Drug Review Center of the CFDA will form a comprehensive opinion based on the technical opinion previously received, the report on site inspection and the result of sample examination and submit the comprehensive opinion and the application materials to the CFDA; and
•: if all the regulatory requirements are satisfied, the CFDA will grant a new drug certificate and a pharmaceutical approval number (assuming the applicant has a valid Pharmaceutical Manufacturing Permit and the requisite production conditions for the new medicine have been met).

Any applicant who is not satisfied with the CFDA's decision to deny an application can appeal within 60 days of its receipt of the CFDA's decision. If the applicant is dissatisfied with the result of the appeal, it may apply for an administrative review with a special committee consisting of senior officials of the CFDA or file an administrative lawsuit with a people's court in China.

Pursuant to the Registration Measures, chemical drugs are categorized into six different registration classes. Class I New Chemical Drug is a new chemical drug that has never been marketed in China or abroad, including (1) crude drugs made by synthesis or semi-synthesis and the preparations thereof; (2) new effective monomer extracted from natural substances or by fermentation and the preparations thereof; (3) optical isomer obtained from existing drugs by chiral separation or synthesis and the preparations thereof; (4) drug with fewer components derived from marketed multi-component drugs; (5) new combination products; and (6) a preparation already marketed in China but with a newly added indication not yet approved in any country. Different application materials are required for each registration category.

In accordance with the Provisions on the Administration of Special Examination and Approval of Registration of New Drugs promulgated by the CFDA, issued and effective on January 7, 2009, an NDA that meets certain requirements as specified below will be handled with priority in the review and approval process, so-called "green-channel" approval. In addition, the applicant is entitled to provide additional materials during the review period besides those requested by the CFDA, and will have access to enhanced communication channels with the CFDA.

Applicants for the registration of the following new drugs are entitled to request priority treatment in review and approval: (i) active ingredients and their preparations extracted from plants, animals and minerals, and newly discovered medical materials and their preparations that have not been sold in the China market, (ii) chemical drugs and their preparations and biological products that have not been approved for sale at its origin country or abroad, (iii) new drugs with obvious clinical treatment advantages for such diseases as AIDS, therioma, and rare diseases, and (iv) new drugs for diseases that have not been treated effectively. Under category (i) or (ii) above, the applicant for drug registration may apply for special examination and approval when applying for the clinical trial of new drugs; under category (iii) or (iv) above, the applicant may only apply for special examination and approval when applying for manufacturing.

135

Table of Contents

In addition, on December 21, 2017, the CFDA released the Opinions on Priority Review and Approval for Encouraging Drug Innovation, which further clarified that a fast track for drug registration will be available to:

•: the following drugs with distinctive clinical value: (1) innovative drugs not sold within or outside China; (2) innovative drug transferred to be manufactured locally in China; (3) drugs using advanced technology, innovative treatment methods, or having distinctive treatment advantages; (4) traditional Chinese medicines (including ethnic medicines) with clear clinical position in treatment of serious diseases; and (5) new drugs listed in national major science and technology projects or national key research and development plans, and recognized by national clinical medicine research centers which conducted clinical trials of such drugs;
•: drugs with distinctive clinical advantages for the prevention and treatment of the following diseases: HIV, phthisis, viral hepatitis, orphan diseases, malignant tumors, children's diseases, and characteristic and prevalent diseases in elders; and
•: drugs which have been concurrently filed with the competent drug approval authorities in the United States or European Union for marketing authorization and passed such authorities' onsite inspections and are manufactured using the same production line in China.

It also specified that fast track status would be given to clinical trial applications for drugs with patent expiry within three years and manufacturing authorization applications for drugs with patent expiry within one year. Concurrent applications for new drug clinical trials which are already approved in the United States or European Union are also eligible for fast track CFDA approval.

Drug Technology Transfer Regulations

On August 19, 2009, the CFDA promulgated the Administrative Regulations for Technology Transfer Registration of Drugs to standardize the registration process of drug technology transfer, which includes application for, and evaluation, examination, approval and monitoring of, drug technology transfer. Drug technology transfer refers to the transfer of drug production technology by the owner to a drug manufacturer and the application for drug registration by the transferee according to the provisions in the new regulations. Drug technology transfer includes new drug technology transfer and drug production technology transfer.

Conditions for the application for new drug technology transfer

Applications for new drug technology transfer may be submitted prior to the expiration date of the monitoring period of the new drugs with respect to:

•: drugs with new drug certificates only; or
•: drugs with new drug certificates and drug approval numbers.

For drugs with new drug certificates only and not yet in the monitoring period, or drug substances with new drug certificates, applications for new drug technology transfer should be submitted prior to the respective expiration date of the monitoring periods for each drug registration category set forth in the new regulations and after the issue date of the new drug certificates.

Conditions for the application of drug production technology transfer

Applications for drug production technology transfer may be submitted if:

•: the transferor holds new drug certificates or both new drug certificates and drug approval numbers, and the monitoring period has expired or there is no monitoring period;
•: with respect to drugs without new drug certificates, both the transferor and the transferee are legally qualified drug manufacturing enterprises, one of which holds over 50% of the equity

136

Table of Contents

interests in the other, or both of which are majority-owned subsidiaries of the same drug manufacturing enterprise;

•: with respect to imported drugs with imported drug licenses, the original applicants for the imported drug registration may transfer these drugs to local drug manufacturing enterprises.

Application for, and examination and approval of, drug technology transfer

Applications for drug technology transfer should be submitted to the provincial food and drug administration. If the transferor and the transferee are located in different provinces, the provincial food and drug administration where the transferor is located should provide examination opinions. The provincial food and drug administration where the transferee is located is responsible for examining application materials for technology transfer and organizing inspections on the production facilities of the transferee. Medical examination institutes are responsible for testing three batches of drug samples.

The Drug Review Center of the CFDA should further review the application materials, provide technical evaluation opinions and form a comprehensive evaluation opinion based on the site inspection reports and the testing results of the samples. The CFDA should determine whether to approve the application according to the comprehensive evaluation opinion of the Drug Review Center of the CFDA. An approval letter of supplementary application and a drug approval number will be issued to qualified applications. An approval letter of clinical trials will be issued when necessary. For rejected applications, a notification letter of the examination opinions will be issued with the reasons for rejection.

Permits and Licenses for Manufacturing and Registration of Drugs

Production Licenses

To manufacture pharmaceutical products in the PRC, a pharmaceutical manufacturing enterprise must first obtain a Pharmaceutical Manufacturing Permit issued by the relevant pharmaceutical administrative authorities at the provincial level where the enterprise is located. Among other things, such a permit must set forth the permit number, the name, legal representative and registered address of the enterprise, the site and scope of production, issuing institution, date of issuance and effective period.

Each Pharmaceutical Manufacturing Permit issued to a pharmaceutical manufacturing enterprise is effective for a period of five years. The enterprise is required to apply for renewal of such permit within six months prior to its expiry and will be subject to reassessment by the issuing authorities in accordance with then prevailing legal and regulatory requirements for the purposes of such renewal.

Business Licenses

In addition to a Pharmaceutical Manufacturing permit, the manufacturing enterprise must also obtain a business license from the administrative bureau of industry and commerce at the local level. The name, legal representative and registered address of the enterprise specified in the business license must be identical to that set forth in the Pharmaceutical Manufacturing Permit.

Registration of Pharmaceutical Products

All pharmaceutical products that are produced in the PRC must bear a registered number issued by the CFDA, with the exception of Chinese herbs and Chinese herbal medicines in soluble form. The medicine manufacturing enterprises must obtain the medicine registration number before manufacturing any medicine.

137

Table of Contents

GMP Certificates

The World Health Organization encourages the adoption of GMP standards in pharmaceutical production in order to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final products.

The Guidelines on Good Manufacturing Practices, as amended in 1998 and 2010, or the Guidelines, took effect on August 1, 1999 and set the basic standards for the manufacture of pharmaceuticals. These Guidelines cover issues such as the production facilities, the qualification of the personnel at the management level, production plant and facilities, documentation, material packaging and labeling, inspection, production management, sales and return of products and customers' complaints. On October 23, 2003, the CFDA issued the Notice on the Overall Implementation and Supervision of Accreditation of Good Manufacturing Practice Certificates for Pharmaceuticals, which required all pharmaceutical manufacturers to apply for the GMP certificates by June 30, 2004. Those enterprises that failed to obtain the GMP certificates by December 31, 2004 would have their Pharmaceutical Manufacturing Permit revoked by the drug administrative authorities at the provincial level. On October 24, 2007, the CFDA issued Evaluation Standard on Good Manufacturing Practices which became effective on January 1, 2008. The GMP certificate is valid for a specific term and application for renewal must be submitted six months prior to its expiration date.

Administrative Protection and Monitoring Periods for New Drugs

According to the Registration Measures, with a view to protecting public health, the CFDA may provide for administrative monitoring periods of up to five years for new drugs approved to be manufactured, to continually monitor the safety of those new drugs.

During the monitoring period of a new drug, the CFDA will not approve any other enterprise's application to manufacture, change the dosage of or import a similar new drug. The only exception is that the CFDA will continue to handle any application if, prior to the commencement of the monitoring period, the CFDA has already approved the applicant's clinical trial for a similar new drug. If such application conforms to the relevant provisions, the CFDA may approve such applicant to manufacture or import the similar new drug during the remainder of the monitoring period.

The Administrative Measures Governing the Production Quality of Pharmaceutical Products, or the Administrative Measures for Production, provides detailed guidelines on practices governing the production of pharmaceutical products. A GMP certification certifies that a manufacturer's factory has met certain criteria in the Administrative Measures for Production, which include: institution and staff qualifications, production premises and facilities, equipment, hygiene conditions, production management, quality controls, product operation, maintenance of sales records and manner of handling customer complaints and adverse reaction reports.

According to the Administrative Measures for Certification of the Good Manufacturing Practices, effective on August 2, 2011, a manufacturer of pharmaceutical products shall reapply for a new GMP certification six months prior to its expiration date.

Distribution of Pharmaceutical Products

According to the PRC Drug Administration Law and its implementing regulations and the Measures for the Supervision and Administration of Circulation of Pharmaceuticals, a manufacturer of pharmaceutical products in the PRC can only engage in the trading of the pharmaceutical products that the manufacturer has produced itself. In addition, such manufacturer can only sell its products to:

•: wholesalers and distributors holding Pharmaceutical Distribution Permits;
•: other holders of Pharmaceutical Manufacturing Permits; or

138

Table of Contents

•: medical practitioners holding Medical Practice Permits.

A pharmaceutical manufacturer in the PRC is prohibited from selling its products to end-users, or individuals or entities other than holders of Pharmaceutical Distribution Permits, the Pharmaceutical Manufacturing Permits or the Medical Practice Permits.

The granting of a Pharmaceutical Distribution Permit to wholesalers shall be subject to approval of the provincial level drug regulatory authorities, while the granting of a retailer permit shall be subject to the approval of the drug regulatory authorities above the county level. Unless otherwise expressly approved, no pharmaceutical wholesaler may engage in the retail of pharmaceutical products, and neither may pharmaceutical retailers engage in wholesale.

A pharmaceutical distributor shall satisfy the following requirements:

•: personnel with pharmaceutical expertise as qualified according to law;
•: business site, facilities, warehousing and sanitary environment compatible to the distributed pharmaceutical products;
•: quality management system and personnel compatible to the distributed pharmaceutical products; and
•: rules and regulations to ensure the quality of the distributed pharmaceutical products.

Operations of pharmaceutical distributors shall be conducted in accordance with the Pharmaceutical Operation Quality Management Rules and shall be granted a GSP certificate under such rules by the CFDA. A GSP certificate is valid for five years and may be renewed three months prior to its expiration date upon a reexamination by the relevant authority.

Pharmaceutical distributors must keep true and complete records of any pharmaceutical products purchased, distributed or sold with the generic name of such products, specification, approval code, term, manufacturer, purchasing or selling party, price and date of purchase or sale. A pharmaceutical distributor must keep such record at least until one year after the expiry date of such products and in any case, such record must be kept for no less than three years. Penalties may be imposed for any violation of record-keeping.

Pharmaceutical distributors can only distribute pharmaceutical products obtained from those with a Pharmaceutical Manufacturing Permit and a Pharmaceutical Distribution Permit.

On December 26, 2016, the Medical Reform Office of the State Council, the National Health and Family Planning Commission, the CFDA and other five government authorities promulgated the "Two-Invoice System" Opinions, which became effective on the same date. On April 25, 2017, the General Office of the State Council further promulgated the Notice on Issuing the Key Working Tasks for Deepening the Reform of Medicine and Health System in 2017. According to these rules, a two-invoice system is encouraged to be gradually adopted for drug procurement. The two-invoice system generally requires a drug manufacturer to issue only one invoice to its distributor followed by the distributor issuing a second invoice directly to the end customer hospital. Only one distributor is permitted to distribute drug products between the manufacturer and the hospital. The system also encourages manufacturers to sell drug products directly to hospitals. Public medical institutions are required to adopt the two-invoice system, and its full implementation nationwide is targeted for 2018. Pharmaceutical manufacturers and distributors who fail to implement the two-invoice system may be disqualified from attending future bidding events or providing distribution for hospitals and blacklisted for drug procurement practices. These rules aim to consolidate drug distribution and reduce drug prices.

139

Table of Contents

Foreign Investment and "State Secret" Technology

The interpretation of certain PRC laws and regulations governing foreign investment and "state secret" technology is uncertain. Depending on the industry sectors, foreign investments are classified as "encouraged", "restricted" or "prohibited" under the Guidance Catalogue of Industries for Foreign Investment, or the Catalogue, published by the MOFCOM and the NDRC. Under the Catalogue, "manufacturing of modern Chinese medicines with confidential proprietary formula" has been deemed prohibited for any foreign investment. The technology and know-how of the She Xiang Bao Xin pill is classified as "state secret" technology by China's Ministry of Science and Technology, or the MOST, and the National Administration for the Protection of State Secrets, or NAPSS.

There are currently no PRC laws or regulations or official interpretations, and therefore there can be no assurance, as to whether the use of "state secret" technology constitutes the "manufacturing of Chinese medicines with confidential proprietary formula" under the Catalogue. However, under the Rules on Confidentiality of Science and Technology promulgated by the State Science and Technology Commission (the predecessor of the MOST and the NAPSS) on January 6, 1995, cooperation with foreign parties or establishing joint ventures with foreign parties in respect of state secret technology is expressly allowed, provided that such cooperation has been duly approved by the relevant science and technology authorities. The establishment of Shanghai Hutchison Pharmaceuticals as a sino-foreign joint venture, including the re-registration of licenses for She Xiang Bao Xin pills in its name, was approved by the local counterpart of the MOFCOM and the Shanghai Drug Administration in 2001. Subsequently, the "Confidential State Secret Technology" status protection for She Xiang Bao Xin pills was also granted in 2005 to Shanghai Hutchison Pharmaceuticals as a sino-foreign joint venture by the MOST and NAPSS. Consequently, we believe Shanghai Hutchison Pharmaceuticals is in compliance with all applicable PRC laws and regulations governing foreign investment and "state secret" technology and will continue to be so following our listing of our ADSs on the Nasdaq Global Select Market. Moreover, we believe that our other joint ventures and wholly-foreign owned enterprises in the PRC are also in compliance with all applicable PRC laws and regulations governing foreign investment and will continue to be so following our listing of our ADSs on the Nasdaq Global Select Market.

U.S. Regulation of Pharmaceutical Product Development and Approval

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. The process of obtaining approvals and the subsequent compliance with appropriate federal, state and local rules and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. regulatory requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of enforcement correspondence, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by FDA and the U.S. Department of Justice, or DOJ, or other governmental entities. Drugs are also subject to other federal, state and local statutes and regulations.

Our drug candidates must be approved by the FDA through the NDA process before they may be legally marketed in the United States. The process required by the FDA before a drug may be marketed in the United States generally involves the following:

•: completion of extensive pre-clinical studies, sometimes referred to as pre-clinical laboratory tests, pre-clinical animal studies and formulation studies all performed in compliance with applicable regulations, including the FDA's GLP regulations;

140

Table of Contents

•: submission to the FDA of an IND application which must become effective before human clinical trials may begin and must be updated annually;
•: IRB approval before each clinical trial may be initiated;
•: performance of adequate and well-controlled human clinical trials in accordance with study protocols, the applicable GCPs and other clinical trial-related regulations, to establish the safety and efficacy of the proposed drug product for its proposed indication;
•: preparation and submission to the FDA of an NDA;
•: a determination by the FDA within 60 days of its receipt of an NDA whether the NDA is acceptable for filing; if the FDA determines that the NDA is not sufficiently complete to permit substantive review, it may request additional information and decline to accept the application for filing until the information is provided;
•: in-depth review of the NDA by FDA, which may include review by a scientific advisory committee;
•: satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the API and finished drug product are produced to assess compliance with the FDA's current good manufacturing practice requirements, or cGMP;
•: potential FDA audit of the pre-clinical and/or clinical trial sites that generated the data in support of the NDA;
•: payment of user fees and FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the United States; and
•: compliance with any post-approval requirements, such as REMS and post-approval studies required by FDA.

Pre-clinical Studies

The data required to support an NDA is generated in two distinct development stages: pre-clinical and clinical. For new chemical entities, or NCEs, the pre-clinical development stage generally involves synthesizing the active component, developing the formulation and determining the manufacturing process, evaluating purity and stability, as well as carrying out non-human toxicology, pharmacology and drug metabolism studies in the laboratory, which support subsequent clinical testing. The conduct of the pre-clinical tests must comply with federal regulations, including GLPs. The sponsor must submit the results of the pre-clinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor must resolve with the FDA any outstanding concerns or questions before the clinical trial can begin. Some long-term pre-clinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, submission of an IND does not guarantee the FDA will allow clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.

141

Table of Contents

Clinical Studies

The clinical stage of development involves the administration of the drug product to human subjects or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor's control, in accordance with GCPs, which include the requirement that, in general, all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also reviews and approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. For example, information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website.

Clinical trials are generally conducted in three sequential phases that may overlap or be combined, known as Phase I, Phase II and Phase III clinical trials.

•

Phase I: In a standard Phase I clinical trial, the drug is initially introduced into a small number of subjects who are initially exposed to a range of doses of the drug candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, appropriate dosing, side effect tolerability and safety of the drug.

•: Phase Ib: Although Phase I clinical trials are not intended to treat disease or illness, a Phase Ib trial is conducted in patient populations who have been diagnosed with the disease for which the study drug is intended. The patient population typically demonstrates a biomarker, surrogate, or other clinical outcome that can be assessed to show "proof-of-concept." In a Phase Ib study, proof-of-concept typically confirms a hypothesis that the current prediction of a biomarker, surrogate or other outcome benefit is compatible with the mechanism of action of the study drug.
•: Phase I/II: A Phase I and Phase II trial for the same treatment is combined into a single study protocol. The drug is administered first to determine a maximum tolerable dose, and then additional patients are treated in the Phase II portion of the study to further assess safety and/or efficacy.

•

Phase II: The drug is administered to a limited patient population to determine dose tolerance and optimal dosage required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, as well as identification of possible adverse effects and safety risks and preliminary evaluation of efficacy.

•

Phase III: The drug is administered to an expanded number of patients, generally at multiple sites that are geographically dispersed, in well-controlled clinical trials to generate enough data to demonstrate the efficacy of the drug for its intended use, its safety profile, and to establish the overall benefit/risk profile of the drug and provide an adequate basis for drug approval and labeling of the drug product. Phase III clinical trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a drug during marketing. Generally, two adequate and well-controlled Phase III clinical trials are required by the FDA for approval of an NDA. A pivotal study is a clinical study that adequately

142

Table of Contents

meets regulatory agency requirements for the evaluation of a drug candidate's efficacy and safety such that it can be used to justify the approval of the drug. Generally, pivotal studies are also Phase III studies but may be Phase II studies if the trial design provides a well-controlled and reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need. Post-approval trials, sometimes referred to as Phase 4 clinical trials, are conducted after initial regulatory approval, and they are used to collect additional information from the treatment of patients in the intended therapeutic indication or to meet other regulatory requirements. In certain instances, FDA may mandate the performance of Phase 4 clinical trials.

Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA, and more frequently if serious adverse events occur. Written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a significant risk to human subjects. The FDA, the IRB, or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. The FDA will typically inspect one or more clinical sites to assure compliance with GCPs and the integrity of the clinical data submitted. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB's requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the drug in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, cGMPs impose extensive procedural, substantive and recordkeeping requirements to ensure and preserve the long-term stability and quality of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.

NDA Submission and FDA Review Process

Following trial completion, trial results and data are analyzed to assess safety and efficacy. The results of pre-clinical studies and clinical trials are then submitted to the FDA as part of an NDA, along with proposed labeling for the drug, information about the manufacturing process and facilities that will be used to ensure drug quality, results of analytical testing conducted on the chemistry of the drug, and other relevant information. The NDA is a request for approval to market the drug and must contain adequate evidence of safety and efficacy, which is demonstrated by extensive pre-clinical and clinical testing. The application includes both negative or ambiguous results of pre-clinical and clinical trials as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a use of a drug, or from a number of alternative sources, including studies initiated by investigators. To support regulatory approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational drug product to the satisfaction of the FDA. Under federal law, the submission of most NDAs is subject to the payment of an application user fees; a waiver of such fees may be obtained under certain limited circumstances. FDA approval of an NDA must be obtained before a drug may be offered for sale in the United States.

In addition, under the Pediatric Research Equity Act of 2003, or PREA, an NDA or supplement to an NDA must contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric

143

Table of Contents

subpopulation for which the drug is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers.

Under the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA must be accompanied by an application user fee. The FDA adjusts the PDUFA user fees on an annual basis. According to the FDA's fee schedule, effective through September 30, 2018, the user fee for an application requiring clinical data, such as an NDA, is $2,421,495. PDUFA also imposes a program fee for prescription human drugs $304,162. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.

The FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than accepting an NDA for filing. The FDA conducts a preliminary review of an NDA within 60 days of receipt and informs the sponsor by the 74th day after FDA's receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months from the filing date in which to complete its initial review of a standard NDA and respond to the applicant, and six months from the filing date for a "priority review" NDA. The FDA does not always meet its PDUFA goal dates for standard and priority review NDAs, and the review process is often significantly extended by FDA requests for additional information or clarification.

After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed drug is safe and effective for its intended use, and whether the drug is being manufactured in accordance with cGMP to assure and preserve the drug's identity, strength, quality and purity. The FDA may refer applications for drugs or drug candidates that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA may re-analyze the clinical trial data, which can result in extensive discussions between the FDA and us during the review process.

Before approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new drug to determine whether they comply with cGMPs. The FDA will not approve the drug unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the drug within required specifications. In addition, before approving an NDA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities where the drug product and/or its API will be produced, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal clinical trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials, pre-clinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.

If a drug receives regulatory approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited. Further, the FDA may require that certain

144

Table of Contents

contraindications, warnings or precautions be included in the drug labeling or may condition the approval of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved drugs. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess a drug's safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved drugs that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a REMS to ensure that the benefits of a drug or biological product outweigh its risks. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of drugs. Drug approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.

Section 505(b)(2) NDAs

NDAs for most new drug products are based on two full clinical studies which must contain substantial evidence of the safety and efficacy of the proposed new product. These applications are submitted under Section 505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative type of NDA under Section 505(b)(2) of the FDCA, which authorizes FDA to approve an NDA based on safety and effectiveness data that were not developed by the applicant. Section 505(b)(2) allows the applicant to rely, in part, on the FDA's previous findings of safety and efficacy for a similar product, or published literature. Specifically, Section 505(b)(2) applies to NDAs for a drug for which the investigations relied upon to show that the drug is safe and effective for the intended use "were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted."

Section 505(b)(2) authorizes NDAs filed under Section 505(b)(2) may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously approved products. If the 505(b)(2) applicant can establish that reliance on the FDA's previous approval is scientifically appropriate, the applicant may eliminate the need to conduct certain pre-clinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant.

Abbreviated New Drug Applications for Generic Drugs

In 1984, with passage of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application, or ANDA, to the agency. In support of such applications, a generic manufacturer may rely on the pre-clinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference listed drug, or RLD.

Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is "bioequivalent" to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if "the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug." The Generic Drug User Fee Act (GDUFA), as reauthorized, sets forth

145

Table of Contents

performance goals for FDA to review standard ANDA's within 10 months of their submission, and priority ANDA's within 8 months of their submission if they satisfy certain requirements.

Upon approval of an ANDA, the FDA indicates that the generic product is "therapeutically equivalent" to the RLD and it assigns a therapeutic equivalence rating to the approved generic drug in its publication "Approved Drug Products with Therapeutic Equivalence Evaluations," also referred to as the "Orange Book." Physicians and pharmacists consider an "AB" therapeutic equivalence rating to mean that a generic drug is fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, FDA's designation of an "AB" rating often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient.

Special FDA Expedited Review and Approval Programs

The FDA has various programs, including Fast Track Designation, accelerated approval, priority review and Breakthrough Therapy Designation, that are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. While these pathways can reduce the time it takes for the FDA to review an NDA, they do not guarantee that a product will receive FDA approval.

Fast Track Designation

To be eligible for a Fast Track Designation, the FDA must determine, based on the request of a sponsor, that a drug is intended to treat a serious or life threatening disease or condition for which there is no effective treatment and demonstrates the potential to address an unmet medical need for the disease or condition. Under the fast track program, the sponsor of a drug candidate may request FDA to designate the product for a specific indication as a fast track product concurrent with or after the filing of the IND for the drug candidate. The FDA must make a fast track designation determination within 60 days after receipt of the sponsor's request.

In addition to other benefits, such as the ability to use surrogate endpoints and have greater interactions with FDA, FDA may initiate review of sections of a fast track product's NDA before the application is complete. This rolling review is available if the applicant provides, and FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, FDA's time period goal for reviewing a fast track application does not begin until the last section of the NDA is submitted. A fast track drug also may be eligible for accelerated approval and priority review. In addition, the fast track designation may be withdrawn by FDA if FDA believes that the designation is no longer supported by data emerging in the clinical trial process.

Priority Review

The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of 10 months under current PDUFA guidelines. These 6- and 10-month review periods are measured from the "filing" date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for Fast Track Designation are also likely to be considered appropriate to receive a priority review.

Breakthrough Therapy Designation

Under the provisions of the new Food and Drug Administration Safety and Innovation Act, or FDASIA, enacted by Congress in 2012, a sponsor can request designation of a drug candidate as a

146

Table of Contents

"breakthrough therapy," typically by the end of the drug's Phase II trials. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. For breakthrough therapies, the FDA may take certain actions, such as intensive and early guidance on the drug development program, that are intended to expedite the development and review of an application for approval.

Accelerated Approval

FDASIA also codified and expanded on FDA's accelerated approval regulations, under which FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit over existing treatments based on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on an intermediate clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. A surrogate endpoint is a marker that does not itself measure clinical benefit but is believed to predict clinical benefit. This determination takes into account the severity, rarity or prevalence of the disease or condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform Phase 4 or post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.

Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, Fast Track Designation, priority review, accelerated approval and Breakthrough Therapy Designation, do not change the standards for approval and may not ultimately expedite the development or approval process.

Pediatric Trials

Under PREA, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With the enactment of FDASIA, a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must also submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-Phase II meeting or as may be agreed between the sponsor and FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. FDA and the sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from pre-clinical studies, early phase clinical trials, and/or other clinical development programs. The law requires the FDA to send a non-compliance letters to sponsors who do not submit their pediatric assessments as required.

Under the Best Pharmaceuticals for Children Act, or BPCA, certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor submits information requested by the FDA, relating to the use of the active moiety of the product candidate in children. Although the FDA may issue a

147

Table of Contents

written request for studies on either approved or unapproved indications, it may only do so where it determines that information relating to that use of a product candidate in a pediatric population, or part of the pediatric population, may produce health benefits in that population.

FDASIA permanently reauthorized PREA and BPCA, modifying some of the requirements under these laws, and established priority review vouchers for rare pediatric diseases.

Orphan Drug Designation and Exclusivity

Under the Orphan Drug Act, FDA may designate a drug product as an "orphan drug" if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, but the product will be entitled to orphan product exclusivity, meaning that FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. Competitors may receive approval of different products for the indication for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or drug product designated as an orphan product ultimately receives regulatory approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. The 21st Century Cures Act, which became law in December 2016, expanded the types of studies that qualify for orphan drug grants. Orphan drug designation also may qualify an applicant for federal tax credits relating to research and development costs.

Post-Marketing Requirements

Following approval of a new drug, a pharmaceutical company and the approved drug are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the drug, providing the regulatory authorities with updated safety and efficacy information, drug sampling and distribution requirements, and complying with applicable promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or in patient populations that are not described in the drug's approved labeling (known as "off-label use"), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may legally prescribe drugs for off-label uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the drug or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process.

Prescription drug advertising is subject to federal, state and foreign regulations. In the United States, the FDA regulates prescription drug promotion, including direct-to-consumer advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution of prescription drugs and pharmaceutical samples also must comply with the U.S. Prescription Drug Marketing Act a part of the FDCA.

In the United States, once a drug is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that drugs be manufactured in specific approved facilities and in accordance with cGMP. Applicants may also rely on third parties for the production of clinical and commercial quantities of drugs, and these third parties must operate in accordance with cGMP regulations. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the

148

Table of Contents

obligation to investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. NDA holders using third-party contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute drugs manufactured, processed or tested by them. Discovery of problems with a drug after approval may result in restrictions on a drug, manufacturer, or holder of an approved NDA, including, among other things, recall or withdrawal of the drug from the market, and may require substantial resources to correct.

The FDA also may require post-approval testing, sometimes referred to as Phase 4 testing, risk minimization action plans and post-marketing surveillance to monitor the effects of an approved drug or place conditions on an approval that could restrict the distribution or use of the drug. Discovery of previously unknown problems with a drug or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a drug's approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA's policies may change, which could delay or prevent regulatory approval of our drugs under development.

Other U.S. Regulatory Matters

Manufacturing, sales, promotion and other activities following drug approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers for Medicare & Medicaid Services, other divisions of the Department of Health and Human Services, the Drug Enforcement Administration for controlled substances, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety & Health Administration, the Environmental Protection Agency and state and local governments. In the United States, sales, marketing and scientific/educational programs must also comply with state and federal fraud and abuse laws. Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Affordable Care Act. If drugs are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Drugs must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws.

The distribution of pharmaceutical drugs is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical drugs.

The failure to comply with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, recall or seizure of drugs, total or partial

149

Table of Contents

suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding the safety or efficacy of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.

Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.

U.S. Patent Term Restoration and Marketing Exclusivity

Depending upon the timing, duration and specifics of the FDA approval of our drug candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product's approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.

Marketing exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a NCE. A drug is a NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA, or a 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. Specifically, the applicant must certify with respect to each relevant patent that: the required patent information has not been filed; the listed patent has expired; the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration, or the listed patent is invalid, unenforceable or will not be infringed by the new product. A certification that the new product will not infringe the already approved product's listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA applicant. To the extent that the Section 505(b)(2) applicant relies on prior FDA findings of safety and efficacy, the applicant is

150

Table of Contents

required to certify to the FDA concerning any patents listed for the previously approved product in the Orange Book to the same extent that an ANDA applicant would.

The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued "Written Request" for such a trial.

Rest of the World Regulation of Pharmaceutical Product Development and Approval

For other countries outside of China and the United States, such as countries in Europe, Latin America or other parts of Asia, the requirements governing the conduct of clinical trials, drug licensing, pricing and reimbursement vary from country to country. In all cases the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and ethical principles.

If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

Coverage and Reimbursement

PRC Coverage and Reimbursement

Historically, most of Chinese healthcare costs have been borne by patients out-of-pocket, which has limited the growth of more expensive pharmaceutical products. However, in recent years the number of people covered by government and private insurance has increased. According to the PRC National Bureau of Statistics, as of December 31, 2016, 744 million employees and residents in China were enrolled in the national medical insurance program, representing an increase of 78.1 million from December 31, 2015. The PRC government has announced a plan to give every person in China access to basic healthcare by year 2020.

Reimbursement under the National Medical Insurance Program

The National Medical Insurance Program was adopted pursuant to the Decision of the State Council on the Establishment of the Urban Employee Basic Medical Insurance Program issued by the State Council on December 14, 1998, under which all employers in urban cities are required to enroll their employees in the basic medical insurance program and the insurance premium is jointly contributed by the employers and employees. The State Council promulgated Guiding Opinions of the State Council about the Pilot Urban Resident Basic Medical Insurance on July 10, 2007, under which urban residents of the pilot district, rather than urban employees, may voluntarily join Urban Resident Basic Medical Insurance. The State Council expects the pilot Urban Resident Basic Medical Insurance to cover the whole nation by 2010.

151

Table of Contents

Participants of the National Medical Insurance Program and their employers, if any, are required to contribute to the payment of insurance premiums on a monthly basis. Program participants are eligible for full or partial reimbursement of the cost of medicines included in the National Medicines Catalogue. The Notice Regarding the Tentative Measures for the Administration of the Scope of Medical Insurance Coverage for Pharmaceutical Products for Urban Employees, jointly issued by several authorities including the Ministry of Labor and Social Security and the MOF, among others, on May 12, 1999, provides that a pharmaceutical product listed in the National Medicines Catalogue must be clinically needed, safe, effective, reasonably priced, easy to use, available in sufficient quantity, and must meet the following requirements:

•: it is set forth in the Pharmacopoeia of the PRC;
•: it meets the standards promulgated by the CFDA; and
•: if imported, it is approved by the CFDA for import.

Factors that affect the inclusion of a pharmaceutical product in the National Medicines Catalogue include whether the product is consumed in large volumes and commonly prescribed for clinical use in the PRC and whether it is considered to be important in meeting the basic healthcare needs of the general public.

The PRC Ministry of Labor and Social Security, together with other government authorities, has the power to determine the medicines included in the National Medicines Catalogue, which is divided into two parts, Part A and Part B. Provincial governments are required to include all Part A medicines listed on the National Medicines Catalogue in their provincial National Medicines Catalogue, but have the discretion to adjust upwards or downwards by no more than 15% from the number of Part B medicines listed in the National Medicines Catalogue. As a result, the contents of Part B of the provincial National Medicines Catalogues may differ from region to region in the PRC.

Patients purchasing medicines included in Part A of the National Medicines Catalogue are entitled to reimbursement of the entire amount of the purchase price. Patients purchasing medicines included in Part B of the National Medicines Catalogue are required to pay a certain percentage of the purchase price and obtain reimbursement for the remainder of the purchase price. The percentage of reimbursement for Part B medicines differs from region to region in the PRC.

The total amount of reimbursement for the cost of medicines, in addition to other medical expenses, for an individual participant under the National Medical Insurance Program in a calendar year is capped at the amounts in such participant's individual account under such program. The amount in a participant's account varies, depending on the amount of contributions from the participant and his or her employer.

National Essential Medicines List

On August 18, 2009, MOH and eight other ministries and commissions in the PRC issued the Provisional Measures on the Administration of the National Essential Medicines List, which was later amended in 2015, and the Guidelines on the Implementation of the Establishment of the National Essential Medicines System, which aim to promote essential medicines sold to consumers at fair prices in the PRC and ensure that the general public in the PRC has equal access to the drugs contained in the National Essential Medicines List. MOH promulgated the National Essential Medicines List (Catalog for the Basic Healthcare Institutions) on August 18, 2009, and promulgated the revised National Essential Medicines List on March 13, 2013. According to these regulations, basic healthcare institutions funded by government, which primarily include county-level hospitals, county-level Chinese medicine hospitals, rural clinics and community clinics, shall store up and use drugs listed in the National Essential Medicines List. The drugs listed in National Essential Medicines List shall be purchased by centralized tender process and shall be subject to the price control by the NDRC. Remedial drugs in the National Essential Medicines List are all listed in the National Medicines Catalogue and the entire amount of the purchase price of such drugs is entitled to reimbursement.

152

Table of Contents

Price Controls

According to the Pharmaceutical Administration Law and the Regulations of Implementation of the Law of the People's Republic of China on the Administration of Pharmaceuticals, pharmaceutical products are subject to fixed or directive pricing system or to be adjusted by the market. Those pharmaceutical products included in the National Medicines Catalogues and the National Essential Medicines List and those drugs the production or trading of which are deemed to constitute monopolies, are subject to price controls by the PRC government in the form of fixed retail prices or maximum retail prices. Manufacturers and distributors cannot set the actual retail price for any given price controlled product above the maximum retail price or deviate from the fixed retail price set by the government. The retail prices of pharmaceutical products that are subject to price controls are administered by the NDRC and provincial and regional price control authorities. From time to time, the NDRC publishes and updates a list of pharmaceutical products that are subject to price controls. According to the Notice Regarding Measures on Government Pricing of Pharmaceutical Products issued by NDRC effective on December 25, 2000, maximum retail prices for pharmaceutical products shall be determined based on a variety of factors, including production costs, the profit margins that the relevant government authorities deem reasonable, the product's type, and quality, as well as the prices of substitute pharmaceutical products.

Further, pursuant to the Notice Regarding Further Improvement of the Order of Market Price of Pharmaceutical Products and Medical Services jointly promulgated by the NDRC, the State Council Legislative Affairs Office and the State Council Office for Rectifying, the MOH, the CFDA, the MOFCOM, the MOF and Ministry of Labor and Social Security on May 19, 2006, the PRC government exercises price control over pharmaceutical products included in the National Medicines Catalogues and made an overall adjustment of their prices by reducing the retail price of certain overpriced pharmaceutical products and increasing the retail price of certain underpriced pharmaceutical products in demand for clinical use but that have not been produced in large quantities by manufacturers due to their low retail price level. In particular, the retail price charged by hospitals at the county level or above may not exceed 115% of the procurement cost of the relevant pharmaceutical products or 125% for Chinese herbal pieces.

On February 9, 2015, the General Office of the State Council issued the Guiding Opinion on Enhancing Consolidated Procurement of Pharmaceutical Products by Public Hospitals. The opinion encourages public hospitals to consolidate their demands and to play a more active role in the procurement of pharmaceutical products. Hospitals are encouraged to directly settle the prices of pharmaceutical products with manufacturers. Consolidated procurement of pharmaceutical products should facilitate hospital reform, reduce patient costs, prevent corrupt conducts, promote fair competition and induce the healthy growth of the pharmaceutical industry. According to the opinion, provincial tendering processes will continue to be used for the pricing of essential drugs and generic drugs with significant demands, and transparent multi-party price negotiation will be used for some patented drugs and exclusive drugs.

On April 26, 2014, the NDRC issued the Notice on Issues concerning Improving the Price Control of Low Price Drugs, or the Low Price Drugs Notice, together with the LPDL. According to the Low Price Drugs Notice, for drugs with relatively low average daily costs within the current government-guided pricing scope (low price drugs), the maximum retail prices set by the government were cancelled. Within the standards of average daily costs, the specific purchase and sale prices are fixed by the producers and operators based on the drug production costs, market supply and demand and market competition. The standards of average daily costs of low price drugs are determined by the NDRC in consideration of the drug production costs, market supply and demand and other factors and based on the current maximum retail prices set by the government (or the national average bid-winning retail prices where the government does not set the maximum retail prices) and the average daily dose calculated according to the package insert. The current standards for the daily cost of low price chemical pharmaceuticals and of low price

153

Table of Contents

traditional Chinese medicine pharmaceuticals are less than RMB3.0 per day and RMB5.0 per day respectively.

On May 4, 2015, the NDRC, the National Health and Family Planning Commission, the CFDA, MOFCOM and three other departments issued Opinions on Promoting Drug Pricing Reform. Under these opinions, beginning on June 1, 2015, the restrictions on the prices of the drugs that were subject to government pricing were cancelled except for narcotic drugs and Class I psychotropic drugs which are still subject to maximum factory prices and maximum retail prices set by the NDRC. The medical insurance regulatory authority now has the power to prescribe the standards, procedures, basis and methods of the payment for drugs paid by medical insurance funds. The prices of patented drugs are set through transparent and public negotiation among multiple parties. The prices for blood products not listed in the National Medicines Catalogue, immunity and prevention drugs that are purchased by the Chinese government in a centralized manner, and AIDS antiviral drugs and contraceptives provided by the Chinese government for free, are set through a tendering process. Except as otherwise mentioned above, the prices for other drugs may be determined by the manufacturers and the operators on their own on the basis of production or operation costs and market supply and demand.

Centralized Procurement and Tenders

The Guiding Opinions concerning the Urban Medical and Health System Reform, promulgated on February 21, 2000, aim to provide medical services with reasonable price and quality to the public through the establishment of an urban medical and health system. One of the measures used to realize this aim is the regulation of the purchasing process of pharmaceutical products by medical institutions. Accordingly, the MOH and other relevant government authorities have promulgated a series of regulations and releases in order to implement the tender requirements.

According to the Notice on Issuing Certain Regulations on the Trial Implementation of Centralized Tender Procurement of Drugs by Medical Institutions promulgated on July 7, 2000 and the Notice on Further Improvement on the Implementation of Centralized Tender Procurement of Drugs by Medical Institutions promulgated on August 8, 2001, medical institutions established by county or higher level government are required to implement centralized tender procurement of drugs.

The MOH promulgated the Working Regulations of Medical Institutions for Procurement of Drugs by Centralized Tender and Price Negotiations (for Trial Implementation), or the Centralized Procurement Regulations, on March 13, 2002, and promulgated Sample Document for Medical Institutions for Procurement of Drugs by Centralized Tender and Price Negotiations (for Trial Implementation), or the Centralized Tender Sample Document in November 2001, as amended in 2010, to implement the tender process requirements and ensure the requirements are followed uniformly throughout the country. The Centralized Tender Regulations and the Centralized Tender Sample Document provide rules for the tender process and negotiations of the prices of drugs, operational procedures, a code of conduct and standards or measures of evaluating bids and negotiating prices. On January 17, 2009, the MOH, the CFDA and other four national departments jointly promulgated the Opinions on Further Regulating Centralized Procurement of Drugs by Medical Institutions. According to the notice, public medical institutions owned by the government at the county level or higher or owned by state-owned enterprises (including state-controlled enterprises) shall purchase pharmaceutical products through centralized procurement. Each provincial government shall formulate its catalogue of drugs subject to centralized procurement. Specifically, the procurement could be achieved through public tendering, online bidding, centralized price negotiations and online competition platform. Except for drugs in the National Essential Medicines List (the procurement of which shall comply with the relevant rules on National Essential Medicines List), certain pharmaceutical products which are under the national government's special control and traditional Chinese medicines, in principle, all drugs used by public medical institutions shall be covered by the catalogue of drugs subject to centralized procurement. On July 7, 2010, the MOH and six other ministries and commissions jointly promulgated the Working Regulations of Medical Institutions for

154

Table of Contents

Centralized Procurement of Drugs to further regulate the centralized procurement of drugs and clarify the code of conduct of the parties in centralized drug procurement.

The centralized tender process takes the form of public tender operated and organized by provincial or municipal government agencies. The centralized tender process is in principle conducted once every year in all provinces and cities in China. Drug manufacturing enterprises, in principle, shall bid directly for the centralized tender process. Certain related parties, however, may be engaged to act as bidding agencies for the centralized tender process. Such intermediaries are not permitted to engage in the distribution of drugs and must have no conflict of interest with the organizing government agencies. The bids are assessed by a committee composed of pharmaceutical experts who will be randomly selected from a database of experts approved by the relevant government authorities. The committee members assess the bids based on a number of factors, including but not limited to, bid price, product quality, clinical effectiveness, qualifications and reputation of the manufacturer, and after-sale services. Only pharmaceuticals that have won in the centralized tender process may be purchased by public medical institutions funded by government in the relevant region.

U.S. Coverage and Reimbursement

Successful sales of our products or drug candidates in the U.S. market, if approved, will depend, in part, on the extent to which our drugs will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. Patients who are provided with prescriptions as part of their medical treatment generally rely on such third-party payors to reimburse all or part of the costs associated with their prescriptions and therefore adequate coverage and reimbursement from such third-party payors are critical to new product success. These third-party payors are increasingly reducing reimbursements for medical drugs and services. Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic drugs. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our drug candidates, if approved, or a decision by a third-party payor to not cover our drug candidates could reduce physician usage of such drugs and have a material adverse effect on our sales, results of operations and financial condition.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Medicare payment for some of the costs of prescription drugs may increase demand for drugs for which we receive regulatory approval. However, any negotiated prices for our drugs covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.

155

Table of Contents

The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. The plan for the research was published in 2012 by the U.S. Department of Health and Human Services, the Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures are made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, if third-party payors do not consider a drug to be cost-effective compared to other available therapies, they may not cover such drugs as a benefit under their plans or, if they do, the level of payment may not be sufficient.

The Affordable Care Act, enacted in March 2010, has had a significant impact on the health care industry. The Affordable Care Act expanded coverage for the uninsured while at the same time containing overall healthcare costs. With regard to pharmaceutical products, the Affordable Care Act, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer's outpatient drugs to be covered under Medicare Part D. The Bipartisan Budget Act of 2018 made certain changes to Medicare Part D coverage, including changing the date when the Medicare Part D coverage gap is eliminated from 2020 to 2019, sunsetting the exclusion of biosimilars from the Medicare Part D coverage gap discount program in 2019 and reallocating responsibility for discounted pricing under the Medicare Part D coverage gap discount program from third-party payors to pharmaceutical companies. In December 2017, Congress also repealed the "individual mandate," which was an Affordable Care Act requirement that individuals obtain healthcare insurance coverage or face a penalty. This repeal could affect the total number of patients who have coverage from third-party payors that reimburse for use of our products.

In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted that affect reimbursement for prescription drugs. On August 2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation's automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, started in April 2013, and, due to subsequent legislative amendments, will stay in effect through 2025 unless additional Congressional action is taken. On January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which among other things, also reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

In addition, other proposed legislative and regulatory changes could affect reimbursement for prescription drugs. In January 2017, the Medicare Prescription Drug Price Negotiation Act was proposed in Congress, which would require the government to negotiate Medicare prescription drug prices with pharmaceutical companies. In October 2017, a similar bill, the Medicare Drug Price Negotiation Act of 2017 was proposed in Congress. In November 2017, the Centers for Medicare & Medicaid Services announced a Final Rule that would adjust the applicable payment rate as necessary for certain separately payable drugs and biologicals acquired under the 340B Program from average sales price plus 6% to average sales price minus 22.5%. Congress and the U.S. administration continue to evaluate other proposals that could affect third-party reimbursement for our drug candidates, if approved.

156

Table of Contents

Rest of the World Coverage and Reimbursement

In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal drugs for which their national health insurance systems provide reimbursement and to control the prices of medicinal drugs for human use. A member state may approve a specific price for the medicinal drug or it may instead adopt a system of direct or indirect controls on the profitability of our company placing the medicinal drug on the market. Historically, drugs launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower.

Other Healthcare Laws

Other PRC Healthcare Laws

Advertising of Pharmaceutical Products

Pursuant to the Provisions for Drug Advertisement Examination, which were promulgated on March 13, 2007 and came into effect on 1 May 2007, an enterprise seeking to advertise its drugs must apply for an advertising approval code. The validity term of an advertisement approval number for pharmaceutical drugs is one year. The content of an approved advertisement may not be altered without prior approval. Where any alteration to the advertisement is needed, a new advertisement approval number shall be obtained.

Packaging of Pharmaceutical Products

According to the Measures for The Administration of Pharmaceutical Packaging, effective on September 1, 1988, pharmaceutical packaging must comply with the provisions of the national standard and professional standard. If there are no standards, the enterprise can formulate its own standard after obtaining the approval of the provincial level food and drug administration or bureau of standards. The enterprise shall reapply for the relevant authorities if it needs to change the packaging standard. Drugs without packing must not be sold in PRC (except for drugs needed by the army).

Labor Protection

Under the Labor Law of the PRC, effective on January 1, 1995 and subsequently amended on August 27, 2009, the PRC Employment Contract Law, effective on January 1, 2008 and subsequently amended on December 28, 2012 and the Implementing Regulations of the Employment Contract Law, effective on September 18, 2008, employers must establish a comprehensive management system to protect the rights of their employees, including a system governing occupational health and safety to provide employees with occupational training to prevent occupational injury, and employers are required to truthfully inform prospective employees of the job description, working conditions, location, occupational hazards and status of safe production as well as remuneration and other conditions as requested by the Labor Contract Law of the PRC.

Pursuant to the Law of Manufacturing Safety of the People's Republic of China effective on November 1, 2002 and subsequently amended on December 1, 2014, manufacturers must establish a comprehensive management system to ensure manufacturing safety in accordance with applicable laws and regulations. Manufacturers not meeting relevant legal requirements are not permitted to commence their manufacturing activities.

Pursuant to the Administrative Measures Governing the Production Quality of Pharmaceutical Products effective on March 1, 2011, manufacturers of pharmaceutical products are required to establish production safety and labor protection measures in connection with the operation of their manufacturing equipment and manufacturing process.

157

Table of Contents

Pursuant to applicable PRC laws, rules and regulations, including the Social Insurance Law which became effective on July 1, 2011, the Interim Regulations on the Collection and Payment of Social Security Funds which became effective on January 22, 1999, the Interim Measures concerning the Maternity Insurance which became effective on January 1, 1995 and the Regulations on Work-related Injury Insurance which became effective on January 1, 2004 and were subsequently amended on December 20, 2010, employers are required to contribute, on behalf of their employees, to a number of social security funds, including funds for basic pension insurance, unemployment insurance, basic medical insurance, work-related injury insurance, and maternity insurance. If an employer fails to make social insurance contributions timely and in full, the social insurance collecting authority will order the employer to make up outstanding contributions within the prescribed time period and impose a late payment fee at the rate of 0.05% per day from the date on which the contribution becomes due. If such employer fails to make social insurance registration, the social insurance collecting authority will order the employer to correct within the prescribed time period. The relevant administrative department may impose a fine equivalent to three times the overdue amount and management personnel who are directly responsible can be fined RMB500 to RMB3,000 if the employer fails to correct within the prescribed time period.

Commercial Bribery

Medical production and operation enterprises involved in criminal, investigation or administrative procedure for commercial bribery will be listed in the Adverse Records of Commercial Briberies by provincial health and family planning administrative department. Pursuant to the Provisions on the Establishment of Adverse Records of Commercial Briberies in the Medicine Purchase and Sales Industry enforced on March 1, 2014 by the National Health and Family Planning Commission, if medical production and operation enterprises are listed into the Adverse Records of Commercial Briberies for the first time, their production shall not be purchased by public medical institutions, and medical and health institutions receiving financial subsidies in local province in two years from public of the record, and public medical institutions, and medical and health institutions receiving financial subsidies in other provinces shall lower their rating in bidding or purchasing process. If medical production and operation enterprises are listed into the Adverse Records of Commercial Briberies twice or more times in five years, their production may not be purchased by public medical institutions, and medical and health institutions receiving financial subsidies nationwide in two years from public of the record.

As advised by our PRC legal advisor, from a PRC law perspective, a pharmaceutical company will not be penalized by the relevant PRC government authorities merely by virtue of having contractual relationships with distributors or third-party promoters who are engaged in bribery activities, so long as such pharmaceutical company and its employees are not utilizing the distributors or third-party promoters for the implementation of, or acting in conjunction with them in, the prohibited bribery activities. In addition, a pharmaceutical company is under no legal obligation to monitor the operating activities of its distributors and third-party promoters, and will not be subject to penalties or sanctions by relevant PRC government authorities as a result of failure to monitor their operating activities.

Product Liability

In addition to the strict new drug approval process, certain PRC laws have been promulgated to protect the rights of consumers and to strengthen the control of medical products in the PRC. Under current PRC law, manufacturers and vendors of defective products in the PRC may incur liability for loss and injury caused by such products. Pursuant to the General Principles of the Civil Law of the PRC, or the PRC Civil Law, promulgated on April 12, 1986 and amended on August 27, 2009, a defective product which causes property damage or physical injury to any person may subject the manufacturer or vendor of such product to civil liability for such damage or injury.

On February 22, 1993 the Product Quality Law of the PRC, or the Product Quality Law, was promulgated to supplement the PRC Civil Law aiming to define responsibilities for product quality, to

158

Table of Contents

protect the legitimate rights and interests of the end-users and consumers and to strengthen the supervision and control of the quality of products. The Product Quality Law was amended by the Ninth National People's Congress on July 8, 2000 and was later amended by the Eleventh National People's Congress on August 27, 2009. Pursuant to the amended Product Quality Law, manufacturers who produce defective products may be subject to civil or criminal liability and have their business licenses revoked.

The Law of the PRC on the Protection of the Rights and Interests of Consumers was promulgated on October 13, 1993 and was amended on October 25, 2013 to protect consumers' rights when they purchase or use goods and accept services. All business operators must comply with this law when they manufacture or sell goods and/or provide services to customers. Under the amendment on October 25, 2013, all business operators shall pay high attention to protect the customers' privacy which they obtain during the business operation. In addition, in extreme situations, pharmaceutical product manufacturers and operators may be subject to criminal liabilities under applicable laws of the PRC if their goods or services lead to the death or injuries of customers or other third parties.

PRC Tort Law

Under the Tort Law of the PRC which became effective on July 1, 2010, if damages to other persons are caused by defective products that are resulted from the fault of a third party such as the parties providing transportation or warehousing, the producers and the sellers of the products have the right to recover their respective losses from such third parties. If defective products are identified after they have been put into circulation, the producers or the sellers shall take remedial measures such as issuance of warning, recall of products, etc. in a timely manner. The producers or the sellers shall be liable under tort if they cause damages due to their failure to take remedial measures in a timely manner or have not made efforts to take remedial measures, thus causing damages. If the products are produced and sold with known defects, causing deaths or severe damage to the health of others, the infringed party shall have the right to claim respective punitive damages in addition to compensatory damages.

Other PRC National- and Provincial-Level Laws and Regulations

We are subject to changing regulations under many other laws and regulations administered by governmental authorities at the national, provincial and municipal levels, some of which are or may become applicable to our business. Our hospital customers are also subject to a wide variety of laws and regulations that could affect the nature and scope of their relationships with us.

For example, regulations control the confidentiality of patients' medical information and the circumstances under which patient medical information may be released for inclusion in our databases, or released by us to third parties. These laws and regulations governing both the disclosure and the use of confidential patient medical information may become more restrictive in the future.

We also comply with numerous additional state and local laws relating to matters such as safe working conditions, manufacturing practices, environmental protection and fire hazard control. We believe that we are currently in compliance with these laws and regulations; however, we may be required to incur significant costs to comply with these laws and regulations in the future. Unanticipated changes in existing regulatory requirements or adoption of new requirements could therefore have a material adverse effect on our business, results of operations and financial condition.

Other U.S. Healthcare Laws

We may also be subject to healthcare regulation and enforcement by the U.S. federal government and the states where we may market our drug candidates, if approved. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations.

159

Table of Contents

Anti-Kickback Statute

The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The majority of states also have anti-kickback laws, which establish similar prohibitions and in some cases may apply to items or services reimbursed by any third-party payor, including commercial insurers. The Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the Anti-Kickback Statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act.

False Claims

Additionally, the civil False Claims Act prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Analogous state law equivalents may apply and may be broader in scope than the federal requirements. Violations of the False Claims Act can result in very significant monetary penalties and treble damages. The federal government is using the False Claims Act, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the U.S., for example, in connection with the promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers' and manufacturers' compliance with applicable fraud and abuse laws.

The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, also created new federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

Payments to Physicians

There has also been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Affordable Care Act, among other things, imposes new reporting requirements on drug manufacturers for payments made by them to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1 million per year for "knowing failures"), for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Drug manufacturers were required to begin collecting data on August 1, 2013 and submit reports to the government by March 31, 2014 and June 30, 2014, and the 90th day of each subsequent calendar year. Certain states also mandate implementation of compliance

160

Table of Contents

programs, impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians.

Data Privacy and Security

We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and their respective implementing regulations, including the final omnibus rule published on January 25, 2013, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA's privacy and security standards directly applicable to "business associates," defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney's fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts.

PRC Regulation of Foreign Currency Exchange, Offshore Investment and State-Owned Assets

PRC Foreign Currency Exchange

Foreign currency exchange regulation in China is primarily governed by the following rules:

•: Foreign Currency Administration Rules (1996), as last amended on August 5, 2008, or the Exchange Rules; and
•: Administration Rules of the Settlement, Sale and Payment of Foreign Exchange (1996), or the Administration Rules.

Under the Exchange Rules, the renminbi is convertible for current account items, including the distribution of dividends, interest payments, trade and service-related foreign exchange transactions. Conversion of renminbi for capital account items, such as direct investment, loan, security investment and repatriation of investment, however, is still subject to the SAFE.

Under the Administration Rules, foreign-invested enterprises may only buy, sell and/or remit foreign currencies at those banks authorized to conduct foreign exchange business after providing valid commercial documents and, in the case of capital account item transactions, obtaining approval from the SAFE. Capital investments by foreign-invested enterprises outside of China are also subject to limitations, which include approvals by the MOFCOM, the SAFE and the NDRC.

Pursuant to the Circular on Further Improving and Adjusting the Direct Investment Foreign Exchange Administration Policies, or Circular 59, promulgated by SAFE on November 19, 2012 and became effective on December 17, 2012, approval is not required for the opening of and payment into foreign exchange accounts under direct investment, for domestic reinvestment with legal income of foreign investors in China. Circular 59 also simplified the capital verification and confirmation formalities for Chinese foreign invested enterprises and the foreign capital and foreign exchange registration formalities required for the foreign investors to acquire the equities and foreign exchange registration formalities required for the foreign investors to acquire the equities of Chinese party and other items. Circular 59 further improved the administration on exchange settlement of foreign exchange capital of Chinese foreign invested enterprises.

161

Table of Contents

Foreign Exchange Registration of Offshore Investment by PRC Residents

In July 2014, SAFE issued the Notice on Relevant Issues Concerning Foreign Exchange Administration for PRC Residents to Engage in Offshore Investment and Financing and Round Trip Investment via Special Purpose Vehicles, or Circular 37, and its implementation guidelines, which abolishes and supersedes the SAFE's Circular on Relevant Issues Concerning Foreign Exchange Administration for PRC Residents to Engage in Financing and Round Trip Investment via Overseas Special Purpose Vehicles, or Circular 75. Pursuant to Circular 37 and its implementation guidelines, PRC residents (including PRC institutions and individuals) must register with local branches of SAFE in connection with their direct or indirect offshore investment in an overseas special purpose vehicle, or SPV, directly established or indirectly controlled by PRC residents for the purposes of offshore investment and financing with their legally owned assets or interests in domestic enterprises, or their legally owned offshore assets or interests. Such PRC residents are also required to amend their registrations with SAFE when there is a significant change to the SPV, such as changes of the PRC individual resident's increase or decrease of its capital contribution in the SPV, or any share transfer or exchange, merger, division of the SPV. Failure to comply with the registration procedures set forth in Circular 37 may result in restrictions being imposed on the foreign exchange activities of the relevant onshore company, including the payment of dividends and other distributions to its offshore parent or affiliate, the capital inflow from the offshore entities and settlement of foreign exchange capital, and may also subject relevant onshore company or PRC residents to penalties under PRC foreign exchange administration regulations.

In February 2012, the SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies. Based on this regulation, directors, supervisors, senior management and other employees of domestic subsidiaries or branches of a company listed on an overseas stock market who are PRC citizens or who are non-PRC citizens residing in China for a continuous period of not less than one year, subject to a few exceptions, are required to register with the SAFE or its local counterparts by following certain procedures if they participate in any stock incentive plan of the company listed on an overseas stock market. Foreign exchange income received from the sale of shares or dividends distributed by the overseas listed company may be remitted into a foreign currency account of such PRC citizen or be exchanged into renminbi. Our PRC citizen employees who have been granted share options have been subject to these rules due to our listing on the AIM market of the London Stock Exchange and the listing of our ADSs on the Nasdaq Global Select Market.

Regulation on Investment in Foreign-invested Enterprises

Pursuant to PRC law, the registered capital of a limited liability company is the total capital contributions subscribed for by all the shareholders as registered with the company registration authority. A foreign-invested enterprise also has a total investment limit that is approved by or filed with the MOFCOM or its local counterpart by reference to both its registered capital and expected investment scale. The difference between the total investment limit and the registered capital of a foreign-invested enterprise or the cross-border financing risk weighted balance calculated based on a formula by the PBOC represents the foreign debt financing quota to which it is entitled (i.e., the maximum amount of debt which the company may borrow from a foreign lender). A foreign-invested enterprise is required to obtain approval from or file with the MOFCOM or its local counterpart for any increases to its total investment limit. In accordance with these regulations, we and our joint venture partners have contributed financing to our PRC subsidiaries and joint ventures in the form of capital contributions up to the registered capital amount and/or in the form of shareholder loans up to the foreign debt quota. According to the financing needs of our PRC subsidiaries and joint ventures, we and our joint venture partners have requested and received approvals from the government authorities for increases to the total investment limit for certain of our PRC subsidiaries and joint ventures from time to time. As a result, these regulations have not had a material impact to date on our ability to finance such entities.

162

Table of Contents

Regulation on Dividend Distribution

The principal regulations governing distribution of dividends paid by wholly foreign-owned enterprises include:

•: Company Law of the PRC (1993), as amended in 1999, 2004, 2005 and 2013;
•: Foreign Investment Enterprise Law of the PRC (1986), as amended in 2000 and 2016; and
•: Implementation Rules for the Foreign Investment Enterprise Law (1990), as amended in 2001 and 2014.

Under these laws and regulations, foreign-invested enterprises in China may pay dividends only out of their accumulated profits, if any, determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise in China is required to set aside at least 10.0% of its after-tax profit based on PRC accounting standards each year to its general reserves until the accumulative amount of such reserves reach 50.0% of its registered capital. These reserves are not distributable as cash dividends. The board of directors of a foreign-invested enterprise has the discretion to allocate a portion of its after-tax profits to staff welfare and bonus funds, which may not be distributed to equity owners except in the event of liquidation.

Filings and Approvals Relating to State-Owned Assets

Pursuant to applicable PRC state-owned assets administration laws and regulations, incorporating a joint venture that will have investments of assets that are both state-owned and non-state-owned and investing in an entity that was previously owned by a state-owned enterprise require the performance of an assessment of the relevant state-owned assets and the filing of the assessment results with the competent state-owned assets administration, finance authorities or other regulatory authorities and, if applicable, the receipt of approvals from such authorities.

Our joint venture partners were required to perform a state-owned asset assessment when Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan were incorporated and our joint venture partners contributed state-owned assets, and when we invested in Hutchison Sinopharm, which was previously wholly-owned by Sinopharm, a state-owned enterprise. In all three instances, our joint venture partners have informed us that they have duly filed the relevant state-owned asset assessment results with, and obtained the requisite approvals from, the relevant governmental authorities as required by the foregoing laws and regulations. Accordingly, we believe that such joint ventures are in full compliance with all applicable laws and regulations governing the administration of state-owned assets, although we are currently unable to obtain copies of certain filing and approval documents of our joint venture partners due to their internal confidentiality constraints. We have not received any notice of warning or been subject to any penalty or other disciplinary action from the relevant governmental authorities with respect to the applicable laws and regulations governing the administration of state-owned assets.

C. Organizational Structure

Our organizational structure is set forth above under "—A. History and Development of the Company—Our Organizational Structure."

D. Property, Plants and Equipment

We are headquartered in Hong Kong where we have our main administrative offices. Our joint ventures, Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan, operate two large-scale research and development and manufacturing facilities for which they have obtained land use rights and property ownership certificates.

163

Table of Contents

Shanghai Hutchison Pharmaceuticals relocated to its current facility outside of Shanghai in September 2016, and it has an aggregate site area of approximately 78,000 square meters (compared to approximately 58,000 square meters for its old facility located in Shanghai). Shanghai Hutchison Pharmaceuticals agreed to surrender its land use rights for the property where its old production facility was located to the Shanghai government for cash consideration. The total cash and subsidies paid by the Shanghai government to Shanghai Hutchison Pharmaceuticals was approximately $113 million, including approximately $101 million for land compensation and $12 million in government subsidies related to research and development projects.

Hutchison Baiyunshan's facility is in Guangzhou and has an aggregate site area of approximately 90,000 square meters. Hutchison Baiyunshan plans to sell its land use rights for an unused portion of its Guangzhou property to the local government for cash consideration. Hutchison Baiyunshan also operates two Chinese GAP-certified cultivation sites through its subsidiaries in Heilongjiang and Henan provinces in China. In December 2016, its subsidiary completed construction of new production facilities in Bozhou and production commenced in 2017.

Our and our joint ventures' manufacturing operations consist of bulk manufacturing and formulation, fill, and finishing activities that produce products and drug candidates for both clinical and commercial purposes. Our manufacturing capabilities have a large operation scale for our own-brand products. We and our joint ventures manufacture and sell about 4.6 billion doses of medicines a year, in the aggregate, through our well-established GMP manufacturing base. See "—Our Commercial Platform—Prescription Drugs Business—Shanghai Hutchison Pharmaceuticals" and "—Our Commercial Platform—Consumer Health Business—Hutchison Baiyunshan" for more details on our manufacturing operations.

Please also see "—Our Commercial Platform—Our Prescription Drugs Business—Shanghai Hutchison Pharmaceuticals" and "—Our Commercial Platform—Our Consumer Health Business—Hutchison Baiyunshan" for more details on the new facilities of Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan mentioned above.

Additionally, we rent and operate a 2,107 square meter manufacturing facility for fruquintinib in Suzhou, Jiangsu Province in Eastern China, and own a 5,024 square meter facility in Shanghai which houses research and development operations. We also lease 907 square meters of office space in Shanghai which houses Hutchison MediPharma's management and staff. In 2017, we entered into a new lease for a 6,129 square meter combined office and lab space in Shanghai to accommodate the anticipated growth of Hutchison MediPharma's management and staff and for a 2,246 square foot facility in Florham Park, New Jersey where we intend to house clinical and regulatory management and staff.

ITEM 4A. UNRESOLVED STAFF COMMENTS

None

ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS

You should read the following discussion and analysis of our financial condition and results of operations together with Item 3.A. "Selected Financial Data," our consolidated financial statements and the related notes and our non-consolidated joint ventures' consolidated financial statements and the related notes appearing elsewhere in this annual report. This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act, including, without limitation, statements regarding our expectations, beliefs, intentions or future strategies that are signified by the words "expect," "anticipate," "intend," "believe," or similar language. All forward-looking statements included in this annual report are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. In evaluating our business, you should carefully consider the information provided under Item 3.D. "Risk Factors." Actual results could differ materially from those projected in the forward-looking statements. The terms "company," "Chi-Med," "we," "our" or "us" as used herein refer to Hutchison China MediTech Limited and its consolidated subsidiaries and joint ventures unless otherwise stated or indicated by context.

164

Table of Contents

A. Operating Results.

Overview

We are an innovative biopharmaceutical company based in China aiming to become a global leader in the discovery, development and commercialization of targeted therapies for oncology and immunological diseases. Our approximately 360-person strong scientific team has created and developed a deep portfolio of eight drug candidates that are being investigated in active or completed clinical studies in 36 target patient populations around the world. These drug candidates are being developed to treat a wide spectrum of diseases, including solid tumors, hematological malignancies and cover immunology applications which we believe address significant unmet medical needs and represent large commercial opportunities. Many of these drugs have the potential to be first-in-class or best-in-class. Our success in research and development has led to partnerships with leading global pharmaceutical companies, including AstraZeneca, Eli Lilly and Nestlé Health Science.

As of December 31, 2017, we and our partners have invested about $500 million in building our Innovation Platform. Since inception to December 31, 2017, our Innovation Platform's drug pipeline has dosed over 3,500 patients/subjects in clinical trials of our drug candidates as of December 31, 2017, with over 700 dosed in 2017, primarily driven by the six Phase III studies of savolitinib, fruquintinib and sulfatinib.

We have also established a profitable commercial infrastructure in China to market and distribute prescription drugs (under our Prescription Drugs business) and consumer health products (under our Consumer Health business) which together form our Commercial Platform. Net income attributable to our company generated from our Commercial Platform was $25.2 million, $70.3 million and $40.0 million for the years ended December 31, 2015, 2016 and 2017, respectively. Net income attributable to our company generated from our Commercial Platform included one-time gains of $40.4 million and $2.5 million in the years ended December 31, 2016 and 2017, respectively, net of tax, from land compensation and other government subsidies paid to Shanghai Hutchison Pharmaceuticals by the Shanghai government. In addition to helping to fund our Innovation Platform, we anticipate that we will be able to utilize Shanghai Hutchison Pharmaceuticals and Hutchison Sinopharm, our Commercial Platform's two Prescription Drugs business joint ventures in which we nominate the management and run the day-to-day operations, to support the launch of products from our Innovation Platform if they are approved by the CFDA for use in China. Our Commercial Platform also includes our Consumer Health business, which is a profitable and cash flow generating business selling primarily over-the-counter pharmaceutical products (through our non-consolidated joint venture Hutchison Baiyunshan) and a range of health-focused consumer products.

Our consolidated revenue was $178.2 million, $216.1 million and $241.2 million for the years ended December 31, 2015, 2016 and 2017, respectively. Net income attributable to our company was $8.0 million and $11.7 million for the years ended December 31, 2015 and 2016, respectively, compared to a net loss attributable to our company of $26.7 million for the year ended December 31, 2017.

Basis of Presentation

Our consolidated statements of operations data presented herein for the years ended December 31, 2017, 2016 and 2015 and our consolidated balance sheet data presented herein as of December 31, 2017 and 2016 have been derived from our audited consolidated financial statements, which were prepared in accordance with U.S. GAAP, and should be read in conjunction with those statements which are included elsewhere in this annual report.

Our Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan joint ventures under our Commercial Platform and our Nutrition Science Partners joint venture under our Innovation Platform are accounted for under the equity accounting method as non-consolidated entities in our consolidated

165

Table of Contents

financial statements, and their consolidated financial statements were prepared in accordance with IFRS as issued by the IASB and included elsewhere in this annual report.

We have two strategic business units, our Innovation Platform and our Commercial Platform, that offer different products and services. Our Commercial Platform is further segregated into the two core business areas of Prescription Drugs and Consumer Health. The presentation of financial data for our business units excludes certain unallocated costs attributed to expenses incurred by our corporate head office. For more information on our corporate structure, see Item 4.A. "History and Development of the Company—Our Corporate Structure."

Factors Affecting our Results of Operations

Innovation Platform

Research and Development Expenses

We believe our ability to successfully develop innovative drug candidates through our Innovation Platform will be the primary factor affecting our long-term competitiveness, as well as our future growth and development. Creating high quality global first-in-class or best-in-class drug candidates requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. As a result of this commitment, our pipeline of drug candidates has been steadily advancing and expanding, with eight clinical-stage drug candidates being investigated in active or completed clinical studies in 36 target patient populations in various countries, including six Phase III studies on savolitinib, fruquintinib and sulfatinib, and further clinical studies targeted to start in 2018. For more information on the nature of the efforts and steps necessary to develop our drug candidates, see Item 4.B. "Business Overview—Our Clinical Pipeline" and "Business Overview—Regulation."

All of the drug candidates of our Innovation Platform are still in development, and we have incurred and will continue to incur significant research and development costs for pre-clinical studies and clinical trials. We expect that our research and development expenses will significantly increase in future periods in line with the advance and expansion of the development of our drug candidates.

We and our collaboration partners have invested about $500 million in our Innovation Platform as of December 31, 2017, with almost all of these funds used to pay for research and development expenses incurred for the development of our drug candidates. These expenses include:

•: employee compensation related expenses, including salaries, benefits and equity compensation expense;
•: expenses incurred for payments to CROs, investigators and clinical trial sites that conduct our clinical studies;
•: the cost of acquiring, developing, and manufacturing clinical study materials;
•: facilities, depreciation, and other expenses, which include office leases and other overhead expenses; and
•: costs associated with pre-clinical activities and regulatory operations.

Research and development costs incurred by our Innovation Platform totaled $47.4 million, $66.9 million and $75.5 million for the years ended December 31, 2015, 2016 and 2017, respectively, representing 26.6%, 31.0% and 31.3% of our total consolidated revenue for the respective period. These figures do not include payments made by our collaboration partners directly to third parties to help fund the research and development of our drug candidates.

166

Table of Contents

We have historically been able to fund the research and development expenses for our Innovation Platform via a range of sources, including financial support provided by our collaboration partners, cash flows generated from and dividend payments from our Commercial Platform, the proceeds raised from our initial public offering on the AIM market of the London Stock Exchange, our initial public offering and follow-on offering on the Nasdaq Global Select Market, banks loans (some of which have been subject to guarantees or certain other arrangements by Hutchison Whampoa Limited, a subsidiary of CK Hutchison) and investments from other third-parties such as Mitsui.

This diversified approach to funding allows us to not depend on any one method of funding for our Innovation Platform, thereby reducing the risk that sufficient financing will be unavailable as we continue to accelerate the development of our drug candidates.

For more information on the research and development expenses incurred for the development of our drug candidates, see "—Key Components of Results of Operations—Research and Development Expenses."

Our Ability to Commercialize Our Drug Candidates

Our ability to generate revenue from our drug candidates depends on our ability to successfully complete clinical trials for our drug candidates and obtain regulatory approvals for them in the United States, Europe, China and other major markets.

We believe that our risk-balanced strategy of focusing on developing tyrosine kinase inhibitors for novel but relatively well-characterized targets and for validated targets, in combination with our development of multiple drug candidates concurrently and testing them for multiple indications, enhances the likelihood that our research and development efforts will yield successful drug candidates. Nonetheless, we cannot be certain if any of our drug candidates will receive regulatory approvals. Even if such approvals are granted, we will need to thereafter establish manufacturing supply and engage in extensive marketing prior to generating any revenue from such drugs, and the ultimate commercial success of our drugs will depend on their acceptance by patients, the medical community and third-party payors and their ability to compete effectively with other therapies on the market.

As a first step towards commercialization, we have incurred a total of approximately $9.8 million in capital expenditures between 2013 and 2017 to establish a GMP standard manufacturing (formulation) facility in Suzhou, China, which now produces Phase III clinical supplies and will be used to produce fruquintinib, as well as our other drugs, for commercial supply, if they receive regulatory approval.

The competitive environment is also an important factor with the commercial success of our potential global first-in-class products, such as savolitinib and HMPL-523, depending on whether we are able to gain regulatory approvals and quickly bring such products to market ahead of competing drug candidates being developed by other companies.

For our drug candidates where we retain all rights worldwide, which currently include sulfatinib, epitinib, theliatinib, HMPL-523, HMPL-689 and HMPL-453, if they remain unpartnered, we will be able to retain all the profits if any of them are successfully commercialized, though we will need to bear all the costs associated with such drug candidates. Conversely, as discussed below, for our drug candidates which are subject to collaboration partnerships, our collaboration partners provide funding for development of the drug candidates but are entitled to retain a significant portion of any revenue generated by such drug candidates.

Our Collaboration Partnerships

Our results of operations have been, and we expect them to continue to be, affected by our collaborations with third parties for the development and commercialization of certain of our drug candidates. Currently, these mainly include savolitinib (collaboration with AstraZeneca), fruquintinib

167

Table of Contents

(collaboration with Eli Lilly) and HM004-6599, a reformulation of HMPL-004 (collaboration with our joint venture partner Nestlé Health Science). In addition to providing us with invaluable technical expertise and organizational resources, the financial support provided by these collaborations has been critical to our ability to develop and quickly advance the pre-clinical and clinical studies of multiple drug candidates concurrently.

In particular, our partners cover a major portion of our research and development costs for drug candidates developed in collaboration with them. For example, under our collaboration agreement with AstraZeneca, it is responsible for a significant portion of the development costs for savolitinib. However, in August 2016 we and AstraZeneca amended our collaboration agreement whereby we agreed to contribute additional funding for the research and development of savolitinib in return for a larger share of the upside if and when savolitinib is approved. Under our collaboration agreement with Eli Lilly, it is responsible for a significant portion of all fruquintinib development costs in an indication after we have achieved proof-of-concept for such indication. We share the research and development costs for HMPL-004/HM004-6599 with Nestlé Health Science through our non-consolidated joint venture Nutrition Science Partners.

In addition, under our licensing, co-development and commercialization agreements, we received upfront payments upon our entry into such agreements and milestone payments upon the achievement of certain development, regulatory and commercial milestones as well as payments for our provision of research and development services for the relevant drug candidate. Revenue recognized in our consolidated financial statements from such agreements with third parties totaled $44.1 million, $26.4 million and $26.3 million for the years ended December 31, 2015, 2016 and 2017, respectively. In addition, income from research and development services from both third parties and related parties totaled $8.0 million, $8.8 million and $9.7 million for the years ended December 31, 2015, 2016 and 2017, respectively.

The achievement of milestones for our drug candidates, which is dependent on the outcome of clinical studies, is subject to a high degree of uncertainty and, as a result, we cannot reasonably estimate when we can expect to receive future milestone payments, or at all. For more information on our revenue recognition policies, see "—Critical Accounting Policies and Significant Judgments and Estimates—Revenue recognition for research and development projects." If we are unable to achieve development milestones for our drug candidates or if our partners were to terminate their collaborative agreements with us, payments for research and development services could also be affected.

Our collaboration partners are entitled to a significant proportion of any future revenue from commercialization of our drug candidates developed in collaboration with them, as well as a degree of influence over the clinical development process for such drug candidates. We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all, which would affect our ability to receive additional upfront, milestone or service payments in the future. For more information regarding our collaboration agreements, see Item 4.B. "Business Overview—Overview of Our Collaborations."

Commercial Platform

China Government Healthcare Spending and Drug Pricing Policies

Revenue of our Prescription Drugs business and our non-consolidated joint venture Hutchison Baiyunshan, part of our Consumer Health business, is directly affected by the sales volume and pricing of their own-brand prescription and over-the-counter pharmaceutical products as well as third-party pharmaceutical products. The principal activities of our Prescription Drugs business are described below under "—Ability of Prescription Drugs Business to Effectively Market Own-Brand and Third-Party Drugs." Hutchison Baiyunshan is a non-consolidated joint venture whose key products are two generic over-the-counter therapies, Fu Fang Dan Shen tablets, a treatment for chest congestion and angina pectoris, and Banlangen granules, an anti-viral treatment.

168

Table of Contents

The sales volume of the products sold by these businesses is driven in part by the level of Chinese government spending on healthcare and the coverage of Chinese government medical insurance schemes, which is correlated with patient reimbursements for drug purchases, all of which have increased significantly in recent years as part of healthcare reforms in China. The sales volume of pharmaceutical products in China is also influenced by their representation on the Medicines Catalogue for the National Basic Medical Insurance, Labor Injury Insurance and Childbirth Insurance Systems in China, or the National Medicines Catalogue, which determines eligibility for drug reimbursement, as well as their representation on the National Essential Medicines List, which mandates distribution of drugs in China. Substantially all pharmaceutical products manufactured and sold by Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan in 2017 were capable of being reimbursed under the National Medicines Catalogue as of December 31, 2017.

In addition, among these two joint ventures an aggregate of 48 drugs, of which 15 were in active production as of December 31, 2017, have been included on the National Essential Medicines List. She Xiang Bao Xin pills, Shanghai Hutchison Pharmaceuticals' top-selling drug, is one of the few proprietary drugs included on the National Essential Medicines List. The National Medicines Catalogue and the National Essential Medicines List are subject to revision by the government from time to time, and our results could be materially and adversely affected if any products sold by our Prescription Drugs business or Hutchison Baiyunshan are removed from the National Medicines Catalogue or the National Essential Medicines List. For more information, see Item 3.D. "Risk Factors—Risks Related to Our Commercial Platform—Reimbursement may not be available for the products currently sold through our Commercial Platform or our drug candidates in China, the United States or other countries, which could diminish our sales or affect our profitability."

The sale prices of certain pharmaceutical products sold by our Commercial Platform joint ventures are also subject to Chinese government's price controls. In April 2014, the China National Development and Reform Commission, or the NDRC, announced a new Low Price Drug List, or LPDL, aimed at making certain low-price pharmaceuticals more profitable for manufacturers to produce. The LPDL established caps for the daily cost of chemical pharmaceuticals at less than RMB3.0 per day and of traditional Chinese medicine pharmaceuticals at less than RMB5.0 per day. The LPDL gives manufacturers flexibility to increase prices within the caps and exempts LPDL pharmaceuticals from hospital tenders. As of the end of 2017, Hutchison Baiyunshan's two top-selling products, Fu Fang Dan Shen tablets and Banlangen, cost consumers RMB1.7 per day and RMB1.6 per day, respectively, and Shanghai Hutchison Pharmaceuticals' two top-selling products, She Xiang Bao Xin pills and Danning tablets, cost RMB4.0 per day and RMB3.3 per day, respectively, well below the established caps for traditional Chinese medicine pharmaceuticals under the LPDL. As a result, we do not expect the LPDL to exert downward pressure on the pricing of these products unless the government makes significant downward adjustments to the LPDL price caps in the future.

Subject to customer demand, we have the ability to increase the prices for these products under the current LPDL price caps. For example, during 2016 we began to phase in, on a province-by-province basis, a 30% price increase for She Xiang Bao Xin pills from RMB2.7 per day to RMB3.5 per day and in 2017 we further increased the price to RMB4.0 per day. In addition, the pricing of Shanghai Hutchison Pharmaceuticals' prescription drugs are influenced by the outcomes of periodic provincial and municipal tender processes organized by the various provincial or municipal government agencies in China. For more information, see Item 4.B. "Business Overview—Coverage and Reimbursement—PRC Coverage and Reimbursement."

Ability of Prescription Drugs Business to Effectively Market Own-Brand and Third-Party Drugs

A key component of our Commercial Platform is the extensive marketing network of our Prescription Drugs business operated by our joint ventures Shanghai Hutchison Pharmaceuticals and Hutchison Sinopharm, which includes approximately 2,300 medical sales staff covering approximately 22,500 hospitals

169

Table of Contents

in over 300 cities and towns in China. Our results of operations are affected by the degree to which this marketing network is successful in not only marketing its existing drugs but also new drugs either from third parties or developed by our Innovation Platform, if approved. Historically, the substantial majority of revenue from our Prescription Drugs business was generated from sales of She Xiang Bao Xin pills, which represented approximately 88% of its total revenue for the years ended December 31, 2015 and 2016 and approximately 86% of its total revenue for the year ended December 31, 2017.

In addition, since our acquisition of a 51% equity interest in Hutchison Sinopharm in April 2014, we have been in the process of migrating its operational focus from the legacy logistics and distribution business of a predecessor entity previously operated by our joint venture partner toward providing a distribution and commercialization service for drugs owned by third parties, which has a relatively higher profit margin.

In the second quarter of 2015, Hutchison Sinopharm became the exclusive first-tier distributor to distribute and market AstraZeneca's quetiapine tablets (under the Seroquel trademark), a medication to treat schizophrenia and bipolar disorder, in all of China. Under this arrangement, Hutchison Sinopharm manages the distribution and logistics for this drug and Shanghai Hutchison Pharmaceuticals markets it. In addition, Hutchison Sinopharm began to exclusively co-promote Merck Serono's bisoprolol fumarate tablets (under the Concor trademark), a beta-blocker to treat hypertension, in a few provinces in China in the first quarter of 2015. In January 2016, Hutchison Healthcare granted a license to Hutchison Sinopharm to distribute Chi-Med-owned Zhi Ling Tong infant nutrition products, which had previously been distributed by a third-party distributor.

Seroquel in particular represents a new therapeutic area for our medical sales representatives, and in the limited time since we commenced our services for these drugs, we have been successful in generating sales. During 2017, Shanghai Hutchison Pharmaceuticals had a dedicated medical sales team of about 120 people to support the commercialization of Seroquel.

China has begun implementing a new regulatory two-invoice system on a province-by-province basis. In principle, the purpose of the two-invoice system is to restrict the number of layers in the drug distribution system in China, in order to improve transparency, compliant business conduct and efficiency. The impact to us is that, starting in October 2017 and by the end of 2018, the original Seroquel sales model, in which our consolidated revenues reflect total gross sales of Seroquel, has begun to shift to a fee-for-service model similar to that used all along on Concor. Transactions under the fee-for-service model applies net accounting as Hutchison Sinopharm acts as a service provider and does not bear inventory risk as it no longer takes delivery of Seroquel. We expect that this change will reduce the top-line revenues Hutchison Sinopharm records from sales of Seroquel in future periods; but it will have no material impact on profitability and limited impact to our commercial team operations and expansion plans.

In the longer term, the ability of our marketing network to adapt to effectively market such drugs to doctors and hospitals, as well as other third-party drugs we may provide services for in the future and any oncology or immunology drugs from our Innovation Platform, will impact our revenue and profitability. In addition, if we are unsuccessful in marketing any third-party drugs, it may adversely affect our ability to enter into commercialization arrangements for additional drugs or prevent us from expanding the geographic scope of existing arrangements.

Seasonality

The results of operations of our Commercial Platform are also affected by seasonal factors. Our Commercial Platform typically experiences higher profits in the first half of the year due to the sale cycles of our distributors, whereby they typically increase their inventories at the beginning of each year. In addition, in the second half of each year, our Commercial Platform typically spends more on marketing

170

Table of Contents

activities to help reduce such inventory held by distributors. We do not experience material seasonal variations in the results of our Innovation Platform.

Overall Economic Growth and Consumer Spending Patterns

The results of operations and growth of our Consumer Health business depend in part on continuing economic growth and increasing income and health awareness of consumers in Asia. Although economic growth in China has slowed in recent periods, it achieved an annual growth rate in real gross domestic product of approximately 6.8% in 2017 according to the International Monetary Fund. As per capita disposable income has increased, consumer spending has also increased, and consumers in China have tended to be more health conscious and to spend more on organic and natural products for their families' health and well-being. However, if customer demand for such products does not achieve the levels we expect, whether due to slowing economic conditions, changing consumer tastes or otherwise, the results of operations and growth of our Consumer Health business could be materially and adversely affected.

Critical Accounting Policies and Significant Judgments and Estimates

Our discussion and analysis of operating results and financial condition are based upon our consolidated financial statements. The preparation of consolidated financial statements requires us to estimate the effect of various matters that are inherently uncertain as of the date of the consolidated financial statements. Each of these required estimates varies with regard to the level of judgment involved and its potential impact on our reported financial results. Estimates are deemed critical when a different estimate could have reasonably been used or where changes in the estimates are reasonably likely to occur from period to period, and a different estimate would materially impact our financial position, changes in financial position or results of operations. Our significant accounting policies are discussed under note 3 to our consolidated financial statements included in this annual report. We believe the following critical accounting policies are affected by significant judgments and estimates used in the preparation of our consolidated financial statements and that the judgments and estimates are reasonable.

Revenue recognition for research and development projects

We recognize revenue for the performance of services when each of the following four criteria are met: (i) persuasive evidence of an arrangement exists; (ii) services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured.

We have entered into research and developments agreements with collaborative partners for the research and development of drug products. The terms of the agreements may include non-refundable upfront and licensing fees, funding for research, development and manufacturing, milestone payments and royalties on any product sales derived from collaborations. These multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. This evaluation requires subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separable from the other aspects of the contractual relationship. In determining the units of accounting, management evaluates certain criteria, including whether the deliverables have standalone value, based on the consideration of the relevant facts and circumstances for each arrangement. We estimate the selling price for each unit of accounting and allocate the arrangement consideration to each unit utilizing the relative selling price method.

We determine the estimated selling price for deliverables within each agreement using vendor-specific objective evidence of selling price, if available, or third-party evidence of selling price if vendor-specific objective evidence is not available, or our best estimate of selling price if neither vendor-specific objective evidence nor third-party evidence is available. Determining the best estimate of selling price for a deliverable requires significant judgment. Our process for determining the best estimate of selling price

171

Table of Contents

involves management's judgment. Our process considers multiple factors such as discounted cash flows, estimated expenses and other costs and available data, which may vary over time, depending upon the circumstances, and relate to each deliverable. If the estimated obligation period of one or more deliverables should change, the future amortization of the revenue would also change. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.

These collaborative and other agreements may contain milestone payments. Revenues from milestones, if they are considered substantive, are recognized upon successful accomplishment of the milestones. Determining whether a milestone is substantive involves judgment, including an assessment of our involvement in achieving the milestones and whether the amount of the payment is commensurate to our performance. If not considered substantive, milestones are initially deferred and recognized over the remaining period of the performance obligation.

We recognize a contingent milestone payment as revenue in its entirety upon our achievement of the milestone. A milestone is substantive if the consideration earned from the achievement of the milestone (i) is consistent with performance required to achieve the milestone or the increase in value to the delivered item; (ii) relates solely to past performance; and (iii) is reasonable relative to all of the other deliverables and payments within the arrangement.

Share-based Compensation

We account for share-based compensation by measuring and recognizing compensation expense for share options made to employees and directors based on the estimated grant date fair values. We used the graded vesting method to allocate compensation expense to reporting periods over each optionee's requisite service period.

We estimate the fair value of share options to employees and directors using the Polynomial model. Determining the fair value of share options requires the use of highly subjective assumptions, including volatility, risk free interest rate, dividend yield and the fair value of the underlying ordinary shares on the dates of grant or the dates of modification, among other inputs. The assumptions in determining the fair value of share options represent our best estimates, which involve inherent uncertainties and the application of judgment. As a result, if factors change and different assumptions are used, our level of share-based compensation could be materially different in the future. We have adopted Accounting Standards Update, or ASU, 2016-09, Improvements to Employee Share-Based Payment Accounting on January 1, 2017. This guidance permitted us to make an accounting policy election to account for forfeitures as they occur. We have adopted using the modified retrospective approach as required, and there was no cumulative effect adjustment. Prior to January 1, 2017, we applied an estimated forfeiture rate derived from historical and expected future employee termination behavior.

Impairment of long-lived property, plant and equipment and other definite life intangible assets

We assess property, plant and equipment and other definite life intangible assets for impairment when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable. Factors that we consider in deciding when to perform an impairment review include significant under-performance of a business or product line in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in our use of the assets. We measure the recoverability of assets that we will continue to use in our operations by comparing the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping's carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired. We measure the impairment by comparing the difference between the asset grouping's carrying value and its fair value. Property, plant and equipment and other definite life intangible assets are considered non-financial assets and are recorded at fair value only if an impairment charge is recognized.

172

Table of Contents

Impairments are determined for groups of assets related to the lowest level of identifiable independent cash flows. When we determine that the useful lives of assets are shorter than we had originally estimated, we accelerate the rate of depreciation over the assets' new, shorter useful lives.

Impairment of Goodwill

Goodwill is recorded when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. Goodwill is allocated to our reporting units based on the relative expected fair value provided by the acquisition. Reporting units may be operating segments as a whole or an operation one level below an operating segment, referred to as a component. The goodwill is attributable to the Prescription Drugs and Consumer Health (PRC) business under the Commercial Platform.

We perform an annual impairment assessment in the fourth quarter of each year, or more frequently if indicators of potential impairment exist, to determine whether it is more likely than not that the fair value of a reporting unit in which goodwill resides is less than its carrying value. For reporting units in which this assessment concludes that it is more likely than not that the fair value is more than its carrying value, goodwill is not considered impaired and we are not required to perform the goodwill impairment test. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance, and other relevant events and factors affecting the reporting unit. Additionally, as part of this assessment, we may perform a quantitative analysis to support the qualitative factors above by applying sensitivities to assumptions and inputs used in measuring a reporting unit's fair value. For reporting units in which the impairment assessment concludes that it is more likely than not that the fair value is less than its carrying value, we perform the goodwill impairment test, which compares the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets assigned to that reporting unit, goodwill is not considered impaired. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of the reporting unit, an impairment loss shall be recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.

Our goodwill impairment test uses the income method to estimate a reporting unit's fair value. The income method is based on a discounted future cash flow approach that uses the following assumptions and inputs: revenue, based on assumed market segment growth rates; estimated costs; and appropriate discount rates based on a reporting unit's weighted average cost of capital as determined by considering the observable weighted average cost of capital of comparable companies. Our estimates of market segment growth and costs are based on historical data, various internal estimates, and a variety of external sources. These estimates are developed as part of our routine long-range planning process. We test the reasonableness of the inputs and outcomes of our discounted cash flow analysis against available comparable market data. A reporting unit's carrying value represents the assignment of various assets and liabilities, excluding certain corporate assets and liabilities, such as cash, investments, and debt. We performed the goodwill impairment test and determined that the fair values of the reporting units exceeded their carrying values and considered that impairment was not necessary for any reporting unit.

We have adopted ASU 2017-04, Simplifying the Accounting for Goodwill Impairment for annual goodwill impairment tests performed on testing dates after January 1, 2017. This guidance removes Step 2 of the goodwill impairment test, which required the estimation of an implied fair value of goodwill in the same manner as the amount of goodwill recognized in a business combination. For prior years' annual goodwill impairment tests, we determined that the fair values of the reporting units exceeded their carrying values and Step 2 has never been required.

173

Table of Contents

Impairment of equity method investments

Our equity method investments represent our investments in our non-consolidated joint ventures. All of these are in non-marketable equity investments. Non-marketable equity investments are inherently risky, and their success depends on their ability to generate revenues, remain profitable, operate efficiently and raise additional funds and other key business factors. The companies could fail or not be able to raise additional funds when needed, or they may receive lower valuations with less favorable investment terms. These events could cause our investments to become impaired. In addition, financial market volatility could negatively affect our ability to realize value in our investments through liquidity events such as initial public offerings, mergers, and private sales.

We consider if our equity method investments are impaired when events or circumstances suggest that their carrying amounts may not be recoverable. An impairment charge would be recognized in earnings for a decline in value that is determined to be other-than-temporary. This is based on our quantitative and qualitative analysis, which includes assessing the severity and duration of the impairment and the likelihood of recovery before disposal. The investments are recorded at fair value only if impairment is recognized. The recognition of impairment and measurement of fair value requires significant judgment and includes a qualitative and quantitative analysis of events or circumstances that impact the fair value of the investment. Qualitative analysis of our investments involves understanding our investee's revenue and earnings trends relative to pre-defined milestones and overall business prospects, the technological feasibility of our investee's products and technologies, the general market conditions in the investee's industry or geographic area including adverse regulatory or economic changes, and the management and governance structure of the investee. We performed the qualitative and quantitative analysis and determined that events or circumstances did not suggest that the carrying amount of each of our equity method investments may not be recoverable and that impairment was not necessary.

Key Components of Results of Operations

Revenue

We derive our consolidated revenue primarily from (i) licensing and collaboration projects conducted by our Innovation Platform, which generates revenue in the form of upfront payments, milestone payments and the payments received for providing research and development services for our collaboration projects and for other third parties and related parties; and (ii) the sales by our Commercial Platform, which generates revenue from the distribution and marketing of prescription pharmaceutical products by our Prescription Drugs business and consumer health products by our Consumer Health business.

The following table sets forth the components of our consolidated revenue for the years indicated, which does not include the revenue from our Commercial Platform's non-consolidated joint ventures, Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan. Our revenue from sales to related parties is attributable to sales by our Commercial Platform to indirect subsidiaries of CK Hutchison. Our revenue from research and development projects for related parties is attributable to income for research

174

Table of Contents

and development services that we receive primarily from Nutrition Science Partners, our non-consolidated joint venture with Nestlé Health Science.

	Year Ended December 31,

	2017		2016		2015
	$'000	%	$'000	%	$'000	%
Revenue
Innovation Platform:
Licensing and collaboration agreements—third parties	26,315	10.9	26,444	12.2	44,060	24.7
R&D services—third parties	—	—	355	0.2	2,573	1.5
R&D services—related parties	9,682	4.0	8,429	3.9	5,383	3.0

Total	35,997	14.9	35,228	16.3	52,016	29.2

Commercial Platform:
Sales—third parties	196,720	81.6	171,058	79.2	118,113	66.3
Sales—related parties	8,486	3.5	9,794	4.5	8,074	4.5

Total	205,206	85.1	180,852	83.7	126,187	70.8

Total	241,203	100.0	216,080	100.0	178,203	100.0

Our Innovation Platform's revenue primarily comprises revenue recognized in our consolidated financial statements under licensing, co-development and commercialization agreements for upfront and milestone payments for our drug candidates developed in collaboration with, among others, AstraZeneca and Eli Lilly, as well as income from research and development services that we receive from certain of our partners, including, among others, AstraZeneca and Eli Lilly as well as Nutrition Science Partners, our non-consolidated joint venture with Nestlé Health Science. Our Innovation Platform revenue also includes income from research and development services provided to other third parties and related parties, which are not related to our licensing and collaboration agreements.

The following table sets forth the components of our consolidated revenue contributed by the two core business areas of our Commercial Platform, namely Prescription Drugs and Consumer Health, for the years indicated.

	Year Ended December 31,

	2017		2016		2015
	$'000	%	$'000	%	$'000	%
Revenue from Commercial Platform
Prescription Drugs	166,435	81.1	149,861	82.9	105,478	83.6
Consumer Health	38,771	18.9	30,991	17.1	20,709	16.4

Total	205,206	100.0	180,852	100.0	126,187	100.0

Our Prescription Drugs business's revenue primarily comprises revenue from the logistics and distribution business of our consolidated Hutchison Sinopharm joint venture with Sinopharm, a leading distributor of pharmaceutical and healthcare products and a leading supply chain service provider in China.

The revenue of our Prescription Drugs business's non-consolidated joint venture, Shanghai Hutchison Pharmaceuticals, the accounts of which are prepared in accordance with IFRS as issued by the IASB and whose revenue is not included in our consolidated revenue, was $181.1 million, $222.4 million and $244.6 million for the years ended December 31, 2015, 2016 and 2017, respectively. Shanghai Hutchison Pharmaceuticals is a joint venture with Shanghai Pharmaceuticals, a leading pharmaceuticals company in

175

Table of Contents

China, and primarily focuses on the manufacture and sale of prescription pharmaceutical products in China. We and Shanghai Pharmaceuticals each own 50% of this joint venture. We have the right to nominate the general manager and other management of this joint venture and run its day-to-day operations. The effect of Shanghai Hutchison Pharmaceuticals on our consolidated financial results is discussed below under "—Equity in Earnings of Equity Investees."

Our Consumer Health business's revenue primarily comprises revenue from sales of organic and natural products by Hutchison Hain Organic, our 50% consolidated joint venture with Hain Celestial, a Nasdaq-listed, natural and organic food and personal care products company. We consolidate the results of this joint venture into our results of operations as we own 50% of its equity and hold an additional casting vote in the event of a deadlock. Our Consumer Health business's revenue is also comprised of revenue from sales of Zhi Ling Tong infant nutrition products manufactured by Hutchison Healthcare, our wholly owned subsidiary, and distributed through Hutchison Sinopharm, and certain third-party consumer products distributed and marketed by Hutchison Consumer Products, a wholly owned subsidiary.

The revenue of our Consumer Health business's non-consolidated joint venture, Hutchison Baiyunshan, the accounts of which are prepared in accordance with IFRS as issued by the IASB and which revenue is not included in our consolidated revenue, was $211.6 million, $224.1 million and $227.4 million for the years ended December 31, 2015, 2016 and 2017, respectively. Hutchison Baiyunshan is a joint venture with Guangzhou Baiyunshan, a leading China-based pharmaceutical company, and primarily focuses on the manufacture and distribution of over-the-counter pharmaceutical products in China. Our interest in Hutchison Baiyunshan is held through an 80%-owned subsidiary of ours, Hutchison BYS (Guangzhou) Holding Limited, which owns 50% of that joint venture, with the other 50% interest held by Guangzhou Baiyunshan. The effect of Hutchison Baiyunshan on our consolidated financial results are discussed under "—Equity in Earnings of Equity Investees."

Cost of Sales and Operating Expenses

Cost of Sales

Our cost of sales are primarily attributable to the cost of sales of our Prescription Drugs business's consolidated Hutchison Sinopharm joint venture as well as the cost of sales of our Consumer Health business. Our cost of sales to related parties is attributable to sales by our Consumer Health business to indirect subsidiaries of CK Hutchison. The following table sets forth the components of our cost of sales attributable to third parties and related parties for the years indicated.

	Year Ended December 31,

	2017		2016		2015
	$'000	%	$'000	%	$'000	%
Cost of Sales
Costs of sales—third parties	169,764	96.6	149,132	95.4	104,859	94.7
Costs of sales—related parties	6,056	3.4	7,196	4.6	5,918	5.3

Total	175,820	100.0	156,328	100.0	110,777	100.0

176

Table of Contents

The following table sets forth the components of our cost of sales attributable to the two core business areas of our Commercial Platform, namely Prescription Drugs and Consumer Health, for the years indicated.

	Year Ended December 31,

	2017		2016		2015
	$'000	%	$'000	%	$'000	%
Cost of Sales
Prescription Drugs	151,521	86.2	136,090	87.1	96,927	87.5
Consumer Health	24,299	13.8	20,238	12.9	13,850	12.5

Total	175,820	100.0	156,328	100.0	110,777	100.0

Our Prescription Drugs business's cost of sales primarily comprises the cost of sales and transportation costs incurred by the legacy logistics and distribution activities of Hutchison Sinopharm, which commenced operations in April 2014, as well as the third-party drugs distribution and commercialization business of Hutchison Sinopharm beginning in the first quarter of 2015.

Our Consumer Health business's cost of sales primarily comprises the cost of goods sold by Hutchison Hain Organic, which purchases its product inventory from Hain Celestial for distribution in Asian markets, as well as the cost of goods sold, contract packing and transportation costs incurred by Hutchison Healthcare and Hutchison Consumer Products.

Research and Development Expenses

Our research and development expenses are attributable to our Innovation Platform. These costs primarily comprise the cost of research and development and clinical trials for our drug candidates, including personnel compensation and related costs, clinical trial related costs such as payments to third-party CROs, and other research and development costs. The following table sets forth the components of our research and development expenses for the years indicated.

	Year Ended December 31,

	2017		2016		2015
	$'000	%	$'000	%	$'000	%
R&D Expenses
Innovation Platform:
Personnel compensation and related costs	24,848	32.9	21,698	32.4	17,339	36.6
Clinical trial related costs	45,250	59.9	38,589	57.7	24,690	52.1
Other costs	5,425	7.2	6,584	9.9	5,339	11.3

Total	75,523	100.0	66,871	100.0	47,368	100.0

177

Table of Contents

The following table summarizes for the years indicated the research and development expenses incurred for the development of our main drug candidates as well as the personnel compensation and other research and development related costs incurred by our Innovation Platform.

	Year Ended December 31,

	2017		2016				2015
	$'000	%	$'000		%		$'000		%
Savolitinib (targeting c-Met)	9,146	12.1	4,945		7.4		2,419		5.1
Fruquintinib (targeting VEGFR1/2/3)	15,660	20.7	12,908		19.3		12,951		27.3
Sulfatinib (targeting VEGFR/FGFR1/CSF-1R)	7,726	10.2	10,815		16.2		6,105		12.9
Epitinib (targeting EGFRm+ with brain metastasis)	3,141	4.2	1,994		3.0		629		1.3
Theliatinib (targeting EGFR wild-type)	1,023	1.4	699		1.0		397		0.8
HMPL-523 (targeting Syk)	1,875	2.5	4,112		6.2		2,880		6.1
HMPL-689 (targeting PI3Kd)	1,140	1.5	2,084		3.1		1,587		3.4
HMPL-453 (targeting FGFR)	1,558	2.1	1,231		1.8		593		1.3
Others and government grant	3,981	5.2	(199	)	(0.3	)	(2,871	)	(6.1	)

Total clinical trial related costs	45,250	59.9	38,589		57.7		24,690		52.1
Personnel compensation and related costs	24,848	32.9	21,698		32.4		17,339		36.6
Other costs	5,425	7.2	6,584		9.9		5,339		11.3

Total R&D expenses	75,523	100.0	66,871		100.0		47,368		100.0

In addition to the research and development costs shown above, the table below summarizes the research and development costs incurred by our non-consolidated Nutrition Science Partners joint venture, primarily in relation to the development of our drug candidate HMPL-004/HM004-6599. The losses incurred by this joint venture during the periods indicated were reflected on our consolidated statements of operations in the equity in earnings of equity investees line item. The consolidated financial statements of Nutrition Science Partners are prepared in accordance with IFRS as issued by the IASB and are presented separately elsewhere in this annual report. For more information on this joint venture, see "—Equity in Earnings of Equity Investees."

	Year Ended December 31,

	2017			2016			2015
	$'000		%	$'000		%	$'000		%
Nutrition Science Partners
HMPL-004/HM004-6599 related development costs	(1,844	)	20.0	(1,180	)	16.0	(3,512	)	46.5
Other research costs	(7,366	)	80.0	(7,302	)	84.0	(4,040	)	53.5

Loss for the year	(9,210	)	100.0	(8,482	)	100.0	(7,552	)	100.0

Equity in earnings of equity investee attributable to our company	(4,605	)	50.0	(4,241	)	50.0	(3,776	)	50.0

We cannot determine with certainty the duration and completion costs of the current or future pre-clinical or clinical studies of our drug candidates or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our drug candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our drug candidates. The

178

Table of Contents

duration, costs, and timing of clinical studies and development of our drug candidates will depend on a variety of factors, including:

•: the scope, rate of progress and expense of our ongoing as well as any additional clinical studies and other research and development activities;
•: future clinical study results;
•: uncertainties in clinical study enrollment rate;
•: significant and changing government regulation; and
•: the timing and receipt of any regulatory approvals.

A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate. For more information on the risks associated with the development of our drug candidates, see Item 3.D. "Risk Factors—Risks Related to Our Innovation Platform—All of our drug candidates are still in development. If we are unable to obtain regulatory approval and ultimately commercialize our drug candidates or experience significant delays in doing so, our business will be materially harmed."

Selling Expenses

The following table sets forth the components of our selling expenses for each of our business units for the years indicated.

	Year Ended December 31,

	2017		2016		2015
	$'000	%	$'000	%	$'000	%
Selling Expenses
Commercial Platform:
Prescription Drugs	9,981	51.7	9,592	53.3	6,635	65.0
Consumer Health	9,341	48.3	8,406	46.7	3,574	35.0

Total	19,322	100.0	17,998	100.0	10,209	100.0

Our selling expenses primarily comprise sales and marketing expenses and related personnel expenses incurred by the Prescription Drugs and Consumer Health businesses of our Commercial Platform in their distribution and marketing of pharmaceutical and consumer health products.

Administrative Expenses

The following table sets forth the components of our administrative expenses for each of our business units for the years indicated. Administrative expenses are also incurred by our corporate head office, which are not allocated to our business units.

	Year Ended December 31,

	2017		2016		2015
	$'000	%	$'000	%	$'000	%
Administrative Expenses
Innovation Platform	6,617	27.6	5,373	24.9	5,116	26.1
Commercial Platform:
Prescription Drugs	1,863	7.8	1,856	8.6	1,465	7.5
Consumer Health	1,640	6.8	1,418	6.6	2,301	11.7
Corporate Head Office	13,835	57.8	12,933	59.9	10,738	54.7

Total	23,955	100.0	21,580	100.0	19,620	100.0

179

Table of Contents

Our Innovation Platform's administrative expenses primarily comprise the salaries and benefits of administrative staff, office leases and other overhead expenses incurred by our Innovation Platform.

Our Prescription Drug business's administrative expenses primarily comprise the salaries and benefits of administrative staff, office leases and other overhead expenses incurred by Hutchison Sinopharm.

Our Consumer Health business's administrative expenses primarily comprise the salaries and benefits of administrative staff, office lease and other overhead expenses incurred by Hutchison Hain Organic and Hutchison Healthcare and, to a lesser extent, Hutchison Consumer Products.

Our corporate head office administrative expenses, which are not allocated to our business units, primarily comprise the salaries and benefits of our corporate head office employees and directors, office leases and other overhead expenses.

Equity in Earnings of Equity Investees

We have historically derived a significant portion of our net income from continuing operations from our equity in earnings of equity investees, which was primarily attributable to two of our Commercial Platform's non-consolidated joint ventures, Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan, partially offset by losses at our Innovation Platform's non-consolidated joint venture, Nutrition Science Partners. Our equity in earnings of equity investees (net of tax) contributed by the non-consolidated joint ventures from our Commercial Platform, Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan, was $26.3 million, $70.5 million and $38.2 million for the years ended December 31, 2015, 2016 and 2017, respectively. Equity in earnings of Shanghai Hutchison Pharmaceuticals included one-time gains of $40.4 million and $2.5 million in the years ended December 31, 2016 and 2017, respectively, net of tax, from land compensation and other government subsidies paid to Shanghai Hutchison Pharmaceuticals by the Shanghai government.

Our equity in earnings of equity investees (net of tax) contributed by our Innovation Platform was losses of $3.8 million, $4.2 million and $4.5 million for the years ended December 31, 2015, 2016 and 2017, respectively, which were primarily attributable to losses at Nutrition Science Partners, which has historically incurred significant losses attributable to research and development expenses and the cost of clinical trials for the drug candidate HMPL-004/HM004-6599.

Revenue of Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan are mainly affected by the sales volume and pricing of their prescription and over-the-counter pharmaceutical products. For more information on the factors affecting our Commercial Platform, see "—Factors Affecting Our Results of Operations—Commercial Platform." Nutrition Science Partners had no revenue for the years ended December 31, 2015, 2016 and 2017. The consolidated financial statements of Shanghai Hutchison Pharmaceuticals, Hutchison Baiyunshan and Nutrition Science Partners are presented separately elsewhere in this annual report.

180

Table of Contents

The following table shows the revenue of these three non-consolidated joint ventures for the years indicated. The consolidated financial statements of these joint ventures are prepared in accordance with IFRS as issued by the IASB and are presented separately elsewhere in this annual report.

	Year Ended December 31,

	2017		2016		2015
	$'000	%	$'000	%	$'000	%
Revenue
Innovation Platform:
Nutrition Science Partners	—	—	—	—	—	—
Commercial Platform:
Shanghai Hutchison Pharmaceuticals	244,557	51.8	222,368	49.8	181,140	46.1
Hutchison Baiyunshan	227,422	48.2	224,131	50.2	211,603	53.9

Total	471,979	100.0	446,499	100.0	392,743	100.0

The following table shows the amount of equity in earnings of equity investees (net of tax), and as a percentage of our total consolidated revenue, of our non-consolidated joint ventures for the years indicated.

	Year Ended December 31,

	2017				2016				2015
	$'000		%		$'000		%		$'000		%
Equity in earnings of equity investees, net of tax
Innovation Platform:
Nutrition Science Partners	(4,605	)	(1.9	)	(4,241	)	(1.9	)	(3,776	)	(2.1	)
Others	58		0.0		47		0.0		6		0.0
Commercial Platform:
Shanghai Hutchison Pharmaceuticals	27,812		11.5		60,250		27.9		15,654		8.8
Hutchison Baiyunshan	10,388		4.3		10,188		4.7		10,688		6.0

Total	33,653		13.9		66,244		30.7		22,572		12.7

Operating Profit/(Loss)

Our operating profit/(loss) represents the sum of (i) earnings/(losses) of subsidiaries before interest income, interest expenses and income tax expenses; (ii) interest income; (iii) our equity in earnings of equity investees; and (iv) unallocated costs attributed to expenses incurred by our corporate head office. See note 25 to our consolidated financial statements in this annual report for additional information.

Taxation

Cayman Islands

Hutchison China MediTech Limited is incorporated in the Cayman Islands. The Cayman Islands currently levies no taxes on profits, income, gains or appreciation earned by individuals or corporations. In addition, our payment of dividends, if any, is not subject to withholding tax in the Cayman Islands. For more information, see Item 10.E. "Taxation—Overview of Tax Implications of Various Other Jurisdictions—Cayman Islands Taxation."

181

Table of Contents

People's Republic of China

Our subsidiaries and joint ventures incorporated in the PRC are governed by the PRC EIT Law and regulations. Under the EIT Law, the standard EIT rate is 25% on taxable profits as reduced by available tax losses. Tax losses may be carried forward to offset any taxable profits for the following five years. Our subsidiary, Hutchison MediPharma, was granted the TASE status from January 1, 2010 to December 31, 2018, and has been successful in its application to renew its HNTE status from January 1, 2017 to December 31, 2019; whereas our non-consolidated joint ventures, Hutchison Baiyunshan and Shanghai Hutchison Pharmaceuticals, have been successful in their respective applications to renew their HNTE status from January 1, 2017 to December 31, 2019. Accordingly, these entities were subject to a preferential EIT rate of 15% for the years ended December 31, 2015, 2016 and 2017.

For more information, see Item 10.E. "Taxation—Taxation in the PRC." Please also see Item. 3 "Key Information—Risk Factors—Our business benefits from certain PRC government tax incentives. The expiration of, changes to, or our PRC subsidiaries/joint ventures failing to continuously meet the criteria for these incentives could have a material adverse effect on our operating results by significantly increasing our tax expenses."

Hong Kong

Hutchison China MediTech Limited and certain subsidiaries which have registered a branch in Hong Kong and are Hong Kong tax residents, as well as our subsidiaries incorporated in Hong Kong, are governed by applicable Hong Kong income tax laws and regulations. As such, they are subject to Hong Kong Profits Tax at the rate of 16.5% on their assessable profits as reduced by available tax losses for the years ended December 31, 2015, 2016 and 2017.

According to the EIT Law, dividends declared after January 1, 2008 and paid by PRC foreign-invested enterprises to their non-PRC parent companies will be subject to PRC withholding tax at 10% unless there is a tax treaty between the PRC and the jurisdiction in which the overseas parent company is a tax resident and which specifically exempts or reduces such withholding tax, and such tax exemption or reduction is approved by the relevant PRC tax authorities. Pursuant to the Arrangement, if the shareholder of the PRC enterprise is a Hong Kong tax resident and directly holds a 25% or more equity interest in the PRC enterprise and is considered to be the beneficial owner of dividends paid by the PRC enterprise, such withholding tax rate may be lowered to 5%, subject to approvals by the relevant PRC tax authorities. For more information, see Item 10.E. "Taxation—Taxation in the PRC" and "Taxation—Hong Kong Taxation."

182

Table of Contents

Results of Operations

The following table sets forth a summary of our consolidated results of operations for the years indicated. This information should be read together with our consolidated financial statements and related notes included elsewhere in this annual report. Our operating results in any period are not necessarily indicative of the results that may be expected for any future period.

	Year Ended December 31,

	2017				2016				2015
	$'000		%		$'000		%		$'000		%
Revenues	241,203		100.0		216,080		100.0		178,203		100.0
Cost of sales	(175,820	)	(72.9	)	(156,328	)	(72.4	)	(110,777	)	(62.2	)
Research and development expenses	(75,523	)	(31.3	)	(66,871	)	(31.0	)	(47,368	)	(26.6	)
Selling expenses	(19,322	)	(8.0	)	(17,998	)	(8.3	)	(10,209	)	(5.7	)
Administrative expenses	(23,955	)	(9.9	)	(21,580	)	(10.0	)	(19,620	)	(11.0	)
Total other expense	(119	)	(0.0	)	(659	)	(0.3	)	(769	)	(0.4	)
Income tax expense	(3,080	)	(1.3	)	(4,331	)	(2.0	)	(1,605	)	(0.9	)
Equity in earnings of equity investees, net of tax	33,653		13.9		66,244		30.7		22,572		12.7

Net (loss)/income	(22,963	)	(9.5	)	14,557		6.7		10,427		5.9



Net (loss)/income attributable to our company	(26,737	)	(11.1	)	11,698		5.4		7,993		4.5

Year Ended December 31, 2017 Compared to Year Ended December 31, 2016

Revenues

Our revenues increased by 11.6% from $216.1 million for the year ended December 31, 2016 to $241.2 million for the year ended December 31, 2017.

This increase was driven by a $24.4 million increase in revenue for the year ended December 31, 2017 from our Commercial Platform, representing a 13.5% increase from the revenue of $180.9 million for the year ended December 31, 2016. The consolidated revenue from our Prescription Drugs business increased by $16.6 million from $149.8 million for the year ended December 31, 2016 to $166.4 million for the year ended December 31, 2017. The increase was primarily attributable to the growth in our third-party drug distribution business. The consolidated revenue from our Consumer Health business also increased by $7.8 million from $31.0 million for the year ended December 31, 2016 to $38.8 million for the year ended December 31, 2017. The increase was primarily attributable to higher levels of infant nutrition products and personal care products sold in 2017. The consolidated revenue from our Innovation Platform increased slightly by $0.8 million from $35.2 million for the year ended December 31, 2016 to $36.0 million for the year ended December 31, 2017. The increase was attributable to a higher level of service fees that we received from our joint ventures.

Our Commercial Platform's results of operations are affected by seasonality. For more information, see "—Factors Affecting our Results of Operations—Commercial Platform—Seasonality."

Cost of Sales

Our cost of sales increased by 12.5% from $156.3 million for the year ended December 31, 2016 to $175.8 million for the year ended December 31, 2017. This increase was primarily driven by a $15.4 million increase in cost of sales from Hutchison Sinopharm under our Prescription Drugs business, as well as a $4.0 million increase in cost of sales from Hutchison Hain Organic under our Consumer Health business. Cost of sales as a percentage of our revenue from our Commercial Platform decreased from 86.4% to

183

Table of Contents

85.7% across these periods, primarily due to product mix resulting in an increased proportion of sales of higher margin products.

Research and Development Expenses

Our research and development expenses increased by 12.9% from $66.9 million for the year ended December 31, 2016 to $75.5 million for the year ended December 31, 2017, which was primarily attributable to a $5.5 million increase in payments to CROs and other clinical trial related costs and a $3.1 million increase in employee compensation related costs. These increased costs incurred by our Innovation Platform was due to a significant expansion of clinical activities and rapid organization growth to support these clinical activities. The number of ongoing clinical studies for our drug candidates increased from studies in 30 target patient populations as of December 31, 2016 to studies in 36 target patient populations as of December 31, 2017. In particular, this increase was attributable to the expansion of the savolitinib and fruquintinib development programs. As a result, research and development expenses as a percentage of our total revenue increased from 31.0% in the year ended December 31, 2016 to 31.3% in the year ended December 31, 2017.

Selling Expenses

Our selling expenses increased by 7.4% from $18.0 million for the year ended December 31, 2016 to $19.3 million for the year ended December 31, 2017. This increase was primarily driven by a $0.9 million increase in selling expenses under our Consumer Health business and a $0.4 million increase in selling expenses under our Prescription Drugs business. Selling expenses as a percentage of our revenue from our Commercial Platform decreased from 10.0% to 9.4% across these periods, primarily due to increased sales by our third-party Prescription Drug distribution and Consumer Health businesses.

Administrative Expenses

Our administrative expenses increased by 11.0% from $21.6 million for the year ended December 31, 2016 to $24.0 million for the year ended December 31, 2017. This increase was primarily due to a $1.2 million and $0.9 million increase in administrative expenses incurred by our Innovation Platform and corporate head office, mainly related to the increased staff cost, office expenses and organization and third-party advisor costs as a result of operating as a U.S. public company for a full calendar year. Administrative expenses had remained relatively stable as a percentage of our total revenue.

Other Expenses

Total other expenses decreased from $0.7 million for the year ended December 31, 2016 to $0.1 million for the year ended December 31, 2017, primarily due to higher interest income offset by higher foreign currency translation loss.

Our interest income increased from $0.5 million for the year ended December 31, 2016 to $1.2 million for the year ended December 31, 2017. The increase was attributable to a higher level of bank deposits after receiving proceeds from our follow-on offering in October 2017. Our interest expense decreased slightly from $1.6 million for the year ended December 31, 2016 to $1.5 million for the year ended December 31, 2017. These interest expenses primarily comprised interest and guarantee fee payments on bank loans in 2016 and 2017.

Income Tax Expense

Our income tax expense decreased by 28.9% from $4.3 million for the year ended December 31, 2016 to $3.1 million for the year ended December 31, 2017 due to a decrease in withholding taxes accrued on the net income from our Commercial Platform businesses for the year ended December 31, 2017. The higher withholding tax accrued for the year ended December 31, 2016 was due to equity in earnings of

184

Table of Contents

Shanghai Hutchison Pharmaceuticals including a one-time gain of $40.4 million relating to land compensation and other government subsidies.

Equity in Earnings of Equity Investees

Our equity in earnings of equity investees, net of tax, decreased by 49.2% from $66.2 million for the year ended December 31, 2016 to $33.7 million for the year ended December 31, 2017. This decrease was primarily due to a decrease in net income at our Commercial Platform's non-consolidated joint ventures as well as an increase in net loss at Nutrition Science Partners, our Innovation Platform's non-consolidated joint venture. Our equity in earnings of Shanghai Hutchison Pharmaceuticals included one-time gains, net of tax, of $40.4 million from land compensation and other government subsidies in the year ended December 31, 2016 and $2.5 million from government subsidies in the year ended December 31, 2017 in each case paid to Shanghai Hutchison Pharmaceuticals by the Shanghai government.

Shanghai Hutchison Pharmaceuticals

The following table shows a summary of the results of operations of Shanghai Hutchison Pharmaceuticals for the years indicated. The consolidated financial statements of Shanghai Hutchison Pharmaceuticals are prepared in accordance with IFRS as issued by the IASB and are presented separately elsewhere in this annual report.

	Year Ended December 31,

	2017				2016
	($'000)		%		($'000)		%
Revenue	244,557		100.0		222,368		100.0
Cost of sales	(68,592	)	(28.0	)	(64,237	)	(28.9	)
Selling expenses	(104,504	)	(42.7	)	(92,487	)	(41.6	)
Administrative expenses	(13,257	)	(5.4	)	(13,278	)	(6.0	)
Gain on disposal of assets held for sale	—		—		88,536		39.8
Taxation charge	(10,874	)	(4.4	)	(27,645	)	(12.4	)
Profit for the year	55,623		22.7		120,499		54.2



Equity in earnings of equity investee attributable to our company	27,812		11.4		60,250		27.1

Shanghai Hutchison Pharmaceuticals' revenue increased by 10.0% from $222.4 million for the year ended December 31, 2016 to $244.6 million for the year ended December 31, 2017, which was primarily due to increased sales of She Xiang Bao Xin pills, a vasodilator used in the treatment of heart conditions. Sales of She Xiang Bao Xin pills grew by 7.1% from $195.4 million for the year ended December 31, 2016 to $209.2 million for the year ended December 31, 2017, primarily due to continued price increases and geographical expansion of sales coverage.

Cost of sales increased by 6.8% from $64.2 million for the year ended December 31, 2016 to $68.6 million for the year ended December 31, 2017, primarily due to increased cost of goods sold as a result of increased sales of She Xiang Bao Xin pills.

Selling expenses during these periods increased by 13.0% from $92.5 million for the year ended December 31, 2016 to $104.5 million for the year ended December 31, 2017 as a result of increased spending on marketing and promotional activities to support the increase in sales.

Administrative expenses remained relatively stable at $13.3 million for the years ended December 31, 2016 and 2017.

Taxation charge decreased by 60.7% from $27.6 million for the year ended December 31, 2016 to $10.9 million for the year ended December 31, 2017, which was primarily due to the decrease in profit before taxation between these periods.

185

Table of Contents

As a result of the foregoing and the one-time gain of $40.4 million from land compensation and other government subsidies received from the Shanghai government in 2016 which did not occur in 2017, profit decreased by 53.8% from $120.5 million for the year ended December 31, 2016 to $55.6 million for the year ended December 31, 2017. Our equity in earnings of equity investees contributed by this joint venture was $60.3 million and $27.8 million for the years ended December 31, 2016 and 2017, respectively.

Hutchison Baiyunshan

The following table shows a summary of the results of operations of Hutchison Baiyunshan for the years indicated. The consolidated financial statements of Hutchison Baiyunshan are prepared in accordance with IFRS as issued by the IASB and are presented separately elsewhere in this annual report.

	Year Ended December 31,

	2017				2016
	($'000)		%		($'000)		%
Revenue	227,422		100.0		224,131		100.0
Cost of sales	(135,964	)	(59.8	)	(134,776	)	(60.1	)
Selling expenses	(45,262	)	(19.9	)	(46,873	)	(20.9	)
Administrative expenses	(24,541	)	(10.8	)	(21,716	)	(9.7	)
Taxation charge	(3,629	)	(1.6	)	(3,631	)	(1.6	)
Profit attributable to equity holders of Hutchison Baiyunshan	20,776		9.1		20,376		9.1



Equity in earnings of equity investee attributable to our company	10,388		4.6		10,188		4.5

Hutchison Baiyunshan's revenue increased slightly by 1.5% from $224.1 million for the year ended December 31, 2016 to $227.4 million for the year ended December 31, 2017, which was primarily due to increased sales of certain of its drug products.

Cost of sales increased by 0.9% from $134.8 million for the year ended December 31, 2016 to $136.0 million for the year ended December 31, 2017, primarily due to increased sales. The increase in cost of sales was smaller than the increase in revenues due to a change in product mix resulting in a higher proportion of sales of higher margin products.

Selling expenses during these periods decreased by 3.4% from $46.9 million for the year ended December 31, 2016 to $45.3 million for the year ended December 31, 2017 due to less sales and marketing activities.

Administrative expenses increased by 13.0% from $21.7 million for the year ended December 31, 2016 to $24.5 million for the year ended December 31, 2017 due to an increase in general overhead costs incurred.

Taxation charge remained relatively stable at $3.6 million for the years ended December 31, 2016 and 2017 due to relatively stable profit before taxation across these periods.

As a result of the foregoing, profit attributable to equity holders of Hutchison Baiyunshan increased by 2.0% from $20.4 million for the year ended December 31, 2016 to $20.8 million for the year ended December 31, 2017. Our equity in earnings of equity investees contributed by this joint venture was $10.2 million and $10.4 million for the years ended December 31, 2016 and 2017, respectively.

186

Table of Contents

Nutrition Science Partners

The following table shows a summary of the results of operations of Nutrition Science Partners for the years indicated. The consolidated financial statements of Nutrition Science Partners are prepared in accordance with IFRS as issued by the IASB and are presented separately elsewhere in this annual report.

	Year Ended December 31,

	2017			2016
	($'000)		%	($'000)		%
Revenue	—		—	—		—
Loss for the year	(9,210	)	100.0	(8,482	)	100.0



Equity in earnings of equity investee attributable to our company	(4,605	)	50.0	(4,241	)	50.0

Nutrition Science Partners had losses of $8.5 million and $9.2 million for the years ended December 31, 2016 and 2017, respectively. Nutrition Science Partners had no revenue during these periods. The increase in net loss across these periods was primarily attributable to higher expenditures on personnel costs related to the development of drug candidates from Nutrition Science Partners' botanical library. Our equity in earnings of equity investees contributed by this joint venture was losses of $4.2 million and $4.6 million for the years ended December 31, 2016 and 2017, respectively.

For more information on the financial results of our non-consolidated joint ventures, see "—Key Components of Results of Operations—Equity in Earnings of Equity Investees."

Net (Loss)/Income

As a result of the foregoing, our net income decreased from a net income of $14.6 million for the year ended December 31, 2016 to a net loss of $23.0 million for the year ended December 31, 2017. Net income attributable to our company decreased from a net income of $11.7 million for the year ended December 31, 2016 to a net loss of $26.7 million for the year ended December 31, 2017.

Operating Profit/(Loss)

Our operating profit decreased from an operating profit of $20.5 million for the year ended December 31, 2016 to an operating loss of $18.4 million for the year ended December 31, 2017 as a result of a significant decrease in operating profit of our Commercial Platform from $74.3 million for the year ended December 31, 2016 to $45.1 million for the year ended December 31, 2017 as well as an increase in operating loss of our Innovative Platform from $40.8 million for the year ended December 31, 2016 to $52.0 million for the year ended December 31, 2017. The decrease in operating profit of our Commercial Platform across these periods was primarily due to equity in earnings of Shanghai Hutchison Pharmaceuticals including a one-time gain of $40.4 million relating to land compensation and other government subsidies in 2016 which did not occur in 2017. The increase in operating loss of our Innovation Platform was due to a significant expansion of clinical activities, rapid organization growth to support these clinical activities and investment in the expansion of small molecule manufacturing operations.

Year Ended December 31, 2016 Compared to Year Ended December 31, 2015

Revenues

Our revenues increased by 21.3% from $178.2 million for the year ended December 31, 2015 to $216.1 million for the year ended December 31, 2016.

This increase was driven by a $54.7 million increase in revenue for the year ended December 31, 2016 from our Commercial Platform, representing a 43.3% increase from the revenue of $126.2 million for the year ended December 31, 2015. The increase was partially offset by a 32.3% decrease in revenue from our

187

Table of Contents

Innovation Platform for the year ended December 31, 2016 to $35.2 million from $52.0 million in the year ended December 31, 2015. The growth in revenue from our Commercial Platform was driven by the inclusion of a full 12-month period of Seroquel sales in China for the year ended December 31, 2016, which our consolidated joint venture Hutchison Sinopharm began marketing under an exclusive license from AstraZeneca in the second quarter of 2015. The decrease in the revenue from our Innovation Platform for the year ended December 31, 2016 was attributable to a lower level of milestone payments, services fees and clinical cost reimbursements that we received from our collaboration partners including AstraZeneca and Eli Lilly.

The consolidated revenue from our Consumer Health business also increased by $10.3 million from $20.7 million for the year ended December 31, 2015 to $31.0 million for the year ended December 31, 2016. The increase was primarily attributable to higher levels of infant nutrition products and personal care products sold in 2016.

Our Commercial Platform's results of operations are affected by seasonality. For more information, see "—Factors Affecting our Results of Operations—Commercial Platform—Seasonality."

Cost of Sales

Our cost of sales increased by 41.1% from $110.8 million for the year ended December 31, 2015 to $156.3 million for the year ended December 31, 2016. This increase was primarily driven by a $39.2 million increase in cost of sales from Hutchison Sinopharm under our Prescription Drugs business, as well as a $4.0 million increase in cost of sales from Hutchison Hain Organic under our Consumer Health business. Cost of sales as a percentage of our revenue from our Commercial Platform decreased from 87.8% to 86.4% across these periods, primarily due to increased sales of Seroquel, which has a relatively higher margin than the other products sold by our Commercial Platform.

Research and Development Expenses

Our research and development expenses increased by 41.2% from $47.4 million for the year ended December 31, 2015 to $66.9 million for the year ended December 31, 2016, which was primarily attributable to a $15.1 million increase in payments to CROs and other clinical trial related costs and a $4.4 million increase in employee compensation related costs. These increased costs incurred by our Innovation Platform was due to a significant expansion of clinical activities and rapid organization growth to support these clinical activities. The number of ongoing clinical studies for our drug candidates increased from 19 studies as of December 31, 2015 to 30 studies as of December 31, 2016. In particular, this increase was attributable to our share of the cost of the savolitinib development program as well as the increased cost associated with the expansion of the sulfatinib and HMPL-523 development programs. As a result, research and development expenses as a percentage of our total revenue increased from 26.6% in the year ended December 31, 2015 to 31.0% in the year ended December 31, 2016.

Selling Expenses

Our selling expenses increased by 76.3% from $10.2 million for the year ended December 31, 2015 to $18.0 million for the year ended December 31, 2016. This increase was primarily driven by a $4.8 million increase in selling expenses under our Consumer Health business and a $3.0 million increase in selling expenses under our Prescription Drugs business. Selling expenses as a percentage of our revenue from our Commercial Platform increased from 8.1% to 10.0% across these periods, primarily due to increased selling expenses incurred by Hutchison Sinopharm for expanding its third-party distribution and commercialization business as well as increased marketing expenses related to the development of the Zhi Ling Tong infant nutrition business after Hutchison Sinopharm took over such business from a third-party distributor.

188

Table of Contents

Administrative Expenses

Our administrative expenses increased by 10.0% from $19.6 million for the year ended December 31, 2015 to $21.6 million for the year ended December 31, 2016. This increase was primarily due to a $2.2 million increase in administrative expenses incurred by our corporate head office, mainly related to the increased organization and third-party advisor costs as a result of us becoming a U.S. public company in March 2016. Administrative expenses as a percentage of our total revenue decreased from 11.0% to 10.0% across these periods, primarily due to the increase in revenue from our Hutchison Sinopharm business, which has relatively lower administrative expenses in proportion to revenue compared to our other businesses, partially offset by the increased administrative expenses at our corporate head office.

Other Expenses

Total other expenses decreased from $0.8 million for the year ended December 31, 2015 to $0.7 million for the year ended December 31, 2016, primarily due to an increase in other income resulting from payments to us by the depositary bank which administers our ADS program in 2016.

Our interest expense increased from $1.4 million for the year ended December 31, 2015 to $1.6 million for the year ended December 31, 2016, while our interest income remained relatively stable at $0.5 million for the years ended December 31, 2015 and 2016. These interest expenses primarily comprised interest and guarantee fee payments on bank loans in 2015 and 2016.

Income Tax Expense

Our income tax expense increased by 169.8% from $1.6 million for the year ended December 31, 2015 to $4.3 million for the year ended December 31, 2016 due to the increase in the net income of our Commercial Platform businesses and the 5% withholding taxes accrued on the net income from our Commercial Platform businesses for the year ended December 31, 2016.

Equity in Earnings of Equity Investees

Our equity in earnings of equity investees (net of tax) increased by 193.5% from $22.6 million for the year ended December 31, 2015 to $66.2 million for the year ended December 31, 2016. This increase was primarily due to an increase in net income at our Commercial Platform's non-consolidated joint ventures, Shanghai Hutchison Pharmaceuticals and Hutchison Baiyunshan, including a one-time gain of $40.4 million, net of tax, relating to land compensation and other subsidies paid to Shanghai Hutchison Pharmaceuticals by the Shanghai government and an increase in net loss at Nutrition Science Partners, our Innovation Platform's non-consolidated joint venture.

Shanghai Hutchison Pharmaceuticals

The following table shows a summary of the results of operations of Shanghai Hutchison Pharmaceuticals for the years indicated. The consolidated financial statements of Shanghai Hutchison

189

Table of Contents

Pharmaceuticals are prepared in accordance with IFRS as issued by the IASB and are presented separately elsewhere in this annual report.

	Year Ended December 31,

	2016				2015
	($'000)		%		($'000)		%
Revenue	222,368		100.0		181,140		100.0
Cost of sales	(64,237	)	(28.9	)	(53,532	)	(29.6	)
Selling expenses	(92,487	)	(41.6	)	(78,429	)	(43.3	)
Administrative expenses	(13,278	)	(6.0	)	(12,317	)	(6.8	)
Gain on disposal of assets held for sale	88,536		39.8		—		—
Taxation charge	(27,645	)	(12.4	)	(6,094	)	(3.4	)
Profit for the year	120,499		54.2		31,307		17.3



Equity in earnings of equity investee attributable to our company	60,250		27.1		15,654		8.6

Shanghai Hutchison Pharmaceuticals' revenue increased by 22.8% from $181.1 million for the year ended December 31, 2015 to $222.4 million for the year ended December 31, 2016, which was primarily due to increased sales of She Xiang Bao Xin pills, a vasodilator used in the treatment of heart conditions. Sales of She Xiang Bao Xin pills grew by 22.6% from $159.3 million for the year ended December 31, 2015 to $195.4 million for the year ended December 31, 2016, primarily due to continued geographical expansion of sales coverage.

Cost of sales increased by 20.0% from $53.5 million for the year ended December 31, 2015 to $64.2 million for the year ended December 31, 2016, primarily due to increased cost of goods sold as a result of increased sales of She Xiang Bao Xin pills.

Selling expenses during these periods increased by 17.9% from $78.4 million for the year ended December 31, 2015 to $92.5 million for the year ended December 31, 2016 as a result of increased spending on marketing and promotional activities to support the increase in sales.

Administrative expenses increased by 7.8% from $12.3 million for the year ended December 31, 2015 to $13.3 million for the year ended December 31, 2016, primarily as a result of compensation expenses due to salary increases.

Taxation charge increased by 353.6% from $6.1 million for the year ended December 31, 2015 to $27.6 million for the year ended December 31, 2016, which was primarily due to the increase in profit before taxation between these periods.

As a result of the foregoing and the one-time gain on disposal of assets held for sale of $88.5 million related to land compensation received from the Shanghai government, profit increased by 284.9% from $31.3 million for the year ended December 31, 2015 to $120.5 million for the year ended December 31, 2016. Our equity in earnings of equity investees contributed by this joint venture was $15.7 million and $60.3 million for the years ended December 31, 2015 and 2016, respectively.

190

Table of Contents

Hutchison Baiyunshan

	Year Ended December 31,

	2016				2015
	($'000)		%		($'000)		%
Revenue	224,131		100.0		211,603		100.0
Cost of sales	(134,776	)	(60.1	)	(120,142	)	(56.8	)
Selling expenses	(46,873	)	(20.9	)	(45,325	)	(21.4	)
Administrative expenses	(21,716	)	(9.7	)	(23,722	)	(11.2	)
Taxation charge	(3,631	)	(1.6	)	(3,948	)	(1.9	)
Profit attributable to equity holders of Hutchison Baiyunshan	20,376		9.1		21,376		10.1



Equity in earnings of equity investee attributable to our company	10,188		4.5		10,688		5.1

Hutchison Baiyunshan's revenue increased by 5.9% from $211.6 million for the year ended December 31, 2015 to $224.1 million for the year ended December 31, 2016, which was primarily due to increased sales of certain of its drug products, for which revenue increased by 7.8% from $144.5 million for the year ended December 31, 2015 to $155.8 million for the year ended December 31, 2016.

Cost of sales increased by 12.2% from $120.1 million for the year ended December 31, 2015 to $134.8 million for the year ended December 31, 2016, primarily due to increased sales. The increase in cost of sales was larger than the increase in revenues due to a change in product mix resulting in a higher proportion of sales of lower margin products.

Selling expenses during these periods increased by 3.4% from $45.3 million for the year ended December 31, 2015 to $46.9 million for the year ended December 31, 2016 to support the growth in sales across these periods.

Administrative expenses decreased from $23.7 million for the year ended December 31, 2015 to $21.7 million for the year ended December 31, 2016 due to a decrease in general overhead costs incurred.

Taxation charge decreased from $3.9 million for the year ended December 31, 2015 to $3.6 million for the year ended December 31, 2016 due to decreased profit before taxation across these periods.

As a result of the foregoing, profit attributable to equity holders of Hutchison Baiyunshan decreased by 4.7% from $21.4 million for the year ended December 31, 2015 to $20.4 million for the year ended December 31, 2016. Our equity in earnings of equity investees contributed by this joint venture was $10.7 million and $10.2 million for the years ended December 31, 2015 and 2016, respectively.

Nutrition Science Partners

	Year Ended December 31,

	2016			2015
	($'000)		%	($'000)		%
Revenue	—		—	—		—
Loss for the year	(8,482	)	100.0	(7,552	)	100.0



Equity in earnings of equity investee attributable to our company	(4,241	)	50.0	(3,776	)	50.0

191

Table of Contents

Nutrition Science Partners had losses of $7.6 million and $8.5 million for the years ended December 31, 2015 and 2016, respectively. Nutrition Science Partners had no revenue during these periods. The increase in net loss across these periods was primarily attributable to higher expenditures on personnel costs related to the development of drug candidates from Nutrition Science Partners' botanical library. Our equity in earnings of equity investees contributed by this joint venture was losses of $3.8 million and $4.2 million for the years ended December 31, 2015 and 2016, respectively.

For more information on the financial results of our non-consolidated joint ventures, see "—Key Components of Results of Operations—Equity in Earnings of Equity Investees."

Net Income

As a result of the foregoing, our net income improved from a net income of $10.4 million for the year ended December 31, 2015 to a net income of $14.6 million for the year ended December 31, 2016. Net income attributable to our company improved from a net income of $8.0 million for the year ended December 31, 2015 to a net income of $11.7 million for the year ended December 31, 2016.

Operating Profit

Our operating profit increased by 52.7% from $13.4 million for the year ended December 31, 2015 to $20.5 million for the year ended December 31, 2016 as a result of a significant increase in operating profit of our Commercial Platform from $28.2 million for the year ended December 31, 2015 to $74.3 million for the year ended December 31, 2016, partially offset by an increase in operating loss of our Innovative Platform from $3.8 million for the year ended December 31, 2015 to $40.8 million for the year ended December 31, 2016. The increase in operating profit of our Commercial Platform across these periods was attributable to an increase in equity in earnings of Shanghai Hutchison Pharmaceuticals of $44.6 million from $15.7 million for the year ended December 31, 2015 to $60.3 million for the year ended December 31, 2016. The increase in operating loss of our Innovation Platform was due to a significant expansion of clinical activities, rapid organization growth to support these clinical activities and a decrease in revenue from license and collaboration agreements due to timing of milestone achievements.

B. Liquidity and Capital Resources

To date, we have taken a multi-source approach to funding through cash flows generated from and dividend payments from our Commercial Platform, service and milestone and upfront payments from our Innovation Platform's collaboration partners, and bank borrowings. We have also received various financial support from Hutchison Whampoa Limited, an affiliate of our majority shareholder, in the form of guarantees and undertakings for bank borrowings as well as investments from other parties since our founding, proceeds from our listings on the AIM market of the London Stock Exchange in 2006 and the Nasdaq Global Select Market in 2016 and follow-on offering in 2017.

Our Innovation Platform has historically not generated significant profits or has operated at a net loss, as creating potential global first-in-class or best-in-class drug candidates requires a significant investment of resources over a prolonged period of time. As a result, we anticipate that we may need additional financing for our Innovation Platform in future periods. See Item 3.D. "Risk Factors—Risks Related to Our Innovation Platform—Historically, our Innovation Platform has not generated significant profits or has operated at a net loss."

As of December 31, 2017, we had cash and cash equivalents and short-term investments of $358.3 million and unutilized bank facilities of $121.3 million. Substantially all of our bank deposits are at major financial institutions, which we believe are of high credit quality. As of December 31, 2017, we had $30.0 million in bank loans, including (i) a $20.0 million term loan from Bank of America N.A. and a $10.0 million term loan from Deutsche Bank AG, Hong Kong Branch, both of which will expire in August 2018. Our total weighted average cost of bank borrowings, including all interest and guarantee fees payable

192

Table of Contents

with respect to our prior loan with Scotiabank, was 2.7% as of December 31, 2017. In February 2017, we entered into new credit facility agreements with each of Bank of America N.A. and Deutsche Bank AG, Hong Kong Branch of $45.0 million and $25.0 million, respectively, which replaced the previous combined $60.0 million credit facility agreement we had entered into with these two banks in February 2016. In November 2017, we entered into a new credit facility agreement with Scotiabank for the provision of unsecured credit facilities in the aggregate amount of $51.3 million. The credit facility includes (i) a $26.9 million 3-year term loan facility; and (ii) a $24.4 million 18-month revolving loan facility, which replaced the previous four-year Scotiabank loan entered in December 2011 and subsequently renewed in June 2014.

Certain of our subsidiaries and non-consolidated joint ventures, including those registered as wholly foreign-owned enterprises in China, are required to set aside at least 10.0% of their after-tax profits to their general reserves until such reserves reach 50.0% of their registered capital. There is no fixed percentage of after-tax profit required to set aside for the general reserves for our PRC joint ventures. Profit appropriated to the reserve funds for our subsidiaries and non-consolidated joint ventures incorporated in the PRC was approximately $24,000, $15,000 and $10,000 for the years ended December 31, 2015, 2016 and 2017, respectively. In addition, as a result of PRC regulations restricting dividend distributions from such reserve funds and from a company's registered capital, our PRC subsidiaries are restricted in their ability to transfer a certain amount of their net assets to us as cash dividends, loans or advances. This restricted portion amounted to $7.3 million as of December 31, 2017. Although we do not currently require any such dividends, loans or advances from our PRC subsidiaries to fund our operations, should we require additional sources of liquidity in the future, such restrictions may have a material adverse effect on our liquidity and capital resources. For more information, see Item 4.B. "Business Overview—Regulation—PRC Regulation of Foreign Currency Exchange, Offshore Investment and State-Owned Assets—Regulation on Dividend Distribution."

In addition, our non-consolidated joint ventures held an aggregate of $67.0 million in cash and cash equivalents and bank deposits maturing over three months and no bank borrowings as of December 31, 2017. These cash and cash equivalents are only accessible by us through dividend payments from these joint ventures. The level of dividends declared by these joint ventures is subject to agreement each year between us and our joint venture partners based on the profitability and working capital needs of the joint ventures. As a result, we cannot guarantee that these joint ventures will continue to pay dividends to us in the future at the same rate we have enjoyed in the past, or at all, which may have a material adverse effect on our liquidity and capital resources. As of December 31, 2017, our Innovation Platform joint venture, Nutrition Science Partners, has not paid any dividends. For more information, see Item 3.D. "Risk Factors—Risks Related to Our Commercial Platform—As a significant portion of our Commercial Platform business is conducted through joint ventures, we are largely dependent on the success of our joint ventures and our receipt of dividends or other payments from our joint ventures for cash to fund our operations."

We believe that our current levels of cash and cash equivalents, short-term investments, along with cash flows from operations, dividend payments and bank borrowings, will be sufficient to meet our anticipated cash needs for at least the next 12 months. However, we may require additional financing in order to fund all of the clinical development efforts at our Innovation Platform that we plan to undertake

193

Table of Contents

to accelerate the development of our clinical-stage drug candidates. For more information, see Item 3.D. "Risk Factors—Risks Related to Our Financial Position and Need for Additional Capital."

	Year Ended December 31,

	2017		2016		2015
	($'000)
Cash Flow Data:
Net cash used in operating activities	(8,943	)	(9,569	)	(9,385	)
Net cash (used in)/generated from investing activities	(260,780	)	(33,597	)	8,855
Net cash generated from/(used in) financing activities	273,196		92,435		(5,471	)

Net increase/(decrease) in cash and cash equivalents	3,473		49,269		(6,001	)
Effect of exchange rate changes	2,361		(1,779	)	(1,004	)
Cash and cash equivalents at beginning of the year	79,431		31,941		38,946

Cash and cash equivalents at end of the year	85,265		79,431		31,941

Net Cash used in Operating Activities

Net cash used in operating activities was $9.6 million for the year ended December 31, 2016 compared to net cash used in operating activities of $8.9 million for the year ended December 31, 2017. The net change was primarily attributable to a $25.1 million increase in dividends received from our equity investees from $30.5 million for the year ended December 31, 2016 to $55.6 million for the year ended December 31, 2017 which was the result of increased revenue and funds available from land compensation paid to our equity investees in 2016. This increase was partially offset by an increase in research and development spending in our Innovation Platform as well as the effects of changes in working capital, namely an aggregate decrease of $14.5 million in the year ended December 31, 2017 primarily due to delayed payments from 2016 which were settled in 2017, as compared to an aggregate increase of $3.4 million in the year ended December 31, 2016.

Net cash used in operating activities was $9.4 million for the year ended December 31, 2015 compared to net cash used in operating activities of $9.6 million for the year ended December 31, 2016. The net change was primarily attributable to a $24.1 million increase in dividends received from our equity investees from $6.4 million for the year ended December 31, 2015 to $30.5 million for the year ended December 31, 2016 resulting from increased revenue and gain from land compensation paid to our equity investees and the effects of changes in working capital due to an increase of $19.0 million in accounts payable and other payables, accruals and advance receipts due to delays in payments to suppliers in the year ended December 31, 2016, as compared to an increase of $8.3 million in the year ended December 31, 2015, offset by increases in research and development spending in our Innovation Platform.

Net Cash (used in)/generated from Investing Activities

Net cash used in investing activities was $33.6 million for the year ended December 31, 2016, compared to net cash used in investing activities of $260.8 million for the year ended December 31, 2017. This change was primarily attributable to net deposits in short-term investments of $248.8 million for the year ended December 31, 2017 compared to $24.3 million for the year ended December 31, 2016. This change was also attributable to an additional $7.0 million share capital contribution to Nutrition Science Partners in 2017 compared to $5.0 million in 2016.

Net cash generated from investing activities was $8.9 million for the year ended December 31, 2015, compared to net cash used in investing activities of $33.6 million for the year ended December 31, 2016. This change was primarily attributable to net deposits in short-term investments of $24.3 million for the year ended December 31, 2016 compared to a net withdrawal of deposits in short-term investments of

194

Table of Contents

$12.2 million for the year ended December 31, 2015. This change was also attributable to an additional $5.0 million share capital contribution to Nutrition Science Partners in 2016 by us.

Net Cash generated from/(used in) Financing Activities

Net cash generated from financing activities was $92.4 million for the year ended December 31, 2016, compared to net cash generated from financing activities of $273.2 million for the year ended December 31, 2017. This change was primarily attributable to net proceeds of $292.7 million from the issuance of ordinary shares in the form of ADS upon our follow-on offering in the United States in October 2017 as compared to net proceeds of $97.3 million from the issuance of ordinary shares in the form of ADS upon our initial public offering in the United States in 2016. The change was also attributable to a net decrease in bank borrowings of $16.9 million for the year ended December 31, 2017 as compared to a net decrease of $3.1 million for the year ended December 31, 2016.

Net cash used in financing activities was $5.5 million for the year ended December 31, 2015, compared to net cash generated from financing activities of $92.4 million for the year ended December 31, 2016. This change was primarily attributable to net proceeds of $97.3 million from the issuance of ordinary shares in the form of ADS upon our initial public offering in the United States in 2016.

Loan Facilities

In November 2015, we renewed a three-year revolving loan facility with HSBC with an annual interest rate of 1.25% over the Hong Kong Inter-bank Offered Rate, or HIBOR. This facility will expire in November 2018. The credit limit of this loan is HK$234.0 million ($30.0 million). In February 2017, $2.5 million was drawn from this facility, and the amount was fully repaid in March 2017. As of December 31, 2017, there were no amounts due under this loan. The proceeds from previous drawdowns of this loan facility were used for working capital purposes prior to repayment. Interest expenses accrued and paid for this loan were approximately $295,000, $243,000 and $3,000 for the years ended December 31, 2015, 2016 and 2017, respectively.

In February 2016, our Hong Kong subsidiary, Hutchison China MediTech (HK) Limited, entered into a facility agreement with Bank of America N.A. and Deutsche Bank AG, Hong Kong Branch for the provision of unsecured credit facilities in the aggregate amount of HK$468.0 million ($60.0 million). These credit facilities included (i) a HK$156.0 million ($20.0 million) term loan facility with a term of 18 months and an annual interest rate of 1.35% over HIBOR; and (ii) a HK$312.0 million ($40.0 million) revolving loan facility with a term of 12 months and an annual interest rate of 1.30% over HIBOR. In March 2017, the term loan facility of HK$156.0 million ($20.0 million) as part of the unsecured credit facilities was fully repaid and the unsecured credit facilities were terminated.

In February 2017, our subsidiary Hutchison China MediTech (HK) Limited entered into new credit facility agreements with each of Bank of America N.A. and Deutsche Bank AG, Hong Kong Branch for the provision of unsecured credit facilities in the aggregate amount of HK$546.0 million ($70.0 million). The credit facility with Bank of America N.A. includes (i) a HK$156.0 million ($20.0 million) term loan facility and (ii) a HK$195.0 million ($25.0 million) revolving loan facility, both with a term of 18 months and an annual interest rate of 1.25% over HIBOR. The term loan was drawn from this credit facility in March 2017 and is due in August 2018. The credit facility with Deutsche Bank AG, Hong Kong Branch includes (i) a HK$78.0 million ($10.0 million) term loan facility and (ii) a HK$117.0 million ($15.0 million) revolving loan facility, both with a term of 18 months and an annual interest rate of 1.25% over HIBOR. The term loan was drawn from this credit facility in August 2017 and is due in August 2018. The two new credit facility agreements replaced the previous credit facility agreement with these two banks. As of December 31, 2017, no amounts were drawn from the revolving loan facilities and HK$156.0 million ($20.0 million) and HK$78.0 million ($10.0 million) was outstanding on the term loan facilities,

195

Table of Contents

respectively. These credit facilities are guaranteed by Chi-Med and include certain financial covenant requirements.

In November 2017, our subsidiary Hutchison China MediTech Finance Holdings Limited entered into a HK$210.0 million ($26.9 million) three-year term loan and HK$190.0 million ($24.4 million) 18-month revolving loan facility with Scotiabank. The new term loan facility bears an annual interest rate of 1.50% over HIBOR and the new revolving loan facility bears an annual interest rate of 1.25% over HIBOR. The new term loan and revolving loan facility will expire in November 2020 and May 2019, respectively. As of December 31, 2017, no amounts have been drawn from the term loan or the revolving loan facilities. Our previous four-year term loan with Scotiabank entered in June 2014 was fully repaid in November 2017. The previous term loan was guaranteed by Hutchison Whampoa Limited for an annual guarantee fee of 1.75%. Interest expenses accrued and paid for this loan were $0.4 million, $0.4 million and $0.3 million for the years ended December 31, 2015, 2016 and 2017, respectively. Guarantee fees accrued and paid for these loans with Scotiabank were $0.5 million, $0.5 million and $0.3 million for the years ended December 31, 2015, 2016 and 2017, respectively.

In addition, our non-consolidated joint ventures Shanghai Hutchison Pharmaceuticals, Hutchison Baiyunshan and Nutrition Science partners had no bank borrowings outstanding as of December 31, 2017.

Capital Expenditures

We had capital expenditures of $3.3 million, $4.3 million and $5.0 million for the years ended December 31, 2015, 2016 and 2017, respectively. Our capital expenditures during these periods were primarily used for the purchases of property, plant and equipment to expand the Hutchison MediPharma research facilities and the new manufacturing facility in Suzhou, China, which produces Phase III clinical supplies and will be used to produce fruquintinib and other drug candidates. Our capital expenditures have been primarily funded by cash flows from operations and financing from bank borrowings.

As of December 31, 2017, we had commitments for capital expenditures of approximately $0.2 million, primarily for purchases of property, plant and equipment to expand the Hutchison MediPharma research facilities and the new Suzhou manufacturing facility. We expect to fund these capital expenditures through cash flows from operations and financing from bank borrowings.

Our non-consolidated joint venture Shanghai Hutchison Pharmaceuticals had capital expenditures (net of government subsidies) of $42.1 million, $11.0 million and $6.2 million for the years ended December 31, 2015, 2016 and 2017, respectively. These capital expenditures were primarily related to the construction of the new production facilities in Feng Pu district in Shanghai. These capital expenditures were primarily funded through cash flows from operations of Shanghai Hutchison Pharmaceuticals and bank borrowings.

Our non-consolidated joint venture Hutchison Baiyunshan had capital expenditures of $21.7 million, $13.2 million and $7.2 million for the years ended December 31, 2015, 2016 and 2017, respectively. These capital expenditures were primarily related to the acquisition of leasehold land in Guangzhou and Bozhou as well as the construction of the new production facilities in Bozhou and an office building in Guangzhou. These capital expenditures were primarily funded through cash flows from operations of Hutchison Baiyunshan.

C. Research and Development, Patents and Licenses, etc.

Full details of our research and development activities and expenditures are given in the "Business" and "Operating and Financial Review and Prospects" sections of this annual report above.

196

Table of Contents

D. Trend Information.

Other than as described elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events that are reasonably likely to have a material adverse effect on our revenue, income from continuing operations, profitability, liquidity or capital resources, or that would cause our reported financial information not necessarily to be indicative of future operation results or financial condition.

E. Off-balance Sheet Arrangements.

Other than some of the operating lease obligations set forth in the table above, we did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements as defined under the rules of the SEC.

F. Tabular Disclosure of Contractual Obligations.

The following table sets forth our contractual obligations as of December 31, 2017. Our purchase obligations relate to property, plant and equipment that are contracted for but not yet paid. Our operating lease obligations primarily comprise future aggregate minimum lease payments in respect of various factories and offices under non-cancellable operating lease agreements.

	Payment Due by Period

	Total		Less Than 1 Year		1-3 Years		3-5 Years		More Than 5 Years
	($'000)
Bank borrowings		30,000		30,000		—		—		—
Loan from a non-controlling shareholder of a subsidiary		1,550		1,550		—		—		—
Interest on bank borrowings		480		480		—		—		—
Interest on loan from a non-controlling shareholder of a subsidiary		55		55		—		—		—
Purchase obligations		161		161		—		—		—
Operating lease obligations		8,860		3,330		5,007		506		17

Total		41,106		35,576		5,007		506		17

Shanghai Hutchison Pharmaceuticals

The following table sets forth the contractual obligations of our non-consolidated joint venture Shanghai Hutchison Pharmaceuticals as of December 31, 2017. Shanghai Hutchison Pharmaceuticals' operating lease obligations primarily comprise future aggregate minimum lease payments in respect of various factories and offices under non-cancellable operating lease agreements.

	Payment Due by Period

	Total		Less Than 1 Year		1-3 Years		3-5 Years		More Than 5 Years
	($'000)
Purchase obligations		574		574		—		—		—
Operating lease obligations		314		283		31		—		—

Total		888		857		31		—		—

197

Table of Contents

Hutchison Baiyunshan

The following table sets forth the contractual obligations of our non-consolidated joint venture Hutchison Baiyunshan as of December 31, 2017. Hutchison Baiyunshan's purchase obligations comprise capital commitments for property, plant and equipment contracted for but not yet paid, which mainly relate to the construction in progress of the new production facilities at Bozhou in Anhui province. Hutchison Baiyunshan's finance and operating lease obligations primarily comprise future aggregate minimum lease payments in respect of various factories, warehouses and equipment under non-cancellable lease agreements.

	Payment Due by Period

	Total		Less Than 1 Year		1-3 Years		3-5 Years		More Than 5 Years
	($'000)
Purchase obligations		460		460		—		—		—
Finance lease obligations		543		125		250		168		—
Operating lease obligations		1,707		999		520		188		—

Total		2,710		1,584		770		356		—

Quantitative and Qualitative Disclosures About Market Risk

Foreign Exchange Risk

Substantially all of our revenue and expenses are denominated in renminbi, and our financial statements are presented in U.S. dollars. We do not believe that we currently have any significant direct foreign exchange risk and have not used any derivative financial instruments to hedge our exposure to such risk. Although, in general, our exposure to foreign exchange risks should be limited, the value of your investment in our ADSs will be affected by the exchange rate between the U.S. dollar and the renminbi because the value of our business is effectively denominated in renminbi, while the ADSs will be traded in U.S. dollars.

The value of the renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in China's political and economic conditions. The conversion of renminbi into foreign currencies, including U.S. dollars, has been based on rates set by the PBOC. On July 21, 2005, the PRC government changed its decade-old policy of pegging the value of the renminbi to the U.S. dollar. Under the revised policy, the renminbi is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. This change in policy resulted in a more than 20% appreciation of the renminbi against the U.S. dollar in the following three years. Between July 2008 and June 2010, this appreciation halted, and the exchange rate between the renminbi and U.S. dollar remained within a narrow band. In June 2010, the PBOC announced that the PRC government would increase the flexibility of the exchange rate, and thereafter allowed the renminbi to appreciate slowly against the U.S. dollar within the narrow band fixed by the PBOC. However, more recently, the PBOC has significantly devalued the renminbi against the U.S. dollar. If we decide to convert renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar against the renminbi would have a negative effect on the U.S. dollar amounts available to us.

Credit Risk

Substantially all of our bank deposits are in major financial institutions, which we believe are of high credit quality. We limit the amount of credit exposure to any financial institution. We make periodic assessments of the recoverability of trade and other receivables and amounts due from related parties. Our

198

Table of Contents

historical experience in collection of receivables falls within the recorded allowances, and we believe that we have made adequate provision for uncollectible receivables.

Interest Rate Risk

We have no significant interest-bearing assets except for bank deposits. Our exposure to changes in interest rates is mainly attributable to our bank borrowings, which bear interest at floating interest rates and expose us to cash flow interest rate risk. We have not used any interest rate swaps to hedge our exposure to interest rate risk. We have performed sensitivity analysis for the effects on our results for the year from changes in interest rates on floating rate borrowings. The sensitivity to interest rates used is based on the market forecasts available at the end of the reporting period and under the economic environments in which we operate, with other variables held constant. According to the analysis, the impact on our net loss of a 1.0% interest rate shift would be a maximum increase/decrease of $0.4 million for the year ended December 31, 2017.

Inflation

In recent years, China has not experienced significant inflation, and thus inflation has not had a material impact on our results of operations. According to the National Bureau of Statistics of China, the Consumer Price Index in China increased by 1.4%, 2.0% and 1.8% in 2015, 2016 and 2017, respectively. Although we have not been materially affected by inflation in the past, we can provide no assurance that we will not be affected in the future by higher rates of inflation in China.

Recently Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board, or FASB, issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), or ASU 2014-09, to clarify the principles of recognizing revenue and create common revenue recognition guidance for U.S. GAAP and International Financial Reporting Standards. An entity has the option to apply the provisions of ASU 2014-09 either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this standard recognized at the date of initial application. ASU 2014-09 is effective for fiscal years and interim periods within those years beginning after December 15, 2017, and early adoption is permitted but not earlier than the original effective date of December 15, 2016. The new standard supersedes U.S. GAAP guidance on revenue recognition and requires the use of more estimates, judgments and additional disclosures.

We adopted the new standard using the modified retrospective method on January 1, 2018 and have assessed the impact on revenue from customers. Our revenue from contracts with customers comprises of research and development projects in our Innovation Platform and sales of goods and services in our Commercial Platform operating segments. We expect the changes from applying the new guidance will primarily impact the Innovation Platform.

Innovation Platform—We have reviewed our research and development contracts and identified two contracts related to our license and collaboration arrangements that will be impacted by the application of ASU 2014-09. The license and collaboration arrangements contain multiple performance obligations: (1) the license to the drug compound; and (2) the research and development services for each specified treatment indication. The transaction price includes fixed and variable consideration in the form of upfront payment, research and development costs reimbursements, contingent milestone payments and sales-based royalties. The allocation of the transaction price to each performance obligation is based on the relative standalone selling price of each performance obligation. We have determined that control of the license to the drug compound was transferred as of the inception date of the collaboration agreements and consequently, amounts allocated to this performance obligation are recognized at a point in time. Conversely, control of the research and development services for each specified indication is transferred

199

Table of Contents

over time and amounts allocated to these performance obligations are recognized over time using cost inputs as a measure of progress. In addition, royalty revenues will be recognized as future sales occur as they meet the requirements for the sales-usage based royalty exception. We expect US$1.1 million deferral of revenue as a cumulative adjustment to opening accumulated loss upon adoption.

Commercial Platform—For sales of goods and services, we have applied a portfolio approach to aggregate contracts into portfolios whose performance obligations do not differ materially from each other. In our assessment of each portfolio, we have assessed the contracts under the new five-step model and do not expect a significant impact to the timing or amount of revenue recognition under the new guidance. Control of the goods passes to the customer when the goods are delivered, which matches the timing of revenue recognition under the our existing accounting policy.

We have applied updates to the new guidance in our assessment including ASU 2016-08, Principal versus Agent Considerations, ASU 2016-10, Identifying Performance Obligations and Licensing.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), or ASU 2016-02. The core principle of ASU 2016-02 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018. We expect to adopt the new standard using the modified retrospective method on January 1, 2019 with a retrospective adjustment to comparable periods presented starting from January 1, 2017. We are currently determining the potential impact ASU 2016-02 will have on our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, or ASU 2017-01, which revises the definition of a business. To be considered a business, an acquisition would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. To be a business without outputs, there will now need to be an organized workforce. ASU 2017-01 is effective for fiscal years and interim periods within those years beginning after December 15, 2018. We currently do not expect ASU 2017-01 to have a material impact on our consolidated financial statements, but will apply the guidance upon adoption to business acquisitions, disposals and segment changes, if any.

In May 2017, the FASB issued ASU 2017-09, Scope of Modification Accounting (Topic 718), or ASU 2017-09, which provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under share-based payment accounting. The guidance clarifies that no new measurement date will be required if there is no change to the fair value, vesting conditions, and classification, and in effect simplifies the accounting for non-substantive changes to share-based payment awards. ASU 2017-09 is effective for fiscal years and interim periods within those years beginning after December 15, 2017. We shall apply the guidance upon adoption to share-based payment modifications, if any.

Other amendments that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

200

Table of Contents

ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

A. Directors and Senior Management.

Below is a list of the names and ages of our directors and officers as of March 1, 2018, and a brief account of the business experience of each of them. The business address for our directors and officers is c/o Hutchison China MediTech Limited, Room 2108, 21/F, Hutchison House, 10 Harcourt Road, Hong Kong.

Name		Position

Simon To	66	Executive Director and Chairman
Christian Hogg	52	Executive Director and Chief Executive Officer
Johnny Cheng	51	Executive Director and Chief Financial Officer
Weiguo Su, Ph.D.	60	Executive Director and Chief Scientific Officer
Dan Eldar, Ph.D.	64	Non-executive Director
Edith Shih	66	Non-executive Director and Company Secretary
Paul Carter	57	Senior Independent Non-executive Director
Karen Ferrante, M.D.	60	Independent Non-executive Director
Graeme Jack	67	Independent Non-executive Director
Tony Mok, M.D.	57	Independent Non-executive Director
Ye Hua, M.D.	50	Senior Vice President, Head of Clinical Development & Regulatory Affairs
May Wang, Ph.D.	54	Senior Vice President, Business Development & Strategic Alliances
Zhenping Wu, Ph.D.	58	Senior Vice President, Pharmaceutical Sciences
Mark Lee	40	Senior Vice President, Corporate Finance & Development

Simon To has been a director since 2000 and an executive director and chairman since 2006. He is also chairman of our remuneration committee and a member of our technical committee. He is managing director of Hutchison Whampoa (China) Limited and has been with Hutchison Whampoa (China) Limited for over 37 years, building its business from a small trading company to a multi-billion dollar investment group. He has negotiated major transactions with multinationals such as Procter & Gamble, or P&G, Lockheed, Pirelli, Beiersdorf, United Airlines, and British Airways. He is currently a director of Gama Aviation Plc. Mr. To's career in China spans more than 37 years. He is the original founder of Hutchison Whampoa Limited's (currently a subsidiary of CK Hutchison) China healthcare businesses and has been instrumental in its acquisitions made to date. He received a First Class Honours Bachelor's Degree in Mechanical Engineering from Imperial College, London and an MBA from Stanford University's Graduate School of Business (graduated top 5% of his class).

Christian Hogg has been an executive director and chief executive officer since 2006. He is also a member of our technical committee. He joined Hutchison Whampoa (China) Limited in 2000 and has since led all aspects of the creation, implementation and management of our strategy, business and listing. This includes the creation of our start-up businesses and the acquisition and operational integration of assets that led to the formation of our China joint ventures. Prior to joining Hutchison Whampoa (China) Limited, Mr. Hogg spent ten years with P&G, starting in the United States in Finance and then Brand Management in the Laundry and Cleaning Products Division. Mr. Hogg then moved to China to manage P&G's detergent business, followed by a move to Brussels to run P&G's global bleach business. Mr. Hogg

201

Table of Contents

received a Bachelor's degree in Civil Engineering from the University of Edinburgh and an MBA from the University of Tennessee.

Johnny Cheng has been an executive director since 2011 and chief financial officer since 2008. He is also a director of Hutchison MediPharma (Hong Kong) Limited, Sen Medicine Company Limited, Hutchison MediPharma, Hutchison MediPharma (Suzhou) Limited, and Hutchison MediPharma (Yulin) Limited. He was a director of Hutchison Healthcare during 2009. Prior to joining our company, Mr. Cheng was vice president, finance of Bristol-Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co., Ltd. in Shanghai between late 2006 and 2008. Mr. Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia and then KPMG in Beijing before spending eight years with Nestlé in China where he was in charge of a number of finance and control functions in various operations. Mr. Cheng received a Bachelor of Economics, Accounting Major from the University of Adelaide and is a member of the Institute of Chartered Accountants in Australia.

Weiguo Su has been an executive director since 2017 and has been our chief scientific officer since 2012. He is also a member of our technical committee. Dr. Su has headed all drug discovery and research since he joined our company, including master-minding our scientific strategy, being a key leader of the Innovation Platform, and responsible for the discovery of each and every small molecule drug candidate in our pipeline. Prior to joining our company in 2005, Dr. Su spent 15 years with Pfizer's U.S. research and development organization where he became a director in their medicinal chemistry department. In March 2017, Dr. Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China. Dr. Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai and completed a Ph.D. and post-doctoral fellowship in chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.

Dan Eldar has been a non-executive director since 2016. He has more than 30 years of experience as a senior executive, leading global operations in telecommunications, water, biotech and healthcare. He is an executive director of Hutchison Water Israel Ltd which focuses on large scale projects including desalination, wastewater treatment and water reuse. He was formerly an independent non-executive director of Leumi Card, a subsidiary of Bank Leumi Le-Israel B.M., one of Israel's leading credit card companies. Dr. Eldar holds a Doctor of Philosophy degree in Government from Harvard University, Master of Arts degree in Government from Harvard University, Master of Arts degree in Political Science and Public Administration from the Hebrew University of Jerusalem and a Bachelor of Arts degree in Political Science from the Hebrew University of Jerusalem.

Edith Shih has been a non-executive director and company secretary since 2006 and company secretary of our subsidiaries since 2000. She is also an executive director and company secretary of CK Hutchison, a group she has been with since 1989, acting in the capacity of director, head group general counsel and company secretary of its subsidiaries and associated companies. Ms. Shih is a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited and Hutchison Port Holdings Management Pte. Limited, the trustee-manager of Hutchison Port Holdings Trust. She has over 35 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is at present the senior vice president and an executive committee member of the Institute of Chartered Secretaries and Administrators in the United Kingdom and a past president and current council member and chairperson of various committees and panels of The Hong Kong Institute of Chartered Secretaries. Ms. Shih received a Bachelor of Science degree in Education and a Master of Arts degree from the University of the Philippines and a Master of Arts degree and a Master of Education degree from Columbia University, New York. Ms. Shih is a solicitor qualified in England and Wales, Hong Kong and Victoria, Australia and a Fellow of both the Institute of Chartered Secretaries and Administrators and The Hong Kong Institute of Chartered Secretaries.

202

Table of Contents

Paul Carter has been a senior independent non-executive director since 2017. He is also a member of our audit committee, remuneration committee and technical committee. He has more than 25 years of experience in the pharmaceutical industry. From 2006 to 2016, Mr. Carter served in various senior executive roles at Gilead, a research-based biopharmaceutical company, with the last position as executive vice president, commercial operations. In this role, Mr. Carter headed the worldwide commercial organization responsible for the launch and commercialization of all of Gilead's products. Prior to joining Gilead, he spent 14 years with GlaxoSmithKline PLC and its group companies, with the last position as a regional head of the international business in Asia. He is currently a director of Alder Biopharmaceuticals, Inc. Mr. Carter holds a degree in Business Studies from the Ealing School of Business and Management (now merged into University of West London) and is a Fellow of the Chartered Institute of Management Accountants in the United Kingdom.

Karen Ferrante has been an independent non-executive director since 2017. She is also the chairman of our technical committee and a member of the audit committee. She has more than 20 years of experience in the pharmaceutical industry. She was the former chief medical officer and head of research and development of Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. From September 2007 to July 2013, Dr. Ferrante held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including chief medical officer and most recently as oncology therapeutic area and Cambridge USA site head. From 1999 to 2007, she held positions of increasing responsibility at Pfizer Inc., with the last position as vice president, oncology development. Dr. Ferrante is currently a member of the board of directors of Progenics Pharmaceuticals, Inc., MacroGenics, Inc. and Unum Therapeutics Inc. She was previously a director of Baxalta Incorporated until it was acquired by Shire plc in 2016. Dr. Ferrante has been an author of a number of papers in the field of oncology, an active participant in academic and professional associations and symposia and holder of several patents. Dr. Ferrante holds a Bachelor of Science Degree in Chemistry and Biology from Providence College and a Doctor of Medicine from Georgetown University.

Graeme Jack has been an independent non-executive director since 2017. He is also chairman of our audit committee and member of our remuneration committee. He has more than 40 years of experience in finance and audit. He retired as partner of PricewaterhouseCoopers in 2006 after a distinguished career with the firm for over 33 years. He is currently an independent non-executive director of The Greenbrier Companies, Inc. (an international supplier of equipment and services to the freight rail transportation markets), Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust (a developer and operator of deep water container terminals) and of COSCO SHIPPING Development Co., Ltd., formerly known as "China Shipping Container Lines Company Limited" (an integrated financial services platform principally engaged in vessel and container leasing). He holds a Bachelor of Commerce degree and is a Fellow of the Hong Kong Institute of Certified Public Accountants and an Associate of Chartered Accountants Australia and New Zealand.

Tony Mok has been an independent non-executive director since 2017. He is also a member of our technical committee. Professor Mok has more than 30 years of experience in clinical oncology with his main research interest focusing on biomarker and molecular targeted therapy in lung cancer. He is currently Li Shu Fan Medical Foundation named professor and chairman of department of clinical oncology at The Chinese University of Hong Kong. Professor Mok has contributed to over 200 articles in international peer-reviewed journals, as well as multiple editorials and textbooks. He is a director of the American Society of Clinical Oncology (ASCO), a member of the ASCO Publications Committee and vice secretary of the Chinese Society of Clinical Oncology (CSCO). He also formerly chaired the ASCO International Affairs Committee. Professor Mok is closely affiliated with the oncology community in China and has been awarded an Honorary Professorship at Guangdong Province People's Hospital, Guest Professorship at Peking University School of Oncology and Visiting Professorship at Shanghai Jiao Tong University and West China School of Medicine/West China Hospital, Sichuan University. He received his

203

Table of Contents

bachelor of medical science degree and a Doctor of Medicine from University of Alberta, Canada. He is also a fellow of the Royal College of Physicians and Surgeons of Canada, Hong Kong College of Physicians, Hong Kong Academy of Medicine, Royal College of Physicians of Edinburgh and ASCO.

Ye Hua has been our senior vice president and head of our clinical development & regulatory affairs group since 2014. He has 19 years' drug development and global new drug registration experience in the pharmaceutical industry, and six years' experience in cancer epidemiology. Prior to joining our company, Dr. Hua was a senior director of global clinical development at Celgene Corporation, a U.S.-based global biopharmaceutical company, from 2011 to 2014. Before joining Celgene, Dr. Hua worked as a medical director at Novartis Pharmaceuticals Corporation for eight years. Dr. Hua received his M.D. from Fudan University Shanghai medical college. He also worked as a cancer epidemiologist at the Shanghai Cancer Institute for four years before attending McGill University where he received a master's degree in cancer epidemiology.

May Wang is our senior vice president of business development & strategic alliances. Prior to joining our company in 2010, Dr. Wang spent 16 years with Eli Lilly where she was the head of Eli Lilly's Asian biology research and responsible for establishing and managing research collaborations in China and across Asia. Dr. Wang holds numerous patents, has published more than 50 peer-reviewed articles and has given dozens of seminars and plenary lectures. Dr. Wang received a Ph.D. in biochemistry from Purdue University.

Zhenping Wu joined our company in 2008 and has been our senior vice president of pharmaceutical sciences since 2012. Dr. Wu has over 25 years of experience in drug discovery and development. His past positions include senior director of pharmaceutical sciences at Phenomix Corporation, a U.S.-based biotechnology company, director of pharmaceutical development at Pfizer Global Research & Development in California (formerly Agouron Pharmaceuticals) and a group leader at Roche at its Palo Alto site. He is a past chairman and president of the board of the Sino-American Biotechnology and Pharmaceutical Association. Dr. Wu received a Ph.D. from the University of Hong Kong and a master in business administration from the University of California at Irvine.

Mark Lee is our senior vice president of corporate finance and development. Prior to joining our company in 2009, he worked in healthcare investment banking in the United States and Europe since 1998. Based in the New York and London offices of Credit Suisse, Mr. Lee was involved in the execution and origination of mergers, acquisitions, public and private financings and corporate strategy for life science companies such as AstraZeneca, Bristol-Myers Squibb and Genzyme, as well as other medical product and service companies. Mr. Lee received his bachelor's degree in biochemical engineering with first class honors from University College London, where he was awarded a Dean's Commendation. He also received a master of business administration from the Massachusetts Institute of Technology's Sloan School of Management.

204

Table of Contents

B. Compensation.

Executive Officer Compensation

Summary Compensation Table

The following table sets forth the compensation paid or accrued during the fiscal year ended December 31, 2017 to our chief executive officer, chief financial officer, chief scientific officer and other executive officers on an aggregate basis.

Name and Principal Position

Christian Hogg Chief Executive Officer and Executive Director	431,862	⁽¹⁾⁽²⁾	769,231		15,768	26,748	1,243,609
Johnny Cheng Chief Financial Officer and Executive Director	347,758	⁽³⁾	284,872		—	24,086	656,716
Weiguo Su Chief Scientific Officer and Executive Director	310,296	⁽⁴⁾	1,222,071	⁽⁵⁾	10,000	21,132	1,563,499
Other Executive Officers in the Aggregate	980,912		1,536,307	⁽⁶⁾	15,291	68,450	2,600,960

(1): Director's fees received from the subsidiaries of the Company during the period he served as director that were paid to a subsidiary or an intermediate holding company of the Company are not included in the amounts above.
(2): Amount includes director's fees of $75,000.
(3): Amount includes director's fees of $70,000.
(4): Amount includes director's fees of $57,534.
(5): Amount includes a $651,273 year-end bonus and a $570,798 cash retention bonus (see footnote (6) below).
(6): In December 2013 and March 2014, we awarded cash retention bonuses to certain of our executive officers in the aggregate amount of $2,977,751. Each such executive officer receives portions of his or her retention bonus upon certain dates in the future depending on when the bonus was granted and, in each case, assuming he or she remains employed by our company on such future dates. An aggregate amount of $848,477 of such retention bonuses was paid in 2015, an aggregate amount of $640,399 was paid in 2016, and another aggregate amount of $1,088,876 was paid in 2017, and such paid amount in 2017 is included in the bonus amount stated in the table above.

During the fiscal year ended December 31, 2017, we also granted share option awards representing 100,000 ordinary shares to Dr. Weiguo Su. The options have an exercise price of £31.05 ($41.61) per share and expire on March 26, 2027. During the fiscal year ended December 31, 2017, we also granted executive officers awards under our long term incentive scheme, or LTIP, giving them a conditional right to receive ordinary shares or ADSs to be purchased by an independent third-party trustee up to a certain maximum cash amount of $5,669,348 in the aggregate. See "Long Term Incentive Compensation" and "Outstanding Awards" for more details.

Employment Arrangements with our Executive Officers

Offer Letters for Executive Officers at Hutchison China MediTech Limited and Hutchison MediPharma (Hong Kong) Limited

We have entered into employment offer letters with each of our executive officers who is employed by our Hong Kong subsidiaries, Hutchison China MediTech (HK) Limited and Hutchison MediPharma (Hong Kong) Limited, namely Mr. Christian Hogg, Mr. Johnny Cheng and Mr. Mark Lee. Under these

205

Table of Contents

our executives receive compensation in the form of salaries, discretionary bonuses, participation in the Hutchison Provident Fund retirement scheme, medical coverage under the Hutchison Group Medical Scheme, personal accident insurance and annual leave. None of the employment arrangements provide benefits to our executive officers upon termination. We may terminate employment by giving the executive three months' prior written notice. The executive officer may also voluntarily terminate his employment with us upon not less than three months' prior written notice to us.

Each executive officer has agreed, for the term of employment with us and thereafter, not to disclose or use for his own purposes any of our and our associated companies' confidential information that the executive officer may develop or learn in the course of employment with us. Moreover, each of our executive officers has agreed, for the term of employment with us and for a period of twelve months thereafter, (i) not to undertake or be employed or interested directly or indirectly anywhere in Hong Kong in any activity which is similar to and competitive with our company or associated companies in which the executive officer had been involved in the period of 12 months prior to such termination and (ii) not to solicit for any employees of our company or our joint ventures or orders from any person, firm or company which was at any time during the 12 months prior to termination of such employment a customer or supplier of our company or associated companies.

Employment Agreements with Executive Officers at Hutchison MediPharma

We have also entered into employment agreements with each of our executive officers who are employed directly by Hutchison MediPharma, namely Dr. Weiguo Su, Dr. Ye Hua, Dr. May Wang and Dr. Zhenping Wu. Under these employment agreements, we engage the executive officer on either an open-ended or a fixed term. Our executive officers receive compensation in the form of salaries, discretionary bonuses, annual leave, statutory maternity leave and nursing leave.

Under the terms of these agreements, we provide labor protection and work conditions that comply with the safety and sanitation requirements stipulated by the relevant PRC laws. The employment agreements prohibit the executive officers from engaging in any conduct and business activities which may compete with the business or interests of Hutchison MediPharma during the term of the executive officer's employment. These executive officers also enjoy the Hutchison Provident Fund retirement scheme, medical coverage under the Hutchison Group Medical Scheme and personal accident insurance.

We may terminate an executive officer's employment for cause at any time without notice. Termination for cause may include a serious breach of our internal rules and policies, serious negligence in the executive officer's performance of his or her duties, an accusation or conviction of a criminal offence, acquisition of another job which materially affects the executive officer's ability to perform his or her duties for our company and other circumstances stipulated by applicable PRC laws. We may terminate an executive officer's employment with three months' prior notice if the executive officer is unable to perform his or her duties (after the expiration of the prescribed medical treatment period) because of an illness or non-work-related injury or the executive officer is incompetent and remains incompetent after training or adjustment of his or her position. The executive officer may voluntarily terminate his or her contract without cause with three months' prior notice. The executive officer may also terminate the employment agreement immediately for cause, which includes a failure by us to provide labor protection and the work conditions as specified under the employment agreement. In case of termination for any reason, we agree to make any mandatory severance payments required by the relevant PRC labor laws.

206

Table of Contents

Share Options

The following table sets forth information concerning the outstanding equity awards held by our chief executive officer, chief financial officer, chief scientific officer and other executive officers on an aggregate basis as of December 31, 2017.

Name and Principal Position

Christian Hogg	—	—	—	—
Chief Executive Officer and Executive Director
Johnny Cheng	—	—	—	—
Chief Financial Officer and Executive Director
Weiguo Su	300,000	—	19.70	Dec. 19, 2023
Chief Scientific Officer and Executive Director	—	100,000	31.05	Mar. 26, 2027
Other Executive Officers in the Aggregate	293,686	—	19.70	Dec. 19, 2023
	75,000	25,000	19.70	Jun. 27, 2024
	—	50,000	31.05	Mar. 26, 2027

Long-Term Incentive Compensation

The following table sets forth information concerning the outstanding LTIP grants held by our chief executive officer, chief financial officer, chief scientific officer and other executive officers on an aggregate basis as of December 31, 2017.

Name and Principal Position	Maximum Aggregate Value of LTIP awards⁽¹⁾

Christian Hogg	$	1,817,884
Chief Executive Officer and Executive Director
Johnny Cheng	$	690,639
Chief Financial Officer and Executive Director
Weiguo Su	$	1,188,995
Chief Scientific Officer and Executive Director
Other Executive Officers in the Aggregate	$	1,971,830

(1): The amounts reflected in the table above represent the maximum aggregate value of all LTIP awards outstanding as of December 31, 2017, which include LTIP awards for the fiscal years 2015 to 2019. Certain of the LTIP awards are conditional upon the achievement of annual performance targets for the fiscal years 2017, 2018 and 2019. The amounts reflected in the table above assume the maximum amount that may be paid under these contingent LTIP awards. The LTIP awards will be settled in a variable number of shares based on a fixed monetary amount awarded upon achievement of performance targets or upon vesting, as applicable. An independent third-party trustee who administers the LTIP purchased shares of Chi-Med on either the AIM and Nasdaq market which will be used to settle the LTIP awards. See "Outstanding Awards" for more details.

207

Table of Contents

Director Compensation

The following table sets forth a summary of the compensation we paid to our directors other than Christian Hogg, Johnny Cheng and Weiguo Su during 2017. Other than as set forth in the table below, we did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to such directors.

Name of Director

Simon To	85,000	⁽¹⁾	—	—	85,000
Dan Eldar	70,000		—	—	70,000
Edith Shih	70,000	⁽²⁾	—	—	70,000
Paul Carter⁽³⁾	102,667		—	—	102,667
Karen Ferrante⁽³⁾	93,958		—	—	93,958
Graeme Jack⁽⁴⁾	86,667		—	—	86,667
Tony Mok⁽⁵⁾	18,641		—	—	18,641
Christopher Huang⁽⁶⁾	7,291		—	—	7,291
Christopher Nash⁽⁶⁾	6,875		—	—	6,875
Shigeru Endo⁽⁶⁾	5,833	⁽⁷⁾	—	—	5,833
Michael Howell⁽⁸⁾	15,000		—	—	15,000

(1): Such director's fees were paid to Hutchison Whampoa (China) Limited, a wholly owned subsidiary of CK Hutchison. Director's fees received from our subsidiaries during the period he served as director that were paid to a subsidiary or an intermediate holding company of our company are not included in the amounts above.
(2): Such director's fees were paid to Hutchison International Limited, a wholly owned subsidiary of CK Hutchison. Director's fees received from our subsidiaries during the period she served as director that were paid to a subsidiary or an intermediate holding company of our company are not included in the amounts above.
(3): Appointed on February 1, 2017.
(4): Appointed on March 1, 2017.
(5): Appointed on October 12, 2017.
(6): Ceased to be a director as of February 1, 2017.
(7): Such director's fees were paid to Hutchison International Limited, a wholly owned subsidiary of CK Hutchison.
(8): Ceased to be a director as of March 1, 2017.

Equity Compensation Schemes and Other Benefit Plans

We have two share option schemes. We refer to these collectively as the Chi-Med Option Schemes. Our shareholder adopted the first Chi-Med Option Scheme, or the 2005 Chi-Med Option Scheme, in June 2005, and it was subsequently approved by the shareholders of Hutchison Whampoa Limited, our then majority shareholder, in May 2006 and later amended by our board of directors in March 2007. This share option scheme expired in 2016. In April 2015, our shareholders adopted the second Chi-Med Option Scheme, or the 2015 Chi-Med Option Scheme, which was later approved by the shareholders of CK Hutchison, the ultimate parent of our majority shareholder, in May 2016.

We also have a long-term incentive scheme which was adopted by our shareholders in April 2015. We refer to this as our LTIP.

208

Table of Contents

In addition, our subsidiary Hutchison MediPharma Holdings has two share option schemes. We refer to these collectively as the Hutchison MediPharma Option Schemes. The first Hutchison MediPharma Option Scheme, or the 2008 Hutchison MediPharma Option Scheme, was adopted in August 2008 upon approval by its shareholder. The 2008 Hutchison MediPharma Option Scheme was thereafter amended by the board of directors of Hutchison MediPharma Holdings in April 2011 and expired in 2014. The second Hutchison MediPharma Option Scheme, or the 2014 Hutchison MediPharma Option Scheme, was adopted in December 2014 upon approval by its shareholders.

Our Chi-Med Option Schemes, our LTIP and the 2014 Hutchison MediPharma Option Scheme each terminate on the tenth anniversary of their adoption. Each may also be terminated by its board of directors at any time. Any termination of the scheme is without prejudice to the awards outstanding at such time. Options are no longer being granted under the 2005 Chi-Med Option Scheme or the 2008 Hutchison MediPharma Option Scheme, but outstanding awards under the 2005 Chi-Med Option Scheme continue to be governed by the terms thereof.

The following describes the material terms of our Chi-Med Option Schemes, our LTIP and the Hutchison MediPharma Option Schemes, or collectively the Schemes.

Awards and Eligible Grantees. The Schemes provide for the award of share options exercisable for ordinary shares of our company (in the case of the Chi-Med Option Schemes) or ordinary shares of Hutchison MediPharma Holdings (in the case of the Hutchison MediPharma Option Schemes) to Eligible Employees (as defined in the Chi-Med Option Schemes) or non-executive directors (excluding any independent non-executive directors under the Chi-Med Option Schemes).

Under our LTIP, awards in the form of contingent rights to receive either shares or cash payments may be granted to the directors of our company, directors of our subsidiaries and employees of our company, subsidiaries, affiliates or such other companies as determined by our board of directors in its absolute discretion.

Scheme Administration. Our board of directors has delegated its authority for administering our Chi-Med Option Schemes and our LTIP to our remuneration committee. The board of directors of Hutchison MediPharma Holdings is responsible for administering the Hutchison MediPharma Option Schemes. Each such plan administrator has the authority to, among other things, select participants and determine the amount and terms and conditions of the awards under the applicable Schemes as it deems necessary and proper, subject to the restrictions described in "—Restrictions on Grants" below.

Restrictions on Grants. Under the Chi-Med Option Schemes, grants may not be made to independent non-executive directors. Furthermore, those grants may not be made to any of our employees or directors if such person is also a director, chief executive or substantial shareholder of any of our direct or indirect parent companies which is listed on a stock exchange, including CK Hutchison, or any of its associates without approval by the independent non-executive directors of such parent company (excluding any independent non-executive director who is a proposed grantee). In addition, approval by our shareholders and the shareholders of such listed parent company is required if an option grant under the Chi-Med Option Schemes is to be made to a substantial shareholder or independent non-executive director of a listed parent company or any of its associates and, upon exercise of such grant and any other grants made during the prior 12-month period to that shareholder, that individual would receive an amount of our ordinary shares equal or greater than 0.1% of our total outstanding shares or with an aggregate value in excess of HK$5 million (equivalent to $0.6 million as of December 31, 2017). The Hutchison MediPharma Option Schemes do not contain these restrictions.

In addition, options under our Chi-Med Option Schemes and the Hutchison MediPharma Option Schemes may not be granted to any individual if, upon the exercise of such options, the individual would receive an amount of shares when aggregated with all other options granted to such individual under the applicable Scheme in the 12-month period up to and including the grant date, that exceeds 1% of the total

209

Table of Contents

shares outstanding of the company granting the award on such date. In the event a grant of share options would exceed 1% of the total number of issued shares of Hutchison MediPharma Holdings, our company must also approve the grant. There are no individual limits under the LTIP.

Under our LTIP, no grant to any director, chief executive or substantial shareholder of our company may be made without the prior approval of our independent non-executive directors (excluding an independent non-executive director who is a proposed grantee).

Vesting. Vesting conditions of options granted under the Schemes are determined by the respective board of directors at the time of grant. Any options granted are normally exercisable to the extent vested within the period specified by the applicable Scheme, which ranges from six to ten years after the date of grant.

Under the Chi-Med Share Option Schemes and the Hutchison MediPharma Option Schemes, if a participant has committed any misconduct or any conduct making such participant's service terminable for cause, all options (whether vested or unvested) lapse unless the respective board of directors otherwise determines in its absolute discretion. Options may be exercised to the extent vested where a participant's service ceases due to the participant's death, serious illness, injury, disability, retirement at the applicable retirement age, or earlier if determined by the participant's employer, or if a participant's service ceases for any other reason other than for cause.

Under the LTIP, if a participant's employment or service with our company or its subsidiaries is terminated for cause or if the participant breaches certain provisions in the LTIP restricting the transfer of awards by grantees and imposing non-competition obligations on grantees, all unvested awards are automatically cancelled. Where a participant's employment or service ceases for any reason other the reasons listed above (including due to the participant's resignation, retirement, death or disability or upon the non-renewal of such participant's employment or service agreement other than for cause), our board of directors may determine at its discretion whether unvested awards shall be deemed vested.

Exercise Price. The exercise price for each share pursuant to the initial options granted under the 2005 Chi-Med Option Scheme was a price determined by our board of directors at the date of grant, and for grants made thereafter, the exercise price was the Market Value of a share at the date of grant (as defined in the Chi-Med Option Schemes). The exercise price for each share pursuant to options granted under our 2008 Hutchison MediPharma Option Scheme was a price determined by the board of directors of Hutchison MediPharma Holdings.

The exercise price for each share pursuant to the options granted under the 2015 Chi-Med Option Scheme must be the Market Value of a share at the date of grant (as defined in the Chi-Med Option Schemes). The exercise price for each share pursuant to options granted under the 2014 Hutchison MediPharma Option Scheme will be determined by the boards of directors of Hutchison MediPharma Holdings at the date of grant.

Non-transferability of Awards. Awards may not be transferred except in the case of a participant's death by the terms of each Scheme.

Takeover or Scheme of Arrangement. In the event of a general or partial offer for the shares of our company (under the Chi-Med Option Schemes) or Hutchison MediPharma Holdings (under the Hutchison MediPharma Option Schemes), whether by way of takeover, offer, share repurchase offer, or scheme of arrangement, the affected company is required to use all reasonable endeavors to procure that such offer is extended to all holders of options granted by such company on the same terms as those applying to shareholders. Both vested and unvested options may be exercised up until (i) the closing date of any such offer, (ii) the record date for entitlements under a scheme of arrangement, or (iii) two business days prior to any general meeting of members convened to consider such offer (under the 2014 Hutchison

210

Table of Contents

MediPharma Option Scheme), and will lapse thereafter. Certain options may also be exercised on a voluntary winding up of our company or Hutchison MediPharma Holdings, as the case may be.

Under our LTIP, in the event of a general offer for all the shares of our company, whether by way of takeover or scheme of arrangement, or if our company is to be voluntarily wound up, our board of directors shall determine in its discretion whether outstanding unvested awards will vest and the period within which such awards will vest.

Amendment. The Chi-Med Option Schemes require that amendments of a material nature only be made with the approval of our shareholders and approval of any of our direct or indirect parent companies which is listed on a stock exchange, including CK Hutchison. The Hutchison MediPharma Option Schemes may be altered by the board of directors of our company or Hutchison MediPharma Holdings, as the case may be, but any amendments which provide a material advantage to grantees cannot take effect without shareholders' approval.

Our board of directors may alter the LTIP, but amendments which are of a material nature cannot take effect without shareholders' approval, unless the changes take effect automatically under the terms of the LTIP.

Authorized Shares. Subject to certain adjustments for share splits, share consolidations and other changes in capitalization, the maximum number of shares that may be issued upon exercise of all options granted may not in the aggregate exceed: (i) 4% of our shares outstanding on the date of adoption of the 2015 Chi-Med Option Scheme or (ii) 5% of the shares of Hutchison MediPharma Holdings outstanding on the date of adoption under the 2014 Hutchison MediPharma Option Scheme. In addition, under our 2015 Chi-Med Option Scheme, our board of directors may, with the approval of the shareholders of any of our direct or indirect parent companies which is listed on a stock exchange, including CK Hutchison, "refresh" the 4% scheme limit provided that the total number of shares which may be issued upon exercise of all options to be granted under the Chi-Med Option Schemes shall not exceed 10% of our total shares outstanding on such date. Further, the maximum number of shares that may be issued upon exercise of all options granted and not yet exercised under the 2015 Chi-Med Option Scheme, when combined with options granted and not yet exercised under any other schemes of our company or our subsidiaries must not exceed 10% of our shares outstanding on such date.

Share awards under our LTIP may not exceed 5% of our shares outstanding on the adoption date of the LTIP.

Outstanding Awards

As of December 31, 2017, the following options were outstanding:

•: options to purchase an aggregate of 282,726 ordinary shares, representing approximately 0.4% of our outstanding share capital, at a weighted average exercise price of £5.65 per share under the 2005 Chi-Med Option Scheme, and
•: options to purchase an aggregate of 843,686 ordinary shares, representing approximately 1.3% of the outstanding share capital, at a weighted average exercise price of £21.72 per share under the 2015 Chi-Med Option Scheme.

In March 2017, we granted awards under our LTIP to 89 senior managers, executives and directors, giving each a conditional right to receive ordinary shares to be purchased by an independent third-party trustee up to a certain maximum cash amount of $5,919,545 per annum depending upon the achievement of annual performance targets from 2017 to 2019. Any ordinary shares purchased on behalf of an LTIP grantee are to be held by the trustee until they are vested. Vesting will occur two business days after the date of announcement of the annual results for the financial year falling two years after the financial year

211

Table of Contents

to which the LTIP award relates. Vesting will also depend upon the continued employment of the award holder and will otherwise be at the discretion of our board of directors.

In March 2017, we also granted additional LTIP awards to 31 senior managers, executives and directors, giving them a conditional right to receive ordinary shares to be purchased by the third-party trustee up to an aggregate maximum cash amount of $353,243. These awards are not related to the achievement of performance targets. These LTIP awards vest after one year, subject to the continued employment of the LTIP holder.

In August 2017, we granted awards under our LTIP to two senior executives, giving each a conditional right to a cash amount which is used to purchase shares by an independent third-party trustee up to a certain maximum cash amount of $64,827 per annum depending upon the achievement of annual performance targets from 2017 to 2019. Vesting will occur two business days after the date of announcement of the annual results for the financial year falling two years after the financial year to which the LTIP award relates.

In December 2017, we granted awards under our LTIP to ten senior executives, giving each a conditional right to a cash amount which is used to purchase ordinary shares by an independent third-party trustee up to a certain maximum cash amount of $529,477 per annum depending upon the achievement of annual performance targets from 2018 to 2019. Vesting will occur two business days after the date of announcement of the annual results for the financial year falling two years after the financial year to which the LTIP award relates.

C. Board Practices.

Our board of directors consists of ten directors including four executive directors, two non-executive directors and four independent non-executive directors. Pursuant to a relationship agreement dated April 21, 2006 by and between our company and Hutchison Whampoa (China) Limited, a parent company of Hutchison Healthcare Holdings Limited, or the Relationship Agreement, our board of directors must consist of at least one director who is independent of the Hutchison Whampoa Limited group so long as Hutchison Whampoa (China) Limited is entitled to cast at least 50% votes eligible to be cast on a poll vote at a general meeting of our company. The Relationship Agreement will continue in effect until our ordinary shares cease to be traded on the AIM market or the CK Hutchison group individually or collectively ceases to hold at least 30% of our shares.

Our directors are subject to a three-year term of office and hold office until such time as they wish to retire and not offer themselves up for re-election, are not re-elected by the shareholders, or are removed from office by special resolution at an annual general meeting of the shareholders. Under our articles of association, a director will be removed from office automatically if, among other things, the director (i) becomes bankrupt or makes any arrangement or composition with his creditors; or (ii) is found to be or becomes of unsound mind. For information regarding the period during which our officers and directors have served in their respective positions, please see Item 6.A. "Directors and Senior Management."

Board Committees

Our board of directors has established an audit committee, a remuneration committee and a technical committee.

Audit Committee

212

Table of Contents

each meet the independence requirements under the rules of the Nasdaq Stock Market and under Rule 10A-3 under the Exchange Act. We have determined that Graeme Jack is an "audit committee financial expert" within the meaning of Item 407 of Regulation S-K. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq Stock Market.

Although we are a foreign private issuer, we are required to comply with Rule 10A-3 of the Exchange Act, relating to audit committee composition and responsibilities. Rule 10A-3 provides that the audit committee must have direct responsibility for the nomination, compensation and choice of our auditor, as well as control over the performance of their duties, management of complaints made, and selection of consultants. Under Rule 10A-3, if the governing law or documents, of a listed issuer require that any such matter be approved by the board of directors or the shareholders of the company, the audit committee's responsibilities or powers with respect to such matter may instead be advisory. Our articles of association provide that the audit committee may only have an advisory role and appointment of our auditor must be decided by our shareholders at our annual general meeting or at a subsequent extraordinary general meeting in each year.

The audit committee formally meets at least twice a year and otherwise as required. The audit committee's purpose is to oversee our accounting and financial reporting process and the audit of our financial statements. Our audit committee's primary duties and responsibilities are to:

•

monitor the integrity of our financial statements, our annual and half-year reports and accounts and our announcements of interim or final results;

•

review significant financial reporting issues and the judgments which they contain;

•

review, whenever practicable without being inconsistent with any requirement for prompt reporting under applicable listing rules, other statements containing financial information such as significant financial returns to regulators and release of price sensitive information first where board of director approval is required; and

•

review and challenge where necessary:

•: the consistency of, and any changes to, accounting policies both on a year-on-year basis and across our company;
•: the methods used to account for significant or unusual transactions where different approaches are possible;
•: whether our company has followed appropriate accounting standards and made appropriate estimates and judgments, taking into account the views of the external auditor;
•: the clarity of the disclosure in our financial reports and the context in which statements are made; and
•: all material information presented with the financial statements, such as any operating and financial review and any corporate governance statements (insofar as it relates to the audit and risk management).

In relation to our internal controls and risk management systems, our audit committee, among other things:

•: reviews the effectiveness of our internal control and risk management systems;
•: reviews the policies and procedures for the identification, assessment and reporting of financial and non-financial risks and our management of those risks in accordance with the requirements of the Sarbanes-Oxley Act and other applicable laws, rules and regulations and the applicable requirements of any stock exchange;

213

Table of Contents

•: approves the appointment and removal of the head of the internal audit function;
•: ensures our internal audit function has adequate standing and resources and is free from management or other restrictions;
•: reviews and monitors our executive management's responsiveness to the findings and recommendations of the internal audit function; and
•: reviews with management and our independent auditors the adequacy and effectiveness of our internal control over financial reporting and disclosure controls and procedures.

In relation to our external auditor, our audit committee, among other things:

•: recommends the appointment, reappointment or removal of the external auditor and considers any issues relating to their resignation, dismissal, remuneration or terms of engagement, subject to approval by the shareholders;
•: considers and monitors the external auditor's independence, objectivity and effectiveness;
•: reviews and monitors the effectiveness of the audit process, considering relevant ethical or professional requirements;
•: develops and implements policy on the engagement of the external auditor to provide non-audit services, taking into any relevant ethical guidance; and
•: pre-approves the external auditors' annual audit fees and the nature and scope of proposed audit coverage, subject to approval by our shareholders.

The audit committee is authorized to obtain, at our company's expense, reasonable outside legal or other professional advice on any matters within the scope of its responsibilities.

Remuneration Committee

Our remuneration committee consists of Simon To, Graeme Jack and Paul Carter, with Simon To serving as chairman of the committee. Michael Howell and Christopher Nash previously served on our remuneration committee until they resigned from our board of directors on March 1, 2017 and February 1, 2017, respectively. The remuneration committee is responsible for considering all material elements of remuneration policy and remuneration and incentives of our executive directors and key employees with reference to independent remuneration research and professional advice. The remuneration committee meets formally at least once each year and otherwise as required and make recommendations to our board of directors on the framework for executive remuneration and on proposals for the granting of share options and other equity incentives. Our board of directors is responsible for implementing these recommendations and agreeing the remuneration packages of individual directors. No director is permitted to participate in discussions or decisions concerning his or her own remuneration.

Technical Committee

Our technical committee consists of Karen Ferrante, Paul Carter, Tony Mok, Simon To, Christian Hogg and Weiguo Su, with Karen Ferrante serving as chairman of the committee. Christopher Huang previously served as chairman and member of our technical committee until he resigned from our board of directors on February 1, 2017. The technical committee's responsibility is to consider, from time to time, matters relating to the technical aspects of the research and development activities of our Innovation Platform. It invites such executives as it deems appropriate to participate in meetings from time to time.

214

Table of Contents

U.K. Corporate Governance Code

We have voluntarily applied, and plan to continue to apply for the foreseeable future, the principles of the U.K. Corporate Governance Code published by the U.K. Financial Reporting Council. The U.K. Corporate Governance Code is the primary source of corporate governance standards for companies in the United Kingdom, and it is recognized as a best practice for companies whose shares are admitted to trading on the AIM market of the London Stock Exchange.

The U.K. Corporate Governance Code is comprised of main and supporting principles of good governance addressing the following areas: director practices, directors' remuneration, accountability and audit and relations with shareholders and institutional investors. It also includes detailed recommendations derived from these principles, such as: the roles of board chairman and chief executive officer should not be exercised by the same individual and the chairman of the board should ensure that new directors receive a full, formal and tailored induction on joining the board.

Except for general fiduciary duties and duties of care, Cayman Islands law has no specific corporate governance regime which prescribes specific corporate governance standards on our directors. See Item 16G. "Corporate Governance" for a discussion of such Cayman Islands law requirements applicable to our company.

Code of Ethics

Our board of directors has adopted a code of ethics to set standards for our directors, officers and employees as are reasonably necessary to promote (i) honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; (ii) full, fair, accurate, timely and understandable disclosure in the reports and documents that we file or submit to the applicable stock exchanges, and in any other public communications; (iii) compliance with applicable governmental and regulatory laws, rules, codes and regulations; (iv) prompt internal reporting of any violations of the code of ethics; and (v) accountability for adherence to the code of ethics.

Code of Ethics for Business Partners

Our board of directors has adopted a code of ethics for our business partners, including our suppliers, vendors, customers, agents, contractors, joint venture partners and representatives. This code of ethics contains general guidelines to promote the standards outlined in our internal code of ethics as described above.

Complaints Procedures

Our board of directors has adopted procedures for the confidential receipt, retention, and treatment of complaints from, or concerns raised by, employees regarding accounting, internal accounting controls and auditing matters as well as illegal or unethical matters. The complaint procedures are reviewed by the audit committee from time to time as warranted to ensure their continuing compliance with applicable laws and listing standards as well as their effectiveness.

Information Security Policy

Our board of directors has adopted an information security policy to define and help communicate the common policies for information confidentiality, integrity and availability to be applied to us and our joint ventures. The purpose of the information security policy is to ensure business continuity by preventing and minimizing the impact of security risks within our company and our joint ventures. Our information security policy applies to all of our and our joint ventures' business entities across all countries. It applies to the creation, communication, storage, transmission and destruction of all different types of information. It applies to all forms of information, including but not limited to electronic copies, hardcopy, and verbal disclosures whether in person, over the telephone, or by other means.

215

Table of Contents

Code on Dealings in Shares

Our board of directors has adopted a policy on the handling of material inside information, consisting of information which is either "inside information" under the EU Market Abuse Regulation (Regulation (EU) 596/2014), or MAR, or "material non-public information" under U.S. law. This policy, among other things, prohibits any employees, directors, other persons discharging managerial responsibilities or their connected persons dealing in our securities or their derivatives, or those of our collaborators, business partners, suppliers and customers, while in possession of material inside information. Certain members of our senior management or staff, including persons discharging managerial responsibilities, and their connected persons are subject to additional compliance requirements which are outlined in the code (including but not limited to obtaining written pre-clearance from designated members of management prior to any dealing in any such securities is allowed).

Board Diversity Policy

Our board of directors has established a board diversity policy as our board of directors recognizes the benefits of a board of directors that possesses a balance of skills, experience, expertise, independence and knowledge and diversity of perspectives appropriate to the requirements of our businesses.

We maintain that appointment to our board of directors should be based on merit that complements and expands the skills, experience, expertise, independence and knowledge of the board of directors as a whole, taking into account gender, age, professional experience and qualifications, cultural and educational background, and any other factors that our board of directors might consider relevant and applicable from time to time towards achieving a diverse board of directors.

D. Employees.

As of December 31, 2015, 2016 and 2017, we had 451, 563 and 590 full-time employees, respectively. None of our employees are represented by labor unions or covered by collective bargaining agreements. The number of employees by function as of the end of the period for our fiscal years ended December 31, 2015, 2016 and 2017 was as follows:



By Function:
Innovation Platform	358	329	281
Commercial Platform	205	209	149
Corporate Head Office	27	25	21

Total	590	563	451

As of December 31, 2017, a total of 75 employees on our Innovation Platform's research and development team have M.D. or Ph.D. degrees. Additionally, our Commercial Platform joint venture Shanghai Hutchison Pharmaceuticals employed a total of 2,911 full-time employees, and Hutchison Baiyunshan employed a total of 1,711 full-time employees and 1,688 outsourced contract staff, who are mostly sales representatives and manufacturing employees as of December 31, 2017. Their employees are represented by labor unions and covered by collective bargaining agreements. To date, neither Shanghai Hutchison Pharmaceuticals nor Hutchison Baiyunshan has experienced any strikes, labor disputes or industrial actions which had a material effect on their business, and consider their relations with the union and our employees to be good.

E. Share Ownership.

See Item 6 B. "Compensation" and Item 7 "Major Shareholders and Related Party Transactions."

216

Table of Contents

ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

A. Major Shareholders.

We had 66,447,037 ordinary shares outstanding as of December 31, 2017. The following table and accompanying footnotes set forth information relating to the beneficial ownership of our ordinary shares as of December 31, 2017 by:

•: each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding ordinary shares;
•: each of our directors; and
•: each of our named executive officers.

Our major shareholders do not have voting rights that are different from our shareholders in general. Beneficial ownership is determined in accordance with the rules and regulations of the SEC.

Name of beneficial owner

Executive Officers and Directors:**
Christian Hogg	1,093,802		40,356	1.7%
Johnny Cheng	256,146		4,626	*
Simon To	180,000		133,237	*
Edith Shih	70,000		100,000	*
Weiguo Su	300,000	⁽¹⁾	56,546	*
Dan Eldar	1,900		6,225	*
Tony Mok	—		10,002	*
Paul Carter	3,524		—	*
Karen Ferrante	—		5,785	*
Graeme Jack	—		—	—
Ye Hua	*		*	*
May Wang	*		*	*
Zhenping Wu	*		*	*
Mark Lee	*		*	*
All Executive Officers and Directors as a Group	2,280,665	⁽²⁾	364,665	3.7%
Principal Shareholder:
Hutchison Healthcare Holdings Limited⁽³⁾	36,666,667		6,862,420	60.4%

*: Less than 1% of our total outstanding ordinary shares.
**: The business address of all the directors and officers is Room 2108, 21/F, Hutchison House, 10 Harcourt Road, Hong Kong.
†: Percentage of beneficial ownership of each listed person or group is based on 66,447,037 ordinary shares outstanding as of December 31, 2017.
(1): Amount includes ordinary shares issuable upon vesting of options within 60 days of December 31, 2017.
(2): Amount includes ordinary shares and ordinary shares issuable upon vesting of options within 60 days of December 31, 2017 held by our executive officers and directors as group.
(3): Hutchison Healthcare Holdings Limited, a British Virgin Islands company, is an indirect wholly owned subsidiary of CK Hutchison, a company incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange. The registered address of Hutchison Healthcare Holdings Limited is

217

Table of Contents

Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola VG1110, British Virgin Islands.

As of December 31, 2017, based on public filings with the SEC and on AIM, there are no major shareholders holding 5% or more of our ordinary shares or ADSs representing ordinary shares, except as described above. As of December 31, 2017, there was one ordinary shareholder of record with an address in the United States. Deutsche Bank Trust Company America, the depositary of our ADS program, held 11,708,338 ordinary shares as of that date in the name of DB London (Investors Services) Nominees Limited and Deutsche Bank AG.

To our knowledge, except as disclosed above, we are not owned or controlled, directly or indirectly, by another corporation, by any foreign government or by any other natural or legal person or persons, severally or jointly. To our knowledge, there are no arrangements the operation of which may at a subsequent date result in us undergoing a change in control. Our major shareholders do not have different voting rights than any of our other shareholders.

B. Related Party Transactions.

Relationship with CK Hutchison

Letters of awareness with respect to loans

CK Hutchison has issued letters of awareness to our lenders Scotiabank (Hong Kong) Limited, Bank of America N.A. and Deutsche Bank AG, Hong Kong Branch, and committed not to reduce its shareholding to less than 40% of our issued share capital while such loans are outstanding. Hutchison Whampoa Limited, a wholly owned subsidiary of CK Hutchison, guaranteed our previous term loan with Scotiabank until such loan was fully repaid in November 2017. For the year ended December 31, 2017, we paid a guarantee fee of $0.3 million to Hutchison Whampoa Limited.

See Item 3.D. "Risk Factors—Risks Related to Our Financial Position and Need for Additional Capital—If the CK Hutchison group ceases to own a majority stake in our company, we may incur significantly higher borrowing costs."

Relationship Agreement with the CK Hutchison group

We entered into a relationship agreement dated April 21, 2006 with Hutchison Whampoa (China) Limited, which is an indirect wholly owned subsidiary of CK Hutchison, with a view to ensuring that our company is capable of carrying on its business independently of the CK Hutchison group. We refer to this agreement as the Relationship Agreement. The Relationship Agreement provides, among other things, that all transactions between any of us or our joint ventures, on the one hand, and the CK Hutchison group, on the other hand, will be on an arm's length basis, on normal commercial terms and in a manner consistent with the AIM Rules. Hutchison Whampoa (China) Limited has agreed that, so long as it holds shares (either directly or indirectly) which in aggregate entitle Hutchison Whampoa (China) Limited to cast at least 50% of the votes eligible to be cast on a poll vote at a general meeting of our company, it shall procure (so far as it is able to use its power as a shareholder) that at least one member of our board of directors is independent of the CK Hutchison group. The Relationship Agreement further provides that the approval of our board of directors shall be required for any transaction between any of us or our joint ventures, on one hand, and the CK Hutchison group, on the other hand, and that in approving any such transaction, our board of directors must consist of at least one director who is independent of CK Hutchison. Hutchison Whampoa (China) Limited has also agreed to procure that each member of the Hutchison Whampoa (China) Limited group will not exercise its voting rights and powers so as to amend our memorandum or articles of association in a manner which is inconsistent with the Relationship Agreement. The Relationship Agreement will continue until the first to occur of: (i) our shares ceasing to

218

Table of Contents

be traded on the AIM market or (ii) the CK Hutchison group individually or collectively cease to hold or control the exercise of at least 30% or more of the rights to vote at our general meetings.

Products sold to group companies of CK Hutchison

We have entered into agreements with members of the CK Hutchison group, including the retail grocery and pharmacy chains PARKnSHOP and Watsons which are owned and operated by the A.S. Watson Group, an indirect subsidiary of CK Hutchison, in respect of the distribution of certain of our Commercial Platform products. For the year ended December 31, 2017, sales of our products to members of the CK Hutchison group amounted to $8.5 million. In addition, for the year ended December 31, 2017, we paid approximately $0.4 million to members of the CK Hutchison group for the provision of marketing services associated with these products. Our sales to CK Hutchison group companies are made pursuant to purchase orders issued by each purchaser periodically, the terms of which are on an arm's length basis on normal commercial terms.

See Item 3.D. "Risk Factors—Risks Related to our Dependence on Third Parties—There is no assurance that the benefits currently enjoyed by virtue of our association with CK Hutchison will continue to be available" for more information on the risks associated with our relationship with CK Hutchison's group companies.

Intellectual property licensed by the CK Hutchison group

We conduct our business using trademarks with various forms of the "Hutchison," "Chi-Med" and "China-MediTech" brands, as well as domain names incorporating some or all of these trademarks. We have entered into a brand license agreement dated April 21, 2006 with Hutchison Whampoa Enterprises Limited, which is an indirect wholly owned subsidiary of CK Hutchison, pursuant to which we have been granted a non-exclusive, non-transferrable, royalty-free right to use such trademarks, domain names and other intellectual property rights owned by the CK Hutchison group in connection with the operation of our business worldwide. We refer to this agreement as the Brand License Agreement. We are also permitted to sub-license such intellectual property rights to our affiliates.

The Brand License Agreement contains provisions on quality control pursuant to which we are obliged to use the brands and related materials in compliance with the brand guidelines, industry best practice and other quality directives issued by Hutchison Whampoa Enterprises Limited from time to time. Under this agreement, we assign all intellectual property rights, including future copyrights in any works incorporating brand-related material or translations thereof, to Hutchison Whampoa Enterprises Limited (subject to any third-party rights).

Hutchison Whampoa Enterprises Limited may terminate the Brand License Agreement (or any sub-license) if, among other things, we commit a material breach of the agreement, or within any twelve-month period aggregate direct or indirect shareholding in our company held by Hutchison Whampoa Limited, our indirect shareholder, is reduced to less than 50%, 40%, 30% or 20%. On termination of the Brand License Agreement, we (and any sub-licensees) must immediately cease using the brands and are obliged to withdraw from sale any products bearing the brands; provided that if the agreement is terminated following a change in Hutchison Whampoa Limited's aggregate direct or indirect shareholding in our company, we will have a six-month transitional period during which we can continue to use the licensed rights. Hutchison Whampoa Limited's interest in our company is less than 20%, but we do not anticipate that Hutchison Whampoa Enterprises Limited will terminate such license in the foreseeable future.

Hutchison Whampoa Enterprises Limited has also granted a royalty-free license to use the Hutchison name and associated trademarks to Hutchison Baiyunshan. The license has a term equal to the operational period of the joint venture but may be terminated by the licensor if, among other things, Hutchison Baiyunshan is in breach of the terms of the license and fails to remedy that breach after an arbitration

219

Table of Contents

award is issued against Hutchison Baiyunshan, the joint venture agreement terminates, or our company's interest in Hutchison Baiyunshan falls below 50%.

Sharing of services with the CK Hutchison group

Pursuant to an amended and restated services agreement dated January 1, 2016 between us and Hutchison Whampoa (China) Limited, an indirect wholly owned subsidiary of CK Hutchison, we share certain services with and receive operational support from the CK Hutchison group including, among others, legal and regulatory services, company secretarial support services, tax and internal audit services, shared use of accounting software system and related services, participation in the CK Hutchison group's pension, medical and insurance plans, participation in the CK Hutchison group's procurement projects with third-party vendors/suppliers, other staff benefits and staff training services, company functions and activities and operation advisory and support services. This amended and restated services agreement replaces our prior services agreement with Hutchison Whampoa (China) Limited, dated April 21, 2006, which had substantially similar terms. We refer to this amended and restated agreement as the Services Agreement. We pay a management fee to Hutchison Whampoa (China) Limited for the provision of such services. In addition, we make payments under the Services Agreement to Hutchison Whampoa (China) Limited for our executive offices in Hong Kong. Furthermore, pursuant to the terms of the Services Agreement, Hutchison Whampoa (China) Limited charges us management fees and other costs through Hutchison Healthcare Holdings Limited, its wholly owned subsidiary.

The Services Agreement may be terminated by either party by giving three months' written notice. Hutchison Whampoa (China) Limited may also immediately terminate if its shareholding in our company falls below 30%. The services provided under the Services Agreement are provided on an arm's length basis, on normal commercial terms.

Any amount unpaid after 30 days accrues interest at the rate of 1.5% per annum. In the year ended December 31, 2017, we paid a management fee of approximately $0.9 million under the Services Agreement. As of December 31, 2017, we had $0.5 million in unpaid fees outstanding to Hutchison Whampoa (China) Limited. In the year ended December 31, 2017, we paid interest in respect of unpaid fees amounting to $0.1 million.

Subscription for ADSs by Hutchison Healthcare

In connection with our underwritten public offering in 2017, Hutchison Healthcare Holdings Limited subscribed for 6,862,420 ADSs for gross consideration of approximately $181.9 million.

Relationships with our Joint Ventures

Nutrition Science Partners

Research and development services provided to Nutrition Science Partners. On March 25, 2013, we entered into a research and development collaboration agreement with Nestlé Health Science under which we provide certain research and development services to Nutrition Science Partners. On the same date, in connection with that agreement, we entered into a services agreement with our non-consolidated joint venture Nutrition Science Partners to provide it with the research and development services in relation to the HMPL-004 project, including: (i) collection, monitoring, processing and distribution of adverse event reports and safety and medical information including side-effects; (ii) development of manufacturing and analytical technologies for raw materials for the drug candidate being developed by such joint venture, HMPL-004; (iii) quality control and assurance of product manufacturing management; and (iv) ongoing discovery research and non-clinical support for the development of HMPL-004 and its reformulations such as HM004-6599. We provide these services on a fee-for-service basis. See Item 4.B. "Business Overview—Overview of Our Collaborations" for more information. For the year ended December 31, 2017, we

220

Table of Contents

received approximately $8.9 million for the provision of these research and development services to Nutrition Science Partners.

Intellectual property rights provided to Nutrition Science Partners. Under the terms of an assignment agreement dated November 26, 2013, we have assigned full title to intellectual property rights in connection with the HMPL-004/HM004-6599 compound on a worldwide basis to Nutrition Science Partners in exchange for $30 million paid by Nutrition Science Partners to us.

Loans provided to Nutrition Science Partners. We and Nestlé Health Science, our joint venture partner in Nutrition Science Partners, had each provided a loan in the principal amount of $5.0 million to Nutrition Science Partners under loan agreements each dated June 10, 2014, which were amended on August 24, 2015. After such amendments, each of the loans has a two-year renewable term with a maturity date of June 9, 2016. In addition, we and Nestlé Health Science have each provided a loan in the principal amount of $2.0 million to Nutrition Science Partners under loan agreements each dated August 24, 2015. During 2016, we and Nestlé Health Science agreed to waive the $7.0 million in loans to Nutrition Science Partners, and each party capitalized the outstanding amount as share capital. Additionally, in 2016 we provided $5.0 million in share capital to Nutrition Science Partners, with Nestlé Health Science providing the same amount. In February 2017, we and Nestlé Health Science each contributed an additional $7.0 million share capital funding to Nutrition Science Partners.

Hutchison Sinopharm

Shanghai Hutchison Pharmaceuticals' provision of promotion and marketing services to Hutchison Sinopharm. On September 29, 2014 and January 29, 2015, our consolidated joint venture Hutchison Sinopharm entered into agreements with multinational pharmaceutical manufacturers Merck Serono and AstraZeneca, respectively, to market and distribute in China certain of their drugs, primarily Concor and Seroquel. In connection with Hutchison Sinopharm's agreements with Merck Serono and AstraZeneca, Hutchison Sinopharm entered into agreements with our non-consolidated joint venture Shanghai Hutchison Pharmaceuticals to provide certain promotion and marketing services within China for these drugs. Under these agreements, Shanghai Hutchison Pharmaceuticals manages marketing and is paid a service fee for medical sales services, and Hutchison Sinopharm manages distribution and logistics for these products. In the year ended December 31, 2017, Hutchison Sinopharm paid Shanghai Hutchison Pharmaceuticals $10.2 million in connection with the provision of such services.

Hutchison Sinopharm's purchase of products from Hutchison Baiyunshan. On April 22, 2014, Hutchison Sinopharm entered into distribution agreements to purchase certain products manufactured by our non-consolidated joint venture Hutchison Baiyunshan. Under the terms of these agreements, Hutchison Sinopharm manages the distribution and delivery logistics of such products.

Hutchison Sinopharm's distribution agreement with Hutchison Baiyunshan has a one-year term. Hutchison Baiyunshan may terminate the agreement prior to that if Hutchison Sinopharm fails to purchase products from Hutchison Baiyunshan for three consecutive months, fails to achieve sales target, engages in sales outside of Shanghai, engages in unfair competition practices or distributes the products through channels other than hospitals without Hutchison Baiyunshan's consent. Hutchison Sinopharm and Hutchison Baiyunshan are in the process of renewing their agreement for the distribution of products.

In the year ended December 31, 2017, Hutchison Sinopharm purchased products from Hutchison Baiyunshan for an amount totaling $0.9 million in the aggregate.

Hutchison Healthcare's grant of license to distribute Zhi Ling Tong products to Hutchison Sinopharm. In January 2016, Hutchison Healthcare granted a license to Hutchison Sinopharm to distribute Chi-Med-owned Zhi Ling Tong infant nutrition products, which had previously been distributed by a third-party distributor. Under such license, Hutchison Sinopharm obtains exclusive distribution rights for Zhi

221

Table of Contents

Ling Tong infant nutrition products from Hutchison Healthcare within China which are subject to annual renewal reviews. The distribution rights were renewed for 2017.

Hutchison Hain Organic

Loans to Hutchison Hain Organic (Hong Kong) Limited. We and Hain Celestial have each provided a loan in the principal amount of $2.55 million to Hutchison Hain Organic (Hong Kong) Limited, a wholly owned subsidiary of our joint venture Hutchison Hain Organic, under loan agreements dated December 24, 2014. On July 15, 2016, Hutchison Hain Organic (Hong Kong) Limited repaid $1.0 million to each of us and Hain Celestial, after which $1.55 million remain outstanding under each loan agreement. Each of the loans has a four-year renewable term with a maturity date of October 8, 2018. Each loan bears an interest rate equal to the 3-month LIBOR plus 3% per annum, payable at maturity. As of December 31, 2017, all such principal amounts remained outstanding to us and Hain Celestial, and we and Hain Celestial are entitled to interest receivables of $80,000 each.

Agreements with Our Directors and Executive Officers

Director and Executive Officer Compensation

See Item 6.B. "Compensation—Executive Officer Compensation" and "Compensation—Director Compensation" for a discussion of our compensation of directors and executive officers.

Equity Compensation

See Item 6.B. "Compensation—Equity Compensation Schemes and Other Benefit Plans."

Employment Agreements

We have entered into employment agreements with our executive officers. For more information regarding these agreements, see Item 6.B. "Compensation—Employment Arrangements with our Executive Officers."

Indemnification Agreements

We have entered into indemnification agreements with each of our directors and executive officers. We also maintain a general liability insurance policy which covers certain liabilities of our directors and executive officers arising out of claims based on acts or omissions in their capabilities as directors or officers.

C. Interests of Experts and Counsel

Not applicable.

ITEM 8. FINANCIAL INFORMATION

A. Consolidated Financial Statements and Other Financial Information.

See Item 18 "Financial Statements."

A.7 Legal Proceedings

There are no material legal proceedings pending or, to our knowledge, threatened against us. From time to time we become subject to legal proceedings and claims in the ordinary course of our business, including claims of alleged infringement of patents and other intellectual property rights. Such legal proceedings or claims, even if not meritorious, could result in the expenditure of significant financial and management resources.

222

Table of Contents

A.8 Dividend Policy

We have never declared or paid dividends on our ordinary shares. We currently expect to retain all future earnings for use in the operation and expansion of our business and do not have any present plan to pay any dividends. The declaration and payment of any dividends in the future will be determined by our board of directors in its discretion, and will depend on a number of factors, including our earnings, capital requirements, overall financial condition, and contractual restrictions.

B. Significant Changes

We have not experienced any significant changes since the date of our audited consolidated financial statements included in this annual report.

ITEM 9. THE OFFER AND LISTING

Not applicable except for Item 9.A.4 and Item 9.C.

Our ADSs have been listed on the Nasdaq Global Select Market since March 17, 2016 under the symbol "HCM." The following table sets forth, for the periods indicated, the reported high and low closing sale prices of our ADSs on the Nasdaq Global Select Market in U.S. dollars.

	Price Per ADS

	High		Low
Annual:
2016 (since March 17, 2016)	$	14.94	$	11.26
2017	$	39.42	$	12.74
2018 (through March 1, 2018)	$	41.14	$	30.62
Quarterly:
First Quarter 2016 (since March 17, 2016)	$	13.50	$	13.20
Second Quarter 2016	$	14.18	$	12.32
Third Quarter 2016	$	13.76	$	11.90
Fourth Quarter 2016	$	14.94	$	11.26
First Quarter 2017	$	20.57	$	12.74
Second Quarter 2017	$	23.69	$	18.30
Third Quarter 2017	$	27.50	$	22.15
Fourth Quarter 2017	$	39.42	$	27.41
First Quarter 2018 (through March 1, 2018)	$	41.14	$	30.62
Most Recent Six Months:
September 2017	$	27.27	$	25.02
October 2017	$	31.74	$	27.41
November 2017	$	35.42	$	29.49
December 2017	$	39.42	$	30.26
January 2018	$	41.14	$	36.01
February 2018	$	37.08	$	30.62
March 2018 (through March 1, 2018)	$	34.80	$	34.80

Our ordinary shares have been listed on the AIM market of the London Stock Exchange since May 19, 2006. The following table sets forth, for the periods indicated, the reported high and low closing

223

Table of Contents

sale prices of our ordinary shares on the AIM in pounds sterling and U.S. dollars. U.S. dollar per ordinary share amounts have been translated into U.S. dollars at £1.00=$1.34.

	Price Per Ordinary Share				Price Per Ordinary Share

	High		Low		High		Low
Annual:
2013	£	6.39	£	4.15	$	8.56	$	5.56
2014	£	15.30	£	6.21	$	20.50	$	8.32
2015	£	28.35	£	11.80	$	37.99	$	15.81
2016	£	27.90	£	16.85	$	37.39	$	22.58
2017	£	56.00	£	20.82	$	75.04	$	27.90
2018 (through March 1, 2018)	£	59.00	£	43.05	$	79.06	$	57.69
Quarterly:
First Quarter 2016	£	27.90	£	18.50	$	37.39	$	24.79
Second Quarter 2016	£	24.08	£	16.80	$	32.27	$	22.51
Third Quarter 2016	£	19.58	£	17.88	$	26.24	$	23.96
Fourth Quarter 2016	£	23.70	£	17.85	$	31.76	$	23.92
First Quarter 2017	£	32.53	£	20.82	$	43.59	$	27.90
Second Quarter 2017	£	36.58	£	29.10	$	49.02	$	38.99
Third Quarter 2017	£	40.50	£	33.88	$	54.27	$	45.40
Fourth Quarter 2017	£	56.00	£	40.18	$	75.04	$	53.84
First Quarter 2018 (through March 1, 2018)	£	59.00	£	43.05	$	79.06	$	57.69
Most Recent Six Months:
September 2017	£	40.25	£	36.48	$	53.94	$	48.88
October 2017	£	48.13	£	40.18	$	64.49	$	53.84
November 2017	£	52.63	£	44.95	$	70.52	$	60.23
December 2017	£	56.00	£	46.13	$	75.04	$	61.81
January 2018	£	59.00	£	50.80	$	79.06	$	68.07
February 2018	£	51.80	£	43.05	$	69.41	$	57.69
March 2018 (through March 1, 2018)	£	47.75	£	47.75	$	63.99	$	63.99

ITEM 10. ADDITIONAL INFORMATION

A. Share Capital.

Not applicable.

B. Memorandum and Articles of Association.

The information contained under the caption of "Our Memorandum and Articles of Association" in the Company's Registration Statement on Form F-1 filed March 4, 2016 (file number 333-207447) is incorporated herein by reference.

C. Material Contracts.

Except as otherwise disclosed in this annual report (including the exhibits hereto), we are not currently, and have not been in the last two years, party to any material contract, other than contracts entered into in the ordinary course of our business.

D. Exchange Controls.

Foreign currency exchange in the PRC is primarily governed by the Foreign Exchange Administration Rules issued by the State Council on January 29, 1996 and effective as of April 1, 1996 (and amended on

224

Table of Contents

January 14, 1997 and August 1, 2008) and the Regulations of Settlement, Sale and Payment of Foreign Exchange which came into effect on July 1, 1996.

Under the Foreign Exchange Administration Rules, renminbi is freely convertible for current account items, including the distribution of dividends payments, interest payments, trade and service-related foreign exchange transactions. Conversion of renminbi for capital account items, such as direct investment, loans, securities investment and repatriation of investment, however, is still generally subject to the approval or verification of SAFE.

Under the Regulations of Settlement, Sale and Payment of Foreign Exchange, foreign invested enterprises including wholly foreign owned enterprises, may buy, sell or remit foreign currencies only at those banks that are authorized to conduct foreign exchange business after providing such banks with valid commercial supporting documents and, in the case of capital account item transactions, after obtaining approvals from SAFE. Capital investments by foreign invested enterprises outside the PRC are also subject to limitations, which include approvals by the MOFCOM, the SAFE and the NDRC.

In March 2015, SAFE released the Circular on Reforming the Management Approach regarding the Foreign Exchange Capital Settlement of Foreign-invested Enterprises, or FIEs, or the Foreign Exchange Capital Settlement Circular, which became effective from June 1, 2015. This circular replaced SAFE's previous related circulars, including the Circular on Issues Relating to the Improvement of Business Operation with Respect to the Administration of Foreign Exchange Capital Payment and Settlement of Foreign Invested Enterprises. The Foreign Exchange Capital Settlement Circular clarifies that FIEs may settle a specified proportion of their foreign exchange capital in banks at their discretion, and may choose the timing for such settlement. The proportion of foreign exchange capital to be settled at FIEs' discretion for the time being is 100% and the SAFE may adjust the proportion in due time based on the situation of international balance of payments. The circular also stipulates that FIEs' usage of capital and settled foreign exchange capital shall comply with relevant provisions concerning foreign exchange control and be subject to the management of a negative list. The FIEs' capital and Renminbi capital gained from the settlement of foreign exchange capital may not be directly or indirectly used for expenditure beyond the business scope of the FIEs or as prohibited by laws and regulations of the PRC. Such capital also may not be directly or indirectly used for issuing renminbi entrusted loans except as permitted by the business scope of the FIE, for repaying inter-enterprise borrowings including any third-party advance, or for repaying the bank loans denominated in renminbi that have been sub-lent to a third party.

In addition, the payment of dividends by entities established in the PRC is subject to limitations. Regulations in the PRC currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in the PRC. Each of our PRC subsidiaries and joint ventures that is a domestic company is also required to set aside at least 10.0% of its after-tax profit based on PRC accounting standards each year to its general reserves or statutory capital reserve fund until the accumulative amount of such reserves reach 50.0% of its respective registered capital. These restricted reserves are not distributable as cash dividends. In addition, if any of our PRC subsidiaries or joint ventures incurs debt on its own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us.

For more information about foreign exchange control, see Item 3.D. "Risk Factors—Risks Related to Doing Business in China—Restrictions on currency exchange may limit our ability to utilize our revenues effectively."

E. Taxation

The following is a general summary of certain PRC, Hong Kong, Cayman Islands and U.S. federal income tax consequences relevant to the acquisition, ownership and disposition of our ADSs. The discussion is not intended to be, nor should it be construed as, legal or tax advice to any particular individual. The discussion is based on laws and relevant interpretations thereof in effect as of March 1,

225

Table of Contents

2018, all of which are subject to change or different interpretations, possibly with retroactive effect. The discussion does not address U.S. state or local tax laws, or tax laws of jurisdictions other than the PRC, Hong Kong, the Cayman Islands, the United Kingdom and the United States. You should consult your own tax advisors with respect to the consequences of acquisition, ownership and disposition of our ADSs and ordinary shares.

Taxation in the PRC

PRC Enterprise Income Tax

Under the EIT Law and its implementation rules which became effective on January 1, 2008 and was later amended on February 24, 2017, the standard tax rate of 25% applies to all enterprises (including FIEs) with exceptions in special situations if relevant criteria are met and subject to the approval of the PRC tax authorities.

An enterprise incorporated outside of the PRC whose "de facto management bodies" are located in the PRC is considered a "resident enterprise" and will be subject to a uniform EIT rate of 25% on its global income. In April 2009, the SAT, in Circular 82, specified certain criteria for the determination of what constitutes "de facto management bodies." If all of these criteria are met, the relevant foreign enterprise will be deemed to have its "de facto management bodies" located in the PRC and therefore be considered a resident enterprise in the PRC. These criteria include: (a) the enterprise's day-to-day operational management is primarily exercised in the PRC; (b) decisions relating to the enterprise's financial and human resource matters are made or subject to approval by organizations or personnel in the PRC; (c) the enterprise's primary assets, accounting books and records, company seals, and board and shareholders' meeting minutes are located or maintained in the PRC; and (d) 50% or more of voting board members or senior executives of the enterprise habitually reside in the PRC. In addition, an enterprise established outside the PRC which meets all of the aforesaid requirements is expected to make an application for the classification as a "resident enterprise" and this will ultimately be confirmed by the province-level tax authority. Although Circular 82 only applies to foreign enterprises that are majority-owned and controlled by PRC enterprises, not those owned and controlled by foreign enterprises or individuals, the determining criteria set forth in Circular 82 may be adopted by the PRC tax authorities as the test for determining whether the enterprises are PRC tax residents, regardless of whether they are majority-owned and controlled by PRC enterprises. However, it is not entirely clear how the PRC tax authorities will determine whether a non-PRC entity (that has not already been notified of its status for EIT purposes) will be classified as a "resident enterprise" in practice.

If a non-PRC enterprise is classified as a "resident enterprise" for EIT purposes, any dividends to be distributed by that enterprise to non-PRC resident shareholders or ADS holders or any gains realized by such investors from the transfer of shares or ADSs may be subject to PRC tax. If the PRC tax authorities determine that we should be considered a PRC resident enterprise for EIT purposes, any dividends payable by us to our non-PRC resident enterprise shareholders or ADS holders, as well as gains realized by such investors from the transfer of our shares or ADSs may be subject to a 10% withholding tax, unless a reduced rate is available under an applicable tax treaty. Furthermore, if we are considered a PRC resident enterprise for EIT purposes, it is unclear whether our non-PRC individual shareholders (including our ADS holders) would be subject to any PRC tax on dividends or gains obtained by such non-PRC individual shareholders. If any PRC tax were to apply to dividends realized by non-PRC individuals, it would generally apply at a rate of up to 20% unless a reduced rate is available under an applicable tax treaty.

226

Table of Contents

According to the EIT Law, dividends declared after January 1, 2008 and paid by PRC FIEs to their non-PRC parent companies will be subject to PRC withholding tax at 10% unless there is a tax treaty between the PRC and the jurisdiction in which the overseas parent company is a tax resident and which specifically exempts or reduces such withholding tax, and such tax exemption or reduction is approved by the relevant PRC tax authorities. Pursuant to the Arrangement, if the non-PRC immediate holding company is a Hong Kong tax resident and directly holds a 25% or more equity interest in the PRC enterprise and is considered to be the beneficial owner of dividends paid by the PRC enterprise, such withholding tax rate may be lowered to 5%, subject to approval by the relevant PRC tax authorities in accordance with relevant tax regulations upon the assessment of beneficial ownership.

Business Tax

A business which provides certain services or sells/transfers immovable or intangible property within the PRC (including when either party of a transaction is within the PRC unless in specified situations) was liable to Business Tax at rates ranging from 3% to 20% of the charges for the services provided or immovable or intangible property sold or transferred (as the case may be). The Business Tax rate of 3% was applicable on taxable services relating to construction, culture and sports. All other services generally attracted a Business Tax rate of 5%, except that services relating to entertainment are subject to a rate ranging from 5% to 20%.

In addition, Business Tax was payable on the gross amount of all billings unless specific rules stipulated the use of a net amount.

A Municipal Maintenance Tax, together with an Education Surcharge and a Local Education Surcharge, were payable at a rate, in aggregate, of 6% to 12% of the Business Tax.

The Business Tax regime has been replaced in full with effect from 1 May 2016, as described in the section below on Value Added Tax, or VAT.

Value Added Tax

The Interim Regulations of the PRC on VAT, or the VAT Regulations, came into effect on January 1, 2009 (subsequently amended on February 6, 2016 and November 19, 2017). Pursuant to the VAT Regulations, VAT is imposed on the goods sold in or imported into the PRC and on processing, repair and replacement services provided within the PRC.

The pilot program of the PRC indirect tax reform was first implemented in Shanghai, the PRC, effective from January 1, 2012 where certain industries are transformed from the Business Tax regime to the VAT regime. The program was expanded in stages.

The MOF, and the SAT jointly promulgated the Circular on Comprehensively Promoting the Pilot Program of the Collection of VAT in Lieu of Business Tax, or the 2016 VAT Circular, on 23 March 2016, which came into effect on 1 May 2016. Pursuant to the 2016 VAT Circular, the sale of services, intangible assets or real property within the PRC (including when either party of a transaction is within the PRC unless in specified situations) is subject to VAT instead of Business Tax, with VAT rates being 6%, 11% or 17%, while the VAT rate could be zero for certain specified cross-border taxable items/services, in accordance with the relevant regulations.

A Municipal Maintenance Tax, together with Education Surcharge and a Local Education Surcharge, are payable at a rate, in aggregate, of 6% to 12% of the VAT.

Land Appreciation Tax

Some of our PRC subsidiaries and joint ventures have obtained certain land use rights and ownership in buildings.

227

Table of Contents

Under the Provisional Regulations of the PRC on Land Appreciation Tax, or LAT, promulgated by the State Council on December 13, 1993 (which became effective on January 1, 1994) and amended on January 8, 2011, together with its implementing rules which were promulgated by the MOF on January 27, 1995, LAT applies to both domestic and foreign investors in real properties in the PRC, irrespective of corporate entities or individuals. The tax is payable by a taxpayer on the gains from the transfer of land use right, buildings or other facilities on such land, after deducting "deductible items" that include: (a) payments made to acquire land use right; (b) costs and charges incurred in connection with land development; (c) construction costs and charges in the case of newly constructed buildings and facilities; (d) assessed value in the case of old buildings and facilities; (f) taxes paid or payable in connection with the transfer of the land use right, buildings or other facilities on such land; and (e) other items allowed by the MOF.

The tax rate is progressive and ranges from 30% to 60% of the appreciation value, as follows:

Appreciation Value		LAT Rate

Portion not exceeding 50% of deductible items:			30%
Portion over 50% but not more than 100% of deductible items:			40%
Portion over 100% but not more than 200% of deductible items:			50%
Portion over 200% of deductible items:			60%

Exemption from LAT is available under certain specified situations.

Deed Tax

Pursuant to the Provisional Regulations of the PRC on Deed Tax promulgated by the State Council on July 7, 1997 and implemented on October 1, 1997, the transferee of the land use right and/or property ownership in the PRC will be the obliged taxpayer for Deed Tax. The rate of Deed Tax ranges from 3% to 5%, subject to determination by local governments at the provincial level in light of local conditions.

Real Estate Tax

Properties owned by an enterprise will be subject to Real Estate Tax at variable rates depending on locality. In certain localities, Real Estate Tax is applicable at a rate of 1.2% of the original value of the building less a standard deduction which ranges from 10% to 30% of the original value or at a rate of 12% of the rental income.

Urban Land Use Tax

According to the Provisional Regulations on Urban Land Use Tax of the PRC promulgated by the State Council in September 1988 and amended in December 2006 and December 2013, Urban Land Use Tax is levied according to the area of relevant land, at between RMB0.6 and RMB30 per square meter.

Stamp Duty

According to the Provisional Regulations of the PRC on Stamp Duty promulgated by the State Council in August 1988 and amended on January 8, 2011, specified documents primarily business contracts are subject to Stamp Duty at the specified rates on the amount stated therein, including but not limited to: purchase and sales agreements—0.03%; loan agreements—0.005%; assets transfer agreements—0.05%. Such Stamp Duty is payable by every party to a contract.

228

Table of Contents

Overview of Tax Implications of Various Other Jurisdictions

Cayman Islands Taxation

According to our Cayman Islands counsel, Conyers Dill & Pearman, the Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us levied by the government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or brought within the jurisdiction of the Cayman Islands. The Cayman Islands is a party to a double tax treaty entered into with the United Kingdom in 2010 but it is otherwise not a party to any double tax treaties that are applicable to any payments made to or by our company. There are no exchange control regulations or currency restrictions in the Cayman Islands.

Pursuant to the Tax Concessions Law (1999 Revision) of the Cayman Islands, Hutchison China MediTech Limited has obtained an undertaking from the Governor-in-Council: (a) that no law which is enacted in the Cayman Islands imposing any tax to be levied on profits or income or gains or appreciations shall apply to us or our operations; and (b) that the aforesaid tax or any tax in the nature of estate duty or inheritance tax shall not be payable on its shares, debentures or other obligations.

The undertaking is for a period of twenty years from January 9, 2001.

Hong Kong Taxation

Profits Tax

Hong Kong tax residents are subject to Hong Kong Profits Tax in respect of profits arising in or derived from Hong Kong at the current rate of 16.5%. Dividend income earned by a Hong Kong tax resident is not subject to Hong Kong Profits Tax. Hutchison China MediTech Limited is a Hong Kong tax resident.

Hong Kong tax on shareholders and ADS holders

No tax is payable in Hong Kong in respect of dividends paid by a Hong Kong tax resident to their shareholders, including our ADS holders.

Hong Kong Profits Tax will not be payable by our shareholders, including our ADS holders (other than shareholders / ADS holders carrying on a trade, profession or business in Hong Kong and holding the shares / ADSs for trading purposes), on any capital gains made on the sale or other disposal of the ADSs. Shareholders, including our ADS holders, should take advice from their own professional advisors as to their particular tax position.

No Hong Kong Stamp Duty is payable by our shareholders, including our ADS holders.

Material U.S. Federal Income Tax Considerations

The following summary, subject to the limitations set forth below, describes the material U.S. federal income tax consequences for a U.S. Holder (as defined below) of the acquisition, ownership and disposition of ordinary shares and ADSs. This discussion is limited to U.S. Holders who hold such ordinary shares or ADSs as capital assets (generally, property held for investment). For purposes of this summary, a "U.S. Holder" is a beneficial owner of an ordinary share or ADS that is for U.S. federal income tax purposes:

•: a citizen or individual resident of the United States;
•: a corporation (or any other entity treated as a corporation for U.S. federal income tax purposes) organized in or under the laws of the United States or any state thereof, or the District of Columbia;

229

Table of Contents

•: an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
•: a trust if (i) it has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes or (ii) a U.S. court can exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of its substantial decisions.

Except as explicitly set forth below, this summary does not address aspects of U.S. federal income taxation that may be applicable to U.S. Holders subject to special rules, including:

•: banks or other financial institutions;
•: insurance companies;
•: real estate investment trusts;
•: regulated investment companies;
•: grantor trusts;
•: tax-exempt organizations;
•: persons holding our ordinary shares or ADSs through a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) or S corporation;
•: dealers or traders in securities, commodities or currencies;
•: persons whose functional currency is not the U.S. dollar;
•: certain former citizens and former long-term residents of the United States;
•: persons holding our ordinary shares or ADSs as part of a position in a straddle or as part of a hedging, conversion or integrated transaction for U.S. federal income tax purposes; or
•: direct, indirect or constructive owners of 10% or more of our equity (by vote or value).

In addition, this summary does not address the 3.8% Medicare contribution tax imposed on certain net investment income, the U.S. federal estate and gift tax or the alternative minimum tax consequences of the acquisition, ownership, and disposition of our ordinary shares or ADSs. We have not received nor do we expect to seek a ruling from the U.S. Internal Revenue Service, or the IRS, regarding any matter discussed herein. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to any of those set forth below. Each prospective investor should consult its own tax advisors with respect to the U.S. federal, state, local and non-U.S. tax consequences of acquiring, owning and disposing of our ordinary shares and ADSs.

This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, U.S. Treasury Regulations promulgated thereunder and administrative and judicial interpretations thereof, and the income tax treaty between the PRC and the United States, or the U.S.-PRC Tax Treaty, each as available and in effect on the date hereof, all of which are subject to change or differing interpretations, possibly with retroactive effect, which could affect the tax consequences described herein. In addition, this summary is based, in part, upon representations made by the depositary to us and assumes that the deposit agreement, and all other related agreements, will be performed in accordance with their terms.

If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our ordinary shares or ADSs, the tax treatment of the partnership and a partner in such partnership generally will depend on the status of the partner and the activities of the partnership. Such partner or partnership should consult its own tax advisors as to the U.S. federal income tax consequences of acquiring, owning and disposing of our ordinary shares or ADSs.

PROSPECTIVE INVESTORS SHOULD CONSULT THEIR OWN TAX ADVISORS WITH REGARD TO THE PARTICULAR TAX CONSEQUENCES APPLICABLE TO THEIR SITUATIONS AS WELL AS THE APPLICATION OF ANY U.S. FEDERAL, STATE, LOCAL, NON-U.S. OR OTHER TAX LAWS, INCLUDING GIFT AND ESTATE TAX LAWS.

230

Table of Contents

ADSs

A U.S. Holder of ADSs will generally be treated, for U.S. federal income tax purposes, as the owner of the underlying ordinary shares that such ADSs represent. Accordingly, no gain or loss will be recognized if a U.S. Holder exchanges ADSs for the underlying shares represented by those ADSs.

The U.S. Treasury has expressed concern that parties to whom ADSs are released before shares are delivered to the depositary or intermediaries in the chain of ownership between holders and the issuer of the security underlying the ADSs, may be taking actions that are inconsistent with the claiming of foreign tax credits by U.S. Holders of ADSs. These actions would also be inconsistent with the claiming of the reduced rate of tax, described below, applicable to dividends received by certain non-corporate U.S. Holders. Accordingly, the creditability of non-U.S. withholding taxes (if any), and the availability of the reduced tax rate for dividends received by certain non-corporate U.S. Holders, each described below, could be affected by actions taken by such parties or intermediaries. For purposes of the discussion below, we assume that intermediaries in the chain of ownership between the holder of an ADS and us are acting consistently with the claim of U.S. foreign tax credits by U.S. Holders.

Taxation of Dividends

As described in "Dividend Policy" above, we do not currently anticipate paying any distributions on our ordinary shares or ADSs in the foreseeable future. However, to the extent there are any distributions made with respect to our ordinary shares or ADSs, and subject to the discussion under "—Passive Foreign Investment Company Considerations" below, the gross amount of any such distribution (including withheld taxes, if any) made out of our current or accumulated earnings and profits (as determined for U.S. federal income tax purposes) will generally be taxable to a U.S. Holder as ordinary dividend income on the date such distribution is actually or constructively received. Distributions in excess of our current and accumulated earnings and profits will be treated as a non-taxable return of capital to the extent of the U.S. Holder's adjusted tax basis in the ordinary shares or ADSs, as applicable, and thereafter as capital gain. However, because we do not maintain calculations of our earnings and profits in accordance with U.S. federal income tax accounting principles, U.S. Holders should expect to treat distributions paid with respect to our ordinary shares and ADSs as dividends. Dividends paid to corporate U.S. Holders generally will not qualify for the dividends received deduction that may otherwise be allowed under the Code. This discussion assumes that distributions made by us, if any, will be paid in U.S. dollars.

Dividends paid to a non-corporate U.S. Holder by a "qualified foreign corporation" may be subject to reduced rates of U.S. federal income taxation if certain holding period and other requirements are met. A qualified foreign corporation generally includes a foreign corporation (other than a PFIC) if (1) its ordinary shares (or ADSs backed by ordinary shares) are readily tradable on an established securities market in the United States or (2) it is eligible for benefits under a comprehensive U.S. income tax treaty that includes an exchange of information program and which the U.S. Treasury Department has determined is satisfactory for these purposes.

IRS guidance indicates that our ADSs (which are listed on the Nasdaq Global Select Market) are readily tradable for purposes of satisfying the conditions required for these reduced tax rates. We do not expect, however, that our ordinary shares will be listed on an established securities market in the United States and therefore do not believe that any dividends paid on our ordinary shares that are not represented by ADSs currently meet the conditions required for these reduced tax rates. There can be no assurance that our ADSs will be considered readily tradable on an established securities market in subsequent years.

The United States does not have a comprehensive income tax treaty with the Cayman Islands. However, in the event that we were deemed to be a PRC resident enterprise under the EIT Law (see "—Taxation in the PRC" above), although no assurance can be given, we might be considered eligible for the benefits of the U.S.-PRC Tax Treaty for purposes of these rules. U.S. Holders should consult their own

231

Table of Contents

tax advisors regarding the availability of the reduced tax rates on dividends paid with respect to our ordinary shares or ADSs in light of their particular circumstances.

Non-corporate U.S. Holders will not be eligible for reduced rates of U.S. federal income taxation on any dividends received from us if we are a PFIC in the taxable year in which such dividends are paid or in the preceding taxable year unless, under certain circumstances, the "deemed sale election" described below under "—Passive Foreign Investment Company Considerations—Status as a PFIC" has been made.

In the event that we were deemed to be a PRC resident enterprise under the EIT Law (see "—Taxation in the PRC" above), U.S. Holders might be subject to PRC withholding taxes on dividends paid by us. In that case, subject to certain conditions and limitations, such PRC withholding tax may be treated as a foreign tax eligible for credit against a U.S. Holder's U.S. federal income tax liability under the U.S. foreign tax credit rules. For purposes of calculating the U.S. foreign tax credit, dividends paid on our ordinary shares or ADSs, will be treated as income from sources outside the United States and will generally constitute passive category income. If a U.S. Holder is eligible for U.S.-PRC Tax Treaty benefits, any PRC taxes on dividends will not be creditable against such U.S. Holder's U.S. federal income tax liability to the extent such tax is withheld at a rate exceeding the applicable U.S.-PRC Tax Treaty rate. An eligible U.S. Holder who does not elect to claim a foreign tax credit for PRC tax withheld may instead be eligible to claim a deduction, for U.S. federal income tax purposes, in respect of such withholding but only for the year in which such U.S. Holder elects to do so for all creditable foreign income taxes. The U.S. foreign tax credit rules are complex. U.S. Holders should consult their own tax advisors regarding the foreign tax credit rules in light of their particular circumstances.

Taxation of Capital Gains

Subject to the discussion below in "—Passive Foreign Investment Company Considerations," upon the sale, exchange, or other taxable disposition of our ordinary shares or ADSs, a U.S. Holder generally will recognize gain or loss in an amount equal to the difference between the amount realized on such sale or exchange (determined in the case of sales or exchanges in currencies other than U.S. dollars by reference to the spot exchange rate in effect on the date of the sale or exchange or, if sold or exchanged on an established securities market and the U.S. Holder is a cash basis taxpayer or an electing accrual basis taxpayer, the spot exchange rate in effect on the settlement date) and the U.S. Holder's adjusted tax basis in such ordinary shares or ADSs determined in U.S. dollars. A U.S. Holder's initial tax basis will be the U.S. Holder's U.S. dollar purchase price for such ordinary shares or ADSs.

Assuming we are not a PFIC and have not been treated as a PFIC during the U.S. Holder's holding period for its ordinary shares or ADSs, such gain or loss will be capital gain or loss. Under current law, capital gains of non-corporate U.S. Holders derived with respect to capital assets held for more than one year are generally eligible for reduced rates of taxation. The deductibility of capital losses is subject to limitations. Capital gain or loss, if any, recognized by a U.S. Holder generally will be treated as U.S. source income or loss for U.S. foreign tax credit purposes. U.S. Holders are encouraged to consult their own tax advisors regarding the availability of the U.S. foreign tax credit in consideration of their particular circumstances.

If we were treated as a PRC resident enterprise for EIT Law purposes and PRC tax were imposed on any gain (see "—Taxation in the PRC" above), and if a U.S. Holder is eligible for the benefits of the U.S.-PRC Tax Treaty, the holder may be able to treat such gain as PRC source gain under the treaty for U.S. foreign tax credit purposes. A U.S. Holder will be eligible for U.S.-PRC Tax Treaty benefits if (for purposes of the treaty) such holder is a resident of the United States and satisfies the other requirements specified in the U.S.-PRC Tax Treaty. Because the determination of treaty benefit eligibility is fact-intensive and depends upon a holder's particular circumstances, U.S. Holders should consult their tax advisors regarding U.S.-PRC Tax Treaty benefit eligibility. U.S. Holders are also encouraged to consult their own tax advisors regarding the tax consequences in the event PRC tax were to be imposed on a

232

Table of Contents

disposition of ordinary shares or ADSs, including the availability of the U.S. foreign tax credit and the ability and whether to treat any gain as PRC source gain for the purposes of the U.S. foreign tax credit in consideration of their particular circumstances.

Passive Foreign Investment Company Considerations

Status as a PFIC

The rules governing PFICs can result in adverse tax consequences to U.S. Holders. We generally will be classified as a PFIC for U.S. federal income tax purposes if, for any taxable year, either: (1) 75% or more of our gross income consists of certain types of passive income, or (2) the average value (determined on a quarterly basis), of our assets that produce, or are held for the production of, passive income is 50% or more of the value of all of our assets.

Passive income generally includes dividends, interest, rents and royalties (other than certain rents and royalties derived in the active conduct of a trade or business), annuities and gains from assets that produce passive income. If a non-U.S. corporation owns at least 25% by value of the stock of another corporation, the non-U.S. corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation and as receiving directly its proportionate share of the other corporation's income. Under this rule, we should be deemed to own a proportionate share of the assets and to have received a proportionate share of the income of our principal subsidiaries, including Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited, Shanghai Hutchison Pharmaceuticals Limited and Nutrition Science Partners Limited, for purpose of the PFIC determination.

Additionally, if we are classified as a PFIC in any taxable year with respect to which a U.S. Holder owns ordinary shares or ADSs, we generally will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding taxable years, regardless of whether we continue to meet the tests described above, unless the U.S. Holder makes the "deemed sale election" described below. Furthermore, if we are treated as a PFIC, then one or more of our subsidiaries may also be treated as PFICs.

Based on certain estimates of our gross income and gross assets (which estimates are inherently imprecise) and the nature of our business, we do not believe that we are currently a PFIC. Notwithstanding the foregoing, the determination of whether we are a PFIC is made annually and depends on particular facts and circumstances (such as the valuation of our assets, including goodwill and other intangible assets) and also may be affected by the application of the PFIC rules, which are subject to differing interpretations. The fair market value of our assets is expected to depend, in part, upon (a) the market price of our ADSs, which is likely to fluctuate, and (b) the composition of our income and assets, which will be affected by how, and how quickly, we spend any cash that is raised in any financing transaction. In light of the foregoing, no assurance can be provided that we are not currently a PFIC or that we will not become a PFIC in any future taxable year. Prospective investors should consult their own tax advisors regarding our PFIC status.

U.S. federal income tax treatment of a shareholder of a PFIC

If we are classified as a PFIC for any taxable year during which a U.S. Holder owns ordinary shares or ADSs, the U.S. Holder, absent certain elections (including the mark-to-market and QEF elections described below), generally will be subject to adverse rules (regardless of whether we continue to be classified as a PFIC) with respect to (1) any "excess distributions" (generally, any distributions received by the U.S. Holder on its ordinary shares or ADSs in a taxable year that are greater than 125% of the average annual distributions received by the U.S. Holder in the three preceding taxable years or, if shorter, the U.S. Holder's holding period) and (2) any gain realized on the sale or other disposition, including a pledge, of such ordinary shares or ADSs.

233

Table of Contents

Under these rules (a) the excess distribution or gain will be allocated ratably over the U.S. Holder's holding period, (b) the amount allocated to the current taxable year and any taxable year prior to the first taxable year in which we are classified as a PFIC will be taxed as ordinary income and (c) the amount allocated to each other taxable year during the U.S. Holder's holding period in which we were classified as a PFIC (i) will be subject to tax at the highest rate of tax in effect for the applicable category of taxpayer for that year and (ii) will be subject to an interest charge at a statutory rate with respect to the resulting tax attributable to each such other taxable year. In addition, non-corporate U.S. Holders will not be eligible for reduced rates of taxation on any dividends received from us if we are a PFIC in the taxable year in which such dividends are paid or in the preceding taxable year.

If we are classified as a PFIC, a U.S. Holder will generally be treated as owning a proportionate amount (by value) of stock or shares owned by us in any direct or indirect subsidiaries that are also PFICs and will be subject to similar adverse rules with respect to any distributions we receive from, and dispositions we make of, the stock or shares of such subsidiaries. U.S. Holders are urged to consult their tax advisors about the application of the PFIC rules to any of our subsidiaries.

If we are classified as a PFIC and then cease to be so classified, a U.S. Holder may make an election (a "deemed sale election") to be treated for U.S. federal income tax purposes as having sold such U.S. Holder's ordinary shares or ADSs on the last day of our taxable year during which we were a PFIC. A U.S. Holder that makes a deemed sale election would then cease to be treated as owning stock in a PFIC. However, gain recognized as a result of making the deemed sale election would be subject to the adverse rules described above and loss would not be recognized.

PFIC "mark-to-market" election

In certain circumstances, a holder of "marketable stock" of a PFIC can avoid certain of the adverse rules described above by making a mark-to-market election with respect to such stock. For purposes of these rules "marketable stock" is stock which is "regularly traded" (traded in greater than de minimis quantities on at least 15 days during each calendar quarter) on a "qualified exchange" or other market within the meaning of applicable U.S. Treasury Regulations. A "qualified exchange" includes a national securities exchange that is registered with the SEC.

A U.S. Holder that makes a mark-to-market election must include in gross income, as ordinary income, for each taxable year that we are a PFIC an amount equal to the excess, if any, of the fair market value of the U.S. Holder's ordinary shares or ADSs that are "marketable stock" at the close of the taxable year over the U.S. Holder's adjusted tax basis in such ordinary shares or ADSs. An electing U.S. Holder may also claim an ordinary loss deduction for the excess, if any, of the U.S. Holder's adjusted tax basis in such ordinary shares or ADSs over their fair market value at the close of the taxable year, but this deduction is allowable only to the extent of any net mark-to-market gains previously included in income pursuant to the mark-to-market election. The adjusted tax basis of a U.S. Holder's ordinary shares or ADSs with respect to which the mark-to-market election applies would be adjusted to reflect amounts included in gross income or allowed as a deduction because of such election. If a U.S. Holder makes an effective mark-to-market election with respect to our ordinary shares or ADSs, gains from an actual sale or other disposition of such ordinary shares or ADSs in a year in which we are a PFIC would be treated as ordinary income, and any losses incurred on such sale or other disposition would be treated as ordinary losses to the extent of any net mark-to-market gains previously included in income.

If we are classified as a PFIC for any taxable year in which a U.S. Holder owns ordinary shares or ADSs but before a mark-to-market election is made, the adverse PFIC rules described above will apply to any mark-to-market gain recognized in the year the election is made. Otherwise, a mark-to-market election will be effective for the taxable year for which the election is made and all subsequent taxable years unless the ordinary shares or ADSs are no longer regularly traded on a qualified exchange or the IRS consents to the revocation of the election. Our ADSs are listed on the Nasdaq Global Select Market, which is a

234

Table of Contents

qualified exchange or other market for purposes of the mark-to-market election. Consequently, if the ADSs continue to be so listed, and are "regularly traded" for purposes of these rules (for which no assurance can be given) we expect that the mark-to-market election would be available to a U.S. Holder with respect to our ADSs.

A mark-to-market election is not permitted for the shares of any of our subsidiaries that are also classified as PFICs. Prospective investors should consult their own tax advisors regarding the availability of, and the procedure for, and the effect of making, a mark-to-market election, and whether making the election would be advisable, including in light of their particular circumstances.

PFIC "QEF" election

In some cases, a shareholder of a PFIC can avoid the interest charge and the other adverse PFIC tax consequences described above by obtaining certain information from the PFIC and by making a QEF election to be taxed currently on its share of the PFIC's undistributed income. We do not, however, expect to provide the information regarding our income that would be necessary in order for a U.S. Holder to make a QEF election if we were classified as a PFIC.

PFIC information reporting requirements

If we are classified as a PFIC in any year with respect to a U.S. Holder, such U.S. Holder will be required to file an annual information return on IRS Form 8621 regarding distributions received on, and any gain realized on the disposition of, our ordinary shares and ADSs, and certain U.S. Holders will be required to file an annual information return (also on IRS Form 8621) relating to their ownership interest.

NO ASSURANCE CAN BE GIVEN THAT WE ARE NOT CURRENTLY A PFIC OR THAT WE WILL NOT BECOME A PFIC IN THE FUTURE. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS WITH RESPECT TO THE OPERATION OF THE PFIC RULES AND RELATED REPORTING REQUIREMENTS IN LIGHT OF THEIR PARTICULAR CIRCUMSTANCES, INCLUDING THE ADVISABILITY AND EFFECTS OF MAKING ANY ELECTION THAT MAY BE AVAILABLE.

U.S. Backup Withholding and Information Reporting and Filing Requirements

Backup withholding and information reporting requirements may apply to distributions on, and proceeds from the sale or disposition of, ordinary shares and ADSs that are held by U.S. Holders. The payor will be required to withhold tax on such payments made within the United States, or by a U.S. payor or a U.S. intermediary (and certain subsidiaries thereof) to a U.S. Holder, other than an exempt recipient, if the U.S. Holder fails to furnish its correct taxpayer identification number or otherwise fails to comply with, or establish an exemption from, the backup withholding requirements. Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against a U.S. Holder's U.S. federal income tax liability (if any) or refunded provided the required information is furnished to the IRS in a timely manner.

Certain U.S. Holders of specified foreign financial assets with an aggregate value in excess of the applicable dollar threshold are required to report information relating to their holding of ordinary shares or ADSs, subject to certain exceptions (including an exception for shares held in accounts maintained by certain financial institutions) with their tax returns for each year in which they hold such interests. U.S. Holders should consult their own tax advisors regarding the information reporting obligations that may arise from their acquisition, ownership or disposition of our ordinary shares or ADSs.

THE ABOVE DISCUSSION DOES NOT COVER ALL TAX MATTERS THAT MAY BE OF IMPORTANCE TO A PARTICULAR INVESTOR. PROSPECTIVE INVESTORS ARE STRONGLY

235

Table of Contents

URGED TO CONSULT THEIR OWN TAX ADVISORS ABOUT THE TAX CONSEQUENCES OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs.

F. Dividends and Payment Agents.

Not applicable.

G. Statement by Experts.

Not applicable.

H. Documents on Display.

We are subject to the informational requirements of the Exchange Act and are required to file reports and other information with the SEC. Shareholders may read and copy any of our reports and other information at, and obtain copies upon payment of prescribed fees from, the public reference room maintained by the SEC at 100 F Street N.E., Washington, D.C. 20549. The public may obtain information on the operation of the public reference room by calling the U.S. Securities and Exchange Commission at 1-800-SEC-0330. The SEC also maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that make electronic filings with the SEC using its EDGAR system.

We are a "foreign private issuer" as such term is defined in Rule 405 under the Securities Act, and are not subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. As a result, we do not file the same reports that a U.S. domestic issuer would file with the SEC, although we are required to file or furnish to the SEC the continuous disclosure documents that we are required to file on the AIM market of the London Stock Exchange.

We will furnish Deutsche Bank Trust Company Americas, the depositary of our ADSs, with our annual reports, which will include a review of operation and annual audited consolidated financial statements prepared in conformity with U.S. GAAP, and all notices of shareholders' meetings and other reports and communications that are made generally available to our shareholders. The depositary will make such notices, reports and communications available to holders of ADSs and, upon our requests, will mail to all record holders of ADSs the information contained in any notice of a shareholders' meeting received by the depositary from us.

We also make available on our website's investor relations page, free of charge, our annual report and the text of our reports on Form 6-K, including any amendments to these reports, as well as certain other SEC filings, as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. The address for our investor relations page is "http://www.chi-med.com/investors/." The information contained on our website is not incorporated by reference in this annual report.

I. Subsidiary information

Not applicable.

ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Please see Item 5.F. "Operating and Financial Review and Prospects—Quantitative and Qualitative Disclosures About Market Risk."

236

Table of Contents

ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

A. Debt Securities

Not applicable.

B. Warrants and Rights.

Not applicable.

C. Other Securities.

Not applicable.

D. American Depositary Shares.

Fees and charges our ADS holders may have to pay

ADS holders will be required to pay the following service fees to Deutsche Bank Trust Company America, the depositary of our ADS program, and certain taxes and governmental charges (in addition to any applicable fees, expenses, taxes and other governmental charges payable on the deposited securities represented by ADSs):

Service		Fees

• To any person to which ADSs are issued or to any person to which a distribution is made in respect of ADS distributions pursuant to stock dividends or other free distributions of stock, bonus distributions, stock splits or other distributions (except where converted to cash)		Up to $0.05 per ADS issued
• Cancellation or withdrawal of ADSs, including the case of termination of the deposit agreement		Up to $0.05 per ADS cancelled
• Distribution of cash dividends		Up to $0.05 per ADS held
• Distribution of cash entitlements (other than cash dividends) and/or cash proceeds from the sale of rights, securities and other entitlements		Up to $0.05 per ADS held
• Distribution of ADSs pursuant to exercise of rights		Up to $0.05 per ADS held
• Depositary services		Up to $0.05 per ADS held on the applicable record date(s) established by the depositary bank (an annual fee)

ADS holders will also be responsible to pay certain fees and expenses incurred by the depositary bank and certain taxes and governmental charges (in addition to any applicable fees, expenses, taxes and other governmental charges payable on the deposited securities represented by any of your ADSs) such as:

•: Fees for the transfer and registration of ordinary shares charged by the registrar and transfer agent for the ordinary shares in the Cayman Islands (i.e., upon deposit and withdrawal of ordinary shares).
•: Expenses incurred for converting foreign currency into U.S. dollars.
•: Expenses for cable, telex and fax transmissions and for delivery of securities.

237

Table of Contents

•: Taxes and duties upon the transfer of securities, including any applicable stamp duties, any stock transfer charges or withholding taxes (i.e., when ordinary shares are deposited or withdrawn from deposit).
•: Fees and expenses incurred in connection with the delivery or servicing of ordinary shares on deposit.
•: Fees and expenses incurred in connection with complying with exchange control regulations and other regulatory requirements applicable to ordinary shares, ordinary shares deposited securities, ADSs and ADRs.
•: Any applicable fees and penalties thereon.

The depositary fees payable upon the issuance and cancellation of ADSs are typically paid to the depositary bank by the brokers (on behalf of their clients) receiving the newly issued ADSs from the depositary bank and by the brokers (on behalf of their clients) delivering the ADSs to the depositary bank for cancellation. The brokers in turn charge these fees to their clients. Depositary fees payable in connection with distributions of cash or securities to ADS holders and the depositary services fee are charged by the depositary bank to the holders of record of ADSs as of the applicable ADS record date.

The depositary fees payable for cash distributions are generally deducted from the cash being distributed or by selling a portion of distributable property to pay the fees. In the case of distributions other than cash (i.e., share dividends, rights), the depositary bank charges the applicable fee to the ADS record date holders concurrent with the distribution. In the case of ADSs registered in the name of the investor (whether certificated or uncertificated in direct registration), the depositary bank sends invoices to the applicable record date ADS holders. In the case of ADSs held in brokerage and custodian accounts (via DTC), the depositary bank generally collects its fees through the systems provided by DTC (whose nominee is the registered holder of the ADSs held in DTC) from the brokers and custodians holding ADSs in their DTC accounts. The brokers and custodians who hold their clients' ADSs in DTC accounts in turn charge their clients' accounts the amount of the fees paid to the depositary banks.

In the event of refusal to pay the depositary fees, the depositary bank may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder.

The depositary has agreed to pay certain amounts to us in exchange for its appointment as depositary. We may use these funds towards our expenses relating to the establishment and maintenance of the ADR program, including investor relations expenses, or otherwise as we see fit. In 2017, we did not collect any reimbursements from the depositary for expenses related to the administration and maintenance of the facility.

PART II

ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

None.

ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

A. Material Modifications to the Rights of Security Holders

None.

238

Table of Contents

B. Use of Proceeds

U.S. Initial Public Offering

As of December 31, 2017, we have used all of the approximately $96.0 million of the net proceeds from our U.S. initial public offering as follows:

•: approximately $40.8 million to accelerate and broaden clinical development of the drug candidates for which we retain all worldwide rights, specifically:
i: approximately $6.6 million to advance HMPL-523 including the Phase I trial in healthy volunteers in Australia & China and the two Phase I studies in hematological cancer in China and Australia;
ii: approximately $20.9 million to advance sulfatinib including the Phase II open-label trial in first-line neuroendocrine tumors in China, the two Phase III trials in pancreatic and extrapancreatic neuroendocrine tumors in China, the Phase I bridging study in the United States, the Phase II trial in thyroid cancer, and the Phase II trial in biliary tract cancer in China;
iii: approximately $5.0 million to advance epitinib including the Phase II trial in non-small cell lung cancer patients with activating EGFR-mutation positive with brain metastasis in China;
iv: approximately $1.4 million to advance theliatinib including the Phase I trial in wild-type EGFR-mutation positive non-small cell lung cancer and the Phase Ib trial in esophageal cancer in China;
v: approximately $3.9 million to advance HMPL-689 including the Phase I dose escalation trial in healthy volunteers in Australia & China; and
vi: approximately $3.0 million to advance HMPL-453 including initiating the Phase I dose escalation trials in China and Australia.
•: approximately $31.8 million to support our share of the research and development costs of our partnered drug candidates, including:
i: approximately $11.5 million to advance savolitinib including preparations to initiate a Phase III study in papillary renal cell carcinoma, the Phase Ib study in second-line, EGFR tyrosine kinase inhibitor refractory non-small cell lung cancer in combination with Iressa, the two Phase Ib trials in c-Met-driven first-line non-small cell lung cancer, and the three Phase Ib trials in gastric cancer with c-Met gene amplification or c-Met over-expression, as monotherapy or in combination with Taxotere;
ii: approximately $19.0 million to advance fruquintinib including Phase II and Phase III trials in third-line colorectal cancer, Phase II and Phase III trials in third-line non-small cell lung cancer, a Phase Ib trial in gastric cancer in combination with Taxol, and initiating a Phase II trial in first-line non-small cell lung cancer in combination with Iressa, which we began enrolling in January 2017; and
iii: approximately $1.3 million to advance new formulations of HMPL-004, including HM004-6599, and other botanical drug candidates.
•: approximately $18.6 million from the net proceeds to support our discovery platform:
i: approximately $8.3 million for external research services and supplies; and
ii: approximately $10.3 million for our development and discovery research team.
•: approximately $4.8 million to build production facilities to produce both clinical and commercial supply of our drug candidates.

239

Table of Contents

C-D. Assets Securing Securities; Trustees; Paying Agents

None.

ITEM 15. CONTROLS AND PROCEDURES

A. Evaluation of Disclosure Controls and Procedures.

As required by Rule 13a-15 under the Exchange Act, management, including our chief executive officer and our chief financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding our required disclosure. Based on such evaluation, our management has concluded that, as of December 31, 2017, our disclosure controls and procedures were effective.

B. Management's Annual Report on Internal Control over Financial Reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) and 15d-15(f) promulgated under the Securities Exchange Act of 1934. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with U.S. GAAP and includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of a company's assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that a company's receipts and expenditures are being made only in accordance with authorizations of a company's management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of a company's assets that could have a material effect on the consolidated financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness of our internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our management, with the participation of our chief executive officer and chief financial officer, has assessed the effectiveness of our internal control over financial reporting as of December 31, 2017. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013 Framework). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2017.

C. Attestation Report of the Independent Registered Public Accounting Firm.

Our independent registered public accounting firm, PricewaterhouseCoopers, has audited the effectiveness of our internal control over financial reporting as of December 31, 2017, as stated in its report, which appears on page F-2 of this annual report.

240

Table of Contents

D. Changes in Internal Control over Financial Reporting.

There were no changes in our internal controls over financial reporting during fiscal 2017 that have materially and adversely affected, or are reasonably likely to materially and adversely affect, our internal control over financial reporting.

ITEM 16. RESERVED

ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERTS

Our audit committee consists of Graeme Jack, Paul Carter and Karen Ferrante, with Graeme Jack serving as chairman of the committee. Michael Howell, Christopher Huang and Christopher Nash previously served on our audit committee until March 1, 2017, February 1, 2017 and February 1, 2017, respectively. Graeme Jack, Paul Carter and Karen Ferrante each meet the independence requirements under the rules of the Nasdaq Stock Market and under Rule 10A-3 under the Exchange Act. We have determined that Graeme Jack is an "audit committee financial expert" within the meaning of Item 407 of Regulation S-K. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq Stock Market. For information relating to qualifications and experience of each audit committee member, see Item 6. "Directors, Senior Management and Employees."

ITEM 16B. CODE OF ETHICS

Our board of directors has adopted a code of ethics applicable to all of our employees, officers and directors, including our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions. This code is intended to qualify as a "code of ethics" within the meaning of the applicable rules of the SEC. Our code of ethics is available on our website at http://www.chi-med.com/leadership-governance/terms-of-reference-policies/code-of-ethics/. Information contained on, or that can be accessed through, our website is not incorporated by reference into this annual report. See Item 6.C. "Board Practices—Code of Ethics" for more information.

ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Principal Accountant Fees and Services

The following table summarizes the fees charged by PricewaterhouseCoopers for certain services rendered to our company, including some of our subsidiaries and joint ventures, during 2016 and 2017.

	For the year ended December 31,

	2017		2016
	(in thousands)
Audit fees⁽¹⁾		2,360		2,115
Tax fees⁽²⁾		—		30
Other service fees⁽³⁾		105		—

Total⁽⁴⁾		2,465		2,145

(1): "Audit fees" means the aggregate fees billed in each of the fiscal years for professional services rendered by PricewaterhouseCoopers for the audit of our annual financial statements and review of our interim financial statements, filing of our Form S-8 and professional services in connection with our initial public offering and follow-on offering in the United States.
(2): "Tax fees" means the aggregate fees billed in each of the fiscal years for professional services rendered by PricewaterhouseCoopers for tax compliance and tax advice.

241

Table of Contents

(3): "Other service fees" means the aggregate fees billed in 2017 for professional services rendered by PricewaterhouseCoopers for IT system and security assessment.
(4): The fees disclosed are exclusive of out-of-pocket expenses and taxes on the amounts paid, which totaled approximately $82,000 and $139,000 in 2016 and 2017, respectively.

Audit Committee Pre-approval Policies and Procedures

Our audit committee reviews and pre-approves the scope and the cost of audit services related to us and permissible non-audit services performed by the independent auditors, other than those for de minimis services which are approved by the audit committee prior to the completion of the audit. All of the services related to our company provided by PricewaterhouseCoopers listed above have been approved by the audit committee.

ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

Not applicable.

ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

None.

ITEM 16F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT

Not applicable.

ITEM 16G. CORPORATE GOVERNANCE

As permitted by Nasdaq, in lieu of the Nasdaq corporate governance rules, but subject to certain exceptions, we may follow the practices of our home country which for the purpose of such rules is the Cayman Islands. Certain corporate governance practices in the Cayman Islands may differ significantly from corporate governance listing standards as, except for general fiduciary duties and duties of care, Cayman Islands law has no corporate governance regime which prescribes specific corporate governance standards. For example, we follow Cayman Islands corporate governance practices in lieu of the corporate governance requirements of the Nasdaq Global Select Market in respect of the following:

(i): the majority independent director requirement under Section 5605(b)(1) of the Nasdaq listing rules,
(ii): the requirement under Section 5605(d) of the Nasdaq listing rules that a remuneration committee comprised solely of independent directors governed by a remuneration committee charter oversee executive compensation, and
(iii): the requirement under Section 5605(e) of the Nasdaq listing rules that director nominees be selected or recommended for selection by either a majority of the independent directors or a nominations committee comprised solely of independent directors.

Cayman Islands law does not impose a requirement that our board of directors consist of a majority of independent directors. Nor does Cayman Islands law impose specific requirements on the establishment of a remuneration committee or nominating committee or nominating process.

ITEM 16H. MINE SAFETY DISCLOSURE

Not applicable.

242

Table of Contents

PART III

ITEM 17. FINANCIAL STATEMENTS

See Item 18 "Financial Statements."

ITEM 18. FINANCIAL STATEMENTS

Our consolidated financial statements and the consolidated financial statements of our three non-consolidated joint ventures, Shanghai Hutchison Pharmaceuticals, Hutchison Baiyunshan and Nutrition Science Partners, are included at the end of this annual report.

The consolidated financial statements of Nutrition Science Partners relating to the year ended December 31, 2017 included herein are not the Hong Kong statutory annual financial statements of Nutrition Science Partners for that year. As Nutrition Science Partners is a private company, it is not required to deliver its financial statements with its annual returns to the Hong Kong Registrar of Companies and has not done so. Nutrition Science Partners' auditor has separately reported on those financial statements. The auditor's report was unqualified; did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying its report; and did not contain a statement under sections 406(2), 407(2) or (3) of the Hong Kong Companies Ordinance Cap. 622.

243

Table of Contents

ITEM 19. EXHIBITS

EXHIBIT INDEX


1.1	*	Memorandum and Articles of Association of Hutchison China MediTech Limited (incorporated by reference to Exhibit 3.1 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

2.1	*	Form of Deposit Agreement and all holders and beneficial owners of ADSs issued thereunder (incorporated by reference to Exhibit 4.1 to Amendment No. 4 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on March 4, 2016)

2.2	*	Form of American Depositary Receipt (incorporated by reference to Exhibit 4.1 to Amendment No. 4 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on March 4, 2016)

2.3	*	Form of Specimen Certificate for Ordinary Shares (incorporated by reference to Exhibit 4.3 to Amendment No. 2 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on February 11, 2016)

4.1	*⁺	License and Collaboration Agreement by and between Hutchison MediPharma Limited and AstraZeneca AB (publ) dated as of December 21, 2011 (incorporated by reference to Exhibit 10.9 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.2	*⁺	Amended and Restated Exclusive License and Collaboration Agreement by and among Hutchison MediPharma Limited, Eli Lilly Trading (Shanghai) Company Limited and Hutchison China MediTech Limited dated as of October 8, 2013 (incorporated by reference to Exhibit 10.10 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.3	*⁺	Option Agreement by and between Hutchison China MediTech Limited and Eli Lilly and Company dated as of October 8, 2013 (incorporated by reference to Exhibit 10.11 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.4	*⁺	Joint Venture Agreement by and among Hutchison MediPharma (Hong Kong) Limited, Nestlé Health Science S.A., Nutrition Science Partners Limited and Hutchison China MediTech Limited dated as of November 27, 2012 (incorporated by reference to Exhibit 10.12 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on November 13, 2015)

4.5	*⁺	English translation of Sino-Foreign Joint Venture Contract by and between Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited and Hutchison Chinese Medicine (Guangzhou) Investment Limited dated as of November 28, 2004 (incorporated by reference to Exhibit 10.13 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.6	*⁺	English translation of Sino-Foreign Joint Venture Contract by and between Shanghai Traditional Chinese Medicine Co., Ltd. and Hutchison Chinese Medicine (Shanghai) Investment Limited dated as of January 6, 2001 (incorporated by reference to Exhibit 10.14 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

244

Table of Contents


4.7	*	English translation of First Amendment to Sino-Foreign Joint Venture Contract by and between Shanghai Traditional Chinese Medicine Co., Ltd. and Hutchison Chinese Medicine (Shanghai) Investment Limited dated as of July 12, 2001 (incorporated by reference to Exhibit 10.15 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.8	*	English translation of Second Amendment to Sino-Foreign Joint Venture Contract by and between Shanghai Traditional Chinese Medicine Co., Ltd. and Shanghai Hutchison Chinese Medicine (HK) Investment Limited dated as of November 5, 2007 (incorporated by reference to Exhibit 10.16 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.9	*	English translation of Third Amendment to Sino-Foreign Joint Venture Contract by and between Shanghai Traditional Chinese Medicine Co., Ltd. and Shanghai Hutchison Chinese Medicine (HK) Investment Limited dated as of June 19, 2012 (incorporated by reference to Exhibit 10.17 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.10	*⁺	English translation of Fourth Amendment to Sino-Foreign Joint Venture Contract by and between Shanghai Traditional Chinese Medicine Co., Ltd. and Shanghai Hutchison Chinese Medicine (HK) Investment Limited dated as of March 8, 2013 (incorporated by reference to Exhibit 10.18 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.11	*	English translation of Sino-Foreign Joint Venture Contract by and between Sinopharm Group Co. Ltd. and Hutchison Chinese Medicine GSP (HK) Holdings Limited dated as of December 18, 2013 (incorporated by reference to Exhibit 10.19 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.12	*	Revolving Loan Facility Agreement by and between Hutchison China MediTech (HK) Limited as borrower and The Hongkong and Shanghai Banking Corporation Limited as lender dated January 3, 2013 (incorporated by reference to Exhibit 10.22 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.13	*	Form of Executive Employment Agreement for Hutchison China MediTech (HK) Limited executive officers (incorporated by reference to Exhibit 10.23 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.14	*	English translation of Form of Executive Employment Agreement for Hutchison MediPharma Limited executive officers (incorporated by reference to Exhibit 10.24 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.15	*	Form of Indemnification Agreement for Directors and Officers (incorporated by reference to Exhibit 10.25 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

4.16	*⁺	First Amendment to License and Collaboration Agreement by and between Hutchison MediPharma Limited and AstraZeneca (publ) dated as of August 1, 2016 (incorporated by reference to Exhibit 4.19 to our annual report on Form 20-F filed with the SEC on March 13, 2017)

245

Table of Contents


8.1	*	List of Significant Subsidiaries of the Company (incorporated by reference to Exhibit 21.1 to our Registration Statement on Form F-1 (file no. 333-207447) filed with the SEC on October 16, 2015)

12.1	**	Certification of Chief Executive Officer Required by Rule 13a-14(a)

12.2	**	Certification of Chief Financial Officer Required by Rule 13a-14(a)

13.1	^†	Certification of Chief Executive Officer Required by Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code

13.2	^†	Certification of Acting Chief Financial Officer Required by Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code

15.1	**	Consent of PricewaterhouseCoopers, an independent registered accounting firm, regarding the consolidated financial statements of Hutchison China MediTech Limited

15.2	**	Consent of PricewaterhouseCoopers, an independent registered accounting firm, regarding the consolidated financial statements of Nutrition Science Partners Limited

15.3	**	Consent of PricewaterhouseCoopers Zhong Tian LLP, independent accountants, regarding the consolidated financial statements of Shanghai Hutchison Pharmaceuticals Limited

15.4	**	Consent of PricewaterhouseCoopers Zhong Tian LLP, independent accountants, regarding the consolidated financial statements of Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited

15.5	**	Consent of Conyers Dill & Pearman

101.INS	**	XBRL Instance Document

101.SCH	**	XBRL Taxonomy Extension Schema Document

101.CAL	**	XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB	**	XBRL Taxonomy Extension Label Linkbase Document

101.PRE	**	XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF	**	XBRL Taxonomy Extension Definitions Linkbase Document

*: Previously filed.
**: Filed herewith.
†: Furnished herewith.
+: Confidential treatment previously requested and granted as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.

246

Table of Contents

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on annual report on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

247

Table of Contents

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS


Audited Consolidated Financial Statements of Hutchison China MediTech Limited
Report of Independent Registered Public Accounting Firm			F-2
As at December 31, 2017 and December 31, 2016:
Consolidated Balance Sheets			F-4
For the Years Ended December 31, 2017, 2016 and 2015:
Consolidated Statements of Operations			F-5
Consolidated Statements of Comprehensive (Loss)/Income			F-6
Consolidated Statements of Changes in Shareholders' Equity			F-7
Consolidated Statements of Cash Flows			F-8
Notes to the Consolidated Financial Statements			F-9
Audited Consolidated Financial Statements of Shanghai Hutchison Pharmaceuticals Limited
Report of Independent Auditors			F-54
For the Years Ended December 31, 2017, 2016 and 2015:
Consolidated Income Statements			F-55
Consolidated Statements of Comprehensive Income			F-56
As at December 31, 2017 and December 31, 2016:
Consolidated Statements of Financial Position			F-57
For the Years Ended December 31, 2017, 2016 and 2015:
Consolidated Statements of Changes in Equity			F-58
Consolidated Statements of Cash Flows			F-59
Notes to the Consolidated Financial Statements			F-60
Audited Consolidated Financial Statements of Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
Report of Independent Auditors			F-83
For the Years Ended December 31, 2017, 2016 and 2015:
Consolidated Income Statements			F-84
Consolidated Statements of Comprehensive Income			F-85
As at December 31, 2017 and December 31, 2016:
Consolidated Statements of Financial Position			F-86
For the Years Ended December 31, 2017, 2016 and 2015:
Consolidated Statements of Changes in Equity			F-87
Consolidated Statements of Cash Flows			F-88
Notes to the Consolidated Financial Statements			F-89
Audited Consolidated Financial Statements of Nutrition Science Partners Limited
Report of Independent Auditors			F-116
For the Years Ended December 31, 2017, 2016 and 2015:
Consolidated Income Statements			F-117
Consolidated Statements of Comprehensive Income			F-118
As at December 31, 2017 and December 31, 2016:
Consolidated Statements of Financial Position			F-119
For the Years Ended December 31, 2017, 2016 and 2015:
Consolidated Statements of Changes in Equity			F-120
Consolidated Statements of Cash Flows			F-121
Notes to the Consolidated Financial Statements			F-122

F-1

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of Hutchison China MediTech Limited

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Hutchison China MediTech Limited and its subsidiaries as of December 31, 2017 and 2016, and the related consolidated statements of operations, of comprehensive (loss)/income, of changes in shareholders' equity and of cash flows for each of the three years in the period ended December 31, 2017, including the related notes (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2017 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control—Integrated Framework (2013) issued by the COSO.

Change in Accounting Principle

As discussed in Note 23 (ii) to the consolidated financial statements, the Company changed the manner in which it classifies deferred income tax assets and liabilities in 2017.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 15 of Form 20-F. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing

F-2

Table of Contents

such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ PricewaterhouseCoopers
Hong Kong
March 12, 2018

We have served as the Company's auditor since 2005, which includes periods before the Company became subject to SEC reporting requirements.

F-3

Table of Contents

Hutchison China MediTech Limited
Consolidated Balance Sheets
(in US$'000)

		December 31,

	Note	2017		2016
Assets
Current assets
Cash and cash equivalents	5	85,265		79,431
Short-term investments	6	273,031		24,270
Accounts receivable—third parties	7	38,410		40,812
Accounts receivable—related parties	22(ii)	3,860		4,223
Other receivables, prepayments and deposits	8	11,296		4,314
Amounts due from related parties	22(ii)	8,544		1,136
Inventories	9	11,789		12,822
Deferred tax assets	23(ii)	—		372

Total current assets		432,195		167,380
Property, plant and equipment	10	14,220		9,954
Leasehold land		1,261		1,220
Goodwill		3,308		3,137
Other intangible asset		430		469
Deferred tax assets	23(ii)	633		—
Long-term prepayment		1,648		1,771
Investments in equity investees	11	144,237		158,506

Total assets		597,932		342,437



Liabilities and shareholders' equity
Current liabilities
Accounts payable	12	24,365		35,538
Other payables, accruals and advance receipts	13	40,953		31,716
Income tax payable	23(iii)	979		274
Deferred revenue		1,295		962
Amounts due to related parties	22(ii)	7,021		5,308
Short-term bank borrowings	14	29,987		19,957
Deferred tax liabilities	23(ii)	—		1,364

Total current liabilities		104,600		95,119
Deferred tax liabilities	23(ii)	4,452		3,997
Long-term bank borrowings	14	—		26,830
Deferred revenue		809		2,039
Other deferred income		1,988		2,263
Other non-current liabilities		1,117		8,129

Total liabilities		112,966		138,377
Commitments and contingencies	15

Company's shareholders' equity
Ordinary shares; $1.00 par value; 75,000,000 shares authorized; 66,447,037 and 60,705,823 shares issued at December 31, 2017 and 2016 respectively	17	66,447		60,706
Additional paid-in capital		496,960		208,196
Accumulated losses		(107,104	)	(80,357	)
Accumulated other comprehensive income/(loss)		5,430		(4,275	)

Total Company's shareholders' equity		461,733		184,270
Non-controlling interests		23,233		19,790

Total shareholders' equity		484,966		204,060

Total liabilities and shareholders' equity		597,932		342,437

The accompanying notes are an integral part of these consolidated financial statements.

F-4

Table of Contents

Hutchison China MediTech Limited
Consolidated Statements of Operations
(in US$'000, except share and per share data)

		Year Ended December 31,

	Note	2017		2016		2015
Revenues
Sales—third parties		196,720		171,058		118,113
Sales—related parties	22(i)	8,486		9,794		8,074
Revenue from license and collaboration agreements—third parties	19	26,315		26,444		44,060
Revenue from research and development services—third parties		—		355		2,573
Revenue from research and development services—related parties	22(i)	9,682		8,429		5,383

Total revenues	25	241,203		216,080		178,203

Operating expenses
Costs of sales—third parties		(169,764	)	(149,132	)	(104,859	)
Costs of sales—related parties		(6,056	)	(7,196	)	(5,918	)
Research and development expenses	20	(75,523	)	(66,871	)	(47,368	)
Selling expenses		(19,322	)	(17,998	)	(10,209	)
Administrative expenses		(23,955	)	(21,580	)	(19,620	)

Total operating expenses		(294,620	)	(262,777	)	(187,974	)

Loss from operations		(53,417	)	(46,697	)	(9,771	)
Other income/(expense)
Interest income	25	1,220		502		451
Other income		808		609		386
Interest expense	25	(1,455	)	(1,631	)	(1,404	)
Other expense		(692	)	(139	)	(202	)

Total other income/(expense)		(119	)	(659	)	(769	)

Loss before income taxes and equity in earnings of equity investees		(53,536	)	(47,356	)	(10,540	)
Income tax expense	23(i)	(3,080	)	(4,331	)	(1,605	)
Equity in earnings of equity investees, net of tax	11	33,653		66,244		22,572

Net (loss)/income		(22,963	)	14,557		10,427
Less: Net income attributable to non-controlling interests		(3,774	)	(2,859	)	(2,434	)

Net (loss)/income attributable to the Company		(26,737	)	11,698		7,993
Accretion on redeemable non-controlling interests		—		—		(43,001	)

Net (loss)/income attributable to ordinary shareholders of the Company		(26,737	)	11,698		(35,008	)



(Losses)/earnings per share attributable to ordinary shareholders of the Company—basic (US$ per share)	24(i)	(0.43	)	0.20		(0.64	)
(Losses)/earnings per share attributable to ordinary shareholders of the Company—diluted (US$ per share)	24(ii)	(0.43	)	0.20		(0.64	)
Number of shares used in per share calculation—basic	24(i)	61,717,171		59,715,173		54,659,315
Number of shares used in per share calculation—diluted	24(ii)	61,717,171		59,971,050		54,659,315

The accompanying notes are an integral part of these consolidated financial statements.

F-5

Table of Contents

Hutchison China MediTech Limited
Consolidated Statements of Comprehensive (Loss)/Income
(in US$'000)

	Year Ended December 31,

	2017		2016		2015
Net (loss)/income	(22,963	)	14,557		10,427
Other comprehensive income/(loss)
Foreign currency translation gain/(loss)	10,964		(10,722	)	(5,557	)

Total comprehensive (loss)/income	(11,999	)	3,835		4,870
Less: Comprehensive income attributable to non-controlling interests	(5,033	)	(1,427	)	(1,732	)

Total comprehensive (loss)/income attributable to the Company	(17,032	)	2,408		3,138

The accompanying notes are an integral part of these consolidated financial statements.

F-6

Table of Contents

Hutchison China MediTech Limited
Consolidated Statements of Changes in Shareholders' Equity
(in US$'000, except share data in '000)

	Ordinary Shares Number	Ordinary Shares Value	Additional Paid-in Capital		Accumulated Losses		Accumulated Other Comprehensive Income/(Loss)		Total Company's Shareholders' Equity		Non- controlling Interests		Total Equity

As at December 31, 2014	53,076	53,076	76,256		(100,051	)	9,870		39,151		17,764		56,915
Net income	—	—	—		7,993		—		7,993		2,434		10,427
Accretion to redemption value of redeemable non-controlling interests	—	—	(43,001	)	—		—		(43,001	)	—		(43,001	)
Issuance in exchange for redeemable non-controlling interest	3,214	3,214	80,823		—		—		84,037		—		84,037
Issuances in relation to share option exercises	243	243	1,131		—		—		1,374		—		1,374
Share-based compensation
Share options	—	—	168		—		—		168		—		168
Long-term incentive plan ("LTIP")	—	—	233		—		—		233		—		233

	—	—	401		—		—		401		—		401

LTIP—treasury shares acquired and held by Trustee	—	—	(1,786	)	—		—		(1,786	)	—		(1,786	)
Dividend paid to a non-controlling shareholder of a subsidiary	—	—	—		—		—		—		(590	)	(590	)
Dilution of interests in a subsidiary in relation to exercise of share options of a subsidiary	—	—	—		42		—		42		15		57
Transfer between reserves	—	—	24		(24	)	—		—		—		—
Foreign currency translation adjustments	—	—	—		—		(4,855	)	(4,855	)	(702	)	(5,557	)

As at December 31, 2015	56,533	56,533	113,848		(92,040	)	5,015		83,356		18,921		102,277



Net income	—	—	—		11,698		—		11,698		2,859		14,557
Issuance in relation to public offering	4,080	4,080	106,080		—		—		110,160		—		110,160
Issuance costs	—	—	(14,227	)	—		—		(14,227	)	—		(14,227	)
Issuances in relation to share option exercises	93	93	333		—		—		426		—		426
Share-based compensation
Share options	—	—	1,373		—		—		1,373		4		1,377
LTIP	—	—	1,378		—		—		1,378		2		1,380

	—	—	2,751		—		—		2,751		6		2,757

LTIP—treasury shares acquired and held by Trustee	—	—	(604	)	—		—		(604	)	—		(604	)
Dividend paid to a non-controlling shareholder of a subsidiary	—	—	—		—		—		—		(564	)	(564	)
Transfer between reserves	—	—	15		(15	)	—		—		—		—
Foreign currency translation adjustments	—	—	—		—		(9,290	)	(9,290	)	(1,432	)	(10,722	)

As at December 31, 2016	60,706	60,706	208,196		(80,357	)	(4,275	)	184,270		19,790		204,060



Net loss	—	—	—		(26,737	)	—		(26,737	)	3,774		(22,963	)
Issuance in relation to public offering	5,685	5,685	295,615		—		—		301,300		—		301,300
Issuance costs	—	—	(8,610	)	—		—		(8,610	)	—		(8,610	)
Issuances in relation to share option exercises	56	56	324		—		—		380		—		380
Share-based compensation
Share options	—	—	1,255		—		—		1,255		3		1,258
LTIP	—	—	1,537		—		—		1,537		1		1,538

	—	—	2,792		—		—		2,792		4		2,796

LTIP—treasury shares acquired and held by Trustee	—	—	(1,367	)	—		—		(1,367	)	—		(1,367	)
Dividends paid to non-controlling shareholders of subsidiaries	—	—	—		—		—		—		(1,594	)	(1,594	)
Transfer between reserves	—	—	10		(10	)	—		—		—		—
Foreign currency translation adjustments	—	—	—		—		9,705		9,705		1,259		10,964

As at December 31, 2017	66,447	66,447	496,960		(107,104	)	5,430		461,733		23,233		484,966

The accompanying notes are an integral part of these consolidated financial statements.

F-7

Table of Contents

Hutchison China MediTech Limited
Consolidated Statements of Cash Flows
(in US$'000)

		Year Ended December 31,

	Note	2017		2016		2015
Net cash used in operating activities	26	(8,943	)	(9,569	)	(9,385	)

Investing activities
Purchases of property, plant and equipment	10	(5,019	)	(4,327	)	(3,324	)
Deposits in short-term investments		(325,032	)	(80,857	)	—
Proceeds from short-term investments		76,271		56,587		12,179
Investment in an equity investee	11	(7,000	)	(5,000	)	—

Net cash (used in)/generated from investing activities		(260,780	)	(33,597	)	8,855

Financing activities
Proceeds from issuance of ordinary shares		301,680		110,586		1,374
Proceeds from exercise of share options of a subsidiary		—		—		57
Purchases of treasury shares		(1,367	)	(604	)	(1,786	)
Dividends paid to non-controlling shareholders of subsidiaries		(1,594	)	(564	)	(590	)
Repayment of loan to a non-controlling shareholder of a subsidiary		—		(1,000	)	—
Proceeds from bank borrowings		32,540		25,128		3,205
Repayment of bank borrowings		(49,487	)	(28,205	)	(6,410	)
Payment of issuance costs		(8,576	)	(12,906	)	(1,321	)

Net cash generated from/(used in) financing activities		273,196		92,435		(5,471	)

Net increase/(decrease) in cash and cash equivalents		3,473		49,269		(6,001	)
Effect of exchange rate changes on cash and cash equivalents		2,361		(1,779	)	(1,004	)

		5,834		47,490		(7,005	)
Cash and cash equivalents
Cash and cash equivalents at beginning of year		79,431		31,941		38,946

Cash and cash equivalents at end of year		85,265		79,431		31,941



Supplemental disclosure for cash flow information
Cash paid for interest		763		1,570		1,220
Cash paid for tax, net of refunds		3,836		2,664		510
Supplemental disclosure for non-cash activities
Accruals made for purchases of property, plant and equipment		1,054		—		—
Accrued issuance costs for public offering		34		—		3,125
Vesting of treasury shares for LTIP	18 (iii)	1,800		—		—
Capitalization of amounts due from related parties to investments in equity investees		—		7,000		—
Issuance of ordinary shares in exchange of redeemable non-controlling interests	16	—		—		84,037

The accompanying notes are an integral part of these consolidated financial statements.

F-8

Table of Contents

Hutchison China MediTech Limited
Notes to the Consolidated Financial Statements

1. Organization and Nature of Business

Hutchison China MediTech Limited (the "Company") and its subsidiaries (together the "Group") are principally engaged in researching, developing, manufacturing and selling pharmaceuticals and healthcare products. The Group and its equity investees have research and development facilities and manufacturing plants in the People's Republic of China (the "PRC") and sell their products mainly in the PRC and Hong Kong.

The Company considers Hutchison Healthcare Holdings Limited as its immediate holding company and CK Hutchison Holdings Limited ("CK Hutchison") as its ultimate holding company.

The Company was incorporated in the Cayman Islands on December 18, 2000 as an exempted company with limited liability under the Companies Law (2000 Revision), Chapter 22 of the Cayman Islands. The address of its registered office is P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

The Company's ordinary shares are listed on the AIM market of the London Stock Exchange, and its American depositary shares ("ADS"), each representing one-half of one ordinary share, are traded on the Nasdaq Global Select Market.

Liquidity

As at December 31, 2017, the Group had accumulated losses of US$107,104,000, primarily due to its significant spending in research and development activities. The Group regularly monitors current and expected liquidity requirements to ensure that it maintains sufficient cash balances and adequate credit facilities to meet its liquidity requirements in the short and long term. As at December 31, 2017, the Group had cash and cash equivalents of US$85,265,000, short-term investments of US$273,031,000 and unutilized bank borrowing facilities of US$121,282,000. Short-term investments comprised of bank deposits maturing over three months. As at December 31, 2016, the Group had cash and cash equivalents of US$79,431,000, short-term investments of US$24,270,000 and unutilized bank borrowing facilities of US$70,000,000. The Group's operating plan includes the continued receipt of dividends from certain of its equity investees. The increase in cash balances is primarily due to a public follow-on offering of the Company's ADS in October 2017, which raised net proceeds of US$292,690,000. Additionally, dividends received from equity investees for the years ended December 31, 2017, 2016 and 2015 were US$55,586,000, US$30,528,000 and US$6,410,000 respectively.

Based on the Group's operating plan, the existing cash and cash equivalents, short-term investments and unutilized bank borrowing facilities are considered to be sufficient to meet the cash requirements to fund planned operations and other commitments for at least the next twelve months (the look-forward period used).

F-9

Table of Contents

2. Particulars of Principal Subsidiaries and Equity Investees

		Equity interest attributable to the Group

		As at December 31,
	Place of establishment and operations	As at December 31,
Name	Place of establishment and operations	2017	2016	Principal activities
Subsidiaries
Hutchison MediPharma Limited ("HMPL")	PRC	99.75%	99.75%	Research and development of pharmaceutical products
Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm")	PRC	51%	51%	Provision of sales, distribution and marketing services to pharmaceutical manufacturers
Hutchison Hain Organic (Hong Kong) Limited ("HHOL") (note (a))	Hong Kong	50%	50%	Wholesale and trading of healthcare and consumer products
Hutchison Hain Organic (Guangzhou) Limited ("HHOGZL") (note (a))	PRC	50%	50%	Wholesale and trading of healthcare and consumer products
Hutchison Healthcare Limited ("HHL")	PRC	100%	100%	Manufacture and distribution of healthcare products
Hutchison Consumer Products Limited	Hong Kong	100%	100%	Wholesale and trading of healthcare and consumer products
Equity investees
Shanghai Hutchison Pharmaceuticals Limited ("SHPL")	PRC	50%	50%	Manufacture and distribution of prescription drug products
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS") (note (b))	PRC	40%	40%	Manufacture and distribution of over-the-counter drug products
Nutrition Science Partners Limited ("NSPL") (note (c))	Hong Kong	49.88%	49.88%	Research and development of pharmaceutical products

Notes:

(a): HHOL and HHOGZL are regarded as subsidiaries of the Company, as while both shareholders of these subsidiaries have equal representation at their respective boards, in the event of a deadlock, the Group has a casting vote and is therefore able to unilaterally control the financial and operating policies of HHOL and HHOGZL.
(b): The 50% equity interest in HBYS is held by an 80% owned subsidiary of the Group. The effective equity interest of the Group in HBYS is therefore 40% for the years presented.
(c): The 50% equity interest in NSPL is held by a 99.75% owned subsidiary of the Group. The effective equity interest of the Group in NSPL is therefore 49.88% for the years presented.

3. Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation

The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Investments in equity investees over which the Group has significant influence are accounted for using the equity method. All inter-company balances and transactions have been eliminated in consolidation. The consolidated financial statements have been

F-10

Table of Contents

prepared in conformity with generally accepted accounting principles in the United States of America ("U.S. GAAP").

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as useful lives of property, plant and equipment, write-down of inventories, allowance for doubtful accounts, share-based compensation, impairments of long-lived assets, impairment of other intangible asset and goodwill, taxes on income, tax valuation allowances, revenues and cost accruals from research and development projects. Actual results could differ from those estimates.

Foreign Currency Translation

The Group's functional currency is Renminbi ("RMB") but the presentation currency is U.S. dollar ("US$"). The financial statements of the Company's subsidiaries with a functional currency other than the US$ have been translated into the Company's reporting currency, the US$. All assets and liabilities of the subsidiaries are translated using year-end exchange rates and revenues and expenses are translated at average exchange rates for the year. Translation adjustments are reflected in accumulated other comprehensive income/(loss) in shareholders' equity.

Net foreign currency exchange losses of US$316,000, US$109,000 and US$79,000 were recorded in other expense in the consolidated statements of operations for the years ended December 31, 2017, 2016 and 2015 respectively.

Cash and Cash Equivalents

The Group considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. Cash and cash equivalents consist primarily of cash on hand and bank deposits and are stated at cost, which approximates fair value.

Short-term Investments

Short-term investments include deposits placed with banks with original maturities of more than three months but less than one year.

Concentration of Credit Risk

Financial instruments that potentially expose the Group to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, accounts receivable, other receivables and amounts due from related parties.

The Group places substantially all of its cash and cash equivalents and short-term investments in major financial institutions, which management believes are of high credit quality. The Group has a practice to limit the amount of credit exposure to any particular financial institution.

The Group has no significant concentration of credit risk. The Group has policies in place to ensure that sales are made to customers with an appropriate credit history and the Group performs periodic credit evaluations of its customers. Normally the Group does not require collateral from trade debtors.

F-11

Table of Contents

Foreign Currency Risk

The Group's operating transactions and its assets and liabilities are mainly denominated in RMB, which is not freely convertible into foreign currencies. In the PRC, the Group's cash and cash equivalents denominated in RMB are subject to such government controls. The value of the RMB is subject to fluctuations from central government policy changes and international economic and political developments that affect the supply and demand of RMB in the foreign exchange market. In the PRC, certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange rates set by the People's Bank of China (the "PBOC"). Remittances in currencies other than RMB by the Group in the PRC must be processed through the PBOC or other PRC foreign exchange regulatory bodies which require certain supporting documentation in order to complete the remittance.

Fair Value of Financial Instruments

The fair value of financial instruments that are measured at fair value is determined according to a fair value hierarchy that prioritizes the inputs and assumptions used, and the valuation techniques used. The three levels of the fair value hierarchy are described as follows:


Level 1		Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2		Inputs are quoted prices for similar assets or liabilities in active markets; or quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.
Level 3		Inputs are unobservable inputs based on the Group's assumptions and valuation techniques used to measure assets or liabilities at fair value. The inputs require significant management judgment or estimation.

The assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of assets and liabilities and their placement within the fair value hierarchy levels.

The fair value of assets and liabilities is established using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, and a fair value hierarchy is established based on the inputs used to measure fair value.

Accounts Receivable

Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable regularly to determine if any receivable will potentially be uncollectible. Estimates are used to determine the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value. The amount of the allowance for doubtful accounts is recognized in the consolidated statements of operations.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined using the weighted average cost method. The cost of finished goods comprises raw materials, direct labor, other direct costs and related production overheads (based on normal operating capacity). Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. A provision for excess and obsolete inventory will be made based primarily on forecasts of product demand

F-12

Table of Contents

and production requirements. The excess balance determined by this analysis becomes the basis for excess inventory charge and the written-down value of the inventory becomes its cost. Written-down inventory is not written up if market conditions improve.

Property, Plant and Equipment

Property, plant and equipment consist of buildings, leasehold improvements, plant and equipment, furniture and fixtures, other equipment and motor vehicles. Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets.


Buildings		20 years
Plant and equipment		5-10 years
Furniture and fixtures, other equipment and motor vehicles		4-5 years
Leasehold improvements		Shorter of (a) 5 years or (b) remaining term of lease

Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations in the year of disposition. Additions and improvements that extend the useful life of an asset are capitalized. Repairs and maintenance costs are expensed as incurred.

Impairment of Long-Lived Assets

The Group evaluates the recoverability of long-lived assets in accordance with authoritative guidance on accounting for the impairment or disposal of long-lived assets. The Group evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. If such indicators exist, the first step of the impairment test is performed to assess if the carrying value of the net assets exceeds the undiscounted cash flows of the assets. If yes, the second step of the impairment test is performed in order to determine if the carrying value of the net assets exceeds the fair value. If yes, impairment is recognized for the excess.

Leasehold Land

Leasehold land represents fees paid to acquire the right to use the land on which various plants and buildings are situated for a specified period of time from the date the respective right was granted and are stated at cost less accumulated amortization and impairment loss, if any. Amortization is computed using the straight-line basis over the lease period of 50 years.

Goodwill

Goodwill represents the excess of the purchase price plus fair value of non-controlling interests over the fair value of identifiable assets and liabilities acquired. Goodwill is not amortized, but is tested for impairment at the reporting unit level on at least an annual basis or when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. When performing an evaluation of goodwill impairment, the Group has the option to first assess qualitative factors, such as significant events and changes to expectations and activities that may have occurred since the last impairment evaluation, to determine if it is more likely than not that goodwill might be impaired. If as a result of the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the quantitative fair value test is performed to determine if the fair value of the reporting unit exceeds its carrying value. No impairment of goodwill occurred in the years presented.

F-13

Table of Contents

The Group has adopted Accounting Standards Update ("ASU") 2017-04, Simplifying the Test for Goodwill Impairment, for annual goodwill impairment tests performed on testing dates after January 1, 2017. This guidance removes Step 2 of the goodwill impairment test, which required the estimation of an implied fair value of goodwill in the same manner as the calculation of goodwill upon a business combination. For prior years' annual goodwill impairment tests, the Group determined that the fair values of their reporting units exceeded their carrying values and Step 2 has never been required.

Other Intangible Assets

Other intangible assets with finite useful lives are carried at cost less accumulated amortization and impairment loss, if any. Amortization is computed using the straight-line basis over the estimated useful lives of the assets.

Borrowings

Borrowings are recognized initially at fair value, net of debt issuance costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations over the period of the borrowings using the effective interest method.

Ordinary Shares

The Company's ordinary shares are stated at par value of US$1.00 per ordinary share. The difference between the consideration received, net of issuance cost, and the par value is recorded in additional paid-in capital.

Treasury Shares

The Group accounts for treasury shares under the cost method. The treasury shares were purchased for the purpose of the LTIP.

Convertible Preferred Shares

When the Company or its subsidiaries issue preferred shares, the Group assesses whether such instruments should be liabilities, mezzanine equity, or permanent equity classified based on multiple indicators such as redemption features, conversion features, voting rights and other embedded features. Freestanding equity instruments with mandatory redemption requirements, embodying an obligation to repurchase the issuer's equity shares by transferring assets, or certain obligations to issue a variable number of shares, are treated as liability-classified instruments. Equity instruments that are redeemable at the option of the holder or not solely within the Group's control are classified as mezzanine equity of the issuer entity (and redeemable non-controlling interests in the consolidated financial statements of the Group if preferred shares are issued by its subsidiaries). Subsequent measurements of financing instruments are driven by the instruments' balance sheet classification.

The Group also reviews the terms of each convertible instrument and determines whether the host instrument is more akin to debt or equity based on the economic characteristics and risks in order to evaluate if there were any embedded features which would require bifurcation and separate accounting from the host contract. For embedded conversion features that are not required to be separated, the Group analyzes the accounting conversion price and the Company's share price at the commitment date to identify any beneficial conversion features.

For any amendment to the terms of the preferred shares not classified as liabilities, the Group assesses whether the amendment is an extinguishment or a modification using the fair value model. The Group considers a significant change in fair value immediately after the amendment to be substantive and to

F-14

Table of Contents

trigger extinguishment. A change in fair value which is not significant immediately after the amendment is considered non-substantive and thus is subject to modification accounting. When preferred shares are extinguished, the difference between the fair value of the consideration transferred to the preferred shareholders and the carrying amount of such preferred shares (net of issuance costs) is treated as a deemed dividend to the preferred shareholders. When preferred shares are modified and such modification results in a value transfer between preferred shareholders and ordinary shareholders, the change in fair value resulting from the amendment is treated as a deemed dividend to or from the preferred shareholders.

Share-Based Compensation

Share options

The Group recognizes share-based compensation expense on share options granted to employees and directors based on their estimated grant date fair value using the Polynomial model. This Polynomial pricing model uses various inputs to measure fair value, including estimated market value of the Company's underlying ordinary shares at the grant date, contractual terms, estimated volatility, risk-free interest rates and expected dividend yields. The Group recognizes share-based compensation expense in the consolidated statements of operations on a graded vesting basis over the requisite service period.

The Group has adopted ASU 2016-09, Improvements to Employee Share-Based Payment Accounting on January 1, 2017. This guidance permitted the Group to make an accounting policy election to account for forfeitures as they occur. The Group has elected to account for forfeitures as they occur and adopted this election using the modified retrospective approach as required with no cumulative effect adjustment. Prior to January 1, 2017, the Group applied an estimated forfeiture rate derived from historical and expected future employee termination behavior.

Share options are classified as equity-settled awards. Share-based compensation expense, when recognized, is charged to the consolidated statements of operations with the corresponding entry to additional paid-in capital.

LTIP

The Group recognizes the share-based compensation expense on the LTIP awards based on a fixed or determinable monetary amount on a straight line basis for each annual tranche awarded over the requisite period. For LTIP awards with performance targets, prior to their determination date, the amount of LTIP awards that is expected to vest takes into consideration the achievement of the performance conditions and the extent to which the performance conditions are likely to be met. Performance conditions vary by awards, including targets for shareholder returns, free cash flows, revenues, net profit after taxes and/or the achievement of clinical and regulatory milestones.

These LTIP awards are classified as liability-settled awards before the determination date (i.e. the date when the achievement of any performance conditions are known), as they settle in a variable number of shares based on a determinable monetary amount, which is determined upon the actual achievement of performance targets. As the extent of achievement of the performance targets is uncertain prior to the determination date, a probability based on management's assessment of the achievement of the performance targets has been assigned to calculate the amount to be recognized as an expense over the requisite period.

After the determination date or if the LTIP awards have no performance conditions, the LTIP awards are classified as equity-settled awards. If the performance target is achieved, the Group will pay the determined monetary amount to a trustee appointed by the Group (the "Trustee") to purchase ordinary shares of the Company or the equivalent ADS. Any cumulative compensation expense previously recognized as a liability will be transferred to additional paid in capital, as an equity-settled award. If the performance target is not achieved, no ordinary shares or ADS of the Company will be purchased and the amount previously recorded in the liability will be reversed and included in the consolidated statements of operations.

F-15

Table of Contents

Defined Contribution Plans

The Group's subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which certain retirement, medical and other welfare benefits are provided to employees. The relevant labor regulations require the Group's subsidiaries in the PRC to pay the local labor and social welfare authority's monthly contributions at a stated contribution rate based on the monthly basic compensation of qualified employees. The relevant local labor and social welfare authorities are responsible for meeting all retirement benefits obligations and the Group's subsidiaries in the PRC have no further commitments beyond their monthly contributions. The contributions to the plan are expensed as incurred.

The Group also makes payments to other defined contribution plans for the benefit of employees employed by subsidiaries outside the PRC. The defined contribution plans are generally funded by the relevant companies and by payments from employees.

The Group's contributions to defined contribution plans for the years ended December 31, 2017, 2016 and 2015 amounted to US$2,092,000, US$2,286,000 and US$1,653,000 respectively.

Revenue Recognition—Accounting Standard Codification 605

Sales

Revenue from sales of goods in the Commercial Platform segment are recognized when goods are delivered and title passes to the customer and there are no further obligations to the customer. Recognition of revenue also requires reasonable assurance of collection of sales proceeds and completion of all performance obligations. Sales discounts are issued to customers as direct discounts at the point-of-sale or indirectly in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns.

Revenue from sales of services in the Commercial Platform segment are recognized based on amounts that can be invoiced to the customer. The amount that can be invoiced corresponds directly with the value to the customer for performance completed to date.

Revenues from research and development projects

The Group recognizes revenue for the performance of services when each of the following four criteria are met: (i) persuasive evidence of an arrangement exists; (ii) services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured.

The Group follows Accounting Standard Codification ("ASC") 605-25, Revenue Recognition—Multiple-Element Arrangements and ASC 808, Collaborative Arrangements, if applicable, to determine the recognition of revenue under the Group's license and collaborative research, development and commercialization agreements. The terms of these agreements generally contain multiple elements, or deliverables, which may include (i) licenses to the Group's intellectual property, (ii) materials and technology, (iii) clinical supply, and/or (iv) participation in joint research or joint steering committees. The payments the Group may receive under these arrangements typically include one or more of the following: non-refundable, upfront license fees; funding of research and/or development efforts; amounts due upon the achievement of specified milestones; and/or royalties on future product sales.

ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable.

F-16

Table of Contents

To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The Group determines the estimated selling price for deliverables within each agreement using vendor-specific objective evidence ("VSOE") of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the Group's best estimate of selling price, if neither VSOE nor third-party evidence is available. Determining the best estimate of selling price for a deliverable requires significant judgment. The Group typically uses its best estimate of a selling price to estimate the selling price for licenses to development work, since it often does not have VSOE or third-party evidence of selling price for these deliverables. In those circumstances where the Group applies its best estimate of selling price to determine the estimated selling price of a license to development work, it considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its best estimate of selling price, the Group evaluates whether changes in the key assumptions used to determine its best estimate of selling price will have a significant effect on the allocation of arrangement consideration between deliverables. The Group recognizes consideration allocated to an individual element when all other revenue recognition criteria are met for that element.

The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria.

If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as unearned revenue in the accompanying balance sheets and recognized as revenue when the related revenue recognition criteria are met.

The Group typically receives non-refundable, upfront payments when licensing the Group's intellectual property, which often occurs in conjunction with a research and development agreement. If management believes that the license to the Group's intellectual property has stand-alone value, the Group generally recognizes revenue attributed to the license upon delivery provided that there are no future performance requirements for use of the license. When management believes that the license to the Group's intellectual property does not have stand-alone value, the Group will recognize revenue attributed to the license ratably over the contractual or estimated performance period. For payments payable on achievement of milestones that do not meet all of the conditions to be considered substantive, the Group recognizes a portion of the payment as revenue when the specific milestone is achieved, and the contingency is removed. Other contingent event-based payments for which payment is either contingent solely upon the passage of time or the result of a collaborator's performance are recognized when earned. The Group's collaboration and license agreements generally include contingent milestone payments related to specified pre-clinical research and development milestones, clinical development milestones, regulatory milestones and sales-based milestones. Pre-clinical research and development milestones are typically payable upon the selection of a compound candidate for the next stage of research and development. Clinical development milestones are typically payable when a product candidate initiates or advances in clinical trial phases or achieves defined clinical events such as proof-of-concept. Regulatory milestones are typically payable upon submission for marketing approval with regulatory authorities or upon receipt of actual marketing approvals for a compound, approvals for additional indications, or upon the first commercial sale. Sales-based milestones are typically payable when annual sales reach specified levels.

F-17

Table of Contents

At the inception of each arrangement that includes milestone payments, the Group evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (i) the entity's performance to achieve the milestone or (ii) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone; (b) the consideration relates solely to past performance; and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Group evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.

Research and Development Expenses

Research and development expenses consist primarily of salaries and benefits, share-based compensation, materials and supplies, contracted research, consulting arrangements and other expenses incurred to sustain the Group's research and development programs. Research and development costs are expensed as incurred.

Government Incentives

Incentives from governments are recognized at their fair values. Government incentives that are received in advance are deferred and recognized in the consolidated statements of operations over the period necessary to match them with the costs that they are intended to compensate. Government incentives in relation to the achievement of stages of research and development projects are recognized in the consolidated statements of operations when amounts have been received and all attached conditions have been met. Non-refundable incentives received without any further obligations or conditions attached are recognized immediately in the consolidated statements of operations.

Operating Leases

Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to the consolidated statements of operations on a straight-line basis over the period of the leases.

Total operating lease rentals for buildings for the years ended December 31, 2017, 2016 and 2015 amounted to US$2,285,000, US$1,838,000 and US$1,426,000 respectively. Sub-lease rentals for the years ended December 31, 2017, 2016 and 2015 amounted to US$274,000, US$228,000 and US$229,000 respectively.

Interest Income

Interest generated from cash and cash equivalents and short-term investments is recorded over the period earned. It is measured based on the actual amount of interest the Group earns.

Income Taxes

The Group accounts for income taxes under the liability method. Under the liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some of the net deferred income tax asset will not be realized.

F-18

Table of Contents

The Group accounts for an uncertain tax position in the consolidated financial statements only if it is more likely than not that the position is sustainable based on its technical merits and consideration of the relevant tax authority's widely understood administrative practices and precedents. If the recognition threshold is met, the Group records the largest amount of tax benefit that is greater than 50 percent likely to be realized upon ultimate settlement.

Comprehensive (Loss)/Income

Comprehensive (loss)/income is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances from non-owner sources, and currently consists of net (loss)/income and foreign currency translation gain/(loss) related to the Company's subsidiaries.

(Losses)/Earnings per Share

Basic (losses)/earnings per share is computed by dividing net (loss)/income attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year. Weighted average number of ordinary shares outstanding during the period excludes treasury shares. In addition, periodic accretion on preferred shares of Hutchison MediPharma Holdings Limited ("HMHL") (Note 16) is recorded as a deduction to consolidated net (loss)/income to arrive at net (loss)/income attributable to ordinary shareholders of the Company for purposes of calculating the consolidated basic (losses)/earnings per share.

Diluted (losses)/earnings per share is computed by dividing net (loss)/income attributable to ordinary shareholders by the weighted average number of ordinary shares and dilutive ordinary share equivalents outstanding during the period. Dilutive ordinary share equivalents include ordinary shares and treasury shares issuable upon the exercise or settlement of share-based awards issued by the Company using the treasury stock method. In determining the impact from share-based awards and convertible preferred shares issued by HMHL, the Company first calculates the diluted earnings per share at HMHL and includes in the numerator of consolidated (losses)/earnings per share the amount based on the diluted earnings per share of HMHL multiplied by the number of shares owned by the Company. The computation of diluted (losses)/earnings per share does not assume conversion, exercise, or contingent issuance of securities that would have an anti-dilutive effect.

Segment Reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief executive officer who is the Group's chief operating decision maker. The chief operating decision maker reviews the Group's internal reporting in order to assess performance and allocate resources and determined that the Group's reportable segments are as disclosed in Note 25.

Discontinued Operations

A discontinued operation is a component of the Group's business, the operations and cash flows of which can be clearly distinguished from the rest of the Group and which represents a separate major line of business or geographic area of operations, or is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations, or is a subsidiary acquired exclusively with a view to resale. When an operation is classified as discontinued, a single amount is presented in the statements of operations, which comprises the post tax profit or loss of the discontinued operation.

Profit Appropriation and Statutory Reserves

The Group's subsidiaries and equity investees established in the PRC are required to make appropriations to certain non-distributable reserve funds.

F-19

Table of Contents

In accordance with the laws applicable to the Foreign Investment Enterprises established in the PRC, the Group's subsidiaries and equity investees registered as wholly-owned foreign enterprise have to make appropriations from its after-tax profit (as determined under generally accepted accounting principles in the PRC ("PRC GAAP") to reserve funds including general reserve fund, the enterprise expansion fund and staff bonus and welfare fund. The appropriation to the general reserve fund must be at least 10% of the after-tax profits calculated in accordance with PRC GAAP. Appropriation is not required if the general reserve fund has reached 50% of the registered capital of the company. Appropriation to the enterprise expansion fund and staff bonus and welfare fund is made at the company's discretion.

The use of the general reserve fund, enterprise expansion fund, statutory surplus reserve and discretionary surplus fund are restricted to the offsetting of losses or increases the registered capital of the respective company. The staff bonus and welfare fund is a liability in nature and is restricted to fund payments of special bonus to employees and for the collective welfare of employees. All these reserves are not allowed to be transferred to the company in terms of cash dividends, loans or advances, nor can they be distributed except under liquidation.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"), to clarify the principles of recognizing revenue and create common revenue recognition guidance for U.S. GAAP and International Financial Reporting Standards. An entity has the option to apply the provisions of ASU 2014-09 either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this standard recognized at the date of initial application. ASU 2014-09 is effective for fiscal years and interim periods within those years beginning after December 15, 2017, and early adoption is permitted but not earlier than the original effective date of December 15, 2016. The new standard supersedes U.S. GAAP guidance on revenue recognition and requires the use of more estimates, judgements and additional disclosures.

The Group will adopt the new standard using the modified retrospective method on January 1, 2018 and has assessed the impact on revenue from customers. The Group's revenue from contracts with customers comprises of research and development projects in its Innovation Platform and sales of goods and services in its Commercial Platform operating segments. The Group expects the changes from applying the new guidance will primarily impact the Innovation Platform.

Innovation Platform—The Group has reviewed its research and development contracts and identified two contracts related to the Group's license and collaboration arrangements that will be impacted by the application of ASU 2014-09. The license and collaboration arrangements contain multiple performance obligations: (1) the license to the drug compound and (2) the research and development services for each specified treatment indication. The transaction price includes fixed and variable consideration in the form of upfront payment, research and development costs reimbursements, contingent milestone payments and sales-based royalties. The allocation of the transaction price to each performance obligation is based on the relative standalone selling price of each performance obligation. The Group has determined that control of the license to the drug compound was transferred as of the inception date of the collaboration agreements and consequently, amounts allocated to this performance obligation are recognized at a point in time. Conversely, control of the research and development services for each specified indication is transferred over time and amounts allocated to these performance obligations are recognized over time using cost inputs as a measure of progress. In addition, royalty revenues will be recognized as future sales occur as they meet the requirements for the sales-usage based royalty exception. The Group expects US$1.1 million deferral of revenue as a cumulative adjustment to opening accumulated loss upon adoption.

Commercial Platform—For sales of goods and services, the Group has applied a portfolio approach to aggregate contracts into portfolios whose performance obligations do not differ materially from each

F-20

Table of Contents

other. In its assessment of each portfolio, the Group has assessed the contracts under the new five-step model and does not expect a significant impact to the timing or amount of revenue recognition under the new guidance. Control of the goods passes to the customer when the goods are delivered, which matches the timing of revenue recognition under the Group's existing accounting policy.

The Group has applied updates to the new guidance in its assessment including ASU 2016-08, Principal versus Agent Considerations, ASU 2016-10, Identifying Performance Obligations and Licensing.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). The core principle of ASU 2016-02 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018. The Group expects to adopt the new standard using the modified retrospective method on January 1, 2019 with a retrospective adjustment to comparable periods presented starting from January 1, 2017. The Group is currently determining the potential impact ASU 2016-02 will have on the Group's consolidated financial statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business ("ASU 2017-01"), which revises the definition of a business. To be considered a business, an acquisition would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. To be a business without outputs, there will now need to be an organized workforce. ASU 2017-01 is effective for fiscal years and interim periods within those years beginning after December 15, 2018. The Group currently does not expect ASU 2017-01 to have a material impact on the Group's consolidated financial statements, but will apply the guidance upon adoption to business acquisitions, disposals and segment changes, if any.

In May 2017, the FASB issued ASU 2017-09, Scope of Modification Accounting (Topic 718) ("ASU 2017-09"), which provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under share-based payment accounting. The guidance clarifies that no new measurement date will be required if there is no change to the fair value, vesting conditions, and classification, and in effect simplifies the accounting for non-substantive changes to share-based payment awards. ASU 2017-09 is effective for fiscal years and interim periods within those years beginning after December 15, 2017. The Group shall apply the guidance upon adoption to share-based payment modifications, if any.

Other amendments that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Group's consolidated financial statements upon adoption.

F-21

Table of Contents

4. Fair Value Disclosures

The following table presents the Group's financial instruments by level within the fair value hierarchy:

	Fair Value Measurement Using

	Level 1	Level 2	Level 3	Total
	(in US$'000)
As at December 31, 2017
Cash and cash equivalents	85,265	—	—	85,265
Short-term investments	273,031	—	—	273,031



As at December 31, 2016
Cash and cash equivalents	79,431	—	—	79,431
Short-term investments	24,270	—	—	24,270

Accounts receivable, other receivables, amounts due from related parties, accounts payable, other payables and amounts due to related parties are carried at cost, which approximates fair value due to the short-term nature of these financial instruments, and are therefore excluded from the above table. Bank borrowings are floating rate instruments and carried at amortized cost, which approximates their fair values, and are therefore excluded from the above table.

5. Cash and Cash Equivalents

	December 31,

	2017	2016
	(in US$'000)
Cash at bank and on hand	30,018	31,218
Bank deposits maturing in three months or less (note (a))	55,247	48,213

	85,265	79,431



Denominated in:
US$(note (b))	66,381	65,509
RMB (note (b))	15,140	9,505
UK Pound Sterling ("£") (note (b))	295	408
Hong Kong dollar ("HK$")	3,449	4,009

	85,265	79,431

Notes:

(a): The weighted average effective interest rate on bank deposits for the years ended December 31, 2017 and 2016 was 1.06% and 0.58% per annum respectively (with maturity ranging from 7 to 90 days).
(b): Certain cash and bank balances denominated in RMB, US$ and £ were deposited with banks in the PRC. The conversion of these RMB, US$ and £ denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the PRC government.

F-22

Table of Contents

6. Short-term Investments

	December 31,

	2017	2016
	(in US$'000)
Bank deposits maturing over three months (note)
Denominated in:
US$	272,659	24,270
HK$	372	—

	273,031	24,270

Note:

The weighted average effective interest rate on bank deposits for the years ended December 31, 2017 and 2016 was 1.32% and 0.71% per annum respectively (with maturity ranging from 91 to 183 days, and 91 to 186 days respectively).

7. Accounts Receivable—Third Parties

	December 31,

	2017		2016
	(in US$'000)
Accounts receivable, gross	38,668		43,532
Allowance for doubtful accounts	(258	)	(2,720	)

Accounts receivable, net	38,410		40,812

Substantially all the accounts receivable are denominated in RMB, US$ and HK$ and are due within one year from the end of the reporting periods. The carrying values of accounts receivable approximates their fair values due to their short-term maturities.

Movements on the allowance for doubtful accounts:

	2017		2016		2015

	(in US$'000)
As at January 1	2,720		3,127		1,793
Increase in allowance for doubtful accounts	242		29		1,408
Decrease in allowance due to subsequent collection	—		(237	)	—
Write-off	(2,874	)	—		—
Exchange difference	170		(199	)	(74	)

As at December 31	258		2,720		3,127

In December 2015, the Group recorded a provision amounting to approximately US$1,322,000 which represented an outstanding balance due from a distributor. In January 2016, the Group terminated the distributor's exclusive distribution rights and in December 2017, the amount due was written off along with other allowance for doubtful accounts balances.

F-23

Table of Contents

8. Other Receivables, Prepayments and Deposits

Other receivables, prepayments and deposits consisted of the following:

	December 31,

	2017	2016
	(in US$'000)
Prepayments	2,565	699
Purchase rebates	284	238
Other service receivables	490	756
Deposits	932	620
Value-added tax receivables	5,436	1,380
Interest receivables	506	63
Others	1,083	558

	11,296	4,314

9. Inventories

Inventories, net of provision for excess and obsolete inventories, consisted of the following:

	December 31,

	2017	2016
	(in US$'000)
Raw materials	314	660
Finished goods	11,475	12,162

	11,789	12,822

Movements on the provision for excess and obsolete inventories are as follows:

	2017		2016		2015

	(in US$'000)
As at January 1	160		25		34
Increase in provision for excess and obsolete inventories	128		163		37
Decrease in provision due to subsequent sale or recovery	(144	)	—		(33	)
Write-off	(32	)	(23	)	(12	)
Exchange difference	9		(5	)	(1	)

As at December 31	121		160		25

F-24

Table of Contents

10. Property, Plant and Equipment

Property, plant and equipment consisted of the following:

	Buildings	Leasehold improvements	Plant and equipment	Furniture and fixtures, other equipment and motor vehicles		Construction in progress		Total

	(in US$'000)
Cost
As at January 1, 2017	2,232	6,296	86	13,976		1,760		24,350
Additions	—	301	155	1,374		4,243		6,073
Disposals	—	—	—	(394	)	—		(394	)
Transfers	—	2,050	2,321	(722	)	(3,649	)	—
Exchange differences	140	410	6	920		204		1,680

As at December 31, 2017	2,372	9,057	2,568	15,154		2,558		31,709

Accumulated depreciation
As at January 1, 2017	971	4,249	71	9,105		—		14,396
Depreciation	105	763	169	1,441		—		2,478
Disposals	—	—	—	(337	)	—		(337	)
Transfers	—	—	255	(255	)	—		—
Exchange differences	65	284	4	599		—		952

As at December 31, 2017	1,141	5,296	499	10,553		—		17,489

Net book value
As at December 31, 2017	1,231	3,761	2,069	4,601		2,558		14,220

	Buildings		Leasehold improvements		Plant and equipment		Furniture and fixtures, other equipment and motor vehicles		Construction in progress		Total

	(in US$'000)
Cost
As at January 1, 2016	2,392		5,989		88		12,806		567		21,842
Additions	—		742		—		1,453		2,132		4,327
Disposals	—		(12	)	—		(248	)	—		(260	)
Transfers	—		—		—		886		(886	)	—
Exchange differences	(160	)	(423	)	(2	)	(921	)	(53	)	(1,559	)

As at December 31, 2016	2,232		6,296		86		13,976		1,760		24,350

Accumulated depreciation
As at January 1, 2016	932		3,549		70		8,784		—		13,335
Depreciation	106		977		3		1,153		—		2,239
Disposals	—		(12	)	—		(218	)	—		(230	)
Exchange differences	(67	)	(265	)	(2	)	(614	)	—		(948	)

As at December 31, 2016	971		4,249		71		9,105		—		14,396

Net book value
As at December 31, 2016	1,261		2,047		15		4,871		1,760		9,954

Depreciation for the year ended December 31, 2015 was US$1,908,000.

F-25

Table of Contents

11. Investments in Equity Investees

Investments in equity investees consisted of the following:

	December 31,

	2017	2016
	(in US$'000)
HBYS	55,308	63,536
SHPL	69,417	77,939
NSPL	19,201	16,806
Other	311	225

	144,237	158,506

Particulars regarding the principal equity investees are disclosed in Note 2. All of the equity investees are private companies and there are no quoted market prices available for their shares.

Summarized financial information for the significant equity investees HBYS, SHPL and NSPL is as follows:

(i) Summarized balance sheets

	Commercial Platform								Innovation Platform

	Consumer Health HBYS				Prescription Drugs SHPL				Drug R&D NSPL
	December 31,				December 31,				December 31,
	2017		2016		2017		2016		2017		2016
	(in US$'000)
Current assets	101,570		123,181		129,535		146,350		9,640		5,393
Non-current assets	107,226		98,554		103,477		97,656		30,000		30,000
Current liabilities	(75,787	)	(70,218	)	(91,665	)	(86,946	)	(1,239	)	(1,782	)
Non-current liabilities	(18,748	)	(18,148	)	(8,616	)	(6,926	)	—		—

Net assets	114,261		133,369		132,731		150,134		38,401		33,611
Non-controlling interests	(3,645	)	(6,297	)	—		—		—		—

	110,616		127,072		132,731		150,134		38,401		33,611

F-26

Table of Contents

(ii) Summarized statements of operations

	Commercial Platform												Innovation Platform

	Consumer Health HBYS						Prescription Drugs SHPL						Drug R&D^{(note (a))} NSPL
	Year Ended December 31,						Year Ended December 31,						Year Ended December 31,
	2017		2016		2015		2017		2016		2015		2017		2016		2015
	(in US$'000)
Revenue	227,422		224,131		211,603		244,557		222,368		181,140		—		—		—
Gross profit	91,458		89,355		91,461		175,965		158,131		127,608		—		—		—
Depreciation and amortization	(4,985	)	(2,958	)	(3,274	)	(6,942	)	(3,526	)	(2,765	)	—		—		—
Interest income	220		238		628		757		565		306		—		—		—
Finance cost	(117	)	(123	)	(158	)	—		—		—		—		—		—
Profit/(loss) before taxation	24,434		23,759		25,164		66,497		148,144		37,401		(9,210	)	(8,482	)	(7,552	)
Income tax expense (note (b))	(3,629	)	(3,631	)	(3,948	)	(10,874	)	(27,645	)	(6,094	)	—		—		—

Net income/(loss)	20,805		20,128		21,216		55,623		120,499		31,307		(9,210	)	(8,482	)	(7,552	)
Non-controlling interests	(29	)	248		160		—		—		—		—		—		—

Net income/(loss) attributable to the shareholders of equity investee	20,776		20,376		21,376		55,623		120,499		31,307		(9,210	)	(8,482	)	(7,552	)

Notes:

(a): NSPL only incurred research and development expenses in the periods presented.
(b): HBYS and SHPL have been successful in their respective applications to renew the High and New Technology Enterprise ("HNTE") status. Accordingly, the companies were eligible to use a preferential income tax rate of 15% for the years ended December 31, 2017, 2016 and 2015.

For the years ended December 31, 2017, 2016 and 2015, other immaterial equity investees had net income of approximately US$117,000, US$95,000 and US$12,000 respectively.

(iii) Reconciliation of summarized financial information

Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees is as follows:

	Commercial Platform												Innovation Platform

	Consumer Health HBYS						Prescription Drugs SHPL						Drug R&D NSPL
	2017		2016		2015		2017		2016		2015		2017		2016		2015
	(in US$'000)
Opening net assets after non-controlling interests as at January 1	127,072		121,523		111,506		150,134		93,263		71,906		33,611		18,093		25,645
Net income/(loss) attributable to the shareholders of equity investee	20,776		20,376		21,376		55,623		120,499		31,307		(9,210	)	(8,482	)	(7,552	)
Dividends declared	(45,128	)	(6,000	)	(6,410	)	(81,299	)	(55,057	)	(6,410	)	—		—		—
Other comprehensive income/(loss)	7,896		(8,827	)	(4,949	)	8,273		(8,571	)	(3,540	)	—		—		—
Investments	—		—		—		—		—		—		14,000		10,000		—
Capitalization of loans	—		—		—		—		—		—		—		14,000		—

Closing net assets after non-controlling interests as at December 31	110,616		127,072		121,523		132,731		150,134		93,263		38,401		33,611		18,093
Group's share of net assets	55,308		63,536		60,762		66,365		75,067		46,632		19,201		16,806		9,046
Goodwill	—		—		—		3,052		2,872		3,077		—		—		—

Carrying amount of investments as at December 31	55,308		63,536		60,762		69,417		77,939		49,709		19,201		16,806		9,046

F-27

Table of Contents

The equity investees had the following lease commitments and capital commitments:

(a): The equity investees lease various factories and offices under non-cancellable operating lease agreements. Future aggregate minimum payments under non-cancellable operating leases as from the dates indicated are as follows:

	December 31,

	2017	2016
	(in US$'000)
Not later than 1 year	1,282	1,511
Between 1 to 2 years	400	1,184
Between 2 to 3 years	151	—
Between 3 to 4 years	141	—
Between 4 to 5 years	47	—

Total minimum lease payments	2,021	2,695

(b): Capital commitments

The equity investees had the following capital commitments:

	December 31,

	2017	2016
	(in US$'000)
Property, plant and equipment
Contracted but not provided for	1,034	6,162

12. Accounts Payable

	December 31,

	2017	2016
	(in US$'000)
Accounts payable—third parties	17,095	30,383
Accounts payable—non-controlling shareholders of subsidiaries	7,250	5,136
Accounts payable—related party (Note 22 (ii))	20	19

	24,365	35,538

Substantially all the accounts payable are denominated in RMB and US$ and due within one year from the end of the reporting period. The carrying values of accounts payable approximate their fair values due to their short-term maturities.

F-28

Table of Contents

13. Other Payables, Accruals and Advance Receipts

Other payables, accruals and advance receipts consisted of the following:

	December 31,

	2017	2016
	(in US$'000)
Accrued salaries and benefits	9,295	7,057
Accrued research and development expenses	14,613	11,771
Accrued selling and marketing expenses	4,121	4,340
Accrued administrative and other general expenses	4,729	4,078
Deferred government incentives	1,790	1,755
Loan from a non-controlling shareholder of a subsidiary (Note 22 (iv))	1,550	—
Payments in advance from customers	1,282	899
Others	3,573	1,816

	40,953	31,716

14. Bank Borrowings

Bank borrowings consisted of the following:

	December 31,

	2017	2016
	(in US$'000)
Current	29,987	19,957
Non-current	—	26,830

	29,987	46,787

The weighted average interest rate for outstanding bank borrowings for the years ended December 31, 2017, 2016 and 2015 was 1.90%, 1.52% and 1.39% per annum respectively. In addition, the Group incurred guarantee fees of US$320,000, US$471,000 and US$471,000 respectively for the years ended December 31, 2017, 2016 and 2015, which was 0.76%, 0.94% and 0.95% per annum respectively of the weighted average outstanding bank borrowings. The carrying amounts of the Group's bank borrowings are all denominated in HK$.

3-year term loan and 18-month revolving loan facilities

In November 2017, the Group through its subsidiary, entered into a facility agreement with a bank for the provision of unsecured credit facilities in the aggregate amount of HK$400,000,000 (US$51,282,000). The credit facilities include (i) a HK$210,000,000 (US$26,923,000) 3-year term loan facility and (ii) a HK$190,000,000 (US$24,359,000) 18-month revolving loan facility. The term loan bears interest at 1.50% over the Hong Kong Interbank Offered Rate ("HIBOR") per annum. The revolving loan facility bears interest at 1.25% over HIBOR per annum. As at December 31, 2017, no amounts have been drawn from the term loan or the revolving loan facilities. These credit facilities are guaranteed by the Company.

In December 2011, the Group through its subsidiary, entered into a three-year term loan with the same bank above in the aggregate principal amount of HK$210,000,000 (US$26,923,000). The term loan bears interest at 1.50% over the HIBOR per annum. In June 2014, the term loan was refinanced into a four-year term loan due June 2018 which bears interest at 1.35% over the HIBOR per annum. The loan was fully repaid in two installments of HK$180,000,000 (US$23,077,000) and HK$30,000,000 (US$3,846,000) in August 2017 and November 2017 respectively. The term loan was unsecured and

F-29

Table of Contents

guaranteed by Hutchison Whampoa Limited, an indirect subsidiary of CK Hutchison. An annual fee was paid to Hutchison Whampoa Limited for the guarantee (Note 22(i)).

18-month term loan and revolving loan facilities

In February 2017, the Group through its subsidiary, entered into two separate facility agreements with banks for the provision of unsecured credit facilities in the aggregate amount of HK$546,000,000 (US$70,000,000). The first credit facility includes (i) a HK$156,000,000 (US$20,000,000) term loan facility and (ii) a HK$195,000,000 (US$25,000,000) revolving loan facility, both with a term of 18 months and an annual interest rate of 1.25% over HIBOR. The term loan was drawn from the first credit facility in March 2017 and is due in August 2018. The second credit facility includes (i) a HK$78,000,000 (US$10,000,000) term loan facility and (ii) a HK$117,000,000 (US$15,000,000) revolving loan facility, both with a term of 18 months and an annual interest rate of 1.25% over HIBOR. The term loan was drawn from the second credit facility in August 2017 and is due in August 2018. Accordingly, the term loans are recorded as short-term bank borrowings as at December 31, 2017. No amounts have been drawn from the revolving loan facilities. These credit facilities are guaranteed by the Company.

In March 2017, the Group repaid the HK$156,000,000 (US$20,000,000) term loan facility with the same banks above, which was part of the unsecured credit facilities in the aggregate amount of HK$468,000,000 (US$60,000,000) entered in February 2016. These unsecured credit facilities have been terminated.

3-year revolving loan facility

In November 2015, the Group through its subsidiary renewed a three year revolving loan facility with a bank in the aggregate amount of HK$234,000,000 (US$30,000,000) with an annual interest rate of 1.25% over HIBOR. This facility will expire in November 2018. In February 2017, HK$20,000,000 (US$2,564,000) was drawn from this facility and the amount was fully repaid in March 2017. As at December 31, 2017 and 2016, there were no amounts due under this loan.

The Group's bank borrowings are repayable as from the dates indicated as follows:

	December 31,

	2017	2016
	(in US$'000)
Not later than 1 year	30,000	20,000
Between 1 to 2 years	—	26,923

	30,000	46,923

As at December 31, 2017 and 2016, the Group had unutilized bank borrowing facilities of HK$946,000,000 (US$121,282,000) and HK$546,000,000 (US$70,000,000) respectively.

F-30

Table of Contents

15. Commitments and Contingencies

(i) Lease commitments

The Group leases various factories and offices under non-cancellable operating lease agreements. Future aggregate minimum payments under non-cancellable operating leases as from the dates indicated as follows:

	December 31,

	2017	2016
	(in US$'000)
Not later than 1 year	3,330	1,711
Between 1 to 2 years	2,875	1,383
Between 2 to 3 years	2,132	1,053
Between 3 to 4 years	345	597
Between 4 to 5 years	161	108
Later than 5 years	17	45

Total minimum lease payments	8,860	4,897

(ii) Capital commitments

The Group had the following capital commitments as from the dates indicated as follows:

	December 31,

	2017	2016
	(in US$'000)
Property, plant and equipment
Contracted but not provided for	161	2,545

In addition, the Group has also undertaken to provide the necessary additional funds for NSPL to finance its ongoing operations.

16. Redeemable Non-controlling Interests

As at December 31, 2017 and 2016, no redeemable non-controlling interests were outstanding.

In November and December 2010, the Company and HMHL, entered into subscription and shareholders' agreements ("SSAs") with Mitsui & Co., Ltd. ("Mitsui") and SBCVC Fund III Company Limited ("SBCVC") (collectively, the "preferred shareholders"), whereby HMHL issued 7,390,029 redeemable convertible preferred shares ("Preferred Shares") for an aggregate consideration of US$20.1 million. The Preferred Shares on an as-if-converted basis represented approximately 19.76% of the aggregate issued and outstanding share capital of HMHL on the closing date.

In October 2012, the Company repurchased all 2,815,249 Preferred Shares from SBCVC. The remaining 4,574,780 Preferred Shares of US$12.5 million held by Mitsui represented approximately 12.24% of HMHL on a fully diluted basis.

In May and June 2014, the Company and HMHL further entered into two subscription agreements with Mitsui, whereby HMHL issued a total of 672,713 HMHL's Preferred Shares to Mitsui and 4,825,418 HMHL's ordinary shares to the Company for an aggregate consideration of US$25.0 million, after which Mitsui's interest in HMHL remained at 12.24% on a fully diluted basis.

On July 23, 2015, the Company entered into a subscription agreement with Mitsui under which the Company issued 3,214,404 new ordinary shares of the Company valued at approximately US$84.0 million in exchange for the Preferred Shares held by Mitsui with carrying value of US$84.0 million (including

F-31

Table of Contents

accretion adjustment up to July 23, 2015). The transaction was completed on July 23, 2015 and as a result of this transaction, Mitsui held approximately 5.69% of the enlarged share capital of the Company at that time. The outstanding balance of redeemable non-controlling interests was extinguished with the corresponding increase in the Company's shares and additional paid-in capital.

Accounting for preferred shares

The Preferred Shares were redeemable upon occurrence of an event that is not solely within the control of the issuer. Accordingly, the Preferred Shares were recorded and accounted for as redeemable non-controlling interests outside of permanent equity in the Group's consolidated balance sheets. The Group recorded accretion when it was probable that the Preferred Shares will become redeemable. The accretion, which increases the carrying value of the redeemable non-controlling interests, was recorded against retained earnings, or in the absence of retained earnings, by recording against the additional paid-in capital. During the year ended December 31, 2015, HMHL recorded an accretion of US$43,001,000 to the Preferred Shares based on such preferred shareholder's share of the estimated valuation of HMHL.

17. Ordinary Shares

The Company is authorized to issue 75,000,000 ordinary shares.

On March 17, 2016, the Company's ADS, each representing one-half of one ordinary share, commenced trading on the Nasdaq Global Select Market. Concurrently, the Company issued 3,750,000 ordinary shares in the form of 7,500,000 ADS for gross proceeds of US$101.3 million. On April 13, 2016, the Company issued an additional 330,000 ordinary shares in the form of 660,000 ADS for gross proceeds of US$8.9 million. Issuance costs totaled US$14.2 million, of which US$12.9 million and US$1.3 million were paid in the years ended December 31, 2016 and 2015 respectively.

In October 2017, the Company issued 5,684,905 ordinary shares in the form of 11,369,810 ADS for gross proceeds of US$301.3 million. Issuance costs totaled US$8.6 million.

A summary of ordinary shares transactions (in thousands) is as follows:

	2017	2016	2015

As at January 1	60,706	56,533	53,076
Public offering	5,685	4,080	—
Share option exercises	56	93	243
Exchange of redeemable non-controlling interest (Note 16)	—	—	3,214

As at December 31	66,447	60,706	56,533

Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company.

18. Share-based Compensation

(i) Share-based Compensation of the Company

The Company conditionally adopted a share option scheme on June 4, 2005 (as amended on March 21, 2007) and such scheme has a term of 10 years. It expired in 2016 and no further share options can be granted. Another share option scheme was conditionally adopted on April 24, 2015 (the "HCML Share Option Scheme"). Pursuant to the HCML Share Option Scheme, the Board of Directors of the Company may, at its discretion, offer any employees and directors (including Executive and Non-executive

F-32

Table of Contents

Directors but excluding Independent Non-executive Directors) of the Company, holding companies of the Company and any of their subsidiaries or affiliates, and subsidiaries or affiliates of the Company share options to subscribe for shares of the Company.

The aggregate number of shares issuable under the HCML Share Option Scheme is 2,425,597 ordinary shares. The aggregate number of shares issuable under the prior share option scheme which expired in 2016 is 282,726 ordinary shares. As at December 31, 2017, the number of shares authorized but unissued was 8,552,963 ordinary shares.

Share options granted are generally subject to a three-year or four-year vesting schedule, depending on the nature and the purpose of the grant. Share options subject to three-year vesting schedule, in general, vest 33.3% upon the first anniversary of the vesting commencement date as defined in the grant letter, and 33.3% every subsequent year. Share options subject to the four-year vesting schedule, in general, vest 25% upon the first anniversary of the vesting commencement date as defined in the grant letter, and 25% every subsequent year. However, certain share option grants may have a different vesting schedule as approved by the Board of Directors of the Company. No outstanding share options will be exercisable or subject to vesting after the expiry of a maximum of eight to ten years from the date of grant.

On June 15, 2016, 1,187,372 share options of a subsidiary were cancelled with the consent of the relevant eligible employees in exchange for 593,686 new share options of the Company (Note 18(ii)). This was accounted for as a modification of the original share options granted which did not result in any incremental fair value to the Group.

A summary of the Company's share option activity and related information is as follows:

	Number of share options		Weighted-average exercise price in £ per share	Weighted-average remaining contractual life (years)	Aggregate intrinsic value (in £'000)

Outstanding at January 1, 2015	684,403		4.67
Granted	—		—
Exercised	(242,038	)	3.77
Cancelled	—		—
Outstanding at December 31, 2015	442,365		5.16	6.53	10,061
Granted	693,686		19.70
Exercised	(92,705	)	3.54
Cancelled	(3,750	)	6.10
Outstanding at December 31, 2016	1,039,596		15.00	6.77	7,900
Granted	150,000		31.05
Exercised	(56,309	)	5.16
Cancelled	(6,875	)	6.10
Outstanding at December 31, 2017	1,126,412		17.69	6.29	43,158
Vested and expected to vest at December 31, 2015	333,393		4.85	6.05	7,685
Vested and exercisable at December 31, 2015	291,015		4.67	5.77	6,762
Vested and expected to vest at December 31, 2016	1,039,596		15.00	6.77	7,900
Vested and exercisable at December 31, 2016	767,376		14.64	6.66	6,106
Vested and expected to vest at December 31, 2017	1,126,412		17.69	6.29	43,158
Vested and exercisable at December 31, 2017	951,412		15.52	5.81	38,508

F-33

Table of Contents

The Company uses the Polynomial model to estimate the fair value of share option awards using various assumptions that require management to apply judgment and make estimates, including:

Volatility

The Company calculated its expected volatility with reference to the historical volatility prior to the issuances of share options.

Risk-free Rate

The risk-free interest rates used in the Polynomial model are with reference to the sovereign yield of the United Kingdom because the Company's ordinary shares are currently listed on AIM and denominated in £.

Dividends

The Company has not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore uses an expected dividend yield of zero in the Polynomial model.

In determining the fair value of share options granted, the following assumptions were used in the Polynomial model for awards granted in the periods indicated:

	Grant date

	June 24, 2011	December 20, 2013	June 15, 2016	March 27, 2017
Value of each share option (in £ per share)	1.84	3.15	8.99	12.69
Significant inputs into the valuation model:
Exercise price (in £ per share)	4.41	6.10	19.70	31.05
Share price at effective date of grant (in £ per share)	4.33	6.10	19.70	31.05
Expected volatility	46.6%	36.0%	39.0%	36.3%
Risk-free interest rate	3.13%	3.16%	1.00%	1.17%
Contractual life of share options	10 years	10 years	8 years	10 years
Expected dividend yield	0%	0%	0%	0%

The following table summarizes the Company's share option values:

	Year Ended December 31,

	2017	2016	2015
Weighted-average grant-date fair value of share options granted during the period (in £ per share)	12.69	8.99	—
Total intrinsic value of share options exercised in US$'000	2,290	1,907	5,020

Share-based Compensation Expense

The Group recognizes compensation expense for only the portion of options expected to vest, on a graded vesting approach over the requisite service period. The following table presents share-based compensation expense included in the Group's consolidated statements of operations:

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Research and development expenses	1,284	1,278	74
Administrative expenses	—	—	14

	1,284	1,278	88

F-34

Table of Contents

As at December 31, 2017, the total unrecognized compensation cost was US$1,539,000, and will be recognized on a graded vesting approach over the weighted-average remaining service period of 3.1 years.

Cash received from share option exercises under the share option plan for the years ended December 31, 2017, 2016 and 2015 was approximately US$380,000, US$426,000 and US$1,374,000 respectively.

The Company will issue new shares to satisfy share option exercises.

(ii) Share-based Compensation of a subsidiary

HMHL adopted a share option scheme on August 6, 2008 (as amended on April 15, 2011) and such scheme has a term of 6 years. It expired in 2014 and no further share options can be granted. Another share option scheme was adopted on December 17, 2014 (the "HMHL Share Option Scheme"). Pursuant to the HMHL Share Option Scheme, any employee or director of HMHL and any of its holding company, subsidiaries and affiliates is eligible to participate in the HMHL Share Option Scheme subject to the discretion of the board of directors of HMHL.

The aggregate number of shares issuable under the HMHL Share Option Scheme is 2,144,408 ordinary shares. As at December 31, 2017, the number of shares authorized but unissued was 157,111,839 ordinary shares of HMHL.

Share options granted are generally subject to a four-year vesting schedule, depending on the nature and the purpose of the grant. Share options subject to the four-year vesting schedule, in general, vest 25% upon the first anniversary of the vesting commencement date as defined in the grant letter, and 25% every subsequent year. No outstanding share options will be exercisable or subject to vesting after the expiry of a maximum of six or nine years from the date of grant.

On December 20, 2013, 2,485,189 share options were cancelled with the consent of the relevant eligible employees in exchange for new share options of the Company vesting over a period of four years and/or cash consideration payable over a period of four years. For the share options in exchange for new share options under HCML Share Option Scheme, this was accounted for as a modification of the original share options which did not result in any incremental fair value to the Group. For the share options in exchange for cash consideration, this was accounted for as a modification in classification that changed the award's classification from equity-settled to a liability.

A liability has been recognized on the modification date taking into account the requisite service period that has been provided by the employee at the modification date. As at December 31, 2017 and 2016, US$0.2 million and US$1.4 million have been recognized in other payables respectively.

On June 15, 2016, 1,187,372 share options pursuant to the HMHL Share Option Schemes were cancelled with the consent of the relevant eligible employees in exchange for 593,686 new share options of the Company pursuant to the HCML Share Option Schemes. This was accounted for as a modification of the original share options granted which did not result in any incremental fair value to the Group.

F-35

Table of Contents

A summary of the HMHL's share option activity and related information is as follows (with no activity for the year ended December 31, 2017):

	Number of share options		Weighted-average exercise price in £ per share	Weighted-average remaining contractual life (years)	Aggregate intrinsic value (in £'000)

Outstanding at January 1, 2015	1,211,772		7.71
Granted	—		—
Exercised	(24,400	)	2.34
Cancelled	—		—
Outstanding at December 31, 2015	1,187,372		7.82	7.97	32,292
Granted	—		—
Exercised	—		—
Cancelled	(1,187,372	)	7.82
Outstanding at December 31, 2016 and 2017	—		—	—	—
Vested and expected to vest at December 31, 2015	759,918		7.82	7.97	20,667
Vested and exercisable at December 31, 2015	593,686		7.82	7.97	16,146
Vested and expected to vest at December 31, 2016 and 2017	—		—	—	—
Vested and exercisable at December 31, 2016 and 2017	—		—	—	—

Share-based Compensation Expense

The subsidiary recognizes compensation expense for only the portion of options expected to vest, on a graded vesting approach over the requisite service period. The following table presents share-based compensation expense included in the Group's consolidated statements of operations:

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Research and development	32	502	1,063

As at December 31, 2017, the total unrecognized compensation cost was nil.

Cash received from option exercises under the share option plan for the year ended December 31, 2015 was US$57,000.

(iii) LTIP

The Company grants awards under the LTIP to participating directors and employees, giving them a conditional right to receive ordinary shares of the Company or the equivalent ADS (collectively the "Awarded Shares") to be purchased by the Trustee up to a cash amount. Vesting will depend upon continued employment of the award holder with the Group and will otherwise be at the discretion of the Board of Directors of the Company. Additionally, some awards are subject to change based on annual performance targets prior to their determination date.

LTIP awards prior to the determination date

Performance targets vary by award, and may include targets for shareholder returns, free cash flows, revenues, net profit after taxes and the achievement of clinical and regulatory milestones. As the extent of achievement of the performance targets is uncertain prior to the determination date, a probability based

F-36

Table of Contents

on management's assessment on the achievement of the performance target has been assigned to calculate the amount to be recognized as an expense over the requisite period with a corresponding entry to liability.

LTIP awards after the determination date

Upon the determination date, the Company will pay a determined monetary amount, up to the maximum cash amount based on the actual achievement of the performance target specified in the award, to the Trustee to purchase the Awarded Shares. Any cumulative compensation expense previously recognized as a liability will be transferred to additional paid-in capital, as an equity-settled award. If the performance target is not achieved, no Awarded Shares of the Company will be purchased and the amount previously recorded in the liability will be reversed through profit or loss.

Granted awards under the LTIP are as follows:

On December 15, 2017, the Company granted awards up to a maximum cash amount per annum of US$0.5 million that stipulated annual performance targets. Shares under such LTIP awards will cover each financial year from 2018 to 2019. The annual performance target determination date is the date of the announcement of the Group's annual results for the covered financial year and vesting occurs two business days after the announcement of the Group's annual results for the financial year falling two years after the covered financial year to which the LTIP award relates.

On March 15, 2017 and August 2, 2017, the Company granted awards up to a maximum cash amount per annum of US$6.0 million that stipulated annual performance targets. Shares under such LTIP awards will cover each financial year from 2017 to 2019. The annual performance target determination date is the date of the announcement of the Group's annual results for the covered financial year and vesting occurs two business days after the announcement of the Group's annual results for the financial year falling two years after the covered financial year to which the LTIP award relates.

On March 15, 2017, the Company granted awards up to a maximum cash amount of US$0.4 million in aggregate that did not stipulate performance targets. Shares under such LTIP awards will vest one business day after the publication date of the annual report for the 2017 financial year.

On March 24, 2016, the Company granted awards up to a maximum cash amount of US$0.3 million in aggregate that do not stipulate performance targets. Shares under such LTIP awards are subject to the vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

On October 19, 2015, the Company granted initial awards under the LTIP up to a maximum cash amount per annum of US$1.8 million that stipulated annual performance targets. Shares under such LTIP awards will cover each financial year from 2014 to 2016. The annual performance target determination date is the date of the announcement of the Group's annual results for the covered financial year and vesting occurs one business day after the publication date of the annual report of the Company for the financial year falling two years after the covered financial year to which the LTIP award relates.

The Trustee has been set up solely for the purpose of purchasing and holding the Awarded Shares during the vesting period on behalf of the Group using funds provided by the Group. On the determination date, if any, the Company will determine the cash amount, based on the actual achievement of each annual performance target, for the Trustee to purchase the Awarded Shares. The Awarded Shares will then be held by the Trustee until they are vested.

F-37

Table of Contents

The Trustee's assets include treasury shares and funds for additional treasury shares, trustee fees and expenses. As at December 31, 2017, the number of treasury shares (in the form of ordinary shares or ADS of the Company) purchased and held by the Trustee are as follows:

	Number of treasury shares		Cost in US$'000

As at January 1, 2017	62,921		2,390
Purchased	35,095		1,367
Vested	(42,038	)	(1,800	)

As at December 31, 2017	55,978		1,957

Based on the actual achievement of performance targets for the 2017 financial year, the Group expects to purchase up to US$5,621,000 of treasury shares in 2018.

For the year ended December 31, 2017, US$1,800,000 and US$79,000 of the LTIP awards have vested and been forfeited respectively.

The following table presents the share-based compensation expenses recognized under the LTIP awards:

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Research and development expenses	1,894	850	156
Selling and administrative expenses	1,529	811	152

	3,423	1,661	308



Recorded with a corresponding credit to:
Liability	2,336	345	75
Additional paid-in capital	1,087	1,316	233

	3,423	1,661	308

For the years ended December 31, 2017, 2016 and 2015, US$451,000, US$64,000 and nil was reclassified from liability to additional paid-in capital respectively upon LTIP awards reaching the determination date. As at December 31, 2017 and 2016, US$2,241,000 and US$356,000 was recorded as liability respectively for LTIP awards prior to the determination date.

As at December 31, 2017, the total unrecognized compensation cost was approximately US$8,681,000, which considers expected performance targets and the amount expected to vest, and will be recognized over the requisite periods.

19. Revenue from License and Collaboration Agreements—Third Parties

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Milestone revenue	9,457	9,931	19,212
Amortization of upfront payment	1,655	1,679	1,907
Research and development services	15,203	14,834	22,941

	26,315	26,444	44,060

F-38

Table of Contents

The revenue is mainly from license and collaboration agreements as follows:

License and collaboration agreement with Eli Lilly

On October 8, 2013, the Group entered into a licensing, co-development and commercialization agreement in China with Eli Lilly ("Lilly") relating to fruquintinib, a targeted oncology therapy for the treatment of various types of solid tumors. Under the terms of the agreement, the Group is entitled to receive a series of payments of up to US$86.5 million, including upfront payments and development and regulatory approval milestones. Should fruquintinib be successfully commercialized in China, the Group would receive tiered royalties based on certain percentages of net sales. Development costs after the first development milestone are shared between the Group and Lilly. Following execution of the agreement, the Group received a non-refundable, upfront payment of US$6.5 million.

In addition, the Group also signed an option agreement which grants Lilly an exclusive option to expand the fruquintinib rights beyond Hong Kong and China. The option agreement further sets out certain milestone payments and royalty rates that apply in the event the option is exercised on a global basis. However, these are subject to further negotiation should the option be exercised on a specific territory basis as opposed to a global basis. The option was not considered to be a separate deliverable in the arrangement as it was not considered to be substantive. As at December 31, 2017, the option has not been exercised.

The license rights to fruquintinib, delivered at the inception of the arrangement, did not have stand-alone value apart from the other deliverables in the arrangement which include the development services, the participation in the joint steering committee and the manufacturing of active pharmaceutical ingredients during the development phase. The non-refundable upfront payment was deferred and is being recognized ratably over the development period. The Group recognizes milestone revenue relating to the deliverables in the agreement as a single unit of accounting using the milestone method.

Under the terms of this agreement, the Group recognized US$4.5 million milestone revenue for the year ended December 31, 2017 in relation to the acceptance of a new drug application by the China Food and Drug Administration for fruquintinib as a treatment of patients with advanced colorectal cancer. For the year ended December 31, 2016, the Group did not recognize any milestone revenue in relation to this contract and for the year ended December 31, 2015, the Group recognized US$19.2 million milestone revenues in relation to the achievement of the "proof of concept" milestone for two indications. The Group recognized US$1.6 million, US$1.7 million and US$1.8 million revenue from amortization of the upfront payment during the years ended December 31, 2017, 2016 and 2015 respectively. In addition, the Group recognized US$12.1 million, US$12.1 million and US$19.4 million revenue from research and development services for the years ended December 31, 2017, 2016 and 2015 respectively.

License and collaboration agreement with AstraZeneca

On December 21, 2011, the Group and AstraZeneca ("AZ") entered into a global licensing, co-development, and commercialization agreement for savolitinib ("AZ Agreement"), a novel targeted therapy and a highly selective inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer. Under the terms of the agreement, development costs for savolitinib in China will be shared between the Group and AZ, with the Group continuing to lead the development in China. AZ will lead and pay for the development of savolitinib for the rest of the world. The Group received a non-refundable upfront payment of US$20.0 million upon the signing of the agreement and may receive up to US$120.0 million contingent upon the successful achievement of clinical development and first-sale milestones. The agreement also contains possible significant future commercial sale milestones and up to double-digit percentage royalties on net sales.

The license right to develop savolitinib in the rest of the world was delivered to AZ at the inception of the arrangement. Such license had stand-alone value apart from the other deliverables in the arrangement

F-39

Table of Contents

which include the development of savolitinib in China and the participation in the joint steering committee. The non-refundable up-front payment was allocated to (a) the license to develop savolitinib in the rest of the world, which was recognized at inception and (b) the research and development services for which the amount allocated has been deferred and is being recognized ratably over the development period. The Group recognizes milestone revenue relating to the deliverables in the agreement as a single unit of accounting using the milestone method.

Under the terms of this agreement, the Group recognized US$5.0 million milestone revenue for the year ended December 31, 2017 in relation to the Phase III initiation for the secondary indication, papillary renal cell carcinoma, and US$9.9 million milestone revenue for the year ended December 31, 2016 in relation to the Phase IIb initiation for the primary indication, non-small cell lung cancer. For the year ended December 31, 2015, the Group did not recognize any milestone revenue in relation to this contract. The Group recognized less than US$0.1 million revenue from amortization of the up-front payment for each of the years ended December 31, 2017, 2016 and 2015. In addition, the Group recognized US$3.1 million, US$2.7 million and US$3.5 million revenue from research and development services for the years ended December 31, 2017, 2016 and 2015 respectively.

In August 2016, the Group entered into an amendment to the AZ Agreement. Under the terms of the amendment, the Group shall pay for up to a maximum of US$50 million of phase III clinical trial costs related to developing savolitinib for papillary renal cell carcinoma. In return, AZ agrees to increase ex-China royalties on net sales by an additional 5% over the royalties stipulated in the original agreement until cumulative additional royalties paid reaches US$250 million, after which the additional royalty decreases to 3% for 24 months and then 1.5% thereafter. The costs of the additional Phase III clinical trial costs shall be expensed to research and development expense as incurred. Under the current revenue recognition policy, future royalties shall be recognized as revenue from license and collaboration agreements—third parties as net sales occur. The amendment does not impact the original accounting for the AZ Agreement under the milestone method.

20. Research and Development Expenses

Research and development expenses are summarized as follows:

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Clinical trial related costs	45,250	38,589	24,690
Personnel compensation and related costs	24,848	21,698	17,339
Other research and development expenses	5,425	6,584	5,339

	75,523	66,871	47,368

21. Government Incentives

The Group receives government grants from the PRC Government (including the National level and Shanghai Municipal City). These grants are given in support of drug research and development activities and are conditional upon i) the Group spending a predetermined amount, regardless of success or failure of the research and development projects and ii) the achievement of certain stages of research and development projects being approved by the relevant PRC government authority. These government grants are subject to ongoing reporting and monitoring by the PRC Government over the period of the grant.

Government incentives, which are deferred and recognized in the consolidated statements of operations over the period necessary to match them with the costs that they are intended to compensate, are recognized in other payable, accruals and advance receipts (Note 13) and other non-current liabilities.

F-40

Table of Contents

They are refundable to the PRC Government if the related research and development projects are suspended. For the years ended December 31, 2017, 2016 and 2015, the Group received government grants of US$1,323,000, US$1,872,000 and US$4,898,000 respectively.

The government grants recorded as a reduction to research and development expenses for the years ended December 31, 2017, 2016 and 2015 were US$876,000 US$1,269,000 and US$3,664,000 respectively.

22. Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries

The Group has the following significant transactions with related parties and non-controlling shareholders of subsidiaries, which were carried out in the normal course of business at terms determined and agreed by the relevant parties.

(i) Transactions with related parties:

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Sales to:
Indirect subsidiaries of CK Hutchison	8,486	9,794	8,074



Revenue from research and development services:
Equity investees	9,682	8,429	5,383



Purchases from:
Equity investees	1,182	280	3,701



Rendering of marketing services from:
Indirect subsidiaries of CK Hutchison	372	741	751
An equity investee	10,195	8,401	5,093

	10,567	9,142	5,844



Rendering of management services from:
Indirect subsidiaries of CK Hutchison	897	874	845



Interest paid to:
Immediate holding company	—	152	144
An indirect subsidiary of CK Hutchison	132	—	—

	132	152	144



Guarantee fee on bank loan to:
An indirect subsidiary of CK Hutchison	320	471	471

F-41

Table of Contents

(ii) Balances with related parties included in:

	December 31,

	2017	2016
	(in US$'000)
Accounts receivable—related parties
Indirect subsidiaries of CK Hutchison (note (a))	2,761	2,589
Equity investees (note (a))	1,099	1,634

	3,860	4,223



Accounts payable
An indirect subsidiary of CK Hutchison (note (a))	—	19
An equity investee (note (a))	20	—

	20	19



Amounts due from related parties
An indirect subsidiary of CK Hutchison (note (a))	23	107
Equity investees (note (a))	893	1,029
Dividend receivable from an equity investee	7,628	—

	8,544	1,136



Amounts due to related parties
Immediate holding company (note (b))	—	2,086
An indirect subsidiary of CK Hutchison (note (b))	454	152
An equity investee (note (a))	6,567	3,070

	7,021	5,308



Other deferred income
An equity investee (note (c))	1,648	1,771



Other non-current liabilities
Immediate holding company (note (d))	—	6,000

Notes:

(a): Balances with related parties are unsecured, interest-free and repayable on demand. The carrying values of balances with related parties approximate their fair values due to their short-term maturities.
(b): Amounts due to immediate holding company and an indirect subsidiary of CK Hutchison are unsecured and interest-bearing. During the year ended December 31, 2017, amounts due to immediate holding company were assigned to an indirect subsidiary of CK Hutchison. As at December 31, 2017, approximately US$454,000 (December 31, 2016: US$2,238,000) of such balances are repayable within one year or repayable on demand.
(c): Other deferred income represents amounts recognized from granting of promotion and marketing rights.
(d): In December 2017, the Group repaid the amount due. As at December 31, 2016, this amount was recorded in non-current liabilities as it was repayable in equal installments of US$3,000,000 in December 2018 and December 2019.

F-42

Table of Contents

(iii) Transactions with non-controlling shareholders of subsidiaries:

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Sales	13,307	12,274	6,196



Purchases	21,236	15,225	12,169



Interest expense	66	78	85



Dividend declared	1,594	564	590

(iv) Balances with non-controlling shareholders of subsidiaries included in:

	December 31,

	2017	2016
	(in US$'000)
Accounts receivable—third parties	1,846	—



Accounts payable	7,250	5,136



Other payables, accruals and advance receipts
Loan	1,550	—
Interest payable	80	14

	1,630	14



Other non-current liabilities
Loans	579	2,129

23. Income Taxes

(i) Income tax expense

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Current tax
HK (note (a))	572	520	150
PRC (note (b))	782	458	415
Deferred income tax	1,726	3,353	1,040

Income tax expense	3,080	4,331	1,605

Notes:

(a): The Company, a subsidiary incorporated in the British Virgin Islands and its Hong Kong subsidiaries are subject to Hong Kong profits tax which has been provided for at the rate of 16.5% on the estimated assessable profits less estimated available tax losses in each entity.
(b): Taxation in the PRC has been provided for at the applicable rate on the estimated assessable profits less estimated available tax losses, if any, in each entity. Under the PRC Enterprise Income Tax Law (the "EIT Law"), the standard enterprise income tax rate is 25%. In addition, the EIT Law provides for, among others, a preferential tax rate of 15% for companies which qualify as HNTE. HMPL qualifies as a HNTE up to December 31, 2019. Pursuant to the EIT law, a 10% withholding tax is levied on dividends declared by PRC

F-43

Table of Contents

companies to their foreign investors. A lower withholding tax rate of 5% is applicable under the China-HK Tax Arrangement if direct foreign investors with at least 25% equity interest in the PRC companies are Hong Kong tax residents, and meet the conditions or requirements pursuant to the relevant PRC tax regulations regarding beneficial ownership. Since the equity holders of the major subsidiaries and equity investees of the Company are Hong Kong incorporated companies and Hong Kong tax residents, and meet the aforesaid conditions or requirements, the Company has used 5% to provide for deferred tax liabilities on retained earnings which are anticipated to be distributed. As at December 31, 2017 and 2016, the amounts accrued in deferred tax liabilities relating to withholding tax on dividends were determined on the basis that 100% of the distributable reserves of the major subsidiaries and equity investees operating in the PRC will be distributed as dividends.

The reconciliation of the Group's reported income tax expense to the theoretical tax amount that would arise using the tax rates of the Company against the Group's loss before income taxes and equity in earnings of equity investees is as follows:

	Year Ended December 31,

	2017		2016		2015
	(in US$'000)
Loss before income taxes and equity in earnings of equity investees	(53,536	)	(47,356	)	(10,540	)



Tax calculated at the statutory tax rate of the Company	(8,833	)	(7,814	)	(1,739	)
Tax effects of:
Different tax rates available in different jurisdictions	2,531		453		(2,953	)
Tax valuation allowance	11,410		9,886		6,601
Preferential tax deduction	(3,347	)	(3,205	)	(2,096	)
Expenses not deductible for tax purposes	391		688		253
Utilization of previously unrecognized tax losses	(387	)	(21	)	(34	)
Withholding tax on undistributed earnings of PRC entities	1,980		3,532		1,216
Others	(665	)	812		357

Income tax expense	3,080		4,331		1,605

(ii) Deferred tax assets and liabilities

The significant components of deferred tax assets and liabilities are as follows:

	December 31,

	2017		2016
	(in US$'000)
Deferred tax assets
Tax losses	31,028		20,145
Others	1,267		372

Total deferred tax assets	32,295		20,517
Less: Valuation allowance	(31,662	)	(20,145	)

Deferred tax assets	633		372



Deferred tax liabilities
Undistributed earnings from PRC entities	4,332		5,230
Others	120		131

Deferred tax liabilities	4,452		5,361

F-44

Table of Contents

As at December 31, 2017, all deferred tax assets and liabilities are classified as non-current after adopting ASU 2015-17. As at December 31, 2016, deferred tax assets and liabilities of US$372,000 and US$1,364,000 respectively were classified as current, with the remainder as non-current.

The significant components of deferred tax assets and liabilities are as follows:

	2017		2016		2015

	(in US'000)
As at January 1	(4,989	)	(3,473	)	(2,842	)
Utilization of previously recognized withholding tax on undistributed earnings	3,179		1,526		321
(Charged)/Credited to the consolidated statements of operations
Withholding tax on undistributed earnings of PRC entities	(1,980	)	(3,532	)	(1,216	)
Deferred tax on amortization of intangible assets	18		32		24
Deferred tax on provision for assets	236		147		152
Exchange differences	(283	)	311		88

As at December 31	(3,819	)	(4,989	)	(3,473	)

The deferred tax assets and liabilities are offset when there is a legally enforceable right to set off and when the deferred income taxes relate to the same fiscal authority.

The tax losses can be carried forward against future taxable income and will expire in the following years:

	December 31,

	2017	2016
	(in US$'000)
No expiry date	42,385	32,859
2017	—	3,651
2018	858	807
2019	4,261	4,012
2020	36,188	34,059
2021	50,494	53,194
2022	65,195	—

	199,381	128,582

The Company believes that it is more likely than not that future operations will not generate sufficient taxable income to realize the benefit of the deferred tax assets. The Company's subsidiaries have had sustained tax losses, which will expire within five years if not utilized in the case of PRC subsidiaries, and which will not be utilized in the case of Hong Kong subsidiaries as they do not generate taxable profits. Accordingly, a valuation allowance has been recorded against the relevant deferred tax assets arising from the tax losses.

F-45

Table of Contents

The table below summarizes changes in the deferred tax valuation allowance:

	2017		2016		2015

	(in US$'000)
As at January 1	20,145		11,393		7,455
Charged to consolidated statements of operations	11,410		9,886		6,601
Utilization of previously unrecognized tax losses	(387	)	(21	)	(34	)
Write-off of expired tax losses	(558	)	—		(1,493	)
Others	(89	)	(288	)	(901	)
Exchange differences	1,141		(825	)	(235	)

As at December 31	31,662		20,145		11,393

The Group recognizes interest and penalties, if any, under income tax payable on its consolidated balance sheets and under other expenses in its consolidated statements of operations. As at December 31, 2017 and 2016, the Group did not have any material unrecognized uncertain tax positions.

(iii) Income tax payable

	2017		2016		2015

	(in US$'000)
As at January 1	274		442		112
Current tax	1,354		978		565
Withholding tax upon dividend declaration from PRC entities	3,179		1,526		321
Tax paid	(3,836	)	(2,664	)	(510	)
Exchange difference	8		(8	)	(46	)

As at December 31	979		274		442

24. (Losses)/Earnings per Share

(i) Basic (losses)/earnings per share

Basic (losses)/earnings per share is calculated by dividing the net (loss)/income attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares in issue during the year. Treasury shares held by the Trustee are excluded from the weighted average number of outstanding ordinary shares in issue for purposes of calculating basic (losses)/earnings per share.

	Year Ended December 31,

	2017		2016		2015
Weighted average number of outstanding ordinary shares in issue	61,717,171		59,715,173		54,659,315



Net (loss)/income (US$'000)	(22,963	)	14,557		10,427
Net income attributable to non-controlling interests (US$'000)	(3,774	)	(2,859	)	(2,434	)
Accretion on redeemable non-controlling interests (US$'000)	—		—		(43,001	)

Net (loss)/income for the year attributable to ordinary shareholders of the Company (US$'000)	(26,737	)	11,698		(35,008	)

(Losses)/earnings per share attributable to ordinary shareholders of the Company (US$ per share)	(0.43	)	0.20		(0.64	)

(ii) Diluted (losses)/earnings per share

Diluted (losses)/earnings per share is calculated by dividing net (loss)/income attributable to ordinary shareholders of the Company, by the weighted average number of ordinary and dilutive ordinary share

F-46

Table of Contents

equivalents outstanding during the year. Dilutive ordinary share equivalents include shares issuable upon the exercise or settlement of share-based awards issued by the Company and its subsidiaries using the treasury stock method.

	Year Ended December 31,

	2017		2016	2015
Weighted average number of outstanding ordinary shares in issue	61,717,171		59,715,173	54,659,315
Adjustment for share options and LTIP	—		255,877	—

	61,717,171		59,971,050	54,659,315



Net (loss)/income for the year attributable to ordinary shareholders of the Company (US$'000)	(26,737	)	11,698	(35,008	)

(Losses)/earnings per share attributable to ordinary shareholders of the Company (US$ per share)	(0.43	)	0.20	(0.64	)

For the years ended December 31, 2017 and 2015, the share options and LTIP awards issued by the Company as well as the preferred shares issued by HMHL were not included in the calculation of diluted losses per share because of their anti-dilutive effect.

25. Segment Reporting

The Group determines its operating segments from both business and geographic perspectives as follows:

(i)

Innovation Platform (Drug research and development ("Drug R&D")): focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases, and the provision of research and development services; and

(ii)

Commercial Platform: comprises of the manufacture, marketing and distribution of prescription and over-the-counter pharmaceuticals in the PRC as well as consumer health products through Hong Kong. The Commercial Platform is further segregated into two core business areas:

(a): Prescription Drugs: comprises the development, manufacture, distribution, marketing and sale of prescription pharmaceuticals; and
(b): Consumer Health: comprises the development, manufacture, distribution, marketing and sale of over-the-counter pharmaceuticals and consumer health products.

Innovation Platform and Prescription Drugs businesses under the Commercial Platform are primarily located in the PRC. The locations for Consumer Health business under the Commercial Platform are further segregated into the PRC and Hong Kong.

The performance of the reportable segments is assessed based on three measurements: (a) losses or earnings of subsidiaries before interest income, interest expense, income tax expenses and equity in earnings of equity investees, net of tax ("Adjusted (LBIT)/EBIT" or "Adjusted LBIT"), (b) equity in earnings of equity investees, net of tax and (c) operating (loss)/profit.

F-47

Table of Contents

The segment information is as follows:

	Year ended December 31, 2017

	Innovation Platform		Commercial Platform
	Drug R&D		Prescription Drugs	Consumer Health
	PRC		PRC	PRC		Hong Kong	Subtotal	Unallocated		Total
	(in US$'000)
Revenue from external customers	35,997		166,435	9,858		28,913	205,206	—		241,203

Adjusted (LBIT)/EBIT	(47,503	)	3,272	578		3,029	6,879	(12,677	)	(53,301	)
Interest income	64		37	13		13	63	1,093		1,220
Equity in earnings of equity investees, net of tax	(4,547	)	27,812	10,388		—	38,200	—		33,653

Operating (loss)/profit	(51,986	)	31,121	10,979		3,042	45,142	(11,584	)	(18,428	)
Interest expense	—		—	—		66	66	1,389		1,455
Income tax expense	26		934	(457	)	509	986	2,068		3,080
Net (loss)/income attributable to ordinary shareholders of the Company	(51,880	)	28,999	9,773		1,261	40,033	(14,890	)	(26,737	)
Depreciation/amortization	2,400		116	17		18	151	27		2,578
Additions to non-current assets (other than financial instrument and deferred tax assets)	5,936		56	43		8	107	30		6,073

	As at December 31, 2017

	Innovation Platform	Commercial Platform
	Drug R&D	Prescription Drugs	Consumer Health
	PRC	PRC	PRC	Hong Kong	Subtotal	Unallocated	Total
	(in US$'000)
Total assets	63,268	122,665	58,961	13,794	195,420	339,244	597,932
Property, plant and equipment	13,917	160	61	30	251	52	14,220
Leasehold land	1,261	—	—	—	—	—	1,261
Goodwill	—	2,901	407	—	3,308	—	3,308
Other intangible asset	—	430	—	—	430	—	430
Investments in equity investees	19,512	69,417	55,308	—	124,725	—	144,237

F-48

Table of Contents

	Year ended December 31, 2016

	Innovation Platform		Commercial Platform
	Drug R&D		Prescription Drugs	Consumer Health
	PRC		PRC	PRC		Hong Kong	Subtotal	Unallocated		Total
	(inUS$'000)
Revenue from external customers	35,228		149,861	6,984		24,007	180,852	—		216,080

Adjusted (LBIT)/EBIT	(36,657	)	2,377	(493	)	1,852	3,736	(13,306	)	(46,227	)
Interest income	52		31	34		1	66	384		502
Equity in earnings of equity investees, net of tax	(4,232	)	60,288	10,188		—	70,476	—		66,244

Operating (loss)/profit	(40,837	)	62,696	9,729		1,853	74,278	(12,922	)	20,519
Interest expense	—		—	—		79	79	1,552		1,631
Income tax expense	—		777	(497	)	289	569	3,762		4,331
Net (loss)/income attributable to ordinary shareholders of the Company	(40,735	)	61,120	8,384		833	70,337	(17,904	)	11,698
Depreciation/amortization	2,176		102	3		19	124	41		2,341
Additions to non-current assets (other than financial instrument and deferred tax assets)	4,138		67	20		51	138	51		4,327

	As at December 31, 2016

	Innovation Platform	Commercial Platform
	Drug R&D	Prescription Drugs	Consumer Health
	PRC	PRC	PRC	Hong Kong	Subtotal	Unallocated	Total
	(in US$'000)
Total assets	53,774	134,681	67,161	10,701	212,543	76,120	342,437
Property, plant and equipment	9,686	145	34	40	219	49	9,954
Leasehold land	1,220	—	—	—	—	—	1,220
Goodwill	—	2,730	407	—	3,137	—	3,137
Other intangible asset	—	469	—	—	469	—	469
Investments in equity investees	17,031	77,939	63,536	—	141,475	—	158,506

F-49

Table of Contents

	Year ended December 31, 2015

	Innovation Platform		Commercial Platform
	Drug R&D		Prescription Drugs	Consumer Health
	PRC		PRC	PRC		Hong Kong	Subtotal	Unallocated		Total
	(in US$'000)
Revenue from external customers	52,016		105,478	3,028		17,681	126,187	—		178,203

Adjusted (LBIT)/EBIT	(119	)	676	(169	)	1,211	1,718	(11,186	)	(9,587	)
Interest income	79		114	29		1	144	228		451
Equity in earnings of equity investees, net of tax	(3,770	)	15,653	10,689		—	26,342	—		22,572

Operating (loss)/profit	(3,810	)	16,443	10,549		1,212	28,204	(10,958	)	13,436
Interest expense	—		—	—		85	85	1,319		1,404
Income tax expense	—		239	—		148	387	1,218		1,605
Net (loss)/income attributable to ordinary shareholders of the Company	(3,810	)	15,934	8,640		581	25,155	(13,352	)	7,993
Depreciation/amortization	1,864		94	11		5	110	41		2,015
Additions to non-current assets (other than financial instrument and deferred tax assets)	3,218		88	5		4	97	9		3,324

Revenue from external customers is after elimination of inter-segment sales. The amount eliminated attributable to sales within Consumer Health business from Hong Kong to the PRC was US$2,536,000, US$1,306,000 and US$2,874,000 for the years ended December 31, 2017, 2016 and 2015 respectively. Sales between segments are carried out at mutually agreed terms.

There were no customers who accounted for over 10% of the Group's revenue for the years ended December 31, 2017 and 2016. There was one customer under the Innovation Platform which accounted for 23% of the Group's revenue for the year ended December 31, 2015.

Unallocated expenses mainly represent corporate expenses which include corporate employee benefit expenses and the relevant share-based compensation expenses. Unallocated assets mainly comprise cash and cash equivalents and short-term investments.

A reconciliation of Adjusted LBIT to net (loss)/income is as follows:

	Year Ended December 31,

	2017		2016		2015
	(in US$'000)
Adjusted LBIT	(53,301	)	(46,227	)	(9,587	)
Interest income	1,220		502		451
Equity in earnings of equity investees, net of tax	33,653		66,244		22,572
Interest expense	(1,455	)	(1,631	)	(1,404	)
Income tax expense	(3,080	)	(4,331	)	(1,605	)

Net (loss)/income	(22,963	)	14,557		10,427

F-50

Table of Contents

26. Note to Consolidated Statements of Cash Flows

Reconciliation of net (loss)/income for the year to net cash used in operating activities:

	Year Ended December 31,

	2017		2016		2015
	(in US$'000)
Net (loss)/income	(22,963	)	14,557		10,427
Adjustments to reconcile net (loss)/income to net cash used in operating activities
Amortization of finance costs	147		92		62
Depreciation and amortization	2,578		2,341		2,015
Loss on retirement of property, plant and equipment	57		30		60
Provision for excess and obsolete inventories	(16	)	163		4
Provision for doubtful accounts	242		(208	)	1,408
Share-based compensation expense—share options	1,316		1,780		1,151
Share-based compensation expense—LTIP	3,423		1,661		308
Equity in earnings of equity investees, net of tax	(33,653	)	(66,244	)	(22,572	)
Dividends received from equity investees	55,586		30,528		6,410
Unrealized currency translation (gain)/loss	(399	)	633		198
Changes in income tax balances	(756	)	1,667		1,093
Changes in working capital
Accounts receivable—third parties	2,160		(7,258	)	(12,030	)
Accounts receivable—related parties	363		(2,354	)	315
Other receivables, prepayments and deposits	(6,982	)	(1,129	)	(459	)
Amounts due from related parties	220		1,157		(3,010	)
Inventories	1,049		(3,430	)	(5,154	)
Long-term prepayment	123		361		(2,132	)
Accounts payable	(11,173	)	11,452		3,659
Other payables, accruals and advance receipts	5,194		7,554		4,660
Deferred revenue	(897	)	(1,668	)	(1,907	)
Other deferred income	(275	)	131		2,132
Amounts due to related parties	(4,287	)	(1,385	)	3,977

Total changes in working capital	(14,505	)	3,431		(9,949	)

Net cash used in operating activities	(8,943	)	(9,569	)	(9,385	)

27. Litigation

From time to time, the Group may become involved in litigation relating to claims arising from the ordinary course of business. The Group believes that there are currently no claims or actions pending against the Group, the ultimate disposition of which could have a material adverse effect on the Group's results of operations, financial position or cash flows. However, litigation is subject to inherent uncertainties and the Group's view of these matters may change in the future. When an unfavorable outcome occurs, there exists the possibility of a material adverse impact on the Group's financial position and results of operations for the periods in which the unfavorable outcome occurs, and potentially in future periods.

28. Restricted Net Assets

Relevant PRC laws and regulations permit payments of dividends by the Company's subsidiaries in the PRC only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. In addition, the Company's subsidiaries in the PRC are required to make

F-51

Table of Contents

certain appropriations of net after-tax profits or increases in net assets to the statutory surplus fund prior to payment of any dividends. In addition, registered share capital and capital reserve accounts are also restricted from withdrawal in the PRC, up to the amount of net assets held in each subsidiary. As a result of these and other restrictions under PRC laws and regulations, the Company's subsidiaries in the PRC are restricted in their ability to transfer their net assets to the Group in terms of cash dividends, loans or advances, with restricted portions amounting to US$7,277,000 and US$6,847,000 as at December 31, 2017 and 2016 respectively, which excludes the Company's subsidiaries with a shareholders' deficit. Even though the Group currently does not require any such dividends, loans or advances from the PRC subsidiaries, for working capital and other funding purposes, the Group may in the future require additional cash resources from the Company's subsidiaries in the PRC due to changes in business conditions, to fund future acquisitions and development, or merely to declare and pay dividends to make distributions to shareholders.

In addition, the Group has certain investments in equity investees in the PRC, where the Group's equity in undistributed earnings amounted to US$85,400,000 and US$116,953,000 as at December 31, 2017 and 2016 respectively.

29. Subsequent Events

The Group evaluated subsequent events through March 12, 2018, which is the date when the consolidated financial statements were issued.

F-52

Table of Contents

SHANGHAI HUTCHISON
PHARMACEUTICALS LIMITED

F-53

Table of Contents

Report of Independent Auditors

To the Board of Directors and Shareholders of Shanghai Hutchison Pharmaceuticals Limited

We have audited the accompanying consolidated financial statements of Shanghai Hutchison Pharmaceuticals Limited and its subsidiaries, which comprise the consolidated statements of financial position as of December 31, 2017 and 2016, and the related consolidated income statements, consolidated statements of comprehensive income, of changes in equity and of cash flows for each of the three years in the period ended December 31, 2017.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the Company's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Shanghai Hutchison Pharmaceuticals Limited and its subsidiaries as of December 31, 2017 and 2016, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2017 in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

/s/ PricewaterhouseCoopers Zhong Tian LLP
Shanghai, the People's Republic of China
March 9, 2018

F-54

Table of Contents

Shanghai Hutchison Pharmaceuticals Limited
Consolidated Income Statements
(in US$'000)

		Year Ended December 31,

	Note	2017		2016		2015
Revenue	5	244,557		222,368		181,140
Cost of sales		(68,592	)	(64,237	)	(53,532	)

Gross profit		175,965		158,131		127,608
Selling expenses		(104,504	)	(92,487	)	(78,429	)
Administrative expenses		(13,257	)	(13,278	)	(12,317	)
Other net operating income	6	8,293		7,242		539
Gain on disposal of assets held for sale	7	—		88,536		—

Profit before taxation	8	66,497		148,144		37,401
Taxation charge	9	(10,874	)	(27,645	)	(6,094	)

Profit for the year		55,623		120,499		31,307

The accompanying notes are an integral part of these consolidated financial statements.

F-55

Table of Contents

Shanghai Hutchison Pharmaceuticals Limited
Consolidated Statements of Comprehensive Income
(in US$'000)

	Year Ended December 31,

	2017	2016		2015
Profit for the year	55,623	120,499		31,307
Other comprehensive income/(loss) that has been or may be reclassified subsequently to profit or loss:
Exchange translation differences	8,273	(8,571	)	(3,540	)

Total comprehensive income	63,896	111,928		27,767

The accompanying notes are an integral part of these consolidated financial statements.

F-56

Table of Contents

Shanghai Hutchison Pharmaceuticals Limited
Consolidated Statements of Financial Position
(in US$'000)

		December 31,

	Note	2017	2016
Assets
Current assets
Cash and cash equivalents	11	43,527	20,292
Bank deposits maturing over three months	11	—	40,205
Trade and bills receivables	12	22,445	23,718
Other receivables, prepayments and deposits	13	2,456	11,262
Inventories	14	61,107	47,844

Total current assets		129,535	143,321
Property, plant and equipment	15	90,734	88,390
Leasehold land		7,528	7,244
Other intangible asset		1,621	1,741
Deferred tax assets	16	3,594	3,310

Total assets		233,012	244,006



Liabilities and shareholders' equity
Current liabilities
Trade payables	17	11,773	7,979
Other payables, accruals and advance receipts	18	74,551	65,249
Current tax liabilities	19	5,341	13,718

Total current liabilities		91,665	86,946
Deferred income		8,616	6,926

Total liabilities		100,281	93,872

Shareholders' equity
Share capital		33,382	33,382
Reserves		99,349	116,752

Total shareholder's equity		132,731	150,134

Total liabilities and shareholders' equity		233,012	244,006

The accompanying notes are an integral part of these consolidated financial statements.

F-57

Table of Contents

Shanghai Hutchison Pharmaceuticals Limited
Consolidated Statements of Changes in Equity
(in US$'000)

	Share capital	Exchange reserve		General reserves	Retained earnings		Total equity

As at January 1, 2015	33,382	5,781		925	31,818		71,906
Profit for the year	—	—		—	31,307		31,307
Other comprehensive loss
Exchange translation differences	—	(3,540	)	—	—		(3,540	)

Total comprehensive (loss)/income	—	(3,540	)	—	31,307		27,767

Dividends declared to shareholders	—	—		—	(6,410	)	(6,410	)

As at December 31, 2015	33,382	2,241		925	56,715		93,263



Profit for the year	—	—		—	120,499		120,499
Other comprehensive loss
Exchange translation differences	—	(8,571	)	—	—		(8,571	)

Total comprehensive (loss)/income	—	(8,571	)	—	120,499		111,928

Transfer between reserves	—	—		30	(30	)	—
Dividends declared to shareholders	—	—		—	(55,057	)	(55,057	)

As at December 31, 2016	33,382	(6,330	)	955	122,127		150,134



Profit for the year	—	—		—	55,623		55,623
Other comprehensive income
Exchange translation differences	—	8,273		—	—		8,273

Total comprehensive income	—	8,273		—	55,623		63,896

Transfer between reserves	—	—		15	(15	)	—
Dividends declared to shareholders	—	—		—	(81,299	)	(81,299	)

As at December 31, 2017	33,382	1,943		970	96,436		132,731

The accompanying notes are an integral part of these consolidated financial statements.

F-58

Table of Contents

Shanghai Hutchison Pharmaceuticals Limited
Consolidated Statements of Cash Flows
(in US$'000)

		Year Ended December 31,

	Note	2017		2016		2015
Operating activities
Net cash generated from operations	20	78,503		64,310		51,007
Interest received		844		467		300
Income tax paid	19	(19,887	)	(15,595	)	(6,199	)

Net cash generated from operating activities		59,460		49,182		45,108

Investing activities
Purchase of property, plant and equipment	15	(7,744	)	(11,171	)	(44,899	)
Deposits into bank deposits maturing over three months		(19,076	)	(57,001	)	(3,087	)
Proceeds from bank deposits maturing over three months		59,281		20,563		1,619
Proceeds from disposal of property, plant and equipment		—		4		1
Proceeds from disposal of assets held for sale, net of costs	7	9,776		58,839		31,146
Capitalized interest expense paid for property, plant and equipment	15	—		(768	)	(1,934	)
Government grants received relating to property, plant and equipment		1,569		166		2,816

Net cash generated from/(used in) investing activities		43,806		10,632		(14,338	)

Financing activities
Dividends paid to shareholders		(81,299	)	(55,057	)	(6,410	)
Proceeds from bank borrowings		—		—		16,764
Repayment of bank borrowings		—		(25,577	)	(13,176	)

Net cash used in financing activities		(81,299	)	(80,634	)	(2,822	)

Net increase/(decrease) in cash and cash equivalents		21,967		(20,820	)	27,948
Effect of exchange rate changes on cash and cash equivalents		1,268		(2,029	)	(1,382	)

		23,235		(22,849	)	26,566
Cash and cash equivalents
Cash and cash equivalents at beginning of year		20,292		43,141		16,575

Cash and cash equivalents at end of year		43,527		20,292		43,141

The accompanying notes are an integral part of these consolidated financial statements.

F-59

Table of Contents

Shanghai Hutchison Pharmaceuticals Limited
Notes to the Consolidated Financial Statements

1. General Information

Shanghai Hutchison Pharmaceuticals Limited (the "Company") and its subsidiaries (together the "Group") are principally engaged in manufacturing, selling and distribution of prescription drug products. The Group has manufacturing plants in the People's Republic of China (the "PRC") and sells mainly in the PRC.

The Company was incorporated in the PRC on April 30, 2001 as a Chinese-Foreign Equity joint venture and the approved operation period is 50 years. The Company is jointly controlled by Shanghai Hutchison Chinese Medicine (HK) Investment Limited ("SHCM(HK)IL") and Shanghai Traditional Chinese Medicine Co., Ltd ("SHTCML").

These consolidated financial statements are presented in United States dollars ("US$"), unless otherwise stated and have been approved for issue by the Company's Board of Directors on March 9, 2018.

2. Summary of Significant Accounting Policies

The consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards ("IFRS") and interpretations issued by the IFRS Interpretations Committee applicable to companies reporting under IFRS. The consolidated financial statements comply with IFRS as issued by the International Accounting Standards Board ("IASB"). These consolidated financial statements have been prepared under the historical cost convention.

During the year, the Group has adopted all of the new standards, amendments and interpretations issued by the IASB that are relevant to the Group's operations and mandatory for annual periods beginning January 1, 2017. The adoption of these new standards, amendments and interpretations did not have any material effects on the Group's results of operations or financial position.

The following standards, amendments and interpretations were in issue but not yet effective for financial year ended December 31, 2017 and have not been early adopted by the Group:


IAS 28 (Amendments)⁽¹⁾		Investments in Associates and Joint Ventures
IAS 40 (Amendments)⁽¹⁾		Transfers of Investment Property
IFRS 2 (Amendments)⁽¹⁾		Classification and Measurement of Share-based Payment Transactions
IFRS 9⁽¹⁾		Financial Instruments
IFRS 10 and IAS 28 (Amendments)⁽³⁾		Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
IFRS 15⁽¹⁾		Revenue from Contracts with Customers
IFRS 15 (Amendments)⁽¹⁾		Revenue from Contracts with Customers
IFRS 16⁽²⁾		Leases
IFRIC 22⁽¹⁾		Foreign Currency Transactions and Advance Consideration
IFRIC 23⁽²⁾		Uncertainty over Income Tax Treatments
Annual improvement 2014-2016⁽¹⁾		Improvements to IFRSs
Annual improvement 2015-2017⁽²⁾		Improvements to IFRSs

(1): Effective for the Group for annual periods beginning on or after January 1, 2018.
(2): Effective for the Group for annual periods beginning on or after January 1, 2019.

F-60

Table of Contents

(3): No mandatory effective date determined yet, but available for adoption.

The adoption of standards, amendments and interpretations listed above in future periods is not expected to have any material effects on the Group's results of operations or financial position, except for the adoption of IFRS 16 for which management is still assessing the impact.

Based on its evaluation of IFRS 15 and its Amendments, the Group expects there will not be a material impact to the timing of revenue recognition. The Group expects the timing of recognition will be at the point when the goods have been transferred to the customer and the customer obtains control of the goods as evidenced by delivery of the product, transfer of title and when no further obligations to the customer remain. The Group will adopt the new standard using the modified retrospective method in the year commencing January 1, 2018.

(a) Basis of Consolidation

The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries.

The accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset.

(b) Subsidiaries

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights, to variable return from its involvement with the entity and has the ability to affect those returns through its power over the entity. In the consolidated financial statements, subsidiaries are accounted for as described in Note 2(a) above.

Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases.

(c) Foreign Currency Translation

Items included in the financial statements of each of the Group's companies are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The functional currency of the Company and its subsidiaries is Renminbi ("RMB") whereas the consolidated financial statements are presented in US$, which is the Company's presentation currency.

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign currency gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in the income statement.

The financial statements of the Company and its subsidiaries are translated into the Company's presentation currency using the year end rates of exchange for the statements of financial position items and the average rates of exchange for the year for the income statement items. Exchange translation differences are recognized directly in other comprehensive income/(loss).

(d) Property, Plant and Equipment

F-61

Table of Contents

price of the asset and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other repairs and maintenance are charged to the income statement during the financial period in which they are incurred.

Depreciation is calculated using the straight-line method to allocate asset costs less accumulated impairment losses over their estimated useful lives. The principal estimated useful lives are as follows:


Buildings		30 years
Leasehold improvements		Over the unexpired period of the lease or 5 years, whichever is shorter
Plant and equipment		10 years
Furniture and fixtures, other equipment and motor vehicles		5 years

The assets' useful lives are reviewed and adjusted, if appropriate, at the end of each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing net sales proceeds with the carrying amount of the relevant assets and are recognized in the income statement.

(e) Construction in Progress

Construction in progress represents buildings, plant and machinery under construction and pending installation and is stated at cost less accumulated impairment losses, if any. Cost includes the costs of construction of buildings and the costs of plant and machinery. No provision for depreciation is made on construction-in-progress until such time as the relevant assets are completed and ready for intended use. When the assets concerned are brought into use, the costs are transferred to property, plant and equipment and depreciated in accordance with the policy as stated in Note 2(d).

(f) Leasehold Land

Leasehold land is stated at cost less accumulated amortization and accumulated impairment losses, if any. Cost mainly represents consideration paid for the rights to use the land on which various plants and buildings are situated for a period of 50 years from the date the respective right was granted. Amortization of leasehold land is calculated on a straight-line basis over the period of the land use rights.

(g) Other Intangible Asset

The Group's other intangible asset represents promotion and marketing rights. Other intangible asset has a definite useful life and is carried at historical cost less accumulated amortization and accumulated impairment losses, if any. Amortization is calculated using the straight-line method to allocate its cost over its estimated useful life of ten years.

(h) Research and Development

F-62

Table of Contents

expense are not recognized as an asset in a subsequent period. Development costs with a finite useful life that have been capitalized, if any, are amortized on a straight-line basis over the period of expected benefit not exceeding five years. The capitalized development costs are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount.

Where the research phase and the development phase of an internal project cannot be clearly distinguished, all expenditure incurred on the project is charged to the income statement.

(i) Impairment of Non-Financial Assets

Assets that have an indefinite useful life such as goodwill or intangible assets not ready to use are not subject to amortization and are tested for impairment annually. Assets are reviewed for impairment to determine whether there is any indication that the carrying value of these assets may not be recoverable and have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use. Such impairment loss is recognized in the income statement.

(j) Non-Current Assets Classified As Held For Sale

Non-current assets are classified as held for sale when their carrying amount is to be recovered principally through a sale transaction and a sale is considered highly probable. The non-current assets are stated at the lower of carrying amount and fair value less costs to sell. Property, plant and equipment and leasehold land classified as held for sale are not depreciated and amortized.

(k) Inventories

(l) Trade and Other Receivables

Trade and other receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less provision for impairment. A provision for impairment of trade and other receivables is established when there is objective evidence that the asset is impaired. The amount of the provision is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the effective interest rate. The amount of the provision is recognized in the income statement.

(m) Cash and Cash Equivalents

In the consolidated statements of cash flows, cash and cash equivalents include cash on hand, bank deposits and other short-term highly liquid investments with original maturities of three months or less.

(n) Borrowings

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method.

F-63

Table of Contents

(o) Financial Liabilities and Equity Instruments

Financial liabilities and equity instruments issued by the Group are classified according to the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. Financial liabilities (including trade and other payables) are initially measured at fair value, and are subsequently measured at amortized cost, using the effective interest method. An equity instrument is any contract that does not meet the definition of a financial liability and evidences a residual interest in the assets of the Group after deducting all of its liabilities.

Ordinary shares are classified as equity. Incremental costs, net of tax, directly attributable to the issue of new shares are shown in equity as a deduction from the proceeds.

(p) Current and Deferred Income Tax

(i): Current income tax

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the country where the Group operates and generates taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

(ii): Deferred income tax

Inside basis differences

Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill and the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.

Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized.

Outside basis differences

Deferred income tax liabilities are provided on taxable temporary differences arising from investments in subsidiaries, except for deferred income tax liabilities where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred income tax assets are recognized on deductible temporary differences arising from investments in subsidiaries, only to the extent that it is probable the temporary difference will reverse in the future and there is sufficient taxable profit available against which the temporary difference can be utilized.

(q) Employee Benefits

F-64

Table of Contents

undertake to assume the retirement benefit obligations to all existing and future retired employees under the plans described above. Other than the monthly contributions, the Group has no further obligations for the payment of the retirement and other post-retirement benefits of its employees.

(r) Provisions

Provisions are recognized when the Group has a present legal or constructive obligation as a result of past events; it is probable that an outflow of resources will be required to settle the obligation; and the amount has been reliably estimated. Provisions are not recognized for future operating losses.

(s) Operating Leases

Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to the income statement on a straight-line basis over the period of the leases.

(t) Borrowing Costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognized in the income statement in the period in which they are incurred.

(u) Government Incentives

Incentives from government are recognized at their fair values where there is a reasonable assurance that the incentives will be received and all attached conditions will be complied with.

Government incentives relating to costs are deferred and recognized in the income statement over the period necessary to match them with the costs that they are intended to compensate.

Government grants relating to property, plant and equipment are included in non-current liabilities as deferred income and credited to the income statement on a straight-line basis over the expected lives of the related assets.

(v) Revenue and Income Recognition

Revenue comprises the fair value of the consideration received and receivable for the sales of goods in the ordinary course of the Group's activities. The Group recognizes revenue when the amount of revenue can be reliably measured; when it is probable that future economic benefits will flow to the entity; and when specific criteria have been met for each of the Group's activities, as described below.

Revenue is shown net of value-added tax, returns, volume rebates and discounts after eliminated sales within the Group. Revenue and income are recognized as follows:

(i): Sales of goods

Sales of goods are recognized when a group entity has delivered products to the customer, the customer has accepted the products and collectability of the related receivables is reasonably assured.

(ii): Sales rebates

Certain sales rebates are provided to customers when their business performance for an agreed period within the year and the whole year meets certain criteria. Sales rebates are recognized in profit or loss based on management's estimation at each year end.

F-65

Table of Contents

(iii): Other service income

Other service income is recognized when services are rendered.

(iv): Interest income

Interest income is recognized on a time-proportion basis using the effective interest method.

(w) Segment Reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision makers. The Board of Directors, which is responsible for allocating resources and assessing performance of the operating segments, has been identified as the steering committee that makes strategic decisions.

(x) General Reserves

In accordance with the laws applicable to Foreign Investment Enterprises established in the PRC, the Company makes appropriations to certain non-distributable reserve funds including the general reserve fund, the enterprise expansion fund and the staff bonus and welfare fund. The amount of appropriations to these funds are made at the discretion of the Company's Board of Directors.

3. Financial Risk Management

(a) Financial risk factors

The Group's activities expose it to a variety of financial risks, including credit risk, cash flow interest rate risk and liquidity risk. The Group does not use any derivative financial instruments for speculative purposes.

(i): Credit risk

The carrying amounts of cash at bank, bank deposits, trade receivables (including bills receivables) and other receivables included in the consolidated statements of financial position represent the Group's maximum exposure to credit risk of the counterparty in relation to its financial assets.

Substantially all of the Group's cash at banks is deposited in major financial institutions, which management believes are of high credit quality. The Group has a practice to limit the amount of credit exposure to any financial institution.

Bills receivables are mostly settled by state-owned banks or other reputable banks and therefore the management considers that they will not expose the Group to any significant credit risk.

The Group has no significant concentrations of credit risk. The Group has policies in place to ensure that the sales of products are made to customers with appropriate credit history and the Group performs periodic credit evaluations of its customers.

Management periodically assesses the recoverability of trade receivables and other receivables. The Group's historical experience collecting receivables falls within the recorded allowances.

(ii): Cash flow interest rate risk

The Group has no significant interest-bearing assets except for bank deposits and cash at bank, details of which have been disclosed in Note 11. The Group's exposure to interest rate risk would mainly be to bank borrowings which bear interest at fixed rates.

F-66

Table of Contents

(iii): Liquidity risk

Prudent liquidity management implies maintaining sufficient cash and cash equivalents and the availability of funding when necessary. The Group's policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient cash balances and adequate credit facilities to meet its liquidity requirements in the short and long term.

As at December 31, 2017 and 2016, the Group's current financial liabilities were mainly due for settlement within twelve months and the Group expects to meet all liquidity requirements.

(b) Capital risk management

The Group's objectives when managing capital are to safeguard the Group's ability to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

The Group regularly reviews and manages its capital structure to ensure an optimal balance between higher shareholders' return that might be possible with higher levels of borrowings and the advantages and security afforded by a sound capital position, and makes adjustments to the capital structure in light of changes in economic conditions.

The Group monitors capital on the basis of the liabilities to assets ratio. This ratio is calculated as total liabilities divided by total assets as shown on the consolidated statements of financial position.

Currently, it is the Group's strategy to maintain a reasonable liabilities to assets ratio. The liabilities to assets ratio as at December 31, 2017 and 2016 was as follows:

	December 31,

	2017	2016
	(in US$'000)
Total liabilities	100,281	93,872
Total assets	233,012	244,006

Liabilities to assets ratio	43.0%	38.5%

(c) Fair value estimation

The Group does not have any financial assets or liabilities which are carried at fair value. The carrying amounts of the Group's current financial assets, including cash and bank balances, trade and bills receivables, and other receivables and current financial liabilities, including trade payables and other payables and accruals approximate their fair values due to their short-term maturities. The carrying amounts of the Group's financial instruments carried at cost or amortized cost are not materially different from their fair values.

The face values less any estimated credit adjustments for financial assets and liabilities with a maturity of less than one year are assumed to approximate their fair values. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Group for similar financial instruments.

4. Critical Accounting Estimates and Judgements

Note 2 includes a summary of the significant accounting policies used in the preparation of the financial statements. The preparation of financial statements often requires the use of judgements to select specific accounting methods and policies from several acceptable alternatives. Furthermore, significant estimates and assumptions concerning the future may be required in selecting and applying those methods and policies in the financial statements. The Group bases its estimates and judgements on historical

F-67

Table of Contents

experience and various other assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates and judgements under different assumptions or conditions.

The following is a review of the more significant assumptions and estimates, as well as the accounting policies and methods used in the preparation of the consolidated financial statements.

(a) Sales rebates

Certain sales rebates are provided to customers when their business performance for an agreed period within the year and the whole year meets certain criteria as stipulated in the contracts. The estimate of sales rebates during the year is based on estimated sales transactions for the entire period stipulated and is subject to change based on actual performance and collection status.

(b) Useful lives of property, plant and equipment

The Group has made substantial investments in property, plant and equipment. Changes in technology or changes in the intended use of these assets may cause the estimated period of use or value of these assets to change.

(c) Impairment of receivables

The Group makes provision for impairment of receivables based on an assessment of the recoverability of the receivables. This assessment is based on the credit history of the relevant counterparty and the current market condition. Provisions are made where events or changes in circumstances indicate that the receivables may not be collectible. The identification of impairment in receivables requires the use of judgement and estimates. Where the expectation is different from the original estimate, such difference will impact the carrying amount of receivables and impairment is recognized in the period in which such estimate has been changed.

(d) Deferred income tax

Deferred tax is recognized using the liability method on temporary differences arising between the tax bases of assets and liabilities against which the deductible temporary differences and the carry forward of unused tax losses and tax credits can be utilized. Where the final outcomes are different from the estimations, such differences will impact the carrying amount of deferred tax in the period in which such determination is made.

(e) Disposal of assets classified as held for sale

On October 20, 2016, the Group completed the disposal of assets classified as held for sale, including leasehold land and property, plant and equipment, to the municipal government. 90% of the consideration had been collected as of December 31, 2016, and the remaining 10% was collected in February 2017. The gain of US$88.5 million representing the consideration less the assets classified as held for sale was recognized in full on the disposal date. The Group determined that the whole transaction had been completed on October 20, 2016 since the risk and rewards of ownership of the land had been passed to the municipal government, no additional costs were expected to be incurred and there was no receivable recoverability risk.

5. Revenue and Segment Information

Management has reviewed the Group's internal reporting in order to assess performance and allocate resources, and has determined that the Group has two reportable operating segments as follows:

—Manufacturing business—manufacture and distribution of drug products

F-68

Table of Contents

—Distribution business—provision of sales, distribution and marketing services to pharmaceutical manufacturers

The operating segments are strategic business units that offer different products and services. They are managed separately because each business requires different technology and marketing approaches. The performance of each of the reportable segments is assessed based on a measure of earnings or losses before interest income, finance costs and taxation charge ("Adjusted EBIT/(LBIT)"). The aggregate amount of operating profit/(loss) for the two operating segments is the same as profit before taxation in the consolidated income statements for each of the years presented.

The segment information for the reportable segments for the year is as follows:

	Year Ended December 31, 2017

	Manufacturing business	Distribution business
	PRC	PRC		Total
	(in US$'000)
Revenue from external customers	226,429	18,128		244,557



Adjusted EBIT/(LBIT)	65,920	(180	)	65,740
Interest income	603	154		757

Operating profit/(loss)	66,523	(26	)	66,497
Depreciation/amortization	6,917	25		6,942
Additions to non-current assets (other than financial instrument and deferred tax assets)	3,469	3		3,472

	As at December 31, 2017

	(in US$'000)
Total segment assets	221,997	11,015	233,012

	Year Ended December 31, 2016

	Manufacturing business	Distribution business
	PRC	PRC		Total
	(in US$'000)
Revenue from external customers	205,809	16,559		222,368



Adjusted EBIT/(LBIT)	169,312	(21,733	)	147,579
Interest income	562	3		565

Operating profit/(loss)	169,874	(21,730	)	148,144
Depreciation/amortization	3,503	23		3,526
Impairment of property, plant and equipment	1,174	—		1,174
Additions to non-current assets (other than financial instrument and deferred tax assets)	11,919	20		11,939

	As at December 31, 2016

	(in US$'000)
Total segment assets	239,843	4,163	244,006

F-69

Table of Contents

	Year Ended December 31, 2015

	Manufacturing business	Distribution business
	PRC	PRC		Total
	(in US$'000)
Revenue from external customers	174,821	6,319		181,140



Adjusted EBIT/(LBIT)	39,387	(2,292	)	37,095
Interest income	301	5		306

Operating profit/(loss)	39,688	(2,287	)	37,401
Depreciation/amortization	2,742	23		2,765
Additions to non-current assets (other than financial instrument and deferred tax assets)	49,231	6		49,237

6. Other Net Operating Income

	Year Ended December 31,

	2017	2016		2015
	(in US$'000)
Interest income	757	565		306
Net foreign exchange gain/(losses)	45	(51	)	(25	)
Other government subsidy (Note 18)	6,388	6,560		—
Other operating income	1,103	168		258

	8,293	7,242		539

7. Gain on disposal of Assets Held for Sale

The Company's prior manufacturing facilities and factory site ("the Site") was located in Putuo District, Shanghai, an area of Shanghai 12 kilometers from the city centre. The area was re-zoned in 2014 from industrial usage into a new science and technology, commercial and residential development area called Smart City.

On December 9, 2015, the Company entered into an agreement ("the Agreement") with the relevant Shanghai government authorities for the surrender of its then remaining 36 years land-use right in respect of the Site. Under the Agreement, the Company received cash compensation in three installments. As at December 31, 2015, the Company received the first installment of approximately US$ 31.1 million of the compensation (which was equivalent to approximately US$29.9 million in October 2016 based on the prevailing exchange rate at that time).

In October 2016, the Company completed the surrender of the Site and received the second installment of US$59.7 million. Upon the disposal of the non-current assets classified as held for sales, the Company derecognized the carrying values of the non-current assets classified as held for sales amounted to approximately US$10.1 million, and recognized a gain of US$88.5 million after deducting the costs of US$0.9 million. The remaining US$9.7 million final installment (which was equivalent to US$9.9 million in October 2016 based on the prevailing exchange rate at that time) was recorded as a current asset as at December 31, 2016. In February 2017, the Company received the final installment of the land compensation (which was equivalent to US$9.8 million based on the prevailing exchange rate at that time).

F-70

Table of Contents

8. Profit before taxation

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Profit before taxation	66,497	148,144	37,401

Profit before taxation is stated after charging/(crediting) the following:

	Year Ended December 31,

	2017	2016		2015
	(in US$'000)
Cost of inventories recognized as expense	45,683	47,047		32,378
Depreciation of property, plant and equipment	6,556	3,135		2,277
Impairment of property, plant and equipment	—	1,174		—
Loss on disposal of property, plant and equipment	2	179		34
Amortization of leasehold land	164	166		271
Amortization of other intangible asset	222	225		217
Operating lease rentals in respect of land and buildings	856	737		670
Reversal of provision for trade receivables	—	(81	)	—
Provision for excess and obsolete inventories	994	1,236		1,569
Research and development expense	3,414	1,753		1,442
Auditor's remuneration	163	138		71
Employee benefit expenses (Note 10)	70,401	61,092		49,398

9. Taxation Charge

	Year Ended December 31,

	2017		2016	2015
	(in US$'000)
Current tax	10,949		26,709	7,928
Deferred income tax (Note 16)	(75	)	936	(1,834	)

Taxation charge	10,874		27,645	6,094

F-71

Table of Contents

The taxation charge on the Group's profit before taxation differs from the theoretical amount that would arise using the Group's weighted average tax rate as follows:

	Year Ended December 31,

	2017		2016		2015
	(in US$'000)
Profit before taxation	66,497		148,144		37,401



Tax calculated at the statutory tax rates of respective companies	16,624		37,036		9,351
Tax effects of:
Expenses not deductible for tax purposes	3,361		8,124		389
Temporary differences for which no deferred tax assets were recognized	555		—		—
Tax concession (note)	(8,497	)	(18,203	)	(4,101	)
(Over)/under provision in prior years	(5	)	237		(98	)
Tax benefits from change in tax law	(1,538	)	—		—
Rate change on deferred tax assets	113		—		—
Tax losses for which no deferred tax assets were recognized	261		451		553

Taxation charge	10,874		27,645		6,094

Note: The Company has been granted the High and New Technology Enterprise status. Accordingly, the Company is subjected to a preferential income tax rate of 15.0% in 2017 and up to 2019 (2016: 15.0%; 2015: 15.0%). Certain research and development expenses are also eligible for super-deduction such that 150% of qualified expenses incurred are deductible for tax purposes.

The weighted average tax rate calculated at the statutory tax rates of respective companies for the year was 25.0% (2016: 25.0%; 2015: 25.0%). The effective tax rate for the year was 16.4% (2016: 18.7%; 2015: 16.3%).

10. Employee Benefit Expenses

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Wages, salaries and bonuses	54,444	48,350	32,776
Pension costs—defined contribution plans	6,635	4,929	3,837
Staff welfare	9,322	7,813	12,785

	70,401	61,092	49,398

Employee benefit expenses of approximately US$14,276,000 (2016: US$13,548,000; 2015: US$19,585,000) are included in cost of sales.

F-72

Table of Contents

11. Cash and bank balances

	December 31,

	2017	2016
	(in US$'000)
Cash at bank and on hand	43,527	20,292
Bank deposits maturing over three months (note)	—	40,205

Cash and bank balances	43,527	60,497

Note: The weighted average effective interest rate on 2016 bank deposits, with maturity ranging from 37 days to 181 days was 2.1% per annum. Cash at bank earns interest at floating rates based on daily bank deposit rates.

The cash and bank balances denominated in RMB were deposited with banks in the PRC. The conversion of these RMB denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the PRC government.

12. Trade and Bills Receivables

	December 31,

	2017	2016
	(in US$'000)
Trade receivables—third parties	11,614	10,657
Trade receivables—related parties (Note 22(b))	6,966	7,010
Bills receivables	3,865	6,051

	22,445	23,718

All the trade and bills receivables are denominated in RMB and are due within one year from the end of the reporting period.

The carrying value of trade and bills receivables approximates their fair values.

Movements on the provision for trade receivables are as follows:

	2017	2016		2015

	(in US$'000)
As at January 1	—	131		137
Reversal of provision for trade receivables	—	(81	)	—
Decreased due to collection or write-off	—	(45	)	—
Exchange difference	—	(5	)	(6	)

As at December 31	—	—		131

There are no impaired receivables as at December 31, 2017 and December 31, 2016.

F-73

Table of Contents

13. Other Receivables, Prepayments and Deposits

	December 31,

	2017	2016
	(in US$'000)
Prepayments to suppliers	358	112
Interest receivables	—	87
Deposits	846	7
Receivable from disposal of asset held for sale (Note 7)	—	9,690
Others	1,252	1,366

	2,456	11,262

14. Inventories

	December 31,

	2017	2016
	(in US$'000)
Raw materials	37,851	29,010
Work in progress	12,656	10,161
Finished goods	10,600	8,673

	61,107	47,844

Movements on the provision for excess and obsolete inventories are as follows:

	2017		2016		2015

	(in US$'000)
As at January 1	1,362		606		343
Provision for excess and obsolete inventories	994		1,236		1,569
Write-off	(522	)	(406	)	(1,309	)
Exchange differences	88		(74	)	3

As at December 31	1,922		1,362		606

F-74

Table of Contents

15. Property, plant and equipment

	Buildings situated in the PRC	Leasehold improvements	Plant and equipment		Furniture and fixtures, other equipment and motor vehicles		Construction in progress		Total

	(in US$'000)
Cost
As at January 1, 2017	67,221	315	20,003		6,213		2,606		96,358
Additions	26	162	541		1,133		1,610		3,472
Disposals	—	—	(8	)	(174	)	—		(182	)
Transfers	603	—	1,316		(15	)	(1,904	)	—
Exchange differences	4,220	24	1,306		417		103		6,070

As at December 31, 2017	72,070	501	23,158		7,574		2,415		105,718

Accumulated depreciation and impairment
As at January 1, 2017	1,120	134	2,613		2,927		1,174		7,968
Depreciation	3,468	62	2,038		988		—		6,556
Disposals	—	—	(6	)	(174	)	—		(180	)
Exchange differences	175	10	225		208		22		640

As at December 31, 2017	4,763	206	4,870		3,949		1,196		14,984

Net book value
As at December 31, 2017	67,307	295	18,288		3,625		1,219		90,734

F-75

Table of Contents

	Buildings situated in the PRC		Leasehold improvements		Plant and equipment		Furniture and fixtures, other equipment and motor vehicles		Construction in progress		Total

	(in US$'000)
Cost
As at January 1, 2016	—		318		1,403		3,925		82,837		88,483
Additions	—		15		349		801		10,774		11,939
Disposals	—		(177	)	(293	)	(234	)	(120	)	(824	)
Transfers	70,222		179		16,553		1,817		(88,771	)	—
Transfer from non-current assets classified as held for sale	—		1		2,794		266		—		3,061
Exchange differences	(3,001	)	(21	)	(803	)	(362	)	(2,114	)	(6,301	)

As at December 31, 2016	67,221		315		20,003		6,213		2,606		96,358

Accumulated depreciation and impairment
As at January 1, 2016	—		279		898		2,515		—		3,692
Depreciation	1,168		45		1,251		671		—		3,135
Disposals	—		(177	)	(246	)	(218	)	—		(641	)
Impairment	—		—		—		—		1,174		1,174
Transfer from non-current assets classified as held for sale	—		—		810		145		—		955
Exchange differences	(48	)	(13	)	(100	)	(186	)	—		(347	)

As at December 31, 2016	1,120		134		2,613		2,927		1,174		7,968

Net book value
As at December 31, 2016	66,101		181		17,390		3,286		1,432		88,390

F-76

Table of Contents

	Buildings situated in the PRC		Leasehold improvements		Plant and equipment		Furniture and fixtures, other equipment and motor vehicles		Construction in progress		Total

	(in US$'000)
Cost
As at January 1, 2015	23,065		2,156		13,660		4,266		39,346		82,493
Additions	—		5		71		470		46,287		46,833
Disposals	—		(41	)	(47	)	(163	)	—		(251	)
Transfers	—		—		—		34		(34	)	—
Transfer to non-current assets classified as held for sale	(22,143	)	(1,716	)	(11,734	)	(501	)	—		(36,094	)
Exchange differences	(922	)	(86	)	(547	)	(181	)	(2,762	)	(4,498	)

As at December 31, 2015	—		318		1,403		3,925		82,837		88,483

Accumulated depreciation and impairment
As at January 1, 2015	16,385		1,368		9,199		2,587		—		29,539
Depreciation	851		244		610		572		—		2,277
Disposals	—		(37	)	(34	)	(145	)	—		(216	)
Transfer to non-current assets classified as held for sale	(16,559	)	(1,237	)	(8,493	)	(384	)	—		(26,673	)
Exchange differences	(677	)	(59	)	(384	)	(115	)	—		(1,235	)

As at December 31, 2015	—		279		898		2,515		—		3,692

Net book value
As at December 31, 2015	—		39		505		1,410		82,837		84,791

During the year ended December 31, 2017, finance cost from bank borrowings of nil (2016: US$639,000; 2015: US$2,029,000) was capitalized.

Construction in progress in 2015 and 2016 mainly related to the construction of a new factory in Fengpu District, Shanghai. In September 2016, the new factory was put into operation.

16. Deferred Tax Assets

The movements in deferred tax assets are as follows:

	2017	2016		2015

	(in US$'000)
As at January 1	3,310	4,509		2,788
Credited/(debited) to the consolidated income statements
—accrued expenses, provisions and depreciation allowances	75	(936	)	1,834
Exchange differences	209	(263	)	(113	)

As at December 31	3,594	3,310		4,509

The Group's deferred tax assets are mainly temporary differences including accrued expenses, provisions and deferred income. The potential deferred tax assets in respect of tax losses which have not

F-77

Table of Contents

been recognized in the consolidated financial statements were approximately US$1,323,000 (2016: US$944,000).

These unrecognized tax losses can be carried forward against future taxable income and will expire in the following years:

	December 31,

	2017	2016
	(in US$'000)
2019	16	15
2020	2,134	2,008
2021	2,097	1,751
2022	1,045	—

	5,292	3,774

17. Trade Payables

	December 31,

	2017	2016
	(in US$'000)
Trade payables—third parties	8,774	6,323
Trade payables—related parties (Note 22(b))	2,999	1,656

	11,773	7,979

All the trade payables are denominated in RMB and due within one year from the end of the reporting period. The carrying value of trade payables approximates their fair values due to their short-term maturities.

18. Other Payables, Accruals and Advance Receipts

	December 31,

	2017	2016
	(in US$'000)
Other payables and accruals
Accrued salaries and benefits	15,484	13,932
Accrued selling and marketing expenses	35,914	31,085
Value-added tax and tax surcharge payables	13,544	1,706
Others	7,450	12,437

	72,392	59,160

Advance receipts
Payments in advance from customers	2,159	274
Payments in advance for other government subsidy (note)	—	5,815

	2,159	6,089

	74,551	65,249

Note: As at December 31, 2016, the Company had received and deferred approximately US$5.8 million from a government subsidy relating to a research and development project. In May 2017, the Company met the criteria of the subsidy and recognized US$5.9 million in other operating income, with difference due to exchange difference.

F-78

Table of Contents

19. Current Tax Liabilities

	2017		2016		2015

	(in US$'000)
As at January 1	13,718		3,275		1,608
Current tax	10,949		26,709		7,928
Tax paid	(19,887	)	(15,595	)	(6,199	)
Exchange difference	561		(671	)	(62	)

As at December 31	5,341		13,718		3,275

20. Notes to the Consolidated Statements of Cash Flows

(a) Reconciliation of profit for the year to net cash generated from operations:

	Year Ended December 31,

	2017		2016		2015
	(in US$'000)
Profit for the year	55,623		120,499		31,307
Adjustments to reconcile profit for the year to net cash generated from operations
Taxation charge	10,874		27,645		6,094
Interest income	(757	)	(565	)	(306	)
Gain on disposal of assets held for sale	—		(88,536	)	—
Depreciation on property, plant and equipment	6,556		3,135		2,277
Loss on disposal of property, plant and equipment	2		179		34
Impairment of property, plant and equipment	—		1,174		—
Amortization of leasehold land	164		166		271
Amortization of other intangible asset	222		225		217
Reversal provision for trade receivables	—		(81	)	—
Provision for excess and obsolete inventories	994		1,236		1,569
Exchange differences	1,377		186		1,720
Changes in working capital:
Trade and bills receivables	1,273		(463	)	(4,236	)
Other receivables, prepayments and deposits	(1,057	)	922		361
Inventories	(14,257	)	(8,395	)	(7,118	)
Trade payables	3,794		3,572		(5,530	)
Other payables, accruals and advance receipts	13,574		3,740		25,979
Deferred income	121		(329	)	(430	)
Payment for other intangible asset	—		—		(1,202	)

Total changes in working capital	3,448		(953	)	7,824

Net cash generated from operations	78,503		64,310		51,007

(b) Supplemental disclosure for non-cash activities

During the year ended December 31, 2017, there was a decrease in accruals made for purchases of property, plant and equipment of US$4.3 million.

F-79

Table of Contents

21. Commitments

(a) Capital commitments

The Group had the following capital commitments:

	December 31,

	2017	2016
	(in US$'000)
Property, plant and equipment
Contracted but not provided for	574	—

Capital commitments for property, plant and equipment are mainly for improvements to the Company's plant.

(b) Operating lease commitments

The Group leases various factories and offices under non-cancellable operating lease agreements. The future aggregate minimum lease payments in respect of land and buildings under non-cancellable operating leases were as follows:

	December 31,

	2017	2016
	(in US$'000)
Not later than 1 year	283	405
Between 1 to 2 years	21	101
Between 2 to 3 years	10	3

	314	509

22. Significant Related Party Transactions

The Group has the following significant transactions during the years with related parties which were carried out in the normal course of business at terms determined and agreed by the relevant parties:

(a) Transactions with related parties:

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Sales of goods to:
—A fellow subsidiary of SHTCML	27,471	26,044	17,478
—A fellow subsidiary of SHCM(HK)IL	—	—	3,549

	27,471	26,044	21,027



Purchase of goods from:
—Fellow subsidiaries of SHTCML	16,469	17,792	11,151



Rendering of marketing services from:
—A fellow subsidiary of SHTCML	—	223	389



Rendering of research and development services from:
—A fellow subsidiary of SHCM(HK)IL	789	315	286



Provision of marketing services to:
—A fellow subsidiary of SHCM(HK)IL	10,195	8,401	5,093

F-80

Table of Contents

No transactions have been entered into with the directors of the Company (being the key management personnel) during the year ended December 31, 2017 (2016 and 2015: nil).

(b) Balances with related parties included in:

	December 31,

	2017	2016
	(in US$'000)
Trade receivables—related parties
—A fellow subsidiary of SHTCML	399	3,943
—A fellow subsidiary of SHCM(HK)IL	6,567	3,067

	6,966	7,010



Other receivables—related parties
—A fellow subsidiary of SHTCML	974	—



Trade payable—related parties
—A fellow subsidiary of SHTCML	2,999	1,656



Other payables, accruals and advance receipts
—Fellow subsidiaries of SHCM(HK)IL	888	739

Balances with related parties are unsecured, interest-free and repayable on demand. The carrying values of balances with related parties approximate their fair values due to their short-term maturities.

23. Particulars of Principal Subsidiaries

		Nominal value of registered capital		Equity interest attributable to the Group

		As at December 31,		As at December 31,
	Place of establishment and operation
						Type of legal entity
Name		2017	2016	2017	2016	Type of legal entity	Principal activity
		(in RMB'000)
Shanghai Shangyao Hutchison Whampoa GSP Company Limited	PRC	20,000	20,000	100%	100%	Limited liability company	Distribution of drug products
Hutchison Heze Bio Resources & Technology Co., Limited	PRC	1,500	1,500	100%	100%	Limited liability company	Agriculture and sales of Chinese herbs

24. Subsequent Events

The Group evaluated subsequent events through March 9, 2018, which is the date when the consolidated financial statements were issued.

F-81

Table of Contents

HUTCHISON WHAMPOA GUANGZHOU
BAIYUNSHAN CHINESE MEDICINE
COMPANY LIMITED

F-82

Table of Contents

Report of Independent Auditors

To the Board of Directors and Shareholders of Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited

We have audited the accompanying consolidated financial statements of Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited and its subsidiaries, which comprise the consolidated statements of financial position as of December 31, 2017 and 2016, and the related consolidated income statements, consolidated statements of comprehensive income, of changes in equity and of cash flows for each of the three years in the period ended December 31, 2017.

Management's Responsibility for the Consolidated Financial Statements

Auditors' Responsibility

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited and its subsidiaries as of December 31, 2017 and 2016, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2017 in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

/s/ PricewaterhouseCoopers Zhong Tian LLP
Guangzhou, the People's Republic of China
March 9, 2018

F-83

Table of Contents

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
Consolidated Income Statements
(in US$'000)

			Year Ended December 31,

	Note		2017		2016		2015
Revenue		5	227,422		224,131		211,603
Cost of sales			(135,964	)	(134,776	)	(120,142	)

Gross profit			91,458		89,355		91,461
Selling expenses			(45,262	)	(46,873	)	(45,325	)
Administrative expenses			(24,541	)	(21,716	)	(23,722	)
Other net operating income		6	3,000		3,097		2,902

Operating profit		7	24,655		23,863		25,316
Share of profits of joint venture and associated companies, net of tax			65		19		6
Finance costs			(117	)	(123	)	(158	)
Loss on divestment of a subsidiary		14	(169	)	—		—

Profit before taxation			24,434		23,759		25,164
Taxation charge		8	(3,629	)	(3,631	)	(3,948	)

Profit for the year			20,805		20,128		21,216



Attributable to:
Shareholders of the Company			20,776		20,376		21,376
Non-controlling interests			29		(248	)	(160	)

			20,805		20,128		21,216

The accompanying notes are an integral part of these consolidated financial statements.

F-84

Table of Contents

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
Consolidated Statements of Comprehensive Income
(in US$'000)

	Year Ended December 31,

	2017	2016		2015
Profit for the year	20,805	20,128		21,216
Other comprehensive income/(loss) that has been or may be reclassified subsequently to profit or loss:
Exchange translation differences	8,293	(9,248	)	(5,097	)

Total comprehensive income	29,098	10,880		16,119



Attributable to:
Shareholders of the Company	28,672	11,549		16,427
Non-controlling interests	426	(669	)	(308	)

	29,098	10,880		16,119

The accompanying notes are an integral part of these consolidated financial statements.

F-85

Table of Contents

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
Consolidated Statements of Financial Position
(in US$'000)

		December 31,

	Note	2017	2016
Assets
Current assets
Cash and cash equivalents	10	13,843	23,448
Bank deposits maturing over three months	10	—	1,675
Trade and bills receivables	11	36,368	39,901
Other receivables, prepayments and deposits	12	6,936	3,671
Inventories	13	44,423	28,839

		101,570	97,534
Assets classified as held for sale	14	—	25,097

Total current assets		101,570	122,631
Property, plant and equipment	15	70,817	65,130
Leasehold land		10,424	10,056
Goodwill		8,751	8,237
Other intangible assets		2,906	3,076
Investments in a joint venture and associated companies		473	384
Deferred tax assets	16	2,489	1,717
Other non-current assets	17	11,366	10,504

Total assets		208,796	221,735



Liabilities and shareholders' equity
Current liabilities
Trade payables	18	15,545	18,575
Other payables, accruals and advance receipts	19	59,015	33,689
Current tax liabilities		1,227	892

		75,787	53,156
Liabilities directly associated with assets classified as held for sale	14	—	17,062

Total current liabilities		75,787	70,218
Deferred tax liabilities	16	114	131
Deferred income	20	18,248	17,566
Finance lease payables		386	451

Total liabilities		94,535	88,366

Company's shareholders' equity
Share capital		24,103	24,103
Reserves		86,513	102,969

Total Company's shareholders' equity		110,616	127,072
Non-controlling interests		3,645	6,297

Total shareholders' equity		114,261	133,369

Total liabilities and shareholder's equity		208,796	221,735

The accompanying notes are an integral part of these consolidated financial statements.

F-86

Table of Contents

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
Consolidated Statements of Changes in Equity
(in US$'000)

	Attributable to shareholders of the Company

	Share capital	Exchange reserve		General reserves	Retained earnings		Total		Non- controlling interests		Total equity
As at January 1, 2015	24,103	12,592		131	74,680		111,506		3,802		115,308
Profit/(loss) for the year	—	—		—	21,376		21,376		(160	)	21,216
Other comprehensive loss
Exchange translation differences	—	(4,949	)	—	—		(4,949	)	(148	)	(5,097	)

Total comprehensive (loss)/income	—	(4,949	)	—	21,376		16,427		(308	)	16,119

Dividends declared to shareholders	—	—		—	(6,410	)	(6,410	)	—		(6,410	)
Capital contribution from a non-controlling shareholder of a subsidiary	—	—		—	—		—		46		46

As at December 31, 2015	24,103	7,643		131	89,646		121,523		3,540		125,063



Profit/(loss) for the year	—	—		—	20,376		20,376		(248	)	20,128
Other comprehensive loss
Exchange translation differences	—	(8,827	)	—	—		(8,827	)	(421	)	(9,248	)

Total comprehensive (loss)/income	—	(8,827	)	—	20,376		11,549		(669	)	10,880

Dividends declared to shareholders	—	—		—	(6,000	)	(6,000	)	—		(6,000	)
Dividend declared to a non-controlling shareholder of a subsidiary	—	—		—	—		—		(174	)	(174	)
Capital contribution from a non-controlling shareholder of a subsidiary	—	—		—	—		—		3,600		3,600

As at December 31, 2016	24,103	(1,184	)	131	104,022		127,072		6,297		133,369



Profit for the year	—	—		—	20,776		20,776		29		20,805
Other comprehensive income
Exchange translation differences	—	7,896		—	—		7,896		397		8,293

Total comprehensive income	—	7,896		—	20,776		28,672		426		29,098

Dividends declared to shareholders	—	—		—	(45,128	)	(45,128	)	—		(45,128	)
Divestment of a subsidiary	—	—		—	—		—		(3,078	)	(3,078	)

As at December 31, 2017	24,103	6,712		131	79,670		110,616		3,645		114,261

The accompanying notes are an integral part of these consolidated financial statements.

F-87

Table of Contents

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
Consolidated Statements of Cash Flows
(in US$'000)

		Year Ended December 31,

	Note	2017		2016		2015
Operating activities
Net cash generated from operations	21(a)	24,844		16,426		12,278
Interest received		220		238		628
Finance costs paid		(117	)	(412	)	(36	)
Income tax paid		(4,040	)	(4,159	)	(4,703	)

Net cash generated from operating activities		20,907		12,093		8,167

Investing activities
Purchase of property, plant and equipment		(7,236	)	(13,219	)	(21,698	)
Deposits into bank deposits maturing over three months		—		(1,466	)	(3,178	)
Proceed from bank deposits maturing over three months		1,780		53		23,749
Government grants received relating to property, plant and equipment		660		3,733		451
Proceeds from divestment of a subsidiary, net of cash held	14	2,641		—		—

Net cash used in investing activities		(2,155	)	(10,899	)	(676	)

Financing activities
Dividends paid to shareholders		(29,872	)	(6,000	)	(6,410	)
Finance lease payments		(93	)	—		—
Proceeds from bank borrowings		—		—		923
Repayment of bank borrowings		—		(923	)	(625	)
Capital contribution from a non-controlling shareholder of a subsidiary		—		—		46

Net cash used in financing activities		(29,965	)	(6,923	)	(6,066	)

Net (decrease)/increase in cash and cash equivalents		(11,213	)	(5,729	)	1,425
Effect of exchange rate changes on cash and cash equivalents		1,474		(1,844	)	(1,274	)

		(9,739	)	(7,573	)	151
Cash and cash equivalents
Cash and cash equivalents at beginning of year		23,582		31,155		31,004

Cash and cash equivalents at end of year		13,843		23,582		31,155

The accompanying notes are an integral part of these consolidated financial statements.

F-88

Table of Contents

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
Notes to the Consolidated Financial Statements

1. General Information

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (the "Company") and its subsidiaries (together the "Group") are principally engaged in manufacturing, selling and distribution of over-the-counter drug products. The Group has manufacturing plants in the People's Republic of China (the "PRC") and sells mainly in the PRC.

The Company was incorporated in the PRC on April 12, 2005 as a Chinese-Foreign Equity joint venture. The Company is jointly controlled by Guangzhou Hutchison Chinese Medicine (HK) Investment Limited ("GZHCMHK") and Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ("GBPHCL").

These consolidated financial statements are presented in United States dollars ("US$"), unless otherwise stated and have been approved for issue by the Company's Board of Directors on March 9, 2018.

2. Summary of Significant Accounting Policies

The following standards, amendments and interpretations were in issue but not yet effective for financial year ended December 31, 2017 and have not been early adopted by the Group:


IAS 28 (Amendments)⁽¹⁾		Investments in Associates and Joint Ventures
IAS 40 (Amendments)⁽¹⁾		Transfers of Investment Property
IFRS 2 (Amendments)⁽¹⁾		Classification and Measurement of Share-based Payment Transactions
IFRS 9⁽¹⁾		Financial Instruments
IFRS 10 and IAS 28 (Amendments)⁽³⁾		Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
IFRS 15⁽¹⁾		Revenue from Contracts with Customers
IFRS 15 (Amendments)⁽¹⁾		Revenue from Contracts with Customers
IFRS 16⁽²⁾		Leases
IFRIC 22⁽¹⁾		Foreign Currency Transactions and Advance Consideration
IFRIC 23⁽²⁾		Uncertainty over Income Tax Treatments
Annual improvement 2014-2016⁽¹⁾		Improvements to IFRSs
Annual improvement 2015-2017⁽²⁾		Improvements to IFRSs

(1): Effective for the Group for annual periods beginning on or after January 1, 2018.
(2): Effective for the Group for annual periods beginning on or after January 1, 2019.

F-89

Table of Contents

(3): No mandatory effective date determined yet, but available for adoption.

The adoption of standards, amendments and interpretations listed above in future periods is not expected to have any material effects on the Group's results of operations and financial position, except for the adoption of IFRS 16 for which management is still assessing the impact.

(a) Basis of Consolidation

The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries, and also include the Group's interests in a joint venture and associated companies on the basis set out in Notes 2(e) and 2(f) below.

The accounting policies of subsidiaries, the joint venture and associated companies have been changed where necessary to ensure consistency with the policies adopted by the Group.

Non-controlling interests represent the interests of outside shareholders in the operating results and net assets of subsidiaries.

(b) Subsidiaries

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. In the consolidated financial statements, subsidiaries are accounted for as described in Note 2(a) above.

Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases.

(c) Business Combinations

The Group applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair values of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Group. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date.

The Group recognizes any non-controlling interest in the acquiree on an acquisition-by-acquisition basis. Non-controlling interests in the acquiree that are present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation are measured at either fair value or the present ownership interests' proportionate share in the recognized amounts of the acquiree's identifiable net assets. All other components of non-controlling interests are measured at their acquisition date fair value, unless another measurement basis is required by IFRS.

Acquisition-related costs are expensed as incurred.

F-90

Table of Contents

The excess of the consideration transferred over the fair value of the identifiable net assets acquired is recorded as goodwill. If the total of consideration transferred, non-controlling interest recognized and previously held interest measured is less than the fair value of the net assets of the acquiree acquired in the case of a bargain purchase, the difference is recognized directly in the income statement.

(d) Transactions with Non-controlling Interests

Transactions with non-controlling interests that do not result in a loss of control are accounted for as transactions with equity owners of the Group. For purchases from non-controlling interests, the difference between any consideration paid and the relevant share acquired of the carrying value of net assets of the subsidiary is recorded in equity. Gains or losses on disposals to non-controlling interests are also recorded in equity.

(e) Joint Arrangements

Investments in joint arrangements are classified either as joint operations or joint ventures depending on the contractual rights and obligations of each investor. The Group has assessed the nature of its joint arrangement and determined it to be a joint venture. The joint venture is accounted for using the equity method.

Under the equity method of accounting, the interest in joint venture is initially recognized at cost and adjusted thereafter to recognize the Group's share of the post-acquisition profits or losses and movements in other comprehensive income. The Group determines at each reporting date whether there is any objective evidence that the investment in the joint venture is impaired. If this is the case, the Group calculates the amount of impairment as the difference between the recoverable amount of the joint venture and its carrying value and recognizes the amount adjacent to "share of profits less losses after tax of joint venture" in the income statement.

(f) Associated Companies

An associate is an entity, other than a subsidiary or a joint venture, in which the Group has a long-term equity interest and over which the Group is in position to exercise significant influence over its management, including participation in the financial and operating policy decisions.

The results and net assets of associates are incorporated in these financial statements using the equity method of accounting, except when the investment is classified as held for sale, in which case it is accounted for under IFRS 5, Non-current assets held for sale and discontinued operations. The total carrying amount of such investments is reduced to recognize any identified impairment loss in the value of individual investments.

(g) Foreign Currency Translation

Items included in the financial statements of each of the Group's companies are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The functional currency of the Company and its subsidiaries, joint venture and associated companies is Renminbi ("RMB") whereas the consolidated financial statements are presented in US$, which is the Company's presentation currency.

The financial statements of the Company, subsidiaries, joint venture and associated companies are translated into the Company's presentation currency using the year end rates of exchange for the

F-91

Table of Contents

statements of financial position items and the average rates of exchange for the year for the income statement items. Exchange translation differences are recognized directly in other comprehensive income/(loss).

(h) Property, Plant and Equipment

Property, plant and equipment other than construction in progress are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes the purchase price of the asset and any directly attributable costs of bringing the asset to its working condition and location for its intended use.


Buildings and facilities		10-30 years
Plant and equipment		10 years
Furniture and fixtures, other equipment and motor vehicles		5 years

Gains and losses on disposals are determined by comparing net sales proceeds with the carrying amount of the relevant assets and are recognized in the income statement.

(i) Construction in Progress

Construction in progress represents buildings, plant and machinery under construction and pending installation and is stated at cost less accumulated impairment losses, if any. Cost includes the costs of construction of buildings and the costs of plant and machinery. No provision for depreciation is made on construction in progress until such time as the relevant assets are completed and ready for intended use. When the assets concerned are brought into use, the costs are transferred to property, plant and equipment and depreciated in accordance with the policy as stated in Note 2(h).

(j) Leasehold Land

(k) Goodwill

Goodwill represents the excess of the cost of an acquisition over the fair value of the Group's share of the net identifiable assets of the acquired subsidiary/business at the date of acquisition, or the excess of fair value of business over its fair value of the net identifiable assets injected into the Company upon its formation. If the cost of acquisition is less than the fair value of the Group's share of the net identifiable assets of the acquired subsidiary, the difference is recognized directly in the consolidated income statement.

F-92

Table of Contents

Goodwill is retained at the carrying amount as a separate asset, and subject to impairment test annually when there are indications that the carrying value may not be recoverable.

The profit or loss on disposal of a subsidiary is calculated by reference to the net assets at the date of disposal including the attributable amount of goodwill.

(l) Other Intangible Assets

The Group's other intangible assets mainly include distribution network and drugs licenses contributed from non-controlling shareholders. Other intangible assets have a definite useful life and are carried at historical cost less accumulated amortization and accumulated impairment losses, if any. Amortization is calculated using the straight-line method to allocate costs over the estimated useful lives of ten years.

(m) Research and Development

Research expenditure is recognized as an expense as incurred. Costs incurred on development projects (relating to the design and testing of new or improved products) are recognized as intangible assets when it is probable that the project will generate future economic benefits by considering its commercial and technological feasibility, and costs can be measured reliably. Other development expenditures are recognized as an expense as incurred. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period. Development costs with a finite useful life that have been capitalized, if any, are amortized on a straight-line basis over the period of expected benefit not exceeding five years. The capitalized development costs are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount.

Where the research phase and the development phase of an internal project cannot be clearly distinguished, all expenditure incurred on the project is charged to the income statement.

(n) Impairment of Non-Financial Assets

(o) Non-current Assets (or Disposal Groups) Classified As Held For Sale

Non-current assets (or disposal groups) are classified as held for sale when their carrying amount is to be recovered principally through a sale transaction and a sale is considered highly probable. The non-current assets (or disposal groups) except for certain assets as explained below, are stated at the lower of carrying amount and fair value less costs to sell. Deferred tax assets, and financial assets (other than investments in subsidiaries and associates), which are classified as held for sale, would continue to be measured in accordance with the policies set out elsewhere in Note 2.

(p) Inventories

F-93

Table of Contents

(q) Trade and Other Receivables

(r) Cash and Cash Equivalents

(s) Borrowings

(t) Financial Liabilities and Equity Instruments

Financial liabilities and equity instruments issued by the Group are classified according to the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. Financial liabilities (including trade and other payables) are initially measured at fair value, and are subsequently measured at amortized cost, using the effective interest method. An equity instrument is any contract that does not meet the definition of financial liability and evidences a residual interest in the assets of the Group after deducting all of its liabilities.

Ordinary shares are classified as equity. Incremental costs, net of tax, directly attributable to the issue of new shares are shown in equity as a deduction from the proceeds.

(u) Current and Deferred Income Tax

(i): Current income tax

(ii): Deferred income tax

Inside basis differences

Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill and deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws)

F-94

Table of Contents

that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.

Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized.

Outside basis differences

Deferred income tax liabilities are provided on taxable temporary differences arising from investments in subsidiaries, associates and joint arrangements, except for deferred income tax liabilities where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the temporary difference will not reverse in the foreseeable future. Generally the Group is unable to control the reversal of the temporary difference for associates. Only when there is an agreement in place that gives the Group the ability to control the reversal of the temporary difference in the foreseeable future, deferred tax liability in relation to taxable temporary differences arising from the associate's undistributed profits is not recognized.

Deferred income tax assets are recognized on deductible temporary differences arising from investments in subsidiaries, associates and joint arrangements only to the extent that it is probable the temporary difference will reverse in the future and there is sufficient taxable profit available against which the temporary difference can be utilized.

(v) Employee Benefits

The employees of the Group participate in defined contribution retirement benefit plans managed by the relevant municipal and provincial governments in the PRC. The assets of these plans are held separately from those of the Group. The Group is required to make monthly contributions to the plans, calculated as a percentage of the employees' salaries. The municipal and provincial governments undertake to assume the retirement benefit obligations to all existing and future retired employees under the plans described above. Other than the monthly contributions, the Group has no further obligations for the payment of the retirement and other post-retirement benefits of its employees.

(w) Provisions

(x) Leases

Leases that transfer substantially all the rewards and risks of ownership of the assets to the Group, other than legal title, are accounted for as finance leases. At the inception of a finance lease, the cost of the leased asset is capitalized at the present value of the minimum lease payments and recorded together with the obligation, excluding the interest element, to reflect the purchase and financing. Assets held under capitalized finance leases, including prepaid land lease payments under finance leases, are included in property, plant and equipment, and depreciated over the shorter of the lease terms and the estimated useful lives of the assets. The finance costs of such leases are charged to the income statement so as to provide a constant periodic rate of charge over the lease terms.

Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to the income statement on a straight-line basis over the period of the leases.

F-95

Table of Contents

(y) Borrowing Costs

(z) Government Incentives

Incentives from government are recognized at their fair values where there is a reasonable assurance that the incentives will be received and all attached conditions will be complied with.

Government incentives relating to costs are deferred and recognized in the income statement over the period necessary to match them with the costs that they are intended to compensate.

Government grants relating to property, plant and equipment are included in other payables, accruals and advance receipts and non-current liabilities as deferred income and credited to the income statement on a straight-line basis over the expected lives of the related assets.

(aa) Revenue and Income Recognition

Revenue is shown net of value-added tax, returns, volume rebates and discounts after eliminated sales within the Group. Revenue and income are recognized as follows:

(i): Sales of goods

Sales of goods are recognized when a group entity has delivered products to the customer, the customer has accepted the products and collectability of the related receivables is reasonably assured.

(ii): Sales rebates

Certain sales rebates are provided to customers when their business performance for the whole year meets certain criteria. Sales rebates are recognized in profit or loss based on management's estimation at each year end.

(iii): Other service income

Other service income is recognized when services are rendered.

(iv): Interest income

Interest income is recognized on a time-proportion basis using the effective interest method.

(ab) Segment Reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-makers. The Board of Directors, which is responsible for allocating resources and assessing performance of the operating segments, has been identified as the steering committee that makes strategic decisions.

F-96

Table of Contents

(ac) General Reserves

3. Financial Risk Management

(a) Financial risk factors

(i): Credit risk

Substantially all of the Group's cash at banks and bank deposits are deposited in major financial institutions, which management believes are of high credit quality.

Bills receivables are mostly settled by state-owned banks or other reputable banks and therefore the management considers that they will not expose the Group to any significant credit risk.

Management periodically assesses the recoverability of trade receivables and other receivables. The Group's historical experience collecting receivables falls within the recorded allowances.

(ii): Cash flow interest rate risk

The Group has no significant interest-bearing assets except for cash at bank and bank deposits, details of which have been disclosed in Note 10. The Group's exposure to interest rate risk would mainly be to bank borrowings which bear interest at fixed rates.

(iii): Liquidity risk

As at December 31, 2017 and 2016, the Group's current financial liabilities were mainly due for settlement within twelve months and the Group expects to meet all liquidity requirements.

(b) Capital risk management

F-97

Table of Contents

Currently, it is the Group's strategy to maintain a reasonable liabilities to assets ratio. The liabilities to assets ratio as at December 31, 2017 and 2016 was as follows:

	December 31,

	2017	2016
	(in US$'000)
Total liabilities	94,535	88,366
Total assets	208,796	221,735

Liabilities to assets ratio	45.3%	39.9%

(c) Fair value estimation

The Group does not have any financial assets or liabilities which are carried at fair value. The carrying amounts of the Group's current financial assets, including cash and bank balances, trade and bills receivables, other receivables and current financial liabilities, including trade payables, and other payables and accruals approximate their fair values due to their short-term maturities. The carrying amounts of the Group's financial instruments carried at cost or amortized cost are not materially different from their fair values.

4. Critical Accounting Estimates and Judgements

The following is a review of the more significant assumptions and estimates, as well as the accounting policies and methods used in the preparation of the consolidated financial statements.

(a) Sales rebates

Certain sales rebates are provided to customers when their business performance for the whole year meets certain criteria as stipulated in the contracts. The estimate of sales rebates during the year is based on estimated sales transactions for the entire period stipulated and is subject to change based on actual performance and collection status.

F-98

Table of Contents

(b) Useful lives of property, plant and equipment

(c) Impairment of non-Financial assets

The Group tests annually whether goodwill has suffered any impairment. Other non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset exceeds its recoverable amount in accordance with the accounting policy stated in Note 2(n). The recoverable amount of an asset or a cash-generating unit is determined based on the higher of the asset's or the cash-generating unit's fair value less costs to disposal and value-in-use. The value-in-use calculation requires the entity to estimate the future cash flows expected to arise from the asset and a suitable discount rate in order to calculate present value, and the growth rate assumptions in the cash flow projections which has been prepared on the basis of management's assumptions and estimates.

(d) Impairment of receivables

(e) Deferred income tax

5. Revenue and Segment Information

Management has reviewed the Group's internal reporting in order to assess performance and allocate resources, and has determined that the Group has two reportable operating segments as follows:

—Manufacturing business—manufacture and distribution of drug products

—Distribution business—provision of sales, distribution and marketing services to pharmaceutical manufacturers

The operating segments are strategic business units that offer different products and services. They are managed separately because each business requires different technology and marketing approaches. The performance of each of the reportable segments is assessed based on a measure of earnings before share of profits of joint venture and associated companies, net of tax, interest income, finance costs and taxation charge ("Adjusted EBIT").

F-99

Table of Contents

The segment information for the reportable segments for the year is as follows:

	Year Ended December 31, 2017

	Manufacturing business	Distribution business
	PRC	PRC	Total
	(in US$'000)
Revenue from external customers	176,134	51,288	227,422



Adjusted EBIT	23,280	1,155	24,435
Interest income	131	89	220

Operating profit	23,411	1,244	24,655
Share of profits of joint venture and associated companies, net of tax	65	—	65
Finance costs	117	—	117
Loss on divestment of a subsidiary	169	—	169
Depreciation/amortization	4,976	9	4,985
Additions to non-current assets (other than financial instrument and deferred tax assets)	6,111	1	6,112

	As at December 31, 2017

	(in US$'000)
Total segment assets	195,135	13,661	208,796

	Year Ended December 31, 2016

	Manufacturing business	Distribution business
	PRC	PRC	Total
	(in US$'000)
Revenue from external customers	155,838	68,293	224,131



Adjusted EBIT	23,077	548	23,625
Interest income	160	78	238

Operating profit	23,237	626	23,863
Share of profits of joint venture and associated companies, net of tax	19	—	19
Finance costs	123	—	123
Depreciation/amortization	2,902	56	2,958
Impairment of property, plant and equipment	617	—	617
Additions to non-current assets (other than financial instrument and deferred tax assets)	20,924	—	20,924

	As at December 31, 2016

	(in US$'000)
Total segment assets	185,407	36,328	221,735

F-100

Table of Contents

	Year Ended December 31, 2015

	Manufacturing business	Distribution business
	PRC	PRC	Total
	(in US$'000)
Revenue from external customers	144,510	67,093	211,603



Adjusted EBIT	24,152	536	24,688
Interest income	496	132	628

Operating profit	24,648	668	25,316
Share of profits of joint venture and associated companies, net of tax	6	—	6
Finance costs	158	—	158
Depreciation/amortization	3,221	53	3,274
Additions to non-current assets (other than financial instrument and deferred tax assets)	21,698	—	21,698

Revenue from external customers is after elimination of inter-segment sales. The amount eliminated was US$3,039,000 for 2017 (2016: US$16,181,000; 2015: US$19,010,000).

Sales between segments are carried out at mutually agreed terms.

A reconciliation of Adjusted EBIT for reportable segments to profit before taxation is provided as follows:

	Year Ended December 31,

	2017		2016		2015
	(in US$'000)
Adjusted EBIT for reportable segments	24,435		23,625		24,688
Interest income	220		238		628
Share of profits of joint venture and associated companies, net of tax	65		19		6
Finance costs	(117	)	(123	)	(158	)
Loss on divestment of a subsidiary	(169	)	—		—

Profit before taxation	24,434		23,759		25,164

6. Other Net Operating Income

	Year Ended December 31,

	2017		2016		2015
	(in US$'000)
Interest income	220		238		628
Other operating income	3,306		3,435		2,574
Other operating expenses	(526	)	(576	)	(300	)

	3,000		3,097		2,902

7. Operating Profit

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Operating profit	24,655	23,863	25,316

F-101

Table of Contents

Operating profit is stated after charging the following:

	Year Ended December 31,

	2017		2016	2015
	(in US$'000)
Cost of inventories recognized as expense	125,156		122,969	111,064
Depreciation of property, plant and equipment	4,380		2,227	2,877
Impairment of property, plant and equipment	—		617	—
Loss on disposal of property, plant and equipment	166		60	54
Amortization of leasehold land	253		255	271
Amortization of other intangible assets	352		476	126
Operating lease rentals in respect of land and buildings	1,214		872	1,022
Movements on the provision for trade receivables	(41	)	38	77
Movements on the provision for excess and obsolete inventories	187		972	340
Research and development expense	1,014		1,098	1,284
Auditor's remuneration	87		90	89
Employee benefit expenses (Note 9)	32,659		31,910	31,838

8. Taxation Charge

	Year Ended December 31,

	2017		2016		2015
	(in US$'000)
Current tax	4,298		4,518		4,034
Deferred income tax (Note 16)	(669	)	(887	)	(86	)

Taxation charge	3,629		3,631		3,948

The taxation charge on the Group's profit before taxation differs from the theoretical amount that would arise using the Group's weighted average tax rate as follows:

	Year Ended December 31,

	2017		2016		2015
	(in US$'000)
Profit before taxation	24,434		23,759		25,164



Tax calculated at the statutory tax rates of respective companies	6,109		5,940		6,291
Tax effects of:
Expenses not deductible for tax purposes	70		244		207
Tax concession (note)	(2,935	)	(2,783	)	(2,699	)
Tax losses for which no deferred tax assets were recognized	396		250		131
Others	(11	)	(20	)	18

Taxation charge	3,629		3,631		3,948

Note: The Company has been successful in its application to renew the High and New Technology Enterprise status. Accordingly, the Company is subjected to a preferential income tax rate of 15% for 2017 and up to 2019 (2016: 15%; 2015: 15%).

F-102

Table of Contents

The weighted average tax rate calculated at the statutory tax rates of respective companies for the year was 25% (2016: 25%; 2015: 25%). The effective tax rate for the year was 14.9% (2016: 15.3%; 2015: 15.7%).

9. Employee Benefit Expenses

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Wages, salaries and bonuses	23,700	23,490	22,902
Pension costs—defined contribution plans	7,637	7,417	7,695
Staff welfare	1,322	1,003	1,241

	32,659	31,910	31,838

Employee benefit expenses of approximately US$9,122,000 (2016: US$8,704,000; 2015: US$8,611,000) are included in cost of sales.

10. Cash and Bank Balances

	December 31,

	2017	2016
	(in US$'000)
Cash and cash equivalents	13,843	23,582
Included in assets classified as held for sale (Note 14)	—	(134	)

Cash and cash equivalents as per consolidated statements of financial position	13,843	23,448
Bank deposits maturing over three months (note)	—	1,675

Cash and bank balances	13,843	25,123

Note: The weighted average effective interest rate on bank deposits as at December 31, 2016 with maturity of 91 days to 365 days was 1.3% per annum. Cash at bank earns interest at floating rates based on daily bank deposit rates.

The cash at bank balances are denominated in RMB and were deposited with banks in the PRC. The conversion of these RMB denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the PRC government.

11. Trade and Bills Receivables

	December 31,

	2017	2016
	(in US$'000)
Trade receivables—third parties	1,755	223
Trade receivables—related parties (Note 23(b))	285	466
Bills receivables	34,328	39,212

	36,368	39,901

F-103

Table of Contents

All trade and bills receivables are denominated in RMB and are due within one year from the end of the reporting period. The carrying value of trade and bills receivables approximates their fair values.

Movements on the provision for trade receivables are as follows:

	2017		2016		2015

	(in US$'000)
As at January 1	110		165		285
Increase in provision for trade receivables	—		38		77
Decrease in provision due to subsequent collection	(41	)	—		(185	)
Transfer to assets classified as held for sale	—		(81	)	—
Exchange differences	6		(12	)	(12	)

As at December 31	75		110		165

The impaired and provided receivables as at December 31, 2017 and December 31, 2016 were aged over 1 year.

12. Other Receivables, Prepayments and Deposits

	December 31,

	2017	2016
	(in US$'000)
Prepayments to suppliers	3,272	850
Value-added tax receivables	2,157	1,352
Others	1,507	1,469

	6,936	3,671

13. Inventories

	December 31,

	2017	2016
	(in US$'000)
Raw materials	14,853	10,326
Work in progress	14,808	9,537
Finished goods	14,762	8,976

	44,423	28,839

Movements on the provision for excess and obsolete inventories are as follows:

	2017		2016		2015

	(in US$'000)
As at January 1	1,241		332		—
Increase in provision for excess and obsolete inventories	529		972		340
Decrease in provision due to subsequent sale	(342	)	—		—
Write-off	(497	)	—		—
Exchange differences	69		(63	)	(8	)

As at December 31	1,000		1,241		332

F-104

Table of Contents

14. Assets Classified as Held For Sale

In December 2016, the board of directors and shareholders of Nanyang Baiyunshan Hutchison Whampoa Guanbao Pharmaceutical Company Limited ("NBHG") agreed in principle to a divestment of the Company's 60% majority interest in NBHG. As at December 31, 2016, the remaining step prior to the divestment was to complete the government-mandated auction process. Since the Company had held discussions with potential buyers, it had determined that a divestment was highly probable and accordingly, the Company reclassified the remaining assets and liabilities of NBHG as assets classified as held for sale and liabilities directly associated with assets classified as held for sale respectively.

The major classes of assets and liabilities associated with NBHG classified as net assets held for sale are as follows:

	December 31, 2016

	(in US$'000)
Assets classified as held for sale:
Cash and cash equivalents	134
Trade and bill receivables	12,360
Other receivables, prepayment and deposits	4,672
Inventories	6,949
Property, plant and equipment	241
Goodwill	172
Other intangible assets	546
Deferred tax assets	23

Total assets classified as held for sale	25,097



Liabilities directly associated with assets classified as held for sale:
Trade payables	(9,400	)
Other payables, accruals and advance receipts	(7,526	)
Deferred tax liabilities	(136	)

Total liabilities directly associated with assets classified as held for sale	(17,062	)

On July 26, 2017, the Company received dividends of US$1.6 million from NBHG and on September 1, 2017 completed the divestment of its majority interest in NBHG for consideration of US$2.7 million (which was US$2.6 million net of cash held at NBHG). Based on the then net assets associated with NBHG attributable to the Company of US$2.9 million, the Company recorded a loss of $0.2 million upon the divestment.

F-105

Table of Contents

15. Property, Plant and Equipment

	Buildings and facilities	Plant and equipment		Furniture and fixtures, other equipment and motor vehicles		Construction in progress		Total

	(in US$'000)
Cost
As at January 1, 2017	25,969	13,701		7,769		42,618		90,057
Additions	2,539	291		677		2,605		6,112
Disposals	—	(328	)	(1,026	)	—		(1,354	)
Transfers	32,214	11,847		580		(44,641	)	—
Exchange differences	2,656	1,209		494		1,391		5,750

As at December 31, 2017	63,378	26,720		8,494		1,973		100,565

Accumulated depreciation
As at January 1, 2017	8,550	10,088		6,289		—		24,927
Depreciation	1,762	1,841		777		—		4,380
Disposals	—	(484	)	(704	)	—		(1,188	)
Exchange differences	568	665		396		—		1,629

As at December 31, 2017	10,880	12,110		6,758		—		29,748

Net book value
As at December 31, 2017	52,498	14,610		1,736		1,973		70,817

	Buildings and facilities		Plant and equipment		Furniture and fixtures, other equipment and motor vehicles		Construction in progress		Total

	(in US$'000)
Cost
As at January 1, 2016	26,757		12,794		7,888		31,259		78,698
Additions	816		706		926		15,390		17,838
Disposals	(25	)	(11	)	(53	)	—		(89	)
Transfers	226		1,134		17		(1,377	)	—
Transfer to assets classified as held for sale	—		—		(447	)	—		(447	)
Exchange differences	(1,805	)	(922	)	(562	)	(2,654	)	(5,943	)

As at December 31, 2016	25,969		13,701		7,769		42,618		90,057

Accumulated depreciation
As at January 1, 2016	7,774		10,070		6,163		—		24,007
Depreciation	842		592		793		—		2,227
Disposals	(1	)	(9	)	(19	)	—		(29	)
Impairment	487		130		—		—		617
Transfer to assets classified as held for sale	—		—		(206	)	—		(206	)
Exchange differences	(552	)	(695	)	(442	)	—		(1,689	)

As at December 31, 2016	8,550		10,088		6,289		—		24,927

Net book value
As at December 31, 2016	17,419		3,613		1,480		42,618		65,130

F-106

Table of Contents

	Buildings and facilities		Plant and equipment		Furniture and fixtures, other equipment and motor vehicles		Construction in progress		Total

	(in US$'000)
Cost
As at January 1, 2015	26,972		13,275		7,842		9,989		58,078
Additions	638		663		352		22,541		24,194
Disposals	(13	)	(609	)	(53	)	—		(675	)
Transfers	260		—		70		(330	)	—
Exchange differences	(1,100	)	(535	)	(323	)	(941	)	(2,899	)

As at December 31, 2015	26,757		12,794		7,888		31,259		78,698

Accumulated depreciation
As at January 1, 2015	6,978		10,276		5,629		—		22,883
Depreciation	1,101		949		827		—		2,877
Disposals	—		(572	)	(49	)	—		(621	)
Exchange differences	(305	)	(583	)	(244	)	—		(1,132	)

As at December 31, 2015	7,774		10,070		6,163		—		24,007

Net book value
As at December 31, 2015	18,983		2,724		1,725		31,259		54,691

Construction in progress in 2015 and 2016 mainly related to the construction of a new office building and a new factory. In March 2017 and December 2017, the new factory and the new office became ready for its intended use respectively.

16. Deferred Tax Assets and Liabilities

	December 31,

	2017		2016
	(in US$'000)
Deferred tax assets	2,489		1,717
Deferred tax liabilities	(114	)	(131	)

Net deferred tax assets	2,375		1,586

The movements in net deferred tax assets are as follows:

	2017	2016		2015

	(in US$'000)
At January 1	1,586	667		606
Credited/(debited) to the consolidated income statements
—tax losses	657	552		354
—accrued expenses, provisions, depreciation allowances	12	335		(268	)
Transfer to assets classified as held for sale (Note 14)	—	113		—
Exchange differences	120	(81	)	(25	)

At December 31	2,375	1,586		667

The deferred tax assets and liabilities are offset when there is a legally enforceable right to set off and when the deferred income taxes related to the same fiscal authority.

The Group's deferred tax assets and liabilities are temporary differences including tax losses, accrued expenses, provisions and depreciation allowances. The potential deferred tax assets in respect of tax losses

F-107

Table of Contents

which have not been recognized in the consolidated financial statements were approximately US$612,000 (2016: US$215,000).

These unrecognized tax losses can be carried forward against future taxable income and will expire in the following years:

	December 31,

	2017	2016
	(in US$'000)
2018	170	160
2019	207	195
2020	240	345
2021	169	159
2022	1,661	—

	2,447	859

17. Other Non-Current Assets

	December 31,

	2017	2016
	(in US$'000)
Leasehold land rights (note (i))	11,160	10,504
Restricted cash (note (ii))	206	—

	11,366	10,504

Notes:

(i): Represents payments for a land use right. The title of the land is in the process of registration, pending remaining administrative procedures. The respective payments are recorded in other non-current assets until the registration is completed and title is transferred to the Company. As at December 31, 2017, this process is still in progress.
(ii): Restricted cash is comprised of a deposit subject to a contractual restriction up to March 2019 and is therefore not available for general use by the Group.

18. Trade Payables

	December 31,

	2017	2016
	(in US$'000)
Trade payables—third parties	11,707	13,285
Trade payables—related parties (Note 23(b))	3,838	5,290

	15,545	18,575

F-108

Table of Contents

19. Other Payables, Accruals and Advance Receipts

	December 31,

	2017	2016
	(in US$'000)
Other payables and accruals
Accrued salaries and benefits	5,512	5,072
Accrued selling and administrative expenses	4,920	9,464
Value-added tax and tax surcharge payables	2,178	2,257
Deposits received	2,894	2,455
Finance lease payables	104	93
Dividends payable	15,256	174
Other payables to manufacturers	4,323	1,766
Others	10,987	6,978

	46,174	28,259

Advance receipts
Payments in advance from customers	11,423	3,499
Deferred government incentives (note)	1,418	1,931

	12,841	5,430

	59,015	33,689

Note: The deferred government incentives are related to the property, plant and equipment and research and development projects which are expected to be completed within one year.

20. Deferred Income

	December 31,

	2017	2016
	(in US$'000)
Deferred government incentives:
Buildings and other non-current assets	13,850	13,462
Others	4,398	4,104

	18,248	17,566

F-109

Table of Contents

21. Notes to the Consolidated Statements of Cash Flows

(a) Reconciliation of profit for the year to net cash generated from operations:

	Year Ended December 31,

	2017		2016		2015
	(in US$'000)
Profit for the year	20,805		20,128		21,216
Adjustments to reconcile profit for the year to net cash generated from operations
Taxation charge	3,629		3,631		3,948
Finance costs	117		123		158
Interest income	(220	)	(238	)	(628	)
Share of profits of joint venture and associated companies, net of tax	(65	)	(19	)	(6	)
Depreciation on property, plant and equipment	4,380		2,227		2,877
Loss on disposal of property, plant and equipment	166		60		54
Impairment of property, plant and equipment	—		617		—
Amortization of leasehold land	253		255		271
Amortization of other intangible assets	352		476		126
Movements on the provision for trade receivables	(41	)	38		77
Movements on the provision for excess and obsolete inventories	187		972		340
Amortization of deferred income	(1,076	)	(1,941	)	(1,262	)
Loss on divestment of a subsidiary	169		—		—
Exchange differences	1,363		(810	)	(710	)
Changes in working capital:
Trade and bills receivables	6,903		(15,266	)	5,992
Other receivables, prepayments and deposits	(3,265	)	(2,153	)	(911	)
Inventories	(15,771	)	2,633		3,837
Other non-current assets	(206	)	—		—
Trade payables	(3,424	)	10,531		(12,424	)
Other payables, accruals and advance receipts	11,194		(4,838	)	(10,677	)
Movements on the net assets classified as held for sale	(606	)	—		—

Total changes in working capital	(5,175	)	(9,093	)	(14,183	)

Net cash generated from operations	24,844		16,426		12,278

(b) Supplemental disclosure for non-cash activities

During the year ended December 31, 2016, a non-controlling shareholder of a subsidiary made an additional capital contribution in the form of intangible assets amounting to US$3.6 million.

During the year ended December 31, 2017, there was a decrease in accruals made for purchases of property, plant and equipment of US$1.1 million. During the year ended December 31, 2016, there was an increase in accruals made for purchases of property, plant and equipment of US$3.7 million.

F-110

Table of Contents

22. Commitments

(a) Capital commitments

The Group had the following capital commitments:

	December 31,

	2017	2016
	(in US$'000)
Property, plant and equipment
Contracted but not provided for	460	6,162

Capital commitments for property, plant and equipment are mainly for the construction in progress of a new office building and a manufacturing plant.

(b) Operating lease commitments

The Group leases various factories and warehouses under non-cancellable operating lease agreements. The future aggregate minimum lease payments in respect of land and buildings under non-cancellable operating leases were as follows:

	December 31,

	2017	2016
	(in US$'000)
Not later than 1 year	999	1,106
Between 1 to 2 years	379	1,080
Between 2 to 3 years	141	—
Between 3 to 4 years	141	—
Between 4 to 5 years	47	—

	1,707	2,186

F-111

Table of Contents

23. Significant Related Party Transactions

(a) Transactions with related parties:

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Sales of goods to:
—Fellow subsidiaries of GBPHCL	24,252	22,872	25,688
—A fellow subsidiary of GZHCMHK	946	280	152

	25,198	23,152	25,840



Other services income from:
—Fellow subsidiaries of GBPHCL	3,171	2,310	875



Purchase of goods from:
—An equity investee	1,726	745	198
—Fellow subsidiaries of GBPHCL	31,446	36,291	32,156



	33,172	37,036	32,354



Advertising expenses to:
—A fellow subsidiary of GBPHCL	5,957	3,527	6,353



Interest paid to:
—A fellow subsidiary of GBPHCL	92	85	122
—A non-controlling shareholder of a subsidiary	25	—	—

	117	85	122

No transactions have been entered into with the directors of the Company (being the key management personnel) during the year ended December 31, 2017 (2016 and 2015: nil).

F-112

Table of Contents

(b) Balances with related parties included in:

	December 31,

	2017	2016
	(in US$'000)
Trade receivable—related parties
—Fellow subsidiaries of GZHCMHK (note (i))	20	—
—Fellow subsidiaries of GBPHCL (note (i))	265	466

	285	466



Trade payables—related parties
—Fellow subsidiaries of GBPHCL (Note 18 and note (i))	3,838	5,290
Other receivables—related parties
—Fellow subsidiaries of GBPHCL (note (i))	727	972
—An equity investee (note (i))	443	—

	1,170	972



Other payables, accruals and advance receipt—related parties
—Fellow subsidiaries of GZHCMHK (note (i))	158	286
—Fellow subsidiaries of GBPHCL (note (i))	3,231	539
—GBPHCL (note (ii))	2,477	2,332
—GZHCMHK (dividend payable)	7,628	—
—GBPHCL (dividend payable)	7,628	—
—Non-controlling shareholder of NBHG (dividend payable)	—	174

	21,122	3,331

Notes:

(i): Balances are unsecured, interest-free and repayable on demand. The carrying values of balances with related parties approximate their fair values due to their short-term maturities.
(ii): Balance is unsecured, interest bearing and repayable on demand. The carrying value of balance with a related party approximates its fair value due to its short-term maturity.

F-113

Table of Contents

24. Particulars of Principal Subsidiaries, Joint Venture and Associated Companies

		Nominal value of registered capital		Equity interest attributable to the Group

		As at December 31,		As at December 31,
	Place of establishment and operation
						Type of legal entity
Name		2017	2016	2017	2016	Type of legal entity	Principal activity
		(in RMB'000)
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine (Bozhou) Co. Ltd	PRC	100,000	100,000	100%	100%	Limited liability company	Manufacture, sales and distribution of drug products
Hutchison Whampoa Guangzhou Baiyunshan Pharmaceuticals Limited	PRC	10,000	10,000	100%	100%	Limited liability company	Sales and marketing of drug products
Hutchison Whampoa Guangzhou Baiyunshan Health & Wellness Co. Ltd	PRC	10,000	10,000	100%	100%	Limited liability company	Health supplemented food distribution
Hutchison Whampoa Baiyunshan Lai Da Pharmaceuticals (Shan Tou) Company Limited	PRC	10,000	10,000	70%	70%	Limited liability company	Manufacture, sales and distribution of drug products
Fuyang Baiyunshan Hutchison Whampoa Chinese Medicine Technology Company Limited	PRC	3,650	3,650	75%	75%	Limited liability company	Agriculture and sales of Chinese herbs
Wenshan Baiyunshan Hutchison Whampoa Qidan Sanqi Chinese Medicine Co. Ltd.	PRC	2,000	2,000	51%	51%	Limited liability company	Agriculture and sales of Chinese herbs
Daqing Baiyunshan Hutchison Whampoa Banlangen Technology Company Limited	PRC	1,020	1,020	51%	51%	Limited liability company	Agriculture and sales of Chinese herbs
Shen Nong Garden Traditional Chinese Medicine Museum	PRC	1,000	1,000	100%	100%	Non-profit making organization	Promote awareness of Chinese herbs
Nanyang Baiyunshan Hutchison Whampoa Danshen R&D Limited	PRC	1,000	1,000	51%	51%	Limited liability company	Agriculture and sales of Chinese herbs
Bozhou Baiyunshan Pharmaceuticals Co Ltd	PRC	500	500	100%	100%	Limited liability company	Manufacture, sales and distribution of drug products
NBHG	PRC	—	30,000	—	60%	Limited liability company	Sales of drug products
Joint Venture
Qing Yuan Baiyunshan Hutchison Whampoa ChuanXinLian R&D Limited	PRC	1,000	1,000	50%	50%	Limited liability company	Agriculture and sales of Chinese herbs
Associated companies
Linyi Shenghe Jiuzhou Pharmaceuticals Company Limited	PRC	3,000	3,000	30%	30%	Limited liability company	Agriculture and sales of Chinese herbs
Tibet Lizhi Guangzhou Pharmaceutical Development Co. Ltd.	PRC	2,000	2,000	20%	20%	Limited liability company	Trading of Chinese herbs

25. Subsequent events

The Group evaluated subsequent events through March 9, 2018, which is the date when the consolidated financial statements were issued.

F-114

Table of Contents

NUTRITION SCIENCE PARTNERS LIMITED

F-115

Table of Contents

Report of Independent Auditors

To the Board of Directors and Shareholders of Nutrition Science Partners Limited

We have audited the accompanying consolidated financial statements of Nutrition Science Partners Limited and its subsidiary, which comprise the consolidated statements of financial position as of December 31, 2017 and 2016, and the related consolidated income statements, consolidated statements of comprehensive income, of changes in equity and of cash flows for each of the three years in the period ended December 31, 2017.

Management's Responsibility for the Consolidated Financial Statements

Auditors' Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with audit standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Nutrition Science Partners Limited and its subsidiary as of December 31, 2017 and 2016, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2017, in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

/s/ PricewaterhouseCoopers
Hong Kong
March 9, 2018

F-116

Table of Contents

Nutrition Science Partners Limited
Consolidated Income Statements
(in US$'000)

		Year Ended December 31,

	Note	2017		2016		2015
Revenue		—		—		—
Service fees charged by related parties	5	(8,893	)	(8,123	)	(5,712	)
Clinical trial expenses		—		(40	)	(427	)
Other research and development costs		(242	)	(281	)	(1,371	)
Other expenses		(75	)	(38	)	(42	)

Loss before taxation		(9,210	)	(8,482	)	(7,552	)

Taxation charge	6	—		—		—
Loss for the year		(9,210	)	(8,482	)	(7,552	)

The accompanying notes are an integral part of these consolidated financial statements.

F-117

Table of Contents

Nutrition Science Partners Limited
Consolidated Statements of Comprehensive Income
(in US$'000)

	Year Ended December 31,

	2017		2016		2015
Loss for the year	(9,210	)	(8,482	)	(7,552	)

Total comprehensive loss for the year	(9,210	)	(8,482	)	(7,552	)

The accompanying notes are an integral part of these consolidated financial statements.

F-118

Table of Contents

Nutrition Science Partners Limited
Consolidated Statements of Financial Position
(in US$'000)

		December 31,

	Note	2017		2016
Assets
Current assets
Cash and cash equivalents	7	9,640		5,393
Non-current assets
Intangible asset	8	30,000		30,000

Total assets		39,640		35,393



Liabilities and shareholders' equity
Current liabilities
Other payables and accruals		289		140
Amounts due to related companies	10	950		1,642

Total liabilities		1,239		1,782

Shareholders' equity
Share capital	9	98,000		84,000
Accumulated losses		(59,599	)	(50,389	)

Total shareholders' equity		38,401		33,611

Total liabilities and shareholders' equity		39,640		35,393

The accompanying notes are an integral part of these consolidated financial statements.

F-119

Table of Contents

Nutrition Science Partners Limited
Consolidated Statements of Changes in Equity
(in US$'000)

	Share capital	Accumulated losses		Total equity

As at January 1, 2015	60,000	(34,355	)	25,645
Total comprehensive loss	—	(7,552	)	(7,552	)

As at December 31, 2015	60,000	(41,907	)	18,093



Issuance of share capital	10,000	—		10,000
Capitalization of shareholders' loans (Note 11)	14,000	—		14,000
Total comprehensive loss	—	(8,482	)	(8,482	)

As at December 31, 2016	84,000	(50,389	)	33,611



Issuance of share capital	14,000	—		14,000
Total comprehensive loss	—	(9,210	)	(9,210	)

As at December 31, 2017	98,000	(59,599	)	38,401

The accompanying notes are an integral part of these consolidated financial statements.

F-120

Table of Contents

Nutrition Science Partners Limited
Consolidated Statements of Cash Flows
(in US$'000)

		Year Ended December 31,

	Note	2017		2016		2015
Operating activities
Loss before taxation		(9,210	)	(8,482	)	(7,552	)
Changes in working capital:
Decrease in prepayments		—		410		1,889
Increase/(decrease) in other payables and accruals		149		(311	)	(1,942	)
(Decrease)/increase in amounts due to related companies		(692	)	1,152		(20	)

Net cash used in operating activities		(9,753	)	(7,231	)	(7,625	)

Financing activities
Proceeds from issuance of share capital	9	14,000		10,000		—
Proceeds from shareholders' loans	11	—		—		4,000

Net cash generated from financing activities		14,000		10,000		4,000

Net increase/(decrease) in cash and cash equivalents		4,247		2,769		(3,625	)
Cash and cash equivalents
Cash and cash equivalents at beginning of year		5,393		2,624		6,249

Cash and cash equivalents at end of year		9,640		5,393		2,624



Supplemental disclosure of non-cash activities
Capitalization of shareholders' loans	11	—		14,000		—

The accompanying notes are an integral part of these consolidated financial statements.

F-121

Table of Contents

Nutrition Science Partners Limited

Notes to the Consolidated Financial Statements

1. General Information

Nutrition Science Partners Limited (the "Company") and its subsidiary (together, the "Group") are principally engaged in the research and development of pharmaceutical products. The Company was incorporated in Hong Kong on May 28, 2012 as a limited liability company. The registered office of the Company is located at 22nd Floor, Hutchison House, 10 Harcourt Road, Hong Kong.

On November 27, 2012, Hutchison MediPharma (Hong Kong) Limited ("HMPHK"), a subsidiary of Hutchison China MediTech Limited ("Chi-Med", which together with its subsidiaries, hereinafter collectively referred to as the "Chi-Med Group") and Nestlé Health Science S.A. ("NHS"), a subsidiary of Nestlé S.A. ("Nestlé"), entered into a joint venture agreement ("JV Agreement"). Pursuant to the JV Agreement, Nestlé agreed to contribute cash of US$30,000,000 and the Chi-Med Group agreed to contribute into the Company assets and business processes including (i) the global development and commercial rights of a novel, oral therapy drug candidate for Inflammatory Bowel Disease ("IBD") and (ii) the exclusive rights to its extensive botanical library and well-established botanical research and development platform in the field of gastrointestinal disease. The Company would be jointly owned by HMPHK and NHS having 50% equity interest each.

These consolidated financial statements are presented in United States dollars ("US$"), unless otherwise stated and have been approved for issue by the Company's Board of Directors on March 9, 2018.

2. Summary of Significant Accounting Policies

The consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards ("IFRS") and interpretations issued by the IFRS Interpretations Committee applicable to companies reporting under IFRS. The consolidated financial statements comply with IFRS as issued by International Accounting Standards Board ("IASB"). These consolidated financial statements have been prepared under the historical cost convention.

As of December 31, 2017, the Company has accumulated losses of US$59,599,000 (2016: US$50,389,000) due to its research and development activities. The Company relies on HMPHK and NHS for financial support. In preparing these consolidated financial statements, management, including the directors of the Company, has taken into account all available information about the foreseeable future, which is at least, but is not limited to, twelve months from the end of the report issuance date. Management considers a wide range of factors relating to the availability and sufficiency of the Group's financial resources to satisfy its working capital and other financing requirements for a reasonable period of time, including, the progress and results of its new and in-progress research and development projects ("IPR&D projects"), the Group's current and expected future financial performance and operating cash flows, availability of loans and other financial support from shareholders, and potential sources of new funds. HMPHK and NHS have confirmed their intention to provide financial support to the Company to meet its liabilities as and when they fall due. Accordingly, the Directors are of the opinion that the Group will be able to meet its liabilities as and when they fall due within the next twelve months and therefore have prepared these consolidated financial statements on a going concern basis.

During the year, the Group has adopted all of the new and revised standards, amendments and interpretations issued by the IASB that are relevant to the Group's operations and mandatory for annual periods beginning January 1, 2017. The adoption of these new and revised standards, amendments and interpretations did not have any material effects on the Group's results of operations or financial position.

F-122

Table of Contents

The following standards, amendments and interpretations were in issue but not yet effective for financial year ended December 31, 2017 and have not been early adopted by the Group:


IAS 28 (Amendments)⁽¹⁾		Investments in Associates and Joint Ventures
IAS 40 (Amendments)⁽¹⁾		Transfers of Investment Property
IFRS 2 (Amendments)⁽¹⁾		Classification and Measurement of Share-based Payment Transactions
IFRS 9⁽¹⁾		Financial Instruments
IFRS 10 and IAS 28 (Amendments)⁽³⁾		Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
IFRS 15⁽¹⁾		Revenue from Contracts with Customers
IFRS 15 (Amendments)⁽¹⁾		Revenue from Contracts with Customers
IFRS 16⁽²⁾		Leases
IFRIC 22⁽¹⁾		Foreign Currency Transactions and Advance Consideration
IFRIC 23⁽²⁾		Uncertainty over Income Tax Treatments
Annual improvement 2014-2016⁽¹⁾		Improvements to IFRSs
Annual improvement 2015-2017⁽²⁾		Improvements to IFRSs

(1): Effective for the Group for annual periods beginning on or after January 1, 2018.
(2): Effective for the Group for annual periods beginning on or after January 1, 2019.
(3): No mandatory effective date determined yet, but available for adoption.

The adoption of standards, amendments and interpretations listed above in future periods is not expected to have any material effect on the Group's result of operations and financial position.

(a) Basis of Consolidation

The consolidated financial statements of the Group include the financial statements of the Company and its subsidiary. The financial statements of the subsidiary are prepared for the same reporting period as the Company, using consistent accounting policies. The results of the subsidiary are consolidated from the date on which the Group obtained control, and will continue to be consolidated until the date that such control ceases. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

(b) Subsidiary

The subsidiary is an entity over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. In the consolidated financial statements, the subsidiary is accounted for as described in Note 2(a) above.

(c) Foreign Currency Translation

Items included in the financial statements of each of the Group's companies are measured using the currency of the primary economic environment in which the entity operates. The consolidated financial statements are presented in US$, which is the Company's functional and presentation currency.

(d) Segment Reporting

The Group has one operating segment which conducts research and development activities. All segment assets are located in Hong Kong. The Group's chief operating decision-makers review the consolidated results of the Group for the purposes of resource allocation and performance assessment. Therefore, no additional reportable segment and geographical information has been presented.

F-123

Table of Contents

(e) Intangible Assets

Intangible assets acquired separately are measured on initial recognition at cost. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least annually. The Group has no intangible assets with indefinite lives.

(f) Research and Development Costs

All research costs are charged to the consolidated income statements as incurred.

Expenditures incurred on projects to develop new products are capitalized and deferred only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the ability to measure the expenditure reliably during the development. Product development expenditures which do not meet these criteria are expensed when incurred.

(g) Cash and Cash Equivalents

In the consolidated statements of cash flows, cash and cash equivalents comprise cash at bank.

(h) Provisions

(i) Income Tax

The current tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Company and its subsidiary operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and establish provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

3. Financial Risk Management

(i) Financial Risk Factors

The Group's activities expose it to a variety of financial risks, including credit risk and liquidity risk. The Group does not use any derivative financial instruments for speculative purposes.

(a): Credit Risk

The carrying amounts of cash and cash equivalents included in the consolidated statements of financial position represent the Group's maximum exposure to credit risk of the counterparty in relation to its financial asset. The Group's bank balance is maintained with a creditworthy bank with no recent history of default.

(b): Liquidity Risk

The Group's objective is to maintain a balance between continuity of funding and flexibility through balances with related companies and shareholders.

F-124

Table of Contents

As at December 31, 2017 and 2016, the Group's current financial liabilities were all contractually due for settlement within twelve months and expects to meet all liquidity requirements.

(ii) Capital Management

The primary objective of the Group's capital management is to safeguard the Group's ability to continue as a going concern.

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may issue new shares. The Group is not subject to any externally imposed capital requirements. No changes were made to these objectives, policies or processes for managing capital during the years ended December 31, 2017, 2016 and 2015.

(iii) Fair Value Estimation

The fair values of the financial asset and liabilities of the Group approximate their carrying amounts largely due to the short term maturities of these instruments.

4. Critical Accounting Estimates and Judgements

Note 2 includes a summary of the significant accounting policies used in the preparation of the consolidated financial statements. The preparation of the consolidated financial statements often requires the use of judgements to select specific accounting methods and policies from several acceptable alternatives. Furthermore, significant estimates and assumptions concerning the future may be required in selecting and applying those methods and policies in the financial statements. The Group bases its estimates and judgements on historical experience and various other assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates and judgements under different assumptions or conditions.

The following is a review of the more significant assumptions and estimates, as well as the accounting policies and methods used in the preparation of the financial statements.

(i) Impairment of intangible asset

The Group tests annually whether an intangible asset not ready for use has incurred any impairment. Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets exceeds its recoverable amount in accordance with the accounting policy stated in Note 2(e). The recoverable amount of an asset or a cash-generating unit is determined based on the higher of the asset's or the cash-generating unit's fair value less costs to sell and value-in-use. The value-in-use calculation requires the entity to estimate the future cash flows expected to arise from the asset and a suitable discount rate in order to calculate present value, and the growth rate assumptions in the cash flow projections which have been prepared on the basis of management's assumptions and estimates.

The Group has adopted an income approach to determine the value-in-use of the intangible asset, which applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, probability of success rate, expected timing of commercialization and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. Key assumptions and sensitivities are disclosed in Note 8.

F-125

Table of Contents

5. Significant Related Party Transactions

(i): The Group has the following significant transactions during the years with related parties which were carried out in the normal course of business at terms equivalent to those that prevail in arm's length transactions and agreed by the relevant parties:

	Year Ended December 31,

	2017	2016	2015
	(in US$'000)
Service fees charged by a subsidiary of Chi-Med	8,893	8,123	5,099
Service fees charged by an affiliate of NHS	—	—	613

	8,893	8,123	5,712

On March 25, 2013, Hutchison MediPharma Limited ("HMP"), a subsidiary of Chi-Med, and NHS entered into a research and development collaboration agreement as contemplated by the JV Agreement for the exclusive rights to conduct research to evaluate and develop products from HMP's extensive botanical library and well established botanical research and development platform in the field of gastrointestinal disease. The collaboration agreement will end on December 31, 2022, until which time the Company is required to spend a minimum of US$500,000 in each calendar year on research activities.

The Company will own the right to any products arising from the future research and development. HMP and NHS will provide the necessary services and employees in order to provide the Company with the on-going research activities. HMP and NHS will be remunerated by a fee paid by the Company for the services and staff provided.

(ii): Other transaction with related party:

On March 25, 2013, the Company and Nestec Ltd., an affiliate of NHS, entered into an option agreement for the exclusive option to obtain exclusive royalty-bearing licenses to commercialize certain products in certain territories. The exercise price of the option is either fixed or subject to negotiation upon the receipt of the exercise notice, depending on the territories. The value of the option is considered as negligible on day one. Because the option is not a derivative, it would not be subject to fair value remeasurement in the subsequent periods. As of December 31, 2017, the option has not been exercised.

(iii): Compensation of key management personnel of the Group:

No compensation was paid by the Group to the key management personnel of the Group in respect of their services rendered to the Group during the years ended December 31, 2017, 2016 and 2015.

6. Taxation Charge

No Hong Kong profits tax has been provided as the Group had no assessable profit for the years ended December 31, 2017, 2016 and 2015.

F-126

Table of Contents

The taxation on the Group's loss before taxation differs from the theoretical account that would arise using the applicable tax rate as follows:

	Year Ended December 31,

	2017		2016		2015
	(in US$'000)
Loss before taxation	(9,210	)	(8,482	)	(7,552	)



Calculated at a taxation rate of 16.5%	(1,520	)	(1,400	)	(1,246	)
Tax effect of expenses not deductible for tax purposes	1,520		1,400		1,246

Taxation	—		—		—

7. Cash and Cash Equivalents

	December 31,

	2017	2016
	(in US$'000)
Cash at bank	9,640	5,393

The carrying amounts of the cash and cash equivalents are denominated in US$.

8. Intangible Asset

	December 31,

	2017	2016
	(in US$'000)
IPR&D projects and others	30,000	30,000

Impairment test for intangible asset

The recoverable amount of the intangible asset is determined based on a value-in-use calculation. The calculation uses cash flow projections based on projected revenues and estimated costs. The projections are based on factors such as projected market size and market share, probability of success rate, timing of commercialization and estimated useful life of the underlying assets. In 2017, the Chi-Med Group and NHS updated the development plan for the Company's drug candidate for IBD, which is an enhanced version of the drug with higher potential efficacy. The development plan was expanded to include more trials and increased numbers of patients, which was primarily due to the Company's strategy to strengthen the clinical data to support a future regulatory approval application.

The corresponding increase in investment reflects the Group's increased projected market size, which has been updated for a significant increase in patients in the past few years and the expected increase through the date of commercialization. In addition, the Group believes the potential market size includes all patients in the IBD market given the higher potential efficacy; therefore, the 2017 value-in-use calculation has been updated to include patients treated with biologic therapies, compared to the 2016 value-in-use calculation which excluded such patients. The Company expects global commercialization to occur in 2026. The discount rate used of 21.60% (2016: 20.37%) is derived from a capital asset pricing model using data from the markets. The budgeted revenues and costs are determined by management based on the most recent development plan of the project and its expectation of market development. Reasonably probable changes in any key assumptions disclosed in the sensitivity table would not cause the carrying amount of the intangible asset to exceed the recoverable amount.

F-127

Table of Contents

The key assumptions used in the value-in-use calculation are as follows:

Key assumptions	2017	2016

Projected market size	US$21 billion	US$10 billion
Projected market share	10% of projected market size	10% of projected market size
Probability of success rate (Phase III)	61%	61%
Period of projected cash flows	23 years	24 years
Headroom	US$22 million	US$9 million

The Company prepared the financial projections taking into account actual and prior year performance and market development expectations. Judgement is required to determine key assumptions adopted in the cash flow projections.

The sensitivity of the value-in-use of the intangible asset to the changes in key assumptions is:

	Impact on the value-in-use of the intangible asset

			Increase in assumption		Decrease in assumption
	Change in assumption		Increase in assumption		Decrease in assumption
	Change in assumption		2017	2016	2017	2016
Market size		5%	Increase by 14%	Increase by 13%	Decrease by 14%	Decrease by 12%
Probability of success rate		2% point	Increase by 15%	Increase by 13%	Decrease by 12%	Decrease by 14%
Discount rate		1% point	Decrease by 22%	Decrease by 16%	Increase by 25%	Increase by 18%

9. Share Capital

	2017		2016		2015

	Number of shares	(in US$'000)	Number of shares	(in US$'000)	Number of shares	(in US$'000)
Issued and fully paid:
Ordinary shares
At January 1	42,000	84,000	20,000	60,000	20,000	60,000
Issuance of shares (notes (i), note (ii))	7,000	14,000	20,000	10,000	—	—
Capitalization of shareholders' loans (Note 11)	—	—	2,000	14,000	—	—

At December 31	49,000	98,000	42,000	84,000	20,000	60,000



Share capital as at December 31		98,000		84,000		60,000

Notes:

(i): On February 22, 2017, 7,000 additional ordinary shares of US$2,000 each were issued at a total cash consideration of US$14,000,000. They are issued equally to the two existing shareholders.
(ii): On March 30, 2016, 20,000 additional ordinary shares of US$500 each were issued at a total cash consideration of US$10,000,000. They are issued equally to the two existing shareholders.

F-128

Table of Contents

10. Amounts Due to Related Companies

	December 31,

	2017	2016
	(in US$'000)
Subsidiaries of Chi-Med	950	1,642

The amounts due to related companies are unsecured, interest free and repayable on demand.

11. Shareholders' Loans

Previously outstanding shareholders' loans of US$5,000,000 each, totaling US$10,000,000 were unsecured, interest-bearing (with immediate waiver of interest) and with an original maturity date of June 9, 2015, which is subject to extension from time to time by written consent from shareholders at the request of the Company. The loan agreement was renewed on August 24, 2015, with an effective date of June 9, 2015, and the maturity date extended to June 9, 2016.

On August 24, 2015, the shareholders have provided a further loan of US$2,000,000 each, totaling US$4,000,000. The loans are unsecured, interest-bearing (with immediate waiver of interest) and with a maturity date of August 23, 2016, which is subject to extension from time to time by written consent from shareholders at the request of the Company.

In June 2016, shareholders' loans of US$14,000,000 in aggregate were waived and capitalized as share capital of the Company. No shareholders' loans were outstanding as at December 31, 2017 and 2016.

12. Directors' Emoluments

None of the directors received any fees or emoluments from the Group in respect of their services rendered to the Group during the years ended December 31, 2017, 2016 and 2015.

13. Subsidiary

		Nominal value of issued ordinary share capital in GBP		Equity interest attributable to the Group

		As at December 31,		As at December 31,
	Place of establishment and operation
						Type of legal entity
Name		2017	2016	2017	2016	Type of legal entity	Principal activity
Nutrition Science Partners (UK) Limited	United Kingdom	1	1	100%	100%	Limited liability company	Inactive

14. Subsequent Events

The Group evaluated subsequent events through March 9, 2018, which is the date when the consolidated financial statements were issued.

F-129

EX-12.1 2 a2234463zex-12_1.htm EX-12.1

Exhibit 12.1

CERTIFICATION

I, Christian Hogg, certify that:

1. I have reviewed this annual report on Form 20-F of Hutchison China MediTech Limited (the “Company”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date:	March 12, 2018

By:	/s/ Christian Hogg
	Christian Hogg
	Chief Executive Officer

EX-12.2 3 a2234463zex-12_2.htm EX-12.2

Exhibit 12.2

CERTIFICATION

I, Johnny Cheng, certify that:

1. I have reviewed this annual report on Form 20-F of Hutchison China MediTech Limited (the “Company”);

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date:	March 12, 2018

By:	/s/ Johnny Cheng
	Johnny Cheng
	Chief Financial Officer

EX-13.1 4 a2234463zex-13_1.htm EX-13.1

Exhibit 13.1

906 Certification

Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Ladies and Gentlemen:

In connection with the annual report of Hutchison China MediTech Limited (the “Company”) on Form 20-F for the year ended December 31, 2017 as filed with the Securities and Exchange Commission (the “Report”), I, Christian Hogg, the Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

This Certificate has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date:	March 12, 2018

By:	/s/ Christian Hogg
Name:	Christian Hogg
Title:	Chief Executive Officer

EX-13.2 5 a2234463zex-13_2.htm EX-13.2

Exhibit 13.2

906 Certification

Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Ladies and Gentlemen:

In connection with the annual report of Hutchison China MediTech Limited (the “Company”) on Form 20-F for the year ended December 31, 2017 as filed with the Securities and Exchange Commission (the “Report”), I, Johnny Cheng, the Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

This Certificate has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date:	March 12, 2018

By:	/s/ Johnny Cheng
Name:	Johnny Cheng
Title:	Chief Financial Officer

EX-15.1 6 a2234463zex-15_1.htm EX-15.1

Exhibit 15.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-212406) and Form F-3 (No. 333-217101) of Hutchison China MediTech Limited of our report dated March 12, 2018 relating to the consolidated financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F.

/s/ PricewaterhouseCoopers
Hong Kong
March 12, 2018

EX-15.2 7 a2234463zex-15_2.htm EX-15.2

Exhibit 15.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-212406) and Form F-3 (No. 333-217101) of Hutchison China MediTech Limited of our report dated March 9, 2018 relating to the consolidated financial statements of Nutrition Science Partners Limited, which appears in this Annual Report on Form 20-F of Hutchison China MediTech Limited.

/s/ PricewaterhouseCoopers
Hong Kong
March 12, 2018

EX-15.3 8 a2234463zex-15_3.htm EX-15.3

Exhibit 15.3

CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-212406) and Form F-3 (No. 333-217101) of Hutchison China MediTech Limited of our report dated March 9, 2018 relating to the consolidated financial statements of Shanghai Hutchison Pharmaceuticals Limited, which appears in this Annual Report on Form 20-F of Hutchison China MediTech Limited.

/s/ PricewaterhouseCoopers ZhongTian LLP
Shanghai, the People’s Republic of China
March 12, 2018

EX-15.4 9 a2234463zex-15_4.htm EX-15.4

Exhibit 15.4

CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-212406) and Form F-3 (No. 333-217101) of Hutchison China MediTech Limited of our report dated March 9, 2018 relating to the consolidated financial statements of Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited, which appears in this Annual Report on Form 20-F of Hutchison China MediTech Limited.

/s/ PricewaterhouseCoopers ZhongTian LLP
Guangzhou, the People’s Republic of China
March 12, 2018

EX-15.5 10 a2234463zex-15_5.htm EX-15.5

Exhibit 15.5

12 March 2018

Matter No.:826040

Doc Ref: 103918225

(852) 2842 9595

Felicity.Lee@conyersdill.com

Hutchison China MediTech Limited

22/F Hutchison House

10 Harcourt Road

Hong Kong

Dear Sirs,

Re: Hutchison China MediTech Limited (the “Company”)

Annual Report on Form 20-F

We hereby consent to the filing of this letter as an exhibit to the Company’s annual report on Form 20-F for the year ended 31 December 2017 with the U.S. Securities and Exchange Commission and to the inclusion therein of the reference to our name on page 229 of the annual report under the heading “Taxation — Overview of Tax Implications of Various Other Jurisdictions — Cayman Islands Taxation” in the form and context in which they appear. In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act, or the Rules and Regulations of the U.S. Securities and Exchange Commission thereunder.

Yours faithfully,

Conyers Dill & Pearman
/s/ Conyers Dill & Pearman

EX-101.INS 11 hcm-20171231.xml EX-101.INS 0001648257 us-gaap:RedeemableConvertiblePreferredStockMember 2015-07-23 0001648257 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0001648257 hcm:AmericanDepositaryShareMember 2017-10-01 2017-10-31 0001648257 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001648257 hcm:AmericanDepositaryShareMember 2016-04-13 2016-04-13 0001648257 2016-04-13 2016-04-13 0001648257 hcm:AmericanDepositaryShareMember 2016-03-17 2016-03-17 0001648257 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001648257 us-gaap:CommonStockMember 2015-07-23 2015-07-23 0001648257 us-gaap:RetainedEarningsMember 2017-12-31 0001648257 us-gaap:ParentMember 2017-12-31 0001648257 us-gaap:NoncontrollingInterestMember 2017-12-31 0001648257 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001648257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001648257 us-gaap:RetainedEarningsMember 2016-12-31 0001648257 us-gaap:ParentMember 2016-12-31 0001648257 us-gaap:NoncontrollingInterestMember 2016-12-31 0001648257 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001648257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001648257 us-gaap:RetainedEarningsMember 2015-12-31 0001648257 us-gaap:ParentMember 2015-12-31 0001648257 us-gaap:NoncontrollingInterestMember 2015-12-31 0001648257 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001648257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001648257 us-gaap:RetainedEarningsMember 2014-12-31 0001648257 us-gaap:ParentMember 2014-12-31 0001648257 us-gaap:NoncontrollingInterestMember 2014-12-31 0001648257 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001648257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0001648257 currency:USD hcm:BankDepositsMaturingOverThreeMonthsMember 2017-12-31 0001648257 currency:HKD hcm:BankDepositsMaturingOverThreeMonthsMember 2017-12-31 0001648257 hcm:BankDepositsMaturingOverThreeMonthsMember 2017-12-31 0001648257 currency:USD hcm:BankDepositsMaturingOverThreeMonthsMember 2016-12-31 0001648257 hcm:BankDepositsMaturingOverThreeMonthsMember 2016-12-31 0001648257 hcm:HMHLShareOptionSchemesMember 2014-12-31 0001648257 hcm:HCMLShareOptionSchemeMember 2014-12-31 0001648257 hcm:HMHLShareOptionSchemesMember 2016-06-15 2016-06-15 0001648257 hcm:HMHLShareOptionSchemesMember 2016-01-01 2016-12-31 0001648257 hcm:HCMLShareOptionSchemeMember 2016-12-31 0001648257 hcm:HMHLShareOptionSchemesMember 2015-12-31 0001648257 hcm:HCMLShareOptionSchemeMember 2015-12-31 0001648257 hcm:HCMLShareOptionSchemeMember 2017-03-27 2017-03-27 0001648257 hcm:HCMLShareOptionSchemeMember 2016-06-15 2016-06-15 0001648257 hcm:HCMLShareOptionSchemeMember 2013-12-20 2013-12-20 0001648257 hcm:HCMLShareOptionSchemeMember 2011-06-24 2011-06-24 0001648257 hcm:HCMLShareOptionSchemeMember 2017-03-27 0001648257 hcm:HCMLShareOptionSchemeMember 2016-06-15 0001648257 hcm:HCMLShareOptionSchemeMember 2013-12-20 0001648257 hcm:HCMLShareOptionSchemeMember 2011-06-24 0001648257 hcm:AwardsExpiringInSixYearsMember hcm:HMHLShareOptionSchemesMember us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001648257 hcm:AwardsExpiringInNineYearsMember hcm:HMHLShareOptionSchemesMember us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001648257 hcm:HCMLShareOptionSchemeMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0001648257 hcm:HCMLShareOptionSchemeMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001648257 hcm:HMHLShareOptionSchemesMember 2008-08-06 2008-08-06 0001648257 hcm:HCMLShareOptionSchemeMember 2005-06-04 2005-06-04 0001648257 us-gaap:RestrictedStockMember hcm:LongTermIncentivePlanMember 2017-12-31 0001648257 us-gaap:RestrictedStockMember hcm:LongTermIncentivePlanMember 2016-12-31 0001648257 hcm:HMHLShareOptionSchemesMember us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001648257 hcm:AwardsVestingInThreeYearsMember hcm:HCMLShareOptionSchemeMember 2017-01-01 2017-12-31 0001648257 hcm:AwardsVestingInFourYearsMember hcm:HCMLShareOptionSchemeMember 2017-01-01 2017-12-31 0001648257 hcm:HMHLShareOptionSchemesMember 2017-01-01 2017-12-31 0001648257 us-gaap:IntersegmentEliminationMember country:CN hcm:ConsumerHealthMember 2017-01-01 2017-12-31 0001648257 us-gaap:IntersegmentEliminationMember country:CN hcm:ConsumerHealthMember 2016-01-01 2016-12-31 0001648257 us-gaap:IntersegmentEliminationMember country:CN hcm:ConsumerHealthMember 2015-01-01 2015-12-31 0001648257 us-gaap:SubsidiaryIssuerMember us-gaap:RedeemableConvertiblePreferredStockMember 2014-05-01 2014-06-30 0001648257 us-gaap:SubsidiaryIssuerMember us-gaap:CommonStockMember 2014-05-01 2014-06-30 0001648257 us-gaap:SubsidiaryIssuerMember 2014-05-01 2014-06-30 0001648257 us-gaap:SubsidiaryIssuerMember us-gaap:RedeemableConvertiblePreferredStockMember 2010-11-01 2010-12-31 0001648257 hcm:RelatedPartyTransactionSalesOfGoodsMember us-gaap:SubsidiaryOfCommonParentMember 2017-01-01 2017-12-31 0001648257 hcm:RelatedPartyTransactionResearchAndDevelopmentServicesMember us-gaap:EquityMethodInvesteeMember 2017-01-01 2017-12-31 0001648257 hcm:RelatedPartyTransactionSalesOfGoodsMember us-gaap:SubsidiaryOfCommonParentMember 2016-01-01 2016-12-31 0001648257 hcm:RelatedPartyTransactionResearchAndDevelopmentServicesMember us-gaap:EquityMethodInvesteeMember 2016-01-01 2016-12-31 0001648257 hcm:RelatedPartyTransactionSalesOfGoodsMember us-gaap:SubsidiaryOfCommonParentMember 2015-01-01 2015-12-31 0001648257 hcm:RelatedPartyTransactionResearchAndDevelopmentServicesMember us-gaap:EquityMethodInvesteeMember 2015-01-01 2015-12-31 0001648257 country:CN 2017-12-31 0001648257 country:CN 2016-12-31 0001648257 us-gaap:AccountingStandardsUpdate201409Member hcm:ProformaAdjustmentMember 2018-01-01 0001648257 hcm:AccountingStandardsUpdate201609Member us-gaap:ScenarioAdjustmentMember 2017-12-31 0001648257 us-gaap:NotesPayableToBanksMember 2017-11-01 2017-11-30 0001648257 us-gaap:NotesPayableToBanksMember 2017-08-01 2017-08-31 0001648257 us-gaap:RevolvingCreditFacilityMember 2017-03-01 2017-03-31 0001648257 us-gaap:NotesPayableToBanksMember 2017-03-01 2017-03-31 0001648257 us-gaap:EquityMethodInvesteeMember 2017-01-01 2017-12-31 0001648257 us-gaap:EquityMethodInvesteeMember 2016-01-01 2016-12-31 0001648257 us-gaap:EquityMethodInvesteeMember 2015-01-01 2015-12-31 0001648257 hcm:RelatedPartyTransactionMarketingServicesMember us-gaap:SubsidiaryOfCommonParentMember 2017-01-01 2017-12-31 0001648257 hcm:RelatedPartyTransactionMarketingServicesMember us-gaap:EquityMethodInvesteeMember 2017-01-01 2017-12-31 0001648257 hcm:RelatedPartyTransactionManagementServiceMember us-gaap:SubsidiaryOfCommonParentMember 2017-01-01 2017-12-31 0001648257 hcm:RelatedPartyTransactionMarketingServicesMember 2017-01-01 2017-12-31 0001648257 hcm:RelatedPartyTransactionMarketingServicesMember us-gaap:SubsidiaryOfCommonParentMember 2016-01-01 2016-12-31 0001648257 hcm:RelatedPartyTransactionMarketingServicesMember us-gaap:EquityMethodInvesteeMember 2016-01-01 2016-12-31 0001648257 hcm:RelatedPartyTransactionManagementServiceMember us-gaap:SubsidiaryOfCommonParentMember 2016-01-01 2016-12-31 0001648257 hcm:RelatedPartyTransactionMarketingServicesMember 2016-01-01 2016-12-31 0001648257 hcm:RelatedPartyTransactionMarketingServicesMember us-gaap:SubsidiaryOfCommonParentMember 2015-01-01 2015-12-31 0001648257 hcm:RelatedPartyTransactionMarketingServicesMember us-gaap:EquityMethodInvesteeMember 2015-01-01 2015-12-31 0001648257 hcm:RelatedPartyTransactionManagementServiceMember us-gaap:SubsidiaryOfCommonParentMember 2015-01-01 2015-12-31 0001648257 hcm:RelatedPartyTransactionMarketingServicesMember 2015-01-01 2015-12-31 0001648257 2015-12-01 2015-12-31 0001648257 us-gaap:PropertyPlantAndEquipmentMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0001648257 us-gaap:PropertyPlantAndEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001648257 us-gaap:LeaseholdImprovementsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001648257 hcm:FurnitureFixturesOtherEquipmentAndMotorVehiclesMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0001648257 hcm:FurnitureFixturesOtherEquipmentAndMotorVehiclesMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001648257 us-gaap:ConstructionInProgressMember 2017-12-31 0001648257 us-gaap:ConstructionInProgressMember 2016-12-31 0001648257 us-gaap:ConstructionInProgressMember 2015-12-31 0001648257 us-gaap:SubsidiaryIssuerMember 2015-01-01 2015-12-31 0001648257 2015-01-01 2016-12-31 0001648257 hcm:LoanPayableToNonControllingShareholdersOfSubsidiariesMember hcm:NonControllingShareholdersOfSubsidiariesMember 2016-12-31 0001648257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001648257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0001648257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0001648257 us-gaap:BuildingMember 2015-01-01 2015-12-31 0001648257 hcm:EquityMethodInvesteesAggregatedDisclosureMember 2017-12-31 0001648257 hcm:EquityMethodInvesteesAggregatedDisclosureMember 2016-12-31 0001648257 hcm:SubsidiaryTwoMember hcm:NutritionSciencePartnersLimitedMember country:HK 2017-12-31 0001648257 hcm:SubsidiaryOneMember hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember country:CN 2017-12-31 0001648257 hcm:HutchisonWhampoaSinopharmPharmaceuticalsShanghaiCompanyLimitedMember country:CN 2017-12-31 0001648257 hcm:HutchisonMediPharmaLimitedMember country:CN 2017-12-31 0001648257 hcm:HutchisonHealthcareLimitedMember country:CN 2017-12-31 0001648257 hcm:HutchisonHainOrganicHongKongLimitedMember country:HK 2017-12-31 0001648257 hcm:HutchisonHainOrganicGuangzhouLimitedMember country:CN 2017-12-31 0001648257 hcm:HutchisonConsumerProductsLimitedMember country:HK 2017-12-31 0001648257 hcm:SubsidiaryTwoMember hcm:NutritionSciencePartnersLimitedMember country:HK 2016-12-31 0001648257 hcm:SubsidiaryOneMember hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember country:CN 2016-12-31 0001648257 hcm:HutchisonWhampoaSinopharmPharmaceuticalsShanghaiCompanyLimitedMember country:CN 2016-12-31 0001648257 hcm:HutchisonMediPharmaLimitedMember country:CN 2016-12-31 0001648257 hcm:HutchisonHealthcareLimitedMember country:CN 2016-12-31 0001648257 hcm:HutchisonHainOrganicHongKongLimitedMember country:HK 2016-12-31 0001648257 hcm:HutchisonHainOrganicGuangzhouLimitedMember country:CN 2016-12-31 0001648257 hcm:HutchisonConsumerProductsLimitedMember country:HK 2016-12-31 0001648257 hcm:SubsidiaryTwoMember hcm:NutritionSciencePartnersLimitedMember 2017-12-31 0001648257 hcm:SubsidiaryOneMember hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember 2017-12-31 0001648257 hcm:SubsidiaryTwoMember hcm:NutritionSciencePartnersLimitedMember 2016-12-31 0001648257 hcm:SubsidiaryOneMember hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember 2016-12-31 0001648257 hcm:MitsuiCompanyLtdMember 2015-07-23 0001648257 us-gaap:SubsidiaryIssuerMember 2014-06-30 0001648257 us-gaap:SubsidiaryIssuerMember us-gaap:RedeemableConvertiblePreferredStockMember 2012-10-31 0001648257 us-gaap:SubsidiaryIssuerMember us-gaap:RedeemableConvertiblePreferredStockMember 2010-12-31 0001648257 hcm:EquityMethodInvesteesAggregatedDisclosureMember us-gaap:CapitalAdditionsMember 2017-01-01 2017-12-31 0001648257 us-gaap:CapitalAdditionsMember 2017-01-01 2017-12-31 0001648257 hcm:EquityMethodInvesteesAggregatedDisclosureMember us-gaap:CapitalAdditionsMember 2016-01-01 2016-12-31 0001648257 us-gaap:CapitalAdditionsMember 2016-01-01 2016-12-31 0001648257 us-gaap:UnsecuredDebtMember us-gaap:NotesPayableToBanksMember 2017-11-30 0001648257 us-gaap:UnsecuredDebtMember 2017-11-30 0001648257 hcm:FirstCreditFacilityMember us-gaap:RevolvingCreditFacilityMember 2017-02-28 0001648257 hcm:FirstCreditFacilityMember us-gaap:NotesPayableToBanksMember 2017-02-28 0001648257 us-gaap:UnsecuredDebtMember 2017-02-28 0001648257 us-gaap:UnsecuredDebtMember 2016-02-29 0001648257 us-gaap:RevolvingCreditFacilityMember 2015-11-30 0001648257 us-gaap:UnsecuredDebtMember us-gaap:RevolvingCreditFacilityMember 2017-12-31 0001648257 hcm:SecondCreditFacilityMember us-gaap:RevolvingCreditFacilityMember 2017-12-31 0001648257 hcm:FirstCreditFacilityMember us-gaap:RevolvingCreditFacilityMember 2017-12-31 0001648257 us-gaap:RevolvingCreditFacilityMember 2017-12-31 0001648257 us-gaap:RevolvingCreditFacilityMember 2017-02-28 0001648257 us-gaap:RevolvingCreditFacilityMember 2016-12-31 0001648257 hcm:ImmediateHoldingCompanyMember 2016-01-01 2016-12-31 0001648257 hcm:ImmediateHoldingCompanyMember 2015-01-01 2015-12-31 0001648257 us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-12-31 0001648257 us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-12-31 0001648257 us-gaap:OtherNonoperatingIncomeExpenseMember 2015-01-01 2015-12-31 0001648257 hcm:AllOtherEquityMethodInvesteesMember 2017-01-01 2017-12-31 0001648257 hcm:AllOtherEquityMethodInvesteesMember 2016-01-01 2016-12-31 0001648257 hcm:AllOtherEquityMethodInvesteesMember 2015-01-01 2015-12-31 0001648257 hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember hcm:CommercialPlatformMember hcm:PrescriptionDrugsMember 2014-12-31 0001648257 hcm:NutritionSciencePartnersLimitedMember hcm:InnovationPlatformMember hcm:DrugResearchAndDevelopmentMember 2014-12-31 0001648257 hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember hcm:CommercialPlatformMember hcm:ConsumerHealthMember 2014-12-31 0001648257 hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember hcm:CommercialPlatformMember hcm:ConsumerHealthMember 2017-12-31 0001648257 hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember 2017-12-31 0001648257 hcm:NutritionSciencePartnersLimitedMember 2017-12-31 0001648257 hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember 2017-12-31 0001648257 hcm:AllOtherEquityMethodInvesteesMember 2017-12-31 0001648257 hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember hcm:CommercialPlatformMember hcm:ConsumerHealthMember 2016-12-31 0001648257 hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember 2016-12-31 0001648257 hcm:NutritionSciencePartnersLimitedMember 2016-12-31 0001648257 hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember 2016-12-31 0001648257 hcm:AllOtherEquityMethodInvesteesMember 2016-12-31 0001648257 hcm:NutritionSciencePartnersLimitedMember hcm:InnovationPlatformMember hcm:DrugResearchAndDevelopmentMember 2015-12-31 0001648257 hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember hcm:CommercialPlatformMember hcm:ConsumerHealthMember 2015-12-31 0001648257 hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember country:CN 2017-12-31 0001648257 hcm:NutritionSciencePartnersLimitedMember country:HK 2017-12-31 0001648257 hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember country:CN 2017-12-31 0001648257 hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember country:CN 2016-12-31 0001648257 hcm:NutritionSciencePartnersLimitedMember country:HK 2016-12-31 0001648257 hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember country:CN 2016-12-31 0001648257 hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember hcm:CommercialPlatformMember hcm:PrescriptionDrugsMember 2017-12-31 0001648257 hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember hcm:CommercialPlatformMember hcm:PrescriptionDrugsMember 2016-12-31 0001648257 hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember hcm:CommercialPlatformMember hcm:PrescriptionDrugsMember 2015-12-31 0001648257 hcm:HCMLShareOptionSchemeMember 2017-12-31 0001648257 hcm:HMHLShareOptionSchemesMember 2015-01-01 2015-12-31 0001648257 hcm:IndirectSubsidiaryOfCkHutchisonAndImmediateHoldingCompanyMember 2017-12-31 0001648257 hcm:IndirectSubsidiaryOfCkHutchisonAndImmediateHoldingCompanyMember 2016-12-31 0001648257 hcm:RelatedPartyTransactionDividendReceivableMember us-gaap:EquityMethodInvesteeMember 2017-12-31 0001648257 hcm:HMHLShareOptionSchemesMember 2017-12-31 0001648257 hcm:HMHLShareOptionSchemesMember 2016-12-31 0001648257 hcm:LongTermIncentivePlanMember 2017-12-31 0001648257 hcm:LongTermIncentivePlanMember 2016-12-31 0001648257 us-gaap:UnsecuredDebtMember us-gaap:RevolvingCreditFacilityMember 2017-11-01 2017-11-30 0001648257 us-gaap:UnsecuredDebtMember us-gaap:NotesPayableToBanksMember 2017-11-01 2017-11-30 0001648257 hcm:SecondCreditFacilityMember us-gaap:RevolvingCreditFacilityMember 2017-02-01 2017-02-28 0001648257 hcm:SecondCreditFacilityMember us-gaap:NotesPayableToBanksMember 2017-02-01 2017-02-28 0001648257 hcm:FirstCreditFacilityMember us-gaap:RevolvingCreditFacilityMember 2017-02-01 2017-02-28 0001648257 hcm:FirstCreditFacilityMember us-gaap:NotesPayableToBanksMember 2017-02-01 2017-02-28 0001648257 us-gaap:RevolvingCreditFacilityMember 2015-11-01 2015-11-30 0001648257 us-gaap:NotesPayableToBanksMember 2014-06-01 2014-06-30 0001648257 us-gaap:NotesPayableToBanksMember 2011-12-01 2011-12-31 0001648257 us-gaap:UnsecuredDebtMember us-gaap:RevolvingCreditFacilityMember 2017-11-30 0001648257 hcm:SecondCreditFacilityMember us-gaap:RevolvingCreditFacilityMember 2017-02-28 0001648257 hcm:SecondCreditFacilityMember us-gaap:NotesPayableToBanksMember 2017-02-28 0001648257 us-gaap:NotesPayableToBanksMember 2011-12-31 0001648257 us-gaap:UnsecuredDebtMember us-gaap:RevolvingCreditFacilityMember hcm:HongKongInterbankOfferedRateMember 2017-11-01 2017-11-30 0001648257 us-gaap:UnsecuredDebtMember us-gaap:NotesPayableToBanksMember hcm:HongKongInterbankOfferedRateMember 2017-11-01 2017-11-30 0001648257 hcm:SecondCreditFacilityMember us-gaap:RevolvingCreditFacilityMember hcm:HongKongInterbankOfferedRateMember 2017-02-01 2017-02-28 0001648257 hcm:SecondCreditFacilityMember us-gaap:NotesPayableToBanksMember hcm:HongKongInterbankOfferedRateMember 2017-02-01 2017-02-28 0001648257 hcm:FirstCreditFacilityMember us-gaap:RevolvingCreditFacilityMember hcm:HongKongInterbankOfferedRateMember 2017-02-01 2017-02-28 0001648257 hcm:FirstCreditFacilityMember us-gaap:NotesPayableToBanksMember hcm:HongKongInterbankOfferedRateMember 2017-02-01 2017-02-28 0001648257 us-gaap:RevolvingCreditFacilityMember hcm:HongKongInterbankOfferedRateMember 2015-11-01 2015-11-30 0001648257 us-gaap:NotesPayableToBanksMember hcm:HongKongInterbankOfferedRateMember 2014-06-01 2014-06-30 0001648257 us-gaap:NotesPayableToBanksMember hcm:HongKongInterbankOfferedRateMember 2011-12-01 2011-12-31 0001648257 country:HK 2017-01-01 2017-12-31 0001648257 country:HK 2016-01-01 2016-12-31 0001648257 country:HK 2015-01-01 2015-12-31 0001648257 hcm:NonControllingShareholdersOfSubsidiariesMember 2017-01-01 2017-12-31 0001648257 hcm:NonControllingShareholdersOfSubsidiariesMember 2016-01-01 2016-12-31 0001648257 hcm:NonControllingShareholdersOfSubsidiariesMember 2015-01-01 2015-12-31 0001648257 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember hcm:CustomerOneMember hcm:InnovationPlatformMember 2015-01-01 2015-12-31 0001648257 us-gaap:CommonStockMember 2017-12-31 0001648257 us-gaap:CommonStockMember 2016-12-31 0001648257 us-gaap:CommonStockMember 2015-12-31 0001648257 us-gaap:CommonStockMember 2014-12-31 0001648257 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001648257 us-gaap:FairValueInputsLevel1Member 2016-12-31 0001648257 currency:USD 2017-12-31 0001648257 currency:HKD 2017-12-31 0001648257 currency:GBP 2017-12-31 0001648257 currency:CNY 2017-12-31 0001648257 currency:USD 2016-12-31 0001648257 currency:HKD 2016-12-31 0001648257 currency:GBP 2016-12-31 0001648257 currency:CNY 2016-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:HK hcm:ConsumerHealthMember 2017-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:CN hcm:PrescriptionDrugsMember 2017-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:CN hcm:ConsumerHealthMember 2017-12-31 0001648257 us-gaap:OperatingSegmentsMember 2017-12-31 0001648257 hcm:CorporateAndReconcilingItemsMember 2017-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:HK hcm:ConsumerHealthMember 2016-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:CN hcm:PrescriptionDrugsMember 2016-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:CN hcm:ConsumerHealthMember 2016-12-31 0001648257 us-gaap:OperatingSegmentsMember 2016-12-31 0001648257 hcm:CorporateAndReconcilingItemsMember 2016-12-31 0001648257 us-gaap:SubsidiariesMember country:CN 2017-12-31 0001648257 us-gaap:SubsidiariesMember country:CN 2016-12-31 0001648257 us-gaap:SellingGeneralAndAdministrativeExpensesMember hcm:LongTermIncentivePlanMember 2017-01-01 2017-12-31 0001648257 us-gaap:ResearchAndDevelopmentExpenseMember hcm:LongTermIncentivePlanMember 2017-01-01 2017-12-31 0001648257 us-gaap:ResearchAndDevelopmentExpenseMember hcm:HMHLShareOptionSchemesMember 2017-01-01 2017-12-31 0001648257 us-gaap:ResearchAndDevelopmentExpenseMember hcm:HCMLShareOptionSchemeMember 2017-01-01 2017-12-31 0001648257 us-gaap:LiabilityMember hcm:LongTermIncentivePlanMember 2017-01-01 2017-12-31 0001648257 us-gaap:AdditionalPaidInCapitalMember hcm:LongTermIncentivePlanMember 2017-01-01 2017-12-31 0001648257 us-gaap:SellingGeneralAndAdministrativeExpensesMember hcm:LongTermIncentivePlanMember 2016-01-01 2016-12-31 0001648257 us-gaap:ResearchAndDevelopmentExpenseMember hcm:LongTermIncentivePlanMember 2016-01-01 2016-12-31 0001648257 us-gaap:ResearchAndDevelopmentExpenseMember hcm:HMHLShareOptionSchemesMember 2016-01-01 2016-12-31 0001648257 us-gaap:ResearchAndDevelopmentExpenseMember hcm:HCMLShareOptionSchemeMember 2016-01-01 2016-12-31 0001648257 us-gaap:LiabilityMember hcm:LongTermIncentivePlanMember 2016-01-01 2016-12-31 0001648257 us-gaap:AdditionalPaidInCapitalMember hcm:LongTermIncentivePlanMember 2016-01-01 2016-12-31 0001648257 hcm:HCMLShareOptionSchemeMember 2016-01-01 2016-12-31 0001648257 us-gaap:SellingGeneralAndAdministrativeExpensesMember hcm:LongTermIncentivePlanMember 2015-01-01 2015-12-31 0001648257 us-gaap:ResearchAndDevelopmentExpenseMember hcm:LongTermIncentivePlanMember 2015-01-01 2015-12-31 0001648257 us-gaap:ResearchAndDevelopmentExpenseMember hcm:HMHLShareOptionSchemesMember 2015-01-01 2015-12-31 0001648257 us-gaap:ResearchAndDevelopmentExpenseMember hcm:HCMLShareOptionSchemeMember 2015-01-01 2015-12-31 0001648257 us-gaap:LiabilityMember hcm:LongTermIncentivePlanMember 2015-01-01 2015-12-31 0001648257 us-gaap:GeneralAndAdministrativeExpenseMember hcm:HCMLShareOptionSchemeMember 2015-01-01 2015-12-31 0001648257 us-gaap:AdditionalPaidInCapitalMember hcm:LongTermIncentivePlanMember 2015-01-01 2015-12-31 0001648257 hcm:HCMLShareOptionSchemeMember 2015-01-01 2015-12-31 0001648257 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0001648257 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-12-31 0001648257 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001648257 us-gaap:BuildingMember 2017-12-31 0001648257 us-gaap:MachineryAndEquipmentMember 2016-12-31 0001648257 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001648257 us-gaap:FurnitureAndFixturesMember 2016-12-31 0001648257 us-gaap:BuildingMember 2016-12-31 0001648257 us-gaap:MachineryAndEquipmentMember 2015-12-31 0001648257 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001648257 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001648257 us-gaap:BuildingMember 2015-12-31 0001648257 2014-12-31 0001648257 us-gaap:SubsidiaryOfCommonParentMember 2017-12-31 0001648257 us-gaap:SubsidiaryOfCommonParentMember 2016-12-31 0001648257 us-gaap:BankTimeDepositsMember us-gaap:WeightedAverageMember 2017-01-01 2017-12-31 0001648257 hcm:BankDepositsMaturingOverThreeMonthsMember us-gaap:WeightedAverageMember 2017-01-01 2017-12-31 0001648257 us-gaap:BankTimeDepositsMember us-gaap:WeightedAverageMember 2016-01-01 2016-12-31 0001648257 hcm:BankDepositsMaturingOverThreeMonthsMember us-gaap:WeightedAverageMember 2016-01-01 2016-12-31 0001648257 us-gaap:ParentMember 2017-01-01 2017-12-31 0001648257 us-gaap:ParentMember 2016-01-01 2016-12-31 0001648257 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001648257 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001648257 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001648257 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001648257 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0001648257 us-gaap:BankTimeDepositsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0001648257 us-gaap:BankTimeDepositsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001648257 hcm:BankDepositsMaturingOverThreeMonthsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0001648257 hcm:BankDepositsMaturingOverThreeMonthsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001648257 us-gaap:BankTimeDepositsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0001648257 us-gaap:BankTimeDepositsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0001648257 hcm:BankDepositsMaturingOverThreeMonthsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0001648257 hcm:BankDepositsMaturingOverThreeMonthsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0001648257 us-gaap:RedeemableConvertiblePreferredStockMember 2012-10-01 2012-10-31 0001648257 hcm:LongTermIncentivePlanMember 2017-01-01 2017-12-31 0001648257 hcm:LongTermIncentivePlanMember 2016-01-01 2016-12-31 0001648257 hcm:LongTermIncentivePlanMember 2015-01-01 2015-12-31 0001648257 hcm:HMHLShareOptionSchemesMember 2013-12-20 2013-12-20 0001648257 hcm:HMHLShareOptionSchemesMember us-gaap:CommonStockMember 2017-12-31 0001648257 hcm:AwardsVestingInThreeYearsMember hcm:HCMLShareOptionSchemeMember 2017-12-31 0001648257 hcm:AwardsVestingInFourYearsMember hcm:HCMLShareOptionSchemeMember 2017-12-31 0001648257 hcm:HCMLShareOptionSchemeMember 2017-01-01 2017-12-31 0001648257 hcm:LongTermIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-10-19 2017-10-19 0001648257 hcm:LongTermIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-03-15 2017-03-15 0001648257 hcm:LongTermIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-10-19 2015-10-19 0001648257 hcm:LongTermIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-12-15 2017-12-15 0001648257 hcm:LongTermIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-08-02 2017-08-02 0001648257 hcm:LongTermIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-03-15 2017-03-15 0001648257 hcm:LongTermIncentivePlanMember us-gaap:MaximumMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-12-15 0001648257 hcm:LongTermIncentivePlanMember us-gaap:MaximumMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-08-02 0001648257 hcm:LongTermIncentivePlanMember us-gaap:MaximumMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-03-15 0001648257 hcm:LongTermIncentivePlanMember us-gaap:MaximumMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-03-15 0001648257 hcm:LongTermIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2016-03-24 0001648257 hcm:LongTermIncentivePlanMember us-gaap:MaximumMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-10-19 0001648257 us-gaap:RestrictedStockMember hcm:LongTermIncentivePlanMember us-gaap:MaximumMember us-gaap:ScenarioForecastMember 2018-01-01 2018-12-31 0001648257 us-gaap:RestrictedStockMember hcm:LongTermIncentivePlanMember 2017-01-01 2017-12-31 0001648257 hcm:LicenseAndCollaborationAgreementAstrazenecaMember 2016-01-01 2016-12-31 0001648257 hcm:LicenseAndCollaborationAgreementAstrazenecaMember 2015-01-01 2015-12-31 0001648257 us-gaap:ConstructionInProgressMember 2017-01-01 2017-12-31 0001648257 us-gaap:ConstructionInProgressMember 2016-01-01 2016-12-31 0001648257 2017-10-01 2017-10-31 0001648257 hcm:LicenseAndCollaborationAgreementAstrazenecaMember 2017-01-01 2017-12-31 0001648257 hcm:ImmediateHoldingCompanyMember 2016-12-31 0001648257 us-gaap:EquityMethodInvesteeMember 2017-12-31 0001648257 us-gaap:EquityMethodInvesteeMember 2016-12-31 0001648257 2014-05-01 2014-06-30 0001648257 us-gaap:UnsecuredDebtMember 2017-02-01 2017-02-28 0001648257 hcm:CommercialPlatformMember 2017-01-01 2017-12-31 0001648257 us-gaap:NotesPayableToBanksMember 2017-08-01 2017-11-30 0001648257 hcm:LicenseAndCollaborationAgreementEliLillyMember 2013-10-08 2013-10-08 0001648257 hcm:LicenseAndCollaborationAgreementAstrazenecaMember 2011-12-21 2011-12-21 0001648257 hcm:LicenseAndCollaborationAgreementAstrazenecaMember 2016-08-31 0001648257 hcm:LicenseAndCollaborationAgreementAstrazenecaMember 2011-12-21 0001648257 hcm:LicenseAndCollaborationAgreementEliLillyMember 2013-10-08 0001648257 us-gaap:OperatingSegmentsMember hcm:InnovationPlatformMember country:CN hcm:DrugResearchAndDevelopmentMember 2017-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:InnovationPlatformMember country:CN hcm:DrugResearchAndDevelopmentMember 2016-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:InnovationPlatformMember country:CN hcm:DrugResearchAndDevelopmentMember 2017-01-01 2017-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:HK hcm:ConsumerHealthMember 2017-01-01 2017-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:CN hcm:PrescriptionDrugsMember 2017-01-01 2017-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:CN hcm:ConsumerHealthMember 2017-01-01 2017-12-31 0001648257 us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001648257 hcm:CorporateAndReconcilingItemsMember 2017-01-01 2017-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:InnovationPlatformMember country:CN hcm:DrugResearchAndDevelopmentMember 2016-01-01 2016-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:HK hcm:ConsumerHealthMember 2016-01-01 2016-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:CN hcm:PrescriptionDrugsMember 2016-01-01 2016-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:CN hcm:ConsumerHealthMember 2016-01-01 2016-12-31 0001648257 us-gaap:OperatingSegmentsMember 2016-01-01 2016-12-31 0001648257 hcm:CorporateAndReconcilingItemsMember 2016-01-01 2016-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:InnovationPlatformMember country:CN hcm:DrugResearchAndDevelopmentMember 2015-01-01 2015-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:HK hcm:ConsumerHealthMember 2015-01-01 2015-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:CN hcm:PrescriptionDrugsMember 2015-01-01 2015-12-31 0001648257 us-gaap:OperatingSegmentsMember hcm:CommercialPlatformMember country:CN hcm:ConsumerHealthMember 2015-01-01 2015-12-31 0001648257 us-gaap:OperatingSegmentsMember 2015-01-01 2015-12-31 0001648257 hcm:CorporateAndReconcilingItemsMember 2015-01-01 2015-12-31 0001648257 us-gaap:SubsidiaryOfCommonParentMember 2017-01-01 2017-12-31 0001648257 us-gaap:SubsidiaryOfCommonParentMember 2016-01-01 2016-12-31 0001648257 us-gaap:SubsidiaryOfCommonParentMember 2015-01-01 2015-12-31 0001648257 hcm:NutritionSciencePartnersLimitedMember hcm:InnovationPlatformMember hcm:DrugResearchAndDevelopmentMember 2017-12-31 0001648257 hcm:NutritionSciencePartnersLimitedMember hcm:InnovationPlatformMember hcm:DrugResearchAndDevelopmentMember 2017-01-01 2017-12-31 0001648257 hcm:NutritionSciencePartnersLimitedMember hcm:InnovationPlatformMember hcm:DrugResearchAndDevelopmentMember 2016-01-01 2016-12-31 0001648257 hcm:NutritionSciencePartnersLimitedMember hcm:InnovationPlatformMember hcm:DrugResearchAndDevelopmentMember 2015-01-01 2015-12-31 0001648257 hcm:NutritionSciencePartnersLimitedMember hcm:InnovationPlatformMember hcm:DrugResearchAndDevelopmentMember 2016-12-31 0001648257 hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember hcm:CommercialPlatformMember hcm:PrescriptionDrugsMember 2017-01-01 2017-12-31 0001648257 hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember hcm:CommercialPlatformMember hcm:ConsumerHealthMember 2017-01-01 2017-12-31 0001648257 hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember hcm:CommercialPlatformMember hcm:PrescriptionDrugsMember 2016-01-01 2016-12-31 0001648257 hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember hcm:CommercialPlatformMember hcm:ConsumerHealthMember 2016-01-01 2016-12-31 0001648257 hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember hcm:CommercialPlatformMember hcm:PrescriptionDrugsMember 2015-01-01 2015-12-31 0001648257 hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember hcm:CommercialPlatformMember hcm:ConsumerHealthMember 2015-01-01 2015-12-31 0001648257 2016-03-17 2016-03-17 0001648257 country:CN 2017-01-01 2017-12-31 0001648257 country:CN 2016-01-01 2016-12-31 0001648257 country:CN 2015-01-01 2015-12-31 0001648257 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0001648257 us-gaap:ParentMember 2015-01-01 2015-12-31 0001648257 us-gaap:NoncontrollingInterestMember 2015-01-01 2015-12-31 0001648257 us-gaap:MaximumMember hcm:LicenseAndCollaborationAgreementAstrazenecaMember 2017-01-01 2017-12-31 0001648257 hcm:LicenseAndCollaborationAgreementEliLillyMember 2017-01-01 2017-12-31 0001648257 us-gaap:MaximumMember hcm:LicenseAndCollaborationAgreementAstrazenecaMember 2016-01-01 2016-12-31 0001648257 hcm:LicenseAndCollaborationAgreementEliLillyMember 2016-01-01 2016-12-31 0001648257 us-gaap:MaximumMember hcm:LicenseAndCollaborationAgreementAstrazenecaMember 2015-01-01 2015-12-31 0001648257 hcm:LicenseAndCollaborationAgreementEliLillyMember 2015-01-01 2015-12-31 0001648257 2015-12-31 0001648257 2015-01-01 2015-12-31 0001648257 us-gaap:MachineryAndEquipmentMember 2017-12-31 0001648257 us-gaap:FurnitureAndFixturesMember 2017-12-31 0001648257 us-gaap:MachineryAndEquipmentMember 2017-01-01 2017-12-31 0001648257 us-gaap:LeaseholdImprovementsMember 2017-01-01 2017-12-31 0001648257 us-gaap:FurnitureAndFixturesMember 2017-01-01 2017-12-31 0001648257 us-gaap:BuildingMember 2017-01-01 2017-12-31 0001648257 us-gaap:MachineryAndEquipmentMember 2016-01-01 2016-12-31 0001648257 us-gaap:LeaseholdImprovementsMember 2016-01-01 2016-12-31 0001648257 us-gaap:FurnitureAndFixturesMember 2016-01-01 2016-12-31 0001648257 us-gaap:BuildingMember 2016-01-01 2016-12-31 0001648257 2016-01-01 2016-12-31 0001648257 hcm:LoanPayableToNonControllingShareholdersOfSubsidiariesMember hcm:NonControllingShareholdersOfSubsidiariesMember 2017-12-31 0001648257 hcm:InterestPayableToNonControllingShareholdersOfSubsidiariesMember hcm:NonControllingShareholdersOfSubsidiariesMember 2017-12-31 0001648257 hcm:NonControllingShareholdersOfSubsidiariesMember 2017-12-31 0001648257 hcm:InterestPayableToNonControllingShareholdersOfSubsidiariesMember hcm:NonControllingShareholdersOfSubsidiariesMember 2016-12-31 0001648257 hcm:NonControllingShareholdersOfSubsidiariesMember 2016-12-31 0001648257 2016-12-31 0001648257 2017-12-31 0001648257 2017-01-01 2017-12-31 iso4217:GBP iso4217:GBP xbrli:shares hcm:claim iso4217:HKD iso4217:USD xbrli:shares hcm:item hcm:agreement hcm:area hcm:installment xbrli:pure iso4217:USD xbrli:shares false --12-31 FY 2017 2017-12-31 20-F 0001648257 66447037 Yes Large Accelerated Filer Hutchison China MediTech Ltd No Yes 31716000 14000 14000 40953000 1630000 80000 1550000 4078000 4729000 -948000 -67000 -614000 -265000 -2000 952000 65000 599000 284000 4000 -255000 255000 1408000 -208000 242000 3664000 1269000 876000 74000 199000 -170000 1907000 1800000 100000 1679000 1700000 100000 1655000 1600000 100000 0.5 0.1 7000000 24690000 38589000 45250000 <div> <div> Convertible Preferred Shares         When the Company or its subsidiaries issue preferred shares, the Group assesses whether such instruments should be liabilities, mezzanine equity, or permanent equity classified based on multiple indicators such as redemption features, conversion features, voting rights and other embedded features. Freestanding equity instruments with mandatory redemption requirements, embodying an obligation to repurchase the issuer's equity shares by transferring assets, or certain obligations to issue a variable number of shares, are treated as liability-classified instruments. Equity instruments that are redeemable at the option of the holder or not solely within the Group's control are classified as mezzanine equity of the issuer entity (and redeemable non-controlling interests in the consolidated financial statements of the Group if preferred shares are issued by its subsidiaries). Subsequent measurements of financing instruments are driven by the instruments' balance sheet classification.         The Group also reviews the terms of each convertible instrument and determines whether the host instrument is more akin to debt or equity based on the economic characteristics and risks in order to evaluate if there were any embedded features which would require bifurcation and separate accounting from the host contract. For embedded conversion features that are not required to be separated, the Group analyzes the accounting conversion price and the Company's share price at the commitment date to identify any beneficial conversion features.         For any amendment to the terms of the preferred shares not classified as liabilities, the Group assesses whether the amendment is an extinguishment or a modification using the fair value model. The Group considers a significant change in fair value immediately after the amendment to be substantive and to trigger extinguishment. A change in fair value which is not significant immediately after the amendment is considered non-substantive and thus is subject to modification accounting. When preferred shares are extinguished, the difference between the fair value of the consideration transferred to the preferred shareholders and the carrying amount of such preferred shares (net of issuance costs) is treated as a deemed dividend to the preferred shareholders. When preferred shares are modified and such modification results in a value transfer between preferred shareholders and ordinary shareholders, the change in fair value resulting from the amendment is treated as a deemed dividend to or from the preferred shareholders. <div /></div> </div> 471000 471000 320000 0.0095 0.0094 0.0076 12000 23000 32000 1755000 1790000 2263000 1988000 3125000 34000 20145000 31028000 6601000 9886000 11410000 -235000 -825000 1141000 -901000 -288000 -89000 -34000 -21000 -387000 -1493000 -558000 -88000 -311000 283000 -24000 -32000 -18000 -152000 -147000 -236000 1216000 3532000 1980000 -321000 -1526000 -3179000 <div> <div> Defined Contribution Plans         The Group's subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which certain retirement, medical and other welfare benefits are provided to employees. The relevant labor regulations require the Group's subsidiaries in the PRC to pay the local labor and social welfare authority's monthly contributions at a stated contribution rate based on the monthly basic compensation of qualified employees. The relevant local labor and social welfare authorities are responsible for meeting all retirement benefits obligations and the Group's subsidiaries in the PRC have no further commitments beyond their monthly contributions. The contributions to the plan are expensed as incurred.         The Group also makes payments to other defined contribution plans for the benefit of employees employed by subsidiaries outside the PRC. The defined contribution plans are generally funded by the relevant companies and by payments from employees.         The Group's contributions to defined contribution plans for the years ended December 31, 2017, 2016 and 2015 amounted to US$2,092,000, US$2,286,000 and US$1,653,000 respectively. <div /></div> </div> 80857000 325032000 57000 15000 42000 42000 0.05 0.05 0.05 0.25 0.25 0.25 0.1 0.1 0.1 0.5 0.5 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Property, plant and equipment </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Contracted but not provided for </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,034 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,162 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 99.98%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:67.52%;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:29.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:67.52%;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;padding:0pt;">   </td> <td valign="bottom" style="width:14.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> <td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:67.52%;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:29.36%;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:67.52%;background-color: #A8D3EC;padding:0pt;"> HBYS </td> <td valign="bottom" style="width:02.04%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:14.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,308 </td> <td valign="bottom" style="width:01.08%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:14.16%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,536 </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:67.52%;padding:0pt;"> SHPL </td> <td valign="bottom" style="width:02.04%;padding:0pt;">   </td> <td valign="bottom" style="width:14.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,417 </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> <td valign="bottom" style="width:14.16%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77,939 </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:67.52%;background-color: #A8D3EC;padding:0pt;"> NSPL </td> <td valign="bottom" style="width:02.04%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:14.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,201 </td> <td valign="bottom" style="width:01.08%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:14.16%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,806 </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:67.52%;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.04%;padding:0pt;">   </td> <td valign="bottom" style="width:14.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>311 </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> <td valign="bottom" style="width:14.16%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>225 </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:67.52%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.04%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:14.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:67.52%;background-color: #A8D3EC;padding:0pt;"> </td> <td valign="bottom" style="width:02.04%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:14.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,237 </td> <td valign="bottom" style="width:01.08%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:14.16%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>158,506 </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:67.52%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.04%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:14.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:67.52%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.04%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:14.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> <a name="_Hlk508391244"></a>  </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Not later than 1 year </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,282 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,511 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Between 1 to 2 years </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>400 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,184 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Between 2 to 3 years </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>151 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Between 3 to 4 years </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>141 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Between 4 to 5 years </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Total minimum lease payments </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,021 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,695 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>     <div /></div> </div> <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health HBYS </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs SHPL </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D NSPL </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Current assets </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101,570 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>123,181 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,535 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>146,350 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,640 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,393 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Non-current assets </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107,226 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>98,554 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103,477 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>97,656 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,000 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,000 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Current liabilities </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(75,787 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(70,218 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(91,665 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(86,946 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,239 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,782 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Non-current liabilities </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18,748 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18,148 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,616 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,926 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Net assets </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114,261 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133,369 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132,731 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150,134 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,401 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,611 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Non-controlling interests </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,645 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,297 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>110,616 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,072 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132,731 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150,134 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,401 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,611 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health HBYS </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs SHPL </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D(note (a)) NSPL </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="17" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Revenue </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>227,422 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>224,131 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>211,603 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>244,557 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>222,368 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>181,140 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Gross profit </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91,458 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,355 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91,461 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>175,965 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>158,131 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,608 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Depreciation and amortization </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,985 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,958 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,274 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,942 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,526 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,765 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest income </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>238 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>628 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>757 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>565 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>306 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Finance cost </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(117 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(123 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(158 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Profit/(loss) before taxation </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,434 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,759 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,164 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,497 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>148,144 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,401 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,210 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,482 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,552 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Income tax expense (note (b)) </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,629 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,631 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,948 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,874 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,645 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,094 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net income/(loss) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,805 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,128 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,216 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,623 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>120,499 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,307 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,210 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,482 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,552 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Non-controlling interests </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(29 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>248 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>160 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net income/(loss) attributable to the shareholders of equity investee </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,776 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,376 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,376 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,623 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>120,499 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,307 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,210 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,482 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,552 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div> Notes: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"> <tr style="CellSpacing:15;"> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (a)           </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> NSPL only incurred research and development expenses in the periods presented. </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (b)           </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> HBYS and SHPL have been successful in their respective applications to renew the High and New Technology Enterprise ("HNTE") status. Accordingly, the companies were eligible to use a preferential income tax rate of 15% for the years ended December 31, 2017, 2016 and 2015. </td> </tr> </table></div>   <div /></div> </div> 14000000 3274000 2765000 2958000 3526000 4985000 6942000 6410000 6410000 6000000 55057000 45128000 81299000 158000 123000 117000 25164000 -7552000 37401000 23759000 -8482000 148144000 24434000 -9210000 66497000 3948000 6094000 3631000 27645000 3629000 10874000 628000 306000 238000 565000 220000 757000 10000000 14000000 -160000 -248000 29000 21216000 -7552000 31307000 20128000 -8482000 120499000 20805000 -9210000 55623000 -4949000 -3540000 -8827000 -8571000 7896000 8273000 <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health HBYS </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs SHPL </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D NSPL </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="17" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Opening net assets after non-controlling interests as at January 1 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,072 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>121,523 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>111,506 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150,134 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>93,263 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71,906 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,611 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,093 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,645 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net income/(loss) attributable to the shareholders of equity investee </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,776 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,376 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,376 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,623 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>120,499 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,307 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,210 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,482 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,552 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Dividends declared </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(45,128 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,000 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,410 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(81,299 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55,057 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,410 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Other comprehensive income/(loss) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,896 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,827 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,949 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,273 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,571 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,540 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Investments </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,000 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,000 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Capitalization of loans </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,000 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Closing net assets after non-controlling interests as at December 31 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>110,616 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,072 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>121,523 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132,731 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150,134 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>93,263 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,401 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,611 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,093 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Group's share of net assets </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,308 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,536 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,762 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,365 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75,067 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,632 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,201 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,806 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,046 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,052 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,872 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,077 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Carrying amount of investments as at December 31 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,308 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,536 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,762 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,417 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77,939 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49,709 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,201 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,806 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,046 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div> Foreign Currency Risk         The Group's operating transactions and its assets and liabilities are mainly denominated in RMB, which is not freely convertible into foreign currencies. In the PRC, the Group's cash and cash equivalents denominated in RMB are subject to such government controls. The value of the RMB is subject to fluctuations from central government policy changes and international economic and political developments that affect the supply and demand of RMB in the foreign exchange market. In the PRC, certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange rates set by the People's Bank of China (the "PBOC"). Remittances in currencies other than RMB by the Group in the PRC must be processed through the PBOC or other PRC foreign exchange regulatory bodies which require certain supporting documentation in order to complete the remittance. <div /></div> </div> <div> <div> 21. Government Incentives         The Group receives government grants from the PRC Government (including the National level and Shanghai Municipal City). These grants are given in support of drug research and development activities and are conditional upon i) the Group spending a predetermined amount, regardless of success or failure of the research and development projects and ii) the achievement of certain stages of research and development projects being approved by the relevant PRC government authority. These government grants are subject to ongoing reporting and monitoring by the PRC Government over the period of the grant.         Government incentives, which are deferred and recognized in the consolidated statements of operations over the period necessary to match them with the costs that they are intended to compensate, are recognized in other payable, accruals and advance receipts (Note 13) and other non-current liabilities. They are refundable to the PRC Government if the related research and development projects are suspended. For the years ended December 31, 2017, 2016 and 2015, the Group received government grants of US$1,323,000, US$1,872,000 and US$4,898,000 respectively.         The government grants recorded as a reduction to research and development expenses for the years ended December 31, 2017, 2016 and 2015 were US$876,000 US$1,269,000 and US$3,664,000 respectively. <div /></div> </div> <div> <div> Government Incentives         Incentives from governments are recognized at their fair values. Government incentives that are received in advance are deferred and recognized in the consolidated statements of operations over the period necessary to match them with the costs that they are intended to compensate. Government incentives in relation to the achievement of stages of research and development projects are recognized in the consolidated statements of operations when amounts have been received and all attached conditions have been met. Non-refundable incentives received without any further obligations or conditions attached are recognized immediately in the consolidated statements of operations. <div /></div> </div> 471000 471000 320000 -9587000 -11186000 1718000 -169000 676000 1211000 -119000 -46227000 -13306000 3736000 -493000 2377000 1852000 -36657000 -53301000 -12677000 6879000 578000 3272000 3029000 -47503000 -2953000 453000 2531000 -34000 -21000 -387000 1216000 3532000 1980000 2132000 131000 -275000 -4000 -163000 16000 4660000 7554000 5194000 33000 144000 <div> <div> Interest Income         Interest generated from cash and cash equivalents and short-term investments is recorded over the period earned. It is measured based on the actual amount of interest the Group earns. <div /></div> </div> -1000 -5000 9000 1220000 1220000 1261000 1261000 <div> <div> Leasehold Land         Leasehold land represents fees paid to acquire the right to use the land on which various plants and buildings are situated for a specified period of time from the date the respective right was granted and are stated at cost less accumulated amortization and impairment loss, if any. Amortization is computed using the straight-line basis over the lease period of 50 years. <div /></div> </div> 86500000 120000000 50000000 2 20000000 6500000 <div> <div> 27. Litigation         From time to time, the Group may become involved in litigation relating to claims arising from the ordinary course of business. The Group believes that there are currently no claims or actions pending against the Group, the ultimate disposition of which could have a material adverse effect on the Group's results of operations, financial position or cash flows. However, litigation is subject to inherent uncertainties and the Group's view of these matters may change in the future. When an unfavorable outcome occurs, there exists the possibility of a material adverse impact on the Group's financial position and results of operations for the periods in which the unfavorable outcome occurs, and potentially in future periods. <div /></div> </div> 1550000 2 2 2 2 1 1 1 3651000 65195000 53194000 50494000 807000 858000 34059000 36188000 4012000 4261000 32859000 42385000 13436000 -10958000 28204000 10549000 16443000 1212000 -3810000 20519000 -12922000 74278000 9729000 62696000 1853000 -40837000 -18428000 -11584000 45142000 10979000 31121000 3042000 -51986000 <div> <div> Ordinary Shares         The Company's ordinary shares are stated at par value of US$1.00 per ordinary share. The difference between the consideration received, net of issuance cost, and the par value is recorded in additional paid-in capital. <div /></div> </div> 1771000 1648000 6000000 3000000 3000000 <div> <div> 8. Other Receivables, Prepayments and Deposits         Other receivables, prepayments and deposits consisted of the following:                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Prepayments </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,565 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>699 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Purchase rebates </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>284 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>238 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Other service receivables </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>490 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>756 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Deposits </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>932 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>620 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Value-added tax receivables </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,436 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,380 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest receivables </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>506 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Others </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,083 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>558 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,296 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,314 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> 4314000 11296000 756000 490000 <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:38.28%;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:16.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Equity interest attributable to the Group </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:38.28%;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;">   </td> <td rowspan="2" valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td colspan="3" rowspan="2" valign="bottom" style="width:16.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> As at December 31, </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:38.28%;padding:0pt;">   </td> <td rowspan="2" valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td rowspan="2" valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Place of establishment and operations </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:38.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Name </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Principal activities </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;background-color: #A8D3EC;padding:0pt;"> Subsidiaries </td> <td valign="top" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:11.58%;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:31.68%;background-color: #A8D3EC;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;padding:0pt;"> Hutchison MediPharma Limited ("HMPL") </td> <td valign="top" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;"> PRC </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99.75% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99.75% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;"> Research and development of pharmaceutical products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;background-color: #A8D3EC;padding:0pt;"> Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm") </td> <td valign="top" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:11.58%;background-color: #A8D3EC;padding:0pt;"> PRC </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:31.68%;background-color: #A8D3EC;padding:0pt;"> Provision of sales, distribution and marketing services to pharmaceutical manufacturers </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;padding:0pt;"> Hutchison Hain Organic (Hong Kong) Limited ("HHOL") (note (a)) </td> <td valign="top" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;"> Wholesale and trading of healthcare and consumer products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;background-color: #A8D3EC;padding:0pt;"> Hutchison Hain Organic (Guangzhou) Limited ("HHOGZL") (note (a)) </td> <td valign="top" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:11.58%;background-color: #A8D3EC;padding:0pt;"> PRC </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:31.68%;background-color: #A8D3EC;padding:0pt;"> Wholesale and trading of healthcare and consumer products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;padding:0pt;"> Hutchison Healthcare Limited ("HHL") </td> <td valign="top" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;"> PRC </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;"> Manufacture and distribution of healthcare products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;background-color: #A8D3EC;padding:0pt;"> Hutchison Consumer Products Limited </td> <td valign="top" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:11.58%;background-color: #A8D3EC;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:31.68%;background-color: #A8D3EC;padding:0pt;"> Wholesale and trading of healthcare and consumer products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;padding:0pt;"> Equity investees </td> <td valign="top" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;background-color: #A8D3EC;padding:0pt;"> Shanghai Hutchison Pharmaceuticals Limited ("SHPL") </td> <td valign="top" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:11.58%;background-color: #A8D3EC;padding:0pt;"> PRC </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:31.68%;background-color: #A8D3EC;padding:0pt;"> Manufacture and distribution of prescription drug products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;padding:0pt;"> Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS") (note (b)) </td> <td valign="top" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;"> PRC </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;"> Manufacture and distribution of over-the-counter drug products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;background-color: #A8D3EC;padding:0pt;"> Nutrition Science Partners Limited ("NSPL") (note (c)) </td> <td valign="top" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:11.58%;background-color: #A8D3EC;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49.88% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49.88% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:31.68%;background-color: #A8D3EC;padding:0pt;"> Research and development of pharmaceutical products </td> </tr> </table></div> Notes: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"> <tr style="CellSpacing:15;"> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (a)           </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> HHOL and HHOGZL are regarded as subsidiaries of the Company, as while both shareholders of these subsidiaries have equal representation at their respective boards, in the event of a deadlock, the Group has a casting vote and is therefore able to unilaterally control the financial and operating policies of HHOL and HHOGZL. </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (b)           </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> The 50% equity interest in HBYS is held by an 80% owned subsidiary of the Group. The effective equity interest of the Group in HBYS is therefore 40% for the years presented. </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (c)           </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> The 50% equity interest in NSPL is held by a 99.75% owned subsidiary of the Group. The effective equity interest of the Group in NSPL is therefore 49.88% for the years presented. </td> </tr> </table></div>   <div /></div> </div> <div> <div> 2. Particulars of Principal Subsidiaries and Equity Investees                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:38.28%;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:16.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Equity interest attributable to the Group </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:38.28%;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;">   </td> <td rowspan="2" valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td colspan="3" rowspan="2" valign="bottom" style="width:16.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> As at December 31, </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:38.28%;padding:0pt;">   </td> <td rowspan="2" valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td rowspan="2" valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Place of establishment and operations </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:38.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Name </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Principal activities </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;background-color: #A8D3EC;padding:0pt;"> Subsidiaries </td> <td valign="top" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:11.58%;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:31.68%;background-color: #A8D3EC;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;padding:0pt;"> Hutchison MediPharma Limited ("HMPL") </td> <td valign="top" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;"> PRC </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99.75% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99.75% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;"> Research and development of pharmaceutical products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;background-color: #A8D3EC;padding:0pt;"> Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm") </td> <td valign="top" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:11.58%;background-color: #A8D3EC;padding:0pt;"> PRC </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:31.68%;background-color: #A8D3EC;padding:0pt;"> Provision of sales, distribution and marketing services to pharmaceutical manufacturers </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;padding:0pt;"> Hutchison Hain Organic (Hong Kong) Limited ("HHOL") (note (a)) </td> <td valign="top" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;"> Wholesale and trading of healthcare and consumer products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;background-color: #A8D3EC;padding:0pt;"> Hutchison Hain Organic (Guangzhou) Limited ("HHOGZL") (note (a)) </td> <td valign="top" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:11.58%;background-color: #A8D3EC;padding:0pt;"> PRC </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:31.68%;background-color: #A8D3EC;padding:0pt;"> Wholesale and trading of healthcare and consumer products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;padding:0pt;"> Hutchison Healthcare Limited ("HHL") </td> <td valign="top" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;"> PRC </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;"> Manufacture and distribution of healthcare products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;background-color: #A8D3EC;padding:0pt;"> Hutchison Consumer Products Limited </td> <td valign="top" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:11.58%;background-color: #A8D3EC;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:31.68%;background-color: #A8D3EC;padding:0pt;"> Wholesale and trading of healthcare and consumer products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;padding:0pt;"> Equity investees </td> <td valign="top" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;background-color: #A8D3EC;padding:0pt;"> Shanghai Hutchison Pharmaceuticals Limited ("SHPL") </td> <td valign="top" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:11.58%;background-color: #A8D3EC;padding:0pt;"> PRC </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:31.68%;background-color: #A8D3EC;padding:0pt;"> Manufacture and distribution of prescription drug products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;padding:0pt;"> Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS") (note (b)) </td> <td valign="top" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:11.58%;padding:0pt;"> PRC </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40% </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:31.68%;padding:0pt;"> Manufacture and distribution of over-the-counter drug products </td> </tr> <tr style="CellSpacing:0;"> <td valign="top" style="width:38.28%;background-color: #A8D3EC;padding:0pt;"> Nutrition Science Partners Limited ("NSPL") (note (c)) </td> <td valign="top" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:11.58%;background-color: #A8D3EC;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49.88% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49.88% </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:31.68%;background-color: #A8D3EC;padding:0pt;"> Research and development of pharmaceutical products </td> </tr> </table></div> Notes: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"> <tr style="CellSpacing:15;"> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (a)    </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> HHOL and HHOGZL are regarded as subsidiaries of the Company, as while both shareholders of these subsidiaries have equal representation at their respective boards, in the event of a deadlock, the Group has a casting vote and is therefore able to unilaterally control the financial and operating policies of HHOL and HHOGZL. </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (b)    </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> The 50% equity interest in HBYS is held by an 80% owned subsidiary of the Group. The effective equity interest of the Group in HBYS is therefore 40% for the years presented. </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (c)    </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> The 50% equity interest in NSPL is held by a 99.75% owned subsidiary of the Group. The effective equity interest of the Group in NSPL is therefore 49.88% for the years presented. </td> </tr> </table></div>   <div /></div> </div> 0.05 0.03 0.015 1 1 4898000 1872000 1323000 292690000 <div> <div> Profit Appropriation and Statutory Reserves         The Group's subsidiaries and equity investees established in the PRC are required to make appropriations to certain non-distributable reserve funds.         In accordance with the laws applicable to the Foreign Investment Enterprises established in the PRC, the Group's subsidiaries and equity investees registered as wholly-owned foreign enterprise have to make appropriations from its after-tax profit (as determined under generally accepted accounting principles in the PRC ("PRC GAAP") to reserve funds including general reserve fund, the enterprise expansion fund and staff bonus and welfare fund. The appropriation to the general reserve fund must be at least 10% of the after-tax profits calculated in accordance with PRC GAAP. Appropriation is not required if the general reserve fund has reached 50% of the registered capital of the company. Appropriation to the enterprise expansion fund and staff bonus and welfare fund is made at the company's discretion.         The use of the general reserve fund, enterprise expansion fund, statutory surplus reserve and discretionary surplus fund are restricted to the offsetting of losses or increases the registered capital of the respective company. The staff bonus and welfare fund is a liability in nature and is restricted to fund payments of special bonus to employees and for the collective welfare of employees. All these reserves are not allowed to be transferred to the company in terms of cash dividends, loans or advances, nor can they be distributed except under liquidation. <div /></div> </div> -1559000 -160000 -53000 -921000 -423000 -2000 1680000 140000 204000 920000 410000 6000 37000 163000 128000 238000 284000 <div> <div>                                                                                                                                                                                                  <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 95.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.98%;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Net (loss)/income </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,963 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,557 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,427 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Adjustments to reconcile net (loss)/income to net cash used in operating activities </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Amortization of finance costs </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>147 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>92 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Depreciation and amortization </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,578 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,341 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,015 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Loss on retirement of property, plant and equipment </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Provision for excess and obsolete inventories </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16 </td> <td valign="bottom" style="width:02.64%;"> ) </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>163 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Provision for doubtful accounts </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>242 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(208 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,408 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Share-based compensation expense—share options </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,316 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,780 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,151 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Share-based compensation expense—LTIP </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,423 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,661 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>308 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Equity in earnings of equity investees, net of tax </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(33,653 </td> <td valign="bottom" style="width:02.64%;"> ) </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(66,244 </td> <td valign="bottom" style="width:02.76%;"> ) </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,572 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Dividends received from equity investees </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,586 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,528 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,410 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Unrealized currency translation (gain)/loss </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(399 </td> <td valign="bottom" style="width:02.64%;"> ) </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>633 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>198 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Changes in income tax balances </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(756 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,667 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,093 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Changes in working capital </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Accounts receivable—third parties </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,160 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,258 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,030 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Accounts receivable—related parties </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>363 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,354 </td> <td valign="bottom" style="width:02.76%;"> ) </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>315 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Other receivables, prepayments and deposits </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,982 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,129 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(459 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Amounts due from related parties </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,157 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,010 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Inventories </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,049 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,430 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,154 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Long-term prepayment </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>123 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>361 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,132 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Accounts payable </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,173 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,452 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,659 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Other payables, accruals and advance receipts </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,194 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,554 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,660 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Deferred revenue </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(897 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,668 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,907 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Other deferred income </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(275 </td> <td valign="bottom" style="width:02.64%;"> ) </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>131 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,132 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Amounts due to related parties </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,287 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,385 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,977 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.20%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Total changes in working capital </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,505 </td> <td valign="bottom" style="width:02.64%;"> ) </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,431 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,949 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.20%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Net cash used in operating activities </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,943 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,569 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,385 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.20%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.20%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div> 26. Note to Consolidated Statements of Cash Flows         Reconciliation of net (loss)/income for the year to net cash used in operating activities:                                                                                                                                                                                                   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 95.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.98%;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Net (loss)/income </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,963 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,557 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,427 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Adjustments to reconcile net (loss)/income to net cash used in operating activities </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Amortization of finance costs </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>147 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>92 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Depreciation and amortization </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,578 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,341 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,015 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Loss on retirement of property, plant and equipment </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Provision for excess and obsolete inventories </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16 </td> <td valign="bottom" style="width:02.64%;"> ) </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>163 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Provision for doubtful accounts </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>242 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(208 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,408 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Share-based compensation expense—share options </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,316 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,780 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,151 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Share-based compensation expense—LTIP </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,423 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,661 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>308 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Equity in earnings of equity investees, net of tax </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(33,653 </td> <td valign="bottom" style="width:02.64%;"> ) </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(66,244 </td> <td valign="bottom" style="width:02.76%;"> ) </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,572 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Dividends received from equity investees </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,586 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,528 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,410 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Unrealized currency translation (gain)/loss </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(399 </td> <td valign="bottom" style="width:02.64%;"> ) </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>633 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>198 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Changes in income tax balances </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(756 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,667 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,093 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Changes in working capital </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Accounts receivable—third parties </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,160 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,258 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,030 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Accounts receivable—related parties </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>363 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,354 </td> <td valign="bottom" style="width:02.76%;"> ) </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>315 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Other receivables, prepayments and deposits </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,982 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,129 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(459 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Amounts due from related parties </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,157 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,010 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Inventories </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,049 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,430 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,154 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Long-term prepayment </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>123 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>361 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,132 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Accounts payable </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,173 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,452 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,659 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Other payables, accruals and advance receipts </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,194 </td> <td valign="bottom" style="width:02.64%;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,554 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,660 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Deferred revenue </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(897 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,668 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,907 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Other deferred income </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(275 </td> <td valign="bottom" style="width:02.64%;"> ) </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>131 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,132 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Amounts due to related parties </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,287 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,385 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,977 </td> <td valign="bottom" style="width:00.72%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.20%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;padding:0pt;"> Total changes in working capital </td> <td valign="bottom" style="width:02.20%;padding:0pt;">   </td> <td valign="bottom" style="width:07.76%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,505 </td> <td valign="bottom" style="width:02.64%;"> ) </td> <td valign="bottom" style="width:06.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,431 </td> <td valign="bottom" style="width:02.76%;padding:0pt;">   </td> <td valign="bottom" style="width:08.12%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,949 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.20%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #A8D3EC;padding:0pt;"> Net cash used in operating activities </td> <td valign="bottom" style="width:02.20%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:07.76%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,943 </td> <td valign="bottom" style="width:02.64%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:06.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,569 </td> <td valign="bottom" style="width:02.76%;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:08.12%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,385 </td> <td valign="bottom" style="width:00.72%;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.20%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:69.10%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.20%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.64%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.76%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.72%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>     <div /></div> </div> <div> <div> 16. Redeemable Non-controlling Interests         As at December 31, 2017 and 2016, no redeemable non-controlling interests were outstanding.         In November and December 2010, the Company and HMHL, entered into subscription and shareholders' agreements ("SSAs") with Mitsui & Co., Ltd. ("Mitsui") and SBCVC Fund III Company Limited ("SBCVC") (collectively, the "preferred shareholders"), whereby HMHL issued 7,390,029 redeemable convertible preferred shares ("Preferred Shares") for an aggregate consideration of US$20.1 million. The Preferred Shares on an as-if-converted basis represented approximately 19.76% of the aggregate issued and outstanding share capital of HMHL on the closing date.         In October 2012, the Company repurchased all 2,815,249 Preferred Shares from SBCVC. The remaining 4,574,780 Preferred Shares of US$12.5 million held by Mitsui represented approximately 12.24% of HMHL on a fully diluted basis.         In May and June 2014, the Company and HMHL further entered into two subscription agreements with Mitsui, whereby HMHL issued a total of 672,713 HMHL's Preferred Shares to Mitsui and 4,825,418 HMHL's ordinary shares to the Company for an aggregate consideration of US$25.0 million, after which Mitsui's interest in HMHL remained at 12.24% on a fully diluted basis.         On July 23, 2015, the Company entered into a subscription agreement with Mitsui under which the Company issued 3,214,404 new ordinary shares of the Company valued at approximately US$84.0 million in exchange for the Preferred Shares held by Mitsui with carrying value of US$84.0 million (including accretion adjustment up to July 23, 2015). The transaction was completed on July 23, 2015 and as a result of this transaction, Mitsui held approximately 5.69% of the enlarged share capital of the Company at that time. The outstanding balance of redeemable non-controlling interests was extinguished with the corresponding increase in the Company's shares and additional paid-in capital. Accounting for preferred shares         The Preferred Shares were redeemable upon occurrence of an event that is not solely within the control of the issuer. Accordingly, the Preferred Shares were recorded and accounted for as redeemable non-controlling interests outside of permanent equity in the Group's consolidated balance sheets. The Group recorded accretion when it was probable that the Preferred Shares will become redeemable. The accretion, which increases the carrying value of the redeemable non-controlling interests, was recorded against retained earnings, or in the absence of retained earnings, by recording against the additional paid-in capital. During the year ended December 31, 2015, HMHL recorded an accretion of US$43,001,000 to the Preferred Shares based on such preferred shareholder's share of the estimated valuation of HMHL. <div /></div> </div> 11771000 14613000 <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Clinical trial related costs </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45,250 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,589 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,690 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Personnel compensation and related costs </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,848 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,698 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,339 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Other research and development expenses </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,425 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,584 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,339 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75,523 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,871 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47,368 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> 22941000 3500000 19400000 14834000 2700000 12100000 15203000 3100000 12100000 <div> <div> 19. Revenue from License and Collaboration Agreements—Third Parties                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Milestone revenue </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,457 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,931 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,212 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Amortization of upfront payment </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,655 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,679 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,907 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Research and development services </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,203 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,834 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,941 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,315 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,444 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,060 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>         The revenue is mainly from license and collaboration agreements as follows: License and collaboration agreement with Eli Lilly         On October 8, 2013, the Group entered into a licensing, co-development and commercialization agreement in China with Eli Lilly ("Lilly") relating to fruquintinib, a targeted oncology therapy for the treatment of various types of solid tumors. Under the terms of the agreement, the Group is entitled to receive a series of payments of up to US$86.5 million, including upfront payments and development and regulatory approval milestones. Should fruquintinib be successfully commercialized in China, the Group would receive tiered royalties based on certain percentages of net sales. Development costs after the first development milestone are shared between the Group and Lilly. Following execution of the agreement, the Group received a non-refundable, upfront payment of US$6.5 million.         In addition, the Group also signed an option agreement which grants Lilly an exclusive option to expand the fruquintinib rights beyond Hong Kong and China. The option agreement further sets out certain milestone payments and royalty rates that apply in the event the option is exercised on a global basis. However, these are subject to further negotiation should the option be exercised on a specific territory basis as opposed to a global basis. The option was not considered to be a separate deliverable in the arrangement as it was not considered to be substantive. As at December 31, 2017, the option has not been exercised.         The license rights to fruquintinib, delivered at the inception of the arrangement, did not have stand-alone value apart from the other deliverables in the arrangement which include the development services, the participation in the joint steering committee and the manufacturing of active pharmaceutical ingredients during the development phase. The non-refundable upfront payment was deferred and is being recognized ratably over the development period. The Group recognizes milestone revenue relating to the deliverables in the agreement as a single unit of accounting using the milestone method.         Under the terms of this agreement, the Group recognized US$4.5 million milestone revenue for the year ended December 31, 2017 in relation to the acceptance of a new drug application by the China Food and Drug Administration for fruquintinib as a treatment of patients with advanced colorectal cancer. For the year ended December 31, 2016, the Group did not recognize any milestone revenue in relation to this contract and for the year ended December 31, 2015, the Group recognized US$19.2 million milestone revenues in relation to the achievement of the "proof of concept" milestone for two indications. The Group recognized US$1.6 million, US$1.7 million and US$1.8 million revenue from amortization of the upfront payment during the years ended December 31, 2017, 2016 and 2015 respectively. In addition, the Group recognized US$12.1 million, US$12.1 million and US$19.4 million revenue from research and development services for the years ended December 31, 2017, 2016 and 2015 respectively. License and collaboration agreement with AstraZeneca         On December 21, 2011, the Group and AstraZeneca ("AZ") entered into a global licensing, co-development, and commercialization agreement for savolitinib ("AZ Agreement"), a novel targeted therapy and a highly selective inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer. Under the terms of the agreement, development costs for savolitinib in China will be shared between the Group and AZ, with the Group continuing to lead the development in China. AZ will lead and pay for the development of savolitinib for the rest of the world. The Group received a non-refundable upfront payment of US$20.0 million upon the signing of the agreement and may receive up to US$120.0 million contingent upon the successful achievement of clinical development and first-sale milestones. The agreement also contains possible significant future commercial sale milestones and up to double-digit percentage royalties on net sales.         The license right to develop savolitinib in the rest of the world was delivered to AZ at the inception of the arrangement. Such license had stand-alone value apart from the other deliverables in the arrangement which include the development of savolitinib in China and the participation in the joint steering committee. The non-refundable up-front payment was allocated to (a) the license to develop savolitinib in the rest of the world, which was recognized at inception and (b) the research and development services for which the amount allocated has been deferred and is being recognized ratably over the development period. The Group recognizes milestone revenue relating to the deliverables in the agreement as a single unit of accounting using the milestone method.         Under the terms of this agreement, the Group recognized US$5.0 million milestone revenue for the year ended December 31, 2017 in relation to the Phase III initiation for the secondary indication, papillary renal cell carcinoma, and US$9.9 million milestone revenue for the year ended December 31, 2016 in relation to the Phase IIb initiation for the primary indication, non-small cell lung cancer. For the year ended December 31, 2015, the Group did not recognize any milestone revenue in relation to this contract. The Group recognized less than US$0.1 million revenue from amortization of the up-front payment for each of the years ended December 31, 2017, 2016 and 2015. In addition, the Group recognized US$3.1 million, US$2.7 million and US$3.5 million revenue from research and development services for the years ended December 31, 2017, 2016 and 2015 respectively.         In August 2016, the Group entered into an amendment to the AZ Agreement. Under the terms of the amendment, the Group shall pay for up to a maximum of US$50 million of phase III clinical trial costs related to developing savolitinib for papillary renal cell carcinoma. In return, AZ agrees to increase ex-China royalties on net sales by an additional 5% over the royalties stipulated in the original agreement until cumulative additional royalties paid reaches US$250 million, after which the additional royalty decreases to 3% for 24 months and then 1.5% thereafter. The costs of the additional Phase III clinical trial costs shall be expensed to research and development expense as incurred. Under the current revenue recognition policy, future royalties shall be recognized as revenue from license and collaboration agreements—third parties as net sales occur. The amendment does not impact the original accounting for the AZ Agreement under the milestone method. <div /></div> </div> 2573000 355000 5383000 8429000 9682000 <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.02%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:72.20%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:25.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:72.20%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:72.20%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:25.56%;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:72.20%;background-color: #A8D3EC;padding:0pt;"> Accounts payable—third parties </td> <td valign="bottom" style="width:01.12%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:12.22%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,095 </td> <td valign="bottom" style="width:01.12%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:12.22%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,383 </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:72.20%;padding:0pt;"> Accounts payable—non-controlling shareholders of subsidiaries </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,250 </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,136 </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:72.20%;background-color: #A8D3EC;padding:0pt;"> Accounts payable—related party (Note 22 (ii)) </td> <td valign="bottom" style="width:01.12%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:12.22%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20 </td> <td valign="bottom" style="width:01.12%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:12.22%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19 </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:72.20%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:01.12%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:72.20%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,365 </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> <td valign="bottom" style="width:12.22%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,538 </td> <td valign="bottom" style="width:01.12%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:72.20%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:01.12%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:72.20%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:01.12%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> As at January 1 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,720 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,127 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,793 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Increase in allowance for doubtful accounts </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>242 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,408 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Decrease in allowance due to subsequent collection </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(237 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Write-off </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,874 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Exchange difference </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>170 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(199 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(74 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> As at December 31 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>258 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,720 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,127 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Accounts receivable—third parties </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,846 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Accounts payable </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,250 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,136 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Other payables, accruals and advance receipts </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Loan </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,550 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Interest payable </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,630 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Other non-current liabilities </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Loans </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>579 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,129 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                       <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Accounts receivable—related parties </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Indirect subsidiaries of CK Hutchison (note (a)) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,761 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,589 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Equity investees (note (a)) </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,099 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,634 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,860 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,223 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Accounts payable </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> An indirect subsidiary of CK Hutchison (note (a)) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> An equity investee (note (a)) </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Amounts due from related parties </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> An indirect subsidiary of CK Hutchison (note (a)) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Equity investees (note (a)) </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>893 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,029 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Dividend receivable from an equity investee </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,628 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,544 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,136 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Amounts due to related parties </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Immediate holding company (note (b)) </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,086 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> An indirect subsidiary of CK Hutchison (note (b)) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>454 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>152 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> An equity investee (note (a)) </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,567 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,070 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,021 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,308 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Other deferred income </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> An equity investee (note (c)) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,648 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,771 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Other non-current liabilities </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Immediate holding company (note (d)) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,000 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div> Notes: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"> <tr style="CellSpacing:15;"> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (a)    </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> Balances with related parties are unsecured, interest-free and repayable on demand. The carrying values of balances with related parties approximate their fair values due to their short-term maturities. </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (b)    </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> Amounts due to immediate holding company and an indirect subsidiary of CK Hutchison are unsecured and interest-bearing. During the year ended December 31, 2017, amounts due to immediate holding company were assigned to an indirect subsidiary of CK Hutchison. As at December 31, 2017, approximately US$454,000 (December 31, 2016: US$2,238,000) of such balances are repayable within one year or repayable on demand. </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (c)    </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> Other deferred income represents amounts recognized from granting of promotion and marketing rights. </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (d)    </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> In December 2017, the Group repaid the amount due. As at December 31, 2016, this amount was recorded in non-current liabilities as it was repayable in equal installments of US$3,000,000 in December 2018 and December 2019. </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> As at January 1 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>442 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>112 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Current tax </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,354 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>978 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>565 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Withholding tax upon dividend declaration from PRC entities </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,179 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,526 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>321 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Tax paid </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,836 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,664 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(510 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Exchange difference </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(46 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> As at December 31 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>979 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>442 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> As at January 1 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>160 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Increase in provision for excess and obsolete inventories </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>128 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>163 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Decrease in provision due to subsequent sale or recovery </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(144 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(33 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Write-off </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(32 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Exchange difference </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> As at December 31 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>121 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>160 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;padding:0pt;"> (in US'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> As at January 1 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,989 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,473 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,842 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Utilization of previously recognized withholding tax on undistributed earnings </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,179 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,526 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>321 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> (Charged)/Credited to the consolidated statements of operations </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Withholding tax on undistributed earnings of PRC entities </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,980 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,532 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,216 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Deferred tax on amortization of intangible assets </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Deferred tax on provision for assets </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>236 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>147 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>152 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Exchange differences </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(283 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>311 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> As at December 31 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,819 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,989 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,473 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Prepayments </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,565 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>699 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Purchase rebates </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>284 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>238 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Other service receivables </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>490 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>756 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Deposits </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>932 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>620 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Value-added tax receivables </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,436 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,380 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest receivables </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>506 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Others </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,083 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>558 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,296 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,314 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                                             <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:53.02%;background-color: #A8D3EC;padding:0pt;"> Buildings </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:46.34%;background-color: #A8D3EC;padding:0pt;"> 20 years </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:53.02%;padding:0pt;"> Plant and equipment </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:46.34%;padding:0pt;"> 5-10 years </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:53.02%;background-color: #A8D3EC;padding:0pt;"> Furniture and fixtures, other equipment and motor vehicles </td> <td valign="bottom" style="width:00.64%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:46.34%;background-color: #A8D3EC;padding:0pt;"> 4-5 years </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:53.02%;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:00.64%;padding:0pt;">   </td> <td valign="bottom" style="width:46.34%;padding:0pt;"> Shorter of (a) 5 years or (b) remaining term of lease </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Adjusted LBIT </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(53,301 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(46,227 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,587 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest income </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,220 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>502 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>451 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Equity in earnings of equity investees, net of tax </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,653 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,244 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,572 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,455 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,631 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,404 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Income tax expense </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,080 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,331 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,605 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net (loss)/income </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,963 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,557 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,427 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Sales </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,307 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,274 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,196 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Purchases </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,236 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,225 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,169 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Dividend declared </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,594 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>564 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div> 79000 1367000 5621000 35095 1800000 300000 6000000 400000 6000000 500000 P2D P2D P2D P1D P1D P2Y P2Y P2Y P2Y <div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Weighted-average grant-date fair value of share options granted during the period (in £ per share) </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12.69 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.99 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Total intrinsic value of share options exercised in US$'000 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,290 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,907 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,020 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> 0.25 0.333 0.25 0.25 0.25 0.25 0.25 0.25 0.333 0.25 P4Y 308000 1661000 3423000 0 64000 451000 <div> <div> Short-term Investments         Short-term investments include deposits placed with banks with original maturities of more than three months but less than one year. <div /></div> </div> 3214000 -46000 -8000 8000 2815249 250000000 P186D P91D P90D P7D P183D P91D P90D P7D 24000 -24000 15000 -15000 10000 -10000 1786000 1786000 1786000 604000 604000 604000 1367000 1367000 1367000 <div> <div> Treasury Shares         The Group accounts for treasury shares under the cost method. The treasury shares were purchased for the purpose of the LTIP. <div /></div> </div> 1800000 321000 1526000 3179000 0.0071 0.0058 0.0132 0.0106 <div> <div>                                                                                                                                                                                                                 <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 90.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Bank deposits maturing over three months (note) </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Denominated in: </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> US$ </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>272,659 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,270 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> HK$ </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>372 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>273,031 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,270 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div> Note: The weighted average effective interest rate on bank deposits for the years ended December 31, 2017 and 2016 was 1.32% and 0.71% per annum respectively (with maturity ranging from 91 to 183 days, and 91 to 186 days respectively).   <div /></div> </div> <div> <div> 6. Short-term Investments                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 90.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Bank deposits maturing over three months (note) </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Denominated in: </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> US$ </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>272,659 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,270 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> HK$ </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>372 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>273,031 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,270 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div> Note: The weighted average effective interest rate on bank deposits for the years ended December 31, 2017 and 2016 was 1.32% and 0.71% per annum respectively (with maturity ranging from 91 to 183 days, and 91 to 186 days respectively). <div /></div> </div>

35538000

24365000

19000

20000

30383000

5136000

17095000

7250000

43532000

38668000

40812000

38410000

1846000

4223000

3860000

4223000

1634000

2589000

3860000

1099000

2761000

112000

442000

274000

979000

4340000

4121000

13335000

932000

8784000

3549000

70000

14396000

971000

9105000

4249000

71000

17489000

1141000

10553000

5296000

499000

230000

218000

12000

337000

-4275000

5430000

208196000

496960000

233000

1380000

1378000

2000

1378000

1538000

1537000

1000

1537000

401000

2757000

2751000

6000

2751000

2796000

2792000

4000

2792000

168000

1377000

1373000

4000

1373000

1258000

1255000

3000

1255000

14227000

8610000

88000

308000

233000

14000

75000

74000

1063000

156000

152000

1278000

1661000

1316000

345000

1278000

502000

850000

811000

1284000

3423000

1087000

2336000

1284000

32000

1894000

1529000

1793000

3127000

2720000

258000

2720000

258000

237000

2874000

62000

92000

147000

6847000

7277000

342437000

76120000

212543000

67161000

134681000

10701000

53774000

597932000

339244000

195420000

58961000

122665000

13794000

63268000

167380000

432195000

1054000

31218000

30018000

38946000

31941000

79431000

9505000

408000

4009000

65509000

85265000

15140000

295000

3449000

66381000

79431000

85265000

-7005000

47490000

5834000

-6001000

49269000

3473000

1.00

75000000

60705823

66447037

53076000

56533000

60706000

66447000

60706000

66447000

3138000

2408000

-17032000

1732000

1427000

5033000

4870000

3835000

-11999000

0.23

104859000

12169000

149132000

15225000

169764000

21236000

187974000

262777000

294620000

565000

415000

150000

978000

458000

520000

1354000

782000

572000

899000

1282000

0.0150

0.0135

0.0125

0.0150

0.0125

46923000

30000000

210000000

26923000

78000000

10000000

117000000

15000000

190000000

24359000

P3Y

P4Y

P3Y

P18M

P3Y

P18M

70000000

121282000

0.0139

0.0152

0.0190

356000

2241000

1400000

200000

1040000

3353000

1726000

5361000

4452000

962000

1295000

2039000

809000

20517000

32295000

372000

633000

372000

633000

372000

1267000

7455000

11393000

20145000

31662000

2842000

3473000

4989000

3819000

1364000

3997000

4452000

131000

120000

1653000

2286000

2092000

620000

932000

1908000

2239000

106000

1153000

977000

3000

2478000

105000

1441000

763000

169000

2015000

41000

110000

11000

94000

5000

1864000

2341000

41000

124000

3000

102000

19000

2176000

2578000

27000

151000

17000

116000

18000

2400000

1136000

1029000

107000

8544000

893000

23000

7628000

5308000

2086000

2238000

3070000

152000

7021000

454000

6567000

454000

-0.64

0.20

-0.43

-0.64

0.20

-0.43

0.25

0.165

0.25

0.165

0.25

0.165

-1004000

-1779000

2361000

7057000

9295000

1374000

57000

426000

380000

P3Y1M6D

1539000

8681000

3077000

2872000

3052000

6410000

30528000

55586000

0.40

0.4988

0.50

0.40

0.4988

0.50

60762000

9046000

49709000

158506000

225000

63536000

16806000

77939000

141475000

63536000

16806000

77939000

63536000

77939000

17031000

144237000

311000

55308000

19201000

69417000

124725000

55308000

19201000

69417000

55308000

69417000

19512000

<div> <div> 11. Investments in Equity Investees         Investments in equity investees consisted of the following:                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.02%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:66.28%;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:30.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.14%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:66.28%;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;padding:0pt;">   </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.14%;padding:0pt;">   </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.14%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:66.28%;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:30.56%;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:01.14%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:66.28%;background-color: #A8D3EC;padding:0pt;"> HBYS </td> <td valign="bottom" style="width:02.02%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:14.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,308 </td> <td valign="bottom" style="width:01.14%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:14.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,536 </td> <td valign="bottom" style="width:01.14%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:66.28%;padding:0pt;"> SHPL </td> <td valign="bottom" style="width:02.02%;padding:0pt;">   </td> <td valign="bottom" style="width:14.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,417 </td> <td valign="bottom" style="width:01.14%;padding:0pt;">   </td> <td valign="bottom" style="width:14.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77,939 </td> <td valign="bottom" style="width:01.14%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:66.28%;background-color: #A8D3EC;padding:0pt;"> NSPL </td> <td valign="bottom" style="width:02.02%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:14.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,201 </td> <td valign="bottom" style="width:01.14%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:14.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,806 </td> <td valign="bottom" style="width:01.14%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:66.28%;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.02%;padding:0pt;">   </td> <td valign="bottom" style="width:14.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>311 </td> <td valign="bottom" style="width:01.14%;padding:0pt;">   </td> <td valign="bottom" style="width:14.70%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>225 </td> <td valign="bottom" style="width:01.14%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:66.28%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.02%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:66.28%;background-color: #A8D3EC;padding:0pt;"> </td> <td valign="bottom" style="width:02.02%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:14.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,237 </td> <td valign="bottom" style="width:01.14%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:14.70%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>158,506 </td> <td valign="bottom" style="width:01.14%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:66.28%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.02%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:66.28%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:02.02%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:14.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>         Particulars regarding the principal equity investees are disclosed in Note 2. All of the equity investees are private companies and there are no quoted market prices available for their shares.         Summarized financial information for the significant equity investees HBYS, SHPL and NSPL is as follows: (i)    Summarized balance sheets                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health HBYS </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs SHPL </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D NSPL </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Current assets </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101,570 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>123,181 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,535 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>146,350 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,640 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,393 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Non-current assets </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107,226 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>98,554 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103,477 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>97,656 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,000 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,000 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Current liabilities </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(75,787 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(70,218 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(91,665 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(86,946 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,239 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,782 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Non-current liabilities </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18,748 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18,148 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,616 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,926 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Net assets </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114,261 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133,369 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132,731 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150,134 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,401 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,611 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Non-controlling interests </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,645 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,297 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>110,616 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,072 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132,731 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150,134 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,401 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,611 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div> (ii)   Summarized statements of operations                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health HBYS </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs SHPL </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D(note (a)) NSPL </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="17" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Revenue </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>227,422 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>224,131 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>211,603 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>244,557 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>222,368 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>181,140 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Gross profit </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91,458 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,355 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91,461 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>175,965 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>158,131 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,608 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Depreciation and amortization </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,985 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,958 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,274 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,942 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,526 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,765 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest income </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>238 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>628 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>757 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>565 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>306 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Finance cost </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(117 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(123 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(158 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Profit/(loss) before taxation </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,434 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,759 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,164 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,497 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>148,144 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,401 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,210 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,482 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,552 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Income tax expense (note (b)) </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,629 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,631 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,948 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,874 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,645 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,094 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net income/(loss) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,805 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,128 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,216 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,623 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>120,499 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,307 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,210 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,482 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,552 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Non-controlling interests </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(29 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>248 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>160 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net income/(loss) attributable to the shareholders of equity investee </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,776 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,376 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,376 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,623 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>120,499 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,307 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,210 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,482 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,552 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div> Notes: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"> <tr style="CellSpacing:15;"> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (a)    </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> NSPL only incurred research and development expenses in the periods presented. </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (b)    </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> HBYS and SHPL have been successful in their respective applications to renew the High and New Technology Enterprise ("HNTE") status. Accordingly, the companies were eligible to use a preferential income tax rate of 15% for the years ended December 31, 2017, 2016 and 2015. </td> </tr> </table></div>         For the years ended December 31, 2017, 2016 and 2015, other immaterial equity investees had net income of approximately US$117,000, US$95,000 and US$12,000 respectively. (iii) Reconciliation of summarized financial information         Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees is as follows:                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health HBYS </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs SHPL </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D NSPL </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="17" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Opening net assets after non-controlling interests as at January 1 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,072 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>121,523 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>111,506 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150,134 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>93,263 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71,906 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,611 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,093 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,645 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net income/(loss) attributable to the shareholders of equity investee </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,776 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,376 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,376 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,623 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>120,499 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,307 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,210 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,482 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,552 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Dividends declared </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(45,128 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,000 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,410 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(81,299 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55,057 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,410 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Other comprehensive income/(loss) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,896 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,827 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,949 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,273 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,571 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,540 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Investments </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,000 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,000 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Capitalization of loans </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,000 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Closing net assets after non-controlling interests as at December 31 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>110,616 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,072 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>121,523 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132,731 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150,134 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>93,263 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,401 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,611 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,093 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Group's share of net assets </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,308 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,536 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,762 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,365 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75,067 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,632 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,201 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,806 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,046 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,052 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,872 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,077 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Carrying amount of investments as at December 31 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,308 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,536 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,762 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,417 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77,939 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49,709 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,201 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,806 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:7.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,046 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>         The equity investees had the following lease commitments and capital commitments: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"> <tr style="CellSpacing:15;"> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (a)    </td> <td colspan="3" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> The equity investees lease various factories and offices under non-cancellable operating lease agreements. Future aggregate minimum payments under non-cancellable operating leases as from the dates indicated are as follows: </td> </tr> </table></div>                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:70.54%;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:26.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:70.54%;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> <td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> <td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:70.54%;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:26.64%;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:70.54%;background-color: #A8D3EC;padding:0pt;"> Not later than 1 year </td> <td valign="bottom" style="width:01.40%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:12.62%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,282 </td> <td valign="bottom" style="width:01.40%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:12.62%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,511 </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:70.54%;padding:0pt;"> Between 1 to 2 years </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> <td valign="bottom" style="width:12.62%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>400 </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> <td valign="bottom" style="width:12.62%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,184 </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:70.54%;background-color: #A8D3EC;padding:0pt;"> Between 2 to 3 years </td> <td valign="bottom" style="width:01.40%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:12.62%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>151 </td> <td valign="bottom" style="width:01.40%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:12.62%;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:70.54%;padding:0pt;"> Between 3 to 4 years </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> <td valign="bottom" style="width:12.62%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>141 </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> <td valign="bottom" style="width:12.62%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:70.54%;background-color: #A8D3EC;padding:0pt;"> Between 4 to 5 years </td> <td valign="bottom" style="width:01.40%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:12.62%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47 </td> <td valign="bottom" style="width:01.40%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:12.62%;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:70.54%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:01.40%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:70.54%;padding:0pt;"> Total minimum lease payments </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> <td valign="bottom" style="width:12.62%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,021 </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> <td valign="bottom" style="width:12.62%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,695 </td> <td valign="bottom" style="width:01.40%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:70.54%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:01.40%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:70.54%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:01.40%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="top" style="width:06.96%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (b)      </td> <td valign="top" style="width:93.04%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> Capital commitments </td> </tr> </table></div>         The equity investees had the following capital commitments:                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Property, plant and equipment </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Contracted but not provided for </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,034 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,162 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div>

123181000

5393000

146350000

101570000

9640000

129535000

70218000

1782000

86946000

75787000

1239000

91665000

133369000

33611000

150134000

114261000

38401000

132731000

111506000

25645000

71906000

121523000

18093000

93263000

127072000

33611000

150134000

110616000

38401000

132731000

91461000

127608000

89355000

158131000

91458000

175965000

6297000

3645000

12000

21376000

-7552000

31307000

95000

20376000

-8482000

120499000

117000

20776000

-9210000

55623000

98554000

30000000

97656000

107226000

30000000

103477000

18148000

6926000

18748000

8616000

211603000

181140000

224131000

222368000

227422000

244557000

60762000

9046000

46632000

63536000

16806000

75067000

55308000

19201000

66365000

469000

430000

-79000

-109000

-316000

-60000

-30000

-57000

19620000

21580000

23955000

3137000

407000

2730000

3308000

407000

2901000

-10540000

-47356000

-53536000

22572000

26342000

10689000

15653000

-3770000

66244000

70476000

10188000

60288000

-4232000

33653000

38200000

10388000

27812000

-4547000

510000

2664000

3836000

1605000

1218000

387000

239000

148000

4331000

3762000

569000

-497000

777000

289000

3080000

2068000

986000

-457000

934000

509000

26000

6601000

9886000

11410000

2096000

3205000

3347000

-1739000

-7814000

-8833000

253000

688000

391000

357000

812000

-665000

459000

1129000

6982000

3659000

11452000

-11173000

12030000

7258000

-2160000

-315000

2354000

-363000

-1907000

-1668000

-897000

3010000

-1157000

-220000

3977000

-1385000

-4287000

1093000

1667000

-756000

5154000

3430000

-1049000

9949000

-3431000

14505000

2132000

-361000

-123000

43001000

255877

1404000

1319000

85000

1631000

1552000

78000

79000

1455000

1389000

66000

144000

152000

132000

1220000

1570000

763000

63000

506000

12162000

11475000

12822000

11789000

660000

314000

34000

25000

160000

121000

451000

228000

144000

29000

114000

1000

79000

502000

384000

66000

34000

31000

1000

52000

1220000

1093000

63000

13000

37000

13000

64000

24270000

273031000

17339000

21698000

24848000

P50Y

138377000

112966000

342437000

597932000

95119000

104600000

44060000

26444000

26315000

20000000

2564000

234000000

30000000

468000000

60000000

546000000

70000000

156000000

20000000

195000000

25000000

400000000

51282000

210000000

26923000

546000000

70000000

946000000

121282000

46787000

29987000

19957000

29987000

20000000

30000000

26923000

26830000

2545000

6162000

161000

1034000

19790000

23233000

590000

564000

1594000

0.1976

0.1224

0.0569

0.5000

1.00

0.50

1.00

0.9975

0.51

0.40

0.4988

0.80

0.9975

1.00

0.50

1.00

0.9975

0.51

0.40

0.4988

0.80

0.9975

-5471000

92435000

273196000

8855000

-33597000

-260780000

-9385000

-9569000

-8943000

7993000

-13352000

25155000

8640000

15934000

581000

-3810000

11698000

-17904000

70337000

8384000

61120000

833000

-40735000

-26737000

-14890000

40033000

9773000

28999000

1261000

-51880000

2434000

2859000

3774000

43001000

-35008000

11698000

-26737000

-35008000

11698000

-26737000

-769000

-659000

-119000

-9771000

-46697000

-53417000

4897000

2695000

8860000

2021000

1711000

1511000

3330000

1282000

108000

161000

47000

597000

345000

141000

1053000

2132000

151000

1383000

1184000

2875000

400000

45000

17000

1426000

1838000

2285000

229000

228000

274000

128582000

199381000

1816000

3573000

-5557000

-4855000

-702000

-4855000

-10722000

-9290000

-1432000

-9290000

10964000

9705000

1259000

9705000

8129000

2129000

1117000

579000

202000

139000

692000

386000

609000

808000

558000

1083000

5339000

6584000

5425000

1786000

604000

1367000

590000

564000

1594000

1321000

14200000

12906000

8576000

5000000

7000000

3324000

9000

97000

5000

88000

4000

3218000

4327000

51000

138000

20000

67000

51000

4138000

6073000

30000

107000

43000

56000

8000

5936000

3324000

4327000

5019000

43001000

699000

2565000

1771000

1648000

3205000

25128000

32540000

6410000

30528000

55586000

1374000

110586000

301680000

12179000

56587000

76271000

57000

10427000

2434000

7993000

14557000

2859000

11698000

-22963000

3774000

-26737000

4327000

2132000

1453000

742000

6073000

4243000

1374000

301000

155000

<div> <div> 10. Property, Plant and Equipment         Property, plant and equipment consisted of the following:                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Buildings </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Plant and equipment </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Furniture and fixtures, other equipment and motor vehicles </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Construction in progress </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Cost </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> As at January 1, 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,232 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,296 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>86 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,976 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,760 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,350 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Additions </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>301 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>155 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,374 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,243 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,073 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Disposals </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(394 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(394 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Transfers </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,050 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,321 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(722 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,649 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Exchange differences </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>410 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>920 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>204 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,680 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> As at December 31, 2017 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,372 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,057 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,568 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,154 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,558 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,709 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Accumulated depreciation </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> As at January 1, 2017 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>971 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,249 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,105 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,396 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Depreciation </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>105 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>763 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,441 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,478 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Disposals </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(337 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(337 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Transfers </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>255 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(255 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Exchange differences </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>65 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>284 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>599 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>952 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> As at December 31, 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,141 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,296 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>499 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,553 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,489 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Net book value </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> As at December 31, 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,231 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,761 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,069 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,601 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,558 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,220 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Buildings </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Plant and equipment </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Furniture and fixtures, other equipment and motor vehicles </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Construction in progress </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Cost </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> As at January 1, 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,392 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,989 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,806 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>567 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,842 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Additions </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>742 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,453 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,132 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,327 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Disposals </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(248 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(260 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Transfers </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>886 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(886 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Exchange differences </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(160 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(423 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(921 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(53 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,559 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> As at December 31, 2016 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,232 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,296 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>86 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,976 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,760 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,350 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Accumulated depreciation </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> As at January 1, 2016 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>932 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,549 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,784 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,335 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Depreciation </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>977 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,153 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,239 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Disposals </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(218 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(230 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Exchange differences </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(67 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(265 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(614 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(948 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> As at December 31, 2016 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>971 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,249 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,105 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,396 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net book value </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> As at December 31, 2016 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,261 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,047 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,871 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,760 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,954 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>         Depreciation for the year ended December 31, 2015 was US$1,908,000.   <div /></div> </div>

260000

248000

12000

394000

21842000

2392000

567000

12806000

5989000

88000

24350000

2232000

1760000

13976000

6296000

86000

31709000

2372000

2558000

15154000

9057000

2568000

9954000

49000

1261000

1760000

4871000

2047000

15000

219000

34000

145000

40000

9686000

14220000

52000

1231000

2558000

4601000

3761000

2069000

251000

61000

160000

30000

13917000

-886000

886000

-3649000

-722000

2050000

2321000

P20Y

P5Y

P4Y

P5Y

P10Y

P5Y

1408000

1322000

29000

242000

5918000

7196000

6056000

5844000

845000

5093000

751000

9142000

874000

8401000

741000

10567000

897000

10195000

372000

3701000

280000

1182000

6410000

28205000

49487000

156000000

20000000

2564000

180000000

23077000

30000000

3846000

1000000

47368000

66871000

75523000

-80357000

-107104000

1100000

116953000

85400000

8074000

5383000

8074000

9794000

8429000

9794000

8486000

9682000

8486000

19212000

19200000

9931000

9900000

9457000

5000000

4500000

<div> <div> <a name="_Hlk508389051"></a>                                                                                                                                                                                                         <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Milestone revenue </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,457 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,931 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,212 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Amortization of upfront payment </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,655 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,679 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,907 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Research and development services </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,203 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,834 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,941 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,315 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,444 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,060 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div>

20100000

25000000

7390029

4825418

672713

118113000

6196000

171058000

12274000

196720000

13307000

178203000

126187000

-2874000

3028000

105478000

17681000

52016000

216080000

180852000

-1306000

6984000

149861000

24007000

35228000

241203000

205206000

-2536000

9858000

166435000

28913000

35997000

<div> <div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year ended December 31, 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unallocated </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Revenue from external customers </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,997 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>166,435 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,858 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,913 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>205,206 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>241,203 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Adjusted (LBIT)/EBIT </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(47,503 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,272 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>578 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,029 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,879 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,677 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(53,301 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Interest income </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>64 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,093 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,220 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Equity in earnings of equity investees, net of tax </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,547 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,812 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,388 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,200 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,653 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Operating (loss)/profit </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(51,986 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,121 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,979 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,042 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45,142 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,584 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18,428 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,389 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,455 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Income tax expense </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>934 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(457 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>509 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>986 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,068 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,080 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net (loss)/income attributable to ordinary shareholders of the Company </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(51,880 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,999 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,773 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,261 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,033 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,890 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(26,737 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Depreciation/amortization </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,400 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>151 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,578 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Additions to non-current assets (other than financial instrument and deferred tax assets) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,936 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,073 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> As at December 31, 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unallocated </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Total assets </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,268 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>122,665 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>58,961 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,794 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>195,420 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>339,244 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>597,932 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Property, plant and equipment </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,917 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>160 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>251 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,220 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Leasehold land </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,261 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,261 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,901 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>407 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,308 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,308 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Other intangible asset </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>430 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>430 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>430 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Investments in equity investees </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,512 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,417 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,308 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>124,725 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,237 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year ended December 31, 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unallocated </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;padding:0pt;"> (inUS$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Revenue from external customers </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,228 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>149,861 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,984 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,007 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>180,852 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>216,080 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Adjusted (LBIT)/EBIT </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(36,657 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,377 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(493 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,852 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,736 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,306 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(46,227 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Interest income </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>384 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>502 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Equity in earnings of equity investees, net of tax </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,232 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,288 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,188 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70,476 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,244 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Operating (loss)/profit </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(40,837 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62,696 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,729 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,853 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,278 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,922 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,519 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,552 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,631 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Income tax expense </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>777 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(497 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>289 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>569 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,762 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,331 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net (loss)/income attributable to ordinary shareholders of the Company </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(40,735 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61,120 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,384 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>833 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70,337 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17,904 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,698 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Depreciation/amortization </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,176 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>102 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>124 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,341 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Additions to non-current assets (other than financial instrument and deferred tax assets) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,138 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>138 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,327 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> As at December 31, 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unallocated </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Total assets </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53,774 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134,681 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67,161 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,701 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>212,543 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76,120 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>342,437 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Property, plant and equipment </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,686 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>145 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>219 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,954 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Leasehold land </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,220 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,220 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,730 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>407 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,137 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,137 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Other intangible asset </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>469 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>469 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>469 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Investments in equity investees </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,031 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77,939 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,536 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>141,475 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>158,506 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year ended December 31, 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unallocated </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Revenue from external customers </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52,016 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>105,478 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,028 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,681 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>126,187 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>178,203 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Adjusted (LBIT)/EBIT </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(119 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>676 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(169 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,211 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,718 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,186 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,587 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Interest income </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>228 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>451 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Equity in earnings of equity investees, net of tax </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,770 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,653 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,689 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,342 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,572 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Operating (loss)/profit </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,810 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,443 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,549 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,212 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,204 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,958 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,436 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,319 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,404 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Income tax expense </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>239 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>148 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>387 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,218 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,605 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net (loss)/income attributable to ordinary shareholders of the Company </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,810 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,934 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,640 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>581 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,155 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,352 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,993 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Depreciation/amortization </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,864 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>110 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Additions to non-current assets (other than financial instrument and deferred tax assets) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,218 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>97 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,324 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div>

<div> <div>           A summary of ordinary shares transactions (in thousands) is as follows:                                                                                                                                                                                                   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:63.18%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:63.18%;background-color: #A8D3EC;padding:0pt;"> As at January 1 </td> <td valign="bottom" style="width:01.00%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:10.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,706 </td> <td valign="bottom" style="width:01.00%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:10.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56,533 </td> <td valign="bottom" style="width:01.00%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:10.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53,076 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:63.18%;padding:0pt;"> Public offering </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> <td valign="bottom" style="width:10.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,685 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> <td valign="bottom" style="width:10.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,080 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> <td valign="bottom" style="width:10.94%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:63.18%;background-color: #A8D3EC;padding:0pt;"> Share option exercises </td> <td valign="bottom" style="width:01.00%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:10.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56 </td> <td valign="bottom" style="width:01.00%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:10.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>93 </td> <td valign="bottom" style="width:01.00%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:10.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:63.18%;padding:0pt;"> Exchange of redeemable non-controlling interest (Note 16) </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> <td valign="bottom" style="width:10.94%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> <td valign="bottom" style="width:10.94%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> <td valign="bottom" style="width:10.94%;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,214 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:63.18%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:01.00%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:63.18%;background-color: #A8D3EC;padding:0pt;"> As at December 31 </td> <td valign="bottom" style="width:01.00%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:10.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,447 </td> <td valign="bottom" style="width:01.00%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:10.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,706 </td> <td valign="bottom" style="width:01.00%;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:10.94%;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56,533 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:63.18%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:01.00%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:63.18%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:01.00%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 25. Segment Reporting         The Group determines its operating segments from both business and geographic perspectives as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"> <tr style="CellSpacing:15;"> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> <td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">   </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">      </td> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (i)    </td> <td colspan="2" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> Innovation Platform (Drug research and development ("Drug R&D")): focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases, and the provision of research and development services; and </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">      </td> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (ii)    </td> <td colspan="2" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> Commercial Platform: comprises of the manufacture, marketing and distribution of prescription and over-the-counter pharmaceuticals in the PRC as well as consumer health products through Hong Kong. The Commercial Platform is further segregated into two core business areas: </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">      </td> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">      </td> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (a)    </td> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> Prescription Drugs: comprises the development, manufacture, distribution, marketing and sale of prescription pharmaceuticals; and </td> </tr> <tr style="CellSpacing:15;"> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">      </td> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">      </td> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> (b)    </td> <td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"> Consumer Health: comprises the development, manufacture, distribution, marketing and sale of over-the-counter pharmaceuticals and consumer health products. </td> </tr> </table></div>         Innovation Platform and Prescription Drugs businesses under the Commercial Platform are primarily located in the PRC. The locations for Consumer Health business under the Commercial Platform are further segregated into the PRC and Hong Kong.         The performance of the reportable segments is assessed based on three measurements: (a) losses or earnings of subsidiaries before interest income, interest expense, income tax expenses and equity in earnings of equity investees, net of tax ("Adjusted (LBIT)/EBIT" or "Adjusted LBIT"), (b) equity in earnings of equity investees, net of tax and (c) operating (loss)/profit.         The segment information is as follows:                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year ended December 31, 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unallocated </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Revenue from external customers </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,997 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>166,435 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,858 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,913 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>205,206 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>241,203 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Adjusted (LBIT)/EBIT </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(47,503 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,272 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>578 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,029 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,879 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,677 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(53,301 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Interest income </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>64 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,093 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,220 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Equity in earnings of equity investees, net of tax </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,547 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,812 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,388 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,200 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,653 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Operating (loss)/profit </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(51,986 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,121 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,979 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,042 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45,142 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,584 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18,428 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,389 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,455 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Income tax expense </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>934 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(457 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>509 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>986 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,068 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,080 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net (loss)/income attributable to ordinary shareholders of the Company </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(51,880 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,999 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,773 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,261 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,033 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,890 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(26,737 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Depreciation/amortization </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,400 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>151 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,578 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Additions to non-current assets (other than financial instrument and deferred tax assets) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,936 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,073 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> As at December 31, 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unallocated </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Total assets </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,268 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>122,665 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>58,961 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,794 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>195,420 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>339,244 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>597,932 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Property, plant and equipment </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,917 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>160 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>251 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,220 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Leasehold land </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,261 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,261 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,901 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>407 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,308 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,308 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Other intangible asset </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>430 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>430 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>430 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Investments in equity investees </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,512 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,417 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,308 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>124,725 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,237 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year ended December 31, 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unallocated </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;padding:0pt;"> (inUS$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Revenue from external customers </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,228 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>149,861 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,984 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,007 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>180,852 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>216,080 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Adjusted (LBIT)/EBIT </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(36,657 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,377 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(493 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,852 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,736 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,306 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(46,227 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Interest income </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>384 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>502 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Equity in earnings of equity investees, net of tax </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,232 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,288 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,188 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70,476 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,244 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Operating (loss)/profit </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(40,837 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62,696 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,729 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,853 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,278 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,922 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,519 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,552 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,631 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Income tax expense </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>777 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(497 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>289 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>569 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,762 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,331 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net (loss)/income attributable to ordinary shareholders of the Company </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(40,735 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61,120 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,384 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>833 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70,337 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17,904 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,698 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Depreciation/amortization </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,176 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>102 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>124 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,341 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Additions to non-current assets (other than financial instrument and deferred tax assets) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,138 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>138 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,327 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> As at December 31, 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unallocated </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Total assets </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53,774 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134,681 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67,161 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,701 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>212,543 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76,120 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>342,437 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Property, plant and equipment </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,686 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>145 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>219 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,954 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Leasehold land </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,220 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,220 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,730 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>407 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,137 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,137 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Other intangible asset </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>469 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>469 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>469 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Investments in equity investees </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,031 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77,939 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,536 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>141,475 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>158,506 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>                                                                                                                                                                                        <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year ended December 31, 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Innovation Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial Platform </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Drug R&D </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prescription Drugs </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Consumer Health </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> PRC </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Hong Kong </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unallocated </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="13" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Revenue from external customers </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52,016 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>105,478 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,028 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,681 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>126,187 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>178,203 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Adjusted (LBIT)/EBIT </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(119 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>676 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(169 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,211 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,718 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,186 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,587 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Interest income </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>228 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>451 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Equity in earnings of equity investees, net of tax </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,770 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,653 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,689 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,342 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,572 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Operating (loss)/profit </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,810 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,443 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,549 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,212 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,204 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,958 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,436 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,319 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,404 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Income tax expense </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>239 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> — </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>148 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>387 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,218 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,605 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net (loss)/income attributable to ordinary shareholders of the Company </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,810 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,934 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,640 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>581 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,155 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,352 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,993 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Depreciation/amortization </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,864 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>110 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Additions to non-current assets (other than financial instrument and deferred tax assets) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,218 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>97 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,324 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>         Revenue from external customers is after elimination of inter-segment sales. The amount eliminated attributable to sales within Consumer Health business from Hong Kong to the PRC was US$2,536,000, US$1,306,000 and US$2,874,000 for the years ended December 31, 2017, 2016 and 2015 respectively. Sales between segments are carried out at mutually agreed terms.         There were no customers who accounted for over 10% of the Group's revenue for the years ended December 31, 2017 and 2016. There was one customer under the Innovation Platform which accounted for 23% of the Group's revenue for the year ended December 31, 2015.         Unallocated expenses mainly represent corporate expenses which include corporate employee benefit expenses and the relevant share-based compensation expenses. Unallocated assets mainly comprise cash and cash equivalents and short-term investments.         A reconciliation of Adjusted LBIT to net (loss)/income is as follows:                                                                                                                                                                                      <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Year Ended December 31, </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:auto;padding:0pt;"> (in US$'000) </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Adjusted LBIT </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(53,301 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(46,227 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,587 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest income </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,220 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>502 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>451 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Equity in earnings of equity investees, net of tax </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,653 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,244 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,572 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,455 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,631 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,404 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> Income tax expense </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;">     </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,080 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,331 </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;padding:0pt;"> )   </td> <td valign="bottom" style="width:auto;background-color: #A8D3EC;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,605 </td> <td valign="bottom" style="width:auto;"> ) </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;padding:0pt;"> Net (loss)/income </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,963 </td> <td valign="bottom" style="width:auto;"> ) </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,557 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> <td valign="bottom" style="width:auto;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,427 </td> <td valign="bottom" style="width:auto;padding:0pt;">   </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> <tr style="CellSpacing:0;"> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> <td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">   </td> <td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"> </td> </tr> </table></div>   <div /></div> </div>

10209000

17998000

19322000

P4Y

P3Y

P4Y

2390000

1957000

1800000

62921

55978

42038

P10Y

P6Y

P10Y

P8Y

P9Y

P6Y

4.41

6.10

19.70

31.05

0.00

P10Y

P8Y

P10Y

0.466

0.360

0.390

0.363

0.0313

0.0316

0.0100

0.0117

2425597

2144408

8552963

157111839

6762000

16146000

6106000

38508000

291015

593686

767376

951412

4.67

7.82

14.64

15.52

P5Y9M7D

P7Y11M19D

P6Y7M28D

P5Y9M22D

5020000

1907000

2290000

282726

6.10

7.82

6.10

2485189

3750

1187372

6875

693686

593686

150000

1.84

3.15

8.99

12.69

10061000

32292000

7900000

43158000

684403

1211772

442365

1187372

1039596

1126412

4.67

7.71

5.16

7.82

15.00

17.69

P6Y6M11D

P7Y11M19D

P6Y9M7D

P6Y3M15D

7685000

20667000

7900000

43158000

333393

759918

1039596

1126412

4.85

7.82

15.00

17.69

P6Y18D

P7Y11M19D

P6Y9M7D

P6Y3M15D

3.77

2.34

3.54

5.16

19.70

31.05

4.33

6.10

19.70

31.05

53076000

56533000

60706000

66447000

24270000

273031000

372000

272659000

184270000

461733000

56915000

9870000

76256000

53076000

17764000

39151000

-100051000

102277000

5015000

113848000

56533000

18921000

83356000

-92040000

204060000

-4275000

208196000

60706000

19790000

184270000

-80357000

484966000

5430000

496960000

66447000

23233000

461733000

-107104000

84037000

3214404

4080000

3750000

7500000

330000

660000

5685000

5684905

11369810

3214000

243000

242038

24400

243000

93000

92705

93000

56000

56309

56000

84000000

110160000

106080000

4080000

110160000

101300000

8900000

301300000

295615000

5685000

301300000

84037000

80823000

3214000

84037000

1374000

1131000

243000

1374000

426000

333000

93000

426000

380000

324000

56000

380000

1151000

1780000

1316000

12500000

84000000

4574780

48213000

55247000

-198000

-633000

399000

5230000

4332000

1380000

5436000

54659315

59971050

61717171

54659315

59715173

61717171

EX-101.SCH 12 hcm-20171231.xsd EX-101.SCH 00100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statements of Comprehensive (Loss)/Income link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Changes in Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Accounts Receivable-Third Parties (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Other Receivables, Prepayments and Deposits (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Investments in Equity Investees - Summarized Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Investments in Equity Investees - Summarized Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - Investments in Equity Investees - Reconciliation of Summarized Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Accounts Payable (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Other Payables, Accruals and Advance Receipts (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Bank Borrowings - Schedule of Bank Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 41403 - Disclosure - Bank Borrowings - Schedule of Maturities of Bank Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 41901 - Disclosure - Revenue from License and Collaboration Agreements-Third Parties (Details) link:presentationLink link:calculationLink link:definitionLink 42001 - Disclosure - Research and Development Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 42301 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 42301 - Disclosure - Income Taxes (Details) - Calc - 2 link:presentationLink link:calculationLink link:definitionLink 42302 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 42304 - Disclosure - Income Taxes - Tax Losses Carryforwards and Deferred Tax Valuation Allowance (Details) link:presentationLink link:calculationLink link:definitionLink 42401 - Disclosure - (Losses)/Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 42501 - Disclosure - Segment Reporting - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 42504 - Disclosure - Segment Reporting - Reconciliation of Adjusted LBIT to net (loss)/income (Details) link:presentationLink link:calculationLink link:definitionLink 42601 - Disclosure - Note to Consolidated Statements of Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Consolidated Balance Sheets (parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Nature of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Particulars of Principal Subsidiaries and Equity Investees link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Fair Value Disclosures link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Short-term Investments link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Accounts Receivable-Third Parties link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Other Receivables, Prepayments and Deposits link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Investments in Equity Investees link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Accounts Payable link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Other Payables, Accruals and Advance Receipts link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Bank Borrowings link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Redeemable Non-controlling Interests link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - Ordinary Shares link:presentationLink link:calculationLink link:definitionLink 11801 - Disclosure - Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 11901 - Disclosure - Revenue from License and Collaboration Agreements-Third Parties link:presentationLink link:calculationLink link:definitionLink 12001 - Disclosure - Research and Development Expenses link:presentationLink link:calculationLink link:definitionLink 12101 - Disclosure - Government Incentives link:presentationLink link:calculationLink link:definitionLink 12201 - Disclosure - Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries link:presentationLink link:calculationLink link:definitionLink 12301 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 12401 - Disclosure - (Losses)/Earnings per Share link:presentationLink link:calculationLink link:definitionLink 12501 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 12601 - Disclosure - Note to Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 12701 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 12801 - Disclosure - Restricted Net Assets link:presentationLink link:calculationLink link:definitionLink 12901 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Particulars of Principal Subsidiaries and Equity Investees (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Fair Value Disclosures (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Short-term investments (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Accounts Receivable-Third Parties (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Other Receivables, Prepayments and Deposits (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Investments in equity investees (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Accounts Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Other Payables, Accruals and Advance Receipts (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Bank Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 31703 - Disclosure - Ordinary Shares (Tables) link:presentationLink link:calculationLink link:definitionLink 31803 - Disclosure - Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31903 - Disclosure - Revenue from License and Collaboration Agreements-Third Parties (Tables) link:presentationLink link:calculationLink link:definitionLink 32003 - Disclosure - Research and Development Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 32203 - Disclosure - Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries (Tables) link:presentationLink link:calculationLink link:definitionLink 32303 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 32403 - Disclosure - (Losses)/Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 32503 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 32603 - Disclosure - Note to Consolidated Statements of Cash Flows (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization and Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Particulars of Principal Subsidiaries and Equity Investees (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of significant accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Fair Value Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Short-term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Accounts Receivable-Third Parties - Movements on the Allowance for Doubtful Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Investments in Equity Investees - Composition (Details) link:presentationLink link:calculationLink link:definitionLink 41105 - Disclosure - Investments in Equity Investees - Lease Commitments and Capital Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 41402 - Disclosure - Bank Borrowings - Loan Facilities (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Redeemable Non-controlling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 41701 - Disclosure - Ordinary Shares (Details) link:presentationLink link:calculationLink link:definitionLink 41801 - Disclosure - Share based Compensation - HCML Share Option Scheme (Details) link:presentationLink link:calculationLink link:definitionLink 41802 - Disclosure - Share-based Compensation - HCML Share Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41803 - Disclosure - Share-based Compensation - HCML Options Fair value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 41804 - Disclosure - Share-based Compensation - HCML Share Option Values (Details) link:presentationLink link:calculationLink link:definitionLink 41805 - Disclosure - Share-based Compensation - HCML Share Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41806 - Disclosure - Share based Compensation - HMHL Share Option Schemes (Details) link:presentationLink link:calculationLink link:definitionLink 41807 - Disclosure - Share based Compensation - HMHL Share Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41808 - Disclosure - Share based Compensation - HMHL Share Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41809 - Disclosure - Share-based Compensation - LTIP (Details) link:presentationLink link:calculationLink link:definitionLink 41810 - Disclosure - Share-based Compensation - LTIP Share Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 42101 - Disclosure - Government Incentives (Details) link:presentationLink link:calculationLink link:definitionLink 42201 - Disclosure - Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries - Related parties (Details) link:presentationLink link:calculationLink link:definitionLink 42202 - Disclosure - Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries - Non-controlling shareholders of subsidiaries(Details) link:presentationLink link:calculationLink link:definitionLink 42303 - Disclosure - Income Taxes - Movements in Net Deferred Income Tax Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 42305 - Disclosure - Income Taxes - Income Tax Payable (Details) link:presentationLink link:calculationLink link:definitionLink 42502 - Disclosure - Segment Reporting - Elimination (Details) link:presentationLink link:calculationLink link:definitionLink 42503 - Disclosure - Segment reporting - Concentration Risk Percentage (Details) link:presentationLink link:calculationLink link:definitionLink 42701 - Disclosure - Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 42801 - Disclosure - Restricted Net assets (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 hcm-20171231_cal.xml EX-101.CAL EX-101.LAB 14 hcm-20171231_lab.xml EX-101.LAB Document and Entity Information Statement [Table] Statement [Line Items] Statement Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Filer Category Entity Ordinary Shares, Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of year Cash and cash equivalents at beginning of year Cash and cash equivalents Cash and cash equivalents Short-term Investments. Short-term investments Accounts Receivable, Net, Current Accounts receivable-third parties Accounts receivable, net Accounts receivable-related parties Amount, after allowance, receivables classified as other receivables and prepayments and deposits due within one year or the normal operating cycle, if longer. Other Receivables, Prepayments and Deposits, Current Other receivables, prepayments and deposits Total Due from Related Parties, Current Amounts due from related parties Inventory, Net Inventories Total Deferred Tax Assets, Net, Current Deferred tax assets Assets, Current Total current assets Property, Plant and Equipment, Net Net book value Property, plant and equipment Amount of land held under leaseholds. Leasehold Land Leasehold land Goodwill Goodwill Finite-Lived Intangible Assets, Net Other intangible asset Deferred Tax Assets, Net, Noncurrent Deferred tax assets Prepaid Expense, Noncurrent Long-term prepayment Equity Method Investments Investments in equity investees Carrying amount of investments as at December 31 Assets Total assets Total assets Liabilities and Equity [Abstract] Liabilities and shareholders' equity Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts Payable Accounts payable Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer) for other payables, accrued liabilities, deferred revenue and advance receipts. Accounts Payable, Accrued Liabilities, Deferred Revenue, Other, Current Other payables, accruals and advance receipts Other payables, accruals and advance receipts Accrued Income Taxes, Current As at December 31 As at January 1 Income tax payable Deferred Revenue, Current Deferred revenue Due to Related Parties, Current Amounts due to related parties Long-term Debt, Current Maturities Short-term bank borrowings Current Deferred Tax Liabilities, Net, Current Deferred tax liabilities Liabilities, Current Total current liabilities Deferred Tax Liabilities, Net, Noncurrent Deferred tax liabilities Long-term Debt, Excluding Current Maturities Non-current Long-term bank borrowings Deferred Revenue, Noncurrent Deferred revenue Deferred income noncurrent. Deferred Income Noncurrent Other deferred income Other Liabilities, Noncurrent Other non-current liabilities Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Company's shareholders' equity Common Stock, Value, Issued Ordinary shares; $1.00 par value; 75,000,000 shares authorized; 66,447,037 and 60,705,823 shares issued at December 31, 2017 and 2016 respectively Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated losses Cumulative adjustment to opening accumulated loss upon adoption Accumulated losses Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income/(loss) Stockholders' Equity Attributable to Parent Total Company's shareholders' equity Stockholders' Equity Attributable to Noncontrolling Interest Non-controlling interests Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Total shareholders' equity Liabilities and Equity Total liabilities and shareholders' equity Common Stock, Par or Stated Value Per Share Ordinary shares, par value Common Stock, Shares Authorized Ordinary shares, authorized Common Stock, Shares, Issued Ordinary shares, issued Condensed Consolidated Statements of Operations Revenues [Abstract] Revenues Sales Revenue, Goods, Net Sales-third parties Sales Revenue from Related Parties Sales-related parties Sales License and Services Revenue Revenue from license and collaboration agreements-third parties Revenue from license and collaboration agreements-third parties Revenue From Research And Development Services Revenue From Research And Development Services Revenue from research and development services-third parties Revenue from research and development services-related parties Revenue From Research And Development Services Related Parties Revenue from research and development services-related parties Revenue, Net Revenue from external customers Total revenues Revenue from external customers Operating Expenses [Abstract] Operating expenses Cost of Goods Sold Costs of sales-third parties Purchases Related Party Costs Costs of sales-related parties Research and Development Expense Research and development expenses Research and development expenses Selling Expense Selling expenses General and Administrative Expense Administrative expenses Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income/(expense) Investment Income, Interest Interest income Interest income Other Nonoperating Income Other income Interest Expense Interest expense Interest expense Other Nonoperating Expense Other expense Nonoperating Income (Expense) Total other income/(expense) Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Loss before income taxes and equity in earnings of equity investees Loss before income taxes and equity in earnings of equity investees Income Tax Expense (Benefit) Income tax expense Income tax expense Income tax expense Income tax expense Income (Loss) from Equity Method Investments Equity in earnings of equity investees, net of tax Equity in earnings of equity investees, net of tax Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income/(loss) Net (loss)/income Net (loss)/income Net Income (Loss) Attributable to Noncontrolling Interest Less: Net income attributable to non-controlling interests Net income attributable to non-controlling interests Net Income (Loss) Attributable to Parent Net (loss)/income attributable to the Company Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Accretion on redeemable non-controlling interests Net Income (Loss) Available to Common Stockholders, Basic Net (loss)/income attributable to ordinary shareholders of the Company (Losses)/Earnings per Share Earnings Per Share Earnings Per Share, Basic (Losses)/earnings per share attributable to ordinary shareholders of the Company-basic (US$ per share) (Losses)/earnings per share attributable to ordinary shareholders of the Company (US$ per share) Earnings Per Share, Diluted (Losses)/earnings per share attributable to ordinary shareholders of the Company-diluted (US$ per share) (Losses)/earnings per share attributable to ordinary shareholders of the Company (US$ per share) Weighted Average Number of Shares Outstanding, Basic Number of shares used in per share calculation-basic Weighted Average Number of Shares Outstanding, Diluted Number of shares used in per share calculation-diluted Weighted average number of outstanding ordinary shares in issue, diluted Consolidated Statements of Comprehensive (Loss)/Income Net Income (Loss) Attributable to the Company [Abstract] Net Income (Loss) Attributable to the Company Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income/(loss) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation gain/(loss) Foreign currency translation adjustments Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Total comprehensive (loss)/income Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Less: Comprehensive income attributable to non-controlling interests Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive (loss)/income attributable to the Company Consolidated Statements of Changes in Shareholders' Equity Increase (Decrease) in Stockholders' Equity Summary of ordinary shares transactions: Common Stock, Shares, Outstanding Balance (in shares) Balance (in shares) Stock Issued During Period, Value, New Issues Issuance in relation to public offering Stock Issued During Period, Shares, New Issues New ordinary shares issued (in shares) Issuance in relation to public offering (in shares) Increase in Carrying Amount of Redeemable Preferred Stock Accretion to redemption value of redeemable non-controlling interests Stock Issued During Period, Value, Purchase of Assets Issuance in exchange for redeemable non-controlling interest Stock Issued During Period, Shares, Purchase of Assets Issuance in exchange for redeemable non-controlling interest (in shares) Stock Issued During Period, Value, Stock Options Exercised Issuances in relation to share option exercises Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Issuances in relation to exercise of share options (in shares) Share option exercises Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Issuance costs Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Share-based compensation - share options Adjustments to Additional Paid in Capital, Share-based Compensation, Other Long-term Incentive Plans, Requisite Service Period Recognition Share-based compensation - long-term incentive plan Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Share-based compensation Represents the amount long-term incentive plan treasury shares held by Trustee of the Company. Treasury Shares Long Term Incentive Plan Held By Trustee LTIP-treasury shares acquired and held by Trustee Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Dividend paid to a non-controlling shareholder of a subsidiary Dividend declared Value of dilution of subsidiary interests in relation to exercise of share options of a subsidiary within the period. Dilution Of Subsidiary Interests In Relation To Exercise Share Options Of Subsidiary Dilution of interests in a subsidiary in relation to exercise of share options of a subsidiary Represents the transfer amount between reserves. Transfers Between Reserves Transfer between reserves Consolidated Statements Of Cash Flows Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property, plant and equipment The net amount paid (received) by the reporting entity from deposit in short-term investments. Deposit in Short-term Investments Deposit in short-term investments Proceeds from Sale of Short-term Investments Proceeds from short-term investments Payments to Acquire Equity Method Investments Investment in an equity investee Net Cash Provided by (Used in) Investing Activities Net cash (used in)/generated from investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities Proceeds from Issuance of Common Stock Proceeds from issuance of ordinary shares Proceeds from Stock Options Exercised Proceeds from exercise of share options of a subsidiary Payments for Repurchase of Common Stock Purchases of treasury shares Payments of Ordinary Dividends, Noncontrolling Interest Dividends paid to non-controlling shareholders of subsidiaries Repayments of Related Party Debt Repayment of loan to a non-controlling shareholder of a subsidiary Proceeds from Bank Debt Proceeds from bank borrowings Repayments of Bank Debt Repayment of bank borrowings Payments of Stock Issuance Costs Payment of issuance costs Issuance costs paid Net Cash Provided by (Used in) Financing Activities Net cash generated from /(used in) financing activities Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net increase/(decrease) in cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase/(decrease) in cash and cash equivalents, including effect of exchange rate changes Supplemental disclosure for cash flow information Interest Paid, Net Cash paid for interest Income Taxes Paid, Net Tax paid Cash paid for tax, net of refunds Supplemental disclosure for non-cash activities Capital Expenditures Incurred but Not yet Paid Accruals made for purchases of property, plant and equipment Deferred initial public offering costs incurred but not paid during the period. Deferred costs for initial public offering in the United States incurred but not yet paid Accrued issuance costs for public offering Vesting of treasury shares for LTIP incurred but not paid during the period. Vesting Of Treasury Shares For LTIP Vesting of treasury shares for LTIP Capitalization of amounts due from related parties to investments in equity investees. Capitalization of Amounts Due from Related Parties to Investments in Equity Investees Capitalization of amounts due from related parties to investments in equity investees Stock Issued Issuance of ordinary shares in exchange of redeemable non-controlling interests Organization and Nature of Business Nature of Operations [Text Block] Organization and Nature of Business n/a Particulars of Principal Subsidiaries and Equity Investees Schedule of Subsidiary or Equity Method Investee [Table] Subsidiary or Equity Method Investee [Line Items] Subsidiary or Equity Method Investee The entire disclosure showing particulars of Principal subsidiaries and Equity investees. Particulars Of Principal Subsidiaries And Equity Investees [Text block] Particulars of Principal Subsidiaries and Equity Investees Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value Disclosures Fair Value Disclosures. Fair Value Disclosures Cash and Cash Equivalents Cash and Cash Equivalents Disclosure [Text Block] Cash and Cash Equivalents Short-term Investments Investment [Table] Short term investments Investment [Line Items] Short term Investments Investment [Text Block] Short-term Investments Accounts Receivable-Third Parties Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Accounts Receivable-Third Parties NA. Other Receivables, Prepayments and Deposits The entire disclosure for other receivable, prepayments and deposits. Other Receivable Prepayments And Deposits Disclosure Text Block Other Receivables, Prepayments and Deposits Inventories Inventory Disclosure [Text Block] Inventories Property, Plant and Equipment Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment Investments in Equity Investees Equity Method Investments and Joint Ventures Disclosure [Text Block] Investments in Equity Investees Accounts Payable Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accounts Payable Other Payables, Accruals and Advance Receipts Accounts Payable and Accrued Liabilities Disclosure [Text Block] Other Payables, Accruals and Advance Receipts Bank Borrowings Debt Instrument [Line Items] Bank Borrowings Long-term Debt [Text Block] Bank Borrowings Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Redeemable Non-controlling Interests Redeemable Noncontrolling Interest [Line Items] Redeemable Non-controlling Interests EX-101.PRE 15 hcm-20171231_pre.xml EX-101.PRE EX-101.DEF 16 hcm-20171231_def.xml EX-101.DEF GRAPHIC 17 g406795.jpg G406795.JPG begin 644 g406795.jpg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end GRAPHIC 18 g236208.jpg G236208.JPG begin 644 g236208.jpg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end GRAPHIC 19 g1003315.jpg G1003315.JPG begin 644 g1003315.jpg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end GRAPHIC 20 g207813.jpg G207813.JPG begin 644 g207813.jpg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
GJ!ZZRKHZ.CJWJ[I&O$D_86;O_ )LJ'^)-*Z>%K];G_K'O M_%7TB7B:NN,\'=_O-*\CC-#^:]'SDW?\ S_(_!X/YKTTTY'1TF_SDW?\ S_(_!X/YKT?. M3=_\_P C\'@_FO333D='2;_.3=_\_P C\'@_FO1\Y-W_ ,_R/P>#^:]--.1T M=)O\Y-W_ ,_R/P>#^:]'SDW?_/\ (_!X/YKTTTY'1TF_SDW?_/\ (_!X/YKT M?.3=_P#/\C\'@_FO333D='2;_.3=_P#/\C\'@_FO1\Y-W_S_ "/P>#^:]--. M1T=)O\Y-W_S_ "/P>#^:]'SDW?\ S_(_!X/YKTTTY'1TF_SDW?\ S_(_!X/Y MKT?.3=_\_P C\'@_FO333D='2;_.3=_\_P C\'@_FO1\Y-W_ ,_R/P>#^:]- M-.1T=)O\Y-W_ ,_R/P>#^:]'SDW?_/\ (_!X/YKTTTY'1TF_SDW?_/\ (_!X M/YKT?.3=_P#/\C\'@_FO333D='2;_.3=_P#/\C\'@_FO1\Y-W_S_ "/P>#^: M]--.1T=)O\Y-W_S_ "/P>#^:]'SDW?\ S_(_!X/YKTTTY'1TF_SDW?\ S_(_ M!X/YKT?.3=_\_P C\'@_FO333D='2;_.3=_\_P C\'@_FO1\Y-W_ ,_R/P># M^:]--4T>,G^R=HO]!%:_Q$VET=0+XM5ML1#D/09$PFZ\]\QP%OTF68R,Y2G8 M^TLIQG#;",9SCS9QWSC*NW;'?MC&,'335PO@>?M1/AV?U3]2_P!Q)ZM4ZJK\ M#S]J)\.S^J?J7^XD]6J=--'1T='331T='1TTT='1T=--'1T=><5+B@8V>8-$ MAX@0+B/D"94I-C#QHV!%1EV5.GSI;K,:)#C,I4](DR'6V66D*6XM*<9STTUZ M&>_;/;X]L]OY?L=5Q7F-LP<;Y#V6SZXV#LR]@;6P;T2$'S]BL:ZLFMH]X0GR%5L *S0(\U\9+FU\N--PXY&,AI<@?)E"Y,MAF9'0^RMZ*ZXE]E+S2 MG&T8<1E48Z0ZWV#K&ON-K8)Y+4&W;E-M5II8)JQ]XK=F8M%S"EX)HY$:.12" MR,0RHZE1JJ6X4]ZBFDI3.R5;,E:1C&5'=5!Y"R##+QD5XVQC/@C.5TDI+7&\ M\;@VD)KMCMB:%6*<4W9I%1:?-P">WYLZ%> $RAV$U(GR,6+7NN"XIJ^ *7/B M)%A)^RVF7L2 =2IXT3+7'0'7!X&M3WJWMT/L1^GQ6;I(VLN_3S;AK.!^;#@V M<+S)M'+%9!MEV0P_593XO,7TF:VF*"\C"6A[8[]^WO\ AW^SV^CKYVQV[=L8 MQ]&/=CZ?L=2QYF=0I & H!7QGB,'E_A%B2Q)\\B3\]9R0*C<@2QRY^+XL/&E;VGS9XG:2LQZF;6W]K2C6ZL00A,_63UA98/BX%C$6$Z MDR1+2'IJ4&Q-3L&&MK%K&(+ M&V)Z_HY0B/5V )'! D-G3!2J2R2BQ+(#A.XKY"/&(9S8!QL*0'Q\CVWY3W\L M9>DM-#&MJV'AX1Y%VG8%D$:Z.-:MTA2=C[$DCS,!]*2-ND&6(DQZC060\2$6 MESR$F-!3D>C,5;+:<-I;K'G[J.>V7)\ LP"@@C/@%3]?G],^,YN%H-F(7&G +.5KDVI$#,'$ MR37"$R"1EBUJ<=0AAZ<-<<@2_.VA#Z'XKF6EMO([9PKS)Q6YS>H/-7>Q9K6> MKM*Z6(:O%FV3X?8-\WK<]?V2%:X5:)PZ^?@P=B07X+TA6%96Z- M5'RMY6'G&G^V4JR8*WE0RD9X>\A.%>N,-2YH5W"OAALCF''RVYW[^9J5' M8\N,>Y:\>_H'# (YP?0D,I5CZ>H],DYQ@8/Z-6@2KI\ M$GU]*3J1X:VV:D-9A',7N[.['KA?5FVS);FEMY1D11KZ&&Q;Y9*:Q)$R98>V MS2T+)F24A7,F*7*5,8&:[8P5=G1)YHK/LH;2A4:M5MG:5XI= MOM047#>RSZQ6N0XDB$V+.:E-825D"+I6'WES%)AM38\=EE+%MK$AB4VEZ.ZV M^TO'=#K*T.MKQ]*5MJ4G/\G?O].,=?EZ)&D=\/L-N]_CYTXSW^QU6(P >)/G MU)\Y&/M@^?4^<^OGSK94-UDHR-(*\$Q8<%HRP(!=&67BH59 M%5G#U8U4#6J:13(I[-FT26GR%R'AQ%B42I1J2MSSR'2;3T\E6Y$B0\I:I))H MH#-O+5AQR2K/=&9?VS*V_?M/7.BUJZS-4V&R#&1];Y Z?8@6HK39C,V)+=+- M4X[^K8PZQ'>@RV8! PXF%,DXC/,O8;?;=>15PD2PISP=@Z+V MUNK70:@0O$:L5%O8IQF!?2%]X_T0,<.D?9QN.01!K-F4%:K9&8].$D&9M6*& MT5Z2&>;K,Q XHMB-843T:=BE4G =NL$8HTWAO$MU8^=F4PG*NZT$V'&;2W98M9E8[Y2I"W5E8?D M7CNG*D16G&O-VPI2.Z<^>F.4;9'S\D>@'H3@Y\YR#_,<:\C>F@!BE/=#B2*1 M7[$\1^'\FW.LU>55()1T]UDRS+]HL,3%1I#KKL6%G#L)2X#4A ZRRBNLRAR)*5M...IPY MGT?DSC.%X[X4A259QY,XSA2.V?+E.4J1G.,]\K3915%.0G!A^LYK3[Z$/J1+ M&,8&Y>CN)4A:9L-&1KBV'LH6TY*2WE?FQY<9:6YA'CZ-L9:K6 S0R1,?-8 R M&\#%19;+C7L23V<@H1&2YER/&\F#X./0> MGU(\@>OKC)SYUD7V:_5$H3MS5@TDX546.QW616LJ8\QM*2(Q-P;B?A("X(U( MW+/5&Z=TZZ8U_IW95+UHV?FE!NPI]UUXG8T)_,+B]:QHP+OO1M93LASQ\I;]&3F1Z0I%BNR+(^(7GUJ3K;FS[3:W.GO<^V4Y=YVN.2';]QE@ MCDM58; Q/%!/Q,D:RQM(IXM\/'_ ,17H=WV]*X_T*> %*1]:FP%6UOK=FN>F9#1W%R'<.SG& M&F[@R!A3Y 17C7*33MCS\3 MS. HP'94O MUP9!NUHNI6MQHR&83*)+R(:DQIOI>FQD3"86O5O5U5G2562P1)7K$YR0\N37 MZPRYE=DN,U2K@V-A:LX(3(\)V,QZ5.4=E+FN9PA#B\29J2GD$HGVFU)A MYM5D6@A8WVLX]5%PX3:\B:M#?4K"5!U7//&L4OK/28P!'C>1C$8Z[5=IVNN9K=B&)I)67E'&L5>*,O5MLK3;KN[M M*\2B;L_$YC!9>+2JHY&5V;\G$/0D%RF1QD&F4>VGYS9)4!M!-7K'JU@,15^A MKJ5Y\JHU*I.)LV$)PXE2W'S9@G+L<^0Z\^6(3\/8CMS"QQ7%&)31$^H@>E8] M&ID?J7B+7X3N =KZ=JF MMFP;4INER!E6CS85P,7-IC,)/=F+BC'(;S\@,_EV,7,X6G+\U+[#QZ6W"#W+3HMD@(@"BR5.).55FR ; M(3KN7)T]H0HF^!ER8[;-A%1(]B"/+2SB>%(1);25(RO.)0)E1H:!-*EI\0:, M'1G9D\A/DLQ(4.(PG*WI$J4^MMAAEI&,J<<=6A"<>_.>IQQA2/D>"Q*I8LQX MJJ *]2T M94]9"&XS^]J]L$[=!5AJ\9>3) X2KST09/JDH(,8;>?S+AF8TPA-**<6T-9' MDT]W=?\ Q'06CY&SQ>\.+\FJ7&I4A\:&.:NN+-H)$]D8+,DZ8!'CQK\IM R$ M:#/5\P[!M!^VAQ$K+])K9 BY+8:3DIMI>R:HE0J36:7I(<4:FV38.Y438%*V M"F#'=>'B ](3($';K5F2:HL^Z=3M)/:I4Y((XI:O9ISRR1YLSS %[5>"62+O5(4!BA=S!3MR-*??HD2% MYLF*(@*S*F<@M\'(XR,!B,X<^I_E 8RN2<=6GVB!2=6:Q$I?4]DV!'3Q:T8?B![9?TD=L73FSJ(L=LW MR ?D>:R7DU8)#9?6KRP@V63EU-\2ABK31Y =%K@ICTUP.*3K8W;+U(=B" 5.8]2@8^8 ).0?KGD3DG)/'55=5T47/76ISF]0>)NT/%5+8)2> M#+E323=_.S5@8!,VE$X@&(U\@1# M.NK!J!.S2R3M6:$#'9]F-UVY%@Y6J9G6"=+&AQS[9-@@*'J)()1IRY R)8ZB MZDV7I)=VWC?+)AI;?M>V3RK%&9K,@EW"[500UT;N.9+-BO$&&(T9P9'C1688 M.X;G%MVVR7[+=NO [%V4&1P7,$<:A0OQ,S,% /%?(8X4$ZLVXUU6B\7-1T[C ML7W77+D?UH&,N$"ATA5*M8Y0Z::G6)XH7K+!F2_ :B(.,IE$I3SRY>74$)DK M+DSOU#7,[FE(U!0*44TD0I5QG7PL0ALVU@E!ME>"0A0P>77Z)H*05#GDBL8I M#=@I?GI8;'Y>G>@DX7'RFGC<5DXU["F[,Y$;LA<7--;!Y#TH\.%VBZ.W6Q-Y MONK*$U4*]>[M6X#Y59Q6OLF!B0HU+M33( FVQ*QAR1/1/7A]#H&0>N&]=:KY M,\.]AU:J6NMM;,TC3](W*MV8[?4:I8B#B42VVFQYDUF0,:=A'&WH;8:O4.FO M?)6QR[DN#$Q*U6_;U9ZGZ!W*]TINS]/2WZ$,NS[W?CDJ 0R/7E6:/*R3Q"[ M7JP2I$;44DR21PB9476%>@L[GM#2;3<[-F_6BGJ62C!0LP28'*J7C+Q%EY=O ME$6Y?G+J_P!X\\R=<[*U75+-LFYZ[UW>"34IDQ72EM$!$OR8IJ>"8*!XILA' MF*@') ]U^%&\TE]EW+L3#LGT*7W9*K8/0^W[0-V96;L*VTY5+ BU5[ G9J[] M3*C:Y@$G7FK"%##SI,"'+/@2!F% >2SAJ,S-*OBF8LB5*D+UOK+Q(VIN^(Y! MNMRI^E ;C]=A@MJ'0P294&$U @-*"VJ%4").H$K$&?2-5'$3A$%Z0IYYDG*' M%,ORDO3QIRO[BX]GJ5K[C9MS9-@K-/4+#;%LMAUA2J5J!^G@!E]P&@ 8MI!U M@B9BC2EU%RIY]TK7QJ28?#,25,C3WQZ=7[/NOMQL]*59^KJMVCO,%AMIBBEK M2C==_2M7K(FZ1[=&G=3W^=I@YC#50T;R"=864C&Z?%^[MB-NE:6M<@E-<^]1 MF-K"PK$!;="H$;2OW,*.0+)SC)1E.KG"]&XO2[#"T6Z:$B[Q'V:5Y$"JH+O! M47@))(-2)C9\"': "(0=F:6 M(M06UMHFG"G[KUPJ[OL32B)H--[$O38&]['S*( MQI@H"T.Q[(KTFWF(CXNEP[1)M4A"71$=UIIIT,9QG'?&<9Q]/?';[OPZBBD; MSU!LB][5U?1MA5^Q['T<3 "-O4:(HA%L^O)]J&+,UANR"B@\>^S'L0EIPB%) M0L311*(G+D6=0JI)WCX+E^)$ *[AV5EF[.[XTMJB+JFG2&ZX M6K.M!NRB(PR"Y"PZ:Z4+@4W@0^L["S!2 MLV<:'./Y1G:ED)<9>76R^>5!K$ MW80E/*B?PYY;4"A.M'+78]>[.T;QP)\:[ H>+>DOJ+:JY(.QZDB0[">GQ:EN M2QX9:P/'NXBM-7+U_>.H[7M?86C*S?P)[;NI155-[.H0OVE*,T(9>(62=.D6 ME]([ 86[91R53Q$!PJHG*AIS)]20SCS]2DIUI"<*6XVA.5H;PI;B$)RXXM+3 M;>%*5C&5N.K0VVC&?,XXM#:,*6I*FJW:SI<&,S#DQH5-H=;B>K*@,QX;T^ M[=M!4K*U)9%\[0NU-&DO$TX4$:E9M2[18D@M4TVW4W8<2P4VU<@I#KU]PK/MZQIQ7UZ#8[FNJ@)%HLR10J1"1):4!K\604 M*H)I'KB,-J;6GUGLQU'UBY9\;*EN2OE;PK!.2>R^+V MR;W6>,]HV]H:J!M9[\U%R#WA&/;2U^$LT;8]$N C9.L]=U*HKL4>VD]S7J[0 M*D:L\\<(D$J]06L5UYL@>V*"#L--/F4V-2 UP!:]GV."F]V47+/!:=#:G%;' M*KT"8V/FV20+$PYSXFM1B#J1ZK$;P-"O$<.CHLZ1/CR(S6*YW[IM)ET"YL$& MU/:-W6L(=>:+LAIMHUL"(6?8-7$69T8FLG+-2J^(,%K( "F)Y4;&"G$.1520 M1F/ I4H-WY#:ROG*3?(W8,2=R0MOC 5+CSL[CD=K52G2+AQ?EW&E:MT;5ZX0 M29->XZW8]_>J(2X0L^F=@R16XKH5U5:588T&-WJ- MV" GGAQYJ.$:?U_H^_Z?Z^MDK7B$<-'Y3T%K>@M>Q(B0+-+98$/OQY"<2\)COJ;FFCHZQ$1L'7]AL1VGU^_4,_;ZOES%GJ(&[54W;*QEJ0B( M[BRU@47F'Z]EJ6XW$=P:'0!5@".;PZ1.V M4R+KP,+C3P4E'SG*<2!Q@1*FC9\=2DYPE^'*?95G&<87G.,] M-->KT='1TTT='1T=--4!^*]^R!H/]"(/_$;:/1T>*]^R!H/]"(/_ !&VCT=- M-74>!Y^U$^'9_5/U+_<2>K5.JJ_ \_:B?#L_JGZE_N)/5JG331T='1TTT='1 MT9SVQG/T8[]--&?=TL.ZN56N=2:]*7L9/%;*D#"@$9\E:5;*M+/2E&CT<$XZ MPWDFZGRCG'G7I",MJ7G,9QG/HL)=>97/8'B)!:/R53I!5"?(5H=: E+L-Q28 M4R2BG3"H+*Y X#[/6S+%BI9*(Q*4\18E2THF/1FT8891*S*7X7_ PG59=.*\ M<*87#3Y:IDU92999QJ7(1(F/Q,R;*^;58GFQ*YLAL&PLGF.$8RVP+:BLLMH3 M&MCZLV+J:?>:NQ;A'=GV#<)-LW5!%8B-:Y&74JIFAC69.<4R+-"9(7:*0)(> M).L2CN.WWI+25Y^\U*?W>RB*PX2*2&4EPG)258*\99&*L WC2<\G/$!W@7 / MZSUCHKD=IBY6.\52HUS=E;&Z:VN$$$,6>5@ZY)!C3=REOUARM@RAM\_"JQY; MU:=C3AL!4J3AIF'Z73_$+Y;';CKLYR?W'K[6T*E,!]B@M\\**%4:MM8?8S]N M08"T6TA)C4X780H%-6K9XL/(O-0E/YMU?B$?2K8;S;E-6^%7$V_:IIUG& KL8VEXI[#4@C!GE@J9UC)AAY>%(K8J5)9>>BRG9 M*T1GT<GYJ\6_Q5(9RVW+:$@1@IA4V M^#H!/[H)E@XRK*\H5;< O4 IDCF4Q_E6P419I!VO(1E.) M"%E*HP'(LJ CN(_%6LZ#K-/Y$Z;_ .485:!W*N[,6%^45.5)MNO72=PI%+EZ MS&%Q\7)<^)"AZZP5C9:@6HZ-CF7H*O;[ZDYCK;FA1N--39':D\.3G/+"['NQ M>\V=-)HH:_&Y=HM $,35<[$LE?56!2;0TD<#%OV%0F?F2.]7D#AHJ&F6EM-K MRJWL*F [U5_59U@C6FIY#DH4M<-2I;)YEE<8@\SV7E0]Q;R%0)Z,2(,I.6EI M8<\R].0-MMZ[MU.AMD5.Q*N\2WMLJ5Z=>Q+>ACC>62.O&BRW[DT$E MB:1I)F$:,3*4>O#'L9*.VU:AEJUUJ/+/*;%5%$7.T9 \TSA2H;$;Q(9#&KNR MJ,$JSG*=#;TQO03:2F-7[:U;FK6:/650-MTR93)Q]3]6K]F4NOF,=L8Q]&,8^YCMU]ZG0S@9.3]<8S_,-:PX M).!@?(9SC^?7X7VPE2N^$YQC]=GW8Q]'?.,X]W?/T]NJB-Y<]]M:OV7>:D+S MH%H< V";H@*';$[35)*R8FNY5U#Q(]PJZ"U=)7![U"5)M-/E"*VFHA'$3'SA M%J$2F1K>NL)>UMKR04.FWZ+3GC-HCIB64LY6 CA.PQ4P)0I,8Y/7!5*+1TBY MLP;AF>Z^WZA*DP\IS&?<:52ZLV.+<2#Y_1C52,JDEEY#'I]\C_=G[_S9U7MP M8YI;FY&R]Q9VU3M)5Z#KTS5@@I.JMCSK"1;(FQ"K!*%VA%D9@"XY1NNRP)Y4 M* 21.%/&7:].@/K%X-D+!1E^%%W'68@ZQ.8:5E"WVPDJ5#PK&,9SA$^!F9"= MSC"D]\-2%]LY\N<=\9QCMU;7]%HXS 6ETRJ5$,EU#^!-8K@4"-P\W&8A-N^H MBH,2-Z5$.+%B(<]'YTQHT=C"L-,MH3EOUK:<8PGLG';&$H3GMC'T82G'NQC^ M+';JD+* !W!X]?AS],8.0?KY.?T?0[*Q)5>(\8&<_(9]?KY/K\]82ZH&I;CL M2!81\I6?,MT8%,PUK7G.WURGFG,YQ\<_#KXV9-1$]% )DFN M^<=I@AP?+PGM[LJ>;=4PM7?W_7160 M0\7/@!!&#C2-XNE1)2O6VUQYH/6NU#.(]>I4&*0-E"T6#2W2 *)EJ6VT+?-P MQ[1N2AZ.)7+6RO./,>?#JN3YXKC)\'_"(S@C/K\S]=>B-R,B-B/^Z?MDYQZ? MSC'GSZZ?]FT-^BR[/#G1B4YSA2I UYYM*3E6,*QC++WHW<9RG/?MY._;^3J'="\F]*\FA=F M,Z7MZK; IIQJL6A;@*P@'@MC7!:).!I46Q"Q4E;:F^2-'S<93+A19&,_NS#:\^_OCW*4G*L?'/OQG'58Y$95E88\9&,_I(/C MS_V?KXU01@X(((]0?!'\QUW<9QG'?'OQGK\J2E>.RDX5CZ,X[XZPDL(KH ?/ M-2#3]4&"(DDH2(Y-9@"A@\>P[-GS9ZY[RA\0?&BLO29K[_HH[,=MUUQ;:$K5 MU#+_ "2U.+ABBS7(/0Q<(<%?*43*)[&IXE9*KXB-3W3PZ=&+JA2@[,-]F6LM MECU%N-(:>??;;<;6KPN5\,O\ZD-@?,X/%CC[*?MYP- I/I^CT/[B/VZ8,C7Q MA)AUB1&;RAY&4+QE"5)7C/?W.(5C*5I^E*L9QG'NSCW]5PK[0H& M!S("'88T+8,;$.,U.E )WG9@+BDTM^ML-12+ZDYBY4N+AR4UEM#&%/J6Y%#Y M%ZBV*J8U5KS5#SPUMAXDJMV8%:X4&/,D2HL"5*(UR>1BQXI"1!FL0)$G,=N6 M]$DH84YEE?:2+('$72M% \I,4H*+CY$20G&6)+#\:4RI"$SG#C>58QG"VE] MO,TZE#B/KDISBAU292%8<@/&#Y'IX(^GH#D?;637L25GQENV^5ECR>+HV PQ MZ$X]#\B!]-)0>OS9(0.F3Y\GT%:8R_34CU>ZP%DW!1 M,C-L=,DS6DCS;@78C3DLE-R]#>8N1T#A#[IF.3 -+'I8B)4^I4B;AG+;K.%XP!.L M?$+J=8IU=C&Y>,C&Y,*6@G*@I=BNN2@Z_!RC2+LG"4 MQ&UHQY,*RIIJ0_1Y$=EO+F<)\Z4K>=;:4M&%.9[>?"%?6]?+*75M!,^A5J1. M8J K/JEH(BWEQ/;YQ#K:TUJ)+0GM*%06L*=L#D?.?32'(XY+F<8?3BA2J$NO MQ/QC2)#CR0@;Y>B^(A(VER(FS)/##FC'2/KJC=91.UZ%AAA$")7!+\HG,01LT)N98YCA MC((8RWZ9<=,8L4&9FPWE.I9._P#*#?;.S3NJI/!/DSLJC5H<1+O%->RJHSK& MX0HPQN2/>9,27$V&_P Y\PZR$E5@?&&#A4EQ)&3%-#D8=5&C83W7Z%G&<=>;M'35/W% MKF\::M 6S20E]"Q:M;#E%)&@INK QDJ/.$"ZA;@DT;.@VL9/BQR*SX^+,UU"4$2G$:K%' M(_YT:+Q [2H56,X\E_,C/\7-2Q&E=XTJI6.':JE;!%7$DPE<@1/DX+(G"ZZC6Y!>0,29GP'I8^$N(B8F#-W)JSZ2L5 M:Q1^3=LUIKBOKAKN42K7#8U#OQ;#$$%(CG(P(^T1D'G3\[E%MR3>;#8)@N& =*6.;%M#D& M2U\GX[X]$.6F8MJ3,R3C9@DX(V7$8G=FB^#0BGZY$;_H>O\ 8*]34%5 UTO9 M<-&P-C(K*:\JN2!T":1-:V:*"TK0R1]^.5626)X MQ(LBMZJRN7#!A^<"/7R3ZZJ4KTD^-WI-O&JI_AL60?',E1&F'K)RTN[]SLU? M$UU$4/L\_%@.LPQEP"$I-;&V@'$A32#8LZDHX7&GEBVBU?/U?O");G@NK+J#N;-K>M=E6P/L$BQL;(5%\V1I9 MFK5,L\6$/29AS/3U4#4O'DY=9%SI7$?7N(382P5BH5V'3*^% CQ=K:B-VT_> M]GS&IP>,68M"B2A6CVWC9Q\%-V. M3$EG1>O]70 40F[#\V(;Q$X5Q--/3F$O/LJ*"8]?F+AO28'ILP2$^-)TFQ1[ M/2K3CIK88J,%FS+9>.G1BVZO:G)1#3.J85G( !9EP?&">(U5EKT'2^/YLG4^/GBOZVK5AN M0ZHP; D,P52O48\H.*G+3#:&-.L(ML(%H?E)U(N)0.P,N6XY95]^LAJD(]FU'-/I@9Z+9KM[2S2A MWRM9'C3,0JWQJA<# ,C(G(M\/YH&"6P2& ) 4 8SJRS5^CM=;$9;O!"\#=\& M9$=#2[\>L5UYH!ZUS(Y?7E>/76SZ1XVTXO4E3+4\6?%6/35?-P@&+/?Z"FLE8=BUW< M&!K-@B[#ADQHB/F)&;CV,\4><1(;8RFB.35@NYS9D:UWU\;M(KJ%>L:&1K 8 M773@B-"BO$Y!B1#FP#F(]?//!V63)J(=KF?).#17"LIJP[5203)'6@5U4M:9 MHSW00O%Y++DO,7&"9))'+9R6.+%E]0JYSC .>('@#QXSD?3UTV4[ M@'PB*3S!4GQ+X[D2=@/+M)T@0U%29LLO979>9SY\B])#N+EF),I2G99!_*Y, MOSK;DN.M+4VKV9/"SB$[9F[U+XV:/>N,6UQ;XBWR-;55RRLVR!(:FP+!@\L< MHFB>-DQV9 ]WUK#(];+2H;3'HD=L.VGS(K58I-MM5"$.6:#5XDUXK=;))C4[ M6-:Q!PG$Z=9+"9DQ22XXS*\.28(H4_,>SA+&'(V'4OX3P+MX_P B+97:RQN# M15CM-@!3;:)U\Y<35P7,K(I[U(&2?0L>U;*0M"H3DN.B:17 MF5$9=P;'4+ )MHK, M%9I@BMGA\?)FXX)XJ&!/$>3Z8 S\M-QO+>=&MDO.BZ1?LNVLPM]=I?K@Y\Y! M@@!:4RB]:+6*)CV0'F6-E7LM]E,W!3(UTBRPJ%+=8D(1F7QMB65XT\6UE:MA MR,28$?VY8;X#UK5XS(>"T-'-TR'!=,DPM-%C$X&A0;S+S4&(RXXTUF7+E2Y& M/C^FG,,ICPB4 M5YY;V7)*W4M+4IA-,:U@[$I%>O$;4#);VY#1-5%VAMFXV@V-6^EU'D(#+"-) M1XCMVYMQ:<[5U EM)*%K;VAB>V29;]ZP]6N$JK!ZVY[#:BFZ=[<%F_"WO5 MU9D>2-ZLR0&&*19N%9F#8D95Y.JB$C/QD^=/E5.@4P363@?B-31U<:<,K2F'J()F/:K) MMN;ZX07"$XL.J..D&IYR'$J4^#J%=)NTH_"J=0")?RD8+K3@)K,IQV=,FRB; MSLW#C.\690YZ3-KVE./(N4[Z9:O3.71U3GG\_P!:XY K\-I+Z_/]=,:1G+6% M9QC#G;.,U^[;XZ\III:Q*8V;RETA7YY*ND@=3X_7GY5:^I#U?;9C.N IAJGV M"QO!+.TW)GW 487">G3(SXV-"5!7F7T>S5MQI7CW"%:=2K$L5$-MW4%^C5[ M/;2(M1H#9=OA"1?#$[5HFB4=N)2AD&LJ!8401Q!510JA$$:*J* %2-0'XHH M 4'BH'H %S/ ^3Q+M9AJ?"IFQ[U>!R'Y Z84.LS;U)D24X]8]A2;9MB*:Q.E M=LJ5@(PPK&$>1'HD8PG"![7U_,NVT;P -ZYOR]8'79*+!2K _88DUK4)%<.( M=%6$@)GFIP>)-%JD,3YT>;*=8E2$SV5/24MKS^K^2V%1+UJ86SM[F-N$J0KM M;?A.5K9&@Q5&>>UX?P8<#NSB?RIY![) S?5L7_7^WZWC@QB1,'-!#*E):CO$";\4!A[[[-EZOK;3+)OJ[6]+=:F]06=GV:&@]F2 M",K$94DE%H-A@\4DL[%"%?MEADZC>]G&\)2C>S9K+3NPW08'RS&$$ M65E )C?)"L#C2';KO7#C3>Z]@ZHUYQOUFU7F:^,1RWL%9UR$U3KJ6+E M 3\0S.JT1EJ&TY6;J*I\-QN!LR_U*T46(Y!FQF(&-AQ%2'R#?IS2Q0TF-)*M M4J?A*$X"*I9:W2[X)DB5)/5=XS[$\[;66'GU)H;66E: 'UK2*^PW60CYR5%082P9)/2[(8FG33EQ M\RI\H@2(27I,B2I;KJQ1Q3*B!Y.4@1!)*,+W7"@._!,*G,CEQ M7X5\*/ ULGL0L%'!GQ_A8\>!^GTQX]<_,_6/.'>]R?(G2H_89SV3DRJW;$K, MY8$23#!GTU*YE@HR5 BE2!9]:)H1@9+=DL%"$&3*>DN0I.6,)0AINN%B.Q&; MPU'9:8:PI:L-LMH:;PIU:G'%80VE*<*<<4I:\XQW6M2E*SE63_/K#)!)(& 3X&6I4 B.G,R(1"#*:RIN3#F,/Q9#6*!7JZ*?(R15?KXJ49E(GF)(L&) M&R3$Y"L+1/+R(,..\6G(7A*D32*Y,I"DI4AY*L8SBF3C3O7D98#7"@K=^1%M MO([97-_FMP?OU=G5?40T21O7''G?$U?RZW)L"H\ @A3?[C5RWYQZ\1I[;B@"M8#;E*OF@@$Y.L[ M)!'QZXZ[3KQ53D&=&]4$BH$.<0AR6B5>E2QW>,TU=?&JU3AEB%@A5BK1#QAI M;!:P0JZ"C'"[#F,(<8*G(T!LH5CK2G"'&"$R2RI"<(4C*4XQCSH>O=>C:XFG M#M?T ?3TS<$DT^!1JE!J*26)K9%)%-5B!F:]@C@BRT120P-Q,P099G8?];9; M>1KNTOE/LC67A@$6[RI( 94G5F2 RX!J]3)(Z[;!OMJ'3& M+76!%@7,H,'0@^M%MA7 I9R%EN=LBHAAB'3$7@S8 M3\QMMIMMN6ZPN0VAMM"'4I;1A*#<5'S6>9/B803FUKG9VA>[]'1:I0K.?K4X M=7*R6XJZEM?>KAXP(>>'@0A(W.$B_5YJ@N(\U]XLV5L\V4;?L3Z::\"35*I, M>#29E5J\R37,)Q7),RM@Y4FN82E*$_)V1('N/ /*A"$)]CKA>5"$(QV0E*<> M*]J_6$DY\J)&L=9R+1[007^4\C75)D6;VNV\F0V7^43P%9OVLW)0B2V4]?\ M:#CIIKQUUVO.'6[2Y7P#EH:A>S6K.X#$KLK0W"'V\#FK$J M'DTV/PU*EM8A(G)BI:ERVDLX;E2$._ABM5N*;F6:-7*[&LQ%KT)&RQ@ >/8R M#/H6(^69Y]F$V8FM9C18L93ICT:4H]'Y$IQCW>CHZ:: M.CHZ.FFCHZ.CIIHZ.CHZ::.NO+;ENQ934"8H=/=C26H)%$9F8L=-<8<;AD$0 MY&4QY;D&2IJ6W%?5AB2ME+#^?1.+Z['7CV*O K=7SU3M F$>K-H"E:Y8@9)M M3PXT!.0) LP)GLH6VIV$2'2I,.4VEQ"EL/+2E:%9PK#35),"M;\\/2K[@LD[7ITVJS:PY8UZBD S6RR5AL_H+;3MDL6 M 4[:&?EC),A)1NL...RYLF];;O%;YK<>]\S:!M.F%^ ^H=]BH(35CE+8$0]W MG=H4*\ZH*-/V:U?+FOL(HD8@&LY5H18^Y0G&G0T-LP$PWW \7./59U9:-)!- M2UB)JF[ GJM+''FPJL:SFIZZ47;];5W3EIE5 M<%/F3)HZ!EQ*F94V:\IY:YDK+S35-HDQ:H'&[E'X2EJ:+S[-Q?J>\ZR4L$]B M8^JT^&V%U/8]C\>;,X73&AHF6&[@951XLEWH^([[9>I7XHTY)D!I/I[*_#"Q MG'AL>'VI3:6E.\*N,TZU$O&Y VC'[!&EL6 G6X3]DL+K M(^257C"SA;*W%^OR//[&O=>TC4](K&MM:U@72Z#2@\.O5"HA,2D!:V!'-X9' M!0[$R5,>ABA[&$QX$%+^8\&,AN+%;9CM-M(::S'HZ.CIIHZ.CHZ::H#\5[]D M#0?Z$0?^(VT>CH\5[]D#0?Z$0?\ B-M'HZ::NH\#S]J)\.S^J?J7^XD]6J=5 M5^!Y^U$^'9_5/U+_ '$GJU3IIHZ.CHZ::.H Y3;G_P"3UQ]VKN1"ZBF91:L^ M1$-WVP+JE,EV*;,AAZT-LMG1'EYKXDJ>)#QLHPJ,ZT/3)]9>QAIM:L3_ ->< M5$"CL%X8:&#RXV0IE4@>4AQB$%]4:0U+C*>B2VGH[JH\IAB2QEQM669#+3S> M4N-I5CPY((!P<>#]->C ()&0",CZC/D:U'HO,:D[7WTWLZT"]$QMEYV*(CF1 M%,V 4MM(@6)AQ-HKA";$1&&2[81;UB&:N"LM0@S!")%DERPMY04BC.R#5.3\ M612JQ;+?6DL0C=4K5C?.4:Q5NXUQ2CX2&97F#&06@VS$'"9B/4'9H!J5-C*: MDXCI0YCJ89VD]-D1,H$0U/K2<#FSU%)P:90JI*%3"+C#$1V?*'/"%Q)$UR)& MCQ5RG65R5QV&6,N9;:0C&OEINPEJGS467V58P%="1;7?(]Y.'B(R'1VJ8%K% MC-HBQB2,YKK P=4PD0E5F(;C,>$+%17H&&(L-W*/G_=$;V4[Q5CVD7]TL>TS MK$F>;W6A'7V<22+DV!!2[UX+/N;2M)-/!:FK5SRN1O [V(W')1Z:O(IIVMQ7 MJ#=,/VS% :0=QE@T,0,[AIS\4V2\:DLW*/+L;S=UI>^7=T 6CCQ:.+\9<&G! MP03.Y"FR*C:CUA36J-JJXRJT\"K[Z@[U!%[ K-G(UF-7!(^IKKX6TS"T.9.AV&.21:D" MC904" OB("L,E4+DS41Y3\K1>Q'"M3XX53=NP*]0[#4K#\O^/E0$[8K^YU%Z M"4M=7U>-.9'+K5=&WB3+@8%6U^V+&P2(EF1?QXG7YA@K/P_4&J.3EB),7K8V M\MLZL'5^Q5(A!T/L348*H4ZSQ6=5 4V.%1+/82\^4$?BW$O-=M+L@NTV]?0) M>%39WS=*'RW^@BA^(;&X[W4H]/C==P>O-OEVO#-M\^Z^[1F.*!E+7&65E8=A MS/(#*?,$KR%M36KM6T>\3S05WJ3W5422=J.:5W0 1RRRHL)=47ER B3!)=W4 MJ3JWK;6F9+T8@>UN[$&S2$E@J;]9%RH\@,V<+6Y$>3A3\%65Y'KR(TL,+QO),TKUN[ X[VX06?,HC"JZE0TB,$54$ICD4 <&9 %-\J%86E*DYPI*L=\9QVSC. M/IQVSG'_ ']'G1GX*3GX?]+'V?A]G[/V.D?T=L/= #5%*QR".:]LMW)UAA5@ MONGDEINOVSD[,OU6=!C&1XLK[!:8<'J]K/P8SF'FY*#$."[E3JE#H_&_F(Y< M9 %[Q5-ZE_DL1U\;-J,:4T&MNQ#,QS!V1'K"H5>3%:K=C*34@B_MF.0)-5X% M$@Q":B[RS69/%NU.7L#N<)+#K'%$^ SN\,EA.!!*21R00RRQ3(S12JA$;LWP MC4O4E3N$X*1J6,@#E2 Z(W\D,K*\BJR,H=21R4#SJY[&<9]^,]\?3CHZB_2U M6O=(U50ZEL[9#NW[_7Z[!&6S9S]?@55^[F8V%XDV%^O"W7AXAZ=C*%.PH;BH M[2TJRWV2KRXE#K9 Y']/V_3ZX_7K%_;_ %^^CJ!]_<>J?R,JX^I72P['KPX6 M2F&(4O6M^L&O#+160!* HPPJ*Y/' M5?/+_P 0VC\/;6)J=BTSOG:LPC1R6P)2CT MN.PB)!AQY*WT3XCF%83EW+?C<O]?ZC6:Z.X0Z M_P! ,'UU6];6NA>RPZZ.)F=R7*3LV5F'6&B46#F @FS#P$($(!!,2R&0"Q): MT/P8)<],G&6W9SLY#J&0KSQ=]F+5; .*0(T&0'D@H0X@[$A,J98'9.*3)64@ MH:5Z"&//)DM1&L)8;FML8[)P+C;R>KW)&L3;,-I5YUVF#) 1,#-A,5R-()OG MJ97KDI(6;7K ?%%5 46%NMV9J+.R\%MPLT"E-8>@96N3C&X]9!K7)H$J^4]N M_P <8DMFE/V,5'L.(CPXL6A.21[DG#\!H@.!&9\-Z:AE#XX06),X=A#)KS-O MA$<.#CP,$,1^C(S@_/PP.?F#XU4>YR(;)/HP(!^GJ?U#.? \ Z0"VV+Q*4W_ M &4.T[7.(HFE0Y#[FL1UN3>(5T9"Q \G -F\5D5';7-#1R2WFS,JH$I#TDF_ M%15UL!_7_3,IQHN')55%N5DY?S./H61#-LKK!?39BQHJ357:#P$%)5DFWOU& M4,(,V7)%A$.4VPJ%!3&9FO/3,N>5"!WB&;MOX&&.9XMZ@M>T2-L+B*92JQS% MU0E1*8&A6.0;"!KBM]IY-]J3PN'#.B@\&5">;P5(,SF(T-+"IT:WK1%+J''$7R VEK079HL(5 M/KD:G#"6'+E%3(^58OK73F-)U0#1M;MHC5BJ#7!01F02+ MSIF=EFH(?7\FVB[*6U[%V6V-C5@W$3BHNVLU1O69L=<7,!! ;; M )4(5KKGH3X>9"S@H-BLO,K=S*+%'B+LR6LNO0XV6>>PVZ;P%%SD0B\MI,)R M="L"(?I6$&F6HK!B*1>:EJ=;8<;>F(RXE,VC:^"#N/."0XH:X^N0X^L>.A0E MO.2Y"IVV<9QVZJYN,ZS@K58M9"LDY-@=+N MK@&DCV%0A@:?$8G,D5IBI;25*G'G..6/7.1Y)88SK,JMW?@9D4QJ0K,<$(P(8_\ :"9)"J.0!\ G&N$\ M5G7%H%JT$W-A&:Z[F08L4"6G":[&88D1!CT)QM:<2B)%I?EB1,NX7'0TI^4A MQEM6%-=KNM0-:5C$F?F&.&"15_JNDSWDMIDD'\X]8GEYJT*>DRGE] M\YPRTM6&\):9;:80E*7%&/REML*QLQU4-J=U3"@ D$\%4 A(U"L\KX M^&-2SG'C "ZJLV.YQKP\C$ASC&&D=B.4C#U7Z*I.$'@$DLQCJQ\J>-PD8[8R M_(+6[8-#R!TJR"+4'L-QLTB09' ODQ0:I5I!:PI:6;+!@KN1 F60ES28^)&; M=ER6Y>+I*(:[!+GV,G7X@ >Q% M61AM,ND"3+A69(]6@>N3$NMIK;I7%7C[K,'50U"TAJJDV7*;A'M5\!U:'5'I M-2O5P3?+)JVJ@2,LHEJC%3D$?%F3;E&2ZA@:V?"BFK&_!>@.P*C:IPM!VS2- M;"929<^,BUX>%&$B6(R)LF$"%QO2324U@>.;E$2#;NK/BV#D"+&$L!-9TP_82"UY9EVD MA5#3HME&<81Z0..4D>V2<9\WI,/&)P82E*$MY0]TR-([9'!PN!PK(0,KR!=O(P M7)*M\_.2#Y_,P,:F8SO/3E$84FL#[7M8PVVOU./KVME+ ->>QW\K:[;Z!JIQ M&4Y1A+SV2KV&$=OK'',X;5')C>G)"^Q&X-(H@73(Z8SE4JRV64S8[$,2A6?, MB".D1&!Z93R492AR2")Q&TY](EW"L)<3^)U3Y 61QAMD_6:R*[(0[#!5J:], M0VWG/=J),*+=C1FUX5C'G1!PME6,Y;PI&>W7"_QHL%AR[D_ZI9Y3N5-H>M\^ MV%FV658QE3,,5%*C1$9I2O?^I#LN8=RK.%^3/EQ[:3J"Z[*)=TAKCX?=Z,-7 M9H9!A?SKIDW7=!D97E":A(\@)X8^JE=?+M&S?X3N9"H'J.'Y./P?.#R^_KJ! MIM!U^6LKM@W!M>S;AO,-E]J'%CSC=@>K$:?V9G10]=J*I,@4S,7V;>?DRH*% MY2EN/'C,MY:1APW7FOV_71E#XV3,#HRG,PRUZ?F!XDB8K*FU+CA,&5SL^7RI MRY)GSA[V,9[9FA MKC=;Y9P _O.X7*6Y6'D)4'F\2R'B!X5<#(' K\+N_IX#!$!^R(R8!SX&<$^3 MKEM7 /3.Q+=:=C;8)@*=<;:]3IDJ?"OGJXR6XIPC:#R;. M-ZMB++8-IE( MEHMWR@=# ,AUQ[19($.8_P!B2(XV2I7LW,*"WF,U->N_$6X8E+F%U;5J58$7 M0G:Q5+C"!FJ30)F.<+D&@XQB40MM4J+;*,%',1)N%NNSPJD2,G(H[+*T]/2> MWNW4F_13=%;EF1F$>]X*,KYN"A"',M*[-A+!.?1A.<*SA&(/G4G"L^3&<9QU MM+=&L]&W5W"[:@@M5'I2RO1Z@GF2%TX$P./=:\#1@_DI8:8"> OY,<=8MA7F M22#@ZK+')$>W+'&P21>#%#EF#@-\+%B0V&\D9U1/K?4MJ S+E&V/J?;?JY"F MV(,+$#M;+.1B=A)1G!S;!M1:"Y&9%1\.Y>FRACS15U;;"X4K*65ID>L M^@=GJ[GU1=I[.N\[K6WF*.A1KUK%I\]N==PB:MP:2&..PTXJ1+'-6CDCE%AI M$YO^*:6T;QTQMCC<&6A#N-U+,8FB$@D,OPV3 MW'<&.9FO*K=9'$FQR0X&6]9]7GRFV:,&)V)I^,VJ&0$A)D=MDU2;(XR/DKBV M.77FCL.+'E#W$HS&DN5;Z[Y \DN,Y]6P=>TB[FRUILD2IWX98]?7:PBGFXED M8CVZ39$#O5&F[75'DR_4(F2Z34Z8\Z" LD99B$RZ[&M.=>FZWK&"%V4/V)0; MIKFL@Z\?J3FL[Q9))-0<+!'PB%,GU@"2%6J"98997%4/F)PQ,S*BNJS#CM$9 M2I!1%[+\A;OR*IVS]:"Y-[L^K[,&H3S>XCI.K JSLVLWU3%@"O4-RDD;>\%$ MSQ[T"DDH28=PE/$)%S+#79(_J*>R_>O:1UY[8>I-W]KW2%;V=[9T1N:$%.?;STET M_+9Z?WK;]RGGW&(FQN->$0A680QA%LJD2SUBC_Q=8+,DDSUN2 D+)(USE$YL ME(7!6B,&:_ E PS1J2\1?)/ MYB(?DQ,2\/Q&US;Q=Y!U;E1K\A;F:NBLF@9U^OV"OOSFRV8G@9[II]]$""5(VR MJUJ##K<]LQ'F_353K7<]V]K7XAVK:@>)G@J"NME42:RC,D8%K<)>JFVV-S'2AV\RSPR5BJ&9RC(8[?$EI LT.4 M)2,(' Y2@\=AVP<".'UMV3L/;UKT%1+)L;:X^LC-@V<[%(%9-CBTY0I=9]8A MS2+XN%*$9"BTQB(F /(*:@M,ORGF(V>2S,GMM2W_ #JGL2FI#F6WI#3KK+2T,[JB],[- MUG0M@L#R@E%SJ("R*%&Q5)'$Q1)B-.'SH,E;T63%DL-NM.-9QE M/;MG,@]=E"H0"%7T&/ '@CQ^S]6I%SD'CFXQXQR/Z,>OVQ_-HQCMCM_Z_P!? M\?T]'1T=5ZHT='1T=--(5XG7[!CD'_V8 _\ GZG=&,X[XR,J&,XS\,X^[/3N-L,9PK.66LYRZ]G.CKAO%J MP0(1)$RO%'H;CD-XD&>A3G8;CD1Q]49UQI=CWJ\?]P9^](_)Z/5X_P"X,_>D M?D]--5?#]-Z@$X"X%:HUF,Q6[*2NE=P-H-3@8K]Q,>E]L6X%B((9P&M9?T[_ M +6LHS$4X3]8D>OSY'K#_I.J%T=I.N6%RW5[3>I0-L=LIZZ.6D+K2D"[(NXV MF.W$L]MR>@@F"N+18HC2(IRPIEI+E8V%,3IC[3CJ'+2_5X_[@S]Z1^3T>KQ_ MW!G[TC\GIIJJ-_CMQ[E1@$*3H/2$B%5(EL@5>$]J'7;L*M0;ZIU=ZAU^&NMY MC!8MT@_HW24J$5&2=-:FD##H #5#@U_6M)= M'&ZM5DI15ZP9@. U0RM;K2$(37:^08DAP24XP*A0_?WM,]7C_N#/WI'Y/1ZO M'_<&?O2/R>FFJWQM*I@8^1M8BGU,5:C @-7B]H&5H) LI8!7$+:KP(I88D!D MR2"@&W7&P@J;-?@"6UJ0/CQTY[=9-T_7J\?]P9^](_)Z/5X_[@S]Z1^3TTT@ MO1T_7J\?]P9^](_)Z/5X_P"X,_>D?D]--(+T=/UZO'_<&?O2/R>CU>/^X,_> MD?D]--(+T=/UZO'_ '!G[TC\GH]7C_N#/WI'Y/332"]'3]>KQ_W!G[TC\GH] M7C_N#/WI'Y/332"]'3]>KQ_W!G[TC\GH]7C_ +@S]Z1^3TTT@O1T_7J\?]P9 M^](_)Z/5X_[@S]Z1^3TTT@O1T_7J\?\ <&?O2/R>CU>/^X,_>D?D]--(+T=/ MUZO'_<&?O2/R>CU>/^X,_>D?D]--(+T=/UZO'_<&?O2/R>CU>/\ N#/WI'Y/ M332"]'3]>KQ_W!G[TC\GH]7C_N#/WI'Y/332"]'3]>KQ_P!P9^](_)Z/5X_[ M@S]Z1^3TTUJ$^*]^R!H/]"(/_$;:/1TS7C)--XY.43&&T8QC1%;QC&$)QC&/ MG%VGGMC';MCWYSGW?9SG/V>CIIJP[P//VHGP[/ZI^I?[B3U:IU57X'G[43X= MG]4_4O\ <2>K5.FFCKYWQ_+]CW>_MGZ,_1_KZ,]^WN^G'W.^._\ W=^J_-=' M[6/ VJ=M6'MF1R;B2MRE(@AD=L^30<-#UVYRD#=?>P67M5R*A,J0\!D$W,D. M'2AAYG-DQF\/JC)N)&7#$$#B5&/4GEGXL?)%X_&W\G*^#G5J24(R@@GD&.?0 M#B5''.#EVY? OCEAO(QJP3O_ .O_ %\/X^_PZ^=\=^W_ *Q_%G/PQG^+/5.] M8QS*8I6K*%8W]O/,:3M6@MAV?8+*#6;9NFNWR\ZPSC7IJ3YW"9=.N@AO;=>L\$.Z.8SI9-*C3>.LW9:6.+&/;7;98H+^X+ B49$L133OP%:0LA7F2+L2$DJ MV E0:@,(ME52?88J&RXK"4X;;KML?(S75"F;7%5(%L1P!4K S41Q:!?9<&': M[7F618DM)!28LD6"$Q60QHBS*0/=4^S"99;'MJ(-I;O0HMWK.RJA7[U3B2"] M8LXY@J'((:=9R]&=RI.4NL/H;?CR8S[;L:7&?;0]&E,NL.H2MO..JWM^>&\* ML]?W03TN>C"KW?YHNT5*N7V9-9UG7[O'..329.5+KHJ;:FAQ(24L0[U)AJT/9NJ]UJ[/N?LY_$\MB9;DUF[9:E.TU6QMCG;):,UY9JJ MUY)RCNT!1G9JKY-7WK-6Z[AU*U6N.GKT:)(9))0NN16SJ,?@PB<.>2'9%V00';M%;/ UL*F^JV.N-CEDA/F8:GMQG/-E$WH?>5!8A;7J+XH@(RC,6X5MV7)1'=0GLR3$& MQ>6[($PI7F5EM]*8[25>1[TC??OKH7#2-YJNP;#0C-1+WS;U.*DHZ:Q5VKE) M7W"2;20()=<6HG. QJPXI'F M\_HI\Q+C7M/#J\^3'KH8DM:?*M;R&[ &E8@& M82TXRI"HR\>KO,_JF<97ZM,:9<6G.,QO(K*>I%7ACDA$";7NNW-'-!;BC:"Q M;I4[<3 MME2DJ?B+2:!A9#;7IQA5*A\U+CF?+A#2)&$M MS,X7A2%)P.:XY+C(!) 4GT)&"9;[X_]?\ KX_Q?'JI MGQ*.&/$78U7M/)G:^B:3MG>54I4&B:N3?=E7#7==*G2IEN'4*?.,A"K(P.U8 M#Y- M1!X9*D2O7$CCKJ&[:BU,K9D-DE)DHF-]DQL? W,<=OKCR!XXW+?&X] M.[NK^V]8C#&VA.HY]TC!6M1/7>TK2. %9:.0D(2Z$U,% %"@[4;!X<9L%KW#POD'.?/IY_FP9,[X9@N%R1D_E M0V< 'U;/R(.0/F,8\A5)_&+BFXJJF37&[5F(@2W0MBU:WT^I5NMMB;E'C(5! MND!E4E##AIQEK#N2X(@3DS4)5EWUMIUWS-16A%0,O3#M+MTIZ>K*F9\D25@R M(V)*?28PV6"QV$0/6&W/-A:)$./*SE"D>F2I&?+6S7/"-X@ZY>6(BB[99X.) M(QNFUTWNZ]C9>N1:0,:N. J%$D'I"7A%@C!V9!.$9DRTRYL+&!RX,6.N+TT> MD](:)T<@H$U[4G:C$*,1G&["*)R7SZ$-&[2:B-DY;! HP:EQR-J.YC&8;Q9V M<-DQA9B.B((A(0 XL.:CSX^+P5( ]&48\^OJ3Y'(J-4-Q(!#NQ'U7QYQGP7) M]?&/0D9 QJ<#@PH$BD&9\.-)#D67G"RH25H#2):EX6V51#7A]ZK&D/(;F8E( M7* R)#25RGQTC").*[2GA@\>=B6VR[J@V#>8VY7,I:9^TZC7=MD157L#]MLH M&X'1)&ER1D\$6#/E:\/FP*L3PH%(AOO1,.*PXA>+1X1RLI;SC*WAJ5*<^O\XQC&>V?'R'99?R;I+ M?/&1@GR2=4J[+Y!P3C!&,''R./ ^7W'C.,#4;\9...O>/>I<:SI-HV+L&I$" M1$PHOMVZ3MBVN5[18APG!LNQ%F6I[PP:P/:A#!4A.6P3#>1L'$>&Q'C,S*.P M_6)L8(^\Y)"S,YC@)4AQQZ5!?0A3N CX8;5D5+><5(RA"X3ZG'$,. M.>76S#8^9+B3&FHT$M-9]UE M.5J0WES.28^.6A.PW^_D=PA;;K>?*ZP\VI+L>2POXH>8=2AUI>/@I/;/UN<] M[BD,H9A\V]%DLRX[<:2U']64AO'= MYMU4E#C3:5/(/*N8P]"*X3')0FENNJ_6QYL5OW8(Q%9SG&65XQ^K-95AV*[Y MFW4X1E#BTQ(V9FP;$)'WJK/6XVRD4+((4AY:L15I:886ZB'#SEYI] M?I$.J:=6AM'E79M(MB$1'F!(03PD>&1>)!.)$9'0@D9(93\CD'!NP/VV9R,C M@R^GJQ]/YACD?!\#7=B0=YN L-A[/+@.9CY;1G H5)C+SA.4YR\VN*R_C"TY MPE6(DB*M.,=TK1G&,=0?,J.YH;;@JS"ML6%C++N&)E-)4M0Y"EN9?4Y$&RI M$F(E.8QZ+#[JIDK'I7,>O9SGTJG%CWMYAE"&Z[>%X2CR(3"(UU+:E83[\X;< M((7G&,X\N,J2GWYQWSG'?./DC8+R4J4]4]HH4GNKSQXU7*>Y.,>;S)265YU* MSG"/AH[+2H02!DJJN<9+'5)M2&@0I3,2?27BM@CS9&:NPH\T#=BB24NP6L =]5K\Z6J9N%H/JHO>AW$O ME]78M>VD!UHQ1QND9*]BD!)\Z,!KV!" 21X9;]< K)LDCC#$F:_&$,3YL F3 M5"D-MV*XW[3Q1$>!+V8@#/%(\Z:*KECJF&#A(>.RWB=,@C1DU201Z9&2!]=9_C5)&.YEU)*6^YC&.RG68+Z?=W[* M\ST;S=\>[.<9SWS[\9SCWXZ\,Z$VF&=;>KQ :]%PG'GB2PD!N;E?FQWRU.2T MY'RG./K$H>CHSC.$=G>V6TT]%<%V".ZX\V\VEUEYK M$9)*&_&?;5A3+[$]Q#B,X<3G*%)SGBOUOOK$PJJ M?*M(^0JOXL,45G!5P(X5Q&:)^IJ:E)A*>=CY4\A+:DU:!T,?7!].KQ9+7?W>EQD;(G2%)]_EPI4#*L=LK6CMWQU$>PKDT2%R!EFV9LV+ E M1E19L,.()U^1-:7G/I._L"G,D6TN85C"LM366\XQV7G&<9QUUJY$\1 L,$F+ M3FGA_6DA!#Z*^X<+NM MR""(H[+R3!=5<;]*1E#XJL-I4]CVBRTRA64XRYE&5O(QA.%Y5Y5*QC[&?+W[ M]]=8VJ:Q$\0N&167B1>2Q,K @ JT<-VK%(N!AE9,-YR"#J\LJ1L"8T)S_P#A M%<>"#@3AK:DF?:XM&<3%P\1Y2I J8J#(P^AM+B4/\ [7\0CA)Q[V08U9M6 M]VFHV8)#"DWW6]3[8M5>E#+%'9?#$!=FI=.LH8I%GNOMP4J@RG7&2*LP933, MC.$YGBA6'0W+&DQ+C2O3V^FD(@B:#.'Z=8ZYZ^.L@. ?&$PL>WB 9^*S)'3F M<+D,QH,EB2B1#D(0_'<3C6)TU/!"#!+M5N<<%5+VW$U^WE2R1Q0V4CAQ&"L3 MK%(R8!;N>0;C6"27,7G M/)$\B'.Z_.E*;.'FC)P:RQ95*S.@.3Y* MEB,9)XA@<9SD?G9/@$#3R[ XR[48(PSNJ=Z[(K_JCKSI*K&K*Y9JN994TC#3 M7IC(PR8!2&5I[M/QE$(;F<^BD#U)SE>*8.4UKWG;=T$-97W7V[SI7584M$CV M^)IPG\UM@2_&@69<&AW.M1$P[L=G0)26\QY%8K1640&O !L0M)8:R[.W(G8' M)?4-RIXL%NZVGJ@05@E2CE-N14]7#QL48D5TZ)8E/234A<\:6@>S"=+F'[+# M$27'F(OHTR'XK$-XY>>)2+KTN$FN#HUJ-P)%5D@QP-N-:RW-37Z9]J%KK3H6YM_5>PMLTFV M'<>%YA4>9IDLPR5(I'M4D(:L.W'+7[5FO)[W G/,L41GEJ=4R;QTW/'9C6B] M;N65"0F0\UE0QR-'+ZL@PLR$O&>XF,?#X5*Y0&\*$G/30'R]@/4D=K2^6.&1S9#]:&L"6F)HE< M6"%-"S<"8NTNMU^1.]$Y<^*$= %50RW(LH7A_)DVB->/#T'T@CE,F$9.[%KS M,A=WB "(FK 4AR0R0.DMVB+'*UX'&B7BZ*LP$5GVC=]>(WMZ^4O6L/;W(&IJ MM#M^B@KENS@H(H80G#J%!J"Q]YM]C$AGA%1%G+2BTDZC65B\9N?I9(8D7J4@ M7%:F=GI[51HTZM"&'E!4K5J<1FC261H:L$<$(ED?XI7$<8#NY/,Y)SDZE,,0 MJP101B/MP11Q)R3&/)(5?.?SCDG)\Z7W2O#K?.\-96;=#E."&MI5 M^T@-:JQ68?CFQ\H&^FO0 M9B0X M[A3B6L+5AM*L(QG/E[Y[/6CI>S_9*/6EOKJ"2\-VN;1%L[U>]&NV15X?=55X M*RPB2.3MTZZ<.^U<%7D6$2N7&@_%58;S/O@>?WJQ52H\9D!@$:=H!@O -R(A MC!!8ID%@@_\ M%7TTUR=8O=+K4M=5@O<[U8P]3JH)AN06/'I[ T9"0_)8A14.R9"DIS(FSY44 M>/B-^DE$",N(/A,R)DIAAS*.D;\070NWM^:)#0="&*I W'J7=NA^16O06P)< M\?KS8-@T)M"O[(;UG>2@P>8G! %[B!I8'%DC!C#U7,/B+&V,F*%81AIID]5[ MJU;NP.?-ZON8BV1*E<#NO+A&BYEP3=*O]8S&^4-&NU;+Q1UBIMR"MS8$@G5[ M.*%'(<0@/F/04Q)\-]](]<$NW:K3P=3@;DEPCWWR$*7JVT4D'T'N[47,+5?(3B5O&6>B79YP%#TW M0^/NZAMO BH0TL,B;!U=!OXV95W2DZ 9*/T//&K-F5O;4HB1P7ORK1;=LT+89LE+G3H==KM/I%UTU=@$%UJ M$04=CB+NN \,C,N9$N0=Y#:HXQE:L,J%S3<:CM#<68 M)"GQ+M4)U=BVFIB"=1F*NP#)2I'K<.@3 85G M 5+\B<2@R)N(,1N6XS@%^XR;RYA\F>)VV=]UVKZ8TAPSV58=\TW5@F[-['ON MVM]2Z<=HM&L-N+B @2L42C:M$6FP&A(L07MIZZV8@R@QBMA ^8YUIJ6=*(/HB?1*HJ)Q'-Z-@:V6 ,DVS.PHVWM%1]M(:M$XTT@4#*8*RF0$=(^ M(X-'Q<>O2ID]2UI9P?0W)OE' Y:[#XL\LJCHIE$/CD'Y1TS:FBRETA56KU>9 ML4KKHYJ_9X[8LR<159 LV LV V8/=KU;O@(?8Y2:?5I0";";XM)Z1WWJ'EWX MFV_G*!73UI*_QTB\@ZEY]F\B^/7+MR\[@DE0Q M82BB:PU8!E\>JR'UWJVH 7;)"8;.%+:T28*V.0; &K-LBXGE-->W0O%. .7+ MQ([5N,&$UUQEX/ZNX_[EJ5\8D29URV#K+;>MM@WN1;28I^:S B2;.[4(+.L* M?$0P<(#S 9PN^DK8FA0?U+5S8WK(X1[LY1:PC\=;7N76@2$;7QA&WB/?54BQ MNNC2D;1&UMKTZ[1!(+<9>NGP<0H18#1J52[-+SZ#%SJ;*;3.1Z=X)VY"%D\3 MN,4Y4;>V8!Y4:>XLUC2Q;D#L,)L!)N^Z&+_.,F?NP%5=94M21 .Z5BM4:M/@ M77_1ZQN.PF)84L1DC\,M!M7A_OG8YWF#R%$:QJ=)V=R/X[<9M 1M/0MCB\C# M!;3-VNMV.;,OMUC"L 7I$"-?7=>47U$1,-O4VJ0I)EL8Z;:!UUIIFM5I+2$&G N:_LZ@66OM MC'5$4$:X;#$(-L"+(@2P.:0L-3GOC&?IQC/W??U6-L#@F>7S:T[S+TE:V-<1 MK-8!..:FF9D>*[5MV0*C1;H/U%M$>L>AY@/O?51XW J,VS1E9:OVJ"$VN&I[ MJZI5O/9RG'9*<9^.,8QG_5CIIK[T='1TTT='1T=--'1T='331T='2WD^6_'L M+M[:NCBVR0PW86C]*CN0NW8,U$N,'UWJP:Y%*P65$@<@A(APY<3]1L0.02#M6$$(6:$)F^KH+D3J;DW2".Q= M-6&;9:D+OVQ=932!&LV>H2X]TU1B+9?<::F[HZA#D7R*U/Q3TY==^[P/$*MJ?7 ]LS>K2.J]GN.:T#7*8AN MFYP.FB#UB>%0WY4?,^4/$S<08[BIDE#<1E]]KI[LY/Z(X[;&X(P)0N?D>4B-3H2Y8V,G^R=HO M]!%:_P 1-I='335A?@>?M1/AV?U3]2_W$GJU3JJOP//VHGP[/ZI^I?[B3U:I MTTT=?.V/Y/C\.^/C\<^[[/\ '\>OO1TTU\[8^C_U_']./XL^[H[8Q_%_)W[> M_P#BQ[N^?^_/\?;K[U3MXNB;X]4M0J ;5UWJ>MU\W<;N0+V^;;$SIQJLUI2. M[\ !%DP5TZO4HK<;&3(3&WIL.W0:0W!=$-291J%2[<5+8SC'CT]2!]_KJM%Y MNJYQGYXS\B?33_\ )_D&%XSZG);(*U^T69Q1(?6@(BJUZ?8GW;$>3*0*E%V( M+L=4"LP'(ZYU@)Y>2\R.8=CB6"1V4*$SM:#F;.^5%,O=*1'K$P3!39-&U^/:$U^BCK:?,LVXZ8$@ "U TV MLUJ.9=+.32"$/V([DL>D.-18Q0U,DQAT&7+9Y#[4^F?X6Q]/5+.YW*^T0;D[ M[QL]:)Y$WRFRP/V'=;=(0V*\D*FG.[L())VL*O*%GPXV;9=-\=*+6=CUX!/>9AR986/J MLEDGA\5*+GI!2QS7[O-J[TN(4*)6^/Q!9]:SAZ0G(]B"U"?D*=S/X_U?D_L0 M+N#C]>+*"W1:"6NZ=LNL[ WAM'4-?BZII;Y0HE5)I(,W6ZW8KM,L4H&Z2BHL MXZ$?@#(RIQ60T/P(*9H$\6#0!;+@8GMC7>V)D(!-M9!FEC;+6#XRJPA)0\Y8 M"E6LPU+$. H$$,DXTI^8+45A""$D3!FHC.Y2P^=Z:?V:#K?L37-@O$.WCAAD M/'C3:=-8P*+P&BHP_,5@Z_[$@/0),>9$FRJ-^L9\J-Q4W)=N@J5* M%R*EME2O4HT-FM;'N![,->&*&M4@W*G/9C>58T6/DC7R<_##R7&I97VF.K!' M!%39!!&L4/,AQXKOUSOE[P^I(#+VQ3+!=YU+-R:?7+L>HTX^\"GT6RR)X#$?!"=C6MJ6V<= M&=W_ #19L.2E9>*TN:(&38669;TB1".XX$=8VFPQ\^MJ0J.H/?[.Y9XK\1QO M#3L5+S%?R2Q']$KT*6),XCAS#>,+4I*\IQ%VW=I:]T$"%6O>$/2>JAQ5XM$@ M&I-,H]%%B9<=4EGJ\_XPDMR3[;^. M-NF=GDE2=1^+I)9. +)7>FZSJW'+-*U&UX.)$+ BN..FD7:FCHS!G!YPE19) M)RY=XI4:-C]%%F/.<)> M8<[?KF9#;3S><92XVE6,XSGGLL:M'E]3C*3G';/ZFC.,X^/O]V<9^Q]CZ?\ M74!K'<6G]VWK->T=R U_/O:),D=*C:]HEY'$89""$=L\@;8WRLR$/:DM!V%D MX" W= BHC3]B22:LY[+F.5*N(<[>;&580E6'$I3V MQE'UV'/=G.?A[NI!3W'="5BM[+89@ &LU9J(K.<*2QAL7$L1$YR(_P N$!QW MF]=:VQ4JH>4-V-0?(BG2<2*,^@=("C@'(Y_!R(\+YP&"E5@++;4VY!C^C7C. M%(]$A2%=\=LYRA6,ISG./CGM[\=1I8-*5HOA*FX\5IQ&59;\[*_S=L]\9QC./00$NSS#:)%S.H=PG/GS#AUN-E2L^]';. KV<_'/ MUO;&?L>;MC'?P"SDX,K#9;996"K/?T:)12NQI3JDX\V<(B^QT/O+[9[8::95 MG.>WOSGW=9%N:-HV-S;5[./)M2[>L?'(QR,EAE'GSY]< ^G@V85<.!#:P_H! M$+!/RS@",'YY\#S_ #G$3[#XURK=4S5.G'B*P!N./BRX[;R%3(\<28A6 O'.MVA9]Y/(NIY4:M-FRS6 M]]W6?5(UEO$Q$NQF\P5]R66I[K3++=E] M]25=\2^_6JZN:XN^F>05 NH1B 5V*+.W;4\:HZQKD^3+AIL4Z]/3(TNWQ(\E MJ''(A:U67+9 7*S.B-" 2N- MOD8\F *CUUGK7D 9IYJX8@M@AX[+$XSR$2$EQ]+"XP?/@X-U>H-9:IU]KBFZ MPIMC-S:U2!/L44Q9+''L)MY.9DR<]**3"D5R9()2)4U]YY]+<9*DJ;2TRAII M"4Q?RLY 57B;4*Z6$@SAZQ7(Q*@!!<*ROCQBDB8C,PH0*R9K1B.Q'CMR8K;< M2"*4[+D24H2J,TAUU-7PKG>L@3B9O7&_DE5JN^CU0IL1_8>G[,-"$7@#Y@! M)B@)9FP0IITC )B!Z9#,!R#(B2');3;L67%C8P5UAS0YMU@G;-=$^-UFH8#9 M%SCZZJERN&T*?M"K5R/%$Q!HV]$V15UJD^PG(KZ3DV< H'-PXL6 U/>D2%R M1\;ZLZBWF2KNO3/2EG:(NOI-J7<-IIO]+76S DTPJVXY:8> D,8F0#D%9@$);3K MT70W'GG2/FIX)JMN,,QXRX\J/$FUN4)[3J MB9 .KPQ&G0Q@Q&%R24J/6!RQ(&!& M=4UZ@#QZ8C*FDI"I$Z;(>4L7"GCCRQT[26:7N$9I&!"R&(')^ M=9WC8DE][91&TY1(;;(&!49J;4$46.*Q&ENA YQ%C;(Q'HSPIN%,D..2IKK" MFO;K-70[CT:FL%[R6RTG*<]TJ;9F#\)4O#F,J2M#/GQGLI&<+QGJ5=._PBCV M+:%ZDCK2;ZE&N-UF@EXQ/>$:"PX[%<0Y9N1<19A+\^T.V5UDT1;%&HFXSJUT M5XA:[*J\??XKS"E65,!O4H @8'@ H76334,"7DJR4Q693+>%QIWKC!D3EOOA M2VD.+RV6:9<\O=;)%EZ-AOOEA:%(\V/4DV:KH1')$IP7,A3:.Y@&<@,K5CR8 MSE[RKE19#K.>V5I9=];QA/=&$N]O?'2@4-_.<#@0DQ(0IMG*A< L42WV[X\Z MR$V"&@K:QW]_<@M.<8QG",]^^/3AZRL4A2G76:N)RYZ/*5-CF')+*4XS[EI9 M;>PMW&<_6YQ/RAK/F\N7._9.Y#6"S<$B((&,,[CP!C(X*H/GY!3C +#UUDD1 M?RF?UP< GT^Y]/!^?GSX^608N=7GLR)T2QCIT?",LON.Q9#,I>$I0OT3^&( MLB&1;PGRY\CL%Q:N_P"INI[9SCPHNT!<)QMD;)GR4>D4VN(L83>'H\C:W<90 MZXSB2-:?\F6HZT^LQ,NK0A3#".^<91#U>I*48(V&5*\N<9[1XC,;OC'Q3E3C MDA/ES[T8\C3><)SG[.?-C(&J ':3Y<2"..^>ZE)?83E?;/=.,XQ%PG&$XSG& M.WO]^>^<]71'9/$Y1"!@X#9SGZ&1@,@#U)/KJ@]OY/3UPH^63Z^OJ= M+QM[<+DRG2(@RC6OUR0H:APDL)2VW,.K86EKT;T5,>2TK+F49\ M[#S;R<=_1K1GMG"S:>)1X.)0D7^KNCIBRD."XM+BGXI)3DZ2.RZOOAWTCKQ* M"C*G,^1U"4NY[I7VI975QW"&+CP0H!PN,@8]?7Y_89]-7EP86X^.+AB,_P"$ M,9\Y^8QGZ9]#ZSW[#6ZQE#$5"_1.9Q,CQ9'*L82TQ' MW=O&,83C.5I?:PQ$*0LSW0R_U.&8$-N2#5>[)7Z<8:')9>I6N;@AV>+EY& MU6GBR6%29FP+&>4)!5QP4*M,$M.)1HHT5*=>6N/654^FK**S,.().?/T],G/C \CZ_+^?501.AVJ(R%!:VIFLIVO M#3NL;&%OH&VFE/W,T9KFWI=ER/L(/"F8E=.TL?$)-P6IT]HG*#SY MU>-\*^ M+_$7<=_SHGD)H#7VQZ]8*C5GJ@O7O&3>FL:S6;LVJYV:\(MU_P#;%CHI*OS# MME-O5$@%N0T>T:-S!Q( X3EN+@>O:>76W>?Q_7^MZGJGAV1V1FYFYE;U.WRI MN(/==.H,1H9#NHJU#,UE0(9:@A^ 5%6H&O+4.$2%BV1#DRP+)#8.Q3QKJM_K M6BM>5VY5RO:LM@,3+%$*/4YJ+/60<:$9*,!DPRDF:0E391 (D<7+O/&23N#) M @SF?)2VES,+VJEUJG7&_P!S<-QI3=$R[?178MOC1#!"N]P;M>>S9A.T25X%HUD91/#.%B[DC%8N?$LLS-RD< M-SC P5P,B:T'K>.%#U^)5J^@0!&0 X>,X)B.N0!@R(U!@169JVE3O+&B,M,H M=S(]-G",+6XIS.5]1'=N/Q 7EHSKDJ4!3XSJGID*$=+(@F&,83_S5UF<\1AQ MW6O)C,1:8?J^%*RA]&,9]*AJ4_*:.G.%Y#$^V<]E?\[%.=OL=\=B;:E?3G&6 M\?Q=OAP*L#D=:FRH(O";QC"E2VF$%(/;XYSEP:N1)0E.?BIZ(UCM[U=O?CKH M"3-'X#.J@8*-DQ$$8PRG*$ ?J]5((R+TD$4H/*-.1.0ZJJR!@00RN '!Y8/T M;R&!7D"F=5)W:+.]GK,"GBC:E*>K.Q*6$=--M]^ZTL& K(IR?"SYL*8EQD3T MX3G&'<]\9[R!8K'(B0T3C>F!EADQ'$*9=J9."U-0G.?+Z5E$\>(EXRG&<96V MER0I..V,(=\OGQ-AJM4V^Q51UY'D'&O*\WEE_P LZ [A6%)=8=8<:(C'L+PC M.5MJ87]:GS=0W9Z%M<-Y%4VXIDCF$83@-9! \NZI6/,G"F[$Y">(YQA&49PU M-BS4Y4CLIW.%9SU[B*0_%V57(.)48Q@CCX5X!S /GPZ^!YYL23JPRS1(V#/* M3_+@>/N8.,DQ6F,0\#)[3>?/&%? *1\@-8\>.3YJK%]OTG>%8L-&KEHKE7?! M;GV%K14"/:$JPX4C2J>[%"S#P&3_ .\*R4E2'I-:(H9EPNRVF?1Q )X6<(X9 M76QR>[RJL1'6NR1NRPYZ3REMFP93UB#3"!(; MS\F]/FC5?B/E)B&P$Z+EO+ M.4-N(SC*L*=Y-TVW5I;D>VZ\'V>'EYS&"(J*\+Q#;1C.?,_@$DYA_"\92KS) MKPYQK/GSZ-W&<9S%VU)^V-AQ@+6B]6\;SMB)$3@VSC]HWPI'GBH.*^[+ GHH MZ+6098DAFQP\"#H!UO,MZ 7C&()!CV1.BRJRL2IW&KJR#QR@F:0#'C(4E2OJ M!AR#Z^3Y.J5GLN8X8KLL,I)Q':KK%X]2#(L;1D-C/)%P?&#XQK]'YR8 MLE3OG(7C0O>EO"5Z?3@!8S2;KZ4%5YTV23(A9\YB6)%L""$F3*<=C2,3<3TO MO1UI7'=4TI6M_:!XEVG6A63KGBI501C6H1V[5(LQK<_=#SDRF2 QQJ.P&-AH M=3*&HP2O/BZ)/MM@ES:S-8#0:BH8RI;&PS- I M5V-0+-$J+Q+*Y ]X4-AN1,849('RY5)4GD]RHXY7.HZ5U=1SU TN"MLF]E:K MCA//L9A\@:M5AF[@GUVQ41^TUBND[9<+Q7[4)LLZ-@3"A#KG.)88CN)0U?+Q MRYC*V!QAUWL0P.L>R=H3!4D/91--JL<'FQ6NMEYU:/'QL1PS,KU;JQ,F,D$! M.25B]*D6_&7Z!:U83U3. Y2\GS&+ N&5V-LS$<+/*SV8A^'@-KT3%:>?F6\N M")098TU78#J(H90-[U3*II*#(R09CQ)N%3IH3=O)_8.M)7JU3W#LUPA;*-6& MQE#-4>MR=>Q[85FM6N57NQ0,XEJI/%6$E>*W M-6DG1=:NIU7#O$M>O3IS5WNBL-;V$'+ DQM:V17*58L-&V\07I178!%)+U=\>T[E402(BBH M=6;:M(.)M:6]7AQ'<984L_<-^$E9G5;8E0C68,'? M$SS57@ZT%U8 %9K3KH0/:Q-O=*2Z_I\/19UB.2=C*-P[@(98#*)Q(5?BP,LT<[% M_ <@QPQ+&,8PBKP!!( )(TY^I-AC]I4$#=!\RN34%VGU2'*D:D6.OLRVI#B' MXP\Y)%AGB3;&/1I5+4+@I=<$X^NCHZ.CJK5.CHZ.CIIHZ.CH MZ::1KQ)/V%F[_P";*A_B32NGA:_6Y_ZQ[_Q5](]XDG["S=_\V5#_ !)I73PM M?K<_]8]_XJ^FFN3I5>1G*%KC_;] T5C4^P=HV/D9>;AK>DL4B71X4,;;JOJZ MW[4BP[/+N-JKF1P\\'I1J)%,1&", 7)8RZ;<@LKC8E-5TM>[./6=P[/XO[*Q M=9E8=XT;7L.U806. &EXMSF6'55YU(^&*S9LEB6'@QP6P#1!B4)QF:HLP-4X MM4)F3#F--*;I7Q-Q.X[%Q]$*XY;BH0C?VQM[ MH;#"K=T.FR,!$?2&P4!=F5D:7I)65 @1FI",S\.,]T!XF])ME,XW6FN:AV)( MG$LD[-1K@28.$((N=:EOHAUH\(4>"M+0^^86/; M2QB3V-:^'1'URC02&-SG"WS#5RG!:IUZ_0 MZ()]7U5RD'JB&:%9[=$;?.GBM.<4C(*\QDAR4^'"'Q28Q;^3$\RTUAE&\5XB M*X'Z-YA;IT)J$FC'5G:=['A6R;"A2IH<=)CHAK(0S+\'=R1 MH?6/'E/++92Z%K_A'L[@6\P1UUKDH[*U!""&LBF@\=&8#SDYIJ<^/')O8FX>3? M-G2MFUJ6%^@"+D3 MGA:B3N;0F6NL0+07%P"A,9791K$)DU.'C9\V,.5)=BQ'WDH;SKET>M$E:R.U:O5-U&-KEN0]CG[=W=:+ +]7?X]4<58;MO:S2Y]+ M(4GM&C5.J2@>!,\S CBZO&V9>CIIK7N\*.B6[3^]FJ=\N ?)[3UKX;T&Q:KW M5(+V&T[)X?"JE8JQ&)\#;?:#WI7Y^NH)2XR[9IIZUY';TQ HUK";J19':C5C M(V# E\M=*\'WQ!+;K/8-GH%Y$>(=SI-U6X4"R30%J'_*?Q)+.6"3!1$:YZ>1 M M5+.9GQF%M3!EEJY7$G#$X5+2XK9[8AQ(WIO5XS#'K+SDB1AEIMO#\AW&,. MOO80E/I7W,8QAQYSS.N8QC"UJ[8ZY,1V,8[89:QCZSMC#:<=O1I\B.W;&.WD M1]8C_P"E'UJ>R?=TTU1#'MX 3M?Q+=)7;:9.]Z&&['\/XM5P.W]EDM@!F4[F M?KC.Y:Z#.W(L3E-5"URJ^@H7J XCFMU^:7.N!QH,=/S"9KRWKKG:M-\.+Q#^ M"FRP-QEZD\.#1'*(/Q]V/8\X>";^JVV=2'B_ ^NU8D[$CS;K9N/6L+M8=NM9*F,81!VZ/5(G;"?5H_E3YO*GT+?E3Y\92ORI\O;'GQG.%] ML8\V,YPKOWZY,LM*PG"FT*PA2%(QE.,X0IOW(4C&<=D*1_T5)QC*?L9QTTU& M>DI\ II[5I 7-BD!\K7=*=B38+[K5.FFCHZBW=FS1FF]3[!V<6G5H= M%IE5+F8[UPL,6J5J09;CY8KHHO8YN%1@T8Y8'Q@7U]Q#OH'2#:D,O.>1I=(M M*\7+D78I+,0EI[ALV["B3/EI'"3/$# \$D@#/T\D:OFN5TJ.NZN< MN]]LP&F4VL#9)BQVJT%8(*N@14-.%RB1@P2>C0!T&.G.,O2I;[3+>,X\R\=\ M=)!R&V1PEY+ZLL>M++R7T"S$?E,KP7^7^MS4RO$ \X4\0:=$GQJ MW9FFI(J8^#LK@E9"'DPSEW)MJ[EU;;J"7UAO/6XVT1[C6XPNY:NR8J=V&&D$ M8<-XF =BB2TR>0CM3LNQFDO"F'Y&8K4A#*,N)\B56JD>'R9BEREGX/:L"%R4 M4F#-9V6.I=%+& Y'V?)+I,/8F2K,;'FEBQ;Y1D@.><**$C9))+^8,-;$=:[QCX$UW2@F,+*H(97[M905 MP&+#N2KD*.18CDH \X\Z]*J>#70*F2AG@G)/?KLP3L>2)BV;VT- M'VE<6&86YHTC:MG#&+O?SZJ^5Q%A#8C)!X2;L<6NM-30S@BLTE2X*4C PF1( M38[*W*+LT S8Z-8,52E"GVH4XO6;5\[J$O2SU MM_VR.Q!% H$=0&6N6CL0 3QM4YV&FD)DJQ$X6X[7;M3;5/M_5-:DE207[\0L M01&?;@4#L7CLM$\!^.',KK6=Y@2[2*B-[7-[CKQ?L'%[857TSK&@-[BAYJ8" MHM5@-7]3[AMV#?**("M9X$.("F8=:2;;DQL/9S+#N$!PUQ#A-.7*R]1:6 MYVTZF@(K-LWT,KL0U8X3,>%RKX_VN'%K;FS]>D D&/ :CLOB8#%('V!B!*;< MD_(FMH-:]<;Q+,Q#T:UR78ZJ5'JG/H&6B(C+,=LT,KUNV.F1+DY1B)$B'+M8 M509\J4\M"(S,9N5Z3*T_\W4G'6?UG3MOM&4LQ!T^K#O*VM30\8-@D4I=SA6$ M*16! Z% 7VQEM>'IQ'*,X4G+>5^?/4WI=4[QN#F.K3V_CLJDLT<< MLEMKLE9(VX2+^4[?(QL(RS*R"5-M]."!9)+$T:.W,R6'5BRE8R>W&(E:08*E M67D/B## .=>L1V7&R3D!AFV4A2;$F7E*@5_.[#+K;]8<6A,89#I@4"A"DY0E M,=^(]AI.4MI2^I&,9R7Y36(K"'L'*RWNV ,EMDQ*-BZGCIEP27HU,HF#R!$= M%@0YBV5*0B*' M H(.D$D!)LG M&JV/=Z,G56Z=(V=[FK=3;5MT.Y71 EZ&G#7LBJZQQS37!MMRQ"EZJ[N^U(&6 M=0#*8IQ'H'ZEVNUND^RTZTUBQ2KI9E6>",HT;]GXED2'OJ<31%D6R,"10K$A MPOL->OY,NV6L:>DZUM4M,IF83!V:NCG/13GTOS66VH@F)QG*8<9J%AY3TI2L M>5#..R\N9PG&,9[XPN=QVN1O[+\EF*^$J(HI']8KR4]IIF"RYA4R78'HSGZC M&80I#RPS*O(CR/)FN/*3Z'J0VOQ-45T33*D<4:W'F>7)(5%SPC& M"[*HSKG'-WVX$DH>M]F.5[#KB5.ND5#8I=_"?0N(B1 S0SN*9RG*LS%/./O/ MX7AES#.,*RRE4U@,@QFWW84.+(4VG&5L16\2%X^/=4J;PTGR83V M\N,8ZF'J4[7LM6J@F<+:LRXD>S(7E8LRJ ())GEE2!%"B)3*[X'*2220M(VH MMW9)6X(##&@""-,)G'J9!&$5G8^6(11YP%50%U%=^TIK+:M)-:ZV34A5UI=B M1!0;KYMIUV 0]FDHI<>IW##S#Z'(9*#$F1W&GFW&WF$*PO/UV,U'\Q^(7A\< M3^/VS9E/XTZO#["V\4L&*M(Q0G-DS/EW84QISUA+U)U5OX@O$;9.^K#1;UKX@$D(KH&?7+ &L1ML%"&C\D M5F/E)"ERFWH:NR''V332\,O9C0ASS67\,N-HU?7FZ[_L73&X;GTOLB[]O%?K),.U62\$VZ%+ 37+2NQL%XSD!U$.&BS;PX9-P)D+CAV+ M9ZGIX#1Q-YV2'VQQWVWKNS8O5K@^GJ6:EL%TK!8DC:A60L]>Q*\T';FBYLB% M,$D"9FO:]]:GG:4\8%BEG+O#.E:Y KXJ$[%K\DXU(C0FMBO1_)VJ\G-;!K91]H [ +*U8*0N>*^ M-*F 0R67&Y:*C(L4I2!=@B 9DYDHQ7W[6L?/,BVO6TMJ0ZAQ4#Z I[3U=:@] MIVX[?1CZK6._L9DVG=DW#;/=ZUB:O%-QAMSP+<:DRQR)Z+25+?O%=8XI#$K\8WE02M"P0DN2 0P505 PZ-SMX7S9 -$ M3D5HVQ+L#(1\'&([AE )!J.,Y4G.$S<*S[\Y M0G*NE0!\5^)1.:/FL\;Z?8781+!,9-B:(UZ/BAS+;KJTF!Q.8*R1%%4K?=<; M+-DDF&E+].F:EY#:T-\J"]Z3*7XCL-.$HPE!J^$D8PC/;">\ <\ZRG.<9PC& M?.K*E9PE7?&,9Z[ F3AAP/IC*!L?8,H) \CR7()SCY9D;9I\Z"@HQA*U)'RCA&0G.>Z4Y2X\ M70A..V,^7*HRTKRG.R*LZA'K*;'8LMN)>0F/'*^K*RC&<81E$%J' M&>:[X^N9DNOX5G.,+[IPGM>$CD^../'JP \X_2V 3CR!J@ 'Z_J^?C] ]3^_ M[Y8_<1+"O1Y:)//>?#>(\: \^^I><]L)PTWW7C/TY5A.,8]^ MBC1599=?>5#$CT2ZF*=D^7,LE M'A8]RE,BHR5J^'O;5*GX>RM/OS]>W%85G.,9QY?>G-:EF_E9_P"ZN!D'Y%O! MSYSC7F,>HQ^DGZ _+SY_WX^6O-(0YZX[KQH^F##]$O+C(YM,)M/N\V?--><< ME+[)QG"<(\F59SWPC*L8QTIWV/B0S]7OC1/T(\4AX+8&82TJD/JDR$3:PJ,O#3K M3TI!M+D!4%2VE2HA1]#;K+B4*S;F7"\O0@@^I+$9&3DXQC \ '[8U>@*\BK9 M(="H \M@$#'U)! /UP?KJJODFWXD?(2,$&QN*FPM#Q:]:CUNA;&X[XPI%[5F>*O!$ADEFGDCBAC1?+/))(51$!\LY*KZ'(\Y M\DL=J-U;MQQJ#R^,XQZO63&T; MHDD3(\7(!@W($ J_.<8Z6VPOF3!8$ %NVUN5+;]BMD#EGKH:&N9EM,@H M<%0&\JE3H[3E1('J0/TZ] )] 3CUP,ZGLE7@Q7.7)T%E;^,8RB8UYHL]K*<9 M[*9GQ1_&._;W9[=1C&)6T 5(B8L[Y:PF);;:TG8E$V5 +$Z#;J]<1X.Q&J>;E MUTK$*LB+577TQ+!6BBHCCF1YX'*7B*7$RL-3ATG.8\MEE[&483&U^&9Q2M^P M;WLZS=@#MG7Q=;W#LJMA;3< XMP2*(FJR(L46ND&X$9:%1HDL8]': M?BP7<(SB!$0S;=,X9/#9SE2!R]/SL##>@QG."!JI<>5!6B=($V2&3=KF2+ M/MI4AP>AE#,QZ(J:Q#E.-L!JFUZ-Y;4&5?*.,)E*S'M=FJ+$ZW4HY3B^2=2* M+%D)HV'8X JP,#GWD8D!RK3,1,^&MJ5&RE"L9QU>-/!WCAQ'P=SHRED*R[9E MD'K#)*6VT6Z:9E%IT0F3FD9MJ*%I0(P?KCQC7D@B=2G$LI R)""I\>04P1C/GU/\^ET?J.RZ M#ZQ*I%@S:!F.SC-.N\F5(2UVSG*F UT;]<.0DJ]R6(QJ,>C-9SY4K9;]V.]6 M]STZS&%4NP1W:S?&(6)TRIF/0))>KI5AN3.$38RWAU@&LNY4E4\/)?5'[IP1 MCCW\Y83ZG(L=L$MH[: W5;LEF_S:>5CUI4*1B+/5,6VG#S0V3G'=@I(@^MQQ MCJ5-J1/=CY2\RORNHUFZ]:2^B5R+%N2B[S]A)E1X0B$+H-PEGF#))9B7,*5@ MG,F@WP=I@IJ%VM=JTJW1*:%K=2MYU MN62'6(:*C0/2V!Q*%H<-*'--.D($_P!%ZJ12XEY:6W5RF&\R$Y])3-=/#8Y@ M"I,%^NTU5Q>8E"XQ 51^02M/"RE8,34(MRW+^((5[88NXUR&.B2JD-K40%#L M#A.1#)['K4',^(^SFIN07B"ZDV3JT57&Y[%1M4MKDJRF&@E>V]J5W%:(+%(S/N%Z1'P S6Y)) [B M)DV9V7;UW&MO AB6[!$RQ]I^*XGC;+R1Q$))($ED42FIX]YT[-J.O=:CKT2L5V7R"-VB,4MQ8<9#U+ *E+(N"B@Z?5B3.+NT^(3 M[/N3N)(HQF(&::G6Y]'1U,T0(, D^2?/]?MK9NY<@D $#'C/U))\D^I)^VE' ML&RKI:=W; U&)O->U#$U[3:-:X,LH$&'K-?VK:W9%DC0R/8IP\3%I=6D!HP. M<^.BE"#YYR'L,Y1AW#:,.85A*<8[BJZ 6E2% MA!"D++1#JT*&0J^HEUIRQE*BD/U&%ZH15C,R-ZI%]"^CU=GR9(DC ( M,0.8^ ]/A?"@R XRQ)!;BV0O(A2/!&(T4I8$3$8DYG\[#IDD1E;99> MG3%,-MYE3'6H\=IR4_EQ]QMAE"W,H:1A/=ZM.0S$JO$8'@?4 GY>I!/\^KL M:LJ@,W,@GXOL6) \DGP"!DG)QDZ.CHZ.J=5Z.CHZ.FFD8\2A:&^%.\G'%)0V MV)J3CBU9QA*&T;(I2EK5G/NPE"<94I6?=C&,YS[NF^^65494ZR[8@S;K3\AM MQ"B$;"D+0^XE:58])[LI5C.,X^G'29^)U^P8Y!_]F /_ )^IW7(6_P K%OYU M)?[\_P!--.3\MJA_"4+_ &A&_P")T?+:H?PE"_VA&_XG23]'333L?+:H?PE" M_P!H1O\ B='RVJ'\)0O]H1O^)TD_7S"DYSG&%8SE/QQC.,YQ_+CXX_U]--.S M\MJA_"4+_:$;_B='RVJ'\)0O]H1O^)TDWF3YO+YL>;..^$]\>;M]/;X]OX^O MO333L?+:H?PE"_VA&_XG1\MJA_"4+_:$;_B=),I24X[J5A./AW5G&,=_H[YZ M^94G';NI./-^M[YQCS?R>_W_ .KIIIVOEM4/X2A?[0C?\3H^6U0_A*%_M"-_ MQ.DG[X[YQWQWQV[X^SCO\.^/X^V>W\G7S"DY[]E8SV^/;.,]OY>WP^&>FFG9 M^6U0_A*%_M"-_P 3H^6U0_A*%_M"-_Q.DG[X]_OQ[L=\_P 6,]^V<_Q>[/W, M_1U\PI*OUN<9_DSC/^SIIIV?EM4/X2A?[0C?\3H^6U0_A*%_M"-_Q.DEPI.< M]L*3G/T8SC.?CV^'?Z?=_+U^NFFG8^6U0_A*%_M"-_Q.CY;5#^$H7^T(W_$Z M2?HZ::=CY;5#^$H7^T(W_$Z/EM4/X2A?[0C?\3I)^CIIIV/EM4/X2A?[0C?\ M3H^6U0_A*%_M"-_Q.DGZ.FFG8^6U0_A*%_M"-_Q.CY;5#^$H7^T(W_$Z2?HZ M::=CY;5#^$H7^T(W_$Z/EM4/X2A?[0C?\3I)^CIIIV/EM4/X2A?[0C?\3H^6 MU0_A*%_M"-_Q.DGZ.FFG8^6U0_A*%_M"-_Q.CY;5#^$H7^T(W_$Z2?HZ::=C MY;5#^$H7^T(W_$Z/EM4/X2A?[0C?\3I)^CIIJHCQB[""EZ=B[3PK&?M1/AV?U3]2_W$GJU3IIK%+O1JALFK MEJ5?*X)ME3.M,,EP!R&W.&$&XLR.1B8D1G<>52HL^'$G17$Y2['EQF)+*T/- M(7A0MP^'YQFV!K;8M1K6MM>ZBM5WK3PF/MRG46NQKS3RK+>,"+B*++:CO.GJ M_(\I(?*GRUI5/CQY$S,G#&&U/1U'^T];U/<.N[GJV\QI,ZH7VNDJM98,,G.# MRI@4NQF//B-$QCTH-8WHPXL!CRH\$BH3-:&M3Y4AXL2].%CVBZ&YAHU%C/E$#1HMY*^HVF M^$!O^E\GC>_.-I;A9H^.&VK/M&N'%ZMV5;[L0I[0*? !Q=HF"ME>@V4^,-6( M\>'/0FXB0[:6QK4R8DFW*KUX>K]8DPE=A2-@XJ)'8$R7+(V\Q31CHD*=*/2G M?1D?59#:)*9*X'JK3Z5YPAMUM>(V$,J2G$'ZFZ,K=3UXMMLLM?;FBG@LK7B6 M.P:]B,I/'!(P>*(N.(1A%RB8&9"9 H&RDM0RT=PJ3]R9=RIS5)>,LD9"3QM$ MS,5()=8W<@ABI+<&!3D&UW+AQ0Y04*B5]"JF3 M(4B]:MK.15;$I3],HXV .&UB:Q8,^W'8R:NS;I,(25>>?_B5@XE5Q6QLU+17:C->FSH/&V7:\IK>-T&ZFV@I31D"$=HL>?3H, M0F5/G")1C5$9K"[8NR%3XY(^R/BEROY3WO1E>NFR:PBT7 ] MHVC7:HMC#PW%EG):^VXK=[:5N,ELV/A[?:>EV@H6CW!W5AD?L_VN=!75K'F@ M:09KH0*@L^^=UB8@@E$H]& @X^.T&PVH+TII+GE2+OK6C7#CK0SFFZ]:1HMJ MZ8W>*DE:D!GDR"[3>LTB(V'R^4'"YJ<5%C$VSS<3E/0I(H,PPDM+2$_QTU2- M)#!(O@_XK,SVB=J(A5AJ&]+1-F5-@=;XD8G<'7[:ZS&@BQ\JE1R6PFQ3AO MS]T.SX"L+\B5*1CSIQREB;IR9F!8RI78UA::5EVJC%,#*H,SV2YYBPR/*0(B M93A241WK.2)SUIQG,:$IS.4XZ=L\NV[+M=/;]FVV]7K5H:M&)MV2>F\BTZ\- M2N':RCWKDQ@A01BG4LJV.*"-0H$U@HR58:],SQ&&E6AK1+7F%IU@A1$4NZ2" M$'PID>::-BQ9B"Q.J@"6DJ5L_:<@L6"\RHUMU_6-812+.S=A56S5"UCQ<.RU M6W'5N,O<".([#@>Q MSQR'6DM+=J0"5'JM+&1W5Y8@MWFUR_4\+CR5YPEN"^N&Z74UA$(5)1GOU&L^ MC[*V-KF^P-7F:6 V+D79P^JY)8/)FZP#VV"C,4//M(&*AI#9>&*7<[*+'((X#$\4-,92.S<,L[)'$[>()8[+Y MTC,L*6)80RNT.9$C!1FCGEX MX&&EZE[)#PB3,I124T0'@TE8[.( $?DN0:A^R:2*[J;1Z/#F4S"N/32Y'E<4 M_/=>5G#;@Z_H8!ZMD8+98+&1,'383#[!08_AM$F*_%3*3AJ9G"DX7E3J>ZLM MNY0I*7,^564HW?\ B'XE&QQ5?"N[HXM!PL./DUT%&C" MQ-)U^N++J TC.01)*(XS:27F)!(M$;D(B18RV;X*K)ZE\>4T.R@H6R]:4DE7 M[W8;I=]K%X$JT.ZTQ2(ETU^Y ?2^(E274R(94:3'99> S!V_),8Y(K%>O7ACC5E$:*LAL<58\D$LDD:,6EEFE6M')-*>,4<.%I6/NBJYIA/(K3TZ M/010T+K:=!U')=35*M C>B@TDF^=FD"UP0$>R\ZU=R,V$:/KFRW"06"I,=+5 MJKD.-(B.P9,=F1#D-/1WXK[:'F'XSZ5MNQWF7,+;=9=:6IIUM:5(<;4I*L92 MK..MQL6W3;50CH2V6M+ >,+M$(>,7%0L04._PHP;CYPJ,L:@)&JC7;C92W8: M=(UCY@(GP:<&2##?*K2+@Z()?.29+=Z$ MN8CB8^TTZ2EFY/ M#D$[$W55=K:[W/9= 5P#7X04SJ/6.K-&JHMQELR)7KMA.XL="*$LG2(M%?!. M3H[[;D415A,"'EJ(N:Q(Y:=P-V-6J)M:I6/FYR5OA#9D"L0(MJ)RZQ7#%)R% M)"R-@(52/2H5='"#.PDPI\&Y' [80NJ*9E) D .(@_,78RK)(CQM'&\;J4=6 M')65AQ96!895@2"",$'S\QK%*PLI!8D,,%2"1@X!!^'!\$Y\X.,?/2C5OPXH M"R5HA5WD_MBNEX\B"S4++Q^"KK5]$"E3D/RVSMALL:?7(V2HEM$"0RRG$5:E M^T_^+2*85J=.Y'\U8MOL5M@VH;8[Y1K2>HD*PG:P?@'R0HL MFKU4],K"HA,;2)C:VL5ZLJ)5N20E)R!:RA6PM=>(9$8"%*A;?$_EB)"[)%F5 M'6)3B/46*O+F%*W3@=?]6O B$8+0Q02FRM@_+!DB3&OF31Y#]H-LW]IP?RZR MY$;WH&QQ-+W)+YJF;W6V)IR;I_9.W^.I8J6B5ZCV>X0II8)K(1 .V.-LB$(- M=@X!_*J_#JV;@1"42GX=D%XOTSTIL71^T_BC8*)HT6M3VS"LUB5FLV3&))'F MM23SL>W'%$@,F$BC1%4%=6-MVJIM5?W6A&D=?N23&(N\C,[A0[%W8N0,(%'( M!0J@>F3;/J7;V]M@'(PK:?%G;.J1OR+A&)AVW;7UNX%Q=%'R(PK1(\*B3VE2 M4#!,<:?9LK[+0D[%+8@!FY$\660QQ,LI@#2<%MO,5N?G,N/NQ='[GU]4+_ M R%>=+6.F4BZ&:D0L59.R*;)MXM\I"&3\U]]^OSY3,B&5@M&8+Y*"5>#3)( MR<_%:])CS-GZ9X5W#:U7NVQ:E226X/2P)5*)IG&1UO2 3X\XSDYXO MX#*1D_",^002<,<$8]? ]!\M*"GA [=H])K>OO$8YOM3:C6XF+/(JN_J$4L= MZ<9L$.2_;#N2"2KH1)5<%L&0Q7@H\1+;0MMO#C=, M.NP0A0 R4#S8E.%"ZT<.1CI@'[&+SY\02*,6=F$;)Q( M86%F<<;:G2B?+6NJ"XOI<82F8PB4M[*L]D,I<3[&3EU7OQ MV90I6!\R,>A^>O'8M@/A MY>A/U'J1@8UE\>.5AL-1(40'"BL)2VPRTN4IIIK&/UJ&D1XZ4]L]\XQC.,*S MG*LY[YSGKES$,.JQETLW'3_TFX,!I.<^[]VF.3,X^COAK&<=N_N]W6'(L!,R M\[#JYB*5D,8\DRE>7/F2/B(=D)3E"Y*X[:L.*RE M:8\RA!(\2?=\N,.9A99%LJSC&/-Y$16\O)1G.,]L*D+5A.>V59]_5U&##X0V M!X\L /EXRI/I]L_//G5LC&:_Z7M.:M MA1/-"@ MD&4XDP)27599BXD0YK+$AII"_.IU"4Y4WW\Z<97A6&\X2I.3 ,"I \CBRJ.1P<#R3@ $?X0Q]\:]5BI5@< M,K!AY\ @@@^A^8\^#\O!QJM#7NU[;0CQJ#:7R1\-#DLSF)T.-B(Z(%DHS,V. MTIQA6)<-6<+FNO,D)4T>R]%>B124=:FXKG[YCZQN/+'7=&EZ?:E../CLYQ#D+4IG#:O-@"KIQ9AK! MWB@=QK6:TS-)6N &1%80S(2ZR_D)2IC\.@(25 ,95I"IXZ6:DZYV9H#AT;J" M2XVG[/K=4OESB6QRE3[RU5);2IUND#X0I0_-?M;8X?%EQ41WBT9B;*?=6/PA M>&,.UR3/$VO>3%5C,<@=<8KXX@78A*U0!4J("J1VR M:T+A5UG7(^4Q88I-HUL(?-)T(;+0.NA:V+MG6S+,>]5S%X%-H2P1,U")Y),) M;A%UIM;P-_*'I,-L2[#DS%LH;5&<],C#L]"<*ZF"C;*UM?&42 $D;F7*4Z^Y M DCVQI?TL)U<)QR0-FLLS\N1W$JC^E2TZE.,^5+OE5VZRMDV>GLVT[;LU!I4 MI[51J[?66=B\_8IPQP1=V0D=R0HJ\V 52V>**/ N4&JU*]>E&C*M:**&*.<@ M2E(41!AF4\S@+R>,LH;(&,X&12-G-+SG.>V5LD/6 MV'/=G&,^=M6,]L=\9[=1!=^'?'+9,O$^_:FH-RG>O%RBI5EI=3+J?)GWPLDW M.G-2@BHQ)XK(K=>D3L$693;LD$(E8;1)'1'6F80XAS&%(6E6,_#*"_+T\?H]/M_O^IUDAF'H2/YSJ(J)IFJ:K#OUW M5\4;KVOR2DLY)"U*K5 ,-E&B"6$$"TF-"!LIDE)Z8T?$XA(RY+EY90J0^XO' MGSEKPJWL-J5#M464^G'="2P&+Z!>?-GW.+&/0GDY\N<8PI"<]LX[Y0KOVQF' MFQ]/\7N]_P!WM\/Y<^[H[X^G_P!?3_)_'\/X^O>VN,#D!]G<8_4VF3ZGR?J0 M#_2/VZK$YI9%B+BQ8:"<=W,HE+> MRT^N0ZRY!AIRMA#DA]MV,V6C]YD-R:MIFQX5-7A-A$)DEAPDV/DR0Y%A]^#. MC*B$LC9"V5RXDEX>I"WE/PLLKRI3F5XQD6Y>/NI]^CPH_:-718&Z]-=G!I#1 M D)(0')6&$3F&9XJ5$E8AD&H[##E]'V M[>6N"9[6LW4D@5K#;UBIU7'T2;28E$2/KU M.:9[@LQ&01>[1HNIK5MR3=[UFQ<1]LE@A2G4"DO#*@C#NWA0OI*20[F4R+R" M=M0&T(;0 !EK2>@60$TCRXQ+*@I3$!S*\X3C#9!OTL+*O-GR^3+V%9S^M3G' MQK0\2+6UXW<)U-8-55RXWGY.2;G$GU\+7R+V?5B(:.>2*I MU0GCHE>KS:;44DE*Q5Y!A :L#5+,76:6//LHD&"#N=?GE]S$V?OR&C5>XM6< M:R:];[?I:[3'HD3D<0HQ\CL,*7DU>T5.[Z\BC6YI77U$G':\?=*)E!:]NTA4 MGY[4L4Q-;@;'K#IW;NK.GMPZ?WN2:/;;\<)LRU95K30&K9@N121SR)+$.W-! M&S"6)XRGB12#J_>J;=O$-G:;%I!RC22>..Q&EF*..1)(YC&W(HG<0?$X9"00 M1C5X7#_DA?J,G2_%XIQDY$3H"618YW=I&IRPU ;@V@">O[I-F*=C1+!"KM#F MJCZTL:#\8$7@6O"&1P@B%]6(N6YX]^,9^GK1U(XK=^H B?M1VXSR M(X?NM[;DTY\N['K(I5Q-B:UO$SZT89A:;K]2K9P=32#%#K^S57B586H-KF#, MR+8N+WC$[-N>_5ZXWM1XL>D8Q$X= MC[,O+YM_7D0O(JPT"7==+X<1M]HIUMIVO;MJJB44]MHU*%3NN)'%6E7BK0F2 M0D,[]N->;D98Y;'G&MG'MZU:\$%?^Y5H(H$#,S.5B0(N21\1XJN6&,DDD#Y; M%'1T@&S?$OXJZ?K^LK/?;%=1H?:X #8JW(&ZSNED=B1;(^F,+AV*%7!A66 + M+6KS2!DQGUB*SCUE["8ZD.JBB1XR_!J', PYEMV.SFQB0!R ^SIW8!%E@9:6 MGW@3Y? D20D E/MQGLE(YF/!DU1>&&;BU7GYT!N5L7FBC4O)(B(,99V"J,D M98X R2 ,GU('J=4<6X\\?!G'+QQSGC^=Z>OCU]=6K='56=F\8[@U4Q\XJ2N] MWECX#AU3CU>U9=;1(<& );%UT<2+H"E9,.1BKS)(^.NW1,,%:U'*")D M*?)=K4VZZ/R-I!NPZT(6*,,2IL.V4+UPO6YK3YJIAK*-)CXA9J)(DL(&64;( M2^UE/JQ)F:(E>K%!LV,QZT@XL4'<8*Q5 0"Y SQ!8@ GTR3@9R? UZ\OTJ5-93*::SAU*FLXPYC*>LIZUM]$*K_"#EIZ;E)M6C:48K],MA=R3;K-$ M8NO3QQ$O'=-/N3O5YK[LP+L)I=W(BKI]ENW=QI-9N[?+M\@GFB$,@?XHXRH$@+HAP68H3C!9"R_"P&F M-Z.CHZG.MKHZ.CHZ::0KQ.OV#'(/_LP!_P#/U.ZY"W^5BW\ZDO\ ?G^N/Q.O MV#'(/_LP!_\ /U.ZY"W^5BW\ZDO]^?Z::Z'46[HV[5M%ZZ,[)M[9&6-&D*L M&A@K45\[:+?>[6$HE%IX!F=*@P%FK7<;&$!P7"$Z$-AYF.$BDKH6LU;%VOY/DAEOI4Z.,NM$N=+LP>[T&_4\A,BS8<6RTN MY5\+8!69L.5"D.0EP9K#D26_CIIKK =_"8R]A,;IKKO&Y="V)\WL,ON&Z40+ M1MG*(*-![& L V:*S'@M$)*"SM^[/TSXF MK%X]-ZBA@8Q'EULR1K=NR3,4F8R M0DRSMO[FV'8;$932=V\,0'!6Q:;#A!8, "TK5SMDLH!VKV^',^5(R MV"BMHGJAEC9&HMTQ:SL^ASR-%K0N%3-AV(G9:J.SL6TVM"2=W@X1#0U7V65HEM-3E MR@U5LW=NA[]1-3;BO7&7<96NSG]<[-I%E[R]GT&G-CD[CFVQ#CF+0*V+K$,X70N9>1CEGL=I]$5AF9,= M(R4L-M2R#[,:,\0DX:2F3-=8A-,PX[LM[SR%QXC34:.IWT,=M#*&TX7CCWQZ M5H0GR!)XV$4O:N0?(.[Q"'./FKK6;?#9>GU'2G#NX:YK)UH;)KE!L6S(7 M(-FTN!APR"(DR!Q>=3:W/*,$Y\PE,]15$268C9C(BQ=6\[*T'RTM"S_)G9FQ M^-8#BA8MK*:T6KNWN39WDKJ^T,W&1 M?=6[&X\\>P 7:%FNGJ^"%GVD=KE=?/7ER,EA"(P JY@ IB("'NQ/9%9!C(K3 M2SUG>7(J[[E\0D"#VW2*Y987"#2FV>-=$LY^G_(30EPN#/*ED?+N\WTTN)+L M+.*90['O$^;S,"54@G(-R.W4:O$<)*E"\2RW5GB]RVW]KF3L,;8=8U+BIID; MQTY469V^[FU'RUWS=85+-MDM5>M=8F;'G7N[?**I[4%!7'XMT%.Z\4*Q4=-J+=>?AC F79E?Q/CRF,QC.,8QG/?.,8QG/TY^G_7TOVN-3;7JT M8&)V)R4MNY E9]0]GN&=;4&AW&P."/5O9$G8UUI#K#ERF,9C(D&W!@"F1[@1 MSF;8HU:PI+P&U)$R;3%%.%1=>R>CP<#S I+S33S]'2: M:^YC [+>=7TN^4J5JIO?.@+#R9TG8#%N"'1-BUE3(-1-WD=>'84,?'UU?J94 M[Y4+N9"NS;'6':N6G.#;E,*5H\.BR=IC>\3=E)B[C#U>74M%6(*NQZ\V%?RT M:L%K]5%9;D#MA,TN;#0[3=>6,0I1VKDKL?#VDH"<''9M/#AS(V6ZTU/O1TO> M_M^P]-Z-W!NFI5Z+NIS3 7D$!_L^L MG&1TJ7F;&2M<;,F+E^-;5SGTX X/.<\P[9VY:JEZ?A[7K-> QVTW2U220_SP M-=P1\KRMPKOBP(EU0O#(8::KQ04:D&/5H0>>MIIISNCJ.=/WYW:VJ-:;1=!I MK2-ET&G;"A <&&SS@H5>*X,M(>'*+,CQ<>9.9%%H:9ZHT)$5N;A]F,[)9;1( M=D;IIHZ.CHZ::H#\5[]D#0?Z$0?^(VT>CH\5[]D#0?Z$0?\ B-M'HZ::NH\# MS]J)\.S^J?J7^XD]6I*4E"5+6I*$)3E2E*SA*4I3C.5*4K.<8PE.,9SG.K2IT..0A2X,MKTT69%D1)#/F4C+K$EE; M#S>%HRE:/?: MS'',VBS4RSI)RODI"VIY\=.,U54B76? GY.VL[ MKNW@3 8Q7K6^S,3!K$.$2JQ6E'S-U41,@!5@=9,:J"&\GP/#"/!!QDX,@((]1\]<.U-L>+ MK'& I],+SALMI!B,D,P3$!H_F'R,IPPEMZMZ7U9H+7X[A]R,T MS6+/0CD-5XW?2-,,6RY02DQJW"##C M(QPQY686YE#< M48+B2E*D*RTV_+SGS)2C0/.30=PF4FHU#1G(RNFKJ7LM5I=8NNMPE+E/66G! M)!BP-V 8NTS#=9#0GV71Q"Z& ^03)3*O3S4JDQ?6NOL_:G.('O&8$U[Q=HN_ M/9J*J0 &B&PF-= *W6C@&;[7?KJR1:6W'<'V]MRJEK%+!23#L=$$NVS.AE61 ML'3PT[-66O6EN69-QL.HG,6X;E%MM:5XI6 L2FTDUJ7A'*(:5):<J MKQS#++Q2K*Z01101CFA>&J;$B*Z!NT.T4C7+#N33]YXTY"-Y2&0MC6[3L+8Y MPH+>-6.O 0<_V7.#*'#:[:#$E^*W(3[2=#M877(C+#S;R8L*>X:6M[+4IV I M*FL9ILD\]JBOB:S5AT6(8(QV\[:4!NY,KP8$MVQ6RC4\0)@[H 6,+8(!>IOV#.!E@ M@^IDT1&[HPS31]GL88/ :%K:-S@<=+F(,3M4TKSWV66O9C8'#"G:K-V@!/JY M)5BY P[D(GC:Q5KFV"71$UVO82 9-6G 6,\,N#S^"J;%@ZB8,8%2F%Y?XFW6 M/:&CBED&]6FG2UN$LQGL5Z[&9XHZCRLZH&5*M7$1C"F1[C+WU+ZQS=J-<5F6 M/W&(1LE>/@B22#MJSS!>+'!:67XPY)58@2A U G+:C[JV$2%:YUOH#8Q#7]/ M-D";-N#QY=GA[%*E0-?D.VT\XRRF-B;B5))C!ZW9A4RJ0P9?*0P,5X7Z^\?A MY#]L#->'*%MK2]OU:[J^PQP=3L=JE#%HV@&.P/E/*-B1T1UPB(CU@.LX3!7SO^*AKU^J!J?P#US;JG[ :A$+4_ONN#[>U-AUL.N) M(*4J799VM5!-(V,2"19 M=OJ@0JDV-!F'//EZ#')H4XB1EMK#*GDMR9S460MZ&R1)-1T3I%G9>@-JVWK' M<.N8I+D>Y;KLU3:I=NYQG;::5TI*WNRB)9 Q%* #DY4,;$JC,Y"1)]KBBWN_ MO:V9IIK\$=5U>8-&5B,/Y7B"7#.($/%V94+.54%P%D7X='1T==#UEZ.CHZA' MD+O&O\>=7F]E'X$LP@>^/&C FKLW1445PZGV/MG\6%(STF0J![*D/,>S4 MDL$.T5+2F5IEXJZVOMOECS-Y"U<;IZR'=:R+:,GSH&OM2>(%#UH:)ZTI$^:! ML9"Y:9,Z@/2HEBBQ+<\1>+5VS!\66+" /MN):C1WQL6V+VB='=37X]LV+>H= MPO2[6F\K7CAM1L*#RK#S9IH(T29)7C66HS"U%S5GA53RUA[?N^U[G.*U.['+ M,U46P@60$P%U3D2ZHJL&8WC@V'X2*ZOIQKF+5KCN7<__O8PJ3LC=\O:YG2A4I7Z_1"P MW5&R!PJER!0JV@:'5;A:X*Z^5&$;L0+2U(PVIYI^;Z+P*XUU.S5*VQ:9>$6: MGI4['*DCD.S0RTID@X5'NV2!B%%>F^Q);GG%1(PT<.0M+;\AB7*3ZQF,]94/ M:EMLV_IR.G36[2N1Q&5KJ;M'+:E7$C7?7(OPKN3U',; H^W=/&+_ *1I9- ':S^O M=CW=C6U,O;\2VW3+;X2$,)#D7<;KR6'?M04DS9A!6 N$+)-$_/"E6\^EA=FI M*+YF4QZ?U; E 6>:]/(;5AS+,@-*EDI+;S:DXREUIJ,M"\X7ES'UN>OPQ2QD MF+/$(U11WPQ.*]&(K*5P(!ADD27O2OQB 1J(5>61\2KC!&,Y4AB/.?7/@8 M&J/];>#M +ZOUQ9ZSM70!1!769-W&PUZ!MV8VPXMR4,M^M=C2JR9VI$CU613 MXS[G_P"1T9M(6UN$T%;6VF;#?%S;N1]=K,-KUJ27:F8PQ#1.S3 ,4/$F36X3 M31)K-0\(1CRI;2E*>RU22P^WT &#Y#9'H#XTY-(0"S$#/D+DJ#CU(QZD?7'\W@-4)+-M1FH0"I%H MD9G'DCHDPXX<>E*E>]STJW5NKPKW+6MJ.^ZYGWJRI>GHK=/I),&'@J&28#BV\*()? M\OKJ\-&E6:FL54SM?F6=)R98XH:V+=N5%SB6\R>@5Z151..CIL MFY,WG */8XD8>2C#US67APMLE.F18>).')^7DNS7W.?>TW9>I=YZ7>/IG>[V MS[KMMJ+=P-KY^];E!0@L2-M4)@>/$MF4PM#')+V)9X8H)U[,KNFBZBI7+6WL M-NNS5;,$J60(0W=LI"CN:ZLKCXI&*E%8A7=51QQ8\6\%\G=-3(+TO7,4YL N MAY4"9$K 0A.G19["%9D1C9LBTS$'JB.I<;?7*FJ]Z5NM-.,X\^,,NFUS!J.S M#LA5FNH+QU8'Z]K$IN;;;'Y&UY=AMO-JQ,F)=4XWB4\/96+A--K=ERT,^E<1 MKI[;TT?UQ+D4[: JY5Z[*C"2C "I[?GT:1 @H,C#T!=DF4'Y1^NH)SJ_&3\F MR,?#,X.YA=>6&YXV!QWU^5AV T(N?S)1)&Q;ID*:*& MF]=*48DM9(@[59JX*=E3Q&*:3:BG!I6.*B):@>1JOV;>T&MUO1:M:K+M'5.W M*1OO3[+9]YVZ5[-B&L9!/7C91/%"LSQ)%)-6DD[%@Q2!<^[!O,.[5CW(Q7W. MN,7J+"3N5F,CK$2'13B14#$ ,\+,(Y"K>N8VD1)=3 S"9C)LM??8(,TVMQWY M;XM$U*%2XYXZWG+3,V5'3B3YY7=J1+892VAU/D6IU-/6N.9#1,-OX<0N.TM" M\*QE&?=Y58[_ /05AS&4J3G'=.,XQ[L=\X5P/#;C!LY>R M+[=BCGZK,L)=\BMR=!:G8RE>%.HQ92[KBTN0A$7#,9<)7_D@QQG;8L,"HV&Q M +<0RBF1"#^*ZR\]"93).2G%S&I1=H4I#T=^!F<.9(S'9:\I0W$9PXJ8;]O& MV]/;7*R7SB4SE;!AIM"'5XQ MZ-HA$1E"6_/G'ZDY*BJ[M>_'I%QEIQW5G&.H9V!HVFWDCB-.'KA3V8?K@4X* MF2A!F&MN:W(EM0"<-2'(V43$QY>6_P!5:=4[EQQI2L>?KIZJW&"Y#:FH6R18 MPB(A'3[HN<"DNMR)PLO!DD0LIM$R*E++_LZ9^IK7G+:2D=;6519>$H]S;)J!ER.YV\S;<]I_&/_@X[5TK M]'=Z5/<*$R6J.X5J]RE8C#!9ZUJ))XI%#JKJ7B/-5<*Z^595*XU81X+M:.9" MD]>Q&DB$J&1XV56C2UY7F',?6OQ9#2\>9MYAS"FGFU8QG"TY^*AD(,:=!?5VSYLDPG *2,1Z@ M9/V^^#G&/ECU^QPI=N8JPK6I(R2/R=DRVX,>/ !ECL1CQ@<)RJ^O;8#B:R]M MS*9LJFU10KF9R=U!*"V:=9:]=8+#LU$R:8J)^GBA9>1BE"Q1:N-%#4*P1QT] M^8X^8$QFXXZN0F)@VBJ/%'TK6]G\3_GB=VT/)Q+"7GQ+:1KUEN91^2$*F ME1:,U39_LP0237EM5VOIR3&5P62.,P(,W)%^4OI[JXO$=8[-E20%TM>O*C=7 M(HX4R/1,QV9,2H)Q*A@<28[/ 'RTDQ+#6&''7' MQ27F,03K?J7J'IV'9I-@Z;FZCEO[W3VV_#"L[-0I3!N[<<0!S&,A56Q*JTX< M\[+H"BMI+6\;YMD,8AV^.6&&R(;9B1Y15BRSO.P[TDYADC(FCEECCA1209)/ M(2Y@3N&+H+7-*UM6F]Y[P*"XLN N_P"SP%QD%UMN$9LYHE>;*BJ(GFIR6YB8 M49H,">E28\!M.?0JQC/496C;>[=@0YT$?9]N5%LI$]4;E/$^FLHH0)+.-).C7*ZB)F.$'/P1U?+XJ@.9.6L1VG5N^;'ZWT:5^?/;R]U9[=3K#L .\B@ M # ^'P, _P HY!^>2?H,9.MF\]"YS/X]@FC=?$<$T=4*K G$5KN_%DDB1F' MD *!XU6PSQWP460F$]#[(V!+)9\Y'.YK]3!-7-S$N>?UJS@JZ5E$3?IUXRZI MDY$/Y6ZYCTB<^_"(PY*:;Y7W"O52)BIB2E/KDEV,)U]J =,]'7U2HS3$:3,& MMQ8"B<>-%;]F0I##*VA;676W6F1J,XRG"E9?9&R+@=PG/?#GH%"F'<-X[.YCK[H3&>K^E*?673NY=-W[UNM M5W%(%DFI%!/&8+->W$5Y(\;(TE=%E1T821%ER&(9==9V?9K=6Q4@GG59T593 MMD<;ES'(KJ;'N=4M8^-?"67=0+8;556I?".IV8P?9%MA9INV3<8B2LT\7 M$)F30Z?9(\T;88:'R5RTUN_;='&3D-N M1:>3VPHU?C"DCX,&OW:D:PIT$4)QZEVA"ZO!B0,^I-J1%E2GI4Q+:&TQWL,Y M2E&%[Y5\D;/%I]WI1;D%3:Y>9M37(CZUTY6YA%#<-]Y#4J/:]F%7YB2A*V7O([4M'IFP+RT'?UU2SZV4!T"Z?Z_+8'B<&8(M#DV3! M-6:2-"B8)2RJD%E..2(HZ$].RTZ_ZQ'=RB ]3]:7/9RW373.U=*;YU-23;=I MJ"_'/,9NW'.FVK&QCI3I9LQ05UFL&1ZRF>Y24!4F=X]/N&]U:DE7:8=OM[H8 MHH(>$^YS3%3&5@425X)K$2,BI^4BE%9E+Q@1*IRMU]0%Z#IP9NHTSE+8(\$: MM]W->UML4"6PS-?6Y(F2W8M(HA1YTG)=PZ](F.*=G/KRO*GEKRK'5<_,<3/G M7D"]6KOL;8U>0&F(:=O*BR)==,RIN7"L%$@K6ZHS&:,LLCYN69#3A!]V,\Y) M<4PU%PCR>)VY?$"U/A%'M^F;[M"9+CU^H1C\>[B;A B+M%HEF;E?[-%UZO-7 MK?S0Q9" 5.F#43IEXK"8 DQ @2@\DV1PO1F^J1QRW;9)7(:Y *^)7 M@38 [ M8=B@CX):VM3!\6(T<*E62H1NP0SY.)(3[0=43<9GNKA-RX[KV.J/:TB[^W2_ M04^T[U8H]7;GQN[SL\H4;0-LEK3I+85ZMJ"Q$W=>:>.O'7E2Y+VWL[56LRQT%@,916C2Y.CKY8F-HX^*1L\:EP ,R.W/G^/ MJ]ZM.N.1%;%ZWIM);MJ#!(1LZV&"HBE469(M8-$>'ILJT\>41CQGQ"T&9F)7RH09C3?(9D5.QBHJLFR$7DP M].U.NI0!)+"8M4])D:6*Q&UCTP)IQKRRYVV1RTX")I2TDAC@18D>29DY22$*#))X9W) MSY8XWE>MM#UC#N->[:L4\*XHP=00ND("HLLT#2]XF5XWYL(VB8'"LP\ZL\!Z M(W%OXU"N/%R1PH!TFAF;_KPS:-A\;+#;;E%V9#/8EVZWU ]M 78[#9AMAB/A M6XAR!;D58VP^8+,S; N4/?A-WQUPS%K-NK5O>N=A@)@6FM6MDB .& M)L,>'G214TO"?D1)-S7M-"*]./;+=6IA(HIYDIQQ1Q8PK2K%9>>+T7D)((^!/Q MA3R.MDKS)^G'W9.?@K&?\ 7CK4C#W;Q,-- 23VZ=U[9&R3T*"% MJMK+[>UW=&\%7JS:AED9#T"J%;!+$2ZW'L(XMFR7N:7A62W @Q6NPJ?&%.!" MO8E;BVS!C4PO$\0[F5?;V;)0W[B% M8 #-YCIW=HHUMQOUC7NS20U;D\%> MNX]WK2B61Y+58F"(O.DC+/!9W&%):T,=B=$2:4I%+(D49 MS#&Z.2\B HC,ZAU9E"98;:F,XS\,XS[N_NS]C/PS_)GK[UKC<>^:ND^/]XHQ MK;//?EQN]1U!_14?6^R]%71P(J^)>3>X9J66"CI$.5<8(@L/KB]AX*%-;6 < MRU !X#%&2+C6Q.&+0CP@6;&N+='F!T$K!==:<8<"U6D66O9ABL5Y4.4F@G19(94/C*2(RLIP/!& M0-;(<6CCE1N<4J+)'( 0KHX#*RY R"I# _0Z1SQ.OV#'(/\ [, ?_/U.ZY"W M^5BW\ZDO]^?ZX_$Z_8,<@_\ LP!_\_4[KD+?Y6+?SJ2_WY_K(TUT.E%Y*;,V MY3=G\/=>ZN.4ZO1.06[;KJNZ&+31YEUF!1(S0^RMD"CE;BLV>NPTE!QVG0)D@;\A]J3YQ1"=!RG#$M]*VFJM^/W*CE/=RG$:1?KIK M.:'W'RRY>\)+V*K6FU 9DHYQ['\D)%5Y!B"\V\%\5\N9EZ,@8.:D:'3J-B&; MFIAF\266G6^IKSF#R1OE%X+DI-FI@4UR>XX<]+;=BXS5@]UL/?N-%=<)4"\U M <2/RH44:J;EMNQT\IDP G+0TC,V-YG&';&0/&C0E7^1^*[JRM!<:^V9;MS4 MC$!X\UBK[8O^#F+QL,1A1I?H+5;L6>RXL!%STN"6+">::J3J'+WE'K7PUN/FV8FUZ[LC:D'POL\T;/ +:P9M>R;, M:'5RKV"#)V4W+.":Q6='^K.V,,[38L&F5^1D/)AKG[E?R]Y0ZI M7S6M>O#6K1E6XI<<>(/)<)4K)JPI82UR9V\9V:QL36)ZRYN@Q8N!/&4R-@/= M!(E)ZO3L,8CAW6%D7I+HO<#>&4@ #JCO&G52JQ6Z-:-8AJ^D24:$1-<7.='* M62A.P6#+;).G3B<2&0C5PQ@B*!3(4*16XP9<.-EK+2/$KC47 W*KE-,4XA7- MAT.E:NO8.7D^\-MVNM73 @F)2A=AXSZQV-ZD*L ^:N6Z MB')LI1DI%?AJ?LI.6[:RLMJ;EB!'?/J.@.H]8UB^6G:-?HX$3L:\"Z^%N5UB M,ROE!:!E4&0PU=CG);TMYN>Z*$#APMDBZQ[5?'CA\.=.EL08B&9%Z::.CHZ. MFFCHZ.CIIHZ.CHZ::.CHZ.FFCHZ.CIIHZ.CHZ::^9RI.,J3A2E)QE24IRE*E M*3C.4I2I2D)2I2L8PE2EH0E6<96M"<95BK^AZ&U1N'=T+?=>XF77C8,LFF-] M:CY85+96G >GYO(@'L6&""5RA7FGU$O/%;;?ITP;9+5 V1 M>L4X$HKD#;8KTNT7"Q2( M@F#66B\8\G^)^PMDZ(Y6S-$<:=DZZKFR_"T:T58^-CE#?@3[]S4CWBN2-;&Z M]1D/2Q1VS:FF/Z_T?J^6J.S6J+;1-O^((:UGQJV\"UYN3B7P* M%4(9KO1I85!N^[->6?8TK:4AH*+B#V9-]"5L[2(UKL1E+9*8T,P/F%ISP!QM MGAOO$[Z<>_&/=C'P^&,> M[&/L=?K*4YQVRG&<9QVSC.,9QG&/ACM]&/HZ::@+BE ,!^+_ !QK]BKMCJ5C MJVA=.4^QUFVA)==L(.QT[6]9J]@&$A,W&'XZX9@3-99>QER/-CH:FPW7HLAE MQ4_=?,8QC&,8QC&,?#&,=L8_DQCK[TTT='1T=--4!^*]^R!H/]"(/_$;:/1T M>*]^R!H/]"(/_$;:/1TTU=1X'G[43X=G]4_4O]Q)ZM4ZJK\#S]J)\.S^J?J7 M^XD]6J=--?.V/?[L>_X^[X_R]&4IS\<8S[^_OQCX_3_+_'\>OO1TTUC]KL@B MFUFPVX^^Y&"5@(4L!>0TR[(=9&!X3T^.O+;325..+PE",>;/ M5:HCQ7N/\E@PJPU[8]9F-NOM52!D$NP.6U:8\B2W']=KRI@VJ25LQ\J6];)8 MX4TI:&&BSTU3<-VS"QU\7:Z\=JYR/ZV%L8\U?Q4*IK=FW[SW^( M/>[1]U\DA^'+%=D0FVXY04\_>/K M#PU.,]."2ANQ*:!WQ-DF&"S4[:E6 &H([$-KT<*&- .1GA33#3NH\>S$814ZQ787J#1*<,$0@ UU]M+BT MI0-!CH @?&9PU%A#846%&9:CL-MIY53]A>[]1T9-UZOZCO;9U)N^RO0W6KMX MKV:L-Q-T2W%<9XI4ALFQ6KP>_P!6-E26W/:FCMA66-=?8V7<]\B6YO.Y6*NY M3[1'M5F&F(UK+%!<[\("Q.D7:,:1B6M&JPF4NZ, 0!5YKG5WBJ3*31)E9WSJ M>F5OV%3)T>J[0IR[#>F1$(KA\Q7#9+Y$N3A)\U5L,#X-E)D[=*J\SS/$Z^=D MYRQ%M&T^(V<#U^&&[CLH"X;$CR[$HS8JR*2&$384FS&959:9'HBPD-RQU3>! M"RKS42,S-*PILYIEMN2A.)-Z.OH[:-N&T[7MNV+9L6QMVWTZ LVGYV+ J5XJ MXGG;T::41=R1OF[,?GJ3UX^Q6KUN1D%>"*$2O@R2") G.1OY3OCDQ/JQ)U\[ M8^C'W,=?>CKSRQ48"&$#1HE #AQ,.22*EBLR./&#!T)I4B:0(3Y;K,6'"AQF MW)$J5)=:889;6XZXA"AWQ_Z^Q_+]'^OHZUO>1W(;D!-Y0Q; *MC] M>A1[0/@:='4O8HXW1[%5DV)8,$1C31Q5BL%Y=Z?CY^48PFZX[!(S7*Q,=2D= M'5U>_KN_W@KK^IGMHZV*4"ZE <)R M1W,#PM\._&"-6YO(+;])U# M[I:/6R5Y*X"C"LH)&C2R45DB\TJ$W)98E MQE-QY+[+TQ;R&83)88&N>T9EI]S?IE\[ K+K MRE[!;6R[B/7;%' 6R:_&>2UF0EP0\*.CAT9_*6TNN$)L9E?D1EW*O*C&/1 : MXA0(;D0)0M;:X&/)>,QS0RAL(RR(S*03Z'P <'6VDB MBEADAFC$DOGSC5;XKPWJH"I!6DV_?JC4&:7; ML<;(2G0!BQ-@B.*C1C2&D&C\KSN5EV37"#<^5D5(87'F-Q8TZ-AYQH].:/U1 MJ\,$@:ZHE<,FQ0^77IFP,:XAD[X:@DY"2)1!38)IL2RD?+DX;<7"8ER145MF M+#BP$MQ(Z4>+OWDWQSXCE41=R =HSDKKXT^S90^L;!L&OO8EDB$%@;'@4N#+ MCPRT-L45+RF\UZ+&@"8#DIT@E:XC,A5R-@H_(2XDMUZ=YO\ ,'4XLCL4D]"U ME6:62)U.P2=:CPU,GI#UFT5,^B'0)[T$T4DQDR:\.*F#TXN6CIDAAN8$?V;H MGIG9;J7-EV';J%Z/;DVA9:<3>\#;HI%F%9G=R&'<1'EE(::4HAED<*,8M39Z M%219ZE**O(L"U5FCBP>PK*RQ$KDD%E!9C\;%1S9L#%H<&A%G)B9"F@(6#C#B M_0+AI-D?39QV:>3A?JP6$IGNONTF*2;7YL=UX\B<=1%R1V]JCC94AENO8\M< MC$TLT+K=:AO0&)I AZ!R4_)Q#QD<&@CQT1E3K\U^*XEK+D=AE#TB0E.4^I^V M]\6>O!Z%J:[;*-UD"+C5E[>NRX6OVYU@G#7'XT\C'1 A&SEL)MN-8B/RA\QB M/F0VGUX\F2F4XYF!O@FC$/)ER9!%*&(_JQ".VWEE>PZMK[[7Z;W8=,&FW4YJ?_9->UVY(DLEX^0G M,K"K'*(>YV%G/:]Y$0L*("YU7N:7A0LMM[P^_B,BHLOA#)D9Y%\*#PY<.9*] MSB)/@+'3):FY7U';E+$G]8T"WSILYBI0V_,F.)6S,>C>2FRN0\[7VE:EMK: M:=AL:WL%OV7)/:]/,@HB'0W6NY[KO5OHGJ+;)-OZAZ>V':+N\[N(P=JN7[=>H]F*J(HV1")+ M!$#1EHK+0737*QUT[FJV?=)[-J7:;E5DO4:-2>Y;XGW5YI4B:58P 0.+/A2N M5D*3=OX$!:>;+RAT31-_KU);0]L/&FC@VL678AV>T'A3RFV9$>&^O+DYVCJB-AR(!EF;_+BJ\B!] KQFSQUK3YL9 M;C$AT5%:QC.4^7&\1Q@N.48K%!:*6NZ M;'>81]C67MGXV[NXG=W@,(N,-M]W9>1J9(!<*"?*A,"1EE#<^6%":S8?R+@3 M9[PVM:KM\E<1[,:;+(SZD,@#92,8RY"G2V395#1%K&4^F'Q\2I,=2DMR4,N? M68SB-M.\S,X5&UE%5'SG./2+O0]*\XQC.4Y]%@(K">_NQE/I,YQWQV\W635C M5-8K,.) '"X4"!!3E$4?!8;C0V$JSYEI;8;3A.,K<[K<<5YG77%+>=<=<<6K M,DM0HK"$H:CM(2G';&,)QV^GZ,?#['N]WV.W4WRI;*Q(J#\T.9"Y\?G-QD5> M1]? \>F6QR.U+19^&/Q_VF;/_P#%AZ_(8./J?G4AR.X5V;DCM!&S&)0O6TLD M-%B[/$>)3K=DI@1'Q#AD!+<,0*;&340$-PGF7)$J*_EAB:GT3N'VWV]UOHV= M0!'L6K.5FB0GH J!.:UE1PM3GF6A#"F83UCLL])PV=GXP[*=>GO9BO.2B$Z1 MA#+LIY;C63YPT/"D$",F(.@0V7)$J9+<:C18S#29S+*'94*X%7;:56U[D-$N9(LMKE82G",NQ7BTA[ B RUA2GI$? R V MA.484M6,-+5+DKJ@-N;%;J=E9IE,W6Y00@<\W81IU]:( MU;K(Z405',AV)$/!>1.:3$F3H:FWX).2VY)=C\/@2.M>%B.47,E$O8QXU;;0 M/3R!G!A-J." \#& T]L*!@.AZ:2@M3\S:K67@PA$R0J0U':8UYO4^Z9&D#=^729LG:44$-N$X61:DQ;.^@?7S\MD;(1=H;$FH'Y;KCLB %G M29T!ILDF-+B^\SQSYLWI PJ6Y^MM36#9UQ*:;H"KU$_P &#?K-2=6GCGHNN6!1)OCWI4X"NN1(:Q1B.O*:M34@.PS!K,&*F6%=B8'+B,HAPAK MS?J,KXZR MDG6'GZI8(?:*_KV_.Y;;6P6COH=R%LJ_(..C'8>'7FYC[:5V MKM=46CAQJ2K L=4:<"JK091-R*@Y$9'C!T/ U^8Z-A-EF$-M+D*@142<.)C, M>6NSFY7R6M+^(V6^-0?TKLF!$UWMVK-#G)V1II/K+M:O#$!E"FIDJ7!;S7YV M7O1/24Q($=,A4M8M+-N9,@2_"?KQ!(X^JMG/KGP?D=%NCBBT>Y1EX^WP MKV7*\HQ"\OP2643XS6BD;$K+RD@CDDL(#VRK2Q:^,M?J!-S#B4N-B9D (6CI5A'L?&5>9*LV* M\\C-%AV[IHW;\:X:>DQVY(1XP/@VH=6&6U(PQ7+"60EPN'!/X=PTQ9YK,U=< M<;Q%LX]B(ARB=+0Z]ANLH2[8Q\<[::L MU2;+-#-*9($*B;+TFQH%/1S0,F:%O)G+MA5=.6 ""%(!\>,>2/&"WI<2J^V3QV90&BA:.G9J31R/&O=HRQVXY DKR(4>FT7KKV,)K^- P.WQK'D;6A$5#C\T_+N=ZVGKME]AA:G:0E M3$FQU6$/2O.,2E0\MNN)JHVWSFL-!L4VKZ%Y5G->C89BC%!]7I6M05\&G,A+ M-9(6ZJ!7P]BV59 U5+5BA1AVT[[)'W.$.&U&)!C4"MRC4Y^&CKZCWUXL[.RV M:[M2N\CMCZHNR80.,2L^I:5:ZH?IMMKM_%M78H7IH&NG:L$FQQ0JPYA V2Y9 M^&>$9?:6Z_&;=HD1S#*:X3OB*3L"8D1M+P_)\R,-QYD!\?$0& /SUL7V_A2] MYBI645XC(M:>*ONU=QQ#,DRV&6]Q^JF9%7!"K\A85QLJW$G>EX,4*FZ^)4HM M 'S3H%H_*S(BV,9"D(9GR(;,0C)]G%(SPM]R(MQQJ4XY"?;PZDGP^ M-3/(F.0H MO3JE!%>QEFX!0H@))HC<1$!:ZCD#FZ//3URC-'M5;ERF M9-?.&LF&13,PA-.-S51(:^3>R[JWJ/>+74'3'6-!QU)TS+";^XPUTK M[=.+Y>2&K%[NKPN]=!F*P@5+E;1],76W6*S5L[%MLL]3B\LJU:=1 M.%A21%P6OPYQX,8X/RDC*N%)#-JUNR>']KJ-Z+!C;-Q$0VG&U.0S>P@LV!(] M"K&$9E0;;!F0IB$)_4E(E17TOX3G#_G3G/F@4IP)T]9(.U!%BYA[!FQ!F?LCAVDY($*[QCN@858VC&/QDX4I^:*-U[454KD88@ZML58+\3<-,#Z_!E$"$PN$%5P/ M'#9@PH;[\F#-DQN_HUMMS4^3*NNP*CXS@<4P?+,X7P"1X*XP1\O3U(]!K8Q; MML>QV%6-8]IN;@%3W==MW5IINR_!%"2Q5U#=QR(PJ_E>8*=Q2#I>H7ANSM3- M BFH]FJ'.17B!W_ '!>-3[ U_R!D4.!'-TZBW&FZ=WI M\@Z])-UJYE+;L6K/:Q/5XN5N]KCZLGU^;9@$:]5XB>#SH0^IVF&6>9G#&;@Z MY\57:%.UJ+I4KD=)K!:P5+8:=DQ>4^K0(P[0YM@47$-1[S##RK*H6[4R\=;X M#Y&9)OCXK8NSRK,=#1"\VDJW(X.>7CTR,> 2.)!(SY'+.<_*%JTO+)P8YVE,;WNB:3N\>N".DRQ MMIE =H#:G49KDJ*Y(.O#U&ZF)8C.8],^XS""Y8)$'&?66LY=4O%,DZR[!',[ M%'4O3=$W)7Y[L=R&7V36;';I5.K#2U-NW$T IRV3HVQLR7?5W$@+..7B7PXURI7)8+R%OU+N=P$U-J+=.36NM@PQ=),;5A';%88K MX(4%GBH(RC9EM945CVUXE'RW6X0,*6'8*$7!QX5&P*I>QELU%RI>I<,9&92T MR5U-%-6!P@LPAV5*781]T I9@H!MYALC(0V&@C.D/K.OSPJLA%)55]4RFV^1(@PL30N&FC6RV M(H=N:2I$'EN2/6L_P8L7-WB;<8]N@VZO''(7VJ%J\=UU 1JT]>1FE"LI8$LS M)%"9(49VF9HY#I7AH:N@&S%ECT" MG@:IBRV'U'-@LKP> S%E6.PN#HL*'(/GI2'RQN8S&:Q-)S) MZU>"K##7KPQP0P0QP10Q*$BBBB18XXHT'PI'&BJB* J@ >-3KPJI&GB.)1' M$H 2-1A54 > !@:0_Q,V5R.#^_([?E])(KU0DM9$9:D$)[S>53GDYRV[+>6C.4YA] M\9RG..^,^_'PSU'OB2?L+-W_ ,V5#_$FE=/"U^MS_P!8]_XJ^K^O-*O\SER_ MT/\ V@[^9]'S.7+_ $/_ &@[^9]-9T=--*G\SER_T/\ V@[^9]'S.7+_ $/_ M &@[^9]-9T=--*G\SER_T/\ V@[^9]'S.7+_ $/_ &@[^9]-9T=--*G\SER_ MT/\ V@[^9]'S.7+_ $/_ &@[^9]-9T=--*G\SER_T/\ V@[^9]'S.7+_ $/_ M &@[^9]-9T=--*G\SER_T/\ V@[^9]'S.7+_ $/_ &@[^9]-9T=--*G\SER_ MT/\ V@[^9]'S.7+_ $/_ &@[^9]-9T=--*G\SER_T/\ V@[^9]'S.7+_ $/_ M &@[^9]-9T=--*G\SER_T/\ V@[^9]'S.7+_ $/_ &@[^9]-9T=--*G\SER_ MT/\ V@[^9]'S.7+_ $/_ &@[^9]-9T=--*G\SER_T/\ V@[^9]'S.7+_ $/_ M &@[^9]-9T=--*G\SER_T/\ V@[^9]'S.7+_ $/_ &@[^9]-9T=--*G\SER_ MT/\ V@[^9]'S.7+_ $/_ &@[^9]-9T=--*G\SER_T/\ V@[^9]'S.7+_ $/_ M &@[^9]-9T=--*G\SER_T/\ V@[^9]'S.7+_ $/_ &@[^9]-9T=--:G'BX4( M\*Y$T&)*4/R]C1H!S.&9+JTIPO8^TO+C*E1D=U=L>;/EQG&,9Q]=YN^,'4T> M,G^R=HO]!%:_Q$VET=--6%^!Y^U$^'9_5/U+_<2>K5.JJ_ \_:B?#L_JGZE_ MN)/5JG331T='1TTT='1T=--'1T='331T='1TTT=8Q=J75MC4^T4"[A8=DIMU M %JM:J^1PXJ ;KQV"\-+B9J6G&G%1"$&0_%D)0XVI33JTX6G.>_63]'33T]- M4C\C^#/ GBP#KUUHGA["DS@?'2LSCMFIBXI2*7A6-%;D6\2U&KS!A MQ4Z:/ YCQ%RV%2YT%QGTTEAO]![BLG)"U'/E%Q?W[Q^K8Y^ZJB$MPUH)6"AV M<#LHX7!E,MH(GYL:+< QAJTUU\1*A--,CSPZ2Z_)'Y=4_/;&?CCOT=L8ZMF, M$_+&0<8 S@ >2,$_S_8>@U7&$^ED.N*PG&$XSA.,8QZO1T=5@ # M'@ :MZBS=6K(.ZM7W'6!"QVJGQ;>-:'N6>CEW@-M"J8GQ"#,X&8CYP]"FMO0 MT(PYC.4+9<>9=0XTZM"E:^W1TXCD'&0RD$,"000< M@^"/0ZJ#L!Q!P"OCSGU'H/3Z:P/'CM MX:CQV&&DMM,1V&DI;8890AIEM*6VTI1C">LU0A#:<(0G"4X]V$XQC&,?<[=? MOHZ 9P,9.3]S]]>$D^I)_3JGKQ74;^D"-:-:FG;FH52A!]D$KONO5NXJWJ4 M#J\B[FH"JX;O\BPRF(\V#'B3C\D8_+&W.$PGVI$@TP-(Z4+[KOMEA;+TCJFFRMIL:QU:$LGALIB M,B'C^R7-4DM7V#:136\Q]I\] H]RUN$+PTE8Y@XMZ46>*PS#;ZITS9.*WL@QK@\$TFU+DO#W:;2]F:=K1.DVBN%78OR@&1R9"O)$PI$5 M@0-C1'9#6&48Y_ZSAR7F+93[_7(S.$J6=C"HMCKGESC/?"9XR8W.<7A6%8QA MD4\VM*?,AQ7?MTB,'4]%UW3A]5V<>IQ1(FRDQ5=AZDX]?(66JDL81$JNN8!2 MPUFMUH0)KT=B9%:9K(,E9)&'$80N:[H]<#E+]7]0!-W[ M(918K=[)@MJ5AMH?#E2RBI4?&(^8394T-:4MQIAJ)EQ6/+MHTJI6BYPS&9P% M')A'\98#XF:1BQ). (H9B;>7@+7CTQYA*^V>TST@Z/'@9;2K&7\SI$9#'_[52>W M4<3^4Q*Q/+A:NU_/*M*;3E%NM$Q@95HZ_2>1YI*!JI\TK,:QA7:(/?QC"NWI MY#*>Z>E9U+5S.QCIR)?791^17SX5B&"+NQW!8F-.!P3PR0Z%@-L US5LDD9[ MR8LYV&\PK#,E3J%.JLJKVO@HR/'4[$;<>0TWA.,X^L;QA*<80A'NPA*<)QA* M<8QA./=C';W=8SLL4C1K$'9>)+O(6C7DBN "BQ=P@'R>*J3Z!EU9D2*%BI!< MX!!+> ?A."%QD8/SQJ 0=;NUY(QBESDN'WXRL/Q&I<9$2N"G5/>?#X< G*XW MK+"4MI8)%%D"B$^=*)+*5*1AF!==A"VTNR%>D=QA2UN.J]R>R,Y6ZZH*XEN3;"EPTDC$K&,LV,)&#A0JHN%RQ8!0!DDY8@,U<\9K5 M(0$"AAMDKTU^?;3C. H:+(2P27F#%G6,HVN;.G98B16,2Y#\A.&UKQF&^D4> MOUC7U7NJ!T"HW&V00!'+[>8H02"%#)9!N.^J,VE@:.G$6Q(1M]>8\:-(GQO. MZTO#?FC 1X9?"FT J7"GZE;6_KIMY-.,Q;;;(5B"IDL'X,AITW$+L33C2AMG M.BTL6%9:,T,(9A1V6F(T/U>I\ 5V$1X&1I,,6'=$?$ 0$A@"0<@9Y $#R5R+*LE8< MNV&V!]+RZY*B2I36)$6/ L#D-+^)N'DJ0I..I^T]8)%2(S->64BIXR#: M1)@RICF?3GZO)RI(DUZ1:$)=DLX1D<9\F,J9(LJ6YA")+?>'./>@-9\>MA[A MU[J"O+KM.@.:VE-"WC!,XMF>4K#[A%SUPS,G3D>G8B#,8;4]Y5K87*5YGY#S MBY)Y.5X_#"TJY4UR#%M0*U01\1^?'6Y&DP[&R[!DBICK&4N1XA.6F%'=E)\Z M8RUID+1];G.?<&65$9L$QAD+'"J[CO9)QX5V=E; 'YP(_-&O2 S",$D/@J3C M(9L,/&3Y);!!; SZ^-.2R\V^VEUI25H6G"L93G&<>_'TXZ\JPB&SH4B*<[8S M+C.(8SD.2C.,=TKC2D,OH5CME*F\9QGW=07HC:,.[UR,^[ER#/QG M,$H&G*0B>"-QE9:GAB*,>]$F(\A;:5=O+(8RU+8\[#J%96W9=$\47!\HK3>] MN*2JQ)-6U\/C9NIKDDV, S"H2=2(,G-4,*@D9X0:S8 -BFX5%0=1/%&!\<3+ M'R8LRR2<%61L_$C+@$J1X((S@Y^Q((^?IJSP(8@L%(QCED9_81_7YZRB^; Y M'5T2#(Z:U97=I;1S'L6;E5B&P!VNQYI@8)E?)\E&;,M9#/RB=LAXJUA(PWF" M5=CK:-+CD8+*!DE*-W\V^0"I]OU#NCC%Q9K(@A1R82$:^M:9Y^E_E<'V#O;2=/A$0 M%T-) F"6/_>\?3)(SZ_H(!P3C.KA6!U> M.98'C>-E8,)'5@XXE&7PI4@E2I!P,CTSI6*E6V*A+DS]!;3U[<[W"?V$UL'4 M]=*1KX]L2BU"Q'!,39 NM0G(3=FEOUH%,7>ZK#*1+5[8%F9U>D12LHD)+K)R M4KVP)\B54^/'%3<>V]:;IUF(FV#;O'=("S4^JE)IIXA-'ZO?N<-I,2PU>6#S M!G5#8 ]0ZM,'I@L0W7Y/KT.;T56N M Z_-*W#RP*\!9P>=.JE!6MF@J\3^;%T M]::/LBAT38-Z!;RUMKXV(L9:7K,1<2-;U_R1KP2N3):!EO;K0-Z->1ZX[+>R MJ[5IA5UMBYB<9G.!.#D D' #$_0X;B1Z'TP<'PA!!U"9-GJ;+:HF.OHE:R;'"26S;"8J=NNMEH+H"/, N J:Q&F/8@&JO608)V'@4,(E9Q M]!_>-J]5&5ZHURJ,8;F0:[7PU>BN+98:2[&"C(@MAS+$="(S7I&8;:\M,--M M-^YMM"4(0E*<7'0M9V8F!MC5=F^2M]E@X3M4P^AY@:91(9]&[Z8=*@2?*\CPJ+RJ(ZWM K5/(9D=4[:4=4/JEA9?RU2=D M/1/+A]57ER\(?#'\-N,R)E--N(GX6\OV)*,PF?3)]C8J3W 26\#P3@ G/P^ M?)^I/KD#4FDW%@4%TQ)&S*L%V-OXI-W2%B5V9B:\[DJJ([O%,Q406))&,:S] MN;BSJ3=XMX?=ZD*+.J8RS$*K;7"L0OZY*TNAK,.5$/AWFG&VW&7!Y)C*%IQG M*5)\R%56[OX<;STHDS?J#M3>%SHP*$V6D5ZI7VQP]NAF!V<*D*K4+,Z/2;[" M'0D+?9 (@5"R$<^E0LL6<2A#EZ(DR/-142X$A#[:\>_RY]Z5=L=TYQ\<9QW[ M9^SC/NZP3$3)<)]R(Z]+PTKJ"G_ Q> M420EWW1;W*J/U;;W8.Q3):_[HV=&V;5-=CHZ+//K(T=EJ'/JYVRVR'#'8K<& MP.UNR:[M!^N7!M\NS5XPZQPAQ"YNR]M7:VJUIQ_JJBECL!@7LG4^VK_4K+7( M\^LL#X!75(3V8]*KAJV64>Y8=OU"T2RFO;"ZY6R(N"^8C6-Y[)K?9^6E2%V_ MB?R&AM;T&;2 3Q6L=NUM 6G6 X@:V@B422"S5AJJ1M]6S%'%Y=2?/U@I8X;D MF96"=AB)EQ!G.!TAN6V=4=7]:[?O-V_>WK8TJ;;T]?)CVRO>IUX?=&[PG"&) MIZRC"0P25EN76,DAD++%8J5_89+DFZ">ZNY4Y:%:2M);W.E!9 "57L">>SN= M66Q(,U75+,58S-"UE"R1BL"T[!RXH'LRV3:T>@4YD?[;C[#"TXHQ APU-3'! M]N)G0:&+8"),07(+1RRIG368L=D40D^E@07Y%RNO_%AT.NEUV:1UML&I1?8L M'$0)7PU1+!QD1*6F!X\1.&6* (>&HC>AQ!?CHA0VHOHF\M,Y1Y.J8]FZSEU" M[N:ZM]1:V"FF75JQUT)8M8#9TBPS1S\64/?'UE8T]+L[?M" ]%KS3_RAR[/9 M0F"P]-890GQ9_'F+NC:E@UKJC72J =VG-2& U DYL:EIKU;='QEPP]AA3?17 M2EUN-78BX]B7%$"SH>+,*SAS XZXTMOYNZ4]H?4?3^YW4MV]QEW[>?:!M&S] M24KNVS7=IIV9&MQ3T=G<;JYJ>\'NK/)&KO"M*H-NH6:A85X[M^Y;U08PQ;A. MMB7<8-KLP6ZK7*\4[*L<,T4SSM("ICE2:&,(I01O&LB!$AO-VMXF5&A:TLN* M_2MR4*^G:U/9H+U\UW@5%:+SD>IBBLIZ,7+1XT=*G5SALR1AT=.7&1Y7'49R MVJNK2/B4;&X_EB .]6()M&/<'\/016X=W0Z 2#SA^7GRQ*N';8--ME%/QL*0 M4JJI G#*6LG8CN&X!&,]'^NO![YD4*TY'UBWYU?KUTS%$S:X%W_<=MZX9I!1 ML(;.O"Z=L^(Y9H,U1<3-&3(0HN&<8CYKN0[I!CVJ_":>LCM@\--@[ M/('3; MN[*D2!!*V&VHLV/)U*"&BRVY4 MK/?^IMCZIO>T[H?>MN?YK#N$%>BLDR6%;WRE),LLSRK)6"=B"\ M)V15<[>*W?ED]W\;[5O6U[AO-R:SMM='$\]"M(*<1>*82BT*SS3<21&5FEI0 MQ\F2(LI0.UG'#CE<5Y15-!XG11M3?;"#2LI8*Y#;@,:D%%J<9%R5PF6I N7B M&IJ7!005B09&^0VQ#A09D-M;I]:U]&Y);4K/)AQ[C[2 P:LV:R0X(#0%"CTT M'2[96V([CHJ"J968)TD.UF.Y;3J3E'O:ZSJ% M"V-PYV?J)RVM5EDZV5/!K"FC%ST I,)1"Q03$2$*CJO)%2!)8H)(Y4^^L>2@ MP5BC(UUR1=%]>[;UH=_2C5W&LW3V]6-FL->KK$MB2%F"RP<'JF^K;EHQS1Q5;!@)F 42 #DLD9+$E6'GBP61 1S49&7GZ.OR MG.\23]A9N_^;*A_B32NGA:_6Y_ZQ[_ ,5?337)U&VTMLT?3M>A M6*\%7(3!BQ J?6Q8^!.-6*V7"SR\P:]4ZK7Q;$HJ?L!>0EW,8? CN*:B19Q. M:N**'$)L:2>DIYS<<]G\A-?:RF:-O]6UUO#06^=<N>0M+G7C6 MTXU)&AKC=M=V(=8JK9*?9*S?-<6*;5+O5+!7+,,&EAQ,"?'RH3CF8[HXBQA@ MH%($A,R'/?KMXU0T-=6P;.AYB3C5!L[A:2-;P%(/M3O8^#-4Y/ =5V7G2-&["W M!K0T8L5;5IC8V^]0Z\I#I4H")1ZZ(@U#8U2*W\:+55PCCQG9L8I*+S\%78X: MO!2>:ZQ &Z?#'*1/B2E=T&*U1. M,G&\OQ7C\?8;->S'L1ZC\A=?(/U*XV4HIV2;/67;AF17YFNZ>/&CI,87=:V M<@D;!)4IJ<;SXJ&D )36(&FU':>P[';^7D;AW?JR$H%F19=-[#SKDGM=U5W" M(&RI;K16B11ECI*P?M0?=PI?!L&2?$B34J# &QO"TV7<;MXC5DJ>QM9ZT:Y2 MV3@SL3CH[!JI*U0=17K@D$J,>A#]C44I!&5BZZ_MI>DB63]:%3(V(-4E$0L; MUV=ZD5C2[8N(/)R^4;C_ &"P3^*%(W1IGE[K[D:Y5=54*Y@-)RJ[5->7S5A8 M DBMN/?S=JGB-AF;3#.EX<(>Q-'A*>F#&%QYEEG--3;XA]DY;:_X^3]P'HG6 HB8+,U(40QMC9-\A0K")K]? ML\I316J/ZCK#S;&VPZH+TR/>K$.HSV0!ZE74>X_+B9"(BL,I:?E-L]V4NN+C M,/R&D]VTNNMLRW([3KB4I<<0Q)6RA65):?4G"%))X=7&:\\0.*51X_; ,4JP M':K=MW67!NA-FHH"7"VWNW8>X8\9N >@PYT.0#Q?5 '<>:2S-]EI(MN1\2\P MHS371X_[AWUL^?S\J4TEKDEGM+S,U@U7:K#KTSCAQ_P!IU?-W@1[$ M;-'I(BP[3,+L$P<7%O'H41J&-;K_ )V7(T8Z W9R(U3M_ESJOECM+7^XM::' MUQI3;8#D)4M89U'.'D-J_.2S9='6JBBK1=!ARV5ABBUNVU1^N2F; 2KFSZ@" M+BB)B:(,&Y+UYHOD/J9?/JSTDOIMZ^-'DS$"%/U*Q:IK-2EQ5DHI=RO-RA[D;VX_$VG^(&^[E1K_ *@YH9T"2UC; MYX._$I/&NT?B(;N&^'GR;YE M:$V?K^VZKI.^=#".+W(Z"I:[C)UC*KU7#2"KPT]/B%CS!XI8VFI$V)S3,/>(CP$XY:7WKKB\ZSW53>5I M'=P8) J-MLB".A*93CE.(0+.(G)Q5F;04L\YDXP@7,C3(XE+0-0I:WW\6Y=( M%NGB]LW:'-_@QR='&J(*I?%JK6IPNAJ0>9G/,)9"K8;=FQQ M\Y\;#01(,0Y3T& [+3!;G3&F'%Q8;DU;4A$-$I]+;"I2F'DQTN9>4T[A&4*K M5TOO?E[4^8)[CMRIE\>+33+'QH-\F*O?=+UF\:_SIYRJ[&KE#L.K]F_+V^7. M),&:*,CQH[L5IJS?HZK4XT\X3^ZN1O-2K6H35Z3 MH+0>K>,>U=46V?Z^.L]BH.WQ>\R5DV-?5DIB8(.O$XNKX1^E"?9\ F.IDB.: MLCGKYW H+BFI/$:B8(\Y+OR@8KVA=(\;MF:&!TLD6&V9ZU#:#N_3&K;S6">V MHL-@HZ+MYNR;#C8D@AHAB)21I$<$/RY!46<(-M-6K='5:/('F98;OQUY'V3P M^K3KV]\D./=MK%*E:WV[K_8\ 43O=ED5EVL4@L$(R=8VN,)V8&MH@CKW9]?? M+U [$FPC=?D6<0I_M"/)'Q645_PHO^7[QKJH:U['OFCK/L/6&MK[@@L;6[7K M^HV2T[D&;1A!)XTTU#T,U1=@#=AP1\X>?ASF6FKG.CJ/=3%+ M(&1F.#0D@N?D"X27966XT-XV5>::0 MG#LZ0O*EYD+IIHZ.CHZ::UH/&3_9.T7^@BM?XB;2Z.CQD_V3M%_H(K7^(FTN MCIIJPOP//VHGP[/ZI^I?[B3U:IU57X'G[43X=G]4_4O]Q)ZM4Z::.CHZ.FFC MHZ.CIIHZ.CHZ::.CHZ.FFCHZ.CIIHZ.CHZ::.CHZ.FFCKYG.,?'.,?RYQC_; MU\7C*D]L?2GX_1A6,Y^'OQ[L9[9^QGW^_P"'5;5UXI\X;=/(JA>(Y8Z8)FV5 M\A&@U3COK6#+%5G).UO1ZY$).$WLO2T!S%:&.GI<9;RI-0;*>HKD'"&$TDD8 MPI.?ICQ^G/Z?Z?IJI0#ZL%_2&.?_ -(/[=2AR(V/SCJMUCB>-G''3&V:4JO M2,FT;$W[,UB3;/N&BK%CKC->AT:SN.HC@61,\.95+1%DSILJ'+8:1$2ZY"%; MVOXK4L843=.,7'0 6.I+"U=;WM+3HVPT4GLBX.62D:QU6>&0*= M,!V,%:H=WFRHH6();%O;#2S2["-.72XJEC;- 75W8KC/F1O$(Y(W"T"@I8D# M* K39@PIL_+3<5GC)L10I7=;TQ,!P[8B,[7@ 3-:BH6^1=?'A MK0T<+5^(RX\N:NQ7(A&*JD_\\:J4=]_+.4JD;LI>IH4^[CH*[79W( @\S;+X M;AEI$ABSQ6AAXDZ? D)FCK%>D(EDISJ(\Q+4P55I4]YMW+#,L M_&8?3@8UT&2 00B5A"D/( 32*'GL95"16KDS*S8;S([QQJ"K,@QK=F-47EQC M))R2"?"^" J$G!S]3CSC'C64UG1A3><:VW1JWWZFR;M69];UE?XQ:J!>Q;,.U%1*)-U>MR FEB8@JB[9V(9+&Z00,BK,V(F&T5IT+:/4;%9<%I<8 M@>B(DHL\WGN>+Q2U9 V85U?M#;"Y5NK%5D5K45=B66VQ<624Y'=/*%2B Y#H M@0EI3LU,5QR:YEQB/#BONN)2F(JES_(6$_K<48X?1 &69SCXCJWW96SA0Z^@^HQCT((8> !GT/Z#C3 Z)U%.IX M7V_8WB,H%H)1;&8%#TOU_T8=I N,/J,9EFMBXD+TK&&!ZY>7G MWY3KRV/ES(@^*]+FR6(D.*TIZ3*E/-L1H[+:?,MV1(>4AEAI"<94MQU:$)3C M.5*QC&<](3MOEOL2%:(&MM-ZJD.74J/9*I([4CDZ] "5Y]]V([<"U:'>D/0* MW#D,KBQW+ ]7R=C,)]CU@08<9(2(,$6^SV^YGLT2,0QN?D- M',K:6N/9#E#%N8'9EY4E]%6JI>78[A:9B([Q9\8'9FST9GNS\@TKHC2*TI\J M66-?!ED"E8X8UQQ',H21PB1F^'5O@[G+G!/D#&3@XP<#P!Y^9'@:\;FQXB>K M*C*":OB/7Z36+"3+CKE<*?1+#98,Z*,I]AN#=7&2!*4O1X-B$5PO/E6EU<80 MH&)(IB29&'D*<@/COXCW""C",,[(W+/K]J'+;?M\BS4VUML/&W8,-^0[#.)& M*$R@$1R9"K]:<:D1XLKRQ!E?CS([#TE'K4O4OB;U>XW4!4]!\,[;KB=;K?/' M;/V_>+7+O6P53X\=@+O'77'(@-R$72KKJ'5$FQE*0&"P79PD+4:T/&4**@QMHW,4W32 M98ZLP3AA911-",NKSB=BV\L,S+7!,%-65^95I)960'E(V>*_$3A4) 0!,?%D M-DCM\#$H.!ABRL&8YXY) 4YQ]\ #U.K"^37(G5&P_EZ#@;)UX!J5=U>L+T$43'P1=5<;61'R'F\.*ES&,O18:GNFCT9R4T?, M#5D&0VOKT!:0^8A755[GC:W$UYJ_:>HS+0&SAH5]H:#5:(-UP-(J,2$.KAAD4!URM$9I$G9YUTA$5Q8-80TI^Q04/1VX^6&G'4JAVV=<[-O_4^ M_=&[;';7 +%*;<4185YT<][MR,BSO;3 M"+'O.W=KOQ+[3:,XPM M42J19MGF.)SW[X2U[/CI=5E.4J0YAM64>?"L+/HFS7*Q;*W18K6P/8-%K;3A M03#'!EAG'-H(E10<#E\1 S@956;P!K9$%9%/@\$C./^T%4#.,^< MC.<@\1G \:3XT/M.D-Q;!V"'7))UTNT-M]JK+.5+>E5=N%(CD[!78R&\N2K5 M62L'+#HS.?*7"DE?JB'H+/FL U1NRH;+'I4'GY5*;B0)BXTAO##ZH)!C#T$D MTG#CKR.XS.BQX,WTK-X1 MB9(68A9'C[2R9P&>NJ*89 1Q,IB"/%R9"X%I4G"L=\XSC&<9PE6>^,^_O[L?#^/X=?5)2XA2%8[I6E2%8 MSC..Z58RE6/?V]V<9SC^3/5&UCXAZCVEB2YL_DKS;&$O03;J):DUNSLX4-;#AI1(E'*1 +J@K<;*4M][2N.^G1FCZ@?K\'8]VV M5BUWNQ[ >.7LXR7?A/V5,#'L"LMQ$-# M/%1X#" 8(4TW!B>DE2$X6_+?>=8 OP_N$RGI4 MG'%C1C4F8:AQ7I6'G8 M[*D2V"U!IK5&+3:*G2:A0U$ L=NSEA(V**C/A*[DL3CMD,-XQ&P-%N%3)!32 M6D-X=FS7W,+6^YE7A\ER_)0-JR9/XGU75=SV]@[6FAX3<1HV I#M>?+--VF3 M*)UY:";1"('R\\*0UAUMR8E"7674?6*06USO%OV'5'J18](\. XF\UW8("Z/ MC=C7XCD2(FQZV+ 1XKWM 3.<+6"#*O*I^1Z7(5=2Y7WVRI.3"DQ"5)XJ?S#X M^87[?;]'[,?35+]UHI"CH7XMP263BK.!E X\GB6P"0#CR<>-=SB=MF55KV_K M^/62 72VYI^P-M\6)RH*Q8V!1F#"5'-=K#R,,OUQ2VU_.C20BF4H73[++8C- M,X&)CM.#R5XVTKDAK0K5SP^&[(D-MD1,R4PA:1A^"GTPHAYO+E>&F92$)F(1 ME*WH3DAI"VW%-N(4C=^K.:[VHN/9+6FF>.=FW5JG<#1+!)-FQ]GUMP[J MU=&MCGP,X6>OMI]O-*"W21*&/I?LH:>+F)-1Z&.D$W8>8C,6?8),&&0S'C.I MM^N>2OCU\*<\O'D8P1]_OD_7&FV_:)8MNFVR_+!=K,IC0L4'*O/$AGK&(@A8 M8;#3I4&7*5/=XRW*'DR/:XW7R2XXCG\$+%@EJNID\4.W/7&K3[9:-)WD--]1 M(C+U)@'Z_9+#JN0W(&$JGL6-&,$HU;FQIUFR\+8]L(E?<7.+DM4JQ)KQTSJ. ML'+1$7+JUSUL'L=B:F FYK;$N8(>*G2F0Y-++B6G7#0"3&SZ3,BOSI[R?-&S M?E/9MCTG;U*,5GCEMBX[!,:AIQ7>S6MZE%M.J-FB7"! -/H \E/>R08NVLY> M"Y<19F?1/,5FPA@-A@V$(<<4!K*B:((6P,4V_2=#;HXSZ:C602BY:[W)2) Z MSZ\''&I9 YLNGUT-,GK*:O'KCK;/!!Z$EJ\23,GPH:Z^WGR0?VC?PH;H[>8N MCZPM[[/'%!!"L\E.4PSV(H[CU;$5NC+#=CK/*\+QVHCRPR/WD6.2)[M1ZBV[ M;)A3EN2PUF[1E&X$&.J0.-B-7:1WK=D!9HS+5FVVP'DB>QMO%:S'@O$6WYJX MX$.6TNYMV#6!$X-;Z6/FUUIJV#U-12%5L4,I'@Y>-2(\<<8'#VL MS(/K2I\E&4;-Y:Z?YLE]3Z\W1PJN=LBPSB;13@RMW4-J$W?;,D]KB#7B ^N' MTLVLRS4BECN%;.C'C>M2,P8TJEW S98D%O$9U?A7S"V'2LC*W3?"^N]5L[:E M#MD6L5N$]8['6H[,:MUIZY#*W)@UK8L4CKA$$66&.%F!$P<,:"&AI1HO+=C6 M4\7> U7I;82T[\T?Q>C[>XVW) M^+J$$E$6[,L\DY%N"Q,\BE(GEF:18PSN7F.PTK&WTB+MYK\LSQS1OWGE,$9J MP1F)9C(QE'<227N*RHYD+@'))]S4GA:<2M); !;(UN'V6$,UPT%,"A\W<6P[ M'78^*HR6A5 4P&LAPNS" UB";*PA0@<[$C/PY[K!GVJG"/)8 W70#1IRQMA! M";$["0,=/X&PO;;HYM7I&Q[I;T'M!R$A?9:(JY&6$K[*PWC/OZ]="4H3A"<= MDIQVQCZ,?1U^NN@^[U^1;L1(@D6W$2&&UY6E2/*I.< M]O>G*?K+2(Z),MN/#D^48WQ7DG6ZQ1@AS:)W%.![ M GM4V566 X6GVB1+CU4P8M%JL%=K<7-J]FE7ZX-9)2BQ2&+GD40FAK&9BL@1 MNP#!"5.?B. OPXSDG &1Y) SX]?&K9EC#%"XY#CE05*D$(B:@A,",FUCG(O MMQLH!)5:=*&Q2S4PDY*7$\RS43Q)=H:@N]IV3OXQ9;IH^/4RUNLPS6^NRUW? MK==B1W$"3U&K56&/VG,*$20R+-0IGKI>$-QT*Z\$P]RP;*9VH^B=(L-UH6Q[]2<,OD8C0Y(D;&"F!XZ>+$ MB&<#HZS(>4J3(D$":F&7Y$?$3BF^;5U]O'M+VFM4,W3W1NP>Y[^-SHRLB=0V M9)*BW]IW2&*RBSBQ";$,(FKM[M$LEDF86HU6%KM=]NIRU*2QM^RQFM=D6M(P MI6;*,L=F(5@ZQ1RV$[B3K&G#,8FD0R2 EF]4<_>-6Y;D#H-+MTZ5:;-*DQ:\ M.<#/OME,P1B2TY_$\0^6'C&(\5:5(]N21;LY.4OBVIT-:)2G2^/2[<>N,FN. M-(6Q@]?9//Q[38&+*6D6(J@K(63B@QM=CJB-LQ(,$NSISQ\>,_0?+^?Y_J&IV_#E^3Y? 'CSX]3GU\>@1KQ) M/V%F[_YLJ'^)-*Z>%K];G_K'O_%7TCWB2?L+-W_S94/\2:5T\+7ZW/\ UCW_ M (J^JM4:Y.D_Y,\F;=HN_P#&C75/U$G:!CDKL6Y:P#S)&P1E%&5.PUK4]UVL M.DFUS0)^;-#E8%&+0YDH3#DS!#:. O=&R>-VS)M\N= M2)<9]EG-I5@/66*@\%MARP:_L^L9H^YXL=8.DW R*C<[-'C,UDE6R#9">P16 M1=<@16TM-([HSQ+=B[:.\:(E@XSC:!7M_;=Y'<6RIS.[HEJF4CE%QK'[K(6J MN0 D#70[-PTR:QH*^PP>TUDJS:E3,@_7M518,]R;'[M8\38C=Z7Q6/@M)QAY MGEGI'ECLBJ#3.QLK'4VX<70Z"+]5LA =2WI)2NW&0\VPU: \%!$*RVZZNLD' M%M-IS[77AKT[6^-&)&;SW,53H;ECO3F%7<&(>HU?*#8O(=K:;&Q*[9LCM9C\ MKHN6MV[.2 @ O8E@%>W8*G+)-R!&9;\O6OA;:KUS<=.6%&XM[V6K\?)O):)I M[5YTU0&:/5=?B[98JL 4^_BF&#MGF7P5%9%CY5MFPA3++K3 M2VU7Q1MRTWPZ>.7,7;>G*:=(7;A) Y?[&)Q-G0J?7ST>-2:S>B.M-5!EU,E: M3FWR]8+';1&K"ZVBA5<+6GOE!LM:)B2#,J\E/$^M^@RO)^8,XS.WS7O$_6G& MC>>P[;\\02LES6FM_%+\-*E:?4GZ<5#KJ'YH:7I&+R Y*PZ-4^&VP.!X/S7:L1F.ZK6T&- MZ\BAPPH+:ZE$ &[8)'-P]FR;JXOUE&=;/\+VF;Z[0!6O>-^UM74+6L^LV T1LI$=B1SB&I%HFO5TM.J^,X35.Z-W;N&7V^FSG()&MB.Q* MT:-<:[KFK&+^(A"*J,-#C=AIE0K0XT+6>DU2.^,7. U\1+(D7I#+= M--'1T='331T='1TTT='1T=--'1T='331T='1TTT='1T=-->4=?,10AB37AT, MP>CBY[X021)N!!Y0LU$><&CYQEH>6=$PILU+$:63:%$W8$=QR4V.FK:3&=JF MU-QYYC[-:W+3^8VN^.]-!$:TGJ^/J MO6=*$%;"V*91;;5-2_,+$I\$O:+U;;,];=T=--4BT?P>H<#D'R[NE[Y%\I;+ MJO?FK>--(K#;O*G:\W8Z3&HC=TLMA*7 O);82[[&,RZG\V;[) C[(&S[^+7" MA#[%+BS8LOOA$;<'TSQ)16O=T7[9!CEY,X_0=81]^CIIJJN5QLY%1-[\U-OBJM MK^8/Y%'^#Y*BB96R)HXD*B\;929%]79GFJ5/BP)1!*5?(]H4Z8;(O^C]LO5] M"G'&UUW#X5FSYNLO% I&J[M6IP#F+1MW ^,&K;3/F J?QUM_+FGBG^4]@,GH M@&P$90B^[B#Q[_#%UH>XT&@$+&+@#\O'IK^;WNCIIK M6BS@/6U#"V:%#'6$ M-3ZV'-PAQ#)8?'*"0\,;-1!)JB0%SH2GXJUQ93D&$ZZPMM3T2,[YVDY[T='3 M31T='1TTUK0>,G^R=HO]!%:_Q$VET='C)_LG:+_016O\1-I='335A?@>?M1/ MAV?U3]2_W$GJU3JJOP//VHGP[/ZI^I?[B3U:ITTT='1T=--'1T='331T='1T MTT='1T=--'1T='331T='1TTT=?E7F[9\O;*O=VQGW8S[\=\9S]COCOCOVSG' MQPE7;MG]='3354B=C^+GBRYJF="<7W1T&VER!'93MT/10A;6#\HF@%!KE>0> MED(FTX63Z;V/XD!&QR'MV!.%8:CM,3H2)=+ MN=P?(-SYT[#%,F$9[QPJPV^:BIA^GKL87Z)10N]&'V5^*)BN'&OWSQ?U'R1A MC(.U!MD(,"(Q*(/57;Q<*5*C-%UPESU,3JD9#S8\I],!B/F?&?8GIA+E0,2? M4IDIAU%#WA-\?-1:BN /B!KI%,O$ZQZYN8$59]M;&E4R19=?ST#AI ABS.[$ MAL31E*+6T: 7,K!P3#+$H1"2'>D08,N#:PZGD"6X^0&;(;&#@CB/O]<^GZ;Z MO&1@JBDX'YA('D#)/.\X2>36(.3D- Z,*%MHAR2&)<""F'+6(F2 MW\&5P9R6DJOXE/ GCR%'5E?&A%.K&V*R+I^O=/TG3#V4P"<)#JT/D!!T^9#C)@X9Q"^J^L MNE]FZAZ(VOJ3;9[5S>]T>GT^]?;Z=E-NN?Q2M+;DLRO'+4DF:[7A:>K'+-VV M?DL4*$ZU.Y[EM].[L]>W"99+UIH:+QPI(:\P[4;2%VXF$N9HU9X0[<68D!58 MZ:72^XZ-NCD&% 9H8*E44$(AA^/- A@H<:!4W:X/]6AE#;:%.8E7Y=6BY&BY MSB7&:H,A* A'V%J>ER[V:76!X0NZW0]N:[N=A"NQY!DX"L17 M88B(6%O2Y3DJLR'B:5R75,3#DMMM;DNT#CSJ3:6I15K'[/WR=WO(,G8,^NSS M=9C5I=3!0*Z*"8!M(;.6&26D$R ^9:#):3/80^;,SFQHL2):A#HSH:;KNSM] MV7K^#;H=R3=KL6VQ[;[N($V5!#[D0*[NI!D-@0M*??'KB%[N;#2.]&T/O#59 MAO1@6RMN<0K %XFJ.':)*9'YW$-%J,W8_9M-4@X3V.),A+LLJ/=F0[ ,L,;U,\Q+%/R5 M"FEFH^5-%I42%'ED,..JE/NK>=4NWUKL/5V]6^F)>E^I$Z?@VW=A9WQ'C:0[ MC0Q'B%45'6M$K4[E7W2>3;SMVX"C'!;66ZI4N;$ X_ MD^/E7P X[4G&-BX=F#1IK7ST'M6\1JO;M.#;F5JZ;C()G4;#]<%1+\L^6D!P M(@,?V98%-QJE18LR:J?+D"0C96),E3X%80-G612F[ -[SK;P\T!36:.U&9L9 MM<^,45,61L1V3">]5E'GY[S&7GU/8DYCM(2]?_(= MXBK0AEW0FN9:&CXFS14313D_$$P"D,3!3PW$N4_D;%@RXL66R,@9CB\28T9] M<);C#*FYQV/K&A[CSAY",[W M4S-AR69+>%N-^DRTZZVO4T.FO:%#[--RZ7W#K".WU9.=P>AU!'[PAK]]T-6& M2YV4N,(XDE5+(A:>@;16J)!3KDXL-+>UV&Q0GW4R[K+WS%?RX[?-E,:]SB)? M0,#($+Q=S\F&$293S@IR=*;@U)+E;5+UZ':Z[;'ZNV7=?%@,VJ+D9 *PYV!J MG8L;)*.F:N!.R-9;COKC-R4QV777FTSIL_YEZB+*V^11M=V*W^UH48/!37JO M,L)R\DY#C8 [&HK=;H?'NC%36W-N66U;*?O!Y^Q6,-"M]Q:B0;A>VS5OGR9H<258 M@1'2,6J0X-=.N1T#@WZK+FH7,^CMKWG;>G=FVWJ"\=XW6A0CBW+Q+SMV:/L)TM59-5$AIL=8@OZ7V\7LJ7J[%8S M#1/S'FS2ND!.[=>['HEV-WPK5B>][ 3)%JS8"]3.FL4NW!RK,%P\ 6R1%!R1 M41(CDH8N3$==%O.06936%9?3"^P.#NE-;&J;K6E;\Y,[7W 0/QL Z9<=^N6? MV+"'G<;+EV#=7U36-H(-KH[O/<-;;H M;>Y6*T$]DI4I3[E-!!PK1RS%4DLO%&K""!V=UA1D0!2PUGE*<$[/B&&:RT:/ M(%6)K#(H6-)6\-(5&50,3Q4$*//$9=J&Q6*E\=ZCBQ&9D6];WN;TM,TO(2BT M*C[8L+Y626D90EI;QH70EQ9$F0RVVS$D.QWDM--H0A-J.KH@' J#%!1F8HD3 M#8&C83*<)9AP8C*6(C#>/?G*4-(Q]=YE*6KS+7GSK5G.O_NDI9;.4U#LHG=( M4TJ.NF]Y(BQ2(4&OU5^!JV; %@:Y5Q<1U@0+C%\J,J'PW)+\DR03"AS2,I,- MMU-F_'[D<*?!1Z.3L-;K=TM=?GS-;VAY#DFG6C+\!:1Q&.V](P[&*A"CB(]K MI9"9'GP7F51X2WG%3>LS M5AU2Y)Q6 H8*DD9_=G)FK[3QE9W)J M_,?,8.>.==<#L4II^V/Z>N]<)6?7J0[Q6D6U3;UC(DJ?$RA$X181DAF2JR$: M:VZEDA*@^O%)(;U$LL9);7)D(DZU:@CV^MLWKC7>95,L;2FY4=%,MTVOU*RH M1C"G:X=@,L&0H-Z0A>'(Y1NJJ*!Y;;*I0^;%R_ RH?RP<%W\EQ4ES(HV51T" M;EQHV"X1]9DBG68JG:_0+,J6YEU\K!CJF5U[#S_K1VL.(8=87)3#DNYG6=X4 M@ZB3L)Z=5J1<:Y/E5/8D?7&S@PO8]+LK!9P43K%KUV=?6$NTF,68D-Q_6HA MM-QZ% 2),DH]502>N[=ZI9K2/&_9G:M9AFKR3\5(6S"'X13.IXVH"W=KSAHV MKAFC)IY1R#E#(C%',' MVR.4@$H&6\;G"2U;IUHI92*<6'4R5,!(%GJ-R'/Q&T&/:0D4#L#Q0#\9+<5KO)RC5+PR>39B=5SY 39?7+KK&OD0(^$_8$Y+$0Q>0P\ZIF M&+%D"T01(*L@XYE/M @E45GVA,%P\0>FZ/AIE72Q0-U@G+:Y3)477U+/C-I5 M.P($O'$5ZY51R*^"6?>"1I93$>7*IJ\,0I#DF/%Q)@MR$&Y.3@_#E$U<856'$A9H7 =8W4D(W&-P_$MW!DZ",%ARB ! MQ@KRX_?P,'/R/CY?+UU;OHCG;$W+L-%1+:K*ZUK.=9/W=6Q;/>J6NN+LJ-A% M:;"HD%A,J'/+/G@0W%ZKMD%IEAIHG) 5.2+-"W(S[?"MMZL.NR(X79%!+OQ( MSTR4P+N5:(O1HD>(]/?E2&X91]3$9F%'?F.ONX0TU%9>DN+2PTXXG2[I6D]+ M[7J44=K?=PS8LG2DNS%CC5HT9MS6I;8EQB5VO6<4>UX/L-W@5\%. :V%SYPD M[' 79VWPR1/!&RCY\$15@K,\&>"$*[GMGQ..L:L:9)QJ?6(I&X0EVA,>$U(- MO"D0W(8V5*A69)77I/9%2=KML1-"S0UIGR?1)?;<>=Y]N77FU[5U=L/15J"_ M)NW4-:Q;I30UD:C&E9;#E;,S3)(LDBU)R@A@F$?Y-IS%&ZL=1= GQV9<*; M#?;DQ)D60VEV/*BR6%N,28[[2D.L2&''&GFE)<;6I"DYSPD1K!&.MEU./-G' MZFY\5MJ]W96%9[YQ\/?\<9Q[E85CNG/F4VI5Z@U.M4>I"V E6IX(56:V&C+= M<*"?3S@>?09\_89^VJ,=@5(AP>Y$9G5*Z2-;Z MBW 1E%:]#C5 G:M?5D_&G-3[S4[@%A$&WA@N>U)=N%&NHJ0(=JKDJT K"F?5 MV1N1\L![_P",G:;,-34ZEP$QK&>9:\]I/V;9LNV1J[+D$\MS6PE:)SQ$Y,6& MX&D1'D$$2341J:X[#$RIS+<%$L<[0=JDFQ?.39H@9J*RL39PBN7G8M5JUSI%6!"G'3$B!$'R51/-!/1'EC!J8D]Z,,]9'H&ML#(C3# M?&=L]MW26ZKTO+!6WV,=6;];Z>H+-1A0Q6Z;4$:Q:=;DB>[,^YTPKPM8D!DE M,D<1@EQS_8-\IT[<<-6K*-HWR_-'MO<$O*C<62N+-9J_?D@2HTEI9HI:HYJ) M#%*A$2E+U..)[GL3N;L;E%3./E:IK56LSCL[4QJQ%YDNXHN^8U.8$^VR2I+( M%[7B,$K1DL-3+8MTA0P2^\*A8G3W:^/PS]S[/50HOC9XKC0,O'D>(I0CA>;; M&S5;LZ>/E-%PQE$?)-DIU%GUJ* E,&B$V!CV(%V$@X/EUV&M4]RLV*X+(OE#PR"Q!BJ9F379, '8F^QXKK8QLG@0-<( ML16I4F(B6X^MSLRDYQAR#D\FP0/3QGQX\G'Z#\M=%< _%F/Y#B@8?+UP0!^G MSZZZ5]T;1=G7.G6^]19%B;H@FUP*[6)[C2JQ')7%L;!*V63";9;DS#S0"#+K M0YZ1,7#AA#]ACHAJ=*./IB<%Q J5,&CQ]&N-M!MQ:&.U83C%8U5N06T:[K1P M\7H-;LU?M5?)#B"M;P[&3K=,,1\0BL>M+8$FY!UB+&PPW71UD"611Q#GB,#C MZKX)(^$Y'YQ+>GYQSZ^=8S0Q,W(H.1)/+R&R0H)Y @^B*OK^:,>F1I5Z)Q9$ MZDB"XNIMB7JFHCTRB4DZA]%5L\>TQ-=A$UNMV E$/UV4S M[%?:BA))<'D;" M(CH0]DD'F.#H+S#3IQG"<8RK*LXQC&59[8RK.,>]6<)QA.,Y^.?+C&._PQC' MNZ^]'5+NSGDYY-\V.,GY#)]3@ 9S@ 8&JDC2,<4'%?DH)XC] )P,DDG &2 M23D^='1T='5.J](GXES^(O"/?$G*(^Q*8[E&,Y]V,JPGM MC.?=C.>^>I]D;I'PY4R)[!GN>JS9D?TGK<5'I/0RG6_/Y.RO)YO+YO+YE>7O MV\RNW?*\^)U^P8Y!_P#9@#_Y^IW7(6_RL6_G4E_OS_334^?/D/\ X/3_ ,-B M_D='SY#_ .#T_P##8OY'2Z='333%_/D/_@]/_#8OY'1\^0_^#T_\-B_D=+IT M=--,7\^0_P#@]/\ PV+^1T?/D/\ X/3_ ,-B_D=+IT=--,7\^0_^#T_\-B_D M='SY#_X/3_PV+^1TNG1TTTQ?SY#_ .#T_P##8OY'1\^0_P#@]/\ PV+^1TNG M1TTTQ?SY#_X/3_PV+^1T?/D/_@]/_#8OY'2Z='333%_/D/\ X/3_ ,-B_D=' MSY#_ .#T_P##8OY'2Z='333%_/D/_@]/_#8OY'1\^0_^#T_\-B_D=+IT=--, M7\^0_P#@]/\ PV+^1T?/D/\ X/3_ ,-B_D=+IT=--,7\^0_^#T_\-B_D='SY M#_X/3_PV+^1TNG1TTTQ?SY#_ .#T_P##8OY'1\^0_P#@]/\ PV+^1TNG1TTT MQ?SY#_X/3_PV+^1T?/D/_@]/_#8OY'2Z='333%_/D/\ X/3_ ,-B_D='SY#_ M .#T_P##8OY'2Z='333%_/D/_@]/_#8OY'1\^0_^#T_\-B_D=+IT=--,7\^0 M_P#@]/\ PV+^1T?/D/\ X/3_ ,-B_D=+IT=--4L>+WL:*7Y(4*:V*E,I5HNO M-Y;QMI8[X4G&<9QG&<9^&,XSWQV[8QG)U%7BO?L@:#_0B#_Q&VCT M=--74>!Y^U$^'9_5/U+_ '$GJU/*DXSV[X\W;OY>_P!=V^'?M\>W?[/;J@G@ M9RNH7"7_ -GTX>W=%12$EV9MH_!;SA@UK.N.GNB MX*\V^6I(WMLZU:E:(V+=@1<>ZZ1\D18X^:SU;,&RQ02;SO.[7DVS9-L-LRBI#8MLDTTMJUV9C#5I5;=@I%),\2 M0HT@WWL9PK'=.<9QWSCOC.,X[X^./=]G'V>OO6ESPY\7+DSP^V#50O++<=CY M,<0K99@53MFP=HQ0.=X\:'+*5CAQ.R9E\K8D#&VKIP>7G0X>Q!EM!8O-*"2L M789;C(P*9!2MSY75R%/K4EI+"6DY=R\I M6&\-8])E6$>_K8=.=2[/U7MJ;KLEKWFJTC0R!D:*:O.BJSP6(7 :.55=&Q\2 M.CK)&[QLKF,>U3V2]=^Q?JR?HSVA;,=GWJ.M#?KF.Q#=H;EMMAY8Z^Y;9>KL M\-JG-)!/%R'":&>&:O:A@LQ2PIV.CKRPQP-8@XJP "PPV!.#H1<*:$$(A,27 M%$8[
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end GRAPHIC 21 g163192.jpg G163192.JPG begin 644 g163192.jpg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end GRAPHIC 22 g700385.jpg G700385.JPG begin 644 g700385.jpg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g216371.jpg G216371.JPG begin 644 g216371.jpg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end GRAPHIC 24 g936552.jpg G936552.JPG begin 644 g936552.jpg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Ō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g991726.jpg G991726.JPG begin 644 g991726.jpg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�.H/,&#'QCU#T<_87I<;MVT\//?K MX0Q7?I>_4'OE[!03\(W\^%[]#WZ@]\O8*"_A&]^OCT?30.H/,�.H/,&)8^ M-Y!P]?7P@XW>4\/7U\(8KOT/GJ#WR]@H)^$;!WZ'OU![Y>P4%^M<8?;P^N@= M0>8,&@=0>8,&/C>0^7'39B@OG_ $QN&#OT M/?J#WR]@H)^$;#ZZ!U!Y@P'KZ^$,5WZ'OU![ MY>P4%Z_HC>7Q8._0]^H/?+V"@GX1L/KH'4'F#!S:>H/,&)8^,>H>CG["YQN\ MIOEZ^OA#%=^A\]0>^7L%!/PC8._0]^H/?+V"@GUKC8?70.H/,�.H/,&#'Q MCU#T<_;,XW>4\/7U\(8KOT/GJ#7R]@H)^$;!WZ'OU![Y>5B@N_\ \QL/KH'4 M'F#!H'4'F#!CXWD'#U]?"#C=Y3P]?7PAB^_0]^H/?+V"@OX1O?X]L)WZ7OU! M[Y>P4$]WOC:8?70.H/,�.H/,&(8^,>H>CG["YQN\IX>OKX0Q??H>_4'OE[ M!07\(V$[]#YZ@]\O8*"?A&P^N@=0>8,&@=0>8,&/C'J'HY^PN<;MVT\//?KX M0Q7?H>_4'OEQT_.*"^?],;A@[]#WZ@]\O8*"?A&P^N@=0>8,&@=0>8,2Q\;R M#AZ^OA4]M_DW78KOT/?J#WR]@H+UZ>J-Y?%@[]+WZ@U\O8*"?A&P^N@= M0>8,&@=0>8,&/C>0>_7PABN_0]^H/?+V" M@GX1L'?H?/4'OE[!03\(V'UT#J#S!@T#J#S!@Q\8]0]'/V%SC=Y3PY^/7PAB MN_0]^H/?+V"@GX1L'?H?/4'OE[!03\(V'UT#J#S!@T#J#S!@QW[M@X>>_7P@ MXW>4\//?KX78KOT/GJ#WR]@H)^$?!WZ7OU![Y>P4$_"-[^''#ZZ!U!Y@P:!U M!Y@Q#'QCU#T<_87.-WEYO0>OA#%=^A[]0>^7L%!/PC8._0^>H-?+V"@GX1L/ MKH'4'F#!H'4'F#!CXQZAZ.?L+G&[RGAZ^OA#%=^A[]0>^7L%!/PC8._0]^H/ M?+V"@OX1O?OA]= Z@\P8- Z@\P8ECXWD'#U]A4\/7U\(8KOT/?J#WR]@ MH)^$;3 -Z'L/[ ]\O8*"_A&Z,/KH'4'F#!H'4'F#$,?&/4/1S]A4\/7U M\(8KOT/?J#WR\7<*"_A&]_3@[]#YZ@]\O8*"?A&P^N@=0>8,&@=0>8,&/C'J M'HY^PN<;O*;Y>OKX0Q7?H>_4'OE[!03\(V#OT/GJ#WR]@H)^$;#ZZ!U!Y@P: M!U!Y@Q+'>_0.'KZ^$'&[RGAZ^OA#%=^E[]0>^7L%!/#_ ,(W@P=^A[UT[P]\ MO8*"Z?Z1L/KH'4'F#!H'4'F#$,?&/4/1S]A4\/0>OA#%=^A[]0>^7L%! M/PC>_IP=^A\]0>^7L%!/PCX?70.H/,�.H/,&#'QCU#T<_87.-WEYO0>OA# M%=^A[]0>^7L%!?PC>_3Q:G?H>_4'OE[!07\(WNX?70.H/,�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g80558.jpg G80558.JPG begin 644 g80558.jpg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
2W M/F)9A$HD"2?K.C+.2HO7R3N;$>(<_-AXCSXXCQ\ 0M)[DX J)U$:AGXC$$8G MN,0 .0ZCJY+Y<][/]N-TWHV_'='@\X0=;#CW!F):@\>R,S(0D"6(2 MK$FX>LZ+46\S$.7$_=+-DM[ L%;6/6B&>/>JE'B7063:72MN4=O\IS94]XC4 M=DV,\MT"6N\-575PIRERNLHW49J2$">2@$[!&J1#AJM/U)X1D_:G0!LNLD0% MUK8'_**9"LDM.62K BA6;II2U\WY95R"ED=&2IF+(<,H;?J=MPGD:Q S M\0PCZ/1YV0G8%W6HD;,Y8PLR@:36C>C(DYA"1:+5%")2<(]4G$IV \N/-JYM M7B\L9\/>$1'O?6]/PZ^[3]=-?W4U_G*6I;=FWZ+S+]:-OW.A_(I MZY6N*R_6C;]SH?R*>N5KL6H]O$MO(QY9LM\I7FS%],;(.[7?\[QU5@472XMF M?7"6K]71(X?.@(H+6/9(@L^D'()JF09-7"I$E3E*D?B7'8J@26K-;PAN,Q'G MVV2>7V."K/585O-4:?J607RZ[8SI*.LRKEU:J%'KLWR-?"@)5R-)-DJ MZCW"J!@713=&61XJ)E >OMF\G%$-:ZID#;EM;K>(\A16;TL[S]WN%N7R;8WD MP19TYJG'V8ZK"0F(-1N3_ "9R=MTQFSM)OV>6 M>3U:XSJV=I%GNI+1\_(,$GHS M$Y48,CYRR;LG46666FNA9KZVK>_BYA7;W$8(VV&Q+(9LR+1+_FZ5E\G/[UUY M:T>[ME;.5\[ M?4=>&')NQQY^J(TQ(QQ Q&..9B=: <<,1R%9&',G'7J-]>=MK&!X:Y63'>(Z M?A:<)BKD^;=F:QO)*/RW%VI>92CZD^CT%+D]G(.]L==>;@L;-K]NHB\:V&B8_3KMF=6.'J=]@IJ9?VBQ M@#E%DG&UQ:+;1*74[HJEDD';P6)6*$.N9PE=_0262,MY +BPR 92V9)[1^M) MKF54802P4=#GOO5H5I() IC,!I6ABE5!$9PPIBJ>G!WM ;.6SW,QL;&$ MNU+%6,L9&KA;:4!O88[8V)EUY+*C7S%K9I8)\3E8FCYH& M>:+IT"W%-W)Y= M6SD(U=SKV[,<=9U[[2I2\ !B>0XDE)Q.;J&LG#NM6K 8==I4BN3@ILE U>V! MO0PZ%5F,M/MO9/==:\]EO)80;QR01+62<(MV4@R18I' M,N&;JQ_EUC 8\F_$CQVB=-@>7EP'SF(UC \A'3B.0;+4VXV;8RI.UO=58\B7 MZOML[X(W$1F*FYF3+(+V*15CE#M4J_S'L1AXW,.X&8O-]Q#M8P;AV6Q=4Y*>AX7)%YKJUTON/Z]9HZM4:L+ M.7EVF7JS61)-V-=[("2.4?+*,FZL>DJ+&(;AO3KEX@=WM9GL.O5XK)\YHZ5,42JIR3=>4+I.8 M;;GQMFK;VZMV&LYV'&EY+18/*3ZMW&@W_&=&A:&RL==O+2";MWJ,Y$1 (RT< M[AFHI(JE3;N5>#@CEW//R;CKUGEV\V_^2 #V..O;M2< =%CF@G#$8+PQU#?C MKI(.3KL[.Z93@[/F[&%9HF-<,4K<(PR^YC[1*TF[8AO$BX91MF@VL8@K.MW* M*+"0$\.#*3=/9)LA%1IW19!K(#;KNDVZ&V[RU-;QV1*_E:D96Q8QRKCJ]U^' MF*VG.5*94?L4%)"MSQE9.$?IN&9C&:KN7 F;K(G.+=P5PT;W 7C?RYN7;YC$ M<5,*Y3\E[<:/MBQ?5(NTN%F^(\?8^FW$O!'=2#V'6=W:16%Z\"0.H,'SEUDS M)+BBWYJ]N6X//09KJN!H0*L:MC@K 47ADSHTT$OV4&A7DC(]D140C(\88KDK MLJ'6DRLF*(I"IUP4 X)DAJ\N7''DYN37R6G3I-6\8QLBUB)#(B>UVCL95\@NZ9QKRTX2P[#-W[MLV.FX<-FBK MLJZR""A%E4R&(F8IS (5TXV,4^+S/:L.36[+%HO\=PLBYR"_JE%R'>9N.M3. MU/*Z3']1Q[7&[JX9 LS1BBSG+3V/MCMJH1Z,8ZZM];>O'8IA?# QZNZCZFZLZD==3=)TO4ZW-Z,U: M8VWT1=0N^\&P3N.+>:&W9S;B>=+8SRP[QCDZ@*!=IBY(0D#DZ.@'4@6"E F% MH2SC'L(QV_:)ENHV/#.$J9DC'EJ1K64&;>#A+><\@PR/.5>+*1\L M F;N*9(4&31EY6/EDE9(&QF8HNBQV^Y,3(C"@/)!;(\"7-4=B4^;7V"^P/(( MBA2$XT9E6,0RZ,<&.WN04(X#*JTM!87?5!10(Y,U,22,M/*$UB\WW-%AM6!' MKNG9VVV4;;Y;J:PR[(L9*,"BJO%X^R0%T5J+V2,BZ.[*#B/EV+N3'H"J*3KA M19?G]A=.4C)?\=JH6?&5[<9G7Q6TQ>XM47N,RG7\,KK,8P89#)"N"Z])1<2I M>.M@B1=H>2- O70])(=5L_\ (1CW._\ E.OJY.35SX[#:4:?$]TB94A6 2\X X<\@!S1$/3#B M&LGRB;I^$A96[%-*64KY(AW8H:MLDJM 3+US 13V6-%N)%6Y=SOV*YS7;\O M]JU0A;5M%6VM=CW9H4PL3JU)E6>S@93L9 ')"J-.K^QSK>B<2*=2]>P.3JDT M!AMW<_(>4](]VTZBM6:48@8*)Q"<<01@->PC.UC9@<>2T6;*L5T[)&0KO,CUI525ZJ9J<8$V,Y"JE1OF1,97V9C*U2]Q^"[]M]E+ M?-.NH(6GS=HCT'-)L\V]$2D8P;2TQC-C,/5E4FD1]-A95^JTR8O#@T!=.4E;9!M1IT9-,W_ %N: M5::M"K?JM298N&P;\,-?3L\A[MB@HJ.!(PS"G ZB,=>(Q&.O$GKQ>\O/I^A5E'$E13@Y)+#M:G4XQCBZKR-982SE2KLGLA)3,Z[AJW#@HF1N M"MCFZ#,"6?MPV8-:VU3;0M92>D*!0(]['XJ-5>I M?4=6. M @C3334MN6S3332RS3332RS3332RS3332RS3332RS3332RUZ>R7YX\]_]V:[ M_E#Q+J?S_JS?MC?A'4 ;)?GCSW_W9KO^4/$NI_/^K-^V-^$=;-Y$_P#5RI?M MV_\ ^!3K:#=E9_KU0O\ M2-_[O5[;=;TSBF;P' M_;K9JOL5T%]E/)%(QU'+@T=7&R1T&+T2=*$>T<*"K)20I:IV MJ0R+QN^I+UQ547[]6&?$I2<>DW:+OE$DWY4),L>F#PQ$Q.D54Y4NDX<3='(Y M;=3>9Y?,EBJE7L[B=MLE:)6FV1LK+U=XC)F53-"K$6YKDS5@T.DA%O0 KIBN MS9/4R"HAT)I96P+#Y'E,MWFCV;'F*\.8^R(WH:;Z_6&;2,@Q,0[")F5%P:3* MTJ[FU6B;UX@BZ25-(RPI,&B$6V.=K"N5,4V;$60Y;&MB4C'\W&'BA1=P+H[Z M*EFDZT:OH5[&KJHMEC)2#9X@)$G*""Z2IC)*D "@H>W:>N[CQ:IT9"6)#%', M+@+BY"'XE.+4)QZ&IS2+;#C*9$+A!:?<>;*F%*=*2VHWI66;Z1D/UJ>ZN7"E MWD%4XT:1$W QD#I$;1E,[6-Q5>B92>F\.W6,AH5@\E):2=-8 MXK5A'1Z"CEZ\<&3DU#@@V;I*+*BF10P)D,)2&$. \/#2.%T&]SGLLLI^W245 M'0[?'N*ZX_F(%[D&PRTB9JZ17L<5%22D:VB&8)+IM"F0=R;IR1)HF_.D#-7I MN4VZ3D-V1$BHK+;#2H;C--GNU!Y_ARY#2A)4F?F//$U*8OAM0>"XC=P^D$%K6,[6Y&IQYYU M9NWYZ UJ#DW#.**VZ?GD^95.F0W-+$U/S_DBE4V[TR)LMF+'VV'@H:,63N%E M9&I"4):$+-T]3;-'Q&\*>D:]1D/'N%BB*G/,D:Y6QX5P=C_,T]4W=6 MR'?Y>4J&.Y;&^ &<\I$65Q<+LU7?3]1MU]:-#)1AZ7'->KD$5Q;OI,9!HBJJ M[!LHHO\ *X;><;H9'W X>JC611LM7QA$Y8H2TO+.7LM7IFNQ3&5,=A*@U4>LW[%H"93HE,-U)J:) M)0Y+4[H8,VMN2'I#;)ANCA<6.]*$5<5NM2J3E'(!=O+$EIK(P 2 !@ !@ !J V _'8U.G.TV?" MJ#"4*=@RF)3:',[1K4PZET(8I*\TG-4E6!'T5WAHD6\E!K-WY MJW6HE:IDZEONL% ?9;G1G(ZGF-*AQK3,Z32M:5MQK2(2'&W$9R%2%C[(TCC^ M%R3'QT4Q<.\F8R>8Q>2+E98KBO0\S-5Z7GUHE-(@I+O)-I %@%1<'(FE'/G9 MTQ.H)2#OJV1GE1I>2ZI$Q+$K_*$= UR7M1UW 2T;38R7+/3=4BVY2]3)L[C) MLX,; ].H#I2.A4HI,HM'ST%+I$]K1)N,VC8BKB,4TSCN3AI[*\A9K/(3#6&K MU)D$I)#'53*VCR/R((O8RN3=EF)((1U*.99VQCT%TXQJ8#QIEO:Q9L4XXB,I MI9"Q7DFI.[S(8PGG>-+$_G.P_(D9'+2CNK32KV*C6[QG.-N/,:!0I[-6I\:;4(RD.)0\N2S$K\<3W&6 MWUPC)"=.V(X+.*HE^\D=X*L*7(E,LU>]MX8LF-$FB>A5?FW3KT^C4&IMNQW' MH;-,E5:XDWB*/+?ALUD4]3A@OKJ#B)5+T#+E0J-:C8J?PY7+M/URRS%EKUC= M62:KB4AUY;0Y#5G)L-!M.DR92HR1A&LO$UE[-0;1-9S+1SU1Y%RKMN>LH/T%L\16BIL[G3IE>%B'SBJ* MJ0B::C,6+>11BW*S0*4H.U;<;E.L-+ICK#5VN-4?KOFS*?A6L%"E5*C0XM&FHD)9X,N7*J$ 4^HH::9:?CRYRY7 VF3)CNLI0IPY*-29I%,H5>77KO.RY4J3"J%*H M;5-35Y4OBV=%E+?1',J0V[6],)NDV&8B(BT2]M&,>M9LO MHY=DYF'7>L'!',12NP&FU&+9(&3;Q58H]=.Y9UY-LKU0B@L1N/,2;E%2[:[8 M;VH6+&%"SA7XK)>!,:.MQ0XBD'E@G7^0G>2L7LXIW*/\KTF.=QA9MO*H@Q!D M^91["4@F#Q\=+_*UF I#R,OXCV]43&V!]P),+WK'M074*4WJFXJJTZSGG<6 M\D'G.45G\CV>+AN+)!PLG$TJM +LX+69NV;02(\1$1\(]\=3GN4P^; V<YNH.H0TN3#J5*I[5&;0PAMI$6/!H,6ET^/ M&2VA:412_++U0?F27VJGW%?0SVG^]MEW_P!X"ZZIC53[BOH9[3_>VR[_ .\! M==9M[&C_ %^J/_:M0_\ =*+;3/\ RCG^PV[O_P#)]"__ *S?&UJ&FFFMZK>) MEIKVZYRLNVW,]%S74HZ+F)JCOW[@D--=*6,F(^8AI&OS,4Z6;E.X:E?1,J[2 M2>H)JJLW'0N 17(0Z"MU+[?ZTCDL,0F+]MV.,54K!^X=/<36JO"7"Y39YNQ& MBW;!_%V:;G4G+UR6178+2J0D MG$C9ARD##7R@$#5B<"=8Q.'+:ZU#=Q9V]5RO5BTV!,CEGTMJLQ1!J)'<.^=&*U7DG"J+]N@45$VZJIB]')^1>4*OV6&N18_(%$@+ M)'VG.E1S_CY*1L]@#ZQ8Y42)+,(V29NF3L"$717;'2.1=(Z2YE2NF[5K /-R'D M/)_CR\F.&W"W& THC #$@$239@EWEDBB).B-*]CY1J M4FVURNC#;]BRN[F-9,Y M"R,UUE!Z$IB-C-T6C)O!EVI*(BU7KE=)FD"R@+KD1,)C1[HD;^3 MW=OCY=FRT2&L">Y.: 3@<3@ G ' ZQW*=1U' 8VE2EQQB.T8LJC MU9!5NR8H"1,ZAA EV,GMOQ)#[J,%87N>W:Y8;I6?:K+5",FI3.D?FE UNN@C M'4')^/[O3W+&NO1I=I"-B)RKOSOX^1;RIQ?1_1NXQVKC$N%5F*);K51[$D1" MP4RRS]3G$4^<"1)>MRSR%D>A X ?H#.V*IT.> '% R8F#B(Z@<=OX.0#GP/) MAU=9(;4<0G D!7*#B,XJU8$C4H8G?:4MQ&=YC<3?8R_3=?C*T]C,>T+'B<=$ MOG<@U594&&-#M),Z[U!NL1U)$,9PY;%3,BV.())*K J&@K334+<@ 2 , - M0%FKC,!?.ONK_P"ZGW'*%:Q@9>;K5NLJZM9ZJ>TR-LZ#*N'?S- MDM]@?U]2:EF@IG$+G,VY;J^-HG>KMWHQ86_T?<9 MEBCY7HV4:[;FKZ.BZ@TF'U]A&#B)09.UG4TNVL1(2=CW\G"RM8F(M^SDXY1P M )ECJP]TX]6K^7D]TC4;2*SL[N<>08W;,* MV)'EG@KR9U#TVR5>UP"3J-B['7K\R2>UI]U%*FZHB'"P*B@\:.G"Z34Z8K@] M5:J%5"6;9R=.[FD5BR7&RX[K+&OU*$E;%//$,R89DUVD1",UW\DX2C8N^/)) M^J@U;JG(R8-'+UR;CRK"XB9-,BJK!XD@Y(4YT@ 6K M7RGFV=>JSY;@C )QP[L'7KU8<98\QWA*^%S#C[(:UPG 8MK-*92N[Z)LG:WN! M%T#/7%:;&G&/4DE%MV[%<"N!L6P5D?%5#=W*,S+A**S52KM64X)9!.83J=^I M ^96C'-W&-E%:Y+F'GLI8B;=(LM'F305=(D0,DZF/(.\,MSW+8-S?&8X M;UFD;=D<05W&>+4+&J_<-*'AV63E8>"D[@O& H[EY9470/9CK2JDUZ9$J;9X M+=1=V&&K'G&S9U*!N!OK@.LC6"L M^UN(SKNSWH3ZD96)52K9AE,:X_4GV3V>F\I;@I1[#5V BT#E9/IN(I\7)3TS M;)]&)(P81[)JJ[3:.9!DB;'*P)T2S%+G<_HEF*7/$. GZ-9 G/$/2$W-YPAZ M0CIL'/KZM6'\OEA:9&=BH'8$ Z\>ZS>Z\6;R6_1A9?K1M^YT/Y%/7*UQ67ZT M;?N=#^13URM<]J7;PO.W"W2G5'I.9S"EA7T(? M;)XRMPGVWB[S+UU"XV"1GC42-8.P@,K<)]MXN\R M]-(WZ<=2MV[?XCS6:='A?O3Y;?CYC;SJZ:]%7H0^V3QE;A/MO%WF7IZ$/MD\ M96X3[;Q=YEZ:1OTXZE;MV_Q'FLTZ/"_>GRV_'S&WG5U\'7ZT=_N1U_-U->C' MT(?;)XRMPGVWB[S+U\UN2%VQG163')6X4"J)*IF$'>+>(%4(8@B'&E"'$ ,( MAQ 0X\.("'>TTC?IQU*W;M_B/-9IT>%^]/EM^/F-L-V[OZ/,_P"X3 O_ +O. M*-6U:].V7^2YV\WZ_2%HFL@9S9R+J H$8JWB7..2L2MZOCNIU./43![4G+@% MW$;!,W#[G+&2%^JZ%L5)J***<9^A#[9/&5N$^V\7>9>FD;]..H[MV_Q'FM*E MY 2D:]20.0\P\O\ V\ZNFO15Z$/MD\96X3[;Q=YEZ>A#[9/&5N$^V\7>9>F MD;]..I6[=O\ $>:TVG1X7[T^6WX^8V\ZO$1\(\?2_>]337HJ]"'VR>,K<)]M MXN\R]/0A]LGC*W"?;>+O,O32-^G'4K=NW^(\UFG1X7[T^6WX^8V\ZO\ \_[? M5 ?5 ?3#3P=X ]( #@ ?6 [P!]8->BKT(?;)XRMPGVWB[S+T]"'VR>,K< M)]MXN\R]-(WZ<=2MV[?XCS6:='A?O3Y;?CYC;SJ\ 'P@ ^GWPX]\/ /?],/2 M'TA[X::]%7H0^V3QE;A/MO%WF7IZ$/MD\96X3[;Q=YEZ:1OTXZE;MV_Q'FLT MZ/"_>GRV_'S&WG5TUZ*O0A]LGC*W"?;>+O,O3T(?;)XRMPGVWB[S+TTC?IQU M*W;M_B/-9IT>%^]/EM^/F-O.KIKT5>A#[9/&5N$^V\7>9>GH0^V3QE;A/MO% MWF7II&_3CJ5NW;_$>:S3H\+]Z?+;\?,;>=737HJ]"'VR>,K<)]MXN\R]/0A] MLGC*W"?;>+O,O32-^G'4K=NW^(\UFG1X7[T^6WX^8V\ZNFO15Z$/MD\96X3[ M;Q=YEZ>A#[9/&5N$^V\7>9>FD;]..I6[=O\ $>:S3H\+]Z?+;\?,;>=737HJ M]"'VR>,K<)]MXN\R]/0A]LGC*W"?;>+O,O32-^G'4K=NW^(\UFG1X7[T^6WX M^8V\ZNFO15Z$/MD\96X3[;Q=YEZ>A#[9/&5N$^V\7>9>FD;]..I6[=O\1YK- M.CPOWI\MOQ\QMYU=->BKT(?;)XRMPGVWB[S+T]"'VR>,K<)]MXN\R]-(WZ<= M2MV[?XCS6:='A?O3Y;?CYC;%1LE^>//?_=FN_P"4/$NI_/\ JS?MC?A'63O# M?)K8!Q8YR+*0-YS9)*V/%TW3Y%*9=8]%-&*D[+3Y1PY8C'U5J8LDFY@V::)G M(K-.IUG0*(&5%$Z=0#L>PF(B/91ESOCQ_7=%#T_2(B@2U(;4TX 2HX$ MH6<#AJ.O9;"E.R,Y1Z74(-3B1Z4F53ID6?%4JIQU)3(B/MR&%*3B,Y(<;05) MQ&(!&(UX6F9!L\?CFGYZV^E;FF5+-F*$N]-3<.X=RFJW756= MFFHB08ND%4!,5$RBR+OHET3IC0V>\L1^8,J.LAQT(ZB6;B'I4:$3++MW*PJ5 M6"CXEP99://T0MWZC(YRE3.58K=7@84U0X%OK#8WA$H<"V;+90XB/ KJB%#B M(\3#P"L@'$P\1,/#B(B(B/$>.M>X=PG[*,N?;E&\VM4Z'>JZ45QJ2HU%Z:EM MY+LG@KK8>F%*AJ" I0:*%9A[MPJK-2R9Y4*A'>@)BTB/2E M/15QH/&4%U49F!+K,JGL<)++;CW!55^HH4XI*2^EQ.E3@TVE%GT_N)@9N#F8 M=';WAR%6EHQ_')3$6YR$:2BE'K95N208%>VEPR%XR,H"[8KINLW%9,@+)*)\ MXAM-M&8L>86F+39+;3;-8K*^AB1%+L%8D:\RDJ.H[(\3F9J*[(V;]DC/N$5& M:$=)@SI:PVI!"0\Y+6ZA"PD(=0A:4.ME;;B5(4H'D;R>Y76ZO M3JX47?O7,S+1EA=H)PC^,LR*S1O(MI- M%9XF=NHX 5BJD20F6+SK!V&ZY?S\,>O78"BX 0PGC:$F)EI*6JQ6*Q, K%9& M7<")3S$DFP3F[%97C=)RVCV#5LFLZ55.1562^X=PG[*,N?;E&\VM:=PYA+CS MNR;+?. ! #=543G 4>'.*!NQGG 4W-#G \!X!Q\ <.G(K5S7P?E];Q4PB*= M.)_ZH%XZUUE<[AW"?LHRY]N4;S:T[AW"?LHRY]N4;S:U<_FBW=]- M/]YJ_G[_ (^8VL49"[__ %+2_A6/N\NOF-L7U9^>2N>Z.O?CN/U;GGGZ.N;? M?ARC_3N?UG/"LD7LQ89*1=), MRN:PJY!HFXS8CKRC0;@-W<4C.I/ >\/#P\![P\/K\..LWW MH:VWOV;YR^W<;>:NGH:VWOV;YR^W<;>:NM ?,EO9STGX13N_W6_Q'FM[8%R/3(B2C65B93^/ MXZP(59V5L^43(E&VRK6TDS&R0I R64B9.-47)((<#VJ26=HM[MCDL!$KTFG* M/=QTAG%.Q&>,1BTHMY5%ZXG7C,RAU<,DDHL#DSLG^0"D42%_1! -9*/0U-O/ M.Y_9KG#G\WF\_JO&G/YO'CS.?V*<[F\[YKF\>;Q[_#CW]:^AK;>_9OG+[=QM MYJZO"?=O*)-;<92NBQV9,5QB6V)K#NG?ETJBTJI2@XN*'6ESVJ'!><;"U)9? M#ZV%(2Z4#$-"RL=CA1WXLMWMPG2Z;5(LZD/JHM0B\ ATF]%[;U7=IJF6:B8\ MENA2[[5J(R^MIM,-9#MD5%@DP(H5FTZ%DF<6R28N!57%14]!1MZHLEFN.R%><<, M3X^5N+*PV3%M->NV<:YA&P)&7JT0^G7KIZG'O56Z970OY RRS5=ZV!RD"J9D M\L'H:VWOV;YR^W<;>:NGH:VWOV;YR^W<;>:NJ4Y<7* \Q3HSSUWWHU*=C/0V M5II82%14I0TF2I%/0[-:S.Y=:F./MOC.+R7%8FUTL=D!V.\2;>&I0F[^0ZC> MF+48E7FLKO2IPMU5P/2W*>T]778U'D!XZ6-(I+$)Z$M $1;"!FBU/-^ZS &6 M,@4[)*N(LIV5Q5K%$D)C+)5YJ+C#3'&2#9=I*X_I]0JD(S[%2&3Z@7B'R75? M1OH]!U-C+"0I==5;,H8FR;0JEM+VZT_(%4J^0L]1F0YV8S-=*_(DK4F^9&KB M4/6#19TXF ID%%.W_9OG+[=QMYJZT-R M:NWDY1*>ZYP.4P<#%.[QJ8I@\/ Q3502B''O\! 0U7'J'E&F/5!V:BZ[IK!S M*HZPBFQ)TB,]H43H[4]N IZ,F='9;CNJ <2A" 6VTD*"[(AY2>QLI,*@1*+- MRE1$W22EZ[$6:N\U5HE.J,3A#U$GR:%(KC<.>:'/F29\5M2H[CSKKJ9$A8+: MF<<.\O*=>S%N2R7=*>IU13DWD-4*D^YQC]=:Y0H&.J,=-E.R M'W/NQ=VZ=*: M,T_WMLN_^\!==9E_0UMO?LWSE]NXV\U=5C=^3+V^WJGXBC92 M^9O9MJ/7+G"Q!XYUCKJATUG,ASEI>*R@NJFNB9RE(R*[=H+(B"(,"(@N11ST MBQ\LY";CUN[%\)M0J:H(CN7>F1$\&E!]S2NU"E.IQ0&Q@C-97BK'4K 8:[:N M=FUE\N#E-R3T2@7956C4(U_:35714*2Y"8$1B@WEBN%+RG5@N:: MK$!!%O,1IKT5>A#[9/&5N$^V\7>9>GH0^V3QE;A/MO%WF7K;;2-^G'4K=NW^ M(\UO++3H\+]Z?+;\?,;>=77:0_]Z?+;\?,;6?YWW!TFB9JW8Y.KD<]N-(W\[8FA MJ#(14O"G6J,O=VD WM#*WMCNC.&;^EVVLSL)+PH)IRA!!@Y1;"T=)JELGSCG M.*RSC?;!1X^ E(=Y@+$4EC:8D'[EBNVL3]]9!FR2L21JH==NR31 J)TY J3D M5Q,()BF4%%,RX;?XC:1*VDX?/$C# YI&H) MS1JW)PQWXGGPQ:5/>-5:Q5ZW7'&T';K97%?A(F'6L4W(Y<),3JT8S0:J3$JG M&W=I'$D9(Z(NWI635NS!PLH#=NDCS$RP3A*\XSIN3.O^7<;NLB8\EHVT0T[6 M*]87M8L$2C96ZR+:=J$R5TDD69K*BA3Q[*;.O%2K/JAC* (K$+O,O3T(?;)XRMPGVWB[S+TTK>KNQU'=R]SOU]!M'2-:\,X9W+AG;L" M->HC5K')[AM:)C[..(,EYLV6T3'\79<9;9=CB=NRJ]LN7K'7W]WD8V&F$%61@(!F0VNPR,X1F?HP*F*C1)ZFV5$@ 054CF+Q 0$<]@\D+MB-S>=D M?<$;FF Y>BKT(?;)XRMP MGVWB[S+T]"'VR>,K<)]MXN\R]0TC?IQU*W;M_B/-:?3H\+]Z?+;\?,;>=75Q MF OG7W5_]U.X?E8PIK,]Z$/MD\96X3[;Q=YEZD?'_):[=ZM%Y88QV08HTN=\YQP*K2'D+;2)U=W%BVJ*)"RA'E;8)(F>E<,P:KO 4;G6%NHD#B#^ MK'4K=NW^(V@7D;^5/ZD\X\O\#;S('_5F_;&_".MO[P=_OCP XCZH\/"(^F( M]\=>BL>2(VRB(B.2MPG?$1_7>+O3_P#]+UIZ$/MD\96X3[;Q=YEZ:1OTXZCN MW;_$>:T=.CPOWI\MOQ\QMYU=->BKT(?;)XRMPGVWB[S+T]"'VR>,K<)]MXN\ MR]-(WZ<=2MV[?XCS6:='A?O3Y;?CYC;SJZ:]%7H0^V3QE;A/MO%WF7IZ$/MD M\96X3[;Q=YEZ:1OTXZE;MV_Q'FLTZ/"_>GRV_'S&WG5]/CP#CPX<>'?X>'AQ M\/#B #P\'$ ]0-+O,O7T2Y(K;*FJD MH7).X,3$52. "[Q=P$Q%2'* \*6 \!$H / >/#CP[^FD;].->Y6[=O\ $>:T M-.CPOWI\MOE@;>CAE^M&W[G0_D4]518E M5$$A?.FD8HU9 L((]5KHBL() <0P$X;W&\M?FO .*M_N/*QM-ON,\NS<+=Z] MR?D757%8RH?;K8K,YBXZ69;HKE;8""'*:-90):3HR[=G7'+55-XWC%E52TQ/ M/YG_ !O6,R4O*&(;LW6=TW*N,Y?&]L;MCD31,38 MF3L2[:'-L:H/H:.SC?J\YZ@K4'@)[E%,0;3; M3M0D=L/*=VN9N61;;G>5R8SS/M^F\E4]''^8Q@X6M1DC7\M-9>N [?4\[]9H MK&RKE,[IE'K)+N'DN4;DN\C8KOV[(E*N=/?8QRER3F%^3WP\ZG9F;;W0+IBC M%SW'9[7D2/9UY>,B:Q**BSDP=0DO8)$A%W*/6 V\OSN..KN M<#G:M>K7CR&SNL=G3AR>/7TZNO$"@+ORKUUR'RB^SS;OMI5EB;9LL;7'&Z:W MY-DML]UNHY*K=DAGDU3S5RQ+OXD:#C2N1(L$\@9+)'BC3\B-YG'ME,=\T(T" M0*'RS>!*#MMV97?.EK \F(:+.D4O4[8^3/SWAC+6R^]VJT8K>Q&WCDA+ M9L%O#:!L-G=OY#,4[9)"89SU71>T^-0D,;D;/@*YF9)S#3Y5TQ*G552&!0M* M[-.2SW"[>+1R0D[WK,>3XC;A=IW#F)LBHIIBQ: MW/(T8Y7BB-9]873>O,85&7MTKULDG:=33CT6SMY6%7Y8_95.8IW%Y7LK_-.( M2;6;-2*CES&&9\)6N@YP8S^506% MG QJ8R V=9CY*'3RF%&WD8Q=2-HM[>$AL8URWT>P2 M43>%FU)=.8N]&:5Q^1G%P[&P0Z[GJ JMB:D545:=+O-Y&G,NZ?*'*<9$99!Q M7"GW095V*YNVW-+'(WIVQ);-H] M5/L51SBWKL9%S%=K%X2M2U]$%R MP6SA?#NX;,&0SYNV_J;5PI7;QQ!N$PG:,7Y\J1\G+BTQ:FUQ=(+O7L\.27H= M1U(\9)'257XJ3)X9CS'RD6[0>4[GMWW*&Y/V]5FAWS'&%Z5LPHN;>P[.^$;/ MAK<%7,LSV4(RMR3&SL+%(KI.:?)TN;A;#5U8=*1B)-G*L9-E.JGZJ8H60&Y% M_)^? MKEPFPM2E4R;&7,SB8?WVM1Z,HE)D;S4JXE(R:709N9=A76<<9K$JR MCF!#0"R#B<,!B<<#@GD &O65:\< -NLL5:M7+ACAS;<<>3RP.RTG;GN5KVN M;4LOWK ]TJNY?(.4\:XWJ^8KO7,%;?K)EAO6\4V5$7:^09J;AY1G%PE7JC'H MGEOE)Y:):QA'3-NS6E'JQVR/#S#ROFTG%-4Q;Z5B5]LN ; M=ED:EM_3R*.VX2UOLW)T;:*;:VFXZ;O5;B(R(M_54'$W&JR=,BY9"2F*G+* MJO'U3L;8L19(Q99(BIWK!)F[H'(G(C[LFN.-ONW:HWW#.=<"8\V*2VW16J9H MS)N&QCC_ !!N3L]OM5RN>YRKXEQ2BG&YL,_4M;J(I]9R(HFG'#&U]>S,P80C M1(T0AON XO%>'+-=%;MCNZ6-F7 M)QY]P!GW85EF]6#%BD/M=Y+&4V.W]E4[39I67D\I*Y(<61I8:AU=2X-N_H;R MOJ #R0DW4)-MGRJL9U@>-0,^4M]S?R4&\&_4+E-<-UJU;<%*!O*WRXKWIXIM M$M:\E15S@I"#R-3)VYT;(,*E1):!CFD?4J\[+792O/)US-V;H47BL1#NNF8@ M&@<,=0S<22#^K&.K#THZCKM E7-[F&X'GQY\,-HPM?WG7E==J.WO-EKPU>Z] MN25CL=Y$J&)\K9XK6WRX6';1A[(]_%@-3IF1,S)+M(MC,O@E6":Y8:+FDD%U M'#=,SES'R"+6L-JNZ;)V9-YG*JHTG9[ES!M&Q:K!PRK">7B,AXHDKG M91MTH:1=HS[U.;9$+&.D&<<5JR$Z D<<\JA-\F[3,VZVPJ6/ &1H7 M(V?Z-F+;KEG-.X'<6TM>%\65:5@WY-ME)P/7J].8;HB:!FLDF[RCULG73^), M[9M6XR5I>.H/,=M=VIY(PQO"Y2_<+;I.FN:CO-RQA*_8TB:_*RTA8H&+QWBJ M0ID^TNS=[ Q4?'OU9M_SHHL-(3C=Y&I"[ZSD'$: MM1(*AAL PY>4,[.U_.XGFYM6_P#OU6Z1?E7=GK3<#G#;B_F\F1UOVSAD1UN" MN+_%<^EA[$,'C2AN<@35FN63F[AW#L868CV;J#IR9&RL]:K6W4A(V"'GM7;J MCL1\LALTRH6[+2B.?\&,:C@NU[GH63W&X"N>)([+.W6EMRNY_,6%W3]24+D2 MK(-56KEHW8 UG9-%VB>,BWG0R ,:"'DSKQ=:KRT..,@WFL5^J[:&,^3\Q]9*;M3R'@+&M[A[!NGW4JY)O=WJ)Z&_MEZQ_GJ[.,;8ZQ M+9JJ*S*[XSK-*>K/%Y%8\!#0B3&.(SCFM$'NL,,W;RX@$D:N2T25 M8[->XZM>W7S>/5;)IB_E:-LN2JQDNTOZ1NAQ"UQOMUG=VJ3#.&WNPX^D,E[; MZ^R*_=Y8Q L,Q,P%XAEVZK3-W,;3-N^_K)TS$8FVSX-1Y,S=70[7MFV][E-P& M?<:9IS#-XYG789@:5+,45'1&%(R#*U.ZK]<@W4Y-MW3I6'27:0CM^F:3MG&Q M/>%O)Q?R8-IW536WVH;4-M&QBQ0V'^TO+WJ1S9E!7K4Q.H888ZSJZ,=O3RZ^088X8Y.L&4#E"\G9MJW.W':@GM"Y-#.F/\ M-E&R/AIYDA7.N?5\'*RR.%H">I-FCDJMC(J,=,ND[^]:RCD\H8@BU4EG($<. M>UC>2@W(,]EV(]NJ]OP\I=:'RMS3?E-/$[3;R51YB!#*\Q=E(&.?!2 DCY$/ M"R"*9(A:'0A"R15&O90"!"/C2YK7.=GZH' $G7B ->&!(PU'J %7^(P]+J]T MXZ]>ZU\3SE9MK#7.EAPFC [B9>-I^>V6U>Y;@J[@:S6/;)4-R$@];1;;#EDR MO"/GKB+LW75XVC'$@M51K+1VH8SB;(P16?I]4UY839N]SHWPH@?. PC[-AMM M,;N5/@^V$VC2FXDC[K4?"\?GP5>L:]R"6X19% BRP"KH2.$ID\,HG+FQQYV26-SG(.V=ANID, M]1F=,@9#W:/,YL<;.K:-V88V+MLK&1JK@!;*$%)\R+ALI.$U8M%N0LF_3DR M:$/'-:P^>_4X\HQ)U^!BB @8![X" @/?#5,ZJF+4,LE;5C\>>O7I!<_ M$W.'GK3,2J;B;FEYP\XX\3 4@&'B(%* \T*6U>MU_P! ._LI?W)FUH7B_1C/ M[&3]U=LTTTU8ZW70, M[L?J&][)-3F,9U=_M?9;G;S2GZAUYJHP:&-3Y'GZ\BX1#MTS:JNE6Z=J>ZK;-N7S;N<:6^:Q-MUW-;6:10Z*7%&W[->X;)&+J M/'YL:RD]*WW+V5<6UW 64Z;F:<;(KUFOXH;WJ0E*W0H^)EYQE52V>=&3972[ MFB*W5 =&'5!=SGE)SR0E>8A85@M0/<%)S0A*1AFI"2H MK2<]>"A;M$-9K"3F:U-Z1:5)Q0D@9X4 HN*4<[>,?YP0V=4;>-FFUYEH=YM]/;.6J!9]Y]&VPYWKFU;:GN@K$E@TX*T'<1;;CA&\X>S!+GABVA-U>Z MW4;E)W#%C2>A9[&V<=NH=;0:N#LY:!1NE_EL0U O4A49 E,B) M60:Q[&1./!A)4I>8ZX$!& M8IQ#;HY@HZD[^^QVM)5[+V3T)(S+:X.(5<.U8:"R M/1I>D9)B8@[IP$2A;CQ**ZS>/25-9"RV(Y;IFZ6A6#%S:MUO$-$R?AF0QUE( MNXK+X!5NX:16[C>#EO.]%09I;Q6A+B5)4"X%XGN5 !*BM.H:DK*4)Y1 MFJ/=$@X<+B&@VM2%)4,UDIP "DJ.*C'- S<;]----=NW4 MMR&?Z\9_NQI_.$]=39?GDL7_ &],_C)SKMF?Z\9_NQI_.$]=39?GDL7_ &], M_C)SK"N6/]#T+_K3_P#$UMAL@'Z-O+^Q:=]VDVZ75$9(L]GIM)G[+3,9V?, MEIBF[52$QA39NEUNSW)ZYD6;$(J(GLB3]7I42N1)TJ_5>6&>CV2;1FX AG#L MS9HXK?7U;G*DY:K&X\U%TV7. F$B*Z:I@* B "82D$"@(@''AQ$ [^L%H( M2M!4E*TA224**@E0!&*5%*DJ (U$I4DX2I3+J4*4A:FUA"T9N>E1 M20E2<]*DYP.!&7D> M\J9$R+NHP=F!QC&WV[:]?L?55QEK#$)8:MCZYIY(H!+X%6E*?9;9?GU)RUC$ M!)$9*JC>\61BU0FJE+)K1CF8=0[*U\VS[=]0]@6']K.)[=06]UC,UVR8SB^B M,OW_ X:U8"MN;LP98LF/\=M$QQ;L1XY=XSEMN>W?;33:VZ0&BT[;KDRQ9&@9()0CIS9YRS+V/# MN)7S>RNY,K1=[,/36^>D.NI6'&DL,-AM1*K8=SF^.YXFH?*%Y9ICFDLZELR@<9XFKZMXC MSNJ[.;E;\C1[19):W/V,K$RJ5#QU7\NXH@7<,P?PYI"2=W9XYF$A8Q2C/D8] MW7Y=MV&\^VO#.7]MN_3+%(F*'3*7CG"&*\@8'5I-INEE1@$YW-L1=\MY(NC: M@M(:3#)*\E'P]:&Q_EJMV[E$<*XE/C-KE:W[C<<; MWL0-LV5M6RXSR+1LEU[%#"YUN=Y\9,KQ)6V2L(9"H(W*NP\Q.8JEIB@W-M$. MW QR+VF=&6%"=1YAFJ[<+#1L*N8?&<^TQBU$+"\D'DJ_!C&]E+5/"$MJX*WW41:7 M75M@/-J:IR@EYL-$2TX527776'TE&#B'.1"54XR*P7ENH5/>"D3T+9CHIR-OKW);?+EG/"64)/;'?[EC6 M)VJV5;<)6*IE''V"<%5[0]QX8(K];K=+>9=N>9;?4V]IF,9N<#XNOMP MQ11,GXB+.N(JTC#;I[Q$1\EA5]9DI!-O1ZQE*> +9'5^&FYBN]F.'+C@R#L. M/'VV/;SMZQ^Y.$^1_AW/5]SK=\BW.3< TL-BRY8LC82QK9KA:7T0FDM(9 MU MLNEEL;OG,) C5B5,Y;8LQ[,,Y7N/CLC3=:HN8;M=\I7^^9ZP&YS_ )/V^T>T MPH5$,?[6ZK$9FQK7GMD>PVU*LQZ#UA6Y:!:UJWW6[Y%R4TVLA*G%VY5)KL=+$IN1.E M-E#FFA:-Y.@;1-#P!??:1)>4&EHC%8C:9UA#SB "E"3>V.8[#6=X#; %M7C% MZOEK!0JNY%NW?,&SF[13L M[IDPB3M[H=8J\78MR(MNDV6TW(%Q=Y.M>Q;93?0S5E@[A\\3MF:-R2&.,<56 M'7DI0I963?.:7B;)%V>.YI-.R/8D:?8; (/[(J"^535)GMM-*CA!05&,DNE MP0HI<=0TX$\J=-&0P\00"2X5$ J-KCI#[\A$Q3J7$MIFK# =(4XA*F67'V5* M&I0CREOLI(*@ @("B$XV:D _SN5+]QS?]('VH_U(!_G+,CR]JPS6A3M%BNN,UG%?B[_/*UN/M!IBLQKN*>13RCDV\ MO)J&\@$\P.HG '58?P>71S[K3'L7W"6S=%@]2\6Z/HPVRO9ES5@V1L^*7DL_ MPYE.0PQDF4QT&6,//YYT_F%<;W]:.ZMAT9"3F%(F4;3L(E.SC6+0EG=#T/>7 M$.,#95W67599]BF2SE=<:[;J34H=JYO62(RHY!5V^X]KM81!<7=ORAN/S76K M0[I4,L+=K"P4U6$5TF<5#668"YK;TQN-7QQ4(2]XFQ'A1U4%TX2%Q=@>VN[C MC*M4B 6:I5EA6)!WC/$9(TAHY-1,]=8T=A&09B)(,GDB10ZI,:NUS9]3;_MV MPWM]R/0@>/Z_86\LA=]N66JY M8*G-@P*=BK:;*$+(M'(RR"<_<$J)& SAJ&O!.LG##> ,=F-I=>K:<#NUZO[] M6JW#Q7OTW,Y9V[;5@9T7"%/W<;K=TFY_;\G&22]MM.&,+5[:_=,WFRA>Y!A# M3\=:\J.:30L3,8>-C(RS5&,R!D*QQLDK*52JN5&J-*Y$Y2K,^+&$_C7(+C:E MC'+.)-P&8,)9@SYEHN8X#:>Y)0L!43<=AY:O1-=EI*_5*\[GJ5D>+A:C4;)< MY=O6;!1\FEKSG*,DWIE2GMN).3@S[MRQ5@2R47(09CS_ +;]XNYG<# TS+^9 MK";'%TQ-N/FHIU^?4 M>-[VMMN',WXKJNZO+MXAL:2&Y;=!EJQ9X<8TA+=*RN):?*UK%M,Q1@?$CK(T ME6HJ1LL;7JYC:L.+[D%O3(H'D[.61S68%-C'PXK3',!) 21BP8[<=>W5JU#'9RXXZCOYK=_MWW$7W<;9HEW$8Z=T.CU7 >+[?FV,L M\;(N[;4MP>:ZI5LBPV"471%F"40\PYCJ1[(2#)-=9%6Q4JV M4_)F+K++-00;SIJG!3YVC5_-/TM8XLU1=LJSF3LX[YJ[1,<14O"YVL.05; UBXNBV]W'R-:KN/*ABYH[+C. MPVQ)*\K"%?=7+?7O6W (D6[$H*B;==F=6E3))HM[79,*.,F9?S1+M4T0%L=" MKWG-\1CE51D8K-"QU>WQ)"G/$F,64A.!(((S=7.#G)WXZP2->&.!U$ &T03J MQ&O;U>6O6/=U"_/3337':-FN_@_UO9OS>YAW^-(?4R/G MA[OQ&T#R>ZGXQ;'!O]W8Y?VI5/&4WC' ;>G=$Q-7,GV+(6\5S:7D!=;7D2Q7Z)QAA:G0E2O./',$@^A<:V* MVY1S'*24W$8XA)*J%)6'*\HNN6Y[>U@:V[DL"ABZD2%>BY\,V;7LD=5V=V^9 M1/63"FY/%F8K2U!>-C95UUT?UJCRK&"0ZCZF=3;A@V>NX]FJN^;PQG/!F>:W MNGRQN9VZXDP+FM[N(VQUW;=?8'.&3)/%JM$4Q_:,CS-3G6CYGC+)J5ZQ9HBFMZY2%;M?8Z N,> MW:QUSCH1LPED8*R,FK=I8VJ#*10023>%(%A$AN!W@K8GP!>Y&P;9-ME.OF#I M+<5GCIW1F-SRA:+?UO5;U%ZI$ M1\K:[2QB6$P,]FKB-Y-178 G=%K2_3V43>U)M?I%-6+"9FGV'93'3,QYO=I.TUS9KE=Z*C:+64MMA&&(L-Q Y"B:0QRS.M+I-T[*E_P 79"BG MR=YQ5"4F%>W*5KLW7%;(M$,ESS#J3M[F_&_[8,[P^,:Q7\2N&"5$I%XB*AD= M3)89T-K0+EW<*.Q=UNN4MS8LA MPW32>PC*?H3UOV(,[I1'^5K12[%'LY8RMCB,24Z2M^>R9G#'M/.XCI>SL,4X MNB':V-<< O#%?FK==@15A(5!<8V,R&[@8G*-OQK>CJ??KBNE7(F]2JY MTE<:P=NED(:[Y%@$$F[L\A>:C0WU@D*-%)BT2D;FG )2$BUB47IQCBC5J![I M8Y2.Y.;FDG6=6O9CTFT,#ARG' ?IY=N%J;PSDJQYAG,TVI@V8HX'K M60WF*,0VZ-8*NY+(#['2TE70Z?AEMD=B)C"5Q"6V%>)%2(Y!(L"!@2#CJ3L P/)@=9Y1B>D<@L&.K'? MCB>@ZAMP)P&P#;KMGR)^H+^U+^ -;M;2?J"_M2_@#6[543R#H'Q6X;677[Y\ M[)_VF;^;-=4AJK[]\^=D_P"TS?S9KJD-4I?SZO\ F5\9MSIY!T#XK----2VC M9IIII99IIII99IIII99K:?\ 4&_:F_ .MVMI_P!0;]J;\ Z66F61QT^F7".D8 MF*>*-FA#D,Y7*F@"B?2<\N%O;%ROFY/.TSMBR#=>2_R_C79EO*M4=4\#;FZA MF>EYYG(M>T ^[ Y_/6&<=U89K#U/LYF"B$A9WMADHJH.UVR,TY6YPF-W T@@ M**>48G6>75CMW[.?JXT25LF*R@Y*TPS>X-:R MLY+/C-1[QU"R+2981[@T,=^B)G:-PUCWW;/*%=\;XGRCN;P'B[,V5*_4)^HX MAO66Z7 7Z3)=F+1S -6L%)R;-X966=.ACH,SQ%@:P.DA+$HN3G*GIH4>E/6= MWQX^/5LP9ZN?Q#\%I+[4\EZ_1'VM*?FNG:GDO7Z(^UI3\UU(5XO%,QE4;)?\ MCVVM4&BTZ*>3MMN5TG(VL5>L0L>7G/I:P3TTY91D1'M $ 7=/G**9#F(EQ%9 M1-,V(.2Y:K!MERKN4Q[MUC\:;C*Q@+84?>]$9BJ^YK%M4Q5?U&]]?4"0Q')7 MFS- IF*WD1)LRKSM\N]I+%U]-0Y)ZOQA$@<*@R@_J3UG=OZ^GHP9ZN?Q#\%L MG7:GDO7Z(^UI3\UT[4\EZ_1'VM*?FNH0GN4,VA8NK&"W^Y#W^W4B@YSW2[?L07;)+5F_H=5R/EJE5& M2?&!E&S*XMXF2=@=!B^<*)JE(T*.8]9W>7N]&#/5S^(?@M6 8C? N4'"35XJ+=P*7TS)O>V;[=[S5<9YZW4[?,-9#N[9D^JE*R;EJET MRRS2]?HC[6E/S73M3R7K]$?:TI^:ZH[*N];9]@O(U0Q#FC='@ M#%&4K\BP<4S'V0LL4RIVVQMI=V,?#NH^&F)9JY!G-2!3,85Z\!JTF'93MXM= MVH0Y2_7=KNBJFSK#LAG&^X_S/D&EP-BKD/:VN#<<2&4K=4X2>=K-'U_F*C%. MFLNM1Z<1(']QD8M-](14L[O+W>C!GJY_$/P6JSM3R7K] M$?:TI^:Z=J>2]?HC[6E/S749[?-^6SO=7B6:SAM[W#XTREC>K5Q]:[G)UN=3 M-.4*%C(UW,2*F0:._(RN]%>LXU@[U/)>OT1]K2G MYKIVIY+U^B/M:4_-=XO7S=?:I8[_6(2QTK#+9 MTLQ0@L;MWK=PS7NDB@A7T7:*K=1^58@D#I6^Z?;&[['NI=Q6#G M 6W$,PC%F+1TZ;O%46RYT[:\Q\JIM4J^S'<_O)VZY0Q+O!KNUV ME.K7;JIA?,%6?K*OTW3%M'U^8G(QK:%:@K+$>*.H^2DJX]0>MF;D\>@_!)44 MHAE',>L[M_EB=V#/5S^(?@M>'VIY+U^B/M:4_-=.U/)>OT1]K2GYKJD*IN^V M\3D.P4L&8\2T>Y(8!J>Y:]X[L63J>UM6,,0VBOQE6.P0GVT*^LY*@L)&A1S'K.[R]WHP9ZN?Q M#\%NZ[4\EZ_1'VM*?FNG:GDO7Z(^UI3\UU->FH:%',>L^7^)W8,]7/XA^"T1 MM,;O(]G.F6G(LQ'4(LR Q&TF/1&5?QRH*G+U-SC)EZ 2"5,#'$QRB 8J!M[Q#DK.65)=:"QSB>FS5ZN4HU8.)9^A"PC<% M5&\3$-.+R9FY-RHUB(&&:?Y5+S;^/C4!*JZ*,\]NX[ #>R.*^TIC\ST[ #>R.*^TIC\SU;I MA/=H_P EY16PIE';EFS:[E)_C9QF2BUC,+[%5B:Y&QG&V"&JUGDZ_9L/W^_P M$;<0XF;@; .;H 3ACJ<=.(&!U$.D'DV M'E)'+JM(H8^$./"Q1(<3&./!A+AQ.#(.)SF$3',/$QSB)S")A$1U[ M#>R.*^TIC\SUC[I/*D8RD65$MN9,)9RVS8DS-AC*.X/ ^7\N$QM)UK*&*<.X MY',MXE9&NXUO5SO&)K(EAKAE6!IF2J_%2E@J1'J3=PVLT M[N<+W]E$7!U79 ZL:L_DH>PQD3**@X<,))U\[;(PPP.)Q:U ZL"<,<=YM,:> MV.6-L!UN.Z^3D^6Z\,->&.&)QPM?)VOS#Q ;'$B @(" L9@0$![P@("SX" A MWA >\(:T#'XE "A8HD * % 8RX !2@ %* R "E* 4I0 *4 -6?P M?*!T>1H^1)BR89SKB[*U GL*59+;=D^(H4/F2ZV'+RY7:F[OU7Q[+1RB)'1QR73JWD)Y3[ U=&:FG:.I6WK!-S8X9T,PG.D8 MB02!FX_*V=6) &/RK5K&O'W>77 P6@0#'P.O %;VO- 4?USDPP./(<3A:M.P M WLCBOM*8_,].P WLCBOM*8_,]5N @( (=\!#B ^J Z:Y.$R?IROX-G^BW?' MSFTG!8WTD?PCV[_>;O&>>U'-J$8CEL<;'%CS'+<_ &4OQ-S%B&$H<6@ F . M "/> 1#CWN.N'-XY53< FHSFA.F"SY=4$SBFS,0QTP-S#&( M82&$!$@B40'4@H_\\C_^LE_*%TD?^D9'_M!]_.EM8_OW':J+=.3-29 :7(+> M*BUFE260K_0%HG$)&.<5;L#CCE/)C+DTM^K*I[IBJ=9B)<*4-/9X0MXI!$I# MX&!).* DG$XDC#"*^UDK[)H7[2G/S+3M9*^R:%^TIS\RU)&@^ >]Q^MZOUM8 MZXCI7U)__L2MW^_W>,\]LO=L5<]45^]*=_4_+$[L(W[62OLFA?M*<_,M.UDK M[)H7[2G/S+5ENXO?-E[;BXE'\]L,S?V>O8JC0B;M*"BC(JS%IL\M)1]:I=%KPB)V[BPWJ\3=>I=>$PF:GEIQFLJ86 MH*'URF[E.&C_ "H#I#@C"3(5B1F8@X/G C$ X[2=]NJB]U55I_S3<3PUDK[)H7[2G/S+5DF8.49C<.3V;V3S;AFW(50VBU6F M63>CE7&,AC*1HNWE>T4-IDR9AF+"X7*EY S:^Q[C]XVOM[3Q=3GZ\/37\4^1 M;/IZ0[&4.3F?E)<>XCM>6F47AO-N6\9;:JI0;SNMSIC9A138[V_57)-9:7V M?2<=;;I6KWDV1A<8/V&6\A5[%%6M$U0\92,;89)L[DI!M &G%V8)PP@DXC$? MEF0=0S, 3PC459R,T' JSQFXXVXNW2>,[\UR"E20H&' !Q5B<0.!8D#,7G$? M.YBL>06O2[62OLFA?M*<_,M.UDK[)H7[2G/S+5M\1OJQI-Y\3PBPHV6%(![E MN2V\0>X88*J=H&P[AX?&JN6I/#43/ENIKT:>0I3=ZJUM3S'K/',I8HV4J4=; MUYQ@H@>JVFZ1I9ML5WW28YQQ:KU4*_$Y#N-&@FLA$QD]F/&N.I:215OU Z8' M2!(^_5J G[?BJ,G2L'UNBBUL7)H9&V,7C:4W;@)SUDK[)H7[2G/S+52TZ MWUG(-0JE^I4RTL=-O-9K]SJ%A8"86,]5;7#LI^NS3,3@4_4LK#2+)^@50I5" M)KE(H4JA3%"H]<1H5+!(,0X@X$%^5B",!@?E^[ ])MVDWDK:DI4FI*4E0"DD M1:<0H* (((AZP1KQVX]&$;]K)7V30OVE.?F6JZ1QH\=0=?11G8H09(2B1E1; M2@$5,O+NG0"F46O2%*F54$C=(4HF.4QB@)! =<[4C0O_ $-'?_MW\]4U6Z!2 MX,68XXPQHUF,M!5I7EXI+K!(P<<6-92#B #RZ]=K2OI5ZE-I3+4N6I]M,YI: M4%B(V L,24A6+$=I9P2I0P*LWNB2,0,(F[4\EZ_1'VM*?FNG:GDO7Z(^UI3\ MUU->FKMT*.8]9\O\3NPQ=GJY_$/P6A3M3R7K]$?:TI^:Z=J>2]?HC[6E/S74 MUZM*W)[L&.!+5B'%56Q/D+/V>,\#?WF,L.XVDJ!6Y%Y5<3Q,-,9-R#:[ME.U MTNA4NC4U&RU>,=ROECLXZ%',>L_AZ^D[L&>KG\0_!: M2NU/)>OT1]K2GYKK0,32(")@G8<#& H&,#62 Q@( @0#&!ISC 0!$" 81 @" M(%X /#71;7=RE1W58M-DFJ5NZ4>2AKQ?\59$QCD6/BH_(>+2]?HC[6E/S7 M5EM0Y4W$V1=K>$MRF/<09TM]O&WW;TG!5: S=D#)-#N63ZU,(2S"T MV>%J6-J_$P&([GDFYS]]LL2WQ[2(Q<;,D2R)! +?8G*@X_<5^,8Q6WCJ62YPV M4&64<=1]$CI.(N\[L15 M]Q3DJ%=LB(BK6,E4::0D&B#ALD[@K+#6ZHO3NG=;5?.VA1S'5KY3NW[?Y>C! MG*Y_$/P6YW:GDO7Z(^UI3\UT[4\EZ_1'VM*?FNIKTU#0HYCUGR_Q.[!GJY_$ M/P6A3M3R7K]$?:TI^:Z[6,QE(-49HIIJ+.+V%78D$J$B )G4>QZX*J2]?HC[6E/S74&[QN4#VZ[(5L2P>8+!(*Y SOD"B MX[Q'C:NQKM]:+G)W3)M)QBZED')VQ:[#5ZGOKQ'S-ED[#,10#'-E6,,G*3CR M.C7/4[C=\QL(9=F\(4#;7G/@7,3?-"@\B3UG=O\L>C!GJY_$/P6 MN([4\EZ_1'VM*?FNM Q-(AQX3L. F,8YA!K)@)CF'B8YN#0.</,^TN?27Q5D_&55S!5;1*IFAD38^N%5972*G95%\8AX M@B->?)O91%X8IXT472:XB*!C#8TARC_9/&8 88BVOYES?E32]?HC[6E/S73M3R7K]$?:TI^:ZLW M2Y2VOY!@MJ\AMDV\YFW(V'==0LUY)K=&AY;%^)K)CRL;?+-2Z%E4F35\NW"O M5R'G:SD>[Q^/UX:*G9@[NQ1\H>*3IB'I]3M M-SEHIK PQG#EH$>E/6=WQ_RG=9GJY_$/P6NK[4\D/$!G8<0$! 0%M)B @/>$ M! 6O 0$.\(#WA#0F)I$O, L[#@!1(!2E:R92@4G "E*4&H%*4"@!2E *4H M!0 -?6@9I@LFY"S?0J?&O7S?!5BKN/['=EG3$E/EPW;'^0 ML?S3UA(3N-56XU^39-I5LF@UGX8\38F2"+*7;ID M:%'I3UG=KY?+'HLSU<_B'X+79E#@4H>'@ !_X:UUH7P!_L#\&M==SDM+:RZ_ M?/G9/^TS?S9KJD-5??OGSLG_ &F;^;-=4AJDK^?5_P ROC-N=/(.@?%9K>FD MJKSNB166Y@ 8_1)**]&4>/ RG1E-S"CP'YHW .\/?[PZVU+(#WP$/ (>KIKSDYQY4#+_)[H;9= MDMQRSM7W1;IWF$[3E')&ZC<-E9QMIP5,T.M6N?K%%9/9.(4MSN=SG=>LBU?? M@29;1JTK$&L&. M P.W$ 88$XZ\, 0"1CKU.J5\R)C&0>P(XE?V M)M2YAZK@N],NGL4O;%FSN?K,U&MHAM'6!JLC.'OGI_*=;FKUD/E!$*UL[QZ[ MPCL!N.=\;V')\UN7JE!>9*R+CNMM97'M7:)9")7:W08Z:Z+9M 1'@ "(CX M!$1^L !WQ'ZP:T\'>$! ?3 0X"'UA >^ _6'7E:E.6/REN>VT5JW)8^S;LMW W/(]6AU)->/K3JKEO;V&K;^.R?0Y6:C#KV3'TS)UXKL MDDT8R!7#1%TMZ'=H,W,67:3M6LEBE9&=L%AVTX"GIZ5D7:BKN0DY.1=.7T@^=*JN7CQPLY74465.<8*0I [K#EPP]P$'J-H!0)P'- MC_=:XC6T_P"H-^U-^ =;M;3_ *@W[4WX!U)::T\Y+8V^3P[>8['T/1K%?9#% M4\QI-?R/A)QX"4WBNP MUM'W(UO*6V8FQKDX.40Y,;=Y$YVQI/;M)J)RL[CN2Q=8[8S_ S:,-'V_+V2 M&62*G-PQ".JC0X.+%<@NEF# )U6/8*K^XIH[9D8QQ%'T6OKV\8.6=I.[[$5,Y8;'N->3OD[4OF/E,J7N2H]]2V M]86SA7I[:--V.*17DMO6/IN9=P^2,VXO>LPN\!B>Y5%U681.2DY59D%B1=H- MK2+1R>6^.V4#>(^1V-;GLL1V5.4YY-KN$1Q'AQ'K MI%\1X>#B/57?X>EQ\&M.JHSZOA^^("/^=(OPE\ _KKPAZ7J>EJ;2;=6/3SYO M]W6/=6\2NY/9GN=W;5WEG<[;>N3DS+L_H6<]G^VG;AB[;1<:)1,=Y1S]F?&> M?J/=+?DUCC"@STK6VC&H4Z">5J-GVLD]C;1"J-96$E7KA6:8QT8[H^33W6.M MP^_;'N0-L6]G/<%OBO\ AR\8EN.W'&^R.8QC)5>&J%:;L*AF+LO[1 M[#@N39#!QC^C2;&*FFT.HDG%DBU6LS(^[GJJ-X"'7"(X#PXAUTB^ \/!Q#JK M@/#TN.@NXT1XC(1 CWN^,I%B/>'B'?ZJ](>^'J#X-0SN@^[_ ,N'Q#KWBRV& MCEG-I^VBZ6'%#^P-TIC<+5\)W"JR^0: M/J-XMC M(3ELCHMU-IF,P:%L,G%]3L8U*1D&# <*-RVS;@]R66>5CSEA?DNLY[-\;[BN M1DDMOV(,:77&F.LT<7L>(S&-]K>]Z$RA;.2YVH[:7-APYB M' &]S;QG&QT'&46ULFWK=5@#,<9#+[6K2*?Y#96ZUUN7B55K.TAH^;B MGR MMN5MONY2FY*L>T"IXZMD0FYIV2<-24=$-$46#^.5GB1$++0GO?%U&CX9"('O MIWW7@^MJ.>-6H=>LZP1_)RX M^.RWA=Y1'8YOUMCO<5MVK>TC/]PCW7)_[1\28)R-@_"6U')C[/<]B7&U2)DU M'>7O/R/6 O\ $V''%AKS^NT^EX&2Q[-945;QQH:*;1DD=W(5COTVD;NDLBV^ MV88VJ[X&>1\V;'-HN)4%J?A?;]O-VL[F9S&V)ZZR?XEW68ES)$PS>7Z/CHB8(NSF?;B+N--Q$9"($1\(C*18\?2[_ !=>IWM! M=1H^%_$#W@+WY2+'YD/ 'ZZ\ >D'@U + PU#5OY>3W->K9RZQ@39;P5;A.3D MWPJ9FWAQ>?\ :!N?RV[WV8ZVN=C+78]CK95?,'Q$G3,.UFKVC!USSEN6H.0< MB;0*YA&WQZL-CVY8VFFT4_K\/$O 0>-&L/,M?4'OPS5NUV)\G33YW:AB"S;D M-QE,C-OV'FL0ZJ5\SS/,T5X>-J=TR=8:SB!G7[-D=W5D8E:4E5X=&N1$Q(.1 MDW#=G'."1ILJ0NXTP\1D(@1[P<1E(L1X /$ XBZ](>^'J#W];P?L2CQ+*1A1 M]4LO'%'^$'@#IG#5R:L#R\I& ^+##IWV6\5VPO:GCW<#N/SCD#-V*>5!=[^= MTFW'+\QT3E1\]99OKI]A+=X< MU56K>**OAUD>_P!FALGP9K01K::_(URO5:*Q]'-HQL5!\G78R9<>T\9%F8.! MI:.,'J&F8\P?P"\$-?,'<< \0D(@!'CQ$)6+ >^/$>^#KTQ[X_7[^HY_+R:P M/B Q]T8:N3D]U;S:\MQL2W(9\W(;3\C[8\ X:N4(*O,H7)4<[4 YCIFF&B34Y%E02<8HY?D;]_63-L'*@8 MX'&1B1X#Q#C*Q@\!#P"'%WWA#U0[^G5<<' M.X2$0'._5?YUC/FN/AYW^5=_C]?4 O9B-GNX88?R#W>^G$>1;OM;P3AYC ;JZGLFVD-\^J8CSM0\H3.(*CA';'B_'T+)/8.K M4R3AJ=GB\R24?<6S^,ITI#E;/FY(2O8[85N,RY@?E/\ )5)VG[_*E>)MYP3G6H;E8*TUG"N8,E62,KF-(C)&TBW9>E8[)4=2+A@N4AY2QX#H M\O7YRB6:.KLQ4WZ#,;\P91UYO(JXNWCU?=UG>Y9.Q/G FW!YMKQWC^M9QWN; M4,)[7-Y"U_I=FC6M=PT5?$,M(/\ -6*:C1F[EVYR)*9U_J4B!^NW MIIZKC1'B,A$<>;S>/72+X\W_ $?UU^I^MX-:@[CB\>;(1!>/#CPE8P./#P<> M#KTN(\/4U#.!!Y->'(=6S9U;=HW66Y6FN-U:P]*@,73AB0,>X1 M:D5 $NHP!/RL<@)_5*M\-6];M<
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�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end GRAPHIC 27 g843712.jpg G843712.JPG begin 644 g843712.jpg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g4100.jpg G4100.JPG begin 644 g4100.jpg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end GRAPHIC 29 g836699.jpg G836699.JPG begin 644 g836699.jpg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¬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�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end GRAPHIC 30 g5338.jpg G5338.JPG begin 644 g5338.jpg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
RHE1L\F MS?/ \-H3"=D>9@OKYA##;:K[DVCIQ'^_HU,^R*5[DHO7<.%7W_&G[[(3 MK^;*8UTOB0&E!KHU-!<<4 AD4K%2:5=KY MT_6VFE7"+A.M@M,LNN']C*8]@!<(CV>+Q^UT3#G_ 'QG7"VR?#/DY>7+,-ZK MS,C[2R,%17[5][M_YJ2WM\5WO^,\_5L?_P VD2K'7#N[^+3#[**7W/R"LB\5 MWO\ G//U;'_\VD2K'7#N[^+3#[**3W/R'X!2*K]D1]\MS3_;X\N\C+I+3(,. M1=+?]&-S6G'16/)2OG;O_%5[_3/7UY"=O\WT9K&O#[[]S2][+C)X_P"YSOXO M]59*XJH_T^F>O(LA/M_L?1CL\]8TX?G?MZ7O9=9/R>[U$34Z0WWRS4!A_ERG M>R..?0&NV=]QM*\_@-G3B_[?'[Y3\?I5Q3YO2"T[?GJ,6B_O MN],?L[8S]TZ'X>_4G>+^/]/OE0/\5<4C[?I":OAX?OU&+1?WW>F/V=L9^Z=# M2<>V!';O58\^EAF/+QRVM&CCW'=EO]'N#_J_#3DXV_?H)O8;@F__ -6EU0?T M5]]_IA]G7&_NB2>0?-4X>-OWZ";V&H(/@_NQ+@]OV_+[<'M%7??Z8?9TQO[H MDE:BT'MBQU?XSN^H<_=<*BM/ VSZ(_<66>_D-FWZMS/T_:&FQQL>_6#V&,=; M>MZ*37?[]5Z:;.^,P![-^)O=]'_S?#:K"^-CWZP>PQCKQ?W4FFWE\?WO)5>F MFSOB]/X_\-^)@\\^C]46G[OYGGW0>^"2QG#TV- M:5QVN^DQ?[ S=_.#.*JHT_\ J\X/]F3%>W_/Z/?FWJU?CM=]+B_V!F[^<&;U M5/@#U>L'>S+BOW>Q^J[7G_?!FF&'9F'QV90V9KY/*VBY./N/;$?R:SSY\[:U MOCM]\_BKV"TWK_1[+/@/M53?"M_3I"]O[\HC[I6K\^U7(<=OOH,5>P6F]WLL M^'P"J;X5]&D,^W*(^Z5JJS;KNXGGQD[_ )F'XCIVX=(;6\E3W*6C3Y&3+Z3G M#7<<>?U;L#^Q3)?-Z=+?S_ZO"%$A6_6E[?OI7XVSX;>'UJO;X\_JW8(]BF2^ M[2W_ ,-O;JB4K?K2]OWTK?UNML]:HTA]VL^Q_NES_0839Z4+5+QS_ %6].'L(.GNI2[>3Q^&J/DG)4F'Q*4W;]<%>0?\ M75X/'0']ES3@'_ @ZC_TI2?#LY>W5'R3YZ2_727^4E>O]ZFD'NSG9_XZ$KT= MCX3S[:C@USD?T^UAT7?$T]Z>ZNT KU>2C?T0F#]H63[#M?\ (2*48/VA9/L. MU_R$BE9AN_6W?O$_-#?.)$>R'_PSWYZFI'US'8GU;9ODVGS35K#T]1O5PKPC MFC2[D+#62BGF0-DA@TX"+SJ4-C.ZQ56@<(]EO&ZJ+M\F-:6H^3F^@"IQ3S*( M D*0N3=(OATO4;GT]U<924YKQWG',S_-,;0;+CY@B,R5LT\06S&$1]0>09=G[GDI=&\EQ]O3.#@[SK%,HNAKV3^[U:GJSRT?!,!Y'*8M+JTO4MC5MBT-:BV^Z(N.LK+N,$D+:7?*.I]X8EC^>P, MA ,D(Q ROBQOQRP)Y@YNDN&\6E5TVU/CX[:TRV-9"J;!WJ'OBAQR)SI7'$M1 MMIDT2:F8E/\ 1%BO*$3Q['L$<-)YS.[XQRY'LBFR.2:CAFD"G.(<46J<:C&& MQ7BLR,X\R&\NV2['>3OY*J;-;:WQ*YX8%REU03LP"T-3-JVUQ%-+:@;"W!?I MY>EQ:!(0CL6O#KCAZ4.;JJL(L+ ]P<5.ZA,W:AEA/ON MM:_;\RTTC_U9O8;@ \]N6W2#Y$1 0 .E;>(TD %'OC\Q0W;APRWM6"2%[.UR M%:$ZQ)W\:M,VH9ZVAVQO&OMW2?D)['X>(>?@J9E0SUM;?$WC0CX)PD'Q_P#F M-Z\&WO>OO5F,]BOO>'QAN>:*O;#LG\:(_F7S5C@']2/CNMV#Q" ^3EN(=O(> M?@Y\IX9(#^DSQB'^&AO;_P 9]NW/GV-+9?:1:=E]&F_U>2T?^ M7B#X/*T$ [0'8=N7/8=PW$!Y=@?(B'+F ;>WOWM#G M5,=O;:(;;[AON._(-]]P\OB#?VN8UGO>7J;A'*0[EI%\?BG1V.C?*V:*4I6^MAPRH'<2(-]+$H\/ZZ8"/9O\ M[:4'@_U^M4\:@=Q(N]8E'9OZ:8%MOY92A#VQ\WCWK1S#V#%_H[WYA;LO0S[; M.C;Y;V8^F8-MVX"',>8^&MC7AP!MI8BGVRSGW3+?AS[>WPUQBS].?+_ $9Y M3IUCKR;_ "MZ"MS+1U[8-A/EE9CZ;@6T. [ _R;?P!6PIH-_K26MSZKF3V_V+XW6O=T+] MK?D;OZFW^Q'Z4/)6RWPJL:KLQ<.G4OBAOI)3WG=8822<489;:-ME]HB%P8J:.'3Q_:"(<.D%X]?2&=NG2*W M2MX\@5(0BJB$@J4H"I( )Q(H2WO9RW(^#E>B*0S./?)AX&7:6-&T=&1"DK6F M'A(2>J#IR[6LI=H6M0!"$J40#K1#R\P?@#Q %7^<*WO&N(=X?U MLROE_P AC_\ AKU@X".4_#J+Q]RV_M>RCP?_ !(&WD\53JP1HADNB;1_K1CD MDGS%/3IYCB?R%*J8F)R8BVXEKQ(_M!B904XN"^]08<8'7V&%7E666?(#;==\ ME7);&6+M-)YV(^92E["0CJ739+Q^I_!O E3V6Q#MV"AS$O%J*EK2FMPYXD"K M=.\I;E-:"])6C!5D;#Z0(*?VCF%L='[Z#ECF3VDA'C]W VTD<;%*2_F,F@X1 M(/T%03=0%+4E)U'2/F!'U G\596Q#PI.\/UW?49U_,1=6N\1\P(^ MH$_B[*V(>%)WA^N[ZC.OYB+JXQHW[I70WRR;TZY;$?7E4GK;N[EM>T=$?+K1 MW^N$J;7=3_.Z;ZV3_B;*V(N";ZC.MKZSB/N&R#\/P5KNI_G9-X/TLG_$V5L0 M\$SU&=;?UI$?7+[G*VGQW8/^L"S)]. M&+:[R?YV3?6J;\07ZU;#W )^B34[]@\3?E"?5KPI_G9+]:IOQ!=;#O )^B74 M[XO0/$WK_MA/M_:\7WZ:,>[>1>_COHJ-S],J-7RX_F)*I&SMR504-]EUEPEGD)BS2QNLNNLN&R\-[;KK1W 1 ?OT[ M:HU;NM[5HO5K6XFM:UK6E:UQKG5M1SN**-68E_J[MRYKGERY0)NW;U+M!2E* M4PI0EM*KBN6B.OG//R(_-L?\]A_WM(EZX\_S>+:L=<.ZV[X^+3".P[!E%+SV M';Z'Y!6W%DO0?I'S%-GO(V2\'Q66S:17(;GJ0N*J0EK'"YM;DK2A$ZQ"])$U MO<[>B2I;.J3E[EDVC?TKQNON^?!>'YHXQE,(]D""8&B4;F,2<;7>./R)5([U M;4Y6$'IK%:>Q6^*$UQEI"D\L .(-LZ)EWR&^PAT2^T5SQY:I<]3'2D0RK0F; MAT7L9SCFYF?/=61S(N];JZINZPHU@ OE/;-ZIRSEZ:,H+0#":)EV3MVJ>N-$ M#O1XJ8(A;/\ 8E4V38P6;,8EX;0)C.Q_//NP68,1/-NV,/K?N3:G_&(G,4Q[ MK;SW(9D[E,3(#Q $%[B>F7*2"U:S'\;M2DF@@3*S"NZ+K+BRC#"["KC>B5T^ MLOLMNQ-PPLF0;)FM'3>M@L@3R)&TYFCJ)Q4I4KBG)3*E+2\*24XWKT:0##;B M+>M&TGK!+LNL$SH=98%V4^,O"6[(NK[4_"G:S=%(4\216G!9=?VPA @ZW:\$:4GI %UUX#PI\ZDGJEC'ZWT:)\G2& MERYA4J<\R7 KFY>KB5CFY>WW:G:W!0(A)O/7#RZ4A:6R?DL?I+3H*LU*X:7V M95HH>\CY_,9E.7KF/-IG-J8;1ZB$<25RM,T3 (A8J'BH>9.HAY*WAU4#,H52 MT/E0ST2AXW$YC>.=:>7Y;+5*Q$PH(YATA:L1-;@[F)A70EH2IS#DC:0H4VIA M47EE&*1+ DF\TL#;[>LMJ(/#FS' ,MZN=/1L#F(*4.B5,6I/N+(,-,(3B8845T3#0LM,L&Z9W&FCK7+M:F<8L]$EGM4@@ M&-VA>5?L(B0MQTV$]9;;N%P&I[[K%)%UNUUIY)=UMP76@(04X5^*+<-YRTGQ M%0J9( MD1M%.GK]<:)^BW3IU!N4/70@UP3V9*6]?O'9AU/2IPIPMTND0@%43#*"2$O M;5B8G2BG0CHT@9:XLXK1/$&@)9"1CN;NH)VXF M;J9PT7"/9V[?>Y5!_179?\ '?Z81&VX M ^+IC@=QM';E(DN_F\?@K:[0>V)';O5.[[_/G7H>IN:Z(S_866>'_,;-MH_B MW,CXCYVFMQLN_6MY_P!IC'0;?\:30?-S[?+M5>FFP/Z8S3_[-^)O=]'Q_-V^ M"K"^-CWZX>PQCK\JS3S^W^:J]--G?&8 ]F_$WN_C]4VGPM_,SM%H.C.*=X>( M;VW'0;[D*Q7\CSW9_D2,]/V-:5QVN^EQ=X_B#-W\X,W]OP551I_]7G!_LR8K M]WT>JU?CM=]+B_V!FW^<&<55/@#U>L'>S+BOVOU_1[_5[=5VO]L&:?'4/_\ MS=1RZ1UMH>3C[CVQ'\FL\^?.N/IN+6N<=OOG\5\_[1:;EX_U_2S\'OU3="OH MTA?VY1'W2M=7(\=OOG\5>P8F]WLLJFZ%?1I#/MRB/NE:JLVZ[N9Y\9.Z[Q]Q MAZ=6'?H=C:[DJ>Y2T:?(R9?2=M42D_-2OJI79 MOS^6V>+X?AJ]KCS^K=@?V*I+X?\ '.T>SP]GM51(5\U*^JE2HTA]VD^R]DN/Z%">+/P;6KY&7N7M$_Q+.1W[4S[RM>-QT _9 M7Z*4E4?)/GI+]=)?Y055X/'0]5S3?["#MX/\:4GA[?7#UJH^2?/27ZY3?R@J MHT@@^K2=TIZ["X89F @ZX;=E:X8M7R/_ ',.B^N([#3VG_BJT'E;^B$P?M"R M?8=K_D)%*,'[0LGV':_Y"12LQ'?K;OWB?FAOG$B/9#_X9[\]35Y9+XLVBO$6 M>'S3]/YS,F66Q9G?5LG7%XBR^[M3.\LCQ'FOTN6@R05R<'D]Q(D!;J@D$>1N MT/O1HSB3I"4O4MZ19GG3!K#QGJY5Y06X>9Y^LQ[CEZC<=090D\)DD(BN0WIX M81?'U%!T8C:)*L7,2)%:[+"T[<>MM+/,+AAQ&M3^7--V3X.X8 M\;W 7%\T^YT;\0L3'BFZ=NV>-3SV[0B(X=PJKE!#.Z.,68&5;(#CQXGADYR-#(O#>YK92D M:E-R)_0.SFTLQF899@W%,X>E$BE4,;'AZ5DIDZAP4FN-AQA2,KJ4UEP)EQ!6 MQ)0="P;2PNVYW"(UCE^T\.CO>NC"7)3FBP^[/\%D"O'2ID)=EC*$$-8U*6-0 M:6*W2TZ+1%Z71QJ%#XP0,*88$T)K15 M*-2FX,R3AB",LLB"<1Q J-H+=3C>?\AKI!!)0\M4*MPYE;+$MQ+#DS98^VS] MD5,@RY-&I5(7!4N,8'5'+'&#/2=7'V]H:E,7(B!*?X>#Y''S-8V MM)M+?6:]P/#3]80WV.B&Y<=>QXW=D[W:6CM/%09'NN.8)DF897@\"]+3>A5M\1F*JY MA)EL3;"&5J<$Q[@EL>GE\3M*$JS$F ()!V761K<=&:&Q5I>YRG'KRMD[B*UQQNXT M(V5K2NW9B&J[4A=-B-@I_;$@5K3&E*TK7.N;3'39#@*QI<7Y)-HBJ8V@XI.Z MO*:3,A[4VGG"6!)+@XE+[D:(TT3B0+*5'E7F":6%EHC?: Q#UJ2V**<6P9:1 M*(X8C?)F0>RJ['UIN3.Y)+.ZD'&-1_=G5.191QY!)MZ*\^PLP\DN\0O-LMNE MRFQQCY$T.4?1P6')6)Y.*4.[*FB[$0TNB@@2[B3W%M*;[$2XXH22A+-5$&WE MB46-EUHV6[1$UIP^(I<6P5 GBL9)1,4R)3L:,N/L]J5G)/:'50<2U)P1"2V% M''D$&G6(;$]IAA)-]X77%6"%F+KS9]6E+AK3/,95X>%N_?7.VW_>\&K=!S;!/R%EHW (!"*UK; ! ++[!+"VP2[C^CT+;;!MVM *FW/8?$F_1G!P0Q:-HK7Y9"%+Y8D8&A M,6\J2!=!)/=BB$=A3B<4-PB6:LM.N+N$;[;K;A&X=FA:7(JE:8K39G ME7K;+G2)SH3;1Q7F]?5[!Z@#67:"'?\ -];MQ[8/KE:=K<_&K!V]^8R24:DU M[9B4KA=T$"DUV;RTRZX+^B-J)08JM)6W!<(6W FO-&VX0#;?E5R6GF61>S&F M-8E=)&"V4WQ-,JLC0O#=:_W)MU2D%%K,*D'*XCN:VY1UUJ42^HMN-Z75@-U4 MW7L+$<4B2G,C(OEA<32I2Y/45SCU+R37ZF[V='9%-8DL:X\(6OSBEDK(H0,HW#?;:#N ML)77IFT;KB[[0!::0(C9> !O:.WBIR) 438UO:R;Q!*SO9AI+,[*9,QD-KL< M3==8<4V+S5]B1P,*OLNL,L2''7%W6W6WA:-H[>*/'./V]N>6A!!H>!@)1L$FRXWI=7:-P0,XA>;V.78_(>K6 MI[;'&YH.NEJ0?: #<28%L\+H;$;Y%9+[XO' M;I664!!3[):0=8^]U#ZM,Z7#2E<*[]C=CZ'KWV5='6INZWU:6:U>LKJ]9 MV7A+M^[VUR]2MWMJ5HVO0*Y%:46=>M1V)S;KK23;E:>THVZT0Z5I1HF!89=8 M(#T@LNN&T0$!V$!K8AX<\KBZ73K"8NID;"GDJY_G*A%'CWEN)?%:>Z1.9]IZ M9H,4VN"@FXD@\VTPE-?8)1!IG2Z!=]P:[HH$!A19-Z!#>02(B23-/&V??+*Y]]B>7\[YK<]6<@N&'UM[7=A+0\YO:S#5:ZFHH O5 M^N=LTXDV0((L)>U"2:1-41&@NND1R>2,IY3#;88<3?<]&E+KRVJVPU.H*N%? MSI0Q%-"U8G X3TB1S,7VH M5*D@$Y_7$$*##2^I-Z=@=7?T2;'6/T1+ZF1P>'I4\HMOLDA":,,1!,@MO,.. MOM?"BD%A;M;>8680G,LOL(.NMN$"[Q#UD\^@RL7RU+,HHINC!1QTD B1LQPQ\E/><6 M>:]@4NO%I+),3J"S3'#N>PN\@ZR^ZVXJ\+?V.A,.4/J*3J(I&CY(VDE)V^0' M,+2:]H2""S2B2$;M>CN<$I)19YY911"DNPNPXVRRVVTR\+O53X\@207ZY+"8 MBF&4E'$284\99"1D1*DP\U02^B4@L%W*/-4J#3BW'NFPTP\Z\RVZXTP;I[;A MMW]7U^!H[7CLW=?U>%O W(^/2&5-)#IU#2H\L5FH$CZ;*&(MF4KB.M$Y&G=+ MW"U >J* @X34Y2B\XL"C>G8'5W]'YLR4XNF#>KQA-7.(.Z/(3"I:SX8[/38! M\KC[XE4IE"KO&WWC<98X/8TT8/@$*.C MB-8:X)& V*,!C(E7G@:!ZU.TWMUS>0K. \X#5)2>P\P#C0O,N R_I>^?!X6I M=VJ0*8C&%#ZQIR$K*]'1]H-=FA,EM.M3)VMR,1W+6\A/:H46D$HSR2R;3S@+ MMM V_I4K0'B5(>)0M"TE"T+3>2M"@0M*DJ!"DJ!(*2"""00UUP_>PSYU$PSY M]#Q$.]0_AW[AXIT^(4E:%A*DD$ M!Y/H4X<"P M][3),)8%5*(R4H/D1"=6D//824=YA2HUZ*+?KS&HI,82:6H,<+4]A-Y1EAMU MMUEP!(#$L7TR8"@2DG$(8NQYCEUDBE6I41^0LZ2,K)0VD@3++16XMC/Y:IZZ?+ ME\ZM+.9I!*>N:ET^5"1T:_<%ZZ)473PH*D5)2H$FOTE$UAR1R:695*XTF=W\ ME.I8VL]^:27%Y3JQNM2GM2$Q9:J<25-UE]J6<-EP%W7#:.V%-1DMBSO M@'4NP-,D8'1\9L'9=!V9FYZ;5KLUB5!WY.9:XMR54:M0B6?L'9=%X>VQD:T#PZB="'Y M2:+BYI$A*Y<)BBT#[Q5*#1O/ #;A$P N"_'UYC&WJ!/-(F]3.FI76E=N>?#- MMNLG>]5-FM736=GY-[MR-T=;C,&&DEVMK>I4EJUUUYQ=Y M-@)231O-LN+M ;K+PMU_2+KNJ(N"ZX+NH)VNZ0]+YE:']5V]G+UN79RJ_P#X M6L3BSQHEUM/SM&F!T?&0N;F,SRX,K8M=FF\K!IIY5S8Y*DIJU!<6>88<6*4\ MH2SK[S;!MOOONNQ1T=EP+2.]5K:]CYS2_>K*6\YIKC3F]VYJ3ZY6]?%*-K^I_G9,/@[F3CS MY)IM^]MEMP@.VOFGNN%*FM$1&T$R?8![/F-G, '?;?PB&V^^_A MK8+X,S&RR3"&M='(F=J?DA00E<4E>FY&ZIBUB.$9"O2++$[@2I)M4I3!&].> M%@&$W;W%W6[CO.C;FYM=+;FNO\WF %ZY=KV(C=;6F/WQ&K V5O&N5/+?[,?: M[VPYQV-U'9RQU_4\ZUM/LAV8Y@$W^TKJ[W/*X:R[J3=J&U]$X?I=,&W.U,G M0Y\A FP! =^8$ M1$1$1WWYB(]HC6P?P$F] ME&ILQ8B1JS+(QC-!88I2D'F6(7)QFXN**PPXN^ M^U(O%*E[M36W 0K%*G%069U)0V-&>H]6LANZX+K'TK<*"KL=&4RQ"=56NW69 M=J26N2*RD"M]*E#$8S)EQX%"2C4.EB^Y 2J- \D2DYBBTXP#2A ML+'K+.E^ZB?09(+&"F911.,G*)/C8'R-F)&0$J+R2TYK(!BZWT6+/,4)RR3& M_NBPV\\FPNZZXVP+O4)QECA.QJ8R1 (41'%BPIQ5L!,48"F54O3@4!"U0U6- MUK>>K) @CJE)J>\\OJ2N@9;U=G1_=3CR K!815PF(*1BQ1!$9%1&6,\8Z2F, M)-3DL76H+_0@H@U,G-)+;NYK"C"";R[;;BBQMRW[;\W+CG7Q4\+?/+VOYV?# M*GCKX&]TF8Q%0]K(T1*(Z=(FXHQ0O82GQK->D1!-A)AQRMJ+5W+TQ11:@@PP MP].7998>3?=<%IE@W?/(R/CU2S+)$FG4-4,#>I)1+WLB4,1K0B6*.I[G2JW, MMPN0IE)_=!'4D'J"S3>N*Z%EW66=+W283#4[ZMDY$3C1,DU MY!Y9)1Y"UV+1VN"HDXI.G+-+/4F6&%D$V7VW6E6!;\XC&6.$K*MC:: PI/'G M)40M<&(B*1\EF7+$P$@F5K&LMNM0*E*<$Z<"5!ZRIR!!$93(>KFD23$2:VVZ.'*)(RD%/\ ;>8239^)2+" M2E%YZAHM5BXD$V$'D'7FFIK++2CBC!N"PRRZ[YZG'./UI+$F60:'JD\7MMLC M1"F,,1Y,?LL-(/LL8RC4%Y;3;:5>G3D$7EFJ;[+B222KK1+*LMM= MMPV;^OPY,[7CMW=7U^!O239&Q^L:7%^23F'JF1G.(3NSPGD[$>UMAZF\LM.2 MXN)2^]&B-/,-+L)+5'E7FWF66EVW77V@/FIR% D:1E7JYM$4J&1@(Q]8IDK( M0E?0"\HL19U)JZPET ##R2Q%#>H +SBK!^2,L ?P2XSQRB:')@1P*%I&)Y.3 MJ'=F311@3M+HH27EFI3W)M*;K$2XY,84480:J(.O)O+LO+NMNLM$/-3C?'JU M&QMZR"PU4@C(7!'$2F+L1Z1@"XPHVX&5,:WWD-07&D$F"""Q. F$E7CO<78- ML=M^;6G'.OBIX6GM?SL^&5/'7P-].V716Z07Q.V31^Z4EE=??&[7IL%_L( B MU4)U[,"H7*TH$U]B@3+DP6=1?:=TNKN"ZOG)LB0!:V.KTCG$/5,['>46].J: M3L9[:T&'W!806Z+RE]Z1OO.,N"PJU8<3<9>(6V!<(@%>[;#(C9([YA;%HY;+ M#213F2>UC:@D-Y I[4@DWO8) =+RA2V6)A+N5#9W/;:3T>JM"T/G)<:X[0M; MLQHH'"TC,_7DFOC2FBK"G;'DQ->!B.S=U_5X6_53D2 HV]H=ECX MD]S]U]<#-W5Z)"5W* J>L[EZ'4?+NEU?R5?+58UQVM;F9G60.&*VF.WFF,#8 MIBK"H;F,P\P#C[V=$:WWI6R\XVVTTVY"41<88 7WB-P -?1])T1&1^G 8O'? M38!74!)_0-K],($]S=Q]5Z-]R>BG5=R?I7J^ZNAW-\HZ/5?(4[;ALWY;?J\+ M.UX[=W5]?@;TDV0X"L0O+FDFT05-L=NLM?W!/)F,]$R7&F&%%VNZLI?>G;+C M#2C"[ 7&)QO,+OLMWNLN .%.1UDXAZ5F>S#BF=V4R=C(;'4U/?<6H M+;5YJ^Q(OO(OMNL.L2''7%7VW6WA:(" >";&N.T2![:T<#AB1LD@EW2%N319 MA(0OMQ)IAY5SRC*;[$[H)9QIII8KRU V&F&&6[7WW"/BJQICI4U@!A!Q8BNO3ATRC;-^D7>%OMW0V(WR(F77Q:.72I.1:F(DM MS&U72 A/:G.2VIR7H4@N91-J90>GM*L56E@0<:2%O5F7VW>@EQQCU"E?$2*" MPU(CDUO1D:1+%V).F?[1,.-&U[3DM]A+M:)J@\P0<+% =8<;?MTC+QN=MPV[ M^KZ_ T=KQV;NOZO"Q1D?'R5I;W]5.HD;'D^4,1+2XJDUQMJA,A<3% M]J)8>1<2KM<%!1A)!YMAA*:^R\LDTRT1L+ON#Y2C&6.%;.WQY5 (2I8&E0H M5M;(HBA1J%-QYPGG)B"C3A.-$RZX3+QN^B;"H<>_) M)4?%(T=)D!19"&1&L+28^HR"BC2"B4CO>CN<4Q19!YY)99*FRRPHXTNT L,O MMN=MPV;\MOAR9VO';NZOK\#?@1/X*JL?3$LSB:DN+VF7R2\B2,IUD?L*,/)- MO>[BUUUK3:6:E4E&7. I@L,3GV7"%Y)@6_B=D?'R9F2R-1.8<1'UJDY$C?#I M0Q%,ZM8G T3TJ9T,<+4*A22!)PFD$J+S2P)-&^RWJ[]O)/CN )+'\I+!X@F+ ME5IEDG+3QAC)LD5AIJ@\VQ]L*066O%IIZI4<9:X@I"\U0>9< WG&77?B?C+' M"ED21I1 84?'4"HY.O@;ZALRB)#RWQTZ41PE_=4Y2ML9#7QK+ M=W%,?8>82H0-EZL%RP@TM,IO*.3$&E&6$'7V7C:48-OKIIY"%ACX4DF,54FQ MDH\^1EIY$S'WL!*6\TM2<]6%+;[FHI.80?8>8O!/83>2;88-MQ=X6_J;"8:> M]-TD.B<9.D+0G)2-3\:P-)CRV)4Y9Y1"9O=;T=R]$G)*5*2RB4J@HHLM0?99 M;;:<8%WKIL?0-$8^G(X5$DILH)4)Y*:FC3(09(2%=YIJHE\O*0V7.Y2DP\\P M\MP%38=><;>9;=<9>-T]MPV[\MGUM':\=F[/;X,F^ NDV'5#99+W)_QJ7)EKK$S6U8O3EF=8BL>E"BY(H6$%IS>FFM57GE6$F;EVVE7='WA78N:7M MG:[ED";9&Z6D*F%O%1&T3TX6*.L!,H:$@WE+U=I_5F@0%WT5,'ABUW:W]9$HPJ?6,H@AE>5+ T'NS02EZP4Q+8Y&H[UK>4 MGZTWJ"TAY-A/6&=7;;T[M[>J16]JW5:@UN"MOL>!M#<3M9P3IM:8$@2MTB;3KE"2]MD15UB4AW1'$7'$VD*P5$&$W7VVVW%B(22 M3P*#I53\M2PV*IUDI)4IY*K(CC,2ID*=9>88K(?#RT5IKN2J,.-O4%.-ZFP^ M\PRXVV^Z^X1]:_&N.S&"R*7P.&7Q@I;+;8LNZ MTWI*K4P'W=89N8/3NWTJI7+EO"_5+H!3]2R\4^5"."\+R]>UA>%V5E=:J*R; MU[&M6W]U;6V+B"1+7-K;3N9<[AQ!H@'4^FCN"1!AT'/-40J(H.$PX=#5!P$! MT'7:7;N#1ZR[IRT:9IG3*_YB@>))M/WYC;&^/JY,X(C'YZ8"S5AK24T)@=TY M[F@$U0MO2&(DY]AMUYO0,OZ(]'J<-T;:!HG,R7^$XCPHU3C&;DGDW=;0J27/ M4-<6-0!Y#LM(M>CC6B]M4%]8)S@0443?8/6;;"%2]/@L)4N3*\*8A%U#M&TR M9''G,Z/,YKBQ)$0WBC2LRXQ%#0M&N?' M1)$8PFGD;@GC[00M?TZH;KE1#TK*1V*'4E3===<>4O,46'#=<)EMPB- M65R23O'YBGDIE;R)4\#Y40N AE/U/00K6EZIT5EY>%Z^5%5:&M:MKH;23I#@ MY6B1PEO;:PLE=PBH!$HAK4SMQ*W<"M!=+@GL0&NB*^>Q^Z MU:V%JR";W%)=;\G:J16GI[K=K@,$*WN"\:X[*8O2P5 X87&^[O1/TOEQ9AL8 M_1+H=7Z(>A%K>#=W=U8 7W7W-W1T Z'6='E7TE$-B*I8S."J+QU2OCI1),?6 MJ&-K.5L9*<;!()9U)J2\]K*($NP22T)B>PH;+!LMM&T-NMYEHH=3*?1,\5.W MCE<3'\^,,)>E:4'6)>:H/3&)*A5-+Y=@D?BX-FS8KE_3.QFB:3:*W>C"!F#B M3V1791,Z7:M_#/7Z%P3Z#YZJ 39]^EVL!Z7FH$6L$INZT U&J]QS'5K<]5&/ MBVUR0.!C5A1$UNA:%:E67MKD5/9D<:WN%B>H/.NL*)())LO-.-, MOM+*+LN,,NMLMNN"TWCEM+4UZI\?&-C:WMICOA1 [.MZ!$E1WN;J=.IB0:YN M-R8DJYW)DZ!"DP&WHTB%$ M26D2)4B6=2LI,E3ID]I9)*=.5;840079:447:%A=EMH;53K#K;39A#B3;;32 M3)?%"KR3;0,*O+,D3;887>5>%Q=]AEE]]AEEUMUAEEUUE]MUMPA5FW1A_5M/ M*Z[6<^1E-S5@U_&OY=K5M=R5>R_VK>C2G8[F?J7C\S$\YYCSRH4$V*+2S"S+B;KP-M+,+ONL"V\!&C\KYH6/;\M*\7+Y;9N/M5=]QQHQ M&XCF/!:"*Q]DC2$[&4I6&HH^TH&9(:K-F!91BHU.VITQ-ZF\HLHJX^ZP3+BR MK"[KAMMM *0RANZVS81^2-*Z0;\KOEMO]5]-N(CV[AN/@W$:C2!S?U9SW6ZV M]SIW>N7+MWL?":NE[&\%TOUPN_>XM/(][+_:QZ+.9"7%SV!F6I$5SDO"]]6, M^YUK=4"FYS7UB[VVO^_&KQ:[;CBN;:NS)@%(B<$*Q6SX9<4;LF2K$ZA0UJSI M$A5E)'$@HR\U$I-2F%J2R5-A1IB>^PZVT2[@N&DM*.RI-N'8J2[[CMM^F"QW M'?UM_6 1[ &KL^.*U-B#,F E:%N0(E;UAIQ7/"E(C3)E#LN)D*!&4L<0-0D((N\RA-92HK6Y=N;+U;V#7.2/V8^UET8F(1(DA%B$@+"4R1*64G3DV?V)1)=A=HN_6T>\3 MX@WSK1'LA_\ #/?GJ:DWC02:=1V-I[GB09^C.&#< 9Q,BB_!%V1TC>NU9I5D M,.PXT9@=L2$'3)%%SXT$Q40Q$[G(<:O$O(-3S4\Y03'TATKN'_.Y#DV;ZMI[ M%GO*L@TLRK)\2>L NF66N7LZA5)U\/[ISU?C!OR&V-$X2X0":FM-D*3.2 AC M32*R<$PZRV-6H;0JL:\\:B-0>*\-YS<->$WQ5;K$U@NFG";8:@RK%4<9L)X$ M"53YH;7/$+J8R&Y%@F6;$&+K+UF3Y%)I%:IMG#MU$=2G(HZL0V@\/J22%CRC MK)TW&YLG6H''V!9WB!PQ;D'*$U3Y*R"ECN8<2-LT>(6^9#)M!5,$<8E29WN8 MG)YN/>DCF;D0@&*@K8(W ';TN7_HW"'G -JKTRYKW;('K4TXZ.8? 5$\6Y2F#I&,R9 M%)?DB".X+6J\*9.S#C>*+T=A"Q9(,CY%:<:.KTGBE@MP1V EE3![5DEO\31O M-1(&?IPZ>#6 "2W!5BAAD,U0_%N@"R$,4;@_P 53'40E,UAQ<,G M<\-8;FQ/&95:2Z.):E/([ [@@<=7&MXQO6I%Q:4_3FW*KT:DE3:F<4.-WPE< M@47$7W@2M1G!U2I(;T#TQ@= XNR[E45!*>GH_%)VTK@?*U:00'E?R!_.(:;% M0SUM>IQ&?MX2?D)Z\X^+:IF5#+6V.V-XUY9PD[=_[A/0]@=O(.SL\=6(SV*^ M]X?&&YYHJ]L.R?QHC/+UE]FU9-H[B ;; %UOAV&WGMVCOX0W\ AR#LV&IWY( M[S/&(?X:&AX_[I_ZM_'4#[1 ! >0B AV !Y^+L#Q["-7.:=_43QORV_6TFY>+Y>I^_X_+5,=NVX# MV;CMRW';GX=^8[@ \^6WBYU-_M:3=OU=35^5^O//@C\]+<(Y2'4?;3 O _[:4/C$*GE4#>)%WJ\I^VF M]H[;_KJ0>'WN=:.8>P8O]'>_,+=EZ&?;9T;?+>S'TS!MKF=NP#X [>SY';P M/;X=A /$-;&_#@[U>)_;).?=,M[?$/D^]6N1V"&W(=^CRY@/9N/W^RMC;AP= MZQ%/MEG6W_.9;7&+/>SE_HSRO_:.F]!.6E[4LM^6\G^B;0-.^E*5S-O+!E*4 MHQE*4HQE*4HQE8.U/!OIKU#!X\&Y9#_H"_UG&L&ZGN]JU#>P;EGW O\ 6CF/ MX/COT.*_F%MR*R'=99BN7JBDOTE#-H"$?,"/J!/XNRMB'A2=X?KN^HSK^8BZ MM=XCY@1]0)_%65L0\*3O#]=WU&=?S$75B7HW[I7?Q9-_HR(R\'AV-]!'+:]H M^)^76CS]<)5N;7>(^=TWULG_ !)=;$'!,]1G6U]:1'[\&R%\ \=:[R?YW3?6 MR?\ $V?#_P :V(>"9ZC.MKZTB/N&R"%5:-.Z^6?H\S^B8QIYE+X*R/Z^66'I7S-L MH4I2LP&^=!E*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQ ME*4HQE*4HQE*4HQE*4HQM4KCM=])BWV!&SW?S;W_ +PU5/@#U>L'>S+BOW>Q MZK6..UWTF+0V_M"-G/P_1_-N7P\O;54^ /5ZP=[,N*_'_?['@^&_+V]JQ!M? M7[(,TW=FH?Q0WUM]%W)Q]Q[8C^36>?.G7'S=&^USCM]\_BKV"TWN]EE4W0KZ M-(7Y)E$?=*UA^>KD..WWS^*O8+3>[V653?"OHTA?VY1'W2M56+==W,\/^478 M[[J&R'#;EAO;6\E7W*6C3Y&3+Z3G'CKYFNXX\_JW8']BF3>[2VJ)2OFI?U0K M\;9\/!5[/'H]6_ _L4R;Q_WYV^]X?>JB8KYJ7]4*_&V>>HTA]VD^V?NF'QV^ MP84D>#K%>EJN1GAR7M$Y_P BSKAG:F?;=G2UXO'0']ES3@'_ (.H_\ 2E)[ MU4?)/GI+]=)?Y055X/'/]5S3A["#KX/'*4GA]KL\/+Q51ZE^>4W@_3*;G_[P M532#W9SSX:%K_L^#SVTSR_9=Y'_N8M%U*']YIZ-HSM7:#.A^L^/^B&P?M"R? M8=K_ )"12C!^T+)]AVO^0D4K,-WZV[]XGYH;YPXCV0_^&>_/4T/5_#2X?#HO M6NCEHJTOKW%R/.4N"Y9A2!J%2T]1?UAYRH\UFN,/,-O +C+C!N&ZX $>P*SM MAC3A@+3HW/K1@7#6,\.-D2+7-,Q(T92Q4F3&&$ M$'G6W&%%7W667!:(A6:J54 !D .@!K94HX%2B-Q)/E:%.3- > I3(L+ENH3*,P:YF[R7%4X@ZL M$'HRN<5ICL\.#ZP-$F72)U7&N^,4CW"+EG<3@G*)N-I2@W?7B#CWFB\K>=W[ M-W4U0FGKAWY7QGD/2ZRS_)>.I#IYT#NN7772PU1F+R1NRE)3,GQ:4X^C5N:% M[DYFQ%/=B3'$VDT60&PI$;Z?W52W2UQ+AUS<='G&4F!T")!JWUNV($:1$6I/ MTYKU-B1.2GM/7K<;/1ZQ8>!%EEIJQ6=<)RI0:%RD\R[K3C+^E9M->H983[[K M6O\ 4M-(?]6;V.V_9X0'H[;AN-PB(76A;! !3AMH/]57I3+;FU0)(74_B^-X MBM/']33-J&6MO;XF\:W[/3PCY<]Q_4-Z^'X*F;4+-<9PI\7L*@"5"D4\Q*4 MF1DBH6*1(CKZ<"9(G"ZP5"M0-G4I2 OL$]1>64%UHW](+$7[&?>\/C#<]T5D M)TAV4)R$T23T!R^)\#5G 'R0;CL'2 $!#P" AS\(;!R';??D(AX)X9([S3& M//;Y?#?#M_=/PUK_ &#.*%I7U$9<9L(XQ,R\OR$\&O5OH8\XAD,?1LQ<;3J% M#\JD3FM57$,2-IN37)%BA99T2UYJ9!T14J";+]@#(_>98Q\'RV&]O(0Y.?:' M/VZV=PZ>.DQ27B2@F&) 4*&A4G'H\?4V5=L)U*IY'Z-XJ41\+,89UI#E\.\? M0CY#YVE^B%?+6Z4I!(#Q*7B"I-:I"DDC$-! -]P$-A#<-_#RW\/A#?<=P[>6 MX[CN-7.:=O43QO\ :TF_'J?*/X1JF0-^D >,0'?<>P1 .71[>7K=(=N6^V]S M>G8-L)XW#_%I-V?5U-7)7Z\\^"/STMQOE(=R\B^/QW^QT:V:*4I6^MAPRH&\ M2+O6)1]M4!]U*"IY5 [B1=ZQ*/MI@/G]-2#;S=OM5HYA[!B_T=[\PMV7H9]M MG1M\M[,?3,&VN8( (AN':/@Y#XQW 1]K??;8>WD%;&W#@V^-8BFW]\LZ]TRW MX>#UJUR.0B @ [CSY\^6_K"(>+?PL13[99U[IUOA\/KUQ>S_LY? MZ,\ZNW=-Z"3_ $3/_3@T[J4I7-&\L&4I2C&4I2C&4I2C&5@[ M4[WM>H7;_>.RS[@G^LXUT'*\-49%Q;DK'R1<2UJIW )C#4SFH(O4IVY1)XZX MLA*X],4848H)2&+K5!I!9I=YMA=Q=AEEUP7!IHQ"WD'%.W8O/'D,_0A((!4M M;I24BIH!51 JK-Q3B!M%(8V*>!S"P%*$K6 M0AVA2B$)4HTHE)- ?YZ!'S CZ@3^*LK8AX4G>'Z[OJ,Z_F(NKK1? .R38679 M\<9!QZ!=E@C\3V1\^A9;;N'ZXN6X@([>*I_:?]%4@T4Z/]7,0D$\9YX?-8=D M65)UK,QKV(E 2EQ(N8[D9Q*]>OO/-O,1W* .+O+LMLOM+Z'2 ;AQPL58RT\G MG0CYG*7L)".I=-$K?+?P2TI+R7OD(%US$O'AO+6D8)-*XT );V9Y3_*:T&:3 M-&(LE8:WT)/[0QML["Q,++7,GM+!+?.8*U,LBHE:8B92:"A$ZEPA;PA;]*E M40%*(!U!4_SNF^MT_P")L'\%;$'!,]1G6U]:1'W#9!Y_#_Q'7>3_ #NFV_W. MG_$V;_?K8AX)@[X9UM_6D1#_ *#9!_-XOP[UQC1F*6PEGZ/,]V/[TQN= .AN M]^7+[G*V?QY8/]?[->7P-KO)_G9+]:IOQ!=;#W )^B34[]@\3?E"?5KQ)_G9 M-OV]S)M__P# 76PYP"?HDU._83$WY0GU-&7=O(??1P_]*C3Z4Z^%WEQ^Y;TI M?!61W_Q\LMZ4/3L;91I2E9?M\Z#*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I M1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C:R_&EPKF+)&I+&SSCS%&29X MT(L)-S8L=8;")))FY(XV3B8*KV]2M9FY8F)6VIE"=1;,-.;EI\S:@;F[+6-%[@O6XLFR5$A0HINQ*5BU8J/9BR4R5(F* M,4*5!U]A1!)9AIEUMEEPAO,[;^/SB'X!IL'E\X^_754UT604UGL3/%S:+)(KVQW!L]K (YVJZA*KIN)J<2VJ?QV^^?Q5[!:7W>R MSS?GY>*J;H5]&D,^W*(^Z5JJY'CM[_'/8I\7Q"4F_K^GR5[?GJFZ%?1I#/MR MB/NE:JZ/MUW3Y995[7'H]6[ _;ZE4EW]N9A[WPWJB4GYJ M7]4*Y>/Y;9RJ-(?=I/OTEQM_Y#">6@ZVJY&7N7]$W"2SGO\ JIGV?&F72<*9 MWB\=#U7-.'L'NONI2? ?:JCY)\])?KI+_*"JO XY_JN:2 MJ/TGSTE^NDW\H*^'9M^&FD'NSG>[70N__%\'LK3?7;N:YR/_ ',.B^F8DL^' M_P"U6A)\#?T0F#]H63[#M?\ (2*48/VA9/L.U_R$BE9AN_6W?O$_-#?.)$>R M'_PSWYZF^]2E*K:RRE*48RH1X"=6MWU;ZXC6IQ0.9:!;IW9UQC>L3K;$;LUX MX>T[DUJC$QAEJ=P;E/2(6H#1M4HS^D6HLL,N$NR;E0MP:00GU<:VK2"2B+3; MM-ZHVTDNPH#5*C&CU<>I,MLM#K#C[K0$T^[>XVZW:X1NLN$:3FCWQ^:IJDY+ M]Z/GH::50RUM^IQ&>8AM.48@(#L-H@QO6P@/@$!Y@/@$*F;4,];7J<1D>?*< M).SG_P"8GNK$9[%?>\/C#<_T5>V'9/XU1_,OFU[,):'<;82U4:BM3T=L3^C. M[P(ZNU(20H1] +#0J\K)'>9XQ^K M0WR?W2\6WYO%RJ"%O: ;#V@/(!\?+UPYCV^ .T?!/#(_>9XQV_?H;SY!_=/Q M\@#X>6MFAUJ6F+*R5$0MT$X]JFZD#O#K-3F2V5UM99 2J8:-X:70SN%2J8P_J@W =^ER'8=^T #U@];<0'L .P;G-. M_J*8X^UI-[7R]3R]KLJ[*_7GGP1^>EN+\H_"RTB%/[_CZ.C<&S12E*WUL.&5 M [B1=ZQ*/MI@/C_OI0#X/A[>U3QJ!O$C[U>4CXI3 1_Z5(//]ZM',/8,7^CO M?F%NR]#/MLZ-OEO9CZ9@VUSA[0[>WP=@\O#SV >6VW,>7,!K8UX<'>L13PCZ M99UN/C'TSKN?C\_.M<<>>P^'?F'+GV=@;>UV#Y:V-^&_WJ\4^V6=>Z9;7%[/ M^SE?H[SJ[=U^QO0/EHBFB26_+>3BO_5$_'D:=]*4KFC>6+*4I1C*4I1C*4I1 MC*4I1C*PQJ/[WK._L-91]PS[69ZPQJ/[WK._L-91]PS[XZTD?[!C?T2)_F5M MOMENZ>SGQ[*/I"'WX=]OY_"?YV3?6Y'XJSX?#>MB'@F>HSK;^M(C[ALA5KOI M_G=-];)_Q-E;$'!,]1G6U]:1'W#Y"^'OUB7HT[L)9^CS/Z)C?!AXV^@[ER^Y MRMI\=V#_ *P+,MKO)_G9+X?TJF_$%UL.\ GZ)-3OV$Q-^4)]6O&G^=TWULG_ M !!=;#G )^B34[]A,3?E"??#X;TT9=V\AS^^CMN /8J,V=&/?:YRX_H56);DJLLBZ>JTLA<,G#>0N)-A;B/N!MA,[Q+B:4P) M3%1:DRAOE$K.N!OQWD%:L.ONN*=X!&7Z=,J.P$]]Y][I'UA2A,8P6@H'TRWC M/#TZ6J3=QO D4PH:8U'DKUTQ;/&L?4V[:6<:P^7QO%RS,,OR'FO#V"85 TTP M9X%8Y3#,LR1PM@.<)6]H'5O:6M N66*7!1>@57]SVW 07=>(5&Q@XGL*Q_-< MFXRUR0=!HGG6-X3BG)UITORI$&'BM@8L M3(-+F/HA#'=MUG:1-0.8))-99.)9+9K!].V0@D][0KG$X6S^82!5'VL]>$ B MSH\IXXU."]=<@-9+UZM4;3C4[A3#O5V5WY'/8P7< K#"RAQQQ&,BSB9$V2TGJV:#X MD/*2Y)FXJQ3@B<(9#%QHMS[+&E2X1Y(YIE[8#D8O;G!,F@M,.'WJ*>9+((XT9IXGTLMQVM6/6GA"JRC*&.1,F0I0:[.$2*87)T@J(V>3 M&H! [^>7>+5!*2<\-IW##$X;<<,*4QV5V8+^(QH@)NQG:JU,8L0AF"RU1CV] MP?#V\M^;CY>? &U[O-7(DY3)''^:ICHM&)+([V>/RI\L]#HTY.Q]UEMW;D>M MW22NRM-L)$:A<5VY/QTVR]VF4652M$@/8T>/$21RR()[DO[E8U"G';>O1K<@ M-Z!T6.$'2*"U$J2M)0C?;51JDX7F9,BZBLR3V)H(_D[%^J3%. ,:9#B$BU<: MG=-$H>]$R#'> D]S/J+QY)HH^F.[/&7IW@D@CTR3.:0I]L89.LQ80SY#;,M,4==R;8FC-AD.P] ,[13*MD( MR_DW%4;R4;!Y==DB%M&,,%3UZFZ2 L,9>5=D\2&R%4SW=#*X+^R(,HY4Q$A<]%VD=GR9#L#X*>LQX_27Y%Q%/3&#,T]EZN8P ME _-S+DE%%5!J1Y9B5^ZJMH K^W+/+9GX641OPZ<3@.&^NSQ-L%8DS+B[/$% M:\EX>G,VA:6-I2QK>V)U3J6Q\8W5*B=V9R M3'H'-$D5DF%6U:XDXK4\FN.,?:CLA:-9=C?2+D/(!>/R1\P3;+XUX=V2X;I\@6%V7) NN6,\1C.$NR! M.9ABM!J-07-MAS8I?75"WO[F6UIZJJ: M XUPP SKOKDT8 D8''.IP&-2*4JL!W%5(7+DI#6TP)C>1C;O.$3JL+3-LD MAS?)!*CBJ3Q14^L9<@4HV3NX71BPK$A.<;]1N-;<;'SM3BXMY] M%%@N/Q2T20');CR^(VMXS4J(A ,5Q',5> M+'>6.5B)KIY,X9 \%Z(G/(LBD6F/%VJ1_12G4)!,7'1*(9GF.0HYCN/JK':*/ M@.,H7M,#%_?4Q!B9+'C'@ED/4*5:%2?=[SCHBEK9PD\O:)8RSQ*'Y%G.G/45 M$D+'$)ODC($.0Y)S/;D"4G(4L^S$[*\A2= Y3&8&EO$CDZI :Y*5[BX)&:/M M9R1C08;Q]HFQKK?RS#-7^78H>JQ9,-"NG;%49A[-D[-&*YG$LD0R;97?T M)QK0@5\&62AGCMV8%OO0SBO3W/$K@4.TLZ-)5EA\D>G.W/\ ,6R:YPQKB!P@ M1Z//&4-.8\,[Y9%'%':WN*%WO1+BCZD]ASB"X\ MS&Y:>2D,'F\2:]0;GFW&J4Z7V-:-[QMJ3T^K'HO(^G/([&W*G).V31&@A>2W M!H?6AZ>(H_68\>+6MQ/3NT:5N\?I!I.M*4TQW!^4T;I$U+;-4!"CN8YO=[EZ=R.O)4'J 4G M8LC>F"9XJ>= ^FQ[?2)YFE[UM9[XC^I2>0QAS1 M%SREG"!X<@)3\L&1R9@(>G]:AO,1OR9 -01C7!-3(146^2_>I=1+E#J^E*$@)0J&6H)H@8%9-=K9?V%Y<&FC M1Y822Z/)"XL8N02&7/I7 JCY'&Q$P,*_?1#]>OB'/1O\6_ _L424?/-+?)XMNSL'R=M$I7S4O;]]*_&6=E7M\>D0^+?@?F M'J423M$ _P!N5GC'LJB,H0 TKY*W?K2MODK?WVSQ#R]?EX>?;6/VD3"VL_W< MZ<#_ ,C"T\W6WKUR,ZGDNZ)Z#^\LYP'RJGU,=@'H0UXO'0]5W3A[![K[J4F_ MGY>:J/TG)4E^NDW\H*^'D[?)5X/'/]5S3A[![KM_SI2[_FJCY)OW4FV_W4E\ M_=)7M5&D'NRGAW/H7Z/@^_UM=Y'_ +F'1=EC)I\,>-JK0^@;^B$P?M"R?8=K M_D)%*,'[0LGV':_Y"12LPW?K;OWB?FAOG#B/9#_X9[\]3?>I2E5M992O"XP M';:\1Y 'RLP;1$>SY(+1MVW'F.^P>'LJBZ-\5V9Y%UF*<.P-1IE;\5L>K1[T MC+87D"29-8,YRU\A2]PCD^G<>R$E8U6 8O)D$D:WM=C?3++5HY8S/C^,.4QC M;RT*7=C83H) IQR[X'E:0":TV>FQKU*AEA+ONM:X?X/34.V_CQD]!TMO+MMT MM^?1Z/1#H=*Z'>G/B&YQR5D72G)('IU%EZ8:M((#RHR0.BNL0,\M[3@K'&3,6QK+#,B8Y08ZE(D#F6 M[$"TK"T1XJBTJE':!AAB=2%Q/5*S1&P++1Z867=(.CL.1Z5*DI4"E0"DG @B MH(W$;6OP,=&2R+<1\OB7T'&PKP/8>)<++M\Y> $!;M8Q2JA(J-A+1+#1CB$! M >ZIH(@(#S?TP\P'?G^I7CKK^IZ+ML*T],,49[E5S8PR*+-R&Y:=:H5"01Z( MB6*@ZTLFTPSF/2O JP!Y"-H;;U-2HFZS.>'R@\AWK$I42 H( M4I-=RCO+56AL(V@&PB \]@VWYAX@VY> ?"/@'>KG-._J)XW^UI-^/4_?\?EJ MF*T0Z0!V;7 .P]@!V>3GZ^V_8.XU<[IV]1/&_P!K2;P;?[.I\'@]:MOE7KSS MX(_/2W=_*/[EI'\H$U_V=&[*\#Z5KFBE*5OK8<,J!W$B#?2O*=NWTT0+;_G2 M@^'_ (U/&L39KPY%\[0)?CN8*GI&QN"]H<3SV!6F1.5I[,O*<4MI:A6C7$VE MWGDV6GVBGNNO*Z5MMUEPA<&GBW2GT+$.D4OO'2T)J:"\I) J=@J6YGHZGD!9 MFWMCK130ODRZ26FDLUCBX=ZY^(2 F,/$Q!=.KR=8\#ITJXB\F\J@J*U;4TY; MAX1\FX".^VXB/+?P[;"(>T'/8VX<'>KQ/[9)S]Z3KOP^';EOO71?Z%MIZ[/3 M%E;P_P"V-@\([_WK^:IH86P]&,%0%OQW$%3TL8VU:ZKR#W]6F6N5QSNN-<%- MIIZ1&A)N+L.-NM)MM3VW6E[!?=?=O<.R2F614'$J>O@BXIRI NK"C>*W:@"* M#8DX]#98\H_3]H^TGV!@K.V7>SAY,G%II=-5B/E?,W'-(:7S:&>D/=>]J\UL M8Y"7=W%)4;PNT.6*4I7(VP;92E*,92E*,92E*,92E*,976YE%6RR4 MJE:$O$J0M(4A:5(6DXA25 A22-H()!X-=E1&UNY9OIZTS6XAG5F[7Z2[76 MBD,?,)6N-E,UFS^*@8E<),86,A5/G"R4K+B*AW#]V3]Z]=(4,4AOYXR?YV3? M6R;R_P"P%UL.< GZ)-3OV$Q-^4)]6O$G^=DOUJF[.SY@7V5L.\ GZ)-3OV#Q M-^4)]\/@-8S:,>[>1>^CMV/[U1O@QKTUZ_<3EQC^Q;TI?!61VG^/EEL]AZ3B MVRC2E*R_;YT64I2C&4I2C&4I2C&4I2C&4I2C&5#Z6ZVL,0[6IB/0HZ."F[,V M8#;G MT'"K5("23>4$X8$USZN_YVMYXAFM4W0?A&,YF)Q'*,W>C6:<48M4P.#K.IF: MALR"_&M[P\Q-M!MI+/#IRSB9Z?VS)#F M0YR>+)=.Z717BG6@V:C2Y$H6QY^B>7LK2+&$18&B-H652Z.*Y[4-3,;'"FP] M<_R1]D:")-4<.>KR"E.7=8&G.3:C&S3JAC3ZP,)F'-7NG342]W/Q3F=8Z1K# M4Q,DKTPM MI)HV/KHFNM3-1RZRQMM."X5II-@@9;5S*N#)/&G/&>LD87S3$H MUCIRMT\9.TIXPF,:D3&$,QX_25K;7>4.K2SQAOE$Y MF4G9HEZ-KG9S1LT>;$#KYD94D/S!F". M8 7VZB\H:@)S&G"=X9;GMLA\V=8^@S,B(>G&01ER6&.3"E,0G*2&AF,L@%5< MO)3+SG#@<2SM*[=G'/,9#+*O>#>Y@773EBA3)7)6E7'+RJCNDI#'B20)XU"(#DS)=S)F&(T438,2D1R-N:0N&6VL,/PTU84R M/F?$".6H*7*%.0C$G62E"YSXL#4;HO[H<75239W5A MF-<)C4G =.#;C9NSE$W4DP2R?-SG,LTX3C6:-+F'\2&X%TVX+F64<+WI M,O,1F+X8R06?.A3.#C&)ED=ODJ.1(G1B?[UMCMA@,3O/0!XZGHWEI[4D[!L MPJ.DUIUG';3%IN%\4_36IG$-O129"IP',,"2G,!6<13RXCT,D4'R%I6LLC9$(D+5:&0>1-;^F7%K]/(G+LAK M0F..)CC;'LEA<9Q]DV>34V=9?B3G.\9*4UP1LD2I MO9VES6N]C>4@57%4K1/@FY^8\F3C!L R'J4Q?C.9XSPYIZE^'KL1R[,>/DD=S":G;YN\QW M+B)V9VI"R3=PCI45ET/;V.X@2@*MW?W4\IZ2,:[*B$;"=M>^*;\:$Y85& M8DG&*TJ1W*F'6/T=7O6%\S:?LX9FCV78S#LL2M\3OV!\K1+&.'KV=MA3=*U[ZQ=W2&U*B: MVE>>57KINX96NK1ZJP]*L+Y$T?/TNQQCK6UB]S:)='VU XHE*8NIE1QG8$S9%T7HY3B=W8,%ZU%.H!;$\YGR8N]JQ[!, M?93Q_B3!.3,B,AC(0#-"-1$EGK%W"\W.P)L?DRJ!#(SC[']S-8YL:1=*QV - M+Y^$WU' &!]E+EE*2S*S%)N27&,)'[*KX]N[J:CD.7Y?,LCS1W2%.I-CS-Y: M\I7.9/*=7(+V&-%KRV-!7)I3T(2++T!T?LNH^*L-D.TS:&=4O#1U%8>E3)(V M]1D-4JO3II+ MKM6&1,717$LSSU#,/)8MD/4/&\#R2581S(]9.B^/+0\693TWQ33OBQ'D2]OQM/4;CE^!,\1:'21R(8PO;Y,[(;G\', MM[=%AY4R*&-2-U- ,L34USSSI4#$BE!0XEKN '7'!N=UKYG$&.1K&]">?W2!HKTB ("&F7!(" @(?L6P_D(" @/[5=H" #[05)V ME:%[+):_>*>OI? OGJR"MX]A(=X\60 5+6[*E$ DG ; W)H*VEL99".8 M"76LM-+X&'2I,/!P4^FD)".$J6IXI+F'<13MRZ2IXM:U!"$@K4I1!4HDT3<5 MS0SJ,U290Q+),(0]C?V.(X[>8V[&N,OC\9N1N"J2EN"-,0E=E!!IY/<-O2ZT MBT2BQM JX0NV :L4_!\UZEJ"#+L81,+2SR+[]LIPD?D;#;+[AY+]QV"T?D0W M'P>':MR>E<%G.B^ST\FD7-HR(FJ(F,6AX]3#Q,(ARDH=.G(#M#R >K2+CH5" MGBJFN-" ,I]''+HTQZ+["R#1[9Z56"B)'9R%BH.!?S:33N)F3QU%QT7,'JHJ M(AK2P3AX\#^,?!"G<*Z =A *5*!6KY+2E/2-36E/M"T]*W(4YUMMUMUMII"4 MHHRT+@':X OLN +@Y7 &X\8Y?DC&J;&B>-R^**,OL[Y$[ RUD2Z7/C?D:W%V/Y5*H)CF^ M,P;'!QK8] \S8R42!O2+;<^80LLLUA;;;T_C;+[QMM .E?=C!W"X;A M$;]@M$=]PV&T0N&X;@MF?4,L)=]UK7'D'RO34&W/<0#&+R/2\6P[B ?V6]MP MB.PV@$$4*:;Z?_B?,.\U0Q"_>C( ?CIW4:9M*4JIJ&5$W69ZCY7VX1S_ ++C MVU+*HFZS?4?*Y;_KQCG+;??DX^4-O7_/M6GB_8S_ .#5XFYOHU[O[(?'\N_G MTU]-C56V@.X=@<]A >>WAW#UO[$ W\//;>KG-.X;84QQ]K2;\>I_#V_>JF2T M!W =A_J@ .0AYQ#?EL #MOOOVUIK:I7Z\\^"/ST>G["V2 M'*0[EI%\?CZ.C6S12E*WUL.&4I2C&4I2C&4I2C&4I2C&4I2C&4I2C&4I2C&4 MI2C&5TO(_J?SC[3Y1^07"NZ5TO(_J?SC[3Y1^07"K,1ZP^^#7\TMKI7^$I=^ MG0G](=M_/%3_ #LF\/Z53<_'\H+K8>X!/T2:G?L'B;\H3ZM>%-\[)?K5-^(+ MK8=X!/T2ZGOL)B8?_P#83[WO'OZP;5B-HR[MY#P5'#_TJ-/I2NSJ^B'EQ^Y; MTI?!61_7VRWIG]6RC2E*R_;YT&4I2C&4I2C&4I2C&4I2C&4I2C&4I2C&4I2C M&4I2C&4I2C&4I2C&4I2C&4VV_#2E&,I2E&,I2E&,I2E&,I2E&,I2E&,I2E&, MI2E&,I2E&,I2E&,J#NGM]:'_ %::YCF9P3N)36[:?V!P,37#=8E>67'+PC=6 MXW>T [I0JK;DZ@;>E:%]O5](1+':<50RPF']-UK7'PB7IJWW_JAVQD]<_%T. M>UH[;C.GSI27CMXDXI6A2 M5).((+8$#3!@H.R I _XXD?_ 'QY.7B\%9BCT?9XJRMT>8$=K>SM*:U(WHK# M3SK4R>RZZZTH#5)IQ]X!=?9N73S6NW,PF49&NG;T)4@/$.XE\]0AX$*4B^D!5U2D MUH2&4I2JVVAE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE=2GR90L@ M\Q2)"#E2I5%9&G3)DY=YQZA0>RKBB2"2K NO,-.-OL+++L ;K[[K;;0&X0"N MVTJAX@/$+030*24U&RHI5KT,^,-$.(A*0I3A\Z?!)) 472TK"21B 2FA(QHV MA 1H\U9@G3A=IDSV%P)T]MUOQ*)GN%P$V!< AZ$\A 0$! >>]7L<$C#.7<4R M#44=D_%V0<=$O;-C$MF-FT2>XR4[&H%TVN7%MU[NC2VK#$=BI+>JL(&\2 4D M"9MUM@CL#;!Y?./OUSMMX_;$1_#75UG=%N'"$+U MT,^A3>4@WA=2^*@1F0 <&SLTQ\O.V.F/1Q:31Q-+!V9DT#:1,L2_F4!'S5]% MPPERU#A=\8.WJU)[8)92E*[4; UE*4HQE*4HQE*4HQE* M4HQE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE*4HQE* M4HQE*4HQE*4HQE*4HQE*4HQE*]$]R0)[C+#5B0LPL!Z19JI.7=:/1Z0!=;>9 M;=;N @/, Y" ]@[U0)).)YG1LXAPZ?$SOBTF.)=:\%TD%8'OQ7/E[B]8WEN) MT&1W#4"?K+2R<,'1[)+9>HFH-Q[0VQD]#T #Z0-^D ]HW7WAOL $%=-&NW4=. M9[HKR5D];BM;I^XDCKFAIPWC>,05_8<@Z?SH)"IEE?%8RK(ZN:/K?EJ^?8TQ M_(BY[T8+ 2HM-U;05&S'!AL5];-O3\Y)7K5;K=N2)B7#T,6W=2H4H+U*7IFV6V'W!T1NI)!*/??^Q1\H:H @+W M717=]^G#OM-RE*56U#*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4 MI1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4 MI1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4I1C*4 MI1C*=O;2E&-%J>Z']&N3Y0_3K)&E73U/9I)C;%4BEDPP_ I%(GU24B3MQ1[N M\.S$J7N!Q:!(E16&*CS;[4J??#WH\.;*4I4M;92E*,92E*,92E*,9 M2E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,9 M2E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,92E*,9 92E*,92E*,92E*,92E*,92E*,92E*,;__V0$! end GRAPHIC 31 g568592.jpg G568592.JPG begin 644 g568592.jpg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�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g701635.jpg G701635.JPG begin 644 g701635.jpg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
QX_=Q@5IVV>'>RE6<039 MJV3J"TQ81YGS#3SJV-@J0UD4_57*\N[)$3J+K5TP_JKIOISK#=Y)K2CN8K^9 M\\9\L%=N>J4E31R,7&ESTJ8_88VD:/.QC1[+*6F"H2BW+FSY 8_P ISU'. M\3N4%B'+=DU31.+LK3%:.P>!)1U!MT^Y[+9RHS*\2;K*)Z)R+<<99I:&K@[3 MU[DTYRL7A]+%^(\Z81U(81IT?EIO1Y;UOO<7N-7.9,NYT>,;1*.(R,S ZDX. M$H!LBL'L[CX9N->O!)6CHJH6?,;ZI=$F+--^G37UBJN4G4M.R>I'0MK.Q+$9 MPT;:)\;&2MR5TR;I%UI7/'-?5BWYE95.1Q#ZK[$M(W%&T2D5*((-'C]O+FX; MCD8)/*>?QG9?=Z?/NT\=+>I ,7
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g991587.jpg G991587.JPG begin 644 g991587.jpg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end GRAPHIC 34 g777897.jpg G777897.JPG begin 644 g777897.jpg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c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g938430.jpg G938430.JPG begin 644 g938430.jpg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end GRAPHIC 36 g328679.jpg G328679.JPG begin 644 g328679.jpg M_]C_X 02D9)1@ ! 0$!L &P #__@ ]1$E32S$R,3I;,3A:04XQ+C$X6D%. M-#8T,#$N3U544%54734P-C1?,5](35!,-3(S7S1#7U1"3"Y%4%/_VP!# $! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1 M" $Y F0# 2( A$! Q$!_\0 '@ ! (" P$! 0 <(!@D!!0H$ M P+_Q !5$ !! (" ($"@@$ @<& 0T% P0&!P$" @1%PD25903%!4A,9&5 MT=35%AA14U168=-!6'&7"B(C)#(S@;'!-$)SDJ&R\"9B)2ED\35$4F-T@K/_ MQ = 0$ @,! 0$! !08"! <#" $*_\0 .!$ 04! $ P0) M P4! 0 $" P0%!@<1$A,4%6$7456Q"!8A(E9DE);3(S-!,31QV/\ W3_Y:?#QQQR, M+F.... .?GE5+535+95+57?'CHELKIJKOCY_GT3SMC??'S9^?77./FS^S//T MQ]/^'C_AZWCX>/\ AZWA\_J^/T^'S^'CX?/S>K$^MYZV.LG7^R^CA2LK"9U] M"0FG9#K3*0D,(G)]:#8ON9FA"8:GF#E20KF$]-@(>/G'X-)K&1X9S7I5-PZR MCM.8F'/N/N,KN>LE2NEGX>")MBY.SWHXY%KU730.F2!CUEF2)SYFL:GMP2N= MY)RKQ2\5L&VCA!)\W,:YW;(Y=KI9V: MO+:5B.>Q)&^O59GW[]>=\:.^);2K36F1>TDC9H%M102.@=*Q/6UJO8R1B*Y( M;>\>>,R;>9E4[5;8W+/7ME5[CH5QI.HV\[!GO)?=3ESM6/ OZE.+6AH6 MG)7EE;6LSU;+F1/U(\F6 M+.%2]53<;-"\./Y;?]RNU76&_"3><:>G]LQ1\ M;_"O36DW-ZZK?DT;56K3BIY^S9GE6]^JWP5I8(3.O0 M9J1W7+/Y-I-MG&NN=MMM=-=<9VVVWVQKKKKCZ=MMMLXUUQC_ !SG.,8_;SGZ M?#.,XSC.,9QG&?'&<9^?&<9Q\V<9Q\^,X^;..;FW?4B&4CW@ZE4]5\JB\JG; M^$0Z5$&5MUD7.P*4R8B$L.1.Y+(T&4B0T2&D-1J8L)&QZ.7<6W$@R;I^473= MKJU'E'5DU+(#VUOP?,X5\H=?;;E :R*KB@QP-ZPGG;56Q;E M[#K=;C^?AFS78Z_!4=32S8F4]FS<;1?8O0T["U9D:LM&\[:ZYUQMMKKG?;U= M,;;:ZYWV\,Y]73&2Q7)X<_D9 -7!74\LE'YW&7S?<&:)/&[@:H;9,';77.H3;7 M?JKBZJT]7-1=+"RELN \G[% R$QD6TO@EN)[+6QUWSSMFL5(&QJW6^4-BCF=96*9 MZV/-7.58F1JUT2JLGMI+L1^/7%KTJ=.ZM=A6"=CI6/B<^-[FN@GEK2H[VWO1/3/!+'^U?)WH5S%#5RJ&Y0DB6Y7KN>D^7J4+2M:U7P?$)!8; M%9CEAC<<< ?G\,CZWJ?#(^OX^'J?"I M^OX^'CX>KZWK>/A_AX>/]..,;>./5_\ M>_9\_CX=E2$2?3(WFM8G(%X.S?'5\QO,YER@1; M9EJLW8ZI#D3?RBX;([-D=56*;A''7]O8\I ?1R=(3F@J(";$/FIVE-9=%V4 M(EY-F-MI4K'M2HJ.6J?RCEP\;;X3M\G)214I+SK< MOL1\]1Z#UI17T/;>LP5FTFR+:1BSQ+89(]WGY*Q'*C45$1WSC2_2%IW^FH\I M#@4?FUWQCZGPA^&=U4:VH)N7Q-';EZ::FW"=9;EW8\NS5@A]'K9:?6:ZPYLD MCH=/^BB:F,Y3434QCPQG*>^F^,9S\^,9SKG/AXX^?'C]/^'.,K(Z[>ILLEKO M\V/4V4TQOXYQXXQZF=L;>.QO44A9-4U[$ -Q]3K8T MKBSQ$'C ...YE%98RCR0N0$F8-@R^/.G*A>+F4W"NJB;99*9?%\(I?"(Z8I- M ,'#>BNESV*QF')2*ONS :EO,9C%XY^ELC:B'$=S.72\JR-4-N!YZ9OI)LQ\ M'^,)QO @.)9D2*6" M:"S7G5TKTBDB8CF_ZS$2)Q_TGL[9R^0FCX^]5W^B\3J?AGK\_:V(&KR]O1DI MOS=BW?CSI%O4=3,UL;7RXX:,"WZ5VRZ&;SS;'JTG8<-\[8UPX0SMG/JXUPLE MG;.W[,8]?QSG^F,>/.=U4DL^JJJDGMX>/JJ*::;>'[?#?;&?#^OAX<]%L2RG:&46%#Z>:QH[7#1$0D4?6$?F8QJHJLT$[%-PCL>\P M<4-?%<);+K*>&^%=<@/7@C>/I-$:2!Q23TW!Z+-S&G]RT>!RP-')0/!F=R)V M#+24<641%MI*W?:1YTFINW<"FS#X/1=@DQSC83A'K-GQ+JQL^8+"C/U_J;#N_2PK-S>PT$X.U83D8]%]GX+ MHF6J39D:SW)7.>C& M-8CO6_U2>2(B_O+^Q5^F.JZ6IR7.[>]?C?8=BXVCKOS*7NV;MY<^I+96G0AB M@?9LS6'Q?#P+'4<]SW-584_:U*F:*I*9]5-5)3;&/'.J:FF^V,>/AXYQKMG. M,>/S>/AX>/SG,KIW8V9E$'E/7&([QNO;=,-1B>$8_8BK4J0-.!HG?5$I MO'&!7 B1C%"[-$XXW^,*"L)[4V1 +1Z9=4+$G-8UU$NPQ^YJQL="Z7CW.^.MSH:/AEK MU.);=Q?$;_7BF9 MJFFRB?S^'_ $FF-L[:?/GP_P";&/G^;C=1 M-/'BHIHGC.?#&5-]=,9S^S&=LXQG/]/IYN@DJ,DL[T6$PL>5T32SW>.6S'6E M7RFG0<( &Z;KMNH'P:(3AN ?N#FC1PY66BZ8XNJ_E9-L:;2B?H)Z(-3JU1?1 MNLAYGNM1$9."Q!V.R61'1,@ 'PXH\&,#L0F4O=6A 899/V:^B3UHV=H*? ZK MH.4$ED5=-]?'GE-S:Q:F#G-MO5F_%G306)*4L#H6Z-I]5GK@DE3W&L>WW/7% M,J/B[FQR5K\,T?G8I^S>FHUIMJICUD]]=]<^.,;:;:[:_-\V?\ MFUSG'S?X_/\ -\_CS^$UT%?6PDN@KG3_ +>$EDE,Z?/X?\V--]LZ_/\ \O\ MS>'_ #?-]/SY&M2/ MW/7F/&&SVM_>S^4Y1NC-R6%R.ETOQ.^E!(];L<"'IJ/.X*KC6&;%NGD6*TNA M&,YQCQ\<\Y^CY\YQC'^ M.;);3ZNM6O:.J>A$6*!(J::BH,.E\_>@%3"\HNJ:P?\ M34\5-N6ZS,QF+!VSYI$8B'8.DQ0 >U7);L7Q8J6)+8%:O24G6=/VK;P*X(G/ M5**NQQ2=G@ \7E4>6C\CU>MV0TD%-2'&C23-]G+X;\?T8LT$1RSE9%N_*9'K MJK6";F=:/X]S($FBS)+,%^1DU9OLV:,+)]"".*2=D\ZTV/59'1Q*U6LD>WSC M8YYR#,\[FIB:G)T[&?LS)I8W5Z=C*Y#2M7ZN5-EY+.DLP- M93AO76/AFLU:MA67)XZZT4T434\?@U$U/5\/6^#4TW\/'Z/'U=L^'CX9\/'Z M>-E4M-L:;JI:;Y\/#3=337?/K9\-?#7;;&V?6S\V/F^?/T4Y.J[@SRP,1B.O)?B5R-_6Q6S&[&6. M!SDP@/8DY03@S)-J]2PW& U/BN4=GBV^\O)Q4S)ID^81.IQXEK8AN-KN7XAU M*.T^S02'WO*.S#)1N12JLSF,=$Q5_9,Q#G53])[.M9F:]>/NUNCL^*&#X;Z? M-V-F%CLB+IKG/08O6/T$S5=;Q=&IUG.:%*./.BLV8;UAD:*N=9>FD_&<9QC. M,XSC./'&<9QG&<9^C.,X\<9Q_7&><\N;8E9CYCU%K3M,*&L!4A%VK(>OENIB MVJ;!C)2K$&WEE>6"H-:HI#V,@(QQ56-S!=@FW:GB3$6<7;)F799=[3+E5O4I M*,D+'N1[+%6M=KRHBM26M:B22-RM555CVJKHIF>;FLFCD8U\C&MD=W_E>HI] M51OV*\3ZUK'W=GFMFC(]LKJ.SA79*5R)LS6L2>K8:V'0SK*QPR6.?V>// MYT615VSHFLBIOC&&/\<^'S,G:.V=%D5D-L?1MIG3?77;&YEM7H M!CV7[L.^SE;UT'Z#1-.0 QLB.0.NP;*+RO&T0;Q014AZ,"&,T;2U14D:2R/& MN5G7QIR-UW3T(+#=5;9A\K)MTFW&7%KH[2?G.]51TM>MZ*+[ZW+MEL[/A:+& M,5DTZPR>RJHY6N;Y^7SWXI>/M3PPZ>;F[7.-UY(N+J]G V#?BI[&TVSUE7E& MKG"F=O4SC;QQZN<;>&WCCP M\>7SZ'U97$Q[(TLXM)@H:@TFMQK%(/#'RK9%W/38[1R:4>&D=]5=%(=!V+<8 M\F&-$5&L@D9$-"VZF471Y0?9.3UG'P,-]+=V&$L1S*;5?>"M;U:_;,6'JP-* M2V[JK*RL<9[--AXHPZ".A\?&D6:&CD0-R4;,-6F'RNV_C2YBS;H,T%L111.? MH^J-&K),ROF94NM-.K?6QOG-!&C*L3G,699(Y7OB@?'*^1Z7QTQ>>Z^;C68] M^]?95XQ(+CYFTL^QK]QWU#P^SLILRP6I?1FZ=UUC>OPP6(\]M6U0@@O:M:W1 MK:?,?/X9Q\^,XQG&;O-DL]3E+^36MVK"I)'7MRUV+ Q)/7##+%"MV=%D:ZM5 MDEFC@A>K95=9]4+VQ_N/?X\+^D#R/B!M\]A8[%JW-GGZ&S:;JV5J?#:.A0OZ M3.7S%95GBVM^E1S+FGI54FSXX<3V=2K+>1;-:K3K*R.NWJ;+(Z[^.,>ILJGK MOXY^C'JYVQMXY_P^;Y_\.<[J)I:^NJHFEIC.,9W5WT3TQG/T8SOOG77QS_AC MQ\<_X"G!8> MB_2=.L*Z(.]<)[.7"C;X!57=3/8VM78;I9T=ZX3:&" N]_\ :S*TID-IDPH6 M0FH- ](ZSD36'5WN<8DFD35;E3HUKH=>*_+>^"*.JH]-AFWE9%HPZ3K MJ-I+B?.[ZF]?NKD.?C9&3SVBQUED-39O2WV?"5 M:L[)([#M0^NVF^N-T]]%--L9SKOIOKOKMC&?#.==M M?UR6YC;#J=P8)'9#'HUO+A$R,R%Y8HR.A F=4 OV;I MX').&VKW+;7>F1[%5/-CW-5%7N&3:TK=5\FMF1Y-R.U:@=6AOMTH)(H9G1P6Z]M*U)\D M%N)&SQ-FJ5K$;'HR>"*9KXVN<8SC/CX9QGPSG&?#.,^&<9\,XSX?1G&<9QG' MTXSC.,^&<.JXK2OIW=-DLAZSAL\+Q&MP^2F\;0>-5QU^?]C*KO[LT9L>#5?'*8?11W. O MZ!FJFOQ,&S14&CXZB+P[<[,62*Y+=P27*)R-;$O7*]>: MNQKW6G7U@B=)%$KH,NO'8OVGRSR111Q0,D;Y>;E5_MV%7T)"GN4S<\4>5YW9 MULO7LS58,*'DV:NA'4OZ#8M?N]>SC,QJV M7::_"4SW433QXJ*:)XSGPQE3?73&<_LQG;.,9S_3Z>?UC.-L8VUSC;7;&,Z[ M:YQMKMC/T9QMC.<9QG]N,YQS9:UI(QTE[:P08;>0VY8P0J&270$T(11+>-6! M# M 1C?K)=-0Z7_ +C #%H,!-G4#CXIT9AK1DQ309#U9R](009A@DFCGY6DY[&J M6FS933233D[J4+MI\K8K>;IQ4-#/>Q%?6AE]IJ:'Q$%DKF-\F-D M;+ZW1JCG45WZ0O+NZWF<.K1L7^>[?B+W61E?;TJ*W9%X_Y1>HTKU'? MMTUNUCAOKO%)K84!%P>-!89-5Y";= M-YFB6&!AC!3UBP;15@R(-5T"8#=)D0 NAY%FBXQK][B46/ZY=B)_5P%\[)Q! MJH'E$"(/]E%'[F!S42VD<82(+J)(;.B(MH]4!D'GP6GQUX*6=[:Z*+;Z::^U MSTF1+H,;9;;9F7*=.U(D*P*U]^FZY4>UBRRJK)&PV8W+ZD5CXD1R?ZK"8\,? M&2EXB4>0LSXLG/6NWYSHNDPZCM%FJR6MR?10__ ,3/_P!F MG').#_:9_P"%_-2F:/\ WMC_ -T_^6GP\._N?$^G\]]4*[<E3UK M/Q>QG0MRV.!9@"D MS5C@B^.-$7SATF&91=^J'VN_RS7[_M'.?R7C]4/M=_EFOW_:.<_DO-^C#MY[ MTD@RKBR-FKV(Y'T+?N13UG.=#)%(QL;V*U7KZD1WH>G[LC7M16E5ZG4\+.OK M.I:O?\XVI-FZ^/;JUNMYY*NAF;D5:'1IWZEJ:W4M1RLK0^T^2#WZC_5-4E@F M5)&V_P =YJ[MVF;QJ'L"$LJ'*SR_)1V,KJ:45D(_)1&32L@X?$H:6%R,_$TB M@#9-Z2:8)[OME7:9-9R\9HO&3-12*X=VLA,.ZK7+1PH/.T)E.KT@URPD\1W# MR(4&Q7A*&/PHR7%7AIB8+$R&\2U<$R \-EFDNZPW:M:<4].EUN%4RI>KPNTBQ(N[RWY5 M3?P9LRQ7L5J]BY/(D%NQE9\]ZI---7DECG6!E9M_2;;LGVY[74[V!F8Z_84/ MNJ&W86%PW$L@I F$WI@;+X:J-RTF(I^R/+GCJ>[04S::QMS'!#-\L@U)E7B: MR3MB0ZCNOV)ZV]K"FEUB(';$/[!R6+!X_-P2KR&[5$D8#,4QB4P8&$U'LT+. MM1::8Q /JP -WS=N.6+O$5&*Z!* _P!4/M=_EFOW_:.<_DO'ZH?:[_+-?O\ MM'.?R7F%O1Z>\W1;9RI)&ZCX)[;5QY?)UR#WO1?C_P!+SAMK\3/ZW1JV-?=> MGM(B(C??G^-\">8EXV?%\0*=.?A*VCE\],SQ(I>Y'SFHF6D_*W7)?3YAS\?R M;(6M7M^[=A=0KN^/6+0=\70&NG3W95I"%-=Q65+W_V'L@=& MG,NK>^0UQB2\%D[(9G4CK-GYB3PC](QNKY^+6TC\D>H,3.&SUQEP!>G/B6VR MKE-IM"_ZH?:[_+-?O^T/U0^UW^6:_?]HYS^2\SDU^NDGCL_!6V6(M&3 M526/*E8YUR>K#3L/>U(?0YD\$+&2Q*ST.\WHB-:YR&K4\//T=*F7G77N$U]-U+PJZ,[4H"8)%XBE")E@ MPX!Y;DT2!)VT+,2*S4#NFHS(_)0@?\9R1C48DK
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end GRAPHIC 37 g544026.jpg G544026.JPG begin 644 g544026.jpg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
%,$RJ')=\LRJDR6@ILMRVFCIJ&C#"G@$T[B$,S M,P620R2M=I'-V(\\DBES3,9*>DIGJ MY(88*>,M3T4--21A8:>%-,4$:'JPS*6+$P.A^CIT\Z[#80B8!YVV =VXIY=-@],F=%=R],5P(O' GZW+O1: MZ;.;88T+=VMF,@I;PZT@\SA,L+%>8R1(VV^SL5)8#3L2R@D\[W)%V:]9UL";L^H#3R+)QDHS=I.X]RZ MIE6B$8D[90AHB025?-A$ZQB:U'0^C9T[* R@TF)K--3$3;,F761MECRT,E:+ M98,JXL?89LCNTR13-R216^/Y%U$0Y"-FXL%53/1.NY'Q@USY5.- \J%4OB_R MACA__P!'?XO9Y:/E48T'SH52]G](8X.WW#^/[&BTAW*QW,2PDEF)ZE L=]- M]"@6"@V%@/8!R+C7( 9'E-K;R27UN1>Q9[MJ)W.HWO?DI^VP-2IR]ERAEAYDJQ0= HK C&IXZJTO8WRSJOT2%$IWS6ML#$9C(JG= MJ =0$_!._P"2RK_MC@?_ #S&_P"-:Q_Y5&,_VA5+V?TBC_+X_P"@=_,=<#BC M&?G\@51Y]HP,\DWON22=R3B.R7)%] MS;%T^,%;F<1;1\FS MN-:YFK-*#U2JP2\1#>$TR#<[B,;6^4[-JJYM D4;59.7][_ PZ*"* @*B0 MGGE"T*CP+\DQ!5*N14D#91LG(Q\0Q:O2M5Q*=5 CI%$JQ45A*0RB93@102E, M8!X#32'>P.BP96N"USI-]KK8[BVQMSW!!&'"R[V;M*0+@ &XM^>_L(^/',X] ML,Y:'V8RR!_H?"_YUQD&VW^N->H_^\?V;_R;%_RZL*:K MU[;?ZXTZC_[Q_9O_ ";%JPII%YO_ !A_,7"-][_%'Y\=!:JM7KO6IVGVR)9S MU8L\4^@Y^%D$_3,9:(DVZC1_'O$N0]*V=ME5$%D^0 Z9S%'L.M$9$V=[8\KU MS'%0R%A>D6BLXD:,X['4*_C!!A5X=BT9L4(%BDW51\=>%I'1Z#B"="O%NR,& M?OIJL+9(2R6Y_+SU^?$';X_L^WUAR'?CMQWTI53>X!O:]QX%Z.D!]2G&$%]3SH[Y6;R=K5L-IW# M9(J#Z*>6B7>4UI%PF'W[]LZB*@X<'A8B;<+JF*_F6+9%\^0*5%RHH4 \+_-- M'K-L!V5Y?QG]G^_QYX>X'5Q$&Y(>)A:-(3PAUEYO,>8-O])8XGIS MVA9./C>L7W(55N%@E8FHY"R<2Y%CJ^R?R57B8M!2">U,L;*1%GN&4:\]FJX_ID.S MC',9)5.#?LQ@+8[?S#*4:/UA6:1ZS9 YQ8) 2HL06?0 =NT+7YV_"%O'N\I# M!("18$K'UI 939-]^>YV)L+FV&TZ- #S_'_%VT:DQ#@T:-&C!@T:-&C!@T:- M&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@ MT:-&C!@T:-&C!@T:-&C!@TG_ *XX<[#E_P!\_LE_];3$0?SZ7QK]8PY?6&&_%\OM?R2Z2AU;QXSIT?._'/4EJG] MYK*O^'3KR^7VOY)=)/ZMX .=.CYSYAU):J(=^/\ J,Y5#[/GS]<-(/5_T3_- MQ)3WZY;6O9^?+U&O]&'8AY?9-]\="F]CUD5D Y^F]O;V=XP MWY;<[QMDS#)VZ(H5]/#*3#^C23*)LB)H*50EF?O%_(1DNT2 SEL0JX*L5O&D M)BE\!A P+EV.] /9IL&W&5_:@/B$1.8QCIJ]@!!R(()N;WVL0=-K[]UMMK6'*YQD)(@C96 M"WML"K&Y!#;V.PNHY$7);4"+##F,=RETFZ/5Y7(M694F\O8=DM:JK&SB%DCH M2;%(H2#-A.MDT4I-B1P!S-'/HDU#-S)@L0JP*!K--'EHT#8 7O8<_'SQC_1] MO/'JOE7*#)VNS:"_=HMG"K5D59)L9XX32.=!J5PN(((&<*E(B"RP^B2$X**? M0%-KYHGNBZ5W\26ZBGO-Z*E-J]9FZ[)S.!L38ZMZ]IJ='IK666BU'4BH=)%- MS!8%$^$Q*02CQSH/,=_B-O/<7MO\ M'RQ-"ZHQU; @C4!=AY &XMX[;VM<#%9_W+N7J$0HV"T8P-4\@;(I*]GIF3,> MVN]##SE%M2K=M(K9$QI%.$%VY'J2 D2G8@%4&5@:K*G!,DFW0<#+7W4?:M^A MNLK!7\Y\D9KLEN7)%PL7/P# $21V.8EV?TRD*HJ=U)O M?&XEA58I-VPV%]@W3SP'TY,8V/$^WU6\K5>TVQ6Y29[Y8R663^%U62+ P-W: M2<5,M?>BJY0*[2%D*BB8B5-5,W!M);OY=H$C8VW'GSMOSY[X M7K%$@:P*BPU68MR%S8N+[W&Y]4V\+?-MZ(SS>PUWRU)#8K.5YMDE*%>V&UTN M]6-S7L>9*HL"=+X8K%M][@8JXJH.C?!+D$SNXMVQR<8V>(-[684$ MVK)8"LDDY0Y5DNQV(=!?9[T^,\MMPV%[=G*:NK2KS-4297ZV5Z7@!CIST/OQ M0[*-J4.Y,Z)Z$OH%/?@$3Y-XDS]@!M6:\3UO.V'\H84N#B4:U3+% MF.;(YA M'"368;P=QA'D#)K1;E=N[0;R";-ZL=HNLU<))K@0QT5"@)!5NT21<6V [-C8 M#U@+CGMW;;H]&; ME8G>WN$B-XEJ87?<9%VQLWR5.Q3\9*!%TXA8R4C(FLG]&FFTKL/#O6+&+CVZ M2:;5% ""!E@55/?A]SRR74'2VDXK8[ED:1>-MUBQE%6O;GDQO<1D,IP=:#8)NYS]DS@XBJ$;2JH:Q2 2LX:'B@4!L,I(E0:E>.Q](;TJX-T0/ MVX3* :;N0HL5T^RVUMA8G8[@@CS'=99)%:-5&Y%Q:QLHVMI)/.X)//F0-ML4 MV?=2)^H++5Z"L5_2IN/MB\1DQA0Z/4:K=SRUMR5=7\7.3EA8,5%F4()&ZZR1Y-8[G2B.@$QW^#NTM-BV$O*,]G*;3XR9S#CS)]G0*FQILX%^NB5ECB1$?)GED!8M$X>-][N MQ=*""BXJ* 9( (! XY$-[6 -[CM;;CLW//9A8VL/"VPPX3((K:5#[@C3==/= M;F=3'UB38C>Q-K5@_=05JZA,Y'8@?YQK].Q#M,?79W6,?8UI>1!M\_=;TC!* MV!Q:\JD9I-HU-;BYN]DX 2CKOI[=(G:ETTK'DNT;=5\GKR>5H>O0EG'(%P3L[[_P"8VM3-S2U-;I-UD)^X*II.(^+D5$_@QB!E7P)&<>]O1_*NQQ*9 M2-G:ERM&N,Y#YJ>99BTJU?4IIRVL#3)$I:TXMO85K$8YW0.%IQP*SUXX.J1R MU46(Z36;JJ)&^SG/1#2PPU-OE;R%%W_YO?5(E#RUDQG8TY MRKY 8-VR(LK>#,4R+5^8?I" 342%,A2%Y'@.1X*'(\!R/?C2_>H1TT]NG4L MI6/*'N*6R C"8RN+Z[ULV/[.G6'HS,C N:ZX"0<*1LD#IG\'NE? @":8E7\* MGI! /"* 6TDW:U]MAOM_-Y?+WVPR-U5R650K @[$VV[A?O-K^5P+#%(WW--, M[_XO.V57VT9"D77$->+15-QF),AV\U7C)N(M#Z:9P]FI2HIK(L+W#IQ$F=*0 M A4';:<1/P81*)C/ M>AQ4G7OOHQA6],4$0 "> ?$SW0 ;L>0)%AMX"YYG>]^_D 3OA9W1W)0 +W6! M%[[G8D\C>V#1HT:=B'!J,V[B6W01>$+6GL^I]'MN=I5L>(J)LCV3Y&Z=6EWR M2B)[3*J$24-QCXT&[1IFJO;F,ZQ>XNVOKMG6J9&L<7DVW+3*LTX?VZ >J"\4CI@1! M0[!@JGX(0&PI),4$&Z;0B14B 'TE^A/9=^KW9YBJ*W=1M4N%(,X^]T#+*^B M"E Y@#N[C!F'*AM[P_CC"-!&4&F8NJ412ZR,T]"1EAB(1N#9F:0? D@#IV*8 M^ MY %R-][WN;^3.'TFVW^N->H_^\?V;_P FQ<_S:9)E*[;M4GTQ-MK% MM\VW8XC)AS$04CDU23R';;<9%VHV9O74?#2%=@8!M-))@^BX]G+3DTDU5XDF MC5PDHD$9<(6N">UW#8 *ER22 !OWG"Z2Q4 @=D<_S 7)^(8[KJ(XYW$9:V<9 MOQYM5LZE0SG9ZVT84V90ED8!X4HS, M^6HF!PFC^3V0=0SYGVA8V:P619AG15<\-81S/F$\?D M)]&*EI_O2YL'M7966W0#9D\;.'4 ^B-Z41OOZ,S7=59MOMBAFVXO(3&K'Q#"Y!CK8K8&F#CHRLA< MGUND'<._3=()J**C!MV159-4RR"168E02LX:0-U*[ZI(=3CHZ8Y^0J]L4Z_N M(R/9_D_D8 6V.9H\MB"19C6H"QBZ-\)VB.*E[\E(TK1(&3,Y%!55$_A*_@._ MVQ_B$0T\>LUO =Y.^I[\_/XA:P &$?]KBV[G\+=0@WO M6;:L6CPV/MUE:?VRG6N50EHF,CV5@%TTFJTH#EG,,)FKRD+.P$G'J*"+22BI M1D]("BA"+>C.?L<:Y]TJ<3YEP=P/G'$.4K2 MM7T'N(P+60M/3GK\PI:9]<:R1,Q$5Z7QXSAF53&(KE^8QC :Z MC)(04B\@4+22!G9^))+R)F%FL,9*6%JNY%RG)@X3153W)A^6Z;][W 8RGJ#C MJSOLS0Z7P30YN?-DI^TCS1K"5.W?NF-BM\E77DM&,'LDG'6*8BG\Y&I+F282 M+8>KU:EQL/X#=GB,/(/?L[P !VY^1R4\P#CU>OZWG MY:\I\+>D5Q]G7$W#^554/#ZT^99UEE!.\66S+*L596P4\K1,:U@LFF1M+%2 MUB0;6'/\MX[SRKKZ*DD-*(ZFIIZ>31%*&,4LL<;*I-00+!FTW4@&QL>6+0.C M1HU[OQUC!HT:-&#!HT:-&#!HT:-&#!HT:-&#!HT:-&#!HT:-&#!HT:-&#!HT M:-&#!HT:-&#!HT:-&#!HT:-&#!HT:-&#!HT:-&#!HT:-&#!I/_7'_6'+_OG] MDO\ ZVF(OLA]CO\ 8YTX#2?^N/\ K#G'M^:?V2\?7^:TQ%]OMSV^SI#R^-?K M&'+ZPPWXOE]K^2723^KA]/7H]^SYY+5?5S_U&2U7U\#])K*H (>WCGR[>>@>K_H'^:7V3??'7.N \OLF^^.N=+B+'Y$I1\7;]6'!NX]PXX[=^W;V<>WSUR4H% " MAV X#N(]@^,1$1^N(\ZYT:,&-,;CI!]$[?,ZRL6]F7ZDO,D.\DY216,V\G*1"JQXVG3,DS\,A"O8^10!-XT05,5!VD M58I!07!5NHJD>'W0X_8E-A_Q8(A@[\\\%F)L \^_D >??Z_GI._XMOCY^7=R M\L/_ /!G^..[R-M^7C<>S#6M&C1I<,P:-&C1@Q4)ZR&>,VX]ZFU8J-%RYD2G MU-;9%+6!6LUVVS4/ J3Z5JL1$YL\:Q=HM#2I$T$4BOA2%R"294_2> I2Z6AT MS-S6XNU9EZ925HSMEZQ(W/.3&+MJ$WD:V2K:RQSB-LAEF,XW>2R[>4:*'11- M[W=IK(E%(@D(42@(38ZX/[*M5//]87->0\#S\EEGX^WP/VOBTK;I6A^C3TIO MWP,9ZO\ WLM/';U?S?8ULNEI5I^ ?1\EIU6&6LXXSZ&JEA41R542UV;A8ZAT M"M.BA%54E+@!5T@!0!V'T4H8:VL].=:R&*K&7=!>0U&7>Z8UG]P3M)DNJ>CZ MT-[EF;K7U2P=7(0S7;-&@/M>?W_Y_/1K6XX]@TB/KS9$OV.\ M.[7W5!NMKI3J;W,Q\/,.:I/RE?YJOC[H7^DMM,]GS54=_>OR)JL\:.\?"/$LD;M'(F29DR.C%'1UI M92K*RD,K @%6!!!L001?'7O1_@AJNG+HBIJF"&IIY^D;A"&>GJ(TF@FBDSRB M22*6*16CDC=25='4JP)!%CC1^M.W*?N&91_N.EM+PH[R<)9 [NSR/D67L\ MCL6=G-%$69G)+%B=RQ-[X9TUPP0=./2C3T\,4%-#TE\60PP0QI%#%#'Q%6HD M<<:*J1QH@"JB*%50 HL!BJ]T=,Z9JNG44P-5;AEG)%JK4MM"RE.2D#8KM8YN M'?S+%3&HM)5W&R4BY:.)%J9ZZ%!^HD9TF#E8"* 54_BG1U^,P95Q;D#IXM<; M9&NM$:VK-%W86=M4K'*0*%A8-ZF51!E,IQKE LBU14.91)!V"B22H^D(!3\& M!8?1. ?GF.W;GG]9?EX?B'^B8K^W][RXU/3W1J CDCIH\>K.=]^OWJ"8?\X> MOZ_&MOZ-)]VMT?\ NPFKZ[.ZQ9O=)]T&51FN8JJR=<7UJ$55 >X"J !8#&\_ M5#Z>GRSI7Z8(R[">N]&CA.LKI8H(XIJVKDK:U9*JKD50]14. H::9 MGD8* 6Q5EZYN8YM,K-&R;?:;79G 65Y>7@JM;)R BI6396AH@TD9%E% MO6J+QXT0$4FJZY3G0(82IB4!'3A^D?:[/=NGOMWLURL,U:K')0MH&0G;#)/) MB8?"WO%E:H"\DI!9=XZ,BV1203.NL<,ZQWTJS#8M;4P&YWQ8N+Z*C3T/.A^O2DIDKI^EGI$IYJU(( MEJIH(XX2 M9SE)MI&/6;NVY73-PLU7]"L05$%5$C&(%EE$#\.YT[PK(PB:1)$"N\88(S+R5B"R]UL;'@NAH9/0 MNZ:,PDHJ1Z^GZ5N ((*YZ:%JR&&6!#+#%4E#-'%(?7C1PC&Q87WQFG6VS1EO M'.\O;K 4')EYI<'*;5\US;>GBE;LZY=LR-NW)S45:&T[D2URC:P1?OR M\)_!LRU>RBS>18%(U;E(TH?T\.VOG[/UN^DJ=(OOF_IG\^O=',F\O7[_ ,@]_5SP/'J[>O77>ED"GZ-^@Z6 M"&6JZ2ZF&IEB CDJ(>KS?WF>1+/+%V$][D+)V1MMCD'HGP05G%WIB)60Q5<= M#Z,]964254:SI158S/AE154JRAA3U 61U$\020*[J&L[#%L;W0+DF_XJZ=DU M;,:76ST.SIYJP5'$L%1FW\!,%82-^C6T@R+(1J[=R#5ZW,9!V@"@)N$3&35* M<@B4:DL3NKW,R.[#>+#/=P6:%XJNUF@'@HTV3+@$?$&=4WWTX/&,B2Y6S!59 M. $>_'J'_!J MF[7A_3@;W2^$"\5C'(B8.0$PC1R]^![=@X . #R'Q (]PQ^D15A]&KC:MA B MK(N-\ACBK(K1U,4;SBY<[5D/I;[,; MI=[)/6^UV#%)WDU9;/*O)R?EW1;79&Q7,I+/UEWCYP"""*/IW"RB@II$*)A MH:TAUX;_ 'G'6T;%TQ0+A9Z5+2.ZO$<$^DZI.2-?D'<*^A+\L]BEWD6Y:N56 M#M1HV.Y:"KZ)8S=$3E'T9>-D]"KCYTAL9X @ &(%> (83D /DQM/8IA$1$/C M$1UHCW0I^LTQ'QY_-?X:X[\=_@#(OKX'C50XF=X^$<\DC9DD3(*]T=25='6A MD96!!!#*0"""""+@@XQ^BZ""7IXX"II88I::3I4X=@DIYHTDAD@?BFEC:&2) M@T;QLA*-&0RLI*V(.-&]!K*N3LA99WQQE^R'=+K'5P<#'KS*UV>8L#>$&5A+ M<>2&+2E7CHK'W^HW0,[!L"0.#HIF4 PE*(63]5<_<]7(9GW^<\>6W?U=^/@& MZ<>L>0^/ZW&K1FL/H^EDFX*X:EED>663*:9I)9&9W=RN[,[DLQ/>223C>>E' M34U%Z0_3!24=/!24M/QQF\4%-31)!3PQK(H6.&&-4CC1>Y$55'("V#1HT:N. M."8-:GSR^?1>#\Q248[<1\C'XNOKU@^:*G0=,WK6K2B[5TV63$#I+MUDR*I* M$$#D.0IBB @ ZVQK3NXCO@'-P?\ P2Y%\O/^I&7TU_5;^*?J.%7F/:/KQ2"Z M9.YW<;=NHYTK*O;LZY:L]:NE2W/+7"OS5\L4C"V=2(H4JXBUK#%O'YVLN>-< MI)KL%7:#@[)8A%4#)CR;5]XOZD/K!]X-?*\J=NN5&SATW+7C^X6*AVN(K&>3 MQ5IJC\L?.1_OJ#6:NTFSLR3@I".FZRC=P44S>--0Y>PASJ^GT8LKY1RYM2L4 MYEG(5IR788C-^2JXQL5P?)24T2"C7C0T=&JO4V[<5F[$%E$VPJ$,J5(0*8Y@ M .+ITPYQEL'3'G?"E-2-3U$.2T.;@PPPQ42TS%*;JT$;*1-UAU,HA5-.^HG; M#.B7HXXAF]&CA_IEJ*^AFR*?CO,. &IY*BJDSE\YCRY\^:K>-X6I_<)I&$0D M]V&/[-_5_VMB_+CUZS&\V]?*V78&I8KEVF.UMQX?0#B6-E7G: MY1=.KE??F1>WQX9J-FN,[2)-FTFLG"Y/ M-/9"7:':L':L2\EY.9?JK(?!KLL,5-RF9J=)F0/#%(G6BPF\PECG-L+B/+5D MB[U5LEY%EJW77>/92QT#&6(WU>CKS;[@BG;2M6:\8[LT:1&JI+'LKE/TZX," M)$(929](VPVV9Q7?J/NBS;:<^S.5&A6%N>1C+Y555AF#1R=:,8X]K=8>FD*H M+0@-A>21IY^_EWC<';DZ:2IF@:O>=+#9U(U*'J3ZCSBY&5ALECLEB);9MK;, MDN;J$<6[1V2)QFX;N+3!VTD-#$G(=R5)DX)%,RI)( "WI7*)!MZJ@(!;22+& MS$BUK$6-@VUB!8D$"F#_ ,)J=NL8EEO8J5%A8Z3L]ST$<;FI!ZQ_BK];V M^.W/#9+:(K V < D6)[5SR)',V[OSDTF+JU_YWAKV^^;)ZQ#R11Y^OV_C\]. M=TF+JU\^CPV(?^R;+];_ #E'X^?(1^+^;CG3]^]5Q-[,L_VO08J?& OP[F'\ M6#XOV1%OMA,FI<;#^?FM,2>?9Y.\^S^IV4]7K'V"'8._.HC_ )<:EQL/_7:8 MC'U>_)X//CO\CDIW^P'J]?.OGYT??NZX/_SFR+G_ )4I<<:R+_'.5\K_ '0H MK7_[3%_OQ: T:-&OK1CT7@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:- M&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@ MTG_KC_K#EQ_[Y_9+R'M_3:8B[?\ /IP&D_\ 7'_6'./7SN>V2@'GY_-:8B]G MG];[/JX%#^=?K&'+ZPPWXOE]K^2724.K?]/3H^?_ (R2J>K_ .!K*GK_ "_B MTZ\OE]K^2724.K?P&=.C[R(!SU):IQS^XSE7GC[ ?S_'H'J_Z!_FG$M.0)EN M0-GYFWWC6Y^/(>)V&^'8!Y?9-]\=\M[<\X8NQA96M-R%D+%EVIM-MCYW-,&EE+LZW%[-\>9?J>?LK.O260<.9@8U9!" L$U[_<-J+,H*D.>%C7Z;, 6=MTRG>G;)G$X MB!P(0YBZ2Z&X<=)/8=\>"(80^,!F)L0'[(" ZG!NC9M%]N6?'"[5LLNVPCEH MS=59NBJHB)L?V(!%(ZA#F)R'F!1 #!V, AVU!_H;_L2FP_\ <)A_+M_JS.:: M+W-R-^7B /+VD[W^+"[:-AOJ%[D$\CRV%AX\][8:WHT:-.PS!HT:-&#%++K@ M?LJ]4$?J"YGS'M_599_M#Y?;^+NK;I6@ YIZ4W/U0,9\7E&6D?(/7SQV\M-) MZX/[*O4P[]]AE,(=OTP,9]H8NT\A]KX MOO=]GTP?O>^CG_G[Q!W?^O9S]K=^.R^B1_AWIY^/]@;(-_\ \S(>_P"/Q^3O M^DKHT:-:S'&AR'^[Z.[!JOC[H7^DMM+_ 'U<=_>OR)]C^?V=N=6#M5\?="_T MEMI?[ZJ/_O7Y$U5^-K?K/XGO_P!!9GYW_8DNV.Q^CQ^_QT.]_P#W2N#=AW_W M>H?'[>&,XZ 7ZU/,/E^NFRMSP A_T&#\^0#D?:(=A]0\::%O)_6F[E/7^@9E M'^XZ6^(?O?:\]*]Z 7ZU/,/[Z;*WJX_Z#!?;^O\ 8]6FA[R/UIVY3]PS*/\ M<=+:7A']R'#O^0,M_P!1BQ'TX?O[=*EO_M/XOY\OW2UWVY8J%=$[@>IEMV'M M^LOR]P/K_5XL#V^OS]??G4]/=&H\9(Z:/;SSG?0__=!/_#_%]J!?1.X^>9;= M?7^DNR[ZNX?1XK\_+X^X!QR(^W@)Z^Z-./ED=-+D>/T/]U\RV'V\?;C>_JCNW2WTRW%_[VN%#W]_ G#7B3^;;F+W MO5%PT7BD9_["'BWB-Q+R @(A\L&A"4P (>0\< (>8=QU]3^-[1[$!\_>;7_B MZ6OEA8= Q:1GT3FY$V\)H)0YYX(;(%" @!QSQV$>"_Z7U_']3Z-_I>R[\_Y$ M:]_;_D=+O]G6 O[Y73>>=^E;B+<7MLX'QV%AW7.^-OTS[]#?H7F]P?1>X/ / M<;5]<-KCN%K_ %#%1WK]_K^=G/L^9QS'Q]?Y+67/\7&G8=&C]COU^OWV=]P_6XYA[>O^JUH'(?%W[_S!IUO1H_8W-M?_ MN\^/]T"U> MS_E'VB.JMEW[Z/$O^:^1_P#QY\63C'^!CT-?RO\ 21_LW+,==UI?V.C.//'' MPCB_S\OII4_SX[\>WC2D^@%^NZWI]N_RE]OO?GL/YXK_ ,!QY!X?(1#S]?EI MMO6D[=.G.'/E\)8OY\O]U*G^WD/M@(>W2DN@%Q\UUO3XYY^4QM]YY'D./DBO MWAX]?/'GZO9P&L;-/WU^%MC^YO/-_P#\Q/9]B/;C8\$?P(^F[^5SH\^+]CIC MI^O4/&^';/\ O0L[^P?^JECWU#Z_L\#Y#I*72-X#.'3.'MR.Z68 .0#D.7^0 M.1^UP'Q.1^+Y:./>/MC[.X^6DI=(WZ=_3.'S_ $TD MQQR'?CX0R!R/U_C^P//;CL72]^]ET$?RGU/_ ,/.<<:]$DD<7^F?;_S7ZL?$ MIUNAW69LPKF*'R9GB0L.-(_>.R@(S%R-%J45#,8BG93:, M*VQ+8F@FGU4X\I$W)CG'TKMP0GIS> ! R[JZ;G=_O=+W^@J^.N>1Y\Z,4W)2 M^1?7Y!P(\"/?4J-]' X1S2 >K?#-!QSY_HQ(@(?&(#QSQSQY^W45JZ/.\#>[ MP(_0U?')1$1Y#DU'*(>$! ! ./,.1 P]^PYZ&EJ.%13TZ%%6Z1!W"ZM3F^[&VU>_4_:NIK/3NX&:IGFJ#!D?2=3 MPF61GZJ"+(^(1''&";+$@8JL8[*WNH Q>MZ%A#I])'8T13CQEQ J!O#QQS\F M-I'MP!0^T ?6UHCW0G^LUQ#S]6!AGO[/SOY&]O;R]H#]_6]^A6)!Z2&QGT8 M!/E0*^$ $P@ ?)C:>W)P P__ !@ ?;K0_NA3GYC7$7 \#\V!AGO[ ^1_(W?X M_P#EUL^*/W'Y]W?WO9C>^W_)\O<+V]@OX"^+%T5D_P!G_H^+;'^RSPU>X L3 MQ92 W47 MX7([KXBA[GK$?ES;_ #V;=O_N%<^>/4/;U@/\VK1FJN7N>KGY<__ !%^W?[3SP:-&C5UQY]P:TYN([X!S<'_ ,$F1?/R_J1E M];CUIW<1]('-W[DN1?+S_J1E]-?U&_BM]1PJ\Q[1]>/E_-3![AJ]KT(>?F0+K^^+ROQ_^LQVJ)382CE#IU@4 M0X^1;.?T(=^#!&'\8B/8>YN1'GUB/LU>UZ$/ZT"ZC_WQ65_^-1VLKID_A0<1 M#EVQ_P H1;'NN/$>=^[':^B'_O:?"W(_\)O-MP+#]P7<+#;PVWPUO./T MF] MRM?L/V-/W=-S7]^6S:QN\>8-OHQQ8>H?;_1QD&VW^N->H_\ O']F_P#)L/J] M?Y>W6H-SF )VB9NF6][M$!49/+UZN\UCV'E>I-NFJLE8F#F3DI@BS2F5G&4K M%U-(S/DR,.V<_!+%4OP-#NGID42'V_MM#GW1KU'_ &_,/[-P^V6Q:W7N3Q]& M[F[E>-Q^W#*.2JO/[9K?6H.Z/*WAN%R9$Y*LF%YQY8BQN,&ME.P-89W'DVL^ M83:4.]5@I"7*I#ND7<@P,1.&07U6MG14W>P M5TPS_:I*O2,OCZP90<-Z&G9++<+M*R%ZLMLC6\>R:P$K!34E873FGMX]@W:R M<86O@DW*4Q]*$MY^JTCMPQ7&6PF[]/)$1:=SL-$S=$>,UKG:LO?)G75MO$[E M-" ;DCV&%EX92WHJLW %KA&23('@D*1KRX.!90">RN]K WTCN!'?ROSL!L1;R%>VUB-F:Y!-P-K7._,]V)4=22D6V.ZH_2"R \RE8I:F6'<%?J[ M#8@=1D0G5JK-Q&())S(W2,E4$2S;F7FVZI(]VS?+*L$$2>D;$3.)O%8'U67W M47S=%:=^G1KAMQ&"H7&#:!W(9 )$7.+R5$7,]VGRX-,VFQ4@(R/9GKR2RR:\ MFB*RS@J95"LR\G(=0]FC3EMJ-N6E3W\RSWY^?VMA);]7 #:X5]Q8BVK;=202 M.1[[W!N0<&DQ=6L/Z'AK_?5D_B11'\N_V/:YW28>K7^HPU[??-E\_+CT2/K\ M^>_;U?S<=Z?OWJN)O9EG^V*#%2XP_<[F'\6'_6(OM]K83+];O^7V=2XV'\_- M9XD]GOR=_BKTI_']@>/7QSJ(^I<;#_UVF(P_]VSOM]5=E![_ )![?(-?/SH] M_=UP?_G-D7^U*7'&LC_QSE7^4:'_ %J+[=_LQ: T:-&OK1CT7@T:-&C!@T:- M&C!@T:-&C!C$+?D&AX_0CG5[NM2I;:7?DBXIQ;;)#5M"2DE"B=./8+3+UFF\ M>J$*8Q&K8RJYB@(@GP CKPL\DX]D;4O1F%ZIKZZ-6@2#FHL[/"NK,@P,F54K MQ:!0>GE$VQDCD5!8[4I/1G(IXO $+'GO#M:H57J&W2PR<]\EU?)8 M,V9*9XPLN.C3L,5NA<\<3,FVD(^05:KIIM;7"E8A)24&X4;QDC'K&,L*X-O^ MT?*^!MYZ^Y(^0MG]K4K,;<+#$R$9G>#KM=N,Q*8*A<;P]49T]P1_+5":7L,8 M!YF[O)J6BA@ .DW@@=J%4T]:>MD&N*DJ9(B"1)%!+(& M?251@QO<6'>"!J8 M 8>'H@IZVM@BF /O3RPJ0=M.K5("@:_-@" 0UM-R+-"N4,:H7!+'B^0J.C?U MB)J(T=:VU].X*D51,X3.G63R(39RJ-R'7(8K$0.B4RI1$A1,&=:K8UC;7>E> MJ##[L6%SVSUJ.M5XJ]MR'>0W 5>^2]@KWRN4:VZPU5\:2#$'4).L;"JX:Q=Z MAYI!-Y')E52C45'"B(V32@ !ZNWK\P\_/X]-,4\07W1!+ SWTK+&\9.D"] M@ZJ2/$@6OY$787@8CJ)XYP$0L8W1PK,#=3I)MR)%]RI!-C<#G1HT:3!@T:-& MC!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@T:-&C!@TG_KC_K# ME_WS^R7OW[?IM,1=^W(_M^SCO];2'E M\:_6,.7UA]OM]N7/#?B^7VOY)=).ZN \9UZ/?8!YZDM6#OY 'RF,K"/J'OV[ M:=B7R^U_)+I)_5P^GKT>^P#QU):KY^K]!K*H=OC^/V<@/GH'J_Z!_FG#H03( MH4V/:WM?8*21;?F+CRO?#L0\OLF^^.O&HLDCQZ50B?B'@OI#D(!A]A1.8H&' MX@Y'7D#R[?[8?Y7?S^+_ ).^JM.Z^TVJW9SR:MNRVA9">5>FVB=98OR)G/!KOIMM>_?X M;@=P)//D >1/($@CCZPD7 L+]US[+E1MWW86\^6+2_GHU$G9;5I.OX/J<@KD MV7R+7[1#1$]6D)'(49F%A5&;IH)G,-6\O,VJ#[(-<.X,*L5*RJCE=LV(FS;K M>@3 H2VTJG4H:UKB]C]'RC?Q\0#MAC"Q(O>VUQB)>^^QWNJ;.MR*7>3 H&1%:0]X_![8Z3ATDH6 M+'0W'GI)[#1'L(X'A!,'^U,,O-"8G(=A\!A$O(>?'/KU.?<^(!MMW! (AR.$ M,M< (AR/&/[$(\ /GP'G[/7J#'0W[])38?VX_0)A^W_SS-Z7O/L'Y_T?;N6_ M8MOZU_+E]?A;SOW8:WHT:-+AN#1HT:,&*677 $0ZJ]2X^H,FO7QW^2NS]_O_ M ,VE;=*WMFGI3<\_K@8OX^!^#+2'V>X^?VM-)ZX/ ]5:J /E\P7,CV\_ZK+1 MW]7'GZ^WUO6K;I6]LT]*;@ _7 QGM'M\&6D.W'U_YQ[:V?3 /^Y[Z.GEQWG_ M /K^<_U^WZNR^B1_AWIY^']@;(/B]]R+_?WCV''TE0_G'[XZYT:-:S'&L&J^ M/NA?Z2VTO]]5'?WK\B?EQ_@U8.U7R]T+_26VF>SYJN.Y_P#1=D3[&JMQO^X[ MB?\ R%F??;_BDO?CL?H\?O\ '0[_ "D\&_[>H<9OT A$=J>8>>.VZ;*P!P// M;T,'Y_'[0TT/>1^M.W*?N&91_N.EM*[Z /ZU/,/8 _33Y7\O7_08/N/QCZ]- M$WD=]INY0/\ X#,I?W'2VG<(_N0X=_R!EOG_ ,1B[N_$?3?^_MTJ?RG\7?\ MS+78J$]$_GYYEMV^/9;ET ^OX\5C\7=]X_ ML0)]_P O9ZQUN?1@';Z.K?\ 3M;WV_Y7S+PY;>WR[L;W]4=_?;Z9;?\ 5GA/ MRV_6)PSY^&*H^'0 */GSPAQSO":B/B 0Y$<@T+Q&#D.X#W\(E'P\^7'?7U/8 MS^ES'_>;3_BZ6OEAX0Y' MMKZGD9_2YC_O-I_Q=+6 G[Y'3?\ RK<1;^/O@\_S#&UZ9_WF_0MN;G^U@X0W MYG_#J^VYW-OL3SQ4>Z_?'S?6SGGCGYG#,? #QS_5:RYX#SX]O'8.0Y\PT[#H MT?L;FVKN _Y26[RY_P!T"U>W[WJTD[K]@ [^MG)A !$-N&8P >.X Y]O'Q:=AT9P .FYMKX_\ :6W"/UQR!:N=5;+OWT>)?\U\C_UB?%GXQ_@8 M]#/\KW21?V_<[+?S6\/CQUW6D[].G. >V1Q?Y^7TTJ?YZ4ET ?UW6]/MW^4O MM\Y'D>_YXK_P''D''M#S]?D&FV]:7]CHSC_PCB_^^E3]*3Z 7Z[G>D/?D<,; M?>?9VL5_ . \^0[\\_8UCYI^^MPM_FWG?Q>^1[W^CO\ SXV'!'\"/INVY]+? M1Y_JZ?+R^UL=/UZ?U\>V8.>.=H.>/;_NI8\X\@'OS\6DI](WMG#IH>T=TDN MCY=_A'( #Q[?5SY>H-.LZ]7Z^+;,'MV@YX >_';Y:6//7ZOK^K24ND:'&;NF M=Y]MTDMWY'_VQR _$/EWXY >WLUV+I>_>RZ"/Y3ZG^9G&.->B2+\7^F=R_@ MOU@%_ 9OPL>8N;?)L.Z^.YWT?22S6(!_LX9KR'D1'Y<2/F';M[ 0'GUB \Z MBO7QYW?;VR<" $JV.PYXX'D](*8?HN>1\_\ 3=P'L @ :E/OG'C".: X#D=\ M$UZO+C,2/JYYY#C@?LAJ+->[[P-[G(\_G6QWX2CX@ GYR"\AW[&\1OHAX$>_ M8P@/(:Y#1D?VKW3G?N](";XC[HX4M]!/Q'Q%C5?U/6Q].W@KOME72C8^']PN M(0>ZVX-[D[[]]@;UG0L,8_21V-&, E$<0*")1*!!#\^-IX 2@ \<<@ '. MM#^Z$_UFN(A'U;P,,C_^[^1OYN=;WZ%JA3])+8T8 . &Q"KP!O$
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£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g404156.jpg G404156.JPG begin 644 g404156.jpg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end GRAPHIC 39 g718310.jpg G718310.JPG begin 644 g718310.jpg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Ȱ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�OR>%VJ; 5L??_ !QC\'K;;?WG/3MLJ<.' /_9 end XML 40 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1

Document and Entity Information
12 Months Ended

Dec. 31, 2017

shares

Document and Entity Information

Entity Registrant Name Hutchison China MediTech Ltd

Entity Central Index Key 0001648257

Document Type 20-F

Document Period End Date Dec. 31, 2017

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Well-known Seasoned Issuer Yes

Entity Filer Category Large Accelerated Filer

Entity Ordinary Shares, Outstanding 66,447,037

Document Fiscal Year Focus 2017

Document Fiscal Period Focus FY

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: hcm_DocumentAndEntityInformationAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1

Consolidated Balance Sheets - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Current assets

Cash and cash equivalents $ 85,265 $ 79,431

Short-term investments 273,031 24,270

Accounts receivable-third parties 38,410 40,812

Accounts receivable-related parties 3,860 4,223

Other receivables, prepayments and deposits 11,296 4,314

Amounts due from related parties 8,544 1,136

Inventories 11,789 12,822

Deferred tax assets 372

Total current assets 432,195 167,380

Property, plant and equipment 14,220 9,954

Leasehold Land 1,261 1,220

Goodwill 3,308 3,137

Other intangible asset 430 469

Deferred tax assets 633

Long-term prepayment 1,648 1,771

Investments in equity investees 144,237 158,506

Total assets 597,932 342,437

Current liabilities

Accounts payable 24,365 35,538

Other payables, accruals and advance receipts 40,953 31,716

Income tax payable 979 274

Deferred revenue 1,295 962

Amounts due to related parties 7,021 5,308

Short-term bank borrowings 29,987 19,957

Deferred tax liabilities 1,364

Total current liabilities 104,600 95,119

Deferred tax liabilities 4,452 3,997

Long-term bank borrowings 26,830

Deferred revenue 809 2,039

Other deferred income 1,988 2,263

Other non-current liabilities 1,117 8,129

Total liabilities 112,966 138,377

Commitments and contingencies

Company's shareholders' equity

Ordinary shares; $1.00 par value; 75,000,000 shares authorized; 66,447,037 and 60,705,823 shares issued at December 31, 2017 and 2016 respectively 66,447 60,706

Additional paid-in capital 496,960 208,196

Accumulated losses (107,104) (80,357)

Accumulated other comprehensive income/(loss) 5,430 (4,275)

Total Company's shareholders' equity 461,733 184,270

Non-controlling interests 23,233 19,790

Total shareholders' equity 484,966 204,060

Total liabilities and shareholders' equity $ 597,932 $ 342,437

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer) for other payables, accrued liabilities, deferred revenue and advance receipts.
+ References
No definition available.
+ Details

Name: hcm_AccountsPayableAccruedLiabilitiesDeferredRevenueOtherCurrent

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Deferred income noncurrent.
+ References
No definition available.
+ Details

Name: hcm_DeferredIncomeNoncurrent

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of land held under leaseholds.
+ References
No definition available.
+ Details

Name: hcm_LeaseholdLand

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allowance, receivables classified as other receivables and prepayments and deposits due within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: hcm_OtherReceivablesPrepaymentsAndDepositsCurrent

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
For an unclassified balance sheet, amount of receivables arising from transactions with related parties.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(3))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(b)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(1))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_AccruedIncomeTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669686-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, netted by jurisdiction and classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31958-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31958-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318
+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueFromRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66022249&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(22))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(24))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4590271-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1

Consolidated Balance Sheets (parenthetical) - $ / shares

Dec. 31, 2017

Dec. 31, 2016

Consolidated Balance Sheets

Ordinary shares, par value $ 1.00 $ 1.00

Ordinary shares, authorized 75,000,000 75,000,000

Ordinary shares, issued 66,447,037 60,705,823

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1

Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Revenues

Sales-third parties $ 196,720 $ 171,058 $ 118,113

Sales-related parties 8,486 9,794 8,074

Revenue from license and collaboration agreements-third parties 26,315 26,444 44,060

Revenue from research and development services-third parties 355 2,573

Revenue from research and development services-related parties 9,682 8,429 5,383

Total revenues 241,203 216,080 178,203

Operating expenses

Costs of sales-third parties (169,764) (149,132) (104,859)

Costs of sales-related parties (6,056) (7,196) (5,918)

Research and development expenses (75,523) (66,871) (47,368)

Selling expenses (19,322) (17,998) (10,209)

Administrative expenses (23,955) (21,580) (19,620)

Total operating expenses (294,620) (262,777) (187,974)

Loss from operations (53,417) (46,697) (9,771)

Other income/(expense)

Interest income 1,220 502 451

Other income 808 609 386

Interest expense (1,455) (1,631) (1,404)

Other expense (692) (139) (202)

Total other income/(expense) (119) (659) (769)

Loss before income taxes and equity in earnings of equity investees (53,536) (47,356) (10,540)

Income tax expense (3,080) (4,331) (1,605)

Equity in earnings of equity investees, net of tax 33,653 66,244 22,572

Net (loss)/income (22,963) 14,557 10,427

Less: Net income attributable to non-controlling interests (3,774) (2,859) (2,434)

Net (loss)/income attributable to the Company (26,737) 11,698 7,993

Accretion on redeemable non-controlling interests (43,001)

Net (loss)/income attributable to ordinary shareholders of the Company $ (26,737) $ 11,698 $ (35,008)

Earnings Per Share

(Losses)/earnings per share attributable to ordinary shareholders of the Company-basic (US$ per share) $ (0.43) $ 0.20 $ (0.64)

(Losses)/earnings per share attributable to ordinary shareholders of the Company-diluted (US$ per share) $ (0.43) $ 0.20 $ (0.64)

Number of shares used in per share calculation-basic 61,717,171 59,715,173 54,659,315

Number of shares used in per share calculation-diluted 61,717,171 59,971,050 54,659,315

X

- Definition
Revenue From Research And Development Services
+ References
No definition available.
+ Details

Name: hcm_RevenueFromResearchAndDevelopmentServices

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue from research and development services-related parties
+ References
No definition available.
+ Details

Name: hcm_RevenueFromResearchAndDevelopmentServicesRelatedParties

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(12))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(10))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66022249&loc=d3e33749-111570

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(f))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_IncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591551-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.19)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense related to nonoperating activities, classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_OtherNonoperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income related to nonoperating activities, classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_OtherNonoperatingIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_RelatedPartyCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Related Parties
-URI http://asc.fasb.org/extlink&oid=16382449

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999
+ Details

Name: us-gaap_RevenueFromRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Expenses recognized in the period that are directly related to the selling and distribution of products or services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SellingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 44 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1

Consolidated Statements of Comprehensive (Loss)/Income - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Net Income (Loss) Attributable to the Company

Net (loss)/income $ (22,963) $ 14,557 $ 10,427

Other comprehensive income/(loss)

Foreign currency translation gain/(loss) 10,964 (10,722) (5,557)

Total comprehensive (loss)/income (11,999) 3,835 4,870

Less: Comprehensive income attributable to non-controlling interests (5,033) (1,427) (1,732)

Total comprehensive (loss)/income attributable to the Company $ (17,032) $ 2,408 $ 3,138

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4613674-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4569643-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591552-111686
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591552-111686
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetIncomeLossAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b,c)
-URI http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 45 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1

Consolidated Statements of Changes in Shareholders' Equity - USD ($)
$ in Thousands

Total Company's Shareholders' Equity

Ordinary Shares

Additional paid-in capital

Accumulated Losses

Accumulated Other Comprehensive Income/(Loss)

Non-controlling Interests

Total

Balance at Dec. 31, 2014 $ 39,151 $ 53,076 $ 76,256 $ (100,051) $ 9,870 $ 17,764 $ 56,915

Balance (in shares) at Dec. 31, 2014 53,076,000

Increase (Decrease) in Stockholders' Equity

Net income/(loss) 7,993 7,993 2,434 10,427

Accretion to redemption value of redeemable non-controlling interests (43,001) (43,001) (43,001)

Issuance in exchange for redeemable non-controlling interest 84,037 $ 3,214 80,823 84,037

Issuance in exchange for redeemable non-controlling interest (in shares) 3,214,000

Issuances in relation to share option exercises 1,374 $ 243 1,131 $ 1,374

Issuances in relation to exercise of share options (in shares) 243,000 243,000

Share-based compensation - share options 168 168 $ 168

Share-based compensation - long-term incentive plan 233 233 233

Share-based compensation 401 401 401

LTIP-treasury shares acquired and held by Trustee (1,786) (1,786) (1,786)

Dividend paid to a non-controlling shareholder of a subsidiary (590) (590)

Dilution of interests in a subsidiary in relation to exercise of share options of a subsidiary 42 42 15 57

Transfer between reserves 24 (24)

Foreign currency translation adjustments (4,855) (4,855) (702) (5,557)

Balance at Dec. 31, 2015 83,356 $ 56,533 113,848 (92,040) 5,015 18,921 102,277

Balance (in shares) at Dec. 31, 2015 56,533,000

Increase (Decrease) in Stockholders' Equity

Net income/(loss) 11,698 11,698 2,859 14,557

Issuance in relation to public offering 110,160 $ 4,080 106,080 $ 110,160

Issuance in relation to public offering (in shares) 4,080,000 4,080,000

Issuances in relation to share option exercises 426 $ 93 333 $ 426

Issuances in relation to exercise of share options (in shares) 93,000 93,000

Issuance costs (14,227) (14,227) $ (14,227)

Share-based compensation - share options 1,373 1,373 4 1,377

Share-based compensation - long-term incentive plan 1,378 1,378 2 1,380

Share-based compensation 2,751 2,751 6 2,757

LTIP-treasury shares acquired and held by Trustee (604) (604) (604)

Dividend paid to a non-controlling shareholder of a subsidiary (564) (564)

Transfer between reserves 15 (15)

Foreign currency translation adjustments (9,290) (9,290) (1,432) (10,722)

Balance at Dec. 31, 2016 184,270 $ 60,706 208,196 (80,357) (4,275) 19,790 204,060

Balance (in shares) at Dec. 31, 2016 60,706,000

Increase (Decrease) in Stockholders' Equity

Net income/(loss) (26,737) (26,737) 3,774 (22,963)

Issuance in relation to public offering 301,300 $ 5,685 295,615 $ 301,300

Issuance in relation to public offering (in shares) 5,685,000 5,685,000

Issuances in relation to share option exercises 380 $ 56 324 $ 380

Issuances in relation to exercise of share options (in shares) 56,000 56,000

Issuance costs (8,610) (8,610) $ (8,610)

Share-based compensation - share options 1,255 1,255 3 1,258

Share-based compensation - long-term incentive plan 1,537 1,537 1 1,538

Share-based compensation 2,792 2,792 4 2,796

LTIP-treasury shares acquired and held by Trustee (1,367) (1,367) (1,367)

Dividend paid to a non-controlling shareholder of a subsidiary (1,594) (1,594)

Transfer between reserves 10 (10)

Foreign currency translation adjustments 9,705 9,705 1,259 10,964

Balance at Dec. 31, 2017 $ 461,733 $ 66,447 $ 496,960 $ (107,104) $ 5,430 $ 23,233 $ 484,966

Balance (in shares) at Dec. 31, 2017 66,447,000

X

- Definition
Value of dilution of subsidiary interests in relation to exercise of share options of a subsidiary within the period.
+ References
No definition available.
+ Details

Name: hcm_DilutionOfSubsidiaryInterestsInRelationToExerciseShareOptionsOfSubsidiary

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the transfer amount between reserves.
+ References
No definition available.
+ Details

Name: hcm_TransfersBetweenReserves

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the amount long-term incentive plan treasury shares held by Trustee of the Company.
+ References
No definition available.
+ Details

Name: hcm_TreasurySharesLongTermIncentivePlanHeldByTrustee

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the amount of recognized equity-based compensation related to other long-term incentive plans during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66904339&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65896087&loc=d3e11149-113907

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65896087&loc=d3e11178-113907
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Adjustment to retained earnings for the increase in carrying amount of redeemable preferred stock that is classified as temporary equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 3.C)
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177168-122764
+ Details

Name: us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b,c)
-URI http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4590271-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 46 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1

Consolidated Statements Of Cash Flows - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Consolidated Statements Of Cash Flows

Net cash used in operating activities $ (8,943) $ (9,569) $ (9,385)

Investing activities

Purchases of property, plant and equipment (5,019) (4,327) (3,324)

Deposit in short-term investments (325,032) (80,857)

Proceeds from short-term investments 76,271 56,587 12,179

Investment in an equity investee (7,000) (5,000)

Net cash (used in)/generated from investing activities (260,780) (33,597) 8,855

Financing activities

Proceeds from issuance of ordinary shares 301,680 110,586 1,374

Proceeds from exercise of share options of a subsidiary 57

Purchases of treasury shares (1,367) (604) (1,786)

Dividends paid to non-controlling shareholders of subsidiaries (1,594) (564) (590)

Repayment of loan to a non-controlling shareholder of a subsidiary (1,000)

Proceeds from bank borrowings 32,540 25,128 3,205

Repayment of bank borrowings (49,487) (28,205) (6,410)

Payment of issuance costs (8,576) (12,906) (1,321)

Net cash generated from /(used in) financing activities 273,196 92,435 (5,471)

Net increase/(decrease) in cash and cash equivalents 3,473 49,269 (6,001)

Effect of exchange rate changes on cash and cash equivalents 2,361 (1,779) (1,004)

Net increase/(decrease) in cash and cash equivalents, including effect of exchange rate changes 5,834 47,490 (7,005)

Cash and cash equivalents at beginning of year 79,431 31,941 38,946

Cash and cash equivalents at end of year 85,265 79,431 31,941

Supplemental disclosure for cash flow information

Cash paid for interest 763 1,570 1,220

Cash paid for tax, net of refunds 3,836 2,664 510

Supplemental disclosure for non-cash activities

Accruals made for purchases of property, plant and equipment 1,054

Accrued issuance costs for public offering 34 3,125

Vesting of treasury shares for LTIP $ 1,800

Capitalization of amounts due from related parties to investments in equity investees $ 7,000

Issuance of ordinary shares in exchange of redeemable non-controlling interests $ 84,037

X

- Definition
Capitalization of amounts due from related parties to investments in equity investees.
+ References
No definition available.
+ Details

Name: hcm_CapitalizationOfAmountsDueFromRelatedPartiesToInvestmentsInEquityInvestees

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Deferred initial public offering costs incurred but not paid during the period.
+ References
No definition available.
+ Details

Name: hcm_DeferredInitialPublicOfferingCostsIncurredButNotPaid

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net amount paid (received) by the reporting entity from deposit in short-term investments.
+ References
No definition available.
+ Details

Name: hcm_DepositInShortTermInvestments

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Vesting of treasury shares for LTIP incurred but not paid during the period.
+ References
No definition available.
+ Details

Name: hcm_VestingOfTreasurySharesForLtip

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDividendsMinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from bank borrowing during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_ProceedsFromBankDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow to settle a bank borrowing during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfBankDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfCashFlowsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The fair value of stock issued in noncash financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586
+ Details

Name: us-gaap_StockIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1

Organization and Nature of Business
12 Months Ended

Dec. 31, 2017

Organization and Nature of Business

Organization and Nature of Business

1. Organization and Nature of Business

 Hutchison China MediTech Limited (the "Company") and its subsidiaries (together the "Group") are principally engaged in researching, developing, manufacturing and selling pharmaceuticals and healthcare products. The Group and its equity investees have research and development facilities and manufacturing plants in the People's Republic of China (the "PRC") and sell their products mainly in the PRC and Hong Kong.

 The Company considers Hutchison Healthcare Holdings Limited as its immediate holding company and CK Hutchison Holdings Limited ("CK Hutchison") as its ultimate holding company.

 The Company was incorporated in the Cayman Islands on December 18, 2000 as an exempted company with limited liability under the Companies Law (2000 Revision), Chapter 22 of the Cayman Islands. The address of its registered office is P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

 The Company's ordinary shares are listed on the AIM market of the London Stock Exchange, and its American depositary shares ("ADS"), each representing one-half of one ordinary share, are traded on the Nasdaq Global Select Market.

Liquidity

 As at December 31, 2017, the Group had accumulated losses of US$107,104,000, primarily due to its significant spending in research and development activities. The Group regularly monitors current and expected liquidity requirements to ensure that it maintains sufficient cash balances and adequate credit facilities to meet its liquidity requirements in the short and long term. As at December 31, 2017, the Group had cash and cash equivalents of US$85,265,000, short-term investments of US$273,031,000 and unutilized bank borrowing facilities of US$121,282,000. Short-term investments comprised of bank deposits maturing over three months. As at December 31, 2016, the Group had cash and cash equivalents of US$79,431,000, short-term investments of US$24,270,000 and unutilized bank borrowing facilities of US$70,000,000. The Group's operating plan includes the continued receipt of dividends from certain of its equity investees. The increase in cash balances is primarily due to a public follow-on offering of the Company's ADS in October 2017, which raised net proceeds of US$292,690,000. Additionally, dividends received from equity investees for the years ended December 31, 2017, 2016 and 2015 were US$55,586,000, US$30,528,000 and US$6,410,000 respectively.

 Based on the Group's operating plan, the existing cash and cash equivalents, short-term investments and unutilized bank borrowing facilities are considered to be sufficient to meet the cash requirements to fund planned operations and other commitments for at least the next twelve months (the look-forward period used).

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6003-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2A
-URI http://asc.fasb.org/extlink&oid=64851502&loc=SL51803626-108592
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1

Particulars of Principal Subsidiaries and Equity Investees
12 Months Ended

Dec. 31, 2017

Particulars of Principal Subsidiaries and Equity Investees

Particulars of Principal Subsidiaries and Equity Investees

2. Particulars of Principal Subsidiaries and Equity Investees



Equity interest
attributable to
the Group

As at
December 31,

Place of
establishment
and operations

Name

2017

2016

Principal activities

Subsidiaries

Hutchison MediPharma Limited ("HMPL")

PRC

99.75%

99.75%

Research and development of pharmaceutical products

Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm")

PRC

51%

51%

Provision of sales, distribution and marketing services to pharmaceutical manufacturers

Hutchison Hain Organic (Hong Kong) Limited ("HHOL") (note (a))

Hong Kong

50%

50%

Wholesale and trading of healthcare and consumer products

Hutchison Hain Organic (Guangzhou) Limited ("HHOGZL") (note (a))

PRC

50%

50%

Wholesale and trading of healthcare and consumer products

Hutchison Healthcare Limited ("HHL")

PRC

100%

100%

Manufacture and distribution of healthcare products

Hutchison Consumer Products Limited

Hong Kong

100%

100%

Wholesale and trading of healthcare and consumer products

Equity investees

Shanghai Hutchison Pharmaceuticals Limited ("SHPL")

PRC

50%

50%

Manufacture and distribution of prescription drug products

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS") (note (b))

PRC

40%

40%

Manufacture and distribution of over-the-counter drug products

Nutrition Science Partners Limited ("NSPL") (note (c))

Hong Kong

49.88%

49.88%

Research and development of pharmaceutical products

Notes:

(a)

HHOL and HHOGZL are regarded as subsidiaries of the Company, as while both shareholders of these subsidiaries have equal representation at their respective boards, in the event of a deadlock, the Group has a casting vote and is therefore able to unilaterally control the financial and operating policies of HHOL and HHOGZL.

(b)

The 50% equity interest in HBYS is held by an 80% owned subsidiary of the Group. The effective equity interest of the Group in HBYS is therefore 40% for the years presented.

(c)

The 50% equity interest in NSPL is held by a 99.75% owned subsidiary of the Group. The effective equity interest of the Group in NSPL is therefore 49.88% for the years presented.

X

- Definition
n/a
+ References
No definition available.
+ Details

Name: hcm_ParticularsOfPrincipalSubsidiariesAndEquityInvesteesAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure showing particulars of Principal subsidiaries and Equity investees.
+ References
No definition available.
+ Details

Name: hcm_ParticularsOfPrincipalSubsidiariesAndEquityInvesteesTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1

Summary of Significant Accounting Policies
12 Months Ended

Dec. 31, 2017

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

3. Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation

 The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Investments in equity investees over which the Group has significant influence are accounted for using the equity method. All inter-company balances and transactions have been eliminated in consolidation. The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America ("U.S. GAAP").

Use of Estimates

 The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as useful lives of property, plant and equipment, write-down of inventories, allowance for doubtful accounts, share-based compensation, impairments of long-lived assets, impairment of other intangible asset and goodwill, taxes on income, tax valuation allowances, revenues and cost accruals from research and development projects. Actual results could differ from those estimates.

Foreign Currency Translation

 The Group's functional currency is Renminbi ("RMB") but the presentation currency is U.S. dollar ("US$"). The financial statements of the Company's subsidiaries with a functional currency other than the US$ have been translated into the Company's reporting currency, the US$. All assets and liabilities of the subsidiaries are translated using year-end exchange rates and revenues and expenses are translated at average exchange rates for the year. Translation adjustments are reflected in accumulated other comprehensive income/(loss) in shareholders' equity.

 Net foreign currency exchange losses of US$316,000, US$109,000 and US$79,000 were recorded in other expense in the consolidated statements of operations for the years ended December 31, 2017, 2016 and 2015 respectively.

Cash and Cash Equivalents

 The Group considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. Cash and cash equivalents consist primarily of cash on hand and bank deposits and are stated at cost, which approximates fair value.

Short-term Investments

 Short-term investments include deposits placed with banks with original maturities of more than three months but less than one year.

Concentration of Credit Risk

 Financial instruments that potentially expose the Group to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, accounts receivable, other receivables and amounts due from related parties.

 The Group places substantially all of its cash and cash equivalents and short-term investments in major financial institutions, which management believes are of high credit quality. The Group has a practice to limit the amount of credit exposure to any particular financial institution.

 The Group has no significant concentration of credit risk. The Group has policies in place to ensure that sales are made to customers with an appropriate credit history and the Group performs periodic credit evaluations of its customers. Normally the Group does not require collateral from trade debtors.

Foreign Currency Risk

 The Group's operating transactions and its assets and liabilities are mainly denominated in RMB, which is not freely convertible into foreign currencies. In the PRC, the Group's cash and cash equivalents denominated in RMB are subject to such government controls. The value of the RMB is subject to fluctuations from central government policy changes and international economic and political developments that affect the supply and demand of RMB in the foreign exchange market. In the PRC, certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange rates set by the People's Bank of China (the "PBOC"). Remittances in currencies other than RMB by the Group in the PRC must be processed through the PBOC or other PRC foreign exchange regulatory bodies which require certain supporting documentation in order to complete the remittance.

Fair Value of Financial Instruments

 The fair value of financial instruments that are measured at fair value is determined according to a fair value hierarchy that prioritizes the inputs and assumptions used, and the valuation techniques used. The three levels of the fair value hierarchy are described as follows:



Level 1

Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2

Inputs are quoted prices for similar assets or liabilities in active markets; or quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.

Level 3

Inputs are unobservable inputs based on the Group's assumptions and valuation techniques used to measure assets or liabilities at fair value. The inputs require significant management judgment or estimation.

 The assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of assets and liabilities and their placement within the fair value hierarchy levels.

 The fair value of assets and liabilities is established using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, and a fair value hierarchy is established based on the inputs used to measure fair value.

Accounts Receivable

 Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable regularly to determine if any receivable will potentially be uncollectible. Estimates are used to determine the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value. The amount of the allowance for doubtful accounts is recognized in the consolidated statements of operations.

Inventories

 Inventories are stated at the lower of cost or net realizable value. Cost is determined using the weighted average cost method. The cost of finished goods comprises raw materials, direct labor, other direct costs and related production overheads (based on normal operating capacity). Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. A provision for excess and obsolete inventory will be made based primarily on forecasts of product demand and production requirements. The excess balance determined by this analysis becomes the basis for excess inventory charge and the written-down value of the inventory becomes its cost. Written-down inventory is not written up if market conditions improve.

Property, Plant and Equipment

 Property, plant and equipment consist of buildings, leasehold improvements, plant and equipment, furniture and fixtures, other equipment and motor vehicles. Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets.



Buildings

20 years

Plant and equipment

5-10 years

Furniture and fixtures, other equipment and motor vehicles

4-5 years

Leasehold improvements

Shorter of (a) 5 years or (b) remaining term of lease

 Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations in the year of disposition. Additions and improvements that extend the useful life of an asset are capitalized. Repairs and maintenance costs are expensed as incurred.

Impairment of Long-Lived Assets

 The Group evaluates the recoverability of long-lived assets in accordance with authoritative guidance on accounting for the impairment or disposal of long-lived assets. The Group evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. If such indicators exist, the first step of the impairment test is performed to assess if the carrying value of the net assets exceeds the undiscounted cash flows of the assets. If yes, the second step of the impairment test is performed in order to determine if the carrying value of the net assets exceeds the fair value. If yes, impairment is recognized for the excess.

Leasehold Land

 Leasehold land represents fees paid to acquire the right to use the land on which various plants and buildings are situated for a specified period of time from the date the respective right was granted and are stated at cost less accumulated amortization and impairment loss, if any. Amortization is computed using the straight-line basis over the lease period of 50 years.

Goodwill

 Goodwill represents the excess of the purchase price plus fair value of non-controlling interests over the fair value of identifiable assets and liabilities acquired. Goodwill is not amortized, but is tested for impairment at the reporting unit level on at least an annual basis or when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. When performing an evaluation of goodwill impairment, the Group has the option to first assess qualitative factors, such as significant events and changes to expectations and activities that may have occurred since the last impairment evaluation, to determine if it is more likely than not that goodwill might be impaired. If as a result of the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the quantitative fair value test is performed to determine if the fair value of the reporting unit exceeds its carrying value. No impairment of goodwill occurred in the years presented.

 The Group has adopted Accounting Standards Update ("ASU") 2017-04, Simplifying the Test for Goodwill Impairment, for annual goodwill impairment tests performed on testing dates after January 1, 2017. This guidance removes Step 2 of the goodwill impairment test, which required the estimation of an implied fair value of goodwill in the same manner as the calculation of goodwill upon a business combination. For prior years' annual goodwill impairment tests, the Group determined that the fair values of their reporting units exceeded their carrying values and Step 2 has never been required.

Other Intangible Assets

 Other intangible assets with finite useful lives are carried at cost less accumulated amortization and impairment loss, if any. Amortization is computed using the straight-line basis over the estimated useful lives of the assets.

Borrowings

 Borrowings are recognized initially at fair value, net of debt issuance costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations over the period of the borrowings using the effective interest method.

Ordinary Shares

 The Company's ordinary shares are stated at par value of US$1.00 per ordinary share. The difference between the consideration received, net of issuance cost, and the par value is recorded in additional paid-in capital.

Treasury Shares

 The Group accounts for treasury shares under the cost method. The treasury shares were purchased for the purpose of the LTIP.

Convertible Preferred Shares

 When the Company or its subsidiaries issue preferred shares, the Group assesses whether such instruments should be liabilities, mezzanine equity, or permanent equity classified based on multiple indicators such as redemption features, conversion features, voting rights and other embedded features. Freestanding equity instruments with mandatory redemption requirements, embodying an obligation to repurchase the issuer's equity shares by transferring assets, or certain obligations to issue a variable number of shares, are treated as liability-classified instruments. Equity instruments that are redeemable at the option of the holder or not solely within the Group's control are classified as mezzanine equity of the issuer entity (and redeemable non-controlling interests in the consolidated financial statements of the Group if preferred shares are issued by its subsidiaries). Subsequent measurements of financing instruments are driven by the instruments' balance sheet classification.

 The Group also reviews the terms of each convertible instrument and determines whether the host instrument is more akin to debt or equity based on the economic characteristics and risks in order to evaluate if there were any embedded features which would require bifurcation and separate accounting from the host contract. For embedded conversion features that are not required to be separated, the Group analyzes the accounting conversion price and the Company's share price at the commitment date to identify any beneficial conversion features.

 For any amendment to the terms of the preferred shares not classified as liabilities, the Group assesses whether the amendment is an extinguishment or a modification using the fair value model. The Group considers a significant change in fair value immediately after the amendment to be substantive and to trigger extinguishment. A change in fair value which is not significant immediately after the amendment is considered non-substantive and thus is subject to modification accounting. When preferred shares are extinguished, the difference between the fair value of the consideration transferred to the preferred shareholders and the carrying amount of such preferred shares (net of issuance costs) is treated as a deemed dividend to the preferred shareholders. When preferred shares are modified and such modification results in a value transfer between preferred shareholders and ordinary shareholders, the change in fair value resulting from the amendment is treated as a deemed dividend to or from the preferred shareholders.

Share-Based Compensation

Share options

 The Group recognizes share-based compensation expense on share options granted to employees and directors based on their estimated grant date fair value using the Polynomial model. This Polynomial pricing model uses various inputs to measure fair value, including estimated market value of the Company's underlying ordinary shares at the grant date, contractual terms, estimated volatility, risk-free interest rates and expected dividend yields. The Group recognizes share-based compensation expense in the consolidated statements of operations on a graded vesting basis over the requisite service period.

 The Group has adopted ASU 2016-09, Improvements to Employee Share-Based Payment Accounting on January 1, 2017. This guidance permitted the Group to make an accounting policy election to account for forfeitures as they occur. The Group has elected to account for forfeitures as they occur and adopted this election using the modified retrospective approach as required with no cumulative effect adjustment. Prior to January 1, 2017, the Group applied an estimated forfeiture rate derived from historical and expected future employee termination behavior.

 Share options are classified as equity-settled awards. Share-based compensation expense, when recognized, is charged to the consolidated statements of operations with the corresponding entry to additional paid-in capital.

LTIP

 The Group recognizes the share-based compensation expense on the LTIP awards based on a fixed or determinable monetary amount on a straight line basis for each annual tranche awarded over the requisite period. For LTIP awards with performance targets, prior to their determination date, the amount of LTIP awards that is expected to vest takes into consideration the achievement of the performance conditions and the extent to which the performance conditions are likely to be met. Performance conditions vary by awards, including targets for shareholder returns, free cash flows, revenues, net profit after taxes and/or the achievement of clinical and regulatory milestones.

 These LTIP awards are classified as liability-settled awards before the determination date (i.e. the date when the achievement of any performance conditions are known), as they settle in a variable number of shares based on a determinable monetary amount, which is determined upon the actual achievement of performance targets. As the extent of achievement of the performance targets is uncertain prior to the determination date, a probability based on management's assessment of the achievement of the performance targets has been assigned to calculate the amount to be recognized as an expense over the requisite period.

 After the determination date or if the LTIP awards have no performance conditions, the LTIP awards are classified as equity-settled awards. If the performance target is achieved, the Group will pay the determined monetary amount to a trustee appointed by the Group (the "Trustee") to purchase ordinary shares of the Company or the equivalent ADS. Any cumulative compensation expense previously recognized as a liability will be transferred to additional paid in capital, as an equity-settled award. If the performance target is not achieved, no ordinary shares or ADS of the Company will be purchased and the amount previously recorded in the liability will be reversed and included in the consolidated statements of operations.

Defined Contribution Plans

 The Group's subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which certain retirement, medical and other welfare benefits are provided to employees. The relevant labor regulations require the Group's subsidiaries in the PRC to pay the local labor and social welfare authority's monthly contributions at a stated contribution rate based on the monthly basic compensation of qualified employees. The relevant local labor and social welfare authorities are responsible for meeting all retirement benefits obligations and the Group's subsidiaries in the PRC have no further commitments beyond their monthly contributions. The contributions to the plan are expensed as incurred.

 The Group also makes payments to other defined contribution plans for the benefit of employees employed by subsidiaries outside the PRC. The defined contribution plans are generally funded by the relevant companies and by payments from employees.

 The Group's contributions to defined contribution plans for the years ended December 31, 2017, 2016 and 2015 amounted to US$2,092,000, US$2,286,000 and US$1,653,000 respectively.

Revenue Recognition—Accounting Standard Codification 605

Sales

 Revenue from sales of goods in the Commercial Platform segment are recognized when goods are delivered and title passes to the customer and there are no further obligations to the customer. Recognition of revenue also requires reasonable assurance of collection of sales proceeds and completion of all performance obligations. Sales discounts are issued to customers as direct discounts at the point-of-sale or indirectly in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns.

 Revenue from sales of services in the Commercial Platform segment are recognized based on amounts that can be invoiced to the customer. The amount that can be invoiced corresponds directly with the value to the customer for performance completed to date.

Revenues from research and development projects

 The Group recognizes revenue for the performance of services when each of the following four criteria are met: (i) persuasive evidence of an arrangement exists; (ii) services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured.

 The Group follows Accounting Standard Codification ("ASC") 605-25, Revenue Recognition—Multiple-Element Arrangements and ASC 808, Collaborative Arrangements, if applicable, to determine the recognition of revenue under the Group's license and collaborative research, development and commercialization agreements. The terms of these agreements generally contain multiple elements, or deliverables, which may include (i) licenses to the Group's intellectual property, (ii) materials and technology, (iii) clinical supply, and/or (iv) participation in joint research or joint steering committees. The payments the Group may receive under these arrangements typically include one or more of the following: non-refundable, upfront license fees; funding of research and/or development efforts; amounts due upon the achievement of specified milestones; and/or royalties on future product sales.

 ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable.

 To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The Group determines the estimated selling price for deliverables within each agreement using vendor-specific objective evidence ("VSOE") of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the Group's best estimate of selling price, if neither VSOE nor third-party evidence is available. Determining the best estimate of selling price for a deliverable requires significant judgment. The Group typically uses its best estimate of a selling price to estimate the selling price for licenses to development work, since it often does not have VSOE or third-party evidence of selling price for these deliverables. In those circumstances where the Group applies its best estimate of selling price to determine the estimated selling price of a license to development work, it considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its best estimate of selling price, the Group evaluates whether changes in the key assumptions used to determine its best estimate of selling price will have a significant effect on the allocation of arrangement consideration between deliverables. The Group recognizes consideration allocated to an individual element when all other revenue recognition criteria are met for that element.

 The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria.

 If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as unearned revenue in the accompanying balance sheets and recognized as revenue when the related revenue recognition criteria are met.

 The Group typically receives non-refundable, upfront payments when licensing the Group's intellectual property, which often occurs in conjunction with a research and development agreement. If management believes that the license to the Group's intellectual property has stand-alone value, the Group generally recognizes revenue attributed to the license upon delivery provided that there are no future performance requirements for use of the license. When management believes that the license to the Group's intellectual property does not have stand-alone value, the Group will recognize revenue attributed to the license ratably over the contractual or estimated performance period. For payments payable on achievement of milestones that do not meet all of the conditions to be considered substantive, the Group recognizes a portion of the payment as revenue when the specific milestone is achieved, and the contingency is removed. Other contingent event-based payments for which payment is either contingent solely upon the passage of time or the result of a collaborator's performance are recognized when earned. The Group's collaboration and license agreements generally include contingent milestone payments related to specified pre-clinical research and development milestones, clinical development milestones, regulatory milestones and sales-based milestones. Pre-clinical research and development milestones are typically payable upon the selection of a compound candidate for the next stage of research and development. Clinical development milestones are typically payable when a product candidate initiates or advances in clinical trial phases or achieves defined clinical events such as proof-of-concept. Regulatory milestones are typically payable upon submission for marketing approval with regulatory authorities or upon receipt of actual marketing approvals for a compound, approvals for additional indications, or upon the first commercial sale. Sales-based milestones are typically payable when annual sales reach specified levels.

 At the inception of each arrangement that includes milestone payments, the Group evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (i) the entity's performance to achieve the milestone or (ii) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone; (b) the consideration relates solely to past performance; and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Group evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.

Research and Development Expenses

 Research and development expenses consist primarily of salaries and benefits, share-based compensation, materials and supplies, contracted research, consulting arrangements and other expenses incurred to sustain the Group's research and development programs. Research and development costs are expensed as incurred.

Government Incentives

 Incentives from governments are recognized at their fair values. Government incentives that are received in advance are deferred and recognized in the consolidated statements of operations over the period necessary to match them with the costs that they are intended to compensate. Government incentives in relation to the achievement of stages of research and development projects are recognized in the consolidated statements of operations when amounts have been received and all attached conditions have been met. Non-refundable incentives received without any further obligations or conditions attached are recognized immediately in the consolidated statements of operations.

Operating Leases

 Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to the consolidated statements of operations on a straight-line basis over the period of the leases.

 Total operating lease rentals for buildings for the years ended December 31, 2017, 2016 and 2015 amounted to US$2,285,000, US$1,838,000 and US$1,426,000 respectively. Sub-lease rentals for the years ended December 31, 2017, 2016 and 2015 amounted to US$274,000, US$228,000 and US$229,000 respectively.

Interest Income

 Interest generated from cash and cash equivalents and short-term investments is recorded over the period earned. It is measured based on the actual amount of interest the Group earns.

Income Taxes

 The Group accounts for income taxes under the liability method. Under the liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some of the net deferred income tax asset will not be realized.

 The Group accounts for an uncertain tax position in the consolidated financial statements only if it is more likely than not that the position is sustainable based on its technical merits and consideration of the relevant tax authority's widely understood administrative practices and precedents. If the recognition threshold is met, the Group records the largest amount of tax benefit that is greater than 50 percent likely to be realized upon ultimate settlement.

Comprehensive (Loss)/Income

 Comprehensive (loss)/income is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances from non-owner sources, and currently consists of net (loss)/income and foreign currency translation gain/(loss) related to the Company's subsidiaries.

(Losses)/Earnings per Share

 Basic (losses)/earnings per share is computed by dividing net (loss)/income attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year. Weighted average number of ordinary shares outstanding during the period excludes treasury shares. In addition, periodic accretion on preferred shares of Hutchison MediPharma Holdings Limited ("HMHL") (Note 16) is recorded as a deduction to consolidated net (loss)/income to arrive at net (loss)/income attributable to ordinary shareholders of the Company for purposes of calculating the consolidated basic (losses)/earnings per share.

 Diluted (losses)/earnings per share is computed by dividing net (loss)/income attributable to ordinary shareholders by the weighted average number of ordinary shares and dilutive ordinary share equivalents outstanding during the period. Dilutive ordinary share equivalents include ordinary shares and treasury shares issuable upon the exercise or settlement of share-based awards issued by the Company using the treasury stock method. In determining the impact from share-based awards and convertible preferred shares issued by HMHL, the Company first calculates the diluted earnings per share at HMHL and includes in the numerator of consolidated (losses)/earnings per share the amount based on the diluted earnings per share of HMHL multiplied by the number of shares owned by the Company. The computation of diluted (losses)/earnings per share does not assume conversion, exercise, or contingent issuance of securities that would have an anti-dilutive effect.

Segment Reporting

 Operating segments are reported in a manner consistent with the internal reporting provided to the chief executive officer who is the Group's chief operating decision maker. The chief operating decision maker reviews the Group's internal reporting in order to assess performance and allocate resources and determined that the Group's reportable segments are as disclosed in Note 25.

Discontinued Operations

 A discontinued operation is a component of the Group's business, the operations and cash flows of which can be clearly distinguished from the rest of the Group and which represents a separate major line of business or geographic area of operations, or is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations, or is a subsidiary acquired exclusively with a view to resale. When an operation is classified as discontinued, a single amount is presented in the statements of operations, which comprises the post tax profit or loss of the discontinued operation.

Profit Appropriation and Statutory Reserves

 The Group's subsidiaries and equity investees established in the PRC are required to make appropriations to certain non-distributable reserve funds.

 In accordance with the laws applicable to the Foreign Investment Enterprises established in the PRC, the Group's subsidiaries and equity investees registered as wholly-owned foreign enterprise have to make appropriations from its after-tax profit (as determined under generally accepted accounting principles in the PRC ("PRC GAAP") to reserve funds including general reserve fund, the enterprise expansion fund and staff bonus and welfare fund. The appropriation to the general reserve fund must be at least 10% of the after-tax profits calculated in accordance with PRC GAAP. Appropriation is not required if the general reserve fund has reached 50% of the registered capital of the company. Appropriation to the enterprise expansion fund and staff bonus and welfare fund is made at the company's discretion.

 The use of the general reserve fund, enterprise expansion fund, statutory surplus reserve and discretionary surplus fund are restricted to the offsetting of losses or increases the registered capital of the respective company. The staff bonus and welfare fund is a liability in nature and is restricted to fund payments of special bonus to employees and for the collective welfare of employees. All these reserves are not allowed to be transferred to the company in terms of cash dividends, loans or advances, nor can they be distributed except under liquidation.

Recent Accounting Pronouncements

 In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"), to clarify the principles of recognizing revenue and create common revenue recognition guidance for U.S. GAAP and International Financial Reporting Standards. An entity has the option to apply the provisions of ASU 2014-09 either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this standard recognized at the date of initial application. ASU 2014-09 is effective for fiscal years and interim periods within those years beginning after December 15, 2017, and early adoption is permitted but not earlier than the original effective date of December 15, 2016. The new standard supersedes U.S. GAAP guidance on revenue recognition and requires the use of more estimates, judgements and additional disclosures.

 The Group will adopt the new standard using the modified retrospective method on January 1, 2018 and has assessed the impact on revenue from customers. The Group's revenue from contracts with customers comprises of research and development projects in its Innovation Platform and sales of goods and services in its Commercial Platform operating segments. The Group expects the changes from applying the new guidance will primarily impact the Innovation Platform.

 Innovation Platform—The Group has reviewed its research and development contracts and identified two contracts related to the Group's license and collaboration arrangements that will be impacted by the application of ASU 2014-09. The license and collaboration arrangements contain multiple performance obligations: (1) the license to the drug compound and (2) the research and development services for each specified treatment indication. The transaction price includes fixed and variable consideration in the form of upfront payment, research and development costs reimbursements, contingent milestone payments and sales-based royalties. The allocation of the transaction price to each performance obligation is based on the relative standalone selling price of each performance obligation. The Group has determined that control of the license to the drug compound was transferred as of the inception date of the collaboration agreements and consequently, amounts allocated to this performance obligation are recognized at a point in time. Conversely, control of the research and development services for each specified indication is transferred over time and amounts allocated to these performance obligations are recognized over time using cost inputs as a measure of progress. In addition, royalty revenues will be recognized as future sales occur as they meet the requirements for the sales-usage based royalty exception. The Group expects US$1.1 million deferral of revenue as a cumulative adjustment to opening accumulated loss upon adoption.

 Commercial Platform—For sales of goods and services, the Group has applied a portfolio approach to aggregate contracts into portfolios whose performance obligations do not differ materially from each other. In its assessment of each portfolio, the Group has assessed the contracts under the new five-step model and does not expect a significant impact to the timing or amount of revenue recognition under the new guidance. Control of the goods passes to the customer when the goods are delivered, which matches the timing of revenue recognition under the Group's existing accounting policy.

 The Group has applied updates to the new guidance in its assessment including ASU 2016-08, Principal versus Agent Considerations, ASU 2016-10, Identifying Performance Obligations and Licensing.

 In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). The core principle of ASU 2016-02 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018. The Group expects to adopt the new standard using the modified retrospective method on January 1, 2019 with a retrospective adjustment to comparable periods presented starting from January 1, 2017. The Group is currently determining the potential impact ASU 2016-02 will have on the Group's consolidated financial statements.

 In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business ("ASU 2017-01"), which revises the definition of a business. To be considered a business, an acquisition would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. To be a business without outputs, there will now need to be an organized workforce. ASU 2017-01 is effective for fiscal years and interim periods within those years beginning after December 15, 2018. The Group currently does not expect ASU 2017-01 to have a material impact on the Group's consolidated financial statements, but will apply the guidance upon adoption to business acquisitions, disposals and segment changes, if any.

 In May 2017, the FASB issued ASU 2017-09, Scope of Modification Accounting (Topic 718) ("ASU 2017-09"), which provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under share-based payment accounting. The guidance clarifies that no new measurement date will be required if there is no change to the fair value, vesting conditions, and classification, and in effect simplifies the accounting for non-substantive changes to share-based payment awards. ASU 2017-09 is effective for fiscal years and interim periods within those years beginning after December 15, 2017. The Group shall apply the guidance upon adoption to share-based payment modifications, if any.

 Other amendments that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Group's consolidated financial statements upon adoption.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18854-107790
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1

Fair Value Disclosures
12 Months Ended

Dec. 31, 2017

Fair Value Disclosures

Fair Value Disclosures

4. Fair Value Disclosures

 The following table presents the Group's financial instruments by level within the fair value hierarchy:



Fair Value Measurement Using

Level 1

Level 2

Level 3

Total

(in US$'000)

As at December 31, 2017

Cash and cash equivalents

85,265

—

—

85,265

Short-term investments

273,031

—

—

273,031

As at December 31, 2016

Cash and cash equivalents

79,431

—

—

79,431

Short-term investments

24,270

—

—

24,270

 Accounts receivable, other receivables, amounts due from related parties, accounts payable, other payables and amounts due to related parties are carried at cost, which approximates fair value due to the short-term nature of these financial instruments, and are therefore excluded from the above table. Bank borrowings are floating rate instruments and carried at amortized cost, which approximates their fair values, and are therefore excluded from the above table.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1

Cash and Cash Equivalents
12 Months Ended

Dec. 31, 2017

Cash and Cash Equivalents

Cash and Cash Equivalents

5. Cash and Cash Equivalents



December 31,

2017

2016

(in US$'000)

Cash at bank and on hand

30,018

31,218

Bank deposits maturing in three months or less (note (a))

55,247

48,213

85,265

79,431

Denominated in:

US$(note (b))

66,381

65,509

RMB (note (b))

15,140

9,505

UK Pound Sterling ("£") (note (b))

295

408

Hong Kong dollar ("HK$")

3,449

4,009

85,265

79,431

Notes:

(a)

The weighted average effective interest rate on bank deposits for the years ended December 31, 2017 and 2016 was 1.06% and 0.58% per annum respectively (with maturity ranging from 7 to 90 days).

(b)

Certain cash and bank balances denominated in RMB, US$ and £ were deposited with banks in the PRC. The conversion of these RMB, US$ and £ denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the PRC government.

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 6.H.3)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13728-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951
+ Details

Name: us-gaap_CashAndCashEquivalentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1

Short-term Investments
12 Months Ended

Dec. 31, 2017

Short-term Investments

Short-term Investments

6. Short-term Investments



December 31,

2017

2016

(in US$'000)

Bank deposits maturing over three months (note)

Denominated in:

US$

272,659

24,270

HK$

372

—

273,031

24,270

Note:

The weighted average effective interest rate on bank deposits for the years ended December 31, 2017 and 2016 was 1.32% and 0.71% per annum respectively (with maturity ranging from 91 to 183 days, and 91 to 186 days respectively).

X

- Definition
The entire disclosure for investments, including all tables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 6
-Section 10
-Paragraph (c)
-Subparagraph (1)
+ Details

Name: invest_InvestmentTextBlock

Namespace Prefix: invest_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShortTermInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1

Accounts Receivable-Third Parties
12 Months Ended

Dec. 31, 2017

Accounts Receivable-Third Parties

Accounts Receivable-Third Parties

7. Accounts Receivable—Third Parties



December 31,

2017

2016

(in US$'000)

Accounts receivable, gross

38,668

43,532

Allowance for doubtful accounts

(258
)

(2,720
)

Accounts receivable, net

38,410

40,812

 Substantially all the accounts receivable are denominated in RMB, US$ and HK$ and are due within one year from the end of the reporting periods. The carrying values of accounts receivable approximates their fair values due to their short-term maturities.

 Movements on the allowance for doubtful accounts:



2017

2016

2015

(in US$'000)

As at January 1

2,720

3,127

1,793

Increase in allowance for doubtful accounts

242

29

1,408

Decrease in allowance due to subsequent collection

—

(237
)

—

Write-off

(2,874
)

—

—

Exchange difference

170

(199
)

(74
)

As at December 31

258

2,720

3,127

 In December 2015, the Group recorded a provision amounting to approximately US$1,322,000 which represented an outstanding balance due from a distributor. In January 2016, the Group terminated the distributor's exclusive distribution rights and in December 2017, the amount due was written off along with other allowance for doubtful accounts balances.

X

- Definition
The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=66008989&loc=d3e5066-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(6))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66008989&loc=d3e5162-111524

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(7))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66008989&loc=d3e5074-111524
+ Details

Name: us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1

Other Receivables, Prepayments and Deposits
12 Months Ended

Dec. 31, 2017

Other Receivables, Prepayments and Deposits

Other Receivables, Prepayments and Deposits

8. Other Receivables, Prepayments and Deposits

 Other receivables, prepayments and deposits consisted of the following:



December 31,

2017

2016

(in US$'000)

Prepayments

2,565

699

Purchase rebates

284

238

Other service receivables

490

756

Deposits

932

620

Value-added tax receivables

5,436

1,380

Interest receivables

506

63

Others

1,083

558

11,296

4,314

X

- Definition
NA.
+ References
No definition available.
+ Details

Name: hcm_OtherReceivablePrepaymentsAndDepositsAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other receivable, prepayments and deposits.
+ References
No definition available.
+ Details

Name: hcm_OtherReceivablePrepaymentsAndDepositsDisclosureTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1

Inventories
12 Months Ended

Dec. 31, 2017

Inventories

Inventories

9. Inventories

 Inventories, net of provision for excess and obsolete inventories, consisted of the following:



December 31,

2017

2016

(in US$'000)

Raw materials

314

660

Finished goods

11,475

12,162

11,789

12,822

 Movements on the provision for excess and obsolete inventories are as follows:



2017

2016

2015

(in US$'000)

As at January 1

160

25

34

Increase in provision for excess and obsolete inventories

128

163

37

Decrease in provision due to subsequent sale or recovery

(144
)

—

(33
)

Write-off

(32
)

(23
)

(12
)

Exchange difference

9

(5
)

(1
)

As at December 31

121

160

25

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1

Property, Plant and Equipment
12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment

Property, Plant and Equipment

10. Property, Plant and Equipment

 Property, plant and equipment consisted of the following:



Buildings

Leasehold
improvements

Plant
and
equipment

Furniture
and
fixtures,
other
equipment
and motor
vehicles

Construction
in progress

Total

(in US$'000)

Cost

As at January 1, 2017

2,232

6,296

86

13,976

1,760

24,350

Additions

—

301

155

1,374

4,243

6,073

Disposals

—

—

—

(394
)

—

(394
)

Transfers

—

2,050

2,321

(722
)

(3,649
)

—

Exchange differences

140

410

6

920

204

1,680

As at December 31, 2017

2,372

9,057

2,568

15,154

2,558

31,709

Accumulated depreciation

As at January 1, 2017

971

4,249

71

9,105

—

14,396

Depreciation

105

763

169

1,441

—

2,478

Disposals

—

—

—

(337
)

—

(337
)

Transfers

—

—

255

(255
)

—

—

Exchange differences

65

284

4

599

—

952

As at December 31, 2017

1,141

5,296

499

10,553

—

17,489

Net book value

As at December 31, 2017

1,231

3,761

2,069

4,601

2,558

14,220



Buildings

Leasehold
improvements

Plant
and
equipment

Furniture
and
fixtures,
other
equipment
and motor
vehicles

Construction
in progress

Total

(in US$'000)

Cost

As at January 1, 2016

2,392

5,989

88

12,806

567

21,842

Additions

—

742

—

1,453

2,132

4,327

Disposals

—

(12
)

—

(248
)

—

(260
)

Transfers

—

—

—

886

(886
)

—

Exchange differences

(160
)

(423
)

(2
)

(921
)

(53
)

(1,559
)

As at December 31, 2016

2,232

6,296

86

13,976

1,760

24,350

Accumulated depreciation

As at January 1, 2016

932

3,549

70

8,784

—

13,335

Depreciation

106

977

3

1,153

—

2,239

Disposals

—

(12
)

—

(218
)

—

(230
)

Exchange differences

(67
)

(265
)

(2
)

(614
)

—

(948
)

As at December 31, 2016

971

4,249

71

9,105

—

14,396

Net book value

As at December 31, 2016

1,261

2,047

15

4,871

1,760

9,954

 Depreciation for the year ended December 31, 2015 was US$1,908,000.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13-14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2921-110230

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1

Investments in Equity Investees
12 Months Ended

Dec. 31, 2017

Investments in Equity Investees

Investments in Equity Investees

11. Investments in Equity Investees

 Investments in equity investees consisted of the following:



December 31,

2017

2016

(in US$'000)

HBYS

55,308

63,536

SHPL

69,417

77,939

NSPL

19,201

16,806

Other

311

225

144,237

158,506

 Particulars regarding the principal equity investees are disclosed in Note 2. All of the equity investees are private companies and there are no quoted market prices available for their shares.

 Summarized financial information for the significant equity investees HBYS, SHPL and NSPL is as follows:

(i) Summarized balance sheets



Commercial Platform

Innovation
Platform

Consumer Health
HBYS

Prescription Drugs
SHPL

Drug R&D
NSPL

December 31,

December 31,

December 31,

2017

2016

2017

2016

2017

2016

(in US$'000)

Current assets

101,570

123,181

129,535

146,350

9,640

5,393

Non-current assets

107,226

98,554

103,477

97,656

30,000

30,000

Current liabilities

(75,787
)

(70,218
)

(91,665
)

(86,946
)

(1,239
)

(1,782
)

Non-current liabilities

(18,748
)

(18,148
)

(8,616
)

(6,926
)

—

—

Net assets

114,261

133,369

132,731

150,134

38,401

33,611

Non-controlling interests

(3,645
)

(6,297
)

—

—

—

—

110,616

127,072

132,731

150,134

38,401

33,611

(ii) Summarized statements of operations



Commercial Platform

Innovation Platform

Consumer Health
HBYS

Prescription Drugs
SHPL

Drug R&D(note (a))
NSPL

Year Ended December 31,

Year Ended December 31,

Year Ended December 31,

2017

2016

2015

2017

2016

2015

2017

2016

2015

(in US$'000)

Revenue

227,422

224,131

211,603

244,557

222,368

181,140

—

—

—

Gross profit

91,458

89,355

91,461

175,965

158,131

127,608

—

—

—

Depreciation and amortization

(4,985
)

(2,958
)

(3,274
)

(6,942
)

(3,526
)

(2,765
)

—

—

—

Interest income

220

238

628

757

565

306

—

—

—

Finance cost

(117
)

(123
)

(158
)

—

—

—

—

—

—

Profit/(loss) before taxation

24,434

23,759

25,164

66,497

148,144

37,401

(9,210
)

(8,482
)

(7,552
)

Income tax expense (note (b))

(3,629
)

(3,631
)

(3,948
)

(10,874
)

(27,645
)

(6,094
)

—

—

—

Net income/(loss)

20,805

20,128

21,216

55,623

120,499

31,307

(9,210
)

(8,482
)

(7,552
)

Non-controlling interests

(29
)

248

160

—

—

—

—

—

—

Net income/(loss) attributable to the shareholders of equity investee

20,776

20,376

21,376

55,623

120,499

31,307

(9,210
)

(8,482
)

(7,552
)

Notes:

(a)

NSPL only incurred research and development expenses in the periods presented.

(b)

HBYS and SHPL have been successful in their respective applications to renew the High and New Technology Enterprise ("HNTE") status. Accordingly, the companies were eligible to use a preferential income tax rate of 15% for the years ended December 31, 2017, 2016 and 2015.

 For the years ended December 31, 2017, 2016 and 2015, other immaterial equity investees had net income of approximately US$117,000, US$95,000 and US$12,000 respectively.

(iii) Reconciliation of summarized financial information

 Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees is as follows:



Commercial Platform

Innovation Platform

Consumer Health
HBYS

Prescription Drugs
SHPL

Drug R&D
NSPL

2017

2016

2015

2017

2016

2015

2017

2016

2015

(in US$'000)

Opening net assets after non-controlling interests as at January 1

127,072

121,523

111,506

150,134

93,263

71,906

33,611

18,093

25,645

Net income/(loss) attributable to the shareholders of equity investee

20,776

20,376

21,376

55,623

120,499

31,307

(9,210
)

(8,482
)

(7,552
)

Dividends declared

(45,128
)

(6,000
)

(6,410
)

(81,299
)

(55,057
)

(6,410
)

—

—

—

Other comprehensive income/(loss)

7,896

(8,827
)

(4,949
)

8,273

(8,571
)

(3,540
)

—

—

—

Investments

—

—

—

—

—

—

14,000

10,000

—

Capitalization of loans

—

—

—

—

—

—

—

14,000

—

Closing net assets after non-controlling interests as at December 31

110,616

127,072

121,523

132,731

150,134

93,263

38,401

33,611

18,093

Group's share of net assets

55,308

63,536

60,762

66,365

75,067

46,632

19,201

16,806

9,046

Goodwill

—

—

—

3,052

2,872

3,077

—

—

—

Carrying amount of investments as at December 31

55,308

63,536

60,762

69,417

77,939

49,709

19,201

16,806

9,046

 The equity investees had the following lease commitments and capital commitments:

(a)

The equity investees lease various factories and offices under non-cancellable operating lease agreements. Future aggregate minimum payments under non-cancellable operating leases as from the dates indicated are as follows:



December 31,

2017

2016

(in US$'000)

Not later than 1 year

1,282

1,511

Between 1 to 2 years

400

1,184

Between 2 to 3 years

151

—

Between 3 to 4 years

141

—

Between 4 to 5 years

47

—

Total minimum lease payments

2,021

2,695

(b)

Capital commitments

 The equity investees had the following capital commitments:



December 31,

2017

2016

(in US$'000)

Property, plant and equipment

Contracted but not provided for

1,034

6,162

X

- References
No definition available.
+ Details

Name: us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 35
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=64825282&loc=d3e32847-111569

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 35
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=64825282&loc=d3e32787-111569
+ Details

Name: us-gaap_EquityMethodInvestmentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1

Accounts Payable
12 Months Ended

Dec. 31, 2017

Accounts Payable

Accounts Payable

12. Accounts Payable



December 31,

2017

2016

(in US$'000)

Accounts payable—third parties

17,095

30,383

Accounts payable—non-controlling shareholders of subsidiaries

7,250

5,136

Accounts payable—related party (Note 22 (ii))

20

19

24,365

35,538

 Substantially all the accounts payable are denominated in RMB and US$ and due within one year from the end of the reporting period. The carrying values of accounts payable approximate their fair values due to their short-term maturities.

X

- Definition
The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountsPayableCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 59 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1

Other Payables, Accruals and Advance Receipts
12 Months Ended

Dec. 31, 2017

Other Payables, Accruals and Advance Receipts

Other Payables, Accruals and Advance Receipts

13. Other Payables, Accruals and Advance Receipts

 Other payables, accruals and advance receipts consisted of the following:



December 31,

2017

2016

(in US$'000)

Accrued salaries and benefits

9,295

7,057

Accrued research and development expenses

14,613

11,771

Accrued selling and marketing expenses

4,121

4,340

Accrued administrative and other general expenses

4,729

4,078

Deferred government incentives

1,790

1,755

Loan from a non-controlling shareholder of a subsidiary (Note 22 (iv))

1,550

—

Payments in advance from customers

1,282

899

Others

3,573

1,816

40,953

31,716

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1

Bank Borrowings
12 Months Ended

Dec. 31, 2017

Bank Borrowings

Bank Borrowings

14. Bank Borrowings

 Bank borrowings consisted of the following:



December 31,

2017

2016

(in US$'000)

Current

29,987

19,957

Non-current

—

26,830

29,987

46,787

 The weighted average interest rate for outstanding bank borrowings for the years ended December 31, 2017, 2016 and 2015 was 1.90%, 1.52% and 1.39% per annum respectively. In addition, the Group incurred guarantee fees of US$320,000, US$471,000 and US$471,000 respectively for the years ended December 31, 2017, 2016 and 2015, which was 0.76%, 0.94% and 0.95% per annum respectively of the weighted average outstanding bank borrowings. The carrying amounts of the Group's bank borrowings are all denominated in HK$.

3-year term loan and 18-month revolving loan facilities

 In November 2017, the Group through its subsidiary, entered into a facility agreement with a bank for the provision of unsecured credit facilities in the aggregate amount of HK$400,000,000 (US$51,282,000). The credit facilities include (i) a HK$210,000,000 (US$26,923,000) 3-year term loan facility and (ii) a HK$190,000,000 (US$24,359,000) 18-month revolving loan facility. The term loan bears interest at 1.50% over the Hong Kong Interbank Offered Rate ("HIBOR") per annum. The revolving loan facility bears interest at 1.25% over HIBOR per annum. As at December 31, 2017, no amounts have been drawn from the term loan or the revolving loan facilities. These credit facilities are guaranteed by the Company.

 In December 2011, the Group through its subsidiary, entered into a three-year term loan with the same bank above in the aggregate principal amount of HK$210,000,000 (US$26,923,000). The term loan bears interest at 1.50% over the HIBOR per annum. In June 2014, the term loan was refinanced into a four-year term loan due June 2018 which bears interest at 1.35% over the HIBOR per annum. The loan was fully repaid in two installments of HK$180,000,000 (US$23,077,000) and HK$30,000,000 (US$3,846,000) in August 2017 and November 2017 respectively. The term loan was unsecured and guaranteed by Hutchison Whampoa Limited, an indirect subsidiary of CK Hutchison. An annual fee was paid to Hutchison Whampoa Limited for the guarantee (Note 22(i)).

18-month term loan and revolving loan facilities

 In February 2017, the Group through its subsidiary, entered into two separate facility agreements with banks for the provision of unsecured credit facilities in the aggregate amount of HK$546,000,000 (US$70,000,000). The first credit facility includes (i) a HK$156,000,000 (US$20,000,000) term loan facility and (ii) a HK$195,000,000 (US$25,000,000) revolving loan facility, both with a term of 18 months and an annual interest rate of 1.25% over HIBOR. The term loan was drawn from the first credit facility in March 2017 and is due in August 2018. The second credit facility includes (i) a HK$78,000,000 (US$10,000,000) term loan facility and (ii) a HK$117,000,000 (US$15,000,000) revolving loan facility, both with a term of 18 months and an annual interest rate of 1.25% over HIBOR. The term loan was drawn from the second credit facility in August 2017 and is due in August 2018. Accordingly, the term loans are recorded as short-term bank borrowings as at December 31, 2017. No amounts have been drawn from the revolving loan facilities. These credit facilities are guaranteed by the Company.

 In March 2017, the Group repaid the HK$156,000,000 (US$20,000,000) term loan facility with the same banks above, which was part of the unsecured credit facilities in the aggregate amount of HK$468,000,000 (US$60,000,000) entered in February 2016. These unsecured credit facilities have been terminated.

3-year revolving loan facility

 In November 2015, the Group through its subsidiary renewed a three year revolving loan facility with a bank in the aggregate amount of HK$234,000,000 (US$30,000,000) with an annual interest rate of 1.25% over HIBOR. This facility will expire in November 2018. In February 2017, HK$20,000,000 (US$2,564,000) was drawn from this facility and the amount was fully repaid in March 2017. As at December 31, 2017 and 2016, there were no amounts due under this loan.

 The Group's bank borrowings are repayable as from the dates indicated as follows:



December 31,

2017

2016

(in US$'000)

Not later than 1 year

30,000

20,000

Between 1 to 2 years

—

26,923

30,000

46,923

 As at December 31, 2017 and 2016, the Group had unutilized bank borrowing facilities of HK$946,000,000 (US$121,282,000) and HK$546,000,000 (US$70,000,000) respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 61 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1

Commitments and Contingencies
12 Months Ended

Dec. 31, 2017

Commitments and Contingencies

Commitments and Contingencies

15. Commitments and Contingencies

(i) Lease commitments

 The Group leases various factories and offices under non-cancellable operating lease agreements. Future aggregate minimum payments under non-cancellable operating leases as from the dates indicated as follows:



December 31,

2017

2016

(in US$'000)

Not later than 1 year

3,330

1,711

Between 1 to 2 years

2,875

1,383

Between 2 to 3 years

2,132

1,053

Between 3 to 4 years

345

597

Between 4 to 5 years

161

108

Later than 5 years

17

45

Total minimum lease payments

8,860

4,897

(ii) Capital commitments

 The Group had the following capital commitments as from the dates indicated as follows:



December 31,

2017

2016

(in US$'000)

Property, plant and equipment

Contracted but not provided for

161

2,545

 In addition, the Group has also undertaken to provide the necessary additional funds for NSPL to finance its ongoing operations.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 62 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1

Redeemable Non-controlling Interests
12 Months Ended

Dec. 31, 2017

Redeemable Non-controlling Interests

Redeemable Non-controlling Interests

16. Redeemable Non-controlling Interests

 As at December 31, 2017 and 2016, no redeemable non-controlling interests were outstanding.

 In November and December 2010, the Company and HMHL, entered into subscription and shareholders' agreements ("SSAs") with Mitsui & Co., Ltd. ("Mitsui") and SBCVC Fund III Company Limited ("SBCVC") (collectively, the "preferred shareholders"), whereby HMHL issued 7,390,029 redeemable convertible preferred shares ("Preferred Shares") for an aggregate consideration of US$20.1 million. The Preferred Shares on an as-if-converted basis represented approximately 19.76% of the aggregate issued and outstanding share capital of HMHL on the closing date.

 In October 2012, the Company repurchased all 2,815,249 Preferred Shares from SBCVC. The remaining 4,574,780 Preferred Shares of US$12.5 million held by Mitsui represented approximately 12.24% of HMHL on a fully diluted basis.

 In May and June 2014, the Company and HMHL further entered into two subscription agreements with Mitsui, whereby HMHL issued a total of 672,713 HMHL's Preferred Shares to Mitsui and 4,825,418 HMHL's ordinary shares to the Company for an aggregate consideration of US$25.0 million, after which Mitsui's interest in HMHL remained at 12.24% on a fully diluted basis.

 On July 23, 2015, the Company entered into a subscription agreement with Mitsui under which the Company issued 3,214,404 new ordinary shares of the Company valued at approximately US$84.0 million in exchange for the Preferred Shares held by Mitsui with carrying value of US$84.0 million (including accretion adjustment up to July 23, 2015). The transaction was completed on July 23, 2015 and as a result of this transaction, Mitsui held approximately 5.69% of the enlarged share capital of the Company at that time. The outstanding balance of redeemable non-controlling interests was extinguished with the corresponding increase in the Company's shares and additional paid-in capital.

Accounting for preferred shares

 The Preferred Shares were redeemable upon occurrence of an event that is not solely within the control of the issuer. Accordingly, the Preferred Shares were recorded and accounted for as redeemable non-controlling interests outside of permanent equity in the Group's consolidated balance sheets. The Group recorded accretion when it was probable that the Preferred Shares will become redeemable. The accretion, which increases the carrying value of the redeemable non-controlling interests, was recorded against retained earnings, or in the absence of retained earnings, by recording against the additional paid-in capital. During the year ended December 31, 2015, HMHL recorded an accretion of US$43,001,000 to the Preferred Shares based on such preferred shareholder's share of the estimated valuation of HMHL.

X

- Definition
The entire disclosure pertaining to the redeemable non controlling interests.
+ References
No definition available.
+ Details

Name: hcm_RedeemableNonControllingInterestsTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 63 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1

Ordinary Shares
12 Months Ended

Dec. 31, 2017

Ordinary Shares

Ordinary Shares

17. Ordinary Shares

 The Company is authorized to issue 75,000,000 ordinary shares.

 On March 17, 2016, the Company's ADS, each representing one-half of one ordinary share, commenced trading on the Nasdaq Global Select Market. Concurrently, the Company issued 3,750,000 ordinary shares in the form of 7,500,000 ADS for gross proceeds of US$101.3 million. On April 13, 2016, the Company issued an additional 330,000 ordinary shares in the form of 660,000 ADS for gross proceeds of US$8.9 million. Issuance costs totaled US$14.2 million, of which US$12.9 million and US$1.3 million were paid in the years ended December 31, 2016 and 2015 respectively.

 In October 2017, the Company issued 5,684,905 ordinary shares in the form of 11,369,810 ADS for gross proceeds of US$301.3 million. Issuance costs totaled US$8.6 million.

 A summary of ordinary shares transactions (in thousands) is as follows:



2017

2016

2015

As at January 1

60,706

56,533

53,076

Public offering

5,685

4,080

—

Share option exercises

56

93

243

Exchange of redeemable non-controlling interest (Note 16)

—

—

3,214

As at December 31

66,447

60,706

56,533

 Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 64 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-based Compensation
12 Months Ended

Dec. 31, 2017

Share-based Compensation

Share-based Compensation

18. Share-based Compensation

(i) Share-based Compensation of the Company

 The Company conditionally adopted a share option scheme on June 4, 2005 (as amended on March 21, 2007) and such scheme has a term of 10 years. It expired in 2016 and no further share options can be granted. Another share option scheme was conditionally adopted on April 24, 2015 (the "HCML Share Option Scheme"). Pursuant to the HCML Share Option Scheme, the Board of Directors of the Company may, at its discretion, offer any employees and directors (including Executive and Non-executive Directors but excluding Independent Non-executive Directors) of the Company, holding companies of the Company and any of their subsidiaries or affiliates, and subsidiaries or affiliates of the Company share options to subscribe for shares of the Company.

 The aggregate number of shares issuable under the HCML Share Option Scheme is 2,425,597 ordinary shares. The aggregate number of shares issuable under the prior share option scheme which expired in 2016 is 282,726 ordinary shares. As at December 31, 2017, the number of shares authorized but unissued was 8,552,963 ordinary shares.

 Share options granted are generally subject to a three-year or four-year vesting schedule, depending on the nature and the purpose of the grant. Share options subject to three-year vesting schedule, in general, vest 33.3% upon the first anniversary of the vesting commencement date as defined in the grant letter, and 33.3% every subsequent year. Share options subject to the four-year vesting schedule, in general, vest 25% upon the first anniversary of the vesting commencement date as defined in the grant letter, and 25% every subsequent year. However, certain share option grants may have a different vesting schedule as approved by the Board of Directors of the Company. No outstanding share options will be exercisable or subject to vesting after the expiry of a maximum of eight to ten years from the date of grant.

 On June 15, 2016, 1,187,372 share options of a subsidiary were cancelled with the consent of the relevant eligible employees in exchange for 593,686 new share options of the Company (Note 18(ii)). This was accounted for as a modification of the original share options granted which did not result in any incremental fair value to the Group.

 A summary of the Company's share option activity and related information is as follows:





Number of
share
options



Weighted-average
exercise price in
£ per share



Weighted-average
remaining
contractual life
(years)



Aggregate
intrinsic value
(in £'000)



Outstanding at January 1, 2015

684,403

4.67

Granted

—

—

Exercised

(242,038
)

3.77

Cancelled

—

—

Outstanding at December 31, 2015

442,365

5.16

6.53

10,061

Granted

693,686

19.70

Exercised

(92,705
)

3.54

Cancelled

(3,750
)

6.10

Outstanding at December 31, 2016

1,039,596

15.00

6.77

7,900

Granted

150,000

31.05

Exercised

(56,309
)

5.16

Cancelled

(6,875
)

6.10

Outstanding at December 31, 2017

1,126,412

17.69

6.29

43,158

Vested and expected to vest at December 31, 2015

333,393

4.85

6.05

7,685

Vested and exercisable at December 31, 2015

291,015

4.67

5.77

6,762

Vested and expected to vest at December 31, 2016

1,039,596

15.00

6.77

7,900

Vested and exercisable at December 31, 2016

767,376

14.64

6.66

6,106

Vested and expected to vest at December 31, 2017

1,126,412

17.69

6.29

43,158

Vested and exercisable at December 31, 2017

951,412

15.52

5.81

38,508

 The Company uses the Polynomial model to estimate the fair value of share option awards using various assumptions that require management to apply judgment and make estimates, including:

Volatility

 The Company calculated its expected volatility with reference to the historical volatility prior to the issuances of share options.

Risk-free Rate

 The risk-free interest rates used in the Polynomial model are with reference to the sovereign yield of the United Kingdom because the Company's ordinary shares are currently listed on AIM and denominated in £.

Dividends

 The Company has not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore uses an expected dividend yield of zero in the Polynomial model.

 In determining the fair value of share options granted, the following assumptions were used in the Polynomial model for awards granted in the periods indicated:



Grant date

June 24,
2011

December 20,
2013

June 15,
2016

March 27,
2017

Value of each share option (in £ per share)

1.84

3.15

8.99

12.69

Significant inputs into the valuation model:

Exercise price (in £ per share)

4.41

6.10

19.70

31.05

Share price at effective date of grant (in £ per share)

4.33

6.10

19.70

31.05

Expected volatility

46.6%

36.0%

39.0%

36.3%

Risk-free interest rate

3.13%

3.16%

1.00%

1.17%

Contractual life of share options

10 years

10 years

8 years

10 years

Expected dividend yield

0%

0%

0%

0%

 The following table summarizes the Company's share option values:



Year Ended December 31,

2017

2016

2015

Weighted-average grant-date fair value of share options granted during the period (in £ per share)

12.69

8.99

—

Total intrinsic value of share options exercised in US$'000

2,290

1,907

5,020

Share-based Compensation Expense

 The Group recognizes compensation expense for only the portion of options expected to vest, on a graded vesting approach over the requisite service period. The following table presents share-based compensation expense included in the Group's consolidated statements of operations:



Year Ended December 31,

2017

2016

2015

(in US$'000)

Research and development expenses

1,284

1,278

74

Administrative expenses

—

—

14

1,284

1,278

88

 As at December 31, 2017, the total unrecognized compensation cost was US$1,539,000, and will be recognized on a graded vesting approach over the weighted-average remaining service period of 3.1 years.

 Cash received from share option exercises under the share option plan for the years ended December 31, 2017, 2016 and 2015 was approximately US$380,000, US$426,000 and US$1,374,000 respectively.

 The Company will issue new shares to satisfy share option exercises.

(ii) Share-based Compensation of a subsidiary

 HMHL adopted a share option scheme on August 6, 2008 (as amended on April 15, 2011) and such scheme has a term of 6 years. It expired in 2014 and no further share options can be granted. Another share option scheme was adopted on December 17, 2014 (the "HMHL Share Option Scheme"). Pursuant to the HMHL Share Option Scheme, any employee or director of HMHL and any of its holding company, subsidiaries and affiliates is eligible to participate in the HMHL Share Option Scheme subject to the discretion of the board of directors of HMHL.

 The aggregate number of shares issuable under the HMHL Share Option Scheme is 2,144,408 ordinary shares. As at December 31, 2017, the number of shares authorized but unissued was 157,111,839 ordinary shares of HMHL.

 Share options granted are generally subject to a four-year vesting schedule, depending on the nature and the purpose of the grant. Share options subject to the four-year vesting schedule, in general, vest 25% upon the first anniversary of the vesting commencement date as defined in the grant letter, and 25% every subsequent year. No outstanding share options will be exercisable or subject to vesting after the expiry of a maximum of six or nine years from the date of grant.

 On December 20, 2013, 2,485,189 share options were cancelled with the consent of the relevant eligible employees in exchange for new share options of the Company vesting over a period of four years and/or cash consideration payable over a period of four years. For the share options in exchange for new share options under HCML Share Option Scheme, this was accounted for as a modification of the original share options which did not result in any incremental fair value to the Group. For the share options in exchange for cash consideration, this was accounted for as a modification in classification that changed the award's classification from equity-settled to a liability.

 A liability has been recognized on the modification date taking into account the requisite service period that has been provided by the employee at the modification date. As at December 31, 2017 and 2016, US$0.2 million and US$1.4 million have been recognized in other payables respectively.

 On June 15, 2016, 1,187,372 share options pursuant to the HMHL Share Option Schemes were cancelled with the consent of the relevant eligible employees in exchange for 593,686 new share options of the Company pursuant to the HCML Share Option Schemes. This was accounted for as a modification of the original share options granted which did not result in any incremental fair value to the Group.

 A summary of the HMHL's share option activity and related information is as follows (with no activity for the year ended December 31, 2017):



Number of
share
options



Weighted-average
exercise price in
£ per share



Weighted-average
remaining
contractual life
(years)



Aggregate
intrinsic value
(in £'000)



Outstanding at January 1, 2015

1,211,772

7.71

Granted

—

—

Exercised

(24,400
)

2.34

Cancelled

—

—

Outstanding at December 31, 2015

1,187,372

7.82

7.97

32,292

Granted

—

—

Exercised

—

—

Cancelled

(1,187,372
)

7.82

Outstanding at December 31, 2016 and 2017

—

—

—

—

Vested and expected to vest at December 31, 2015

759,918

7.82

7.97

20,667

Vested and exercisable at December 31, 2015

593,686

7.82

7.97

16,146

Vested and expected to vest at December 31, 2016 and 2017

—

—

—

—

Vested and exercisable at December 31, 2016 and 2017

—

—

—

—

Share-based Compensation Expense

 The subsidiary recognizes compensation expense for only the portion of options expected to vest, on a graded vesting approach over the requisite service period. The following table presents share-based compensation expense included in the Group's consolidated statements of operations:



Year Ended December 31,

2017

2016

2015

(in US$'000)

Research and development

32

502

1,063

 As at December 31, 2017, the total unrecognized compensation cost was nil.

 Cash received from option exercises under the share option plan for the year ended December 31, 2015 was US$57,000.

(iii) LTIP

 The Company grants awards under the LTIP to participating directors and employees, giving them a conditional right to receive ordinary shares of the Company or the equivalent ADS (collectively the "Awarded Shares") to be purchased by the Trustee up to a cash amount. Vesting will depend upon continued employment of the award holder with the Group and will otherwise be at the discretion of the Board of Directors of the Company. Additionally, some awards are subject to change based on annual performance targets prior to their determination date.

LTIP awards prior to the determination date

 Performance targets vary by award, and may include targets for shareholder returns, free cash flows, revenues, net profit after taxes and the achievement of clinical and regulatory milestones. As the extent of achievement of the performance targets is uncertain prior to the determination date, a probability based on management's assessment on the achievement of the performance target has been assigned to calculate the amount to be recognized as an expense over the requisite period with a corresponding entry to liability.

LTIP awards after the determination date

 Upon the determination date, the Company will pay a determined monetary amount, up to the maximum cash amount based on the actual achievement of the performance target specified in the award, to the Trustee to purchase the Awarded Shares. Any cumulative compensation expense previously recognized as a liability will be transferred to additional paid-in capital, as an equity-settled award. If the performance target is not achieved, no Awarded Shares of the Company will be purchased and the amount previously recorded in the liability will be reversed through profit or loss.

 Granted awards under the LTIP are as follows:

 On December 15, 2017, the Company granted awards up to a maximum cash amount per annum of US$0.5 million that stipulated annual performance targets. Shares under such LTIP awards will cover each financial year from 2018 to 2019. The annual performance target determination date is the date of the announcement of the Group's annual results for the covered financial year and vesting occurs two business days after the announcement of the Group's annual results for the financial year falling two years after the covered financial year to which the LTIP award relates.

 On March 15, 2017 and August 2, 2017, the Company granted awards up to a maximum cash amount per annum of US$6.0 million that stipulated annual performance targets. Shares under such LTIP awards will cover each financial year from 2017 to 2019. The annual performance target determination date is the date of the announcement of the Group's annual results for the covered financial year and vesting occurs two business days after the announcement of the Group's annual results for the financial year falling two years after the covered financial year to which the LTIP award relates.

 On March 15, 2017, the Company granted awards up to a maximum cash amount of US$0.4 million in aggregate that did not stipulate performance targets. Shares under such LTIP awards will vest one business day after the publication date of the annual report for the 2017 financial year.

 On March 24, 2016, the Company granted awards up to a maximum cash amount of US$0.3 million in aggregate that do not stipulate performance targets. Shares under such LTIP awards are subject to the vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

 On October 19, 2015, the Company granted initial awards under the LTIP up to a maximum cash amount per annum of US$1.8 million that stipulated annual performance targets. Shares under such LTIP awards will cover each financial year from 2014 to 2016. The annual performance target determination date is the date of the announcement of the Group's annual results for the covered financial year and vesting occurs one business day after the publication date of the annual report of the Company for the financial year falling two years after the covered financial year to which the LTIP award relates.

 The Trustee has been set up solely for the purpose of purchasing and holding the Awarded Shares during the vesting period on behalf of the Group using funds provided by the Group. On the determination date, if any, the Company will determine the cash amount, based on the actual achievement of each annual performance target, for the Trustee to purchase the Awarded Shares. The Awarded Shares will then be held by the Trustee until they are vested.

 The Trustee's assets include treasury shares and funds for additional treasury shares, trustee fees and expenses. As at December 31, 2017, the number of treasury shares (in the form of ordinary shares or ADS of the Company) purchased and held by the Trustee are as follows:



Number of
treasury shares

Cost in
US$'000

As at January 1, 2017

62,921

2,390

Purchased

35,095

1,367

Vested

(42,038
)

(1,800
)

As at December 31, 2017

55,978

1,957

 Based on the actual achievement of performance targets for the 2017 financial year, the Group expects to purchase up to US$5,621,000 of treasury shares in 2018.

 For the year ended December 31, 2017, US$1,800,000 and US$79,000 of the LTIP awards have vested and been forfeited respectively.

 The following table presents the share-based compensation expenses recognized under the LTIP awards:



Year Ended December 31,

2017

2016

2015

(in US$'000)

Research and development expenses

1,894

850

156

Selling and administrative expenses

1,529

811

152

3,423

1,661

308

Recorded with a corresponding credit to:

Liability

2,336

345

75

Additional paid-in capital

1,087

1,316

233

3,423

1,661

308

 For the years ended December 31, 2017, 2016 and 2015, US$451,000, US$64,000 and nil was reclassified from liability to additional paid-in capital respectively upon LTIP awards reaching the determination date. As at December 31, 2017 and 2016, US$2,241,000 and US$356,000 was recorded as liability respectively for LTIP awards prior to the determination date.

 As at December 31, 2017, the total unrecognized compensation cost was approximately US$8,681,000, which considers expected performance targets and the amount expected to vest, and will be recognized over the requisite periods.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65895303&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 65 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1

Revenue from License and Collaboration Agreements-Third Parties
12 Months Ended

Dec. 31, 2017

Revenue from License and Collaboration Agreements-Third Parties

Revenue from License and Collaboration Agreements-Third Parties

19. Revenue from License and Collaboration Agreements—Third Parties



Year Ended December 31,

2017

2016

2015

(in US$'000)

Milestone revenue

9,457

9,931

19,212

Amortization of upfront payment

1,655

1,679

1,907

Research and development services

15,203

14,834

22,941

26,315

26,444

44,060

 The revenue is mainly from license and collaboration agreements as follows:

License and collaboration agreement with Eli Lilly

 On October 8, 2013, the Group entered into a licensing, co-development and commercialization agreement in China with Eli Lilly ("Lilly") relating to fruquintinib, a targeted oncology therapy for the treatment of various types of solid tumors. Under the terms of the agreement, the Group is entitled to receive a series of payments of up to US$86.5 million, including upfront payments and development and regulatory approval milestones. Should fruquintinib be successfully commercialized in China, the Group would receive tiered royalties based on certain percentages of net sales. Development costs after the first development milestone are shared between the Group and Lilly. Following execution of the agreement, the Group received a non-refundable, upfront payment of US$6.5 million.

 In addition, the Group also signed an option agreement which grants Lilly an exclusive option to expand the fruquintinib rights beyond Hong Kong and China. The option agreement further sets out certain milestone payments and royalty rates that apply in the event the option is exercised on a global basis. However, these are subject to further negotiation should the option be exercised on a specific territory basis as opposed to a global basis. The option was not considered to be a separate deliverable in the arrangement as it was not considered to be substantive. As at December 31, 2017, the option has not been exercised.

 The license rights to fruquintinib, delivered at the inception of the arrangement, did not have stand-alone value apart from the other deliverables in the arrangement which include the development services, the participation in the joint steering committee and the manufacturing of active pharmaceutical ingredients during the development phase. The non-refundable upfront payment was deferred and is being recognized ratably over the development period. The Group recognizes milestone revenue relating to the deliverables in the agreement as a single unit of accounting using the milestone method.

 Under the terms of this agreement, the Group recognized US$4.5 million milestone revenue for the year ended December 31, 2017 in relation to the acceptance of a new drug application by the China Food and Drug Administration for fruquintinib as a treatment of patients with advanced colorectal cancer. For the year ended December 31, 2016, the Group did not recognize any milestone revenue in relation to this contract and for the year ended December 31, 2015, the Group recognized US$19.2 million milestone revenues in relation to the achievement of the "proof of concept" milestone for two indications. The Group recognized US$1.6 million, US$1.7 million and US$1.8 million revenue from amortization of the upfront payment during the years ended December 31, 2017, 2016 and 2015 respectively. In addition, the Group recognized US$12.1 million, US$12.1 million and US$19.4 million revenue from research and development services for the years ended December 31, 2017, 2016 and 2015 respectively.

License and collaboration agreement with AstraZeneca

 On December 21, 2011, the Group and AstraZeneca ("AZ") entered into a global licensing, co-development, and commercialization agreement for savolitinib ("AZ Agreement"), a novel targeted therapy and a highly selective inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer. Under the terms of the agreement, development costs for savolitinib in China will be shared between the Group and AZ, with the Group continuing to lead the development in China. AZ will lead and pay for the development of savolitinib for the rest of the world. The Group received a non-refundable upfront payment of US$20.0 million upon the signing of the agreement and may receive up to US$120.0 million contingent upon the successful achievement of clinical development and first-sale milestones. The agreement also contains possible significant future commercial sale milestones and up to double-digit percentage royalties on net sales.

 The license right to develop savolitinib in the rest of the world was delivered to AZ at the inception of the arrangement. Such license had stand-alone value apart from the other deliverables in the arrangement which include the development of savolitinib in China and the participation in the joint steering committee. The non-refundable up-front payment was allocated to (a) the license to develop savolitinib in the rest of the world, which was recognized at inception and (b) the research and development services for which the amount allocated has been deferred and is being recognized ratably over the development period. The Group recognizes milestone revenue relating to the deliverables in the agreement as a single unit of accounting using the milestone method.

 Under the terms of this agreement, the Group recognized US$5.0 million milestone revenue for the year ended December 31, 2017 in relation to the Phase III initiation for the secondary indication, papillary renal cell carcinoma, and US$9.9 million milestone revenue for the year ended December 31, 2016 in relation to the Phase IIb initiation for the primary indication, non-small cell lung cancer. For the year ended December 31, 2015, the Group did not recognize any milestone revenue in relation to this contract. The Group recognized less than US$0.1 million revenue from amortization of the up-front payment for each of the years ended December 31, 2017, 2016 and 2015. In addition, the Group recognized US$3.1 million, US$2.7 million and US$3.5 million revenue from research and development services for the years ended December 31, 2017, 2016 and 2015 respectively.

 In August 2016, the Group entered into an amendment to the AZ Agreement. Under the terms of the amendment, the Group shall pay for up to a maximum of US$50 million of phase III clinical trial costs related to developing savolitinib for papillary renal cell carcinoma. In return, AZ agrees to increase ex-China royalties on net sales by an additional 5% over the royalties stipulated in the original agreement until cumulative additional royalties paid reaches US$250 million, after which the additional royalty decreases to 3% for 24 months and then 1.5% thereafter. The costs of the additional Phase III clinical trial costs shall be expensed to research and development expense as incurred. Under the current revenue recognition policy, future royalties shall be recognized as revenue from license and collaboration agreements—third parties as net sales occur. The amendment does not impact the original accounting for the AZ Agreement under the milestone method.

X

- References
No definition available.
+ Details

Name: hcm_RevenueFromLicenseAndCollaborationAgreementsDisclosureAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure on revenue from license and collaboration agreements with third parties.
+ References
No definition available.
+ Details

Name: hcm_RevenueFromLicenseAndCollaborationAgreementsDisclosureTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 66 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1

Research and Development Expenses
12 Months Ended

Dec. 31, 2017

Research and Development Expenses

Research and Development Expenses

20. Research and Development Expenses

 Research and development expenses are summarized as follows:



Year Ended December 31,

2017

2016

2015

(in US$'000)

Clinical trial related costs

45,250

38,589

24,690

Personnel compensation and related costs

24,848

21,698

17,339

Other research and development expenses

5,425

6,584

5,339

75,523

66,871

47,368

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23218-108380

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 67 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1

Government Incentives
12 Months Ended

Dec. 31, 2017

Government Incentives

Government Incentives

21. Government Incentives

 The Group receives government grants from the PRC Government (including the National level and Shanghai Municipal City). These grants are given in support of drug research and development activities and are conditional upon i) the Group spending a predetermined amount, regardless of success or failure of the research and development projects and ii) the achievement of certain stages of research and development projects being approved by the relevant PRC government authority. These government grants are subject to ongoing reporting and monitoring by the PRC Government over the period of the grant.

 Government incentives, which are deferred and recognized in the consolidated statements of operations over the period necessary to match them with the costs that they are intended to compensate, are recognized in other payable, accruals and advance receipts (Note 13) and other non-current liabilities. They are refundable to the PRC Government if the related research and development projects are suspended. For the years ended December 31, 2017, 2016 and 2015, the Group received government grants of US$1,323,000, US$1,872,000 and US$4,898,000 respectively.

 The government grants recorded as a reduction to research and development expenses for the years ended December 31, 2017, 2016 and 2015 were US$876,000 US$1,269,000 and US$3,664,000 respectively.

X

- Definition
n/a
+ References
No definition available.
+ Details

Name: hcm_GovernmentIncentiveAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the entire disclosure for government incentives.
+ References
No definition available.
+ Details

Name: hcm_GovernmentIncentivesDisclosureTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 68 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1

Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries
12 Months Ended

Dec. 31, 2017

Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries

Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries

22. Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries

 The Group has the following significant transactions with related parties and non-controlling shareholders of subsidiaries, which were carried out in the normal course of business at terms determined and agreed by the relevant parties.

(i) Transactions with related parties:



Year Ended December 31,

2017

2016

2015

(in US$'000)

Sales to:

Indirect subsidiaries of CK Hutchison

8,486

9,794

8,074

Revenue from research and development services:

Equity investees

9,682

8,429

5,383

Purchases from:

Equity investees

1,182

280

3,701

Rendering of marketing services from:

Indirect subsidiaries of CK Hutchison

372

741

751

An equity investee

10,195

8,401

5,093

10,567

9,142

5,844

Rendering of management services from:

Indirect subsidiaries of CK Hutchison

897

874

845

Interest paid to:

Immediate holding company

—

152

144

An indirect subsidiary of CK Hutchison

132

—

—

132

152

144

Guarantee fee on bank loan to:

An indirect subsidiary of CK Hutchison

320

471

471

(ii) Balances with related parties included in:



December 31,

2017

2016

(in US$'000)

Accounts receivable—related parties

Indirect subsidiaries of CK Hutchison (note (a))

2,761

2,589

Equity investees (note (a))

1,099

1,634

3,860

4,223

Accounts payable

An indirect subsidiary of CK Hutchison (note (a))

—

19

An equity investee (note (a))

20

—

20

19

Amounts due from related parties

An indirect subsidiary of CK Hutchison (note (a))

23

107

Equity investees (note (a))

893

1,029

Dividend receivable from an equity investee

7,628

—

8,544

1,136

Amounts due to related parties

Immediate holding company (note (b))

—

2,086

An indirect subsidiary of CK Hutchison (note (b))

454

152

An equity investee (note (a))

6,567

3,070

7,021

5,308

Other deferred income

An equity investee (note (c))

1,648

1,771

Other non-current liabilities

Immediate holding company (note (d))

—

6,000

Notes:

(a)

Balances with related parties are unsecured, interest-free and repayable on demand. The carrying values of balances with related parties approximate their fair values due to their short-term maturities.

(b)

Amounts due to immediate holding company and an indirect subsidiary of CK Hutchison are unsecured and interest-bearing. During the year ended December 31, 2017, amounts due to immediate holding company were assigned to an indirect subsidiary of CK Hutchison. As at December 31, 2017, approximately US$454,000 (December 31, 2016: US$2,238,000) of such balances are repayable within one year or repayable on demand.

(c)

Other deferred income represents amounts recognized from granting of promotion and marketing rights.

(d)

In December 2017, the Group repaid the amount due. As at December 31, 2016, this amount was recorded in non-current liabilities as it was repayable in equal installments of US$3,000,000 in December 2018 and December 2019.

(iii) Transactions with non-controlling shareholders of subsidiaries:



Year Ended December 31,

2017

2016

2015

(in US$'000)

Sales

13,307

12,274

6,196

Purchases

21,236

15,225

12,169

Interest expense

66

78

85

Dividend declared

1,594

564

590

(iv) Balances with non-controlling shareholders of subsidiaries included in:



December 31,

2017

2016

(in US$'000)

Accounts receivable—third parties

1,846

—

Accounts payable

7,250

5,136

Other payables, accruals and advance receipts

Loan

1,550

—

Interest payable

80

14

1,630

14

Other non-current liabilities

Loans

579

2,129

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 69 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes
12 Months Ended

Dec. 31, 2017

Income Taxes

Income Taxes

23. Income Taxes

(i) Income tax expense



Year Ended December 31,

2017

2016

2015

(in US$'000)

Current tax

HK (note (a))

572

520

150

PRC (note (b))

782

458

415

Deferred income tax

1,726

3,353

1,040

Income tax expense

3,080

4,331

1,605

Notes:

(a)

The Company, a subsidiary incorporated in the British Virgin Islands and its Hong Kong subsidiaries are subject to Hong Kong profits tax which has been provided for at the rate of 16.5% on the estimated assessable profits less estimated available tax losses in each entity.

(b)

Taxation in the PRC has been provided for at the applicable rate on the estimated assessable profits less estimated available tax losses, if any, in each entity. Under the PRC Enterprise Income Tax Law (the "EIT Law"), the standard enterprise income tax rate is 25%. In addition, the EIT Law provides for, among others, a preferential tax rate of 15% for companies which qualify as HNTE. HMPL qualifies as a HNTE up to December 31, 2019. Pursuant to the EIT law, a 10% withholding tax is levied on dividends declared by PRC companies to their foreign investors. A lower withholding tax rate of 5% is applicable under the China-HK Tax Arrangement if direct foreign investors with at least 25% equity interest in the PRC companies are Hong Kong tax residents, and meet the conditions or requirements pursuant to the relevant PRC tax regulations regarding beneficial ownership. Since the equity holders of the major subsidiaries and equity investees of the Company are Hong Kong incorporated companies and Hong Kong tax residents, and meet the aforesaid conditions or requirements, the Company has used 5% to provide for deferred tax liabilities on retained earnings which are anticipated to be distributed. As at December 31, 2017 and 2016, the amounts accrued in deferred tax liabilities relating to withholding tax on dividends were determined on the basis that 100% of the distributable reserves of the major subsidiaries and equity investees operating in the PRC will be distributed as dividends.

 The reconciliation of the Group's reported income tax expense to the theoretical tax amount that would arise using the tax rates of the Company against the Group's loss before income taxes and equity in earnings of equity investees is as follows:



Year Ended December 31,

2017

2016

2015

(in US$'000)

Loss before income taxes and equity in earnings of equity investees

(53,536
)

(47,356
)

(10,540
)

Tax calculated at the statutory tax rate of the Company

(8,833
)

(7,814
)

(1,739
)

Tax effects of:

Different tax rates available in different jurisdictions

2,531

453

(2,953
)

Tax valuation allowance

11,410

9,886

6,601

Preferential tax deduction

(3,347
)

(3,205
)

(2,096
)

Expenses not deductible for tax purposes

391

688

253

Utilization of previously unrecognized tax losses

(387
)

(21
)

(34
)

Withholding tax on undistributed earnings of PRC entities

1,980

3,532

1,216

Others

(665
)

812

357

Income tax expense

3,080

4,331

1,605

(ii) Deferred tax assets and liabilities

 The significant components of deferred tax assets and liabilities are as follows:



December 31,

2017

2016

(in US$'000)

Deferred tax assets

Tax losses

31,028

20,145

Others

1,267

372

Total deferred tax assets

32,295

20,517

Less: Valuation allowance

(31,662
)

(20,145
)

Deferred tax assets

633

372

Deferred tax liabilities

Undistributed earnings from PRC entities

4,332

5,230

Others

120

131

Deferred tax liabilities

4,452

5,361

 As at December 31, 2017, all deferred tax assets and liabilities are classified as non-current after adopting ASU 2015-17. As at December 31, 2016, deferred tax assets and liabilities of US$372,000 and US$1,364,000 respectively were classified as current, with the remainder as non-current.

 The significant components of deferred tax assets and liabilities are as follows:



2017

2016

2015

(in US'000)

As at January 1

(4,989
)

(3,473
)

(2,842
)

Utilization of previously recognized withholding tax on undistributed earnings

3,179

1,526

321

(Charged)/Credited to the consolidated statements of operations

Withholding tax on undistributed earnings of PRC entities

(1,980
)

(3,532
)

(1,216
)

Deferred tax on amortization of intangible assets

18

32

24

Deferred tax on provision for assets

236

147

152

Exchange differences

(283
)

311

88

As at December 31

(3,819
)

(4,989
)

(3,473
)

 The deferred tax assets and liabilities are offset when there is a legally enforceable right to set off and when the deferred income taxes relate to the same fiscal authority.

 The tax losses can be carried forward against future taxable income and will expire in the following years:



December 31,

2017

2016

(in US$'000)

No expiry date

42,385

32,859

2017

—

3,651

2018

858

807

2019

4,261

4,012

2020

36,188

34,059

2021

50,494

53,194

2022

65,195

—

199,381

128,582

 The Company believes that it is more likely than not that future operations will not generate sufficient taxable income to realize the benefit of the deferred tax assets. The Company's subsidiaries have had sustained tax losses, which will expire within five years if not utilized in the case of PRC subsidiaries, and which will not be utilized in the case of Hong Kong subsidiaries as they do not generate taxable profits. Accordingly, a valuation allowance has been recorded against the relevant deferred tax assets arising from the tax losses.

 The table below summarizes changes in the deferred tax valuation allowance:



2017

2016

2015

(in US$'000)

As at January 1

20,145

11,393

7,455

Charged to consolidated statements of operations

11,410

9,886

6,601

Utilization of previously unrecognized tax losses

(387
)

(21
)

(34
)

Write-off of expired tax losses

(558
)

—

(1,493
)

Others

(89
)

(288
)

(901
)

Exchange differences

1,141

(825
)

(235
)

As at December 31

31,662

20,145

11,393

 The Group recognizes interest and penalties, if any, under income tax payable on its consolidated balance sheets and under other expenses in its consolidated statements of operations. As at December 31, 2017 and 2016, the Group did not have any material unrecognized uncertain tax positions.

(iii) Income tax payable



2017

2016

2015

(in US$'000)

As at January 1

274

442

112

Current tax

1,354

978

565

Withholding tax upon dividend declaration from PRC entities

3,179

1,526

321

Tax paid

(3,836
)

(2,664
)

(510
)

Exchange difference

8

(8
)

(46
)

As at December 31

979

274

442

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 70 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1

(Losses)/Earnings per Share
12 Months Ended

Dec. 31, 2017

(Losses)/Earnings per Share

(Losses)/Earnings per Share

24. (Losses)/Earnings per Share

(i) Basic (losses)/earnings per share

 Basic (losses)/earnings per share is calculated by dividing the net (loss)/income attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares in issue during the year. Treasury shares held by the Trustee are excluded from the weighted average number of outstanding ordinary shares in issue for purposes of calculating basic (losses)/earnings per share.



Year Ended December 31,



2017



2016



2015

Weighted average number of outstanding ordinary shares in issue

61,717,171

59,715,173

54,659,315

Net (loss)/income (US$'000)

(22,963
)

14,557

10,427

Net income attributable to non-controlling interests (US$'000)

(3,774
)

(2,859
)

(2,434
)

Accretion on redeemable non-controlling interests (US$'000)

—

—

(43,001
)

Net (loss)/income for the year attributable to ordinary shareholders of the Company (US$'000)

(26,737
)

11,698

(35,008
)

(Losses)/earnings per share attributable to ordinary shareholders of the Company (US$ per share)

(0.43
)

0.20

(0.64
)

(ii) Diluted (losses)/earnings per share

 Diluted (losses)/earnings per share is calculated by dividing net (loss)/income attributable to ordinary shareholders of the Company, by the weighted average number of ordinary and dilutive ordinary share equivalents outstanding during the year. Dilutive ordinary share equivalents include shares issuable upon the exercise or settlement of share-based awards issued by the Company and its subsidiaries using the treasury stock method.



Year Ended December 31,

2017

2016

2015

Weighted average number of outstanding ordinary shares in issue

61,717,171

59,715,173

54,659,315

Adjustment for share options and LTIP

—

255,877

—

61,717,171

59,971,050

54,659,315

Net (loss)/income for the year attributable to ordinary shareholders of the Company (US$'000)

(26,737
)

11,698

(35,008
)

(Losses)/earnings per share attributable to ordinary shareholders of the Company (US$ per share)

(0.43
)

0.20

(0.64
)

 For the years ended December 31, 2017 and 2015, the share options and LTIP awards issued by the Company as well as the preferred shares issued by HMHL were not included in the calculation of diluted losses per share because of their anti-dilutive effect.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 71 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1

Segment Reporting
12 Months Ended

Dec. 31, 2017

Segment Reporting

Segment Reporting

25. Segment Reporting

 The Group determines its operating segments from both business and geographic perspectives as follows:



(i)

Innovation Platform (Drug research and development ("Drug R&D")): focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases, and the provision of research and development services; and



(ii)

Commercial Platform: comprises of the manufacture, marketing and distribution of prescription and over-the-counter pharmaceuticals in the PRC as well as consumer health products through Hong Kong. The Commercial Platform is further segregated into two core business areas:





(a)

Prescription Drugs: comprises the development, manufacture, distribution, marketing and sale of prescription pharmaceuticals; and





(b)

Consumer Health: comprises the development, manufacture, distribution, marketing and sale of over-the-counter pharmaceuticals and consumer health products.

 Innovation Platform and Prescription Drugs businesses under the Commercial Platform are primarily located in the PRC. The locations for Consumer Health business under the Commercial Platform are further segregated into the PRC and Hong Kong.

 The performance of the reportable segments is assessed based on three measurements: (a) losses or earnings of subsidiaries before interest income, interest expense, income tax expenses and equity in earnings of equity investees, net of tax ("Adjusted (LBIT)/EBIT" or "Adjusted LBIT"), (b) equity in earnings of equity investees, net of tax and (c) operating (loss)/profit.

 The segment information is as follows:



Year ended December 31, 2017

Innovation
Platform

Commercial Platform

Drug
R&D

Prescription
Drugs

Consumer Health

PRC

PRC

PRC

Hong
Kong

Subtotal

Unallocated

Total

(in US$'000)

Revenue from external customers

35,997

166,435

9,858

28,913

205,206

—

241,203

Adjusted (LBIT)/EBIT

(47,503
)

3,272

578

3,029

6,879

(12,677
)

(53,301
)

Interest income

64

37

13

13

63

1,093

1,220

Equity in earnings of equity investees, net of tax

(4,547
)

27,812

10,388

—

38,200

—

33,653

Operating (loss)/profit

(51,986
)

31,121

10,979

3,042

45,142

(11,584
)

(18,428
)

Interest expense

—

—

—

66

66

1,389

1,455

Income tax expense

26

934

(457
)

509

986

2,068

3,080

Net (loss)/income attributable to ordinary shareholders of the Company

(51,880
)

28,999

9,773

1,261

40,033

(14,890
)

(26,737
)

Depreciation/amortization

2,400

116

17

18

151

27

2,578

Additions to non-current assets (other than financial instrument and deferred tax assets)

5,936

56

43

8

107

30

6,073



As at December 31, 2017

Innovation
Platform

Commercial Platform

Drug
R&D

Prescription
Drugs

Consumer Health

PRC

PRC

PRC

Hong
Kong

Subtotal

Unallocated

Total

(in US$'000)

Total assets

63,268

122,665

58,961

13,794

195,420

339,244

597,932

Property, plant and equipment

13,917

160

61

30

251

52

14,220

Leasehold land

1,261

—

—

—

—

—

1,261

Goodwill

—

2,901

407

—

3,308

—

3,308

Other intangible asset

—

430

—

—

430

—

430

Investments in equity investees

19,512

69,417

55,308

—

124,725

—

144,237



Year ended December 31, 2016

Innovation
Platform

Commercial Platform

Drug
R&D

Prescription
Drugs

Consumer Health

PRC

PRC

PRC

Hong
Kong

Subtotal

Unallocated

Total

(inUS$'000)

Revenue from external customers

35,228

149,861

6,984

24,007

180,852

—

216,080

Adjusted (LBIT)/EBIT

(36,657
)

2,377

(493
)

1,852

3,736

(13,306
)

(46,227
)

Interest income

52

31

34

1

66

384

502

Equity in earnings of equity investees, net of tax

(4,232
)

60,288

10,188

—

70,476

—

66,244

Operating (loss)/profit

(40,837
)

62,696

9,729

1,853

74,278

(12,922
)

20,519

Interest expense

—

—

—

79

79

1,552

1,631

Income tax expense

—

777

(497
)

289

569

3,762

4,331

Net (loss)/income attributable to ordinary shareholders of the Company

(40,735
)

61,120

8,384

833

70,337

(17,904
)

11,698

Depreciation/amortization

2,176

102

3

19

124

41

2,341

Additions to non-current assets (other than financial instrument and deferred tax assets)

4,138

67

20

51

138

51

4,327



As at December 31, 2016

Innovation
Platform

Commercial Platform

Drug
R&D

Prescription
Drugs

Consumer Health

PRC

PRC

PRC

Hong
Kong

Subtotal

Unallocated

Total

(in US$'000)

Total assets

53,774

134,681

67,161

10,701

212,543

76,120

342,437

Property, plant and equipment

9,686

145

34

40

219

49

9,954

Leasehold land

1,220

—

—

—

—

—

1,220

Goodwill

—

2,730

407

—

3,137

—

3,137

Other intangible asset

—

469

—

—

469

—

469

Investments in equity investees

17,031

77,939

63,536

—

141,475

—

158,506



Year ended December 31, 2015

Innovation
Platform

Commercial Platform

Drug
R&D

Prescription
Drugs

Consumer Health

PRC

PRC

PRC

Hong
Kong

Subtotal

Unallocated

Total

(in US$'000)

Revenue from external customers

52,016

105,478

3,028

17,681

126,187

—

178,203

Adjusted (LBIT)/EBIT

(119
)

676

(169
)

1,211

1,718

(11,186
)

(9,587
)

Interest income

79

114

29

1

144

228

451

Equity in earnings of equity investees, net of tax

(3,770
)

15,653

10,689

—

26,342

—

22,572

Operating (loss)/profit

(3,810
)

16,443

10,549

1,212

28,204

(10,958
)

13,436

Interest expense

—

—

—

85

85

1,319

1,404

Income tax expense

—

239

—

148

387

1,218

1,605

Net (loss)/income attributable to ordinary shareholders of the Company

(3,810
)

15,934

8,640

581

25,155

(13,352
)

7,993

Depreciation/amortization

1,864

94

11

5

110

41

2,015

Additions to non-current assets (other than financial instrument and deferred tax assets)

3,218

88

5

4

97

9

3,324

 Revenue from external customers is after elimination of inter-segment sales. The amount eliminated attributable to sales within Consumer Health business from Hong Kong to the PRC was US$2,536,000, US$1,306,000 and US$2,874,000 for the years ended December 31, 2017, 2016 and 2015 respectively. Sales between segments are carried out at mutually agreed terms.

 There were no customers who accounted for over 10% of the Group's revenue for the years ended December 31, 2017 and 2016. There was one customer under the Innovation Platform which accounted for 23% of the Group's revenue for the year ended December 31, 2015.

 Unallocated expenses mainly represent corporate expenses which include corporate employee benefit expenses and the relevant share-based compensation expenses. Unallocated assets mainly comprise cash and cash equivalents and short-term investments.

 A reconciliation of Adjusted LBIT to net (loss)/income is as follows:



Year Ended December 31,

2017

2016

2015

(in US$'000)

Adjusted LBIT

(53,301
)

(46,227
)

(9,587
)

Interest income

1,220

502

451

Equity in earnings of equity investees, net of tax

33,653

66,244

22,572

Interest expense

(1,455
)

(1,631
)

(1,404
)

Income tax expense

(3,080
)

(4,331
)

(1,605
)

Net (loss)/income

(22,963
)

14,557

10,427

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 72 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1

Note to Consolidated Statements of Cash Flows
12 Months Ended

Dec. 31, 2017

Note to Consolidated Statements of Cash Flows

Note to Consolidated Statements of Cash Flows

26. Note to Consolidated Statements of Cash Flows

 Reconciliation of net (loss)/income for the year to net cash used in operating activities:



Year Ended December 31,

2017



2016



2015

(in US$'000)

Net (loss)/income

(22,963
)

14,557

10,427

Adjustments to reconcile net (loss)/income to net cash used in operating activities

Amortization of finance costs

147

92

62

Depreciation and amortization

2,578

2,341

2,015

Loss on retirement of property, plant and equipment

57

30

60

Provision for excess and obsolete inventories

(16
)

163

4

Provision for doubtful accounts

242

(208
)

1,408

Share-based compensation expense—share options

1,316

1,780

1,151

Share-based compensation expense—LTIP

3,423

1,661

308

Equity in earnings of equity investees, net of tax

(33,653
)

(66,244
)

(22,572
)

Dividends received from equity investees

55,586

30,528

6,410

Unrealized currency translation (gain)/loss

(399
)

633

198

Changes in income tax balances

(756
)

1,667

1,093

Changes in working capital

Accounts receivable—third parties

2,160

(7,258
)

(12,030
)

Accounts receivable—related parties

363

(2,354
)

315

Other receivables, prepayments and deposits

(6,982
)

(1,129
)

(459
)

Amounts due from related parties

220

1,157

(3,010
)

Inventories

1,049

(3,430
)

(5,154
)

Long-term prepayment

123

361

(2,132
)

Accounts payable

(11,173
)

11,452

3,659

Other payables, accruals and advance receipts

5,194

7,554

4,660

Deferred revenue

(897
)

(1,668
)

(1,907
)

Other deferred income

(275
)

131

2,132

Amounts due to related parties

(4,287
)

(1,385
)

3,977

Total changes in working capital

(14,505
)

3,431

(9,949
)

Net cash used in operating activities

(8,943
)

(9,569
)

(9,385
)

X

- References
No definition available.
+ Details

Name: hcm_NoteToCondensedConsolidatedStatementsOfCashFlowsAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure pertaining to the reconciliation of net income/(loss) for the year to net cash (used in)/generated from operating activities.
+ References
No definition available.
+ Details

Name: hcm_ReconciliationOfNetIncomeLossToNetCashUsedInGeneratedFromOperatingActivitiesTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 73 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1

Litigation
12 Months Ended

Dec. 31, 2017

Litigation

Litigation

27. Litigation

 From time to time, the Group may become involved in litigation relating to claims arising from the ordinary course of business. The Group believes that there are currently no claims or actions pending against the Group, the ultimate disposition of which could have a material adverse effect on the Group's results of operations, financial position or cash flows. However, litigation is subject to inherent uncertainties and the Group's view of these matters may change in the future. When an unfavorable outcome occurs, there exists the possibility of a material adverse impact on the Group's financial position and results of operations for the periods in which the unfavorable outcome occurs, and potentially in future periods.

X

- References
No definition available.
+ Details

Name: hcm_LitigationAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure pertaining to the litigation.
+ References
No definition available.
+ Details

Name: hcm_LitigationTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 74 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1

Restricted Net Assets
12 Months Ended

Dec. 31, 2017

Restricted Net Assets

Restricted Net Assets

28. Restricted Net Assets

 Relevant PRC laws and regulations permit payments of dividends by the Company's subsidiaries in the PRC only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. In addition, the Company's subsidiaries in the PRC are required to make certain appropriations of net after-tax profits or increases in net assets to the statutory surplus fund prior to payment of any dividends. In addition, registered share capital and capital reserve accounts are also restricted from withdrawal in the PRC, up to the amount of net assets held in each subsidiary. As a result of these and other restrictions under PRC laws and regulations, the Company's subsidiaries in the PRC are restricted in their ability to transfer their net assets to the Group in terms of cash dividends, loans or advances, with restricted portions amounting to US$7,277,000 and US$6,847,000 as at December 31, 2017 and 2016 respectively, which excludes the Company's subsidiaries with a shareholders' deficit. Even though the Group currently does not require any such dividends, loans or advances from the PRC subsidiaries, for working capital and other funding purposes, the Group may in the future require additional cash resources from the Company's subsidiaries in the PRC due to changes in business conditions, to fund future acquisitions and development, or merely to declare and pay dividends to make distributions to shareholders.

 In addition, the Group has certain investments in equity investees in the PRC, where the Group's equity in undistributed earnings amounted to US$85,400,000 and US$116,953,000 as at December 31, 2017 and 2016 respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_OtherRestrictedAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.
+ References
No definition available.
+ Details

Name: us-gaap_RestrictedAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 75 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1

Subsequent Events
12 Months Ended

Dec. 31, 2017

Subsequent Events

Subsequent Events

29. Subsequent Events

 The Group evaluated subsequent events through March 12, 2018, which is the date when the consolidated financial statements were issued.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 76 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1

Summary of Significant Accounting Policies (Policies)
12 Months Ended

Dec. 31, 2017

Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation

Principles of Consolidation and Basis of Presentation

 The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Investments in equity investees over which the Group has significant influence are accounted for using the equity method. All inter-company balances and transactions have been eliminated in consolidation. The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America ("U.S. GAAP").

Use of Estimates

Use of Estimates

 The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as useful lives of property, plant and equipment, write-down of inventories, allowance for doubtful accounts, share-based compensation, impairments of long-lived assets, impairment of other intangible asset and goodwill, taxes on income, tax valuation allowances, revenues and cost accruals from research and development projects. Actual results could differ from those estimates.

Foreign Currency Translation

Foreign Currency Translation

 The Group's functional currency is Renminbi ("RMB") but the presentation currency is U.S. dollar ("US$"). The financial statements of the Company's subsidiaries with a functional currency other than the US$ have been translated into the Company's reporting currency, the US$. All assets and liabilities of the subsidiaries are translated using year-end exchange rates and revenues and expenses are translated at average exchange rates for the year. Translation adjustments are reflected in accumulated other comprehensive income/(loss) in shareholders' equity.

 Net foreign currency exchange losses of US$316,000, US$109,000 and US$79,000 were recorded in other expense in the consolidated statements of operations for the years ended December 31, 2017, 2016 and 2015 respectively.

Cash and Cash Equivalents

Cash and Cash Equivalents

 The Group considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. Cash and cash equivalents consist primarily of cash on hand and bank deposits and are stated at cost, which approximates fair value.

Short-term Investments

Short-term Investments

 Short-term investments include deposits placed with banks with original maturities of more than three months but less than one year.

Concentration of Credit Risk

Concentration of Credit Risk

 Financial instruments that potentially expose the Group to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, accounts receivable, other receivables and amounts due from related parties.

 The Group places substantially all of its cash and cash equivalents and short-term investments in major financial institutions, which management believes are of high credit quality. The Group has a practice to limit the amount of credit exposure to any particular financial institution.

 The Group has no significant concentration of credit risk. The Group has policies in place to ensure that sales are made to customers with an appropriate credit history and the Group performs periodic credit evaluations of its customers. Normally the Group does not require collateral from trade debtors.

Foreign Currency Risk

Foreign Currency Risk

 The Group's operating transactions and its assets and liabilities are mainly denominated in RMB, which is not freely convertible into foreign currencies. In the PRC, the Group's cash and cash equivalents denominated in RMB are subject to such government controls. The value of the RMB is subject to fluctuations from central government policy changes and international economic and political developments that affect the supply and demand of RMB in the foreign exchange market. In the PRC, certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange rates set by the People's Bank of China (the "PBOC"). Remittances in currencies other than RMB by the Group in the PRC must be processed through the PBOC or other PRC foreign exchange regulatory bodies which require certain supporting documentation in order to complete the remittance.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 The fair value of financial instruments that are measured at fair value is determined according to a fair value hierarchy that prioritizes the inputs and assumptions used, and the valuation techniques used. The three levels of the fair value hierarchy are described as follows:



Level 1

Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2

Inputs are quoted prices for similar assets or liabilities in active markets; or quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.

Level 3

Inputs are unobservable inputs based on the Group's assumptions and valuation techniques used to measure assets or liabilities at fair value. The inputs require significant management judgment or estimation.

 The assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of assets and liabilities and their placement within the fair value hierarchy levels.

 The fair value of assets and liabilities is established using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, and a fair value hierarchy is established based on the inputs used to measure fair value.

Accounts Receivable

Accounts Receivable

 Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable regularly to determine if any receivable will potentially be uncollectible. Estimates are used to determine the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value. The amount of the allowance for doubtful accounts is recognized in the consolidated statements of operations.

Inventories

Inventories

 Inventories are stated at the lower of cost or net realizable value. Cost is determined using the weighted average cost method. The cost of finished goods comprises raw materials, direct labor, other direct costs and related production overheads (based on normal operating capacity). Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. A provision for excess and obsolete inventory will be made based primarily on forecasts of product demand and production requirements. The excess balance determined by this analysis becomes the basis for excess inventory charge and the written-down value of the inventory becomes its cost. Written-down inventory is not written up if market conditions improve.

Property, Plant and Equipment

Property, Plant and Equipment

 Property, plant and equipment consist of buildings, leasehold improvements, plant and equipment, furniture and fixtures, other equipment and motor vehicles. Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets.



Buildings

20 years

Plant and equipment

5-10 years

Furniture and fixtures, other equipment and motor vehicles

4-5 years

Leasehold improvements

Shorter of (a) 5 years or (b) remaining term of lease

 Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations in the year of disposition. Additions and improvements that extend the useful life of an asset are capitalized. Repairs and maintenance costs are expensed as incurred.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 The Group evaluates the recoverability of long-lived assets in accordance with authoritative guidance on accounting for the impairment or disposal of long-lived assets. The Group evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. If such indicators exist, the first step of the impairment test is performed to assess if the carrying value of the net assets exceeds the undiscounted cash flows of the assets. If yes, the second step of the impairment test is performed in order to determine if the carrying value of the net assets exceeds the fair value. If yes, impairment is recognized for the excess.

Leasehold Land

Leasehold Land

 Leasehold land represents fees paid to acquire the right to use the land on which various plants and buildings are situated for a specified period of time from the date the respective right was granted and are stated at cost less accumulated amortization and impairment loss, if any. Amortization is computed using the straight-line basis over the lease period of 50 years.

Goodwill

Goodwill

 Goodwill represents the excess of the purchase price plus fair value of non-controlling interests over the fair value of identifiable assets and liabilities acquired. Goodwill is not amortized, but is tested for impairment at the reporting unit level on at least an annual basis or when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. When performing an evaluation of goodwill impairment, the Group has the option to first assess qualitative factors, such as significant events and changes to expectations and activities that may have occurred since the last impairment evaluation, to determine if it is more likely than not that goodwill might be impaired. If as a result of the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the quantitative fair value test is performed to determine if the fair value of the reporting unit exceeds its carrying value. No impairment of goodwill occurred in the years presented.

 The Group has adopted Accounting Standards Update ("ASU") 2017-04, Simplifying the Test for Goodwill Impairment, for annual goodwill impairment tests performed on testing dates after January 1, 2017. This guidance removes Step 2 of the goodwill impairment test, which required the estimation of an implied fair value of goodwill in the same manner as the calculation of goodwill upon a business combination. For prior years' annual goodwill impairment tests, the Group determined that the fair values of their reporting units exceeded their carrying values and Step 2 has never been required.

Other Intangible Assets

Other Intangible Assets

 Other intangible assets with finite useful lives are carried at cost less accumulated amortization and impairment loss, if any. Amortization is computed using the straight-line basis over the estimated useful lives of the assets.

Borrowings

Borrowings

 Borrowings are recognized initially at fair value, net of debt issuance costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations over the period of the borrowings using the effective interest method.

Ordinary Shares

Ordinary Shares

 The Company's ordinary shares are stated at par value of US$1.00 per ordinary share. The difference between the consideration received, net of issuance cost, and the par value is recorded in additional paid-in capital.

Treasury Shares

Treasury Shares

 The Group accounts for treasury shares under the cost method. The treasury shares were purchased for the purpose of the LTIP.

Convertible Preferred Shares

Convertible Preferred Shares

 When the Company or its subsidiaries issue preferred shares, the Group assesses whether such instruments should be liabilities, mezzanine equity, or permanent equity classified based on multiple indicators such as redemption features, conversion features, voting rights and other embedded features. Freestanding equity instruments with mandatory redemption requirements, embodying an obligation to repurchase the issuer's equity shares by transferring assets, or certain obligations to issue a variable number of shares, are treated as liability-classified instruments. Equity instruments that are redeemable at the option of the holder or not solely within the Group's control are classified as mezzanine equity of the issuer entity (and redeemable non-controlling interests in the consolidated financial statements of the Group if preferred shares are issued by its subsidiaries). Subsequent measurements of financing instruments are driven by the instruments' balance sheet classification.

 The Group also reviews the terms of each convertible instrument and determines whether the host instrument is more akin to debt or equity based on the economic characteristics and risks in order to evaluate if there were any embedded features which would require bifurcation and separate accounting from the host contract. For embedded conversion features that are not required to be separated, the Group analyzes the accounting conversion price and the Company's share price at the commitment date to identify any beneficial conversion features.

 For any amendment to the terms of the preferred shares not classified as liabilities, the Group assesses whether the amendment is an extinguishment or a modification using the fair value model. The Group considers a significant change in fair value immediately after the amendment to be substantive and to trigger extinguishment. A change in fair value which is not significant immediately after the amendment is considered non-substantive and thus is subject to modification accounting. When preferred shares are extinguished, the difference between the fair value of the consideration transferred to the preferred shareholders and the carrying amount of such preferred shares (net of issuance costs) is treated as a deemed dividend to the preferred shareholders. When preferred shares are modified and such modification results in a value transfer between preferred shareholders and ordinary shareholders, the change in fair value resulting from the amendment is treated as a deemed dividend to or from the preferred shareholders.

Share-Based Compensation

Share-Based Compensation

Share options

 The Group recognizes share-based compensation expense on share options granted to employees and directors based on their estimated grant date fair value using the Polynomial model. This Polynomial pricing model uses various inputs to measure fair value, including estimated market value of the Company's underlying ordinary shares at the grant date, contractual terms, estimated volatility, risk-free interest rates and expected dividend yields. The Group recognizes share-based compensation expense in the consolidated statements of operations on a graded vesting basis over the requisite service period.

 The Group has adopted ASU 2016-09, Improvements to Employee Share-Based Payment Accounting on January 1, 2017. This guidance permitted the Group to make an accounting policy election to account for forfeitures as they occur. The Group has elected to account for forfeitures as they occur and adopted this election using the modified retrospective approach as required with no cumulative effect adjustment. Prior to January 1, 2017, the Group applied an estimated forfeiture rate derived from historical and expected future employee termination behavior.

 Share options are classified as equity-settled awards. Share-based compensation expense, when recognized, is charged to the consolidated statements of operations with the corresponding entry to additional paid-in capital.

LTIP

 The Group recognizes the share-based compensation expense on the LTIP awards based on a fixed or determinable monetary amount on a straight line basis for each annual tranche awarded over the requisite period. For LTIP awards with performance targets, prior to their determination date, the amount of LTIP awards that is expected to vest takes into consideration the achievement of the performance conditions and the extent to which the performance conditions are likely to be met. Performance conditions vary by awards, including targets for shareholder returns, free cash flows, revenues, net profit after taxes and/or the achievement of clinical and regulatory milestones.

 These LTIP awards are classified as liability-settled awards before the determination date (i.e. the date when the achievement of any performance conditions are known), as they settle in a variable number of shares based on a determinable monetary amount, which is determined upon the actual achievement of performance targets. As the extent of achievement of the performance targets is uncertain prior to the determination date, a probability based on management's assessment of the achievement of the performance targets has been assigned to calculate the amount to be recognized as an expense over the requisite period.

 After the determination date or if the LTIP awards have no performance conditions, the LTIP awards are classified as equity-settled awards. If the performance target is achieved, the Group will pay the determined monetary amount to a trustee appointed by the Group (the "Trustee") to purchase ordinary shares of the Company or the equivalent ADS. Any cumulative compensation expense previously recognized as a liability will be transferred to additional paid in capital, as an equity-settled award. If the performance target is not achieved, no ordinary shares or ADS of the Company will be purchased and the amount previously recorded in the liability will be reversed and included in the consolidated statements of operations.

Defined Contribution Plans

Defined Contribution Plans

 The Group's subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which certain retirement, medical and other welfare benefits are provided to employees. The relevant labor regulations require the Group's subsidiaries in the PRC to pay the local labor and social welfare authority's monthly contributions at a stated contribution rate based on the monthly basic compensation of qualified employees. The relevant local labor and social welfare authorities are responsible for meeting all retirement benefits obligations and the Group's subsidiaries in the PRC have no further commitments beyond their monthly contributions. The contributions to the plan are expensed as incurred.

 The Group also makes payments to other defined contribution plans for the benefit of employees employed by subsidiaries outside the PRC. The defined contribution plans are generally funded by the relevant companies and by payments from employees.

 The Group's contributions to defined contribution plans for the years ended December 31, 2017, 2016 and 2015 amounted to US$2,092,000, US$2,286,000 and US$1,653,000 respectively.

Revenue Recognition-Accounting Standard Codification 605

Revenue Recognition—Accounting Standard Codification 605

Sales

 Revenue from sales of goods in the Commercial Platform segment are recognized when goods are delivered and title passes to the customer and there are no further obligations to the customer. Recognition of revenue also requires reasonable assurance of collection of sales proceeds and completion of all performance obligations. Sales discounts are issued to customers as direct discounts at the point-of-sale or indirectly in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns.

 Revenue from sales of services in the Commercial Platform segment are recognized based on amounts that can be invoiced to the customer. The amount that can be invoiced corresponds directly with the value to the customer for performance completed to date.

Revenues from research and development projects

 The Group recognizes revenue for the performance of services when each of the following four criteria are met: (i) persuasive evidence of an arrangement exists; (ii) services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured.

 The Group follows Accounting Standard Codification ("ASC") 605-25, Revenue Recognition—Multiple-Element Arrangements and ASC 808, Collaborative Arrangements, if applicable, to determine the recognition of revenue under the Group's license and collaborative research, development and commercialization agreements. The terms of these agreements generally contain multiple elements, or deliverables, which may include (i) licenses to the Group's intellectual property, (ii) materials and technology, (iii) clinical supply, and/or (iv) participation in joint research or joint steering committees. The payments the Group may receive under these arrangements typically include one or more of the following: non-refundable, upfront license fees; funding of research and/or development efforts; amounts due upon the achievement of specified milestones; and/or royalties on future product sales.

 ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable.

 To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The Group determines the estimated selling price for deliverables within each agreement using vendor-specific objective evidence ("VSOE") of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the Group's best estimate of selling price, if neither VSOE nor third-party evidence is available. Determining the best estimate of selling price for a deliverable requires significant judgment. The Group typically uses its best estimate of a selling price to estimate the selling price for licenses to development work, since it often does not have VSOE or third-party evidence of selling price for these deliverables. In those circumstances where the Group applies its best estimate of selling price to determine the estimated selling price of a license to development work, it considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements as well as internally developed estimates that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating its best estimate of selling price, the Group evaluates whether changes in the key assumptions used to determine its best estimate of selling price will have a significant effect on the allocation of arrangement consideration between deliverables. The Group recognizes consideration allocated to an individual element when all other revenue recognition criteria are met for that element.

 The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria.

 If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as unearned revenue in the accompanying balance sheets and recognized as revenue when the related revenue recognition criteria are met.

 The Group typically receives non-refundable, upfront payments when licensing the Group's intellectual property, which often occurs in conjunction with a research and development agreement. If management believes that the license to the Group's intellectual property has stand-alone value, the Group generally recognizes revenue attributed to the license upon delivery provided that there are no future performance requirements for use of the license. When management believes that the license to the Group's intellectual property does not have stand-alone value, the Group will recognize revenue attributed to the license ratably over the contractual or estimated performance period. For payments payable on achievement of milestones that do not meet all of the conditions to be considered substantive, the Group recognizes a portion of the payment as revenue when the specific milestone is achieved, and the contingency is removed. Other contingent event-based payments for which payment is either contingent solely upon the passage of time or the result of a collaborator's performance are recognized when earned. The Group's collaboration and license agreements generally include contingent milestone payments related to specified pre-clinical research and development milestones, clinical development milestones, regulatory milestones and sales-based milestones. Pre-clinical research and development milestones are typically payable upon the selection of a compound candidate for the next stage of research and development. Clinical development milestones are typically payable when a product candidate initiates or advances in clinical trial phases or achieves defined clinical events such as proof-of-concept. Regulatory milestones are typically payable upon submission for marketing approval with regulatory authorities or upon receipt of actual marketing approvals for a compound, approvals for additional indications, or upon the first commercial sale. Sales-based milestones are typically payable when annual sales reach specified levels.

 At the inception of each arrangement that includes milestone payments, the Group evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (i) the entity's performance to achieve the milestone or (ii) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone; (b) the consideration relates solely to past performance; and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Group evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.

Research and Development Expenses

Research and Development Expenses

 Research and development expenses consist primarily of salaries and benefits, share-based compensation, materials and supplies, contracted research, consulting arrangements and other expenses incurred to sustain the Group's research and development programs. Research and development costs are expensed as incurred.

Government Incentives

Government Incentives

 Incentives from governments are recognized at their fair values. Government incentives that are received in advance are deferred and recognized in the consolidated statements of operations over the period necessary to match them with the costs that they are intended to compensate. Government incentives in relation to the achievement of stages of research and development projects are recognized in the consolidated statements of operations when amounts have been received and all attached conditions have been met. Non-refundable incentives received without any further obligations or conditions attached are recognized immediately in the consolidated statements of operations.

Operating Leases

Operating Leases

 Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to the consolidated statements of operations on a straight-line basis over the period of the leases.

 Total operating lease rentals for buildings for the years ended December 31, 2017, 2016 and 2015 amounted to US$2,285,000, US$1,838,000 and US$1,426,000 respectively. Sub-lease rentals for the years ended December 31, 2017, 2016 and 2015 amounted to US$274,000, US$228,000 and US$229,000 respectively.

Interest Income

Interest Income

 Interest generated from cash and cash equivalents and short-term investments is recorded over the period earned. It is measured based on the actual amount of interest the Group earns.

Income Taxes

Income Taxes

 The Group accounts for income taxes under the liability method. Under the liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some of the net deferred income tax asset will not be realized.

 The Group accounts for an uncertain tax position in the consolidated financial statements only if it is more likely than not that the position is sustainable based on its technical merits and consideration of the relevant tax authority's widely understood administrative practices and precedents. If the recognition threshold is met, the Group records the largest amount of tax benefit that is greater than 50 percent likely to be realized upon ultimate settlement.

Comprehensive (Loss)/Income

Comprehensive (Loss)/Income

 Comprehensive (loss)/income is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances from non-owner sources, and currently consists of net (loss)/income and foreign currency translation gain/(loss) related to the Company's subsidiaries.

(Losses)/Earnings per Share

(Losses)/Earnings per Share

 Basic (losses)/earnings per share is computed by dividing net (loss)/income attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year. Weighted average number of ordinary shares outstanding during the period excludes treasury shares. In addition, periodic accretion on preferred shares of Hutchison MediPharma Holdings Limited ("HMHL") (Note 16) is recorded as a deduction to consolidated net (loss)/income to arrive at net (loss)/income attributable to ordinary shareholders of the Company for purposes of calculating the consolidated basic (losses)/earnings per share.

 Diluted (losses)/earnings per share is computed by dividing net (loss)/income attributable to ordinary shareholders by the weighted average number of ordinary shares and dilutive ordinary share equivalents outstanding during the period. Dilutive ordinary share equivalents include ordinary shares and treasury shares issuable upon the exercise or settlement of share-based awards issued by the Company using the treasury stock method. In determining the impact from share-based awards and convertible preferred shares issued by HMHL, the Company first calculates the diluted earnings per share at HMHL and includes in the numerator of consolidated (losses)/earnings per share the amount based on the diluted earnings per share of HMHL multiplied by the number of shares owned by the Company. The computation of diluted (losses)/earnings per share does not assume conversion, exercise, or contingent issuance of securities that would have an anti-dilutive effect.

Segment Reporting

Segment Reporting

 Operating segments are reported in a manner consistent with the internal reporting provided to the chief executive officer who is the Group's chief operating decision maker. The chief operating decision maker reviews the Group's internal reporting in order to assess performance and allocate resources and determined that the Group's reportable segments are as disclosed in Note 25.

Discontinued Operations

Discontinued Operations

 A discontinued operation is a component of the Group's business, the operations and cash flows of which can be clearly distinguished from the rest of the Group and which represents a separate major line of business or geographic area of operations, or is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations, or is a subsidiary acquired exclusively with a view to resale. When an operation is classified as discontinued, a single amount is presented in the statements of operations, which comprises the post tax profit or loss of the discontinued operation.

Profit Appropriation and Statutory Reserves

Profit Appropriation and Statutory Reserves

 The Group's subsidiaries and equity investees established in the PRC are required to make appropriations to certain non-distributable reserve funds.

 In accordance with the laws applicable to the Foreign Investment Enterprises established in the PRC, the Group's subsidiaries and equity investees registered as wholly-owned foreign enterprise have to make appropriations from its after-tax profit (as determined under generally accepted accounting principles in the PRC ("PRC GAAP") to reserve funds including general reserve fund, the enterprise expansion fund and staff bonus and welfare fund. The appropriation to the general reserve fund must be at least 10% of the after-tax profits calculated in accordance with PRC GAAP. Appropriation is not required if the general reserve fund has reached 50% of the registered capital of the company. Appropriation to the enterprise expansion fund and staff bonus and welfare fund is made at the company's discretion.

 The use of the general reserve fund, enterprise expansion fund, statutory surplus reserve and discretionary surplus fund are restricted to the offsetting of losses or increases the registered capital of the respective company. The staff bonus and welfare fund is a liability in nature and is restricted to fund payments of special bonus to employees and for the collective welfare of employees. All these reserves are not allowed to be transferred to the company in terms of cash dividends, loans or advances, nor can they be distributed except under liquidation.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"), to clarify the principles of recognizing revenue and create common revenue recognition guidance for U.S. GAAP and International Financial Reporting Standards. An entity has the option to apply the provisions of ASU 2014-09 either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this standard recognized at the date of initial application. ASU 2014-09 is effective for fiscal years and interim periods within those years beginning after December 15, 2017, and early adoption is permitted but not earlier than the original effective date of December 15, 2016. The new standard supersedes U.S. GAAP guidance on revenue recognition and requires the use of more estimates, judgements and additional disclosures.

 The Group will adopt the new standard using the modified retrospective method on January 1, 2018 and has assessed the impact on revenue from customers. The Group's revenue from contracts with customers comprises of research and development projects in its Innovation Platform and sales of goods and services in its Commercial Platform operating segments. The Group expects the changes from applying the new guidance will primarily impact the Innovation Platform.

 Innovation Platform—The Group has reviewed its research and development contracts and identified two contracts related to the Group's license and collaboration arrangements that will be impacted by the application of ASU 2014-09. The license and collaboration arrangements contain multiple performance obligations: (1) the license to the drug compound and (2) the research and development services for each specified treatment indication. The transaction price includes fixed and variable consideration in the form of upfront payment, research and development costs reimbursements, contingent milestone payments and sales-based royalties. The allocation of the transaction price to each performance obligation is based on the relative standalone selling price of each performance obligation. The Group has determined that control of the license to the drug compound was transferred as of the inception date of the collaboration agreements and consequently, amounts allocated to this performance obligation are recognized at a point in time. Conversely, control of the research and development services for each specified indication is transferred over time and amounts allocated to these performance obligations are recognized over time using cost inputs as a measure of progress. In addition, royalty revenues will be recognized as future sales occur as they meet the requirements for the sales-usage based royalty exception. The Group expects US$1.1 million deferral of revenue as a cumulative adjustment to opening accumulated loss upon adoption.

 Commercial Platform—For sales of goods and services, the Group has applied a portfolio approach to aggregate contracts into portfolios whose performance obligations do not differ materially from each other. In its assessment of each portfolio, the Group has assessed the contracts under the new five-step model and does not expect a significant impact to the timing or amount of revenue recognition under the new guidance. Control of the goods passes to the customer when the goods are delivered, which matches the timing of revenue recognition under the Group's existing accounting policy.

 The Group has applied updates to the new guidance in its assessment including ASU 2016-08, Principal versus Agent Considerations, ASU 2016-10, Identifying Performance Obligations and Licensing.

 In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). The core principle of ASU 2016-02 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018. The Group expects to adopt the new standard using the modified retrospective method on January 1, 2019 with a retrospective adjustment to comparable periods presented starting from January 1, 2017. The Group is currently determining the potential impact ASU 2016-02 will have on the Group's consolidated financial statements.

 In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business ("ASU 2017-01"), which revises the definition of a business. To be considered a business, an acquisition would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. To be a business without outputs, there will now need to be an organized workforce. ASU 2017-01 is effective for fiscal years and interim periods within those years beginning after December 15, 2018. The Group currently does not expect ASU 2017-01 to have a material impact on the Group's consolidated financial statements, but will apply the guidance upon adoption to business acquisitions, disposals and segment changes, if any.

 In May 2017, the FASB issued ASU 2017-09, Scope of Modification Accounting (Topic 718) ("ASU 2017-09"), which provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under share-based payment accounting. The guidance clarifies that no new measurement date will be required if there is no change to the fair value, vesting conditions, and classification, and in effect simplifies the accounting for non-substantive changes to share-based payment awards. ASU 2017-09 is effective for fiscal years and interim periods within those years beginning after December 15, 2017. The Group shall apply the guidance upon adoption to share-based payment modifications, if any.

 Other amendments that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Group's consolidated financial statements upon adoption.

X

- Definition
Disclosure of accounting policy for convertible preferred shares.
+ References
No definition available.
+ Details

Name: hcm_ConvertiblePreferredSharesPolicyTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for defined contribution plans.
+ References
No definition available.
+ Details

Name: hcm_DefinedContributionPlansPolicyTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy relating to foreign currency risk.
+ References
No definition available.
+ Details

Name: hcm_ForeignCurrencyRiskPolicyTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for government incentives.
+ References
No definition available.
+ Details

Name: hcm_GovernmentIncentivesPolicyTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for interest income.
+ References
No definition available.
+ Details

Name: hcm_InterestIncomePolicyTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for leasehold land.
+ References
No definition available.
+ Details

Name: hcm_LeaseholdLandPolicyTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for ordinary shares.
+ References
No definition available.
+ Details

Name: hcm_OrdinarySharesPolicyTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for profit appropriation and statutory reserves.
+ References
No definition available.
+ Details

Name: hcm_ProfitAppropriationAndStatutoryReservesPolicyTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for short term investments with maturities between three months and one year and investments in money market funds or other investments whereby the Company has the intention to redeem within one year.
+ References
No definition available.
+ Details

Name: hcm_ShortTermInvestmentsPolicyTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for treasury shares.
+ References
No definition available.
+ Details

Name: hcm_TreasurySharesPolicyTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 55
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68064133&loc=d3e61082-112788

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68064133&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790
+ Details

Name: us-gaap_DebtPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section S99
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_DiscontinuedOperationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64802544&loc=d3e202-110218
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e32280-109318
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6453394&loc=d3e39740-112701

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65670824&loc=d3e14754-158437

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 40
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6456037&loc=d3e48589-112741

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737
+ Details

Name: us-gaap_LeasePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65890831&loc=d3e10133-111534

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66008989&loc=d3e4975-111524
+ Details

Name: us-gaap_ReceivablesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Research and Development
-URI http://asc.fasb.org/extlink&oid=6523717
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.B.Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790
+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6132-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 77 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1

Particulars of Principal Subsidiaries and Equity Investees (Tables)
12 Months Ended

Dec. 31, 2017

Particulars of Principal Subsidiaries and Equity Investees

Schedule of particulars of principal subsidiaries and equity investees



Equity interest
attributable to
the Group

As at
December 31,

Place of
establishment
and operations

Name

2017

2016

Principal activities

Subsidiaries

Hutchison MediPharma Limited ("HMPL")

PRC

99.75%

99.75%

Research and development of pharmaceutical products

Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm")

PRC

51%

51%

Provision of sales, distribution and marketing services to pharmaceutical manufacturers

Hutchison Hain Organic (Hong Kong) Limited ("HHOL") (note (a))

Hong Kong

50%

50%

Wholesale and trading of healthcare and consumer products

Hutchison Hain Organic (Guangzhou) Limited ("HHOGZL") (note (a))

PRC

50%

50%

Wholesale and trading of healthcare and consumer products

Hutchison Healthcare Limited ("HHL")

PRC

100%

100%

Manufacture and distribution of healthcare products

Hutchison Consumer Products Limited

Hong Kong

100%

100%

Wholesale and trading of healthcare and consumer products

Equity investees

Shanghai Hutchison Pharmaceuticals Limited ("SHPL")

PRC

50%

50%

Manufacture and distribution of prescription drug products

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS") (note (b))

PRC

40%

40%

Manufacture and distribution of over-the-counter drug products

Nutrition Science Partners Limited ("NSPL") (note (c))

Hong Kong

49.88%

49.88%

Research and development of pharmaceutical products

Notes:

(a)

HHOL and HHOGZL are regarded as subsidiaries of the Company, as while both shareholders of these subsidiaries have equal representation at their respective boards, in the event of a deadlock, the Group has a casting vote and is therefore able to unilaterally control the financial and operating policies of HHOL and HHOGZL.

(b)

The 50% equity interest in HBYS is held by an 80% owned subsidiary of the Group. The effective equity interest of the Group in HBYS is therefore 40% for the years presented.

(c)

The 50% equity interest in NSPL is held by a 99.75% owned subsidiary of the Group. The effective equity interest of the Group in NSPL is therefore 49.88% for the years presented.

X

- Definition
n/a
+ References
No definition available.
+ Details

Name: hcm_ParticularsOfPrincipalSubsidiariesAndEquityInvesteesAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of Particulars of principal subsidiaries and equity investees.
+ References
No definition available.
+ Details

Name: hcm_ParticularsOfPrincipalSubsidiariesAndEquityInvesteesTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 78 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1

Summary of significant accounting policies (Tables)
12 Months Ended

Dec. 31, 2017

Summary of Significant Accounting Policies

Schedule of estimated useful lives of property, plant, and equipment



Buildings

20 years

Plant and equipment

5-10 years

Furniture and fixtures, other equipment and motor vehicles

4-5 years

Leasehold improvements

Shorter of (a) 5 years or (b) remaining term of lease

X

- Definition
Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
No definition available.
+ Details

Name: hcm_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 79 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1

Fair Value Disclosures (Tables)
12 Months Ended

Dec. 31, 2017

Fair Value Disclosures

Schedule of financial instruments by level within the fair value hierarchy



Fair Value Measurement Using

Level 1

Level 2

Level 3

Total

(in US$'000)

As at December 31, 2017

Cash and cash equivalents

85,265

—

—

85,265

Short-term investments

273,031

—

—

273,031

As at December 31, 2016

Cash and cash equivalents

79,431

—

—

79,431

Short-term investments

24,270

—

—

24,270

X

- Definition
Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13476-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13467-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611
+ Details

Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 80 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1

Cash and Cash Equivalents (Tables)
12 Months Ended

Dec. 31, 2017

Cash and Cash Equivalents

Schedule of cash and cash equivalents



December 31,

2017

2016

(in US$'000)

Cash at bank and on hand

30,018

31,218

Bank deposits maturing in three months or less (note (a))

55,247

48,213

85,265

79,431

Denominated in:

US$(note (b))

66,381

65,509

RMB (note (b))

15,140

9,505

UK Pound Sterling ("£") (note (b))

295

408

Hong Kong dollar ("HK$")

3,449

4,009

85,265

79,431

Notes:

(a)

The weighted average effective interest rate on bank deposits for the years ended December 31, 2017 and 2016 was 1.06% and 0.58% per annum respectively (with maturity ranging from 7 to 90 days).

(b)

Certain cash and bank balances denominated in RMB, US$ and £ were deposited with banks in the PRC. The conversion of these RMB, US$ and £ denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the PRC government.

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of cash and cash equivalents.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 81 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1

Short-term investments (Tables)
12 Months Ended

Dec. 31, 2017

Short-term Investments

Schedule of short term investments



December 31,

2017

2016

(in US$'000)

Bank deposits maturing over three months (note)

Denominated in:

US$

272,659

24,270

HK$

372

—

273,031

24,270

Note:

The weighted average effective interest rate on bank deposits for the years ended December 31, 2017 and 2016 was 1.32% and 0.71% per annum respectively (with maturity ranging from 91 to 183 days, and 91 to 186 days respectively).

X

- Definition
A table of investments, shown as a text block.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 6
-Section 10
-Paragraph (c)
-Subparagraph (1)
+ Details

Name: invest_InvestmentTableTextBlock

Namespace Prefix: invest_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShortTermInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 82 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1

Accounts Receivable-Third Parties (Tables)
12 Months Ended

Dec. 31, 2017

Accounts Receivable-Third Parties

Schedule of accounts receivable



December 31,

2017

2016

(in US$'000)

Accounts receivable, gross

38,668

43,532

Allowance for doubtful accounts

(258
)

(2,720
)

Accounts receivable, net

38,410

40,812

Schedule of movement on the allowance for doubtful accounts



2017

2016

2015

(in US$'000)

As at January 1

2,720

3,127

1,793

Increase in allowance for doubtful accounts

242

29

1,408

Decrease in allowance due to subsequent collection

—

(237
)

—

Write-off

(2,874
)

—

—

Exchange difference

170

(199
)

(74
)

As at December 31

258

2,720

3,127

X

- Definition
Tabular disclosure of the activity by class in allowance for doubtful accounts - including but not limited to beginning and ending balances, aggregate additions charged and recoveries credited to operations, and aggregate write-downs charged against allowance.
+ References
No definition available.
+ Details

Name: hcm_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3,4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 83 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1

Other Receivables, Prepayments and Deposits (Tables)
12 Months Ended

Dec. 31, 2017

Other Receivables, Prepayments and Deposits

Schedule of other receivables, prepayments and deposits



December 31,

2017

2016

(in US$'000)

Prepayments

2,565

699

Purchase rebates

284

238

Other service receivables

490

756

Deposits

932

620

Value-added tax receivables

5,436

1,380

Interest receivables

506

63

Others

1,083

558

11,296

4,314

X

- Definition
NA.
+ References
No definition available.
+ Details

Name: hcm_OtherReceivablePrepaymentsAndDepositsAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amounts of Other receivable, prepayments and deposits.
+ References
No definition available.
+ Details

Name: hcm_ScheduleOfOtherReceivablesPrepaymentsAndDepositsTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 84 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1

Inventories (Tables)
12 Months Ended

Dec. 31, 2017

Inventories

Schedule of inventories, net of provision for excess and obsolete inventories



December 31,

2017

2016

(in US$'000)

Raw materials

314

660

Finished goods

11,475

12,162

11,789

12,822

Schedule of movement on the provision for excess and obsolete inventories



2017

2016

2015

(in US$'000)

As at January 1

160

25

34

Increase in provision for excess and obsolete inventories

128

163

37

Decrease in provision due to subsequent sale or recovery

(144
)

—

(33
)

Write-off

(32
)

(23
)

(12
)

Exchange difference

9

(5
)

(1
)

As at December 31

121

160

25

X

- Definition
Tabular disclosure of the movement during the period with regard to provision for the excess and obsolete inventories.
+ References
No definition available.
+ Details

Name: hcm_ScheduleOfMovementOnProvisionForExcessAndObsoleteInventoriesTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 85 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1

Property, Plant and Equipment (Tables)
12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment

Schedule of plant, property and equipment



Buildings

Leasehold
improvements

Plant
and
equipment

Furniture
and
fixtures,
other
equipment
and motor
vehicles

Construction
in progress

Total

(in US$'000)

Cost

As at January 1, 2017

2,232

6,296

86

13,976

1,760

24,350

Additions

—

301

155

1,374

4,243

6,073

Disposals

—

—

—

(394
)

—

(394
)

Transfers

—

2,050

2,321

(722
)

(3,649
)

—

Exchange differences

140

410

6

920

204

1,680

As at December 31, 2017

2,372

9,057

2,568

15,154

2,558

31,709

Accumulated depreciation

As at January 1, 2017

971

4,249

71

9,105

—

14,396

Depreciation

105

763

169

1,441

—

2,478

Disposals

—

—

—

(337
)

—

(337
)

Transfers

—

—

255

(255
)

—

—

Exchange differences

65

284

4

599

—

952

As at December 31, 2017

1,141

5,296

499

10,553

—

17,489

Net book value

As at December 31, 2017

1,231

3,761

2,069

4,601

2,558

14,220



Buildings

Leasehold
improvements

Plant
and
equipment

Furniture
and
fixtures,
other
equipment
and motor
vehicles

Construction
in progress

Total

(in US$'000)

Cost

As at January 1, 2016

2,392

5,989

88

12,806

567

21,842

Additions

—

742

—

1,453

2,132

4,327

Disposals

—

(12
)

—

(248
)

—

(260
)

Transfers

—

—

—

886

(886
)

—

Exchange differences

(160
)

(423
)

(2
)

(921
)

(53
)

(1,559
)

As at December 31, 2016

2,232

6,296

86

13,976

1,760

24,350

Accumulated depreciation

As at January 1, 2016

932

3,549

70

8,784

—

13,335

Depreciation

106

977

3

1,153

—

2,239

Disposals

—

(12
)

—

(218
)

—

(230
)

Exchange differences

(67
)

(265
)

(2
)

(614
)

—

(948
)

As at December 31, 2016

971

4,249

71

9,105

—

14,396

Net book value

As at December 31, 2016

1,261

2,047

15

4,871

1,760

9,954

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 86 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1

Investments in equity investees (Tables)
12 Months Ended

Dec. 31, 2017

Investments in Equity Investees

Schedule of composition of equity investees



December 31,

2017

2016

(in US$'000)

HBYS

55,308

63,536

SHPL

69,417

77,939

NSPL

19,201

16,806

Other

311

225

144,237

158,506

Summarized balance sheet information for significant equity investees



Commercial Platform

Innovation
Platform

Consumer Health
HBYS

Prescription Drugs
SHPL

Drug R&D
NSPL

December 31,

December 31,

December 31,

2017

2016

2017

2016

2017

2016

(in US$'000)

Current assets

101,570

123,181

129,535

146,350

9,640

5,393

Non-current assets

107,226

98,554

103,477

97,656

30,000

30,000

Current liabilities

(75,787
)

(70,218
)

(91,665
)

(86,946
)

(1,239
)

(1,782
)

Non-current liabilities

(18,748
)

(18,148
)

(8,616
)

(6,926
)

—

—

Net assets

114,261

133,369

132,731

150,134

38,401

33,611

Non-controlling interests

(3,645
)

(6,297
)

—

—

—

—

110,616

127,072

132,731

150,134

38,401

33,611

Summarized statements of operations information for significant equity investees



Commercial Platform

Innovation Platform

Consumer Health
HBYS

Prescription Drugs
SHPL

Drug R&D(note (a))
NSPL

Year Ended December 31,

Year Ended December 31,

Year Ended December 31,

2017

2016

2015

2017

2016

2015

2017

2016

2015

(in US$'000)

Revenue

227,422

224,131

211,603

244,557

222,368

181,140

—

—

—

Gross profit

91,458

89,355

91,461

175,965

158,131

127,608

—

—

—

Depreciation and amortization

(4,985
)

(2,958
)

(3,274
)

(6,942
)

(3,526
)

(2,765
)

—

—

—

Interest income

220

238

628

757

565

306

—

—

—

Finance cost

(117
)

(123
)

(158
)

—

—

—

—

—

—

Profit/(loss) before taxation

24,434

23,759

25,164

66,497

148,144

37,401

(9,210
)

(8,482
)

(7,552
)

Income tax expense (note (b))

(3,629
)

(3,631
)

(3,948
)

(10,874
)

(27,645
)

(6,094
)

—

—

—

Net income/(loss)

20,805

20,128

21,216

55,623

120,499

31,307

(9,210
)

(8,482
)

(7,552
)

Non-controlling interests

(29
)

248

160

—

—

—

—

—

—

Net income/(loss) attributable to the shareholders of equity investee

20,776

20,376

21,376

55,623

120,499

31,307

(9,210
)

(8,482
)

(7,552
)

Notes:

(a)

NSPL only incurred research and development expenses in the periods presented.

(b)

HBYS and SHPL have been successful in their respective applications to renew the High and New Technology Enterprise ("HNTE") status. Accordingly, the companies were eligible to use a preferential income tax rate of 15% for the years ended December 31, 2017, 2016 and 2015.

Reconciliation of summarized financial information presented to carrying amount of investments in equity investees



Commercial Platform

Innovation Platform

Consumer Health
HBYS

Prescription Drugs
SHPL

Drug R&D
NSPL

2017

2016

2015

2017

2016

2015

2017

2016

2015

(in US$'000)

Opening net assets after non-controlling interests as at January 1

127,072

121,523

111,506

150,134

93,263

71,906

33,611

18,093

25,645

Net income/(loss) attributable to the shareholders of equity investee

20,776

20,376

21,376

55,623

120,499

31,307

(9,210
)

(8,482
)

(7,552
)

Dividends declared

(45,128
)

(6,000
)

(6,410
)

(81,299
)

(55,057
)

(6,410
)

—

—

—

Other comprehensive income/(loss)

7,896

(8,827
)

(4,949
)

8,273

(8,571
)

(3,540
)

—

—

—

Investments

—

—

—

—

—

—

14,000

10,000

—

Capitalization of loans

—

—

—

—

—

—

—

14,000

—

Closing net assets after non-controlling interests as at December 31

110,616

127,072

121,523

132,731

150,134

93,263

38,401

33,611

18,093

Group's share of net assets

55,308

63,536

60,762

66,365

75,067

46,632

19,201

16,806

9,046

Goodwill

—

—

—

3,052

2,872

3,077

—

—

—

Carrying amount of investments as at December 31

55,308

63,536

60,762

69,417

77,939

49,709

19,201

16,806

9,046

Schedule of equity investees future aggregate minimum payments under non-cancellable operating lease agreements



December 31,

2017

2016

(in US$'000)

Not later than 1 year

1,282

1,511

Between 1 to 2 years

400

1,184

Between 2 to 3 years

151

—

Between 3 to 4 years

141

—

Between 4 to 5 years

47

—

Total minimum lease payments

2,021

2,695



Schedule of equity investees capital commitments



December 31,

2017

2016

(in US$'000)

Property, plant and equipment

Contracted but not provided for

1,034

6,162

X

- Definition
Tabular disclosure of capital commitments of equity method investees.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentsCapitalCommitmentsOfInvesteesTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of equity method investments by name of each investee or group of investments.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentsCompositionTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Refers to equity investees leases under non-cancellable operation lease agreements.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentsNonCancellableOperatingLeaseAgreementsTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of summarized balance sheet information for equity method investments.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentsSummarizedFinancialInformationBalanceSheetTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of summarized statement of operations information for equity method investments.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentsSummarizedFinancialInformationStatementOfOperationsTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of difference between recorded amount of an equity method investment and the value of the underlying equity in the net assets.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentsUnderlyingEquityInNetAssetsReconciliationTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 87 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1

Accounts Payable (Tables)
12 Months Ended

Dec. 31, 2017

Accounts Payable

Schedule of accounts payable



December 31,

2017

2016

(in US$'000)

Accounts payable—third parties

17,095

30,383

Accounts payable—non-controlling shareholders of subsidiaries

7,250

5,136

Accounts payable—related party (Note 22 (ii))

20

19

24,365

35,538

X

- Definition
Tabular disclosure of the carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable).
+ References
No definition available.
+ Details

Name: hcm_ScheduleOfAccountsPayableTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountsPayableCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 88 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1

Other Payables, Accruals and Advance Receipts (Tables)
12 Months Ended

Dec. 31, 2017

Other Payables, Accruals and Advance Receipts

Schedule of other payables, accruals and advance receipts



December 31,

2017

2016

(in US$'000)

Accrued salaries and benefits

9,295

7,057

Accrued research and development expenses

14,613

11,771

Accrued selling and marketing expenses

4,121

4,340

Accrued administrative and other general expenses

4,729

4,078

Deferred government incentives

1,790

1,755

Loan from a non-controlling shareholder of a subsidiary (Note 22 (iv))

1,550

—

Payments in advance from customers

1,282

899

Others

3,573

1,816

40,953

31,716

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 89 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1

Bank Borrowings (Tables)
12 Months Ended

Dec. 31, 2017

Bank Borrowings

Schedule of bank borrowings



December 31,

2017

2016

(in US$'000)

Current

29,987

19,957

Non-current

—

26,830

29,987

46,787

Schedule of maturities of bank borrowings



December 31,

2017

2016

(in US$'000)

Not later than 1 year

30,000

20,000

Between 1 to 2 years

—

26,923

30,000

46,923

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644
+ Details

Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 90 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1

Commitments and Contingencies (Tables)
12 Months Ended

Dec. 31, 2017

Commitments and Contingencies

Schedule of aggregate minimum payments under non-cancellable operating leases



December 31,

2017

2016

(in US$'000)

Not later than 1 year

3,330

1,711

Between 1 to 2 years

2,875

1,383

Between 2 to 3 years

2,132

1,053

Between 3 to 4 years

345

597

Between 4 to 5 years

161

108

Later than 5 years

17

45

Total minimum lease payments

8,860

4,897

Schedule of capital commitments



December 31,

2017

2016

(in US$'000)

Property, plant and equipment

Contracted but not provided for

161

2,545

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.
+ References
No definition available.
+ Details

Name: us-gaap_LongTermPurchaseCommitmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 91 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1

Ordinary Shares (Tables)
12 Months Ended

Dec. 31, 2017

Ordinary Shares

Summary of ordinary shares transactions

 A summary of ordinary shares transactions (in thousands) is as follows:



2017

2016

2015

As at January 1

60,706

56,533

53,076

Public offering

5,685

4,080

—

Share option exercises

56

93

243

Exchange of redeemable non-controlling interest (Note 16)

—

—

3,214

As at December 31

66,447

60,706

56,533

X

- Definition
Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_ScheduleOfStockholdersEquityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 92 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-based Compensation (Tables)
12 Months Ended

Dec. 31, 2017

HCML Share Option Scheme

Share-based Compensation

A summary of share option activity and related information



Number of
share
options

Weighted-average
exercise price in
£ per share

Weighted-average
remaining
contractual life
(years)

Aggregate
intrinsic value
(in £'000)

Outstanding at January 1, 2015

684,403

4.67

Granted

—

—

Exercised

(242,038
)

3.77

Cancelled

—

—

Outstanding at December 31, 2015

442,365

5.16

6.53

10,061

Granted

693,686

19.70

Exercised

(92,705
)

3.54

Cancelled

(3,750
)

6.10

Outstanding at December 31, 2016

1,039,596

15.00

6.77

7,900

Granted

150,000

31.05

Exercised

(56,309
)

5.16

Cancelled

(6,875
)

6.10

Outstanding at December 31, 2017

1,126,412

17.69

6.29

43,158

Vested and expected to vest at December 31, 2015

333,393

4.85

6.05

7,685

Vested and exercisable at December 31, 2015

291,015

4.67

5.77

6,762

Vested and expected to vest at December 31, 2016

1,039,596

15.00

6.77

7,900

Vested and exercisable at December 31, 2016

767,376

14.64

6.66

6,106

Vested and expected to vest at December 31, 2017

1,126,412

17.69

6.29

43,158

Vested and exercisable at December 31, 2017

951,412

15.52

5.81

38,508

Assumption for fair value of share options granted



Grant date

June 24,
2011

December 20,
2013

June 15,
2016

March 27,
2017

Value of each share option (in £ per share)

1.84

3.15

8.99

12.69

Significant inputs into the valuation model:

Exercise price (in £ per share)

4.41

6.10

19.70

31.05

Share price at effective date of grant (in £ per share)

4.33

6.10

19.70

31.05

Expected volatility

46.6%

36.0%

39.0%

36.3%

Risk-free interest rate

3.13%

3.16%

1.00%

1.17%

Contractual life of share options

10 years

10 years

8 years

10 years

Expected dividend yield

0%

0%

0%

0%

Summary of share option values



Year Ended December 31,

2017

2016

2015

Weighted-average grant-date fair value of share options granted during the period (in £ per share)

12.69

8.99

—

Total intrinsic value of share options exercised in US$'000

2,290

1,907

5,020

Summary of share-based compensation expenses



Year Ended December 31,

2017

2016

2015

(in US$'000)

Research and development expenses

1,284

1,278

74

Administrative expenses

—

—

14

1,284

1,278

88

HMHL Share Option Scheme

Share-based Compensation

A summary of share option activity and related information



Number of
share
options



Weighted-average
exercise price in
£ per share



Weighted-average
remaining
contractual life
(years)



Aggregate
intrinsic value
(in £'000)

Outstanding at January 1, 2015

1,211,772

7.71

Granted

—

—

Exercised

(24,400
)

2.34

Cancelled

—

—

Outstanding at December 31, 2015

1,187,372

7.82

7.97

32,292

Granted

—

—

Exercised

—

—

Cancelled

(1,187,372
)

7.82

Outstanding at December 31, 2016 and 2017

—

—

—

—

Vested and expected to vest at December 31, 2015

759,918

7.82

7.97

20,667

Vested and exercisable at December 31, 2015

593,686

7.82

7.97

16,146

Vested and expected to vest at December 31, 2016 and 2017

—

—

—

—

Vested and exercisable at December 31, 2016 and 2017

—

—

—

—

Summary of share-based compensation expenses



Year Ended December 31,

2017

2016

2015

(in US$'000)

Research and development

32

502

1,063

LTIP

Share-based Compensation

Schedule of treasury shares (in the form of ordinary shares or ADS of the Company) purchased and held by the Trustee



Number of
treasury shares

Cost in
US$'000

As at January 1, 2017

62,921

2,390

Purchased

35,095

1,367

Vested

(42,038
)

(1,800
)

As at December 31, 2017

55,978

1,957

Summary of share-based compensation expenses



Year Ended December 31,

2017

2016

2015

(in US$'000)

Research and development expenses

1,894

850

156

Selling and administrative expenses

1,529

811

152

3,423

1,661

308

Recorded with a corresponding credit to:

Liability

2,336

345

75

Additional paid-in capital

1,087

1,316

233

3,423

1,661

308

X

- Definition
Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year and intrinsic value of share options exercised.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueExercisedIntrinsicValueTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656
+ Details

Name: us-gaap_ScheduleOfTreasuryStockByClassTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=hcm_HCMLShareOptionSchemeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=hcm_HMHLShareOptionSchemesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=hcm_LongTermIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 93 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1

Revenue from License and Collaboration Agreements-Third Parties (Tables)
12 Months Ended

Dec. 31, 2017

Revenue from License and Collaboration Agreements-Third Parties

Summary of revenue from license and collaboration agreements-third parties



Year Ended December 31,

2017

2016

2015

(in US$'000)

Milestone revenue

9,457

9,931

19,212

Amortization of upfront payment

1,655

1,679

1,907

Research and development services

15,203

14,834

22,941

26,315

26,444

44,060

X

- References
No definition available.
+ Details

Name: hcm_RevenueFromLicenseAndCollaborationAgreementsDisclosureAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68059916&loc=d3e50766-111635

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68059916&loc=SL6750900-111635
+ Details

Name: us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 94 R55.htm IDEA: XBRL DOCUMENT v3.8.0.1

Research and Development Expenses (Tables)
12 Months Ended

Dec. 31, 2017

Research and Development Expenses

Summary of research and development expenses



Year Ended December 31,

2017

2016

2015

(in US$'000)

Clinical trial related costs

45,250

38,589

24,690

Personnel compensation and related costs

24,848

21,698

17,339

Other research and development expenses

5,425

6,584

5,339

75,523

66,871

47,368

X

- Definition
Tabular disclosure of research and development expenses summary.
+ References
No definition available.
+ Details

Name: hcm_ResearchAndDevelopmentExpensesTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 95 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1

Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries (Tables)
12 Months Ended

Dec. 31, 2017

Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries

Schedule of transactions with related parties



Year Ended December 31,

2017

2016

2015

(in US$'000)

Sales to:

Indirect subsidiaries of CK Hutchison

8,486

9,794

8,074

Revenue from research and development services:

Equity investees

9,682

8,429

5,383

Purchases from:

Equity investees

1,182

280

3,701

Rendering of marketing services from:

Indirect subsidiaries of CK Hutchison

372

741

751

An equity investee

10,195

8,401

5,093

10,567

9,142

5,844

Rendering of management services from:

Indirect subsidiaries of CK Hutchison

897

874

845

Interest paid to:

Immediate holding company

—

152

144

An indirect subsidiary of CK Hutchison

132

—

—

132

152

144

Guarantee fee on bank loan to:

An indirect subsidiary of CK Hutchison

320

471

471

Schedule of balances with related parties



December 31,

2017

2016

(in US$'000)

Accounts receivable—related parties

Indirect subsidiaries of CK Hutchison (note (a))

2,761

2,589

Equity investees (note (a))

1,099

1,634

3,860

4,223

Accounts payable

An indirect subsidiary of CK Hutchison (note (a))

—

19

An equity investee (note (a))

20

—

20

19

Amounts due from related parties

An indirect subsidiary of CK Hutchison (note (a))

23

107

Equity investees (note (a))

893

1,029

Dividend receivable from an equity investee

7,628

—

8,544

1,136

Amounts due to related parties

Immediate holding company (note (b))

—

2,086

An indirect subsidiary of CK Hutchison (note (b))

454

152

An equity investee (note (a))

6,567

3,070

7,021

5,308

Other deferred income

An equity investee (note (c))

1,648

1,771

Other non-current liabilities

Immediate holding company (note (d))

—

6,000

Notes:

(a)

Balances with related parties are unsecured, interest-free and repayable on demand. The carrying values of balances with related parties approximate their fair values due to their short-term maturities.

(b)

Amounts due to immediate holding company and an indirect subsidiary of CK Hutchison are unsecured and interest-bearing. During the year ended December 31, 2017, amounts due to immediate holding company were assigned to an indirect subsidiary of CK Hutchison. As at December 31, 2017, approximately US$454,000 (December 31, 2016: US$2,238,000) of such balances are repayable within one year or repayable on demand.

(c)

Other deferred income represents amounts recognized from granting of promotion and marketing rights.

(d)

In December 2017, the Group repaid the amount due. As at December 31, 2016, this amount was recorded in non-current liabilities as it was repayable in equal installments of US$3,000,000 in December 2018 and December 2019.

Schedule of transactions with non-controlling shareholders of subsidiaries



Year Ended December 31,

2017

2016

2015

(in US$'000)

Sales

13,307

12,274

6,196

Purchases

21,236

15,225

12,169

Interest expense

66

78

85

Dividend declared

1,594

564

590

Schedule of balances with non-controlling shareholders of subsidiaries



December 31,

2017

2016

(in US$'000)

Accounts receivable—third parties

1,846

—

Accounts payable

7,250

5,136

Other payables, accruals and advance receipts

Loan

1,550

—

Interest payable

80

14

1,630

14

Other non-current liabilities

Loans

579

2,129

X

- Definition
Tabular disclosure of balances with non-controlling shareholders of subsidiaries.
+ References
No definition available.
+ Details

Name: hcm_ScheduleOfBalancesWithNonControllingShareholdersOfSubsidiariesTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of balances with related party.
+ References
No definition available.
+ Details

Name: hcm_ScheduleOfBalancesWithRelatedPartyTransactionsTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of transactions with non-controlling shareholders of subsidiaries.
+ References
No definition available.
+ Details

Name: hcm_ScheduleOfTransactionsWithNonControllingShareholdersOfSubsidiariesTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 96 R57.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes (Tables)
12 Months Ended

Dec. 31, 2017

Income Taxes

Components of income tax expense



Year Ended December 31,

2017

2016

2015

(in US$'000)

Current tax

HK (note (a))

572

520

150

PRC (note (b))

782

458

415

Deferred income tax

1,726

3,353

1,040

Income tax expense

3,080

4,331

1,605

Notes:

(a)

The Company, a subsidiary incorporated in the British Virgin Islands and its Hong Kong subsidiaries are subject to Hong Kong profits tax which has been provided for at the rate of 16.5% on the estimated assessable profits less estimated available tax losses in each entity.

(b)

Taxation in the PRC has been provided for at the applicable rate on the estimated assessable profits less estimated available tax losses, if any, in each entity. Under the PRC Enterprise Income Tax Law (the "EIT Law"), the standard enterprise income tax rate is 25%. In addition, the EIT Law provides for, among others, a preferential tax rate of 15% for companies which qualify as HNTE. HMPL qualifies as a HNTE up to December 31, 2019. Pursuant to the EIT law, a 10% withholding tax is levied on dividends declared by PRC companies to their foreign investors. A lower withholding tax rate of 5% is applicable under the China-HK Tax Arrangement if direct foreign investors with at least 25% equity interest in the PRC companies are Hong Kong tax residents, and meet the conditions or requirements pursuant to the relevant PRC tax regulations regarding beneficial ownership. Since the equity holders of the major subsidiaries and equity investees of the Company are Hong Kong incorporated companies and Hong Kong tax residents, and meet the aforesaid conditions or requirements, the Company has used 5% to provide for deferred tax liabilities on retained earnings which are anticipated to be distributed. As at December 31, 2017 and 2016, the amounts accrued in deferred tax liabilities relating to withholding tax on dividends were determined on the basis that 100% of the distributable reserves of the major subsidiaries and equity investees operating in the PRC will be distributed as dividends.

Schedule of reconciliation of the Group's reported income tax expense to the theoretical tax amount



Year Ended December 31,

2017

2016

2015

(in US$'000)

Loss before income taxes and equity in earnings of equity investees

(53,536
)

(47,356
)

(10,540
)

Tax calculated at the statutory tax rate of the Company

(8,833
)

(7,814
)

(1,739
)

Tax effects of:

Different tax rates available in different jurisdictions

2,531

453

(2,953
)

Tax valuation allowance

11,410

9,886

6,601

Preferential tax deduction

(3,347
)

(3,205
)

(2,096
)

Expenses not deductible for tax purposes

391

688

253

Utilization of previously unrecognized tax losses

(387
)

(21
)

(34
)

Withholding tax on undistributed earnings of PRC entities

1,980

3,532

1,216

Others

(665
)

812

357

Income tax expense

3,080

4,331

1,605

Significant components of deferred tax assets and liabilities



December 31,

2017

2016

(in US$'000)

Deferred tax assets

Tax losses

31,028

20,145

Others

1,267

372

Total deferred tax assets

32,295

20,517

Less: Valuation allowance

(31,662
)

(20,145
)

Deferred tax assets

633

372

Deferred tax liabilities

Undistributed earnings from PRC entities

4,332

5,230

Others

120

131

Deferred tax liabilities

4,452

5,361

Schedule of movements in net deferred income tax liabilities



2017

2016

2015

(in US'000)

As at January 1

(4,989
)

(3,473
)

(2,842
)

Utilization of previously recognized withholding tax on undistributed earnings

3,179

1,526

321

(Charged)/Credited to the consolidated statements of operations

Withholding tax on undistributed earnings of PRC entities

(1,980
)

(3,532
)

(1,216
)

Deferred tax on amortization of intangible assets

18

32

24

Deferred tax on provision for assets

236

147

152

Exchange differences

(283
)

311

88

As at December 31

(3,819
)

(4,989
)

(3,473
)

Summary of tax loss carryforwards



December 31,

2017

2016

(in US$'000)

No expiry date

42,385

32,859

2017

—

3,651

2018

858

807

2019

4,261

4,012

2020

36,188

34,059

2021

50,494

53,194

2022

65,195

—

199,381

128,582

Summary of changes in the deferred tax valuation allowance



2017

2016

2015

(in US$'000)

As at January 1

20,145

11,393

7,455

Charged to consolidated statements of operations

11,410

9,886

6,601

Utilization of previously unrecognized tax losses

(387
)

(21
)

(34
)

Write-off of expired tax losses

(558
)

—

(1,493
)

Others

(89
)

(288
)

(901
)

Exchange differences

1,141

(825
)

(235
)

As at December 31

31,662

20,145

11,393

Schedule of income tax payable



2017

2016

2015

(in US$'000)

As at January 1

274

442

112

Current tax

1,354

978

565

Withholding tax upon dividend declaration from PRC entities

3,179

1,526

321

Tax paid

(3,836
)

(2,664
)

(510
)

Exchange difference

8

(8
)

(46
)

As at December 31

979

274

442

X

- Definition
Tabular disclosure on current tax liabilities.
+ References
No definition available.
+ Details

Name: hcm_ScheduleOfCurrentTaxLiability

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Schedule of movements in the net deferred income tax liabilities.
+ References
No definition available.
+ Details

Name: hcm_ScheduleOfMovementsInNetDeferredIncomeTaxLiabilities

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319
+ Details

Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Carryforwards
-URI http://asc.fasb.org/extlink&oid=6506874

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319
+ Details

Name: us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Valuation Allowance
-URI http://asc.fasb.org/extlink&oid=6528051

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_SummaryOfValuationAllowanceTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 97 R58.htm IDEA: XBRL DOCUMENT v3.8.0.1

(Losses)/Earnings per Share (Tables)
12 Months Ended

Dec. 31, 2017

(Losses)/Earnings per Share

Schedule of basic (losses)/earnings per share



Year Ended December 31,



2017



2016



2015

Weighted average number of outstanding ordinary shares in issue

61,717,171

59,715,173

54,659,315

Net (loss)/income (US$'000)

(22,963
)

14,557

10,427

Net income attributable to non-controlling interests (US$'000)

(3,774
)

(2,859
)

(2,434
)

Accretion on redeemable non-controlling interests (US$'000)

—

—

(43,001
)

Net (loss)/income for the year attributable to ordinary shareholders of the Company (US$'000)

(26,737
)

11,698

(35,008
)

(Losses)/earnings per share attributable to ordinary shareholders of the Company (US$ per share)

(0.43
)

0.20

(0.64
)

Schedule of diluted (losses)/earnings per share



Year Ended December 31,

2017



2016



2015

Weighted average number of outstanding ordinary shares in issue

61,717,171

59,715,173

54,659,315

Adjustment for share options and LTIP

—

255,877

—

61,717,171

59,971,050

54,659,315

Net (loss)/income for the year attributable to ordinary shareholders of the Company (US$'000)

(26,737
)

11,698

(35,008
)

(Losses)/earnings per share attributable to ordinary shareholders of the Company (US$ per share)

(0.43
)

0.20

(0.64
)

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the effect of income (loss) on basic earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1311-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 98 R59.htm IDEA: XBRL DOCUMENT v3.8.0.1

Segment Reporting (Tables)
12 Months Ended

Dec. 31, 2017

Segment Reporting

Schedule of segment information for the reportable segments



Year ended December 31, 2017

Innovation
Platform

Commercial Platform

Drug
R&D

Prescription
Drugs

Consumer Health

PRC

PRC

PRC

Hong
Kong

Subtotal

Unallocated

Total

(in US$'000)

Revenue from external customers

35,997

166,435

9,858

28,913

205,206

—

241,203

Adjusted (LBIT)/EBIT

(47,503
)

3,272

578

3,029

6,879

(12,677
)

(53,301
)

Interest income

64

37

13

13

63

1,093

1,220

Equity in earnings of equity investees, net of tax

(4,547
)

27,812

10,388

—

38,200

—

33,653

Operating (loss)/profit

(51,986
)

31,121

10,979

3,042

45,142

(11,584
)

(18,428
)

Interest expense

—

—

—

66

66

1,389

1,455

Income tax expense

26

934

(457
)

509

986

2,068

3,080

Net (loss)/income attributable to ordinary shareholders of the Company

(51,880
)

28,999

9,773

1,261

40,033

(14,890
)

(26,737
)

Depreciation/amortization

2,400

116

17

18

151

27

2,578

Additions to non-current assets (other than financial instrument and deferred tax assets)

5,936

56

43

8

107

30

6,073



As at December 31, 2017

Innovation
Platform

Commercial Platform

Drug
R&D

Prescription
Drugs

Consumer Health

PRC

PRC

PRC

Hong
Kong

Subtotal

Unallocated

Total

(in US$'000)

Total assets

63,268

122,665

58,961

13,794

195,420

339,244

597,932

Property, plant and equipment

13,917

160

61

30

251

52

14,220

Leasehold land

1,261

—

—

—

—

—

1,261

Goodwill

—

2,901

407

—

3,308

—

3,308

Other intangible asset

—

430

—

—

430

—

430

Investments in equity investees

19,512

69,417

55,308

—

124,725

—

144,237



Year ended December 31, 2016

Innovation
Platform

Commercial Platform

Drug
R&D

Prescription
Drugs

Consumer Health

PRC

PRC

PRC

Hong
Kong

Subtotal

Unallocated

Total

(inUS$'000)

Revenue from external customers

35,228

149,861

6,984

24,007

180,852

—

216,080

Adjusted (LBIT)/EBIT

(36,657
)

2,377

(493
)

1,852

3,736

(13,306
)

(46,227
)

Interest income

52

31

34

1

66

384

502

Equity in earnings of equity investees, net of tax

(4,232
)

60,288

10,188

—

70,476

—

66,244

Operating (loss)/profit

(40,837
)

62,696

9,729

1,853

74,278

(12,922
)

20,519

Interest expense

—

—

—

79

79

1,552

1,631

Income tax expense

—

777

(497
)

289

569

3,762

4,331

Net (loss)/income attributable to ordinary shareholders of the Company

(40,735
)

61,120

8,384

833

70,337

(17,904
)

11,698

Depreciation/amortization

2,176

102

3

19

124

41

2,341

Additions to non-current assets (other than financial instrument and deferred tax assets)

4,138

67

20

51

138

51

4,327



As at December 31, 2016

Innovation
Platform

Commercial Platform

Drug
R&D

Prescription
Drugs

Consumer Health

PRC

PRC

PRC

Hong
Kong

Subtotal

Unallocated

Total

(in US$'000)

Total assets

53,774

134,681

67,161

10,701

212,543

76,120

342,437

Property, plant and equipment

9,686

145

34

40

219

49

9,954

Leasehold land

1,220

—

—

—

—

—

1,220

Goodwill

—

2,730

407

—

3,137

—

3,137

Other intangible asset

—

469

—

—

469

—

469

Investments in equity investees

17,031

77,939

63,536

—

141,475

—

158,506



Year ended December 31, 2015

Innovation
Platform

Commercial Platform

Drug
R&D

Prescription
Drugs

Consumer Health

PRC

PRC

PRC

Hong
Kong

Subtotal

Unallocated

Total

(in US$'000)

Revenue from external customers

52,016

105,478

3,028

17,681

126,187

—

178,203

Adjusted (LBIT)/EBIT

(119
)

676

(169
)

1,211

1,718

(11,186
)

(9,587
)

Interest income

79

114

29

1

144

228

451

Equity in earnings of equity investees, net of tax

(3,770
)

15,653

10,689

—

26,342

—

22,572

Operating (loss)/profit

(3,810
)

16,443

10,549

1,212

28,204

(10,958
)

13,436

Interest expense

—

—

—

85

85

1,319

1,404

Income tax expense

—

239

—

148

387

1,218

1,605

Net (loss)/income attributable to ordinary shareholders of the Company

(3,810
)

15,934

8,640

581

25,155

(13,352
)

7,993

Depreciation/amortization

1,864

94

11

5

110

41

2,015

Additions to non-current assets (other than financial instrument and deferred tax assets)

3,218

88

5

4

97

9

3,324

Schedule of reconciliation of adjusted LBIT to net (loss)/income



Year Ended December 31,

2017

2016

2015

(in US$'000)

Adjusted LBIT

(53,301
)

(46,227
)

(9,587
)

Interest income

1,220

502

451

Equity in earnings of equity investees, net of tax

33,653

66,244

22,572

Interest expense

(1,455
)

(1,631
)

(1,404
)

Income tax expense

(3,080
)

(4,331
)

(1,605
)

Net (loss)/income

(22,963
)

14,557

10,427

X

- Definition
Tabular disclosure of reconciliation of adjusted earning/(loss) before interest and taxes for reportable segments to net income/(loss).
+ References
No definition available.
+ Details

Name: hcm_ScheduleOfReconciliationOfEarningLossBeforeInterestAndTaxesForReportableSegmentsToNetIncomeLossTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599
+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 99 R60.htm IDEA: XBRL DOCUMENT v3.8.0.1

Note to Consolidated Statements of Cash Flows (Tables)
12 Months Ended

Dec. 31, 2017

Note to Consolidated Statements of Cash Flows

Schedule of reconciliation of net (loss)/income for the year to net cash used in operating activities



Year Ended December 31,

2017



2016



2015

(in US$'000)

Net (loss)/income

(22,963
)

14,557

10,427

Adjustments to reconcile net (loss)/income to net cash used in operating activities

Amortization of finance costs

147

92

62

Depreciation and amortization

2,578

2,341

2,015

Loss on retirement of property, plant and equipment

57

30

60

Provision for excess and obsolete inventories

(16
)

163

4

Provision for doubtful accounts

242

(208
)

1,408

Share-based compensation expense—share options

1,316

1,780

1,151

Share-based compensation expense—LTIP

3,423

1,661

308

Equity in earnings of equity investees, net of tax

(33,653
)

(66,244
)

(22,572
)

Dividends received from equity investees

55,586

30,528

6,410

Unrealized currency translation (gain)/loss

(399
)

633

198

Changes in income tax balances

(756
)

1,667

1,093

Changes in working capital

Accounts receivable—third parties

2,160

(7,258
)

(12,030
)

Accounts receivable—related parties

363

(2,354
)

315

Other receivables, prepayments and deposits

(6,982
)

(1,129
)

(459
)

Amounts due from related parties

220

1,157

(3,010
)

Inventories

1,049

(3,430
)

(5,154
)

Long-term prepayment

123

361

(2,132
)

Accounts payable

(11,173
)

11,452

3,659

Other payables, accruals and advance receipts

5,194

7,554

4,660

Deferred revenue

(897
)

(1,668
)

(1,907
)

Other deferred income

(275
)

131

2,132

Amounts due to related parties

(4,287
)

(1,385
)

3,977

Total changes in working capital

(14,505
)

3,431

(9,949
)

Net cash used in operating activities

(8,943
)

(9,569
)

(9,385
)

X

- References
No definition available.
+ Details

Name: hcm_NoteToCondensedConsolidatedStatementsOfCashFlowsAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of reconciliation of net income/(loss) for the year to net cash (used in)/generated from operating activities.
+ References
No definition available.
+ Details

Name: hcm_ReconciliationOfNetIncomeLossToNetCashUsedInGeneratedFromOperatingActivitiesTableTextBlock

Namespace Prefix: hcm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 100 R61.htm IDEA: XBRL DOCUMENT v3.8.0.1

Organization and Nature of Business (Details) - USD ($)
1 Months Ended 12 Months Ended

Mar. 17, 2016

Oct. 31, 2017

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Organization and Nature of Business

Each ADS as ordinary share 0.5 0.5

Accumulated losses $ 107,104,000 $ 80,357,000

Cash and cash equivalents 85,265,000 79,431,000 $ 31,941,000 $ 38,946,000

Short-term investments 273,031,000 24,270,000

Unutilized bank borrowing facilities 121,282,000 70,000,000

Net proceeds from public follow-on offering $ 292,690,000

Dividends received from equity investees $ 55,586,000 $ 30,528,000 $ 6,410,000

X

- Definition
Each American Depository Share ("ADS") represent number of ordinary shares.
+ References
No definition available.
+ Details

Name: hcm_EachAmericanDepositoryShareAsOrdinaryShares

Namespace Prefix: hcm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's public offering of stock subsequent to initial public offering.
+ References
No definition available.
+ Details

Name: hcm_ProceedsFromIssuancePublicFollowOnOffering

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Dividends received on equity and other investments during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromDividendsReceived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 101 R62.htm IDEA: XBRL DOCUMENT v3.8.0.1

Particulars of Principal Subsidiaries and Equity Investees (Details)

Dec. 31, 2017

Dec. 31, 2016

Hutchison MediPharma Limited ("HMPL") | PRC

Subsidiary or Equity Method Investee

Equity interest attributable to the Group 99.75% 99.75%

Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm") | PRC

Subsidiary or Equity Method Investee

Equity interest attributable to the Group 51.00% 51.00%

Hutchison Hain Organic (Hong Kong) Limited ("HHOL") | Hong Kong

Subsidiary or Equity Method Investee

Equity interest attributable to the Group 50.00% 50.00%

Hutchison Hain Organic (Guangzhou) Limited ("HHOGZL") | PRC

Subsidiary or Equity Method Investee

Equity interest attributable to the Group 50.00% 50.00%

Hutchison Healthcare Limited ("HHL") | PRC

Subsidiary or Equity Method Investee

Equity interest attributable to the Group 100.00% 100.00%

Hutchison Consumer Products Limited | Hong Kong

Subsidiary or Equity Method Investee

Equity interest attributable to the Group 100.00% 100.00%

Shanghai Hutchison Pharmaceuticals Limited ("SHPL") | PRC

Subsidiary or Equity Method Investee

Equity investees 50.00% 50.00%

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS") | PRC

Subsidiary or Equity Method Investee

Equity investees 40.00% 40.00%

Nutrition Science Partners Limited ("NSPL") | Hong Kong

Subsidiary or Equity Method Investee

Equity investees 49.88% 49.88%

Subsidiary 80% owned by the Group | Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")

Subsidiary or Equity Method Investee

Equity interest attributable to the Group 40.00% 40.00%

Equity interest attributable to subsidiaries (as a percent) 50.00% 50.00%

Subsidiary 80% owned by the Group | Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS") | PRC

Subsidiary or Equity Method Investee

Equity interest attributable to the Group 80.00% 80.00%

Subsidiary 99.75% owned by the Group | Nutrition Science Partners Limited ("NSPL")

Subsidiary or Equity Method Investee

Equity interest attributable to the Group 49.88% 49.88%

Equity interest attributable to subsidiaries (as a percent) 50.00% 50.00%

Subsidiary 99.75% owned by the Group | Nutrition Science Partners Limited ("NSPL") | Hong Kong

Subsidiary or Equity Method Investee

Equity interest attributable to the Group 99.75% 99.75%

X

- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The parent entity's interest in net assets of the subsidiary, expressed as a percentage.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByParent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hcm_HutchisonMediPharmaLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_CN

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hcm_HutchisonWhampoaSinopharmPharmaceuticalsShanghaiCompanyLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hcm_HutchisonHainOrganicHongKongLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_HK

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hcm_HutchisonHainOrganicGuangzhouLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hcm_HutchisonHealthcareLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hcm_HutchisonConsumerProductsLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hcm_ShanghaiHutchisonPharmaceuticalsLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hcm_HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hcm_NutritionSciencePartnersLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=hcm_SubsidiaryOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=hcm_SubsidiaryTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 102 R63.htm IDEA: XBRL DOCUMENT v3.8.0.1

Summary of significant accounting policies (Details) - USD ($)
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Jan. 01, 2018

Lease term for leasehold land 50 years

Goodwill impairment $ 0 $ 0 $ 0

Ordinary shares, par value $ 1.00 $ 1.00

Cumulative adjustment to opening accumulated loss upon adoption $ (107,104,000) $ (80,357,000)

Contributions to defined contribution plans 2,092,000 2,286,000 1,653,000

Sub-lease rentals $ 274,000 228,000 229,000

Minimum percentage of after-tax profits appropriated to the general reserve fund 10.00%

Maximum percentage of after-tax profits appropriated to the general reserve fund 50.00%

Adjustment | ASU 2016-09

Cumulative adjustment to opening accumulated loss upon adoption $ 0

Adjustment expected | ASU 2014-09

Cumulative adjustment to opening accumulated loss upon adoption $ 1,100,000

Other expense

Net foreign currency exchange losses $ 316,000 109,000 79,000

Buildings

Property plant and equipment useful life 20 years

Operating lease rentals $ 2,285,000 $ 1,838,000 $ 1,426,000

Minimum | Plant and equipment

Property plant and equipment useful life 5 years

Minimum | Furniture and fixtures, other equipment and motor vehicles

Property plant and equipment useful life 4 years

Maximum | Plant and equipment

Property plant and equipment useful life 10 years

Maximum | Furniture and fixtures, other equipment and motor vehicles

Property plant and equipment useful life 5 years

Maximum | Leasehold improvements

Property plant and equipment useful life 5 years

X

- Definition
Percentage of appropriation to the general reserve fund as of the registered capital of the Company over which appropriation is not required.
+ References
No definition available.
+ Details

Name: hcm_AppropriationToGeneralReserveFundMaximumPercentage

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum percentage of appropriation to the general reserve fund to the after tax profits calculated in accordance with PRC GAAP.
+ References
No definition available.
+ Details

Name: hcm_AppropriationToGeneralReserveFundMinimumPercentage

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of the cost recognized during the period for defined contribution plans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942
+ Details

Name: us-gaap_DefinedContributionPlanCostRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30700-110894

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30690-110894
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13777-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717
+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesRentExpenseSubleaseRentals1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=hcm_AccountingStandardsUpdate201609Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=hcm_ProformaAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=hcm_FurnitureFixturesOtherEquipmentAndMotorVehiclesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 103 R64.htm IDEA: XBRL DOCUMENT v3.8.0.1

Fair Value Disclosures (Details) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Fair value measurements

Cash and cash equivalents $ 85,265 $ 79,431

Short-term investments 273,031 24,270

Level 1

Fair value measurements

Cash and cash equivalents 85,265 79,431

Short-term investments $ 273,031 $ 24,270

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016
+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Trading Securities
-URI http://asc.fasb.org/extlink&oid=6526789

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 35
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=27723805&loc=d3e24584-111560

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Available-for-Sale Securities
-URI http://asc.fasb.org/extlink&oid=6505594
+ Details

Name: us-gaap_InvestmentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 104 R65.htm IDEA: XBRL DOCUMENT v3.8.0.1

Cash and Cash Equivalents (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Cash and Cash Equivalents

Cash at bank and on hand $ 30,018 $ 31,218

Bank deposits maturing in three months or less 55,247 48,213

Cash and cash equivalents 85,265 79,431 $ 31,941 $ 38,946

US dollar

Cash and Cash Equivalents

Cash and cash equivalents 66,381 65,509

RMB

Cash and Cash Equivalents

Cash and cash equivalents 15,140 9,505

UK pound Sterling

Cash and Cash Equivalents

Cash and cash equivalents 295 408

Hong Kong dollar

Cash and Cash Equivalents

Cash and cash equivalents $ 3,449 $ 4,009

Bank deposits maturing in three months or less | Weighted average

Cash and Cash Equivalents

Effective interest rate (in percentage) 1.06% 0.58%

Bank deposits maturing in three months or less | Minimum

Cash and Cash Equivalents

Bank deposit maturity period (in days) 7 days 7 days

Bank deposits maturing in three months or less | Maximum

Cash and Cash Equivalents

Bank deposit maturity period (in days) 90 days 90 days

X

- Definition
Period until the time deposit matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: hcm_TimeDepositMaturityPeriod

Namespace Prefix: hcm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The interest rate for investments that have an interest rate. For fixed rate investments, this indicates the fixed interest rate. If the investment has a variable interest rate, the rate stated here may be the rate that is currently relevant. In this case the "Investment, Interest Rate is Current Rate for Variable Rate Investment Flag", "Investment, Interest Rate is Discount Rate at Purchase Flag", "Investment, Interest Rate Reflects Current Yield Flag" should be used. If one of these flags are not appropriate to explain the interest rate that is indicated, then a new flag should be added or an explanation should be included in "Investment, Additional Information".
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 12
-Section 12
-Sentence Column A
+ Details

Name: invest_InvestmentInterestRate

Namespace Prefix: invest_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Any certificate of deposit or savings account held by a bank or other financial institution for a short-term specified period of time. Because of their short-term, time deposits are considered highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TimeDepositsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_CurrencyAxis=currency_USD

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CurrencyAxis=currency_CNY

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CurrencyAxis=currency_GBP

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CurrencyAxis=currency_HKD

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_WeightedAverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 105 R66.htm IDEA: XBRL DOCUMENT v3.8.0.1

Short-term Investments (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Short term Investments

Short-term investments $ 273,031 $ 24,270

Bank deposits maturing over three months

Short term Investments

Short-term investments $ 273,031 $ 24,270

Bank deposits maturing over three months | Weighted average

Short term Investments

Effective interest rate (in percentage) 1.32% 0.71%

Bank deposits maturing over three months | Minimum

Short term Investments

Bank deposit maturity period (in days) 91 days 91 days

Bank deposits maturing over three months | Maximum

Short term Investments

Bank deposit maturity period (in days) 183 days 186 days

Bank deposits maturing over three months | US dollar

Short term Investments

Short-term investments $ 272,659 $ 24,270

Bank deposits maturing over three months | Hong Kong dollar

Short term Investments

Short-term investments $ 372

X

- Definition
Period until the time deposit matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: hcm_TimeDepositMaturityPeriod

Namespace Prefix: hcm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The interest rate for investments that have an interest rate. For fixed rate investments, this indicates the fixed interest rate. If the investment has a variable interest rate, the rate stated here may be the rate that is currently relevant. In this case the "Investment, Interest Rate is Current Rate for Variable Rate Investment Flag", "Investment, Interest Rate is Discount Rate at Purchase Flag", "Investment, Interest Rate Reflects Current Yield Flag" should be used. If one of these flags are not appropriate to explain the interest rate that is indicated, then a new flag should be added or an explanation should be included in "Investment, Additional Information".
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 12
-Section 12
-Sentence Column A
+ Details

Name: invest_InvestmentInterestRate

Namespace Prefix: invest_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent reporting concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 12
-Section 12
-Sentence Column A
+ Details

Name: invest_InvestmentLineItems

Namespace Prefix: invest_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InvestmentTypeAxis=hcm_BankDepositsMaturingOverThreeMonthsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_WeightedAverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CurrencyAxis=currency_USD

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CurrencyAxis=currency_HKD

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 106 R67.htm IDEA: XBRL DOCUMENT v3.8.0.1

Accounts Receivable-Third Parties (Details) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Accounts Receivable-Third Parties

Accounts receivable, gross $ 38,668 $ 43,532

Allowance for doubtful accounts (258) (2,720)

Accounts receivable, net $ 38,410 $ 40,812

X

- Definition
Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_AccountsReceivableGrossCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66008989&loc=d3e5074-111524
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 107 R68.htm IDEA: XBRL DOCUMENT v3.8.0.1

Accounts Receivable-Third Parties - Movements on the Allowance for Doubtful Accounts Receivable (Details) - USD ($)
1 Months Ended 12 Months Ended

Dec. 31, 2015

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Allowance for Doubtful Accounts Receivable

As at January 1 $ 2,720,000 $ 3,127,000 $ 1,793,000

Increase in allowance for doubtful accounts $ 1,322,000 242,000 29,000 1,408,000

Decrease in allowance due to subsequent collection (237,000)

Write-off (2,874,000)

Exchange difference (74,000) 170,000 (199,000) (74,000)

As at December 31 $ 3,127,000 $ 258,000 $ 2,720,000 $ 3,127,000

X

- Definition
Amount of expense related to write-down of receivables with regard to exchange difference. Includes, but is not limited to, accounts receivable and notes receivable.
+ References
No definition available.
+ Details

Name: hcm_AllowanceForDoubtfulAccountsReceivableDueToExchangeDifference

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66008989&loc=d3e5074-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of recoveries of receivables doubtful of collection that were previously charged off.
+ References
No definition available.
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of direct write-downs of accounts receivable charged against the allowance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 310
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68075217&loc=SL9156395-115594

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66008989&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.5)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 108 R69.htm IDEA: XBRL DOCUMENT v3.8.0.1

Other Receivables, Prepayments and Deposits (Details) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Other Receivables, Prepayments and Deposits

Prepayments $ 2,565 $ 699

Purchase rebates 284 238

Other service receivables 490 756

Deposits 932 620

Value-added tax receivables 5,436 1,380

Interest receivable 506 63

Others 1,083 558

Total $ 11,296 $ 4,314

X

- Definition
NA.
+ References
No definition available.
+ Details

Name: hcm_OtherReceivablePrepaymentsAndDepositsAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after allowance, receivables classified as other receivables and prepayments and deposits due within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: hcm_OtherReceivablesPrepaymentsAndDepositsCurrent

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of other services receivables.
+ References
No definition available.
+ Details

Name: hcm_OtherServicesReceivables

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of purchase rebate.
+ References
No definition available.
+ Details

Name: hcm_PurchaseRebate

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DepositsAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_OtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Assets
-URI http://asc.fasb.org/extlink&oid=6509628

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ValueAddedTaxReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 109 R70.htm IDEA: XBRL DOCUMENT v3.8.0.1

Inventories (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Inventories

Raw materials $ 314 $ 660

Finished goods 11,475 12,162

Total 11,789 12,822

Movements on the provision for excess and obsolete inventories

As at January 1 160 25 $ 34

Increase in provision for excess and obsolete inventories 128 163 37

Decrease in provision due to subsequent sale or recovery (144) (33)

Write-off (32) (23) (12)

Exchange difference 9 (5) (1)

As at December 31 $ 121 $ 160 $ 25

X

- Definition
Amount of decrease in provision for excess and obsolete inventories due to sale or write-off.
+ References
No definition available.
+ Details

Name: hcm_DecreaseInProvisionForExcessAndObsoleteInventoriesDueToSaleOrWriteOff

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The (increase)/decrease in the provision for excess and obsolete inventories due to sale of inventories.
+ References
No definition available.
+ Details

Name: hcm_IncreaseDecreaseInProvisionForExcessAndObsoleteInventoryDueToSaleOfInventory

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The change in provision for excess and obsolete inventory, due to the exchange differences on valuation of inventories.
+ References
No definition available.
+ Details

Name: hcm_InventoryAdjustmentsExchangeDifference

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The provision for excess and obsolete inventory.
+ References
No definition available.
+ Details

Name: hcm_ProvisionForExcessAndObsoleteInventory

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryAdjustmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729
+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729
+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312
+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 110 R71.htm IDEA: XBRL DOCUMENT v3.8.0.1

Property, Plant and Equipment (Details) - USD ($)
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Cost

As at January 1 $ 24,350,000 $ 21,842,000

Additions 6,073,000 4,327,000

Disposals (394,000) (260,000)

Exchange differences 1,680,000 (1,559,000)

As at December 31 31,709,000 24,350,000 $ 21,842,000

Accumulated depreciation

As at January 1 14,396,000 13,335,000

Depreciation 2,478,000 2,239,000 1,908,000

Disposals (337,000) (230,000)

Exchange differences 952,000 (948,000)

As at December 31 17,489,000 14,396,000 13,335,000

Net book value 14,220,000 9,954,000

Buildings

Cost

As at January 1 2,232,000 2,392,000

Exchange differences 140,000 (160,000)

As at December 31 2,372,000 2,232,000 2,392,000

Accumulated depreciation

As at January 1 971,000 932,000

Depreciation 105,000 106,000

Exchange differences 65,000 (67,000)

As at December 31 1,141,000 971,000 932,000

Net book value 1,231,000 1,261,000

Leasehold improvements

Cost

As at January 1 6,296,000 5,989,000

Additions 301,000 742,000

Disposals (12,000)

Transfers 2,050,000

Exchange differences 410,000 (423,000)

As at December 31 9,057,000 6,296,000 5,989,000

Accumulated depreciation

As at January 1 4,249,000 3,549,000

Depreciation 763,000 977,000

Disposals (12,000)

Exchange differences 284,000 (265,000)

As at December 31 5,296,000 4,249,000 3,549,000

Net book value 3,761,000 2,047,000

Plant and equipment

Cost

As at January 1 86,000 88,000

Additions 155,000

Transfers 2,321,000

Exchange differences 6,000 (2,000)

As at December 31 2,568,000 86,000 88,000

Accumulated depreciation

As at January 1 71,000 70,000

Depreciation 169,000 3,000

Transfers 255,000

Exchange differences 4,000 (2,000)

As at December 31 499,000 71,000 70,000

Net book value 2,069,000 15,000

Furniture and fixtures, other equipment and motor vehicles

Cost

As at January 1 13,976,000 12,806,000

Additions 1,374,000 1,453,000

Disposals (394,000) (248,000)

Transfers (722,000) 886,000

Exchange differences 920,000 (921,000)

As at December 31 15,154,000 13,976,000 12,806,000

Accumulated depreciation

As at January 1 9,105,000 8,784,000

Depreciation 1,441,000 1,153,000

Disposals (337,000) (218,000)

Transfers (255,000)

Exchange differences 599,000 (614,000)

As at December 31 10,553,000 9,105,000 8,784,000

Net book value 4,601,000 4,871,000

Construction in Progress

Cost

As at January 1 1,760,000 567,000

Additions 4,243,000 2,132,000

Transfers (3,649,000) (886,000)

Exchange differences 204,000 (53,000)

As at December 31 2,558,000 1,760,000 $ 567,000

Accumulated depreciation

Net book value $ 2,558,000 $ 1,760,000

X

- Definition
Amount of increase or decrease in accumulated depreciation, depletion and amortization as a result of foreign currency translation adjustments.
+ References
No definition available.
+ Details

Name: hcm_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase/(decrease) in accumulated depreciation, depletion and amortization as a result of transfers between property, plant and equipment.
+ References
No definition available.
+ Details

Name: hcm_AccumulatedDepreciationDepletionAndAmortizationTransfersBetweenPropertyPlantAndEquipment

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of exchange differences on the long-lived, physical assets used in the normal conduct of business and not intended for resale.
+ References
No definition available.
+ Details

Name: hcm_PropertyPlantAndEquipmentExchangeDifferences

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment.
+ References
No definition available.
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_MovementInAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_MovementInPropertyPlantAndEquipmentRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisposals

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2921-110230
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTransfersAndChanges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 111 R72.htm IDEA: XBRL DOCUMENT v3.8.0.1

Investments in Equity Investees - Composition (Details) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Investments in Equity Investees

Investments in equity investees $ 144,237 $ 158,506

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")

Investments in Equity Investees

Investments in equity investees 55,308 63,536

Shanghai Hutchison Pharmaceuticals Limited ("SHPL")

Investments in Equity Investees

Investments in equity investees 69,417 77,939

Nutrition Science Partners Limited ("NSPL")

Investments in Equity Investees

Investments in equity investees 19,201 16,806

Other

Investments in Equity Investees

Investments in equity investees $ 311 $ 225

X

- Definition
This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66022249&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_ShanghaiHutchisonPharmaceuticalsLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_NutritionSciencePartnersLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_AllOtherEquityMethodInvesteesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 112 R73.htm IDEA: XBRL DOCUMENT v3.8.0.1

Investments in Equity Investees - Summarized Balance Sheet (Details) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Consumer Health | Commercial Platform | Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")

Summarized balance sheet

Current assets $ 101,570 $ 123,181

Non-current assets 107,226 98,554

Current liabilities (75,787) (70,218)

Non-current liabilities (18,748) (18,148)

Net assets 114,261 133,369

Non-controlling interests (3,645) (6,297)

Net assets, excluding non-controlling interests 110,616 127,072 $ 121,523 $ 111,506

Prescription Drugs | Commercial Platform | Shanghai Hutchison Pharmaceuticals Limited ("SHPL")

Summarized balance sheet

Current assets 129,535 146,350

Non-current assets 103,477 97,656

Current liabilities (91,665) (86,946)

Non-current liabilities (8,616) (6,926)

Net assets 132,731 150,134

Net assets, excluding non-controlling interests 132,731 150,134 93,263 71,906

Drug R&D | Innovation Platform | Nutrition Science Partners Limited ("NSPL")

Summarized balance sheet

Current assets 9,640 5,393

Non-current assets 30,000 30,000

Current liabilities (1,239) (1,782)

Net assets 38,401 33,611

Net assets, excluding non-controlling interests $ 38,401 $ 33,611 $ 18,093 $ 25,645

X

- References
No definition available.
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of current assets reported by an equity method investment of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33912-111571

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of current liabilities reported by an equity method investment of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33912-111571

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of equity, including noncontrolling interest, reported by an equity method investment of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.g)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of equity, excluding noncontrolling interest, attributable to the equity method investment of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33912-111571

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of equity attributable to noncontrolling interests of an equity method investment of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33912-111571
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of noncurrent assets reported by an equity method investment of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33912-111571

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of noncurrent liabilities reported by an equity method investment of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33912-111571

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_ConsumerHealthMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=hcm_CommercialPlatformMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_PrescriptionDrugsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_ShanghaiHutchisonPharmaceuticalsLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_DrugResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=hcm_InnovationPlatformMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_NutritionSciencePartnersLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 113 R74.htm IDEA: XBRL DOCUMENT v3.8.0.1

Investments in Equity Investees - Summarized Statements of Operations (Details) - USD ($)
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Other

Summarized statements of operations

Net income/(loss) attributable to the shareholders of equity investee $ 117,000 $ 95,000 $ 12,000

Consumer Health | Commercial Platform | Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")

Summarized statements of operations

Revenue 227,422,000 224,131,000 211,603,000

Gross profit 91,458,000 89,355,000 91,461,000

Depreciation and amortization (4,985,000) (2,958,000) (3,274,000)

Interest income 220,000 238,000 628,000

Finance cost (117,000) (123,000) (158,000)

Income/(loss) before taxation 24,434,000 23,759,000 25,164,000

Income tax expense (3,629,000) (3,631,000) (3,948,000)

Net income/(loss) 20,805,000 20,128,000 21,216,000

Non-controlling interests (29,000) 248,000 160,000

Net income/(loss) attributable to the shareholders of equity investee $ 20,776,000 $ 20,376,000 $ 21,376,000

Preferential income tax rate (as a percent) 15.00% 15.00% 15.00%

Prescription Drugs | Commercial Platform | Shanghai Hutchison Pharmaceuticals Limited ("SHPL")

Summarized statements of operations

Revenue $ 244,557,000 $ 222,368,000 $ 181,140,000

Gross profit 175,965,000 158,131,000 127,608,000

Depreciation and amortization (6,942,000) (3,526,000) (2,765,000)

Interest income 757,000 565,000 306,000

Income/(loss) before taxation 66,497,000 148,144,000 37,401,000

Income tax expense (10,874,000) (27,645,000) (6,094,000)

Net income/(loss) 55,623,000 120,499,000 31,307,000

Net income/(loss) attributable to the shareholders of equity investee $ 55,623,000 $ 120,499,000 $ 31,307,000

Preferential income tax rate (as a percent) 15.00% 15.00% 15.00%

Drug R&D | Innovation Platform | Nutrition Science Partners Limited ("NSPL")

Summarized statements of operations

Income/(loss) before taxation $ (9,210,000) $ (8,482,000) $ (7,552,000)

Net income/(loss) (9,210,000) (8,482,000) (7,552,000)

Net income/(loss) attributable to the shareholders of equity investee $ (9,210,000) $ (8,482,000) $ (7,552,000)

X

- Definition
Preferential tax rate for companies that qualify as High and New Technology Enterprises.
+ References
No definition available.
+ Details

Name: hcm_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRate

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of the depreciation and amortization reported by an equity method investment of the entity.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentSummarizedFinancialInformationDepreciationAndAmortization

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of the finance cost reported by an equity method investment of the entity.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentSummarizedFinancialInformationFinanceCost

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of income (loss) from continuing operations, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest reported by an equity method investment of the entity.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterest

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of income tax expense (benefit) reported by an equity method investment of the entity.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxExpenseBenefitAndNetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of the interest income reported by an equity method investment of the entity.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentSummarizedFinancialInformationInterestIncome

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) reported by an equity method investment of the entity attributable to noncontrolling interest.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) reported by an equity method investment of the entity, including the portion attributable to the noncontrolling interest.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of gross profit (loss) reported by an equity method investment of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33912-111571

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) reported by an equity method investment of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33912-111571
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of revenue from sale of goods and services reduced by sales returns, allowances, and discounts reported by an equity method investment of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_AllOtherEquityMethodInvesteesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_ConsumerHealthMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=hcm_CommercialPlatformMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_PrescriptionDrugsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_ShanghaiHutchisonPharmaceuticalsLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_DrugResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=hcm_InnovationPlatformMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_NutritionSciencePartnersLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 114 R75.htm IDEA: XBRL DOCUMENT v3.8.0.1

Investments in Equity Investees - Reconciliation of Summarized Financial Information (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees

Carrying amount of investments as at December 31 $ 144,237 $ 158,506

Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")

Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees

Carrying amount of investments as at December 31 55,308 63,536

Shanghai Hutchison Pharmaceuticals Limited ("SHPL")

Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees

Carrying amount of investments as at December 31 69,417 77,939

Nutrition Science Partners Limited ("NSPL")

Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees

Carrying amount of investments as at December 31 19,201 16,806

Consumer Health | Commercial Platform | Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")

Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees

Opening net assets after non-controlling interests as at January 1 127,072 121,523 $ 111,506

Net income/(loss) attributable to the shareholders of equity investee 20,776 20,376 21,376

Dividend declared (45,128) (6,000) (6,410)

Other comprehensive income/(loss) 7,896 (8,827) (4,949)

Closing net assets after non-controlling interests as at December 31 110,616 127,072 121,523

Group's share of net assets 55,308 63,536 60,762

Carrying amount of investments as at December 31 55,308 63,536 60,762

Prescription Drugs | Commercial Platform | Shanghai Hutchison Pharmaceuticals Limited ("SHPL")

Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees

Opening net assets after non-controlling interests as at January 1 150,134 93,263 71,906

Net income/(loss) attributable to the shareholders of equity investee 55,623 120,499 31,307

Dividend declared (81,299) (55,057) (6,410)

Other comprehensive income/(loss) 8,273 (8,571) (3,540)

Closing net assets after non-controlling interests as at December 31 132,731 150,134 93,263

Group's share of net assets 66,365 75,067 46,632

Goodwill 3,052 2,872 3,077

Carrying amount of investments as at December 31 69,417 77,939 49,709

Drug R&D | Innovation Platform | Nutrition Science Partners Limited ("NSPL")

Reconciliation of the summarized financial information presented to the carrying amount of investments in equity investees

Opening net assets after non-controlling interests as at January 1 33,611 18,093 25,645

Net income/(loss) attributable to the shareholders of equity investee (9,210) (8,482) (7,552)

Investments 14,000 10,000

Capitalization of loans 14,000

Closing net assets after non-controlling interests as at December 31 38,401 33,611 18,093

Group's share of net assets 19,201 16,806 9,046

Carrying amount of investments as at December 31 $ 19,201 $ 16,806 $ 9,046

X

- Definition
The amount of capitalized loans reported by an equity method investment of the entity.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentSummarizedFinancialInformationCapitalizationOfLoans

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of paid and unpaid dividends declared reported by an equity method investment of the entity.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentSummarizedFinancialInformationDividends

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of investment made by shareholders of the equity method investment during the period.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentSummarizedFinancialInformationInvestments

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of other comprehensive income (loss) and net income (Loss) attributable to noncontrolling interest reported by an equity method investment of the entity.
+ References
No definition available.
+ Details

Name: hcm_EquityMethodInvestmentSummarizedFinancialInformationOtherComprehensiveIncomeLossNetOfTaxAndNetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of equity, excluding noncontrolling interest, attributable to the equity method investment of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33912-111571

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of net income (loss) reported by an equity method investment of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33912-111571
+ Details

Name: us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66022249&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_ShanghaiHutchisonPharmaceuticalsLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hcm_NutritionSciencePartnersLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_ConsumerHealthMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=hcm_CommercialPlatformMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_PrescriptionDrugsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_DrugResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=hcm_InnovationPlatformMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 115 R76.htm IDEA: XBRL DOCUMENT v3.8.0.1

Investments in Equity Investees - Lease Commitments and Capital Commitments (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Future aggregate minimum payments under non-cancellable operating leases

Not later than 1 year $ 3,330 $ 1,711

Between 1 to 2 years 2,875 1,383

Between 2 to 3 years 2,132 1,053

Between 3 to 4 years 345 597

Between 4 to 5 years 161 108

Total minimum lease payments 8,860 4,897

Property, plant and equipment

Capital commitments

Long-term Purchase Commitment, Amount 161 2,545

Equity investees

Future aggregate minimum payments under non-cancellable operating leases

Not later than 1 year 1,282 1,511

Between 1 to 2 years 400 1,184

Between 2 to 3 years 151

Between 3 to 4 years 141

Between 4 to 5 years 47

Total minimum lease payments 2,021 2,695

Equity investees | Property, plant and equipment

Capital commitments

Long-term Purchase Commitment, Amount $ 1,034 $ 6,162

X

- References
No definition available.
+ Details

Name: us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum amount the entity agreed to spend under the long-term purchase commitment.
+ References
No definition available.
+ Details

Name: us-gaap_LongTermPurchaseCommitmentAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=hcm_EquityMethodInvesteesAggregatedDisclosureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 116 R77.htm IDEA: XBRL DOCUMENT v3.8.0.1

Accounts Payable (Details) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Accounts payable-third parties $ 17,095 $ 30,383

Accounts payable-related parties 20 19

Accounts Payable 24,365 35,538

Non-controlling shareholders of subsidiaries

Accounts payable-third parties $ 7,250 $ 5,136

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableTradeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_CounterpartyNameAxis=hcm_NonControllingShareholdersOfSubsidiariesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 117 R78.htm IDEA: XBRL DOCUMENT v3.8.0.1

Other Payables, Accruals and Advance Receipts (Details) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Other Payables, Accruals and Advance Receipts

Accrued salaries and benefits $ 9,295 $ 7,057

Accrued research and development expenses 14,613 11,771

Accrued selling and marketing expenses 4,121 4,340

Accrued administrative and other general expenses 4,729 4,078

Deferred government incentives 1,790 1,755

Loan from a non-controlling shareholder of a subsidiary 1,550

Payments in advance from customers 1,282 899

Others 3,573 1,816

Other payables, accruals and advance receipts $ 40,953 $ 31,716

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer) for other payables, accrued liabilities, deferred revenue and advance receipts.
+ References
No definition available.
+ Details

Name: hcm_AccountsPayableAccruedLiabilitiesDeferredRevenueOtherCurrent

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of accrued general administration and other expenses.
+ References
No definition available.
+ Details

Name: hcm_AccruedGeneralAdministrationAndOtherExpenses

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligations with regard to deferred government incentives, payable within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: hcm_DeferredGovernmentIncentivesCurrent

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligations with regard to Loan from a non-controlling shareholder of a subsidiary, payable within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: hcm_LoanFromNonControllingShareholderOfSubsidiary

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligations incurred with regard to research and development, payable within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: hcm_ResearchAndDevelopmentExpensesPayableCurrent

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: us-gaap_AccruedMarketingCostsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The current portion of prepayments received from customers for goods or services to be provided in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CustomerAdvancesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 118 R79.htm IDEA: XBRL DOCUMENT v3.8.0.1

Bank Borrowings - Schedule of Bank Borrowings (Details) - USD ($)
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Bank Borrowings

Current $ 29,987,000 $ 19,957,000

Non-current 26,830,000

Bank borrowings $ 29,987,000 $ 46,787,000

Weighted average interest rate for bank borrowings outstanding 1.90% 1.52% 1.39%

Guarantee fees incurred $ 320,000 $ 471,000 $ 471,000

Guarantee fees as a percentage of the weighted average outstanding bank borrowings 0.76% 0.94% 0.95%

X

- Definition
Amount of guarantee fees.
+ References
No definition available.
+ Details

Name: hcm_DebtInstrumentGuaranteeFees

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents guarantee fees incurred as a percentage of the weighted average outstanding debt instrument.
+ References
No definition available.
+ Details

Name: hcm_DebtInstrumentGuaranteeFeesPercentage

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average interest rate of debt outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_DebtWeightedAverageInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 119 R80.htm IDEA: XBRL DOCUMENT v3.8.0.1

Bank Borrowings - Loan Facilities (Details)
1 Months Ended 4 Months Ended

Nov. 30, 2017

HKD ($)

Nov. 30, 2017

USD ($)

Aug. 31, 2017

HKD ($)

Aug. 31, 2017

USD ($)

Mar. 31, 2017

HKD ($)

Mar. 31, 2017

USD ($)

Feb. 28, 2017

HKD ($)

agreement

Nov. 30, 2015

HKD ($)

Jun. 30, 2014

Dec. 31, 2011

HKD ($)

Nov. 30, 2017

HKD ($)

installment

Dec. 31, 2017

USD ($)

Nov. 30, 2017

USD ($)

Feb. 28, 2017

USD ($)

Dec. 31, 2016

USD ($)

Feb. 29, 2016

HKD ($)

Feb. 29, 2016

USD ($)

Nov. 30, 2015

USD ($)

Dec. 31, 2011

USD ($)

Term loan

Bank Borrowings

Term 4 years 3 years

Principal amount $ 210,000,000 $ 26,923,000

Loan facility repaid $ 30,000,000 $ 3,846,000 $ 180,000,000 $ 23,077,000 $ 156,000,000 $ 20,000,000

Number of installments | installment 2

Term loan | HIBOR

Bank Borrowings

Basis spread on variable rate 1.35% 1.50%

Revolving loan facility

Bank Borrowings

Term 3 years

Aggregate amount of credit facilities $ 234,000,000 $ 30,000,000

Amount drawn from the credit facility $ 20,000,000 $ 0 $ 2,564,000 $ 0

Loan facility repaid $ 20,000,000 $ 2,564,000

Revolving loan facility | HIBOR

Bank Borrowings

Basis spread on variable rate 1.25%

Unsecured credit facility

Bank Borrowings

Number of facility agreements entered | agreement 2

Aggregate amount of credit facilities $ 400,000,000 $ 546,000,000 $ 400,000,000 $ 51,282,000 70,000,000 $ 468,000,000 $ 60,000,000

Unsecured credit facility | Term loan

Bank Borrowings

Term 3 years 3 years

Aggregate amount of credit facilities $ 210,000,000 210,000,000 26,923,000

Unsecured credit facility | Term loan | HIBOR

Bank Borrowings

Basis spread on variable rate 1.50% 1.50%

Unsecured credit facility | Revolving loan facility

Bank Borrowings

Term 18 months 18 months

Principal amount $ 190,000,000 $ 190,000,000 $ 24,359,000

Amount drawn from the credit facility 0

Unsecured credit facility | Revolving loan facility | HIBOR

Bank Borrowings

Basis spread on variable rate 1.25% 1.25%

First unsecured credit facility | Term loan

Bank Borrowings

Term 18 months

Aggregate amount of credit facilities $ 156,000,000 20,000,000

First unsecured credit facility | Term loan | HIBOR

Bank Borrowings

Basis spread on variable rate 1.25%

First unsecured credit facility | Revolving loan facility

Bank Borrowings

Term 18 months

Aggregate amount of credit facilities $ 195,000,000 25,000,000

Amount drawn from the credit facility 0

First unsecured credit facility | Revolving loan facility | HIBOR

Bank Borrowings

Basis spread on variable rate 1.25%

Second unsecured credit facility | Term loan

Bank Borrowings

Term 18 months

Principal amount $ 78,000,000 10,000,000

Second unsecured credit facility | Term loan | HIBOR

Bank Borrowings

Basis spread on variable rate 1.25%

Second unsecured credit facility | Revolving loan facility

Bank Borrowings

Term 18 months

Principal amount $ 117,000,000 $ 15,000,000

Amount drawn from the credit facility $ 0

Second unsecured credit facility | Revolving loan facility | HIBOR

Bank Borrowings

Basis spread on variable rate 1.25%

X

- Definition
Number of installments that takes to fully repaid the loan.
+ References
No definition available.
+ Details

Name: hcm_LoanFullyRepaidNumberOfInstallments

Namespace Prefix: hcm_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of facility agreements with banks entered into by the Group through its subsidiary.
+ References
No definition available.
+ Details

Name: hcm_NumberOfFacilityAgreements

Namespace Prefix: hcm_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_LineOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_RepaymentsOfLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableToBanksMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VariableRateAxis=hcm_HongKongInterbankOfferedRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_RevolvingCreditFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_UnsecuredDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=hcm_FirstCreditFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=hcm_SecondCreditFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 120 R81.htm IDEA: XBRL DOCUMENT v3.8.0.1

Bank Borrowings - Schedule of Maturities of Bank Borrowings (Details)

Dec. 31, 2017

HKD ($)

Dec. 31, 2017

USD ($)

Dec. 31, 2016

HKD ($)

Dec. 31, 2016

USD ($)

Bank Borrowings

Not later than 1 year $ 30,000,000 $ 20,000,000

Between 1 to 2 years 26,923,000

Bank borrowings 30,000,000 46,923,000

Unutilized bank borrowing facilities $ 946,000,000 $ 121,282,000 $ 546,000,000 $ 70,000,000

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 121 R82.htm IDEA: XBRL DOCUMENT v3.8.0.1

Commitments and Contingencies (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Future aggregate minimum payments under non-cancellable operating leases

Not later than 1 year $ 3,330 $ 1,711

Between 1 to 2 years 2,875 1,383

Between 2 to 3 years 2,132 1,053

Between 3 to 4 years 345 597

Between 4 to 5 years 161 108

Later than 5 years 17 45

Total minimum lease payments 8,860 4,897

Property, plant and equipment

Capital commitments

Property, plant and equipment - Contracted but not provided for $ 161 $ 2,545

X

- References
No definition available.
+ Details

Name: us-gaap_LongTermCommitmentExcludingUnconditionalPurchaseObligationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum amount the entity agreed to spend under the long-term purchase commitment.
+ References
No definition available.
+ Details

Name: us-gaap_LongTermPurchaseCommitmentAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 122 R83.htm IDEA: XBRL DOCUMENT v3.8.0.1

Redeemable Non-controlling Interests (Details)
1 Months Ended 2 Months Ended 12 Months Ended

Apr. 13, 2016

USD ($)

shares

Mar. 17, 2016

USD ($)

shares

Jul. 23, 2015

USD ($)

shares

Oct. 31, 2017

USD ($)

shares

Oct. 31, 2012

USD ($)

shares

Jun. 30, 2014

USD ($)

agreement

shares

Dec. 31, 2010

USD ($)

shares

Dec. 31, 2017

USD ($)

shares

Dec. 31, 2016

USD ($)

shares

Dec. 31, 2015

USD ($)

Redeemable Non-controlling Interests

Redeemable noncontrolling interests outstanding $ 0 $ 0

Number of subscription agreements entered | agreement 2

New ordinary shares issued (in shares) | shares 330,000 3,750,000 5,684,905 5,685,000 4,080,000

Issuance in relation to public offering $ 8,900,000 $ 101,300,000 $ 301,300,000 $ 301,300,000 $ 110,160,000

Ordinary Shares

Redeemable Non-controlling Interests

New ordinary shares issued (in shares) | shares 3,214,404 5,685,000 4,080,000

Issuance in relation to public offering $ 84,000,000 $ 5,685,000 $ 4,080,000

Redeemable convertible preferred shares

Redeemable Non-controlling Interests

Preferred shares repurchased (in shares) | shares 2,815,249

Preferred shares outstanding $ 84,000,000

HMHL

Redeemable Non-controlling Interests

Aggregate consideration $ 25,000,000

Preferred shares as a percentage of the aggregate issued and outstanding share capital 12.24%

Accretion of preferred shares $ 43,001,000

HMHL | Ordinary Shares

Redeemable Non-controlling Interests

Number of shares issued (in shares) | shares 4,825,418

HMHL | Redeemable convertible preferred shares

Redeemable Non-controlling Interests

Number of shares issued (in shares) | shares 672,713 7,390,029

Aggregate consideration $ 20,100,000

Preferred shares as a percentage of the aggregate issued and outstanding share capital 12.24% 19.76%

Preferred shares outstanding (in shares) | shares 4,574,780

Preferred shares outstanding $ 12,500,000

Mitsui

Redeemable Non-controlling Interests

Preferred shares as a percentage of the aggregate issued and outstanding share capital 5.69%

X

- Definition
Represents the number of subscription agreement entered into by the entity.
+ References
No definition available.
+ Details

Name: hcm_NumberOfSubscriptionAgreementsEntered

Namespace Prefix: hcm_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of temporary equity repurchased during the period.
+ References
No definition available.
+ Details

Name: hcm_TemporaryEquitySharesRepurchased

Namespace Prefix: hcm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of accretion of the preferred stock redemption discount during the period.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockAccretionOfRedemptionDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph (12)(c)
-URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph (16)(c)
-URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph 15
-URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph 14
-URI http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764
+ Details

Name: us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RedeemableNoncontrollingInterestLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedPerTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.27(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=us-gaap_SubsidiaryIssuerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=hcm_MitsuiCompanyLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 123 R84.htm IDEA: XBRL DOCUMENT v3.8.0.1

Ordinary Shares (Details)
$ in Thousands
1 Months Ended 12 Months Ended 24 Months Ended

Apr. 13, 2016

USD ($)

shares

Mar. 17, 2016

USD ($)

shares

Oct. 31, 2017

USD ($)

shares

Dec. 31, 2017

USD ($)

item

shares

Dec. 31, 2016

USD ($)

item

shares

Dec. 31, 2015

USD ($)

item

shares

Dec. 31, 2016

USD ($)

item

shares

Ordinary shares, authorized 75,000,000 75,000,000 75,000,000

Each ADS as ordinary share 0.5 0.5

Issuance in relation to public offering | $ $ 8,900 $ 101,300 $ 301,300 $ 301,300 $ 110,160

Issuance costs paid | $ $ 8,576 $ 12,906 $ 1,321 $ 14,200

Summary of ordinary shares transactions:

Balance as at January 1 60,706,000 56,533,000 53,076,000 53,076,000

Issuance in relation to public offering (in shares) 330,000 3,750,000 5,684,905 5,685,000 4,080,000

Share option exercises 56,000 93,000 243,000

Exchange of redeemable non-controlling interest (Note 16) 3,214,000

Balance as at December 31 66,447,000 60,706,000 56,533,000 60,706,000

Votes per ordinary share | item 1 1 1 1

ADS

Summary of ordinary shares transactions:

Issuance in relation to public offering (in shares) 660,000 7,500,000 11,369,810

X

- Definition
Each American Depository Share ("ADS") represent number of ordinary shares.
+ References
No definition available.
+ Details

Name: hcm_EachAmericanDepositoryShareAsOrdinaryShares

Namespace Prefix: hcm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of votes entitled for each ordinary share.
+ References
No definition available.
+ Details

Name: hcm_NumberOfVotesForOrdinaryShare

Namespace Prefix: hcm_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the exchange of redeemable non-controlling interest.
+ References
No definition available.
+ Details

Name: hcm_StockIssuedDuringPeriodSharesExchangeOfRedeemableNoncontrollingInterest

Namespace Prefix: hcm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=hcm_AmericanDepositaryShareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 124 R85.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share based Compensation - HCML Share Option Scheme (Details) - shares
12 Months Ended

Jun. 15, 2016

Dec. 20, 2013

Aug. 06, 2008

Jun. 04, 2005

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

HCML Share Option Scheme

Share-based Compensation

Expiry period 10 years

Aggregate number of shares issuable 2,425,597

Number of issuable shares expired 282,726

Number of shares authorized but unissued 8,552,963

Number of share options cancelled 6,875 3,750

Number of share options granted 593,686 150,000 693,686

Outstanding share options 1,126,412 1,039,596 442,365 684,403

HCML Share Option Scheme | Minimum

Share-based Compensation

Expiry period 8 years

HCML Share Option Scheme | Maximum

Share-based Compensation

Expiry period 10 years

HCML Share Option Scheme | Three-year awards

Share-based Compensation

Vesting period 3 years

Vesting percentage upon first anniversary 33.30%

Annual vesting percentage after the first anniversary 33.30%

HCML Share Option Scheme | Four-year awards

Share-based Compensation

Vesting period 4 years

Vesting percentage upon first anniversary 25.00%

Annual vesting percentage after the first anniversary 25.00%

HMHL Share Option Scheme

Share-based Compensation

Expiry period 6 years

Aggregate number of shares issuable 2,144,408

Number of share options cancelled 1,187,372 2,485,189 1,187,372

Outstanding share options 1,187,372 1,211,772

X

- Definition
Represents the percentage of stock awards vesting each year after the first anniversary of the vesting commencement date as defined in the grant letter.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageAnnuallyAfterFirstAnniversary

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the percentage of stock awards vesting upon first anniversary of the vesting commencement date as defined in the grant letter.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageUponFirstAnniversary

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=hcm_HCMLShareOptionSchemeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: hcm_ClassificationOfAwardsByVestingScheduleAxis=hcm_AwardsVestingInThreeYearsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: hcm_ClassificationOfAwardsByVestingScheduleAxis=hcm_AwardsVestingInFourYearsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=hcm_HMHLShareOptionSchemesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 125 R86.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-based Compensation - HCML Share Option Activity (Details) - GBP (£)
£ / shares in Units, £ in Thousands
12 Months Ended

Jun. 15, 2016

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Number of share options

Exercised (in shares) (56,000) (93,000) (243,000)

HCML Share Option Scheme

Number of share options

Outstanding as at beginning of period (in shares) 1,039,596 442,365 684,403

Granted (in shares) 593,686 150,000 693,686

Exercised (in shares) (56,309) (92,705) (242,038)

Cancelled (in shares) (6,875) (3,750)

Outstanding as at end of period (in shares) 1,126,412 1,039,596 442,365

Vested and expected to vest (in shares) 1,126,412 1,039,596 333,393

Vested and exercisable (in shares) 951,412 767,376 291,015

Weighted-average exercise price

Outstanding balance as at beginning of period (in GBP per share) £ 15.00 £ 5.16 £ 4.67

Granted (in GBP per share) 31.05 19.70

Exercised (in GBP per share) 5.16 3.54 3.77

Cancelled (in GBP per share) 6.10 6.10

Outstanding balance as at end of period (in GBP per share) 17.69 15.00 5.16

Vested and expected to vest (in GBP per share) 17.69 15.00 4.85

Vested and exercisable (in GBP per share) £ 15.52 £ 14.64 £ 4.67

Weighted average remaining contractual life

Outstanding 6 years 3 months 15 days 6 years 9 months 7 days 6 years 6 months 11 days

Vested and expected to vest 6 years 3 months 15 days 6 years 9 months 7 days 6 years 18 days

Vested and exercisable 5 years 9 months 22 days 6 years 7 months 28 days 5 years 9 months 7 days

Aggregate intrinsic value

Outstanding (in GBP) £ 43,158 £ 7,900 £ 10,061

Vested and expected to vest (in GBP) 43,158 7,900 7,685

Vested and exercisable (in GBP) £ 38,508 £ 6,106 £ 6,762

X

- References
No definition available.
+ Details

Name: hcm_ContractualTermAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=hcm_HCMLShareOptionSchemeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 126 R87.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-based Compensation - HCML Options Fair value Assumptions (Details) - HCML Share Option Scheme - £ / shares
12 Months Ended

Mar. 27, 2017

Jun. 15, 2016

Dec. 20, 2013

Jun. 24, 2011

Dec. 31, 2017

Dec. 31, 2016

Share-based Compensation

Value of each share option (in GBP per share) £ 12.69 £ 8.99 £ 3.15 £ 1.84 £ 12.69 £ 8.99

Significant inputs into the valuation model:

Exercise price (in GBP per share) 31.05 19.70 6.10 4.41

Share price at effective date of grant (in GBP per share) £ 31.05 £ 19.70 £ 6.10 £ 4.33

Expected volatility (in percentage) 36.30% 39.00% 36.00% 46.60%

Risk-free interest rate (in percentage) 1.17% 1.00% 3.16% 3.13%

Contractual life of share options (in years) 10 years 8 years 10 years 10 years

Expected dividend yield (in percentage) 0.00% 0.00% 0.00% 0.00%

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=hcm_HCMLShareOptionSchemeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 127 R88.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-based Compensation - HCML Share Option Values (Details) - HCML Share Option Scheme
$ in Thousands
12 Months Ended

Mar. 27, 2017

£ / shares

Jun. 15, 2016

£ / shares

Dec. 20, 2013

£ / shares

Jun. 24, 2011

£ / shares

Dec. 31, 2017

£ / shares

Dec. 31, 2017

USD ($)

Dec. 31, 2016

£ / shares

Dec. 31, 2016

USD ($)

Dec. 31, 2015

USD ($)

Share option values

Weighted average grant date fair value of share option granted during the period (in GBP per share) | £ / shares £ 12.69 £ 8.99 £ 3.15 £ 1.84 £ 12.69 £ 8.99

Total intrinsic value of share options exercised | $ $ 2,290 $ 1,907 $ 5,020

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=hcm_HCMLShareOptionSchemeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 128 R89.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-based Compensation - HCML Share Based Compensation Expense (Details) - HCML Share Option Scheme - USD ($)
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Share-based Compensation

Share-based compensation expense $ 1,284,000 $ 1,278,000 $ 88,000

Unrecognized compensation cost $ 1,539,000

Unrecognized compensation cost recognition period 3 years 1 month 6 days

Cash received from option exercises $ 380,000 426,000 1,374,000

Research and development expenses

Share-based Compensation

Share-based compensation expense $ 1,284,000 $ 1,278,000 74,000

Administrative expenses

Share-based Compensation

Share-based compensation expense $ 14,000

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=hcm_HCMLShareOptionSchemeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 129 R90.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share based Compensation - HMHL Share Option Schemes (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 15, 2016

Dec. 20, 2013

Aug. 06, 2008

Jun. 04, 2005

Dec. 31, 2017

Dec. 31, 2016

HMHL Share Option Scheme

Share-based Compensation

Expiry period 6 years

Aggregate number of shares issuable 2,144,408

Share options cancelled (in shares) 1,187,372 2,485,189 1,187,372

Cash payment of cancelled share options period 4 years

Liability of modified awards in other payables $ 0.2 $ 1.4

HMHL Share Option Scheme | Ordinary Shares

Share-based Compensation

Number of shares authorized but unissued 157,111,839

Vesting period 4 years

Vesting percentage upon first anniversary 25.00%

Annual vesting percentage after the first anniversary 25.00%

HMHL Share Option Scheme | Six-year awards | Ordinary Shares

Share-based Compensation

Expiry period 6 years

HMHL Share Option Scheme | Nine-year awards | Ordinary Shares

Share-based Compensation

Expiry period 9 years

HCML Share Option Scheme

Share-based Compensation

Expiry period 10 years

Aggregate number of shares issuable 2,425,597

Number of shares authorized but unissued 8,552,963

Share options cancelled (in shares) 6,875 3,750

Number of share options granted 593,686 150,000 693,686

X

- Definition
Represents the percentage of stock awards vesting each year after the first anniversary of the vesting commencement date as defined in the grant letter.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageAnnuallyAfterFirstAnniversary

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the percentage of stock awards vesting upon first anniversary of the vesting commencement date as defined in the grant letter.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageUponFirstAnniversary

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Period from cancellation of share options that cash payment consideration is paid , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationCashPaymentPeriodCancelledShares

Namespace Prefix: hcm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=hcm_HMHLShareOptionSchemesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: hcm_ClassificationOfAwardsByTermAxis=hcm_AwardsExpiringInSixYearsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: hcm_ClassificationOfAwardsByTermAxis=hcm_AwardsExpiringInNineYearsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=hcm_HCMLShareOptionSchemeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 130 R91.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share based Compensation - HMHL Share Option Activity (Details) - GBP (£)
£ / shares in Units, £ in Thousands
12 Months Ended

Jun. 15, 2016

Dec. 20, 2013

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Number of share options

Exercised (in shares) (56,000) (93,000) (243,000)

HMHL Share Option Scheme

Number of share options

Outstanding as at beginning of period (in shares) 1,187,372 1,211,772

Exercised (in shares) (24,400)

Cancelled (in shares) (1,187,372) (2,485,189) (1,187,372)

Outstanding as at end of period (in shares) 1,187,372

Vested and expected to vest (in shares) 759,918

Vested and exercisable (in shares) 593,686

Weighted-average exercise price

Outstanding balance as at beginning of period (in GBP per share) £ 7.82 £ 7.71

Exercised (in GBP per share) 2.34

Cancelled (in GBP per share) £ 7.82

Outstanding balance as at end of period (in GBP per share) 7.82

Vested and expected to vest (in GBP per share) 7.82

Vested and exercisable (in GBP per share) £ 7.82

Weighted average remaining contractual life

Outstanding 7 years 11 months 19 days

Vested and expected to vest 7 years 11 months 19 days

Vested and exercisable 7 years 11 months 19 days

Aggregate intrinsic value

Outstanding (in GBP) £ 32,292

Vested and expected to vest (in GBP) 20,667

Vested and exercisable (in GBP) £ 16,146

X

- References
No definition available.
+ Details

Name: hcm_ContractualTermAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=hcm_HMHLShareOptionSchemesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 131 R92.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share based Compensation - HMHL Share Based Compensation Expense (Details) - HMHL Share Option Scheme - USD ($)
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Share-based Compensation

Unrecognized compensation cost $ 0

Cash received from option exercises $ 57,000

Research and development expenses

Share-based Compensation

Share-based compensation expense $ 32,000 $ 502,000 $ 1,063,000

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=hcm_HMHLShareOptionSchemesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 132 R93.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-based Compensation - LTIP (Details) - LTIP - USD ($)
12 Months Ended

Dec. 15, 2017

Oct. 19, 2017

Aug. 02, 2017

Mar. 15, 2017

Oct. 19, 2015

Dec. 31, 2018

Dec. 31, 2017

Mar. 24, 2016

Shared-based Compensation Award, Performance

Share-based Compensation

Number of business days for vesting after announcement of group's annual results 2 days 2 days 2 days

Number of years after the covered financial year to which the LTIP award relates 2 years 2 years 2 years 2 years

Number of business days for vesting after publication date of annual report 1 day

Shared-based Compensation Award, Performance | Maximum

Share-based Compensation

Cash amount of ordinary shares to be purchased per annum $ 500,000 $ 6,000,000 $ 6,000,000 $ 1,800,000

Shared-based Compensation Award, Non-performance

Share-based Compensation

Cash amount of ordinary shares to be purchased per annum $ 300,000

Number of business days for vesting after publication date of annual report 1 day

Vesting percentage upon first anniversary 25.00%

Vesting percentage on second anniversary 25.00%

Vesting percentage on third anniversary 25.00%

Vesting percentage on fourth anniversary 25.00%

Shared-based Compensation Award, Non-performance | Maximum

Share-based Compensation

Cash amount of ordinary shares to be purchased per annum $ 400,000

Ordinary Shares

Ordinary Shares Purchased and Held by Trustee - Number of treasury shares

As at January 1 55,978 62,921

Purchased 35,095

Vested (42,038)

As at December 31 55,978

Ordinary Shares Purchased and Held by Trustee - Cost

As at January 1 $ 1,957,000 $ 2,390,000

Purchased 1,367,000

Vesting (1,800,000)

As at December 31 1,957,000

Awards forfeited $ 79,000

Ordinary Shares | Maximum | Forecast

Ordinary Shares Purchased and Held by Trustee - Cost

Purchased $ 5,621,000

X

- Definition
Intrinsic value of equity-based compensation awards forfeited. Excludes stock and unit options.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Purchase cost of treasury shares acquired during the period.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValuePurchases

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares purchased made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPurchasedInPeriod

Namespace Prefix: hcm_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum cash amount for the purchase of entity shares for long-term incentive plan awards during the plan period.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerAnnum

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of business days for occurrence of vesting after announcement of group's annual results.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfBusinessDaysForVestingOccurrenceAfterAnnouncementOfGroupSAnnualResults

Namespace Prefix: hcm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of business days for occurrence of vesting after publication date of annual report.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfBusinessDaysVestingOccurrenceAfterPublicationDateOfAnnualReport

Namespace Prefix: hcm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of years after the covered financial year to which the award relates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfYearsAfterCoveredFinancialYearToWhichAwardRelates

Namespace Prefix: hcm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the percentage of stock awards vesting on Fourth anniversary of the vesting commencement date as defined in the grant letter.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageFourthAnniversary

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the percentage of stock awards vesting on second anniversary of the vesting commencement date as defined in the grant letter.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageSecondAnniversary

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the percentage of stock awards vesting on third anniversary of the vesting commencement date as defined in the grant letter.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageThirdAnniversary

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the percentage of stock awards vesting upon first anniversary of the vesting commencement date as defined in the grant letter.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageUponFirstAnniversary

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Intrinsic value of equity-based compensation awards vested. Excludes stock and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=hcm_LongTermIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 133 R94.htm IDEA: XBRL DOCUMENT v3.8.0.1

Share-based Compensation - LTIP Share Based Compensation Expense (Details) - LTIP - USD ($)
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Share-based Compensation

Share-based compensation expense $ 3,423,000 $ 1,661,000 $ 308,000

Share-based compensation reclassified from liability to additional paid-in capital 451,000 64,000 0

Share-based compensation recorded as liability 2,241,000 356,000

Unrecognized compensation cost 8,681,000

Liability

Share-based Compensation

Share-based compensation expense 2,336,000 345,000 75,000

Additional paid-in capital

Share-based Compensation

Share-based compensation expense 1,087,000 1,316,000 233,000

Research and development expenses

Share-based Compensation

Share-based compensation expense 1,894,000 850,000 156,000

Selling and administrative expenses

Share-based Compensation

Share-based compensation expense $ 1,529,000 $ 811,000 $ 152,000

X

- Definition
Amount of share-based compensation reclassified from liability to additional paid-in capital upon awards reaching the determination date.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationReclassifiedFromLiabilityToAdditionalPaidInCapital

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=hcm_LongTermIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_LiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 134 R95.htm IDEA: XBRL DOCUMENT v3.8.0.1

Revenue from License and Collaboration Agreements-Third Parties (Details) - USD ($)
12 Months Ended

Oct. 08, 2013

Dec. 21, 2011

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Aug. 31, 2016

Revenue from license and collaboration agreements-third parties

Milestone revenue $ 9,457,000 $ 9,931,000 $ 19,212,000

Amortization of upfront payment 1,655,000 1,679,000 1,907,000

Research and development services 15,203,000 14,834,000 22,941,000

Revenue from license and collaboration agreements-third parties 26,315,000 26,444,000 44,060,000

License and collaboration agreement with Eli Lilly

Revenue from license and collaboration agreements-third parties

Milestone revenue 4,500,000 19,200,000

Number of indications achieved 2

Amortization of upfront payment 1,600,000 1,700,000 1,800,000

Research and development services 12,100,000 12,100,000 19,400,000

Maximum amount of series of payments expected to be received $ 86,500,000

Upfront payment received $ 6,500,000

License and collaboration agreement with AstraZeneca

Revenue from license and collaboration agreements-third parties

Milestone revenue 5,000,000 9,900,000

Research and development services $ 3,100,000 2,700,000 3,500,000

Upfront payment received $ 20,000,000

Maximum amount of series of milestone payments expected to be received $ 120,000,000

Maximum phase III clinical trial costs $ 50,000,000

Percentage of additional royalties on net sales 5.00%

Threshold amount of royalties $ 250,000,000

Royalty percentage after achievement of threshold for 24 months 3.00%

Royalty percentage after achievement of threshold thereafter 1.50%

License and collaboration agreement with AstraZeneca | Maximum

Revenue from license and collaboration agreements-third parties

Amortization of upfront payment $ 100,000 $ 100,000 $ 100,000

X

- Definition
Revenue from amortization of upfront payment in a license and collaboration agreement recognized during the period.
+ References
No definition available.
+ Details

Name: hcm_AmortizationOfUpfrontPaymentRevenue

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of upfront payment received in a license and collaboration agreement.
+ References
No definition available.
+ Details

Name: hcm_LicenseAndCollaborationAgreementUpFrontPaymentReceived

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Maximum amount of series of payments the entity is entitled to receive, including upfront payments and development and regulatory approval milestones, in a license and collaboration agreement.
+ References
No definition available.
+ Details

Name: hcm_LicenseAndCollaborationAgreementsMaximumAmountToBeReceived

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Maximum amount of series of milestone payments expected to be received.
+ References
No definition available.
+ Details

Name: hcm_LicenseAndCollaborationAgreementsMilestoneMaximumAmountToBeReceived

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the amount of milestone payment expected to be incurred under the license and collaboration agreement.
+ References
No definition available.
+ Details

Name: hcm_LicenseAndCollaborationAgreementsMilestonePaymentExpectedToBeIncurred

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The number of indications achieved in accordance with a license and collaborative agreements. The achievement triggers the recognition of revenue.
+ References
No definition available.
+ Details

Name: hcm_LicenseAndCollaborationAgreementsNumberOfIndicationsAchieved

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the percentage of additional royalties on net sales.
+ References
No definition available.
+ Details

Name: hcm_PercentageOfAdditionalRoyaltiesOnNetSales

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the percentage of additional royalties on net sales after achievement of threshold for twenty four months under the license and collaboration agreement.
+ References
No definition available.
+ Details

Name: hcm_PercentageOfAdditionalRoyaltiesOnNetSalesAfterAchievementOfThresholdForTwoYears

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the percentage of additional royalties on net sales after achievement of threshold thereafter under the license and collaboration agreement.
+ References
No definition available.
+ Details

Name: hcm_PercentageOfAdditionalRoyaltiesOnNetSalesAfterAchievementOfThresholdThereafter

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue from research and development services recognized during the period.
+ References
No definition available.
+ Details

Name: hcm_ResearchAndDevelopmentServicesRevenue

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the threshold amount of royalties under the license and collaboration agreement.
+ References
No definition available.
+ Details

Name: hcm_ThresholdAmountOfRoyaltiesUnderLicenseAndCollaborationAgreements

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of consideration recognized during the period for the milestone or milestones.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501
+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=hcm_LicenseAndCollaborationAgreementEliLillyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=hcm_LicenseAndCollaborationAgreementAstrazenecaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 135 R96.htm IDEA: XBRL DOCUMENT v3.8.0.1

Research and Development Expenses (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Research and Development Expenses

Clinical trial related costs $ 45,250 $ 38,589 $ 24,690

Personnel compensation and related costs 24,848 21,698 17,339

Other research and development expenses 5,425 6,584 5,339

Research and development expenses $ 75,523 $ 66,871 $ 47,368

X

- Definition
Represents the research and development expense in connection with clinical trial.
+ References
No definition available.
+ Details

Name: hcm_ClinicalTrialRelatedCosts

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LaborAndRelatedExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of other research and development expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_OtherResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 136 R97.htm IDEA: XBRL DOCUMENT v3.8.0.1

Government Incentives (Details) - USD ($)
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Government Incentives

Government grants received $ 1,323,000 $ 1,872,000 $ 4,898,000

Reduction to research and development expenses $ 876,000 $ 1,269,000 $ 3,664,000

X

- Definition
Represents the amount of adjustment to the research and development expense disclosed, on account of government grants received.
+ References
No definition available.
+ Details

Name: hcm_AdjustmentToResearchAndDevelopmentExpenseOnAccountOfGovernmentGrantsReceived

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
n/a
+ References
No definition available.
+ Details

Name: hcm_GovernmentIncentiveAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the amount of government grants received .
+ References
No definition available.
+ Details

Name: hcm_ProceedsFromGovernmentGrantsReceived

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 137 R98.htm IDEA: XBRL DOCUMENT v3.8.0.1

Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries - Related parties (Details) - USD ($)
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Related party transaction

Sales $ 8,486,000 $ 9,794,000 $ 8,074,000

Interest paid 132,000 152,000 144,000

Balances with related parties included in:

Accounts receivable-related parties 3,860,000 4,223,000

Accounts payable-related parties 20,000 19,000

Amounts due from related parties 8,544,000 1,136,000

Amounts due to related parties 7,021,000 5,308,000

Amounts due to related parties - equal installment due Dec 31,2018 3,000,000

Amounts due to related parties - equal installment due Dec 31,2019 3,000,000

Marketing services

Related party transaction

Expenses 10,567,000 9,142,000 5,844,000

Indirect subsidiaries of CK Hutchison

Related party transaction

Interest paid 132,000

Guarantee fee on bank loan 320,000 471,000 471,000

Balances with related parties included in:

Accounts receivable-related parties 2,761,000 2,589,000

Accounts payable-related parties 19,000

Amounts due from related parties 23,000 107,000

Amounts due to related parties 454,000 152,000

Indirect subsidiaries of CK Hutchison | Sales

Related party transaction

Sales 8,486,000 9,794,000 8,074,000

Indirect subsidiaries of CK Hutchison | Marketing services

Related party transaction

Expenses 372,000 741,000 751,000

Indirect subsidiaries of CK Hutchison | Management service

Related party transaction

Expenses 897,000 874,000 845,000

Equity investees

Related party transaction

Purchases 1,182,000 280,000 3,701,000

Balances with related parties included in:

Accounts receivable-related parties 1,099,000 1,634,000

Accounts payable-related parties 20,000

Amounts due from related parties 893,000 1,029,000

Amounts due to related parties 6,567,000 3,070,000

Other deferred income 1,648,000 1,771,000

Equity investees | Research and development services

Related party transaction

Sales 9,682,000 8,429,000 5,383,000

Equity investees | Marketing services

Related party transaction

Expenses 10,195,000 8,401,000 5,093,000

Equity investees | Dividend receivable

Balances with related parties included in:

Amounts due from related parties 7,628,000

Immediate holding company

Related party transaction

Interest paid 152,000 $ 144,000

Balances with related parties included in:

Amounts due to related parties 2,086,000

Other non-current liabilities 6,000,000

Immediate holding company and an indirect subsidiary of CK Hutchison

Balances with related parties included in:

Amounts due to related parties $ 454,000 $ 2,238,000

X

- Definition
Amount of guarantee fee on bank loan incurred with related party.
+ References
No definition available.
+ Details

Name: hcm_GuaranteeFeeOnBankLoanRelatedParty

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of other deferred income as of balance sheet date with related parties.
+ References
No definition available.
+ Details

Name: hcm_OtherDeferredIncomeFromRelatedParties

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of other noncurrent liabilities to related parties, which are due after one year.
+ References
No definition available.
+ Details

Name: hcm_OtherNoncurrentLiabilitiesRelatedParties

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
One of the equal installment of other non-current liabilities due to related parties.
+ References
No definition available.
+ Details

Name: hcm_OtherNoncurrentLiabilitiesRelatedPartiesEqualInstallmentDueOne

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The other one of the equal installment of other non-current liabilities due to related parties.
+ References
No definition available.
+ Details

Name: hcm_OtherNoncurrentLiabilitiesRelatedPartiesEqualInstallmentDueTwo

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864
+ Details

Name: us-gaap_AccountsReceivableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueFromRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of interest expense incurred on a debt or other obligation to related party.
+ References
No definition available.
+ Details

Name: us-gaap_InterestExpenseRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Related Parties
-URI http://asc.fasb.org/extlink&oid=16382449

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999
+ Details

Name: us-gaap_RevenueFromRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=hcm_RelatedPartyTransactionMarketingServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=hcm_RelatedPartyTransactionSalesOfGoodsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=hcm_RelatedPartyTransactionManagementServiceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=hcm_RelatedPartyTransactionResearchAndDevelopmentServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=hcm_RelatedPartyTransactionDividendReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hcm_ImmediateHoldingCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hcm_IndirectSubsidiaryOfCkHutchisonAndImmediateHoldingCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 138 R99.htm IDEA: XBRL DOCUMENT v3.8.0.1

Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries - Non-controlling shareholders of subsidiaries(Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Non-controlling shareholders of subsidiaries

Sales $ 196,720 $ 171,058 $ 118,113

Purchases 169,764 149,132 104,859

Interest expense 1,455 1,631 1,404

Dividend declared 1,594 564 590

Balances with non-controlling shareholders of subsidiaries

Accounts receivable-third parties 38,410 40,812

Accounts payable 17,095 30,383

Other payables, accruals and advance receipts 40,953 31,716

Other non-current liabilities 1,117 8,129

Non-controlling shareholders of subsidiaries

Non-controlling shareholders of subsidiaries

Sales 13,307 12,274 6,196

Purchases 21,236 15,225 12,169

Interest expense 66 78 85

Dividend declared 1,594 564 $ 590

Balances with non-controlling shareholders of subsidiaries

Accounts receivable-third parties 1,846

Accounts payable 7,250 5,136

Other payables, accruals and advance receipts 1,630 14

Loan | Non-controlling shareholders of subsidiaries

Balances with non-controlling shareholders of subsidiaries

Other payables, accruals and advance receipts 1,550

Other non-current liabilities 579 2,129

Interest Payable | Non-controlling shareholders of subsidiaries

Balances with non-controlling shareholders of subsidiaries

Other payables, accruals and advance receipts $ 80 $ 14

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer) for other payables, accrued liabilities, deferred revenue and advance receipts.
+ References
No definition available.
+ Details

Name: hcm_AccountsPayableAccruedLiabilitiesDeferredRevenueOtherCurrent

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableTradeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_CounterpartyNameAxis=hcm_NonControllingShareholdersOfSubsidiariesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=hcm_LoanPayableToNonControllingShareholdersOfSubsidiariesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=hcm_InterestPayableToNonControllingShareholdersOfSubsidiariesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 139 R100.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Current tax $ 1,354 $ 978 $ 565

Deferred income tax 1,726 3,353 1,040

Income tax expense 3,080 4,331 1,605

Reconciliation of reported income tax expense to the theoretical tax amount

Loss before income taxes and equity in earnings of equity investees (53,536) (47,356) (10,540)

Tax calculated at the statutory tax rate of the Company (8,833) (7,814) (1,739)

Different tax rates available in different jurisdictions 2,531 453 (2,953)

Tax valuation allowance 11,410 9,886 6,601

Preferential tax deduction (3,347) (3,205) (2,096)

Expenses not deductible for tax purposes 391 688 253

Utilization of previously unrecognized tax losses (387) (21) (34)

Withholding tax on undistributed earnings of PRC entities 1,980 3,532 1,216

Others (665) 812 357

Income tax expense 3,080 4,331 1,605

Hong Kong

Current tax $ 572 $ 520 $ 150

Tax rates

Income tax rate (as a percent) 16.50% 16.50% 16.50%

PRC

Current tax $ 782 $ 458 $ 415

Tax rates

Income tax rate (as a percent) 25.00% 25.00% 25.00%

Preferential income tax rate (as a percent) 15.00% 15.00% 15.00%

Dividends declared withholding tax rate (as a percent) 10.00% 10.00% 10.00%

Lower withholding tax rate (as a percent) 5.00% 5.00% 5.00%

Minimum equity interest of foreign investor required for lower withholding tax rate (as a percent) 25.00% 25.00% 25.00%

Distributable reserves expected to be distributed as dividends (as a percent) 100.00% 100.00%

X

- Definition
A lower withholding tax rate on dividends declared to foreign investors for those investors that have at least 25% equity interest in the PRC, are incorporated in Hong Kong and meet the condition or requirements pursuant to the tax arrangement between the PRC and Hong Kong.
+ References
No definition available.
+ Details

Name: hcm_DividendsDeclaredAlternateWithHoldingTaxRate

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Minimum equity interest of foreign investor required for an entity to qualify for a lower withholding tax rate on dividends declared to foreign investors.
+ References
No definition available.
+ Details

Name: hcm_DividendsDeclaredAlternateWithHoldingTaxRateEquityThreshold

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Withholding tax rate on dividends declared to foreign investors.
+ References
No definition available.
+ Details

Name: hcm_DividendsDeclaredWithHoldingTaxRate

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Preferential tax rate for companies that qualify as High and New Technology Enterprises.
+ References
No definition available.
+ Details

Name: hcm_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRate

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax expense (benefit) from other jurisdictions.
+ References
No definition available.
+ Details

Name: hcm_IncomeTaxReconciliationOtherJurisdictionsIncomeTaxRateDifferential

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to previously unrecorded tax losses.
+ References
No definition available.
+ Details

Name: hcm_IncomeTaxReconciliationPreviouslyUnrecognizedTaxLosses

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to withholding tax on undistributed earnings of domestic subsidiaries or domestic joint ventures intended to be permanent.
+ References
No definition available.
+ Details

Name: hcm_IncomeTaxReconciliationWithholdingTaxOnUndistributedEarningsOfEquityInvestees

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of distributable reserves of the major subsidiaries and equity investees operating in the PRC that are expected to be distributed as dividends, as a percent.
+ References
No definition available.
+ Details

Name: hcm_PercentDistributableReservesExpectedToBeDistributed

Namespace Prefix: hcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=63044130

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e32123-109318
+ Details

Name: us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationDeductions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationNondeductibleExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_HK

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_CN

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 140 R101.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Deferred tax assets

Tax losses $ 31,028,000 $ 20,145,000

Others 1,267,000 372,000

Total deferred tax assets 32,295,000 20,517,000

Less: Valuation allowance (31,662,000) (20,145,000) $ (11,393,000) $ (7,455,000)

Deferred tax assets 633,000 372,000

Deferred tax liabilities

Undistributed earnings from PRC entities 4,332,000 5,230,000

Others 120,000 131,000

Deferred tax liabilities $ 4,452,000 5,361,000

Deferred tax assets, current 372,000

Deferred tax liabilities, current $ 1,364,000

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from tax losses.
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxAssetsTaxLosses

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(15)(b)(2))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(2))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Liability
-URI http://asc.fasb.org/extlink&oid=6510232

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredIncomeTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Asset
-URI http://asc.fasb.org/extlink&oid=6510090
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31928-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31958-109318
+ Details

Name: us-gaap_DeferredTaxAssetsNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredTaxLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesGrossCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of undistributed earnings of domestic subsidiaries or domestic joint ventures intended to be permanent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)(c)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 3
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=68052875&loc=d3e28200-109314
+ Details

Name: us-gaap_UndistributedEarningsOfDomesticSubsidiaries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 141 R102.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes - Movements in Net Deferred Income Tax Liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Movements in net deferred income tax liabilities

As at January 1 $ (4,989) $ (3,473) $ (2,842)

Utilization of previously recognized withholding tax on undistributed earnings 3,179 1,526 321

(Charged)/Credited to the consolidated statements of operations

Withholding tax on undistributed earnings of PRC entities (1,980) (3,532) (1,216)

Deferred tax on amortization of intangible assets 18 32 24

Deferred tax on provision for assets 236 147 152

Exchange differences (283) 311 88

As at December 31 $ (3,819) $ (4,989) $ (3,473)

X

- Definition
Movements in net deferred income tax liabilities.
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxLiabilitiesIncreaseDecreaseAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase/(decrease) in net deferred income tax liabilities due to exchange differences.
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxLiabilitiesIncreaseDecreaseCurrencyExchangeDifferences

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase/(decrease) in deferred tax liabilities resulting from deferred tax on amortization of intangible assets (charged)/credited to the consolidated statement of operations.
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxLiabilitiesIncreaseDecreaseDeferredTaxOnAmortizationIntangibleAssetsChargedCreditedToStatementOfOperations

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase/(decrease) in deferred tax liabilities resulting from deferred tax on provision of assets (charged)/credited to the consolidated statement of operations.
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxLiabilitiesIncreaseDecreaseDeferredTaxOnProvisionOfAssetsChargedCreditedToStatementOfOperations

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
(Charged)/Credited to the consolidated statement of operations
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxLiabilitiesIncreaseDecreaseTaxWithholding

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase/(decrease) in deferred tax liabilities resulting from withholding tax on undistributed earnings of equity investees (charged)/credited to the consolidated statement of operations.
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxLiabilitiesIncreaseDecreaseTaxWithholdingUndistributedEarningsChargedCreditedToStatementOfOperations

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase/(decrease) in deferred tax liabilities resulting from utilization of previously recognized withholding tax on undistributed earnings.
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxLiabilitiesIncreaseDecreaseUtilizationTaxWithholding

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 142 R103.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes - Tax Losses Carryforwards and Deferred Tax Valuation Allowance (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Tax losses carried forward

No expiry date $ 42,385 $ 32,859

2017 3,651

2018 858 807

2019 4,261 4,012

2020 36,188 34,059

2021 50,494 53,194

2022 65,195

Operating loss carryforwards 199,381 128,582

Deferred income tax valuation allowance:

At January 1 20,145 11,393 $ 7,455

Charged to consolidated statements of operations 11,410 9,886 6,601

Utilization of previously unrecognized tax losses (387) (21) (34)

Write-off of expired tax losses (558) (1,493)

Others (89) (288) (901)

Exchange differences 1,141 (825) (235)

At December 31 $ 31,662 $ 20,145 $ 11,393

X

- Definition
Amount of increase/(decrease) in deferred income tax valuation allowance resulting from other activity not separately disclosed.
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxAssetValuationAllowanceIncreaseDecreaseOthers

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase/(decrease) in deferred income tax valuation allowance resulting from utilization of previously unrecognized tax losses.
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxAssetValuationAllowanceIncreaseDecreaseUtilizationOfPreviouslyUnrecognizedTaxLosses

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase/(decrease) in deferred income tax valuation allowance resulting from write-off of expired tax losses.ax losses.
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxAssetValuationAllowanceIncreaseDecreaseWriteOffOfExpiredTaxLosses

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase/(decrease) in deferred income tax valuation allowance resulting from activity charged to the consolidated statement of operations.
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxAssetsValuationAllowanceIncreaseDecreaseChargedToStatementOfOperations

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase/(decrease) in deferred income tax valuation allowance due to exchange differences.
+ References
No definition available.
+ Details

Name: hcm_DeferredTaxAssetsValuationAllowanceIncreaseDecreaseCurrencyExchangeDifferences

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: hcm_OperatingLossCarryforwardsAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws that expire within the fiscal year ended.
+ References
No definition available.
+ Details

Name: hcm_OperatingLossCarryforwardsExpiringCurrentYear

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws that expire within the fifth year following the fiscal year ended.
+ References
No definition available.
+ Details

Name: hcm_OperatingLossCarryforwardsExpiringInYearFive

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws that expire within the fourth year following the fiscal year ended.
+ References
No definition available.
+ Details

Name: hcm_OperatingLossCarryforwardsExpiringInYearFour

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws that expire within the year following the fiscal year ended.
+ References
No definition available.
+ Details

Name: hcm_OperatingLossCarryforwardsExpiringInYearOne

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws that expire within the third year following the fiscal year ended.
+ References
No definition available.
+ Details

Name: hcm_OperatingLossCarryforwardsExpiringInYearThree

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws that expire within the second year following the fiscal year ended.
+ References
No definition available.
+ Details

Name: hcm_OperatingLossCarryforwardsExpiringInYearTwo

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws that do not have an expiration date.
+ References
No definition available.
+ Details

Name: hcm_OperatingLossCarryforwardsWithNoExpirationDate

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ValuationAllowanceAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 143 R104.htm IDEA: XBRL DOCUMENT v3.8.0.1

Income Taxes - Income Tax Payable (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Income Taxes

As at January 1 $ 274 $ 442 $ 112

Current tax 1,354 978 565

Withholding tax upon dividend declaration from PRC entities 3,179 1,526 321

Tax paid (3,836) (2,664) (510)

Exchange difference 8 (8) (46)

As at December 31 $ 979 $ 274 $ 442

X

- Definition
Represents the amount of exchange difference in income tax liability.
+ References
No definition available.
+ Details

Name: hcm_TaxesPayableExchangeDifference

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of withholding tax upon dividend declaration from PRC entities.
+ References
No definition available.
+ Details

Name: hcm_WithholdingTaxUponDividendDeclarationFromPrcEntities

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(b)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(1))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_AccruedIncomeTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 144 R105.htm IDEA: XBRL DOCUMENT v3.8.0.1

(Losses)/Earnings per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Basic (losses)/earnings per share

Number of shares used in per share calculation-basic 61,717,171 59,715,173 54,659,315

Net (loss)/income $ (22,963) $ 14,557 $ 10,427

Net income attributable to non-controlling interests (3,774) (2,859) (2,434)

Accretion on redeemable non-controlling interests (43,001)

Net (loss)/income attributable to ordinary shareholders of the Company $ (26,737) $ 11,698 $ (35,008)

(Losses)/earnings per share attributable to ordinary shareholders of the Company (US$ per share) $ (0.43) $ 0.20 $ (0.64)

Diluted (losses)/earnings per share

Number of shares used in per share calculation-basic 61,717,171 59,715,173 54,659,315

Adjustment for share options and LTIP 255,877

Weighted average number of outstanding ordinary shares in issue, diluted 61,717,171 59,971,050 54,659,315

Net (loss)/income for the year attributable to ordinary shareholders of the Company $ (26,737) $ 11,698 $ (35,008)

(Losses)/earnings per share attributable to ordinary shareholders of the Company (US$ per share) $ (0.43) $ 0.20 $ (0.64)

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 28A
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1500-109256
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591551-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.19)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 145 R106.htm IDEA: XBRL DOCUMENT v3.8.0.1

Segment Reporting - Segment Information (Details)
$ in Thousands
12 Months Ended

Dec. 31, 2017

USD ($)

area

Dec. 31, 2016

USD ($)

Dec. 31, 2015

USD ($)

Segment reporting

Revenue from external customers $ 241,203 $ 216,080 $ 178,203

Adjusted (LBIT)/EBIT (53,301) (46,227) (9,587)

Interest income 1,220 502 451

Equity in earnings of equity investees, net of tax 33,653 66,244 22,572

Operating (loss)/profit (18,428) 20,519 13,436

Interest expense 1,455 1,631 1,404

Income tax expense 3,080 4,331 1,605

Net (loss)/income attributable to the Company (26,737) 11,698 7,993

Depreciation/amortization 2,578 2,341 2,015

Additions to non-current assets (other than financial instrument and deferred tax assets) 6,073 4,327 3,324

Segment information

Total assets 597,932 342,437

Property, plant and equipment 14,220 9,954

Leasehold land 1,261 1,220

Goodwill 3,308 3,137

Other intangible asset 430 469

Investments in equity investees $ 144,237 158,506

Commercial Platform

Segment reporting

Number of core business areas | area 2

Reportable segment

Segment reporting

Revenue from external customers $ 205,206 180,852 126,187

Adjusted (LBIT)/EBIT 6,879 3,736 1,718

Interest income 63 66 144

Equity in earnings of equity investees, net of tax 38,200 70,476 26,342

Operating (loss)/profit 45,142 74,278 28,204

Interest expense 66 79 85

Income tax expense 986 569 387

Net (loss)/income attributable to the Company 40,033 70,337 25,155

Depreciation/amortization 151 124 110

Additions to non-current assets (other than financial instrument and deferred tax assets) 107 138 97

Segment information

Total assets 195,420 212,543

Property, plant and equipment 251 219

Goodwill 3,308 3,137

Other intangible asset 430 469

Investments in equity investees 124,725 141,475

Reportable segment | Innovation Platform | Drug R&D | PRC

Segment reporting

Revenue from external customers 35,997 35,228 52,016

Adjusted (LBIT)/EBIT (47,503) (36,657) (119)

Interest income 64 52 79

Equity in earnings of equity investees, net of tax (4,547) (4,232) (3,770)

Operating (loss)/profit (51,986) (40,837) (3,810)

Income tax expense 26

Net (loss)/income attributable to the Company (51,880) (40,735) (3,810)

Depreciation/amortization 2,400 2,176 1,864

Additions to non-current assets (other than financial instrument and deferred tax assets) 5,936 4,138 3,218

Segment information

Total assets 63,268 53,774

Property, plant and equipment 13,917 9,686

Leasehold land 1,261 1,220

Investments in equity investees 19,512 17,031

Reportable segment | Commercial Platform | Prescription Drugs | PRC

Segment reporting

Revenue from external customers 166,435 149,861 105,478

Adjusted (LBIT)/EBIT 3,272 2,377 676

Interest income 37 31 114

Equity in earnings of equity investees, net of tax 27,812 60,288 15,653

Operating (loss)/profit 31,121 62,696 16,443

Income tax expense 934 777 239

Net (loss)/income attributable to the Company 28,999 61,120 15,934

Depreciation/amortization 116 102 94

Additions to non-current assets (other than financial instrument and deferred tax assets) 56 67 88

Segment information

Total assets 122,665 134,681

Property, plant and equipment 160 145

Goodwill 2,901 2,730

Other intangible asset 430 469

Investments in equity investees 69,417 77,939

Reportable segment | Commercial Platform | Consumer Health | PRC

Segment reporting

Revenue from external customers 9,858 6,984 3,028

Adjusted (LBIT)/EBIT 578 (493) (169)

Interest income 13 34 29

Equity in earnings of equity investees, net of tax 10,388 10,188 10,689

Operating (loss)/profit 10,979 9,729 10,549

Income tax expense (457) (497)

Net (loss)/income attributable to the Company 9,773 8,384 8,640

Depreciation/amortization 17 3 11

Additions to non-current assets (other than financial instrument and deferred tax assets) 43 20 5

Segment information

Total assets 58,961 67,161

Property, plant and equipment 61 34

Goodwill 407 407

Investments in equity investees 55,308 63,536

Reportable segment | Commercial Platform | Consumer Health | Hong Kong

Segment reporting

Revenue from external customers 28,913 24,007 17,681

Adjusted (LBIT)/EBIT 3,029 1,852 1,211

Interest income 13 1 1

Operating (loss)/profit 3,042 1,853 1,212

Interest expense 66 79 85

Income tax expense 509 289 148

Net (loss)/income attributable to the Company 1,261 833 581

Depreciation/amortization 18 19 5

Additions to non-current assets (other than financial instrument and deferred tax assets) 8 51 4

Segment information

Total assets 13,794 10,701

Property, plant and equipment 30 40

Unallocated

Segment reporting

Adjusted (LBIT)/EBIT (12,677) (13,306) (11,186)

Interest income 1,093 384 228

Operating (loss)/profit (11,584) (12,922) (10,958)

Interest expense 1,389 1,552 1,319

Income tax expense 2,068 3,762 1,218

Net (loss)/income attributable to the Company (14,890) (17,904) (13,352)

Depreciation/amortization 27 41 41

Additions to non-current assets (other than financial instrument and deferred tax assets) 30 51 $ 9

Segment information

Total assets 339,244 76,120

Property, plant and equipment $ 52 $ 49

X

- Definition
The amount of income or loss before interest and taxes.
+ References
No definition available.
+ Details

Name: hcm_IncomeLossBeforeInterestAndTaxes

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of land held under leaseholds.
+ References
No definition available.
+ Details

Name: hcm_LeaseholdLand

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the number of core business areas of the segment.
+ References
No definition available.
+ Details

Name: hcm_NumberOfCoreBusinessAreas

Namespace Prefix: hcm_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating (loss)/profit.
+ References
No definition available.
+ Details

Name: hcm_OperatingLossProfit

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66022249&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(12))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(10))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66022249&loc=d3e33749-111570

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(f))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_IncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationAdditionalInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=hcm_CommercialPlatformMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=hcm_InnovationPlatformMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_DrugResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_CN

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_PrescriptionDrugsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_ConsumerHealthMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_HK

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConsolidationItemsAxis=hcm_CorporateAndReconcilingItemsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 146 R107.htm IDEA: XBRL DOCUMENT v3.8.0.1

Segment Reporting - Elimination (Details) - USD ($)
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Revenue from External Customers

Revenue from external customers $ 241,203,000 $ 216,080,000 $ 178,203,000

Intersegment elimination | Consumer Health | PRC

Revenue from External Customers

Revenue from external customers $ (2,536,000) $ (1,306,000) $ (2,874,000)

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=hcm_ConsumerHealthMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_CN

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 147 R108.htm IDEA: XBRL DOCUMENT v3.8.0.1

Segment reporting - Concentration Risk Percentage (Details)
12 Months Ended

Dec. 31, 2015

Revenue | Customer | Customer one | Innovation Platform

Revenue, Major Customer [Line Items]

Concentration risk percentage (as a percent) 23.00%

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EntityWideRevenueMajorCustomerLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=hcm_CustomerOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=hcm_InnovationPlatformMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 148 R109.htm IDEA: XBRL DOCUMENT v3.8.0.1

Segment Reporting - Reconciliation of Adjusted LBIT to net (loss)/income (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Segment Reporting

Adjusted LBIT $ (53,301) $ (46,227) $ (9,587)

Interest income 1,220 502 451

Equity in earnings of equity investees, net of tax 33,653 66,244 22,572

Interest expense (1,455) (1,631) (1,404)

Income tax expense (3,080) (4,331) (1,605)

Net (loss)/income $ (22,963) $ 14,557 $ 10,427

X

- Definition
The amount of income or loss before interest and taxes.
+ References
No definition available.
+ Details

Name: hcm_IncomeLossBeforeInterestAndTaxes

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(12))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(10))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66022249&loc=d3e33749-111570

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(f))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_IncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 149 R110.htm IDEA: XBRL DOCUMENT v3.8.0.1

Note to Consolidated Statements of Cash Flows (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Operating activities

Net (loss)/income $ (22,963) $ 14,557 $ 10,427

Adjustments to reconcile net (loss)/income to net cash used in operating activities

Amortization of finance costs 147 92 62

Depreciation and amortization 2,578 2,341 2,015

Loss on retirement of property, plant and equipment 57 30 60

Provision for excess and obsolete inventories (16) 163 4

Provision for doubtful accounts 242 (208) 1,408

Share-based compensation expense-share options 1,316 1,780 1,151

Share-based compensation expense-LTIP 3,423 1,661 308

Equity in earnings of equity investees, net of tax (33,653) (66,244) (22,572)

Dividend received from equity investees 55,586 30,528 6,410

Unrealized currency translation (gain)/loss (399) 633 198

Changes in income tax balances (756) 1,667 1,093

Changes in working capital

Accounts receivable-third parties 2,160 (7,258) (12,030)

Accounts receivable-related parties 363 (2,354) 315

Other receivables, prepayments and deposits (6,982) (1,129) (459)

Amounts due from related parties 220 1,157 (3,010)

Inventories 1,049 (3,430) (5,154)

Long-term prepayment 123 361 (2,132)

Accounts payable (11,173) 11,452 3,659

Other payables, accruals and advance receipts 5,194 7,554 4,660

Deferred revenue (897) (1,668) (1,907)

Other deferred income (275) 131 2,132

Amounts due to related parties (4,287) (1,385) 3,977

Total changes in working capital (14,505) 3,431 (9,949)

Net cash used in operating activities $ (8,943) $ (9,569) $ (9,385)

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period for the provision for doubtful accounts.
+ References
No definition available.
+ Details

Name: hcm_AdjustmentForProvisionForDoubtfulAccounts

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) in deferred income during the period.
+ References
No definition available.
+ Details

Name: hcm_IncreaseDecreaseInDeferredIncome

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all excess and obsolete inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
No definition available.
+ Details

Name: hcm_IncreaseDecreaseInExcessAndObsoleteInventories

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of other payables accruals and advances.
+ References
No definition available.
+ Details

Name: hcm_IncreaseDecreaseInOtherPayablesAccrualsAndAdvances

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The Company granted awards under a long term incentive plan ("LTIP"). The LTIP awards granted participating directors or employees a conditional right to receive ordinary shares in the Company (the "Ordinary Shares"), to be purchased by a trustee consolidated by the Company (the "Trustee") up to a maximum cash amount depending upon the achievement of annual performance targets for each financial year of the Company stipulated in the LTIP awards. The Trustee has been set up solely for the purpose of purchasing and holding the Ordinary Shares during the vesting period on behalf of the Group using funds provided by the Group. This element represents the associated non-cash expense.
+ References
No definition available.
+ Details

Name: hcm_ShareBasedCompensationLongTermIncentivePlan

Namespace Prefix: hcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense attributable to debt issuance costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(8))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(8))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This item represents disclosure of the amount of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporation; these investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(10))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(12))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_EquityMethodInvestmentDividendsOrDistributions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(12))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(10))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66022249&loc=d3e33749-111570

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(f))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_IncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDueFromRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDueToRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cumulative translation gain (loss), before tax, from translating foreign currency financial statements into the reporting currency.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=64808268&loc=d3e32022-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900
+ Details

Name: us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 150 R111.htm IDEA: XBRL DOCUMENT v3.8.0.1

Litigation (Details)

Dec. 31, 2017

claim

Litigation

Number of claims or actions pending 0

X

- References
No definition available.
+ Details

Name: hcm_LitigationAbstract

Namespace Prefix: hcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of pending claims pertaining to a loss contingency.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349
+ Details

Name: us-gaap_LossContingencyPendingClaimsNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

XML 151 R112.htm IDEA: XBRL DOCUMENT v3.8.0.1

Restricted Net assets (Details) - PRC - USD ($)

Dec. 31, 2017

Dec. 31, 2016

Undistributed earnings in equity investees $ 85,400,000 $ 116,953,000

Subsidiaries

Restricted net assets $ 7,277,000 $ 6,847,000

X

- Definition
Amount of restricted net assets of consolidated and unconsolidated subsidiaries as of the end of the most recently completed fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e)(3)(ii))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of consolidated retained earnings that represent undistributed (not yet received) earnings from 50% or less owned persons accounted for by the equity method (equity method investees).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6462270&loc=d3e57205-112772
+ Details

Name: us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_CN

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=us-gaap_SubsidiariesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 152 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( %@S;$P?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ 6#-L3&;S"V"" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " !8,VQ,?269[N\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+!3L,P#(9?!>7>NFG%0%'7"]-.("$Q"<0M 40\DM,Q3XDN-?=] M<)K3,QS :_S0!X*R*%;@B+71K&$"9GXABJ8VJ#"0YCZ<\087O/\,[0PS"-22 MHXXCR%R":*:)_C2V-5P!$XPIN/A=(+,0Y^J?V+D#XIP7^9U,]M%UAU2^A6MXI.GM;A,?JT>-KNM:,I"WF=%E:NJN_?) M]8??5=CUQN[M/S:^"#8U_+J+Y@M02P,$% @ 6#-L3)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " !8,VQ,.,]X>&@" "," & 'AL+W=OB\&/AI;G6RBQ$9=&3*_U!U<_^*/0LFJ*^.,+'0O*PF"L_AN]4Z;A)A.M47$F M[36H;E+Q=HRB4VG)^W!O.GM_#$^2?*3!!#P2\$3 &UO+(&0S_T04*0O!'X$8 M-K\GYHS1%NN]JJ]C(OH;L*,B,. P#,$FA"1CCT)8$C@@#TZ MAND)F%]BZ0F8WW_T%*2GEI[.Z(E3GH](88$,%,@\>N8(#(C,(KIA__)TC;,5 M+).#,KDGDSLR/F)!8 4*K#SZVA'P$1M88 T*K#TZ,'G"#8Z\GV,D:N2>E;,\S1=Q1[[IL?NB(=_V.%X\']CT MR/FD\&) M*]V2;..X<*ZH3B5^TL76^M=@FC!Z46:XTF,Q],=AHG@_]OYH^@$I_P)02P,$ M% @ 6#-L3#PC"Y8$!0 >AD !@ !X;"]W;W)KN_#;N4QL7W0WL<[I>[<3S=5=7PN$N'9OC< MG=(Q_^>IZP_-F&_[YVHX]:G9SD&'M@*E7'5H]L?E>C4_^]*O5]W+V.Z/Z4N_ M&%X.AZ;_;Y/:[NU^J9?O#[[NGW?C]*!:KT[-<_HSC7^=OO3YKKJ6LMT?TG'8 M=\=%GY[NES_IN]J8*6!6_+U/;\/-]6)JRD/7?9MN?MO>+]7D*+7I<9R*:/+/ M:ZI3VTXE91__7@I=7NN< F^OWTO_96Y\;LQ#,Z2Z:__9;\?=_3(L%]OTU+RT MX]?N[==T:9!=+BZM_SV]IC;+)R>YCL>N'>:_B\>78>P.EU*RE4/S_?R[/\Z_ M;Y?RW\/D +@$P#5 FQ\&X"4 24!U=C8W]>=F;-:KOGM;].?>.C73H-!WF%_F MX_1P?G?S_W)KA_ST=0UV5;U.Y5PDF[,$;B7NHZ06)/XJJ;*!JPL07< ',;'TDKSA(W2XZS)%API*TU5_EH4,M>C.C%,"^HB)>SQ-[4 A[5 M335G,X+,@%>R&2N:L=P,J65C62T8C":6:ZXR*FB0O3C1B^->@'AQ@A='K7"1 M 4#9B1>=>.X$B1//*M$:(AWW7)4'BY&M!-%*X%8,L1)8)<$:(JJY2&MTLI,H M.HG<"25!%"KQ@6P:HY69&2]:+YV.&.PDQ4 M0>GER&C5G*V&LE5S:B*J0-T(*HV%-4O+;-4%A5;+[-0C0 M LZ^[)1E5X(,K<5"J@>%7)$3TE!F T>?4=$B]<-EJ+TN]#G(B 2.2#K:-\#A ME[N0^0B\OTCVYD0@(GI*6T!DY(B#%05@@RG5?6TL2440H:X (64,8H"1MD>E?,Q*(H)000*"WV ,D.1,]329!^%+#,&NHX+*@!7 MR"JPL'OG!+5TA4$A?W2ILD&//.4,7^5J2*5_* MV%#&(W(\.DHCY-@ST45V,"'H0 4=2XYD/B+GHZ/ 1DZ^3UKY#&UJ21 &A:6U MRLB0-!R2CJ:UAD/2\JV.H/IDP!GO/4@DZ'\BF; MD7EJ.$\I"S9&("4"-R1AU\>2'YFHAA/54889SDH3#&>8H -E5&G>F\*I**>J MHPR[:&Y/7\6=D: 3=T;5S2'X]%7BCZ9_WA^'Q4,WCMUA/O5^ZKHQY3+5Y]R^ M76JVUYLV/8W3I<_7_?EKP/EF[$Z7+QW5]7/+^G]02P,$% @ 6#-L3#^\ MIWSD 0 [@0 !@ !X;"]W;W)K)$=@/)>&1UD@3JEQ@/&LNZ $?G 1QCT2LL%(TJ'XHSE*( TUL0H#GT_ MQ8ST RISFSN*,N<71?L!CL*3%\:(^/L$E$\%"M!;XKD_=\HD<)F/Y P_0/T< MCT)'>*G2] P&V?/!$] 6Z&-PJ!*CMX)?/4QR-?=,)R?.7TSPM2F0;X" 0JU, M!:*'*U1 J2FD,?[,-=&RI3&NYV_5/]O>=2\G(J'B]'??J*Y C\AKH"47JI[Y M] 7F?A+DSH^:4VE_O?HB%6=S%8W"R*L;^\&.DUM)LMFV;PAG M0[@8@OA=0S0;HHT!.S+;ZB>B2)D+/GG"?:R1F#,1'"+],FN3M._.KNENI MR_1#CJ^FSBQY+;9X/R'\(;HF27*+DGBC9$ MR=U&:1K'F1]E&Z(=H9_YR6,8;8CPZN29F^ [$>=^D-Z)*WV([5%K.5>@B_H/ MNEZG+Y\EH- J,\WT7+B_H L4'^?;!2]77/D/4$L#!!0 ( %@S;$SSF0BP M304 /49 8 >&PO=V]R:W-H965T&ULA9G=;N,V$(5? MQ?!]8L[P3PP2 Y&-H@5:(-BB[;62,+&QMN5*2K)]^U*RXI5GAKM88&TK9\A# MBIIO2-U^U,W7=A-C-_NVWQW:N_FFZXXWBT7[M(G[JKVNC_&0_O)2-_NJ2S^; MUT5[;&+U/ 3M=PM4RBWVU?8P7]X.UQZ:Y6W]UNVVA_C0S-JW_;YJ_BOCKOZX MF\/\\\*7[>NFZR\LEK?'ZC7^&;N_C@]-^K4XM_*\W<=#NZT/LR:^W,WOX6:M M71\P*/[>QH]V\GW6#^6QKK_V/WY[OINKWE'N;Z)*'^]Q%7>[OJ7DX]^Q MT?FYSSYP^OVS]5^&P:?!/%9M7-6[?[;/W>9N7LQGS_&E>MMU7^J/7^,X(#N? MC:/_/;['79+W3E(?3_6N'?Z?/;VU7;T?6TE6]M6WT^?V,'Q^C.U_ALD!. ;@ M.0#<#P/T&*"_!Y@?!I@QP)" Q6DHP]RLJZY:WC;UQZPYW=YCU:\BN#%I]I_Z MB\-D#W]+T].FJ^]+;VX7[WT[HZ0\27 B@;-BD1H_]X!2#R6R<'27/:P$B;^4 MK+G$6]F%%L>IAW@]C7=RO!'CS1!OIO'$8GF2N$%R.,U3@]9D[78A&"FX$R-05 M_":Z HE;+BH,DINPYB*KBXS=(-H-W"YQ4@8^)P90:6)8D(%3]"ZLN0Q\,6WM MPC0H.5$\*5*#0!-)G*M2A4IK A8UY,Y/> MW+REYI%WY92E"462^90MJ7%!9@,4&=MRY@?-;3MJ6PM^K$6ZVB2=I MD^-*U(%EC[BD2TL*,PD=9 8!AU!!(02<'%<8C&.H%X4./2T=UI(0"A]R_ 09 M1\!Y%!0USV%S9;4!3[T+.N-2'J+6!5WP/E,B@HPO*%AF#;D69*( 1TJ@2 &! M LAO&E=9Q5(J%QF;*XMEFJ#BCDF^*4?-95%%'J25('**,EL0Z2)3 :,,+^3P MHD5@B2*3V#,MRE(A1TV+K:G,0X$RMI!C*U!LH80MNGY6D@HTFVE!A9,%=.E9 M9A9R9E$XEB@P!B!0SQ*Q+/,L\<]E5BB0)=-*LS5Y+,:+ZP)5:E.BEC6T85 D,P"NM"'TYZ%T>RQ>C[_V,67KO_JT_?F]"+B]*.KC^-+EL7Y3<_R?U!+ M P04 " !8,VQ,[IGQC7@" #N!P & 'AL+W=O&0M;=23,^,U MD6K*+X%H.24G0ZJK (9A'-2D;/SMVJP]\^V:7655-O29>^):UX3_RVG%NHT/ M_/O"2WDII%X(MNN67.A/*G^USUS-@E'E5-:T$25K/$[/&_$K/:9QAO [Y)V M8C+V=)(#8Z]Z\NVT\4-MB%;T*+4"4;<;W=&JTD+*QM]!TQ^WU,3I^*[^Q617 M60Y$T!VK_I0G66S\U/=.]$RNE7QAW5#:B=KCR"IAKM[Q M*B2K!Q5EI29O_;ULS+T;].\T-P$.!#@20/PI 0T$]$[ GQ+P0, 6(>BCF-KL MB23;-6>=Q_NWVQ+]$8$55M4_ZD53;/-,E4>HU=L6@' =W+30@,E[#)QB1D2@ MU,9?I.^(/P2]D([\"D.I/-R7EF3%+E,7Q4%2U4\QTG%3U+/4S4F/&PO=V]R M:W-H965T&ULC9K;;MM&$(9?1="]HCTO&=@&*M(B"[1 D*+M M-6/3MA!)5"7:;M^^),4HVIF?)F^L@[^=G9T]_#,KWKQ7Q^^GE[*L9__NMOO3 M[?REK@^?E\O3PTNY*TZ?JD.Y;_[S5!UW1=U\/#XO3X=C63QVC7;;I1+"+7?% M9C^_N^F^^W*\NZE>Z^UF7WXYSDZONUUQ_&]5;JOWV[F<__CBZ^;YI6Z_6-[= M'(KG\H^R_O/PY=A\6EZL/&YVY?ZTJ?:S8_ET._]%?LZM:AMTQ%^;\OUT]7[6 M#N5;57UO/_SZ>#L7K4?EMGRH6Q-%\_)6)N5VVUIJ_/BG-SJ_]-DVO'[_P_JZ M&WPSF&_%J4RJ[=^;Q_KE=A[-9X_E4_&ZK;]6[WG9#\C.9_WH?RO?RFV#MYXT M?3Q4VU/W=_;P>JJK76^E<657_'M^W>R[U_?>_H]FN('J&ZA+ ^T_;*#[!OK2 M0+H/&YB^@;DT4!_W8/L&]FX$^3EJ5M!#^V6W8+K_-5-\:KY]NY/2WRS? M6D,]LSHS*F"BD$D0$X=,RAFG0N0>F%$B9-:(D2&3(8;TE2-&7YAE$[9+[!2, MG>H,F," (;$[,ZYC]AVC8VF)NPFGK!;>D?AQRCME"77/J8440M ^UYR+(T]B MG7%(>N_(('/@OFM&B6.I82PUB*4E43HSED:I&1SNR<">3&=%!STY;,!" Q:X M2K>,9:[Z.-9DIJ9 &8>4T70"."2%N7(J&)6#HW)@5&23KQSK9F&T$&1EI=.P M?!0+O/;0:P^\)L?.RK-^(B,TF;'$\XVJ)(ES"DR)2)$IR\A26(6OV:=DO !0ZRWG!L*>@O&) 46 M-0%&18[_I(?(SKH.7R\3HUSHTH#.2N 2B<^JAX( .;()TRE0WD-N H]QNHF M@;S1@V?50T%PZ+#2*5 ^ H4>8PV10$2TI1YS%3'L!)L"Y2-0Z#'6(FF QXYZ M;/A!*7U$LX-I6#Z*A7YC"91 ^F)FDFN2@L;L^TU0H7N8.V20+PT%2_)]<:P M]'.W"-2BN"HNK MDM-S>C50RZ%BCF;UBFN4E"ZFTS8-RP"F(DOV>(Z,F<$UKK R*J",-#M;*:YG M4@KI:-[9<]>+W(B(4"FR)ASC+XOIG%#U7>B@HUNFA @QIEF4!0V9PIV"Q54ALV<[F AB#W'H4"QW" M4JF 5!J:]BD@@\V!1+=X.I'+%:\7"1>ZCI55H3J/[4NNE.JN6AW\1K4;8UU6_OI6;O& M^JF!?K*L78,J43E/CXK[B5P&N$8?V9&"K*G8#5QI:2RD&A6G-$'07-FTD)IF M6XE&U6EDZ3H'4AI;Q^XX@#72:_AC#%94@^I$FK@;5"=&EN>3$\#0*2R'!LDA M3=P-ES!-JYO$\'M8>FF0(D/T&B<'A@:3%X/UTB"]I(F[X4IH'0CT&!8ZA!73 MH*J49E,&J&'D)"TWIV&YX=5FB(5^#_R"B&YMZ:8T7.BDHO=4J3=T-NAL F@'/.T&PU1>9B%]-;S7O M86)I*7K&H#6 MT!_G,T IS7_U1-Y%C7]##Z1@9;= V4U,X\4ENXL75^WEU<-C[2.,OQ?'Y\W^ M-/M6U76UZYX6>ZJJNFRLBD^-O9>R>+Q\V)9/=?O6-^^/YT<'SQ_JZM _%KF\ M/)MY]S]02P,$% @ 6#-L3)Y(^F*M! ,A8 !@ !X;"]W;W)K@?EKMA.-XG M2;_9N:;JO[1'=_#_>6V[IAK\8_>6],?.5=LIJ*D3$B)-FFI_6*Y7T[OG;KUJ MWX=Z?W#/W:)_;YJJ^Z]P=7MZ6,KEYXNO^[?=,+Y(UJMC]>;^=,-?Q^?./R67 M+-M]XP[]OCTL.O?ZL'R4]T]*CP$3XN^]._57WQ=C*2]M^VU\^&W[L!0C(U>[ MS3"FJ/S'ARM=78^9/(]_YZ3+RYACX/7WS^R_3,7[8EZJWI5M_<]^.^P>EMER ML76OU7L]?&U/O[JY(+-$C$S_&IJW[Z>]B\]X/;3-G\52:ZOOY M@[0+" YES+UYJD:JO6J:T^+ M[CR]QVI<1?)>^^YOQI=3LZ?_^?;T_NW'6AJQ2C[&1#.F.&/H&G-!)#[[90A" M0Q04A%-Z.T()(/86\A1"K,$L%"Q43?'JIM!(&1HFT%,"?9. 6*?.F'3"'";, M799KQ:H%J-RD.2L8H506J=E R@;4K'""%"9(01DA630E06@63 M#%!*D<:4+:1L 67#*%LP#!FAV'26 )>)S%C,)X-\,L"'+?\B"\:Q*5G)V(0H MDYJ,MS!$29(VQY1S2#D'E-DP11ZVQ@K!E*,$*'.-NB$C!58H >AD7*)$.!*E MPF:<$0(J97+>1H#+,A/9?3*BK1+LO\A,2*B=CY+"XM- GRG@JH1,P]I#G)3" M9"FO'>"4C>Q"B>56*D!<\H%4N*0CFTMB499 E5.NRC/H9LZE2BUO#X"E0G/. M*)F]ZN$M;2S,T@#:BM,V8"23:TX;P$P:T$:H/+83L1M(8 =\H%("#9?Q/8]% M7 (53[F*RU">O8KK8-6',#*2,MX@E$W$-CS6>@G$/N5B+T.%OM.YYD)>(AQE MUY1FX@"7:AEK.)9\"32?;Y!" CGW;L@/!S""(R7P(8*.\)P&[+N^6-'8[2\,06._@0MBX"UF6Y=5%H-I;[?PE M_AP>K#. (HJH/V'?(N!;7-8+"GU&92J0T!!%:7 : 2@3)^2::'XBDFN+LX:U[U- MEY+]8M.^'X;Q^NGJ[>7B\Y'&BS?VOI#W3^?KRQ]ISK>I?U3=V_[0+U[:86B; MZ?+MM6T'YUF*+WYJ=Z[:7AYJ]SJ,7ZW_WIUO,<\/0WN<;VB3RS7Q^G]02P,$ M% @ 6#-L3.XIL#6T 0 TP, !@ !X;"]W;W)KM.IO3UKG^Q)@M6]#"WF$/G?]3H]'"^= T MS/8&1!5)6C&^VQV8%K*C119S%U-D.#@E.[@88@>MA?EQ!H5C3O?T-?$HF]:% M!"NR7C3P!=S7_F)\Q!:52FKHK,2.&*AS>K\_G=. CX!O$D:[VI/0R17Q.00? MJYSN@B%04+J@(/QR@P=0*@AY&]]G3;J4#,3U_E7]?>S=]W(5%AY0/'ISX&B4J&[^D'*Q#/:MX*UJ\3*OLXCI. M?Y+#3-LF\)G %\(QUF%3H>C\G7"BR R.Q$QGWXMPQ?L3]V=3AF0\BOC/F[<^ M>ROVQR1CMR T8\X3AJ\Q"X)Y]:4$WRIQYG_1^6&;GVQ:3"(_^8?%WP3238$T M"J3_[7$+D_Y1A*T.58-IXCA94N+0Q5%>99>)O>?Q4G[!IW'_+$PC.TNNZ/S5 MQ@NH$1UX*[L[/T.M?V%+H*!V8?O6[\TT9U/@L)^?$%O>&PO=V]R:W-H965T&UL M?5-_;YLP$/TJEC] G9"DS2) :CI-F]1*4:=U?SMP@%7_8+8)[;??V5#&5KI_ ML.]X[]T[^YSVQCZ[!L"3%R6URVCC?7M@S!4-*.ZN3 L:_U3&*NXQM#5SK05> M1I*2+%FMKIGB0M,\C;F3S5/3>2DTG"QQG5+!1UXT."Y6G+ M:_@._D=[LABQ2:44"K031A,+549OUX?C-N CX$E [V9[$CHY&_,<@F]E1E?! M$$@H?%#@N%S@#J0,0FCCUZA)IY*!.-^_J7^)O6,O9^[@SLB?HO1-1O>4E%#Q M3OI'TW^%L9\=)6/S]W !B?#@!&L41KKX)47GO%&C"EI1_&58A8YK/_S9?1II MRX1D)"0381_KL*%0=/Z9>YZGUO3$#F??\G#%ZT."9U.$9#R*^ _-.\Q>\O5^ ME[)+$!HQQP&3S#$3@J'Z5")9*G%,WM&3ZV7^9M'B)O(W'UC\2V"[*+"- MO_ M]KB$^=9L"+QIQR?$IG><_P902P,$% @ 6#-L M3&[GO4:U 0 TP, !D !X;"]W;W)K&UL?5/1 M;IPP$/P5RQ\0WW$T.9T *9>H:J5&.B5J^^R#!:S87FJ;(_G[V(90VM*\8.\R M,SMKK[,!S;-M 1QY45+;G+;.=0?&;-F"XO8*.]#^3XU&<>=#TS#;&>!5)"G) MDLWFFBDN-"VRF#N9(L/>2:'A9(CME>+F]0@2AYQNZ7OB432M"PE69!UOX G< M]^YD?,1FE4HHT%:@)@;JG-YN#\^/W9IRS,7#834^(S>^X> -02P,$% @ 6#-L3.KL M$K^V 0 TP, !D !X;"]W;W)K&UL?5/1;IPP M$/P5RQ\0<[YK>CD!4BY5E4JM=$K5Y-D'"UBQ,;'-D?Y]UX80VM*^8.\R,SMK MK]/!V&?7 'CRJE7K,MIXWQT8R>6IZKV0+)TM;@['7'#B>31&2\2CB/S3O,'O)-_N;E%V"T(0Y MCAB^Q,P(ANIS";Y6XLC_HO/K=?YVU>(V\K?_L/B;P&Y58!<%=O_M<05SD_Q1 MA"T.58.MXS@Y4IB^C:.\R,X3>\OCI;S#QW'_)FPM6T?.QN/5Q@NHC/& 5I(K MG*$&7]@<**A\V'[$O1WG; R\Z:8GQ.9WG/\"4$L#!!0 ( %@S;$S0,CP0 MM0$ -,# 9 >&PO=V]R:W-H965T&4)K0OF#O,C,[:Z_3 MP=@GUP!X\JQ5ZS+:>-\=&'-% UJX*]-!BW\J8[7P&-J:NG2Q& M;%8II8;62=,2"U5&;Y/#<1?P$?!#PN 6>Q(Z.1OS%(*O948WP1 H*'Q0$+A< MX Z4"D)HX]>D2>>2@;CN>-GE30BA;/XRK;N [C'[Z?:.L$/A'X3+B) M==A8*#K_)+S(4VL&8L>S[T2XXN3 \6R*D(Q'$?^A>8?92YY\3%)V"4(3YCAB M^!(S(QBJSR7X6HDC?T?G^W7^=M7B-O*W_[#XE\!N56 7!7;_[7$-P]\488M# MU6#K.$Z.%*9OXR@OLO/$WO)X*7_@X[@_"%O+UI&S\7BU\0(J8SR@E ,M $ M -,# 9 >&PO=V]R:W-H965T0]LPUUL0521IQ?AN=\VTD!TM MLI@[V2(S@U>R@Y,E;M!:V-[8 @4E#XH"%PN< =* M!2&T\3QKTJ5D(*[W;^KWL7?LY2PD-)1748E#^T8R?8.[G'25S M\U_@ @KAP0G6*(UR\4O*P7FC9Q6THL7+M,HNKN/TARQ#IL* M1>TLKO"&6KQA2V! M@MJ'[7O&UL?5/M;IPP$'P5RP\0WW'D MHR= RJ6J6BF13JF:_O;! E9L+[7-D;Q];4,H;4C_8.\R,SMKK[,!S;-M 1QY M45+;G+;.=7O&;-F"XO8".]#^3XU&<>=#TS#;&>!5)"G)DLWFBBDN-"VRF#N: M(L/>2:'A:(CME>+F]0 2AYQNZ5OB432M"PE69!UOX#NX']W1^(C-*I50H*U M30S4.;W=[@]IP$? DX#!+O8D=')"? [!MRJGFV ())0N*'"_G.$.I Q"WL:O M29/.)0-QN7]3_Q)[][V43,W?PQFD MAP+/I@S)>!3QGS=O??9<;#]=9NP0(WHP%O97/@9:OT+FP,)M0O; M:[\WXYR-@<-N>D)L?L?%;U!+ P04 " !8,VQ,L4[X8[4! #3 P &0 M 'AL+W=O8ILC_?O:AA#:TKY@[S(S.VNOLP'-LVT!''E54MN< MMLYU!\9LV8+B]@H[T/Y/C49QYT/3,-L9X%4D*::*2XT+;*8.YDBP]Y) MH>%DB.V5XN;G$20..=W2M\2#:%H7$JS(.M[ =W _NI/Q$9M5*J% 6X&:&*AS M>KL]'-. CX!' 8-=[$GHY(SX'((O54XWP1!(*%U0X'ZYP!U(&82\C9=)D\XE M W&Y?U/_''OWO9RYA3N43Z)R;4[WE%10\UZZ!QSN8>KG R53\U_A M+#@Q-? MHT1IXY>4O76H)A5O1?'7<14ZKL/X)TTGVCHAF0C)3-C'.FPL%)U_XHX7F<&! MF/'L.QZN>'M(_-F4(1F/(O[SYJW/7HKMQYN,78+0A#F.F&2)F1',J\\EDK42 MQ^0O>G*]SM^M6MQ%_NX?%G\32%<%TBB0_K?'-QU' M>9&=)_8VB9?R#A_'_1LWC="6G-'YJXT74",Z\%8V5WZ&6O_"YD!"[<+VQN_- M.&=CX+";GA";WW'Q"U!+ P04 " !8,VQ,H_L=-+4! #0 P &0 'AL M+W=O1DO*2:>4P;B M\OP6_5NLW==R8A;NM/C-:]<5^!JC&AHV"/>DQWM(]5QBE(I_@#,(#P]*?(Y* M"QM75 W6:9FB>"F2O4X[5W$?TPU-M'4"300Z$ZYC'C(EBLJ_,L?*W.@1F:GW M/0M/G.VI[TT5G+$5\7.3F'. ERF"!T ,L653I0<4Y7GCG M<;V-3TC^P:=9?V2FY"F;"S] G?]>LR&@<>'XQ9_--&23 MX72?_@^9/W'Y%U!+ P04 " !8,VQ,875B2K0! #3 P &0 'AL+W=O M_8M0" O6AF?TS:$[L"8 M+UO0PM_8#@S>U-9I$=!T#?.= U$ED%:,;S:W3 MI:)$EW\D5F>V#D@9.COA> M:^%^'4'9(:=;>G4\RJ8-T<&*K!,-?(/PO3LYM-C,4DD-QDMKB(,ZI_?;PW$? MXU/ #PF#7YQ)K.1L[7,T/E=4T;@\GQE M_YAJQUK.PL.#54^R"FU.[RBIH!:]"H]V^ 13/>\HF8K_ A=0&!Z58([2*I]6 M4O8^6#VQH!0M7L9=FK0/X\WN"EL'\ G 9\!= K Q45+^00119,X.Q(UOWXG8 MXNV!X]N4T9F>(MVA>(_>2X$-S=@E$DTQQS&&+V*VTZ M?K/D26E[DT9YX9TG]IZG MIKR&C^/^5;A&&D_.-F!K4P-J:P.@E,T-SE"+/VPV%-0A'M_CV8US-AK!=M,7 M8O,_+GX#4$L#!!0 ( %@S;$P7ED#.M $ -,# 9 >&PO=V]R:W-H M965TM<_V!,5NVH(6] MPAXZ_Z=&HX7SH6F8[0V(*I*T8CQ)KID6LJ-%%G,G4V0X."4[.!EB!ZV%^7$$ MA6-.=_0]\22;UH4$*[)>-/ 5W+?^9'S$%I5*:NBLQ(X8J'-ZNSL<]P$? =\E MC':U)Z&3,^)+"!ZKG";!$"@H75 0?KG '2@5A+R-UUF3+B4#<;U_5[^/O?M> MSL+"':IG6;DVIS>45%"+0;DG'!]@[N<#)7/SG^$"RL.#$U^C1&7CEY2#=:AG M%6]%B[=IE5U\.W!_ M-F5(QJ.(_[QYZ[.7@B<\8Y<@-&..$X:O,+L%P;SZ4H)OE3CRO^C\>IN?;EI, M(S_]A\7?!/:; OLHL/]OCUN8](\B;'6H&DP3Q\F2$H_-].<38'#?GY";'G' MQ4]02P,$% @ 6#-L3-Q68OFT 0 TP, !D !X;"]W;W)K&UL?5/;;IPP$/T5RQ\0LUYRT0J0LJFJ5FJE5:JVSUX8P(HO MU#9+^O>UC4-H2_*"/<,Y9\[8XV+2YLGV X]2Z%LB7OGA@,AMNY!,GNE!U#^ M3ZN-9,Z'IB-V,,":2)*"T"R[(9)QA:LBYDZF*O3H!%=P,LB.4C+S^PA"3R7> MX9?$(^]Z%Q*D*@;6P3=PWX>3\1%95!HN05FN%3+0EOA^=SCF 1\!/SA,=K5' MH9.SUD\A^-R4. N&0$#M@@+SRP4>0(@@Y&W\2IIX*1F(Z_V+^L?8N^_ES"P\ M:/&3-ZXO\1U&#;1L%.Y13Y\@]7.-46K^"UQ >'APXFO46MCX1?5HG99)Q5N1 M['E>N8KKE/[<)MHV@28"70AWL0Z9"T7G'YAC56'TA,Q\]@,+5[P[4'\V=4C& MHXC_O'GKLY>*9GE!+D$H88XSAJXPNP5!O/I2@FZ5.-+_Z/1FF[_?M+B/_/T; M%O\2R#<%\BB0O]OC%N;ZGR)D=:@23!?'R:):CRJ.\BJ[3.P]C9?R"I_'_2LS M'5<6G;7S5QLOH-7:@;>27?D9ZOT+6P(!K0O;6[\W\YS-@=-#>D)D>F8;8W(*I(4I+Q)#DP)3I-BRSFSJ;(<'"RTW VQ Y*"?/S!!+'G.[H:^*I M:UH7$JS(>M' %W!?^[/Q$5M4JDZ!MAUJ8J#.Z?WN>$H#/@*^=3#:U9Z$3BZ( MSR'X6.4T"89 0NF"@O#+%1Y RB#D;?R8->E2,A#7^U?U][%WW\M%6'A ^;VK M7)O3.THJJ,4@W1..'V#NYQTE<_.?X K2PX,37Z-$:>.7E(-UJ&85;T6)EVGM M=%S'Z4]ZF&G;!#X3^$*XBW785"@Z?Q1.%)G!D9CI['L1KGAWY/YLRI",1Q'_ M>?/69Z\%3PX9NP:A&7.:,'R%V2T(YM67$GRKQ(G_0^>';?Y^T^(^\O?_L?B' M0+HID$:!],T>MS"W?Q5AJT-58)HX3I:4..@XRJOL,K'W/%[*;_@T[I^%:3IM MR06=O]IX 36B V\EN?$SU/H7M@02:A>VMWYOICF; H?]_(38\HZ+7U!+ P04 M " !8,VQ,+E<3Q+4! #3 P &0 'AL+W=O3[:E7*JHE1KIE*KM;\Y>VRA\.(#/R=L7 M,''=UNT?PZYG9F=AR4=MGFP'X-"+%,H6N'.N/Q)BJPXDLS>Z!^7_--I(YGQH M6F)[ ZR.)"D(S;(]D8PK7.8Q=S9EK@*Y9" N]V_J][%WW\N%6;C3X@>O75?@ M T8U-&P0[E&/GR#U\PZCU/P7N(+P\.#$UZBTL/&+JL$Z+9.*MR+9R[1R%=O/79 M:TFS0TZN02AA3A.&+C";&4&\^ER"KI4XT;_H=+_.WZY:W$;^]A\6?Q/8K0KL MHL#NOSVN83[\480L#E6":>,X653I0<517F3GB;VE\5)^P:=Q?V"FYRO(R@SYC2EU\2C;%H?$JS( M>M' -_#?^Y/%B"TJE=30.6DZ8J'.Z7UZ..X#/@)^2!C=:D]")V=CGD/PNSD+!P]&/3O_F/Q#X']IL ^"NS? M['$+\W>7;'6H&FP3Q\F1T@Q='.55=IG8>QXOY14^C?M781O9.7(V'J\V7D!M MC >TDMS@#+7XPI9 0>W#]CWN[31G4^!-/S\AMKSCXC=02P,$% @ 6#-L M3* 9NM:U 0 TP, !D !X;"]W;W)K&UL?5/1 M;IPP$/P5RQ\0'^::1"= RJ6J4JF53HG:/OM@ 2LV)K8YTK_/VA!*6]H7[%UF M9F?M=38:^^Q: $]>M>I<3EOO^P-CKFQ!"W=E>NCP3VVL%AY#VS#76Q!5)&G% M^&YWS;20'2VRF#O9(C.#5[*#DR5NT%K8GT=09LQI0M\3C[)I?4BP(NM% T_@ MO_4GBQ%;5"JIH7/2=,1"G=.[Y'#A$[.QCR'X'.5TUTP! I* M'Q0$+A>X!Z6"$-IXF37I4C(0U_MW]4^Q=^SE+!S<&_5#5K[-Z2TE%=1B4/[1 MC \P]_.!DKGY+W !A?#@!&N41KGX)>7@O-&S"EK1XG5:91?7JP39QG!PIS=#%45YEEXF]X_%2?L&G9L"KSIYR?$EG=U 0 TP, !D !X;"]W;W)K&UL?5/M;M0P M$'P5RP]07WSA**HM;#QB^K1.BV3BK\*<@U""7.: M,72-61#$JR\EZ%:)$WU%IX=M_G[3XC[R]_^P^(= OBF01X'\OSV^QM L_ZL( M61VJ!-/%<;*HUJ.*H[S*+A-[1^.E_(;/X_Z%F8XKBR[:^:N-%]!J[K]"UL" :T+V[=^;^8YFP.GA_2$R/*.JU]02P,$% @ 6#-L3(AN?@JT M 0 TP, !D !X;"]W;W)K&UL?5/1;IPP$/P5 MRQ\0'[Z[-#H!4BY1U4J-=$K4]MD'"UBQ,;7-D?Q]UH90VM*\8.\R,SMKK]/! MV&?7 'CRHE7K,MIXWQT8;:Z:% M;&F>QMS)YJGIO9(MG"QQO=;"OAY!F2&C"7U//,JZ\2'!\K03-3R!_]Z=+$9L M5BFEAM9)TQ(+549OD\-Q%_ 1\$/"X!9[$CHY&_,<@J]E1C?!$"@H?% 0N%S@ M#I0*0FCCUZ1)YY*!N-R_JW^.O6,O9^'@SJB?LO1-1F\H*:$2O?*/9O@"4S][ M2J;FO\$%%,*#$ZQ1&.7BEQ2]\T9/*FA%BY=QE6UP[$:XX.7 \FR(DXU'$?VC>8?:2\V2?LDL0FC#'$<,7 MF&1&,%2?2_"U$D?^#YU?K_.WJQ:WD;_]C\4_!':K KLHL/NPQS7,WR[9XE U MV#J.DR.%Z=LXRHOL/+&W/%[*;_@X[@_"UK)UY&P\7FV\@,H8#VAE+>9@,DMV>,)IILSJB?NS! M' 9_!?^HO%B"TJE=30 M.6DZ8J'.Z4-R.JADZLQSR'X4.5T%PR!@M('!8'+#1Y!J2"$ M-K[/FG0I&8CK_:OZN]@[]G(5#AZ-^B8KW^;T2$D%M1B4?S+C>YC[>4/)W/Q' MN(%">'""-4JC7/R2Z%D%K6CQ,JVRB^LX_3FD,VV;P&<"7PC'6(=-A:+S MM\*+(K-F)'8Z^UZ$*TY.',^F#,EX%/$?FG>8O14\N<_8+0C-F/.$X2M,LB 8 MJB\E^%:),_^+S@_;_/VFQ7WD[_]A\3>!=%,@C0+I?WO M&R"Y/6,TT61S1OW]O"(2KZA7:&]]Z\::?YA.;)=@"./&O5 MVX)VS@U'QFS5@1;V!@?H_9\&C1;.AZ9E=C @ZDC2BO$DN65:R)Z6>E+XE&VG0L)5N:#:.$SN"_#V?B(K2JUU-!;B3TQ MT!3T/CV>LH"/@*\2)KO9D]#)!?$I!!_J@B;!$"BH7% 0?KG" R@5A+R-[XLF M74L&XG;_HOXN]NY[N0@+#ZB^R=IU!;VCI(9&C,H]XO0>EGY>4;(T_Q&NH#P\ M./$U*E0V?DDU6H=Z4?%6M'B>5]G'=9K_'+*%MD_@"X&OA+M8A\V%HO.WPHDR M-S@1,Y_](,(5IT?NSZ8*R7@4\9\W;WWV6O+T3(C\PS\L_B:0[0ID42#[;X\[&)[\481M#E6#:>,X65+A MV,=1WF37B;WG\5)^P>=Q_R1,*WM++NC\U<8+:! =>"O)C9^ASK^P-5#0N+!] M[?=FGK,Y<#@L3XBM[[C\"5!+ P04 " !8,VQ,C.O'?;0! #3 P &0 M 'AL+W=OY>9V5E[G0W6/?L6() 7K8S/ M:1M"=V#,ERUHX:]L!P;_U-9I$3!T#?.= U$EDE:,;S;73 MI:)&EW,D5F>V# MD@9.COA>:^%>CZ#LD-,M?4L\R:8-,<&*K!,-?(7PK3LYC-BL4DD-QDMKB(,Z MI[?;PW$?\0GP7<+@%WL2.SE;^QR#SU5.-]$0*"A#5!"X7. .E(I":./GI$GG MDI&XW+^IWZ?>L9>S\'!GU0]9A3:G-Y144(M>A2<[/,#4SP=*IN:_P 44PJ,3 MK%%:Y=.7E+T/5D\J:$6+EW&5)JW#^(?SB;9.X!.!SX2;5(>-A9+S3R*((G-V M(&X\^T[$*]X>.)Y-&9/I*-(_-.\Q>RDXWV;L$H4FS''$\ 7F'<%0?2[!UTH< M^5]T?KW.WZU:W"7^[A\6?Q/8KPKLD\#^OSVN8?@?1=CB4#6X)HV3)Z7M31KE M17:>V-MTB^P=/H[[HW"--)Z<;<"K31=06QL K6RN<(9:?&%SH* .$)O?&PO M=V]R:W-H965T=6JM1EMG.OV MC-FB 2WL%7;0^C\5&BV<#TW-;&= E)&D%>.;S3730K8T3V/N:/(4>Z=D"T=# M;*^U,+\/H'#(Z)9>$O>R;EQ(L#SM1 T/X!Z[H_$1FU5*J:&U$EMBH,KHS79_ M2 (^ IXD#':Q)Z&3$^)+"+Z7&=T$0Z"@<$%!^.4,MZ!4$/(V?DV:="X9B,O] M1?UK[-WW<07EX<.)K%*AL M_)*BMP[UI.*M:/$ZKK*-ZS#I7VCK!#X1^ <"&PM%YW?"B3PU.! SGGTGPA5O M]]R?31&2\2CB/V_>^NPYYWR7LG,0FC"'$<,7F.V,8%Y]+L'72ASX7W1^O<[? MK5K<1?[N'Q;_$$A6!9(HD/RWQS5,\J$(6QRJ!E/'<;*DP+Z-H[S(SA-[P^.E MO,/'&UL?5/M;IPP$'P5RP\0W_DN:70"I%RJJI$:Z92J[6\? M+&#%'\0V1_+V71M":4O[!WN7F=E9>YT-UCW[%B"05ZV,SVD;0G=@S)!ZLG M%;2BQ>NX2I/68?JSFVCK!#X1^$RX37786"@Y_RB"*#)G!^+&L^]$O.+M@>/9 ME#&9CB+]0_,>LY>"\^N,7:+0A#F.&+[ ;&<$0_6Y!%\K<>1_T?G-.G^W:G&7 M^+M_6/Q-8+\JL$\"^__VN(;YTR5;'*H&UZ1Q\J2TO4FCO,C.$WO'TZ7\@H_C M_BA<(XTG9QOP:M,%U-8&0"N;*YRA%E_8'"BH0]Q^P+T;YVP,@NVF)\3F=US\ M!%!+ P04 " !8,VQ,F?0#/;4! #3 P &0 'AL+W=OJ/ M8#N7\O:LG30$"/T3>S_8M0" O6AF?TS:$[LB8+UO0PM_8#@S^ MJ:W3(F#H&N8[!Z)*)*T8WVQNF1;2T")+N;,K,ML')0V<'?&]UL+]/(&R0TZW M]#7Q))LVQ 0KLDXT\ 7"U^[L,&*S2B4U&"^M(0[JG-YOCZ=]Q"? -PF#7^Q) M[.1B[7,,/E8YW41#H* ,44'@!_9L]KF$.?Q5ABT/5X)HT3IZ4MC=IE!?9>6+O>;J4W_!QW#\+ MUTCCR<4&O-IT ;6U =#*Y@9GJ,47-@<*ZA"W=[AWXYR-0;#=](38_(Z+7U!+ M P04 " !8,VQ,HWBN8[8! #3 P &0 'AL+W=OO;10^7,#G MY.T+F+ANXO:/8=2V2O=@_)_&FTD M?2]G9N%.BY^\ M=EV!]QC5T+!!N$<]?H'4SP>,4O/W< 'AX<&)KU%I8>,758-U6B85;T6RYVGE M*JYC^K-/M'4"300Z$_:Q#ID*1>>?F&-E;O2(S'3V/0M7O#E0?S952,:CB/^\ M>>NSEY+2CSFY!*&$.4X8NL!L9@3QZG,)NE;B2-_1Z?4Z?[MJ<1OYVW]8_$M@ MMRJPBP*[__:X@MEF;XJ0Q:%*,&T<)XLJ/:@XRHOL/+&W-%[*'_@T[@_,M%Q9 M=-;.7VV\@$9K!]Y*=N5GJ/,O; X$-"YL;_S>3',V!4[WZ0F1^1V7OP%02P,$ M% @ 6#-L3-L-'KZT 0 TP, !D !X;"]W;W)K&UL?5/1;IPP$/P5RQ\0W_GH-3H!4BY5E$BM=$K5]MD'"UBQ,;'-D?Y] MUX80VI*\8.\R,SMKK]/!V"?7 'CRHE7K,MIXWQT8;/=-"MC1/8^YD\]3T7LD63I:X7FMA?Q]!F2&C6_J:>)1U MXT."Y6DG:O@._D=WLABQ6:64&EHG34LL5!F]V1Z.2CD;,Q3 M"![*C&Z"(5!0^* @<+G +2@5A-#&\Z1)YY*!N-R_JM_%WK&7LW!P:]0O6?HF MH]>4E%")7OE',]S#U,\G2J;FO\(%%,*#$ZQ1&.7BEQ2]\T9/*FA%BY=QE6U< MA_%/LI]HZP0^$?A,N(YUV%@H.O\BO,A3:P9BQ[/O1+CB[8'CV10A&8\B_D/S M#K.7G.^V*;L$H0ES'#%\@7E#,%2?2_"U$D?^'YWOU_F[58N[R-^]8_$O@615 M((D"R8<]KF'X/T78XE UV#J.DR.%Z=LXRHOL/+$W/%[*&WP<]V_"UK)UY&P\ M7FV\@,H8#VAE*YSAU\0C[P<7$J0N M1];#%W!?Q[/Q$5E56BY!6:X5,M!5^#X[GHJ CX!O'&:[V:/0R47KYQ!\;"M\ M"(9 0.." O/+%1Y B"#D;7Q/FG@M&8C;_:OZ^]B[[^7"+#QH\<1;-U3X#J,6 M.C8)]ZCG#Y#Z>8-1:OX37$%X>'#B:S1:V/A%S62=EDG%6Y'L95FYBNN<_F2) MMD^@B4!7PEVL0Y9"T?D[YEA=&CTCLYS]R,(59T?JSZ8)R7@4\9\W;WWV6M,\ M+\DU""7,:<'0#29;$<2KKR7H7HD3_8M.;_?Y^:[%//+S?UC\3:#8%2BB0/'? M'OQHOY1=\&??/S/1<6731SE]MO(!. M:P?>RN'&S]#@7]@:".A[/,V1(X/:8G1-9W7/\$4$L#!!0 ( %@S M;$RB-]:HM $ -,# 9 >&PO=V]R:W-H965TMC,]I&T)W8,R7+6CAKVP'!O_4UFD1,'0-\YT#4262 M5HQO-C=,"VEHD:7Q([.5O['(.'*J>;: @4 ME"$J"%PN< ]*12&T\3)ITKED)"[W[^J?4N_8RUEXN+?JAZQ"F]-;2BJH1:_" MDQT^P]3/-253\U_@ @KAT0G6**WRZ4O*W@>K)Q6THL7KN$J3UF'\P_E$6R?P MB":-$Z>E+8W:907V7EB[](MLE_P<=P?A6ND\>1L UYMNH#:V@!H M97.%,]3B"YL#!76(VP^X=^.&UL?5-A;]L@ M$/TKB!]0$I*U461;:EI-F[1)4:=MGXE]ME&!\P#'W;\?8-?S-J]?#'=^[]T[ M.+(![;-K 3QYT=T?&7-F"%NX&.S#A3XU6"Q]"VS#761!5(FG%^&9S MR[20AA99RIUMD6'OE31PML3U6@O[\P0*AYQNZ6OB23:MCPE69)UHX OXK]W9 MAHC-*I748)Q$0RS4.;W?'D_[B$^ ;Q(&M]B3V,D%\3D&'ZN<;J(A4%#ZJ"#" M4'V7E6]S>J"D@EKTRC_A\ &F M?MY1,C7_":Z@ CPZ"35*5"Y]2=D[CWI2"5:T>!E7:=(Z3'\.$VV=P"<"GPF' M5(>-A9+S1^%%D5D+_T/GM.G^W:G&7^+O_6/Q#8+\JL$\"^S=[7,,<_BK" M%H>JP39IG!PIL3=IE!?9>6+O>;J4W_!QW#\+VTCCR 5]N-IT 36BAV!ECG,V!AZ[Z0FQ^1T7OP!02P,$% @ 6#-L3!&UL=5AM;YLP&/PK MB!]0\&/>4B61FD[3)FU2U6G;9Y(X"2K@#)RD^_K>!9U/532X_@S%0UGSJ'C_?U']<]F\GHRV[(7 MS[+^7>W5:1468; 7A_)2JU=Y^R*F":5A,,W^F[B*6L.'D6B.G:Q[\QGL+KV2 MS51%#Z4IW\=KU9KK;?PFS:=NN --'6CN4!B>:"0R(_]4JG*][.0MZ,:7?RZ' M-6:/I-_-;F@TK\)\IP??Z];KFOAB&5V'0A-F,V+H#L-F1*2KSQ2$*#;D=*<, M]^=PB-STY_?T18X+)+! 8@HD]P-(8FN."..990I)4E" +!*$X9@D@R09*)!8 M) B38I(A5] D@4H4%@D"+/ )"S& M%HK=$JFM+PCR"(QYK,I "5MB$.31&(-^?6($2M@J@R"/S!CV->-."9[:-"Z& M4H_0&'8_ ]:.G>4!H-2C-88#@ %WI[;:(,@G-YP!S#6XF]@@!++80X-3@+D6 M=T(38"CSB1KG ,FSQQ1(Y!/U#@*&/!YYH@:@3RB)AP&Y/J<,7MY (@RCZH) MAP$!GV>YS8- A8<'AP$!GV?.? H]\B-G 8$C)[;&P\$ M)1X>G 8$C)[;Z09!/AW@-"#@=%=O )1[THUP'!"P.CGK T"Y3V\X#PA8/7?F M T"%3V\X#PA8O7#F@T >O7&.\X #JQ=VOD&0)]\XS@,. MK$YV[B!0X?O-[_G1#ZQ.M@X0R'_:$.39M3G. PZLOK#W4PCR M[*<B.YO#/I_OO M97>LVC[82J4/LN:X>9!2"3V6^$'/^23*_?Q0BX,:;G-]WXVGZO%!R?/TCT$T M_VVQ_@=02P,$% @ 6#-L3+)T_@RX 0 TP, !D !X;"]W;W)K&UL;5/M;IPP$'P5RP\0'SXNN9X *9Z M ^7_U-I(YGQH&F([ ZR*)"D(W6RNB61(2E.5:(0-UCF^3PS$-^ AXX3#8 MQ1Z%3LY:OX;@>Y7C33 $ DH7%)A?+G '0@0A;^-MTL1SR4!<[C_5'V+OOIN3;'>XPJJ%DOW+,>'F'J9X?1U/P/N(#P\.#$URBUL/&+RMXZ+2<5 M;T6R]W'E*J[#^."?DLS<@E"$^8X8N@"D\P(XM7G$G2MQ)'^1Z?7Z_SMJL5M MY&^7Y?>[=8%T52"- ND_/>Z^]+B&^>J2+ Y5@FGB.%E4ZE[%45YDYXF]I?%2 M_L+'<7]BIN'*HK-V_FKC!=1:._!6-E=^AEK_PN9 0.W"]L;OS3AG8^!T-STA M,K_CX@]02P,$% @ 6#-L3 NE0I2X 0 TP, !D !X;"]W;W)K&UL;5/;;MP@$/T5Q >$77:S-]F6LHFJ5FJE5:JFSZP] MME' XP)>IW]?P([KIGX!9CCGS(4AZ=&\VAK D3>M&IO2VKGVQ)C-:]#"WF$+ MC;\IT6CAO&DJ9EL#HH@DK1A?K79,"]G0+(F^B\D2[)R2#5P,L9W6POP^@\(^ MI6OZ[GB65>V"@V5)*RKX#NY'>S'>8I-*(34T5F)##)0I?5B?SMN CX 7";V= MG4FHY(KX&HPO14I7(2%0D+N@(/QV@T=0*@CY-'Z-FG0*&8CS\[OZIUB[K^4J M+#RB^BD+5Z?T0$D!I>B4>\;^,XSUW%,R%O\5;J \/&3B8^2H;%Q)WEF'>E3Q MJ6CQ-NRRB7L_W.R.(VV9P$<"GPB'&(<-@6+F3\*)+#'8$S/TOA7AB=D(PKSZ%X$LASOP_.M\M\S>+*6XB M?S,/?]@O"VP7!;918/M/C82*SC]M?( 2T8%/977G9ZCV/VPR%)0N'/?^;(8Y&PR'[?B% MV/2/LS]02P,$% @ 6#-L3"_4),.Y 0 TP, !D !X;"]W;W)K&UL;5/;;MP@$/T5Q <$F]VDVY5M*9NH:J566J5J^\S: MXXL"C MXG?Y] 3NNF_@%F.&<,Q>&;$3S;%L 1UZ4U#:GK7/]D3%;MJ"$O<$> MM+^IT2CAO&D:9GL#HHHD)1E/DCNF1*=ID47?V109#DYV&LZ&V$$I8?Z<0.*8 MTY2^.IZZIG7!P8JL%PU\!_>C/QMOL46EZA1HVZ$F!NJ\+Q,\SUW%(R%_\5KB ]/&3B8Y0H;5Q).5B':E;Q MJ2CQ,NV=COLXW7RXG6G;!#X3^$(XQ#AL"A0S?Q1.%)G!D9BI][T(3YP>N>]- M&9RQ%?'.)V^]]UKLDB1CUR T8TX3AJ\PZ8)@7GT)P;="G/@[.K_;YN\V4]Q% M_FX=_O!Q6V"_*;"/ OO_:DS?U+B%X6^"L%53%9@FCI,E)0XZCO+*NTSL/8^/ M\@\^C?LW89I.6W)!YY\V/D"-Z,"GDMSX&6K]#UL,";4+1S\1Q$QS-AD.^_D+ ML>4?%W\!4$L#!!0 ( %@S;$Q$E,IYN0$ -,# 9 >&PO=V]R:W-H M965TP.LCB0I"$V2&R(95[C,8^YDREP/3G %)X/L("4S;T<0 M>BSP#K\GGGC;N9 @9=ZS%KZ#^]&?C(_(HE)S".8P MVM4>A4[.6K^$X%M=X"08 @&5"PK,+Q>X!R&"D+?Q:];$2\E 7._?U;_$WGTO M9V;A7HN?O'9=@?<8U="P0;@G/7Z%N9]KC.;F'^ "PL.#$U^CTL+&+ZH&Z[2< M5;P5R5ZGE:NXCM.?=#_3M@ET)M"%L(]UR%0H.O_,'"MSHT=DIK/O6;CBW8'Z MLZE",AY%_.?-6Y^]E&F2YN02A&;,<<+0%6:W((A77TK0K1)'^@^=WFSSTTV+ M:>2GZ_*?_F,@VQ3(HD#V5X_9AQZW,-H\R]L"00T+FQO_=Y,I-"V1RWSG4'0FS9@F3V M2G>@_$VMC63.FZ8AMC/ JDB2@M DV1')N,)%%GTG4V2Z=X(K.!ED>RF9>3^" MT$..-_C#\<2;U@4'*;*.-? +W._N9+Q%9I6*2U"6:X4,U#F^W1R.VX"/@&<. M@UV<4:CDK/5K,'Y4.4Y"0B"@=$&!^>T"=R!$$/)I_)DT\1PR$)?G#_6'6+NO MY*S.@!F;'W'0M/O#E0 MWYLR.&,KXIU/WGKOI4B3748N06C"'$<,76 V,X)X]3D$70MQI/_1Z6Z=GZZF MF$9^N@S_+5T7V*X*;*/ ]I\:;[[4N(;9?PE"%DV58)HX3A:5NE=QE!?>>6)O M:7R43_@X[H_,-%Q9=-;./VU\@%IK!SZ5Y,K/4.M_V&P(J%TXWOBS&>=L-)SN MIB]$YG]<_ 502P,$% @ 6#-L3#Q(WU3' 0 . 0 !D !X;"]W;W)K M&UL=53;;IPP$/T5RQ\0@UFVR0J0LHFB5FJE5:JF MSUX8+HJ-J6V6].]K&Y:BK?N"/>-SSLQX/&235.^Z!3#H0_!>Y[@U9C@0HLL6 M!--WGM12"6:LJ1JB!P6L\B3!"8VB/1&LZW&1>=])%9D<#>]Z."FD1R&8 M^GT$+J<.V:UC@'*;*!-? =S(_AI*Q%5I6J$]#K3O9(09WCQ_AP3!W> M ]XZF/1FCUPE9RG?G?&ERG'D$@(.I7$*S"X7> +.G9!-X]>BB=>0CKC=7]5? M?.VVEC/3\"3YSZXR;8[O,:J@9B,WKW+Z#$L]*49+\5_A MS"728V1BFY]E]4 MCMI(L:C85 3[F->N]^LTG^ROM#"!+@2Z$NX]@8'=ML8XNJDQA/E/E6DP2!H0H#=!0ICD)@C9=$Z M:OR;U:B48^_G9>-=Q^*1^L[_A<\S]8VIINLU.DMCWX_OT8 MKP:'VKCM)[M7\V.>#2.'94[)^K,H_@!02P,$% @ 6#-L3#)UQ[*X 0 MTP, !D !X;"]W;W)K&UL;5/M;IPP$'P5RP\0 M'S[NDIX *9Z ^7_U-I(YGQH&F([ ZR*)"D(W6SV1#*N<)'% MW,D4F>Z=X I.!ME>2F;>CR#TD.,$?R2>>-.ZD"!%UK$&?H'[W9V,C\BL4G$) MRG*MD($ZQ[?)X9@&? 0\M7T/PH\KQ)A@" :4+"LPO%[@#(8*0 MM_%GTL1SR4!<[C_4'V+OOIOL/4SPZCJ?F? M< 'AX<&)KU%J8>,7E;UU6DXJWHID;^/*55R'\<]N/]'6"70BT)EP$^N0L5!T M?L\<*S*C!V3&L^]8N.+D0/W9E"$9CR+^\^:MSUZ*;9)FY!*$)LQQQ- %)ID1 MQ*O/)>A:B2/]CT[WZ_SMJL5MY&^7Y;]=KPNDJP)I%$C_Z7'WI<79'&H M$DP3Q\FB4O&UL;51M;]L@$/XKB!]0 M;!(W:61;:EI5F[1*4:=MGXE]?E'!>(#C]M\7L.MY*5\,=SS/W7,'YW24ZE4W M :]"=[I##?&] ="=-& 8/I&]M#9DTHJP8PU54UTKX"5GB0XH5%T2P1K.YRG MWG=2>2H'P]L.3@KI00BFWH_ Y9CA&'\Z7MJZ, #. M72 KX^\<$R\I'7&]_XS^Y&NWM9R9A@?)_[2E:3*\QZB$B@W92KNJ;_X?_!II)Z9JMM.H[,T M]OGX2ZZD-&"E1#=62V.G>#$X5,9M=W:OIK<\&4;V\YB2Y5^1?P!02P,$% M @ 6#-L3.#2?0:W 0 TP, !D !X;"]W;W)K&UL;5/;;IPP$/T5RQ\0LX:DT0J0LHFJ5FJE5:JVSUX8P(K-4-LLZ=_7-H32 ME!?;,S[GS,7C?$+S8CL 1UZUZFU!.^>&(V.VZD +>X,#]/ZF0:.%\Z9IF1T, MB#J2M&(\2>Z8%K*G91Y]9U/F.#HE>S@;8D>MA?E] H5300_TS?$LV\X%!ROS M0;3P#=SWX6R\Q5:56FKHK<2>&&@*^G XGK* CX ?$B:[.9-0R07Q)1B?ZX(F M(2%04+F@(/QVA4=0*@CY-'XMFG0-&8C;\YOZQUB[K^4B+#RB^BEKUQ7TGI(: M&C$J]XS3)UCJN:5D*?X+7$%Y>,C$QZA0V;B2:K0.]:+B4]'B==YE'_=IOLGX M0MLG$7 5$]C,/F0#'S)^%$F1N!6&;IFHP;1PG2RH<^SC*&^\ZL0_Q%=E?^#SN7X5I96_)!9U_ MVO@ #:(#GTIRXV>H\S]L-10T+AP_^+.9YVPV' [+%V+K/R[_ %!+ P04 M" !8,VQ,MZ:I%/8! #,!0 &0 'AL+W=O0B@K39:M5*K11MU?;9(<-%:V/6=L+V[VL;0BD[ M?8D]P[G,V/%DO52ON@8PP;O@K3Z$M3'=GA!=U""8?I =M/9+*95@QH:J(KI3 MP"Z>)#BA4902P9HVS#.?.ZD\DU?#FQ9.*M!7(9CZ?00N^T.X"N^)EZ:JC4N0 M/.M8!=_!_.A.RD9D4KDT EK=R#904!["Q]7^N'-X#_C90*]G^\!U7,-#Q)_JNYF/H0 M;L/@ B6[VK/IG!)?Q3^FRU>V^PM MCVF2D9L3&C'' 4-GF-6$(%9]LJ"8Q9%^H-,4Y\=HB;'GQW-^1'&!-2JP]@+K M?WI,%SUBF UNDJ F"2*P79A@F!UNDJ(FZ4>!.%J88)C_W-<&-=D@ G1A@F%B MW&2+FFP1@?7"!,,DN,D.-=DA LN+QS#+BR>SUR1 57Z.Z*"0U];/L%EV&E6/ MU+_&O_!ASGUCJFI:'9REL6_:O[Q22@.VE.C!_C]J.UJG@$-IW'9C]VH8,$-@ M9#?.3C(-\/P/4$L#!!0 ( %@S;$PJ?-1WN0$ -,# 9 >&PO=V]R M:W-H965TI%"VP)US_8$06W4@ MF;W2/2A_TV@CF?.F:8GM#; ZDJ0@-$ENB&1LQP>8Z[G&:"[^$2X@/#QDXF-46MBXHFJP M3LM9Q:A2?> M':CO316-D4:4'%4=YY5TF M]H[&1_D'G\;]B9F6*XO.VOFGC0_0:.W IY)<^1GJ_ ];# &-"\O3" %5^(;9;T[VL;0DA"7VS/^)PS%X_S49LGVP$X]"*%L@7NG.L/A-BJ M \GLE>Y!^9M&&\F<-TU+;&^ U9$D!:%)?2=3)GKP0FNX&20':1D MYN\1A!X+O,.OC@?>=BXX2)GWK(5?X'[W)^,MLJC47(*R7"MDH"GP[>YPS (^ M OYP&.WJC$(E9ZV?@G%?%S@)"8& R@4%YK<+W($00'A(1,?H]+"QA55 M@W5:SBH^%IIVKN(_3S?5^IFT3Z$R@"V$?XY I4,S\*W.LS(T>D9EZW[/P MQ+L#];VI@C.V(M[YY*WW7LHTV^7D$H1FS''"T!7F#4&\^A*";H4XTD]T>K/- M3S=33",_7?.3_PADFP)9%,C>U4@_U+B%23\$(:NF2C!M'">+*CVH.,HK[S*Q MMS0^RAM\&O>?S+1<6736SC]M?(!&:P<^E>3*SU#G?]AB"&A<.'[Q9S/-V60X MW<]?B"S_N/P'4$L#!!0 ( %@S;$Q_B-R4Q0$ #@$ 9 >&PO=V]R M:W-H965T@"+7@67IL2]M<.1$%/W M(*BY4P-(M],J+:AU2]T1,VB@32 )3M(DN2>",HFK(L3.NBK4:#F3<-;(C$)0 M_?L$7$TEWN&WP#/K>NL#I"H&VL$WL-^'LW8KLJHT3( T3$FDH2WQX^YXRCT^ M 'XPF,QFCGPE%Z5>_.)S4^+$&P(.M?4*U U7> +.O9"S\6O1Q&M*3]S.W]0_ MAMI=+1=JX$GQGZRQ?8D/FTI';9S5]@J6>'*.E^"]P!>[@WHG+42MNPA?5 MH[%*+"K.BJ"O\\AD&*=Y)TL76IR0+H1T)1Q"'C(G"LX_4$NK0JL)Z?GL!^JO M>'=,W=G4/AB.(NPY\\9%K]4^RPIR]4(+YC1CT@UFMR*(4U]3I+$4I_0?>GH? MY^^C%O>!O]_RDT-<((L*9$$@^ZO&_*;&&.8_+O-HDCPB\'"3)(:YK81L;DZ M[L*;-:A6HPS]LHFN;?$8G@IYA\\]]97JCDF#+LJZ]Q-NN57*@K.2W#DOO6OC M=<&AM7[ZX.9Z?LSSPJIAZ5.R_BRJ/U!+ P04 " !8,VQ,:K/0A<@! X M! &0 'AL+W=OU%()9JRI&J('!:SR),$)C:)[(EC7XR+S MOK,J,CD:WO5P5DB/0C#U^P1<3CF.\8?CI6M:XQRDR ;6P'
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end XML 153 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 154 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 156 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 416 520 1 false 99 0 false 12 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.chi-med.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Consolidated Balance Sheets Sheet http://www.chi-med.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Consolidated Balance Sheets (parenthetical) Sheet http://www.chi-med.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (parenthetical) Statements 3 false false R4.htm 00200 - Statement - Consolidated Statements of Operations Sheet http://www.chi-med.com/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Consolidated Statements of Comprehensive (Loss)/Income Sheet http://www.chi-med.com/role/StatementConsolidatedStatementsOfComprehensiveLossIncome Consolidated Statements of Comprehensive (Loss)/Income Statements 5 false false R6.htm 00400 - Statement - Consolidated Statements of Changes in Shareholders' Equity Sheet http://www.chi-med.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity Consolidated Statements of Changes in Shareholders' Equity Statements 6 false false R7.htm 00500 - Statement - Consolidated Statements Of Cash Flows Sheet http://www.chi-med.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements Of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Organization and Nature of Business Sheet http://www.chi-med.com/role/DisclosureOrganizationAndNatureOfBusiness Organization and Nature of Business Notes 8 false false R9.htm 10201 - Disclosure - Particulars of Principal Subsidiaries and Equity Investees Sheet http://www.chi-med.com/role/DisclosureParticularsOfPrincipalSubsidiariesAndEquityInvestees Particulars of Principal Subsidiaries and Equity Investees Notes 9 false false R10.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.chi-med.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 10401 - Disclosure - Fair Value Disclosures Sheet http://www.chi-med.com/role/DisclosureFairValueDisclosures Fair Value Disclosures Notes 11 false false R12.htm 10501 - Disclosure - Cash and Cash Equivalents Sheet http://www.chi-med.com/role/DisclosureCashAndCashEquivalents Cash and Cash Equivalents Notes 12 false false R13.htm 10601 - Disclosure - Short-term Investments Sheet http://www.chi-med.com/role/DisclosureShortTermInvestments Short-term Investments Notes 13 false false R14.htm 10701 - Disclosure - Accounts Receivable-Third Parties Sheet http://www.chi-med.com/role/DisclosureAccountsReceivableThirdParties Accounts Receivable-Third Parties Notes 14 false false R15.htm 10801 - Disclosure - Other Receivables, Prepayments and Deposits Sheet http://www.chi-med.com/role/DisclosureOtherReceivablesPrepaymentsAndDeposits Other Receivables, Prepayments and Deposits Notes 15 false false R16.htm 10901 - Disclosure - Inventories Sheet http://www.chi-med.com/role/DisclosureInventories Inventories Notes 16 false false R17.htm 11001 - Disclosure - Property, Plant and Equipment Sheet http://www.chi-med.com/role/DisclosurePropertyPlantAndEquipment Property, Plant and Equipment Notes 17 false false R18.htm 11101 - Disclosure - Investments in Equity Investees Sheet http://www.chi-med.com/role/DisclosureInvestmentsInEquityInvestees Investments in Equity Investees Notes 18 false false R19.htm 11201 - Disclosure - Accounts Payable Sheet http://www.chi-med.com/role/DisclosureAccountsPayable Accounts Payable Notes 19 false false R20.htm 11301 - Disclosure - Other Payables, Accruals and Advance Receipts Sheet http://www.chi-med.com/role/DisclosureOtherPayablesAccrualsAndAdvanceReceipts Other Payables, Accruals and Advance Receipts Notes 20 false false R21.htm 11401 - Disclosure - Bank Borrowings Sheet http://www.chi-med.com/role/DisclosureBankBorrowings Bank Borrowings Notes 21 false false R22.htm 11501 - Disclosure - Commitments and Contingencies Sheet http://www.chi-med.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 22 false false R23.htm 11601 - Disclosure - Redeemable Non-controlling Interests Sheet http://www.chi-med.com/role/DisclosureRedeemableNonControllingInterests Redeemable Non-controlling Interests Notes 23 false false R24.htm 11701 - Disclosure - Ordinary Shares Sheet http://www.chi-med.com/role/DisclosureOrdinaryShares Ordinary Shares Notes 24 false false R25.htm 11801 - Disclosure - Share-based Compensation Sheet http://www.chi-med.com/role/DisclosureShareBasedCompensation Share-based Compensation Notes 25 false false R26.htm 11901 - Disclosure - Revenue from License and Collaboration Agreements-Third Parties Sheet http://www.chi-med.com/role/DisclosureRevenueFromLicenseAndCollaborationAgreementsThirdParties Revenue from License and Collaboration Agreements-Third Parties Notes 26 false false R27.htm 12001 - Disclosure - Research and Development Expenses Sheet http://www.chi-med.com/role/DisclosureResearchAndDevelopmentExpenses Research and Development Expenses Notes 27 false false R28.htm 12101 - Disclosure - Government Incentives Sheet http://www.chi-med.com/role/DisclosureGovernmentIncentives Government Incentives Notes 28 false false R29.htm 12201 - Disclosure - Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries Sheet http://www.chi-med.com/role/DisclosureSignificantTransactionsWithRelatedPartiesAndNonControllingShareholdersOfSubsidiaries Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries Notes 29 false false R30.htm 12301 - Disclosure - Income Taxes Sheet http://www.chi-med.com/role/DisclosureIncomeTaxes Income Taxes Notes 30 false false R31.htm 12401 - Disclosure - (Losses)/Earnings per Share Sheet http://www.chi-med.com/role/DisclosureLossesEarningsPerShare (Losses)/Earnings per Share Notes 31 false false R32.htm 12501 - Disclosure - Segment Reporting Sheet http://www.chi-med.com/role/DisclosureSegmentReporting Segment Reporting Notes 32 false false R33.htm 12601 - Disclosure - Note to Consolidated Statements of Cash Flows Sheet http://www.chi-med.com/role/DisclosureNoteToConsolidatedStatementsOfCashFlows Note to Consolidated Statements of Cash Flows Notes 33 false false R34.htm 12701 - Disclosure - Litigation Sheet http://www.chi-med.com/role/DisclosureLitigation Litigation Notes 34 false false R35.htm 12801 - Disclosure - Restricted Net Assets Sheet http://www.chi-med.com/role/DisclosureRestrictedNetAssets Restricted Net Assets Notes 35 false false R36.htm 12901 - Disclosure - Subsequent Events Sheet http://www.chi-med.com/role/DisclosureSubsequentEvents Subsequent Events Notes 36 false false R37.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.chi-med.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.chi-med.com/role/DisclosureSummaryOfSignificantAccountingPolicies 37 false false R38.htm 30203 - Disclosure - Particulars of Principal Subsidiaries and Equity Investees (Tables) Sheet http://www.chi-med.com/role/DisclosureParticularsOfPrincipalSubsidiariesAndEquityInvesteesTables Particulars of Principal Subsidiaries and Equity Investees (Tables) Tables http://www.chi-med.com/role/DisclosureParticularsOfPrincipalSubsidiariesAndEquityInvestees 38 false false R39.htm 30303 - Disclosure - Summary of significant accounting policies (Tables) Sheet http://www.chi-med.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of significant accounting policies (Tables) Tables 39 false false R40.htm 30403 - Disclosure - Fair Value Disclosures (Tables) Sheet http://www.chi-med.com/role/DisclosureFairValueDisclosuresTables Fair Value Disclosures (Tables) Tables http://www.chi-med.com/role/DisclosureFairValueDisclosures 40 false false R41.htm 30503 - Disclosure - Cash and Cash Equivalents (Tables) Sheet http://www.chi-med.com/role/DisclosureCashAndCashEquivalentsTables Cash and Cash Equivalents (Tables) Tables http://www.chi-med.com/role/DisclosureCashAndCashEquivalents 41 false false R42.htm 30603 - Disclosure - Short-term investments (Tables) Sheet http://www.chi-med.com/role/DisclosureShortTermInvestmentsTables Short-term investments (Tables) Tables 42 false false R43.htm 30703 - Disclosure - Accounts Receivable-Third Parties (Tables) Sheet http://www.chi-med.com/role/DisclosureAccountsReceivableThirdPartiesTables Accounts Receivable-Third Parties (Tables) Tables http://www.chi-med.com/role/DisclosureAccountsReceivableThirdParties 43 false false R44.htm 30803 - Disclosure - Other Receivables, Prepayments and Deposits (Tables) Sheet http://www.chi-med.com/role/DisclosureOtherReceivablesPrepaymentsAndDepositsTables Other Receivables, Prepayments and Deposits (Tables) Tables http://www.chi-med.com/role/DisclosureOtherReceivablesPrepaymentsAndDeposits 44 false false R45.htm 30903 - Disclosure - Inventories (Tables) Sheet http://www.chi-med.com/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.chi-med.com/role/DisclosureInventories 45 false false R46.htm 31003 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://www.chi-med.com/role/DisclosurePropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://www.chi-med.com/role/DisclosurePropertyPlantAndEquipment 46 false false R47.htm 31103 - Disclosure - Investments in equity investees (Tables) Sheet http://www.chi-med.com/role/DisclosureInvestmentsInEquityInvesteesTables Investments in equity investees (Tables) Tables 47 false false R48.htm 31203 - Disclosure - Accounts Payable (Tables) Sheet http://www.chi-med.com/role/DisclosureAccountsPayableTables Accounts Payable (Tables) Tables http://www.chi-med.com/role/DisclosureAccountsPayable 48 false false R49.htm 31303 - Disclosure - Other Payables, Accruals and Advance Receipts (Tables) Sheet http://www.chi-med.com/role/DisclosureOtherPayablesAccrualsAndAdvanceReceiptsTables Other Payables, Accruals and Advance Receipts (Tables) Tables http://www.chi-med.com/role/DisclosureOtherPayablesAccrualsAndAdvanceReceipts 49 false false R50.htm 31403 - Disclosure - Bank Borrowings (Tables) Sheet http://www.chi-med.com/role/DisclosureBankBorrowingsTables Bank Borrowings (Tables) Tables http://www.chi-med.com/role/DisclosureBankBorrowings 50 false false R51.htm 31503 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.chi-med.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.chi-med.com/role/DisclosureCommitmentsAndContingencies 51 false false R52.htm 31703 - Disclosure - Ordinary Shares (Tables) Sheet http://www.chi-med.com/role/DisclosureOrdinarySharesTables Ordinary Shares (Tables) Tables http://www.chi-med.com/role/DisclosureOrdinaryShares 52 false false R53.htm 31803 - Disclosure - Share-based Compensation (Tables) Sheet http://www.chi-med.com/role/DisclosureShareBasedCompensationTables Share-based Compensation (Tables) Tables http://www.chi-med.com/role/DisclosureShareBasedCompensation 53 false false R54.htm 31903 - Disclosure - Revenue from License and Collaboration Agreements-Third Parties (Tables) Sheet http://www.chi-med.com/role/DisclosureRevenueFromLicenseAndCollaborationAgreementsThirdPartiesTables Revenue from License and Collaboration Agreements-Third Parties (Tables) Tables http://www.chi-med.com/role/DisclosureRevenueFromLicenseAndCollaborationAgreementsThirdParties 54 false false R55.htm 32003 - Disclosure - Research and Development Expenses (Tables) Sheet http://www.chi-med.com/role/DisclosureResearchAndDevelopmentExpensesTables Research and Development Expenses (Tables) Tables http://www.chi-med.com/role/DisclosureResearchAndDevelopmentExpenses 55 false false R56.htm 32203 - Disclosure - Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries (Tables) Sheet http://www.chi-med.com/role/DisclosureSignificantTransactionsWithRelatedPartiesAndNonControllingShareholdersOfSubsidiariesTables Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries (Tables) Tables http://www.chi-med.com/role/DisclosureSignificantTransactionsWithRelatedPartiesAndNonControllingShareholdersOfSubsidiaries 56 false false R57.htm 32303 - Disclosure - Income Taxes (Tables) Sheet http://www.chi-med.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.chi-med.com/role/DisclosureIncomeTaxes 57 false false R58.htm 32403 - Disclosure - (Losses)/Earnings per Share (Tables) Sheet http://www.chi-med.com/role/DisclosureLossesEarningsPerShareTables (Losses)/Earnings per Share (Tables) Tables http://www.chi-med.com/role/DisclosureLossesEarningsPerShare 58 false false R59.htm 32503 - Disclosure - Segment Reporting (Tables) Sheet http://www.chi-med.com/role/DisclosureSegmentReportingTables Segment Reporting (Tables) Tables http://www.chi-med.com/role/DisclosureSegmentReporting 59 false false R60.htm 32603 - Disclosure - Note to Consolidated Statements of Cash Flows (Tables) Sheet http://www.chi-med.com/role/DisclosureNoteToConsolidatedStatementsOfCashFlowsTables Note to Consolidated Statements of Cash Flows (Tables) Tables http://www.chi-med.com/role/DisclosureNoteToConsolidatedStatementsOfCashFlows 60 false false R61.htm 40101 - Disclosure - Organization and Nature of Business (Details) Sheet http://www.chi-med.com/role/DisclosureOrganizationAndNatureOfBusinessDetails Organization and Nature of Business (Details) Details http://www.chi-med.com/role/DisclosureOrganizationAndNatureOfBusiness 61 false false R62.htm 40201 - Disclosure - Particulars of Principal Subsidiaries and Equity Investees (Details) Sheet http://www.chi-med.com/role/DisclosureParticularsOfPrincipalSubsidiariesAndEquityInvesteesDetails Particulars of Principal Subsidiaries and Equity Investees (Details) Details http://www.chi-med.com/role/DisclosureParticularsOfPrincipalSubsidiariesAndEquityInvesteesTables 62 false false R63.htm 40301 - Disclosure - Summary of significant accounting policies (Details) Sheet http://www.chi-med.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of significant accounting policies (Details) Details http://www.chi-med.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 63 false false R64.htm 40401 - Disclosure - Fair Value Disclosures (Details) Sheet http://www.chi-med.com/role/DisclosureFairValueDisclosuresDetails Fair Value Disclosures (Details) Details http://www.chi-med.com/role/DisclosureFairValueDisclosuresTables 64 false false R65.htm 40501 - Disclosure - Cash and Cash Equivalents (Details) Sheet http://www.chi-med.com/role/DisclosureCashAndCashEquivalentsDetails Cash and Cash Equivalents (Details) Details http://www.chi-med.com/role/DisclosureCashAndCashEquivalentsTables 65 false false R66.htm 40601 - Disclosure - Short-term Investments (Details) Sheet http://www.chi-med.com/role/DisclosureShortTermInvestmentsDetails Short-term Investments (Details) Details http://www.chi-med.com/role/DisclosureShortTermInvestments 66 false false R67.htm 40701 - Disclosure - Accounts Receivable-Third Parties (Details) Sheet http://www.chi-med.com/role/DisclosureAccountsReceivableThirdPartiesDetails Accounts Receivable-Third Parties (Details) Details http://www.chi-med.com/role/DisclosureAccountsReceivableThirdPartiesTables 67 false false R68.htm 40702 - Disclosure - Accounts Receivable-Third Parties - Movements on the Allowance for Doubtful Accounts Receivable (Details) Sheet http://www.chi-med.com/role/DisclosureAccountsReceivableThirdPartiesMovementsOnAllowanceForDoubtfulAccountsReceivableDetails Accounts Receivable-Third Parties - Movements on the Allowance for Doubtful Accounts Receivable (Details) Details 68 false false R69.htm 40801 - Disclosure - Other Receivables, Prepayments and Deposits (Details) Sheet http://www.chi-med.com/role/DisclosureOtherReceivablesPrepaymentsAndDepositsDetails Other Receivables, Prepayments and Deposits (Details) Details http://www.chi-med.com/role/DisclosureOtherReceivablesPrepaymentsAndDepositsTables 69 false false R70.htm 40901 - Disclosure - Inventories (Details) Sheet http://www.chi-med.com/role/DisclosureInventoriesDetails Inventories (Details) Details http://www.chi-med.com/role/DisclosureInventoriesTables 70 false false R71.htm 41001 - Disclosure - Property, Plant and Equipment (Details) Sheet http://www.chi-med.com/role/DisclosurePropertyPlantAndEquipmentDetails Property, Plant and Equipment (Details) Details http://www.chi-med.com/role/DisclosurePropertyPlantAndEquipmentTables 71 false false R72.htm 41101 - Disclosure - Investments in Equity Investees - Composition (Details) Sheet http://www.chi-med.com/role/DisclosureInvestmentsInEquityInvesteesCompositionDetails Investments in Equity Investees - Composition (Details) Details 72 false false R73.htm 41102 - Disclosure - Investments in Equity Investees - Summarized Balance Sheet (Details) Sheet http://www.chi-med.com/role/DisclosureInvestmentsInEquityInvesteesSummarizedBalanceSheetDetails Investments in Equity Investees - Summarized Balance Sheet (Details) Details 73 false false R74.htm 41103 - Disclosure - Investments in Equity Investees - Summarized Statements of Operations (Details) Sheet http://www.chi-med.com/role/DisclosureInvestmentsInEquityInvesteesSummarizedStatementsOfOperationsDetails Investments in Equity Investees - Summarized Statements of Operations (Details) Details 74 false false R75.htm 41104 - Disclosure - Investments in Equity Investees - Reconciliation of Summarized Financial Information (Details) Sheet http://www.chi-med.com/role/DisclosureInvestmentsInEquityInvesteesReconciliationOfSummarizedFinancialInformationDetails Investments in Equity Investees - Reconciliation of Summarized Financial Information (Details) Details 75 false false R76.htm 41105 - Disclosure - Investments in Equity Investees - Lease Commitments and Capital Commitments (Details) Sheet http://www.chi-med.com/role/DisclosureInvestmentsInEquityInvesteesLeaseCommitmentsAndCapitalCommitmentsDetails Investments in Equity Investees - Lease Commitments and Capital Commitments (Details) Details 76 false false R77.htm 41201 - Disclosure - Accounts Payable (Details) Sheet http://www.chi-med.com/role/DisclosureAccountsPayableDetails Accounts Payable (Details) Details http://www.chi-med.com/role/DisclosureAccountsPayableTables 77 false false R78.htm 41301 - Disclosure - Other Payables, Accruals and Advance Receipts (Details) Sheet http://www.chi-med.com/role/DisclosureOtherPayablesAccrualsAndAdvanceReceiptsDetails Other Payables, Accruals and Advance Receipts (Details) Details http://www.chi-med.com/role/DisclosureOtherPayablesAccrualsAndAdvanceReceiptsTables 78 false false R79.htm 41401 - Disclosure - Bank Borrowings - Schedule of Bank Borrowings (Details) Sheet http://www.chi-med.com/role/DisclosureBankBorrowingsScheduleOfBankBorrowingsDetails Bank Borrowings - Schedule of Bank Borrowings (Details) Details 79 false false R80.htm 41402 - Disclosure - Bank Borrowings - Loan Facilities (Details) Sheet http://www.chi-med.com/role/DisclosureBankBorrowingsLoanFacilitiesDetails Bank Borrowings - Loan Facilities (Details) Details 80 false false R81.htm 41403 - Disclosure - Bank Borrowings - Schedule of Maturities of Bank Borrowings (Details) Sheet http://www.chi-med.com/role/DisclosureBankBorrowingsScheduleOfMaturitiesOfBankBorrowingsDetails Bank Borrowings - Schedule of Maturities of Bank Borrowings (Details) Details 81 false false R82.htm 41501 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.chi-med.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.chi-med.com/role/DisclosureCommitmentsAndContingenciesTables 82 false false R83.htm 41601 - Disclosure - Redeemable Non-controlling Interests (Details) Sheet http://www.chi-med.com/role/DisclosureRedeemableNonControllingInterestsDetails Redeemable Non-controlling Interests (Details) Details http://www.chi-med.com/role/DisclosureRedeemableNonControllingInterests 83 false false R84.htm 41701 - Disclosure - Ordinary Shares (Details) Sheet http://www.chi-med.com/role/DisclosureOrdinarySharesDetails Ordinary Shares (Details) Details http://www.chi-med.com/role/DisclosureOrdinarySharesTables 84 false false R85.htm 41801 - Disclosure - Share based Compensation - HCML Share Option Scheme (Details) Sheet http://www.chi-med.com/role/DisclosureShareBasedCompensationHcmlShareOptionSchemeDetails Share based Compensation - HCML Share Option Scheme (Details) Details 85 false false R86.htm 41802 - Disclosure - Share-based Compensation - HCML Share Option Activity (Details) Sheet http://www.chi-med.com/role/DisclosureShareBasedCompensationHcmlShareOptionActivityDetails Share-based Compensation - HCML Share Option Activity (Details) Details 86 false false R87.htm 41803 - Disclosure - Share-based Compensation - HCML Options Fair value Assumptions (Details) Sheet http://www.chi-med.com/role/DisclosureShareBasedCompensationHcmlOptionsFairValueAssumptionsDetails Share-based Compensation - HCML Options Fair value Assumptions (Details) Details 87 false false R88.htm 41804 - Disclosure - Share-based Compensation - HCML Share Option Values (Details) Sheet http://www.chi-med.com/role/DisclosureShareBasedCompensationHcmlShareOptionValuesDetails Share-based Compensation - HCML Share Option Values (Details) Details 88 false false R89.htm 41805 - Disclosure - Share-based Compensation - HCML Share Based Compensation Expense (Details) Sheet http://www.chi-med.com/role/DisclosureShareBasedCompensationHcmlShareBasedCompensationExpenseDetails Share-based Compensation - HCML Share Based Compensation Expense (Details) Details 89 false false R90.htm 41806 - Disclosure - Share based Compensation - HMHL Share Option Schemes (Details) Sheet http://www.chi-med.com/role/DisclosureShareBasedCompensationHmhlShareOptionSchemesDetails Share based Compensation - HMHL Share Option Schemes (Details) Details 90 false false R91.htm 41807 - Disclosure - Share based Compensation - HMHL Share Option Activity (Details) Sheet http://www.chi-med.com/role/DisclosureShareBasedCompensationHmhlShareOptionActivityDetails Share based Compensation - HMHL Share Option Activity (Details) Details 91 false false R92.htm 41808 - Disclosure - Share based Compensation - HMHL Share Based Compensation Expense (Details) Sheet http://www.chi-med.com/role/DisclosureShareBasedCompensationHmhlShareBasedCompensationExpenseDetails Share based Compensation - HMHL Share Based Compensation Expense (Details) Details 92 false false R93.htm 41809 - Disclosure - Share-based Compensation - LTIP (Details) Sheet http://www.chi-med.com/role/DisclosureShareBasedCompensationLtipDetails Share-based Compensation - LTIP (Details) Details 93 false false R94.htm 41810 - Disclosure - Share-based Compensation - LTIP Share Based Compensation Expense (Details) Sheet http://www.chi-med.com/role/DisclosureShareBasedCompensationLtipShareBasedCompensationExpenseDetails Share-based Compensation - LTIP Share Based Compensation Expense (Details) Details 94 false false R95.htm 41901 - Disclosure - Revenue from License and Collaboration Agreements-Third Parties (Details) Sheet http://www.chi-med.com/role/DisclosureRevenueFromLicenseAndCollaborationAgreementsThirdPartiesDetails Revenue from License and Collaboration Agreements-Third Parties (Details) Details http://www.chi-med.com/role/DisclosureRevenueFromLicenseAndCollaborationAgreementsThirdPartiesTables 95 false false R96.htm 42001 - Disclosure - Research and Development Expenses (Details) Sheet http://www.chi-med.com/role/DisclosureResearchAndDevelopmentExpensesDetails Research and Development Expenses (Details) Details http://www.chi-med.com/role/DisclosureResearchAndDevelopmentExpensesTables 96 false false R97.htm 42101 - Disclosure - Government Incentives (Details) Sheet http://www.chi-med.com/role/DisclosureGovernmentIncentivesDetails Government Incentives (Details) Details http://www.chi-med.com/role/DisclosureGovernmentIncentives 97 false false R98.htm 42201 - Disclosure - Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries - Related parties (Details) Sheet http://www.chi-med.com/role/DisclosureSignificantTransactionsWithRelatedPartiesAndNonControllingShareholdersOfSubsidiariesRelatedPartiesDetails Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries - Related parties (Details) Details http://www.chi-med.com/role/DisclosureSignificantTransactionsWithRelatedPartiesAndNonControllingShareholdersOfSubsidiariesTables 98 false false R99.htm 42202 - Disclosure - Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries - Non-controlling shareholders of subsidiaries(Details) Sheet http://www.chi-med.com/role/DisclosureSignificantTransactionsWithRelatedPartiesAndNonControllingShareholdersOfSubsidiariesNonControllingShareholdersOfSubsidiariesDetails Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries - Non-controlling shareholders of subsidiaries(Details) Details 99 false false R100.htm 42301 - Disclosure - Income Taxes (Details) Sheet http://www.chi-med.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://www.chi-med.com/role/DisclosureIncomeTaxesTables 100 false false R101.htm 42302 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) Sheet http://www.chi-med.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) Details 101 false false R102.htm 42303 - Disclosure - Income Taxes - Movements in Net Deferred Income Tax Liabilities (Details) Sheet http://www.chi-med.com/role/DisclosureIncomeTaxesMovementsInNetDeferredIncomeTaxLiabilitiesDetails Income Taxes - Movements in Net Deferred Income Tax Liabilities (Details) Details 102 false false R103.htm 42304 - Disclosure - Income Taxes - Tax Losses Carryforwards and Deferred Tax Valuation Allowance (Details) Sheet http://www.chi-med.com/role/DisclosureIncomeTaxesTaxLossesCarryforwardsAndDeferredTaxValuationAllowanceDetails Income Taxes - Tax Losses Carryforwards and Deferred Tax Valuation Allowance (Details) Details 103 false false R104.htm 42305 - Disclosure - Income Taxes - Income Tax Payable (Details) Sheet http://www.chi-med.com/role/DisclosureIncomeTaxesIncomeTaxPayableDetails Income Taxes - Income Tax Payable (Details) Details 104 false false R105.htm 42401 - Disclosure - (Losses)/Earnings per Share (Details) Sheet http://www.chi-med.com/role/DisclosureLossesEarningsPerShareDetails (Losses)/Earnings per Share (Details) Details http://www.chi-med.com/role/DisclosureLossesEarningsPerShareTables 105 false false R106.htm 42501 - Disclosure - Segment Reporting - Segment Information (Details) Sheet http://www.chi-med.com/role/DisclosureSegmentReportingSegmentInformationDetails Segment Reporting - Segment Information (Details) Details 106 false false R107.htm 42502 - Disclosure - Segment Reporting - Elimination (Details) Sheet http://www.chi-med.com/role/DisclosureSegmentReportingEliminationDetails Segment Reporting - Elimination (Details) Details 107 false false R108.htm 42503 - Disclosure - Segment reporting - Concentration Risk Percentage (Details) Sheet http://www.chi-med.com/role/DisclosureSegmentReportingConcentrationRiskPercentageDetails Segment reporting - Concentration Risk Percentage (Details) Details 108 false false R109.htm 42504 - Disclosure - Segment Reporting - Reconciliation of Adjusted LBIT to net (loss)/income (Details) Sheet http://www.chi-med.com/role/DisclosureSegmentReportingReconciliationOfAdjustedLbitToNetLossIncomeDetails Segment Reporting - Reconciliation of Adjusted LBIT to net (loss)/income (Details) Details 109 false false R110.htm 42601 - Disclosure - Note to Consolidated Statements of Cash Flows (Details) Sheet http://www.chi-med.com/role/DisclosureNoteToConsolidatedStatementsOfCashFlowsDetails Note to Consolidated Statements of Cash Flows (Details) Details http://www.chi-med.com/role/DisclosureNoteToConsolidatedStatementsOfCashFlowsTables 110 false false R111.htm 42701 - Disclosure - Litigation (Details) Sheet http://www.chi-med.com/role/DisclosureLitigationDetails Litigation (Details) Details http://www.chi-med.com/role/DisclosureLitigation 111 false false R112.htm 42801 - Disclosure - Restricted Net assets (Details) Sheet http://www.chi-med.com/role/DisclosureRestrictedNetAssetsDetails Restricted Net assets (Details) Details 112 false false All Reports Book All Reports hcm-20171231.xml hcm-20171231.xsd hcm-20171231_cal.xml hcm-20171231_def.xml hcm-20171231_lab.xml hcm-20171231_pre.xml http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/country/2016-01-31 http://fasb.org/us-gaap/2016-01-31 http://xbrl.sec.gov/currency/2016-01-31 true true ZIP 158 0001047469-18-001485-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001047469-18-001485-xbrl.zip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
S+;1[6 A*3"1QX1A MF85S>@"))D'"$OOB83TI,)'W+'G?,>QB32E<2]YEV$;'1ME0_?) ZRS2M&H6 M^SYG?E15V:PZBPCK$[ ^ 6 "F F@ E@>KEPMN\Q#[I0*!0*A>JK4-.PBV]C M IUJIM-.\3#F'NJTZC!%,X. Y[+:MRAS57$(HYGBTR.PCG$&L*@+%G1?F3Q_>+*4>FK9A=PNO-ZN;)IOC$/6-X1![P^@WH&YFV.J,S4/F MN#1V _\UG05A[/Y7GFP]=%5G*>YO\&_0PS)60"('B2'P #SD303VT08>\F$$ MP %PR)L'%-,"('* Z*"_ ![R04JC;2)&J5\XI,XB/>%-%S&.2*02^('_REF$ M(>-WH5'$XH@4I],7)_ZCDL]XOI1'"YF\G?^F(S9A/&KQG(]BKJP MJB!DG67=P!"[7486''2JE4X'4&BS% J?H5GZ1(I0L_0Y++RT K52Z'09Z/T M:1NV!:.KW\ ;>Z)4&.:")+$1$S9B E5 %5 %5 %50!50!50!54 54 54 54T M%2JH JJ *J *J *J[(@JF/:HC:F")&'T8?1!%5 %5 %50!50!50!54 54$4' MH8(JH JH JJ *J *J *J@"HZ4V5MVD.=BET*THN3Y33+;]=%PYM UI;O_+&( M8G=RJSY*3OC[Q)P,[I@%5R&=3ZM8*?-L4:XODRGEZ N[9OZ"D4D8S B7 M] MZA&'BR&8B4T>W(C0"?^4,,^=N;XL5BEV?E "BMB5K- 048]%+7(Y983..'SC M].=L?&IC/FL-F(A9D@;-,@5MOLR[][\B[\H$M"%LV9$[O7S+MMD0O9]A&+;QCS M2?+Z7$0A(PX-0Y??.EC$_)7);!$OJ.?=$GH5,C;.'L3E-HM:*[!/L3P'=I]Q MQ.'&Y7XC_O*#'&9OI@&ACB-PR/4AU!]<S3F#YKQ]KG.=*V%EOVDQCW4 MMNQ$ !<(*^'H*S>&7N!(,Y9L@AR1&>6-N.7JF7/;(*R?$X3S(.0_RGZC5.SZ MCK<8L_P/9G,ON&6,FQ"?3=PXNT)@2F@Y9!Z[IN+%Q5X[KT8TXL]V@IGXF<+1 M\I(6R3$BEZ M>] ^D.>12@25YTD RF&BMT\#4$GHS^%.!YU'['AY\$8]B S:+?&LU:Q2Y6ZH M<./=CA^U+]4G-ZH9H\ ;;ZETS7.EE7,,%2Q*D5^_?/%E=^^O11)?+DZ.=$X/ M+L_N@=[A]_W2ZN\BTO'^@4@'J+,SZJR%X!MA[347.1"$W'"X&])DR*J#DJ M$J!$GA(]4 *4 "7RE.B"$G#]X?H#P=N,^^R7: ]=/Y/NUXL??N0=T1% VURS MV\P=W%9R+:KR_!HIN0RF^[7WW6'7-NPV-D3<"(JC/<-"IV=85N%-4X"%)F!A M:'0'A:%0.R5KY:/4F2[GPE%E44Q4BJ$"U"=LE%\,X+G#]_^I^_$?+/^R[XS"V'0*<:-Y M&%R[8F>Y.) _<:8NFQ#VG3F+V+UF))A,7(??[F8:B,VXQ4]^X=9__F.4_#1( MVS1FCAN)K;UG]$\6MLAE>KO[?L/;<>VRF]7;;F@D?R_9]8M&BHW=HXCP.TY$ MG^$[3&[=OMSYG5\5!8O02;:0'S.QFSM7D=A-GL8K#U+WEQN%KHB31F2L[(T2 MZ<<@9ID.K.Y#^\$7-70;[=:ZJ?,XYJ[>JP6I#]JT[HI-ZQZ0A>^J7W[E!Z9U M(/7!.][H[<$K^^ GLVVUA]S5RKXPWI#X>#*AJR;N4?;).X[8^JB@Y\^ M=W[/B:I$<31'T)?3D+$2)&TW6]+W2^6W#W>ELB[+BYCW!:(MJLR@:#L?*W(+ M+V^S_!7_>,;O$',;NPL CQZ_\VC]SNI]SOTH#A>RR_K$N[3P^V)^$^Q/B%XFH'S.]EBVZHO::-G8DLWIH MKZ^/]LQAMP_MJ98(0\#&+[)^N]?CH+UC%BKIE=0K/=J(CX$J/3O^N!#RT=-6 MYI5T_O'G@Y]ZUM R2^BWGBL>#;6R.^[J3O.O^_&1$5@T;872O]'O[FPQ:Q*.MB0XUU\1W*"I M4P MYR2*%C/E*KS_SD+'C=AG[@.Q#;XN[[)$)VZ:+^O$UUPB<\4ILKA+U.J4,99X M],UV*$$.;JLM1&A7($>RUP?,C=-A+UO9G=U%%RJ!,UAJ]]T$=K?K/[+?89' M16B;K7:W]B*<,S$./'/%++4__B*F>.\9Y"R-HASEE&DA[37!MEMW F)5OJ\6 MXLU93.44[HG0RC2/)051-)=8F19OER KVW;^)_#X;3PWOMV],VF+ MWJ+3ZU7<7:R^LB8RWIY'*:5L]ZKNE+64\K;<2B7CX5[*>%N^98)CNRDR_N)& M?_X<,K;<-F_W]K@CO7?;K$K$F]Y8"P%OSQ@O15Q5GZ>MB+=EB96 S%MF.!&PV:^?@%5^T*>)_#8Z6<33('3_NY:;>&]"51$)WDF\L3J6R(\J08;W MO92F,GLHG^11H9F=3J==1K[2=H5V35U/++3Z.0A_X=?&.\#;H-NUAJ7X3H^\ MF]X2K'*F_3$5F-V^:9H#>[@3);PD7O%I9;9+/& U-]E\2 TOS+%;G]:[DY+= MZ_>LR3(DF;J[^+1;.^3&$N:K;\C1GO0;0]V M)\>7&.&[SWD\/[\? M]YZU$NYSW,%UZ?9;@VI 6BOI5I7-R;';@70K2O0TNZVN%M@MQU==>^@7-J.N M[_I7IURP(77B!?4>RJ[96/KFI6D/W=^'O_7/*G')G_J:39'SP^OH^K^;YF_F M$*)^[HB^Q'9:EG:"+]PPL6BYCO@QBZJW&%JJWRH^5 MK.BVK0TE*RI^;+S&2WM#C9?]$G0IMN+14DC6IE)(-1/TLEPI_AR$$^;&"S'EY8\W/.[)(Y-MR+NJ99%E"*-Y M>M$G^+$7BJG"\.\E81[I#IZ?F%@HP:8SZ)J#,A(4[G_174ERBQVKW>]6@]NZ MR; (%DUST+?[U=CE'[M M8J_D&?<-+[DC*5:8W5YYWH(^4MPFG\UNN3&%+4MQS5>57Y[1F*49]5M?271W M7JXU*''2\YFOKZ'L*UUD=+?\3:O,?+ &2'^+@9Y!:UCB&*K^LJ^P=X3LGX;[ MK<1K3*O5@_"WLR:OT<+/;5[PP&34EA:J"H1U.NTR%I+>]TZ: MBJQ0#-8RS7Z9,5B=A%;1DJ9.Q[)[)0YAZR(RK6+].@FMHG"JV;:'W6&)\52= M9%95\-2T>J6N:MJ>S%ZZ>*&?^CHV0^];[&)M8T% M>;W?>[^99HF+:E[PGDT1]+97Y#5.U*6MR"MWD6GCY%S2@KS>[_9O9E<[01?H M&=2FHBJ96Q51#\1'N7;=LZGR+J:1^KU!M]28\XO?ON9**#0+9;5[O7)7[359 M#;69Q6JR$NHS"U8;+>QL4L/F_PU+G#Q[ZJO62\!%ID#ZW>'0+*-$<.TE7)?Y MDOI*N"ZS*[I*6+. =J#-8:O_G'%U>>^NI]"W@G7;;+6?$^3;KM#53;D#=>X[_$'N-1,O M'WT./->Y?8[P#G[Z7R]^,W:O__'LQH>.7Z MQ]UY3-K\C_C7Y =OQ)->N?Z8-^.8O,H^HIY[Y1__L8AB=W*K/DI.CEVQ8^OIE(DQV:[_8\W$_X"KR9TYGJWQYJ3&]6&4>"-DWN+ MJX_=F+^,DWM:]C"IGE=2/R2O(/'\U^*"O"Q?SR'9C9+-1$D"19>7RZ^6,I*7 M_B^=S=_XHVA>TM'EE)%?PF Q)R%S@BN?MS0BD02L')AQ.Y$!EK#OXI@KP%>_ M66J"7 G+Q7\=!X3-YEYPR_AM^"B-C%U^WS@((Z)NQZ^,N1Q#PH=RW)"*:^2U M9"SV(IY0_LVUS&%81'PD)WY+N,&Z]8.92STR"\;,:Y'+J1OE/YYSDRA^+;_F M5_)G7U-N0A<16O\U>QY!&-AF)$@ZH663D'G2=[@UO MD-"-_GPU"1DC;K)3,>$F.9$A2P; 7)C7')+\DUN7>>-(".(EVG.E#D3C(MX7 MC&5CHN4^I9%XYV#.DG*F0F%4O--8M%@TGK\YOS=70,#[)7FCD/VU<".7ZX]C M_IKW3AF\YK(G:X&I93)U2CDNQIQZ7"4G%U^)\"I?M8<&.9_-0ZX5I48.^?<) M%4F^!TK\#G+B.,'"E_KD.OX7]1<_!K:CK<$.R8A(F"WG!TNA**\.MDGS=$9O2 M:]XJT*^$HQ7/@XACQZ-1I% D8"KW=WX5L3CVQ"?"K><6^N(18VR0FRGS,_,] MYIU21!Q^U97"_-,MM<2I^GG(63$/?-6S\2[H5K)G/';%+T6'2=TQ]QJ)0^?" MNRH D+WU1'^]//\,7E7D@ H4/\4)%;\3BDCHEOF8E$S<[^(PY&8TL8DC3]A] MG\7"9Z,SV9/(GT;<1Q.")>*]$^=&=#%,]@2^+[TW[M4Y_&GR0>+&=YV?Q-<+_L,Y1*G+96OJ3Q(\8AE6R;J>M,'[R$6T7/_9-YTMZ,N+B9Z!DW__A:J&%TF[Q.WA=/Y"-U(%$P MY3SDXN9]]2+T^4^EH^S0:$HF7G##/PCY*_D+CGG"U,HY[+DP.EPC=9SDTCU:Y>K<+]5PZDN.AM5Z4 M(XE#@4GMW>4(.71;K)4]2?Y*?"X[U@T:YP.YAP#\IQ_<^$=&ZE2JMHA!$Y6C M2FE'?)7.R>^6#/YREN6*,:S#PICR-\H;H(WFAPHRC1*U9"_);TE52/-'X7WS 7>4?^X3FR*\ M^Q'C2A(@N/*5">-4= 0'6=[T*6N2.4E".337$]QKC$'=XD-4= ^,>\ MD^>Z97(8&+@RGC6ZS=WKD!]F8CFX5+\^.!(7SQB0JL1)))T0N+U MKJDGQ^%G%YS-_*O<^'*COS/GO9R(:?'>=8T)F>54[\NY(OR5:,+",!DYK_K^ M)//]C267-@C\$7G[09R3.5?WG7AB[46EOY7$K.Z^ MJ.CZP^5-E ^1_?S^@5.FQVP$]9"U2&8]R.OER>O\?,CRY+&YH >G9#;,Z=R7 M&5IQL?5.RUY?5G3?K-,#N:N55B3?L)O3WH33.RSVUBQ55^-\U?WM?$ MZ#R*%FS\4)IRYZ'%*'(W4;O=[]U=))C<^F4/[3[ZT%[7MDM^:.^QA_;:_7;9 M;]I_]*&]3F?#>\\=W%T!VKO[X.]^XS"K8BY4%V MP>7M/&/#.^K_><;F ?0GWD%<3OF0\3=^X^D]N5L[?IW3!>^I M?>=6OHB3G'S[>G'6K!>^ ^&[K>C;;7N]0';IS=BB5+?[/IMQ].'?6\21W5\O MS+WMU]TN;?I6KSM\[AOS424?ZCC4C[-I..D%NBRZY*_]S@NDN@>>)!Z=Y+%S18EV&B#A\GLA7PV1<:H)+8ANB,VSDU0 MQS)AB*OH9,9$I@ Y//C:NLA%QG\Y.?E\<(3)WN?;LZ^13 5[G^1J(/.P)%.E M^*#Z!3$7]RB5-O#F+L:7J3M1;IXB35):YMLHTE,^-)XE.1UR0I6JS!XUF3#G M?IR@X2PUBF*N(U:7+D.1+LOF2KDD'2^0:8;J=01WQ=/ONTX]2472)W=#EAME ML'S8IO8M)T+3)"%?)$..I7^;NTA:E&2Z^GTFD%"D78J,)S%SEC,^PJPN'Y*/ MR/*V^DEJE50%==3TBPKR9Q.Z+C=5XB5RZ9TK4PF/B3;@+0^%[:;^E2MFU9:_ MC<@-XU:=JBZ):UW(.O>4).=3RHUW &D0W+LU\D!8OC=_I66[9+.YQ,6=53X8 M_\5DX?&V72LK.P]%Y%@D;W+R"!4+B?/WGXNG&>0FY)>_&@8 MH^;/#VYD+%T(=APL1K&X\[+S->Y-?> RY1V7&Z;9/U[@7[WR9):8$DG^%S(] M:*/D9%NO@F L@NA&,D7.E<@U%LR8_$ *,''8ELW-3;3+.SA!)"8 G'#!1T,J M34VXE'CON%[R13:\L(A/!YOS"?FY&1 MR[VP+[^].S@BHX4R]O/XD]>_)#S5.,$,-(J)@D"V2.R7F1Y-V-Y#^5GWV/,D[:NM%!8 MW]S3E/M^RZW(*R;[,&,C%3'P.V!2,*=*%O)72.-@M,V>T6ZW#7%LMH?B6**&G_;5V0T+V8I/HW3[ MHJ42>61%A*.7__B,.3*.F#7?3O/!Q0R ;(Z8QA(=8I*&[A7!R=[V>:L6,(E MH^U9;R!2.68:GC]*]6H2'B9W&<,N2SD\$O\ MBIOUJ1SH\3\CZO_)G5(5]5?#/TY^26?980A_=IF@)U>"?$\&"&)$D#;U4R*RLXFH M1C;QPEU1QG\^\IB1N*+9)TF?E03BQ@NVC+FH4)+%3Y83DPM6$R772]B+F+5(%!:+(P201!+^/>T# MPDI?SNT'*_.;SGI_D+,YZVJ>)VD* E02K+((@Z\4*BQ<1+T$-S,ZEM\Z7-C! M3/CP*CSD*W>7&S$Q$9$\2ZTXODVG&Q(ZJ$SP*)D^<)T41&G .$JIL7Q,BWP4 MV>.".=F=Q@%3*>3); U_:4\8LE!,%,@XL"@ZD N(L9&H(P'WHH1P,/R*\N/ M22!(S+/E,PGDLH0XNG=Z2]*2M_J6>^FBG$F::O#EMW>YU6*"*&+9HRQ7+N9FVFZ.X\;+>9S[S:9D9K)^<2):J"2T5)\:0A158!9 ME>%RQ=R='Z\J.V19W8C1+?'H31+-6/Y,KI_SU,+71ZZJH;%,'94*P#EE[YC+^\6B28O6V8OB1ZB1?T$F+> M_#]+%F=#IO-LR(0^HYP^(Y>BP$4]N7]T*KL'E<0@0Y2Y"U>7$(L!9*A6SXN5 MC+G?35W>+X7.]#89[XHEO]QL+LLL) 6RUI-A1#Z$D?I^63) S)RI[_XEIM_$ M3Y3I5^$A3QCA=(YO8PO$ZXQ9Y(3N2*8L9%*9!"++(#I^ <*$DO-H\:6O^6S M58ZO2M"$(QSA"$2P?@[8$8:XK%7,G]1G(@\4I&G.81.UX>O%$/(OQ)+?&P M4WZW"W6WX_8;Y6^\\M@D/K[;\\?A\NZK5V6_4C\;"Z](-FH4Q'$P.UA]R7:_ M->!/'E'GSRL^OO+'HI5!>$S^?C(XL]^?ODG>=JT%3W.-2G*D7^Q+_RI/U-\[5:OTU3Q99(C]S"I%!D.S5:WUU09GB?C'9'S[:N,/SX4 M^6L1R"DT4?P@4NE^LA"+"@6IU"Y1>E>%FY)8GLA7R4)YK6 M);,%N5OFHS=RAE?9CC20H^HEB;N_D9$56:[\U;+,;V[^+%M2Z7EKZQ[38$W^ MXV1)C;A/F,P0CT0I;CI*"M>MO))6AJJ9G/KWX:94Q,&.Q/))%!>X4^2B2V+.=W-\U$J,D*9#*5!(_5":U[]"2* M54>"BFXT35=ZJ25Q,DE-^$DW9*I8)!QE\_/\MO&-6-R6;/&B\.K.J M+">C4GS21,.UW9^";!=?D1@;B(%5B_R6W5&4@&4WT:;$Z"23)%15YM,Y<%&' M6&2OYGZHBO_F$KQ'PA]*6BCRIS96/UBYZ6K"[",K]XG/1&X,5?MMA&R\<-C& M-^#?BIRP;.\74;8^9!R"_Y7?YQRG[.&R*8\TP(WRM8%+KX(+<[39')UGY1U@ MAHH?Y<2YP?QP!JC2^[+^!*?!9O*4Q:\2NV)\)B2 MLE%.NHHY+<_-C46H*AJ-A$BXR3+4BBZY+Y63W#C9ZF!YJ^5*^Q8Y$>V_=B/1 M?+E/RG='7BPR*T?HR@*[U/O5E2;&S&Q0%\)*K?'B[I!UERU M]5*:^23*N/#^0Q5R64EQS2Y9WEGFO'-=M\C_Y:_*?ICD\2;W)"+!5 M,);(3A:];:R;-%F$OMH$3WPQ<;_++?Z6%C5[E J@ M+R"E=J10M\^*6KV$]+H#^[]9]?'-6"'P _8,LR[+SJZFU#FFPI?MT8+(*1 M14'53/DA/755N-+^*36M^E;F])Q*NF),7"U<]5UP9ULHF0F34V^8$)AZ&Y^5 M+UZ9-?1ND^0:N^RV8D,J)F;4Q=8?:KW)LD:<*&;FAMRD16EUL['KT#C))Y=V MB(:AW PQG[\3I8M7Q(H#D98SRDE+I(:>3U3%N^2&@=C3X;LKL@;DJ@)N0X3. MV3Q-",K:&R<;'R;5,E52J5I"(5)^[FV4S$=(FB4RD]A8:9$/,-QHNS=Q.V3V*ITN0I%;GL7JESQ4$A! M?+A("HG+*X/E@EZ151DL(I6?I'R0-%%*)2BYHDAF0@Q*Q)8P[L05.9.RWJZD M'G_AS$$;*U/'O&_V4Z].>(*/\]( MLNRY:Y;_Y5,2HU3.99H7)8<4N;?JKL;P)^2?;T _F+'RUEF:=]G*4< M)WW@HV@*3?%+@W26/RN3PX4S:S"2Y M.&&PJ-XH-NH0F>$L6AJ4')MI?I-3T2ZQS[U:%BG=O%@R-)8#*=\7.S8F! Z3 M[4%]Y8R1@)L/%418]<.6]7&S57UR/Q'/_9/).N#43ZI_RU4R=\5 U]LV8MSG M26KN)^Z(6AS3(O\G6I3X,O)S/U>/7-SL*I52*H%<76191UUFR,_5@N<@<>\2 METT5V%>^$0ZPA4TTGU!\TN9$_=4UE=._%-1C%VNCJ+90%;68U"*E.(1'JC< M>D_*4I3ZY#;46?8?PE/+]):]EW''57/5;MN;Q"R?DTIA)CN(T=(EE/MRB^"! M%+H8WR_AG7_S; FPH6[WV./NZG0#XO@=LLUD-BC76+:#5YR=QH2W=DDN!&6$-4]-YGC,* MTN]2!F^#T9" R\--ED>(5+5JM8QP(F*N_Z+\#N%M]A[)IG]B_,OAF@ZH5;PM MXF_!AVG6$IWW/=A8+9D]SB>8+Y?(^T2^KC#X*ZC/[JG &M&96)/C^V+U=)2, M\CRQ>O^.S5R(R"--UPH)5V^4[-S<(C^+Y=BBIK""_X^/"B]O=W/K=398C&4G MZX9K?%V.-]ERW?\J9Y6152+--""WV9!!!+'!:3[:G72E\#>?[6]^DM/7Y]GV MT@CHE67XE&CO[GDNPW-B46+,5E>4J$!W&+IZC.\>7/>2O>;+%[WL._?>!6$8 MW-Q)%07=7G2423.9!\LMHG>7NW[ERQJE:\?$OD2<(-$B-XN43A:1M?N*;<1X M?\,ARN^7!6/^?WM?VMRX<;7[_5;=_X"KO*EHJBB9.ZF9Q%7R++;>LCTJ:YQ\ MG(+(IH0,"# *(WRZ^]9>@7!320EBFJG'),BEN[3?4Z?]3G::*/[WU&@;1B- M1@*;= B-6$8*2GKJL?P?C/^ZH&\L:)_0\'H3J9D>!VD #MBIWG<\DEA4:V9 MJI$1@J!\N$$VV[VJRMJS_/K'K2K@OL+>XI[OMV1?F+[VND*>FK>7P0:!T&\>XYK"O:I\[/7^MSU]?,D)I\ORU"_M=9Y)0R$]16C+:-!G*,V4&B*-\Z3UPE=5= M7 6AX2_4O+6L8/[ZY>+2\\*C6A+K+G.7F0!9A@X'SQC;8@QR61?F]$$'.GHV M4$.,AE&8,6)>/D653Y&?6<#VH+!3EIJI";(89_ M88*&&_H_$#,!'3DB SJ2FYG^& QB> $'(#4ZS1CSOR:$)JH3(Y0SW%(S1R*4 M2>[GPP<9'TBO81.&RMV?"1W(H4P)I'L&"H%\FQ0]UP\:<3"CQY#Q M2I13W>O,8\GUSPL8&C2=9 KSHT0WM9:H8Z",(R4C-SB&)Q;MK=F>$IY)B0(: M8AKG+L8<.2KLD(;4T3&830H+>>D1JR=^L+$R=9M(#EBQ4\&, \97WC8TN-)6 MF(WWF%N]V&ADAK[4MPSAM1/5']'Z]6\:?BB_%8CD(^DUJ "O]<)R4RTBSE,- M#H@+@0YD6CD1@@AR>Z.J)9*]/Z6OV)-AJ4RP+H/"?T;J24\_!TX5:O)U M- (I99QWN0## !]H)^6IQ!":&+$:C(S]]/HM%1+9A:DW$0;J7JI>-'2.'D36 M4FT$K1%8#^>@N+)BC)U%C*I^E4EZZ7@<%1IWE80G!\(?B$+7(A' 4R@+*D;O MN6P+GSY1Z O(#:LPY(!-ZO(8.Z!*XA;WBWM&.(K& EV%P375RPBL#5.Z81-- MH_Q6)92&V"A!RU/+MV3C2F,K!3NY5-G9&-)V.JMS5@)V\K5::8['8HB]S]') M1_$[=V22">#4*# ,?2>W-.(/1S.HY@T:$O,KW.-V>$(*% MPADZ,YC;:5[JN.Q0S?"GRI:H.C7-/!2KSW%CS$;47<>&5I-8A%3L&]9$-'AW M.>Q/&A(JE3/CG/%[EEV>F/)B]*DP0-T#:QVB.Q0H2\:SB#I,4)E-1X-S2,R9 M$YQ.K=(3%#ZUHMT"(KA.)/F+K.ZHVDRF$,,4:]@;9AD-@+/TC7-HX2T.SPI'T=*:;]XE\-6M6@=^9&JV FKM0-KPZHJ*-1U>@$]M8 K%C"U6>/FOR5_//P[TA$;&9RKMD#)T_:NQIG*F0!Z:KWLA&)FBU;9,%%FJBR3""1 P5&Y+:>Z2*S%) YDQ@]=Q!#O@5I&LWE]2 MOAL,6!F1+P?J"9PI)'!/!#\G#I-VB)A-*4;E- -V)\1 MRM8FM^$=C,JSWQ8^.9I'A0^4?4$GN2B*&/]RC_FGIY+SY@OC&F?.F[2+&AEV M!#BNS9+5)#7M4[X\P\*?5#K'X0BBWA,^+KS5RKHO%Y>>KW:D@%(FX0I**%Z' M"R'9S>B8(>(IX<=,^W@IU#!.$U&@SJ8\"GBIRED,K)Q%Z@- )P&G+J/5/D!S M&E\DAE7*C]1UR*MJ#XKX4F:'TQE:(',3V+DZ,U@EUB.E:;(&R2:\\G[8C^5R MB]P<2NJD6W M6%4?Y!X;"SP9JR^^PV6X?I#3L75Q21]NS6I\#WA63[,$+B5%V90\U]#Y+Y(I M>A8Q9P;.\%%4**=9^)W5Z!]D4D") @-8='VLI^\ MJ6FEDL>B/'AS0K:VY%DD<&K&WVOWH)EH[B13L33@"MEQ&ISG-G=2OX*%G*V8 M*D(;5D6F;0%4*7Y"9*9KA11APOVZ*1I=$Y#D=F_A@S-^]/*4% '4C^&0A[459 :F$?FS9&2?GW7L))$= M?>&KC][@S3I5I.P5/Y0Y MP6ITJ3HKE8(M)=T_,+I_3?%2!<&7T)M[ERN:)^GLW#.<79D$:H@F7T^I&G(M M2A-5>:UXQ>Q$\>C/U$-8AU@E=]V*%ODN=QN801_$B/CI/7HZH^LI[5@$+O;> M^6T:1W\K)P'R_K[\X[WI6%M()>4&C\,$-_H))\"AN,.PX(GT$J&EP:LVL%<- M\4>0*3%R:NG[2E(12G%,R9'H4M80;EL("[-_+1"SN M\#W4'$\IWJ2$J#;.ZD5QNKZG7(WIR<,IC0*!H+ M02[6D) H-/J?IKV=<*ADZS)*JB-[-,UH04WN#2II#ZGNIUU)/-4?T::GBJGC MMMHEA)X7%W-2XL;D")BPOY_60[:@G,?]N(3I I\S1")^"$?%TZ+"<[V2L="S6WS%&B M2I4?]DVG-M/AL*4/6V6SDPZ,RG"8IXF"_9IF#+F*?:YC%=5&)R3-79>!$]84 M')^QT! PZ 6QC'AK8*KEF&&,@G<4A6*.WC]8F;[8CF7JVXP,72UZ651%#U'9O*6Q,"(J^4LCR>Q M(+W>4 -/@65%0B42=)%]%249R(,3BXXPZE^5-/". M]MAQ=&?=*X]?Y8R.K(/Z@0]J[]+8\A;D[9-7X?RY1@F"_;T_>H/&R4FS4PN6 M&#F_R=+EDX\Q[ZESL[]8E8+'!?UZOP:OB%+9D^>EQO&ZR820Q<%?2N5:^'#]LZ5N MH5F/2I0NYA:QFAVQ!.G#.+U)C@\&)#I#0A[9BJ M2D;6S#[[$T/R06I _UVR0>O$=#F-IK, M""]* ]#)W[E@[ -6153INC6*6H46P@E ,OW/ *_9&IG.8[0>Y;ET&XI)^8"O MXAP^&<*%>[QF;VW3_T9Y-&29/>Y?I3';N9)VV;2S9RF>1P@IL%QX[,B2)R>. MJ8,MB& N_48.8+M)@S4#/@U^LWB1M'RYC67BKK.5]1,(5'M6L$BAHB #%@D5 M\Y@IUDW]5Q5S,)O=E=]L T:5H(5E[MP<[AN5M!T%AL*$4)J3K"8!-6Z89B?R M !T$*=5:.V;+\=$_KSY_!(V4S"/K3:PUWH51S!Q.%E64#4]097EP[!YWA' ; M/E(GX90>8?2M:TP(5O.L?G\B(MI!],!DWA PO4J]Y33X( FI5F#Q:V3?$HND M1JS;%>]*GMM+9E0H*NN+BHHYA:77X591/U=O2%L]M76F^S3[5I- ^[1;"]C= MPU0"&A!+$9E67BAI).+3A;0JU1 M5LX_,KR7JW)(.TD6\=;BF++T"-G';'[=",%*YJ9IRA_H=,2 ;2A; B;B)BTB MJ*EAH_$]GJA,$GZ15$CD5-()XH:C''FP MRS%M.A!J0,W)?67L 6KSH?2A ION)!)S/'6,,,&9LZ@BHVMQ2"EH3G(-9[/1 M*M!VP,ZC0R;$\M6V,QS-D:'. JL-&E[V33PX5)GFHMP28?GVHG0[8@ 7.T-6 MPBFK8D4-44$?N$Q1Z6YR;U2G!23-7&VAM4G=MZ)I(>U*[9=9N!O\ M6F_ATX6"L;)"J,H&+9N>#KI4R;Y:T[:B2HT2:EXHFU)@@<7,YJI9VT-OS;)K MV[W?A<8.5:,,VL\Y56'H1U9M,VL72O&/N'*QHQ;IM&7KO:>J8CO7T,"F;@.3 M#G/3QD3K\TNEGHZ'AE@/(L(LL>8?*1\1YV ]<,V_A6R>(.Z7D64K32IYE*C&J,(*-]F2\WQ4AKK#@-#>C M0JJ7DQ]5#1[OM:Z@\Z./1<,-*H<6*5XTT:/'II;@Z1!S%(Z<, ^ ME'%"ZJ9^&GR6:=;R5]DH3A8\FUQ7ZJV'[*7&@B6_4?E>B=JJW?N8J 1;1[<& M397JI!JYA59L*4546WMMJA*C^(BPE'1*$-7A*8D^J8-75?$E9:)9XS:TFYA# M3AMM5J?33)SH:,]<*6(V2JT^#]XLG/6= ;#%5V*O*>::1OB%AGA+V$9%U_$VS\WJ<+J2MD&48%"P\O2$2:,P688B$F!Z5J5 MZS&?A,#/XRC/E17!UCVY%1'%Y0[K*?#4L=;9KJM N3M1[18F4CLDD37[H%QZ ML-0*U#DVN_QN[!TV!"N$TD-=[ !!?)G'W&+=]FEY0Y2F\G:!0-C?(S= MCMP.IJ$YN--I 6.O1,U<:Z3O@N/KA43B(RU7IS05K8$PL)XMUL07R@/H9*(A&]1$RK4[FF*S./;#\\D@D-LLX7D4YH6C8J];('TKUVQ,S\ ML@ZEEY!XEKSXIS&"AZ,U%=F("3X1]#&)H);Z\\%2=#YR@:%/_=Q*GO8<]596 M<>;*[X6^*"!B%#_(0@0N":2:/5F/6IN+Y82Q;SO7B_*X(MD?A&Q(\A^IM#=\ MI93483E)3W8*4:-3=:5D1L#BA:5F%HORAV%IQU0_,.<2[N>WRY+65\O;/^O: M]> "CD52A#P_;\,OKZG)2HX!"9AI;LG^I2BSNRZ?!M;*1.995I,9Z9JF!G1W MVHTP5"#B)8?Q1LTE$X%QV)!A#4&","K9V$9 S OC*N/( "YU8D*U+(/$O(E% MB8XP*']7.642S?%\D3VN:Q%FVX>N,7DV^F0.)[GO"#-)$UPFT:"##D;( 3;E M S.7$Q+;[X[KUYZN?AJ2$'/I$*BEJHHMS9Q4 /7.\@2MW@4>BN6I.H$R]>!P M_%6$7@W:RB>F).YA=L*ZR0\E;S&;.RSH&-<*.?D^$1D&*26/H"9BT ZP&3[33VM3+]>7A^LVTCI;3 MB(F[IEB_5"A'X_4TBH?437G+> O-?D?C+31J_5;?Q5MH-[NS> O8,NUD=HS; M&U6O;3 @FLZ(FLTSC_^PA2/C0C4; /4P'0O/Q-M0M"5).>Y5* !W@JNE!&O\ M8/#_I.%["T?)"?J/+-]6[G1V+@MB%9"[X/YTW-UBZ.9W*SQ1#2"LNTMH6]A* M>0LW*W)_Q5Q$'LTOB#3L66B;Z2M.?^B(RZ2YTT7S5BJ,-8I@5:[O9 T\U),T':H:QRL-YVS;'2T=S7)D.9ERHY MVG2ML)Z2F=X#Y=B\@NR?5ZD*;9_P>(4-&5^ZDK?Y=@\ MPEJ' YE?8\5][K0J72I@Q+LPY97\,'!(38'MY*T4IDD*1C[ 6!8=RWAVN;/ M:[$! :RUO&<@F[Y+!_$-2+8?^)YRS9'5W]A"S/1LO#X;$^,*6)6/8*>0#P0V M!O=7\FR\^:>?",J8-C$26=A$YEZ/G.HSF4IVO,X,E/"TI=QK=*\:"\3:?!OS9^CC*LO\N<**PE 15BK5KR:O!IJ!BI5)H+V*)L'P^E^FQ> VRN'7W\0PNH2_C\/@EU1Z\GZ5P';' M1[_\]LNO1V^"X]_3PE*,&]TWCC(N>_=BJJ8,3CE:V^QJ8-9*EE%&6?'HQ2IA M^!/4V30##8^GJ+IV*%(Z0[J>O[7,-.EM7OG?PJ_80EX]#3ZL\ @-OE,QA!*/<^-P)TM;?,>\-NKL82GBNO6/S&J1C4PD;*8D MA^(68\&;UQ7IX)OV6%PDVM.@;7VX%4QYQDFSD7677:R:6O@+=-Q6X!N8$/L5MLZ#0W6&%!-02,2FJQ_:+]1\Y)-IQ*?I6Y M@T!!BH.06!J1(?-,,R;4]\^MF*0,"_4M:C"EG-UW?(H"[8&0Y!L M4\KL'^TOUFXPDW*(SZ?#Q2%GR,##((*8I*[ZU^QX-X2GEZ-II,")UG@S M1FOGOCLT3J0',#MEX0/9JSGE0*@Z:Y1R'./A*K-_<>&8NUANPI&]J#4S.ZFD MX<29EB9]<5XND:H'QZV GKQBI!A>(0#JM93)=/,DYP M82K4/NJ8QKSUKSDGY?)=E(D;5+4SEMR@*L?QPPD;O2I.8052R-2'XR0+Q+I\/<\1'\OWGFS^?G ME]P[56Y> C96WAI\C'R)\WM-E6>JV8GO8-US$3C6SE,R51&.X'Q-DRG33[75 MPPMDYP='.,JEJWJ=KEL$71Y3'?%(^:MN->?'$Y*BXYB)+*V<@0YTX5'. M#G$O?[9TP%@(,=5,,7<=:Z2F\;&?3[,):(KZ5G;!JL4*K2MX!W#G23AE!E9 M$PQT]()* '+VFW'#GT'&.>B+]Z-5ESNP/7/+]IK=Y!B/0*YP#_E'=YATB\83 M4>CF, 1^NMV,5,5VY1;FGDIW0K_=[G\(+!3'>&&NS]M1[%R#Y:D#-,'&P-FH$R(J6$)4Q79.>K'%X0/$'T2LED!),Q9-%N;4,5;!HO<2I(*V"WBCK<43-5 MP]>=SF#X%M',ZR5>!YP#66H**C3D-J,-6CYZ\IQ31=[156[$@" M"Y'ZB./4P BY:N@R4XX:#"4LK;Q5J=XD[ZIGA4@G]$9\-])\!&<=W,G%*1S+ MPN+SL9R0!8Z!OAN^[!H.LH2"-=VY[^ORL9F )-!4RZ?8-4E@=*YB?^G]-V=_ M9VTFVDM]6D@4(ASM$$,[!&UM%ZYD4>+4!8-S MKW$EL.DA:9R"*Q5.1YPD?)$DZ1T;+KH?H$9J,ST_Z4]6*T&\M:J58#H3UW( M<+XSZ*Q)5Y1VLB6K> DT1]'R&" ,23B\K&+DGC6VHDO,T)5^E$V]S&JRP8P. M<<*$6H#\8?8LG0VR=PSRPGUJ_5A*\%S2MBM-7*@2MV*#]HE)5;#.M-)9S?MS MQ7?,]/&:T_GU;7#<* %.E4!%A]GTQN 2$D15LW3'7')J1M00WP:FCE":)>3" M4)_B7VZ%G>"K>EVHA!-NSH>ON0,V(Z=;";7);31; K:M+5KYG!8V&E]/X?R4 MR&V+82K+0)&Z29;T,#E(^$7ES+1^5;D\J#N4F[7(-BJ\LY\4 =TKL6/B]\M MD8KED8HHSC)G_X%1=IE8)>ABB@,2%TP);];FA0?IH"AM/76\8F'Y:<,($^"Q MF+8-);*QPT@;6!1:-I9$.,0#3S4#@^.<-?2!O 2!,#&VB#E\Y@5**??G[W:J M/LIJE7W^?M(]M2N5,[NFBM3."2?T,0#S*(6-P#YZ9#NT9F]@8]^P?:W.86I< MIR^G,,@"MI)XT5P0J5''0%+\JG\7@5EJ*:FS+1J24)6K;*UE6!XV LH--4!P\ M<\[:C39S32=#3O9-9PV8:&;3FS"<5$.[)]@"]Y*=8<#V>*!.\^"<%*3WMB(& M[*WO:=1KP06KTF0Z75K\^=D^]I*A&?^OJOF WPW;<;M^$M>9:_CCXDC?Z_G5 M3R67*BQULR91I)3/M-]N5OE,\=*C-RJY.K.\I98%@Q LYAH(LDMT)'.I_[L$A!)5O]2YQHD@J-,Y2-5O"/BQF8(W/3 M&U;O@HS@DM+1"?K*N+I=9YVI5EYT#;X%KR&_&LI#]B3P+4J3XI>@5LY]$22H MDTSJ(G00(&K#HN48MM MA8QBRJW3-'4$ O%S)+(FD8;PAR4M3.+!HC[E4ZF='=NO3/3=L6^SU6>*2[)W8?4)(UC'P:3&6#L.:_IV?/" MO$)=5ENN:9FDF!^..J-4;2I7Q;2:2UW,UJ7H!/ZXV,YQ,;/0'-^8@FMH-'[ R/#+]+_039D\9? 5&YE1>[YU. M*QV6'J*R:F%/EON_A%8.,DE"L&4E0(55DP,LH5M))FQI2UEO8_.#:4*M(#G) M/[V1G:.-\LY%Y3)4KQ%$S8DCPX7IM$!37HW6JH170)SR"J)^)A1VRCWUG939 M!IC8F]V$LEE+FGT#488:O[4^>R'S+,%0LGNLD>*<9)])9:59@8BUQ$&-(FX< M.M'A4*WR4H&?#M0A)17IK9T!S^!<;HU0+>N,9& .^A:'H;$VR\[2A18*'[. M:L'5()V0ROD;'9;2.6=E$TA)U&OTJ]38G@S]RU9+7*24.R%3LG,?)K+>6<:% ME&W.&3T.-FZI0%2WDN+Z3;A1(HKJ(#X+H6LW$Y@W[MB>U$Q_\W10\TC$> KF'5KC.H&B[Y=TDC+#PF0]_E9ASHO(CKV'!%)])_Z-D M)[/6N,EA2RCO._&>RBFTT=JV="0^PB6.GX;17?"#^O(#?,//@?WE[S],\Y.; M,)R\O3)*D!&_EVAK C&^P+;Z*4X'WW[\O_\G"/ZN[\%J>(DE\)&SW:E3^/?B M#S'ZQ]%Y_O7SZ&NC^;75^(KFPA$U1J6?_H0/C>81%7J.X9#^Q]%)Z^C'1K_= M[-7A'VM8,Z_89 B]I4-H=QN]5FO#(5PH)]PE(TV?6V ,7]+?TT0&LS &J(%' M%PR[O738G>Y9H[-DU(\9U9//]*M\U]]5@6)^_CW*]57G)G9$0L!! MM6*PL-](PB^EX%E_Z).\Y[7M%HO6ZS4[W%5+M/:6+TKA6 MI%2G5>^]1DI5OV%%HC5ZO6[[%1+M,D2#>T4BM4#R-UXAD?Z0/1D4KMR*Y#I! M6AT$P3K+^:?>;/9ZAS#59U,+.O6#T*O6)N!&:D&CT>JW^Z^0;(_0"[J=I>;& M(5)J,[V@?]8\" F^2[V@WVH=A&Z^+I$>JQ><->OM0[ E[M9<*+=@YCJLZD% M)^UF[Q#T@K4IN)%>T*SW&V>'()/6)=OZ>D&WWJN_1DIMIA><]HUQ;2R]8 MRRZLX-0 M2-1!.EG6)MI9>L%+D^Q"I]/A 0J]1?X[P%")- M?]"8'3HWPZ')ARD7]7QM?)5$^9+:JL"/,C]$9X3(SQYH2C_;/!K3P3ZK+A34 MNL@#2VVIWDWUMD"H..X-^%_.G**MF7)WD =)<#[)HMBB6*N"8FJ@86(C+L$Y MN]:@P2A;8\C]T[.* 5^HYB8,FU%@UWK!C>+;I\V9&VH&TATO:58\4S>:KR!0 M<(])QQ,P!M1<5FHN;[65WU*3>,_C5GK^YT&1.F0W*?JE_=JI=?OMVEF]L_(> M;31JK>Y9K=]8=9NVYG#6_(W:/^W.7N^WQN:?SH-\.A[CVE:T_+*;=P;'D96' MC*5..3!L3JWN$(PD13S5_.TCU@3)8M,WP7+S>.TEVOF*[(3^_I/_Y#_Y3_Z3 M__2B/BT_Y[$&29ZD]]&PN&7%Z4A5)7$?E(&(XPG:1\G-/X[J1_0]GX0#]9T4 M@'\<#0@O_T@][YJZO9T02-TD%V_5AW?\HJ!?/\5WO8>'7?'#WM;?L;IQ$HM1 M\7;VX"\R]7#W+G,57X9@ACRFZ[0HTO&1.\=P6J3OY(1*;UE-^]F2=KD5CUA9 MX['7W%UON?[%\ FH92F&O"VV0K_>]LEGGMX[[:C'[YR*=/*V,<%ZX40$ M?_EPAO\+U(_$ W-_Y6?3[U2<&/RE3O_H"S*F],S]KVLET8+V+.%9PK.$S1)= MSQ*>)3Q+V"S1\2SQ?"S!W[.=Z?K7X>#;3888VVB.I-G;X"_G_0^MC^_779Y M_3LOR+XG5@+=?9XC;/(M'B/Y508]TZ[5>O>OWA-\39D]TNK5.J^7W MA-\3UIYHU>J]C>7$8:S\7ND\AZS97$ZOXVB 75/A#I_>%"A%4[V#Q M'=LZY:7"!.][\395M9WM]X/?#V8_G'F?B]\/UGYHMC?>$(>Q['NEYARR,O/Q MNVQ-0,T(AT*,*3$0.PA8%;*,\8_UO\=8!&N%G+IOO+KN;3]O^_G-M$?4\IOI M%7D:6[5FH^W7=.^TI@J]^A/]LQ&Q97GB8\B]G4PIWLBEQ"@4./6?GM!"\91\ M:7F7.UW$&9FZGZOZ+,:\9Q7/*IY5/*MX5O&LXEEE)ZSR#*;$*X@S.G=G8B"B.Q' P@ YDV$>W-^*1-R)+!A-\2O>%8N;,(X?@O N MC&*JT<..77@A]L>,X9)A8%-;]J+.RDV7$Z:7:6]@GMM^NMBHZ]\E5S!P&O MQ:ZAL#/3(;>Y6)=_/YI#^;=^MKHZ8GK+\LV6:^SCZ.> M7:WW<9CGGT?T*EJIV\'XZ_D87C0(DP]BDN91 4*8WKGBBO'4GW'N[:^-EIZ[ M_K)TW-1)>N^&_21+UJUJ9?_TLJ7<\7F)2.QT^YT]'/;.1>+SS[MN3[R^RGJI M@;?/ZIV]&_B3\%BCT>J>]1N[7+;+:3:X#7/Q>72>YZ)8O&M+2N'.=RWJ7:OO MVO)4UJ "_?B9,,;RCQ)C;+B)?ER6.\UV:_6)5([F*6>CE^PR#I/?P['0^_F7 M][_]2B_AQU\-;F'=5US-9KM9;_4/@ :__3)+@WQE(K1?X#[8%8/O.5NL:6^= MO:3)[(;'SYJ]E0_K_2'!KK;W?F^(M57G%S29W>SN3K=5/WMQ)-B=3?$4&^*? M83P5>^$4='V>'?)YKN:V<.>PM6FO=DK-N&H;#;AJ_\:]YG*=#X<1/BV,+\-H M>)&\#R=@7\6K+!W2H-Y=T4FXSS18<\NNX1+>YUE?@D!)BE47^KDW^VJ^X!G9 M L-N/:MP6NYJ;V5(WPSD=@\ZW0;*SD)]YD&ZXO$ M55VC^SSKM43B\V_VU7S!,[)E]P/?Q!NZ68A\Z5">9A)/*G'Z]7YS)0OYY1!D M??&SJH_[Y=!@+6'T5$RQ=0__K*;9ZJV^D!O:PT_MV=W0V&JT&H=*F?49?D6? M]TLDQGJ6V5[SR[I.E79S)6_87DSF29F_U=KC[?[4[I?5 @(OD19KL?Y>,\O: MOH,U/&K//9FGY?SF'LOWI_%2FW/ZYUQ2'H^A5;?=FXIM>Y^,\4M]H=;C!=O;#6T'Z4112Z M;&*UVIN@LP"B]"76Y=!?[GD,UVD\+&/:T:.;9Z>!(7O =%]0H.(+F%;\A#5) M/V?I=!*(.Q!C($*'06X(+8C007$+E]S#6W-QHU@+8R_U:<'\;#6ZQ M\@EKC(;P%*X^PF_ $U0K28\>14F8#*(PAEE+<9T']R*SRH\BDJ];K3Z:QZ]E MMA[#+GGX//H2?G^?"5 FWH=9]C!*L_LP&SX1ER\O\5QIOS[-]BPQZ9SZSM4X M\Z5,?"=\ZH9O1=(C\,!)[V&OE!8FX,TC@.)[EXJSZ\XQ<%_?IIO?G7=RY$&JL;C/,Q M>_!O"5BMVSH]Z__UI0)?SUAD.V\/66^<]KOKT\M2#GEK;(6"O>T3T#R]5X+Q M>#Q!8;<#BP!%6T>+B=MJGIZU__JO:UVKNK+4=L(SS:;GF>?&T'Q&4;_G M1/>2_SD(VFB?MKI>VC_96J*7;P=LT3SM>>&^3;;HD)SQ;/%T;-'U.H_7>;S. MXW6>Y[!V7Q=QCZ/$T/?/J__Y&QQ(;[SX/6SQ^SH[W_Z>!N+[),H>*,U@9\+9 M]['<@@VZ1YTLV\U:J]_9W"+S^V(+1M@>[8M6L];OG#W]F;B?J[]G)]PAGV,[ M\AL]SK38)$\P<&T@0++0F?OZ(7= !KM7=BJCW-$[AV!=GNB/<.Y5>MV&O[8 MVLMCZW4:9I@([LVQO52[]\\[.VAO;2'VK5ZH^E/C[T\/5ZK/=2L>WMH+U7?_;.'6MU:H^]- M(F\2E?<%G&L^/+6GY]J!GUX-;Q6]%JNH4Z^US]K>+#HXLZC3JC4V6UA_?GB[ M:-LG2]/;17NI_^Z?7=3M@/SR:7M[;A?Y?!I_GN[G>?J)_MF(W!*([#$$WTZ% M DO74D$";M#Z3[LK3O*TW.*!^GQ%ISM=QADQOI_KNM.S<;Y^X=GEY=5H>W;9 M-;NP^N/9Y;EUI;WT,#2WN0Q-9Q7VJY3[ -3Y_79H-\[.:JV^3_0Y/(]VH]FO M=?H^U<>;X"_Q8/M*S[T"7E?RNI(7 M_EY7VEMV\;K2'JRKUY6>GUU*NA)_Q<8N9>>=^O7EMF5&*7)>1RG]V$R$+YAH6]8Z!L6^D_^D__D/_E/_M-DE7/^F1L6UI^E M86$X+=*7&A&GOSQIN$'4>M5HN"O3D[?F>>)5G(WP,.>)3Q+O-B5W$VS*L\2 MGB5>[$H"2W0\2QQD^Z!GT_7WG.1^!^^$G+IS6V=)Y[972-HGZMOV"BF[IV+W M=4*^G.=!6 3_&R;3,'LP*[,#@+'M$GFOB&CHMM.4AR447)Q+L(N"GV:]UFAO M @'C]\3![8E&H]8Z:_D]X?>$V1.]6KNSL9@XC(7?*Y7GD!6;][Q&F>BUUI$]XL.B2SZ+C5WZ2KW@'OB#>O;",T-S[J_#XXA'W0 MVJ0? $WGQ:WP7FDWAZS#_"N+"G&2CD:HP8CODRA["HWE)4N? S2KCCL;=7=^ M!2+F2:+VKPU:WXN"/10%C5I[\T#=2UO(_=(W7JFV760-9./WP>W87(C@F$T&HE, M) /O&'D=UE"CUFC[>/-AK>EQO[EQUN%+6\9=.;N>0^5K^=7;-^^$QU;.+@]X2$7_)Z8B5UL!7+A,%9^W[4>KW5Z_=V; MNM[4]::N9Q7/*IY5/*MX5O&LLI=$]:;$"Z*_IZ07^E[H>U;QK.)9Q;.*9Q7/ M*IY5]H>HFY@2_-6W;']DR_8%S=?==NU?Q'B29G#/Q_],H^*!.KS#9CP?PTXM M+I)!/,6]>9EF]+"BR*+K*2W+E_3W-,$^[ED:PZQN+I"L(B]RI[G[>?[U\^AK MHRZ[N3>_#D7T]5=Q$\8?DP+>=_X]RK_*L7R]FE[GT3""P5SD^51DOU$"B?E9 M81B_C\,\_SRZ*F VS@/^$$,AQCBZ]VER)V#,\/$R$R.196)(U_,SCX)I$O$( M_X0/C>91,!2#"%@I_\?12>?HQT:S0\+3D';[A'J&A>A];;9P'3K/0M1^N_Z\ M1+VZ#>&BS],B+$$G_P2]ZI-U?K1C^U.K]WKSZ?IS)Q+% *!]D%,TCPJ\O-" M+0"*#U%%G*8D3G?Q8K=@7/UFH^4N]OQ7;65,O:5CZG2:[=XCQY2%21ZS2!WB M48*+^VF:#/ O8?PE_0.> HN8W+R?9EA"^P#;-Q-A#H_G__Z/?;J(#)#,HY:O0RH#R"16K:+]#/7[XMLCRU;"N?OMP*Q ^?A)F&$W?Z MDXRB!(R4*(P#JU-)E.!%(S!Q08$[J/B-OCS].K4//7G\_/+(!.@YX"*$P!- MPANZ%=N?C,-O(A":?T#W"4 3FXXGU/U M28'K1<&WQE%X'<51$&HV=0!:83#-X8'WMR()PL$ M'XN7 KWU2Q#E/1O"1;P4B:#3@Y NGJ#.K&^-@_N11SC?W.0FK#J2&OK+6,XM& Q MB&ZGP?EP&/%1%S_4[(V@Y@U34N.B80/%\KCP=&=_#=*\P%%G4SCL@E&6CN'W7(09$@Q^ M'\+%<4KT0&K]&[8*KL*@@.OQRFE,%NDT'DJ8&7Y&<9OF%I^>;M$9XIZ@[NE* M&CYL$3$$]>8/,1#1'9EBI H5FZDMC5;?55L6OVQ; UO!_&FWNH\>V+_H5!+# M<[!50NG,(\&S[&QJD>RJTFLNZEZC4ZCU]JS M2>QH0RV:Q/\[.?F4ID62@GYUQ9K*R0G\]/X0$ $ &AC;2TR,#$W,3(S,2YXMSXS:2_WY5 M]S_PYLMEJ]9C>Y[Q5+);LCW.^,ZV7+8FR7W:@DE(PH8"%9#T(W_]=0-\BB#X MDB:!S0^[\8B-!M"_!M!H= ,__/-QY3OW5(0LX#^^.GQ]\,JAW T\QA<_OHK# M/1*ZC+WZYS_^\S]^^*^]/>=$4!)1S[E[ MWUPX7N#&*\HCQTU*/;!HF94[%LQ;4,?Y^/KMZ[=OCEX?Y*6/20C4P$^R>?/Z M,/N2UA_P3\[;_:/]-P>'WSL?/QU^^/3^R+F^S.@NH0=SUD3X&'J?0G=)5\2) MB%C0Z(JL:+@F+OWQU3**UI_V]Q\>'EZ[2[:WHMYK-U@AGX^';]X>OG)(% EV M%T?T+!"K4SHGL1^!R/CO,?%EW2!)GV+_2P2%SR!Z'GZ"1I1J>WC[.A +J.C@ MK_2$7B3V MHZE)4K-NC]OOJ8DGJ4E>E"ZKY>!/?[\ %Q M>+=W<+B'2"AR4-8%(>NLR)R$=Y)U\@&+?"@7X72!VE0KHJ-]$?C0#466=<$W M(/#K!4"00\N:H=UC/(P(=VE11,Q0Q29]"T5,&[ZI/4F##H^.CO;EUY1TZ:Z: MAP ,(<>1@XAP'D1R"I"_I;^NUXS/@^0G^!%K^(0BG8%V./C'UYOSVGJD[&^! MK1Q$)P$/ Y]YB,0Q\5$ MTM*H_"5PP#!%G19.]*6>'3..).M!D0.8 )R,C;P M=Y&3D[!R%*\?]C<9;/*.80:;\G_(O]>"AL!2R@?5(RF=D)A*NL1W8[]'P;QE M]>627U,\M@]3]F,XG4_75*T1)KQJ"IB!>V,&+N?I!',GYSI"V!7"DV %8EA2 M'K)[>A&$X3D8"BO:$L^ZTF9PWW8!MU2%\QU6\K=]5TEX0O**!TNR0@ MU,#WP$C\_'O,HJ>VB!LXF%%_UPEU58W#N%.LZ+\=5=6(?&?D2;@\\X.'MC-U M3F]&]7UK5*> *C!U)-<1P T 3UGH^D$8"XI"FG /_X/*?D]\%-\IC0CS$_3: M$IN@>P?0'0)<.2_$#@$BW%-_%#@ZWR4\_S8B5XOR%,. MK(SKB&'+D15&/!&-TZ3JG 3 MHBISLMK0YLTJ+/N11I78FDKH74>#E,/,LDE-W@Y2DSJOU:@Q S4&C*" N\QG MLD?3>2[S,\9A9#+BG_-Y(%;R>P_]Z5=!DS:]ZZY-Y8:@&A7T*VN+4VC,J%P= M=F[7Y E-Z8:MV@:5&>8WAKU9PFB$J.U6+!%8"!(4,?%Q'S7Q[G'ME?N@M7DO MUKZT&=*W=9NQM(*_.VD5TEI,*G'26D:\6^!]3/AOQX$0P0/CBQ!/5;W8I]-Y M^?<:N+L5-J/]KHHVLG%R/KC*)U7@C+SY=42[/]J7)(H%0W_50.2;&35I0<7V M,VM!7N&H$ST=X<%JQ:+47W82\ A$1\' J770M"AA1EGG$L]Y*L]XD>N(8PL< M;^@]Y3$]$\'J@KF4AU2"X_OD+@DQFRP$51NC%@[SH>S,&J!QV245.G.HT4FJ M3%2A4*F3USHZVGOH2$B)<)?2,7Y/_4!ZUSX_KE'8]9K0II 1[S<:AU_*-G&A M9XR=E/.(:*O].H9HS,BCP9U>H3!CI;&[%0]',AEAZ07+"73B33,VBFQ+ ,FC M9M^%_[P9L6J#U2U;<#9G+L&(C=4ZX,J#>4KG5 CJ RX8N6,^,ZR@ M6^/;I T:KWI!&\!>SFMW\NK17DX;@*2.:H*2 >B/#4270&]L_$CY4)Y?O! SHMFE5H&-\F%=+X2$LJA/JAJG=*]2>+=T&+ MLC8X62-&%6JA0DJZGXG@N'.]ID(&Y-7HA9G8#+;&T?*=XO>W_92CLZ9"102. MV+7 [I8NT'*]H>M X*XU^7?S84C[@F9,-1OJA)63\2[\-IY;#,-W\YQJXOT[ M#B/J7=RQ:!9K1L;19%3Y4)P?DC]B:0L.S(.(1[WJ\DRS-]+\8 M"<4C>:2=S; )MFTH33@>'!P<80QXRJ#XIXR5DMR*4_N(5N=\N&NP>'BTI!%L MEORVR7'E0F8,#P_>M\^4<[Y;%UF/P\]P;"T6A+,_U.:'>U=X*H0'D7'(. VK MY]0-Y"80#P'$ZL%T@:$?H@L?&RU@=;L68&:P-?%OX[N0 M>8Q@$&\28EJ(%:I$I/;A8<99$U-2J 6QS>IQBA5EL:O%J*(1_GKS6L96/4WG M!4=5$KP#5NHUS(YX"%@QH=N5,D.L<:4F?&705\%QEK-V4MXCI+60GA$FT!-$ M\Y\J &IIS'!I?!?(13J=:.'W$9JNB6_M,MX:X.F2ZC8B5#\?+F%_/J-B50A4 MKB3@] A M^: !H:Y9!R->ACARC](53CY7 4>AP7=@N#CG$04Y5&?"Y@)F[#2^BYRE SSW MW)RIDW$=(32 M%H,&FJC,N&C\#I+/WIV\([K(:01HZWE5VTJH:@!Y^YE4HR[TS)_JECAEQK57 MQM2(7"UR/P7W5' 57 L#(F+W5;RT-&:4- Z/G(N3LQF1J5\ \T/VF2"P'KG8 MBO 7%BUOJ(]A4.Q>&4M7A:31V!4EL]=U&'6#(W#I1A.4&R&>MLA M:4B6SRJCB,"P+32F=$FONI4F;\^H8FW2+OF-K2+J>E 91N MR2PC1JU3')H2%AIP:9.0,J(Q-'N@9]I W9#\P5&7.MG0JAUH=W@%[Z8T=$X M6_*RH^A-6[=(,!<4]XI&*M59LU^KD)C!T'A8@?6BV\UWZUY@UL]V\ MBYD\(O1[P&)GCHD6M5QHSAQRJ&+9Z6&N'<3M:''M9. M9E?(E1HAZ9T?4K.%;" WPG5XH-DG MFE^4&@$?$91?,\?OKB:SZFCV MKKL-T!_UKN-#&GH/TR:!&67-CK;\5LZ(2;_P?3T\1EHS4IH-K/%=BA&XKC'] M-1.PGLH,EF;;6GU>8(1H6X'^>N2Z%38#J@DBZ/A(P CVP$O*Z][4;E?*!.^[ MGE>6CR\_["B(M@;J(:S,^&_U*O-1+;861UOW/%"GPF;HS5><-T;2CE#W"J6M M =9$:H:Q]=7G(V0]PS+KQJ*!U Q9ZPNW1\@&1V9>!O>)X9L_?GD6B-,@OHOF ML5\M7(/VCFHQ*\K':JI3<_3GGI.UQ@$++EK2PHN;\T X::MTO$:-&QC_)-_1 M#66S:M]N[53:J"$]+M95!\EI+2/> _&^H"3RX"PL^(:WXEO$T1,^[OJJO'9N0/X R,G9SSB.8V M;CFM@;1U.3.N/>\\':'M'")4ZWG3$9E!:[X+=<2G=Y30%W?ERR_3-?[SUEW2 M^A>6NW,P(UMWFZJCB2C:<[Z<7%XDWU55CJIK1'];Z$_31I0 MO9&B+J9,IP%I;:,.#-(!)J=\ZZT(+7DTZT3[.,-&)I$[EOKN7 M[KM"M:-R;&N"D(!V5XE:#DV*\&[0Y*#J&M$?CG[E2Q+XUT\3FK@U:45E3]Y. M*XZKWY.*1Q7IKR*K9=7ZZSA#&%DT*<.'+A;DY1>M!3G.$5M3@'XFI)E'DPI\ M'*0"HPFY/1W8SCK1EEN37GS?3R_&=6('*G(1L74G+2@6: +ZJ(-!<#$[OQYQ M'(3C]H9Z:VX-&G!XT%4#QJ&^!171O>Y1@[^)U ANZ_= 1L3^I"2D,2D6ZS3W<534/T51V])]0Q7NVJ0FY:YZTW>MW)N'IN$&>5@@ M'Q6_4[I>%HQVSJ]H=$KG5 CJ9007C-R9 R$&\3*K6E,28#&4CG%Y;W]::8'0 M*=0[3HO=M"/[,[E(J%D'ZDHT(:V)@2HA7< SNZ%JQ+)S+N%GGZT8EUVH6X&: M2YBQ?*]9("HYAGM.@>^(9 \D8?G$78FZ ^.&A;]=4X$_D$7M]K@[AR:D:[-) M10'I4CT.5N3D-8W8=WI_J ;:*H$9.>-K1",D_=XEJ@TKK*4T@]3\2A&1W%X4 M7OA_Z'&[H7/G4?X2 =&/KT*V6OOT5?+;4M Y(.FN]F O_O'PS=O#?T%O7S^N M_)0"V9>P?KP3_NM +/;QA=1]O0CN0?48]/+PW=[!X=[;PU=.B"?CY")P)3=S&?QC+R_\&FI- MFVINP::,CY2,.5V@6Z*V$:5BOA"E4GO(9^_PS=[AAYX-\2*QCPJTSP.^Q^,5 MA6F]75N*):]4P6TVIU]3MM4..088#R-,AVO7"%D$_[67EL-FO,5F=%&3(K_W M\E]>U+H!:0&L^7VISMKZYB2\D\7C<&]!R!J5_$.;@:$MN$_]*$Q_VQ?WZC5Z@9RK/IMES87 MBB5_[^4L=BIES $5/81<*)?^8["(<0117[K<9+O!S@W<&/^)-USP2*;(S0.Q M4M>>W(&U2MQ(6<2P*/ZK';5:6+$W[!/:NWQQ'M$5&H.OI*L7"L98XB<1Q.N4 MD ')*XIWAZELJE"WC9D$L[4KO%H9WAR@/$3&+I.*DNF.4SU_J%M4)G M^6+@DS"4$0A8RW0^>2#""X^??@8S'4,>H+07^W3RR,)LQNQ4Q"">E@:J%WWR M�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
<)!'=!??)IU$M#H/T\$RZU6F-%A^"TA MM[TZ,KWS^9='L:^Y4OS\/?#\.72O7@Y)WSKQJ-9X(=!?W?N MD29U$>X##S4ME]3/PUB4W>GY.(D8G"?/? %)\&"5LX MSP$+IC&_Q:2GB2UV])I(>Y1I4'$4HQ*9@,PGD1!9^1BEQ5XKBP&(,P#WF3C> MR\D@^$.8_?X^I;"K2MGGSJ?"[Q:^WQ)Z=YG>&G8W,?U6D+M3=X2X#?(2$)A( MB4\%MJU\"2#Z;@GF"J6Y4DC#<0'WF$,P79'/2CD.'89S@&JKQC9R_K"7&W9P MMJLT0E0N<\,9EL.P;_C+O1*P^WOY&8?C'?72S#42FYZ#7(6O84#C8.HED#V^ M<\#E*4QO??E#98H=I2?1'3-82X%/)8.V\B%*:P726KN01@&R#/J(\VX'#XH^ M);D737++5I/UJ:+WB ]@X?&73KZGB.%CU,=PMKGQD6,\=W^P?PI.<[_8T6$J M3N6+Q^X0_3SBQ&G0;%>(2''6ALG:G9&CZC CJ+BHUQ,QL@U48'0%,,F&M*)4 MP-BL_'0Y8/U$]>XO /9M \\7\OL+?%^%/Q1HY"DWX"%<0F88P8 Z?5?_3D ML)"2%&*V(ND9*645>1W+YVI(R\0D.YJ32M SPD65^9\;#)['9_@Y"Y$?*% MX&29I$01_<2PW\[7Z0X")*UX%1=ED<>%2R];,0/1$4&[QF"R462Q=)4^J[- MX100?9@Y!\.U'OFY8_% +2< 6I"(2)$(C(OJAE.RG$T*/9%AN;72FK6*<@)R MV7-<57._Z:7KR,LR?JL5&"R6(D!<[/C#NU_#?>32[((4BH8H7#Z"W=,>^VO8 MNN*/':PW,4N#UB*$/^]@.2Y,=X3YV_H,(GA>O,:3)X3^:QOFNZ8U/*_:@\@F M?D_;MGGJ#,AB6:2:Y&(G']IF; YNW5OQYZL$7@P::(6RTTQ]NJZTCE>+'C/V MZST%CCA3(5VYNA (987:_!B/ZQJR0+_S"D83%\W KOUH\!+T^;CCI?@?PZ^_ MP'G+3W3]3-,&*_1V0 Q:>LI*P.INC1RL-(4?O44JAF6^@HO,P(1/*CRR]KZ& MZ^V:9.%7<6Y7Y-)5Y:YI 6L:*TCZY"8FC /A+,BO@HD#H+*L-2/W#KXM\3@? M:U!T%\9T&!8=]I@1&+6HVX9&>\UG!D=MTMO"(S8AHA@!R9(=5$0"%N@@R;3> M0,\**+6O2A7']<2:_:7'?#V*BB,Y34LXHPDAAK#CC".1;1P5Y(!WI%)C_4!N MDP'&^8*VF$H<'.?D4.G#LN>F.%;+/G86!C05'<*,_1 &Y P.U?[E/OXE_A1? M/<4?V3\>_T+$ M09WX^C7[WU!LKM_^7^AU_^[=,/_[CZ"TGIAJD#BTN\5A_[ MSR2%3;^EY_,);5+ ,:, %7#629ROLC->(S%?A:PIC1DZ[R9>FG+TT41AH(O# M4X9\55J>>I8'FTON8O%_XL5[AV:Z5 >*(!),$W)@G%QEO$27QRSN^.1/&<+\54M<-DT2ZM_KD /Q9 M9"(8Y^D\+X6/8$ O>J#9EJ7D)K^4</((OIG$K7B9L!R.!N]9)A3[H1?!+T_)/U>AO^(]'FCDY0.V:"P+<B/8BP1&"S!J%.HO?732<*9D#;_L#99""5)JP5O4!XO(/ IU9I@ES,TY;Y]N[NL>BB '2Q5+F6H /MI/ <2*=*F42(D<*CX$* M91,*%@+81![:BG/X$HKGG5IYLXRU..4MD"[@X] MK;RX*'M8UIA]2*+H?9)"I[W/YTP(I*'3[4#!SU^@AO M%[+/]I1N&6-*WBDVSU/J9=OR7LU)AQ*AM;LO7O+_,X#4/\7$L4,P_[;#QIX- M9A@QK 0&<:WU.@XP&M%4@0EU"QX;UCY/UD67 MH@=O>;;W-V^S2:D?BI";AB\K%CQ%.R8#OSP"1PL9,+]00>#M3-8T'7SDZ5*9 M:G96/NH\HX5/!Y^FI'B*T].?>>;2$K<=L$<:N%U]B&GFIG7>W^34M,4$^.%< M"&X+RW\4WR2F+_ LMIOYE>%/(\@YQO+G?D,]#S;4^GT4?#)[;S8YEG.+!'&+U@^?5VD/^-.[P=S&GH4>?Z,/MUFF7$ M.B.*0HXWU.;Z&?'ML;=##]=<4=MOG.U]TFZI.%A M)' N#-) X-PN;N=JI21_SM7Z##,64BID?N6;9/!>%1>J0'Y?C1#%/?"EY/X] MN?[J1]N 3>F*B^)Q(,Y*%F]HGOATSMQG0!&42W6^@>F+3*DBE7BU/"K?3\T3XI62\B$2EOCBV)AF1C"N M!\KWWT$^CX,[AM*#WR7OHX,T[!QMFKY7R#N)(%XM&Z^+V3?'#U\6YY.6BB^> MA\;MFJ<+B)(T@+-]605![D#F@;[2>$L95"\?OS%"\-3<[L!81[E>2>V4W.]0J:E=$"0@7 1'%P40 MV*R8@/@L*Z \0?*3B$F9I,5"\$M*!>MWH@#PQDOST&5%JP:;A1'-\B2FGVB^ M2H)Z@S]:#R.,(C0_G-(T3@\^]5"9%R[I*F,6CR17(MB>D;UF?TR]'._00I4Q M4D';V%KZK8 R-H6Z5('LO,0Q^7[631P4CU)EY_XJ9&(T[54?20XI7)@RE%PG M/X86\K5Q(ZJ9J9 35AR(5[" ^_&>#_-X7I/F2P@UC-OB^2M5XOGW!*@7=/CV M8IZ&+R\,+(I'CTLT -Z%FTZ[,.[4]@5SPKB3&GM2\9<5/Q=+HHA I S3KWX[ MM=A=YT@UAO#GZX2EH']P\HOEYPV#M#@O=HJ+2-5@&;U>B/%Z@-H2EC6Z($?? M(1H8F0EY"D,8R5O!DDU[Q!$,@%N=Z9+$SS_V8KN)0G5QZ:LSS[ M@.A"^;TQ8PSX'FA&&5BL&+I?,=&C9 /D'VGZRL9CU@Y]NOT0@]\@U27\:75" M#H##=# "@6G!DL-;4#$E6<$5$;9-99["(I +*GR(9.0.WR8V0-N0F&[Z_LG[ M&JZW:W%2Z"FY@%4)&HZ^+>2@DY;AI0;/3:EJ ,J:0\S,:0 MD8$$^[0X8ZDFG+@&=-U+*+(#-X3_3NG+ M-@(OV_'ZM2_)F2/S$ UMI#9E"MV;Y.!"Z"GLII=!5^<>YI9+SV7D.0#^(J9=%P*! M46[$B?7CH+^;[DF OX;IAL-_!]&3"0 Z.HY?X:R]C5[YXX$7[CMA6(A MG' M[V#3^:7ST]AX8+B0^;V4I0@84AS, <.F%67(V/#">SN\.B"_6)8"OD_2IR_)+]1+C\I[M3D@!GI+YAR<0^N11QX&;&GK)A\G'DA9 MNV,"->)++X?GF?,O[,\[]J_;E*R3.%^ACB[8OL_ F0'A8A%%+NA6P2X3C3#9 M"!<.\31BJM'/.>_48:\QHO_^/XN!C"IB/:UH2KGTE@Q?8W#B\>K0F";#547] M&XA6#BI!RB#G\1P?*HDFV=P,CG8!\>FO-5XHP/39;'S\ 0;#P\T M@G+\\"1HTZ2HJRWB<-&KHD3^UH;(0;Q?;D-XW'JO"#94 42ATF42Q]3G ,JO MLM>WMJ:%4GN&D90))TT*VOPQ70=9]P1ZBHW)M-!S_ :ED0)"MQ"DS^.@4/5: MC+X]P_0V1@I9>DJJQ7Z:6R(NZ-,C\.C3"4"68Y/TQX*RFZ(\EK1D64P&&!OM MO?? +Q"A<$]>UK_Y6F.WJVIU1.ZV^LJK+MS?"[$[#Q!^[* 7KV/4+K&JMWB= M^OEDZO>E7P:7J]+$IS3(H-#ZA^25IC'P^9!Z+!/LN!^@V0VI!P]5O%PPTNB# M? 8Q2 7C!S1?2H[DA;.L[E9-O/0RA1DD$P)<2,6&"#X.C]-/HOZ'UH]MKKQ4 M\-LVRX'%4]*)RXOXW/?%1OD E#-,'C$:VC!D6=G*(&WDZ&I%5>,H[)52PK%X MK>6>(,S\*,EH< ;K\)Z0O1O1)RZ.JR_C."AS$:K73; M^_Q%;S?D'J2K>+U4?'. MSUS5-L-,UT5FGH[?:Q@-(&BE,3]@Z%?%.%"KDC(Z'"FF+5QE-I8F-!0!B;3/%SRU=T22'#O8G] M9$WWEI/#QK*#NOV0NO9@U>6L2JL3\HG5,!V.GULE_&Q\4#"$V,8X$H\78'X6 M89!D*TIS$C !&@/BM!.M:0PDK@Q(-D3P.=R":O!V^[.M*2VP-S#,0MM=(F;O M<7X;>L]A%(+@>NBFUQ4[P TP0 WC-/K- >:&J&$*Z>*2)XDJIN+T8PW5SLB7 M50AG(5-*@JTL+@!UF7?42QU@WA36$DY?<2(**R3 -YT9V%!YUS!6)L? ZW]M MO>@FSG(OBL"GV-QW$3>]210V'FYR+0^TA&..$6UL&[ #AAFDWEX(H8O#U/"8(7H"V9#@1Z]O&$'G7 M,!ZAZ17UR3]^.&/X_!\8L/WI2V+6M(+@:6*[8BP#V,ZHG2ZVJ\J-+U!,"_Q. MOF64-V%*(RC/!)D5RILPW-$H_Z.[39M/89RD8;Z3AV^ZKJFUM44*Y%HJJMLO MC0T1;[9TRSMV-(,?)7'.N$?PTGEY*LOY+;!]=6][KG]UM9_9D#U0M6O8WL[@ MIE>_S,:'[ZWK"UY6=7ZG*IVMO)1"A5$F$G_!!:>7AQM$#N!3][7XK3X M!8WI,FSS]-Y.R#U=3VG5T[M[(/9T3<%'%ZDMYI_%'C=C4!91>5/P>.O&UR=2 M//>^NG/>^CZ^KO?V]T+NOIIJJ_[;TP6Q ^M*/G8@[Q]3F#F]9"E$&&]9!K'84/$\1E;\]$#!6<(H%$_)=6?GYJ@C M1P?#9E11Q!!IQ&AC6L/1=X"E'."2A+&<^L@(-H,\M9G!-3[MZ9N_IVR"XT6/ MN9=OF2"[6N-!1AY*>9:X-,I\_9@TB.SL\&B<=L=CD9(B 652E^.,>#DI1"&E M+/N=SDCQ%A(F/)O6H#=ELL4AC;SQ,N+)MY@.R'%FH%JRU,/&EV0'VT8HL'880LD5X)D-7:3F 22-PD* MYK"UO$Q2&K[ )?-7FK$!._$!A2D,4O(@D@D!+D0:24+>]*<,IM6^_.Q?FD;( M5.AV'C&3Q(SC.)CK[CXGO-,P1"OP=?2=&P+JJ#+Z& V)DB\T;1[P^I HWK!> M)?SY.OFW?,72J)7'TBWVSXAZ64[^_F__ P[FA/F.M2OVDL*8GQ^[?[@\X]HU7$*#]FPPB=@?,D.+=[;-,AM^]!'@/77 MW$_*1U./--8AM1.)!"UF&A,8]DB=4)QHTVRLYWP*XW"]71]@>;(\B T2F\6K M\%Y,F$K0AX$SG- ,ESOQ@YE A!>^37^"X6A.A C50]*XX1W-F.T8F);"1+&P M=!5F>1H^;W-1R"*C*1,/-LY\EAH])1>T;-#\DMPH*HC#PA%F*=^9&TX">1@X M1J-C+H!4CQX%*FO^? SPEO="UMYOS(?4,U(\X2Z]$#R.0G.Q_\*\JYH0B"D$ M3 IHH0F _C.M6+*_,!I,262*Y%LX:VD"TH4S@X> MQG-@GJOFD:DYF$R@NY']NI9#$TU[E]7Z_I C!489( T@]HQ9+ZELBCKBO3P+ M2HZO9ZB2A9B3TDV2YK630.5;>W)!:$59PI>'OA>)Q2$>RA#X=UV;%C./VYDW MS6,N7F[2I(V.;H+!''S=J)ZV=_ U-_#/&QU_FOU[7(8%FS X]+?B&JTGUMBS MTG354HS(ZB^3]<:+#XI,CY[QMEB#7S+^KVT:9D'H[P44)LU5R,8#G-X.O::4 MTPA1I$!GUFAR>GP\1>2S98,*'E^+#!PI*$C[M-R7ZLI@WCP7![G%)%I.9#I; MLI\V?'+SO"/>9A/M^!(6\&9],I8&D64!E96_*P3Y845(G38L9V+_7?ST)DJR M[*THANB7F9^N;6-YL8 W.LXSF MV<]>M!63J"A*OL ]Q6$9QC#"2,.?>>-I)/<#J,XOHQ^CG/V#N$(J\-ORA@^T M%9*14C12RH8RJ9_2MF">U](NGJ2+#M^NY)OS;:5$=/K-$YT.5=< GZK3_+"E M07;[T%$RM0,)/PIKQ/0%9LPC0,&@4>Y36F90/.\))&UT;G^7Q(5P+!\KUCB& MV:V%PCRAH,L<&J#0U'U^\-"IA7V@J+&O7GY$F$?8,91\R#9.MRD-2[;.U/7/\#4P?.T?V&;8M%5-3FAA_,PIKJ'6'BO5&]?P M\R(F-9F(%(HLEO*:0BD7FC#JR*S[U]4[!S*[("=QX'R=$3/.?5QE)"#Q!'FJ16V'4X&,7@YQ[=&D$'N6&,-TU1N5I<& M8I<:KQGI)EE8/6ELC72C0$/W+AXYG"[6Y^ M$,8O5R@;#LBT /W!LH*R0Y;3-=2I27?*LDHFEBAF_?5E.ST/MYR3MY7%]BH]W'2=KPOR;UHD/>94?,)^#;->A$YI/8U MB).XYS#R(L.\;RI,<5R^T:,;[A6X.CP\A0UN:9;]IZ)TZZ4!(U]\0],P":YC MYVJ?YU ZC:Z?:4K^\8-%71]S+\T1:/M?7KR%V>J!KFX7*P>L5\T0J!4%^Q86 MYP3%JKA&L9<1AI48ZQ \.L4RJCFRU$I_*ZZWTWS\5'.#K;O'/'S7QK99;2RC MV!%K.9=S51SE>E2.>+68;!@%Y$-]A#G4<3^@.V(G&*/%Z./0S4?;6%23[,AC MQYO!TRS5R-[Y3@.+#6C)&:2^X-/9!#@H:Z_:%O1BOPK5(;25T5ZEC6 MXHTKC&5!OCPTIVC88XZ6+C-QT2Z%.Q]&5MK/P$D[Q3;OI0C6[.UJC"89;YH_ M%V^N#YAQ5SUFXK8=ZO8M Q7-9^"T75)/M"AT1@K&KE\VMVJ+:IGHC/C-^KK. ME3FB:CMV>\?Y^'>/\OT)M-IK'M[>)[RE0&W7R4?FU78,L!>WCW/WGI.SBC(L M&4DID^2*BG^VK/Z.(H#4H\<;H^'4K4;O^9S$':+,Z->8DM?BN<8P)C'-J],F MREU@Q1&<':.=PAAM\$=JAF?HBE%=UA#I4C M:.3NHH@4G R::UA6UTKN)-*\?NV.+T<3%CS_^B8HN+[E]=E;9D+P?-LVX@\$ M\GW#;6O-*:7BE'8-&(SII;V/,"#?5$M[06M%C*F/Q&*P7'NELS&C;N*(82A, MG%YL,!$03C *&/:=-YR$$:'>H;!6)S2T%.!Y 6?<(FA1M&X];%?I(;9Z21RGZ8EF]H6G(_,=) M<&(8;^!S'!,>CF!_@I'%A#6/W\C2^AS1\1&S'.7O!\XO%QM:U( M92$X*3 5O&![&+U 3 M1AP!L1S7SWOKK_Z_/7DJZK$ZFA;=].@<%UI=A'(I"A*]>&$'A]6G! M;@(]2Q:\?#JI,7%ZQV,"W9_*ZNK$9PQ"AND%CPD0"?::[I+KKYM0Y,Y7#+<' MF:&%P"R1JLL8_:C5U'NV"-:IS/$Y8%+Z.XQ\/NXEZS/Y1 4D?Y0_9I:=5= ' M^5\*;TY0LMS"VY/0CO]0Y(S;.* IH;''G^;D&:3W)2/YRF/Y9<)?=5]YKY1X M,3S66:A'8 $#"ZI:L7TGP@)'PF)-Q9, 4TQP:\4H=XD8 SO^_2> 6RX_^Z&X M)_T+]?;K:8WI/TNP[3!%/]8V=)XMU';I,ENDY6Y%^2DP-K>'E>)EF/E>1'9, M/<*?"L8"MS;LWXFVDJ&LXD" )2:LM6$1 ,D) ?8F!JD7\;!DMJGWK,'UP SZ MT%IVG3VP'FIR0K#*\7290/TG^; \>J0U]T'T,,&O.' PH_V-R MD'WZDARAMNA] B"KF&$HR+*N)P*RJB8G!+(9O$@>S!AK37R785C+..+%6A/F M8'CYX_18RV@ MZHI!B,N=#X5S*WI"(& M7B,F^?O?_OZWR:'W/;/8$9H7W4\ >%5##,5=Z'LBL%M3Y810=\GTREQ1 RY)@S"(/?O[HKXMJNZ9Q>M#D@Q6%]9M:!O>VO$17TUA+;A MN6X>%9I$V8.@X;#D]N$+V3T/UG9V0.ZM_&K&W:@A]],T1Y9+-Z^%C M]_]IXX);VW/N!W<_Q#V_49?(C?% Z@563=IP(W'^_>] M&82$KU!MK;C3/8N;W$B^2<-C;$V/L#7=P2N,/=65[(%%2Y'8][(:DLY*F')3 M]%M"J7R]6-Z7=:\_QU7A:[C>R._U:-C>.,,9!2\[QFZ+9&:YS2RL65(>6XQK M?PQAJ^@AEN6X)FX#&[*O+)5_[-!WO.LF?5'3K-^3X6-9.^^0BEX:JV.+4%Q#Y7;)< M\B+80FHU*LTF/EFT_>AHQ&5B<6@)L:@0:V:QQZ)9_]D]]!S&E46^8E8T8K^2 MU$G%B[J!QL<&0>?DXL">6M@P/P'QJE4XJ$>0T8V7>CEE:5X09C[SP*DW^IU9 M>32Z"_YS '%#EFI6>-)-F;$E",TPF!&&FS'F,7LQIU"IT*2RSJ, QM*%& Q\ MQ);*=&4-;>VFS+7"H?)"#5/W\R:)KU@V$] X8*I%GMB=><_@\3[UKXO':1I, M-I(,XD!PC&$DW(^A@1S4CU+I>.C>?XMLNX&*7X4$#,%+$42&KCZI-"TV.[&3 M^MP4@#"P)9(O41B3]]PZS(VN6QZB8D-B2BDLPV%MW?38J!E M@W#RI*#?E#I.CVF6-6[(!-V=4Y9/*=[3]''EI?3"RT*_YZAR7Q^D0#9(9?7 M6]>0>/8SEHY>,/.'TSPCGX*P^]#1Z"QW?B&V9MW\MW_[<,#-DP Z/ M,U^%$;Q/.M"=#WO-S*%;U.YRZ;TN,W+J-LE-NG7! YUCF]9=ZHG2N?EB%<]< MH\MDO4YB;H+L/!?/$$.R\I1(O*,!RU^@\7F:0J[!S^JV6-4(8>008N%@S;F\X/^4 M%.;*$_]W6/MAAB[@NL728^@@1['1IE%!:S 1Q!@U7I?1+Q307*0';_]:+,V M#Y6%?[T]7$K2((R]=">\K) %T EZ,"DW7KPSMB1YMUT_TW2QO$P8>FRS,*;, M*+"QU;#&T=46J1=HJ2C7(%L;(E]^[)?;T,ICS!G!4/2AK,ISP8MXP$R.T(R^ M@+#3+CC:,\%=J3/0)I(XX=2G7V><0M&&CVL,;RKHO>"U>6YBIB[-\O,XX$NH M#2IK=$&,/KH*2Q#J:X\(I"Z>\D$=1[RDLF/+,- >VTZ*1 M=2,(!J)2BV!!) _"F!#.97IPLJZWF(; :LOMQL_^WHN8K39\3#(K> M-FAHIF3??9HLP]Y73,M6B"&V0ZW&.GNB"7(@[9+89-6\8F*RX1P<5J8SI&)5 MV>G-+5=,T)VV@M4$RJE?S=VZRQ7,#_R0CV'V[Q'E1R7C@ VT-"_NP+9,PS6[ M(H6=,090%U1T^B%>0QDD_OA3Q163,U*RX4F=RLC-HNSD)N!Z>[;U[DA\G&G^ MURZMIP.[8ET]>TK._7]MPY0R5 ^V< >,BL/B+?;2Z8180ZD0,Y868N0Y6J6Q/EDP)B5GHG Y(Q5S]>_.C_'9VWW#UZ \MANOI@GS,ZRBL M#O2N]HA'MY;8HRL-J\0)4#\C%7TW^>B$"J>,.APR+\B3-UY&//D'AS/A.YI? M>MGJ/DW@ F+C;(PXTH>X"ET/XQH[2SL4Z)IMAX7M<0*N?QN"+V"78A$XZ5V.-H5QT&= ;^6GMD4FY*_,*MWSGS(LB*"7&+WLQKTD*@5D/(?&.K&C$9RYU MPKP^'G,X+\L2.*K'4FVHTBC>38]V7)+4BS-(N?E9'W@X'2Z.^Q'K$BY#U@'N M#3;DYI/?UYGRZY5E<-]V.R/%[N!Y'W5\L M,;BZR9A2. ,)*!BS;P5K%_3KAL8,)>0;K]Z+!R<@25E@J$#T M]E38%-S8F" M0GZ&K4*!:9%U.KON52BI0XGD1B2[Z>]&3F>)^^X!X/"4&M366/"B,3 EN!;C MN^UX45MCI#"JIV3M>%AC2\23WAZ!1Q_B K)PA?MS'.9$T.=36E)P<'2RU)*V M2HDI/UD#4;&X5<#]NUIM)6-)3E4>ZE)A>IO$+T\T7=_P;(S1I-CTIVB9A%Y89-!F"1Z7[PTR,0TD7@D2F"BR#C#E%:P MYFLXY,UW4%7LN[??$Z "_RZ[2DH;C\U$_7 CIH]!R)(HY@X9@ E=;Z)D1RF< MB6&#HCR\GH8OJ[S80J+ JEYNJUW"]78N-JR(Q#"C[/KQF M/:]7SR?P_BJDK^6ZEQ?'6Z862P+Y.718&\\A7\PS,8EBS94K-+S@5+V4%,GR M<+.-N*2%[HJIA>T+80G3E"E-8P)O?#&Y8586[:K4 'RD9\N@[?8H\N3FZ MPK#;@H:P6I[O/M%\E02PPB)F#O*9C&R17H69J!H'64)+!C.8"-+ ?9Q1:L?% M!U% G(J/5.2(*:5/*8-;_C:*8$X$=U*Q/RM?G.$1N":"H^+/TYJI?'"GR"T" M82\J[!5R :C+@R=/L!P?%;?CRO6(;>R+Y B.^Q2+^_)9L_T58!9?LVRQ?/*^ MMIC<, ODD&3#H"I@F:2/&,ZLJ#EZRE()0Y15Q4H<<>9/[H))B&" M0?[*1'.U,8_*O)]C1C$*_X#$2[[^F"LF?P/+W&__"D?Z'!?.KVU\B<./334J M=?L@AS(ME0\JV;=U0 PV>G(;WMPM3@4[*,PXC=J7_'FJ;._YL6AF;7V4%!NP&Z4>"PWZP H$-\PPF MY$0J5JZF Y.8H=0W+6F^RU=A6FS:X,H)#O5_H'Q'Y%[(>H0A#PB= #0T&V]AWPC#+IO M0VATFYWS-BO>[;_U/K-RX1;1#7MQP<7.U8EC/-FP^G J]!T_-%[EZYB\6DY: M[KW=J-V$JM_L_+I%=;UY?-%I5I[=)KNM^7K!!\O.H6GU2STWS7H:+-[!I_^% MW!GCFVZ]"-89SH-7?FYASP:CB2#UX>.,TE[(HX\"\OM11RCDHJ!']:@C7\PJ MO":#"[]<3O%P6"&IZ\(:UBU9@J?DR28VQ>JF9$LD7UYK0W)V\ESNU-99U(;( M6>,8$_UEH8-^2+%XL.H]ZYOU3K/*I]ID-[VF*=\/*_A@ MR:=,JU_JF3;K:3"?DJS$R5(MR#OH@M0_ARCUJC"L!;"O=$QFXX-O1%ZNBC3-"[V;C?<5X!N4-^ M"QN-_'J5Q6W&(T*S!4.H6XR\+ 7:#<;RB/BE.,"M;;:&CK-S_C;E-2])%+UF MY?:MPAOV^>H5A,OFFP$F=RV>$L9@F-<;MP.7 >KZH;L9 ;65Q:LX+W Q\UX4 MG[F,O'"=W6W7SS1ML9I61^1.KZ^\ZO3]O1 [_0#ACRK7K?" -]I$22/!YHP( M1FYB_ 0&$&1@@=;G9*$VABR)7%1W)^FE M4L;J/ X^QVI=J\?M308=B,>V^AF""-&(1,:WA<)B[>$I:2 M\">=A"R\S)DJ#5\TK\M#5(&"PIJ*#>$Y)G'[U1W0/=#<"V,:7!?5DS\S MX"UJ_U1_A!.DAS6#:"N^'4T4.:R9,9J*9L=11 QBAA0;[VV"/9&LSDA-@O+O M[26\&BI338-8CDU7MY-:71U/X:['G.$SK-4+$T!]Q"2&*RKG7\,V<.KK@QQ[ MM%2NU]/NZ( 8.?3D'CNZ"T^OJ))?@:[#M][WU+Q*ULS[6VS3UA;YV.U4\; @ MY5Y#Q&.U6UY38Y3\*@@[>@#5L9+3>>*]ES)!/M&.=;V])LC]KDDAU=W4WQ%[ M6:.8HVNWMSYI7;J]SO<-4ZD.\YW'LA MFPH6&W.=_M;7![GO::E<6S?NZH#8)_7D'KW&6U(G0!X.AQ<,''OK9&K#+;QW M8>Q^KWE_V:?3>UL;(W?;;B6[5D;1.VJ/P,96,AT[IB4USWU_NRZ>W8%-:*?A MM)*%GT.%U)IEU#3.PE((X_UWC) MDMF.PS(R<_SU#8#%6W=8<9? EG'.K,=(O]S$S((TZUY#ZNF"'!%T%%9!H*L] M8K_7$GOT$:@:<2*I._9MVRJ_:]+9X).>\K3&;A$WQ^?V5DA]KD>M\BG.PR;( MKU)U23P^42Y?-0QC_O@C?S]E0U-(6/EM*7A6,BM9DR^KT%^1,"/_\;?_09(O M\?ZSB=,^?FC!)!5-PH@Z@I<)E&O^?A:0Y>E+HH$L:JM9(,N!6H?(4C:9#;(< M2NP 67[\\?O_]]\P@8LYJRC^QXBB !65NQU_S*PX/W^Q4W_I M. LUB !2"!MOC/HRHVYOQ).5$4J,Q\+J)NK.^=DI5;W.@U.-#6UABYYW4K65OB;FR) MV -[!!Z]6EN2)8*NZW5JUVJ.GFQ^W.;^*LR2^!,-PON5QV8;M^$Z9"Q;9YX: M79 ZW!"%Y9RTKSWR":JV^(9GJ[*0!INJ5A/5:6>AUE4O&1#@0 0+4O!P.$.= M6/$]O=]\]_'3_>UWXS;).B'JGRMOO4F\QS!.-L!3,/;I-@]]+\H>H:+#R@N+ MHZG:,'829=4P( M/1<;OI&2O#VP(L/[DE!)P ;\?V13T47ZXL6A_S&)7WYB_]/&>(V^)XR[UFU0^3.P(@4O LP(<,,$H*Z,\::TQEL5"3\NK&2^BI8? MMDR//U;)=@SVM7:>&?AU&Z$+_9I[SA#^>A3Y-O#/DA%:?+[DAA0 I[7&FY+= M'@)^^&\[&$B]*%_Y7DKUD:^URRSPKEOA0Y1K;C\;;.L1_Y01S9+JBN>6'%!A MEPN] :.L !04=V-#/;U/DV#KYYDV3/5UG -8:2E_ %F=O>8"7'I*G#!\V35 MY5"CLP-2M--7]K#"5%-KQ(-,R8:N5R%,>O!#PWX[%\/MY(>/][?OCTC7EG\& M _&4GX::^%+#I-8M-RTKV^[OR;E/?M":Y,UW,)(LGD$IQW/'+(U:L1V)V4[9&,#T^#4.^^0Y&K<&X MAK=4*.Z<-T, #9)4-2<"22 M936P[QZ'9-[BP7+R6Q+&.7EE?]NFE#S3_ NEL=+L+YEZ2[GQU'#3.0H@?L>X M1L7R?2GVX_?GWY_5KSXSL413^&W2&#'-9]3X=N[0'8T)WGP'XWZ2@K:UJX[,0^XT1KW_VRSQV**L$G=]F?J0O^TIV M7FKN:H]]R/:I6ANR;8TQ#]E>F4>ON@C*I#YTG=Y[MJ>LEI)#/32C_OGO'RY=C/.//[6HQ'] /LXKX=5Q_O$GQ.-<$6[T6@KY]2='X]R$]'*ZZ?#= MGS2!6EZ[>Z9"?AX'L$>\@8!VL7MBO#LF#7H]D7K-"/5KCP?U=T/H=V.D'PWA M!8\SPKGP9922SQD!/L[G'*UV .DZ9Q]Z/>'?C'RG4Y9IK1!I_\[K^ATL0VC((Q?.@$'C1"[M?-2JDN7&^!V%M;!!T[ M*"4YQT?\+&GE\-605D3I=*S^7L@]35-MK>B)WA=U);<2-1T_66E;]3)$4DG9 MV*;^^VT:A[ E^C[\"O_(^(,BI09,FT$H_0S785^1)M?WCJ&#E(7/MHT\A# M*"+(#P4-;]:;-'GEV\'=;R1V]T"* MR0/455.JCN:(TRD=J<>.\9(V48D[3J*F43A4B#NLS<[4Z%H[5W]'[HP'JM0* ML,L?$3O:H8RC$Q2@Y'S5FDO1"?[U%G,87^W@KOR,?8R92H/%*'.*U1;T<;[6 M^XG-(=;;=:?G[+=![CN-*JG>4VN V'^:Y1P[X@IJCGW(BDX.WVVP MNT^32C7W41M@=I]&.44F<2.K.YQ\M6G>>E^GK,\_1W'Y&IK/#_$:TH3,A M'6/:Z7D8;%I/Y\M\Q?TNB6%[D\D$+Y^#L-=?-S3.NA<9-+LB]^PA!E =7*_]P" '$8#!.C[$.H7 CRX3A _U"*H:D MSM%YL@OG5!?+\R#90,3N#(@M39%[09>"ZF!O:H=X3'>*.W;H\D/+BR619!W' M+WLZ)JJ.SI/4"AU8#AT'7AIDGS84SINPM&"9Z7WXG#D27% M:4^+.K>7X./P).A$%A#X]N]C\F6=W1-FX*8\[FN%.1SG&VH'RY#&G278.IHCWV(]JE:&Z9MC3$/U5Z9 MCQZN"FG7)9BL*WNFI>WTKEHMIG7.@CN:S\11VQ1M\M/]MC-PTU:1C_;2BK+C M.:PU52N"QF:M]VG"[Y_UN%=/4Z2NI:.@G(ZVM4,^ ^T5>_3JZ(J2E&Z2E,^C M,NEDVTP\?A;&0>C#!'13"$"\4H)IYY36+" )NP<6JVHJVL'>K>_T2;/W7IC^ M[$5;>K$K__5C2%/F[*O=+7VE7;5]M3LCA:MQ1E#S KV>B+.$@0J,OAG+:!-. M_(R4Y)W/2DN-/U$OVZ9B+>_0#)TSU:$TYN(*0TS2Z!$Z!.;@&(/T.-X_B,J/ M*']7W,;IC-B98?H-X Y;N+--L\X4/[0.4_N[C$75&A7MQ$##IO/P>,[I#8P MC 5U(L@[GCC;5)D3(S^X\]'+;9K2V-]U)+![39![89-"JMNIOR/VLT8Q1QGH?1:0BZBA9PZ#A1+[W^?&J37GQ$W;?4A2H^1+[.V;?4<4;.Y(^DT_M*DG?L(^^A4%:J.?_1WSZ%?%&YV[D#ORZR^N M1K\)#1X^73@:]Q\N[ML4$S]A'_>* K5QS_Z.>=RKXHT=-1_(!?GUWM6X-Z'! MYY_()MG& 7ED_-B?CWYD9:07?/RI-?<1/V'W D6!FA>POV/V E6\L6/H(_G) M8>YC1 /YQ)"A%.B(I1XO6YW' ?P#:KR^>E'/?=/.#DB=1E_9VJ)0:VN$#C9 MZ-%)%Z/)"_#R?U&H.]^-?*!9GH9P'*!9_>:_=E=K/(XD>'%OS^%:WI%-TD6]H!0:V/D M\-*M9.W-H\:6B"&A1^"Q0Q;($J!+)&'7KR%9U#.0*JZ]?)O"FPLYM;9$[::>*JH\V-D3LHMWRCAVY MDBHIR#KV3\M*>H*LRWJ&KU0<]87:%YT%.1L:(G>]=N7JY0KW6R%VN@YAQY?H MDR1Q/$Q;5_'2R^E+DH9_>+TUB+0ZSFK(=BG?/H2;>LUF2'<*;VJ(UYDX#C&3 MZG_DW*SIOACDFF7Z6F2:"Q;7GB#3_,03S=8+9$/Z(O7<42:05\RT.R*_7%Z]A?E,YKW":[#$$U4U,O(ES%?$@[?.X)H: M3=?D3<(DJTV$>,]M'#!7A1(<_+6]%27^-LN3-6OK>S%)XFC'B06I]X4\[\A+ M")R(%[QZ;' $)$[RT*>2WS/,P!A5\;+:,HQ9H]"+V!0LR\-\"W:<]E+<=)^( M3S[+^;7D18 9X=R(8.?PZMS$QCB2'%Z@+KU M5S!:FR/.J72D'CNB2]JH7BFVJ;&I%XK-7.R13W@R1>7;H=WW>KHZ('?6?F5K MMWI:6R-V50VA1]_I*5][!4\MW\5U?*-G"GWG\[KM9<(2PG3K0T)X$]^GR0L3 MN=NA>[H@=VD=A6O'0SK:(W9K+;%'3X(4XN0F)I*\8]>>3N>PTMEE':H5#;81 M72PAX7PKY3>>>NN5?8C22)W?1,&J]>\&D\/,7084>OXI<(S M D2=;P>T:=M9\Z*W$W)/T5-:]87N'HA'NZ;@8\>S($\$?2(9%$/;:9D*RXH? M.K+IA?_S*.(/_#0ITK[DK]<+J7\.5+LL;-[?!?D"_Q -QI_$W##11;7R%9O# MO;#\[D7LT,&,K2H]ERR)GZR?PQA.4*S%,C_[&Q2@>PV#K1=%.Q*NUQYS05AR M9Q3#'.X!YRLO)V&6;5F_UT14LRHE$ 2_H>9):@%)L: LNB@]Q,8-V6 M."K&6-=KN]/H3]G@*"6 M^L4V8YZ098_TI>\1L[X^2%%WD,J--=:;.B#.B?3D'ET>MR#F/+4O!.FNL[[7 M!OL0;5*I-B35!IB'8*.<1PXYUZ72;>ADX43-9;)>TQ2."]Q'7@XU7ENSZ8ZF M2#U%1T&9-[>U0YXL]XH]?@UTO4G#K,B!(;U<>_%VZ?FPT7'&_B/]G?+D$Y+7 M((2[0<_\J DTA^3:3\--F5 79Q H$5,1Y89LT^>;>&PS"9-@JW/D_@TV;ZL2'D+ M=]HNYGP94LW3/AAG;S&8,=,^+]1O,8AZ9FD>I( M=#L[=J+;$9-D,=_XR*$C%P]*A7/6O6V PY?/1);15! M:DMG 7"?^D$S.\JK= DG[/0YLZF4- 8H0.V!C1YX].4\#J[@08FD_?Z49A?$ M$*.KL,2:OO;(04=;?*OH X!#TD(,L;1?"3(M$%DW"# @D@._MJ+P< A.$RG^ M_WCKS?^Z[HC+!;K&\R6G9(NA8,QM/ M#2D$&C*3NOHQDA3B-9)C-1I?CE#0AKU.H$Y*\LZ7^-I-TF*0SH7 \=1FZU9: M9M)SJTY2LW0K/8W&NA7P)<"X]"=2L2:ETRT.G<[I:J9+<[W+6\QU1KI RGG1 MU$MO$^9>=!X$(:2A/;=0VQHC!YEN)>N%R9M:(H:('H''!U9.EI1T75\SM:/F M?9K O&MW!H<*\-1[N!2'LS8>$ZWG]FA+4^P.V:%@_2+X83O,SM@E[OB5\8HH MCNN9#W131+#SEY3R0^O[FG6E=)5$4#%OL81]_C (O33LN/+Z]-;17MX.,S[4\KF-^\]/XS"O/.)^*:&2,&S7[E:QG_0"G'R MTR'LZ+#.21))TWFN7U>Q,ZUO:3JK8=F>K#>UF\W0-)5S[@].I[FV4Q6G\\#/ M<4;]+1/KBCYWU^AM;HG<_SK44]VOH1EB[^N2=NS(+&D2(.IX/=:N@KYPPF7A MA,8FM._#-,OKL-$Z=^UJB]2EM%24,]+6AL@GG_UR'SW/+(KXM$TUER#!_AB= M=DYISPB<,CF(@L[FB;8UW5H'G4?*7#;01)W.QHAAIU])B3OM+9$#CX;@YI$G MXTS[QJ95K+&HMR"-"&WLZVH6;XQ,,""%N^&%EF'X=ZPZ-39$"DK]RJFSB\-6 MB"<7'<*./HD,,XJ*IO-5I[J*O1O*'I?D-+OW=MYS1)\2>/2J^_1@5WOD;MJKJNJGK8T1.VJ_S.-WWN#5 MOH(T>4H()^YX^NOS4=)1XLM'KSHZ(/93 M/;G'ST,+ZDBF9%-K#7Z+8$+VLY>&@$P/7MYU]+>A&7(W;5-,]+)>413#@UKH#H-4)J7,-4UKN"/3W0+XS,$"!\=4S&6F:Y22% MD?K,+P\F<55FF92\2<%OZK9^ M)3\NN[N!IW72SKEE:V.D**:GY'XYR\.6B%.%'H&/*?XHR!)!U_&\T9*:'S]] MO#66)'P*\VP;0I5_+][=YD%K8M#:$*D;]2LG$X#F5LB#?H_0!BZ[=)]"$OP) MKQX$_R.%*(3),FVPMV2)0D%%+8P--X.H^)-;1'"D/: MJC8^(K;?&'-,[Y5Y])EX( BWI#A)Y^M2JG[=%U*:&B(?INW*U2ZC'+1"/# [ MA#UN1"[*$>GV'HHM_9(^_:;<4PPH7<-:V642O[)$)&3_>L\8T)1-;+F4/?N+ M^OV1>^A@4]3W'34[(_;GX3J,3X8E)Z*P(B4OZ1Z.-R<=F,-7S+$IS<%O-9LK M=7R^IFGH>_$5W219F+-I-+^GW3I#[6N/U+&U52V?]NYJC'S:JB>[U5(-4@12 MR2"J%) OJ]!?\<>WR>?O'[\G01)%7OHNH'&R#F/^Y&#Q_#8?Z?SU;7B>FX8O M\3NQ*.X7TT7OU0LC[BKP?'=9.88_@UA)()X"IU_9C_$+G?B];JM?HMW(#E_H MMJOQU:/+_*BI3O3UUPV-LV; '-83*72.4+^>#?5V0YT'Z4L_'E!;RJ(7;)SG M/A.:8*\*/H-MSL9AO98/-*:I%S'MSP,6H.#Q71;P7JF.W^OV1>[Y@TR@^KY6 M1\3>/TS^L8._X,+=O\X'"0),8X8]U=U[_OD7+PV>&)>.Q?+]-L@]N5$EU6-K M#1![9K.4"- SOG"-\^6+V": QM1S /X[.H\36'RPI]Z]';\? M"/)7)HF#>V:(WAMUEE@A=P&;!JYM+UG@@]@AK:H[^JP*GPQSCD05BZARD0LY M:Q8-"]F( 4%&B ^@X 8+B*B-/>U6+<1)L.PG\&2B=#/]?8NFMLB![-.%?=F MX8<-$<-)M[Q'3#,+JDAV%6PHN4B#,"Z7 AWFSS\S]<+XI>MV4ZT%#-UET>..+>7E";5 MR?G4D^>++*_T5W01=Z]W#J. W ='F$-C_M?4';'_CM'"_&Q-S,$$/\(8NKYR M,+51@F+C^] J9^2>IGP3GHUGS-#Q]"4Y$CI4"K.'C@-S#(..LONLH>-0"\O0 MP1BBAP[#1NF"#G@P8X,"/GS*9JQA\CY)J>]EW1706QMC!X5.)6O^W]@2LZMW M"SQZ !=DB:3KVGGMJ"G).?0_RE_,Z=GG[:[\-I0&=F\=8Y*:$P\A@-FW1^DQ MOH*N>+NI_TR$Z_)R;NP"YZ,\; C.7)0Z%-4 M]?^VMHA=O5?DL:.W($PX92)).U\X;M*WM@*N7>VJ*6ZY%X3Q'[8)NG8P5C2#V$A:I78@?!@)Q.XR5I/1A\K5 M,Z;GPH/:'$? M8O+E23E(&)/+51A[Y$N8KP@3BW"YR)OO^#^GK@3KQ&[B/'Z-(2DY*C9Q=Q7> MD5G$X%'-4@V<^GB9#%#/8;'Z#QI3WQN-J4TT9@RKK2;11=8# C,'UW9]1M^K MC9)G+R)1&\R>]>(L=Q[;I15EEV+B\ M A5!19U[+\UW2D[=L8=KI[ATWKT=E_BR*/7D2SQ?)#D@3- MRZY#^R)UUU$FD%F^=D?DV?UP/:R6'\R +^QBO !G^$M:^,.&21C2;-H4?DKK MM+D]9P;EE#D[ASG[=,;@)&W#7'-YM$>:OK*9PF#@TZ0V/R@<8J8><-0A-4^X M'*2950!-VPKR984P9),FKV' H 8IN$YDRS:X;2WJ*"7 A\ 36:QG8-G&ZT]> M^CN%&]=C(;J=P/Q0N<<8/4#V-NGC%6X74OF#?CZO$.)K_;LU0:I)4?$ M&&K+*I\.!HA]G(P]<1JC4&4X3K81F"-.=AJC%R<;>\\5)[N5L8R3DKGT@QG@ MI"U[M>-D::2")4:%^2%EGSEZ MH+*M^SRQLE<; V#9_8)H4$C H%&*@ (5+5JF#18E2U+QQ(>+UNQR=3@0,#PM MOEA>)NMU$C,[L-'<76"@KQ-2L!RF=/.3XTT]$&_H:@H^>EV_>H)\L22" 1$< M7!<%L*OX31R$S']9;B/YA&*;Z_(G\G&;^ZLP2V)C"<_->DT9CYQ^3** Q9/B M9>36]*:O/5+_U%95IBZ=C9$G*GJR6YW#A5($LA(RR/?XMYY' Q&K*,I8L8T,^8J4>\X"R5WL&T]2FY2^++),Z9"2/8:8$RER B,^9B^:ADQNUWC8ZBAACS#9BIO'\T MGA1RK#>AF?6%.Q"2;(24\-\Q:^%7@HK'D0M)P>O4&>'$]Y,.V)(ND80=[_#; M4I3--A(VJ8"$.!.4C4W2+Y-T T5*H$S* X61&D*ZRMV_=1ZNU0FIQPU36LZF M^WL@GS /4,#0G-A[>4GI"VP1Y$GN13"Q]8+?MEDN/)5-F/E$."F=V)^N4"C>%"8R(#N;WTZ@_.?8BSARTG(?M0)34"<*><=)R81**]#L M=$[O,V%$X;6',/O]8G=!8W\%URB[%Z+ZNB%W8UW%]^;ZG7T0.[.VZ$=,B"L& M!#B0D@&&E:L][:5H?2M8?=UF-\J;%>\>Y?4^LQKE+:+;&>6NE[H0ZC[A31@H M4?1 7VF\I7>TYP),2UODWMRI8NVZ2U-#Q'[;+>]11:M(098PNJZOM%C1LB"( M*;CNX.6;8=FCT@.Y$VJHVY,SRN:('5)':H-QA+^4A"Y)!*F&Y8>U'G,;QX?J M=H[CJOFG07]$G#,'>;.$ZEN3O__>3]EJ12C*X3<(T-D7MINW*J8QZV0NR+'<(> M[7ZN\\ [;TT7RYJ&G5E@5WOD([-7576 MC9&/$[[91X[7($R'*CFM$DU>)TF M?_;4[55P_)F:@O(B;B_WU=0&J6MUJE0>D-EO@/T\3*N\5F]I^W+0)?'$M;;, M*UPZ$"/I\F"*/<781T)0!ZOM1EQG0Z18TJ]<8XTK+-?2.E?\S=_I07"U:2+M M5*7^]U\K 6[9O[$_RC\5??^__PM02P,$% @ 63-L3$)Z"+L[D@ 44@+ M !0 !H8VTM,C Q-S$R,S%?<')E+GAM;.R];7/C.)(N^OU&W/^@V^?#G8V8 MZK+\[HG=>T*VR]7><=D.V]U]YE,'34(2MBE2PQ=5N7_]!?@BD2( B0@@)!B M8Z==-I% 9CY()!*)Q'_^[Q\+?[0"40S#X+]^&O]\]-,(!&[HP6#V7S^E\2?KSX?'XTO1Q?_&)__X^QJ]/QM_=TWQ,$4MGWHP^#/ M?^#_>4<=CG[$\!^Q.P<+YR%T,W[^ZZ=YDBS_\?GS]^_??_[Q'OD_A]$,D3HZ M^;QN1?T"_^M3^=DG_*M/X^-/)^.??\3>3R,D]B#.^N;HI/P3\MOQ MY__S[>$U&_PG&,2)$[B;5HU>BG;CJZNKS]E?UY^B[B%C0&O22'JCT7]&H0]> MP'24T?A'\K$$__53#!=+'_>=_6X>@2FBYRZ0 ,87X^.<_?]U6R"C_.\D\+X$ M"4P^[H-I&"TRX?\TPN1_?;FOC<>=PT\+X/WLAHO/^.^?^4AE['%)^G-/UEX3 M!% \D)LPB$,?>ABOUXZ/Q?8Z!R").1GC(6026\].A/X\!PET'5\:CUM4-3.\ M_F7\-'U:@MSJ]5(HC:)!C-Z$BV4$YB"(X0H\A'%\CQ:(!9#%-96\22*8.\$, MH)&]SA$>YZ'OH17SR[]39&:DB8'5A4FB<.+YG1]^EX;Z"L'=L7D+8]!?V;Q#:\>CD^!?3J_3& 8@YN52@)X.)I$5108T]9T("?PY@H$+EX[_ MFK['T(-.!$&,E\T,;/?!"L0) .*<=^M$ASA>T\7"B3Z>IJ]P%B _T760W^"Z M88H1LD;B!;YY%AT8HA,1 <[!?#C%^ ")-AW'[S-8>1E1J(#]-K( M:5DZD%\:;084/T=@Z7QD,D>@N@7+,(8==,A+5@?+&%9!$D9=5%AKJV45C$+D M82OVVHQ% M,8(8C2A*'1_/YXFWPKO=;+XONUH+'KHZF+YV@C^OPR@*OR,'2)RW[>9:/(UP ML8!):7W1)@;[E@[@5X "PP=![# (\'T40M9_=! I!OUP&.'!3U M[/(\&"#?/-M<=]G4U9OK\0\=/"-BX.&("0ABH2AI*QD]\$,>00KNHG#Q %TT M%I!-"]]WWHL3A
CQ9W$$^,WYT8X5GV@K:>$799Q*'9(*"#C<
L-I7JBOC:0!AS@][=HOZSD*[X)!(QYURDL_/&(C:D,Y*. NC; MG7GG)9T%P4/4EL.&KM-%X5 T'SQT=K\:%,PYA.C($YN8"0<27>%+(6/PX41' M3@6I&YB(?PL2!_K2\_'79(<22>XJAUY]F1M+[BH.0>JF1).[LLND94X\N2M[ M+=1,B2AW!BN+EGDQY:YLVA0G0=1V":(!\ ZFSK#,)9PL3Q*[]4(3^QC@TXC.SKCFV3,?@XLI<_)4!> M_X$DKH;DI3Z.]=1^WU4"@M3U"^ A=(([!]NQ/ILR+IKZF=WHXQN.\&7#4ZUY MCIX,.\CN'%_A(&GD_<6N#/,3UG^"WSTR3J1BSAG^+^["S_[RM,3_S,K;=5ZK MNW1AK"@F;@)7R.52*HQ&)V:)(Q]DO(YL3^(X72Q[[:?Z=6:6>"J*S$:L0"CT M+@P41>,O12J'(K&T=F>0B!;SI@V4#1=V'\8*0Y&A;>G$0''L:/IP=V>.B!X2 MN)0KA1I%LQC=(1;XNQM26F;W#4G/_LQ+S.PN"BZJII2UZ,HFDY8M>:?UAIT- MR.Y&9HO@>;\S227"8]:<0MS];*5)0C,K%75F)]%!?IQX"Z8@BH"'OLEK*R!M M/D#GO6?,65['FL6VSLBY#Q[Q^70^Z/4'*/J9A]-V) MO#P_9ZU>'%G(_9LRI4F"J'IVK%ELZQ]['E_RD#3G\D)7+ENHF7!]H?BWA+0& M 0?^3^U"(=#RHZA&"K^(=H5?1!N?9W*K M]U ,=1F!&!NP+!Z(Z!>]8#HMHN-[%:S"!_B1@, #WOJW,,&='*%1'HT^C4I" MU1^=P!OE5$?='AO+F,0:"=W:6'S\_EP8M2 -_>(/%G^3=P0:M.\NR?A8M!D= MSF:?Q<:7LYNQ&@/WYUFX^NP!B%_>.\4_X,&??CH:%T_@_2_TJS_RSE_ #.(^ M@^3168"MX=(^^^/\Y/SL_'A\=3D^OCB].CVZ.JZ,N J<250?O1.Y91_HQP:6 MZKHJOOB\S-XA^X2 YJ\A,HW"A8@\BT&$@DR%D0>B__II_-,HC=%0P^S,R/%W MIY^;S*GP[]'T^/%/\$%5T-9WEFB(AZM"1<<:5%0R]H;($C13_?/@%=+*3*&' M$XUZ0#XW#!%+WBU:SA@*J7UGC6;:N2I4=*I!11,T0@^/\LYW9@35U/X^>)6T M 5.' ; NX_C%$1455&^MT1E(MP5JKO2IKH,5C?(:,_"B+XQJGUEB9K: M>2KWK4?ZUJQPL0B#UR1T_\PO.3RE"7[ WLN?H*"L7(Q&ENA.F,52E3IB$"6; M&S_I#OV&M)!1OAR\TD3X*C6E,Q21CS/?"O+IJO*M9=IJXZS4%RUD\9^?MV/@ M/2/CQ/?8JU44UMIJB8N/CW!OX9^$E<_@:#]KP"VN+7?ZR9>)JN;_@_%]4V*%%TD:98\2=(\V?CD\NS MX\O+XZ/C/M.Q.Y]%JA2;H_I'QDS'W@+?S%(!3JFQ=\1YGBGT4)RJT#C+V$K0 MW@/4CK9T*+[8MG+I?^M;XV# H3N:PGE84Z#W)5H((K2$9.%I'2 @%\F;)%D. M'/+\LCM\%%!PM344)#SZ;F*E.\S'"@\<'LK]"J':^IQ[("MP6U^9;4.;_9RP6IB!5HZ,TH] QXP0,H*MA]H MJ:0 HOI)32YG1\,&0"MCU,/C 2N\<7.O0X(].)>R M]\A*!^-+_0].X!'V%K6_#UN1?.PP0@3==WU29N77,/2^0]^GS,#RS\-6$AXPG4 $B>80;0US05 MYWL1G;HLP./5F[/V<[E8QBX??SQ M37L[4-./71NW[UF4"WI%\:U6O- ^MP,>0MS9N+?/WX'X!I)YZ+4?%%*^M@,+ M(LS9NT]G;M#M4#2#%QOWXI45#VTZLQ3BH@9;COB6Y"+>YL9A0V+:62\9*,@I MT PCOJPT>@/CH-)+OTRX\'!N8_;1UCM+?.DF]8]-1@F/6NE)!!Q\2L($+?1W M)B7TM\5/]L84J!=US,=:E$+.#MSI60A]R-D#%B624)K7)@XF628&2Z52$K'5 MRI"_MP<[W5BU,:=M:X+PG5'7/[8/%@)\,@+DP\5$"MY"P;PF2@,+L2'&JZ30 MNKRC23E[G#"8X33Q6_#>DM9"^-(^3/ R:6.8O')PT)1C^]E*LXU]\!!GU\8( M.COL>&^?;-B.Q[:6)6U:25N5C0! )>3 M@TEYU14_T0>#&0A<.B 8+6P'B"CK2I/#- &F*42TU/HI+C_XC"OJ(MTF203? MTP0?6+Z%V*AN'GZ\#Q S(&[+&)';25TWQ];!<@?2DI4.9Q*2*Y4TF>63MCXS M#DT[4#_9%+9*QN@M>$!63WD9&/!IA?\ M3E@ O/(!S(GKIHLT.YE%^USH0MKZV=[P@+4>(GSD( M8K@JWIO%+RT^@N1I^N;\H"=7B5 YX%"6T&Q,U&DJ@WO#8!RPE#O]3!>L6(_?MKG MQR"TQRF1NI^B;*1>%G5[!E'V"%![Z)+6LCY?3O3;"Q$54@*20KQ:\DI$XUFH M29K,D8'Z:V, Z.#8;F$C*+AXM.2&=H/M[!D^;B#D7]L+ @9_"F[ [=(W6/\R M?IH^+4&4D>5]%.J8_2C4AO8HG(YJU WV"/+@V7KL+4X Y>NL. 02T.7E)8+, MZ2D"BZX#@2R+L>T9J.W/C)O*(G(F1>TYV+-D77]U?! 7#.-"AHS:?Z1/C=,\ ME^X(T05>WFP\VH$&,01M/AA^@B^O4X1 (B%;H'^7DH(:- M*-_; @DQ!@TK=$#*\Z]A/ 9(@//L+9(5\,.L5G3))R'QG[OMT+7?G]D!W/C@ M9I"Y./2@M%;J-?3IP<+:5\8I7DQUI&!A.W]]]YA7N<(# M,,,KC2E5U"H+WP>6 GUWN?6==1C@X[#OM&]!@:;"1V3GJ! D%1&,-A:B0Y3; MOKM-,Y'R"K+,'38TZA]9AP4.]OIN,,U4_E<0(,GY: Y,O 4,()9: E> C8:6 M5M;!HPN_?3>79N(E6T;Q2V>%(!G>9?4SZQ#!Q6#?K68= F_$':51:>$ 3$A[#(*RS7PBQ)0;1VLXXE/2+173C5UD>R^Y?F,Y? MW\E9;\G4IWUN'"2Z*;4)#B&&E1Z-ZXI@XMMR36G2UA3RU];"0X1?&T_)R^G MWI5L?64M&GCX5!RJ,,5*L %!^]Q:9 @Q;&= @RI*43?46I"(<2SKC-RDX]+- M+@VG$>3EOU(DC4TN]#68AA&HO+:R?247;?WK5,2>W=SA".I:/=6/XW[;*-V2 MDY5G5)D/^J8 $D\Q]Z]! *;4,C24KZV$%A^72J*[^FUA'RNVC_:G@^7HFWA4 M+S:DY[WQ$$T+1LAW\X%ERF]A3$%X5XL+#9(-RGO4VQ"F8QE:Y/#?M_:L,2M- M31P\D+$9#BQ5RWRK7+NBZ[A_ 1X "_RS+$O21M%F$$F01.^R8F::E\G*@7XN MELJM\:+ S+430Y<+::U4K$97-^ZEU273;,7*4J)ET9&6XVS:YY8A1(A-6?6^ M]&]YMMEFF1#BM\;!0$B1[3AHMP=*SB./S8##+?33A%J7A?*U[9!@L:GTD%H3 M*'X'<#9'#$^0N7)FX#%=O(/H:9J7JGE*DSAQ EQ%D64[A&C8!J#^S"N]#FX6 MK(K9U1".&+!H5/8$6D+L*[UAOA;O[NM+U6J48\>_GGK54FSJ1*385*VKT=]P M9__Q>=V=P=6G*B7+\N%FST8U:KOSEZ;DHZ)_']V2PTOZUCC;T5%Y](TQSYYG MX F[0S[CX5=6UQ.>OMJE/1ARH3&MKN6I"K3P0GS&Z48 V>!;D/^WKS$.[1),]"Y$)"M8H?F< MA"$J-1@]8%*>2)3< 3 ,A>((VS/TL) A,^]?6X!K[@0S$-\'69R/^#A/2Y#K M5"C(E7?,XZ-G9A@"?DY >D1;"8;PV7"#[2DOP)7UK)1KX.95U M%U;WLVVET![0ZGJ/?FR-)JP_-!< G4((;+ZHNP]--0UJA]CW03,Z]H(,VET8 M?7?T\B=(\$]32=Q#*A%$D5([ GD>HM$08S9C+@$ MS?3WPQJ91EVRY_K!UAL6@NLIET"47C,QT*IE?WO*N(R__ "1"V-J81-A.L9! M;O?VC5\N"DY0S-X?2( >@Y!QV).#$D&;)PP_-89/$_PV5POCMY"20U41'_Y? M)W !ZQ7E/B2-@Z0: M0;2"+L@G_PMPPUF04>R#X_Z]'R"O7)JRJ@B;] 8MSS?M^699;<]A,$,\;- MRD8DX H\^\X.IHK4P1QFSJZ%V[LV\F!=(*)\6X68>:[2YPQ?MX?9H4Z,*BHZ M]YD'[@*#^V)\7$ ;_>*/-RSD-/K(=SG8"KQM6X%?@.]=?[Q%2(!@&Z9=2%@. M.6DBZ5T%VLRW*+=?%2NECI\%NH5QGKB$O3A:XM(ON5XH!E,6>R[&R.>>XER7,4KB#2W/7'KS'P[H/B"?9@-D&K_PHFD)KIS4^@/DTN M]%L*'@5NO1S0AU5+"CI1I) _F5V30ON+$X*$;$60*,N6U(=Z=C[*XP\7+'5\@-^D:\60 M6&/[ 25!'DIOXFHZ1FR8WGRS^0TD<_P:1RNZ.)OO$;[Z2$1)/7SM&..7=6^O M>W]PUE,F"NKKFXJS.Q@X@2MAE\<@9!SN).WR1%FVI,QKU4DH[P-D+Y66\50. M9XO8SCB<2-([V\_B%X6-KVK5/$Z!.V:M[?833/RB4/K*NZ;\Z=*]O NC%[!< MWR#F,$VM#?<(3MUDT7=Q:_'.-2,*/T>.Y1QX\78V8PND&"WW#U.BPE"\Y=,4 MLD+3:BV/+.,0>,].E'S<@G<:FEA-]@=&PE*PL_!-=<&_=H(_&;@A?;H_>.'F M7FG-&DU+5W6RM*"$].G^H(2;^[Y%/\P,0&[6YO4]_[:Z"JPF^X,;82DH+HV@ MR<[PR[=W0'%_L-53)K+*#)@4P,;RP$_KHO_@4Z.5X^/)EU^5W4X1_?*C2!I& M/V0OOKZ@&?-E.@74J+8DZL8A5#34K5(.LAZWTORH>L[AT[3*]5- %AP%;2(D M!@^IWLQ:\J*5R-228*4&CYO>S,K:U6FV-V0Y3)*R)#"KM =76TN1PL.EI#J. MS:^%K7I7@Y M/*O2AT_J!DQ/G?[\B 57(D(;2XI:M[XR3WT]U-%4+@^W2O,M]+W9$"[ F_,# MQ&UPV/[0>D1P,:PT;^)*WUN[2'Z;],C 6T>:LL<)VU(">=N;!R'13,!>G-*+ M%NIQ%[.2=%]^+$'@P21%TD=S %>*\*[3Y#%,_@4R\TCU&/F:&Z?S?CHD^90] M!&'8&D.^G)4/Y![7(G3\Y_3=A^[3%/T2"2P[[:BS2\!,5S+68D>J0)0N27(P M]%LNKJ=IO6KA71@])'!)0 N[@=6XZ,"ZTLM7HID3%%,$2>O1P1[=T_0ZC6$ 8KX".>,C M]'^C3Z,-5?2/*N&1$WBCG/0HG(XJQ VNCU-E8%/N)Q?3-HVN?&A<>9"JHIK&V<^WI65U%%H,+(%TTU])XJ? MIL_(>7?A$HFE+!6+DW_R(AT$'Z;%BAPWK4BE-VPYUOV-JAUFYB7OEAM.EB5.G#8'^D*9,6 M)X/50,OF@J5?FO40:VR,J>!76FV[T9W)(<[\.P=&60K"YE>\\_RT.<\QM5%& M;E2G9_"<)DF@95:SF^B8UZ01M4UG9ILZP*_TSV(>-57GL3AW0YR^[!S@E@E\ MUIS 6>%<[,IG/]1)&CR'*4E6[%G1WB M;&?5&6R9Z^<$IQQ3^X2?1QS5Z1D\T4D2:$L>9#;I/LECX/X\"U>?8486LW!2 M_(P'?U(9?/[;/S;]TV8Q_4/CIBN/(O!D%61IB+.RV";$+\ %R KA5R+F,"I/ MM3CGYT5S?I9T1QO"GS+*HPUI@Z?J9M1M,Y3XI8[5]R%T@O@Q3)"G&#D>0(M+ M]M)-97S\*W$G6L9-7V.UO?[D22*LLF\AN"2<(R'Z5>L M0/SW4:6+S%VO=+*[B/L6WV2V&2%VP?828NIUUGMM!S%:$QH+9EG-7$F*DLH*+Z M_0-!WH8X25L?!&%/V?$1X4"\((F684QT??1=DC5X$E.ET3*5.=IIJDM&'A;_ M!!V6 )"@EV%Z@@&N\M_D5-5A/P2 D+$?X
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end

Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2017 shares
Document and Entity Information
Entity Registrant Name	Hutchison China MediTech Ltd
Entity Central Index Key	0001648257
Document Type	20-F
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Filer Category	Large Accelerated Filer
Entity Ordinary Shares, Outstanding	66,447,037
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 85,265	$ 79,431
Short-term investments	273,031	24,270
Accounts receivable-third parties	38,410	40,812
Accounts receivable-related parties	3,860	4,223
Other receivables, prepayments and deposits	11,296	4,314
Amounts due from related parties	8,544	1,136
Inventories	11,789	12,822
Deferred tax assets		372
Total current assets	432,195	167,380
Property, plant and equipment	14,220	9,954
Leasehold Land	1,261	1,220
Goodwill	3,308	3,137
Other intangible asset	430	469
Deferred tax assets	633
Long-term prepayment	1,648	1,771
Investments in equity investees	144,237	158,506
Total assets	597,932	342,437
Current liabilities
Accounts payable	24,365	35,538
Other payables, accruals and advance receipts	40,953	31,716
Income tax payable	979	274
Deferred revenue	1,295	962
Amounts due to related parties	7,021	5,308
Short-term bank borrowings	29,987	19,957
Deferred tax liabilities		1,364
Total current liabilities	104,600	95,119
Deferred tax liabilities	4,452	3,997
Long-term bank borrowings		26,830
Deferred revenue	809	2,039
Other deferred income	1,988	2,263
Other non-current liabilities	1,117	8,129
Total liabilities	112,966	138,377
Commitments and contingencies
Company's shareholders' equity
Ordinary shares; $1.00 par value; 75,000,000 shares authorized; 66,447,037 and 60,705,823 shares issued at December 31, 2017 and 2016 respectively	66,447	60,706
Additional paid-in capital	496,960	208,196
Accumulated losses	(107,104)	(80,357)
Accumulated other comprehensive income/(loss)	5,430	(4,275)
Total Company's shareholders' equity	461,733	184,270
Non-controlling interests	23,233	19,790
Total shareholders' equity	484,966	204,060
Total liabilities and shareholders' equity	$ 597,932	$ 342,437

Consolidated Balance Sheets (parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Consolidated Balance Sheets
Ordinary shares, par value	$ 1.00	$ 1.00
Ordinary shares, authorized	75,000,000	75,000,000
Ordinary shares, issued	66,447,037	60,705,823

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues
Sales-third parties	$ 196,720	$ 171,058	$ 118,113
Sales-related parties	8,486	9,794	8,074
Revenue from license and collaboration agreements-third parties	26,315	26,444	44,060
Revenue from research and development services-third parties		355	2,573
Revenue from research and development services-related parties	9,682	8,429	5,383
Total revenues	241,203	216,080	178,203
Operating expenses
Costs of sales-third parties	(169,764)	(149,132)	(104,859)
Costs of sales-related parties	(6,056)	(7,196)	(5,918)
Research and development expenses	(75,523)	(66,871)	(47,368)
Selling expenses	(19,322)	(17,998)	(10,209)
Administrative expenses	(23,955)	(21,580)	(19,620)
Total operating expenses	(294,620)	(262,777)	(187,974)
Loss from operations	(53,417)	(46,697)	(9,771)
Other income/(expense)
Interest income	1,220	502	451
Other income	808	609	386
Interest expense	(1,455)	(1,631)	(1,404)
Other expense	(692)	(139)	(202)
Total other income/(expense)	(119)	(659)	(769)
Loss before income taxes and equity in earnings of equity investees	(53,536)	(47,356)	(10,540)
Income tax expense	(3,080)	(4,331)	(1,605)
Equity in earnings of equity investees, net of tax	33,653	66,244	22,572
Net (loss)/income	(22,963)	14,557	10,427
Less: Net income attributable to non-controlling interests	(3,774)	(2,859)	(2,434)
Net (loss)/income attributable to the Company	(26,737)	11,698	7,993
Accretion on redeemable non-controlling interests			(43,001)
Net (loss)/income attributable to ordinary shareholders of the Company	$ (26,737)	$ 11,698	$ (35,008)
Earnings Per Share
(Losses)/earnings per share attributable to ordinary shareholders of the Company-basic (US$ per share)	$ (0.43)	$ 0.20	$ (0.64)
(Losses)/earnings per share attributable to ordinary shareholders of the Company-diluted (US$ per share)	$ (0.43)	$ 0.20	$ (0.64)
Number of shares used in per share calculation-basic	61,717,171	59,715,173	54,659,315
Number of shares used in per share calculation-diluted	61,717,171	59,971,050	54,659,315

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total Company's Shareholders' Equity	Ordinary Shares	Additional paid-in capital	Accumulated Losses	Accumulated Other Comprehensive Income/(Loss)	Non-controlling Interests	Total
Balance at Dec. 31, 2014	$ 39,151	$ 53,076	$ 76,256	$ (100,051)	$ 9,870	$ 17,764	$ 56,915
Balance (in shares) at Dec. 31, 2014		53,076,000
Increase (Decrease) in Stockholders' Equity
Net income/(loss)	7,993			7,993		2,434	10,427
Accretion to redemption value of redeemable non-controlling interests	(43,001)		(43,001)				(43,001)
Issuance in exchange for redeemable non-controlling interest	84,037	$ 3,214	80,823				84,037
Issuance in exchange for redeemable non-controlling interest (in shares)		3,214,000
Issuances in relation to share option exercises	1,374	$ 243	1,131				$ 1,374
Issuances in relation to exercise of share options (in shares)		243,000					243,000
Share-based compensation - share options	168		168				$ 168
Share-based compensation - long-term incentive plan	233		233				233
Share-based compensation	401		401				401
LTIP-treasury shares acquired and held by Trustee	(1,786)		(1,786)				(1,786)
Dividend paid to a non-controlling shareholder of a subsidiary						(590)	(590)
Dilution of interests in a subsidiary in relation to exercise of share options of a subsidiary	42			42		15	57
Transfer between reserves			24	(24)
Foreign currency translation adjustments	(4,855)				(4,855)	(702)	(5,557)
Balance at Dec. 31, 2015	83,356	$ 56,533	113,848	(92,040)	5,015	18,921	102,277
Balance (in shares) at Dec. 31, 2015		56,533,000
Increase (Decrease) in Stockholders' Equity
Net income/(loss)	11,698			11,698		2,859	14,557
Issuance in relation to public offering	110,160	$ 4,080	106,080				$ 110,160
Issuance in relation to public offering (in shares)		4,080,000					4,080,000
Issuances in relation to share option exercises	426	$ 93	333				$ 426
Issuances in relation to exercise of share options (in shares)		93,000					93,000
Issuance costs	(14,227)		(14,227)				$ (14,227)
Share-based compensation - share options	1,373		1,373			4	1,377
Share-based compensation - long-term incentive plan	1,378		1,378			2	1,380
Share-based compensation	2,751		2,751			6	2,757
LTIP-treasury shares acquired and held by Trustee	(604)		(604)				(604)
Dividend paid to a non-controlling shareholder of a subsidiary						(564)	(564)
Transfer between reserves			15	(15)
Foreign currency translation adjustments	(9,290)				(9,290)	(1,432)	(10,722)
Balance at Dec. 31, 2016	184,270	$ 60,706	208,196	(80,357)	(4,275)	19,790	204,060
Balance (in shares) at Dec. 31, 2016		60,706,000
Increase (Decrease) in Stockholders' Equity
Net income/(loss)	(26,737)			(26,737)		3,774	(22,963)
Issuance in relation to public offering	301,300	$ 5,685	295,615				$ 301,300
Issuance in relation to public offering (in shares)		5,685,000					5,685,000
Issuances in relation to share option exercises	380	$ 56	324				$ 380
Issuances in relation to exercise of share options (in shares)		56,000					56,000
Issuance costs	(8,610)		(8,610)				$ (8,610)
Share-based compensation - share options	1,255		1,255			3	1,258
Share-based compensation - long-term incentive plan	1,537		1,537			1	1,538
Share-based compensation	2,792		2,792			4	2,796
LTIP-treasury shares acquired and held by Trustee	(1,367)		(1,367)				(1,367)
Dividend paid to a non-controlling shareholder of a subsidiary						(1,594)	(1,594)
Transfer between reserves			10	(10)
Foreign currency translation adjustments	9,705				9,705	1,259	10,964
Balance at Dec. 31, 2017	$ 461,733	$ 66,447	$ 496,960	$ (107,104)	$ 5,430	$ 23,233	$ 484,966
Balance (in shares) at Dec. 31, 2017		66,447,000

Organization and Nature of Business	12 Months Ended
Organization and Nature of Business	Dec. 31, 2017
Organization and Nature of Business
Organization and Nature of Business	1. Organization and Nature of Business Hutchison China MediTech Limited (the "Company") and its subsidiaries (together the "Group") are principally engaged in researching, developing, manufacturing and selling pharmaceuticals and healthcare products. The Group and its equity investees have research and development facilities and manufacturing plants in the People's Republic of China (the "PRC") and sell their products mainly in the PRC and Hong Kong. The Company considers Hutchison Healthcare Holdings Limited as its immediate holding company and CK Hutchison Holdings Limited ("CK Hutchison") as its ultimate holding company. The Company was incorporated in the Cayman Islands on December 18, 2000 as an exempted company with limited liability under the Companies Law (2000 Revision), Chapter 22 of the Cayman Islands. The address of its registered office is P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. The Company's ordinary shares are listed on the AIM market of the London Stock Exchange, and its American depositary shares ("ADS"), each representing one-half of one ordinary share, are traded on the Nasdaq Global Select Market. Liquidity As at December 31, 2017, the Group had accumulated losses of US$107,104,000, primarily due to its significant spending in research and development activities. The Group regularly monitors current and expected liquidity requirements to ensure that it maintains sufficient cash balances and adequate credit facilities to meet its liquidity requirements in the short and long term. As at December 31, 2017, the Group had cash and cash equivalents of US$85,265,000, short-term investments of US$273,031,000 and unutilized bank borrowing facilities of US$121,282,000. Short-term investments comprised of bank deposits maturing over three months. As at December 31, 2016, the Group had cash and cash equivalents of US$79,431,000, short-term investments of US$24,270,000 and unutilized bank borrowing facilities of US$70,000,000. The Group's operating plan includes the continued receipt of dividends from certain of its equity investees. The increase in cash balances is primarily due to a public follow-on offering of the Company's ADS in October 2017, which raised net proceeds of US$292,690,000. Additionally, dividends received from equity investees for the years ended December 31, 2017, 2016 and 2015 were US$55,586,000, US$30,528,000 and US$6,410,000 respectively. Based on the Group's operating plan, the existing cash and cash equivalents, short-term investments and unutilized bank borrowing facilities are considered to be sufficient to meet the cash requirements to fund planned operations and other commitments for at least the next twelve months (the look-forward period used).

Redeemable Non-controlling Interests	12 Months Ended
Redeemable Non-controlling Interests	Dec. 31, 2017
Redeemable Non-controlling Interests
Redeemable Non-controlling Interests	16. Redeemable Non-controlling Interests As at December 31, 2017 and 2016, no redeemable non-controlling interests were outstanding. In November and December 2010, the Company and HMHL, entered into subscription and shareholders' agreements ("SSAs") with Mitsui & Co., Ltd. ("Mitsui") and SBCVC Fund III Company Limited ("SBCVC") (collectively, the "preferred shareholders"), whereby HMHL issued 7,390,029 redeemable convertible preferred shares ("Preferred Shares") for an aggregate consideration of US$20.1 million. The Preferred Shares on an as-if-converted basis represented approximately 19.76% of the aggregate issued and outstanding share capital of HMHL on the closing date. In October 2012, the Company repurchased all 2,815,249 Preferred Shares from SBCVC. The remaining 4,574,780 Preferred Shares of US$12.5 million held by Mitsui represented approximately 12.24% of HMHL on a fully diluted basis. In May and June 2014, the Company and HMHL further entered into two subscription agreements with Mitsui, whereby HMHL issued a total of 672,713 HMHL's Preferred Shares to Mitsui and 4,825,418 HMHL's ordinary shares to the Company for an aggregate consideration of US$25.0 million, after which Mitsui's interest in HMHL remained at 12.24% on a fully diluted basis. On July 23, 2015, the Company entered into a subscription agreement with Mitsui under which the Company issued 3,214,404 new ordinary shares of the Company valued at approximately US$84.0 million in exchange for the Preferred Shares held by Mitsui with carrying value of US$84.0 million (including accretion adjustment up to July 23, 2015). The transaction was completed on July 23, 2015 and as a result of this transaction, Mitsui held approximately 5.69% of the enlarged share capital of the Company at that time. The outstanding balance of redeemable non-controlling interests was extinguished with the corresponding increase in the Company's shares and additional paid-in capital. Accounting for preferred shares The Preferred Shares were redeemable upon occurrence of an event that is not solely within the control of the issuer. Accordingly, the Preferred Shares were recorded and accounted for as redeemable non-controlling interests outside of permanent equity in the Group's consolidated balance sheets. The Group recorded accretion when it was probable that the Preferred Shares will become redeemable. The accretion, which increases the carrying value of the redeemable non-controlling interests, was recorded against retained earnings, or in the absence of retained earnings, by recording against the additional paid-in capital. During the year ended December 31, 2015, HMHL recorded an accretion of US$43,001,000 to the Preferred Shares based on such preferred shareholder's share of the estimated valuation of HMHL.

Government Incentives	12 Months Ended
Government Incentives	Dec. 31, 2017
Government Incentives
Government Incentives	21. Government Incentives The Group receives government grants from the PRC Government (including the National level and Shanghai Municipal City). These grants are given in support of drug research and development activities and are conditional upon i) the Group spending a predetermined amount, regardless of success or failure of the research and development projects and ii) the achievement of certain stages of research and development projects being approved by the relevant PRC government authority. These government grants are subject to ongoing reporting and monitoring by the PRC Government over the period of the grant. Government incentives, which are deferred and recognized in the consolidated statements of operations over the period necessary to match them with the costs that they are intended to compensate, are recognized in other payable, accruals and advance receipts (Note 13) and other non-current liabilities. They are refundable to the PRC Government if the related research and development projects are suspended. For the years ended December 31, 2017, 2016 and 2015, the Group received government grants of US$1,323,000, US$1,872,000 and US$4,898,000 respectively. The government grants recorded as a reduction to research and development expenses for the years ended December 31, 2017, 2016 and 2015 were US$876,000 US$1,269,000 and US$3,664,000 respectively.

Litigation	12 Months Ended
Litigation	Dec. 31, 2017
Litigation
Litigation	27. Litigation From time to time, the Group may become involved in litigation relating to claims arising from the ordinary course of business. The Group believes that there are currently no claims or actions pending against the Group, the ultimate disposition of which could have a material adverse effect on the Group's results of operations, financial position or cash flows. However, litigation is subject to inherent uncertainties and the Group's view of these matters may change in the future. When an unfavorable outcome occurs, there exists the possibility of a material adverse impact on the Group's financial position and results of operations for the periods in which the unfavorable outcome occurs, and potentially in future periods.

Restricted Net Assets	12 Months Ended
Restricted Net Assets	Dec. 31, 2017
Restricted Net Assets
Restricted Net Assets	28. Restricted Net Assets Relevant PRC laws and regulations permit payments of dividends by the Company's subsidiaries in the PRC only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. In addition, the Company's subsidiaries in the PRC are required to make certain appropriations of net after-tax profits or increases in net assets to the statutory surplus fund prior to payment of any dividends. In addition, registered share capital and capital reserve accounts are also restricted from withdrawal in the PRC, up to the amount of net assets held in each subsidiary. As a result of these and other restrictions under PRC laws and regulations, the Company's subsidiaries in the PRC are restricted in their ability to transfer their net assets to the Group in terms of cash dividends, loans or advances, with restricted portions amounting to US$7,277,000 and US$6,847,000 as at December 31, 2017 and 2016 respectively, which excludes the Company's subsidiaries with a shareholders' deficit. Even though the Group currently does not require any such dividends, loans or advances from the PRC subsidiaries, for working capital and other funding purposes, the Group may in the future require additional cash resources from the Company's subsidiaries in the PRC due to changes in business conditions, to fund future acquisitions and development, or merely to declare and pay dividends to make distributions to shareholders. In addition, the Group has certain investments in equity investees in the PRC, where the Group's equity in undistributed earnings amounted to US$85,400,000 and US$116,953,000 as at December 31, 2017 and 2016 respectively.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2017
Subsequent Events
Subsequent Events	29. Subsequent Events The Group evaluated subsequent events through March 12, 2018, which is the date when the consolidated financial statements were issued.

Organization and Nature of Business (Details) - USD ($)		1 Months Ended	12 Months Ended
Organization and Nature of Business (Details) - USD ($)	Mar. 17, 2016	Oct. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Organization and Nature of Business
Each ADS as ordinary share	0.5		0.5
Accumulated losses			$ 107,104,000	$ 80,357,000
Cash and cash equivalents			85,265,000	79,431,000	$ 31,941,000	$ 38,946,000
Short-term investments			273,031,000	24,270,000
Unutilized bank borrowing facilities			121,282,000	70,000,000
Net proceeds from public follow-on offering		$ 292,690,000
Dividends received from equity investees			$ 55,586,000	$ 30,528,000	$ 6,410,000

Particulars of Principal Subsidiaries and Equity Investees (Details)	Dec. 31, 2017	Dec. 31, 2016
Hutchison MediPharma Limited ("HMPL") \| PRC
Subsidiary or Equity Method Investee
Equity interest attributable to the Group	99.75%	99.75%
Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm") \| PRC
Subsidiary or Equity Method Investee
Equity interest attributable to the Group	51.00%	51.00%
Hutchison Hain Organic (Hong Kong) Limited ("HHOL") \| Hong Kong
Subsidiary or Equity Method Investee
Equity interest attributable to the Group	50.00%	50.00%
Hutchison Hain Organic (Guangzhou) Limited ("HHOGZL") \| PRC
Subsidiary or Equity Method Investee
Equity interest attributable to the Group	50.00%	50.00%
Hutchison Healthcare Limited ("HHL") \| PRC
Subsidiary or Equity Method Investee
Equity interest attributable to the Group	100.00%	100.00%
Hutchison Consumer Products Limited \| Hong Kong
Subsidiary or Equity Method Investee
Equity interest attributable to the Group	100.00%	100.00%
Shanghai Hutchison Pharmaceuticals Limited ("SHPL") \| PRC
Subsidiary or Equity Method Investee
Equity investees	50.00%	50.00%
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS") \| PRC
Subsidiary or Equity Method Investee
Equity investees	40.00%	40.00%
Nutrition Science Partners Limited ("NSPL") \| Hong Kong
Subsidiary or Equity Method Investee
Equity investees	49.88%	49.88%
Subsidiary 80% owned by the Group \| Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")
Subsidiary or Equity Method Investee
Equity interest attributable to the Group	40.00%	40.00%
Equity interest attributable to subsidiaries (as a percent)	50.00%	50.00%
Subsidiary 80% owned by the Group \| Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS") \| PRC
Subsidiary or Equity Method Investee
Equity interest attributable to the Group	80.00%	80.00%
Subsidiary 99.75% owned by the Group \| Nutrition Science Partners Limited ("NSPL")
Subsidiary or Equity Method Investee
Equity interest attributable to the Group	49.88%	49.88%
Equity interest attributable to subsidiaries (as a percent)	50.00%	50.00%
Subsidiary 99.75% owned by the Group \| Nutrition Science Partners Limited ("NSPL") \| Hong Kong
Subsidiary or Equity Method Investee
Equity interest attributable to the Group	99.75%	99.75%

Fair Value Disclosures (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair value measurements
Cash and cash equivalents	$ 85,265	$ 79,431
Short-term investments	273,031	24,270
Level 1
Fair value measurements
Cash and cash equivalents	85,265	79,431
Short-term investments	$ 273,031	$ 24,270

Short-term Investments (Details) - USD ($) $ in Thousands	12 Months Ended
Short-term Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Short term Investments
Short-term investments	$ 273,031	$ 24,270
Bank deposits maturing over three months
Short term Investments
Short-term investments	$ 273,031	$ 24,270
Bank deposits maturing over three months \| Weighted average
Short term Investments
Effective interest rate (in percentage)	1.32%	0.71%
Bank deposits maturing over three months \| Minimum
Short term Investments
Bank deposit maturity period (in days)	91 days	91 days
Bank deposits maturing over three months \| Maximum
Short term Investments
Bank deposit maturity period (in days)	183 days	186 days
Bank deposits maturing over three months \| US dollar
Short term Investments
Short-term investments	$ 272,659	$ 24,270
Bank deposits maturing over three months \| Hong Kong dollar
Short term Investments
Short-term investments	$ 372

Accounts Receivable-Third Parties (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts Receivable-Third Parties
Accounts receivable, gross	$ 38,668	$ 43,532
Allowance for doubtful accounts	(258)	(2,720)
Accounts receivable, net	$ 38,410	$ 40,812

Other Receivables, Prepayments and Deposits (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Receivables, Prepayments and Deposits
Prepayments	$ 2,565	$ 699
Purchase rebates	284	238
Other service receivables	490	756
Deposits	932	620
Value-added tax receivables	5,436	1,380
Interest receivable	506	63
Others	1,083	558
Total	$ 11,296	$ 4,314

Inventories (Details) - USD ($) $ in Thousands	12 Months Ended
Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Inventories
Raw materials	$ 314	$ 660
Finished goods	11,475	12,162
Total	11,789	12,822
Movements on the provision for excess and obsolete inventories
As at January 1	160	25	$ 34
Increase in provision for excess and obsolete inventories	128	163	37
Decrease in provision due to subsequent sale or recovery	(144)		(33)
Write-off	(32)	(23)	(12)
Exchange difference	9	(5)	(1)
As at December 31	$ 121	$ 160	$ 25

Property, Plant and Equipment (Details) - USD ($)	12 Months Ended
Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cost
As at January 1	$ 24,350,000	$ 21,842,000
Additions	6,073,000	4,327,000
Disposals	(394,000)	(260,000)
Exchange differences	1,680,000	(1,559,000)
As at December 31	31,709,000	24,350,000	$ 21,842,000
Accumulated depreciation
As at January 1	14,396,000	13,335,000
Depreciation	2,478,000	2,239,000	1,908,000
Disposals	(337,000)	(230,000)
Exchange differences	952,000	(948,000)
As at December 31	17,489,000	14,396,000	13,335,000
Net book value	14,220,000	9,954,000
Buildings
Cost
As at January 1	2,232,000	2,392,000
Exchange differences	140,000	(160,000)
As at December 31	2,372,000	2,232,000	2,392,000
Accumulated depreciation
As at January 1	971,000	932,000
Depreciation	105,000	106,000
Exchange differences	65,000	(67,000)
As at December 31	1,141,000	971,000	932,000
Net book value	1,231,000	1,261,000
Leasehold improvements
Cost
As at January 1	6,296,000	5,989,000
Additions	301,000	742,000
Disposals		(12,000)
Transfers	2,050,000
Exchange differences	410,000	(423,000)
As at December 31	9,057,000	6,296,000	5,989,000
Accumulated depreciation
As at January 1	4,249,000	3,549,000
Depreciation	763,000	977,000
Disposals		(12,000)
Exchange differences	284,000	(265,000)
As at December 31	5,296,000	4,249,000	3,549,000
Net book value	3,761,000	2,047,000
Plant and equipment
Cost
As at January 1	86,000	88,000
Additions	155,000
Transfers	2,321,000
Exchange differences	6,000	(2,000)
As at December 31	2,568,000	86,000	88,000
Accumulated depreciation
As at January 1	71,000	70,000
Depreciation	169,000	3,000
Transfers	255,000
Exchange differences	4,000	(2,000)
As at December 31	499,000	71,000	70,000
Net book value	2,069,000	15,000
Furniture and fixtures, other equipment and motor vehicles
Cost
As at January 1	13,976,000	12,806,000
Additions	1,374,000	1,453,000
Disposals	(394,000)	(248,000)
Transfers	(722,000)	886,000
Exchange differences	920,000	(921,000)
As at December 31	15,154,000	13,976,000	12,806,000
Accumulated depreciation
As at January 1	9,105,000	8,784,000
Depreciation	1,441,000	1,153,000
Disposals	(337,000)	(218,000)
Transfers	(255,000)
Exchange differences	599,000	(614,000)
As at December 31	10,553,000	9,105,000	8,784,000
Net book value	4,601,000	4,871,000
Construction in Progress
Cost
As at January 1	1,760,000	567,000
Additions	4,243,000	2,132,000
Transfers	(3,649,000)	(886,000)
Exchange differences	204,000	(53,000)
As at December 31	2,558,000	1,760,000	$ 567,000
Accumulated depreciation
Net book value	$ 2,558,000	$ 1,760,000

Investments in Equity Investees - Composition (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Investments in Equity Investees
Investments in equity investees	$ 144,237	$ 158,506
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")
Investments in Equity Investees
Investments in equity investees	55,308	63,536
Shanghai Hutchison Pharmaceuticals Limited ("SHPL")
Investments in Equity Investees
Investments in equity investees	69,417	77,939
Nutrition Science Partners Limited ("NSPL")
Investments in Equity Investees
Investments in equity investees	19,201	16,806
Other
Investments in Equity Investees
Investments in equity investees	$ 311	$ 225

Investments in Equity Investees - Summarized Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Consumer Health \| Commercial Platform \| Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS")
Summarized balance sheet
Current assets	$ 101,570	$ 123,181
Non-current assets	107,226	98,554
Current liabilities	(75,787)	(70,218)
Non-current liabilities	(18,748)	(18,148)
Net assets	114,261	133,369
Non-controlling interests	(3,645)	(6,297)
Net assets, excluding non-controlling interests	110,616	127,072	$ 121,523	$ 111,506
Prescription Drugs \| Commercial Platform \| Shanghai Hutchison Pharmaceuticals Limited ("SHPL")
Summarized balance sheet
Current assets	129,535	146,350
Non-current assets	103,477	97,656
Current liabilities	(91,665)	(86,946)
Non-current liabilities	(8,616)	(6,926)
Net assets	132,731	150,134
Net assets, excluding non-controlling interests	132,731	150,134	93,263	71,906
Drug R&D \| Innovation Platform \| Nutrition Science Partners Limited ("NSPL")
Summarized balance sheet
Current assets	9,640	5,393
Non-current assets	30,000	30,000
Current liabilities	(1,239)	(1,782)
Net assets	38,401	33,611
Net assets, excluding non-controlling interests	$ 38,401	$ 33,611	$ 18,093	$ 25,645

Investments in Equity Investees - Lease Commitments and Capital Commitments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Future aggregate minimum payments under non-cancellable operating leases
Not later than 1 year	$ 3,330	$ 1,711
Between 1 to 2 years	2,875	1,383
Between 2 to 3 years	2,132	1,053
Between 3 to 4 years	345	597
Between 4 to 5 years	161	108
Total minimum lease payments	8,860	4,897
Property, plant and equipment
Capital commitments
Long-term Purchase Commitment, Amount	161	2,545
Equity investees
Future aggregate minimum payments under non-cancellable operating leases
Not later than 1 year	1,282	1,511
Between 1 to 2 years	400	1,184
Between 2 to 3 years	151
Between 3 to 4 years	141
Between 4 to 5 years	47
Total minimum lease payments	2,021	2,695
Equity investees \| Property, plant and equipment
Capital commitments
Long-term Purchase Commitment, Amount	$ 1,034	$ 6,162

Accounts Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts payable-third parties	$ 17,095	$ 30,383
Accounts payable-related parties	20	19
Accounts Payable	24,365	35,538
Non-controlling shareholders of subsidiaries
Accounts payable-third parties	$ 7,250	$ 5,136

Other Payables, Accruals and Advance Receipts (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Payables, Accruals and Advance Receipts
Accrued salaries and benefits	$ 9,295	$ 7,057
Accrued research and development expenses	14,613	11,771
Accrued selling and marketing expenses	4,121	4,340
Accrued administrative and other general expenses	4,729	4,078
Deferred government incentives	1,790	1,755
Loan from a non-controlling shareholder of a subsidiary	1,550
Payments in advance from customers	1,282	899
Others	3,573	1,816
Other payables, accruals and advance receipts	$ 40,953	$ 31,716

Bank Borrowings - Loan Facilities (Details)	1 Months Ended										4 Months Ended
Bank Borrowings - Loan Facilities (Details)	Nov. 30, 2017 HKD ($)	Nov. 30, 2017 USD ($)	Aug. 31, 2017 HKD ($)	Aug. 31, 2017 USD ($)	Mar. 31, 2017 HKD ($)	Mar. 31, 2017 USD ($)	Feb. 28, 2017 HKD ($) agreement	Nov. 30, 2015 HKD ($)	Jun. 30, 2014	Dec. 31, 2011 HKD ($)	Nov. 30, 2017 HKD ($) installment	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	Feb. 28, 2017 USD ($)	Dec. 31, 2016 USD ($)	Feb. 29, 2016 HKD ($)	Feb. 29, 2016 USD ($)	Nov. 30, 2015 USD ($)	Dec. 31, 2011 USD ($)
Term loan
Bank Borrowings
Term									4 years	3 years
Principal amount										$ 210,000,000									$ 26,923,000
Loan facility repaid	$ 30,000,000	$ 3,846,000	$ 180,000,000	$ 23,077,000	$ 156,000,000	$ 20,000,000
Number of installments \| installment											2
Term loan \| HIBOR
Bank Borrowings
Basis spread on variable rate									1.35%	1.50%
Revolving loan facility
Bank Borrowings
Term								3 years
Aggregate amount of credit facilities								$ 234,000,000										$ 30,000,000
Amount drawn from the credit facility							$ 20,000,000					$ 0		$ 2,564,000	$ 0
Loan facility repaid					$ 20,000,000	$ 2,564,000
Revolving loan facility \| HIBOR
Bank Borrowings
Basis spread on variable rate								1.25%
Unsecured credit facility
Bank Borrowings
Number of facility agreements entered \| agreement							2
Aggregate amount of credit facilities	$ 400,000,000						$ 546,000,000				$ 400,000,000		$ 51,282,000	70,000,000		$ 468,000,000	$ 60,000,000
Unsecured credit facility \| Term loan
Bank Borrowings
Term	3 years	3 years
Aggregate amount of credit facilities	$ 210,000,000										210,000,000		26,923,000
Unsecured credit facility \| Term loan \| HIBOR
Bank Borrowings
Basis spread on variable rate	1.50%	1.50%
Unsecured credit facility \| Revolving loan facility
Bank Borrowings
Term	18 months	18 months
Principal amount	$ 190,000,000										$ 190,000,000		$ 24,359,000
Amount drawn from the credit facility												0
Unsecured credit facility \| Revolving loan facility \| HIBOR
Bank Borrowings
Basis spread on variable rate	1.25%	1.25%
First unsecured credit facility \| Term loan
Bank Borrowings
Term							18 months
Aggregate amount of credit facilities							$ 156,000,000							20,000,000
First unsecured credit facility \| Term loan \| HIBOR
Bank Borrowings
Basis spread on variable rate							1.25%
First unsecured credit facility \| Revolving loan facility
Bank Borrowings
Term							18 months
Aggregate amount of credit facilities							$ 195,000,000							25,000,000
Amount drawn from the credit facility												0
First unsecured credit facility \| Revolving loan facility \| HIBOR
Bank Borrowings
Basis spread on variable rate							1.25%
Second unsecured credit facility \| Term loan
Bank Borrowings
Term							18 months
Principal amount							$ 78,000,000							10,000,000
Second unsecured credit facility \| Term loan \| HIBOR
Bank Borrowings
Basis spread on variable rate							1.25%
Second unsecured credit facility \| Revolving loan facility
Bank Borrowings
Term							18 months
Principal amount							$ 117,000,000							$ 15,000,000
Amount drawn from the credit facility												$ 0
Second unsecured credit facility \| Revolving loan facility \| HIBOR
Bank Borrowings
Basis spread on variable rate							1.25%

Redeemable Non-controlling Interests (Details)				1 Months Ended		2 Months Ended		12 Months Ended
Redeemable Non-controlling Interests (Details)	Apr. 13, 2016 USD ($) shares	Mar. 17, 2016 USD ($) shares	Jul. 23, 2015 USD ($) shares	Oct. 31, 2017 USD ($) shares	Oct. 31, 2012 USD ($) shares	Jun. 30, 2014 USD ($) agreement shares	Dec. 31, 2010 USD ($) shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($)
Redeemable Non-controlling Interests
Redeemable noncontrolling interests outstanding								$ 0	$ 0
Number of subscription agreements entered \| agreement						2
New ordinary shares issued (in shares) \| shares	330,000	3,750,000		5,684,905				5,685,000	4,080,000
Issuance in relation to public offering	$ 8,900,000	$ 101,300,000		$ 301,300,000				$ 301,300,000	$ 110,160,000
Ordinary Shares
Redeemable Non-controlling Interests
New ordinary shares issued (in shares) \| shares			3,214,404					5,685,000	4,080,000
Issuance in relation to public offering			$ 84,000,000					$ 5,685,000	$ 4,080,000
Redeemable convertible preferred shares
Redeemable Non-controlling Interests
Preferred shares repurchased (in shares) \| shares					2,815,249
Preferred shares outstanding			$ 84,000,000
HMHL
Redeemable Non-controlling Interests
Aggregate consideration						$ 25,000,000
Preferred shares as a percentage of the aggregate issued and outstanding share capital						12.24%
Accretion of preferred shares										$ 43,001,000
HMHL \| Ordinary Shares
Redeemable Non-controlling Interests
Number of shares issued (in shares) \| shares						4,825,418
HMHL \| Redeemable convertible preferred shares
Redeemable Non-controlling Interests
Number of shares issued (in shares) \| shares						672,713	7,390,029
Aggregate consideration							$ 20,100,000
Preferred shares as a percentage of the aggregate issued and outstanding share capital					12.24%		19.76%
Preferred shares outstanding (in shares) \| shares					4,574,780
Preferred shares outstanding					$ 12,500,000
Mitsui
Redeemable Non-controlling Interests
Preferred shares as a percentage of the aggregate issued and outstanding share capital			5.69%

Ordinary Shares (Details) $ in Thousands			1 Months Ended	12 Months Ended			24 Months Ended
Ordinary Shares (Details) $ in Thousands	Apr. 13, 2016 USD ($) shares	Mar. 17, 2016 USD ($) shares	Oct. 31, 2017 USD ($) shares	Dec. 31, 2017 USD ($) item shares	Dec. 31, 2016 USD ($) item shares	Dec. 31, 2015 USD ($) item shares	Dec. 31, 2016 USD ($) item shares
Ordinary shares, authorized				75,000,000	75,000,000		75,000,000
Each ADS as ordinary share		0.5		0.5
Issuance in relation to public offering \| $	$ 8,900	$ 101,300	$ 301,300	$ 301,300	$ 110,160
Issuance costs paid \| $				$ 8,576	$ 12,906	$ 1,321	$ 14,200
Summary of ordinary shares transactions:
Balance as at January 1				60,706,000	56,533,000	53,076,000	53,076,000
Issuance in relation to public offering (in shares)	330,000	3,750,000	5,684,905	5,685,000	4,080,000
Share option exercises				56,000	93,000	243,000
Exchange of redeemable non-controlling interest (Note 16)						3,214,000
Balance as at December 31				66,447,000	60,706,000	56,533,000	60,706,000
Votes per ordinary share \| item				1	1	1	1
ADS
Summary of ordinary shares transactions:
Issuance in relation to public offering (in shares)	660,000	7,500,000	11,369,810

Share based Compensation - HCML Share Option Scheme (Details) - shares					12 Months Ended
	Jun. 15, 2016	Dec. 20, 2013	Aug. 06, 2008	Jun. 04, 2005	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
HCML Share Option Scheme
Share-based Compensation
Expiry period				10 years
Aggregate number of shares issuable					2,425,597
Number of issuable shares expired						282,726
Number of shares authorized but unissued					8,552,963
Number of share options cancelled					6,875	3,750
Number of share options granted	593,686				150,000	693,686
Outstanding share options					1,126,412	1,039,596	442,365	684,403
HCML Share Option Scheme \| Minimum
Share-based Compensation
Expiry period					8 years
HCML Share Option Scheme \| Maximum
Share-based Compensation
Expiry period					10 years
HCML Share Option Scheme \| Three-year awards
Share-based Compensation
Vesting period					3 years
Vesting percentage upon first anniversary					33.30%
Annual vesting percentage after the first anniversary					33.30%
HCML Share Option Scheme \| Four-year awards
Share-based Compensation
Vesting period					4 years
Vesting percentage upon first anniversary					25.00%
Annual vesting percentage after the first anniversary					25.00%
HMHL Share Option Scheme
Share-based Compensation
Expiry period			6 years
Aggregate number of shares issuable					2,144,408
Number of share options cancelled	1,187,372	2,485,189				1,187,372
Outstanding share options							1,187,372	1,211,772

Share-based Compensation - HCML Options Fair value Assumptions (Details) - HCML Share Option Scheme - £ / shares					12 Months Ended
	Mar. 27, 2017	Jun. 15, 2016	Dec. 20, 2013	Jun. 24, 2011	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation
Value of each share option (in GBP per share)	£ 12.69	£ 8.99	£ 3.15	£ 1.84	£ 12.69	£ 8.99
Significant inputs into the valuation model:
Exercise price (in GBP per share)	31.05	19.70	6.10	4.41
Share price at effective date of grant (in GBP per share)	£ 31.05	£ 19.70	£ 6.10	£ 4.33
Expected volatility (in percentage)	36.30%	39.00%	36.00%	46.60%
Risk-free interest rate (in percentage)	1.17%	1.00%	3.16%	3.13%
Contractual life of share options (in years)	10 years	8 years	10 years	10 years
Expected dividend yield (in percentage)	0.00%	0.00%	0.00%	0.00%

Share-based Compensation - HCML Share Option Values (Details) - HCML Share Option Scheme $ in Thousands					12 Months Ended
	Mar. 27, 2017 £ / shares	Jun. 15, 2016 £ / shares	Dec. 20, 2013 £ / shares	Jun. 24, 2011 £ / shares	Dec. 31, 2017 £ / shares	Dec. 31, 2017 USD ($)	Dec. 31, 2016 £ / shares	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Share option values
Weighted average grant date fair value of share option granted during the period (in GBP per share) \| £ / shares	£ 12.69	£ 8.99	£ 3.15	£ 1.84	£ 12.69		£ 8.99
Total intrinsic value of share options exercised \| $						$ 2,290		$ 1,907	$ 5,020

Hutchison China MediTech Limited

/s/ CHRISTIAN HOGG

Christian Hogg

Chief Executive Officer

Date: March 12, 2018